From 09b5029df710c5906eea8aceed621e189b2af95b Mon Sep 17 00:00:00 2001 From: namucris Date: Wed, 18 Oct 2023 20:15:28 -0300 Subject: [PATCH] Exercicios S11 - Cris Pereira --- .../MaternalMortality_HealthIndicators.csv | 34194 +++++++++ .../exercicioCrisPereiraS11/analiseCEIS.ipynb | 1306 + .../health_indicators_ocde.csv | 62545 ++++++++++++++++ .../maternal-mortality-who.csv | 3421 + 4 files changed, 101466 insertions(+) create mode 100644 exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv create mode 100644 exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb create mode 100644 exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv create mode 100644 exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv b/exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv new file mode 100644 index 0000000..ce842c3 --- /dev/null +++ b/exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv @@ -0,0 +1,34194 @@ +,Country,Year,Indicator:Maternal mortality ratio (per 100 000 live births),Type_of_Medicine,Measure,Total_Sales_Value +0,Australia,2016,6,B-Blood and blood forming organs,Million of national currency units,667.0 +1,Australia,2016,6,M-Musculo-skeletal system,Million US$ at exchange rate,316.7 +2,Australia,2016,6,M-Musculo-skeletal system,Million of national currency units,426.0 +3,Australia,2016,6,R03-Drugs for obstructive airway diseases,Million of national currency units,629.0 +4,Australia,2016,6,B-Blood and blood forming organs,Million US$ at exchange rate,495.8 +5,Australia,2016,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",460.0 +6,Australia,2016,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,467.6 +7,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,361.3 +8,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.9 +9,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",335.1 +10,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,486.0 +11,Australia,2016,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.1 +12,Australia,2016,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",293.8 +13,Australia,2016,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.1 +14,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1 +15,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2 +16,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.5 +17,Australia,2016,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.0 +18,Australia,2016,6,B-Blood and blood forming organs,% of total sales,4.4 +19,Australia,2016,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.5 +20,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",438.6 +21,Australia,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.3 +22,Australia,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.9 +23,Australia,2016,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",433.7 +24,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,472.8 +25,Australia,2016,6,R03-Drugs for obstructive airway diseases,% of total sales,4.1 +26,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,636.0 +27,Australia,2016,6,R-Respiratory system,"Million US$, purchasing power parity",489.6 +28,Australia,2016,6,R-Respiratory system,"/capita, US$ exchange rate",21.8 +29,Australia,2016,6,R-Respiratory system,Million US$ at exchange rate,527.8 +30,Australia,2016,6,C08-Calcium channel blockers,Million of national currency units,133.0 +31,Australia,2016,6,R-Respiratory system,"/capita, US$ purchasing power parity",20.2 +32,Australia,2016,6,R-Respiratory system,% of total sales,4.6 +33,Australia,2016,6,C07-Beta blocking agents,"Million US$, purchasing power parity",105.5 +34,Australia,2016,6,C07-Beta blocking agents,Million US$ at exchange rate,113.7 +35,Australia,2016,6,C07-Beta blocking agents,Million of national currency units,153.0 +36,Australia,2016,6,C07-Beta blocking agents,% of total sales,1.0 +37,Australia,2016,6,R-Respiratory system,Million of national currency units,710.0 +38,Australia,2016,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7 +39,Australia,2016,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.4 +40,Australia,2016,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.5 +41,Australia,2016,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1028.1 +42,Australia,2016,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",953.7 +43,Australia,2016,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.4 +44,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.2 +45,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9 +46,Australia,2016,6,A-Alimentary tract and metabolism,% of total sales,9.0 +47,Australia,2016,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +48,Australia,2016,6,C08-Calcium channel blockers,Million US$ at exchange rate,98.9 +49,Australia,2016,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",91.7 +50,Australia,2016,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8 +51,Australia,2016,6,A-Alimentary tract and metabolism,Million of national currency units,1383.0 +52,Australia,2016,6,M-Musculo-skeletal system,% of total sales,2.8 +53,Australia,2016,6,C08-Calcium channel blockers,% of total sales,0.9 +54,Australia,2016,6,A02A-Antacids,% of total sales,0.0 +55,Australia,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.2 +56,Australia,2016,6,G-Genito urinary system and sex hormones,% of total sales,2.3 +57,Australia,2016,6,A02A-Antacids,"Million US$, purchasing power parity",0.0 +58,Australia,2016,6,A02A-Antacids,Million US$ at exchange rate,0.0 +59,Australia,2016,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +60,Australia,2016,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +61,Australia,2016,6,J-Antiinfectives for systemic use,Million of national currency units,3422.0 +62,Australia,2016,6,C-Cardiovascular system,Million of national currency units,1860.0 +63,Australia,2016,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2543.8 +64,Australia,2016,6,G-Genito urinary system and sex hormones,Million of national currency units,359.0 +65,Australia,2016,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",247.6 +66,Australia,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.0 +67,Australia,2016,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,266.9 +68,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",191.7 +69,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.5 +70,Australia,2016,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,206.7 +71,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,224.0 +72,Australia,2016,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +73,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.9 +74,Australia,2016,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,278.0 +75,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5 +76,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4 +77,Australia,2016,6,A02A-Antacids,Million of national currency units,0.0 +78,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,166.5 +79,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.9 +80,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.5 +81,Australia,2016,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.2 +82,Australia,2016,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",488.9 +83,Australia,2016,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.8 +84,Australia,2016,6,J01-Antibacterials for systemic use,% of total sales,2.6 +85,Australia,2016,6,C10-Lipid modifying agents,% of total sales,4.6 +86,Australia,2016,6,Products not elsewhere classified,% of total sales,28.5 +87,Australia,2016,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +88,Australia,2016,6,Products not elsewhere classified,"Million US$, purchasing power parity",3003.8 +89,Australia,2016,6,Products not elsewhere classified,Million of national currency units,4356.0 +90,Australia,2016,6,Products not elsewhere classified,Million US$ at exchange rate,3238.1 +91,Australia,2016,6,Products not elsewhere classified,"/capita, US$ exchange rate",133.9 +92,Australia,2016,6,C10-Lipid modifying agents,Million of national currency units,709.0 +93,Australia,2016,6,C10-Lipid modifying agents,Million US$ at exchange rate,527.1 +94,Australia,2016,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",124.2 +95,Australia,2016,6,C-Cardiovascular system,% of total sales,12.2 +96,Australia,2016,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2359.7 +97,Australia,2016,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.0 +98,Australia,2016,6,C-Cardiovascular system,"Million US$, purchasing power parity",1282.6 +99,Australia,2016,6,C-Cardiovascular system,Million US$ at exchange rate,1382.7 +100,Australia,2016,6,C-Cardiovascular system,"/capita, US$ exchange rate",57.2 +101,Australia,2016,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",105.2 +102,Australia,2016,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",270.3 +103,Australia,2016,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,291.4 +104,Australia,2016,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0 +105,Australia,2016,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",97.5 +106,Australia,2016,6,J01-Antibacterials for systemic use,Million of national currency units,392.0 +107,Australia,2016,6,J-Antiinfectives for systemic use,% of total sales,22.4 +108,Australia,2016,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4 +109,Australia,2016,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +110,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.9 +111,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.8 +112,Australia,2016,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +113,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +114,Australia,2016,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.5 +115,Australia,2016,6,C01A-Cardiac glycosides,% of total sales,0.0 +116,Australia,2016,6,C03-Diuretics,Million of national currency units,46.0 +117,Australia,2016,6,C03-Diuretics,Million US$ at exchange rate,34.2 +118,Australia,2016,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.0 +119,Australia,2016,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8 +120,Australia,2016,6,C01A-Cardiac glycosides,Million of national currency units,5.0 +121,Australia,2016,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.7 +122,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,20.0 +123,Australia,2016,6,C02-Antihypertensives,% of total sales,0.6 +124,Australia,2016,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9 +125,Australia,2016,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",446.8 +126,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +127,Australia,2016,6,N-Nervous system,Million US$ at exchange rate,1411.7 +128,Australia,2016,6,N-Nervous system,"Million US$, purchasing power parity",1309.5 +129,Australia,2016,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.8 +130,Australia,2016,6,N05C-Hypnotics and sedatives,Million of national currency units,28.0 +131,Australia,2016,6,N-Nervous system,Million of national currency units,1899.0 +132,Australia,2016,6,N05B-Anxiolytics,% of total sales,0.3 +133,Australia,2016,6,A10-Drugs used in diabetes,% of total sales,4.2 +134,Australia,2016,6,N05B-Anxiolytics,Million of national currency units,45.0 +135,Australia,2016,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3 +136,Australia,2016,6,N-Nervous system,"/capita, US$ purchasing power parity",54.1 +137,Australia,2016,6,N-Nervous system,"/capita, US$ exchange rate",58.4 +138,Australia,2016,6,N-Nervous system,% of total sales,12.4 +139,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +140,Australia,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +141,Australia,2016,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.3 +142,Australia,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8 +143,Australia,2016,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +144,Australia,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",436.3 +145,Australia,2016,6,N06A-Antidepressants,Million of national currency units,441.0 +146,Australia,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",10554.0 +147,Australia,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",470.3 +148,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",79.3 +149,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.5 +150,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,115.0 +151,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,85.5 +152,Australia,2016,6,Total pharmaceutical sales,Million of national currency units,15305.0 +153,Australia,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,11377.4 +154,Australia,2016,6,A10-Drugs used in diabetes,Million of national currency units,648.0 +155,Australia,2016,6,N05B-Anxiolytics,Million US$ at exchange rate,33.5 +156,Australia,2016,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.6 +157,Australia,2016,6,N06A-Antidepressants,"Million US$, purchasing power parity",304.1 +158,Australia,2016,6,N06A-Antidepressants,Million US$ at exchange rate,327.8 +159,Australia,2016,6,N06A-Antidepressants,% of total sales,2.9 +160,Australia,2016,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.6 +161,Australia,2016,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +162,Australia,2016,6,C03-Diuretics,% of total sales,0.3 +163,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +164,Australia,2016,6,A10-Drugs used in diabetes,Million US$ at exchange rate,481.7 +165,Australia,2016,6,C03-Diuretics,"/capita, US$ exchange rate",1.4 +166,Australia,2016,6,C03-Diuretics,"Million US$, purchasing power parity",31.7 +167,Australia,2016,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.3 +168,Australia,2016,6,C02-Antihypertensives,Million of national currency units,98.0 +169,Australia,2016,6,N02-Analgesics,"Million US$, purchasing power parity",342.7 +170,Australia,2016,6,N02-Analgesics,"/capita, US$ exchange rate",15.3 +171,Australia,2016,6,N02-Analgesics,Million US$ at exchange rate,369.5 +172,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.3 +173,Australia,2016,6,N02-Analgesics,Million of national currency units,497.0 +174,Australia,2016,6,C02-Antihypertensives,Million US$ at exchange rate,72.9 +175,Australia,2016,6,C02-Antihypertensives,"Million US$, purchasing power parity",67.6 +176,Australia,2016,6,N05B-Anxiolytics,"Million US$, purchasing power parity",31.0 +177,Australia,2016,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.2 +178,Australia,2016,6,N02-Analgesics,% of total sales,3.2 +179,Australia,2015,6,B-Blood and blood forming organs,Million of national currency units,617.0 +180,Australia,2015,6,M-Musculo-skeletal system,Million of national currency units,401.0 +181,Australia,2015,6,M-Musculo-skeletal system,Million US$ at exchange rate,301.3 +182,Australia,2015,6,R03-Drugs for obstructive airway diseases,Million of national currency units,618.0 +183,Australia,2015,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,464.3 +184,Australia,2015,6,B-Blood and blood forming organs,Million US$ at exchange rate,463.5 +185,Australia,2015,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",418.7 +186,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,369.6 +187,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",333.9 +188,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5 +189,Australia,2015,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.6 +190,Australia,2015,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",272.1 +191,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,492.0 +192,Australia,2015,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.4 +193,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.3 +194,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.5 +195,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.4 +196,Australia,2015,6,B-Blood and blood forming organs,% of total sales,5.0 +197,Australia,2015,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.6 +198,Australia,2015,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.5 +199,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",460.7 +200,Australia,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.5 +201,Australia,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6 +202,Australia,2015,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",419.4 +203,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,510.1 +204,Australia,2015,6,R03-Drugs for obstructive airway diseases,% of total sales,5.0 +205,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,679.0 +206,Australia,2015,6,R-Respiratory system,"/capita, US$ exchange rate",22.0 +207,Australia,2015,6,R-Respiratory system,"Million US$, purchasing power parity",473.0 +208,Australia,2015,6,R-Respiratory system,Million US$ at exchange rate,523.6 +209,Australia,2015,6,C08-Calcium channel blockers,Million of national currency units,124.0 +210,Australia,2015,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.9 +211,Australia,2015,6,R-Respiratory system,% of total sales,5.7 +212,Australia,2015,6,C07-Beta blocking agents,"Million US$, purchasing power parity",97.7 +213,Australia,2015,6,C07-Beta blocking agents,Million of national currency units,144.0 +214,Australia,2015,6,C07-Beta blocking agents,Million US$ at exchange rate,108.2 +215,Australia,2015,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5 +216,Australia,2015,6,C07-Beta blocking agents,% of total sales,1.2 +217,Australia,2015,6,R-Respiratory system,Million of national currency units,697.0 +218,Australia,2015,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.1 +219,Australia,2015,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.7 +220,Australia,2015,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",38.5 +221,Australia,2015,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1016.5 +222,Australia,2015,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",918.1 +223,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0 +224,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0 +225,Australia,2015,6,A-Alimentary tract and metabolism,% of total sales,11.0 +226,Australia,2015,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9 +227,Australia,2015,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +228,Australia,2015,6,C08-Calcium channel blockers,Million US$ at exchange rate,93.2 +229,Australia,2015,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",84.1 +230,Australia,2015,6,A-Alimentary tract and metabolism,Million of national currency units,1353.0 +231,Australia,2015,6,C08-Calcium channel blockers,% of total sales,1.0 +232,Australia,2015,6,A02A-Antacids,% of total sales,0.0 +233,Australia,2015,6,G-Genito urinary system and sex hormones,% of total sales,2.4 +234,Australia,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.5 +235,Australia,2015,6,A02A-Antacids,"Million US$, purchasing power parity",1.4 +236,Australia,2015,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +237,Australia,2015,6,A02A-Antacids,"/capita, US$ exchange rate",0.1 +238,Australia,2015,6,A02A-Antacids,Million US$ at exchange rate,1.5 +239,Australia,2015,6,J-Antiinfectives for systemic use,Million of national currency units,822.0 +240,Australia,2015,6,C-Cardiovascular system,Million of national currency units,1992.0 +241,Australia,2015,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,617.5 +242,Australia,2015,6,G-Genito urinary system and sex hormones,Million of national currency units,298.0 +243,Australia,2015,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",202.2 +244,Australia,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4 +245,Australia,2015,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,223.9 +246,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",149.3 +247,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9 +248,Australia,2015,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.3 +249,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,191.0 +250,Australia,2015,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +251,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +252,Australia,2015,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,220.0 +253,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6 +254,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.4 +255,Australia,2015,6,A02A-Antacids,Million of national currency units,2.0 +256,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,143.5 +257,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0 +258,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",129.6 +259,Australia,2015,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.4 +260,Australia,2015,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9 +261,Australia,2015,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",556.4 +262,Australia,2015,6,J01-Antibacterials for systemic use,% of total sales,3.0 +263,Australia,2015,6,C10-Lipid modifying agents,% of total sales,6.7 +264,Australia,2015,6,Products not elsewhere classified,% of total sales,32.5 +265,Australia,2015,6,Products not elsewhere classified,"Million US$, purchasing power parity",2705.5 +266,Australia,2015,6,Products not elsewhere classified,Million of national currency units,3987.0 +267,Australia,2015,6,Products not elsewhere classified,Million US$ at exchange rate,2995.3 +268,Australia,2015,6,Products not elsewhere classified,"/capita, US$ exchange rate",125.8 +269,Australia,2015,6,C10-Lipid modifying agents,Million of national currency units,820.0 +270,Australia,2015,6,C10-Lipid modifying agents,Million US$ at exchange rate,616.0 +271,Australia,2015,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",113.6 +272,Australia,2015,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3 +273,Australia,2015,6,C-Cardiovascular system,% of total sales,16.2 +274,Australia,2015,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",557.8 +275,Australia,2015,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",56.8 +276,Australia,2015,6,C-Cardiovascular system,"Million US$, purchasing power parity",1351.7 +277,Australia,2015,6,C-Cardiovascular system,Million US$ at exchange rate,1496.5 +278,Australia,2015,6,C-Cardiovascular system,"/capita, US$ exchange rate",62.8 +279,Australia,2015,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.9 +280,Australia,2015,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",246.3 +281,Australia,2015,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,272.7 +282,Australia,2015,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5 +283,Australia,2015,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.4 +284,Australia,2015,6,J01-Antibacterials for systemic use,Million of national currency units,363.0 +285,Australia,2015,6,J-Antiinfectives for systemic use,% of total sales,6.7 +286,Australia,2015,6,M-Musculo-skeletal system,% of total sales,3.3 +287,Australia,2015,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +288,Australia,2015,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4 +289,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.3 +290,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.9 +291,Australia,2015,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +292,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +293,Australia,2015,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.6 +294,Australia,2015,6,C01A-Cardiac glycosides,% of total sales,0.0 +295,Australia,2015,6,C03-Diuretics,Million of national currency units,43.0 +296,Australia,2015,6,C03-Diuretics,Million US$ at exchange rate,32.3 +297,Australia,2015,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.5 +298,Australia,2015,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.9 +299,Australia,2015,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6 +300,Australia,2015,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.8 +301,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0 +302,Australia,2015,6,C01A-Cardiac glycosides,Million of national currency units,5.0 +303,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5 +304,Australia,2015,6,C02-Antihypertensives,% of total sales,0.7 +305,Australia,2015,6,N-Nervous system,"Million US$, purchasing power parity",1306.9 +306,Australia,2015,6,N-Nervous system,Million US$ at exchange rate,1446.9 +307,Australia,2015,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.0 +308,Australia,2015,6,N05C-Hypnotics and sedatives,Million of national currency units,24.0 +309,Australia,2015,6,N-Nervous system,Million of national currency units,1926.0 +310,Australia,2015,6,N05B-Anxiolytics,% of total sales,0.3 +311,Australia,2015,6,A10-Drugs used in diabetes,% of total sales,5.0 +312,Australia,2015,6,N05B-Anxiolytics,Million of national currency units,39.0 +313,Australia,2015,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1 +314,Australia,2015,6,N-Nervous system,"/capita, US$ purchasing power parity",54.9 +315,Australia,2015,6,N-Nervous system,% of total sales,15.7 +316,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +317,Australia,2015,6,N-Nervous system,"/capita, US$ exchange rate",60.8 +318,Australia,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +319,Australia,2015,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",16.3 +320,Australia,2015,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +321,Australia,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.7 +322,Australia,2015,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",418.7 +323,Australia,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",350.0 +324,Australia,2015,6,N06A-Antidepressants,Million of national currency units,438.0 +325,Australia,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8335.5 +326,Australia,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",387.5 +327,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",80.7 +328,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.8 +329,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,119.0 +330,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.4 +331,Australia,2015,6,N06A-Antidepressants,Million US$ at exchange rate,329.1 +332,Australia,2015,6,N05B-Anxiolytics,"Million US$, purchasing power parity",26.5 +333,Australia,2015,6,Total pharmaceutical sales,Million of national currency units,12284.0 +334,Australia,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,9228.5 +335,Australia,2015,6,A10-Drugs used in diabetes,Million of national currency units,617.0 +336,Australia,2015,6,N05B-Anxiolytics,Million US$ at exchange rate,29.3 +337,Australia,2015,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.8 +338,Australia,2015,6,N06A-Antidepressants,"Million US$, purchasing power parity",297.2 +339,Australia,2015,6,N06A-Antidepressants,% of total sales,3.6 +340,Australia,2015,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.5 +341,Australia,2015,6,C03-Diuretics,% of total sales,0.4 +342,Australia,2015,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +343,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0 +344,Australia,2015,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.2 +345,Australia,2015,6,A10-Drugs used in diabetes,Million US$ at exchange rate,463.5 +346,Australia,2015,6,C03-Diuretics,"Million US$, purchasing power parity",29.2 +347,Australia,2015,6,C03-Diuretics,"/capita, US$ exchange rate",1.4 +348,Australia,2015,6,N02-Analgesics,"Million US$, purchasing power parity",375.9 +349,Australia,2015,6,C02-Antihypertensives,Million of national currency units,91.0 +350,Australia,2015,6,N02-Analgesics,"/capita, US$ exchange rate",17.5 +351,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.4 +352,Australia,2015,6,N02-Analgesics,Million of national currency units,554.0 +353,Australia,2015,6,N02-Analgesics,Million US$ at exchange rate,416.2 +354,Australia,2015,6,C02-Antihypertensives,"Million US$, purchasing power parity",61.7 +355,Australia,2015,6,C02-Antihypertensives,Million US$ at exchange rate,68.4 +356,Australia,2015,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.8 +357,Australia,2015,6,N02-Analgesics,% of total sales,4.5 +358,Australia,2014,6,M-Musculo-skeletal system,Million of national currency units,383.0 +359,Australia,2014,6,B-Blood and blood forming organs,Million of national currency units,545.0 +360,Australia,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,345.2 +361,Australia,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,634.0 +362,Australia,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,571.5 +363,Australia,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,491.3 +364,Australia,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",375.2 +365,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,479.6 +366,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",20.4 +367,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",366.3 +368,Australia,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.7 +369,Australia,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",263.7 +370,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,532.0 +371,Australia,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.2 +372,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",20.7 +373,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9 +374,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.1 +375,Australia,2014,6,B-Blood and blood forming organs,% of total sales,4.6 +376,Australia,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.0 +377,Australia,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.9 +378,Australia,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.6 +379,Australia,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.3 +380,Australia,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",436.5 +381,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,636.4 +382,Australia,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.3 +383,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,706.0 +384,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",486.1 +385,Australia,2014,6,R-Respiratory system,"/capita, US$ exchange rate",25.3 +386,Australia,2014,6,R-Respiratory system,Million US$ at exchange rate,594.0 +387,Australia,2014,6,R-Respiratory system,"Million US$, purchasing power parity",453.7 +388,Australia,2014,6,C08-Calcium channel blockers,Million of national currency units,119.0 +389,Australia,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.3 +390,Australia,2014,6,R-Respiratory system,% of total sales,5.5 +391,Australia,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",97.8 +392,Australia,2014,6,C07-Beta blocking agents,Million of national currency units,142.0 +393,Australia,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,128.0 +394,Australia,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.5 +395,Australia,2014,6,C07-Beta blocking agents,% of total sales,1.2 +396,Australia,2014,6,R-Respiratory system,Million of national currency units,659.0 +397,Australia,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2 +398,Australia,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,107.3 +399,Australia,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.9 +400,Australia,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.6 +401,Australia,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",930.1 +402,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5 +403,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.6 +404,Australia,2014,6,A-Alimentary tract and metabolism,% of total sales,11.4 +405,Australia,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1217.8 +406,Australia,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.6 +407,Australia,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +408,Australia,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.9 +409,Australia,2014,6,A-Alimentary tract and metabolism,Million of national currency units,1351.0 +410,Australia,2014,6,M-Musculo-skeletal system,% of total sales,3.2 +411,Australia,2014,6,C08-Calcium channel blockers,% of total sales,1.0 +412,Australia,2014,6,A02A-Antacids,% of total sales,0.0 +413,Australia,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.0 +414,Australia,2014,6,G-Genito urinary system and sex hormones,% of total sales,2.0 +415,Australia,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.7 +416,Australia,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +417,Australia,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +418,Australia,2014,6,J-Antiinfectives for systemic use,Million of national currency units,801.0 +419,Australia,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,240.0 +420,Australia,2014,6,C-Cardiovascular system,Million of national currency units,2200.0 +421,Australia,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,722.0 +422,Australia,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",165.2 +423,Australia,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.2 +424,Australia,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,216.3 +425,Australia,2014,6,A02A-Antacids,Million US$ at exchange rate,0.9 +426,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",115.0 +427,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4 +428,Australia,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,150.5 +429,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,168.0 +430,Australia,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4 +431,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.9 +432,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +433,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.9 +434,Australia,2014,6,A02A-Antacids,Million of national currency units,1.0 +435,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,151.4 +436,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",115.7 +437,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5 +438,Australia,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,167.0 +439,Australia,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.1 +440,Australia,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",707.8 +441,Australia,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",39.5 +442,Australia,2014,6,C10-Lipid modifying agents,% of total sales,8.6 +443,Australia,2014,6,J01-Antibacterials for systemic use,% of total sales,2.7 +444,Australia,2014,6,Products not elsewhere classified,% of total sales,30.4 +445,Australia,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",2489.5 +446,Australia,2014,6,Products not elsewhere classified,Million of national currency units,3616.0 +447,Australia,2014,6,Products not elsewhere classified,Million US$ at exchange rate,3259.5 +448,Australia,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",138.8 +449,Australia,2014,6,C10-Lipid modifying agents,Million of national currency units,1028.0 +450,Australia,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,926.7 +451,Australia,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.0 +452,Australia,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4 +453,Australia,2014,6,C-Cardiovascular system,% of total sales,18.5 +454,Australia,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.8 +455,Australia,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",551.5 +456,Australia,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",1514.6 +457,Australia,2014,6,C-Cardiovascular system,Million US$ at exchange rate,1983.1 +458,Australia,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.5 +459,Australia,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",84.5 +460,Australia,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",220.3 +461,Australia,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,288.5 +462,Australia,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3 +463,Australia,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.5 +464,Australia,2014,6,J-Antiinfectives for systemic use,% of total sales,6.7 +465,Australia,2014,6,J01-Antibacterials for systemic use,Million of national currency units,320.0 +466,Australia,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +467,Australia,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +468,Australia,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.8 +469,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.1 +470,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.1 +471,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +472,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +473,Australia,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.3 +474,Australia,2014,6,C01A-Cardiac glycosides,% of total sales,0.0 +475,Australia,2014,6,C03-Diuretics,Million US$ at exchange rate,34.3 +476,Australia,2014,6,C03-Diuretics,Million of national currency units,38.0 +477,Australia,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.6 +478,Australia,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.2 +479,Australia,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.4 +480,Australia,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.6 +481,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0 +482,Australia,2014,6,C01A-Cardiac glycosides,Million of national currency units,4.0 +483,Australia,2014,6,C02-Antihypertensives,% of total sales,0.7 +484,Australia,2014,6,N-Nervous system,"Million US$, purchasing power parity",1324.6 +485,Australia,2014,6,N-Nervous system,Million US$ at exchange rate,1734.3 +486,Australia,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.9 +487,Australia,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,21.0 +488,Australia,2014,6,N05B-Anxiolytics,% of total sales,0.3 +489,Australia,2014,6,A10-Drugs used in diabetes,% of total sales,5.0 +490,Australia,2014,6,N05B-Anxiolytics,Million of national currency units,33.0 +491,Australia,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +492,Australia,2014,6,N-Nervous system,Million of national currency units,1924.0 +493,Australia,2014,6,N-Nervous system,% of total sales,16.2 +494,Australia,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",56.4 +495,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +496,Australia,2014,6,N-Nervous system,"/capita, US$ exchange rate",73.9 +497,Australia,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +498,Australia,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.5 +499,Australia,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6 +500,Australia,2014,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +501,Australia,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",348.6 +502,Australia,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8184.6 +503,Australia,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",456.5 +504,Australia,2014,6,N06A-Antidepressants,Million of national currency units,464.0 +505,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",84.0 +506,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.7 +507,Australia,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",405.5 +508,Australia,2014,6,N06A-Antidepressants,Million US$ at exchange rate,418.3 +509,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,122.0 +510,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,110.0 +511,Australia,2014,6,Total pharmaceutical sales,Million of national currency units,11888.0 +512,Australia,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",22.7 +513,Australia,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,10716.1 +514,Australia,2014,6,A10-Drugs used in diabetes,Million of national currency units,589.0 +515,Australia,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,29.7 +516,Australia,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",17.8 +517,Australia,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",319.5 +518,Australia,2014,6,N06A-Antidepressants,% of total sales,3.9 +519,Australia,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.6 +520,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.6 +521,Australia,2014,6,C03-Diuretics,% of total sales,0.3 +522,Australia,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +523,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0 +524,Australia,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,530.9 +525,Australia,2014,6,C03-Diuretics,"Million US$, purchasing power parity",26.2 +526,Australia,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.1 +527,Australia,2014,6,C03-Diuretics,"/capita, US$ exchange rate",1.5 +528,Australia,2014,6,C02-Antihypertensives,Million of national currency units,83.0 +529,Australia,2014,6,N02-Analgesics,"Million US$, purchasing power parity",355.3 +530,Australia,2014,6,N02-Analgesics,Million of national currency units,516.0 +531,Australia,2014,6,N02-Analgesics,Million US$ at exchange rate,465.1 +532,Australia,2014,6,N02-Analgesics,"/capita, US$ exchange rate",19.8 +533,Australia,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",57.1 +534,Australia,2014,6,C02-Antihypertensives,Million US$ at exchange rate,74.8 +535,Australia,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.1 +536,Australia,2014,6,N02-Analgesics,% of total sales,4.3 +537,Australia,2013,6,M-Musculo-skeletal system,Million of national currency units,378.0 +538,Australia,2013,6,B-Blood and blood forming organs,Million of national currency units,481.0 +539,Australia,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,364.9 +540,Australia,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,464.4 +541,Australia,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,617.0 +542,Australia,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,595.7 +543,Australia,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",332.4 +544,Australia,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",261.2 +545,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,568.6 +546,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",407.0 +547,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",24.6 +548,Australia,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.8 +549,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,589.0 +550,Australia,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3 +551,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.1 +552,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3 +553,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.9 +554,Australia,2013,6,B-Blood and blood forming organs,% of total sales,4.1 +555,Australia,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.4 +556,Australia,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1 +557,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",511.4 +558,Australia,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.4 +559,Australia,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",426.4 +560,Australia,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.8 +561,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,714.4 +562,Australia,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,5.2 +563,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,740.0 +564,Australia,2013,6,R-Respiratory system,"/capita, US$ exchange rate",26.6 +565,Australia,2013,6,R-Respiratory system,"Million US$, purchasing power parity",440.9 +566,Australia,2013,6,R-Respiratory system,Million US$ at exchange rate,615.9 +567,Australia,2013,6,C08-Calcium channel blockers,Million of national currency units,131.0 +568,Australia,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.1 +569,Australia,2013,6,R-Respiratory system,% of total sales,5.4 +570,Australia,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",104.3 +571,Australia,2013,6,C07-Beta blocking agents,Million of national currency units,151.0 +572,Australia,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,145.8 +573,Australia,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3 +574,Australia,2013,6,C07-Beta blocking agents,% of total sales,1.3 +575,Australia,2013,6,R-Respiratory system,Million of national currency units,638.0 +576,Australia,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5 +577,Australia,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.4 +578,Australia,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8 +579,Australia,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",966.7 +580,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.0 +581,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.6 +582,Australia,2013,6,A-Alimentary tract and metabolism,% of total sales,11.8 +583,Australia,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,126.5 +584,Australia,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1350.6 +585,Australia,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5 +586,Australia,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.9 +587,Australia,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",90.5 +588,Australia,2013,6,A-Alimentary tract and metabolism,Million of national currency units,1399.0 +589,Australia,2013,6,M-Musculo-skeletal system,% of total sales,3.2 +590,Australia,2013,6,C08-Calcium channel blockers,% of total sales,1.1 +591,Australia,2013,6,A02A-Antacids,% of total sales,0.0 +592,Australia,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7 +593,Australia,2013,6,G-Genito urinary system and sex hormones,% of total sales,1.9 +594,Australia,2013,6,A02A-Antacids,"Million US$, purchasing power parity",1.4 +595,Australia,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +596,Australia,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.1 +597,Australia,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,225.0 +598,Australia,2013,6,J-Antiinfectives for systemic use,Million of national currency units,790.0 +599,Australia,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,762.7 +600,Australia,2013,6,C-Cardiovascular system,Million of national currency units,2516.0 +601,Australia,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4 +602,Australia,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",155.5 +603,Australia,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,217.2 +604,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",110.6 +605,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.7 +606,Australia,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,154.5 +607,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,156.0 +608,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.8 +609,Australia,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4 +610,Australia,2013,6,A02A-Antacids,Million US$ at exchange rate,1.9 +611,Australia,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,160.0 +612,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3 +613,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.7 +614,Australia,2013,6,A02A-Antacids,Million of national currency units,2.0 +615,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,150.6 +616,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",107.8 +617,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5 +618,Australia,2013,6,C-Cardiovascular system,Million US$ at exchange rate,2428.9 +619,Australia,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.5 +620,Australia,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",890.0 +621,Australia,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",53.8 +622,Australia,2013,6,C10-Lipid modifying agents,% of total sales,10.9 +623,Australia,2013,6,J01-Antibacterials for systemic use,% of total sales,2.7 +624,Australia,2013,6,Products not elsewhere classified,% of total sales,27.4 +625,Australia,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",2238.2 +626,Australia,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",135.2 +627,Australia,2013,6,Products not elsewhere classified,Million of national currency units,3239.0 +628,Australia,2013,6,Products not elsewhere classified,Million US$ at exchange rate,3126.9 +629,Australia,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,1243.4 +630,Australia,2013,6,C10-Lipid modifying agents,Million of national currency units,1288.0 +631,Australia,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",96.8 +632,Australia,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.6 +633,Australia,2013,6,C-Cardiovascular system,% of total sales,21.3 +634,Australia,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.0 +635,Australia,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",545.9 +636,Australia,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",1738.6 +637,Australia,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.2 +638,Australia,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",105.0 +639,Australia,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",221.1 +640,Australia,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,308.9 +641,Australia,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.4 +642,Australia,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.6 +643,Australia,2013,6,J-Antiinfectives for systemic use,% of total sales,6.7 +644,Australia,2013,6,J01-Antibacterials for systemic use,Million of national currency units,320.0 +645,Australia,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +646,Australia,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +647,Australia,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.8 +648,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.4 +649,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.4 +650,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +651,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5 +652,Australia,2013,6,C01A-Cardiac glycosides,% of total sales,0.0 +653,Australia,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.7 +654,Australia,2013,6,C03-Diuretics,Million US$ at exchange rate,35.7 +655,Australia,2013,6,C03-Diuretics,Million of national currency units,37.0 +656,Australia,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6 +657,Australia,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",24.8 +658,Australia,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.7 +659,Australia,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.9 +660,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0 +661,Australia,2013,6,C02-Antihypertensives,% of total sales,0.7 +662,Australia,2013,6,C01A-Cardiac glycosides,Million of national currency units,4.0 +663,Australia,2013,6,N-Nervous system,"Million US$, purchasing power parity",1380.7 +664,Australia,2013,6,N-Nervous system,Million US$ at exchange rate,1928.9 +665,Australia,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.3 +666,Australia,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,21.0 +667,Australia,2013,6,N-Nervous system,Million of national currency units,1998.0 +668,Australia,2013,6,N05B-Anxiolytics,% of total sales,0.3 +669,Australia,2013,6,A10-Drugs used in diabetes,% of total sales,5.0 +670,Australia,2013,6,N05B-Anxiolytics,Million of national currency units,34.0 +671,Australia,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +672,Australia,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.5 +673,Australia,2013,6,N-Nervous system,% of total sales,16.9 +674,Australia,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",59.7 +675,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +676,Australia,2013,6,N-Nervous system,"/capita, US$ exchange rate",83.4 +677,Australia,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +678,Australia,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6 +679,Australia,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +680,Australia,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",410.5 +681,Australia,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",353.2 +682,Australia,2013,6,N06A-Antidepressants,Million US$ at exchange rate,505.9 +683,Australia,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8167.9 +684,Australia,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",493.4 +685,Australia,2013,6,N06A-Antidepressants,Million of national currency units,524.0 +686,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",88.5 +687,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3 +688,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,128.0 +689,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,123.6 +690,Australia,2013,6,Total pharmaceutical sales,Million of national currency units,11820.0 +691,Australia,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,11411.0 +692,Australia,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",23.5 +693,Australia,2013,6,A10-Drugs used in diabetes,Million of national currency units,594.0 +694,Australia,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,32.8 +695,Australia,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.9 +696,Australia,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",362.1 +697,Australia,2013,6,N06A-Antidepressants,% of total sales,4.4 +698,Australia,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.7 +699,Australia,2013,6,C03-Diuretics,% of total sales,0.3 +700,Australia,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +701,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.8 +702,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1 +703,Australia,2013,6,C02-Antihypertensives,Million of national currency units,88.0 +704,Australia,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,573.4 +705,Australia,2013,6,C03-Diuretics,"Million US$, purchasing power parity",25.6 +706,Australia,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.1 +707,Australia,2013,6,C03-Diuretics,"/capita, US$ exchange rate",1.5 +708,Australia,2013,6,N02-Analgesics,"Million US$, purchasing power parity",347.6 +709,Australia,2013,6,N02-Analgesics,"/capita, US$ exchange rate",21.0 +710,Australia,2013,6,N02-Analgesics,Million of national currency units,503.0 +711,Australia,2013,6,N02-Analgesics,Million US$ at exchange rate,485.6 +712,Australia,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",60.8 +713,Australia,2013,6,C02-Antihypertensives,Million US$ at exchange rate,85.0 +714,Australia,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.0 +715,Australia,2013,6,N02-Analgesics,% of total sales,4.3 +716,Australia,2012,6,M-Musculo-skeletal system,Million of national currency units,312.0 +717,Australia,2012,6,B-Blood and blood forming organs,Million of national currency units,405.0 +718,Australia,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,323.0 +719,Australia,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,419.3 +720,Australia,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,586.0 +721,Australia,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,606.8 +722,Australia,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",263.0 +723,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",325.9 +724,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,519.8 +725,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.9 +726,Australia,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.2 +727,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,502.0 +728,Australia,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9 +729,Australia,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",202.6 +730,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.1 +731,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4 +732,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.6 +733,Australia,2012,6,B-Blood and blood forming organs,% of total sales,3.9 +734,Australia,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.4 +735,Australia,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",11.6 +736,Australia,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.7 +737,Australia,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.7 +738,Australia,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",380.5 +739,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,581.9 +740,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",364.9 +741,Australia,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,5.7 +742,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,562.0 +743,Australia,2012,6,R-Respiratory system,"/capita, US$ exchange rate",27.2 +744,Australia,2012,6,R-Respiratory system,Million US$ at exchange rate,619.2 +745,Australia,2012,6,R-Respiratory system,"Million US$, purchasing power parity",388.3 +746,Australia,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",17.1 +747,Australia,2012,6,C08-Calcium channel blockers,Million of national currency units,118.0 +748,Australia,2012,6,R-Respiratory system,% of total sales,5.8 +749,Australia,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",89.0 +750,Australia,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.2 +751,Australia,2012,6,C07-Beta blocking agents,Million of national currency units,137.0 +752,Australia,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,141.9 +753,Australia,2012,6,C07-Beta blocking agents,% of total sales,1.3 +754,Australia,2012,6,R-Respiratory system,Million of national currency units,598.0 +755,Australia,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.9 +756,Australia,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,122.2 +757,Australia,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.3 +758,Australia,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.7 +759,Australia,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",788.3 +760,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.8 +761,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.3 +762,Australia,2012,6,A-Alimentary tract and metabolism,% of total sales,11.7 +763,Australia,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4 +764,Australia,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4 +765,Australia,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",76.6 +766,Australia,2012,6,A-Alimentary tract and metabolism,Million of national currency units,1214.0 +767,Australia,2012,6,M-Musculo-skeletal system,% of total sales,3.0 +768,Australia,2012,6,C08-Calcium channel blockers,% of total sales,1.1 +769,Australia,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1257.0 +770,Australia,2012,6,Products not elsewhere classified,Million of national currency units,2822.0 +771,Australia,2012,6,A02A-Antacids,% of total sales,0.0 +772,Australia,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.4 +773,Australia,2012,6,G-Genito urinary system and sex hormones,% of total sales,1.5 +774,Australia,2012,6,A02A-Antacids,"Million US$, purchasing power parity",1.3 +775,Australia,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +776,Australia,2012,6,A02A-Antacids,"/capita, US$ exchange rate",0.1 +777,Australia,2012,6,J-Antiinfectives for systemic use,Million of national currency units,446.0 +778,Australia,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,155.0 +779,Australia,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,461.8 +780,Australia,2012,6,C-Cardiovascular system,Million of national currency units,2538.0 +781,Australia,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.1 +782,Australia,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",100.6 +783,Australia,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,160.5 +784,Australia,2012,6,A02A-Antacids,Million US$ at exchange rate,2.1 +785,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.9 +786,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7 +787,Australia,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,106.6 +788,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,98.0 +789,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.9 +790,Australia,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +791,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9 +792,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.8 +793,Australia,2012,6,A02A-Antacids,Million of national currency units,2.0 +794,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,101.5 +795,Australia,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,103.0 +796,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.6 +797,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.5 +798,Australia,2012,6,C-Cardiovascular system,Million US$ at exchange rate,2627.9 +799,Australia,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",43.9 +800,Australia,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",998.6 +801,Australia,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",70.0 +802,Australia,2012,6,C10-Lipid modifying agents,% of total sales,14.9 +803,Australia,2012,6,J01-Antibacterials for systemic use,% of total sales,1.8 +804,Australia,2012,6,Products not elsewhere classified,% of total sales,27.3 +805,Australia,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",1832.3 +806,Australia,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",128.5 +807,Australia,2012,6,Products not elsewhere classified,Million US$ at exchange rate,2921.9 +808,Australia,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,1592.5 +809,Australia,2012,6,C10-Lipid modifying agents,Million of national currency units,1538.0 +810,Australia,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",80.6 +811,Australia,2012,6,C-Cardiovascular system,% of total sales,24.5 +812,Australia,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.3 +813,Australia,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",289.6 +814,Australia,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",1647.9 +815,Australia,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.5 +816,Australia,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.6 +817,Australia,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",119.5 +818,Australia,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,190.5 +819,Australia,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.3 +820,Australia,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.4 +821,Australia,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",12.7 +822,Australia,2012,6,J-Antiinfectives for systemic use,% of total sales,4.3 +823,Australia,2012,6,J01-Antibacterials for systemic use,Million of national currency units,184.0 +824,Australia,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +825,Australia,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +826,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.6 +827,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.0 +828,Australia,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.6 +829,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +830,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5 +831,Australia,2012,6,C01A-Cardiac glycosides,% of total sales,0.0 +832,Australia,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.8 +833,Australia,2012,6,C03-Diuretics,Million US$ at exchange rate,31.1 +834,Australia,2012,6,C03-Diuretics,Million of national currency units,30.0 +835,Australia,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.2 +836,Australia,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.6 +837,Australia,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.6 +838,Australia,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1 +839,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0 +840,Australia,2012,6,C01A-Cardiac glycosides,Million of national currency units,4.0 +841,Australia,2012,6,C02-Antihypertensives,% of total sales,0.8 +842,Australia,2012,6,N-Nervous system,"Million US$, purchasing power parity",1148.0 +843,Australia,2012,6,N-Nervous system,Million US$ at exchange rate,1830.6 +844,Australia,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.6 +845,Australia,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,17.0 +846,Australia,2012,6,N05B-Anxiolytics,% of total sales,0.3 +847,Australia,2012,6,A10-Drugs used in diabetes,% of total sales,5.0 +848,Australia,2012,6,N-Nervous system,Million of national currency units,1768.0 +849,Australia,2012,6,N05B-Anxiolytics,Million of national currency units,27.0 +850,Australia,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.0 +851,Australia,2012,6,N-Nervous system,% of total sales,17.1 +852,Australia,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",50.5 +853,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +854,Australia,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.8 +855,Australia,2012,6,N-Nervous system,"/capita, US$ exchange rate",80.5 +856,Australia,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5 +857,Australia,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +858,Australia,2012,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +859,Australia,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",295.8 +860,Australia,2012,6,N06A-Antidepressants,Million US$ at exchange rate,461.8 +861,Australia,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",6723.5 +862,Australia,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",471.6 +863,Australia,2012,6,N06A-Antidepressants,Million of national currency units,446.0 +864,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",55.2 +865,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.9 +866,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,85.0 +867,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,88.0 +868,Australia,2012,6,Total pharmaceutical sales,Million of national currency units,10355.0 +869,Australia,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,10721.7 +870,Australia,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",17.5 +871,Australia,2012,6,A10-Drugs used in diabetes,Million of national currency units,519.0 +872,Australia,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,28.0 +873,Australia,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.3 +874,Australia,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",289.6 +875,Australia,2012,6,N06A-Antidepressants,% of total sales,4.3 +876,Australia,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7 +877,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.4 +878,Australia,2012,6,C03-Diuretics,% of total sales,0.3 +879,Australia,2012,6,C02-Antihypertensives,Million of national currency units,78.0 +880,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +881,Australia,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +882,Australia,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,537.4 +883,Australia,2012,6,C03-Diuretics,"Million US$, purchasing power parity",19.5 +884,Australia,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",337.0 +885,Australia,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",0.9 +886,Australia,2012,6,C03-Diuretics,"/capita, US$ exchange rate",1.4 +887,Australia,2012,6,N02-Analgesics,"Million US$, purchasing power parity",281.1 +888,Australia,2012,6,N02-Analgesics,"/capita, US$ exchange rate",19.7 +889,Australia,2012,6,N02-Analgesics,Million of national currency units,433.0 +890,Australia,2012,6,N02-Analgesics,Million US$ at exchange rate,448.3 +891,Australia,2012,6,C02-Antihypertensives,Million US$ at exchange rate,80.8 +892,Australia,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",50.6 +893,Australia,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",12.4 +894,Australia,2012,6,N02-Analgesics,% of total sales,4.2 +895,Australia,2011,6,M-Musculo-skeletal system,Million of national currency units,309.0 +896,Australia,2011,6,B-Blood and blood forming organs,Million of national currency units,417.0 +897,Australia,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,318.7 +898,Australia,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,430.1 +899,Australia,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,562.0 +900,Australia,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,579.7 +901,Australia,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",276.0 +902,Australia,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",204.5 +903,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",375.2 +904,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,584.9 +905,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",26.2 +906,Australia,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.3 +907,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,567.0 +908,Australia,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.2 +909,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9 +910,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.0 +911,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.1 +912,Australia,2011,6,B-Blood and blood forming organs,% of total sales,4.1 +913,Australia,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.3 +914,Australia,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.4 +915,Australia,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.6 +916,Australia,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",371.9 +917,Australia,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.9 +918,Australia,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,5.5 +919,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,628.2 +920,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",403.0 +921,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,609.0 +922,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.8 +923,Australia,2011,6,R-Respiratory system,"/capita, US$ exchange rate",26.4 +924,Australia,2011,6,R-Respiratory system,Million US$ at exchange rate,590.0 +925,Australia,2011,6,R-Respiratory system,"Million US$, purchasing power parity",378.5 +926,Australia,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",16.9 +927,Australia,2011,6,C08-Calcium channel blockers,Million of national currency units,142.0 +928,Australia,2011,6,R-Respiratory system,% of total sales,5.6 +929,Australia,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,146.5 +930,Australia,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",93.3 +931,Australia,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5 +932,Australia,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,145.4 +933,Australia,2011,6,R-Respiratory system,Million of national currency units,572.0 +934,Australia,2011,6,C07-Beta blocking agents,% of total sales,1.4 +935,Australia,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2 +936,Australia,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2 +937,Australia,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",36.1 +938,Australia,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",806.1 +939,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.5 +940,Australia,2011,6,A-Alimentary tract and metabolism,% of total sales,11.9 +941,Australia,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1256.4 +942,Australia,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.6 +943,Australia,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2 +944,Australia,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",94.0 +945,Australia,2011,6,M-Musculo-skeletal system,% of total sales,3.0 +946,Australia,2011,6,A-Alimentary tract and metabolism,Million of national currency units,1218.0 +947,Australia,2011,6,C08-Calcium channel blockers,% of total sales,1.4 +948,Australia,2011,6,Products not elsewhere classified,Million of national currency units,2515.0 +949,Australia,2011,6,A02A-Antacids,% of total sales,0.0 +950,Australia,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.2 +951,Australia,2011,6,G-Genito urinary system and sex hormones,% of total sales,1.4 +952,Australia,2011,6,A02A-Antacids,"Million US$, purchasing power parity",1.3 +953,Australia,2011,6,A02A-Antacids,"/capita, US$ exchange rate",0.1 +954,Australia,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +955,Australia,2011,6,J-Antiinfectives for systemic use,Million of national currency units,386.0 +956,Australia,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,143.0 +957,Australia,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,398.2 +958,Australia,2011,6,C-Cardiovascular system,Million of national currency units,2825.0 +959,Australia,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.6 +960,Australia,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",94.6 +961,Australia,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,147.5 +962,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.6 +963,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.2 +964,Australia,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,103.1 +965,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,86.0 +966,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0 +967,Australia,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +968,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8 +969,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.5 +970,Australia,2011,6,A02A-Antacids,Million US$ at exchange rate,2.1 +971,Australia,2011,6,A02A-Antacids,Million of national currency units,2.0 +972,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.9 +973,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.7 +974,Australia,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,100.0 +975,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.0 +976,Australia,2011,6,C-Cardiovascular system,Million US$ at exchange rate,2914.0 +977,Australia,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.0 +978,Australia,2011,6,C10-Lipid modifying agents,% of total sales,17.1 +979,Australia,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",1162.1 +980,Australia,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",81.1 +981,Australia,2011,6,J01-Antibacterials for systemic use,% of total sales,1.9 +982,Australia,2011,6,Products not elsewhere classified,% of total sales,24.5 +983,Australia,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",1664.4 +984,Australia,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",116.1 +985,Australia,2011,6,Products not elsewhere classified,Million US$ at exchange rate,2594.2 +986,Australia,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,1811.3 +987,Australia,2011,6,C10-Lipid modifying agents,Million of national currency units,1756.0 +988,Australia,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",74.5 +989,Australia,2011,6,C-Cardiovascular system,% of total sales,27.5 +990,Australia,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.8 +991,Australia,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",255.5 +992,Australia,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",1869.6 +993,Australia,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",83.7 +994,Australia,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",130.4 +995,Australia,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",131.0 +996,Australia,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.9 +997,Australia,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.1 +998,Australia,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,204.2 +999,Australia,2011,6,C07-Beta blocking agents,Million of national currency units,141.0 +1000,Australia,2011,6,J-Antiinfectives for systemic use,% of total sales,3.8 +1001,Australia,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.4 +1002,Australia,2011,6,J01-Antibacterials for systemic use,Million of national currency units,198.0 +1003,Australia,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +1004,Australia,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +1005,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.5 +1006,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3 +1007,Australia,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.6 +1008,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +1009,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5 +1010,Australia,2011,6,C01A-Cardiac glycosides,% of total sales,0.0 +1011,Australia,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.9 +1012,Australia,2011,6,C03-Diuretics,Million US$ at exchange rate,30.9 +1013,Australia,2011,6,C03-Diuretics,Million of national currency units,30.0 +1014,Australia,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1 +1015,Australia,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.7 +1016,Australia,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.3 +1017,Australia,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1 +1018,Australia,2011,6,C02-Antihypertensives,% of total sales,0.7 +1019,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0 +1020,Australia,2011,6,C01A-Cardiac glycosides,Million of national currency units,4.0 +1021,Australia,2011,6,N-Nervous system,"Million US$, purchasing power parity",1184.6 +1022,Australia,2011,6,N-Nervous system,Million US$ at exchange rate,1846.4 +1023,Australia,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.6 +1024,Australia,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,18.0 +1025,Australia,2011,6,N05B-Anxiolytics,% of total sales,0.3 +1026,Australia,2011,6,A10-Drugs used in diabetes,% of total sales,4.6 +1027,Australia,2011,6,N-Nervous system,Million of national currency units,1790.0 +1028,Australia,2011,6,N05B-Anxiolytics,Million of national currency units,28.0 +1029,Australia,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.9 +1030,Australia,2011,6,N-Nervous system,% of total sales,17.4 +1031,Australia,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",53.0 +1032,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +1033,Australia,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5 +1034,Australia,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +1035,Australia,2011,6,N-Nervous system,"/capita, US$ exchange rate",82.6 +1036,Australia,2011,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +1037,Australia,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",304.0 +1038,Australia,2011,6,N02-Analgesics,Million of national currency units,408.0 +1039,Australia,2011,6,N06A-Antidepressants,Million US$ at exchange rate,503.4 +1040,Australia,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",6790.6 +1041,Australia,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",473.8 +1042,Australia,2011,6,N06A-Antidepressants,Million of national currency units,488.0 +1043,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.3 +1044,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",61.5 +1045,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,93.0 +1046,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,95.9 +1047,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.8 +1048,Australia,2011,6,Total pharmaceutical sales,Million of national currency units,10261.0 +1049,Australia,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,10584.2 +1050,Australia,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",18.5 +1051,Australia,2011,6,A10-Drugs used in diabetes,Million of national currency units,470.0 +1052,Australia,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,28.9 +1053,Australia,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",22.5 +1054,Australia,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",323.0 +1055,Australia,2011,6,N06A-Antidepressants,% of total sales,4.8 +1056,Australia,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.5 +1057,Australia,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.8 +1058,Australia,2011,6,C03-Diuretics,% of total sales,0.3 +1059,Australia,2011,6,C02-Antihypertensives,Million of national currency units,72.0 +1060,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9 +1061,Australia,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +1062,Australia,2011,6,C03-Diuretics,"Million US$, purchasing power parity",19.9 +1063,Australia,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,484.8 +1064,Australia,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",311.0 +1065,Australia,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",0.9 +1066,Australia,2011,6,C03-Diuretics,"/capita, US$ exchange rate",1.4 +1067,Australia,2011,6,N02-Analgesics,"Million US$, purchasing power parity",270.0 +1068,Australia,2011,6,N02-Analgesics,"/capita, US$ exchange rate",18.8 +1069,Australia,2011,6,N02-Analgesics,Million US$ at exchange rate,420.9 +1070,Australia,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",47.6 +1071,Australia,2011,6,C02-Antihypertensives,Million US$ at exchange rate,74.3 +1072,Australia,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",12.1 +1073,Australia,2011,6,N02-Analgesics,% of total sales,4.0 +1074,Australia,2010,5,Total pharmaceutical sales,Million of national currency units,9795.0 +1075,Australia,2010,5,M-Musculo-skeletal system,Million of national currency units,324.0 +1076,Australia,2010,5,B-Blood and blood forming organs,Million of national currency units,406.0 +1077,Australia,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,372.4 +1078,Australia,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,297.2 +1079,Australia,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,497.2 +1080,Australia,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,542.0 +1081,Australia,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",270.0 +1082,Australia,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",215.5 +1083,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",417.7 +1084,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,576.1 +1085,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",26.1 +1086,Australia,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.5 +1087,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,628.0 +1088,Australia,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.8 +1089,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0 +1090,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",24.6 +1091,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.9 +1092,Australia,2010,5,B-Blood and blood forming organs,% of total sales,4.1 +1093,Australia,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.9 +1094,Australia,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.3 +1095,Australia,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.4 +1096,Australia,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",360.5 +1097,Australia,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.6 +1098,Australia,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,5.5 +1099,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,543.0 +1100,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",393.7 +1101,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,592.0 +1102,Australia,2010,5,R-Respiratory system,"/capita, US$ exchange rate",22.9 +1103,Australia,2010,5,R-Respiratory system,Million US$ at exchange rate,505.4 +1104,Australia,2010,5,R-Respiratory system,"Million US$, purchasing power parity",366.4 +1105,Australia,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",16.6 +1106,Australia,2010,5,C08-Calcium channel blockers,Million of national currency units,159.0 +1107,Australia,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,145.9 +1108,Australia,2010,5,R-Respiratory system,% of total sales,5.6 +1109,Australia,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",94.4 +1110,Australia,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.9 +1111,Australia,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,130.3 +1112,Australia,2010,5,R-Respiratory system,Million of national currency units,551.0 +1113,Australia,2010,5,C07-Beta blocking agents,% of total sales,1.4 +1114,Australia,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.3 +1115,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.0 +1116,Australia,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.1 +1117,Australia,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.0 +1118,Australia,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",816.0 +1119,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,6.4 +1120,Australia,2010,5,A-Alimentary tract and metabolism,% of total sales,12.5 +1121,Australia,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.6 +1122,Australia,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8 +1123,Australia,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",105.7 +1124,Australia,2010,5,M-Musculo-skeletal system,% of total sales,3.3 +1125,Australia,2010,5,A-Alimentary tract and metabolism,Million of national currency units,1227.0 +1126,Australia,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,1125.5 +1127,Australia,2010,5,C08-Calcium channel blockers,% of total sales,1.6 +1128,Australia,2010,5,Products not elsewhere classified,Million of national currency units,2266.0 +1129,Australia,2010,5,A02A-Antacids,% of total sales,0.0 +1130,Australia,2010,5,G-Genito urinary system and sex hormones,% of total sales,1.4 +1131,Australia,2010,5,A02A-Antacids,"Million US$, purchasing power parity",1.3 +1132,Australia,2010,5,A02A-Antacids,"/capita, US$ exchange rate",0.1 +1133,Australia,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +1134,Australia,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.2 +1135,Australia,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,324.7 +1136,Australia,2010,5,J-Antiinfectives for systemic use,Million of national currency units,354.0 +1137,Australia,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,138.0 +1138,Australia,2010,5,C-Cardiovascular system,Million of national currency units,2744.0 +1139,Australia,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.7 +1140,Australia,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,126.6 +1141,Australia,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",91.8 +1142,Australia,2010,5,C-Cardiovascular system,Million US$ at exchange rate,2517.1 +1143,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.2 +1144,Australia,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,91.7 +1145,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.5 +1146,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,79.0 +1147,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0 +1148,Australia,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +1149,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8 +1150,Australia,2010,5,A02A-Antacids,Million US$ at exchange rate,1.8 +1151,Australia,2010,5,A02A-Antacids,Million of national currency units,2.0 +1152,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.4 +1153,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.5 +1154,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.5 +1155,Australia,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,100.0 +1156,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3 +1157,Australia,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.7 +1158,Australia,2010,5,C10-Lipid modifying agents,% of total sales,17.2 +1159,Australia,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",69.9 +1160,Australia,2010,5,J01-Antibacterials for systemic use,% of total sales,2.0 +1161,Australia,2010,5,Products not elsewhere classified,% of total sales,23.1 +1162,Australia,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",1117.3 +1163,Australia,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",1507.0 +1164,Australia,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",94.3 +1165,Australia,2010,5,Products not elsewhere classified,Million US$ at exchange rate,2078.6 +1166,Australia,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,1541.1 +1167,Australia,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",68.4 +1168,Australia,2010,5,C10-Lipid modifying agents,Million of national currency units,1680.0 +1169,Australia,2010,5,C-Cardiovascular system,% of total sales,28.0 +1170,Australia,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",235.4 +1171,Australia,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.7 +1172,Australia,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",1824.9 +1173,Australia,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8 +1174,Australia,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",114.2 +1175,Australia,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",129.0 +1176,Australia,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.9 +1177,Australia,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1 +1178,Australia,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,178.0 +1179,Australia,2010,5,J-Antiinfectives for systemic use,% of total sales,3.6 +1180,Australia,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.7 +1181,Australia,2010,5,J01-Antibacterials for systemic use,Million of national currency units,194.0 +1182,Australia,2010,5,C07-Beta blocking agents,Million of national currency units,142.0 +1183,Australia,2010,5,C01A-Cardiac glycosides,Million of national currency units,4.0 +1184,Australia,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +1185,Australia,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +1186,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3 +1187,Australia,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.7 +1188,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,15.6 +1189,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +1190,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5 +1191,Australia,2010,5,C01A-Cardiac glycosides,% of total sales,0.0 +1192,Australia,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.8 +1193,Australia,2010,5,C03-Diuretics,Million US$ at exchange rate,28.4 +1194,Australia,2010,5,C03-Diuretics,Million of national currency units,31.0 +1195,Australia,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9 +1196,Australia,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.7 +1197,Australia,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +1198,Australia,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,3.7 +1199,Australia,2010,5,C02-Antihypertensives,% of total sales,0.7 +1200,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0 +1201,Australia,2010,5,A10-Drugs used in diabetes,Million of national currency units,424.0 +1202,Australia,2010,5,N-Nervous system,"Million US$, purchasing power parity",1135.3 +1203,Australia,2010,5,N-Nervous system,Million US$ at exchange rate,1565.8 +1204,Australia,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,19.0 +1205,Australia,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.4 +1206,Australia,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",12.6 +1207,Australia,2010,5,A10-Drugs used in diabetes,% of total sales,4.3 +1208,Australia,2010,5,N05B-Anxiolytics,% of total sales,0.3 +1209,Australia,2010,5,N-Nervous system,Million of national currency units,1707.0 +1210,Australia,2010,5,N05B-Anxiolytics,Million of national currency units,29.0 +1211,Australia,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,26.6 +1212,Australia,2010,5,N-Nervous system,% of total sales,17.4 +1213,Australia,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",51.5 +1214,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +1215,Australia,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6 +1216,Australia,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +1217,Australia,2010,5,N-Nervous system,"/capita, US$ exchange rate",71.1 +1218,Australia,2010,5,N05C-Hypnotics and sedatives,% of total sales,0.2 +1219,Australia,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",295.7 +1220,Australia,2010,5,N02-Analgesics,Million of national currency units,378.0 +1221,Australia,2010,5,N06A-Antidepressants,Million US$ at exchange rate,429.3 +1222,Australia,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",6514.3 +1223,Australia,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",407.8 +1224,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.2 +1225,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.1 +1226,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",67.8 +1227,Australia,2010,5,N06A-Antidepressants,Million of national currency units,468.0 +1228,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,102.0 +1229,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,93.6 +1230,Australia,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,8984.9 +1231,Australia,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",19.3 +1232,Australia,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",19.5 +1233,Australia,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",311.2 +1234,Australia,2010,5,N06A-Antidepressants,% of total sales,4.8 +1235,Australia,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.1 +1236,Australia,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9 +1237,Australia,2010,5,C03-Diuretics,% of total sales,0.3 +1238,Australia,2010,5,C02-Antihypertensives,Million of national currency units,64.0 +1239,Australia,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +1240,Australia,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,388.9 +1241,Australia,2010,5,C03-Diuretics,"Million US$, purchasing power parity",20.6 +1242,Australia,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",282.0 +1243,Australia,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",0.9 +1244,Australia,2010,5,C03-Diuretics,"/capita, US$ exchange rate",1.3 +1245,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0 +1246,Australia,2010,5,N02-Analgesics,"Million US$, purchasing power parity",251.4 +1247,Australia,2010,5,N02-Analgesics,"/capita, US$ exchange rate",15.7 +1248,Australia,2010,5,N02-Analgesics,Million US$ at exchange rate,346.7 +1249,Australia,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",42.6 +1250,Australia,2010,5,C02-Antihypertensives,Million US$ at exchange rate,58.7 +1251,Australia,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",11.4 +1252,Australia,2010,5,N02-Analgesics,% of total sales,3.9 +1253,Australia,2017,6,B-Blood and blood forming organs,Million of national currency units,748.0 +1254,Australia,2017,6,M-Musculo-skeletal system,Million of national currency units,429.0 +1255,Australia,2017,6,M-Musculo-skeletal system,Million US$ at exchange rate,328.8 +1256,Australia,2017,6,R03-Drugs for obstructive airway diseases,Million of national currency units,650.0 +1257,Australia,2017,6,B-Blood and blood forming organs,Million US$ at exchange rate,573.3 +1258,Australia,2017,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",506.2 +1259,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,346.4 +1260,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.1 +1261,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",305.9 +1262,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,452.0 +1263,Australia,2017,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.4 +1264,Australia,2017,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",290.3 +1265,Australia,2017,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.8 +1266,Australia,2017,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,498.2 +1267,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.5 +1268,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.0 +1269,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",404.7 +1270,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.6 +1271,Australia,2017,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.6 +1272,Australia,2017,6,B-Blood and blood forming organs,% of total sales,5.1 +1273,Australia,2017,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",23.3 +1274,Australia,2017,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.3 +1275,Australia,2017,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.9 +1276,Australia,2017,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",439.9 +1277,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,458.3 +1278,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,598.0 +1279,Australia,2017,6,R03-Drugs for obstructive airway diseases,% of total sales,4.4 +1280,Australia,2017,6,R-Respiratory system,"Million US$, purchasing power parity",493.4 +1281,Australia,2017,6,R-Respiratory system,"/capita, US$ exchange rate",22.7 +1282,Australia,2017,6,R-Respiratory system,Million US$ at exchange rate,558.7 +1283,Australia,2017,6,C08-Calcium channel blockers,Million of national currency units,130.0 +1284,Australia,2017,6,R-Respiratory system,"/capita, US$ purchasing power parity",20.1 +1285,Australia,2017,6,R-Respiratory system,% of total sales,4.9 +1286,Australia,2017,6,R-Respiratory system,Million of national currency units,729.0 +1287,Australia,2017,6,C07-Beta blocking agents,"Million US$, purchasing power parity",103.5 +1288,Australia,2017,6,C07-Beta blocking agents,Million of national currency units,153.0 +1289,Australia,2017,6,C07-Beta blocking agents,Million US$ at exchange rate,117.3 +1290,Australia,2017,6,C07-Beta blocking agents,% of total sales,1.0 +1291,Australia,2017,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8 +1292,Australia,2017,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2 +1293,Australia,2017,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",44.4 +1294,Australia,2017,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1091.4 +1295,Australia,2017,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",963.8 +1296,Australia,2017,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.2 +1297,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.4 +1298,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1 +1299,Australia,2017,6,A-Alimentary tract and metabolism,% of total sales,9.6 +1300,Australia,2017,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +1301,Australia,2017,6,C08-Calcium channel blockers,Million US$ at exchange rate,99.6 +1302,Australia,2017,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",88.0 +1303,Australia,2017,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6 +1304,Australia,2017,6,A-Alimentary tract and metabolism,Million of national currency units,1424.0 +1305,Australia,2017,6,C08-Calcium channel blockers,% of total sales,0.9 +1306,Australia,2017,6,M-Musculo-skeletal system,% of total sales,2.9 +1307,Australia,2017,6,A02A-Antacids,% of total sales,0.0 +1308,Australia,2017,6,G-Genito urinary system and sex hormones,% of total sales,2.5 +1309,Australia,2017,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.0 +1310,Australia,2017,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +1311,Australia,2017,6,A02A-Antacids,"Million US$, purchasing power parity",0.0 +1312,Australia,2017,6,A02A-Antacids,Million US$ at exchange rate,0.0 +1313,Australia,2017,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +1314,Australia,2017,6,J-Antiinfectives for systemic use,Million of national currency units,2540.0 +1315,Australia,2017,6,C-Cardiovascular system,Million of national currency units,1798.0 +1316,Australia,2017,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,1946.7 +1317,Australia,2017,6,G-Genito urinary system and sex hormones,Million of national currency units,362.0 +1318,Australia,2017,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",245.0 +1319,Australia,2017,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3 +1320,Australia,2017,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,277.4 +1321,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",183.4 +1322,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.4 +1323,Australia,2017,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,271.0 +1324,Australia,2017,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,207.7 +1325,Australia,2017,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +1326,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,237.0 +1327,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.5 +1328,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.5 +1329,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6 +1330,Australia,2017,6,A02A-Antacids,Million of national currency units,0.0 +1331,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,181.6 +1332,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.4 +1333,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.4 +1334,Australia,2017,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.5 +1335,Australia,2017,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.0 +1336,Australia,2017,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",456.2 +1337,Australia,2017,6,J01-Antibacterials for systemic use,% of total sales,2.7 +1338,Australia,2017,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9 +1339,Australia,2017,6,C10-Lipid modifying agents,% of total sales,4.6 +1340,Australia,2017,6,Products not elsewhere classified,% of total sales,31.0 +1341,Australia,2017,6,Products not elsewhere classified,"Million US$, purchasing power parity",3104.5 +1342,Australia,2017,6,Products not elsewhere classified,Million US$ at exchange rate,3515.6 +1343,Australia,2017,6,Products not elsewhere classified,Million of national currency units,4587.0 +1344,Australia,2017,6,C10-Lipid modifying agents,Million of national currency units,674.0 +1345,Australia,2017,6,C10-Lipid modifying agents,Million US$ at exchange rate,516.6 +1346,Australia,2017,6,Products not elsewhere classified,"/capita, US$ exchange rate",142.9 +1347,Australia,2017,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.2 +1348,Australia,2017,6,C-Cardiovascular system,% of total sales,12.2 +1349,Australia,2017,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1719.1 +1350,Australia,2017,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",49.5 +1351,Australia,2017,6,C-Cardiovascular system,"Million US$, purchasing power parity",1216.9 +1352,Australia,2017,6,C-Cardiovascular system,Million US$ at exchange rate,1378.0 +1353,Australia,2017,6,C-Cardiovascular system,"/capita, US$ exchange rate",56.0 +1354,Australia,2017,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",79.2 +1355,Australia,2017,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,302.7 +1356,Australia,2017,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",267.3 +1357,Australia,2017,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3 +1358,Australia,2017,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",69.9 +1359,Australia,2017,6,J01-Antibacterials for systemic use,Million of national currency units,395.0 +1360,Australia,2017,6,J-Antiinfectives for systemic use,% of total sales,17.2 +1361,Australia,2017,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4 +1362,Australia,2017,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +1363,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,15.3 +1364,Australia,2017,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.8 +1365,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +1366,Australia,2017,6,C01A-Cardiac glycosides,% of total sales,0.0 +1367,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.5 +1368,Australia,2017,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +1369,Australia,2017,6,C03-Diuretics,Million of national currency units,48.0 +1370,Australia,2017,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",485.9 +1371,Australia,2017,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.3 +1372,Australia,2017,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9 +1373,Australia,2017,6,C01A-Cardiac glycosides,Million of national currency units,5.0 +1374,Australia,2017,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.8 +1375,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,20.0 +1376,Australia,2017,6,C02-Antihypertensives,% of total sales,0.7 +1377,Australia,2017,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.4 +1378,Australia,2017,6,N-Nervous system,Million US$ at exchange rate,1471.5 +1379,Australia,2017,6,N-Nervous system,Million of national currency units,1920.0 +1380,Australia,2017,6,N-Nervous system,"Million US$, purchasing power parity",1299.4 +1381,Australia,2017,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,21.5 +1382,Australia,2017,6,N05C-Hypnotics and sedatives,Million of national currency units,28.0 +1383,Australia,2017,6,N05B-Anxiolytics,% of total sales,0.3 +1384,Australia,2017,6,A10-Drugs used in diabetes,% of total sales,4.9 +1385,Australia,2017,6,N05B-Anxiolytics,Million of national currency units,48.0 +1386,Australia,2017,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3 +1387,Australia,2017,6,N-Nervous system,"/capita, US$ purchasing power parity",52.8 +1388,Australia,2017,6,N-Nervous system,"/capita, US$ exchange rate",59.8 +1389,Australia,2017,6,N-Nervous system,% of total sales,13.0 +1390,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +1391,Australia,2017,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +1392,Australia,2017,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.0 +1393,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +1394,Australia,2017,6,N05C-Hypnotics and sedatives,% of total sales,0.2 +1395,Australia,2017,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8 +1396,Australia,2017,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",406.6 +1397,Australia,2017,6,N06A-Antidepressants,Million of national currency units,433.0 +1398,Australia,2017,6,Total pharmaceutical sales,"/capita, US$ exchange rate",460.4 +1399,Australia,2017,6,Total pharmaceutical sales,"Million US$, purchasing power parity",9999.0 +1400,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",70.4 +1401,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.2 +1402,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,104.0 +1403,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,79.7 +1404,Australia,2017,6,N06A-Antidepressants,Million US$ at exchange rate,331.9 +1405,Australia,2017,6,Total pharmaceutical sales,Million of national currency units,14774.0 +1406,Australia,2017,6,Total pharmaceutical sales,Million US$ at exchange rate,11323.2 +1407,Australia,2017,6,A10-Drugs used in diabetes,Million of national currency units,718.0 +1408,Australia,2017,6,N05B-Anxiolytics,Million US$ at exchange rate,36.8 +1409,Australia,2017,6,N06A-Antidepressants,"Million US$, purchasing power parity",293.1 +1410,Australia,2017,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.5 +1411,Australia,2017,6,N06A-Antidepressants,% of total sales,2.9 +1412,Australia,2017,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9 +1413,Australia,2017,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +1414,Australia,2017,6,C03-Diuretics,% of total sales,0.3 +1415,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.7 +1416,Australia,2017,6,N05B-Anxiolytics,"Million US$, purchasing power parity",32.5 +1417,Australia,2017,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.3 +1418,Australia,2017,6,C03-Diuretics,Million US$ at exchange rate,36.8 +1419,Australia,2017,6,A10-Drugs used in diabetes,Million US$ at exchange rate,550.3 +1420,Australia,2017,6,C03-Diuretics,"/capita, US$ exchange rate",1.5 +1421,Australia,2017,6,C03-Diuretics,"Million US$, purchasing power parity",32.5 +1422,Australia,2017,6,N02-Analgesics,"Million US$, purchasing power parity",346.5 +1423,Australia,2017,6,N02-Analgesics,"/capita, US$ exchange rate",16.0 +1424,Australia,2017,6,N02-Analgesics,Million US$ at exchange rate,392.4 +1425,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.9 +1426,Australia,2017,6,N02-Analgesics,Million of national currency units,512.0 +1427,Australia,2017,6,C02-Antihypertensives,Million US$ at exchange rate,82.0 +1428,Australia,2017,6,C02-Antihypertensives,Million of national currency units,107.0 +1429,Australia,2017,6,C02-Antihypertensives,"Million US$, purchasing power parity",72.4 +1430,Australia,2017,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.1 +1431,Australia,2017,6,N02-Analgesics,% of total sales,3.5 +1432,Austria,2016,5,N-Nervous system,% of total sales,14.8 +1433,Austria,2016,5,N-Nervous system,"Million US$, purchasing power parity",571.1 +1434,Austria,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",65.4 +1435,Austria,2016,5,N-Nervous system,"/capita, US$ exchange rate",56.2 +1436,Austria,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.3 +1437,Austria,2016,5,J01-Antibacterials for systemic use,Million of national currency units,62.6 +1438,Austria,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,288.4 +1439,Austria,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",335.4 +1440,Austria,2016,5,J-Antiinfectives for systemic use,Million of national currency units,260.6 +1441,Austria,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.4 +1442,Austria,2016,5,J-Antiinfectives for systemic use,% of total sales,8.7 +1443,Austria,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.0 +1444,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +1445,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1 +1446,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.0 +1447,Austria,2016,5,N02-Analgesics,"/capita, US$ exchange rate",8.3 +1448,Austria,2016,5,N02-Analgesics,Million US$ at exchange rate,72.7 +1449,Austria,2016,5,N02-Analgesics,"Million US$, purchasing power parity",84.5 +1450,Austria,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4 +1451,Austria,2016,5,N02-Analgesics,Million of national currency units,65.7 +1452,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0 +1453,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,60.9 +1454,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.8 +1455,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.0 +1456,Austria,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.1 +1457,Austria,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0 +1458,Austria,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +1459,Austria,2016,5,A02A-Antacids,% of total sales,0.0 +1460,Austria,2016,5,A10-Drugs used in diabetes,Million of national currency units,149.7 +1461,Austria,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,165.8 +1462,Austria,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",192.7 +1463,Austria,2016,5,N02-Analgesics,% of total sales,2.2 +1464,Austria,2016,5,A10-Drugs used in diabetes,% of total sales,5.0 +1465,Austria,2016,5,A02A-Antacids,Million of national currency units,0.6 +1466,Austria,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.7 +1467,Austria,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.1 +1468,Austria,2016,5,A02A-Antacids,"Million US$, purchasing power parity",0.8 +1469,Austria,2016,5,A02A-Antacids,Million US$ at exchange rate,0.6 +1470,Austria,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",80.6 +1471,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",66.6 +1472,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.5 +1473,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3 +1474,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.6 +1475,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,46.0 +1476,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,41.6 +1477,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7 +1478,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.6 +1479,Austria,2016,5,R-Respiratory system,% of total sales,5.7 +1480,Austria,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",25.4 +1481,Austria,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5 +1482,Austria,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +1483,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,51.7 +1484,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,57.3 +1485,Austria,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +1486,Austria,2016,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +1487,Austria,2016,5,N06A-Antidepressants,% of total sales,2.8 +1488,Austria,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.6 +1489,Austria,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1 +1490,Austria,2016,5,M-Musculo-skeletal system,% of total sales,3.4 +1491,Austria,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",110.0 +1492,Austria,2016,5,N06A-Antidepressants,Million US$ at exchange rate,94.6 +1493,Austria,2016,5,N06A-Antidepressants,Million of national currency units,85.5 +1494,Austria,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8 +1495,Austria,2016,5,R-Respiratory system,Million of national currency units,172.2 +1496,Austria,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.3 +1497,Austria,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.0 +1498,Austria,2016,5,M-Musculo-skeletal system,Million of national currency units,102.8 +1499,Austria,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,113.7 +1500,Austria,2016,5,R-Respiratory system,Million US$ at exchange rate,190.6 +1501,Austria,2016,5,R-Respiratory system,"Million US$, purchasing power parity",221.6 +1502,Austria,2016,5,R-Respiratory system,"/capita, US$ exchange rate",21.8 +1503,Austria,2016,5,N-Nervous system,Million of national currency units,443.7 +1504,Austria,2016,5,B-Blood and blood forming organs,% of total sales,9.3 +1505,Austria,2016,5,Products not elsewhere classified,Million of national currency units,920.3 +1506,Austria,2016,5,N-Nervous system,Million US$ at exchange rate,491.2 +1507,Austria,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",360.9 +1508,Austria,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,310.3 +1509,Austria,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.3 +1510,Austria,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.5 +1511,Austria,2016,5,J01-Antibacterials for systemic use,% of total sales,2.1 +1512,Austria,2016,5,Products not elsewhere classified,% of total sales,30.6 +1513,Austria,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +1514,Austria,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.9 +1515,Austria,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",1184.5 +1516,Austria,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1018.7 +1517,Austria,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.6 +1518,Austria,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",116.6 +1519,Austria,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,146.7 +1520,Austria,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +1521,Austria,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,162.3 +1522,Austria,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.8 +1523,Austria,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,2.7 +1524,Austria,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.0 +1525,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1 +1526,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4 +1527,Austria,2016,5,N05B-Anxiolytics,% of total sales,0.2 +1528,Austria,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.6 +1529,Austria,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.6 +1530,Austria,2016,5,B-Blood and blood forming organs,Million of national currency units,280.4 +1531,Austria,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +1532,Austria,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",188.8 +1533,Austria,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,7.2 +1534,Austria,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.4 +1535,Austria,2016,5,N05B-Anxiolytics,Million of national currency units,6.5 +1536,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7 +1537,Austria,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.7 +1538,Austria,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",382.2 +1539,Austria,2016,5,A-Alimentary tract and metabolism,Million of national currency units,296.9 +1540,Austria,2016,5,A-Alimentary tract and metabolism,% of total sales,9.9 +1541,Austria,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.6 +1542,Austria,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",37.6 +1543,Austria,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.7 +1544,Austria,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4 +1545,Austria,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4 +1546,Austria,2016,5,C07-Beta blocking agents,% of total sales,1.5 +1547,Austria,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",56.1 +1548,Austria,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.5 +1549,Austria,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.0 +1550,Austria,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,12.0 +1551,Austria,2016,5,C08-Calcium channel blockers,Million of national currency units,10.9 +1552,Austria,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.9 +1553,Austria,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.1 +1554,Austria,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,113.1 +1555,Austria,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",131.5 +1556,Austria,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.0 +1557,Austria,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",54.2 +1558,Austria,2016,5,C10-Lipid modifying agents,% of total sales,3.4 +1559,Austria,2016,5,C-Cardiovascular system,% of total sales,14.2 +1560,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,176.2 +1561,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",204.9 +1562,Austria,2016,5,C08-Calcium channel blockers,% of total sales,0.4 +1563,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,159.2 +1564,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.3 +1565,Austria,2016,5,C10-Lipid modifying agents,Million of national currency units,102.2 +1566,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.2 +1567,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5 +1568,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +1569,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +1570,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +1571,Austria,2016,5,C02-Antihypertensives,Million of national currency units,48.7 +1572,Austria,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.2 +1573,Austria,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",62.7 +1574,Austria,2016,5,C02-Antihypertensives,Million US$ at exchange rate,53.9 +1575,Austria,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3869.5 +1576,Austria,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",380.9 +1577,Austria,2016,5,Total pharmaceutical sales,Million of national currency units,3006.4 +1578,Austria,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,3327.8 +1579,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5 +1580,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.8 +1581,Austria,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.9 +1582,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.8 +1583,Austria,2016,5,C03-Diuretics,"Million US$, purchasing power parity",21.7 +1584,Austria,2016,5,C03-Diuretics,"/capita, US$ exchange rate",2.1 +1585,Austria,2016,5,C03-Diuretics,Million of national currency units,16.9 +1586,Austria,2016,5,C03-Diuretics,Million US$ at exchange rate,18.7 +1587,Austria,2016,5,C07-Beta blocking agents,Million of national currency units,43.6 +1588,Austria,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,48.3 +1589,Austria,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.5 +1590,Austria,2016,5,C03-Diuretics,% of total sales,0.6 +1591,Austria,2016,5,C01A-Cardiac glycosides,% of total sales,0.0 +1592,Austria,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +1593,Austria,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.2 +1594,Austria,2016,5,C02-Antihypertensives,% of total sales,1.6 +1595,Austria,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5 +1596,Austria,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.5 +1597,Austria,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +1598,Austria,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +1599,Austria,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,46.6 +1600,Austria,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,51.6 +1601,Austria,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.4 +1602,Austria,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.9 +1603,Austria,2016,5,G-Genito urinary system and sex hormones,% of total sales,1.5 +1604,Austria,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",60.0 +1605,Austria,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.9 +1606,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3 +1607,Austria,2016,5,C-Cardiovascular system,Million of national currency units,427.9 +1608,Austria,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,14.9 +1609,Austria,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",550.8 +1610,Austria,2016,5,C-Cardiovascular system,Million US$ at exchange rate,473.7 +1611,Austria,2015,5,N-Nervous system,% of total sales,15.9 +1612,Austria,2015,5,N-Nervous system,"Million US$, purchasing power parity",582.2 +1613,Austria,2015,5,N-Nervous system,"/capita, US$ exchange rate",59.7 +1614,Austria,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",67.4 +1615,Austria,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.3 +1616,Austria,2015,5,J01-Antibacterials for systemic use,Million of national currency units,65.2 +1617,Austria,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,326.8 +1618,Austria,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",368.8 +1619,Austria,2015,5,J-Antiinfectives for systemic use,Million of national currency units,294.6 +1620,Austria,2015,5,J-Antiinfectives for systemic use,% of total sales,10.1 +1621,Austria,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.7 +1622,Austria,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.8 +1623,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +1624,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.8 +1625,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6 +1626,Austria,2015,5,N02-Analgesics,Million US$ at exchange rate,70.2 +1627,Austria,2015,5,N02-Analgesics,"/capita, US$ exchange rate",8.1 +1628,Austria,2015,5,N02-Analgesics,"Million US$, purchasing power parity",79.2 +1629,Austria,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4 +1630,Austria,2015,5,N02-Analgesics,Million of national currency units,63.3 +1631,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9 +1632,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,58.3 +1633,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.8 +1634,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,52.6 +1635,Austria,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4 +1636,Austria,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.2 +1637,Austria,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +1638,Austria,2015,5,A02A-Antacids,% of total sales,0.0 +1639,Austria,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,148.7 +1640,Austria,2015,5,A10-Drugs used in diabetes,Million of national currency units,134.0 +1641,Austria,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",167.8 +1642,Austria,2015,5,N02-Analgesics,% of total sales,2.2 +1643,Austria,2015,5,A10-Drugs used in diabetes,% of total sales,4.6 +1644,Austria,2015,5,A02A-Antacids,Million of national currency units,0.2 +1645,Austria,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",81.6 +1646,Austria,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.2 +1647,Austria,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +1648,Austria,2015,5,A02A-Antacids,Million US$ at exchange rate,0.2 +1649,Austria,2015,5,A02A-Antacids,"Million US$, purchasing power parity",0.3 +1650,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",95.7 +1651,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",52.4 +1652,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.4 +1653,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.8 +1654,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,46.4 +1655,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,41.8 +1656,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +1657,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.1 +1658,Austria,2015,5,R-Respiratory system,% of total sales,5.8 +1659,Austria,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +1660,Austria,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +1661,Austria,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.4 +1662,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,76.5 +1663,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,84.8 +1664,Austria,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +1665,Austria,2015,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +1666,Austria,2015,5,N06A-Antidepressants,% of total sales,3.3 +1667,Austria,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.8 +1668,Austria,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.5 +1669,Austria,2015,5,M-Musculo-skeletal system,% of total sales,3.4 +1670,Austria,2015,5,N06A-Antidepressants,Million of national currency units,95.3 +1671,Austria,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",119.3 +1672,Austria,2015,5,N06A-Antidepressants,Million US$ at exchange rate,105.7 +1673,Austria,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.2 +1674,Austria,2015,5,R-Respiratory system,Million of national currency units,168.4 +1675,Austria,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",125.4 +1676,Austria,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.9 +1677,Austria,2015,5,M-Musculo-skeletal system,Million of national currency units,100.2 +1678,Austria,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,111.1 +1679,Austria,2015,5,R-Respiratory system,Million US$ at exchange rate,186.9 +1680,Austria,2015,5,R-Respiratory system,"Million US$, purchasing power parity",210.9 +1681,Austria,2015,5,R-Respiratory system,"/capita, US$ exchange rate",21.6 +1682,Austria,2015,5,N-Nervous system,Million of national currency units,465.1 +1683,Austria,2015,5,B-Blood and blood forming organs,% of total sales,8.4 +1684,Austria,2015,5,Products not elsewhere classified,Million of national currency units,832.2 +1685,Austria,2015,5,N-Nervous system,Million US$ at exchange rate,516.0 +1686,Austria,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",308.3 +1687,Austria,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,273.2 +1688,Austria,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.7 +1689,Austria,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",31.6 +1690,Austria,2015,5,J01-Antibacterials for systemic use,% of total sales,2.2 +1691,Austria,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.4 +1692,Austria,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4 +1693,Austria,2015,5,Products not elsewhere classified,% of total sales,28.4 +1694,Austria,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1041.8 +1695,Austria,2015,5,Products not elsewhere classified,Million US$ at exchange rate,923.3 +1696,Austria,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",120.5 +1697,Austria,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",106.8 +1698,Austria,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,146.9 +1699,Austria,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +1700,Austria,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,162.9 +1701,Austria,2015,5,N05B-Anxiolytics,% of total sales,0.2 +1702,Austria,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6 +1703,Austria,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.9 +1704,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1 +1705,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4 +1706,Austria,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9 +1707,Austria,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.3 +1708,Austria,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.9 +1709,Austria,2015,5,B-Blood and blood forming organs,Million of national currency units,246.3 +1710,Austria,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,5.0 +1711,Austria,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.5 +1712,Austria,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,7.6 +1713,Austria,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",183.8 +1714,Austria,2015,5,N05B-Anxiolytics,Million of national currency units,6.8 +1715,Austria,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,329.7 +1716,Austria,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",372.0 +1717,Austria,2015,5,A-Alimentary tract and metabolism,Million of national currency units,297.1 +1718,Austria,2015,5,A-Alimentary tract and metabolism,% of total sales,10.1 +1719,Austria,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0 +1720,Austria,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",38.1 +1721,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7 +1722,Austria,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0 +1723,Austria,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +1724,Austria,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4 +1725,Austria,2015,5,C07-Beta blocking agents,% of total sales,1.5 +1726,Austria,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",55.7 +1727,Austria,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7 +1728,Austria,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",25.8 +1729,Austria,2015,5,C08-Calcium channel blockers,Million of national currency units,20.6 +1730,Austria,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,22.9 +1731,Austria,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.2 +1732,Austria,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.8 +1733,Austria,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,105.3 +1734,Austria,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",118.8 +1735,Austria,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",61.8 +1736,Austria,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",54.8 +1737,Austria,2015,5,C10-Lipid modifying agents,% of total sales,3.2 +1738,Austria,2015,5,C-Cardiovascular system,% of total sales,14.6 +1739,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,174.8 +1740,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",197.2 +1741,Austria,2015,5,C08-Calcium channel blockers,% of total sales,0.7 +1742,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,157.5 +1743,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4 +1744,Austria,2015,5,C10-Lipid modifying agents,Million of national currency units,94.9 +1745,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.2 +1746,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.8 +1747,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +1748,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +1749,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +1750,Austria,2015,5,C02-Antihypertensives,Million of national currency units,45.7 +1751,Austria,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.9 +1752,Austria,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",57.2 +1753,Austria,2015,5,C02-Antihypertensives,Million US$ at exchange rate,50.7 +1754,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.8 +1755,Austria,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3666.5 +1756,Austria,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",376.0 +1757,Austria,2015,5,Total pharmaceutical sales,Million of national currency units,2928.9 +1758,Austria,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,3249.6 +1759,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.8 +1760,Austria,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",424.2 +1761,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.0 +1762,Austria,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.6 +1763,Austria,2015,5,C03-Diuretics,"Million US$, purchasing power parity",20.6 +1764,Austria,2015,5,C03-Diuretics,"/capita, US$ exchange rate",2.1 +1765,Austria,2015,5,C03-Diuretics,Million of national currency units,16.5 +1766,Austria,2015,5,C03-Diuretics,Million US$ at exchange rate,18.3 +1767,Austria,2015,5,C07-Beta blocking agents,Million of national currency units,44.5 +1768,Austria,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,49.4 +1769,Austria,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +1770,Austria,2015,5,C03-Diuretics,% of total sales,0.6 +1771,Austria,2015,5,C01A-Cardiac glycosides,% of total sales,0.0 +1772,Austria,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +1773,Austria,2015,5,C02-Antihypertensives,% of total sales,1.6 +1774,Austria,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +1775,Austria,2015,5,C01A-Cardiac glycosides,Million of national currency units,0.5 +1776,Austria,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +1777,Austria,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7 +1778,Austria,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,45.5 +1779,Austria,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,50.5 +1780,Austria,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.0 +1781,Austria,2015,5,C-Cardiovascular system,Million of national currency units,426.9 +1782,Austria,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6 +1783,Austria,2015,5,G-Genito urinary system and sex hormones,% of total sales,1.6 +1784,Austria,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",57.0 +1785,Austria,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.8 +1786,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.3 +1787,Austria,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,14.4 +1788,Austria,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",534.4 +1789,Austria,2015,5,C-Cardiovascular system,Million US$ at exchange rate,473.6 +1790,Austria,2014,5,N-Nervous system,% of total sales,17.1 +1791,Austria,2014,5,N-Nervous system,"/capita, US$ exchange rate",74.2 +1792,Austria,2014,5,N-Nervous system,"Million US$, purchasing power parity",597.9 +1793,Austria,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",70.0 +1794,Austria,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,87.8 +1795,Austria,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",82.7 +1796,Austria,2014,5,J01-Antibacterials for systemic use,Million of national currency units,66.1 +1797,Austria,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",302.3 +1798,Austria,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,320.8 +1799,Austria,2014,5,J-Antiinfectives for systemic use,Million of national currency units,241.5 +1800,Austria,2014,5,J-Antiinfectives for systemic use,% of total sales,8.7 +1801,Austria,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.4 +1802,Austria,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.5 +1803,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +1804,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.9 +1805,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.5 +1806,Austria,2014,5,N02-Analgesics,"/capita, US$ exchange rate",9.6 +1807,Austria,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.0 +1808,Austria,2014,5,N02-Analgesics,Million US$ at exchange rate,81.9 +1809,Austria,2014,5,N02-Analgesics,"Million US$, purchasing power parity",77.1 +1810,Austria,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5 +1811,Austria,2014,5,N02-Analgesics,Million of national currency units,61.6 +1812,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9 +1813,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",64.0 +1814,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.9 +1815,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,51.1 +1816,Austria,2014,5,A02A-Antacids,Million of national currency units,0.1 +1817,Austria,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1 +1818,Austria,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +1819,Austria,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.2 +1820,Austria,2014,5,A02A-Antacids,% of total sales,0.0 +1821,Austria,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,164.5 +1822,Austria,2014,5,A10-Drugs used in diabetes,Million of national currency units,123.8 +1823,Austria,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",155.0 +1824,Austria,2014,5,A10-Drugs used in diabetes,% of total sales,4.4 +1825,Austria,2014,5,N02-Analgesics,% of total sales,2.2 +1826,Austria,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +1827,Austria,2014,5,A02A-Antacids,"Million US$, purchasing power parity",0.2 +1828,Austria,2014,5,A02A-Antacids,Million US$ at exchange rate,0.2 +1829,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.3 +1830,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.4 +1831,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",99.7 +1832,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6 +1833,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,56.5 +1834,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.6 +1835,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.7 +1836,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9 +1837,Austria,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +1838,Austria,2014,5,R-Respiratory system,% of total sales,5.9 +1839,Austria,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5 +1840,Austria,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +1841,Austria,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.0 +1842,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,79.6 +1843,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,105.8 +1844,Austria,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +1845,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.2 +1846,Austria,2014,5,N06A-Antidepressants,% of total sales,3.9 +1847,Austria,2014,5,M-Musculo-skeletal system,% of total sales,3.6 +1848,Austria,2014,5,N06A-Antidepressants,Million of national currency units,109.5 +1849,Austria,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",137.1 +1850,Austria,2014,5,N06A-Antidepressants,Million US$ at exchange rate,145.5 +1851,Austria,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0 +1852,Austria,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",17.0 +1853,Austria,2014,5,R-Respiratory system,Million of national currency units,163.8 +1854,Austria,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",125.9 +1855,Austria,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6 +1856,Austria,2014,5,M-Musculo-skeletal system,Million of national currency units,100.5 +1857,Austria,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,133.6 +1858,Austria,2014,5,R-Respiratory system,"Million US$, purchasing power parity",205.0 +1859,Austria,2014,5,R-Respiratory system,Million US$ at exchange rate,217.5 +1860,Austria,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7 +1861,Austria,2014,5,R-Respiratory system,"/capita, US$ exchange rate",25.5 +1862,Austria,2014,5,N-Nervous system,Million of national currency units,477.6 +1863,Austria,2014,5,B-Blood and blood forming organs,% of total sales,7.9 +1864,Austria,2014,5,Products not elsewhere classified,Million of national currency units,767.7 +1865,Austria,2014,5,N-Nervous system,Million US$ at exchange rate,634.5 +1866,Austria,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",275.5 +1867,Austria,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,292.4 +1868,Austria,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.2 +1869,Austria,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.2 +1870,Austria,2014,5,Products not elsewhere classified,Million US$ at exchange rate,1020.0 +1871,Austria,2014,5,J01-Antibacterials for systemic use,% of total sales,2.4 +1872,Austria,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.3 +1873,Austria,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.7 +1874,Austria,2014,5,Products not elsewhere classified,% of total sales,27.5 +1875,Austria,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",961.1 +1876,Austria,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",119.3 +1877,Austria,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",112.5 +1878,Austria,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,141.9 +1879,Austria,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +1880,Austria,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,188.5 +1881,Austria,2014,5,N05B-Anxiolytics,% of total sales,0.3 +1882,Austria,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,2.8 +1883,Austria,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7 +1884,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5 +1885,Austria,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.8 +1886,Austria,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1 +1887,Austria,2014,5,B-Blood and blood forming organs,Million of national currency units,220.1 +1888,Austria,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1 +1889,Austria,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +1890,Austria,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.8 +1891,Austria,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,9.4 +1892,Austria,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",177.7 +1893,Austria,2014,5,N05B-Anxiolytics,Million of national currency units,7.1 +1894,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0 +1895,Austria,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,381.4 +1896,Austria,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",359.4 +1897,Austria,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0 +1898,Austria,2014,5,A-Alimentary tract and metabolism,Million of national currency units,287.1 +1899,Austria,2014,5,A-Alimentary tract and metabolism,% of total sales,10.3 +1900,Austria,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",44.6 +1901,Austria,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.0 +1902,Austria,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8 +1903,Austria,2014,5,C07-Beta blocking agents,% of total sales,1.7 +1904,Austria,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",57.8 +1905,Austria,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2 +1906,Austria,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",34.5 +1907,Austria,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3 +1908,Austria,2014,5,C08-Calcium channel blockers,Million of national currency units,27.6 +1909,Austria,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,36.7 +1910,Austria,2014,5,C08-Calcium channel blockers,% of total sales,1.0 +1911,Austria,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.3 +1912,Austria,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.5 +1913,Austria,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,122.0 +1914,Austria,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",115.0 +1915,Austria,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.4 +1916,Austria,2014,5,C10-Lipid modifying agents,% of total sales,3.3 +1917,Austria,2014,5,C-Cardiovascular system,% of total sales,15.5 +1918,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,213.4 +1919,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",201.1 +1920,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,160.7 +1921,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.8 +1922,Austria,2014,5,C10-Lipid modifying agents,Million of national currency units,91.8 +1923,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.0 +1924,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5 +1925,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +1926,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +1927,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +1928,Austria,2014,5,C02-Antihypertensives,Million of national currency units,42.7 +1929,Austria,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6 +1930,Austria,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",53.4 +1931,Austria,2014,5,C02-Antihypertensives,Million US$ at exchange rate,56.7 +1932,Austria,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3489.5 +1933,Austria,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",433.3 +1934,Austria,2014,5,Total pharmaceutical sales,Million of national currency units,2787.4 +1935,Austria,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,3703.1 +1936,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.6 +1937,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.0 +1938,Austria,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",408.3 +1939,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.2 +1940,Austria,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",67.3 +1941,Austria,2014,5,C03-Diuretics,"Million US$, purchasing power parity",20.6 +1942,Austria,2014,5,C03-Diuretics,"/capita, US$ exchange rate",2.6 +1943,Austria,2014,5,C03-Diuretics,Million of national currency units,16.5 +1944,Austria,2014,5,C03-Diuretics,Million US$ at exchange rate,21.9 +1945,Austria,2014,5,C07-Beta blocking agents,Million of national currency units,46.2 +1946,Austria,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,61.3 +1947,Austria,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +1948,Austria,2014,5,C03-Diuretics,% of total sales,0.6 +1949,Austria,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3 +1950,Austria,2014,5,C01A-Cardiac glycosides,% of total sales,0.0 +1951,Austria,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +1952,Austria,2014,5,C02-Antihypertensives,% of total sales,1.5 +1953,Austria,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +1954,Austria,2014,5,C01A-Cardiac glycosides,Million of national currency units,0.6 +1955,Austria,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +1956,Austria,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7 +1957,Austria,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,60.2 +1958,Austria,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,45.3 +1959,Austria,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.1 +1960,Austria,2014,5,C-Cardiovascular system,Million of national currency units,432.8 +1961,Austria,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6 +1962,Austria,2014,5,G-Genito urinary system and sex hormones,% of total sales,1.6 +1963,Austria,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",56.7 +1964,Austria,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.0 +1965,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.4 +1966,Austria,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.4 +1967,Austria,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",541.8 +1968,Austria,2014,5,C-Cardiovascular system,Million US$ at exchange rate,574.9 +1969,Austria,2013,5,N-Nervous system,% of total sales,18.0 +1970,Austria,2013,5,N-Nervous system,"/capita, US$ exchange rate",74.2 +1971,Austria,2013,5,N-Nervous system,"Million US$, purchasing power parity",594.4 +1972,Austria,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",70.1 +1973,Austria,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,92.6 +1974,Austria,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",87.5 +1975,Austria,2013,5,J01-Antibacterials for systemic use,Million of national currency units,69.7 +1976,Austria,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",229.4 +1977,Austria,2013,5,J-Antiinfectives for systemic use,Million of national currency units,182.9 +1978,Austria,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,242.9 +1979,Austria,2013,5,J-Antiinfectives for systemic use,% of total sales,6.9 +1980,Austria,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.1 +1981,Austria,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.6 +1982,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +1983,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.9 +1984,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.4 +1985,Austria,2013,5,N02-Analgesics,Million US$ at exchange rate,78.1 +1986,Austria,2013,5,N02-Analgesics,"/capita, US$ exchange rate",9.2 +1987,Austria,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.7 +1988,Austria,2013,5,N02-Analgesics,"Million US$, purchasing power parity",73.8 +1989,Austria,2013,5,N02-Analgesics,Million of national currency units,58.8 +1990,Austria,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5 +1991,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1 +1992,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.0 +1993,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50.2 +1994,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.6 +1995,Austria,2013,5,A02A-Antacids,Million of national currency units,0.1 +1996,Austria,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.0 +1997,Austria,2013,5,A02A-Antacids,% of total sales,0.0 +1998,Austria,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0 +1999,Austria,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,152.9 +2000,Austria,2013,5,A10-Drugs used in diabetes,Million of national currency units,115.2 +2001,Austria,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +2002,Austria,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",144.5 +2003,Austria,2013,5,A10-Drugs used in diabetes,% of total sales,4.4 +2004,Austria,2013,5,N02-Analgesics,% of total sales,2.2 +2005,Austria,2013,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +2006,Austria,2013,5,A02A-Antacids,Million US$ at exchange rate,0.2 +2007,Austria,2013,5,A02A-Antacids,"Million US$, purchasing power parity",0.2 +2008,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",54.5 +2009,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.0 +2010,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",104.2 +2011,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.8 +2012,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,57.6 +2013,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,43.4 +2014,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.3 +2015,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.2 +2016,Austria,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +2017,Austria,2013,5,R-Respiratory system,% of total sales,6.2 +2018,Austria,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +2019,Austria,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +2020,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,83.0 +2021,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,110.3 +2022,Austria,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +2023,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.4 +2024,Austria,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.4 +2025,Austria,2013,5,N06A-Antidepressants,% of total sales,4.1 +2026,Austria,2013,5,R-Respiratory system,Million of national currency units,164.6 +2027,Austria,2013,5,M-Musculo-skeletal system,% of total sales,3.8 +2028,Austria,2013,5,N06A-Antidepressants,Million of national currency units,107.2 +2029,Austria,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",134.5 +2030,Austria,2013,5,N06A-Antidepressants,Million US$ at exchange rate,142.4 +2031,Austria,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9 +2032,Austria,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",16.8 +2033,Austria,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",127.0 +2034,Austria,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.9 +2035,Austria,2013,5,M-Musculo-skeletal system,Million of national currency units,101.2 +2036,Austria,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,134.4 +2037,Austria,2013,5,R-Respiratory system,"Million US$, purchasing power parity",206.5 +2038,Austria,2013,5,R-Respiratory system,Million US$ at exchange rate,218.6 +2039,Austria,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.0 +2040,Austria,2013,5,R-Respiratory system,"/capita, US$ exchange rate",25.8 +2041,Austria,2013,5,N-Nervous system,Million of national currency units,473.8 +2042,Austria,2013,5,B-Blood and blood forming organs,% of total sales,7.3 +2043,Austria,2013,5,Products not elsewhere classified,Million of national currency units,712.5 +2044,Austria,2013,5,N-Nervous system,Million US$ at exchange rate,629.3 +2045,Austria,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",240.2 +2046,Austria,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,254.2 +2047,Austria,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.3 +2048,Austria,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.0 +2049,Austria,2013,5,Products not elsewhere classified,Million US$ at exchange rate,946.3 +2050,Austria,2013,5,J01-Antibacterials for systemic use,% of total sales,2.6 +2051,Austria,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.9 +2052,Austria,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3 +2053,Austria,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",893.9 +2054,Austria,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",111.6 +2055,Austria,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",105.4 +2056,Austria,2013,5,Products not elsewhere classified,% of total sales,27.0 +2057,Austria,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,143.5 +2058,Austria,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +2059,Austria,2013,5,N05B-Anxiolytics,% of total sales,0.3 +2060,Austria,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,190.6 +2061,Austria,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6 +2062,Austria,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.4 +2063,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6 +2064,Austria,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +2065,Austria,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.2 +2066,Austria,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.5 +2067,Austria,2013,5,B-Blood and blood forming organs,Million of national currency units,191.4 +2068,Austria,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +2069,Austria,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.5 +2070,Austria,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,9.0 +2071,Austria,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",180.1 +2072,Austria,2013,5,N05B-Anxiolytics,Million of national currency units,6.8 +2073,Austria,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,365.9 +2074,Austria,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",345.6 +2075,Austria,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2 +2076,Austria,2013,5,A-Alimentary tract and metabolism,Million of national currency units,275.5 +2077,Austria,2013,5,A-Alimentary tract and metabolism,% of total sales,10.5 +2078,Austria,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",43.1 +2079,Austria,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.8 +2080,Austria,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.9 +2081,Austria,2013,5,C07-Beta blocking agents,% of total sales,1.8 +2082,Austria,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",58.4 +2083,Austria,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.3 +2084,Austria,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",35.7 +2085,Austria,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5 +2086,Austria,2013,5,C08-Calcium channel blockers,Million of national currency units,28.4 +2087,Austria,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,37.8 +2088,Austria,2013,5,C08-Calcium channel blockers,% of total sales,1.1 +2089,Austria,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.1 +2090,Austria,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.3 +2091,Austria,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,119.6 +2092,Austria,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",113.0 +2093,Austria,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.8 +2094,Austria,2013,5,C-Cardiovascular system,% of total sales,16.6 +2095,Austria,2013,5,C10-Lipid modifying agents,% of total sales,3.4 +2096,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",209.6 +2097,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,221.9 +2098,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,167.1 +2099,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3 +2100,Austria,2013,5,C10-Lipid modifying agents,Million of national currency units,90.0 +2101,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.2 +2102,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.7 +2103,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +2104,Austria,2013,5,C02-Antihypertensives,Million of national currency units,42.1 +2105,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +2106,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +2107,Austria,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6 +2108,Austria,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",52.8 +2109,Austria,2013,5,C02-Antihypertensives,Million US$ at exchange rate,55.9 +2110,Austria,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3306.0 +2111,Austria,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",412.7 +2112,Austria,2013,5,Total pharmaceutical sales,Million of national currency units,2635.2 +2113,Austria,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,3499.8 +2114,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.7 +2115,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.1 +2116,Austria,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",389.9 +2117,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.3 +2118,Austria,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.2 +2119,Austria,2013,5,C03-Diuretics,"Million US$, purchasing power parity",19.3 +2120,Austria,2013,5,C03-Diuretics,"/capita, US$ exchange rate",2.4 +2121,Austria,2013,5,C03-Diuretics,Million of national currency units,15.4 +2122,Austria,2013,5,C03-Diuretics,Million US$ at exchange rate,20.5 +2123,Austria,2013,5,C07-Beta blocking agents,Million of national currency units,46.5 +2124,Austria,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,61.8 +2125,Austria,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.3 +2126,Austria,2013,5,C03-Diuretics,% of total sales,0.6 +2127,Austria,2013,5,C01A-Cardiac glycosides,% of total sales,0.0 +2128,Austria,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +2129,Austria,2013,5,C02-Antihypertensives,% of total sales,1.6 +2130,Austria,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7 +2131,Austria,2013,5,C01A-Cardiac glycosides,Million of national currency units,0.6 +2132,Austria,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +2133,Austria,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7 +2134,Austria,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",68.6 +2135,Austria,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,60.2 +2136,Austria,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,45.4 +2137,Austria,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,14.0 +2138,Austria,2013,5,C-Cardiovascular system,Million of national currency units,437.7 +2139,Austria,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",56.9 +2140,Austria,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7 +2141,Austria,2013,5,G-Genito urinary system and sex hormones,% of total sales,1.7 +2142,Austria,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.1 +2143,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.2 +2144,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.5 +2145,Austria,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.6 +2146,Austria,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",549.1 +2147,Austria,2013,5,C-Cardiovascular system,Million US$ at exchange rate,581.3 +2148,Austria,2012,5,N-Nervous system,% of total sales,18.6 +2149,Austria,2012,5,N-Nervous system,"/capita, US$ exchange rate",74.2 +2150,Austria,2012,5,N-Nervous system,"Million US$, purchasing power parity",598.7 +2151,Austria,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",71.0 +2152,Austria,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,87.6 +2153,Austria,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",83.8 +2154,Austria,2012,5,J01-Antibacterials for systemic use,Million of national currency units,68.2 +2155,Austria,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",218.4 +2156,Austria,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,228.4 +2157,Austria,2012,5,J-Antiinfectives for systemic use,Million of national currency units,177.7 +2158,Austria,2012,5,J-Antiinfectives for systemic use,% of total sales,6.8 +2159,Austria,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.1 +2160,Austria,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.9 +2161,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +2162,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3 +2163,Austria,2012,5,N02-Analgesics,Million US$ at exchange rate,77.4 +2164,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.0 +2165,Austria,2012,5,N02-Analgesics,"/capita, US$ exchange rate",9.2 +2166,Austria,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.8 +2167,Austria,2012,5,N02-Analgesics,"Million US$, purchasing power parity",74.1 +2168,Austria,2012,5,N02-Analgesics,Million of national currency units,60.3 +2169,Austria,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5 +2170,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0 +2171,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.1 +2172,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,61.8 +2173,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,48.1 +2174,Austria,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.1 +2175,Austria,2012,5,A02A-Antacids,% of total sales,0.0 +2176,Austria,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8 +2177,Austria,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,142.0 +2178,Austria,2012,5,A10-Drugs used in diabetes,Million of national currency units,110.5 +2179,Austria,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",135.8 +2180,Austria,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +2181,Austria,2012,5,A10-Drugs used in diabetes,% of total sales,4.2 +2182,Austria,2012,5,N02-Analgesics,% of total sales,2.3 +2183,Austria,2012,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +2184,Austria,2012,5,A02A-Antacids,Million US$ at exchange rate,0.2 +2185,Austria,2012,5,A02A-Antacids,"Million US$, purchasing power parity",0.2 +2186,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.3 +2187,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.5 +2188,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6 +2189,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.7 +2190,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.9 +2191,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.4 +2192,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",108.5 +2193,Austria,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +2194,Austria,2012,5,R-Respiratory system,% of total sales,6.2 +2195,Austria,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +2196,Austria,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +2197,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,43.4 +2198,Austria,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",23.5 +2199,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,88.3 +2200,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,113.4 +2201,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.3 +2202,Austria,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +2203,Austria,2012,5,N06A-Antidepressants,% of total sales,3.9 +2204,Austria,2012,5,N06A-Antidepressants,Million of national currency units,103.2 +2205,Austria,2012,5,R-Respiratory system,Million of national currency units,161.4 +2206,Austria,2012,5,M-Musculo-skeletal system,% of total sales,4.1 +2207,Austria,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",126.8 +2208,Austria,2012,5,N06A-Antidepressants,Million US$ at exchange rate,132.6 +2209,Austria,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.0 +2210,Austria,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",15.7 +2211,Austria,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.4 +2212,Austria,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.4 +2213,Austria,2012,5,M-Musculo-skeletal system,Million of national currency units,107.7 +2214,Austria,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,138.4 +2215,Austria,2012,5,R-Respiratory system,"Million US$, purchasing power parity",198.4 +2216,Austria,2012,5,R-Respiratory system,Million US$ at exchange rate,207.4 +2217,Austria,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.7 +2218,Austria,2012,5,R-Respiratory system,"/capita, US$ exchange rate",24.6 +2219,Austria,2012,5,N-Nervous system,Million of national currency units,487.1 +2220,Austria,2012,5,B-Blood and blood forming organs,% of total sales,6.3 +2221,Austria,2012,5,N-Nervous system,Million US$ at exchange rate,625.9 +2222,Austria,2012,5,Products not elsewhere classified,Million of national currency units,664.5 +2223,Austria,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",202.5 +2224,Austria,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,211.7 +2225,Austria,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.0 +2226,Austria,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.1 +2227,Austria,2012,5,Products not elsewhere classified,Million US$ at exchange rate,853.7 +2228,Austria,2012,5,J01-Antibacterials for systemic use,% of total sales,2.6 +2229,Austria,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.4 +2230,Austria,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9 +2231,Austria,2012,5,Products not elsewhere classified,% of total sales,25.4 +2232,Austria,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",816.7 +2233,Austria,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",101.3 +2234,Austria,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",96.9 +2235,Austria,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,139.9 +2236,Austria,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9 +2237,Austria,2012,5,N05B-Anxiolytics,% of total sales,0.2 +2238,Austria,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,179.7 +2239,Austria,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6 +2240,Austria,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +2241,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +2242,Austria,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.4 +2243,Austria,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.3 +2244,Austria,2012,5,B-Blood and blood forming organs,Million of national currency units,164.8 +2245,Austria,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +2246,Austria,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.0 +2247,Austria,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0 +2248,Austria,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",171.9 +2249,Austria,2012,5,N05B-Anxiolytics,Million of national currency units,6.5 +2250,Austria,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,8.3 +2251,Austria,2012,5,A02A-Antacids,Million of national currency units,0.1 +2252,Austria,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",335.6 +2253,Austria,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,350.8 +2254,Austria,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3 +2255,Austria,2012,5,A-Alimentary tract and metabolism,Million of national currency units,273.0 +2256,Austria,2012,5,A-Alimentary tract and metabolism,% of total sales,10.4 +2257,Austria,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",41.6 +2258,Austria,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.8 +2259,Austria,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5 +2260,Austria,2012,5,C07-Beta blocking agents,% of total sales,2.0 +2261,Austria,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",63.0 +2262,Austria,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8 +2263,Austria,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",36.2 +2264,Austria,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5 +2265,Austria,2012,5,C08-Calcium channel blockers,Million of national currency units,29.5 +2266,Austria,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,37.8 +2267,Austria,2012,5,C08-Calcium channel blockers,% of total sales,1.1 +2268,Austria,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.6 +2269,Austria,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.9 +2270,Austria,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,131.1 +2271,Austria,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",125.4 +2272,Austria,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.4 +2273,Austria,2012,5,C-Cardiovascular system,% of total sales,18.5 +2274,Austria,2012,5,C10-Lipid modifying agents,% of total sales,3.9 +2275,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",239.2 +2276,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,250.0 +2277,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,194.6 +2278,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.7 +2279,Austria,2012,5,C10-Lipid modifying agents,Million of national currency units,102.1 +2280,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.4 +2281,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.4 +2282,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +2283,Austria,2012,5,C02-Antihypertensives,Million of national currency units,41.4 +2284,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +2285,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +2286,Austria,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.3 +2287,Austria,2012,5,C02-Antihypertensives,Million US$ at exchange rate,53.2 +2288,Austria,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",50.9 +2289,Austria,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.0 +2290,Austria,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3211.4 +2291,Austria,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",398.2 +2292,Austria,2012,5,Total pharmaceutical sales,Million of national currency units,2613.0 +2293,Austria,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,3357.1 +2294,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.4 +2295,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.0 +2296,Austria,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",381.0 +2297,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.3 +2298,Austria,2012,5,C03-Diuretics,"Million US$, purchasing power parity",19.2 +2299,Austria,2012,5,C03-Diuretics,"/capita, US$ exchange rate",2.4 +2300,Austria,2012,5,C03-Diuretics,Million US$ at exchange rate,20.1 +2301,Austria,2012,5,C07-Beta blocking agents,Million of national currency units,51.3 +2302,Austria,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,65.9 +2303,Austria,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.3 +2304,Austria,2012,5,C03-Diuretics,Million of national currency units,15.6 +2305,Austria,2012,5,C03-Diuretics,% of total sales,0.6 +2306,Austria,2012,5,C01A-Cardiac glycosides,% of total sales,0.0 +2307,Austria,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +2308,Austria,2012,5,C02-Antihypertensives,% of total sales,1.6 +2309,Austria,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +2310,Austria,2012,5,C01A-Cardiac glycosides,Million of national currency units,0.6 +2311,Austria,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +2312,Austria,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8 +2313,Austria,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,58.3 +2314,Austria,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.7 +2315,Austria,2012,5,C-Cardiovascular system,Million of national currency units,483.2 +2316,Austria,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.6 +2317,Austria,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,45.4 +2318,Austria,2012,5,G-Genito urinary system and sex hormones,% of total sales,1.7 +2319,Austria,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6 +2320,Austria,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",55.8 +2321,Austria,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.9 +2322,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1 +2323,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.8 +2324,Austria,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.6 +2325,Austria,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",593.9 +2326,Austria,2012,5,C-Cardiovascular system,Million US$ at exchange rate,620.8 +2327,Austria,2011,5,N-Nervous system,% of total sales,19.2 +2328,Austria,2011,5,N06A-Antidepressants,Million US$ at exchange rate,138.3 +2329,Austria,2011,5,N-Nervous system,"/capita, US$ exchange rate",81.3 +2330,Austria,2011,5,N-Nervous system,"Million US$, purchasing power parity",589.6 +2331,Austria,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",70.3 +2332,Austria,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",86.4 +2333,Austria,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,100.0 +2334,Austria,2011,5,J01-Antibacterials for systemic use,Million of national currency units,71.8 +2335,Austria,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",200.3 +2336,Austria,2011,5,J-Antiinfectives for systemic use,Million of national currency units,166.5 +2337,Austria,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,231.8 +2338,Austria,2011,5,J-Antiinfectives for systemic use,% of total sales,6.5 +2339,Austria,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.6 +2340,Austria,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.9 +2341,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +2342,Austria,2011,5,N02-Analgesics,Million US$ at exchange rate,82.8 +2343,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.9 +2344,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.0 +2345,Austria,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.5 +2346,Austria,2011,5,N02-Analgesics,"/capita, US$ exchange rate",9.9 +2347,Austria,2011,5,N02-Analgesics,"Million US$, purchasing power parity",71.5 +2348,Austria,2011,5,N02-Analgesics,Million of national currency units,59.5 +2349,Austria,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5 +2350,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0 +2351,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",57.7 +2352,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,47.9 +2353,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.7 +2354,Austria,2011,5,A02A-Antacids,Million of national currency units,0.1 +2355,Austria,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.9 +2356,Austria,2011,5,A02A-Antacids,% of total sales,0.0 +2357,Austria,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.3 +2358,Austria,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,144.9 +2359,Austria,2011,5,A10-Drugs used in diabetes,Million of national currency units,104.1 +2360,Austria,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",125.2 +2361,Austria,2011,5,A10-Drugs used in diabetes,% of total sales,4.1 +2362,Austria,2011,5,N02-Analgesics,% of total sales,2.3 +2363,Austria,2011,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +2364,Austria,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +2365,Austria,2011,5,A02A-Antacids,Million US$ at exchange rate,0.2 +2366,Austria,2011,5,A02A-Antacids,"Million US$, purchasing power parity",0.2 +2367,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.2 +2368,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.0 +2369,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1 +2370,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.1 +2371,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,59.2 +2372,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.8 +2373,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8 +2374,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",115.8 +2375,Austria,2011,5,R-Respiratory system,% of total sales,6.3 +2376,Austria,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +2377,Austria,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +2378,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,134.0 +2379,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,96.2 +2380,Austria,2011,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +2381,Austria,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +2382,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.6 +2383,Austria,2011,5,N06A-Antidepressants,% of total sales,3.9 +2384,Austria,2011,5,N06A-Antidepressants,Million of national currency units,99.3 +2385,Austria,2011,5,R-Respiratory system,Million of national currency units,159.6 +2386,Austria,2011,5,M-Musculo-skeletal system,% of total sales,4.3 +2387,Austria,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",119.5 +2388,Austria,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",16.5 +2389,Austria,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.2 +2390,Austria,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",131.7 +2391,Austria,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.2 +2392,Austria,2011,5,M-Musculo-skeletal system,Million of national currency units,109.5 +2393,Austria,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,152.4 +2394,Austria,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.7 +2395,Austria,2011,5,R-Respiratory system,"Million US$, purchasing power parity",192.0 +2396,Austria,2011,5,R-Respiratory system,Million US$ at exchange rate,222.2 +2397,Austria,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",22.9 +2398,Austria,2011,5,R-Respiratory system,"/capita, US$ exchange rate",26.5 +2399,Austria,2011,5,N-Nervous system,Million of national currency units,490.1 +2400,Austria,2011,5,B-Blood and blood forming organs,% of total sales,5.7 +2401,Austria,2011,5,Products not elsewhere classified,Million of national currency units,617.8 +2402,Austria,2011,5,N-Nervous system,Million US$ at exchange rate,682.3 +2403,Austria,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",175.4 +2404,Austria,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,203.0 +2405,Austria,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.9 +2406,Austria,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.2 +2407,Austria,2011,5,Products not elsewhere classified,Million US$ at exchange rate,859.9 +2408,Austria,2011,5,J01-Antibacterials for systemic use,% of total sales,2.8 +2409,Austria,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.9 +2410,Austria,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3 +2411,Austria,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",102.5 +2412,Austria,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",743.1 +2413,Austria,2011,5,Products not elsewhere classified,% of total sales,24.2 +2414,Austria,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",88.6 +2415,Austria,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,136.9 +2416,Austria,2011,5,N05B-Anxiolytics,% of total sales,0.3 +2417,Austria,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9 +2418,Austria,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,190.6 +2419,Austria,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6 +2420,Austria,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7 +2421,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +2422,Austria,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.6 +2423,Austria,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.7 +2424,Austria,2011,5,B-Blood and blood forming organs,Million of national currency units,145.8 +2425,Austria,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +2426,Austria,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",7.8 +2427,Austria,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +2428,Austria,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",164.7 +2429,Austria,2011,5,N05B-Anxiolytics,Million of national currency units,6.5 +2430,Austria,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,9.0 +2431,Austria,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",327.7 +2432,Austria,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,379.2 +2433,Austria,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4 +2434,Austria,2011,5,A-Alimentary tract and metabolism,Million of national currency units,272.4 +2435,Austria,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",45.2 +2436,Austria,2011,5,A-Alimentary tract and metabolism,% of total sales,10.7 +2437,Austria,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0 +2438,Austria,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.2 +2439,Austria,2011,5,C07-Beta blocking agents,% of total sales,2.3 +2440,Austria,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",69.0 +2441,Austria,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.5 +2442,Austria,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",36.7 +2443,Austria,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1 +2444,Austria,2011,5,C08-Calcium channel blockers,Million of national currency units,30.5 +2445,Austria,2011,5,C08-Calcium channel blockers,% of total sales,1.2 +2446,Austria,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,42.5 +2447,Austria,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.0 +2448,Austria,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.7 +2449,Austria,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",123.4 +2450,Austria,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.1 +2451,Austria,2011,5,C-Cardiovascular system,% of total sales,19.5 +2452,Austria,2011,5,C10-Lipid modifying agents,% of total sales,4.0 +2453,Austria,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,142.8 +2454,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",237.0 +2455,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,197.0 +2456,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,274.2 +2457,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",32.7 +2458,Austria,2011,5,C10-Lipid modifying agents,Million of national currency units,102.6 +2459,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.7 +2460,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.2 +2461,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +2462,Austria,2011,5,C02-Antihypertensives,Million of national currency units,39.6 +2463,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3 +2464,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +2465,Austria,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6 +2466,Austria,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.7 +2467,Austria,2011,5,C02-Antihypertensives,Million US$ at exchange rate,55.2 +2468,Austria,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",47.7 +2469,Austria,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3066.7 +2470,Austria,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",422.9 +2471,Austria,2011,5,Total pharmaceutical sales,Million of national currency units,2549.6 +2472,Austria,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,3548.9 +2473,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,10.6 +2474,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.2 +2475,Austria,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",365.4 +2476,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.6 +2477,Austria,2011,5,C03-Diuretics,"/capita, US$ exchange rate",2.6 +2478,Austria,2011,5,C03-Diuretics,"Million US$, purchasing power parity",18.5 +2479,Austria,2011,5,C03-Diuretics,Million US$ at exchange rate,21.4 +2480,Austria,2011,5,C07-Beta blocking agents,Million of national currency units,57.4 +2481,Austria,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,79.9 +2482,Austria,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +2483,Austria,2011,5,C03-Diuretics,% of total sales,0.6 +2484,Austria,2011,5,C03-Diuretics,Million of national currency units,15.4 +2485,Austria,2011,5,C01A-Cardiac glycosides,% of total sales,0.0 +2486,Austria,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +2487,Austria,2011,5,C02-Antihypertensives,% of total sales,1.6 +2488,Austria,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9 +2489,Austria,2011,5,C01A-Cardiac glycosides,Million of national currency units,0.7 +2490,Austria,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +2491,Austria,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8 +2492,Austria,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",82.3 +2493,Austria,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,61.1 +2494,Austria,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,43.9 +2495,Austria,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.9 +2496,Austria,2011,5,C-Cardiovascular system,Million of national currency units,495.9 +2497,Austria,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",52.8 +2498,Austria,2011,5,G-Genito urinary system and sex hormones,% of total sales,1.7 +2499,Austria,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.3 +2500,Austria,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.3 +2501,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3 +2502,Austria,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3 +2503,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.7 +2504,Austria,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",596.5 +2505,Austria,2011,5,C-Cardiovascular system,Million US$ at exchange rate,690.3 +2506,Austria,2010,5,N-Nervous system,"/capita, US$ exchange rate",74.1 +2507,Austria,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",66.3 +2508,Austria,2010,5,N-Nervous system,"Million US$, purchasing power parity",554.9 +2509,Austria,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",88.2 +2510,Austria,2010,5,J01-Antibacterials for systemic use,Million of national currency units,74.3 +2511,Austria,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,98.5 +2512,Austria,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",193.3 +2513,Austria,2010,5,J-Antiinfectives for systemic use,Million of national currency units,162.8 +2514,Austria,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,215.8 +2515,Austria,2010,5,J-Antiinfectives for systemic use,% of total sales,6.5 +2516,Austria,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.8 +2517,Austria,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.1 +2518,Austria,2010,5,N-Nervous system,% of total sales,18.7 +2519,Austria,2010,5,A10-Drugs used in diabetes,Million of national currency units,96.6 +2520,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +2521,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.8 +2522,Austria,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.8 +2523,Austria,2010,5,N02-Analgesics,"/capita, US$ exchange rate",9.8 +2524,Austria,2010,5,N02-Analgesics,"Million US$, purchasing power parity",73.4 +2525,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.5 +2526,Austria,2010,5,N02-Analgesics,Million of national currency units,61.9 +2527,Austria,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.6 +2528,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1 +2529,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.5 +2530,Austria,2010,5,A02A-Antacids,Million of national currency units,0.2 +2531,Austria,2010,5,N02-Analgesics,Million US$ at exchange rate,82.0 +2532,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,47.6 +2533,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.0 +2534,Austria,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.7 +2535,Austria,2010,5,A02A-Antacids,% of total sales,0.0 +2536,Austria,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,128.1 +2537,Austria,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.3 +2538,Austria,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",114.7 +2539,Austria,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +2540,Austria,2010,5,A10-Drugs used in diabetes,% of total sales,3.9 +2541,Austria,2010,5,A02A-Antacids,Million US$ at exchange rate,0.3 +2542,Austria,2010,5,N02-Analgesics,% of total sales,2.5 +2543,Austria,2010,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +2544,Austria,2010,5,A02A-Antacids,"Million US$, purchasing power parity",0.2 +2545,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",50.0 +2546,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1 +2547,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.0 +2548,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7 +2549,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.8 +2550,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.3 +2551,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.3 +2552,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",127.9 +2553,Austria,2010,5,R-Respiratory system,% of total sales,6.2 +2554,Austria,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +2555,Austria,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +2556,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,142.8 +2557,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,107.7 +2558,Austria,2010,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +2559,Austria,2010,5,M-Musculo-skeletal system,Million of national currency units,109.6 +2560,Austria,2010,5,N06A-Antidepressants,Million of national currency units,94.0 +2561,Austria,2010,5,N06A-Antidepressants,% of total sales,3.8 +2562,Austria,2010,5,R-Respiratory system,Million of national currency units,154.8 +2563,Austria,2010,5,M-Musculo-skeletal system,% of total sales,4.4 +2564,Austria,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",111.6 +2565,Austria,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",14.9 +2566,Austria,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.3 +2567,Austria,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.4 +2568,Austria,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",130.1 +2569,Austria,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,145.2 +2570,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.1 +2571,Austria,2010,5,R-Respiratory system,"Million US$, purchasing power parity",183.8 +2572,Austria,2010,5,R-Respiratory system,Million US$ at exchange rate,205.3 +2573,Austria,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",22.0 +2574,Austria,2010,5,R-Respiratory system,"/capita, US$ exchange rate",24.5 +2575,Austria,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6 +2576,Austria,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.0 +2577,Austria,2010,5,N-Nervous system,Million of national currency units,467.4 +2578,Austria,2010,5,B-Blood and blood forming organs,% of total sales,6.1 +2579,Austria,2010,5,Products not elsewhere classified,Million US$ at exchange rate,773.7 +2580,Austria,2010,5,Products not elsewhere classified,Million of national currency units,583.6 +2581,Austria,2010,5,N-Nervous system,Million US$ at exchange rate,619.6 +2582,Austria,2010,5,N06A-Antidepressants,Million US$ at exchange rate,124.6 +2583,Austria,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",179.5 +2584,Austria,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,200.4 +2585,Austria,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.5 +2586,Austria,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.0 +2587,Austria,2010,5,J01-Antibacterials for systemic use,% of total sales,3.0 +2588,Austria,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.8 +2589,Austria,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6 +2590,Austria,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",92.5 +2591,Austria,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",693.0 +2592,Austria,2010,5,Products not elsewhere classified,% of total sales,23.4 +2593,Austria,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",82.9 +2594,Austria,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,132.5 +2595,Austria,2010,5,N05B-Anxiolytics,% of total sales,0.2 +2596,Austria,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9 +2597,Austria,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,175.7 +2598,Austria,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +2599,Austria,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,2.5 +2600,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +2601,Austria,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.8 +2602,Austria,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.0 +2603,Austria,2010,5,B-Blood and blood forming organs,Million of national currency units,151.2 +2604,Austria,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,5.3 +2605,Austria,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",7.3 +2606,Austria,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0 +2607,Austria,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",157.3 +2608,Austria,2010,5,N05B-Anxiolytics,Million of national currency units,6.2 +2609,Austria,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,8.2 +2610,Austria,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",325.9 +2611,Austria,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9 +2612,Austria,2010,5,A-Alimentary tract and metabolism,Million of national currency units,274.4 +2613,Austria,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,363.8 +2614,Austria,2010,5,C08-Calcium channel blockers,% of total sales,1.4 +2615,Austria,2010,5,A-Alimentary tract and metabolism,% of total sales,11.0 +2616,Austria,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",43.5 +2617,Austria,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0 +2618,Austria,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.0 +2619,Austria,2010,5,C07-Beta blocking agents,% of total sales,2.6 +2620,Austria,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",75.7 +2621,Austria,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.1 +2622,Austria,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",40.9 +2623,Austria,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5 +2624,Austria,2010,5,C08-Calcium channel blockers,Million of national currency units,34.5 +2625,Austria,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,45.7 +2626,Austria,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.7 +2627,Austria,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.3 +2628,Austria,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",114.5 +2629,Austria,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.7 +2630,Austria,2010,5,C-Cardiovascular system,% of total sales,20.0 +2631,Austria,2010,5,C10-Lipid modifying agents,% of total sales,3.9 +2632,Austria,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,127.8 +2633,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",232.0 +2634,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,259.1 +2635,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,195.4 +2636,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",31.0 +2637,Austria,2010,5,C10-Lipid modifying agents,Million of national currency units,96.4 +2638,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8 +2639,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7 +2640,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +2641,Austria,2010,5,C02-Antihypertensives,Million of national currency units,39.3 +2642,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +2643,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +2644,Austria,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.2 +2645,Austria,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6 +2646,Austria,2010,5,C02-Antihypertensives,Million US$ at exchange rate,52.1 +2647,Austria,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",46.6 +2648,Austria,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2959.9 +2649,Austria,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",395.2 +2650,Austria,2010,5,Total pharmaceutical sales,Million of national currency units,2493.0 +2651,Austria,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,3305.0 +2652,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.0 +2653,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.1 +2654,Austria,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",353.9 +2655,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.8 +2656,Austria,2010,5,C03-Diuretics,"/capita, US$ exchange rate",2.5 +2657,Austria,2010,5,C03-Diuretics,"Million US$, purchasing power parity",18.8 +2658,Austria,2010,5,C03-Diuretics,Million US$ at exchange rate,21.0 +2659,Austria,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +2660,Austria,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,84.5 +2661,Austria,2010,5,C07-Beta blocking agents,Million of national currency units,63.7 +2662,Austria,2010,5,C03-Diuretics,% of total sales,0.6 +2663,Austria,2010,5,C01A-Cardiac glycosides,Million of national currency units,0.7 +2664,Austria,2010,5,C01A-Cardiac glycosides,% of total sales,0.0 +2665,Austria,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +2666,Austria,2010,5,C02-Antihypertensives,% of total sales,1.6 +2667,Austria,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0 +2668,Austria,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +2669,Austria,2010,5,C03-Diuretics,Million of national currency units,15.8 +2670,Austria,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.9 +2671,Austria,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,57.9 +2672,Austria,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",51.8 +2673,Austria,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,14.5 +2674,Austria,2010,5,C-Cardiovascular system,Million of national currency units,498.0 +2675,Austria,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,43.7 +2676,Austria,2010,5,G-Genito urinary system and sex hormones,% of total sales,1.8 +2677,Austria,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.9 +2678,Austria,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.2 +2679,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3 +2680,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3 +2681,Austria,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3 +2682,Austria,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",78.9 +2683,Austria,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",591.3 +2684,Austria,2010,5,C-Cardiovascular system,Million US$ at exchange rate,660.2 +2685,Austria,2017,5,N-Nervous system,% of total sales,14.1 +2686,Austria,2017,5,N-Nervous system,"Million US$, purchasing power parity",567.4 +2687,Austria,2017,5,N-Nervous system,"/capita, US$ exchange rate",56.5 +2688,Austria,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",64.5 +2689,Austria,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,67.6 +2690,Austria,2017,5,N-Nervous system,Million US$ at exchange rate,496.7 +2691,Austria,2017,5,J01-Antibacterials for systemic use,Million of national currency units,59.8 +2692,Austria,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,300.3 +2693,Austria,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",343.1 +2694,Austria,2017,5,J-Antiinfectives for systemic use,Million of national currency units,265.9 +2695,Austria,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",39.0 +2696,Austria,2017,5,J-Antiinfectives for systemic use,% of total sales,8.5 +2697,Austria,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",34.1 +2698,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +2699,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.3 +2700,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3 +2701,Austria,2017,5,N02-Analgesics,"/capita, US$ exchange rate",8.7 +2702,Austria,2017,5,N02-Analgesics,Million US$ at exchange rate,76.4 +2703,Austria,2017,5,N02-Analgesics,"Million US$, purchasing power parity",87.2 +2704,Austria,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4 +2705,Austria,2017,5,N02-Analgesics,Million of national currency units,67.6 +2706,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0 +2707,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.9 +2708,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",73.0 +2709,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,56.5 +2710,Austria,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.3 +2711,Austria,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.3 +2712,Austria,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +2713,Austria,2017,5,A02A-Antacids,% of total sales,0.0 +2714,Austria,2017,5,A10-Drugs used in diabetes,Million of national currency units,165.7 +2715,Austria,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",213.8 +2716,Austria,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,187.2 +2717,Austria,2017,5,N02-Analgesics,% of total sales,2.2 +2718,Austria,2017,5,A10-Drugs used in diabetes,% of total sales,5.3 +2719,Austria,2017,5,A02A-Antacids,Million of national currency units,0.9 +2720,Austria,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.9 +2721,Austria,2017,5,A02A-Antacids,"Million US$, purchasing power parity",1.1 +2722,Austria,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.1 +2723,Austria,2017,5,A02A-Antacids,Million US$ at exchange rate,1.0 +2724,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,45.7 +2725,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",49.7 +2726,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",52.2 +2727,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.2 +2728,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",4.9 +2729,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7 +2730,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,40.5 +2731,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2 +2732,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.7 +2733,Austria,2017,5,R-Respiratory system,% of total sales,5.7 +2734,Austria,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",26.0 +2735,Austria,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.8 +2736,Austria,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +2737,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,38.5 +2738,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.5 +2739,Austria,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4 +2740,Austria,2017,5,N05C-Hypnotics and sedatives,% of total sales,0.1 +2741,Austria,2017,5,N06A-Antidepressants,% of total sales,2.6 +2742,Austria,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.7 +2743,Austria,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5 +2744,Austria,2017,5,M-Musculo-skeletal system,% of total sales,3.4 +2745,Austria,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",103.3 +2746,Austria,2017,5,N06A-Antidepressants,Million US$ at exchange rate,90.4 +2747,Austria,2017,5,N06A-Antidepressants,Million of national currency units,80.1 +2748,Austria,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.3 +2749,Austria,2017,5,R-Respiratory system,Million of national currency units,177.4 +2750,Austria,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",136.1 +2751,Austria,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.5 +2752,Austria,2017,5,M-Musculo-skeletal system,Million of national currency units,105.5 +2753,Austria,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,119.2 +2754,Austria,2017,5,R-Respiratory system,Million US$ at exchange rate,200.4 +2755,Austria,2017,5,R-Respiratory system,"Million US$, purchasing power parity",228.9 +2756,Austria,2017,5,R-Respiratory system,"/capita, US$ exchange rate",22.8 +2757,Austria,2017,5,N-Nervous system,Million of national currency units,439.7 +2758,Austria,2017,5,B-Blood and blood forming organs,% of total sales,9.9 +2759,Austria,2017,5,Products not elsewhere classified,Million of national currency units,987.4 +2760,Austria,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",399.7 +2761,Austria,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,350.0 +2762,Austria,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.4 +2763,Austria,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.8 +2764,Austria,2017,5,J01-Antibacterials for systemic use,% of total sales,1.9 +2765,Austria,2017,5,Products not elsewhere classified,% of total sales,31.6 +2766,Austria,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.8 +2767,Austria,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.7 +2768,Austria,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",1274.1 +2769,Austria,2017,5,Products not elsewhere classified,Million US$ at exchange rate,1115.5 +2770,Austria,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",144.8 +2771,Austria,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",126.8 +2772,Austria,2017,5,B-Blood and blood forming organs,Million of national currency units,309.8 +2773,Austria,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0 +2774,Austria,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,148.3 +2775,Austria,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.8 +2776,Austria,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,167.5 +2777,Austria,2017,5,N05B-Anxiolytics,% of total sales,0.2 +2778,Austria,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,2.9 +2779,Austria,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +2780,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3 +2781,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.9 +2782,Austria,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",77.2 +2783,Austria,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.0 +2784,Austria,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.8 +2785,Austria,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.7 +2786,Austria,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,7.3 +2787,Austria,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.4 +2788,Austria,2017,5,N05B-Anxiolytics,Million of national currency units,6.5 +2789,Austria,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",191.4 +2790,Austria,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,343.6 +2791,Austria,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",392.5 +2792,Austria,2017,5,A-Alimentary tract and metabolism,Million of national currency units,304.2 +2793,Austria,2017,5,A-Alimentary tract and metabolism,% of total sales,9.7 +2794,Austria,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.5 +2795,Austria,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",39.1 +2796,Austria,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.6 +2797,Austria,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.3 +2798,Austria,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.0 +2799,Austria,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3 +2800,Austria,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",53.0 +2801,Austria,2017,5,C07-Beta blocking agents,% of total sales,1.3 +2802,Austria,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.0 +2803,Austria,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,11.4 +2804,Austria,2017,5,C08-Calcium channel blockers,Million of national currency units,10.1 +2805,Austria,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.2 +2806,Austria,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",16.2 +2807,Austria,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,125.0 +2808,Austria,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",142.8 +2809,Austria,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.8 +2810,Austria,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",55.8 +2811,Austria,2017,5,C10-Lipid modifying agents,% of total sales,3.5 +2812,Austria,2017,5,C-Cardiovascular system,% of total sales,13.9 +2813,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,181.3 +2814,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",207.0 +2815,Austria,2017,5,C08-Calcium channel blockers,% of total sales,0.3 +2816,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,160.5 +2817,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1 +2818,Austria,2017,5,C10-Lipid modifying agents,Million of national currency units,110.6 +2819,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.6 +2820,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5 +2821,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +2822,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +2823,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +2824,Austria,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",64.0 +2825,Austria,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.4 +2826,Austria,2017,5,C02-Antihypertensives,Million of national currency units,49.6 +2827,Austria,2017,5,C02-Antihypertensives,Million US$ at exchange rate,56.0 +2828,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.5 +2829,Austria,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4035.1 +2830,Austria,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,3532.8 +2831,Austria,2017,5,Total pharmaceutical sales,Million of national currency units,3127.2 +2832,Austria,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",401.6 +2833,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.4 +2834,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.6 +2835,Austria,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",458.7 +2836,Austria,2017,5,C03-Diuretics,"Million US$, purchasing power parity",23.6 +2837,Austria,2017,5,C03-Diuretics,"/capita, US$ exchange rate",2.4 +2838,Austria,2017,5,C03-Diuretics,Million of national currency units,18.3 +2839,Austria,2017,5,C03-Diuretics,Million US$ at exchange rate,20.7 +2840,Austria,2017,5,C07-Beta blocking agents,Million of national currency units,41.1 +2841,Austria,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,46.4 +2842,Austria,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.7 +2843,Austria,2017,5,C03-Diuretics,% of total sales,0.6 +2844,Austria,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +2845,Austria,2017,5,C01A-Cardiac glycosides,% of total sales,0.0 +2846,Austria,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.3 +2847,Austria,2017,5,C02-Antihypertensives,% of total sales,1.6 +2848,Austria,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5 +2849,Austria,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.4 +2850,Austria,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +2851,Austria,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +2852,Austria,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,46.1 +2853,Austria,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,52.1 +2854,Austria,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.4 +2855,Austria,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.8 +2856,Austria,2017,5,G-Genito urinary system and sex hormones,% of total sales,1.5 +2857,Austria,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",59.5 +2858,Austria,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.9 +2859,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3 +2860,Austria,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,15.2 +2861,Austria,2017,5,C-Cardiovascular system,Million of national currency units,434.7 +2862,Austria,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",560.8 +2863,Austria,2017,5,C-Cardiovascular system,Million US$ at exchange rate,491.0 +2864,Belgium,2010,6,C03-Diuretics,Million US$ at exchange rate,50.5 +2865,Belgium,2010,6,Total pharmaceutical sales,Million of national currency units,5881.5 +2866,Belgium,2010,6,C03-Diuretics,"Million US$, purchasing power parity",45.6 +2867,Belgium,2010,6,C03-Diuretics,"/capita, US$ exchange rate",4.6 +2868,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,122.5 +2869,Belgium,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,317.7 +2870,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,162.4 +2871,Belgium,2010,6,C03-Diuretics,Million of national currency units,38.1 +2872,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",146.4 +2873,Belgium,2010,6,N06A-Antidepressants,Million of national currency units,186.8 +2874,Belgium,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",223.2 +2875,Belgium,2010,6,N06A-Antidepressants,Million US$ at exchange rate,247.6 +2876,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9 +2877,Belgium,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.2 +2878,Belgium,2010,6,C03-Diuretics,% of total sales,0.6 +2879,Belgium,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,67.6 +2880,Belgium,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",80.9 +2881,Belgium,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,89.7 +2882,Belgium,2010,6,G-Genito urinary system and sex hormones,% of total sales,4.1 +2883,Belgium,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.8 +2884,Belgium,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +2885,Belgium,2010,6,C01A-Cardiac glycosides,Million of national currency units,1.3 +2886,Belgium,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3 +2887,Belgium,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",29.2 +2888,Belgium,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",286.5 +2889,Belgium,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.2 +2890,Belgium,2010,6,N05C-Hypnotics and sedatives,% of total sales,1.2 +2891,Belgium,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.4 +2892,Belgium,2010,6,C07-Beta blocking agents,% of total sales,1.8 +2893,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.0 +2894,Belgium,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",129.6 +2895,Belgium,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",11.9 +2896,Belgium,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",13.2 +2897,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,177.4 +2898,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,235.2 +2899,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,135.6 +2900,Belgium,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,239.7 +2901,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.5 +2902,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.6 +2903,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",212.0 +2904,Belgium,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,143.7 +2905,Belgium,2010,6,M-Musculo-skeletal system,% of total sales,4.3 +2906,Belgium,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.5 +2907,Belgium,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",22.7 +2908,Belgium,2010,6,N06A-Antidepressants,% of total sales,3.2 +2909,Belgium,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.5 +2910,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +2911,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4 +2912,Belgium,2010,6,C07-Beta blocking agents,Million of national currency units,108.4 +2913,Belgium,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",299.2 +2914,Belgium,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.5 +2915,Belgium,2010,6,M-Musculo-skeletal system,Million of national currency units,250.3 +2916,Belgium,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,331.9 +2917,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1 +2918,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9 +2919,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8 +2920,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.3 +2921,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.9 +2922,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.2 +2923,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0 +2924,Belgium,2010,6,N02-Analgesics,"/capita, US$ exchange rate",29.9 +2925,Belgium,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",26.9 +2926,Belgium,2010,6,N02-Analgesics,% of total sales,4.2 +2927,Belgium,2010,6,N02-Analgesics,Million of national currency units,245.6 +2928,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +2929,Belgium,2010,6,N02-Analgesics,"Million US$, purchasing power parity",293.5 +2930,Belgium,2010,6,N02-Analgesics,Million US$ at exchange rate,325.6 +2931,Belgium,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",645.2 +2932,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.5 +2933,Belgium,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,7797.2 +2934,Belgium,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",715.6 +2935,Belgium,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7030.2 +2936,Belgium,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",166.8 +2937,Belgium,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.0 +2938,Belgium,2010,6,A10-Drugs used in diabetes,Million of national currency units,139.5 +2939,Belgium,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,184.9 +2940,Belgium,2010,6,N-Nervous system,% of total sales,17.3 +2941,Belgium,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3 +2942,Belgium,2010,6,A10-Drugs used in diabetes,% of total sales,2.4 +2943,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +2944,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3 +2945,Belgium,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",7.8 +2946,Belgium,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",76.9 +2947,Belgium,2010,6,N05B-Anxiolytics,% of total sales,1.1 +2948,Belgium,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.1 +2949,Belgium,2010,6,C01A-Cardiac glycosides,% of total sales,0.0 +2950,Belgium,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +2951,Belgium,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +2952,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",133.9 +2953,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6 +2954,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,112.0 +2955,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,148.5 +2956,Belgium,2010,6,N-Nervous system,Million of national currency units,1019.6 +2957,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",162.1 +2958,Belgium,2010,6,N-Nervous system,Million US$ at exchange rate,1351.7 +2959,Belgium,2010,6,C02-Antihypertensives,Million US$ at exchange rate,23.5 +2960,Belgium,2010,6,C02-Antihypertensives,Million of national currency units,17.7 +2961,Belgium,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",111.9 +2962,Belgium,2010,6,N-Nervous system,"/capita, US$ exchange rate",124.1 +2963,Belgium,2010,6,N-Nervous system,"Million US$, purchasing power parity",1218.7 +2964,Belgium,2010,6,C02-Antihypertensives,% of total sales,0.3 +2965,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.8 +2966,Belgium,2010,6,N05B-Anxiolytics,Million of national currency units,64.4 +2967,Belgium,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,85.3 +2968,Belgium,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",21.2 +2969,Belgium,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.2 +2970,Belgium,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9 +2971,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",299.4 +2972,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5 +2973,Belgium,2010,6,A02A-Antacids,"/capita, US$ exchange rate",1.3 +2974,Belgium,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,250.5 +2975,Belgium,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,332.1 +2976,Belgium,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2 +2977,Belgium,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.3 +2978,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,234.8 +2979,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5 +2980,Belgium,2010,6,J01-Antibacterials for systemic use,Million of national currency units,251.4 +2981,Belgium,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +2982,Belgium,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,416.1 +2983,Belgium,2010,6,C08-Calcium channel blockers,% of total sales,1.2 +2984,Belgium,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.4 +2985,Belgium,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.8 +2986,Belgium,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9 +2987,Belgium,2010,6,A02A-Antacids,Million US$ at exchange rate,14.2 +2988,Belgium,2010,6,A02A-Antacids,"Million US$, purchasing power parity",12.8 +2989,Belgium,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",38.2 +2990,Belgium,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",375.1 +2991,Belgium,2010,6,A02A-Antacids,Million of national currency units,10.7 +2992,Belgium,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",131.1 +2993,Belgium,2010,6,A02A-Antacids,% of total sales,0.2 +2994,Belgium,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",54.6 +2995,Belgium,2010,6,Products not elsewhere classified,% of total sales,20.3 +2996,Belgium,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",145.5 +2997,Belgium,2010,6,Products not elsewhere classified,Million of national currency units,1195.5 +2998,Belgium,2010,6,Products not elsewhere classified,Million US$ at exchange rate,1584.9 +2999,Belgium,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",1428.9 +3000,Belgium,2010,6,C10-Lipid modifying agents,% of total sales,5.3 +3001,Belgium,2010,6,C10-Lipid modifying agents,Million of national currency units,313.8 +3002,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.8 +3003,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.0 +3004,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.6 +3005,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,311.3 +3006,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",280.7 +3007,Belgium,2010,6,B-Blood and blood forming organs,% of total sales,7.6 +3008,Belgium,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",49.3 +3009,Belgium,2010,6,B-Blood and blood forming organs,Million of national currency units,448.9 +3010,Belgium,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,595.2 +3011,Belgium,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",536.6 +3012,Belgium,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.2 +3013,Belgium,2010,6,R-Respiratory system,% of total sales,8.7 +3014,Belgium,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",68.8 +3015,Belgium,2010,6,R-Respiratory system,"Million US$, purchasing power parity",612.9 +3016,Belgium,2010,6,R-Respiratory system,Million US$ at exchange rate,679.7 +3017,Belgium,2010,6,R-Respiratory system,"/capita, US$ exchange rate",62.4 +3018,Belgium,2010,6,J-Antiinfectives for systemic use,% of total sales,9.7 +3019,Belgium,2010,6,C08-Calcium channel blockers,Million of national currency units,72.4 +3020,Belgium,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",62.7 +3021,Belgium,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.5 +3022,Belgium,2010,6,A-Alimentary tract and metabolism,% of total sales,10.7 +3023,Belgium,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",749.5 +3024,Belgium,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.3 +3025,Belgium,2010,6,R-Respiratory system,Million of national currency units,512.7 +3026,Belgium,2010,6,A-Alimentary tract and metabolism,Million of national currency units,627.0 +3027,Belgium,2010,6,C-Cardiovascular system,Million US$ at exchange rate,1184.9 +3028,Belgium,2010,6,C-Cardiovascular system,Million of national currency units,893.8 +3029,Belgium,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,831.3 +3030,Belgium,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,757.6 +3031,Belgium,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",683.1 +3032,Belgium,2010,6,J-Antiinfectives for systemic use,Million of national currency units,571.5 +3033,Belgium,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",1068.3 +3034,Belgium,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",108.7 +3035,Belgium,2010,6,J01-Antibacterials for systemic use,% of total sales,4.3 +3036,Belgium,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,95.9 +3037,Belgium,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",86.5 +3038,Belgium,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.1 +3039,Belgium,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",300.5 +3040,Belgium,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",30.6 +3041,Belgium,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",27.6 +3042,Belgium,2010,6,C-Cardiovascular system,% of total sales,15.2 +3043,Belgium,2011,6,C03-Diuretics,Million US$ at exchange rate,51.3 +3044,Belgium,2011,6,C03-Diuretics,"/capita, US$ exchange rate",4.6 +3045,Belgium,2011,6,C03-Diuretics,"Million US$, purchasing power parity",44.3 +3046,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,125.4 +3047,Belgium,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,336.1 +3048,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,174.6 +3049,Belgium,2011,6,C03-Diuretics,Million of national currency units,36.9 +3050,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",150.8 +3051,Belgium,2011,6,N06A-Antidepressants,Million of national currency units,188.6 +3052,Belgium,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",226.7 +3053,Belgium,2011,6,N06A-Antidepressants,Million US$ at exchange rate,262.5 +3054,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.8 +3055,Belgium,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0 +3056,Belgium,2011,6,C03-Diuretics,% of total sales,0.6 +3057,Belgium,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,71.2 +3058,Belgium,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",85.5 +3059,Belgium,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,99.1 +3060,Belgium,2011,6,G-Genito urinary system and sex hormones,% of total sales,4.0 +3061,Belgium,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0 +3062,Belgium,2011,6,C01A-Cardiac glycosides,Million of national currency units,1.5 +3063,Belgium,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3 +3064,Belgium,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.5 +3065,Belgium,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",290.3 +3066,Belgium,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0 +3067,Belgium,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7 +3068,Belgium,2011,6,N05C-Hypnotics and sedatives,% of total sales,1.2 +3069,Belgium,2011,6,C07-Beta blocking agents,% of total sales,1.7 +3070,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9 +3071,Belgium,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",119.6 +3072,Belgium,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8 +3073,Belgium,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",12.5 +3074,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,176.7 +3075,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,246.0 +3076,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,132.5 +3077,Belgium,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,241.5 +3078,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.2 +3079,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.3 +3080,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",212.4 +3081,Belgium,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,138.5 +3082,Belgium,2011,6,M-Musculo-skeletal system,% of total sales,4.2 +3083,Belgium,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.3 +3084,Belgium,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",23.8 +3085,Belgium,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.5 +3086,Belgium,2011,6,N06A-Antidepressants,% of total sales,3.1 +3087,Belgium,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8 +3088,Belgium,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.6 +3089,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +3090,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.7 +3091,Belgium,2011,6,C07-Beta blocking agents,Million of national currency units,99.5 +3092,Belgium,2011,6,M-Musculo-skeletal system,Million of national currency units,250.8 +3093,Belgium,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",301.5 +3094,Belgium,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,349.2 +3095,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",18.1 +3096,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9 +3097,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6 +3098,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.2 +3099,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.4 +3100,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.0 +3101,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.1 +3102,Belgium,2011,6,N02-Analgesics,"/capita, US$ exchange rate",32.2 +3103,Belgium,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.8 +3104,Belgium,2011,6,N02-Analgesics,% of total sales,4.3 +3105,Belgium,2011,6,N02-Analgesics,Million of national currency units,255.3 +3106,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +3107,Belgium,2011,6,N02-Analgesics,"Million US$, purchasing power parity",306.9 +3108,Belgium,2011,6,N02-Analgesics,Million US$ at exchange rate,355.3 +3109,Belgium,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",652.7 +3110,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.7 +3111,Belgium,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,8342.4 +3112,Belgium,2011,6,Total pharmaceutical sales,Million of national currency units,5993.3 +3113,Belgium,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",755.8 +3114,Belgium,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7204.3 +3115,Belgium,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",180.8 +3116,Belgium,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0 +3117,Belgium,2011,6,A10-Drugs used in diabetes,Million of national currency units,150.4 +3118,Belgium,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,209.4 +3119,Belgium,2011,6,N-Nervous system,% of total sales,17.5 +3120,Belgium,2011,6,A10-Drugs used in diabetes,% of total sales,2.5 +3121,Belgium,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.4 +3122,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +3123,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.8 +3124,Belgium,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.2 +3125,Belgium,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",78.2 +3126,Belgium,2011,6,N05B-Anxiolytics,% of total sales,1.1 +3127,Belgium,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.1 +3128,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.8 +3129,Belgium,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +3130,Belgium,2011,6,C01A-Cardiac glycosides,% of total sales,0.0 +3131,Belgium,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +3132,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",141.3 +3133,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,117.5 +3134,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,163.6 +3135,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",159.3 +3136,Belgium,2011,6,N-Nervous system,Million of national currency units,1050.7 +3137,Belgium,2011,6,C02-Antihypertensives,Million US$ at exchange rate,28.8 +3138,Belgium,2011,6,C02-Antihypertensives,Million of national currency units,20.7 +3139,Belgium,2011,6,N-Nervous system,Million US$ at exchange rate,1462.5 +3140,Belgium,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",114.4 +3141,Belgium,2011,6,N-Nervous system,"/capita, US$ exchange rate",132.5 +3142,Belgium,2011,6,N-Nervous system,"Million US$, purchasing power parity",1263.0 +3143,Belgium,2011,6,C02-Antihypertensives,% of total sales,0.3 +3144,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,184.5 +3145,Belgium,2011,6,N05B-Anxiolytics,Million of national currency units,65.0 +3146,Belgium,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,90.5 +3147,Belgium,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.9 +3148,Belgium,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.3 +3149,Belgium,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +3150,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",306.7 +3151,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.2 +3152,Belgium,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,355.1 +3153,Belgium,2011,6,J01-Antibacterials for systemic use,Million of national currency units,244.6 +3154,Belgium,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,255.1 +3155,Belgium,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.3 +3156,Belgium,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,340.5 +3157,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,233.0 +3158,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.8 +3159,Belgium,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +3160,Belgium,2011,6,A02A-Antacids,"/capita, US$ exchange rate",1.4 +3161,Belgium,2011,6,C08-Calcium channel blockers,% of total sales,1.1 +3162,Belgium,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",35.7 +3163,Belgium,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.5 +3164,Belgium,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.4 +3165,Belgium,2011,6,A02A-Antacids,Million US$ at exchange rate,16.0 +3166,Belgium,2011,6,A02A-Antacids,"Million US$, purchasing power parity",13.8 +3167,Belgium,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.4 +3168,Belgium,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,456.5 +3169,Belgium,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",394.3 +3170,Belgium,2011,6,A02A-Antacids,Million of national currency units,11.5 +3171,Belgium,2011,6,A02A-Antacids,% of total sales,0.2 +3172,Belgium,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.5 +3173,Belgium,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",56.0 +3174,Belgium,2011,6,Products not elsewhere classified,% of total sales,20.6 +3175,Belgium,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",155.7 +3176,Belgium,2011,6,Products not elsewhere classified,Million of national currency units,1234.9 +3177,Belgium,2011,6,Products not elsewhere classified,Million US$ at exchange rate,1719.0 +3178,Belgium,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",1484.5 +3179,Belgium,2011,6,C10-Lipid modifying agents,% of total sales,5.5 +3180,Belgium,2011,6,C10-Lipid modifying agents,Million of national currency units,328.0 +3181,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.4 +3182,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9 +3183,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.4 +3184,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,324.3 +3185,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",280.0 +3186,Belgium,2011,6,B-Blood and blood forming organs,% of total sales,7.4 +3187,Belgium,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",48.4 +3188,Belgium,2011,6,B-Blood and blood forming organs,Million of national currency units,444.1 +3189,Belgium,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,618.2 +3190,Belgium,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",533.9 +3191,Belgium,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.9 +3192,Belgium,2011,6,R-Respiratory system,% of total sales,8.7 +3193,Belgium,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.5 +3194,Belgium,2011,6,R-Respiratory system,Million US$ at exchange rate,726.9 +3195,Belgium,2011,6,R-Respiratory system,"Million US$, purchasing power parity",627.7 +3196,Belgium,2011,6,R-Respiratory system,"/capita, US$ exchange rate",65.8 +3197,Belgium,2011,6,J-Antiinfectives for systemic use,% of total sales,9.8 +3198,Belgium,2011,6,C08-Calcium channel blockers,Million of national currency units,67.8 +3199,Belgium,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.8 +3200,Belgium,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",73.9 +3201,Belgium,2011,6,A-Alimentary tract and metabolism,% of total sales,10.8 +3202,Belgium,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",778.6 +3203,Belgium,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",81.7 +3204,Belgium,2011,6,R-Respiratory system,Million of national currency units,522.2 +3205,Belgium,2011,6,C-Cardiovascular system,Million of national currency units,889.8 +3206,Belgium,2011,6,A-Alimentary tract and metabolism,Million of national currency units,647.7 +3207,Belgium,2011,6,C-Cardiovascular system,Million US$ at exchange rate,1238.6 +3208,Belgium,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,901.6 +3209,Belgium,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,815.8 +3210,Belgium,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",704.5 +3211,Belgium,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",1069.6 +3212,Belgium,2011,6,J-Antiinfectives for systemic use,Million of national currency units,586.1 +3213,Belgium,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",112.2 +3214,Belgium,2011,6,J01-Antibacterials for systemic use,% of total sales,4.1 +3215,Belgium,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,94.4 +3216,Belgium,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.5 +3217,Belgium,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.9 +3218,Belgium,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",30.8 +3219,Belgium,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",26.6 +3220,Belgium,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",294.1 +3221,Belgium,2011,6,C-Cardiovascular system,% of total sales,14.8 +3222,Belgium,2012,6,C03-Diuretics,Million US$ at exchange rate,45.8 +3223,Belgium,2012,6,C03-Diuretics,"/capita, US$ exchange rate",4.1 +3224,Belgium,2012,6,C03-Diuretics,"Million US$, purchasing power parity",43.4 +3225,Belgium,2012,6,C03-Diuretics,Million of national currency units,35.7 +3226,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,124.4 +3227,Belgium,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,303.9 +3228,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",151.3 +3229,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,159.8 +3230,Belgium,2012,6,N06A-Antidepressants,Million of national currency units,185.6 +3231,Belgium,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",225.7 +3232,Belgium,2012,6,N06A-Antidepressants,Million US$ at exchange rate,238.4 +3233,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.4 +3234,Belgium,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +3235,Belgium,2012,6,C03-Diuretics,% of total sales,0.6 +3236,Belgium,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,70.2 +3237,Belgium,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",85.4 +3238,Belgium,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,90.2 +3239,Belgium,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.8 +3240,Belgium,2012,6,G-Genito urinary system and sex hormones,% of total sales,4.0 +3241,Belgium,2012,6,C01A-Cardiac glycosides,Million of national currency units,1.4 +3242,Belgium,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.4 +3243,Belgium,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.9 +3244,Belgium,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",287.7 +3245,Belgium,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.1 +3246,Belgium,2012,6,N05C-Hypnotics and sedatives,% of total sales,1.2 +3247,Belgium,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7 +3248,Belgium,2012,6,C07-Beta blocking agents,% of total sales,1.6 +3249,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7 +3250,Belgium,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",119.0 +3251,Belgium,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.7 +3252,Belgium,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.3 +3253,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,158.3 +3254,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,203.4 +3255,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,124.1 +3256,Belgium,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,236.6 +3257,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.3 +3258,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.3 +3259,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",192.6 +3260,Belgium,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,125.7 +3261,Belgium,2012,6,M-Musculo-skeletal system,% of total sales,4.2 +3262,Belgium,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.3 +3263,Belgium,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.5 +3264,Belgium,2012,6,N06A-Antidepressants,% of total sales,3.1 +3265,Belgium,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.3 +3266,Belgium,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.9 +3267,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +3268,Belgium,2012,6,C07-Beta blocking agents,Million of national currency units,97.8 +3269,Belgium,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.7 +3270,Belgium,2012,6,M-Musculo-skeletal system,Million of national currency units,249.7 +3271,Belgium,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,320.8 +3272,Belgium,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7 +3273,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",18.4 +3274,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +3275,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.7 +3276,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,19.4 +3277,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.1 +3278,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.6 +3279,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.1 +3280,Belgium,2012,6,N02-Analgesics,"/capita, US$ exchange rate",28.9 +3281,Belgium,2012,6,N02-Analgesics,% of total sales,4.2 +3282,Belgium,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.4 +3283,Belgium,2012,6,N02-Analgesics,"Million US$, purchasing power parity",304.4 +3284,Belgium,2012,6,N02-Analgesics,Million of national currency units,250.3 +3285,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +3286,Belgium,2012,6,N02-Analgesics,Million US$ at exchange rate,321.5 +3287,Belgium,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",650.4 +3288,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.4 +3289,Belgium,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,7630.9 +3290,Belgium,2012,6,Total pharmaceutical sales,Million of national currency units,5939.4 +3291,Belgium,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",687.0 +3292,Belgium,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7224.3 +3293,Belgium,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",188.8 +3294,Belgium,2012,6,A10-Drugs used in diabetes,Million of national currency units,155.2 +3295,Belgium,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,199.4 +3296,Belgium,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0 +3297,Belgium,2012,6,N-Nervous system,% of total sales,16.9 +3298,Belgium,2012,6,A10-Drugs used in diabetes,% of total sales,2.6 +3299,Belgium,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.0 +3300,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +3301,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.8 +3302,Belgium,2012,6,N05B-Anxiolytics,% of total sales,1.1 +3303,Belgium,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",7.4 +3304,Belgium,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",77.6 +3305,Belgium,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.0 +3306,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6 +3307,Belgium,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +3308,Belgium,2012,6,C01A-Cardiac glycosides,% of total sales,0.0 +3309,Belgium,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +3310,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",142.5 +3311,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,117.2 +3312,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,150.6 +3313,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",151.0 +3314,Belgium,2012,6,N-Nervous system,Million of national currency units,1005.5 +3315,Belgium,2012,6,C02-Antihypertensives,Million of national currency units,19.6 +3316,Belgium,2012,6,N-Nervous system,Million US$ at exchange rate,1291.9 +3317,Belgium,2012,6,N-Nervous system,"/capita, US$ exchange rate",116.3 +3318,Belgium,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",110.1 +3319,Belgium,2012,6,C02-Antihypertensives,Million US$ at exchange rate,25.2 +3320,Belgium,2012,6,N-Nervous system,"Million US$, purchasing power parity",1223.1 +3321,Belgium,2012,6,C02-Antihypertensives,% of total sales,0.3 +3322,Belgium,2012,6,N05B-Anxiolytics,Million of national currency units,63.8 +3323,Belgium,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,82.0 +3324,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,159.5 +3325,Belgium,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",23.9 +3326,Belgium,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +3327,Belgium,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1 +3328,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.6 +3329,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",308.6 +3330,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.4 +3331,Belgium,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,326.0 +3332,Belgium,2012,6,J01-Antibacterials for systemic use,Million of national currency units,225.8 +3333,Belgium,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,253.7 +3334,Belgium,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.3 +3335,Belgium,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,290.2 +3336,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,226.4 +3337,Belgium,2012,6,A02A-Antacids,"/capita, US$ exchange rate",1.3 +3338,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.8 +3339,Belgium,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +3340,Belgium,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,379.9 +3341,Belgium,2012,6,C08-Calcium channel blockers,% of total sales,1.1 +3342,Belgium,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",32.4 +3343,Belgium,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.4 +3344,Belgium,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0 +3345,Belgium,2012,6,A02A-Antacids,Million US$ at exchange rate,14.9 +3346,Belgium,2012,6,A02A-Antacids,"Million US$, purchasing power parity",14.1 +3347,Belgium,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",34.2 +3348,Belgium,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",359.7 +3349,Belgium,2012,6,A02A-Antacids,Million of national currency units,11.6 +3350,Belgium,2012,6,A02A-Antacids,% of total sales,0.2 +3351,Belgium,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",140.7 +3352,Belgium,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",52.1 +3353,Belgium,2012,6,Products not elsewhere classified,% of total sales,21.6 +3354,Belgium,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",148.6 +3355,Belgium,2012,6,Products not elsewhere classified,Million of national currency units,1284.3 +3356,Belgium,2012,6,Products not elsewhere classified,Million US$ at exchange rate,1650.1 +3357,Belgium,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",1562.2 +3358,Belgium,2012,6,C10-Lipid modifying agents,% of total sales,5.0 +3359,Belgium,2012,6,C10-Lipid modifying agents,Million of national currency units,295.7 +3360,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.8 +3361,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.8 +3362,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.2 +3363,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,290.9 +3364,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",275.4 +3365,Belgium,2012,6,B-Blood and blood forming organs,% of total sales,7.6 +3366,Belgium,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",49.3 +3367,Belgium,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",548.0 +3368,Belgium,2012,6,B-Blood and blood forming organs,Million of national currency units,450.6 +3369,Belgium,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,578.9 +3370,Belgium,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.6 +3371,Belgium,2012,6,R-Respiratory system,% of total sales,8.7 +3372,Belgium,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.9 +3373,Belgium,2012,6,R-Respiratory system,Million US$ at exchange rate,664.4 +3374,Belgium,2012,6,R-Respiratory system,"Million US$, purchasing power parity",629.0 +3375,Belgium,2012,6,R-Respiratory system,"/capita, US$ exchange rate",59.8 +3376,Belgium,2012,6,J-Antiinfectives for systemic use,% of total sales,9.8 +3377,Belgium,2012,6,C08-Calcium channel blockers,Million of national currency units,63.9 +3378,Belgium,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",67.5 +3379,Belgium,2012,6,A-Alimentary tract and metabolism,% of total sales,10.9 +3380,Belgium,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",787.5 +3381,Belgium,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",74.9 +3382,Belgium,2012,6,R-Respiratory system,Million of national currency units,517.1 +3383,Belgium,2012,6,C-Cardiovascular system,Million of national currency units,840.1 +3384,Belgium,2012,6,A-Alimentary tract and metabolism,Million of national currency units,647.4 +3385,Belgium,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,831.8 +3386,Belgium,2012,6,C-Cardiovascular system,Million US$ at exchange rate,1079.3 +3387,Belgium,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,750.0 +3388,Belgium,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",710.0 +3389,Belgium,2012,6,J-Antiinfectives for systemic use,Million of national currency units,583.7 +3390,Belgium,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",1021.8 +3391,Belgium,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",97.2 +3392,Belgium,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.9 +3393,Belgium,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,82.0 +3394,Belgium,2012,6,J01-Antibacterials for systemic use,% of total sales,3.8 +3395,Belgium,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",77.7 +3396,Belgium,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",274.7 +3397,Belgium,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",92.0 +3398,Belgium,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",24.7 +3399,Belgium,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1 +3400,Belgium,2012,6,C-Cardiovascular system,% of total sales,14.1 +3401,Belgium,2016,5,C03-Diuretics,Million US$ at exchange rate,36.5 +3402,Belgium,2016,5,C03-Diuretics,Million of national currency units,33.0 +3403,Belgium,2016,5,C03-Diuretics,"Million US$, purchasing power parity",42.2 +3404,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,126.2 +3405,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,139.7 +3406,Belgium,2016,5,N06A-Antidepressants,Million of national currency units,130.1 +3407,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3 +3408,Belgium,2016,5,N06A-Antidepressants,Million US$ at exchange rate,144.0 +3409,Belgium,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +3410,Belgium,2016,5,C03-Diuretics,"/capita, US$ exchange rate",3.2 +3411,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",161.6 +3412,Belgium,2016,5,C03-Diuretics,% of total sales,0.5 +3413,Belgium,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,249.6 +3414,Belgium,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,77.6 +3415,Belgium,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.5 +3416,Belgium,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,85.9 +3417,Belgium,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0 +3418,Belgium,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.9 +3419,Belgium,2016,5,G-Genito urinary system and sex hormones,% of total sales,3.6 +3420,Belgium,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",99.4 +3421,Belgium,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.0 +3422,Belgium,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",288.7 +3423,Belgium,2016,5,N05C-Hypnotics and sedatives,% of total sales,1.2 +3424,Belgium,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.6 +3425,Belgium,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.8 +3426,Belgium,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",166.5 +3427,Belgium,2016,5,C07-Beta blocking agents,% of total sales,1.4 +3428,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +3429,Belgium,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.7 +3430,Belgium,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",110.3 +3431,Belgium,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,95.3 +3432,Belgium,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4 +3433,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.4 +3434,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,163.2 +3435,Belgium,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,225.5 +3436,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,109.3 +3437,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,180.7 +3438,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.9 +3439,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",209.0 +3440,Belgium,2016,5,M-Musculo-skeletal system,% of total sales,4.1 +3441,Belgium,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.8 +3442,Belgium,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.7 +3443,Belgium,2016,5,N06A-Antidepressants,% of total sales,2.1 +3444,Belgium,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.7 +3445,Belgium,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.7 +3446,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.3 +3447,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +3448,Belgium,2016,5,C07-Beta blocking agents,Million of national currency units,86.1 +3449,Belgium,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",325.6 +3450,Belgium,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,281.5 +3451,Belgium,2016,5,M-Musculo-skeletal system,Million of national currency units,254.3 +3452,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.0 +3453,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.4 +3454,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +3455,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4 +3456,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.4 +3457,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +3458,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,14.8 +3459,Belgium,2016,5,N02-Analgesics,"/capita, US$ exchange rate",24.1 +3460,Belgium,2016,5,N02-Analgesics,"Million US$, purchasing power parity",316.0 +3461,Belgium,2016,5,N02-Analgesics,% of total sales,4.0 +3462,Belgium,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",27.9 +3463,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +3464,Belgium,2016,5,N02-Analgesics,Million of national currency units,246.8 +3465,Belgium,2016,5,N02-Analgesics,Million US$ at exchange rate,273.2 +3466,Belgium,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",705.4 +3467,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",140.0 +3468,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.7 +3469,Belgium,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",609.8 +3470,Belgium,2016,5,N-Nervous system,% of total sales,14.6 +3471,Belgium,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,6910.0 +3472,Belgium,2016,5,Total pharmaceutical sales,Million of national currency units,6242.6 +3473,Belgium,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",7993.0 +3474,Belgium,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",245.6 +3475,Belgium,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,212.4 +3476,Belgium,2016,5,A10-Drugs used in diabetes,Million of national currency units,191.8 +3477,Belgium,2016,5,A10-Drugs used in diabetes,% of total sales,3.1 +3478,Belgium,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.7 +3479,Belgium,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.7 +3480,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +3481,Belgium,2016,5,N05B-Anxiolytics,% of total sales,1.2 +3482,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.6 +3483,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3 +3484,Belgium,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",92.8 +3485,Belgium,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",7.1 +3486,Belgium,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.2 +3487,Belgium,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +3488,Belgium,2016,5,C01A-Cardiac glycosides,% of total sales,0.0 +3489,Belgium,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.1 +3490,Belgium,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +3491,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",139.6 +3492,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,120.7 +3493,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,109.0 +3494,Belgium,2016,5,N-Nervous system,Million of national currency units,910.9 +3495,Belgium,2016,5,C02-Antihypertensives,Million of national currency units,25.9 +3496,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,121.0 +3497,Belgium,2016,5,N-Nervous system,"/capita, US$ exchange rate",89.0 +3498,Belgium,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",102.9 +3499,Belgium,2016,5,N-Nervous system,Million US$ at exchange rate,1008.3 +3500,Belgium,2016,5,N-Nervous system,"Million US$, purchasing power parity",1166.3 +3501,Belgium,2016,5,C02-Antihypertensives,% of total sales,0.4 +3502,Belgium,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,80.2 +3503,Belgium,2016,5,N05B-Anxiolytics,Million of national currency units,72.5 +3504,Belgium,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",33.2 +3505,Belgium,2016,5,C02-Antihypertensives,Million US$ at exchange rate,28.7 +3506,Belgium,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9 +3507,Belgium,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.5 +3508,Belgium,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,269.6 +3509,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",311.9 +3510,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.8 +3511,Belgium,2016,5,J01-Antibacterials for systemic use,Million of national currency units,197.1 +3512,Belgium,2016,5,A02A-Antacids,"Million US$, purchasing power parity",12.5 +3513,Belgium,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,243.6 +3514,Belgium,2016,5,A02A-Antacids,"/capita, US$ exchange rate",1.0 +3515,Belgium,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1 +3516,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5 +3517,Belgium,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,3.9 +3518,Belgium,2016,5,C08-Calcium channel blockers,% of total sales,0.7 +3519,Belgium,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.6 +3520,Belgium,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5 +3521,Belgium,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.2 +3522,Belgium,2016,5,A02A-Antacids,Million US$ at exchange rate,10.8 +3523,Belgium,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,241.4 +3524,Belgium,2016,5,A02A-Antacids,Million of national currency units,9.8 +3525,Belgium,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.3 +3526,Belgium,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",279.3 +3527,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,190.4 +3528,Belgium,2016,5,A02A-Antacids,% of total sales,0.2 +3529,Belgium,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",187.2 +3530,Belgium,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",161.8 +3531,Belgium,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",54.7 +3532,Belgium,2016,5,Products not elsewhere classified,% of total sales,26.5 +3533,Belgium,2016,5,Products not elsewhere classified,Million of national currency units,1656.3 +3534,Belgium,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1833.4 +3535,Belgium,2016,5,C10-Lipid modifying agents,Million of national currency units,218.1 +3536,Belgium,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",2120.7 +3537,Belgium,2016,5,C10-Lipid modifying agents,% of total sales,3.5 +3538,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.6 +3539,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.5 +3540,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,210.7 +3541,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.0 +3542,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",243.7 +3543,Belgium,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",716.6 +3544,Belgium,2016,5,B-Blood and blood forming organs,% of total sales,9.0 +3545,Belgium,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",63.2 +3546,Belgium,2016,5,B-Blood and blood forming organs,Million of national currency units,559.7 +3547,Belgium,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,619.5 +3548,Belgium,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",57.7 +3549,Belgium,2016,5,R-Respiratory system,% of total sales,8.2 +3550,Belgium,2016,5,R-Respiratory system,Million US$ at exchange rate,565.2 +3551,Belgium,2016,5,R-Respiratory system,"/capita, US$ exchange rate",49.9 +3552,Belgium,2016,5,R-Respiratory system,"Million US$, purchasing power parity",653.8 +3553,Belgium,2016,5,J-Antiinfectives for systemic use,% of total sales,10.2 +3554,Belgium,2016,5,C08-Calcium channel blockers,Million of national currency units,45.9 +3555,Belgium,2016,5,A-Alimentary tract and metabolism,% of total sales,10.9 +3556,Belgium,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.0 +3557,Belgium,2016,5,C-Cardiovascular system,% of total sales,11.0 +3558,Belgium,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6 +3559,Belgium,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",71.7 +3560,Belgium,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",867.6 +3561,Belgium,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",66.2 +3562,Belgium,2016,5,C-Cardiovascular system,Million of national currency units,686.7 +3563,Belgium,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,750.1 +3564,Belgium,2016,5,A-Alimentary tract and metabolism,Million of national currency units,677.6 +3565,Belgium,2016,5,J-Antiinfectives for systemic use,Million of national currency units,634.8 +3566,Belgium,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,702.6 +3567,Belgium,2016,5,R-Respiratory system,Million of national currency units,510.7 +3568,Belgium,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",812.7 +3569,Belgium,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",879.3 +3570,Belgium,2016,5,C-Cardiovascular system,Million US$ at exchange rate,760.2 +3571,Belgium,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",67.1 +3572,Belgium,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,50.9 +3573,Belgium,2016,5,J01-Antibacterials for systemic use,% of total sales,3.2 +3574,Belgium,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",58.8 +3575,Belgium,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",252.4 +3576,Belgium,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,218.2 +3577,Belgium,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.3 +3578,Belgium,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.3 +3579,Belgium,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.6 +3580,Belgium,2014,6,C03-Diuretics,Million US$ at exchange rate,46.1 +3581,Belgium,2014,6,C03-Diuretics,"Million US$, purchasing power parity",43.4 +3582,Belgium,2014,6,C03-Diuretics,Million of national currency units,34.7 +3583,Belgium,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.1 +3584,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,123.1 +3585,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",153.8 +3586,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,163.6 +3587,Belgium,2014,6,N06A-Antidepressants,Million of national currency units,179.1 +3588,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.6 +3589,Belgium,2014,6,N06A-Antidepressants,Million US$ at exchange rate,238.0 +3590,Belgium,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +3591,Belgium,2014,6,C03-Diuretics,% of total sales,0.6 +3592,Belgium,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,301.1 +3593,Belgium,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,75.3 +3594,Belgium,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.3 +3595,Belgium,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.0 +3596,Belgium,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5 +3597,Belgium,2014,6,G-Genito urinary system and sex hormones,% of total sales,3.8 +3598,Belgium,2014,6,C01A-Cardiac glycosides,Million of national currency units,1.1 +3599,Belgium,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",94.0 +3600,Belgium,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.9 +3601,Belgium,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",283.2 +3602,Belgium,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.9 +3603,Belgium,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.3 +3604,Belgium,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.4 +3605,Belgium,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",223.8 +3606,Belgium,2014,6,C07-Beta blocking agents,% of total sales,1.5 +3607,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +3608,Belgium,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.2 +3609,Belgium,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",114.8 +3610,Belgium,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,122.1 +3611,Belgium,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",10.9 +3612,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,144.1 +3613,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,113.7 +3614,Belgium,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,226.7 +3615,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,191.4 +3616,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1 +3617,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.1 +3618,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",180.0 +3619,Belgium,2014,6,M-Musculo-skeletal system,% of total sales,4.3 +3620,Belgium,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4 +3621,Belgium,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.2 +3622,Belgium,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.2 +3623,Belgium,2014,6,N06A-Antidepressants,% of total sales,3.0 +3624,Belgium,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.0 +3625,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +3626,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.7 +3627,Belgium,2014,6,C07-Beta blocking agents,Million of national currency units,91.9 +3628,Belgium,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",318.5 +3629,Belgium,2014,6,M-Musculo-skeletal system,Million of national currency units,254.9 +3630,Belgium,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,338.6 +3631,Belgium,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +3632,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.4 +3633,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +3634,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8 +3635,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,20.6 +3636,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.9 +3637,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.7 +3638,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.5 +3639,Belgium,2014,6,N02-Analgesics,"/capita, US$ exchange rate",28.0 +3640,Belgium,2014,6,N02-Analgesics,% of total sales,4.0 +3641,Belgium,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",26.3 +3642,Belgium,2014,6,N02-Analgesics,"Million US$, purchasing power parity",295.3 +3643,Belgium,2014,6,N02-Analgesics,Million of national currency units,236.3 +3644,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +3645,Belgium,2014,6,N02-Analgesics,Million US$ at exchange rate,314.0 +3646,Belgium,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",663.1 +3647,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.5 +3648,Belgium,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,7901.2 +3649,Belgium,2014,6,Total pharmaceutical sales,Million of national currency units,5947.5 +3650,Belgium,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7432.3 +3651,Belgium,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",704.9 +3652,Belgium,2014,6,N-Nervous system,% of total sales,16.1 +3653,Belgium,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",214.2 +3654,Belgium,2014,6,A10-Drugs used in diabetes,Million of national currency units,171.4 +3655,Belgium,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,227.7 +3656,Belgium,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.3 +3657,Belgium,2014,6,A10-Drugs used in diabetes,% of total sales,2.9 +3658,Belgium,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.1 +3659,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +3660,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.4 +3661,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1 +3662,Belgium,2014,6,N05B-Anxiolytics,% of total sales,1.2 +3663,Belgium,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.3 +3664,Belgium,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",87.8 +3665,Belgium,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.8 +3666,Belgium,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +3667,Belgium,2014,6,C01A-Cardiac glycosides,% of total sales,0.0 +3668,Belgium,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +3669,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",138.5 +3670,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,147.2 +3671,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,110.8 +3672,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",142.0 +3673,Belgium,2014,6,N-Nervous system,Million of national currency units,958.5 +3674,Belgium,2014,6,C02-Antihypertensives,Million of national currency units,20.2 +3675,Belgium,2014,6,N-Nervous system,Million US$ at exchange rate,1273.4 +3676,Belgium,2014,6,N-Nervous system,"/capita, US$ exchange rate",113.6 +3677,Belgium,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",106.9 +3678,Belgium,2014,6,N-Nervous system,"Million US$, purchasing power parity",1197.8 +3679,Belgium,2014,6,C02-Antihypertensives,% of total sales,0.3 +3680,Belgium,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,93.4 +3681,Belgium,2014,6,N05B-Anxiolytics,Million of national currency units,70.3 +3682,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,151.0 +3683,Belgium,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",25.2 +3684,Belgium,2014,6,C02-Antihypertensives,Million US$ at exchange rate,26.8 +3685,Belgium,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.2 +3686,Belgium,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.4 +3687,Belgium,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,333.1 +3688,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",313.3 +3689,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.7 +3690,Belgium,2014,6,J01-Antibacterials for systemic use,Million of national currency units,213.6 +3691,Belgium,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,250.7 +3692,Belgium,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2 +3693,Belgium,2014,6,A02A-Antacids,"/capita, US$ exchange rate",1.2 +3694,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.0 +3695,Belgium,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,4.2 +3696,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,199.3 +3697,Belgium,2014,6,C08-Calcium channel blockers,% of total sales,1.0 +3698,Belgium,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.2 +3699,Belgium,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8 +3700,Belgium,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4 +3701,Belgium,2014,6,A02A-Antacids,Million US$ at exchange rate,13.9 +3702,Belgium,2014,6,A02A-Antacids,"Million US$, purchasing power parity",13.1 +3703,Belgium,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,300.6 +3704,Belgium,2014,6,A02A-Antacids,Million of national currency units,10.5 +3705,Belgium,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.8 +3706,Belgium,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",282.8 +3707,Belgium,2014,6,A02A-Antacids,% of total sales,0.2 +3708,Belgium,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",160.9 +3709,Belgium,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",171.1 +3710,Belgium,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.4 +3711,Belgium,2014,6,Products not elsewhere classified,% of total sales,24.3 +3712,Belgium,2014,6,Products not elsewhere classified,Million of national currency units,1443.5 +3713,Belgium,2014,6,Products not elsewhere classified,Million US$ at exchange rate,1917.7 +3714,Belgium,2014,6,C10-Lipid modifying agents,Million of national currency units,226.3 +3715,Belgium,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",1803.9 +3716,Belgium,2014,6,C10-Lipid modifying agents,% of total sales,3.8 +3717,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.6 +3718,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.2 +3719,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4 +3720,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,264.8 +3721,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",249.1 +3722,Belgium,2014,6,B-Blood and blood forming organs,% of total sales,8.4 +3723,Belgium,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",55.9 +3724,Belgium,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",626.5 +3725,Belgium,2014,6,B-Blood and blood forming organs,Million of national currency units,501.4 +3726,Belgium,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,666.1 +3727,Belgium,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.4 +3728,Belgium,2014,6,R-Respiratory system,% of total sales,8.5 +3729,Belgium,2014,6,R-Respiratory system,Million US$ at exchange rate,671.6 +3730,Belgium,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.6 +3731,Belgium,2014,6,R-Respiratory system,"Million US$, purchasing power parity",631.7 +3732,Belgium,2014,6,R-Respiratory system,"/capita, US$ exchange rate",59.9 +3733,Belgium,2014,6,J-Antiinfectives for systemic use,% of total sales,9.7 +3734,Belgium,2014,6,C08-Calcium channel blockers,Million of national currency units,57.1 +3735,Belgium,2014,6,A-Alimentary tract and metabolism,% of total sales,10.6 +3736,Belgium,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.3 +3737,Belgium,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.3 +3738,Belgium,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",791.5 +3739,Belgium,2014,6,R-Respiratory system,Million of national currency units,505.5 +3740,Belgium,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",75.1 +3741,Belgium,2014,6,C-Cardiovascular system,Million of national currency units,724.2 +3742,Belgium,2014,6,A-Alimentary tract and metabolism,Million of national currency units,633.4 +3743,Belgium,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,841.4 +3744,Belgium,2014,6,C-Cardiovascular system,Million US$ at exchange rate,962.1 +3745,Belgium,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,765.8 +3746,Belgium,2014,6,J-Antiinfectives for systemic use,Million of national currency units,576.4 +3747,Belgium,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",720.3 +3748,Belgium,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",905.0 +3749,Belgium,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",85.8 +3750,Belgium,2014,6,J01-Antibacterials for systemic use,% of total sales,3.6 +3751,Belgium,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,75.9 +3752,Belgium,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.7 +3753,Belgium,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.4 +3754,Belgium,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,283.7 +3755,Belgium,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",266.9 +3756,Belgium,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.8 +3757,Belgium,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",25.3 +3758,Belgium,2014,6,C-Cardiovascular system,% of total sales,12.2 +3759,Belgium,2015,5,C03-Diuretics,Million US$ at exchange rate,37.2 +3760,Belgium,2015,5,C03-Diuretics,Million of national currency units,33.5 +3761,Belgium,2015,5,C03-Diuretics,"Million US$, purchasing power parity",41.9 +3762,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,126.9 +3763,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",158.6 +3764,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,140.8 +3765,Belgium,2015,5,C03-Diuretics,"/capita, US$ exchange rate",3.3 +3766,Belgium,2015,5,N06A-Antidepressants,Million of national currency units,155.6 +3767,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.5 +3768,Belgium,2015,5,N06A-Antidepressants,Million US$ at exchange rate,172.7 +3769,Belgium,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +3770,Belgium,2015,5,C03-Diuretics,% of total sales,0.5 +3771,Belgium,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,78.0 +3772,Belgium,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.9 +3773,Belgium,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,86.6 +3774,Belgium,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1 +3775,Belgium,2015,5,G-Genito urinary system and sex hormones,% of total sales,3.6 +3776,Belgium,2015,5,C01A-Cardiac glycosides,Million of national currency units,1.0 +3777,Belgium,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",97.6 +3778,Belgium,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.1 +3779,Belgium,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",280.9 +3780,Belgium,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,249.3 +3781,Belgium,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.7 +3782,Belgium,2015,5,N05C-Hypnotics and sedatives,% of total sales,1.3 +3783,Belgium,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.7 +3784,Belgium,2015,5,C07-Beta blocking agents,% of total sales,1.4 +3785,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +3786,Belgium,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.7 +3787,Belgium,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",109.2 +3788,Belgium,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,96.9 +3789,Belgium,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.6 +3790,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,154.7 +3791,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,111.0 +3792,Belgium,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,224.7 +3793,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,171.7 +3794,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.2 +3795,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.2 +3796,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",193.4 +3797,Belgium,2015,5,M-Musculo-skeletal system,% of total sales,4.1 +3798,Belgium,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.2 +3799,Belgium,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4 +3800,Belgium,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",15.3 +3801,Belgium,2015,5,N06A-Antidepressants,% of total sales,2.5 +3802,Belgium,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.3 +3803,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.1 +3804,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +3805,Belgium,2015,5,C07-Beta blocking agents,Million of national currency units,87.3 +3806,Belgium,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",194.5 +3807,Belgium,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",320.4 +3808,Belgium,2015,5,M-Musculo-skeletal system,Million of national currency units,256.3 +3809,Belgium,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,284.4 +3810,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",138.8 +3811,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1 +3812,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +3813,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +3814,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.9 +3815,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +3816,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.3 +3817,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.3 +3818,Belgium,2015,5,N02-Analgesics,"/capita, US$ exchange rate",23.6 +3819,Belgium,2015,5,N02-Analgesics,% of total sales,3.9 +3820,Belgium,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.6 +3821,Belgium,2015,5,N02-Analgesics,"Million US$, purchasing power parity",299.9 +3822,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +3823,Belgium,2015,5,N02-Analgesics,Million of national currency units,239.9 +3824,Belgium,2015,5,N02-Analgesics,Million US$ at exchange rate,266.2 +3825,Belgium,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",686.5 +3826,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.9 +3827,Belgium,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",609.3 +3828,Belgium,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,6869.7 +3829,Belgium,2015,5,Total pharmaceutical sales,Million of national currency units,6191.6 +3830,Belgium,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",7739.6 +3831,Belgium,2015,5,N-Nervous system,% of total sales,15.2 +3832,Belgium,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",223.5 +3833,Belgium,2015,5,A10-Drugs used in diabetes,Million of national currency units,178.8 +3834,Belgium,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,198.4 +3835,Belgium,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.6 +3836,Belgium,2015,5,A10-Drugs used in diabetes,% of total sales,2.9 +3837,Belgium,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.8 +3838,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +3839,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.8 +3840,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.2 +3841,Belgium,2015,5,N05B-Anxiolytics,% of total sales,1.1 +3842,Belgium,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9 +3843,Belgium,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",87.1 +3844,Belgium,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.7 +3845,Belgium,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +3846,Belgium,2015,5,C01A-Cardiac glycosides,% of total sales,0.0 +3847,Belgium,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2 +3848,Belgium,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +3849,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",137.2 +3850,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,109.7 +3851,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,121.7 +3852,Belgium,2015,5,N-Nervous system,Million of national currency units,940.8 +3853,Belgium,2015,5,C02-Antihypertensives,Million of national currency units,24.3 +3854,Belgium,2015,5,N-Nervous system,"/capita, US$ exchange rate",92.6 +3855,Belgium,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",104.3 +3856,Belgium,2015,5,N-Nervous system,Million US$ at exchange rate,1043.8 +3857,Belgium,2015,5,N-Nervous system,"Million US$, purchasing power parity",1176.0 +3858,Belgium,2015,5,C02-Antihypertensives,Million US$ at exchange rate,27.0 +3859,Belgium,2015,5,C02-Antihypertensives,% of total sales,0.4 +3860,Belgium,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,77.3 +3861,Belgium,2015,5,N05B-Anxiolytics,Million of national currency units,69.7 +3862,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,123.2 +3863,Belgium,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",30.4 +3864,Belgium,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7 +3865,Belgium,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.4 +3866,Belgium,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,274.9 +3867,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",309.7 +3868,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.4 +3869,Belgium,2015,5,J01-Antibacterials for systemic use,Million of national currency units,215.7 +3870,Belgium,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,247.8 +3871,Belgium,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1 +3872,Belgium,2015,5,A02A-Antacids,"/capita, US$ exchange rate",1.0 +3873,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5 +3874,Belgium,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +3875,Belgium,2015,5,C08-Calcium channel blockers,% of total sales,0.8 +3876,Belgium,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.4 +3877,Belgium,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.8 +3878,Belgium,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4 +3879,Belgium,2015,5,A02A-Antacids,Million US$ at exchange rate,11.1 +3880,Belgium,2015,5,A02A-Antacids,"Million US$, purchasing power parity",12.5 +3881,Belgium,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,243.8 +3882,Belgium,2015,5,A02A-Antacids,Million of national currency units,10.0 +3883,Belgium,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.6 +3884,Belgium,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",274.7 +3885,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,196.5 +3886,Belgium,2015,5,A02A-Antacids,% of total sales,0.2 +3887,Belgium,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",173.0 +3888,Belgium,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",153.6 +3889,Belgium,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.4 +3890,Belgium,2015,5,Products not elsewhere classified,% of total sales,25.2 +3891,Belgium,2015,5,Products not elsewhere classified,Million of national currency units,1560.4 +3892,Belgium,2015,5,Products not elsewhere classified,Million US$ at exchange rate,1731.3 +3893,Belgium,2015,5,C10-Lipid modifying agents,Million of national currency units,219.7 +3894,Belgium,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1950.5 +3895,Belgium,2015,5,C10-Lipid modifying agents,% of total sales,3.5 +3896,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.3 +3897,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.8 +3898,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.2 +3899,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,218.0 +3900,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",245.6 +3901,Belgium,2015,5,B-Blood and blood forming organs,% of total sales,8.4 +3902,Belgium,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",58.0 +3903,Belgium,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",653.4 +3904,Belgium,2015,5,B-Blood and blood forming organs,Million of national currency units,522.8 +3905,Belgium,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,580.0 +3906,Belgium,2015,5,C-Cardiovascular system,% of total sales,11.3 +3907,Belgium,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",58.3 +3908,Belgium,2015,5,R-Respiratory system,% of total sales,8.5 +3909,Belgium,2015,5,R-Respiratory system,Million US$ at exchange rate,583.5 +3910,Belgium,2015,5,R-Respiratory system,"/capita, US$ exchange rate",51.8 +3911,Belgium,2015,5,R-Respiratory system,"Million US$, purchasing power parity",657.4 +3912,Belgium,2015,5,J-Antiinfectives for systemic use,% of total sales,11.0 +3913,Belgium,2015,5,C08-Calcium channel blockers,Million of national currency units,48.6 +3914,Belgium,2015,5,A-Alimentary tract and metabolism,% of total sales,10.5 +3915,Belgium,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",67.0 +3916,Belgium,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",75.5 +3917,Belgium,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.2 +3918,Belgium,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",814.2 +3919,Belgium,2015,5,R-Respiratory system,Million of national currency units,525.9 +3920,Belgium,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.1 +3921,Belgium,2015,5,C-Cardiovascular system,Million of national currency units,701.7 +3922,Belgium,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,722.7 +3923,Belgium,2015,5,A-Alimentary tract and metabolism,Million of national currency units,651.4 +3924,Belgium,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,755.4 +3925,Belgium,2015,5,J-Antiinfectives for systemic use,Million of national currency units,680.8 +3926,Belgium,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",851.0 +3927,Belgium,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",877.1 +3928,Belgium,2015,5,C-Cardiovascular system,Million US$ at exchange rate,778.5 +3929,Belgium,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",69.1 +3930,Belgium,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,53.9 +3931,Belgium,2015,5,J01-Antibacterials for systemic use,% of total sales,3.5 +3932,Belgium,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",60.7 +3933,Belgium,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",269.6 +3934,Belgium,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,239.3 +3935,Belgium,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.8 +3936,Belgium,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.9 +3937,Belgium,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.2 +3938,Belgium,2013,6,C03-Diuretics,Million US$ at exchange rate,46.8 +3939,Belgium,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.2 +3940,Belgium,2013,6,C03-Diuretics,"Million US$, purchasing power parity",43.7 +3941,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,124.8 +3942,Belgium,2013,6,C03-Diuretics,Million of national currency units,35.2 +3943,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,165.8 +3944,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.8 +3945,Belgium,2013,6,N06A-Antidepressants,Million of national currency units,181.3 +3946,Belgium,2013,6,N06A-Antidepressants,Million US$ at exchange rate,240.8 +3947,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9 +3948,Belgium,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +3949,Belgium,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,308.1 +3950,Belgium,2013,6,C03-Diuretics,% of total sales,0.6 +3951,Belgium,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,75.4 +3952,Belgium,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.8 +3953,Belgium,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.2 +3954,Belgium,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6 +3955,Belgium,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",93.6 +3956,Belgium,2013,6,G-Genito urinary system and sex hormones,% of total sales,3.9 +3957,Belgium,2013,6,C01A-Cardiac glycosides,Million of national currency units,1.2 +3958,Belgium,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6 +3959,Belgium,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",224.9 +3960,Belgium,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",287.7 +3961,Belgium,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0 +3962,Belgium,2013,6,N05C-Hypnotics and sedatives,% of total sales,1.3 +3963,Belgium,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.4 +3964,Belgium,2013,6,C07-Beta blocking agents,% of total sales,1.6 +3965,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +3966,Belgium,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8 +3967,Belgium,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",120.4 +3968,Belgium,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.6 +3969,Belgium,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,128.9 +3970,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,142.9 +3971,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,118.0 +3972,Belgium,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,232.0 +3973,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,189.8 +3974,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.0 +3975,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.9 +3976,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",177.2 +3977,Belgium,2013,6,M-Musculo-skeletal system,% of total sales,4.2 +3978,Belgium,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.0 +3979,Belgium,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.6 +3980,Belgium,2013,6,N06A-Antidepressants,% of total sales,3.0 +3981,Belgium,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.2 +3982,Belgium,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.0 +3983,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +3984,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9 +3985,Belgium,2013,6,C07-Beta blocking agents,Million of national currency units,97.1 +3986,Belgium,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",312.5 +3987,Belgium,2013,6,M-Musculo-skeletal system,Million of national currency units,251.9 +3988,Belgium,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,334.6 +3989,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1 +3990,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +3991,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8 +3992,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +3993,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.1 +3994,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.4 +3995,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,20.5 +3996,Belgium,2013,6,N02-Analgesics,"/capita, US$ exchange rate",29.2 +3997,Belgium,2013,6,N02-Analgesics,% of total sales,4.1 +3998,Belgium,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.3 +3999,Belgium,2013,6,N02-Analgesics,"Million US$, purchasing power parity",304.5 +4000,Belgium,2013,6,N02-Analgesics,Million of national currency units,245.5 +4001,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +4002,Belgium,2013,6,N02-Analgesics,Million US$ at exchange rate,326.1 +4003,Belgium,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",661.1 +4004,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.0 +4005,Belgium,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",707.9 +4006,Belgium,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,7899.5 +4007,Belgium,2013,6,Total pharmaceutical sales,Million of national currency units,5947.9 +4008,Belgium,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7378.0 +4009,Belgium,2013,6,N-Nervous system,% of total sales,16.5 +4010,Belgium,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",202.5 +4011,Belgium,2013,6,A10-Drugs used in diabetes,Million of national currency units,163.2 +4012,Belgium,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,216.8 +4013,Belgium,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.4 +4014,Belgium,2013,6,A10-Drugs used in diabetes,% of total sales,2.7 +4015,Belgium,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1 +4016,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +4017,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.7 +4018,Belgium,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.1 +4019,Belgium,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",84.5 +4020,Belgium,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.6 +4021,Belgium,2013,6,N05B-Anxiolytics,% of total sales,1.1 +4022,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6 +4023,Belgium,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +4024,Belgium,2013,6,C01A-Cardiac glycosides,% of total sales,0.0 +4025,Belgium,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +4026,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",141.9 +4027,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,114.4 +4028,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,151.9 +4029,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",146.4 +4030,Belgium,2013,6,N-Nervous system,Million of national currency units,978.6 +4031,Belgium,2013,6,C02-Antihypertensives,Million of national currency units,19.3 +4032,Belgium,2013,6,N-Nervous system,Million US$ at exchange rate,1299.7 +4033,Belgium,2013,6,N-Nervous system,"/capita, US$ exchange rate",116.5 +4034,Belgium,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",108.8 +4035,Belgium,2013,6,N-Nervous system,"Million US$, purchasing power parity",1213.9 +4036,Belgium,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +4037,Belgium,2013,6,C02-Antihypertensives,Million US$ at exchange rate,25.7 +4038,Belgium,2013,6,C02-Antihypertensives,% of total sales,0.3 +4039,Belgium,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,90.4 +4040,Belgium,2013,6,N05B-Anxiolytics,Million of national currency units,68.1 +4041,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,156.7 +4042,Belgium,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.0 +4043,Belgium,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1 +4044,Belgium,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +4045,Belgium,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,340.5 +4046,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",318.0 +4047,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5 +4048,Belgium,2013,6,J01-Antibacterials for systemic use,Million of national currency units,218.9 +4049,Belgium,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,256.4 +4050,Belgium,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2 +4051,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,218.2 +4052,Belgium,2013,6,A02A-Antacids,"/capita, US$ exchange rate",1.3 +4053,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.5 +4054,Belgium,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +4055,Belgium,2013,6,C08-Calcium channel blockers,% of total sales,1.0 +4056,Belgium,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.9 +4057,Belgium,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4 +4058,Belgium,2013,6,A02A-Antacids,Million US$ at exchange rate,14.7 +4059,Belgium,2013,6,A02A-Antacids,"Million US$, purchasing power parity",13.8 +4060,Belgium,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,337.2 +4061,Belgium,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",30.2 +4062,Belgium,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",314.9 +4063,Belgium,2013,6,A02A-Antacids,Million of national currency units,11.1 +4064,Belgium,2013,6,A02A-Antacids,% of total sales,0.2 +4065,Belgium,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",147.2 +4066,Belgium,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",157.7 +4067,Belgium,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",58.5 +4068,Belgium,2013,6,Products not elsewhere classified,% of total sales,22.3 +4069,Belgium,2013,6,Products not elsewhere classified,Million of national currency units,1324.7 +4070,Belgium,2013,6,Products not elsewhere classified,Million US$ at exchange rate,1759.4 +4071,Belgium,2013,6,C10-Lipid modifying agents,Million of national currency units,253.9 +4072,Belgium,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",1643.2 +4073,Belgium,2013,6,C10-Lipid modifying agents,% of total sales,4.3 +4074,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.0 +4075,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.2 +4076,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.7 +4077,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,289.7 +4078,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",270.6 +4079,Belgium,2013,6,B-Blood and blood forming organs,% of total sales,8.3 +4080,Belgium,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",54.6 +4081,Belgium,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",609.2 +4082,Belgium,2013,6,B-Blood and blood forming organs,Million of national currency units,491.1 +4083,Belgium,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,652.3 +4084,Belgium,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.2 +4085,Belgium,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",59.0 +4086,Belgium,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.2 +4087,Belgium,2013,6,R-Respiratory system,% of total sales,8.9 +4088,Belgium,2013,6,R-Respiratory system,Million US$ at exchange rate,705.1 +4089,Belgium,2013,6,R-Respiratory system,"/capita, US$ exchange rate",63.2 +4090,Belgium,2013,6,R-Respiratory system,"Million US$, purchasing power parity",658.5 +4091,Belgium,2013,6,J-Antiinfectives for systemic use,% of total sales,9.8 +4092,Belgium,2013,6,C08-Calcium channel blockers,Million of national currency units,57.9 +4093,Belgium,2013,6,A-Alimentary tract and metabolism,% of total sales,10.9 +4094,Belgium,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.2 +4095,Belgium,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.6 +4096,Belgium,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",805.9 +4097,Belgium,2013,6,R-Respiratory system,Million of national currency units,530.9 +4098,Belgium,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.3 +4099,Belgium,2013,6,C-Cardiovascular system,Million of national currency units,782.9 +4100,Belgium,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,862.9 +4101,Belgium,2013,6,A-Alimentary tract and metabolism,Million of national currency units,649.7 +4102,Belgium,2013,6,C-Cardiovascular system,Million US$ at exchange rate,1039.8 +4103,Belgium,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,772.0 +4104,Belgium,2013,6,J-Antiinfectives for systemic use,Million of national currency units,581.3 +4105,Belgium,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",721.0 +4106,Belgium,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",971.2 +4107,Belgium,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",93.2 +4108,Belgium,2013,6,J01-Antibacterials for systemic use,% of total sales,3.7 +4109,Belgium,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,76.9 +4110,Belgium,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.0 +4111,Belgium,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.8 +4112,Belgium,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,290.7 +4113,Belgium,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",271.5 +4114,Belgium,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1 +4115,Belgium,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",24.3 +4116,Belgium,2013,6,C-Cardiovascular system,% of total sales,13.2 +4117,Belgium,2017,5,C03-Diuretics,Million US$ at exchange rate,37.1 +4118,Belgium,2017,5,C03-Diuretics,Million of national currency units,32.8 +4119,Belgium,2017,5,C03-Diuretics,"Million US$, purchasing power parity",42.3 +4120,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,128.1 +4121,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,144.7 +4122,Belgium,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.3 +4123,Belgium,2017,5,N06A-Antidepressants,Million of national currency units,125.3 +4124,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.7 +4125,Belgium,2017,5,N06A-Antidepressants,Million US$ at exchange rate,141.6 +4126,Belgium,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +4127,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",165.2 +4128,Belgium,2017,5,C03-Diuretics,% of total sales,0.5 +4129,Belgium,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,77.2 +4130,Belgium,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.3 +4131,Belgium,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,87.2 +4132,Belgium,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0 +4133,Belgium,2017,5,G-Genito urinary system and sex hormones,% of total sales,3.4 +4134,Belgium,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.8 +4135,Belgium,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.2 +4136,Belgium,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,252.5 +4137,Belgium,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",288.2 +4138,Belgium,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.7 +4139,Belgium,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",99.5 +4140,Belgium,2017,5,N05C-Hypnotics and sedatives,% of total sales,1.2 +4141,Belgium,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.7 +4142,Belgium,2017,5,C07-Beta blocking agents,% of total sales,1.3 +4143,Belgium,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.4 +4144,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +4145,Belgium,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",106.6 +4146,Belgium,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,93.4 +4147,Belgium,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.2 +4148,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,155.3 +4149,Belgium,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,223.5 +4150,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,108.0 +4151,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.4 +4152,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.6 +4153,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,175.4 +4154,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",200.2 +4155,Belgium,2017,5,M-Musculo-skeletal system,% of total sales,3.8 +4156,Belgium,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.6 +4157,Belgium,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.1 +4158,Belgium,2017,5,N06A-Antidepressants,% of total sales,1.9 +4159,Belgium,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.4 +4160,Belgium,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",161.5 +4161,Belgium,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.2 +4162,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5 +4163,Belgium,2017,5,C07-Beta blocking agents,Million of national currency units,82.7 +4164,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +4165,Belgium,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",319.3 +4166,Belgium,2017,5,M-Musculo-skeletal system,Million of national currency units,247.7 +4167,Belgium,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,279.8 +4168,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.2 +4169,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.8 +4170,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +4171,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +4172,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.2 +4173,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +4174,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,14.9 +4175,Belgium,2017,5,N02-Analgesics,"/capita, US$ exchange rate",24.5 +4176,Belgium,2017,5,N02-Analgesics,"Million US$, purchasing power parity",318.0 +4177,Belgium,2017,5,N02-Analgesics,% of total sales,3.8 +4178,Belgium,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",28.0 +4179,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +4180,Belgium,2017,5,N02-Analgesics,Million US$ at exchange rate,278.6 +4181,Belgium,2017,5,N02-Analgesics,Million of national currency units,246.6 +4182,Belgium,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",741.6 +4183,Belgium,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",649.8 +4184,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",139.2 +4185,Belgium,2017,5,N-Nervous system,% of total sales,13.8 +4186,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.7 +4187,Belgium,2017,5,Total pharmaceutical sales,Million of national currency units,6543.2 +4188,Belgium,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,7391.7 +4189,Belgium,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",8435.9 +4190,Belgium,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",259.9 +4191,Belgium,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,227.8 +4192,Belgium,2017,5,A10-Drugs used in diabetes,Million of national currency units,201.6 +4193,Belgium,2017,5,A10-Drugs used in diabetes,% of total sales,3.1 +4194,Belgium,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",102.1 +4195,Belgium,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.0 +4196,Belgium,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.9 +4197,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6 +4198,Belgium,2017,5,N05B-Anxiolytics,% of total sales,1.1 +4199,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4 +4200,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.8 +4201,Belgium,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",88.7 +4202,Belgium,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.8 +4203,Belgium,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.8 +4204,Belgium,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +4205,Belgium,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.1 +4206,Belgium,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +4207,Belgium,2017,5,C01A-Cardiac glycosides,% of total sales,0.0 +4208,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",134.8 +4209,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,118.1 +4210,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,104.5 +4211,Belgium,2017,5,N-Nervous system,Million of national currency units,901.0 +4212,Belgium,2017,5,C02-Antihypertensives,Million of national currency units,26.1 +4213,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,122.0 +4214,Belgium,2017,5,N-Nervous system,"/capita, US$ exchange rate",89.5 +4215,Belgium,2017,5,N-Nervous system,Million US$ at exchange rate,1017.8 +4216,Belgium,2017,5,N-Nervous system,"Million US$, purchasing power parity",1161.6 +4217,Belgium,2017,5,C02-Antihypertensives,% of total sales,0.4 +4218,Belgium,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,77.7 +4219,Belgium,2017,5,N05B-Anxiolytics,Million of national currency units,68.8 +4220,Belgium,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",33.6 +4221,Belgium,2017,5,C02-Antihypertensives,Million US$ at exchange rate,29.5 +4222,Belgium,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.0 +4223,Belgium,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +4224,Belgium,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,283.9 +4225,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",324.0 +4226,Belgium,2017,5,J01-Antibacterials for systemic use,Million of national currency units,189.6 +4227,Belgium,2017,5,A02A-Antacids,"Million US$, purchasing power parity",12.3 +4228,Belgium,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,251.3 +4229,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.0 +4230,Belgium,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.9 +4231,Belgium,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1 +4232,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.5 +4233,Belgium,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,3.8 +4234,Belgium,2017,5,C08-Calcium channel blockers,% of total sales,0.7 +4235,Belgium,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.1 +4236,Belgium,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9 +4237,Belgium,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3 +4238,Belgium,2017,5,A02A-Antacids,Million US$ at exchange rate,10.8 +4239,Belgium,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,240.3 +4240,Belgium,2017,5,A02A-Antacids,Million of national currency units,9.5 +4241,Belgium,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.1 +4242,Belgium,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",274.2 +4243,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,175.5 +4244,Belgium,2017,5,A02A-Antacids,% of total sales,0.1 +4245,Belgium,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",216.6 +4246,Belgium,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",189.8 +4247,Belgium,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.1 +4248,Belgium,2017,5,Products not elsewhere classified,% of total sales,29.2 +4249,Belgium,2017,5,C10-Lipid modifying agents,Million of national currency units,212.7 +4250,Belgium,2017,5,Products not elsewhere classified,Million of national currency units,1910.8 +4251,Belgium,2017,5,Products not elsewhere classified,Million US$ at exchange rate,2158.6 +4252,Belgium,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",2463.6 +4253,Belgium,2017,5,C10-Lipid modifying agents,% of total sales,3.3 +4254,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",17.4 +4255,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.9 +4256,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,198.3 +4257,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",226.3 +4258,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7 +4259,Belgium,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",767.1 +4260,Belgium,2017,5,B-Blood and blood forming organs,% of total sales,9.1 +4261,Belgium,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.4 +4262,Belgium,2017,5,B-Blood and blood forming organs,Million of national currency units,595.0 +4263,Belgium,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,672.1 +4264,Belgium,2017,5,C-Cardiovascular system,% of total sales,10.0 +4265,Belgium,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",57.8 +4266,Belgium,2017,5,R-Respiratory system,% of total sales,7.8 +4267,Belgium,2017,5,R-Respiratory system,"/capita, US$ exchange rate",50.6 +4268,Belgium,2017,5,R-Respiratory system,Million US$ at exchange rate,575.9 +4269,Belgium,2017,5,R-Respiratory system,"Million US$, purchasing power parity",657.2 +4270,Belgium,2017,5,A-Alimentary tract and metabolism,% of total sales,10.7 +4271,Belgium,2017,5,J-Antiinfectives for systemic use,% of total sales,10.3 +4272,Belgium,2017,5,C08-Calcium channel blockers,Million of national currency units,43.1 +4273,Belgium,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.9 +4274,Belgium,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",79.1 +4275,Belgium,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",76.4 +4276,Belgium,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",899.3 +4277,Belgium,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",69.3 +4278,Belgium,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,788.0 +4279,Belgium,2017,5,C-Cardiovascular system,Million of national currency units,655.8 +4280,Belgium,2017,5,A-Alimentary tract and metabolism,Million of national currency units,697.5 +4281,Belgium,2017,5,J-Antiinfectives for systemic use,Million of national currency units,674.1 +4282,Belgium,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,761.5 +4283,Belgium,2017,5,R-Respiratory system,Million of national currency units,509.8 +4284,Belgium,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",869.1 +4285,Belgium,2017,5,C-Cardiovascular system,Million US$ at exchange rate,740.9 +4286,Belgium,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",845.5 +4287,Belgium,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",65.1 +4288,Belgium,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,48.7 +4289,Belgium,2017,5,J01-Antibacterials for systemic use,% of total sales,2.9 +4290,Belgium,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",55.6 +4291,Belgium,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",244.4 +4292,Belgium,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,214.2 +4293,Belgium,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.5 +4294,Belgium,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",18.8 +4295,Belgium,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.3 +4296,Canada,2017,10,C-Cardiovascular system,Million of national currency units,3999.3 +4297,Canada,2017,10,N-Nervous system,"/capita, US$ purchasing power parity",128.8 +4298,Canada,2017,10,C-Cardiovascular system,"Million US$, purchasing power parity",3298.9 +4299,Canada,2017,10,C-Cardiovascular system,Million US$ at exchange rate,3081.3 +4300,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,22.7 +4301,Canada,2017,10,N-Nervous system,% of total sales,19.2 +4302,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +4303,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +4304,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.3 +4305,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.0 +4306,Canada,2017,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.7 +4307,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.4 +4308,Canada,2017,10,C-Cardiovascular system,"/capita, US$ exchange rate",84.3 +4309,Canada,2017,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.3 +4310,Canada,2017,10,G-Genito urinary system and sex hormones,% of total sales,5.1 +4311,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0 +4312,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +4313,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.2 +4314,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",671.0 +4315,Canada,2017,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.5 +4316,Canada,2017,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2 +4317,Canada,2017,10,B-Blood and blood forming organs,% of total sales,3.9 +4318,Canada,2017,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1920.3 +4319,Canada,2017,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,1793.6 +4320,Canada,2017,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",958.4 +4321,Canada,2017,10,N-Nervous system,"Million US$, purchasing power parity",4706.2 +4322,Canada,2017,10,J-Antiinfectives for systemic use,Million of national currency units,2328.0 +4323,Canada,2017,10,N-Nervous system,Million of national currency units,5705.3 +4324,Canada,2017,10,N-Nervous system,Million US$ at exchange rate,4395.7 +4325,Canada,2017,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.3 +4326,Canada,2017,10,C-Cardiovascular system,% of total sales,13.4 +4327,Canada,2017,10,B-Blood and blood forming organs,Million of national currency units,1161.9 +4328,Canada,2017,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,813.5 +4329,Canada,2017,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,626.8 +4330,Canada,2017,10,N-Nervous system,"/capita, US$ exchange rate",120.3 +4331,Canada,2017,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",49.1 +4332,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.5 +4333,Canada,2017,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.5 +4334,Canada,2017,10,B-Blood and blood forming organs,Million US$ at exchange rate,895.2 +4335,Canada,2017,10,J-Antiinfectives for systemic use,% of total sales,7.8 +4336,Canada,2017,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.6 +4337,Canada,2017,10,J01-Antibacterials for systemic use,Million of national currency units,694.6 +4338,Canada,2017,10,C03-Diuretics,% of total sales,0.8 +4339,Canada,2017,10,C03-Diuretics,"/capita, US$ purchasing power parity",5.1 +4340,Canada,2017,10,M-Musculo-skeletal system,Million of national currency units,929.4 +4341,Canada,2017,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,535.2 +4342,Canada,2017,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",766.6 +4343,Canada,2017,10,M-Musculo-skeletal system,Million US$ at exchange rate,716.1 +4344,Canada,2017,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",573.0 +4345,Canada,2017,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.0 +4346,Canada,2017,10,C08-Calcium channel blockers,Million of national currency units,531.6 +4347,Canada,2017,10,C08-Calcium channel blockers,Million US$ at exchange rate,409.6 +4348,Canada,2017,10,M-Musculo-skeletal system,% of total sales,3.1 +4349,Canada,2017,10,C03-Diuretics,"Million US$, purchasing power parity",187.0 +4350,Canada,2017,10,C03-Diuretics,"/capita, US$ exchange rate",4.8 +4351,Canada,2017,10,C03-Diuretics,Million of national currency units,226.7 +4352,Canada,2017,10,C03-Diuretics,Million US$ at exchange rate,174.7 +4353,Canada,2017,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4 +4354,Canada,2017,10,C07-Beta blocking agents,"/capita, US$ exchange rate",6.9 +4355,Canada,2017,10,C07-Beta blocking agents,Million US$ at exchange rate,251.8 +4356,Canada,2017,10,C07-Beta blocking agents,"Million US$, purchasing power parity",269.6 +4357,Canada,2017,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.8 +4358,Canada,2017,10,C10-Lipid modifying agents,% of total sales,4.1 +4359,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",430.0 +4360,Canada,2017,10,C07-Beta blocking agents,% of total sales,1.1 +4361,Canada,2017,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9 +4362,Canada,2017,10,J01-Antibacterials for systemic use,% of total sales,2.3 +4363,Canada,2017,10,C10-Lipid modifying agents,Million US$ at exchange rate,947.3 +4364,Canada,2017,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.6 +4365,Canada,2017,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.7 +4366,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,401.6 +4367,Canada,2017,10,C07-Beta blocking agents,Million of national currency units,326.8 +4368,Canada,2017,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",1014.2 +4369,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,521.3 +4370,Canada,2017,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",438.5 +4371,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4 +4372,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0 +4373,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +4374,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6 +4375,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8 +4376,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",254.6 +4377,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,237.8 +4378,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.6 +4379,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5 +4380,Canada,2017,10,C02-Antihypertensives,"Million US$, purchasing power parity",106.9 +4381,Canada,2017,10,C01A-Cardiac glycosides,% of total sales,0.1 +4382,Canada,2017,10,C02-Antihypertensives,Million of national currency units,129.6 +4383,Canada,2017,10,C02-Antihypertensives,Million US$ at exchange rate,99.9 +4384,Canada,2017,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",13.7 +4385,Canada,2017,10,C01A-Cardiac glycosides,Million US$ at exchange rate,12.8 +4386,Canada,2017,10,C10-Lipid modifying agents,Million of national currency units,1229.5 +4387,Canada,2017,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +4388,Canada,2017,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +4389,Canada,2017,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9 +4390,Canada,2017,10,C02-Antihypertensives,% of total sales,0.4 +4391,Canada,2017,10,G-Genito urinary system and sex hormones,Million of national currency units,1517.6 +4392,Canada,2017,10,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +4393,Canada,2017,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.2 +4394,Canada,2017,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.0 +4395,Canada,2017,10,C08-Calcium channel blockers,% of total sales,1.8 +4396,Canada,2017,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1169.2 +4397,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1009.3 +4398,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1310.0 +4399,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,308.6 +4400,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1080.6 +4401,Canada,2017,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.0 +4402,Canada,2017,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1251.8 +4403,Canada,2017,10,C01A-Cardiac glycosides,Million of national currency units,16.6 +4404,Canada,2017,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3337.3 +4405,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.3 +4406,Canada,2017,10,N06A-Antidepressants,% of total sales,4.7 +4407,Canada,2017,10,A-Alimentary tract and metabolism,Million of national currency units,4045.8 +4408,Canada,2017,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,3117.1 +4409,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,765.8 +4410,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,994.0 +4411,Canada,2017,10,R-Respiratory system,Million of national currency units,1991.3 +4412,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.4 +4413,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.0 +4414,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",819.9 +4415,Canada,2017,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3 +4416,Canada,2017,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6 +4417,Canada,2017,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",167.3 +4418,Canada,2017,10,N05C-Hypnotics and sedatives,Million of national currency units,202.8 +4419,Canada,2017,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,156.2 +4420,Canada,2017,10,N06A-Antidepressants,"Million US$, purchasing power parity",1148.0 +4421,Canada,2017,10,N06A-Antidepressants,"/capita, US$ exchange rate",29.3 +4422,Canada,2017,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",31.4 +4423,Canada,2017,10,N05C-Hypnotics and sedatives,% of total sales,0.7 +4424,Canada,2017,10,N06A-Antidepressants,Million of national currency units,1391.7 +4425,Canada,2017,10,N06A-Antidepressants,Million US$ at exchange rate,1072.2 +4426,Canada,2017,10,Products not elsewhere classified,Million US$ at exchange rate,5837.3 +4427,Canada,2017,10,Products not elsewhere classified,"Million US$, purchasing power parity",6249.7 +4428,Canada,2017,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",36.0 +4429,Canada,2017,10,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +4430,Canada,2017,10,Products not elsewhere classified,Million of national currency units,7576.5 +4431,Canada,2017,10,Products not elsewhere classified,"/capita, US$ exchange rate",159.7 +4432,Canada,2017,10,A02A-Antacids,Million US$ at exchange rate,1.2 +4433,Canada,2017,10,A02A-Antacids,"Million US$, purchasing power parity",1.3 +4434,Canada,2017,10,A02A-Antacids,"/capita, US$ exchange rate",0.0 +4435,Canada,2017,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +4436,Canada,2017,10,A02A-Antacids,Million of national currency units,1.6 +4437,Canada,2017,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",171.0 +4438,Canada,2017,10,Products not elsewhere classified,% of total sales,25.4 +4439,Canada,2017,10,R-Respiratory system,"/capita, US$ purchasing power parity",44.9 +4440,Canada,2017,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",85.3 +4441,Canada,2017,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.3 +4442,Canada,2017,10,R-Respiratory system,Million US$ at exchange rate,1534.2 +4443,Canada,2017,10,R-Respiratory system,"/capita, US$ exchange rate",42.0 +4444,Canada,2017,10,R-Respiratory system,"Million US$, purchasing power parity",1642.6 +4445,Canada,2017,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1227.6 +4446,Canada,2017,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1314.4 +4447,Canada,2017,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",33.6 +4448,Canada,2017,10,A-Alimentary tract and metabolism,% of total sales,13.6 +4449,Canada,2017,10,R-Respiratory system,% of total sales,6.7 +4450,Canada,2017,10,R03-Drugs for obstructive airway diseases,Million of national currency units,1593.4 +4451,Canada,2017,10,N05B-Anxiolytics,% of total sales,0.5 +4452,Canada,2017,10,A02A-Antacids,% of total sales,0.0 +4453,Canada,2017,10,N02-Analgesics,"/capita, US$ exchange rate",22.7 +4454,Canada,2017,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1794.7 +4455,Canada,2017,10,N02-Analgesics,"/capita, US$ purchasing power parity",24.3 +4456,Canada,2017,10,N02-Analgesics,% of total sales,3.6 +4457,Canada,2017,10,N02-Analgesics,Million of national currency units,1077.1 +4458,Canada,2017,10,N02-Analgesics,Million US$ at exchange rate,829.9 +4459,Canada,2017,10,A10-Drugs used in diabetes,Million US$ at exchange rate,1676.3 +4460,Canada,2017,10,A10-Drugs used in diabetes,Million of national currency units,2175.7 +4461,Canada,2017,10,Total pharmaceutical sales,Million of national currency units,29776.2 +4462,Canada,2017,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",45.9 +4463,Canada,2017,10,A10-Drugs used in diabetes,% of total sales,7.3 +4464,Canada,2017,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.1 +4465,Canada,2017,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",672.1 +4466,Canada,2017,10,Total pharmaceutical sales,Million US$ at exchange rate,22941.2 +4467,Canada,2017,10,Total pharmaceutical sales,"Million US$, purchasing power parity",24561.7 +4468,Canada,2017,10,Total pharmaceutical sales,"/capita, US$ exchange rate",627.7 +4469,Canada,2017,10,N05B-Anxiolytics,"Million US$, purchasing power parity",132.1 +4470,Canada,2017,10,N05B-Anxiolytics,Million US$ at exchange rate,123.4 +4471,Canada,2017,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6 +4472,Canada,2017,10,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4 +4473,Canada,2017,10,N05B-Anxiolytics,Million of national currency units,160.2 +4474,Canada,2017,10,N02-Analgesics,"Million US$, purchasing power parity",888.5 +4475,Canada,2016,10,N-Nervous system,"/capita, US$ purchasing power parity",128.7 +4476,Canada,2016,10,C-Cardiovascular system,Million of national currency units,3942.4 +4477,Canada,2016,10,C-Cardiovascular system,"Million US$, purchasing power parity",3266.2 +4478,Canada,2016,10,C-Cardiovascular system,Million US$ at exchange rate,2974.0 +4479,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.9 +4480,Canada,2016,10,N-Nervous system,% of total sales,19.8 +4481,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.0 +4482,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +4483,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +4484,Canada,2016,10,C-Cardiovascular system,"/capita, US$ exchange rate",82.4 +4485,Canada,2016,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.8 +4486,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.5 +4487,Canada,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.1 +4488,Canada,2016,10,G-Genito urinary system and sex hormones,% of total sales,5.2 +4489,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.4 +4490,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1 +4491,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +4492,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.8 +4493,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",666.8 +4494,Canada,2016,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.2 +4495,Canada,2016,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.4 +4496,Canada,2016,10,B-Blood and blood forming organs,% of total sales,3.8 +4497,Canada,2016,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1901.4 +4498,Canada,2016,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,1731.3 +4499,Canada,2016,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",881.7 +4500,Canada,2016,10,N-Nervous system,"/capita, US$ exchange rate",117.2 +4501,Canada,2016,10,N-Nervous system,"Million US$, purchasing power parity",4646.5 +4502,Canada,2016,10,J-Antiinfectives for systemic use,Million of national currency units,2295.1 +4503,Canada,2016,10,N-Nervous system,Million of national currency units,5608.5 +4504,Canada,2016,10,N-Nervous system,Million US$ at exchange rate,4230.9 +4505,Canada,2016,10,C-Cardiovascular system,% of total sales,13.9 +4506,Canada,2016,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.5 +4507,Canada,2016,10,B-Blood and blood forming organs,Million of national currency units,1064.2 +4508,Canada,2016,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,804.9 +4509,Canada,2016,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,607.2 +4510,Canada,2016,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",47.9 +4511,Canada,2016,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.7 +4512,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0 +4513,Canada,2016,10,B-Blood and blood forming organs,Million US$ at exchange rate,802.8 +4514,Canada,2016,10,J-Antiinfectives for systemic use,% of total sales,8.1 +4515,Canada,2016,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0 +4516,Canada,2016,10,J01-Antibacterials for systemic use,Million of national currency units,687.1 +4517,Canada,2016,10,C03-Diuretics,% of total sales,0.8 +4518,Canada,2016,10,M-Musculo-skeletal system,Million of national currency units,910.8 +4519,Canada,2016,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,518.3 +4520,Canada,2016,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",569.2 +4521,Canada,2016,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",754.6 +4522,Canada,2016,10,M-Musculo-skeletal system,Million US$ at exchange rate,687.1 +4523,Canada,2016,10,C03-Diuretics,"/capita, US$ purchasing power parity",4.9 +4524,Canada,2016,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.9 +4525,Canada,2016,10,C08-Calcium channel blockers,Million of national currency units,546.9 +4526,Canada,2016,10,C08-Calcium channel blockers,Million US$ at exchange rate,412.6 +4527,Canada,2016,10,M-Musculo-skeletal system,% of total sales,3.2 +4528,Canada,2016,10,C03-Diuretics,"/capita, US$ exchange rate",4.5 +4529,Canada,2016,10,C03-Diuretics,"Million US$, purchasing power parity",177.5 +4530,Canada,2016,10,C03-Diuretics,Million of national currency units,214.3 +4531,Canada,2016,10,C03-Diuretics,Million US$ at exchange rate,161.7 +4532,Canada,2016,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4 +4533,Canada,2016,10,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7 +4534,Canada,2016,10,C07-Beta blocking agents,Million US$ at exchange rate,241.9 +4535,Canada,2016,10,C07-Beta blocking agents,"Million US$, purchasing power parity",265.7 +4536,Canada,2016,10,C07-Beta blocking agents,% of total sales,1.1 +4537,Canada,2016,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.4 +4538,Canada,2016,10,C10-Lipid modifying agents,% of total sales,4.4 +4539,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",412.9 +4540,Canada,2016,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9 +4541,Canada,2016,10,J01-Antibacterials for systemic use,% of total sales,2.4 +4542,Canada,2016,10,C10-Lipid modifying agents,Million US$ at exchange rate,934.8 +4543,Canada,2016,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.4 +4544,Canada,2016,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.8 +4545,Canada,2016,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",1026.6 +4546,Canada,2016,10,C07-Beta blocking agents,Million of national currency units,320.7 +4547,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,376.0 +4548,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,498.4 +4549,Canada,2016,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",453.1 +4550,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5 +4551,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4 +4552,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +4553,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4 +4554,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.2 +4555,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",266.7 +4556,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,242.8 +4557,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.6 +4558,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7 +4559,Canada,2016,10,C02-Antihypertensives,"Million US$, purchasing power parity",98.8 +4560,Canada,2016,10,C02-Antihypertensives,Million of national currency units,119.2 +4561,Canada,2016,10,C01A-Cardiac glycosides,% of total sales,0.1 +4562,Canada,2016,10,C02-Antihypertensives,Million US$ at exchange rate,89.9 +4563,Canada,2016,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",14.6 +4564,Canada,2016,10,C10-Lipid modifying agents,Million of national currency units,1239.2 +4565,Canada,2016,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +4566,Canada,2016,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4 +4567,Canada,2016,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7 +4568,Canada,2016,10,C02-Antihypertensives,% of total sales,0.4 +4569,Canada,2016,10,G-Genito urinary system and sex hormones,Million of national currency units,1485.0 +4570,Canada,2016,10,C02-Antihypertensives,"/capita, US$ exchange rate",2.5 +4571,Canada,2016,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.4 +4572,Canada,2016,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.5 +4573,Canada,2016,10,C08-Calcium channel blockers,% of total sales,1.9 +4574,Canada,2016,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1120.2 +4575,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,959.6 +4576,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1272.1 +4577,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,321.9 +4578,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1053.9 +4579,Canada,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.0 +4580,Canada,2016,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1230.3 +4581,Canada,2016,10,C01A-Cardiac glycosides,Million US$ at exchange rate,13.3 +4582,Canada,2016,10,C01A-Cardiac glycosides,Million of national currency units,17.6 +4583,Canada,2016,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3166.9 +4584,Canada,2016,10,A02A-Antacids,% of total sales,0.0 +4585,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7 +4586,Canada,2016,10,N06A-Antidepressants,% of total sales,5.0 +4587,Canada,2016,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,2883.6 +4588,Canada,2016,10,A-Alimentary tract and metabolism,Million of national currency units,3822.6 +4589,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,782.4 +4590,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1037.1 +4591,Canada,2016,10,R-Respiratory system,Million of national currency units,1936.0 +4592,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.8 +4593,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.7 +4594,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",859.2 +4595,Canada,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3 +4596,Canada,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.7 +4597,Canada,2016,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",168.6 +4598,Canada,2016,10,N05C-Hypnotics and sedatives,Million of national currency units,203.5 +4599,Canada,2016,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,153.5 +4600,Canada,2016,10,N06A-Antidepressants,"Million US$, purchasing power parity",1174.8 +4601,Canada,2016,10,N06A-Antidepressants,"/capita, US$ exchange rate",29.6 +4602,Canada,2016,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",32.5 +4603,Canada,2016,10,N05C-Hypnotics and sedatives,% of total sales,0.7 +4604,Canada,2016,10,N06A-Antidepressants,Million of national currency units,1418.0 +4605,Canada,2016,10,N06A-Antidepressants,Million US$ at exchange rate,1069.7 +4606,Canada,2016,10,Products not elsewhere classified,Million US$ at exchange rate,5108.0 +4607,Canada,2016,10,Products not elsewhere classified,"Million US$, purchasing power parity",5609.8 +4608,Canada,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.3 +4609,Canada,2016,10,Products not elsewhere classified,"/capita, US$ exchange rate",141.5 +4610,Canada,2016,10,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +4611,Canada,2016,10,Products not elsewhere classified,Million of national currency units,6771.3 +4612,Canada,2016,10,A02A-Antacids,Million US$ at exchange rate,1.1 +4613,Canada,2016,10,A02A-Antacids,"Million US$, purchasing power parity",1.2 +4614,Canada,2016,10,A02A-Antacids,"/capita, US$ exchange rate",0.0 +4615,Canada,2016,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +4616,Canada,2016,10,A02A-Antacids,Million of national currency units,1.5 +4617,Canada,2016,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",155.4 +4618,Canada,2016,10,Products not elsewhere classified,% of total sales,23.9 +4619,Canada,2016,10,R-Respiratory system,"/capita, US$ purchasing power parity",44.4 +4620,Canada,2016,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9 +4621,Canada,2016,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",87.7 +4622,Canada,2016,10,R-Respiratory system,Million US$ at exchange rate,1460.5 +4623,Canada,2016,10,R-Respiratory system,"Million US$, purchasing power parity",1603.9 +4624,Canada,2016,10,R-Respiratory system,"/capita, US$ exchange rate",40.4 +4625,Canada,2016,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1161.7 +4626,Canada,2016,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1275.8 +4627,Canada,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.2 +4628,Canada,2016,10,A-Alimentary tract and metabolism,% of total sales,13.5 +4629,Canada,2016,10,R-Respiratory system,% of total sales,6.8 +4630,Canada,2016,10,R03-Drugs for obstructive airway diseases,Million of national currency units,1540.0 +4631,Canada,2016,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1613.1 +4632,Canada,2016,10,N02-Analgesics,"/capita, US$ exchange rate",23.3 +4633,Canada,2016,10,N02-Analgesics,"/capita, US$ purchasing power parity",25.6 +4634,Canada,2016,10,N02-Analgesics,% of total sales,3.9 +4635,Canada,2016,10,Total pharmaceutical sales,Million of national currency units,28334.3 +4636,Canada,2016,10,N02-Analgesics,Million of national currency units,1117.2 +4637,Canada,2016,10,N02-Analgesics,Million US$ at exchange rate,842.8 +4638,Canada,2016,10,A10-Drugs used in diabetes,Million US$ at exchange rate,1468.8 +4639,Canada,2016,10,A10-Drugs used in diabetes,Million of national currency units,1947.1 +4640,Canada,2016,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",40.7 +4641,Canada,2016,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",44.7 +4642,Canada,2016,10,A10-Drugs used in diabetes,% of total sales,6.9 +4643,Canada,2016,10,Total pharmaceutical sales,"Million US$, purchasing power parity",23474.1 +4644,Canada,2016,10,Total pharmaceutical sales,Million US$ at exchange rate,21374.5 +4645,Canada,2016,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",650.1 +4646,Canada,2016,10,Total pharmaceutical sales,"/capita, US$ exchange rate",591.9 +4647,Canada,2016,10,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4 +4648,Canada,2016,10,N05B-Anxiolytics,"Million US$, purchasing power parity",135.4 +4649,Canada,2016,10,N05B-Anxiolytics,Million US$ at exchange rate,123.3 +4650,Canada,2016,10,N05B-Anxiolytics,% of total sales,0.6 +4651,Canada,2016,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.7 +4652,Canada,2016,10,N02-Analgesics,"Million US$, purchasing power parity",925.6 +4653,Canada,2016,10,N05B-Anxiolytics,Million of national currency units,163.4 +4654,Canada,2015,11,N-Nervous system,"/capita, US$ purchasing power parity",122.0 +4655,Canada,2015,11,C-Cardiovascular system,Million of national currency units,3888.7 +4656,Canada,2015,11,C-Cardiovascular system,"Million US$, purchasing power parity",3115.8 +4657,Canada,2015,11,C-Cardiovascular system,Million US$ at exchange rate,3040.9 +4658,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,22.1 +4659,Canada,2015,11,N-Nervous system,% of total sales,20.0 +4660,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",22.7 +4661,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +4662,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +4663,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.6 +4664,Canada,2015,11,C-Cardiovascular system,"/capita, US$ exchange rate",85.2 +4665,Canada,2015,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.0 +4666,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.2 +4667,Canada,2015,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.9 +4668,Canada,2015,11,G-Genito urinary system and sex hormones,% of total sales,5.6 +4669,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +4670,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +4671,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.7 +4672,Canada,2015,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.4 +4673,Canada,2015,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.9 +4674,Canada,2015,11,B-Blood and blood forming organs,% of total sales,3.5 +4675,Canada,2015,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1960.8 +4676,Canada,2015,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1913.7 +4677,Canada,2015,11,N-Nervous system,"/capita, US$ exchange rate",119.1 +4678,Canada,2015,11,J-Antiinfectives for systemic use,Million of national currency units,2447.2 +4679,Canada,2015,11,N-Nervous system,"Million US$, purchasing power parity",4355.4 +4680,Canada,2015,11,N-Nervous system,Million of national currency units,5435.7 +4681,Canada,2015,11,N-Nervous system,Million US$ at exchange rate,4250.7 +4682,Canada,2015,11,C-Cardiovascular system,% of total sales,14.3 +4683,Canada,2015,11,B-Blood and blood forming organs,Million of national currency units,954.8 +4684,Canada,2015,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.3 +4685,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",648.5 +4686,Canada,2015,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,809.3 +4687,Canada,2015,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,632.9 +4688,Canada,2015,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.9 +4689,Canada,2015,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6 +4690,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.3 +4691,Canada,2015,11,B-Blood and blood forming organs,Million US$ at exchange rate,746.6 +4692,Canada,2015,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",765.0 +4693,Canada,2015,11,J-Antiinfectives for systemic use,% of total sales,9.0 +4694,Canada,2015,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9 +4695,Canada,2015,11,C03-Diuretics,% of total sales,0.8 +4696,Canada,2015,11,J01-Antibacterials for systemic use,Million of national currency units,678.2 +4697,Canada,2015,11,M-Musculo-skeletal system,Million of national currency units,907.0 +4698,Canada,2015,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,530.4 +4699,Canada,2015,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",543.4 +4700,Canada,2015,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",726.7 +4701,Canada,2015,11,M-Musculo-skeletal system,Million US$ at exchange rate,709.3 +4702,Canada,2015,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.4 +4703,Canada,2015,11,C08-Calcium channel blockers,Million US$ at exchange rate,426.7 +4704,Canada,2015,11,C08-Calcium channel blockers,Million of national currency units,545.6 +4705,Canada,2015,11,M-Musculo-skeletal system,% of total sales,3.3 +4706,Canada,2015,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6 +4707,Canada,2015,11,C03-Diuretics,"/capita, US$ exchange rate",4.5 +4708,Canada,2015,11,C03-Diuretics,"Million US$, purchasing power parity",165.9 +4709,Canada,2015,11,C03-Diuretics,Million of national currency units,207.0 +4710,Canada,2015,11,C03-Diuretics,Million US$ at exchange rate,161.9 +4711,Canada,2015,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1 +4712,Canada,2015,11,C07-Beta blocking agents,"/capita, US$ exchange rate",6.9 +4713,Canada,2015,11,C07-Beta blocking agents,% of total sales,1.2 +4714,Canada,2015,11,C07-Beta blocking agents,"Million US$, purchasing power parity",253.6 +4715,Canada,2015,11,C07-Beta blocking agents,Million US$ at exchange rate,247.5 +4716,Canada,2015,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.8 +4717,Canada,2015,11,C10-Lipid modifying agents,% of total sales,4.6 +4718,Canada,2015,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",27.1 +4719,Canada,2015,11,J01-Antibacterials for systemic use,% of total sales,2.5 +4720,Canada,2015,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.9 +4721,Canada,2015,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.2 +4722,Canada,2015,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",991.4 +4723,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",379.8 +4724,Canada,2015,11,C07-Beta blocking agents,Million of national currency units,316.5 +4725,Canada,2015,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",437.2 +4726,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,370.7 +4727,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,474.0 +4728,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4 +4729,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5 +4730,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7 +4731,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6 +4732,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",270.8 +4733,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,264.3 +4734,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.6 +4735,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.4 +4736,Canada,2015,11,C02-Antihypertensives,"Million US$, purchasing power parity",83.6 +4737,Canada,2015,11,C10-Lipid modifying agents,Million of national currency units,1237.3 +4738,Canada,2015,11,C02-Antihypertensives,Million of national currency units,104.3 +4739,Canada,2015,11,C02-Antihypertensives,Million US$ at exchange rate,81.6 +4740,Canada,2015,11,C01A-Cardiac glycosides,% of total sales,0.1 +4741,Canada,2015,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",15.2 +4742,Canada,2015,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +4743,Canada,2015,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4 +4744,Canada,2015,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.3 +4745,Canada,2015,11,C02-Antihypertensives,% of total sales,0.4 +4746,Canada,2015,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +4747,Canada,2015,11,G-Genito urinary system and sex hormones,Million of national currency units,1511.3 +4748,Canada,2015,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1181.8 +4749,Canada,2015,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.2 +4750,Canada,2015,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",12.0 +4751,Canada,2015,11,C10-Lipid modifying agents,Million US$ at exchange rate,967.6 +4752,Canada,2015,11,C08-Calcium channel blockers,% of total sales,2.0 +4753,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,961.1 +4754,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",984.7 +4755,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,338.0 +4756,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1229.0 +4757,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.9 +4758,Canada,2015,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.1 +4759,Canada,2015,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1210.9 +4760,Canada,2015,11,C01A-Cardiac glycosides,Million US$ at exchange rate,14.9 +4761,Canada,2015,11,C01A-Cardiac glycosides,Million of national currency units,19.0 +4762,Canada,2015,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",83.8 +4763,Canada,2015,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3064.8 +4764,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2 +4765,Canada,2015,11,N06A-Antidepressants,% of total sales,5.3 +4766,Canada,2015,11,A-Alimentary tract and metabolism,Million of national currency units,3825.0 +4767,Canada,2015,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,2991.1 +4768,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,896.9 +4769,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1146.9 +4770,Canada,2015,11,R-Respiratory system,Million of national currency units,1874.5 +4771,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",25.7 +4772,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.1 +4773,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",919.0 +4774,Canada,2015,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.5 +4775,Canada,2015,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6 +4776,Canada,2015,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",163.6 +4777,Canada,2015,11,N05C-Hypnotics and sedatives,Million of national currency units,204.2 +4778,Canada,2015,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,159.7 +4779,Canada,2015,11,N05C-Hypnotics and sedatives,% of total sales,0.8 +4780,Canada,2015,11,N06A-Antidepressants,"Million US$, purchasing power parity",1148.1 +4781,Canada,2015,11,N06A-Antidepressants,"/capita, US$ exchange rate",31.4 +4782,Canada,2015,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",32.2 +4783,Canada,2015,11,N06A-Antidepressants,Million of national currency units,1432.9 +4784,Canada,2015,11,N06A-Antidepressants,Million US$ at exchange rate,1120.5 +4785,Canada,2015,11,Products not elsewhere classified,Million US$ at exchange rate,4788.3 +4786,Canada,2015,11,Products not elsewhere classified,"Million US$, purchasing power parity",4906.2 +4787,Canada,2015,11,Products not elsewhere classified,"/capita, US$ exchange rate",134.1 +4788,Canada,2015,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.6 +4789,Canada,2015,11,Products not elsewhere classified,Million of national currency units,6123.2 +4790,Canada,2015,11,R03-Drugs for obstructive airway diseases,% of total sales,5.5 +4791,Canada,2015,11,A02A-Antacids,Million US$ at exchange rate,1.1 +4792,Canada,2015,11,A02A-Antacids,"Million US$, purchasing power parity",1.1 +4793,Canada,2015,11,A02A-Antacids,"/capita, US$ exchange rate",0.0 +4794,Canada,2015,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +4795,Canada,2015,11,A02A-Antacids,% of total sales,0.0 +4796,Canada,2015,11,A02A-Antacids,Million of national currency units,1.4 +4797,Canada,2015,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",137.4 +4798,Canada,2015,11,Products not elsewhere classified,% of total sales,22.6 +4799,Canada,2015,11,R-Respiratory system,"/capita, US$ purchasing power parity",42.1 +4800,Canada,2015,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",85.8 +4801,Canada,2015,11,R-Respiratory system,Million US$ at exchange rate,1465.8 +4802,Canada,2015,11,R-Respiratory system,"Million US$, purchasing power parity",1502.0 +4803,Canada,2015,11,R-Respiratory system,"/capita, US$ exchange rate",41.1 +4804,Canada,2015,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1171.9 +4805,Canada,2015,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1200.8 +4806,Canada,2015,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.8 +4807,Canada,2015,11,A-Alimentary tract and metabolism,% of total sales,14.1 +4808,Canada,2015,11,R-Respiratory system,% of total sales,6.9 +4809,Canada,2015,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1498.6 +4810,Canada,2015,11,N05B-Anxiolytics,% of total sales,0.6 +4811,Canada,2015,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.1 +4812,Canada,2015,11,N02-Analgesics,"/capita, US$ exchange rate",24.5 +4813,Canada,2015,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1363.8 +4814,Canada,2015,11,Total pharmaceutical sales,Million of national currency units,27126.4 +4815,Canada,2015,11,N02-Analgesics,% of total sales,4.1 +4816,Canada,2015,11,N02-Analgesics,Million of national currency units,1117.2 +4817,Canada,2015,11,N02-Analgesics,Million US$ at exchange rate,873.6 +4818,Canada,2015,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1331.0 +4819,Canada,2015,11,A10-Drugs used in diabetes,Million of national currency units,1702.1 +4820,Canada,2015,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.3 +4821,Canada,2015,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",38.2 +4822,Canada,2015,11,A10-Drugs used in diabetes,% of total sales,6.3 +4823,Canada,2015,11,Total pharmaceutical sales,"Million US$, purchasing power parity",21735.2 +4824,Canada,2015,11,Total pharmaceutical sales,Million US$ at exchange rate,21212.6 +4825,Canada,2015,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",608.8 +4826,Canada,2015,11,Total pharmaceutical sales,"/capita, US$ exchange rate",594.1 +4827,Canada,2015,11,N05B-Anxiolytics,"Million US$, purchasing power parity",130.7 +4828,Canada,2015,11,N05B-Anxiolytics,Million US$ at exchange rate,127.5 +4829,Canada,2015,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.7 +4830,Canada,2015,11,N05B-Anxiolytics,"/capita, US$ exchange rate",3.6 +4831,Canada,2015,11,N02-Analgesics,"Million US$, purchasing power parity",895.2 +4832,Canada,2015,11,N05B-Anxiolytics,Million of national currency units,163.1 +4833,Canada,2014,11,C-Cardiovascular system,Million of national currency units,3973.2 +4834,Canada,2014,11,C-Cardiovascular system,"Million US$, purchasing power parity",3229.3 +4835,Canada,2014,11,C-Cardiovascular system,Million US$ at exchange rate,3596.5 +4836,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",23.5 +4837,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,26.2 +4838,Canada,2014,11,N-Nervous system,% of total sales,20.9 +4839,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +4840,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +4841,Canada,2014,11,C-Cardiovascular system,"/capita, US$ exchange rate",101.5 +4842,Canada,2014,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.1 +4843,Canada,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.7 +4844,Canada,2014,11,G-Genito urinary system and sex hormones,% of total sales,5.9 +4845,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.3 +4846,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +4847,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +4848,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",20.4 +4849,Canada,2014,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.0 +4850,Canada,2014,11,B-Blood and blood forming organs,% of total sales,3.4 +4851,Canada,2014,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.2 +4852,Canada,2014,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1363.9 +4853,Canada,2014,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1519.0 +4854,Canada,2014,11,N-Nervous system,"/capita, US$ exchange rate",135.9 +4855,Canada,2014,11,N-Nervous system,"/capita, US$ purchasing power parity",122.1 +4856,Canada,2014,11,N-Nervous system,Million of national currency units,5321.8 +4857,Canada,2014,11,J-Antiinfectives for systemic use,Million of national currency units,1678.1 +4858,Canada,2014,11,N-Nervous system,"Million US$, purchasing power parity",4325.4 +4859,Canada,2014,11,N-Nervous system,Million US$ at exchange rate,4817.2 +4860,Canada,2014,11,C-Cardiovascular system,% of total sales,15.6 +4861,Canada,2014,11,B-Blood and blood forming organs,Million of national currency units,870.2 +4862,Canada,2014,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,798.1 +4863,Canada,2014,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.1 +4864,Canada,2014,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,722.4 +4865,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",648.7 +4866,Canada,2014,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.5 +4867,Canada,2014,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.9 +4868,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.9 +4869,Canada,2014,11,B-Blood and blood forming organs,Million US$ at exchange rate,787.7 +4870,Canada,2014,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",707.3 +4871,Canada,2014,11,J-Antiinfectives for systemic use,% of total sales,6.6 +4872,Canada,2014,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,618.4 +4873,Canada,2014,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7 +4874,Canada,2014,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.2 +4875,Canada,2014,11,C03-Diuretics,% of total sales,0.8 +4876,Canada,2014,11,J01-Antibacterials for systemic use,Million of national currency units,683.2 +4877,Canada,2014,11,M-Musculo-skeletal system,Million of national currency units,988.0 +4878,Canada,2014,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",555.3 +4879,Canada,2014,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",803.0 +4880,Canada,2014,11,M-Musculo-skeletal system,Million US$ at exchange rate,894.3 +4881,Canada,2014,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6 +4882,Canada,2014,11,C08-Calcium channel blockers,Million US$ at exchange rate,495.6 +4883,Canada,2014,11,C08-Calcium channel blockers,Million of national currency units,547.5 +4884,Canada,2014,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",445.0 +4885,Canada,2014,11,M-Musculo-skeletal system,% of total sales,3.9 +4886,Canada,2014,11,C03-Diuretics,Million of national currency units,201.9 +4887,Canada,2014,11,C03-Diuretics,"/capita, US$ exchange rate",5.2 +4888,Canada,2014,11,C03-Diuretics,"Million US$, purchasing power parity",164.1 +4889,Canada,2014,11,C03-Diuretics,Million US$ at exchange rate,182.8 +4890,Canada,2014,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1 +4891,Canada,2014,11,C07-Beta blocking agents,% of total sales,1.2 +4892,Canada,2014,11,C07-Beta blocking agents,"/capita, US$ exchange rate",8.0 +4893,Canada,2014,11,C07-Beta blocking agents,"Million US$, purchasing power parity",253.3 +4894,Canada,2014,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",31.4 +4895,Canada,2014,11,C10-Lipid modifying agents,% of total sales,5.4 +4896,Canada,2014,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",35.0 +4897,Canada,2014,11,C07-Beta blocking agents,Million US$ at exchange rate,282.1 +4898,Canada,2014,11,J01-Antibacterials for systemic use,% of total sales,2.7 +4899,Canada,2014,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",17.5 +4900,Canada,2014,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.7 +4901,Canada,2014,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1113.6 +4902,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",368.9 +4903,Canada,2014,11,C07-Beta blocking agents,Million of national currency units,311.6 +4904,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,410.9 +4905,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,453.9 +4906,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.6 +4907,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7 +4908,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +4909,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.4 +4910,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7 +4911,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",365.9 +4912,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,407.5 +4913,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5 +4914,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3 +4915,Canada,2014,11,C02-Antihypertensives,"Million US$, purchasing power parity",74.8 +4916,Canada,2014,11,C10-Lipid modifying agents,Million of national currency units,1370.1 +4917,Canada,2014,11,C02-Antihypertensives,Million of national currency units,92.0 +4918,Canada,2014,11,C02-Antihypertensives,Million US$ at exchange rate,83.3 +4919,Canada,2014,11,C01A-Cardiac glycosides,% of total sales,0.1 +4920,Canada,2014,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",16.7 +4921,Canada,2014,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +4922,Canada,2014,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +4923,Canada,2014,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1 +4924,Canada,2014,11,C02-Antihypertensives,% of total sales,0.4 +4925,Canada,2014,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1369.1 +4926,Canada,2014,11,G-Genito urinary system and sex hormones,Million of national currency units,1512.5 +4927,Canada,2014,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +4928,Canada,2014,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.6 +4929,Canada,2014,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",14.0 +4930,Canada,2014,11,C10-Lipid modifying agents,Million US$ at exchange rate,1240.2 +4931,Canada,2014,11,C08-Calcium channel blockers,% of total sales,2.1 +4932,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1094.1 +4933,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",982.4 +4934,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,450.2 +4935,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.9 +4936,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1208.7 +4937,Canada,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.6 +4938,Canada,2014,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1229.3 +4939,Canada,2014,11,C01A-Cardiac glycosides,Million US$ at exchange rate,18.6 +4940,Canada,2014,11,C01A-Cardiac glycosides,Million of national currency units,20.5 +4941,Canada,2014,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2745.1 +4942,Canada,2014,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",86.3 +4943,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.4 +4944,Canada,2014,11,N06A-Antidepressants,% of total sales,5.9 +4945,Canada,2014,11,A-Alimentary tract and metabolism,Million of national currency units,3377.5 +4946,Canada,2014,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3057.3 +4947,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1027.3 +4948,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1134.9 +4949,Canada,2014,11,R-Respiratory system,Million of national currency units,1794.4 +4950,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.0 +4951,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",922.4 +4952,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.0 +4953,Canada,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1 +4954,Canada,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6 +4955,Canada,2014,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",162.4 +4956,Canada,2014,11,N05C-Hypnotics and sedatives,Million of national currency units,199.8 +4957,Canada,2014,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,180.9 +4958,Canada,2014,11,N06A-Antidepressants,"/capita, US$ exchange rate",38.2 +4959,Canada,2014,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",34.3 +4960,Canada,2014,11,N06A-Antidepressants,"Million US$, purchasing power parity",1216.3 +4961,Canada,2014,11,N06A-Antidepressants,Million of national currency units,1496.5 +4962,Canada,2014,11,N05C-Hypnotics and sedatives,% of total sales,0.8 +4963,Canada,2014,11,N06A-Antidepressants,Million US$ at exchange rate,1354.6 +4964,Canada,2014,11,Products not elsewhere classified,Million US$ at exchange rate,5021.1 +4965,Canada,2014,11,Products not elsewhere classified,"Million US$, purchasing power parity",4508.4 +4966,Canada,2014,11,Products not elsewhere classified,"/capita, US$ exchange rate",141.7 +4967,Canada,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.6 +4968,Canada,2014,11,R03-Drugs for obstructive airway diseases,% of total sales,5.7 +4969,Canada,2014,11,Products not elsewhere classified,Million of national currency units,5547.0 +4970,Canada,2014,11,A02A-Antacids,Million US$ at exchange rate,1.2 +4971,Canada,2014,11,A02A-Antacids,"Million US$, purchasing power parity",1.1 +4972,Canada,2014,11,A02A-Antacids,"/capita, US$ exchange rate",0.0 +4973,Canada,2014,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +4974,Canada,2014,11,A02A-Antacids,% of total sales,0.0 +4975,Canada,2014,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",127.2 +4976,Canada,2014,11,Products not elsewhere classified,% of total sales,21.7 +4977,Canada,2014,11,A02A-Antacids,Million of national currency units,1.3 +4978,Canada,2014,11,R-Respiratory system,"/capita, US$ purchasing power parity",41.2 +4979,Canada,2014,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.5 +4980,Canada,2014,11,R-Respiratory system,Million US$ at exchange rate,1624.3 +4981,Canada,2014,11,R-Respiratory system,"Million US$, purchasing power parity",1458.4 +4982,Canada,2014,11,R-Respiratory system,"/capita, US$ exchange rate",45.8 +4983,Canada,2014,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1325.2 +4984,Canada,2014,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1189.9 +4985,Canada,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",37.4 +4986,Canada,2014,11,A-Alimentary tract and metabolism,% of total sales,13.2 +4987,Canada,2014,11,R-Respiratory system,% of total sales,7.0 +4988,Canada,2014,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1464.0 +4989,Canada,2014,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.4 +4990,Canada,2014,11,N02-Analgesics,"/capita, US$ exchange rate",28.3 +4991,Canada,2014,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1230.6 +4992,Canada,2014,11,Total pharmaceutical sales,Million of national currency units,25517.0 +4993,Canada,2014,11,N02-Analgesics,% of total sales,4.3 +4994,Canada,2014,11,N02-Analgesics,Million US$ at exchange rate,1002.9 +4995,Canada,2014,11,N02-Analgesics,Million of national currency units,1107.9 +4996,Canada,2014,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1370.5 +4997,Canada,2014,11,A10-Drugs used in diabetes,Million of national currency units,1514.1 +4998,Canada,2014,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",38.7 +4999,Canada,2014,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",34.7 +5000,Canada,2014,11,A10-Drugs used in diabetes,% of total sales,5.9 +5001,Canada,2014,11,Total pharmaceutical sales,"Million US$, purchasing power parity",20739.5 +5002,Canada,2014,11,Total pharmaceutical sales,Million US$ at exchange rate,23097.6 +5003,Canada,2014,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",585.2 +5004,Canada,2014,11,Total pharmaceutical sales,"/capita, US$ exchange rate",651.8 +5005,Canada,2014,11,N05B-Anxiolytics,"Million US$, purchasing power parity",133.1 +5006,Canada,2014,11,N05B-Anxiolytics,Million US$ at exchange rate,148.3 +5007,Canada,2014,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8 +5008,Canada,2014,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.2 +5009,Canada,2014,11,N05B-Anxiolytics,% of total sales,0.6 +5010,Canada,2014,11,N02-Analgesics,"Million US$, purchasing power parity",900.5 +5011,Canada,2014,11,N05B-Anxiolytics,Million of national currency units,163.8 +5012,Canada,2013,11,C-Cardiovascular system,Million of national currency units,4082.7 +5013,Canada,2013,11,C-Cardiovascular system,"Million US$, purchasing power parity",3335.5 +5014,Canada,2013,11,C-Cardiovascular system,Million US$ at exchange rate,3963.3 +5015,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",23.3 +5016,Canada,2013,11,N-Nervous system,% of total sales,21.3 +5017,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +5018,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +5019,Canada,2013,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.2 +5020,Canada,2013,11,G-Genito urinary system and sex hormones,% of total sales,6.0 +5021,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +5022,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +5023,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.3 +5024,Canada,2013,11,C-Cardiovascular system,"/capita, US$ exchange rate",113.0 +5025,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.7 +5026,Canada,2013,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.0 +5027,Canada,2013,11,B-Blood and blood forming organs,% of total sales,3.1 +5028,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,27.7 +5029,Canada,2013,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1210.9 +5030,Canada,2013,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4 +5031,Canada,2013,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1438.8 +5032,Canada,2013,11,N-Nervous system,"/capita, US$ exchange rate",144.6 +5033,Canada,2013,11,N-Nervous system,"/capita, US$ purchasing power parity",121.7 +5034,Canada,2013,11,J-Antiinfectives for systemic use,Million of national currency units,1482.2 +5035,Canada,2013,11,N-Nervous system,Million of national currency units,5224.8 +5036,Canada,2013,11,N-Nervous system,Million US$ at exchange rate,5071.9 +5037,Canada,2013,11,N-Nervous system,"Million US$, purchasing power parity",4268.6 +5038,Canada,2013,11,C-Cardiovascular system,% of total sales,16.6 +5039,Canada,2013,11,B-Blood and blood forming organs,Million of national currency units,774.2 +5040,Canada,2013,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",95.1 +5041,Canada,2013,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,784.7 +5042,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",641.1 +5043,Canada,2013,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,761.7 +5044,Canada,2013,11,B-Blood and blood forming organs,Million US$ at exchange rate,751.6 +5045,Canada,2013,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.5 +5046,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.5 +5047,Canada,2013,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.0 +5048,Canada,2013,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",632.5 +5049,Canada,2013,11,J-Antiinfectives for systemic use,% of total sales,6.0 +5050,Canada,2013,11,C10-Lipid modifying agents,Million of national currency units,1484.4 +5051,Canada,2013,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,658.8 +5052,Canada,2013,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.0 +5053,Canada,2013,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.4 +5054,Canada,2013,11,C03-Diuretics,% of total sales,0.8 +5055,Canada,2013,11,J01-Antibacterials for systemic use,Million of national currency units,678.7 +5056,Canada,2013,11,M-Musculo-skeletal system,Million of national currency units,989.4 +5057,Canada,2013,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",554.5 +5058,Canada,2013,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",808.3 +5059,Canada,2013,11,M-Musculo-skeletal system,Million US$ at exchange rate,960.5 +5060,Canada,2013,11,C08-Calcium channel blockers,Million US$ at exchange rate,545.8 +5061,Canada,2013,11,C08-Calcium channel blockers,Million of national currency units,562.3 +5062,Canada,2013,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",459.4 +5063,Canada,2013,11,M-Musculo-skeletal system,% of total sales,4.0 +5064,Canada,2013,11,C03-Diuretics,"/capita, US$ exchange rate",5.5 +5065,Canada,2013,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.7 +5066,Canada,2013,11,C03-Diuretics,"Million US$, purchasing power parity",163.5 +5067,Canada,2013,11,C03-Diuretics,Million of national currency units,200.1 +5068,Canada,2013,11,C03-Diuretics,Million US$ at exchange rate,194.2 +5069,Canada,2013,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2 +5070,Canada,2013,11,C07-Beta blocking agents,% of total sales,1.3 +5071,Canada,2013,11,C07-Beta blocking agents,"Million US$, purchasing power parity",252.0 +5072,Canada,2013,11,C07-Beta blocking agents,"/capita, US$ exchange rate",8.5 +5073,Canada,2013,11,C10-Lipid modifying agents,% of total sales,6.0 +5074,Canada,2013,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.6 +5075,Canada,2013,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.1 +5076,Canada,2013,11,C07-Beta blocking agents,Million US$ at exchange rate,299.5 +5077,Canada,2013,11,J01-Antibacterials for systemic use,% of total sales,2.8 +5078,Canada,2013,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",18.8 +5079,Canada,2013,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1212.7 +5080,Canada,2013,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.8 +5081,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",355.5 +5082,Canada,2013,11,C07-Beta blocking agents,Million of national currency units,308.5 +5083,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,435.1 +5084,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,422.4 +5085,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.0 +5086,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.9 +5087,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +5088,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.1 +5089,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",371.8 +5090,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6 +5091,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.1 +5092,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6 +5093,Canada,2013,11,C02-Antihypertensives,"Million US$, purchasing power parity",62.5 +5094,Canada,2013,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.1 +5095,Canada,2013,11,C02-Antihypertensives,Million of national currency units,76.5 +5096,Canada,2013,11,C02-Antihypertensives,Million US$ at exchange rate,74.3 +5097,Canada,2013,11,C01A-Cardiac glycosides,% of total sales,0.1 +5098,Canada,2013,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",17.7 +5099,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,441.8 +5100,Canada,2013,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6 +5101,Canada,2013,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +5102,Canada,2013,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8 +5103,Canada,2013,11,C02-Antihypertensives,% of total sales,0.3 +5104,Canada,2013,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1430.8 +5105,Canada,2013,11,G-Genito urinary system and sex hormones,Million of national currency units,1473.9 +5106,Canada,2013,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",13.1 +5107,Canada,2013,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",15.6 +5108,Canada,2013,11,C10-Lipid modifying agents,Million US$ at exchange rate,1441.0 +5109,Canada,2013,11,C08-Calcium channel blockers,% of total sales,2.3 +5110,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1172.3 +5111,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",986.6 +5112,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,455.1 +5113,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",33.4 +5114,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1207.6 +5115,Canada,2013,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",40.8 +5116,Canada,2013,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1204.2 +5117,Canada,2013,11,C01A-Cardiac glycosides,Million US$ at exchange rate,21.1 +5118,Canada,2013,11,C01A-Cardiac glycosides,Million of national currency units,21.7 +5119,Canada,2013,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.3 +5120,Canada,2013,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2651.3 +5121,Canada,2013,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",89.8 +5122,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.9 +5123,Canada,2013,11,N06A-Antidepressants,% of total sales,5.9 +5124,Canada,2013,11,A-Alimentary tract and metabolism,Million of national currency units,3245.2 +5125,Canada,2013,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3150.3 +5126,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1160.7 +5127,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1195.7 +5128,Canada,2013,11,R-Respiratory system,Million of national currency units,1729.2 +5129,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",27.8 +5130,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",33.1 +5131,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",976.9 +5132,Canada,2013,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.3 +5133,Canada,2013,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.5 +5134,Canada,2013,11,N05C-Hypnotics and sedatives,Million of national currency units,193.2 +5135,Canada,2013,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,187.5 +5136,Canada,2013,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",157.8 +5137,Canada,2013,11,N05C-Hypnotics and sedatives,% of total sales,0.8 +5138,Canada,2013,11,N06A-Antidepressants,"/capita, US$ exchange rate",40.3 +5139,Canada,2013,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",33.9 +5140,Canada,2013,11,N06A-Antidepressants,"Million US$, purchasing power parity",1189.9 +5141,Canada,2013,11,N06A-Antidepressants,Million of national currency units,1456.4 +5142,Canada,2013,11,N06A-Antidepressants,Million US$ at exchange rate,1413.8 +5143,Canada,2013,11,R-Respiratory system,Million US$ at exchange rate,1678.6 +5144,Canada,2013,11,Products not elsewhere classified,Million US$ at exchange rate,4992.5 +5145,Canada,2013,11,Products not elsewhere classified,"Million US$, purchasing power parity",4201.8 +5146,Canada,2013,11,Products not elsewhere classified,"/capita, US$ exchange rate",142.3 +5147,Canada,2013,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.6 +5148,Canada,2013,11,R03-Drugs for obstructive airway diseases,% of total sales,5.7 +5149,Canada,2013,11,Products not elsewhere classified,Million of national currency units,5143.0 +5150,Canada,2013,11,A02A-Antacids,Million US$ at exchange rate,1.3 +5151,Canada,2013,11,A02A-Antacids,"Million US$, purchasing power parity",1.1 +5152,Canada,2013,11,A02A-Antacids,"/capita, US$ exchange rate",0.0 +5153,Canada,2013,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +5154,Canada,2013,11,A02A-Antacids,% of total sales,0.0 +5155,Canada,2013,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",119.8 +5156,Canada,2013,11,Products not elsewhere classified,% of total sales,20.9 +5157,Canada,2013,11,A02A-Antacids,Million of national currency units,1.3 +5158,Canada,2013,11,R-Respiratory system,"/capita, US$ purchasing power parity",40.3 +5159,Canada,2013,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",75.6 +5160,Canada,2013,11,R-Respiratory system,"Million US$, purchasing power parity",1412.7 +5161,Canada,2013,11,R-Respiratory system,"/capita, US$ exchange rate",47.8 +5162,Canada,2013,11,A-Alimentary tract and metabolism,% of total sales,13.2 +5163,Canada,2013,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1143.6 +5164,Canada,2013,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.7 +5165,Canada,2013,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1358.8 +5166,Canada,2013,11,R-Respiratory system,% of total sales,7.0 +5167,Canada,2013,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1399.8 +5168,Canada,2013,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.5 +5169,Canada,2013,11,N02-Analgesics,"/capita, US$ exchange rate",30.3 +5170,Canada,2013,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1118.5 +5171,Canada,2013,11,Total pharmaceutical sales,Million of national currency units,24579.2 +5172,Canada,2013,11,N02-Analgesics,% of total sales,4.4 +5173,Canada,2013,11,N02-Analgesics,Million US$ at exchange rate,1061.6 +5174,Canada,2013,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1328.9 +5175,Canada,2013,11,N02-Analgesics,Million of national currency units,1093.6 +5176,Canada,2013,11,A10-Drugs used in diabetes,Million of national currency units,1369.0 +5177,Canada,2013,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.9 +5178,Canada,2013,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.9 +5179,Canada,2013,11,A10-Drugs used in diabetes,% of total sales,5.6 +5180,Canada,2013,11,Total pharmaceutical sales,"Million US$, purchasing power parity",20081.0 +5181,Canada,2013,11,Total pharmaceutical sales,Million US$ at exchange rate,23860.1 +5182,Canada,2013,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",572.4 +5183,Canada,2013,11,Total pharmaceutical sales,"/capita, US$ exchange rate",680.1 +5184,Canada,2013,11,N02-Analgesics,"Million US$, purchasing power parity",893.5 +5185,Canada,2013,11,N05B-Anxiolytics,"Million US$, purchasing power parity",134.2 +5186,Canada,2013,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8 +5187,Canada,2013,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.5 +5188,Canada,2013,11,N05B-Anxiolytics,Million US$ at exchange rate,159.4 +5189,Canada,2013,11,N05B-Anxiolytics,% of total sales,0.7 +5190,Canada,2013,11,N05B-Anxiolytics,Million of national currency units,164.2 +5191,Canada,2012,11,C-Cardiovascular system,Million of national currency units,4627.3 +5192,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +5193,Canada,2012,11,C-Cardiovascular system,"Million US$, purchasing power parity",3717.9 +5194,Canada,2012,11,C-Cardiovascular system,Million US$ at exchange rate,4630.2 +5195,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.6 +5196,Canada,2012,11,N-Nervous system,% of total sales,21.4 +5197,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +5198,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +5199,Canada,2012,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.1 +5200,Canada,2012,11,G-Genito urinary system and sex hormones,% of total sales,5.9 +5201,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",17.4 +5202,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +5203,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.7 +5204,Canada,2012,11,C-Cardiovascular system,"/capita, US$ exchange rate",133.4 +5205,Canada,2012,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",107.1 +5206,Canada,2012,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.2 +5207,Canada,2012,11,B-Blood and blood forming organs,% of total sales,3.1 +5208,Canada,2012,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4 +5209,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,30.6 +5210,Canada,2012,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1158.4 +5211,Canada,2012,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1442.7 +5212,Canada,2012,11,N-Nervous system,"/capita, US$ exchange rate",149.9 +5213,Canada,2012,11,N-Nervous system,"/capita, US$ purchasing power parity",120.4 +5214,Canada,2012,11,N-Nervous system,Million of national currency units,5200.6 +5215,Canada,2012,11,N-Nervous system,Million US$ at exchange rate,5203.9 +5216,Canada,2012,11,N-Nervous system,"Million US$, purchasing power parity",4178.5 +5217,Canada,2012,11,J-Antiinfectives for systemic use,Million of national currency units,1441.8 +5218,Canada,2012,11,C-Cardiovascular system,% of total sales,19.0 +5219,Canada,2012,11,B-Blood and blood forming organs,Million of national currency units,742.9 +5220,Canada,2012,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,751.1 +5221,Canada,2012,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,751.6 +5222,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",603.5 +5223,Canada,2012,11,B-Blood and blood forming organs,Million US$ at exchange rate,743.4 +5224,Canada,2012,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.4 +5225,Canada,2012,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.6 +5226,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,30.6 +5227,Canada,2012,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",596.9 +5228,Canada,2012,11,J-Antiinfectives for systemic use,% of total sales,5.9 +5229,Canada,2012,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,694.6 +5230,Canada,2012,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7 +5231,Canada,2012,11,C03-Diuretics,% of total sales,0.8 +5232,Canada,2012,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.3 +5233,Canada,2012,11,J01-Antibacterials for systemic use,Million of national currency units,694.2 +5234,Canada,2012,11,M-Musculo-skeletal system,Million of national currency units,980.8 +5235,Canada,2012,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",557.8 +5236,Canada,2012,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",788.0 +5237,Canada,2012,11,M-Musculo-skeletal system,Million US$ at exchange rate,981.4 +5238,Canada,2012,11,C08-Calcium channel blockers,Million US$ at exchange rate,613.8 +5239,Canada,2012,11,M-Musculo-skeletal system,% of total sales,4.0 +5240,Canada,2012,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",492.8 +5241,Canada,2012,11,C08-Calcium channel blockers,Million of national currency units,613.4 +5242,Canada,2012,11,C03-Diuretics,Million of national currency units,198.4 +5243,Canada,2012,11,C03-Diuretics,"/capita, US$ exchange rate",5.7 +5244,Canada,2012,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6 +5245,Canada,2012,11,C03-Diuretics,Million US$ at exchange rate,198.5 +5246,Canada,2012,11,C03-Diuretics,"Million US$, purchasing power parity",159.4 +5247,Canada,2012,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4 +5248,Canada,2012,11,C07-Beta blocking agents,% of total sales,1.3 +5249,Canada,2012,11,C07-Beta blocking agents,"Million US$, purchasing power parity",258.3 +5250,Canada,2012,11,C07-Beta blocking agents,"/capita, US$ exchange rate",9.3 +5251,Canada,2012,11,C10-Lipid modifying agents,% of total sales,7.5 +5252,Canada,2012,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",42.2 +5253,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9 +5254,Canada,2012,11,C07-Beta blocking agents,Million US$ at exchange rate,321.7 +5255,Canada,2012,11,J01-Antibacterials for systemic use,% of total sales,2.9 +5256,Canada,2012,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1465.0 +5257,Canada,2012,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",20.0 +5258,Canada,2012,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",16.1 +5259,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",332.5 +5260,Canada,2012,11,C07-Beta blocking agents,Million of national currency units,321.5 +5261,Canada,2012,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",52.6 +5262,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,413.8 +5263,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,414.1 +5264,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6 +5265,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7 +5266,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.6 +5267,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",364.9 +5268,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1 +5269,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.5 +5270,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5 +5271,Canada,2012,11,C02-Antihypertensives,"Million US$, purchasing power parity",59.0 +5272,Canada,2012,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.1 +5273,Canada,2012,11,C02-Antihypertensives,Million of national currency units,73.4 +5274,Canada,2012,11,C02-Antihypertensives,Million US$ at exchange rate,73.4 +5275,Canada,2012,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",17.9 +5276,Canada,2012,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6 +5277,Canada,2012,11,C01A-Cardiac glycosides,% of total sales,0.1 +5278,Canada,2012,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +5279,Canada,2012,11,C10-Lipid modifying agents,Million of national currency units,1823.4 +5280,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,454.4 +5281,Canada,2012,11,C02-Antihypertensives,% of total sales,0.3 +5282,Canada,2012,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7 +5283,Canada,2012,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1431.5 +5284,Canada,2012,11,G-Genito urinary system and sex hormones,Million of national currency units,1430.6 +5285,Canada,2012,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",14.2 +5286,Canada,2012,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",17.7 +5287,Canada,2012,11,C10-Lipid modifying agents,Million US$ at exchange rate,1824.6 +5288,Canada,2012,11,C08-Calcium channel blockers,% of total sales,2.5 +5289,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1363.6 +5290,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1094.9 +5291,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,454.1 +5292,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",39.3 +5293,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1362.7 +5294,Canada,2012,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",41.2 +5295,Canada,2012,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1149.4 +5296,Canada,2012,11,C01A-Cardiac glycosides,Million US$ at exchange rate,22.3 +5297,Canada,2012,11,C01A-Cardiac glycosides,Million of national currency units,22.3 +5298,Canada,2012,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.1 +5299,Canada,2012,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2570.7 +5300,Canada,2012,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",92.2 +5301,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.3 +5302,Canada,2012,11,A-Alimentary tract and metabolism,Million of national currency units,3199.5 +5303,Canada,2012,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3201.5 +5304,Canada,2012,11,N06A-Antidepressants,% of total sales,5.9 +5305,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1299.0 +5306,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1298.2 +5307,Canada,2012,11,R-Respiratory system,Million of national currency units,1676.3 +5308,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",30.0 +5309,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",37.4 +5310,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1043.1 +5311,Canada,2012,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.4 +5312,Canada,2012,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3 +5313,Canada,2012,11,N05C-Hypnotics and sedatives,Million of national currency units,187.0 +5314,Canada,2012,11,N05C-Hypnotics and sedatives,% of total sales,0.8 +5315,Canada,2012,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,187.1 +5316,Canada,2012,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",150.2 +5317,Canada,2012,11,N06A-Antidepressants,"/capita, US$ exchange rate",41.6 +5318,Canada,2012,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",33.4 +5319,Canada,2012,11,N06A-Antidepressants,"Million US$, purchasing power parity",1160.4 +5320,Canada,2012,11,N06A-Antidepressants,Million of national currency units,1444.2 +5321,Canada,2012,11,N06A-Antidepressants,Million US$ at exchange rate,1445.1 +5322,Canada,2012,11,Products not elsewhere classified,Million US$ at exchange rate,4586.9 +5323,Canada,2012,11,Products not elsewhere classified,"Million US$, purchasing power parity",3683.1 +5324,Canada,2012,11,Products not elsewhere classified,"/capita, US$ exchange rate",132.1 +5325,Canada,2012,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.3 +5326,Canada,2012,11,R03-Drugs for obstructive airway diseases,% of total sales,5.6 +5327,Canada,2012,11,Products not elsewhere classified,Million of national currency units,4584.0 +5328,Canada,2012,11,A02A-Antacids,"Million US$, purchasing power parity",1.1 +5329,Canada,2012,11,A02A-Antacids,"/capita, US$ exchange rate",0.0 +5330,Canada,2012,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +5331,Canada,2012,11,A02A-Antacids,% of total sales,0.0 +5332,Canada,2012,11,A02A-Antacids,Million US$ at exchange rate,1.4 +5333,Canada,2012,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.1 +5334,Canada,2012,11,A02A-Antacids,Million of national currency units,1.4 +5335,Canada,2012,11,Products not elsewhere classified,% of total sales,18.9 +5336,Canada,2012,11,R-Respiratory system,Million US$ at exchange rate,1677.4 +5337,Canada,2012,11,R-Respiratory system,% of total sales,6.9 +5338,Canada,2012,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",74.1 +5339,Canada,2012,11,R-Respiratory system,"/capita, US$ purchasing power parity",38.8 +5340,Canada,2012,11,R-Respiratory system,"Million US$, purchasing power parity",1346.9 +5341,Canada,2012,11,R-Respiratory system,"/capita, US$ exchange rate",48.3 +5342,Canada,2012,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1085.0 +5343,Canada,2012,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.9 +5344,Canada,2012,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1351.3 +5345,Canada,2012,11,A-Alimentary tract and metabolism,% of total sales,13.2 +5346,Canada,2012,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1350.4 +5347,Canada,2012,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.8 +5348,Canada,2012,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",991.2 +5349,Canada,2012,11,N02-Analgesics,% of total sales,4.6 +5350,Canada,2012,11,Total pharmaceutical sales,Million of national currency units,24297.8 +5351,Canada,2012,11,N02-Analgesics,Million US$ at exchange rate,1116.2 +5352,Canada,2012,11,N02-Analgesics,Million of national currency units,1115.5 +5353,Canada,2012,11,A10-Drugs used in diabetes,Million of national currency units,1233.7 +5354,Canada,2012,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",35.6 +5355,Canada,2012,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.6 +5356,Canada,2012,11,A10-Drugs used in diabetes,% of total sales,5.1 +5357,Canada,2012,11,Total pharmaceutical sales,"Million US$, purchasing power parity",19522.5 +5358,Canada,2012,11,Total pharmaceutical sales,Million US$ at exchange rate,24313.2 +5359,Canada,2012,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",562.4 +5360,Canada,2012,11,Total pharmaceutical sales,"/capita, US$ exchange rate",700.4 +5361,Canada,2012,11,N02-Analgesics,"Million US$, purchasing power parity",896.3 +5362,Canada,2012,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1234.5 +5363,Canada,2012,11,N05B-Anxiolytics,"Million US$, purchasing power parity",132.4 +5364,Canada,2012,11,N05B-Anxiolytics,Million US$ at exchange rate,164.9 +5365,Canada,2012,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.8 +5366,Canada,2012,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8 +5367,Canada,2012,11,N05B-Anxiolytics,% of total sales,0.7 +5368,Canada,2012,11,N02-Analgesics,"/capita, US$ exchange rate",32.2 +5369,Canada,2012,11,N05B-Anxiolytics,Million of national currency units,164.8 +5370,Chile,2015,14,B-Blood and blood forming organs,Million of national currency units,92673.7 +5371,Chile,2015,14,B-Blood and blood forming organs,Million US$ at exchange rate,141.7 +5372,Chile,2015,14,G-Genito urinary system and sex hormones,Million of national currency units,165236.3 +5373,Chile,2015,14,C10-Lipid modifying agents,"Million US$, purchasing power parity",101.3 +5374,Chile,2015,14,G-Genito urinary system and sex hormones,Million US$ at exchange rate,252.6 +5375,Chile,2015,14,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",422.4 +5376,Chile,2015,14,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.6 +5377,Chile,2015,14,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.2 +5378,Chile,2015,14,B-Blood and blood forming organs,% of total sales,5.1 +5379,Chile,2015,14,B-Blood and blood forming organs,"Million US$, purchasing power parity",236.9 +5380,Chile,2015,14,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.9 +5381,Chile,2015,14,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.4 +5382,Chile,2015,14,C10-Lipid modifying agents,% of total sales,2.2 +5383,Chile,2015,14,A-Alimentary tract and metabolism,% of total sales,17.4 +5384,Chile,2015,14,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +5385,Chile,2015,14,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +5386,Chile,2015,14,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",812.4 +5387,Chile,2015,14,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.2 +5388,Chile,2015,14,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.0 +5389,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.2 +5390,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7 +5391,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +5392,Chile,2015,14,C01A-Cardiac glycosides,Million of national currency units,173.5 +5393,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,43736.2 +5394,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.9 +5395,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.8 +5396,Chile,2015,14,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.1 +5397,Chile,2015,14,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.5 +5398,Chile,2015,14,G03-Sex hormones and modulators of the genital system,Million of national currency units,117332.5 +5399,Chile,2015,14,G-Genito urinary system and sex hormones,% of total sales,9.1 +5400,Chile,2015,14,C10-Lipid modifying agents,Million US$ at exchange rate,60.6 +5401,Chile,2015,14,C01A-Cardiac glycosides,% of total sales,0.0 +5402,Chile,2015,14,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +5403,Chile,2015,14,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +5404,Chile,2015,14,G03-Sex hormones and modulators of the genital system,% of total sales,6.4 +5405,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",16.7 +5406,Chile,2015,14,A-Alimentary tract and metabolism,Million of national currency units,317777.7 +5407,Chile,2015,14,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.4 +5408,Chile,2015,14,A-Alimentary tract and metabolism,Million US$ at exchange rate,485.8 +5409,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",299.9 +5410,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.0 +5411,Chile,2015,14,Total pharmaceutical sales,"/capita, US$ purchasing power parity",259.4 +5412,Chile,2015,14,C07-Beta blocking agents,Million of national currency units,16311.0 +5413,Chile,2015,14,C07-Beta blocking agents,Million US$ at exchange rate,24.9 +5414,Chile,2015,14,Total pharmaceutical sales,Million US$ at exchange rate,2788.0 +5415,Chile,2015,14,Total pharmaceutical sales,"Million US$, purchasing power parity",4662.0 +5416,Chile,2015,14,Total pharmaceutical sales,"/capita, US$ exchange rate",155.1 +5417,Chile,2015,14,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +5418,Chile,2015,14,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +5419,Chile,2015,14,C02-Antihypertensives,"Million US$, purchasing power parity",9.1 +5420,Chile,2015,14,C-Cardiovascular system,% of total sales,7.6 +5421,Chile,2015,14,C07-Beta blocking agents,"Million US$, purchasing power parity",41.7 +5422,Chile,2015,14,C02-Antihypertensives,% of total sales,0.2 +5423,Chile,2015,14,C-Cardiovascular system,Million of national currency units,138496.2 +5424,Chile,2015,14,C03-Diuretics,Million US$ at exchange rate,10.4 +5425,Chile,2015,14,C03-Diuretics,Million of national currency units,6793.5 +5426,Chile,2015,14,C-Cardiovascular system,Million US$ at exchange rate,211.7 +5427,Chile,2015,14,C-Cardiovascular system,"/capita, US$ exchange rate",11.8 +5428,Chile,2015,14,C-Cardiovascular system,"Million US$, purchasing power parity",354.0 +5429,Chile,2015,14,C03-Diuretics,"/capita, US$ purchasing power parity",1.0 +5430,Chile,2015,14,C03-Diuretics,% of total sales,0.4 +5431,Chile,2015,14,Total pharmaceutical sales,Million of national currency units,1823693.1 +5432,Chile,2015,14,C-Cardiovascular system,"/capita, US$ purchasing power parity",19.7 +5433,Chile,2015,14,C03-Diuretics,"Million US$, purchasing power parity",17.4 +5434,Chile,2015,14,C03-Diuretics,"/capita, US$ exchange rate",0.6 +5435,Chile,2015,14,C08-Calcium channel blockers,% of total sales,0.4 +5436,Chile,2015,14,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0 +5437,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,49040.7 +5438,Chile,2015,14,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.2 +5439,Chile,2015,14,C08-Calcium channel blockers,Million US$ at exchange rate,10.3 +5440,Chile,2015,14,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6 +5441,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7 +5442,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.0 +5443,Chile,2015,14,C10-Lipid modifying agents,Million of national currency units,39621.5 +5444,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",125.4 +5445,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,75.0 +5446,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.2 +5447,Chile,2015,14,C02-Antihypertensives,Million US$ at exchange rate,5.4 +5448,Chile,2015,14,C02-Antihypertensives,Million of national currency units,3557.7 +5449,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +5450,Chile,2015,14,C07-Beta blocking agents,"/capita, US$ exchange rate",1.4 +5451,Chile,2015,14,C07-Beta blocking agents,% of total sales,0.9 +5452,Chile,2015,14,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.3 +5453,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.6 +5454,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1679.1 +5455,Chile,2015,14,C08-Calcium channel blockers,Million of national currency units,6710.2 +5456,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2 +5457,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.1 +5458,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.3 +5459,Chile,2015,14,N-Nervous system,"/capita, US$ purchasing power parity",40.3 +5460,Chile,2015,14,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3 +5461,Chile,2015,14,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8 +5462,Chile,2015,14,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",202.9 +5463,Chile,2015,14,N06A-Antidepressants,% of total sales,3.1 +5464,Chile,2015,14,J01-Antibacterials for systemic use,% of total sales,4.4 +5465,Chile,2015,14,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.4 +5466,Chile,2015,14,A10-Drugs used in diabetes,% of total sales,4.8 +5467,Chile,2015,14,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.4 +5468,Chile,2015,14,A10-Drugs used in diabetes,Million of national currency units,87238.4 +5469,Chile,2015,14,A10-Drugs used in diabetes,Million US$ at exchange rate,133.4 +5470,Chile,2015,14,A10-Drugs used in diabetes,"Million US$, purchasing power parity",223.0 +5471,Chile,2015,14,N06A-Antidepressants,Million of national currency units,56272.0 +5472,Chile,2015,14,N06A-Antidepressants,"Million US$, purchasing power parity",143.9 +5473,Chile,2015,14,N06A-Antidepressants,Million US$ at exchange rate,86.0 +5474,Chile,2015,14,M-Musculo-skeletal system,Million of national currency units,123321.4 +5475,Chile,2015,14,N05C-Hypnotics and sedatives,% of total sales,0.5 +5476,Chile,2015,14,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.0 +5477,Chile,2015,14,Products not elsewhere classified,"Million US$, purchasing power parity",616.7 +5478,Chile,2015,14,Products not elsewhere classified,"/capita, US$ exchange rate",20.5 +5479,Chile,2015,14,N06A-Antidepressants,"/capita, US$ exchange rate",4.8 +5480,Chile,2015,14,Products not elsewhere classified,% of total sales,13.2 +5481,Chile,2015,14,Products not elsewhere classified,"/capita, US$ purchasing power parity",34.3 +5482,Chile,2015,14,R-Respiratory system,% of total sales,9.6 +5483,Chile,2015,14,R-Respiratory system,"/capita, US$ purchasing power parity",25.0 +5484,Chile,2015,14,A02A-Antacids,"Million US$, purchasing power parity",28.9 +5485,Chile,2015,14,R03-Drugs for obstructive airway diseases,Million of national currency units,46814.6 +5486,Chile,2015,14,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,71.6 +5487,Chile,2015,14,A02A-Antacids,Million of national currency units,11322.5 +5488,Chile,2015,14,R-Respiratory system,Million of national currency units,175733.0 +5489,Chile,2015,14,A02A-Antacids,Million US$ at exchange rate,17.3 +5490,Chile,2015,14,R-Respiratory system,"Million US$, purchasing power parity",449.2 +5491,Chile,2015,14,R-Respiratory system,Million US$ at exchange rate,268.7 +5492,Chile,2015,14,R-Respiratory system,"/capita, US$ exchange rate",14.9 +5493,Chile,2015,14,A02A-Antacids,"/capita, US$ purchasing power parity",1.6 +5494,Chile,2015,14,Products not elsewhere classified,Million US$ at exchange rate,368.8 +5495,Chile,2015,14,A02A-Antacids,% of total sales,0.6 +5496,Chile,2015,14,J01-Antibacterials for systemic use,Million US$ at exchange rate,121.4 +5497,Chile,2015,14,J01-Antibacterials for systemic use,Million of national currency units,79384.9 +5498,Chile,2015,14,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.0 +5499,Chile,2015,14,A02A-Antacids,"/capita, US$ exchange rate",1.0 +5500,Chile,2015,14,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",119.7 +5501,Chile,2015,14,M-Musculo-skeletal system,Million US$ at exchange rate,188.5 +5502,Chile,2015,14,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",6.7 +5503,Chile,2015,14,Products not elsewhere classified,Million of national currency units,241259.0 +5504,Chile,2015,14,R03-Drugs for obstructive airway diseases,% of total sales,2.6 +5505,Chile,2015,14,N02-Analgesics,"Million US$, purchasing power parity",193.2 +5506,Chile,2015,14,N02-Analgesics,"/capita, US$ exchange rate",6.4 +5507,Chile,2015,14,N02-Analgesics,"/capita, US$ purchasing power parity",10.7 +5508,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,30504.0 +5509,Chile,2015,14,N02-Analgesics,Million US$ at exchange rate,115.5 +5510,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",166.2 +5511,Chile,2015,14,J-Antiinfectives for systemic use,Million of national currency units,241797.7 +5512,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,99.4 +5513,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2 +5514,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6 +5515,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.5 +5516,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,46.6 +5517,Chile,2015,14,N-Nervous system,Million of national currency units,283661.8 +5518,Chile,2015,14,N-Nervous system,Million US$ at exchange rate,433.7 +5519,Chile,2015,14,N-Nervous system,% of total sales,15.6 +5520,Chile,2015,14,N-Nervous system,"/capita, US$ exchange rate",24.1 +5521,Chile,2015,14,N-Nervous system,"Million US$, purchasing power parity",725.1 +5522,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6 +5523,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",78.0 +5524,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.3 +5525,Chile,2015,14,N02-Analgesics,Million of national currency units,75558.7 +5526,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7 +5527,Chile,2015,14,N05B-Anxiolytics,% of total sales,0.7 +5528,Chile,2015,14,N05C-Hypnotics and sedatives,Million of national currency units,9241.4 +5529,Chile,2015,14,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.1 +5530,Chile,2015,14,N05B-Anxiolytics,"Million US$, purchasing power parity",32.5 +5531,Chile,2015,14,N05B-Anxiolytics,Million US$ at exchange rate,19.4 +5532,Chile,2015,14,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8 +5533,Chile,2015,14,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +5534,Chile,2015,14,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5 +5535,Chile,2015,14,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.5 +5536,Chile,2015,14,M-Musculo-skeletal system,"Million US$, purchasing power parity",315.3 +5537,Chile,2015,14,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +5538,Chile,2015,14,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6 +5539,Chile,2015,14,M-Musculo-skeletal system,% of total sales,6.8 +5540,Chile,2015,14,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +5541,Chile,2015,14,N02-Analgesics,% of total sales,4.1 +5542,Chile,2015,14,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.4 +5543,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,65023.8 +5544,Chile,2015,14,J-Antiinfectives for systemic use,% of total sales,13.3 +5545,Chile,2015,14,J-Antiinfectives for systemic use,Million US$ at exchange rate,369.7 +5546,Chile,2015,14,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.6 +5547,Chile,2015,14,N05B-Anxiolytics,Million of national currency units,12721.9 +5548,Chile,2015,14,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",618.1 +5549,Chile,2014,15,B-Blood and blood forming organs,Million US$ at exchange rate,120.2 +5550,Chile,2014,15,G-Genito urinary system and sex hormones,Million of national currency units,145380.0 +5551,Chile,2014,15,B-Blood and blood forming organs,Million of national currency units,68583.3 +5552,Chile,2014,15,C10-Lipid modifying agents,"Million US$, purchasing power parity",91.7 +5553,Chile,2014,15,G-Genito urinary system and sex hormones,Million US$ at exchange rate,254.9 +5554,Chile,2014,15,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",395.9 +5555,Chile,2014,15,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",10.5 +5556,Chile,2014,15,B-Blood and blood forming organs,% of total sales,4.4 +5557,Chile,2014,15,B-Blood and blood forming organs,"Million US$, purchasing power parity",186.8 +5558,Chile,2014,15,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.8 +5559,Chile,2014,15,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3 +5560,Chile,2014,15,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.2 +5561,Chile,2014,15,C10-Lipid modifying agents,% of total sales,2.2 +5562,Chile,2014,15,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.3 +5563,Chile,2014,15,A-Alimentary tract and metabolism,% of total sales,16.8 +5564,Chile,2014,15,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7 +5565,Chile,2014,15,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +5566,Chile,2014,15,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",708.1 +5567,Chile,2014,15,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.8 +5568,Chile,2014,15,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.6 +5569,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.8 +5570,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8 +5571,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +5572,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,38190.1 +5573,Chile,2014,15,C01A-Cardiac glycosides,Million of national currency units,247.9 +5574,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",104.0 +5575,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.0 +5576,Chile,2014,15,A-Alimentary tract and metabolism,Million US$ at exchange rate,455.9 +5577,Chile,2014,15,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.3 +5578,Chile,2014,15,G03-Sex hormones and modulators of the genital system,Million of national currency units,102222.0 +5579,Chile,2014,15,G-Genito urinary system and sex hormones,% of total sales,9.4 +5580,Chile,2014,15,C01A-Cardiac glycosides,% of total sales,0.0 +5581,Chile,2014,15,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +5582,Chile,2014,15,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +5583,Chile,2014,15,G03-Sex hormones and modulators of the genital system,% of total sales,6.6 +5584,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.6 +5585,Chile,2014,15,A-Alimentary tract and metabolism,Million of national currency units,260015.0 +5586,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",278.4 +5587,Chile,2014,15,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.2 +5588,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.1 +5589,Chile,2014,15,C10-Lipid modifying agents,Million US$ at exchange rate,59.0 +5590,Chile,2014,15,Total pharmaceutical sales,"/capita, US$ purchasing power parity",236.8 +5591,Chile,2014,15,C07-Beta blocking agents,Million of national currency units,15358.9 +5592,Chile,2014,15,C07-Beta blocking agents,Million US$ at exchange rate,26.9 +5593,Chile,2014,15,Total pharmaceutical sales,Million US$ at exchange rate,2711.4 +5594,Chile,2014,15,Total pharmaceutical sales,"Million US$, purchasing power parity",4211.3 +5595,Chile,2014,15,Total pharmaceutical sales,"/capita, US$ exchange rate",152.4 +5596,Chile,2014,15,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +5597,Chile,2014,15,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +5598,Chile,2014,15,C02-Antihypertensives,"Million US$, purchasing power parity",8.5 +5599,Chile,2014,15,C-Cardiovascular system,% of total sales,8.0 +5600,Chile,2014,15,C07-Beta blocking agents,"Million US$, purchasing power parity",41.8 +5601,Chile,2014,15,C02-Antihypertensives,% of total sales,0.2 +5602,Chile,2014,15,C-Cardiovascular system,Million of national currency units,124399.3 +5603,Chile,2014,15,C03-Diuretics,Million US$ at exchange rate,7.9 +5604,Chile,2014,15,C03-Diuretics,Million of national currency units,4497.4 +5605,Chile,2014,15,C-Cardiovascular system,"/capita, US$ exchange rate",12.3 +5606,Chile,2014,15,C-Cardiovascular system,Million US$ at exchange rate,218.1 +5607,Chile,2014,15,C-Cardiovascular system,"Million US$, purchasing power parity",338.8 +5608,Chile,2014,15,C03-Diuretics,"/capita, US$ purchasing power parity",0.7 +5609,Chile,2014,15,C03-Diuretics,% of total sales,0.3 +5610,Chile,2014,15,Total pharmaceutical sales,Million of national currency units,1546451.1 +5611,Chile,2014,15,C-Cardiovascular system,"/capita, US$ purchasing power parity",19.0 +5612,Chile,2014,15,C03-Diuretics,"/capita, US$ exchange rate",0.4 +5613,Chile,2014,15,C03-Diuretics,"Million US$, purchasing power parity",12.2 +5614,Chile,2014,15,C08-Calcium channel blockers,% of total sales,0.4 +5615,Chile,2014,15,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0 +5616,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,44854.1 +5617,Chile,2014,15,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.0 +5618,Chile,2014,15,C08-Calcium channel blockers,Million US$ at exchange rate,11.6 +5619,Chile,2014,15,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7 +5620,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.9 +5621,Chile,2014,15,C10-Lipid modifying agents,Million of national currency units,33677.0 +5622,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",6.9 +5623,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",122.1 +5624,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,78.6 +5625,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.4 +5626,Chile,2014,15,C02-Antihypertensives,Million US$ at exchange rate,5.5 +5627,Chile,2014,15,C02-Antihypertensives,Million of national currency units,3129.0 +5628,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +5629,Chile,2014,15,C07-Beta blocking agents,"/capita, US$ exchange rate",1.5 +5630,Chile,2014,15,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.4 +5631,Chile,2014,15,C07-Beta blocking agents,% of total sales,1.0 +5632,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0 +5633,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1688.5 +5634,Chile,2014,15,C08-Calcium channel blockers,Million of national currency units,6613.0 +5635,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3 +5636,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.6 +5637,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2 +5638,Chile,2014,15,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.1 +5639,Chile,2014,15,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",196.9 +5640,Chile,2014,15,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1 +5641,Chile,2014,15,N06A-Antidepressants,% of total sales,3.2 +5642,Chile,2014,15,J01-Antibacterials for systemic use,% of total sales,4.7 +5643,Chile,2014,15,A10-Drugs used in diabetes,"/capita, US$ exchange rate",6.5 +5644,Chile,2014,15,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",10.1 +5645,Chile,2014,15,A10-Drugs used in diabetes,% of total sales,4.3 +5646,Chile,2014,15,A10-Drugs used in diabetes,Million of national currency units,66175.6 +5647,Chile,2014,15,A10-Drugs used in diabetes,Million US$ at exchange rate,116.0 +5648,Chile,2014,15,A10-Drugs used in diabetes,"Million US$, purchasing power parity",180.2 +5649,Chile,2014,15,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.5 +5650,Chile,2014,15,N06A-Antidepressants,Million of national currency units,48805.4 +5651,Chile,2014,15,N06A-Antidepressants,Million US$ at exchange rate,85.6 +5652,Chile,2014,15,N06A-Antidepressants,"Million US$, purchasing power parity",132.9 +5653,Chile,2014,15,M-Musculo-skeletal system,Million of national currency units,107902.8 +5654,Chile,2014,15,M-Musculo-skeletal system,Million US$ at exchange rate,189.2 +5655,Chile,2014,15,N05C-Hypnotics and sedatives,% of total sales,0.6 +5656,Chile,2014,15,Products not elsewhere classified,"Million US$, purchasing power parity",594.8 +5657,Chile,2014,15,Products not elsewhere classified,"/capita, US$ exchange rate",21.5 +5658,Chile,2014,15,N06A-Antidepressants,"/capita, US$ exchange rate",4.8 +5659,Chile,2014,15,Products not elsewhere classified,% of total sales,14.1 +5660,Chile,2014,15,Products not elsewhere classified,"/capita, US$ purchasing power parity",33.4 +5661,Chile,2014,15,R-Respiratory system,% of total sales,9.9 +5662,Chile,2014,15,R-Respiratory system,"/capita, US$ purchasing power parity",23.5 +5663,Chile,2014,15,R03-Drugs for obstructive airway diseases,Million of national currency units,37615.6 +5664,Chile,2014,15,A02A-Antacids,"Million US$, purchasing power parity",28.3 +5665,Chile,2014,15,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,66.0 +5666,Chile,2014,15,R-Respiratory system,"/capita, US$ exchange rate",15.2 +5667,Chile,2014,15,A02A-Antacids,Million of national currency units,10396.9 +5668,Chile,2014,15,R-Respiratory system,Million of national currency units,153706.6 +5669,Chile,2014,15,A02A-Antacids,Million US$ at exchange rate,18.2 +5670,Chile,2014,15,R-Respiratory system,"Million US$, purchasing power parity",418.6 +5671,Chile,2014,15,R-Respiratory system,Million US$ at exchange rate,269.5 +5672,Chile,2014,15,A02A-Antacids,"/capita, US$ purchasing power parity",1.6 +5673,Chile,2014,15,A02A-Antacids,% of total sales,0.7 +5674,Chile,2014,15,Products not elsewhere classified,Million US$ at exchange rate,383.0 +5675,Chile,2014,15,J01-Antibacterials for systemic use,Million US$ at exchange rate,126.8 +5676,Chile,2014,15,J01-Antibacterials for systemic use,Million of national currency units,72295.7 +5677,Chile,2014,15,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.7 +5678,Chile,2014,15,A02A-Antacids,"/capita, US$ exchange rate",1.0 +5679,Chile,2014,15,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.4 +5680,Chile,2014,15,Products not elsewhere classified,Million of national currency units,218422.5 +5681,Chile,2014,15,R03-Drugs for obstructive airway diseases,% of total sales,2.4 +5682,Chile,2014,15,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",5.8 +5683,Chile,2014,15,N02-Analgesics,"/capita, US$ exchange rate",6.6 +5684,Chile,2014,15,N02-Analgesics,"Million US$, purchasing power parity",181.0 +5685,Chile,2014,15,N02-Analgesics,"/capita, US$ purchasing power parity",10.2 +5686,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,26581.9 +5687,Chile,2014,15,N02-Analgesics,Million US$ at exchange rate,116.6 +5688,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,46.6 +5689,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",157.6 +5690,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,101.5 +5691,Chile,2014,15,J-Antiinfectives for systemic use,Million of national currency units,180250.2 +5692,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7 +5693,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.9 +5694,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7 +5695,Chile,2014,15,N-Nervous system,Million US$ at exchange rate,437.6 +5696,Chile,2014,15,N-Nervous system,Million of national currency units,249601.3 +5697,Chile,2014,15,N-Nervous system,% of total sales,16.1 +5698,Chile,2014,15,N-Nervous system,"/capita, US$ exchange rate",24.6 +5699,Chile,2014,15,N-Nervous system,"/capita, US$ purchasing power parity",38.2 +5700,Chile,2014,15,N-Nervous system,"Million US$, purchasing power parity",679.7 +5701,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6 +5702,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",72.4 +5703,Chile,2014,15,N02-Analgesics,Million of national currency units,66475.8 +5704,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7 +5705,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.1 +5706,Chile,2014,15,N05B-Anxiolytics,% of total sales,0.8 +5707,Chile,2014,15,N05C-Hypnotics and sedatives,Million of national currency units,8655.6 +5708,Chile,2014,15,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.2 +5709,Chile,2014,15,N05B-Anxiolytics,"Million US$, purchasing power parity",32.0 +5710,Chile,2014,15,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8 +5711,Chile,2014,15,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +5712,Chile,2014,15,N05B-Anxiolytics,Million US$ at exchange rate,20.6 +5713,Chile,2014,15,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.5 +5714,Chile,2014,15,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.6 +5715,Chile,2014,15,M-Musculo-skeletal system,"Million US$, purchasing power parity",293.8 +5716,Chile,2014,15,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +5717,Chile,2014,15,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6 +5718,Chile,2014,15,M-Musculo-skeletal system,% of total sales,7.0 +5719,Chile,2014,15,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +5720,Chile,2014,15,N02-Analgesics,% of total sales,4.3 +5721,Chile,2014,15,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.6 +5722,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,57880.5 +5723,Chile,2014,15,J-Antiinfectives for systemic use,% of total sales,11.7 +5724,Chile,2014,15,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.8 +5725,Chile,2014,15,N05B-Anxiolytics,Million of national currency units,11744.7 +5726,Chile,2014,15,J-Antiinfectives for systemic use,Million US$ at exchange rate,316.0 +5727,Chile,2014,15,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",490.9 +5728,Chile,2013,16,B-Blood and blood forming organs,Million US$ at exchange rate,151.7 +5729,Chile,2013,16,B-Blood and blood forming organs,Million of national currency units,75138.6 +5730,Chile,2013,16,G-Genito urinary system and sex hormones,Million of national currency units,134181.4 +5731,Chile,2013,16,G-Genito urinary system and sex hormones,Million US$ at exchange rate,270.9 +5732,Chile,2013,16,C10-Lipid modifying agents,"Million US$, purchasing power parity",85.8 +5733,Chile,2013,16,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",383.7 +5734,Chile,2013,16,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.2 +5735,Chile,2013,16,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.4 +5736,Chile,2013,16,B-Blood and blood forming organs,% of total sales,5.2 +5737,Chile,2013,16,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.6 +5738,Chile,2013,16,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.9 +5739,Chile,2013,16,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.4 +5740,Chile,2013,16,B-Blood and blood forming organs,"Million US$, purchasing power parity",214.9 +5741,Chile,2013,16,C10-Lipid modifying agents,% of total sales,2.1 +5742,Chile,2013,16,A-Alimentary tract and metabolism,% of total sales,15.2 +5743,Chile,2013,16,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +5744,Chile,2013,16,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +5745,Chile,2013,16,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",630.8 +5746,Chile,2013,16,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.8 +5747,Chile,2013,16,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.3 +5748,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.9 +5749,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.7 +5750,Chile,2013,16,C01A-Cardiac glycosides,Million of national currency units,136.0 +5751,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6 +5752,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,23741.8 +5753,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,47.9 +5754,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",67.9 +5755,Chile,2013,16,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.8 +5756,Chile,2013,16,G03-Sex hormones and modulators of the genital system,Million of national currency units,95808.5 +5757,Chile,2013,16,G-Genito urinary system and sex hormones,% of total sales,9.3 +5758,Chile,2013,16,C01A-Cardiac glycosides,% of total sales,0.0 +5759,Chile,2013,16,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +5760,Chile,2013,16,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +5761,Chile,2013,16,G03-Sex hormones and modulators of the genital system,% of total sales,6.6 +5762,Chile,2013,16,A-Alimentary tract and metabolism,Million US$ at exchange rate,445.4 +5763,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.6 +5764,Chile,2013,16,A-Alimentary tract and metabolism,Million of national currency units,220594.0 +5765,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",274.0 +5766,Chile,2013,16,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,193.4 +5767,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.0 +5768,Chile,2013,16,Total pharmaceutical sales,"/capita, US$ purchasing power parity",235.0 +5769,Chile,2013,16,C07-Beta blocking agents,Million of national currency units,12752.7 +5770,Chile,2013,16,C07-Beta blocking agents,Million US$ at exchange rate,25.7 +5771,Chile,2013,16,Total pharmaceutical sales,Million US$ at exchange rate,2921.6 +5772,Chile,2013,16,Total pharmaceutical sales,"Million US$, purchasing power parity",4138.0 +5773,Chile,2013,16,Total pharmaceutical sales,"/capita, US$ exchange rate",165.9 +5774,Chile,2013,16,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +5775,Chile,2013,16,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +5776,Chile,2013,16,C02-Antihypertensives,"Million US$, purchasing power parity",8.2 +5777,Chile,2013,16,C-Cardiovascular system,% of total sales,7.3 +5778,Chile,2013,16,C07-Beta blocking agents,"Million US$, purchasing power parity",36.5 +5779,Chile,2013,16,C02-Antihypertensives,% of total sales,0.2 +5780,Chile,2013,16,C-Cardiovascular system,Million of national currency units,105559.0 +5781,Chile,2013,16,C03-Diuretics,Million of national currency units,3467.2 +5782,Chile,2013,16,C03-Diuretics,Million US$ at exchange rate,7.0 +5783,Chile,2013,16,C-Cardiovascular system,Million US$ at exchange rate,213.1 +5784,Chile,2013,16,C-Cardiovascular system,"/capita, US$ exchange rate",12.1 +5785,Chile,2013,16,C-Cardiovascular system,"Million US$, purchasing power parity",301.9 +5786,Chile,2013,16,C03-Diuretics,"/capita, US$ purchasing power parity",0.6 +5787,Chile,2013,16,C03-Diuretics,% of total sales,0.2 +5788,Chile,2013,16,Total pharmaceutical sales,Million of national currency units,1446986.6 +5789,Chile,2013,16,C-Cardiovascular system,"/capita, US$ purchasing power parity",17.1 +5790,Chile,2013,16,C03-Diuretics,"Million US$, purchasing power parity",9.9 +5791,Chile,2013,16,C03-Diuretics,"/capita, US$ exchange rate",0.4 +5792,Chile,2013,16,C08-Calcium channel blockers,% of total sales,0.4 +5793,Chile,2013,16,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.9 +5794,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,36639.5 +5795,Chile,2013,16,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.2 +5796,Chile,2013,16,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7 +5797,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,74.0 +5798,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5 +5799,Chile,2013,16,C10-Lipid modifying agents,Million of national currency units,30013.4 +5800,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.9 +5801,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",104.8 +5802,Chile,2013,16,C08-Calcium channel blockers,Million US$ at exchange rate,11.5 +5803,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.2 +5804,Chile,2013,16,C02-Antihypertensives,Million US$ at exchange rate,5.8 +5805,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +5806,Chile,2013,16,C02-Antihypertensives,Million of national currency units,2861.8 +5807,Chile,2013,16,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.1 +5808,Chile,2013,16,C07-Beta blocking agents,"/capita, US$ exchange rate",1.5 +5809,Chile,2013,16,C07-Beta blocking agents,% of total sales,0.9 +5810,Chile,2013,16,C10-Lipid modifying agents,Million US$ at exchange rate,60.6 +5811,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3 +5812,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1625.7 +5813,Chile,2013,16,C08-Calcium channel blockers,Million of national currency units,5672.3 +5814,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3 +5815,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2 +5816,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.6 +5817,Chile,2013,16,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5 +5818,Chile,2013,16,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1 +5819,Chile,2013,16,N06A-Antidepressants,% of total sales,2.1 +5820,Chile,2013,16,J01-Antibacterials for systemic use,% of total sales,4.9 +5821,Chile,2013,16,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",202.3 +5822,Chile,2013,16,A10-Drugs used in diabetes,"/capita, US$ exchange rate",5.8 +5823,Chile,2013,16,A10-Drugs used in diabetes,% of total sales,3.5 +5824,Chile,2013,16,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",8.2 +5825,Chile,2013,16,A10-Drugs used in diabetes,Million US$ at exchange rate,101.6 +5826,Chile,2013,16,A10-Drugs used in diabetes,Million of national currency units,50330.5 +5827,Chile,2013,16,A10-Drugs used in diabetes,"Million US$, purchasing power parity",143.9 +5828,Chile,2013,16,N06A-Antidepressants,Million of national currency units,30007.6 +5829,Chile,2013,16,N06A-Antidepressants,"Million US$, purchasing power parity",85.8 +5830,Chile,2013,16,N06A-Antidepressants,Million US$ at exchange rate,60.6 +5831,Chile,2013,16,M-Musculo-skeletal system,Million of national currency units,87138.2 +5832,Chile,2013,16,M-Musculo-skeletal system,Million US$ at exchange rate,175.9 +5833,Chile,2013,16,N05C-Hypnotics and sedatives,% of total sales,0.5 +5834,Chile,2013,16,Products not elsewhere classified,"/capita, US$ exchange rate",27.0 +5835,Chile,2013,16,Products not elsewhere classified,"Million US$, purchasing power parity",673.1 +5836,Chile,2013,16,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.9 +5837,Chile,2013,16,N06A-Antidepressants,"/capita, US$ exchange rate",3.4 +5838,Chile,2013,16,Products not elsewhere classified,% of total sales,16.3 +5839,Chile,2013,16,Products not elsewhere classified,"/capita, US$ purchasing power parity",38.2 +5840,Chile,2013,16,R-Respiratory system,% of total sales,9.7 +5841,Chile,2013,16,R-Respiratory system,"/capita, US$ purchasing power parity",22.8 +5842,Chile,2013,16,R03-Drugs for obstructive airway diseases,Million of national currency units,30901.9 +5843,Chile,2013,16,A02A-Antacids,"Million US$, purchasing power parity",27.9 +5844,Chile,2013,16,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,62.4 +5845,Chile,2013,16,A02A-Antacids,Million of national currency units,9763.4 +5846,Chile,2013,16,R-Respiratory system,Million of national currency units,140586.0 +5847,Chile,2013,16,A02A-Antacids,Million US$ at exchange rate,19.7 +5848,Chile,2013,16,R-Respiratory system,"Million US$, purchasing power parity",402.0 +5849,Chile,2013,16,R-Respiratory system,"/capita, US$ exchange rate",16.1 +5850,Chile,2013,16,R-Respiratory system,Million US$ at exchange rate,283.9 +5851,Chile,2013,16,A02A-Antacids,"/capita, US$ purchasing power parity",1.6 +5852,Chile,2013,16,A02A-Antacids,% of total sales,0.7 +5853,Chile,2013,16,J01-Antibacterials for systemic use,Million US$ at exchange rate,142.8 +5854,Chile,2013,16,J01-Antibacterials for systemic use,Million of national currency units,70741.0 +5855,Chile,2013,16,Products not elsewhere classified,Million US$ at exchange rate,475.2 +5856,Chile,2013,16,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.5 +5857,Chile,2013,16,A02A-Antacids,"/capita, US$ exchange rate",1.1 +5858,Chile,2013,16,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",88.4 +5859,Chile,2013,16,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",5.0 +5860,Chile,2013,16,Products not elsewhere classified,Million of national currency units,235364.6 +5861,Chile,2013,16,R03-Drugs for obstructive airway diseases,% of total sales,2.1 +5862,Chile,2013,16,N02-Analgesics,"/capita, US$ exchange rate",7.3 +5863,Chile,2013,16,N02-Analgesics,"Million US$, purchasing power parity",183.0 +5864,Chile,2013,16,N02-Analgesics,"/capita, US$ purchasing power parity",10.4 +5865,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,24042.2 +5866,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,48.5 +5867,Chile,2013,16,N02-Analgesics,Million US$ at exchange rate,129.2 +5868,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",154.6 +5869,Chile,2013,16,J-Antiinfectives for systemic use,Million of national currency units,209955.4 +5870,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.2 +5871,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7 +5872,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8 +5873,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.2 +5874,Chile,2013,16,N-Nervous system,Million US$ at exchange rate,433.6 +5875,Chile,2013,16,N-Nervous system,% of total sales,14.8 +5876,Chile,2013,16,N-Nervous system,Million of national currency units,214727.7 +5877,Chile,2013,16,N-Nervous system,"/capita, US$ exchange rate",24.6 +5878,Chile,2013,16,N-Nervous system,"/capita, US$ purchasing power parity",34.9 +5879,Chile,2013,16,N-Nervous system,"Million US$, purchasing power parity",614.1 +5880,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.8 +5881,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.8 +5882,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.9 +5883,Chile,2013,16,N02-Analgesics,Million of national currency units,63983.2 +5884,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7 +5885,Chile,2013,16,N05B-Anxiolytics,% of total sales,0.8 +5886,Chile,2013,16,N05C-Hypnotics and sedatives,Million of national currency units,7153.9 +5887,Chile,2013,16,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.4 +5888,Chile,2013,16,N05B-Anxiolytics,"Million US$, purchasing power parity",31.6 +5889,Chile,2013,16,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8 +5890,Chile,2013,16,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +5891,Chile,2013,16,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.1 +5892,Chile,2013,16,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.0 +5893,Chile,2013,16,M-Musculo-skeletal system,"Million US$, purchasing power parity",249.2 +5894,Chile,2013,16,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +5895,Chile,2013,16,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",20.5 +5896,Chile,2013,16,M-Musculo-skeletal system,% of total sales,6.0 +5897,Chile,2013,16,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2 +5898,Chile,2013,16,N05B-Anxiolytics,Million US$ at exchange rate,22.3 +5899,Chile,2013,16,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.1 +5900,Chile,2013,16,N02-Analgesics,% of total sales,4.4 +5901,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,54075.4 +5902,Chile,2013,16,J-Antiinfectives for systemic use,% of total sales,14.5 +5903,Chile,2013,16,N05B-Anxiolytics,Million of national currency units,11038.7 +5904,Chile,2013,16,J-Antiinfectives for systemic use,Million US$ at exchange rate,423.9 +5905,Chile,2013,16,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.1 +5906,Chile,2013,16,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",600.4 +5907,Chile,2012,17,B-Blood and blood forming organs,Million US$ at exchange rate,135.8 +5908,Chile,2012,17,B-Blood and blood forming organs,Million of national currency units,66082.9 +5909,Chile,2012,17,G-Genito urinary system and sex hormones,Million of national currency units,122348.3 +5910,Chile,2012,17,B-Blood and blood forming organs,"Million US$, purchasing power parity",190.3 +5911,Chile,2012,17,C10-Lipid modifying agents,"Million US$, purchasing power parity",79.6 +5912,Chile,2012,17,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.4 +5913,Chile,2012,17,G-Genito urinary system and sex hormones,Million US$ at exchange rate,251.5 +5914,Chile,2012,17,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",352.4 +5915,Chile,2012,17,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",10.9 +5916,Chile,2012,17,B-Blood and blood forming organs,% of total sales,5.3 +5917,Chile,2012,17,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.8 +5918,Chile,2012,17,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.6 +5919,Chile,2012,17,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3 +5920,Chile,2012,17,C10-Lipid modifying agents,% of total sales,2.2 +5921,Chile,2012,17,A-Alimentary tract and metabolism,% of total sales,16.3 +5922,Chile,2012,17,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +5923,Chile,2012,17,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +5924,Chile,2012,17,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",586.3 +5925,Chile,2012,17,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.0 +5926,Chile,2012,17,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",33.6 +5927,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.5 +5928,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.2 +5929,Chile,2012,17,C01A-Cardiac glycosides,Million of national currency units,185.5 +5930,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +5931,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,55.7 +5932,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,27115.2 +5933,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",78.1 +5934,Chile,2012,17,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.2 +5935,Chile,2012,17,G-Genito urinary system and sex hormones,% of total sales,9.8 +5936,Chile,2012,17,G03-Sex hormones and modulators of the genital system,Million of national currency units,87798.2 +5937,Chile,2012,17,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +5938,Chile,2012,17,C01A-Cardiac glycosides,% of total sales,0.0 +5939,Chile,2012,17,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +5940,Chile,2012,17,G03-Sex hormones and modulators of the genital system,% of total sales,7.0 +5941,Chile,2012,17,A-Alimentary tract and metabolism,Million US$ at exchange rate,418.5 +5942,Chile,2012,17,A-Alimentary tract and metabolism,Million of national currency units,203569.3 +5943,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.5 +5944,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",252.9 +5945,Chile,2012,17,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,180.5 +5946,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.3 +5947,Chile,2012,17,C10-Lipid modifying agents,Million US$ at exchange rate,56.8 +5948,Chile,2012,17,Total pharmaceutical sales,"/capita, US$ purchasing power parity",206.1 +5949,Chile,2012,17,C07-Beta blocking agents,Million of national currency units,11971.2 +5950,Chile,2012,17,C07-Beta blocking agents,Million US$ at exchange rate,24.6 +5951,Chile,2012,17,Total pharmaceutical sales,Million US$ at exchange rate,2565.9 +5952,Chile,2012,17,Total pharmaceutical sales,"Million US$, purchasing power parity",3594.9 +5953,Chile,2012,17,Total pharmaceutical sales,"/capita, US$ exchange rate",147.1 +5954,Chile,2012,17,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4 +5955,Chile,2012,17,C02-Antihypertensives,"Million US$, purchasing power parity",7.3 +5956,Chile,2012,17,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +5957,Chile,2012,17,C-Cardiovascular system,% of total sales,8.1 +5958,Chile,2012,17,C07-Beta blocking agents,"Million US$, purchasing power parity",34.5 +5959,Chile,2012,17,C02-Antihypertensives,% of total sales,0.2 +5960,Chile,2012,17,C-Cardiovascular system,Million of national currency units,100837.7 +5961,Chile,2012,17,C03-Diuretics,Million of national currency units,3547.9 +5962,Chile,2012,17,C03-Diuretics,Million US$ at exchange rate,7.3 +5963,Chile,2012,17,C-Cardiovascular system,Million US$ at exchange rate,207.3 +5964,Chile,2012,17,C-Cardiovascular system,"/capita, US$ exchange rate",11.9 +5965,Chile,2012,17,C-Cardiovascular system,"Million US$, purchasing power parity",290.4 +5966,Chile,2012,17,C03-Diuretics,"/capita, US$ purchasing power parity",0.6 +5967,Chile,2012,17,C03-Diuretics,% of total sales,0.3 +5968,Chile,2012,17,Total pharmaceutical sales,Million of national currency units,1248234.6 +5969,Chile,2012,17,C03-Diuretics,"Million US$, purchasing power parity",10.2 +5970,Chile,2012,17,C-Cardiovascular system,"/capita, US$ purchasing power parity",16.6 +5971,Chile,2012,17,C03-Diuretics,"/capita, US$ exchange rate",0.4 +5972,Chile,2012,17,C08-Calcium channel blockers,% of total sales,0.5 +5973,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35202.9 +5974,Chile,2012,17,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0 +5975,Chile,2012,17,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.0 +5976,Chile,2012,17,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7 +5977,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.4 +5978,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8 +5979,Chile,2012,17,C10-Lipid modifying agents,Million of national currency units,27634.2 +5980,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.8 +5981,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",101.4 +5982,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.1 +5983,Chile,2012,17,C08-Calcium channel blockers,Million US$ at exchange rate,12.2 +5984,Chile,2012,17,C02-Antihypertensives,Million US$ at exchange rate,5.2 +5985,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +5986,Chile,2012,17,C02-Antihypertensives,Million of national currency units,2551.3 +5987,Chile,2012,17,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.0 +5988,Chile,2012,17,C07-Beta blocking agents,"/capita, US$ exchange rate",1.4 +5989,Chile,2012,17,C07-Beta blocking agents,% of total sales,1.0 +5990,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0 +5991,Chile,2012,17,C08-Calcium channel blockers,Million of national currency units,5913.9 +5992,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1457.1 +5993,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2 +5994,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2 +5995,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2 +5996,Chile,2012,17,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +5997,Chile,2012,17,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.0 +5998,Chile,2012,17,N06A-Antidepressants,% of total sales,2.3 +5999,Chile,2012,17,J01-Antibacterials for systemic use,% of total sales,5.4 +6000,Chile,2012,17,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",195.7 +6001,Chile,2012,17,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.9 +6002,Chile,2012,17,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.9 +6003,Chile,2012,17,A10-Drugs used in diabetes,% of total sales,3.3 +6004,Chile,2012,17,A10-Drugs used in diabetes,Million US$ at exchange rate,85.8 +6005,Chile,2012,17,A10-Drugs used in diabetes,Million of national currency units,41736.2 +6006,Chile,2012,17,A10-Drugs used in diabetes,"Million US$, purchasing power parity",120.2 +6007,Chile,2012,17,N06A-Antidepressants,Million of national currency units,28119.5 +6008,Chile,2012,17,N06A-Antidepressants,Million US$ at exchange rate,57.8 +6009,Chile,2012,17,N06A-Antidepressants,"Million US$, purchasing power parity",81.0 +6010,Chile,2012,17,M-Musculo-skeletal system,Million US$ at exchange rate,177.1 +6011,Chile,2012,17,M-Musculo-skeletal system,Million of national currency units,86133.7 +6012,Chile,2012,17,N05C-Hypnotics and sedatives,% of total sales,0.5 +6013,Chile,2012,17,Products not elsewhere classified,"/capita, US$ exchange rate",20.0 +6014,Chile,2012,17,N06A-Antidepressants,"/capita, US$ exchange rate",3.3 +6015,Chile,2012,17,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6 +6016,Chile,2012,17,Products not elsewhere classified,% of total sales,13.6 +6017,Chile,2012,17,Products not elsewhere classified,"/capita, US$ purchasing power parity",28.1 +6018,Chile,2012,17,R-Respiratory system,% of total sales,10.7 +6019,Chile,2012,17,R-Respiratory system,"/capita, US$ purchasing power parity",22.1 +6020,Chile,2012,17,R03-Drugs for obstructive airway diseases,Million of national currency units,29207.1 +6021,Chile,2012,17,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",84.1 +6022,Chile,2012,17,A02A-Antacids,"Million US$, purchasing power parity",26.5 +6023,Chile,2012,17,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,60.0 +6024,Chile,2012,17,A02A-Antacids,Million of national currency units,9204.3 +6025,Chile,2012,17,R-Respiratory system,Million of national currency units,133945.9 +6026,Chile,2012,17,A02A-Antacids,Million US$ at exchange rate,18.9 +6027,Chile,2012,17,R-Respiratory system,"Million US$, purchasing power parity",385.8 +6028,Chile,2012,17,R-Respiratory system,"/capita, US$ exchange rate",15.8 +6029,Chile,2012,17,R-Respiratory system,Million US$ at exchange rate,275.3 +6030,Chile,2012,17,A02A-Antacids,"/capita, US$ purchasing power parity",1.5 +6031,Chile,2012,17,A02A-Antacids,% of total sales,0.7 +6032,Chile,2012,17,Products not elsewhere classified,"Million US$, purchasing power parity",489.5 +6033,Chile,2012,17,J01-Antibacterials for systemic use,Million US$ at exchange rate,139.7 +6034,Chile,2012,17,J01-Antibacterials for systemic use,Million of national currency units,67944.0 +6035,Chile,2012,17,Products not elsewhere classified,Million US$ at exchange rate,349.4 +6036,Chile,2012,17,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.4 +6037,Chile,2012,17,A02A-Antacids,"/capita, US$ exchange rate",1.1 +6038,Chile,2012,17,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",4.8 +6039,Chile,2012,17,Products not elsewhere classified,Million of national currency units,169953.3 +6040,Chile,2012,17,R03-Drugs for obstructive airway diseases,% of total sales,2.3 +6041,Chile,2012,17,N02-Analgesics,"/capita, US$ exchange rate",7.5 +6042,Chile,2012,17,N02-Analgesics,"Million US$, purchasing power parity",184.5 +6043,Chile,2012,17,N02-Analgesics,"/capita, US$ purchasing power parity",10.6 +6044,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,22320.2 +6045,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,45.9 +6046,Chile,2012,17,N02-Analgesics,Million US$ at exchange rate,131.7 +6047,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",145.8 +6048,Chile,2012,17,J-Antiinfectives for systemic use,Million of national currency units,132266.7 +6049,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,104.1 +6050,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1 +6051,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4 +6052,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0 +6053,Chile,2012,17,N-Nervous system,Million US$ at exchange rate,423.4 +6054,Chile,2012,17,N-Nervous system,Million of national currency units,205981.7 +6055,Chile,2012,17,N-Nervous system,% of total sales,16.5 +6056,Chile,2012,17,N-Nervous system,"/capita, US$ purchasing power parity",34.0 +6057,Chile,2012,17,N-Nervous system,"/capita, US$ exchange rate",24.3 +6058,Chile,2012,17,N-Nervous system,"Million US$, purchasing power parity",593.2 +6059,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6 +6060,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.3 +6061,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.7 +6062,Chile,2012,17,N02-Analgesics,Million of national currency units,64056.5 +6063,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8 +6064,Chile,2012,17,N05C-Hypnotics and sedatives,Million of national currency units,5909.7 +6065,Chile,2012,17,N05B-Anxiolytics,% of total sales,0.9 +6066,Chile,2012,17,N05C-Hypnotics and sedatives,Million US$ at exchange rate,12.1 +6067,Chile,2012,17,N05B-Anxiolytics,"Million US$, purchasing power parity",30.6 +6068,Chile,2012,17,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8 +6069,Chile,2012,17,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +6070,Chile,2012,17,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",17.0 +6071,Chile,2012,17,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.2 +6072,Chile,2012,17,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.2 +6073,Chile,2012,17,M-Musculo-skeletal system,"Million US$, purchasing power parity",248.1 +6074,Chile,2012,17,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.7 +6075,Chile,2012,17,M-Musculo-skeletal system,% of total sales,6.9 +6076,Chile,2012,17,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.0 +6077,Chile,2012,17,N05B-Anxiolytics,Million US$ at exchange rate,21.9 +6078,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,50640.7 +6079,Chile,2012,17,J-Antiinfectives for systemic use,% of total sales,10.6 +6080,Chile,2012,17,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.8 +6081,Chile,2012,17,N02-Analgesics,% of total sales,5.1 +6082,Chile,2012,17,N05B-Anxiolytics,Million of national currency units,10633.1 +6083,Chile,2012,17,J-Antiinfectives for systemic use,Million US$ at exchange rate,271.9 +6084,Chile,2012,17,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.6 +6085,Chile,2012,17,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",380.9 +6086,Chile,2011,18,B-Blood and blood forming organs,Million US$ at exchange rate,114.1 +6087,Chile,2011,18,B-Blood and blood forming organs,Million of national currency units,55202.5 +6088,Chile,2011,18,G-Genito urinary system and sex hormones,Million of national currency units,111351.6 +6089,Chile,2011,18,G-Genito urinary system and sex hormones,Million US$ at exchange rate,230.2 +6090,Chile,2011,18,C10-Lipid modifying agents,"Million US$, purchasing power parity",71.9 +6091,Chile,2011,18,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.3 +6092,Chile,2011,18,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",320.0 +6093,Chile,2011,18,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.2 +6094,Chile,2011,18,B-Blood and blood forming organs,% of total sales,4.7 +6095,Chile,2011,18,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.6 +6096,Chile,2011,18,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.2 +6097,Chile,2011,18,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0 +6098,Chile,2011,18,B-Blood and blood forming organs,"Million US$, purchasing power parity",158.6 +6099,Chile,2011,18,C10-Lipid modifying agents,% of total sales,2.1 +6100,Chile,2011,18,C01A-Cardiac glycosides,% of total sales,0.0 +6101,Chile,2011,18,A-Alimentary tract and metabolism,% of total sales,15.7 +6102,Chile,2011,18,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +6103,Chile,2011,18,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +6104,Chile,2011,18,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",530.5 +6105,Chile,2011,18,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",22.1 +6106,Chile,2011,18,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",30.7 +6107,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.1 +6108,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.2 +6109,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6 +6110,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,38.2 +6111,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18495.4 +6112,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",53.1 +6113,Chile,2011,18,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.5 +6114,Chile,2011,18,G-Genito urinary system and sex hormones,% of total sales,9.4 +6115,Chile,2011,18,G03-Sex hormones and modulators of the genital system,Million of national currency units,80168.5 +6116,Chile,2011,18,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +6117,Chile,2011,18,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +6118,Chile,2011,18,G03-Sex hormones and modulators of the genital system,% of total sales,6.8 +6119,Chile,2011,18,A-Alimentary tract and metabolism,Million US$ at exchange rate,381.7 +6120,Chile,2011,18,A-Alimentary tract and metabolism,Million of national currency units,184612.6 +6121,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.4 +6122,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",230.4 +6123,Chile,2011,18,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.8 +6124,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.6 +6125,Chile,2011,18,C07-Beta blocking agents,Million of national currency units,10586.3 +6126,Chile,2011,18,Total pharmaceutical sales,"/capita, US$ purchasing power parity",196.4 +6127,Chile,2011,18,C07-Beta blocking agents,Million US$ at exchange rate,21.9 +6128,Chile,2011,18,Total pharmaceutical sales,"Million US$, purchasing power parity",3388.6 +6129,Chile,2011,18,Total pharmaceutical sales,Million US$ at exchange rate,2438.2 +6130,Chile,2011,18,Total pharmaceutical sales,"/capita, US$ exchange rate",141.3 +6131,Chile,2011,18,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4 +6132,Chile,2011,18,C02-Antihypertensives,"Million US$, purchasing power parity",6.7 +6133,Chile,2011,18,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +6134,Chile,2011,18,C-Cardiovascular system,% of total sales,7.8 +6135,Chile,2011,18,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4 +6136,Chile,2011,18,C02-Antihypertensives,% of total sales,0.2 +6137,Chile,2011,18,C-Cardiovascular system,Million of national currency units,91532.1 +6138,Chile,2011,18,C-Cardiovascular system,Million US$ at exchange rate,189.2 +6139,Chile,2011,18,C03-Diuretics,Million of national currency units,2756.0 +6140,Chile,2011,18,C03-Diuretics,Million US$ at exchange rate,5.7 +6141,Chile,2011,18,C-Cardiovascular system,"/capita, US$ exchange rate",11.0 +6142,Chile,2011,18,C-Cardiovascular system,"/capita, US$ purchasing power parity",15.2 +6143,Chile,2011,18,C-Cardiovascular system,"Million US$, purchasing power parity",263.0 +6144,Chile,2011,18,C03-Diuretics,% of total sales,0.2 +6145,Chile,2011,18,C03-Diuretics,"/capita, US$ purchasing power parity",0.5 +6146,Chile,2011,18,Total pharmaceutical sales,Million of national currency units,1179279.0 +6147,Chile,2011,18,C03-Diuretics,"Million US$, purchasing power parity",7.9 +6148,Chile,2011,18,C03-Diuretics,"/capita, US$ exchange rate",0.3 +6149,Chile,2011,18,C08-Calcium channel blockers,% of total sales,0.5 +6150,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,32614.1 +6151,Chile,2011,18,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.9 +6152,Chile,2011,18,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0 +6153,Chile,2011,18,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7 +6154,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,67.4 +6155,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8 +6156,Chile,2011,18,C10-Lipid modifying agents,Million US$ at exchange rate,51.7 +6157,Chile,2011,18,C10-Lipid modifying agents,Million of national currency units,25005.3 +6158,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",93.7 +6159,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.4 +6160,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.9 +6161,Chile,2011,18,C08-Calcium channel blockers,Million US$ at exchange rate,12.2 +6162,Chile,2011,18,C02-Antihypertensives,Million US$ at exchange rate,4.8 +6163,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +6164,Chile,2011,18,C02-Antihypertensives,Million of national currency units,2317.9 +6165,Chile,2011,18,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.8 +6166,Chile,2011,18,C07-Beta blocking agents,"/capita, US$ exchange rate",1.3 +6167,Chile,2011,18,C07-Beta blocking agents,% of total sales,0.9 +6168,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.8 +6169,Chile,2011,18,C08-Calcium channel blockers,Million of national currency units,5881.7 +6170,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1341.3 +6171,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2 +6172,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9 +6173,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2 +6174,Chile,2011,18,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.0 +6175,Chile,2011,18,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2 +6176,Chile,2011,18,N06A-Antidepressants,% of total sales,2.2 +6177,Chile,2011,18,J01-Antibacterials for systemic use,% of total sales,5.1 +6178,Chile,2011,18,A10-Drugs used in diabetes,Million of national currency units,34618.4 +6179,Chile,2011,18,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.8 +6180,Chile,2011,18,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.1 +6181,Chile,2011,18,A10-Drugs used in diabetes,% of total sales,2.9 +6182,Chile,2011,18,A10-Drugs used in diabetes,Million US$ at exchange rate,71.6 +6183,Chile,2011,18,A10-Drugs used in diabetes,"Million US$, purchasing power parity",99.5 +6184,Chile,2011,18,N06A-Antidepressants,Million US$ at exchange rate,53.2 +6185,Chile,2011,18,N06A-Antidepressants,Million of national currency units,25714.6 +6186,Chile,2011,18,N06A-Antidepressants,"Million US$, purchasing power parity",73.9 +6187,Chile,2011,18,M-Musculo-skeletal system,Million US$ at exchange rate,127.2 +6188,Chile,2011,18,M-Musculo-skeletal system,Million of national currency units,61502.0 +6189,Chile,2011,18,N05C-Hypnotics and sedatives,% of total sales,0.4 +6190,Chile,2011,18,Products not elsewhere classified,"/capita, US$ exchange rate",20.0 +6191,Chile,2011,18,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3 +6192,Chile,2011,18,N06A-Antidepressants,"/capita, US$ exchange rate",3.1 +6193,Chile,2011,18,Products not elsewhere classified,% of total sales,14.1 +6194,Chile,2011,18,Products not elsewhere classified,"/capita, US$ purchasing power parity",27.8 +6195,Chile,2011,18,R-Respiratory system,% of total sales,10.6 +6196,Chile,2011,18,R03-Drugs for obstructive airway diseases,Million of national currency units,26263.5 +6197,Chile,2011,18,R-Respiratory system,"/capita, US$ purchasing power parity",20.8 +6198,Chile,2011,18,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",75.5 +6199,Chile,2011,18,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,54.3 +6200,Chile,2011,18,A02A-Antacids,Million of national currency units,9337.8 +6201,Chile,2011,18,R-Respiratory system,Million of national currency units,124669.7 +6202,Chile,2011,18,A02A-Antacids,Million US$ at exchange rate,19.3 +6203,Chile,2011,18,R-Respiratory system,"/capita, US$ exchange rate",14.9 +6204,Chile,2011,18,R-Respiratory system,"Million US$, purchasing power parity",358.2 +6205,Chile,2011,18,R-Respiratory system,Million US$ at exchange rate,257.8 +6206,Chile,2011,18,A02A-Antacids,"/capita, US$ exchange rate",1.1 +6207,Chile,2011,18,A02A-Antacids,% of total sales,0.8 +6208,Chile,2011,18,A02A-Antacids,"/capita, US$ purchasing power parity",1.6 +6209,Chile,2011,18,Products not elsewhere classified,"Million US$, purchasing power parity",479.3 +6210,Chile,2011,18,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",173.3 +6211,Chile,2011,18,J01-Antibacterials for systemic use,Million US$ at exchange rate,124.7 +6212,Chile,2011,18,J01-Antibacterials for systemic use,Million of national currency units,60319.9 +6213,Chile,2011,18,Products not elsewhere classified,Million US$ at exchange rate,344.9 +6214,Chile,2011,18,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.1 +6215,Chile,2011,18,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",4.4 +6216,Chile,2011,18,Products not elsewhere classified,Million of national currency units,166797.1 +6217,Chile,2011,18,R03-Drugs for obstructive airway diseases,% of total sales,2.2 +6218,Chile,2011,18,N02-Analgesics,"/capita, US$ exchange rate",7.1 +6219,Chile,2011,18,N02-Analgesics,"/capita, US$ purchasing power parity",9.8 +6220,Chile,2011,18,N02-Analgesics,"Million US$, purchasing power parity",169.5 +6221,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.7 +6222,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,21124.4 +6223,Chile,2011,18,N02-Analgesics,Million US$ at exchange rate,122.0 +6224,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",136.3 +6225,Chile,2011,18,J-Antiinfectives for systemic use,Million of national currency units,177900.9 +6226,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,98.1 +6227,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0 +6228,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7 +6229,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.9 +6230,Chile,2011,18,N-Nervous system,Million US$ at exchange rate,387.1 +6231,Chile,2011,18,N-Nervous system,% of total sales,15.9 +6232,Chile,2011,18,N-Nervous system,Million of national currency units,187215.0 +6233,Chile,2011,18,N-Nervous system,"/capita, US$ purchasing power parity",31.2 +6234,Chile,2011,18,N-Nervous system,"/capita, US$ exchange rate",22.4 +6235,Chile,2011,18,N-Nervous system,"Million US$, purchasing power parity",537.9 +6236,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.5 +6237,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.5 +6238,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",60.7 +6239,Chile,2011,18,N02-Analgesics,Million of national currency units,58995.7 +6240,Chile,2011,18,C01A-Cardiac glycosides,Million of national currency units,91.5 +6241,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8 +6242,Chile,2011,18,N05C-Hypnotics and sedatives,Million of national currency units,5170.6 +6243,Chile,2011,18,N05B-Anxiolytics,% of total sales,0.8 +6244,Chile,2011,18,N05C-Hypnotics and sedatives,Million US$ at exchange rate,10.7 +6245,Chile,2011,18,N05B-Anxiolytics,"Million US$, purchasing power parity",28.1 +6246,Chile,2011,18,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6 +6247,Chile,2011,18,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +6248,Chile,2011,18,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.2 +6249,Chile,2011,18,M-Musculo-skeletal system,"Million US$, purchasing power parity",176.7 +6250,Chile,2011,18,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.4 +6251,Chile,2011,18,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.9 +6252,Chile,2011,18,M-Musculo-skeletal system,% of total sales,5.2 +6253,Chile,2011,18,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.6 +6254,Chile,2011,18,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9 +6255,Chile,2011,18,A02A-Antacids,"Million US$, purchasing power parity",26.8 +6256,Chile,2011,18,N05B-Anxiolytics,Million US$ at exchange rate,20.2 +6257,Chile,2011,18,J-Antiinfectives for systemic use,% of total sales,15.1 +6258,Chile,2011,18,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.6 +6259,Chile,2011,18,N02-Analgesics,% of total sales,5.0 +6260,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,47430.8 +6261,Chile,2011,18,N05B-Anxiolytics,Million of national currency units,9773.0 +6262,Chile,2011,18,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.8 +6263,Chile,2011,18,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.3 +6264,Chile,2011,18,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",511.2 +6265,Chile,2010,20,B-Blood and blood forming organs,Million of national currency units,19663.6 +6266,Chile,2010,20,G-Genito urinary system and sex hormones,Million US$ at exchange rate,159.7 +6267,Chile,2010,20,B-Blood and blood forming organs,Million US$ at exchange rate,38.5 +6268,Chile,2010,20,G-Genito urinary system and sex hormones,Million of national currency units,81496.5 +6269,Chile,2010,20,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.0 +6270,Chile,2010,20,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4 +6271,Chile,2010,20,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",226.5 +6272,Chile,2010,20,B-Blood and blood forming organs,% of total sales,2.4 +6273,Chile,2010,20,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",3.2 +6274,Chile,2010,20,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.3 +6275,Chile,2010,20,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",3.2 +6276,Chile,2010,20,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.2 +6277,Chile,2010,20,B-Blood and blood forming organs,"Million US$, purchasing power parity",54.6 +6278,Chile,2010,20,C10-Lipid modifying agents,% of total sales,2.4 +6279,Chile,2010,20,A-Alimentary tract and metabolism,% of total sales,18.3 +6280,Chile,2010,20,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +6281,Chile,2010,20,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +6282,Chile,2010,20,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",420.5 +6283,Chile,2010,20,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",17.4 +6284,Chile,2010,20,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",24.6 +6285,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.1 +6286,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5 +6287,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.5 +6288,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,25.1 +6289,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,12798.0 +6290,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",35.6 +6291,Chile,2010,20,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.3 +6292,Chile,2010,20,G-Genito urinary system and sex hormones,% of total sales,9.9 +6293,Chile,2010,20,G03-Sex hormones and modulators of the genital system,Million of national currency units,64724.6 +6294,Chile,2010,20,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +6295,Chile,2010,20,C01A-Cardiac glycosides,% of total sales,0.0 +6296,Chile,2010,20,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +6297,Chile,2010,20,G03-Sex hormones and modulators of the genital system,% of total sales,7.8 +6298,Chile,2010,20,A-Alimentary tract and metabolism,Million US$ at exchange rate,296.5 +6299,Chile,2010,20,A-Alimentary tract and metabolism,Million of national currency units,151311.4 +6300,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.5 +6301,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.9 +6302,Chile,2010,20,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,126.8 +6303,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.4 +6304,Chile,2010,20,C07-Beta blocking agents,Million of national currency units,8640.2 +6305,Chile,2010,20,Total pharmaceutical sales,"/capita, US$ purchasing power parity",134.5 +6306,Chile,2010,20,C07-Beta blocking agents,Million US$ at exchange rate,16.9 +6307,Chile,2010,20,Total pharmaceutical sales,"Million US$, purchasing power parity",2295.8 +6308,Chile,2010,20,Total pharmaceutical sales,Million US$ at exchange rate,1619.0 +6309,Chile,2010,20,Total pharmaceutical sales,"/capita, US$ exchange rate",94.9 +6310,Chile,2010,20,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3 +6311,Chile,2010,20,C02-Antihypertensives,"Million US$, purchasing power parity",4.7 +6312,Chile,2010,20,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +6313,Chile,2010,20,C07-Beta blocking agents,"Million US$, purchasing power parity",24.0 +6314,Chile,2010,20,C02-Antihypertensives,% of total sales,0.2 +6315,Chile,2010,20,C-Cardiovascular system,Million of national currency units,74875.9 +6316,Chile,2010,20,C-Cardiovascular system,Million US$ at exchange rate,146.7 +6317,Chile,2010,20,C03-Diuretics,Million of national currency units,1770.5 +6318,Chile,2010,20,C03-Diuretics,Million US$ at exchange rate,3.5 +6319,Chile,2010,20,C-Cardiovascular system,"/capita, US$ exchange rate",8.6 +6320,Chile,2010,20,C-Cardiovascular system,"/capita, US$ purchasing power parity",12.2 +6321,Chile,2010,20,C-Cardiovascular system,"Million US$, purchasing power parity",208.1 +6322,Chile,2010,20,C03-Diuretics,% of total sales,0.2 +6323,Chile,2010,20,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +6324,Chile,2010,20,Total pharmaceutical sales,Million of national currency units,826115.8 +6325,Chile,2010,20,C03-Diuretics,"Million US$, purchasing power parity",4.9 +6326,Chile,2010,20,C-Cardiovascular system,% of total sales,9.1 +6327,Chile,2010,20,C03-Diuretics,"/capita, US$ exchange rate",0.2 +6328,Chile,2010,20,C08-Calcium channel blockers,% of total sales,0.6 +6329,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28108.5 +6330,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,55.1 +6331,Chile,2010,20,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8 +6332,Chile,2010,20,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.8 +6333,Chile,2010,20,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6 +6334,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4 +6335,Chile,2010,20,C10-Lipid modifying agents,Million US$ at exchange rate,38.1 +6336,Chile,2010,20,C10-Lipid modifying agents,Million of national currency units,19420.8 +6337,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",78.1 +6338,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.6 +6339,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.2 +6340,Chile,2010,20,C08-Calcium channel blockers,Million US$ at exchange rate,9.8 +6341,Chile,2010,20,C02-Antihypertensives,Million US$ at exchange rate,3.3 +6342,Chile,2010,20,C02-Antihypertensives,Million of national currency units,1699.3 +6343,Chile,2010,20,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.4 +6344,Chile,2010,20,C07-Beta blocking agents,"/capita, US$ exchange rate",1.0 +6345,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +6346,Chile,2010,20,C07-Beta blocking agents,% of total sales,1.0 +6347,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.3 +6348,Chile,2010,20,C08-Calcium channel blockers,Million of national currency units,4975.3 +6349,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1169.2 +6350,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2 +6351,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2 +6352,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.1 +6353,Chile,2010,20,C01A-Cardiac glycosides,Million of national currency units,49.0 +6354,Chile,2010,20,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",6.3 +6355,Chile,2010,20,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.4 +6356,Chile,2010,20,J01-Antibacterials for systemic use,% of total sales,4.7 +6357,Chile,2010,20,N06A-Antidepressants,% of total sales,3.9 +6358,Chile,2010,20,A02A-Antacids,"Million US$, purchasing power parity",23.2 +6359,Chile,2010,20,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",3.5 +6360,Chile,2010,20,A10-Drugs used in diabetes,"/capita, US$ exchange rate",2.5 +6361,Chile,2010,20,A10-Drugs used in diabetes,% of total sales,2.6 +6362,Chile,2010,20,A10-Drugs used in diabetes,Million US$ at exchange rate,42.3 +6363,Chile,2010,20,A10-Drugs used in diabetes,"Million US$, purchasing power parity",60.0 +6364,Chile,2010,20,A10-Drugs used in diabetes,Million of national currency units,21597.9 +6365,Chile,2010,20,N06A-Antidepressants,Million US$ at exchange rate,62.6 +6366,Chile,2010,20,N06A-Antidepressants,Million of national currency units,31955.1 +6367,Chile,2010,20,N06A-Antidepressants,"Million US$, purchasing power parity",88.8 +6368,Chile,2010,20,M-Musculo-skeletal system,Million US$ at exchange rate,134.1 +6369,Chile,2010,20,M-Musculo-skeletal system,Million of national currency units,68438.5 +6370,Chile,2010,20,N05C-Hypnotics and sedatives,% of total sales,0.4 +6371,Chile,2010,20,Products not elsewhere classified,"/capita, US$ exchange rate",11.0 +6372,Chile,2010,20,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.2 +6373,Chile,2010,20,N06A-Antidepressants,"/capita, US$ exchange rate",3.7 +6374,Chile,2010,20,Products not elsewhere classified,% of total sales,11.6 +6375,Chile,2010,20,Products not elsewhere classified,"/capita, US$ purchasing power parity",15.6 +6376,Chile,2010,20,R-Respiratory system,% of total sales,13.1 +6377,Chile,2010,20,R03-Drugs for obstructive airway diseases,Million of national currency units,15206.7 +6378,Chile,2010,20,R-Respiratory system,"/capita, US$ purchasing power parity",17.6 +6379,Chile,2010,20,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",42.3 +6380,Chile,2010,20,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.8 +6381,Chile,2010,20,R-Respiratory system,Million of national currency units,108206.7 +6382,Chile,2010,20,A02A-Antacids,Million of national currency units,8337.3 +6383,Chile,2010,20,A02A-Antacids,Million US$ at exchange rate,16.3 +6384,Chile,2010,20,R-Respiratory system,"/capita, US$ exchange rate",12.4 +6385,Chile,2010,20,R-Respiratory system,"Million US$, purchasing power parity",300.7 +6386,Chile,2010,20,R-Respiratory system,Million US$ at exchange rate,212.1 +6387,Chile,2010,20,A02A-Antacids,"/capita, US$ exchange rate",1.0 +6388,Chile,2010,20,A02A-Antacids,% of total sales,1.0 +6389,Chile,2010,20,A02A-Antacids,"/capita, US$ purchasing power parity",1.4 +6390,Chile,2010,20,Products not elsewhere classified,"Million US$, purchasing power parity",265.7 +6391,Chile,2010,20,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",106.9 +6392,Chile,2010,20,J01-Antibacterials for systemic use,Million US$ at exchange rate,75.4 +6393,Chile,2010,20,J01-Antibacterials for systemic use,Million of national currency units,38463.8 +6394,Chile,2010,20,Products not elsewhere classified,Million US$ at exchange rate,187.4 +6395,Chile,2010,20,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.7 +6396,Chile,2010,20,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.5 +6397,Chile,2010,20,Products not elsewhere classified,Million of national currency units,95614.1 +6398,Chile,2010,20,R03-Drugs for obstructive airway diseases,% of total sales,1.8 +6399,Chile,2010,20,N02-Analgesics,"/capita, US$ exchange rate",6.2 +6400,Chile,2010,20,N02-Analgesics,"/capita, US$ purchasing power parity",8.8 +6401,Chile,2010,20,N02-Analgesics,"Million US$, purchasing power parity",150.1 +6402,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,31.7 +6403,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,16183.9 +6404,Chile,2010,20,N02-Analgesics,Million US$ at exchange rate,105.8 +6405,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",98.3 +6406,Chile,2010,20,J-Antiinfectives for systemic use,Million of national currency units,58760.8 +6407,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,69.3 +6408,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.3 +6409,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.1 +6410,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.8 +6411,Chile,2010,20,N-Nervous system,Million US$ at exchange rate,303.7 +6412,Chile,2010,20,N-Nervous system,% of total sales,18.8 +6413,Chile,2010,20,N-Nervous system,Million of national currency units,154950.4 +6414,Chile,2010,20,N-Nervous system,"/capita, US$ purchasing power parity",25.2 +6415,Chile,2010,20,N-Nervous system,"/capita, US$ exchange rate",17.8 +6416,Chile,2010,20,N-Nervous system,"Million US$, purchasing power parity",430.6 +6417,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.9 +6418,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",2.6 +6419,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",45.0 +6420,Chile,2010,20,N02-Analgesics,Million of national currency units,54002.2 +6421,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0 +6422,Chile,2010,20,N05C-Hypnotics and sedatives,Million of national currency units,3361.7 +6423,Chile,2010,20,N05B-Anxiolytics,% of total sales,1.0 +6424,Chile,2010,20,N05C-Hypnotics and sedatives,Million US$ at exchange rate,6.6 +6425,Chile,2010,20,N05B-Anxiolytics,"Million US$, purchasing power parity",23.9 +6426,Chile,2010,20,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4 +6427,Chile,2010,20,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0 +6428,Chile,2010,20,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",9.3 +6429,Chile,2010,20,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.1 +6430,Chile,2010,20,M-Musculo-skeletal system,"Million US$, purchasing power parity",190.2 +6431,Chile,2010,20,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.9 +6432,Chile,2010,20,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4 +6433,Chile,2010,20,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5 +6434,Chile,2010,20,M-Musculo-skeletal system,% of total sales,8.3 +6435,Chile,2010,20,J-Antiinfectives for systemic use,% of total sales,7.1 +6436,Chile,2010,20,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.6 +6437,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,35363.2 +6438,Chile,2010,20,N02-Analgesics,% of total sales,6.5 +6439,Chile,2010,20,N05B-Anxiolytics,Million of national currency units,8596.0 +6440,Chile,2010,20,J-Antiinfectives for systemic use,Million US$ at exchange rate,115.2 +6441,Chile,2010,20,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.7 +6442,Chile,2010,20,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",163.3 +6443,Chile,2010,20,N05B-Anxiolytics,Million US$ at exchange rate,16.8 +6444,Chile,2017,13,B-Blood and blood forming organs,Million US$ at exchange rate,143.7 +6445,Chile,2017,13,G-Genito urinary system and sex hormones,Million of national currency units,178137.8 +6446,Chile,2017,13,B-Blood and blood forming organs,Million of national currency units,93218.1 +6447,Chile,2017,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",90.0 +6448,Chile,2017,13,C10-Lipid modifying agents,Million US$ at exchange rate,55.1 +6449,Chile,2017,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,274.6 +6450,Chile,2017,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",447.9 +6451,Chile,2017,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.7 +6452,Chile,2017,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",234.4 +6453,Chile,2017,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.8 +6454,Chile,2017,13,B-Blood and blood forming organs,% of total sales,4.5 +6455,Chile,2017,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0 +6456,Chile,2017,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.9 +6457,Chile,2017,13,C10-Lipid modifying agents,% of total sales,1.7 +6458,Chile,2017,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +6459,Chile,2017,13,A-Alimentary tract and metabolism,% of total sales,18.6 +6460,Chile,2017,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +6461,Chile,2017,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",968.8 +6462,Chile,2017,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",52.6 +6463,Chile,2017,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.2 +6464,Chile,2017,13,C01A-Cardiac glycosides,Million of national currency units,198.3 +6465,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.6 +6466,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6 +6467,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +6468,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55462.8 +6469,Chile,2017,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,593.8 +6470,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",139.5 +6471,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,85.5 +6472,Chile,2017,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.3 +6473,Chile,2017,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,124650.7 +6474,Chile,2017,13,G-Genito urinary system and sex hormones,% of total sales,8.6 +6475,Chile,2017,13,C01A-Cardiac glycosides,% of total sales,0.0 +6476,Chile,2017,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.9 +6477,Chile,2017,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +6478,Chile,2017,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +6479,Chile,2017,13,G03-Sex hormones and modulators of the genital system,% of total sales,6.0 +6480,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",17.0 +6481,Chile,2017,13,A-Alimentary tract and metabolism,Million of national currency units,385291.1 +6482,Chile,2017,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,192.1 +6483,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",313.4 +6484,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.4 +6485,Chile,2017,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",282.3 +6486,Chile,2017,13,C07-Beta blocking agents,Million US$ at exchange rate,28.9 +6487,Chile,2017,13,C07-Beta blocking agents,Million of national currency units,18779.6 +6488,Chile,2017,13,Total pharmaceutical sales,Million US$ at exchange rate,3187.0 +6489,Chile,2017,13,Total pharmaceutical sales,"/capita, US$ exchange rate",173.0 +6490,Chile,2017,13,Total pharmaceutical sales,"Million US$, purchasing power parity",5199.6 +6491,Chile,2017,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.4 +6492,Chile,2017,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.7 +6493,Chile,2017,13,C02-Antihypertensives,"Million US$, purchasing power parity",12.4 +6494,Chile,2017,13,C07-Beta blocking agents,"Million US$, purchasing power parity",47.2 +6495,Chile,2017,13,C-Cardiovascular system,% of total sales,7.1 +6496,Chile,2017,13,C02-Antihypertensives,% of total sales,0.2 +6497,Chile,2017,13,C-Cardiovascular system,Million of national currency units,146723.5 +6498,Chile,2017,13,C03-Diuretics,Million of national currency units,5534.7 +6499,Chile,2017,13,C03-Diuretics,Million US$ at exchange rate,8.5 +6500,Chile,2017,13,C-Cardiovascular system,"/capita, US$ exchange rate",12.3 +6501,Chile,2017,13,C-Cardiovascular system,Million US$ at exchange rate,226.1 +6502,Chile,2017,13,C-Cardiovascular system,"Million US$, purchasing power parity",368.9 +6503,Chile,2017,13,C03-Diuretics,"/capita, US$ purchasing power parity",0.8 +6504,Chile,2017,13,Total pharmaceutical sales,Million of national currency units,2067820.4 +6505,Chile,2017,13,C03-Diuretics,% of total sales,0.3 +6506,Chile,2017,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",20.0 +6507,Chile,2017,13,C03-Diuretics,"/capita, US$ exchange rate",0.5 +6508,Chile,2017,13,C03-Diuretics,"Million US$, purchasing power parity",13.9 +6509,Chile,2017,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.2 +6510,Chile,2017,13,C08-Calcium channel blockers,% of total sales,0.4 +6511,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,55530.1 +6512,Chile,2017,13,C08-Calcium channel blockers,Million US$ at exchange rate,13.1 +6513,Chile,2017,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.3 +6514,Chile,2017,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7 +6515,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7 +6516,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6 +6517,Chile,2017,13,C10-Lipid modifying agents,Million of national currency units,35776.7 +6518,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",139.6 +6519,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,85.6 +6520,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.6 +6521,Chile,2017,13,C02-Antihypertensives,Million US$ at exchange rate,7.6 +6522,Chile,2017,13,C02-Antihypertensives,Million of national currency units,4932.3 +6523,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +6524,Chile,2017,13,C07-Beta blocking agents,"/capita, US$ exchange rate",1.6 +6525,Chile,2017,13,C07-Beta blocking agents,% of total sales,0.9 +6526,Chile,2017,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6 +6527,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2149.5 +6528,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3 +6529,Chile,2017,13,C08-Calcium channel blockers,Million of national currency units,8473.5 +6530,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2 +6531,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3 +6532,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.4 +6533,Chile,2017,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9 +6534,Chile,2017,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.7 +6535,Chile,2017,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",200.6 +6536,Chile,2017,13,N06A-Antidepressants,% of total sales,3.0 +6537,Chile,2017,13,J01-Antibacterials for systemic use,% of total sales,3.9 +6538,Chile,2017,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.6 +6539,Chile,2017,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",9.3 +6540,Chile,2017,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.2 +6541,Chile,2017,13,A10-Drugs used in diabetes,Million of national currency units,111563.3 +6542,Chile,2017,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",280.5 +6543,Chile,2017,13,A10-Drugs used in diabetes,Million US$ at exchange rate,171.9 +6544,Chile,2017,13,N06A-Antidepressants,Million of national currency units,62830.3 +6545,Chile,2017,13,N06A-Antidepressants,Million US$ at exchange rate,96.8 +6546,Chile,2017,13,M-Musculo-skeletal system,Million of national currency units,116144.0 +6547,Chile,2017,13,N05C-Hypnotics and sedatives,% of total sales,0.6 +6548,Chile,2017,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.7 +6549,Chile,2017,13,N06A-Antidepressants,"Million US$, purchasing power parity",158.0 +6550,Chile,2017,13,Products not elsewhere classified,"Million US$, purchasing power parity",820.0 +6551,Chile,2017,13,N06A-Antidepressants,"/capita, US$ exchange rate",5.3 +6552,Chile,2017,13,Products not elsewhere classified,"/capita, US$ exchange rate",27.3 +6553,Chile,2017,13,Products not elsewhere classified,% of total sales,15.8 +6554,Chile,2017,13,Products not elsewhere classified,"/capita, US$ purchasing power parity",44.5 +6555,Chile,2017,13,A10-Drugs used in diabetes,% of total sales,5.4 +6556,Chile,2017,13,R-Respiratory system,% of total sales,9.7 +6557,Chile,2017,13,R-Respiratory system,"/capita, US$ purchasing power parity",27.4 +6558,Chile,2017,13,A02A-Antacids,"Million US$, purchasing power parity",29.2 +6559,Chile,2017,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,86.4 +6560,Chile,2017,13,R03-Drugs for obstructive airway diseases,Million of national currency units,56041.0 +6561,Chile,2017,13,R-Respiratory system,"/capita, US$ exchange rate",16.8 +6562,Chile,2017,13,A02A-Antacids,Million of national currency units,11617.0 +6563,Chile,2017,13,A02A-Antacids,Million US$ at exchange rate,17.9 +6564,Chile,2017,13,R-Respiratory system,Million of national currency units,200656.9 +6565,Chile,2017,13,R-Respiratory system,"Million US$, purchasing power parity",504.6 +6566,Chile,2017,13,R-Respiratory system,Million US$ at exchange rate,309.3 +6567,Chile,2017,13,A02A-Antacids,"/capita, US$ purchasing power parity",1.6 +6568,Chile,2017,13,Products not elsewhere classified,Million US$ at exchange rate,502.6 +6569,Chile,2017,13,A02A-Antacids,% of total sales,0.6 +6570,Chile,2017,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,123.0 +6571,Chile,2017,13,J01-Antibacterials for systemic use,Million of national currency units,79791.6 +6572,Chile,2017,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.7 +6573,Chile,2017,13,A02A-Antacids,"/capita, US$ exchange rate",1.0 +6574,Chile,2017,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",140.9 +6575,Chile,2017,13,Products not elsewhere classified,Million of national currency units,326087.2 +6576,Chile,2017,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",7.7 +6577,Chile,2017,13,R03-Drugs for obstructive airway diseases,% of total sales,2.7 +6578,Chile,2017,13,N02-Analgesics,"Million US$, purchasing power parity",200.3 +6579,Chile,2017,13,M-Musculo-skeletal system,Million US$ at exchange rate,179.0 +6580,Chile,2017,13,N02-Analgesics,"/capita, US$ exchange rate",6.7 +6581,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,31943.0 +6582,Chile,2017,13,N02-Analgesics,Million US$ at exchange rate,122.8 +6583,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8 +6584,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,87.9 +6585,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",143.4 +6586,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.8 +6587,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.8 +6588,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,49.2 +6589,Chile,2017,13,N-Nervous system,Million of national currency units,310804.0 +6590,Chile,2017,13,N-Nervous system,Million US$ at exchange rate,479.0 +6591,Chile,2017,13,N-Nervous system,"/capita, US$ purchasing power parity",42.4 +6592,Chile,2017,13,N-Nervous system,"/capita, US$ exchange rate",26.0 +6593,Chile,2017,13,N-Nervous system,"Million US$, purchasing power parity",781.5 +6594,Chile,2017,13,N-Nervous system,% of total sales,15.0 +6595,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.7 +6596,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",80.3 +6597,Chile,2017,13,J-Antiinfectives for systemic use,Million of national currency units,255295.0 +6598,Chile,2017,13,N02-Analgesics,Million of national currency units,79662.9 +6599,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.4 +6600,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +6601,Chile,2017,13,N05B-Anxiolytics,% of total sales,0.8 +6602,Chile,2017,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.8 +6603,Chile,2017,13,N05C-Hypnotics and sedatives,Million of national currency units,12193.6 +6604,Chile,2017,13,N05B-Anxiolytics,"Million US$, purchasing power parity",39.2 +6605,Chile,2017,13,N05B-Anxiolytics,Million US$ at exchange rate,24.0 +6606,Chile,2017,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +6607,Chile,2017,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.1 +6608,Chile,2017,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.7 +6609,Chile,2017,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.9 +6610,Chile,2017,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",292.0 +6611,Chile,2017,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0 +6612,Chile,2017,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.7 +6613,Chile,2017,13,M-Musculo-skeletal system,% of total sales,5.6 +6614,Chile,2017,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.9 +6615,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,57012.2 +6616,Chile,2017,13,J-Antiinfectives for systemic use,% of total sales,12.3 +6617,Chile,2017,13,N02-Analgesics,"/capita, US$ purchasing power parity",10.9 +6618,Chile,2017,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.4 +6619,Chile,2017,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,393.5 +6620,Chile,2017,13,N05B-Anxiolytics,Million of national currency units,15592.8 +6621,Chile,2017,13,N02-Analgesics,% of total sales,3.9 +6622,Chile,2017,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",641.9 +6623,Chile,2016,13,B-Blood and blood forming organs,Million US$ at exchange rate,147.5 +6624,Chile,2016,13,G-Genito urinary system and sex hormones,Million of national currency units,191680.8 +6625,Chile,2016,13,B-Blood and blood forming organs,Million of national currency units,99840.0 +6626,Chile,2016,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",108.0 +6627,Chile,2016,13,C10-Lipid modifying agents,Million US$ at exchange rate,63.4 +6628,Chile,2016,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,283.2 +6629,Chile,2016,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",482.5 +6630,Chile,2016,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.8 +6631,Chile,2016,13,B-Blood and blood forming organs,% of total sales,4.9 +6632,Chile,2016,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",251.3 +6633,Chile,2016,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.1 +6634,Chile,2016,13,N-Nervous system,"/capita, US$ purchasing power parity",42.0 +6635,Chile,2016,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.5 +6636,Chile,2016,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.9 +6637,Chile,2016,13,C10-Lipid modifying agents,% of total sales,2.1 +6638,Chile,2016,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.6 +6639,Chile,2016,13,A-Alimentary tract and metabolism,% of total sales,17.8 +6640,Chile,2016,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8 +6641,Chile,2016,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5 +6642,Chile,2016,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",909.1 +6643,Chile,2016,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.0 +6644,Chile,2016,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.4 +6645,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.1 +6646,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.1 +6647,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +6648,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50996.5 +6649,Chile,2016,13,C01A-Cardiac glycosides,Million of national currency units,335.1 +6650,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",128.4 +6651,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,75.3 +6652,Chile,2016,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,533.5 +6653,Chile,2016,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.6 +6654,Chile,2016,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,139368.4 +6655,Chile,2016,13,G-Genito urinary system and sex hormones,% of total sales,9.5 +6656,Chile,2016,13,C01A-Cardiac glycosides,% of total sales,0.0 +6657,Chile,2016,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +6658,Chile,2016,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +6659,Chile,2016,13,G03-Sex hormones and modulators of the genital system,% of total sales,6.9 +6660,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.3 +6661,Chile,2016,13,A-Alimentary tract and metabolism,Million of national currency units,361148.7 +6662,Chile,2016,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,205.9 +6663,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.3 +6664,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",350.8 +6665,Chile,2016,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",280.4 +6666,Chile,2016,13,C07-Beta blocking agents,Million US$ at exchange rate,28.2 +6667,Chile,2016,13,C07-Beta blocking agents,Million of national currency units,19105.1 +6668,Chile,2016,13,Total pharmaceutical sales,Million US$ at exchange rate,2989.7 +6669,Chile,2016,13,Total pharmaceutical sales,"/capita, US$ exchange rate",164.6 +6670,Chile,2016,13,Total pharmaceutical sales,"Million US$, purchasing power parity",5094.7 +6671,Chile,2016,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +6672,Chile,2016,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.4 +6673,Chile,2016,13,C02-Antihypertensives,"Million US$, purchasing power parity",11.2 +6674,Chile,2016,13,C-Cardiovascular system,% of total sales,7.5 +6675,Chile,2016,13,C07-Beta blocking agents,"Million US$, purchasing power parity",48.1 +6676,Chile,2016,13,C02-Antihypertensives,% of total sales,0.2 +6677,Chile,2016,13,C-Cardiovascular system,Million of national currency units,152031.5 +6678,Chile,2016,13,C03-Diuretics,Million US$ at exchange rate,8.9 +6679,Chile,2016,13,C03-Diuretics,Million of national currency units,6034.4 +6680,Chile,2016,13,C-Cardiovascular system,"/capita, US$ exchange rate",12.4 +6681,Chile,2016,13,C-Cardiovascular system,Million US$ at exchange rate,224.6 +6682,Chile,2016,13,C-Cardiovascular system,"Million US$, purchasing power parity",382.7 +6683,Chile,2016,13,C03-Diuretics,"/capita, US$ purchasing power parity",0.8 +6684,Chile,2016,13,Total pharmaceutical sales,Million of national currency units,2023878.4 +6685,Chile,2016,13,C03-Diuretics,% of total sales,0.3 +6686,Chile,2016,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",21.1 +6687,Chile,2016,13,C03-Diuretics,"/capita, US$ exchange rate",0.5 +6688,Chile,2016,13,C03-Diuretics,"Million US$, purchasing power parity",15.2 +6689,Chile,2016,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0 +6690,Chile,2016,13,C08-Calcium channel blockers,% of total sales,0.3 +6691,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54643.5 +6692,Chile,2016,13,C08-Calcium channel blockers,Million US$ at exchange rate,10.3 +6693,Chile,2016,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.6 +6694,Chile,2016,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6 +6695,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7 +6696,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6 +6697,Chile,2016,13,C10-Lipid modifying agents,Million of national currency units,42911.6 +6698,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",137.6 +6699,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.7 +6700,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.4 +6701,Chile,2016,13,C02-Antihypertensives,Million US$ at exchange rate,6.6 +6702,Chile,2016,13,C02-Antihypertensives,Million of national currency units,4456.9 +6703,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +6704,Chile,2016,13,C07-Beta blocking agents,"/capita, US$ exchange rate",1.6 +6705,Chile,2016,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6 +6706,Chile,2016,13,C07-Beta blocking agents,% of total sales,0.9 +6707,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3 +6708,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2214.9 +6709,Chile,2016,13,C08-Calcium channel blockers,Million of national currency units,6996.6 +6710,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2 +6711,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3 +6712,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.6 +6713,Chile,2016,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.6 +6714,Chile,2016,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",210.0 +6715,Chile,2016,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8 +6716,Chile,2016,13,N06A-Antidepressants,% of total sales,3.0 +6717,Chile,2016,13,J01-Antibacterials for systemic use,% of total sales,4.1 +6718,Chile,2016,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.9 +6719,Chile,2016,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.4 +6720,Chile,2016,13,A10-Drugs used in diabetes,Million of national currency units,96716.5 +6721,Chile,2016,13,A10-Drugs used in diabetes,Million US$ at exchange rate,142.9 +6722,Chile,2016,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",243.5 +6723,Chile,2016,13,A10-Drugs used in diabetes,% of total sales,4.8 +6724,Chile,2016,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.3 +6725,Chile,2016,13,N06A-Antidepressants,Million of national currency units,60183.9 +6726,Chile,2016,13,N06A-Antidepressants,Million US$ at exchange rate,88.9 +6727,Chile,2016,13,M-Musculo-skeletal system,Million of national currency units,120374.3 +6728,Chile,2016,13,N05C-Hypnotics and sedatives,% of total sales,0.5 +6729,Chile,2016,13,N06A-Antidepressants,"Million US$, purchasing power parity",151.5 +6730,Chile,2016,13,Products not elsewhere classified,"Million US$, purchasing power parity",686.4 +6731,Chile,2016,13,Products not elsewhere classified,"/capita, US$ exchange rate",22.2 +6732,Chile,2016,13,N06A-Antidepressants,"/capita, US$ exchange rate",4.9 +6733,Chile,2016,13,Products not elsewhere classified,% of total sales,13.5 +6734,Chile,2016,13,Products not elsewhere classified,"/capita, US$ purchasing power parity",37.8 +6735,Chile,2016,13,R-Respiratory system,% of total sales,9.4 +6736,Chile,2016,13,R-Respiratory system,"/capita, US$ purchasing power parity",26.4 +6737,Chile,2016,13,A02A-Antacids,"Million US$, purchasing power parity",28.4 +6738,Chile,2016,13,R03-Drugs for obstructive airway diseases,Million of national currency units,52879.3 +6739,Chile,2016,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,78.1 +6740,Chile,2016,13,R-Respiratory system,"/capita, US$ exchange rate",15.5 +6741,Chile,2016,13,A02A-Antacids,Million of national currency units,11264.6 +6742,Chile,2016,13,R-Respiratory system,Million of national currency units,190353.2 +6743,Chile,2016,13,A02A-Antacids,Million US$ at exchange rate,16.6 +6744,Chile,2016,13,R-Respiratory system,"Million US$, purchasing power parity",479.2 +6745,Chile,2016,13,R-Respiratory system,Million US$ at exchange rate,281.2 +6746,Chile,2016,13,A02A-Antacids,"/capita, US$ purchasing power parity",1.6 +6747,Chile,2016,13,Products not elsewhere classified,Million US$ at exchange rate,402.8 +6748,Chile,2016,13,A02A-Antacids,% of total sales,0.6 +6749,Chile,2016,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,123.2 +6750,Chile,2016,13,J01-Antibacterials for systemic use,Million of national currency units,83434.7 +6751,Chile,2016,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.3 +6752,Chile,2016,13,A02A-Antacids,"/capita, US$ exchange rate",0.9 +6753,Chile,2016,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",133.1 +6754,Chile,2016,13,Products not elsewhere classified,Million of national currency units,272690.5 +6755,Chile,2016,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",7.3 +6756,Chile,2016,13,R03-Drugs for obstructive airway diseases,% of total sales,2.6 +6757,Chile,2016,13,M-Musculo-skeletal system,Million US$ at exchange rate,177.8 +6758,Chile,2016,13,N02-Analgesics,"Million US$, purchasing power parity",216.1 +6759,Chile,2016,13,N02-Analgesics,"/capita, US$ purchasing power parity",11.9 +6760,Chile,2016,13,N02-Analgesics,"/capita, US$ exchange rate",7.0 +6761,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,27671.1 +6762,Chile,2016,13,N02-Analgesics,Million US$ at exchange rate,126.8 +6763,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",154.1 +6764,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,90.4 +6765,Chile,2016,13,J-Antiinfectives for systemic use,Million of national currency units,281371.0 +6766,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5 +6767,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0 +6768,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.0 +6769,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.9 +6770,Chile,2016,13,N-Nervous system,Million of national currency units,303392.0 +6771,Chile,2016,13,N-Nervous system,Million US$ at exchange rate,448.2 +6772,Chile,2016,13,N-Nervous system,"/capita, US$ exchange rate",24.7 +6773,Chile,2016,13,N-Nervous system,"Million US$, purchasing power parity",763.7 +6774,Chile,2016,13,N-Nervous system,% of total sales,15.0 +6775,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.2 +6776,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",69.7 +6777,Chile,2016,13,N02-Analgesics,Million of national currency units,85860.4 +6778,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.8 +6779,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4 +6780,Chile,2016,13,N05B-Anxiolytics,% of total sales,0.7 +6781,Chile,2016,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.0 +6782,Chile,2016,13,N05C-Hypnotics and sedatives,Million of national currency units,10849.8 +6783,Chile,2016,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.9 +6784,Chile,2016,13,N05B-Anxiolytics,"Million US$, purchasing power parity",35.2 +6785,Chile,2016,13,N05B-Anxiolytics,Million US$ at exchange rate,20.6 +6786,Chile,2016,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +6787,Chile,2016,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.8 +6788,Chile,2016,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.7 +6789,Chile,2016,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.0 +6790,Chile,2016,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +6791,Chile,2016,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",27.3 +6792,Chile,2016,13,M-Musculo-skeletal system,% of total sales,5.9 +6793,Chile,2016,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5 +6794,Chile,2016,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",39.0 +6795,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,61219.5 +6796,Chile,2016,13,J-Antiinfectives for systemic use,% of total sales,13.9 +6797,Chile,2016,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",22.9 +6798,Chile,2016,13,N05B-Anxiolytics,Million of national currency units,13974.1 +6799,Chile,2016,13,N02-Analgesics,% of total sales,4.2 +6800,Chile,2016,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,415.6 +6801,Chile,2016,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",708.3 +6802,Costa Rica,2016,28,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3 +6803,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0 +6804,Costa Rica,2016,28,C02-Antihypertensives,Million US$ at exchange rate,1.0 +6805,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,5.7 +6806,Costa Rica,2016,28,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4 +6807,Costa Rica,2016,28,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5 +6808,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +6809,Costa Rica,2016,28,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4 +6810,Costa Rica,2016,28,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +6811,Costa Rica,2016,28,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6 +6812,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +6813,Costa Rica,2016,28,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.0 +6814,Costa Rica,2016,28,B-Blood and blood forming organs,"Million US$, purchasing power parity",46.6 +6815,Costa Rica,2016,28,C08-Calcium channel blockers,Million of national currency units,298.2 +6816,Costa Rica,2016,28,N02-Analgesics,"/capita, US$ exchange rate",1.0 +6817,Costa Rica,2016,28,C03-Diuretics,"/capita, US$ exchange rate",0.2 +6818,Costa Rica,2016,28,C08-Calcium channel blockers,Million US$ at exchange rate,0.5 +6819,Costa Rica,2016,28,N06A-Antidepressants,"/capita, US$ exchange rate",0.6 +6820,Costa Rica,2016,28,C-Cardiovascular system,Million of national currency units,5484.2 +6821,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1689.2 +6822,Costa Rica,2016,28,C-Cardiovascular system,Million US$ at exchange rate,10.1 +6823,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9 +6824,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.1 +6825,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5 +6826,Costa Rica,2016,28,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0 +6827,Costa Rica,2016,28,C02-Antihypertensives,Million of national currency units,539.3 +6828,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1877.2 +6829,Costa Rica,2016,28,J-Antiinfectives for systemic use,Million of national currency units,19042.5 +6830,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6 +6831,Costa Rica,2016,28,N02-Analgesics,"Million US$, purchasing power parity",7.7 +6832,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",1.9 +6833,Costa Rica,2016,28,J-Antiinfectives for systemic use,Million US$ at exchange rate,35.0 +6834,Costa Rica,2016,28,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.0 +6835,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.4 +6836,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +6837,Costa Rica,2016,28,N05B-Anxiolytics,Million US$ at exchange rate,0.7 +6838,Costa Rica,2016,28,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +6839,Costa Rica,2016,28,C-Cardiovascular system,"/capita, US$ exchange rate",2.1 +6840,Costa Rica,2016,28,C10-Lipid modifying agents,Million US$ at exchange rate,3.1 +6841,Costa Rica,2016,28,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.0 +6842,Costa Rica,2016,28,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.5 +6843,Costa Rica,2016,28,N06A-Antidepressants,"Million US$, purchasing power parity",4.4 +6844,Costa Rica,2016,28,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.9 +6845,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.8 +6846,Costa Rica,2016,28,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.5 +6847,Costa Rica,2016,28,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1 +6848,Costa Rica,2016,28,C10-Lipid modifying agents,"Million US$, purchasing power parity",4.9 +6849,Costa Rica,2016,28,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +6850,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +6851,Costa Rica,2016,28,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +6852,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +6853,Costa Rica,2016,28,C07-Beta blocking agents,Million US$ at exchange rate,1.6 +6854,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2333.1 +6855,Costa Rica,2016,28,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.9 +6856,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,Million of national currency units,3104.4 +6857,Costa Rica,2016,28,C10-Lipid modifying agents,Million of national currency units,1683.6 +6858,Costa Rica,2016,28,A02A-Antacids,Million of national currency units,927.7 +6859,Costa Rica,2016,28,B-Blood and blood forming organs,Million of national currency units,15990.6 +6860,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.5 +6861,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +6862,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.6 +6863,Costa Rica,2016,28,A02A-Antacids,Million US$ at exchange rate,1.7 +6864,Costa Rica,2016,28,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.6 +6865,Costa Rica,2016,28,B-Blood and blood forming organs,Million US$ at exchange rate,29.4 +6866,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4 +6867,Costa Rica,2016,28,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +6868,Costa Rica,2016,28,A02A-Antacids,"/capita, US$ exchange rate",0.3 +6869,Costa Rica,2016,28,C-Cardiovascular system,"Million US$, purchasing power parity",16.0 +6870,Costa Rica,2016,28,C07-Beta blocking agents,Million of national currency units,868.6 +6871,Costa Rica,2016,28,C03-Diuretics,"Million US$, purchasing power parity",1.2 +6872,Costa Rica,2016,28,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +6873,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +6874,Costa Rica,2016,28,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.4 +6875,Costa Rica,2016,28,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.5 +6876,Costa Rica,2016,28,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2 +6877,Costa Rica,2016,28,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3 +6878,Costa Rica,2016,28,N06A-Antidepressants,Million of national currency units,1494.7 +6879,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.1 +6880,Costa Rica,2016,28,N02-Analgesics,Million of national currency units,2631.2 +6881,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6 +6882,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.1 +6883,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +6884,Costa Rica,2016,28,N02-Analgesics,Million US$ at exchange rate,4.8 +6885,Costa Rica,2016,28,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +6886,Costa Rica,2016,28,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9 +6887,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.3 +6888,Costa Rica,2016,28,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.9 +6889,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.0 +6890,Costa Rica,2016,28,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.6 +6891,Costa Rica,2016,28,N06A-Antidepressants,Million US$ at exchange rate,2.7 +6892,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.2 +6893,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3 +6894,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.8 +6895,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,Million of national currency units,1812.8 +6896,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7 +6897,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1357.8 +6898,Costa Rica,2016,28,C03-Diuretics,Million US$ at exchange rate,0.8 +6899,Costa Rica,2016,28,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3 +6900,Costa Rica,2016,28,N05C-Hypnotics and sedatives,Million of national currency units,213.0 +6901,Costa Rica,2016,28,J01-Antibacterials for systemic use,Million of national currency units,5106.3 +6902,Costa Rica,2016,28,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",55.5 +6903,Costa Rica,2016,28,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +6904,Costa Rica,2016,28,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +6905,Costa Rica,2016,28,C01A-Cardiac glycosides,Million of national currency units,201.9 +6906,Costa Rica,2016,28,A02A-Antacids,"Million US$, purchasing power parity",2.7 +6907,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.5 +6908,Costa Rica,2016,28,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +6909,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3 +6910,Costa Rica,2016,28,C03-Diuretics,Million of national currency units,427.5 +6911,Costa Rica,2016,28,A10-Drugs used in diabetes,Million of national currency units,4281.7 +6912,Costa Rica,2016,28,N05B-Anxiolytics,Million of national currency units,355.5 +6913,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.9 +6914,Costa Rica,2016,28,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.9 +6915,Costa Rica,2016,28,C02-Antihypertensives,"Million US$, purchasing power parity",1.6 +6916,Costa Rica,2016,28,N02-Analgesics,"/capita, US$ purchasing power parity",1.6 +6917,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0 +6918,Costa Rica,2015,28,C02-Antihypertensives,Million US$ at exchange rate,1.0 +6919,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.9 +6920,Costa Rica,2015,28,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4 +6921,Costa Rica,2015,28,C07-Beta blocking agents,"Million US$, purchasing power parity",2.3 +6922,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +6923,Costa Rica,2015,28,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +6924,Costa Rica,2015,28,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6 +6925,Costa Rica,2015,28,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.2 +6926,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +6927,Costa Rica,2015,28,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9 +6928,Costa Rica,2015,28,B-Blood and blood forming organs,"Million US$, purchasing power parity",47.2 +6929,Costa Rica,2015,28,C08-Calcium channel blockers,Million of national currency units,362.9 +6930,Costa Rica,2015,28,N02-Analgesics,"/capita, US$ exchange rate",1.0 +6931,Costa Rica,2015,28,C03-Diuretics,"/capita, US$ exchange rate",0.2 +6932,Costa Rica,2015,28,C08-Calcium channel blockers,Million US$ at exchange rate,0.7 +6933,Costa Rica,2015,28,N06A-Antidepressants,"/capita, US$ exchange rate",0.5 +6934,Costa Rica,2015,28,C-Cardiovascular system,Million of national currency units,5719.1 +6935,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1648.5 +6936,Costa Rica,2015,28,C-Cardiovascular system,Million US$ at exchange rate,10.7 +6937,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9 +6938,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0 +6939,Costa Rica,2015,28,C02-Antihypertensives,Million of national currency units,519.3 +6940,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.3 +6941,Costa Rica,2015,28,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0 +6942,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1858.9 +6943,Costa Rica,2015,28,J-Antiinfectives for systemic use,Million of national currency units,17281.8 +6944,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6 +6945,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.1 +6946,Costa Rica,2015,28,N02-Analgesics,"Million US$, purchasing power parity",7.4 +6947,Costa Rica,2015,28,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.3 +6948,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +6949,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.5 +6950,Costa Rica,2015,28,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.5 +6951,Costa Rica,2015,28,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +6952,Costa Rica,2015,28,C-Cardiovascular system,"/capita, US$ exchange rate",2.2 +6953,Costa Rica,2015,28,C10-Lipid modifying agents,Million US$ at exchange rate,3.2 +6954,Costa Rica,2015,28,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.0 +6955,Costa Rica,2015,28,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.5 +6956,Costa Rica,2015,28,N06A-Antidepressants,"Million US$, purchasing power parity",3.6 +6957,Costa Rica,2015,28,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.7 +6958,Costa Rica,2015,28,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.8 +6959,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.5 +6960,Costa Rica,2015,28,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.7 +6961,Costa Rica,2015,28,C10-Lipid modifying agents,"Million US$, purchasing power parity",4.8 +6962,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +6963,Costa Rica,2015,28,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +6964,Costa Rica,2015,28,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +6965,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +6966,Costa Rica,2015,28,C07-Beta blocking agents,Million US$ at exchange rate,1.6 +6967,Costa Rica,2015,28,A02A-Antacids,Million US$ at exchange rate,1.7 +6968,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2298.6 +6969,Costa Rica,2015,28,A02A-Antacids,Million of national currency units,882.4 +6970,Costa Rica,2015,28,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.9 +6971,Costa Rica,2015,28,B-Blood and blood forming organs,Million of national currency units,16694.8 +6972,Costa Rica,2015,28,C10-Lipid modifying agents,Million of national currency units,1710.2 +6973,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6 +6974,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,Million of national currency units,3675.4 +6975,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,64.5 +6976,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +6977,Costa Rica,2015,28,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.3 +6978,Costa Rica,2015,28,B-Blood and blood forming organs,Million US$ at exchange rate,31.2 +6979,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.3 +6980,Costa Rica,2015,28,N05B-Anxiolytics,Million US$ at exchange rate,0.7 +6981,Costa Rica,2015,28,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +6982,Costa Rica,2015,28,A02A-Antacids,"/capita, US$ exchange rate",0.3 +6983,Costa Rica,2015,28,C07-Beta blocking agents,Million of national currency units,830.8 +6984,Costa Rica,2015,28,C-Cardiovascular system,"Million US$, purchasing power parity",16.2 +6985,Costa Rica,2015,28,C03-Diuretics,"Million US$, purchasing power parity",1.2 +6986,Costa Rica,2015,28,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +6987,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +6988,Costa Rica,2015,28,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.1 +6989,Costa Rica,2015,28,A10-Drugs used in diabetes,"Million US$, purchasing power parity",11.4 +6990,Costa Rica,2015,28,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3 +6991,Costa Rica,2015,28,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2 +6992,Costa Rica,2015,28,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3 +6993,Costa Rica,2015,28,N06A-Antidepressants,Million of national currency units,1278.7 +6994,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.1 +6995,Costa Rica,2015,28,N02-Analgesics,Million of national currency units,2634.7 +6996,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6 +6997,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.4 +6998,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +6999,Costa Rica,2015,28,N02-Analgesics,Million US$ at exchange rate,4.9 +7000,Costa Rica,2015,28,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7001,Costa Rica,2015,28,A10-Drugs used in diabetes,Million US$ at exchange rate,7.5 +7002,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0 +7003,Costa Rica,2015,28,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.9 +7004,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.5 +7005,Costa Rica,2015,28,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.7 +7006,Costa Rica,2015,28,N06A-Antidepressants,Million US$ at exchange rate,2.4 +7007,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4 +7008,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3 +7009,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,Million of national currency units,1760.3 +7010,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7 +7011,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1579.9 +7012,Costa Rica,2015,28,C03-Diuretics,Million US$ at exchange rate,0.8 +7013,Costa Rica,2015,28,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3 +7014,Costa Rica,2015,28,N05C-Hypnotics and sedatives,Million of national currency units,195.8 +7015,Costa Rica,2015,28,J01-Antibacterials for systemic use,Million of national currency units,4904.9 +7016,Costa Rica,2015,28,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",48.8 +7017,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.9 +7018,Costa Rica,2015,28,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7019,Costa Rica,2015,28,C01A-Cardiac glycosides,Million of national currency units,200.6 +7020,Costa Rica,2015,28,C03-Diuretics,"/capita, US$ purchasing power parity",0.2 +7021,Costa Rica,2015,28,A02A-Antacids,"Million US$, purchasing power parity",2.5 +7022,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.0 +7023,Costa Rica,2015,28,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7024,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3 +7025,Costa Rica,2015,28,C03-Diuretics,Million of national currency units,413.6 +7026,Costa Rica,2015,28,A10-Drugs used in diabetes,Million of national currency units,4018.0 +7027,Costa Rica,2015,28,N05B-Anxiolytics,Million of national currency units,348.3 +7028,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.7 +7029,Costa Rica,2015,28,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.0 +7030,Costa Rica,2015,28,C02-Antihypertensives,"Million US$, purchasing power parity",1.5 +7031,Costa Rica,2015,28,N02-Analgesics,"/capita, US$ purchasing power parity",1.5 +7032,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,7.9 +7033,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0 +7034,Costa Rica,2014,29,C02-Antihypertensives,Million US$ at exchange rate,0.9 +7035,Costa Rica,2014,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3 +7036,Costa Rica,2014,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.9 +7037,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +7038,Costa Rica,2014,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +7039,Costa Rica,2014,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.7 +7040,Costa Rica,2014,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.7 +7041,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +7042,Costa Rica,2014,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.4 +7043,Costa Rica,2014,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",52.6 +7044,Costa Rica,2014,29,C08-Calcium channel blockers,Million of national currency units,319.1 +7045,Costa Rica,2014,29,N02-Analgesics,"/capita, US$ exchange rate",1.1 +7046,Costa Rica,2014,29,C03-Diuretics,"/capita, US$ exchange rate",0.2 +7047,Costa Rica,2014,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.6 +7048,Costa Rica,2014,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4 +7049,Costa Rica,2014,29,C-Cardiovascular system,Million of national currency units,6768.8 +7050,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1732.8 +7051,Costa Rica,2014,29,C-Cardiovascular system,Million US$ at exchange rate,12.6 +7052,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.1 +7053,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0 +7054,Costa Rica,2014,29,C02-Antihypertensives,Million of national currency units,481.8 +7055,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7 +7056,Costa Rica,2014,29,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0 +7057,Costa Rica,2014,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",4.0 +7058,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1674.9 +7059,Costa Rica,2014,29,J-Antiinfectives for systemic use,Million of national currency units,16847.2 +7060,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.7 +7061,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.5 +7062,Costa Rica,2014,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.3 +7063,Costa Rica,2014,29,N02-Analgesics,"Million US$, purchasing power parity",8.0 +7064,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.1 +7065,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +7066,Costa Rica,2014,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.6 +7067,Costa Rica,2014,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.2 +7068,Costa Rica,2014,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +7069,Costa Rica,2014,29,C10-Lipid modifying agents,Million US$ at exchange rate,5.5 +7070,Costa Rica,2014,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.7 +7071,Costa Rica,2014,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4 +7072,Costa Rica,2014,29,N06A-Antidepressants,"Million US$, purchasing power parity",3.2 +7073,Costa Rica,2014,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.7 +7074,Costa Rica,2014,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.6 +7075,Costa Rica,2014,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",11.0 +7076,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.6 +7077,Costa Rica,2014,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",8.4 +7078,Costa Rica,2014,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +7079,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +7080,Costa Rica,2014,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +7081,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +7082,Costa Rica,2014,29,A02A-Antacids,Million US$ at exchange rate,1.6 +7083,Costa Rica,2014,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2 +7084,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2700.8 +7085,Costa Rica,2014,29,A02A-Antacids,Million of national currency units,864.0 +7086,Costa Rica,2014,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.2 +7087,Costa Rica,2014,29,B-Blood and blood forming organs,Million of national currency units,18566.0 +7088,Costa Rica,2014,29,C10-Lipid modifying agents,Million of national currency units,2949.9 +7089,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6 +7090,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,Million of national currency units,4275.6 +7091,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,71.7 +7092,Costa Rica,2014,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.5 +7093,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +7094,Costa Rica,2014,29,B-Blood and blood forming organs,Million US$ at exchange rate,34.5 +7095,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.6 +7096,Costa Rica,2014,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +7097,Costa Rica,2014,29,N05B-Anxiolytics,Million US$ at exchange rate,0.7 +7098,Costa Rica,2014,29,A02A-Antacids,"/capita, US$ exchange rate",0.3 +7099,Costa Rica,2014,29,C-Cardiovascular system,"Million US$, purchasing power parity",19.2 +7100,Costa Rica,2014,29,C07-Beta blocking agents,Million of national currency units,656.4 +7101,Costa Rica,2014,29,C03-Diuretics,"Million US$, purchasing power parity",1.2 +7102,Costa Rica,2014,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +7103,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0 +7104,Costa Rica,2014,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.1 +7105,Costa Rica,2014,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0 +7106,Costa Rica,2014,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2 +7107,Costa Rica,2014,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3 +7108,Costa Rica,2014,29,N06A-Antidepressants,Million of national currency units,1118.1 +7109,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.2 +7110,Costa Rica,2014,29,N02-Analgesics,Million of national currency units,2811.6 +7111,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.5 +7112,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.1 +7113,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +7114,Costa Rica,2014,29,N02-Analgesics,Million US$ at exchange rate,5.2 +7115,Costa Rica,2014,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7116,Costa Rica,2014,29,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9 +7117,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0 +7118,Costa Rica,2014,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",16.3 +7119,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.6 +7120,Costa Rica,2014,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.1 +7121,Costa Rica,2014,29,N06A-Antidepressants,Million US$ at exchange rate,2.1 +7122,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.7 +7123,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.0 +7124,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.0 +7125,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1766.7 +7126,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7 +7127,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1623.3 +7128,Costa Rica,2014,29,C03-Diuretics,Million US$ at exchange rate,0.8 +7129,Costa Rica,2014,29,N05C-Hypnotics and sedatives,Million of national currency units,176.3 +7130,Costa Rica,2014,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3 +7131,Costa Rica,2014,29,J01-Antibacterials for systemic use,Million of national currency units,5751.6 +7132,Costa Rica,2014,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.7 +7133,Costa Rica,2014,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7134,Costa Rica,2014,29,C01A-Cardiac glycosides,Million of national currency units,227.2 +7135,Costa Rica,2014,29,A02A-Antacids,"Million US$, purchasing power parity",2.4 +7136,Costa Rica,2014,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +7137,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.0 +7138,Costa Rica,2014,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7139,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3 +7140,Costa Rica,2014,29,C03-Diuretics,Million of national currency units,427.6 +7141,Costa Rica,2014,29,A10-Drugs used in diabetes,Million of national currency units,4269.6 +7142,Costa Rica,2014,29,N05B-Anxiolytics,Million of national currency units,351.2 +7143,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.9 +7144,Costa Rica,2014,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.9 +7145,Costa Rica,2014,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.4 +7146,Costa Rica,2014,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.7 +7147,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.8 +7148,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,7.3 +7149,Costa Rica,2013,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3 +7150,Costa Rica,2013,29,C02-Antihypertensives,Million US$ at exchange rate,0.8 +7151,Costa Rica,2013,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.8 +7152,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +7153,Costa Rica,2013,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +7154,Costa Rica,2013,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.5 +7155,Costa Rica,2013,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.2 +7156,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.3 +7157,Costa Rica,2013,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.1 +7158,Costa Rica,2013,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",42.6 +7159,Costa Rica,2013,29,C08-Calcium channel blockers,Million of national currency units,276.6 +7160,Costa Rica,2013,29,N02-Analgesics,"/capita, US$ exchange rate",0.8 +7161,Costa Rica,2013,29,C03-Diuretics,"/capita, US$ exchange rate",0.2 +7162,Costa Rica,2013,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.6 +7163,Costa Rica,2013,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4 +7164,Costa Rica,2013,29,C-Cardiovascular system,Million of national currency units,5356.4 +7165,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1381.1 +7166,Costa Rica,2013,29,C-Cardiovascular system,Million US$ at exchange rate,10.7 +7167,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0 +7168,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0 +7169,Costa Rica,2013,29,C02-Antihypertensives,Million of national currency units,394.0 +7170,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5 +7171,Costa Rica,2013,29,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9 +7172,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1915.9 +7173,Costa Rica,2013,29,J-Antiinfectives for systemic use,Million of national currency units,14080.5 +7174,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6 +7175,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.2 +7176,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,Million of national currency units,3657.2 +7177,Costa Rica,2013,29,N02-Analgesics,"Million US$, purchasing power parity",5.5 +7178,Costa Rica,2013,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.2 +7179,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +7180,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.8 +7181,Costa Rica,2013,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.3 +7182,Costa Rica,2013,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.3 +7183,Costa Rica,2013,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +7184,Costa Rica,2013,29,C10-Lipid modifying agents,Million US$ at exchange rate,3.9 +7185,Costa Rica,2013,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.2 +7186,Costa Rica,2013,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.0 +7187,Costa Rica,2013,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4 +7188,Costa Rica,2013,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.6 +7189,Costa Rica,2013,29,N06A-Antidepressants,"Million US$, purchasing power parity",3.0 +7190,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.9 +7191,Costa Rica,2013,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.7 +7192,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.1 +7193,Costa Rica,2013,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +7194,Costa Rica,2013,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +7195,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.2 +7196,Costa Rica,2013,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.0 +7197,Costa Rica,2013,29,A02A-Antacids,Million US$ at exchange rate,2.0 +7198,Costa Rica,2013,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2 +7199,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2416.6 +7200,Costa Rica,2013,29,A02A-Antacids,Million of national currency units,975.1 +7201,Costa Rica,2013,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.2 +7202,Costa Rica,2013,29,B-Blood and blood forming organs,Million of national currency units,14811.2 +7203,Costa Rica,2013,29,C10-Lipid modifying agents,Million of national currency units,1969.3 +7204,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6 +7205,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,114.0 +7206,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +7207,Costa Rica,2013,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.2 +7208,Costa Rica,2013,29,B-Blood and blood forming organs,Million US$ at exchange rate,29.6 +7209,Costa Rica,2013,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +7210,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.5 +7211,Costa Rica,2013,29,N05B-Anxiolytics,Million US$ at exchange rate,0.6 +7212,Costa Rica,2013,29,A02A-Antacids,"/capita, US$ exchange rate",0.4 +7213,Costa Rica,2013,29,C07-Beta blocking agents,Million of national currency units,622.3 +7214,Costa Rica,2013,29,C-Cardiovascular system,"Million US$, purchasing power parity",15.4 +7215,Costa Rica,2013,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +7216,Costa Rica,2013,29,C03-Diuretics,"Million US$, purchasing power parity",1.2 +7217,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.2 +7218,Costa Rica,2013,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",10.2 +7219,Costa Rica,2013,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2 +7220,Costa Rica,2013,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.6 +7221,Costa Rica,2013,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.1 +7222,Costa Rica,2013,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3 +7223,Costa Rica,2013,29,N06A-Antidepressants,Million of national currency units,1043.0 +7224,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,2.8 +7225,Costa Rica,2013,29,N02-Analgesics,Million of national currency units,1924.0 +7226,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.5 +7227,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4 +7228,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +7229,Costa Rica,2013,29,N02-Analgesics,Million US$ at exchange rate,3.8 +7230,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.9 +7231,Costa Rica,2013,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7232,Costa Rica,2013,29,A10-Drugs used in diabetes,Million US$ at exchange rate,7.1 +7233,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.8 +7234,Costa Rica,2013,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.6 +7235,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.1 +7236,Costa Rica,2013,29,N06A-Antidepressants,Million US$ at exchange rate,2.1 +7237,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.6 +7238,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8 +7239,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1682.6 +7240,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.8 +7241,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1436.0 +7242,Costa Rica,2013,29,C03-Diuretics,Million US$ at exchange rate,0.8 +7243,Costa Rica,2013,29,J01-Antibacterials for systemic use,Million of national currency units,5081.9 +7244,Costa Rica,2013,29,N05C-Hypnotics and sedatives,Million of national currency units,138.7 +7245,Costa Rica,2013,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3 +7246,Costa Rica,2013,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2 +7247,Costa Rica,2013,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",40.5 +7248,Costa Rica,2013,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7249,Costa Rica,2013,29,C01A-Cardiac glycosides,Million of national currency units,137.7 +7250,Costa Rica,2013,29,A02A-Antacids,"Million US$, purchasing power parity",2.8 +7251,Costa Rica,2013,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.2 +7252,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.9 +7253,Costa Rica,2013,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7254,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.4 +7255,Costa Rica,2013,29,C03-Diuretics,Million of national currency units,406.6 +7256,Costa Rica,2013,29,A10-Drugs used in diabetes,Million of national currency units,3557.3 +7257,Costa Rica,2013,29,N05B-Anxiolytics,Million of national currency units,314.0 +7258,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.0 +7259,Costa Rica,2013,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8 +7260,Costa Rica,2013,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.8 +7261,Costa Rica,2013,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.2 +7262,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.4 +7263,Costa Rica,2012,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3 +7264,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6 +7265,Costa Rica,2012,29,C02-Antihypertensives,Million US$ at exchange rate,0.8 +7266,Costa Rica,2012,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.7 +7267,Costa Rica,2012,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.7 +7268,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +7269,Costa Rica,2012,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +7270,Costa Rica,2012,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.4 +7271,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +7272,Costa Rica,2012,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.0 +7273,Costa Rica,2012,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.5 +7274,Costa Rica,2012,29,C08-Calcium channel blockers,Million of national currency units,204.0 +7275,Costa Rica,2012,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.4 +7276,Costa Rica,2012,29,C03-Diuretics,"/capita, US$ exchange rate",0.2 +7277,Costa Rica,2012,29,N02-Analgesics,"/capita, US$ exchange rate",0.7 +7278,Costa Rica,2012,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4 +7279,Costa Rica,2012,29,C-Cardiovascular system,Million of national currency units,5057.2 +7280,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1000.3 +7281,Costa Rica,2012,29,C-Cardiovascular system,Million US$ at exchange rate,10.1 +7282,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9 +7283,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0 +7284,Costa Rica,2012,29,C02-Antihypertensives,Million of national currency units,379.8 +7285,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.1 +7286,Costa Rica,2012,29,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8 +7287,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1763.9 +7288,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4 +7289,Costa Rica,2012,29,J-Antiinfectives for systemic use,Million of national currency units,13948.3 +7290,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.0 +7291,Costa Rica,2012,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,27.7 +7292,Costa Rica,2012,29,N02-Analgesics,"Million US$, purchasing power parity",4.9 +7293,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +7294,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.5 +7295,Costa Rica,2012,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.2 +7296,Costa Rica,2012,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +7297,Costa Rica,2012,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.2 +7298,Costa Rica,2012,29,C10-Lipid modifying agents,Million US$ at exchange rate,4.2 +7299,Costa Rica,2012,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3 +7300,Costa Rica,2012,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.0 +7301,Costa Rica,2012,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4 +7302,Costa Rica,2012,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.6 +7303,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.4 +7304,Costa Rica,2012,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.1 +7305,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +7306,Costa Rica,2012,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +7307,Costa Rica,2012,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +7308,Costa Rica,2012,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.6 +7309,Costa Rica,2012,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.1 +7310,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +7311,Costa Rica,2012,29,A02A-Antacids,Million US$ at exchange rate,1.5 +7312,Costa Rica,2012,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2 +7313,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2194.5 +7314,Costa Rica,2012,29,A02A-Antacids,Million of national currency units,765.2 +7315,Costa Rica,2012,29,B-Blood and blood forming organs,Million of national currency units,12208.2 +7316,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.5 +7317,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.5 +7318,Costa Rica,2012,29,C10-Lipid modifying agents,Million of national currency units,2104.9 +7319,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +7320,Costa Rica,2012,29,B-Blood and blood forming organs,Million US$ at exchange rate,24.3 +7321,Costa Rica,2012,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +7322,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4 +7323,Costa Rica,2012,29,N05B-Anxiolytics,Million US$ at exchange rate,0.6 +7324,Costa Rica,2012,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.1 +7325,Costa Rica,2012,29,C07-Beta blocking agents,Million of national currency units,591.5 +7326,Costa Rica,2012,29,A02A-Antacids,"/capita, US$ exchange rate",0.3 +7327,Costa Rica,2012,29,C-Cardiovascular system,"Million US$, purchasing power parity",14.7 +7328,Costa Rica,2012,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +7329,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +7330,Costa Rica,2012,29,C03-Diuretics,"Million US$, purchasing power parity",1.1 +7331,Costa Rica,2012,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",9.7 +7332,Costa Rica,2012,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.7 +7333,Costa Rica,2012,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1 +7334,Costa Rica,2012,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3 +7335,Costa Rica,2012,29,N06A-Antidepressants,Million of national currency units,933.3 +7336,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,2.0 +7337,Costa Rica,2012,29,N02-Analgesics,Million of national currency units,1696.3 +7338,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +7339,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.3 +7340,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.8 +7341,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4 +7342,Costa Rica,2012,29,N02-Analgesics,Million US$ at exchange rate,3.4 +7343,Costa Rica,2012,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7344,Costa Rica,2012,29,A10-Drugs used in diabetes,Million US$ at exchange rate,6.6 +7345,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.6 +7346,Costa Rica,2012,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.1 +7347,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.5 +7348,Costa Rica,2012,29,N06A-Antidepressants,Million US$ at exchange rate,1.9 +7349,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4 +7350,Costa Rica,2012,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.1 +7351,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4 +7352,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.8 +7353,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1597.4 +7354,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1212.1 +7355,Costa Rica,2012,29,C03-Diuretics,Million US$ at exchange rate,0.7 +7356,Costa Rica,2012,29,J01-Antibacterials for systemic use,Million of national currency units,4854.0 +7357,Costa Rica,2012,29,N05C-Hypnotics and sedatives,Million of national currency units,141.2 +7358,Costa Rica,2012,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.2 +7359,Costa Rica,2012,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2 +7360,Costa Rica,2012,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",40.6 +7361,Costa Rica,2012,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7362,Costa Rica,2012,29,C01A-Cardiac glycosides,Million of national currency units,126.1 +7363,Costa Rica,2012,29,A02A-Antacids,"Million US$, purchasing power parity",2.2 +7364,Costa Rica,2012,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.2 +7365,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.4 +7366,Costa Rica,2012,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7367,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.2 +7368,Costa Rica,2012,29,C03-Diuretics,Million of national currency units,364.4 +7369,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,Million of national currency units,3202.7 +7370,Costa Rica,2012,29,N06A-Antidepressants,"Million US$, purchasing power parity",2.7 +7371,Costa Rica,2012,29,A10-Drugs used in diabetes,Million of national currency units,3318.6 +7372,Costa Rica,2012,29,N05B-Anxiolytics,Million of national currency units,282.2 +7373,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.9 +7374,Costa Rica,2012,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.9 +7375,Costa Rica,2012,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.6 +7376,Costa Rica,2012,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.1 +7377,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.1 +7378,Costa Rica,2011,30,C02-Antihypertensives,Million US$ at exchange rate,0.7 +7379,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6 +7380,Costa Rica,2011,30,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3 +7381,Costa Rica,2011,30,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +7382,Costa Rica,2011,30,C07-Beta blocking agents,"Million US$, purchasing power parity",1.5 +7383,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +7384,Costa Rica,2011,30,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.2 +7385,Costa Rica,2011,30,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.9 +7386,Costa Rica,2011,30,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.6 +7387,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +7388,Costa Rica,2011,30,C08-Calcium channel blockers,Million of national currency units,177.2 +7389,Costa Rica,2011,30,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.4 +7390,Costa Rica,2011,30,C03-Diuretics,"/capita, US$ exchange rate",0.3 +7391,Costa Rica,2011,30,N02-Analgesics,"/capita, US$ exchange rate",0.7 +7392,Costa Rica,2011,30,N06A-Antidepressants,"/capita, US$ exchange rate",0.6 +7393,Costa Rica,2011,30,C08-Calcium channel blockers,Million US$ at exchange rate,0.4 +7394,Costa Rica,2011,30,C-Cardiovascular system,Million of national currency units,4872.5 +7395,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,886.3 +7396,Costa Rica,2011,30,C-Cardiovascular system,Million US$ at exchange rate,9.6 +7397,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0 +7398,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.1 +7399,Costa Rica,2011,30,C02-Antihypertensives,Million of national currency units,347.1 +7400,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.0 +7401,Costa Rica,2011,30,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8 +7402,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.0 +7403,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1662.2 +7404,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4 +7405,Costa Rica,2011,30,J-Antiinfectives for systemic use,Million of national currency units,14773.7 +7406,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.0 +7407,Costa Rica,2011,30,J-Antiinfectives for systemic use,Million US$ at exchange rate,29.2 +7408,Costa Rica,2011,30,N02-Analgesics,"Million US$, purchasing power parity",4.6 +7409,Costa Rica,2011,30,C02-Antihypertensives,"/capita, US$ exchange rate",0.1 +7410,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +7411,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.3 +7412,Costa Rica,2011,30,C-Cardiovascular system,"/capita, US$ exchange rate",2.1 +7413,Costa Rica,2011,30,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.1 +7414,Costa Rica,2011,30,C10-Lipid modifying agents,Million US$ at exchange rate,3.9 +7415,Costa Rica,2011,30,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3 +7416,Costa Rica,2011,30,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.4 +7417,Costa Rica,2011,30,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.3 +7418,Costa Rica,2011,30,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.9 +7419,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.6 +7420,Costa Rica,2011,30,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.9 +7421,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +7422,Costa Rica,2011,30,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +7423,Costa Rica,2011,30,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.7 +7424,Costa Rica,2011,30,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +7425,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +7426,Costa Rica,2011,30,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.4 +7427,Costa Rica,2011,30,A02A-Antacids,Million US$ at exchange rate,1.5 +7428,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2218.4 +7429,Costa Rica,2011,30,C07-Beta blocking agents,Million US$ at exchange rate,1.0 +7430,Costa Rica,2011,30,A02A-Antacids,Million of national currency units,749.2 +7431,Costa Rica,2011,30,B-Blood and blood forming organs,Million of national currency units,11848.0 +7432,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.4 +7433,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,Million of national currency units,3103.4 +7434,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.6 +7435,Costa Rica,2011,30,C10-Lipid modifying agents,Million of national currency units,1973.1 +7436,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +7437,Costa Rica,2011,30,B-Blood and blood forming organs,Million US$ at exchange rate,23.4 +7438,Costa Rica,2011,30,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +7439,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4 +7440,Costa Rica,2011,30,N05B-Anxiolytics,Million US$ at exchange rate,0.5 +7441,Costa Rica,2011,30,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",1.8 +7442,Costa Rica,2011,30,C07-Beta blocking agents,Million of national currency units,501.3 +7443,Costa Rica,2011,30,A02A-Antacids,"/capita, US$ exchange rate",0.3 +7444,Costa Rica,2011,30,C-Cardiovascular system,"Million US$, purchasing power parity",14.5 +7445,Costa Rica,2011,30,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +7446,Costa Rica,2011,30,C03-Diuretics,"Million US$, purchasing power parity",2.0 +7447,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +7448,Costa Rica,2011,30,A10-Drugs used in diabetes,"Million US$, purchasing power parity",8.5 +7449,Costa Rica,2011,30,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1 +7450,Costa Rica,2011,30,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.6 +7451,Costa Rica,2011,30,C02-Antihypertensives,"Million US$, purchasing power parity",1.0 +7452,Costa Rica,2011,30,N06A-Antidepressants,Million of national currency units,1440.9 +7453,Costa Rica,2011,30,C07-Beta blocking agents,"/capita, US$ exchange rate",0.2 +7454,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1.8 +7455,Costa Rica,2011,30,N02-Analgesics,Million of national currency units,1540.2 +7456,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +7457,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.3 +7458,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.6 +7459,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4 +7460,Costa Rica,2011,30,N02-Analgesics,Million US$ at exchange rate,3.0 +7461,Costa Rica,2011,30,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7462,Costa Rica,2011,30,A10-Drugs used in diabetes,Million US$ at exchange rate,5.6 +7463,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0 +7464,Costa Rica,2011,30,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",16.5 +7465,Costa Rica,2011,30,N06A-Antidepressants,Million US$ at exchange rate,2.8 +7466,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.3 +7467,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4 +7468,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7 +7469,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,Million of national currency units,1661.5 +7470,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,996.1 +7471,Costa Rica,2011,30,C03-Diuretics,Million US$ at exchange rate,1.3 +7472,Costa Rica,2011,30,J01-Antibacterials for systemic use,Million of national currency units,5512.1 +7473,Costa Rica,2011,30,N05C-Hypnotics and sedatives,Million of national currency units,129.2 +7474,Costa Rica,2011,30,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.2 +7475,Costa Rica,2011,30,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",44.1 +7476,Costa Rica,2011,30,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2 +7477,Costa Rica,2011,30,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7478,Costa Rica,2011,30,C01A-Cardiac glycosides,Million of national currency units,132.1 +7479,Costa Rica,2011,30,A02A-Antacids,"Million US$, purchasing power parity",2.2 +7480,Costa Rica,2011,30,C03-Diuretics,"/capita, US$ purchasing power parity",0.4 +7481,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.0 +7482,Costa Rica,2011,30,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7483,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3 +7484,Costa Rica,2011,30,C03-Diuretics,Million of national currency units,671.9 +7485,Costa Rica,2011,30,N06A-Antidepressants,"Million US$, purchasing power parity",4.3 +7486,Costa Rica,2011,30,A10-Drugs used in diabetes,Million of national currency units,2834.0 +7487,Costa Rica,2011,30,N05B-Anxiolytics,Million of national currency units,277.6 +7488,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.6 +7489,Costa Rica,2011,30,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8 +7490,Costa Rica,2011,30,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.5 +7491,Costa Rica,2011,30,N02-Analgesics,"/capita, US$ purchasing power parity",1.0 +7492,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.3 +7493,Costa Rica,2010,32,C02-Antihypertensives,Million US$ at exchange rate,0.5 +7494,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6 +7495,Costa Rica,2010,32,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3 +7496,Costa Rica,2010,32,C07-Beta blocking agents,"Million US$, purchasing power parity",1.0 +7497,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +7498,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.4 +7499,Costa Rica,2010,32,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +7500,Costa Rica,2010,32,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.1 +7501,Costa Rica,2010,32,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.5 +7502,Costa Rica,2010,32,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",4.1 +7503,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +7504,Costa Rica,2010,32,C08-Calcium channel blockers,Million of national currency units,175.2 +7505,Costa Rica,2010,32,C08-Calcium channel blockers,Million US$ at exchange rate,0.3 +7506,Costa Rica,2010,32,C03-Diuretics,"/capita, US$ exchange rate",0.2 +7507,Costa Rica,2010,32,N02-Analgesics,"/capita, US$ exchange rate",0.6 +7508,Costa Rica,2010,32,N06A-Antidepressants,"/capita, US$ exchange rate",0.7 +7509,Costa Rica,2010,32,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.0 +7510,Costa Rica,2010,32,C-Cardiovascular system,Million of national currency units,4821.9 +7511,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,924.5 +7512,Costa Rica,2010,32,C-Cardiovascular system,Million US$ at exchange rate,9.2 +7513,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0 +7514,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0 +7515,Costa Rica,2010,32,C02-Antihypertensives,Million of national currency units,286.8 +7516,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7 +7517,Costa Rica,2010,32,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8 +7518,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1530.3 +7519,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4 +7520,Costa Rica,2010,32,J-Antiinfectives for systemic use,Million of national currency units,17239.8 +7521,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.2 +7522,Costa Rica,2010,32,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.8 +7523,Costa Rica,2010,32,N02-Analgesics,"Million US$, purchasing power parity",4.4 +7524,Costa Rica,2010,32,C02-Antihypertensives,"/capita, US$ exchange rate",0.1 +7525,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +7526,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,2.9 +7527,Costa Rica,2010,32,C-Cardiovascular system,"/capita, US$ exchange rate",2.0 +7528,Costa Rica,2010,32,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.8 +7529,Costa Rica,2010,32,C10-Lipid modifying agents,Million US$ at exchange rate,3.6 +7530,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +7531,Costa Rica,2010,32,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3 +7532,Costa Rica,2010,32,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.2 +7533,Costa Rica,2010,32,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.2 +7534,Costa Rica,2010,32,N06A-Antidepressants,"/capita, US$ purchasing power parity",1.1 +7535,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.1 +7536,Costa Rica,2010,32,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.8 +7537,Costa Rica,2010,32,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +7538,Costa Rica,2010,32,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +7539,Costa Rica,2010,32,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.7 +7540,Costa Rica,2010,32,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.5 +7541,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +7542,Costa Rica,2010,32,A02A-Antacids,Million US$ at exchange rate,1.2 +7543,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2333.6 +7544,Costa Rica,2010,32,C07-Beta blocking agents,Million US$ at exchange rate,0.6 +7545,Costa Rica,2010,32,A02A-Antacids,Million of national currency units,649.4 +7546,Costa Rica,2010,32,B-Blood and blood forming organs,Million of national currency units,11435.7 +7547,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6 +7548,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,55.7 +7549,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,Million of national currency units,3327.3 +7550,Costa Rica,2010,32,C10-Lipid modifying agents,Million of national currency units,1900.8 +7551,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.6 +7552,Costa Rica,2010,32,B-Blood and blood forming organs,Million US$ at exchange rate,21.7 +7553,Costa Rica,2010,32,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +7554,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.6 +7555,Costa Rica,2010,32,N05B-Anxiolytics,Million US$ at exchange rate,0.5 +7556,Costa Rica,2010,32,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",1.8 +7557,Costa Rica,2010,32,C07-Beta blocking agents,Million of national currency units,314.6 +7558,Costa Rica,2010,32,A02A-Antacids,"/capita, US$ exchange rate",0.3 +7559,Costa Rica,2010,32,C-Cardiovascular system,"Million US$, purchasing power parity",14.8 +7560,Costa Rica,2010,32,C02-Antihypertensives,"Million US$, purchasing power parity",0.9 +7561,Costa Rica,2010,32,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +7562,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0 +7563,Costa Rica,2010,32,C03-Diuretics,"Million US$, purchasing power parity",1.5 +7564,Costa Rica,2010,32,A10-Drugs used in diabetes,"Million US$, purchasing power parity",8.3 +7565,Costa Rica,2010,32,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1 +7566,Costa Rica,2010,32,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.6 +7567,Costa Rica,2010,32,N06A-Antidepressants,Million of national currency units,1617.5 +7568,Costa Rica,2010,32,C07-Beta blocking agents,"/capita, US$ exchange rate",0.1 +7569,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1.8 +7570,Costa Rica,2010,32,N02-Analgesics,Million of national currency units,1450.0 +7571,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +7572,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.2 +7573,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.0 +7574,Costa Rica,2010,32,N02-Analgesics,Million US$ at exchange rate,2.8 +7575,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.5 +7576,Costa Rica,2010,32,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7577,Costa Rica,2010,32,A10-Drugs used in diabetes,Million US$ at exchange rate,5.2 +7578,Costa Rica,2010,32,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.5 +7579,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.5 +7580,Costa Rica,2010,32,N06A-Antidepressants,Million US$ at exchange rate,3.1 +7581,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4 +7582,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4 +7583,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.6 +7584,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,Million of national currency units,1471.6 +7585,Costa Rica,2010,32,J01-Antibacterials for systemic use,Million of national currency units,6059.1 +7586,Costa Rica,2010,32,C03-Diuretics,Million US$ at exchange rate,0.9 +7587,Costa Rica,2010,32,N05C-Hypnotics and sedatives,Million of national currency units,166.7 +7588,Costa Rica,2010,32,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3 +7589,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1443.7 +7590,Costa Rica,2010,32,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",52.7 +7591,Costa Rica,2010,32,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2 +7592,Costa Rica,2010,32,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7593,Costa Rica,2010,32,C01A-Cardiac glycosides,Million of national currency units,157.0 +7594,Costa Rica,2010,32,A02A-Antacids,"Million US$, purchasing power parity",2.0 +7595,Costa Rica,2010,32,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +7596,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.7 +7597,Costa Rica,2010,32,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7598,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,2.8 +7599,Costa Rica,2010,32,C03-Diuretics,Million of national currency units,488.0 +7600,Costa Rica,2010,32,N05B-Anxiolytics,Million of national currency units,272.4 +7601,Costa Rica,2010,32,N06A-Antidepressants,"Million US$, purchasing power parity",4.9 +7602,Costa Rica,2010,32,A10-Drugs used in diabetes,Million of national currency units,2715.6 +7603,Costa Rica,2010,32,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.5 +7604,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.8 +7605,Costa Rica,2010,32,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8 +7606,Costa Rica,2010,32,N02-Analgesics,"/capita, US$ purchasing power parity",1.0 +7607,Costa Rica,2017,27,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.8 +7608,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1 +7609,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,5.3 +7610,Costa Rica,2017,27,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4 +7611,Costa Rica,2017,27,C07-Beta blocking agents,"Million US$, purchasing power parity",2.8 +7612,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +7613,Costa Rica,2017,27,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +7614,Costa Rica,2017,27,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7 +7615,Costa Rica,2017,27,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6 +7616,Costa Rica,2017,27,C02-Antihypertensives,Million US$ at exchange rate,1.1 +7617,Costa Rica,2017,27,C-Cardiovascular system,Million US$ at exchange rate,11.4 +7618,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2 +7619,Costa Rica,2017,27,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.6 +7620,Costa Rica,2017,27,B-Blood and blood forming organs,"Million US$, purchasing power parity",45.0 +7621,Costa Rica,2017,27,C08-Calcium channel blockers,Million of national currency units,364.0 +7622,Costa Rica,2017,27,N02-Analgesics,"/capita, US$ exchange rate",1.0 +7623,Costa Rica,2017,27,C03-Diuretics,"/capita, US$ exchange rate",0.1 +7624,Costa Rica,2017,27,C08-Calcium channel blockers,Million US$ at exchange rate,0.6 +7625,Costa Rica,2017,27,N06A-Antidepressants,"/capita, US$ exchange rate",0.5 +7626,Costa Rica,2017,27,C-Cardiovascular system,Million of national currency units,6494.7 +7627,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1838.9 +7628,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9 +7629,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.2 +7630,Costa Rica,2017,27,C02-Antihypertensives,Million of national currency units,625.9 +7631,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.6 +7632,Costa Rica,2017,27,N05B-Anxiolytics,"Million US$, purchasing power parity",1.2 +7633,Costa Rica,2017,27,J-Antiinfectives for systemic use,Million of national currency units,19558.1 +7634,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1901.9 +7635,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.7 +7636,Costa Rica,2017,27,N02-Analgesics,"Million US$, purchasing power parity",8.2 +7637,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",1.8 +7638,Costa Rica,2017,27,J-Antiinfectives for systemic use,Million US$ at exchange rate,34.5 +7639,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.4 +7640,Costa Rica,2017,27,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.5 +7641,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +7642,Costa Rica,2017,27,N05B-Anxiolytics,Million US$ at exchange rate,0.7 +7643,Costa Rica,2017,27,C02-Antihypertensives,"/capita, US$ exchange rate",0.2 +7644,Costa Rica,2017,27,C-Cardiovascular system,"/capita, US$ exchange rate",2.3 +7645,Costa Rica,2017,27,C10-Lipid modifying agents,Million US$ at exchange rate,3.4 +7646,Costa Rica,2017,27,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.1 +7647,Costa Rica,2017,27,N06A-Antidepressants,"Million US$, purchasing power parity",4.2 +7648,Costa Rica,2017,27,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.6 +7649,Costa Rica,2017,27,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.8 +7650,Costa Rica,2017,27,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.1 +7651,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.2 +7652,Costa Rica,2017,27,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.0 +7653,Costa Rica,2017,27,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +7654,Costa Rica,2017,27,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.6 +7655,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0 +7656,Costa Rica,2017,27,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +7657,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1 +7658,Costa Rica,2017,27,C07-Beta blocking agents,Million US$ at exchange rate,1.7 +7659,Costa Rica,2017,27,C10-Lipid modifying agents,Million of national currency units,1908.2 +7660,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2446.5 +7661,Costa Rica,2017,27,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.6 +7662,Costa Rica,2017,27,B-Blood and blood forming organs,Million of national currency units,15352.6 +7663,Costa Rica,2017,27,A02A-Antacids,Million of national currency units,1006.5 +7664,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.7 +7665,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7 +7666,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,76.7 +7667,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,Million of national currency units,3015.6 +7668,Costa Rica,2017,27,A02A-Antacids,Million US$ at exchange rate,1.8 +7669,Costa Rica,2017,27,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.7 +7670,Costa Rica,2017,27,B-Blood and blood forming organs,Million US$ at exchange rate,27.1 +7671,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.5 +7672,Costa Rica,2017,27,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +7673,Costa Rica,2017,27,A02A-Antacids,"/capita, US$ exchange rate",0.4 +7674,Costa Rica,2017,27,C-Cardiovascular system,"Million US$, purchasing power parity",19.0 +7675,Costa Rica,2017,27,C07-Beta blocking agents,Million of national currency units,941.0 +7676,Costa Rica,2017,27,C03-Diuretics,"Million US$, purchasing power parity",1.2 +7677,Costa Rica,2017,27,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +7678,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +7679,Costa Rica,2017,27,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.6 +7680,Costa Rica,2017,27,A10-Drugs used in diabetes,"Million US$, purchasing power parity",13.5 +7681,Costa Rica,2017,27,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2 +7682,Costa Rica,2017,27,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3 +7683,Costa Rica,2017,27,N06A-Antidepressants,Million of national currency units,1423.3 +7684,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.2 +7685,Costa Rica,2017,27,N02-Analgesics,Million of national currency units,2796.1 +7686,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6 +7687,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.8 +7688,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0 +7689,Costa Rica,2017,27,N02-Analgesics,Million US$ at exchange rate,4.9 +7690,Costa Rica,2017,27,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1 +7691,Costa Rica,2017,27,A10-Drugs used in diabetes,Million US$ at exchange rate,8.1 +7692,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.0 +7693,Costa Rica,2017,27,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.9 +7694,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",5.7 +7695,Costa Rica,2017,27,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.7 +7696,Costa Rica,2017,27,N06A-Antidepressants,Million US$ at exchange rate,2.5 +7697,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.1 +7698,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3 +7699,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,Million of national currency units,2033.8 +7700,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7 +7701,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1954.6 +7702,Costa Rica,2017,27,C03-Diuretics,Million US$ at exchange rate,0.7 +7703,Costa Rica,2017,27,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4 +7704,Costa Rica,2017,27,N05C-Hypnotics and sedatives,Million of national currency units,212.0 +7705,Costa Rica,2017,27,J01-Antibacterials for systemic use,Million of national currency units,4383.7 +7706,Costa Rica,2017,27,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",57.4 +7707,Costa Rica,2017,27,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +7708,Costa Rica,2017,27,C03-Diuretics,"/capita, US$ purchasing power parity",0.2 +7709,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.2 +7710,Costa Rica,2017,27,A02A-Antacids,"Million US$, purchasing power parity",3.0 +7711,Costa Rica,2017,27,C01A-Cardiac glycosides,Million of national currency units,185.4 +7712,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.4 +7713,Costa Rica,2017,27,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +7714,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.6 +7715,Costa Rica,2017,27,C03-Diuretics,Million of national currency units,405.0 +7716,Costa Rica,2017,27,A10-Drugs used in diabetes,Million of national currency units,4591.0 +7717,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",5.4 +7718,Costa Rica,2017,27,N05B-Anxiolytics,Million of national currency units,399.9 +7719,Costa Rica,2017,27,C02-Antihypertensives,"Million US$, purchasing power parity",1.8 +7720,Costa Rica,2017,27,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.1 +7721,Costa Rica,2017,27,N02-Analgesics,"/capita, US$ purchasing power parity",1.7 +7722,Croatia,2016,7,C07-Beta blocking agents,Million US$ at exchange rate,94.1 +7723,Croatia,2016,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,36.5 +7724,Croatia,2016,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",859.9 +7725,Croatia,2016,7,N-Nervous system,"/capita, US$ exchange rate",225.3 +7726,Croatia,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",383.2 +7727,Croatia,2016,7,A02A-Antacids,"/capita, US$ exchange rate",2.7 +7728,Croatia,2016,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",218.3 +7729,Croatia,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",118.3 +7730,Croatia,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1724.3 +7731,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.2 +7732,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,116.2 +7733,Croatia,2016,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",23.0 +7734,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0 +7735,Croatia,2016,7,C07-Beta blocking agents,Million of national currency units,85.0 +7736,Croatia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",260.0 +7737,Croatia,2016,7,A02A-Antacids,Million of national currency units,10.0 +7738,Croatia,2016,7,R-Respiratory system,"Million US$, purchasing power parity",802.0 +7739,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",58.1 +7740,Croatia,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,6424.2 +7741,Croatia,2016,7,N02-Analgesics,Million US$ at exchange rate,203.7 +7742,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,124.0 +7743,Croatia,2016,7,N05B-Anxiolytics,"Million US$, purchasing power parity",205.0 +7744,Croatia,2016,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",39.0 +7745,Croatia,2016,7,C-Cardiovascular system,Million of national currency units,777.0 +7746,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",294.1 +7747,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,112.0 +7748,Croatia,2016,7,N05C-Hypnotics and sedatives,Million of national currency units,33.0 +7749,Croatia,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1084.9 +7750,Croatia,2016,7,N-Nervous system,Million of national currency units,849.0 +7751,Croatia,2016,7,B-Blood and blood forming organs,Million of national currency units,446.0 +7752,Croatia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",91.8 +7753,Croatia,2016,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",52.3 +7754,Croatia,2016,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",43.8 +7755,Croatia,2016,7,N02-Analgesics,Million of national currency units,184.0 +7756,Croatia,2016,7,N06A-Antidepressants,Million of national currency units,82.0 +7757,Croatia,2016,7,C02-Antihypertensives,Million of national currency units,43.0 +7758,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",728.5 +7759,Croatia,2016,7,C10-Lipid modifying agents,Million of national currency units,147.0 +7760,Croatia,2016,7,R03-Drugs for obstructive airway diseases,Million of national currency units,219.0 +7761,Croatia,2016,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.7 +7762,Croatia,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,493.7 +7763,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",135.9 +7764,Croatia,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",57.6 +7765,Croatia,2016,7,N06A-Antidepressants,Million US$ at exchange rate,90.8 +7766,Croatia,2016,7,C03-Diuretics,"Million US$, purchasing power parity",115.8 +7767,Croatia,2016,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",49.1 +7768,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",86.8 +7769,Croatia,2016,7,A02A-Antacids,Million US$ at exchange rate,11.1 +7770,Croatia,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",3098.4 +7771,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.7 +7772,Croatia,2016,7,M-Musculo-skeletal system,Million of national currency units,217.0 +7773,Croatia,2016,7,C02-Antihypertensives,"Million US$, purchasing power parity",95.8 +7774,Croatia,2016,7,N-Nervous system,Million US$ at exchange rate,939.9 +7775,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.2 +7776,Croatia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.8 +7777,Croatia,2016,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",206.1 +7778,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.9 +7779,Croatia,2016,7,N02-Analgesics,"/capita, US$ purchasing power parity",98.2 +7780,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",70.5 +7781,Croatia,2016,7,C02-Antihypertensives,Million US$ at exchange rate,47.6 +7782,Croatia,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",192.2 +7783,Croatia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",413.3 +7784,Croatia,2016,7,C-Cardiovascular system,Million US$ at exchange rate,860.2 +7785,Croatia,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",1539.7 +7786,Croatia,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",115.9 +7787,Croatia,2016,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,242.4 +7788,Croatia,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",414.9 +7789,Croatia,2016,7,C10-Lipid modifying agents,Million US$ at exchange rate,162.7 +7790,Croatia,2016,7,Total pharmaceutical sales,Million of national currency units,5803.0 +7791,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",59.8 +7792,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,105.0 +7793,Croatia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",79.9 +7794,Croatia,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",238.1 +7795,Croatia,2016,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",327.5 +7796,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,362.0 +7797,Croatia,2016,7,A02A-Antacids,"/capita, US$ purchasing power parity",5.3 +7798,Croatia,2016,7,C03-Diuretics,Million US$ at exchange rate,57.6 +7799,Croatia,2016,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",102.4 +7800,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6 +7801,Croatia,2016,7,A10-Drugs used in diabetes,% of total sales,6.7 +7802,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.1 +7803,Croatia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",129.2 +7804,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",116.9 +7805,Croatia,2016,7,C01A-Cardiac glycosides,Million US$ at exchange rate,5.5 +7806,Croatia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",205.4 +7807,Croatia,2016,7,N02-Analgesics,"Million US$, purchasing power parity",409.9 +7808,Croatia,2016,7,C08-Calcium channel blockers,Million of national currency units,98.0 +7809,Croatia,2016,7,C03-Diuretics,"/capita, US$ exchange rate",13.8 +7810,Croatia,2016,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.4 +7811,Croatia,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",1731.0 +7812,Croatia,2016,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.2 +7813,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.5 +7814,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",233.9 +7815,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",35.0 +7816,Croatia,2016,7,N05B-Anxiolytics,"/capita, US$ exchange rate",24.4 +7817,Croatia,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,172.0 +7818,Croatia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",17.6 +7819,Croatia,2016,7,M-Musculo-skeletal system,% of total sales,3.7 +7820,Croatia,2016,7,C10-Lipid modifying agents,% of total sales,2.5 +7821,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +7822,Croatia,2016,7,C-Cardiovascular system,% of total sales,13.4 +7823,Croatia,2016,7,N06A-Antidepressants,% of total sales,1.4 +7824,Croatia,2016,7,N02-Analgesics,% of total sales,3.2 +7825,Croatia,2016,7,C02-Antihypertensives,% of total sales,0.7 +7826,Croatia,2016,7,C08-Calcium channel blockers,% of total sales,1.7 +7827,Croatia,2016,7,G-Genito urinary system and sex hormones,% of total sales,3.0 +7828,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +7829,Croatia,2016,7,A-Alimentary tract and metabolism,% of total sales,13.3 +7830,Croatia,2016,7,J-Antiinfectives for systemic use,% of total sales,8.4 +7831,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9 +7832,Croatia,2016,7,R-Respiratory system,% of total sales,6.2 +7833,Croatia,2016,7,B-Blood and blood forming organs,% of total sales,7.7 +7834,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +7835,Croatia,2016,7,N05B-Anxiolytics,% of total sales,1.6 +7836,Croatia,2016,7,C01A-Cardiac glycosides,% of total sales,0.1 +7837,Croatia,2016,7,C03-Diuretics,% of total sales,0.9 +7838,Croatia,2016,7,N05C-Hypnotics and sedatives,% of total sales,0.6 +7839,Croatia,2016,7,J01-Antibacterials for systemic use,% of total sales,5.2 +7840,Croatia,2016,7,N-Nervous system,% of total sales,14.6 +7841,Croatia,2016,7,C07-Beta blocking agents,% of total sales,1.5 +7842,Croatia,2016,7,R03-Drugs for obstructive airway diseases,% of total sales,3.8 +7843,Croatia,2016,7,N05B-Anxiolytics,Million of national currency units,92.0 +7844,Croatia,2016,7,A02A-Antacids,% of total sales,0.2 +7845,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.6 +7846,Croatia,2016,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",26.0 +7847,Croatia,2016,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",73.5 +7848,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",32.6 +7849,Croatia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",45.6 +7850,Croatia,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",993.6 +7851,Croatia,2016,7,N05B-Anxiolytics,Million US$ at exchange rate,101.8 +7852,Croatia,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,190.4 +7853,Croatia,2016,7,N06A-Antidepressants,"/capita, US$ exchange rate",21.8 +7854,Croatia,2016,7,N02-Analgesics,"/capita, US$ exchange rate",48.8 +7855,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,146.1 +7856,Croatia,2016,7,C02-Antihypertensives,"/capita, US$ exchange rate",11.4 +7857,Croatia,2016,7,A10-Drugs used in diabetes,Million US$ at exchange rate,427.3 +7858,Croatia,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",453.3 +7859,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,327.0 +7860,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",487.9 +7861,Croatia,2016,7,C07-Beta blocking agents,"/capita, US$ exchange rate",22.6 +7862,Croatia,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,240.2 +7863,Croatia,2016,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.1 +7864,Croatia,2016,7,R-Respiratory system,Million US$ at exchange rate,398.5 +7865,Croatia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",160.7 +7866,Croatia,2016,7,J01-Antibacterials for systemic use,Million of national currency units,301.0 +7867,Croatia,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,856.8 +7868,Croatia,2016,7,C07-Beta blocking agents,"Million US$, purchasing power parity",189.4 +7869,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0 +7870,Croatia,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",12928.0 +7871,Croatia,2016,7,J-Antiinfectives for systemic use,Million of national currency units,487.0 +7872,Croatia,2016,7,A-Alimentary tract and metabolism,Million of national currency units,774.0 +7873,Croatia,2016,7,N06A-Antidepressants,"Million US$, purchasing power parity",182.7 +7874,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.5 +7875,Croatia,2016,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3 +7876,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",56.1 +7877,Croatia,2016,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",78.5 +7878,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",249.5 +7879,Croatia,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",483.4 +7880,Croatia,2016,7,A10-Drugs used in diabetes,Million of national currency units,386.0 +7881,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,132.0 +7882,Croatia,2016,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",670.6 +7883,Croatia,2016,7,A02A-Antacids,"Million US$, purchasing power parity",22.3 +7884,Croatia,2016,7,C01A-Cardiac glycosides,Million of national currency units,5.0 +7885,Croatia,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",206.2 +7886,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.7 +7887,Croatia,2016,7,C08-Calcium channel blockers,Million US$ at exchange rate,108.5 +7888,Croatia,2016,7,C03-Diuretics,"/capita, US$ purchasing power parity",27.8 +7889,Croatia,2016,7,C03-Diuretics,Million of national currency units,52.0 +7890,Croatia,2016,7,R-Respiratory system,"/capita, US$ exchange rate",95.5 +7891,Croatia,2016,7,R-Respiratory system,Million of national currency units,360.0 +7892,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",174.6 +7893,Croatia,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,539.1 +7894,Croatia,2016,7,N-Nervous system,"Million US$, purchasing power parity",1891.4 +7895,Croatia,2015,8,C07-Beta blocking agents,Million US$ at exchange rate,97.8 +7896,Croatia,2015,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",25.0 +7897,Croatia,2015,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",737.9 +7898,Croatia,2015,8,N-Nervous system,"/capita, US$ exchange rate",212.0 +7899,Croatia,2015,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",353.9 +7900,Croatia,2015,8,A02A-Antacids,"/capita, US$ exchange rate",2.6 +7901,Croatia,2015,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",218.8 +7902,Croatia,2015,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",92.7 +7903,Croatia,2015,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1544.5 +7904,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.4 +7905,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,106.6 +7906,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0 +7907,Croatia,2015,8,C07-Beta blocking agents,Million of national currency units,89.0 +7908,Croatia,2015,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",209.5 +7909,Croatia,2015,8,A02A-Antacids,Million of national currency units,10.0 +7910,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",56.7 +7911,Croatia,2015,8,R-Respiratory system,"Million US$, purchasing power parity",746.5 +7912,Croatia,2015,8,Total pharmaceutical sales,Million US$ at exchange rate,5786.3 +7913,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,125.2 +7914,Croatia,2015,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",43.3 +7915,Croatia,2015,8,C-Cardiovascular system,Million of national currency units,782.0 +7916,Croatia,2015,8,N05B-Anxiolytics,"Million US$, purchasing power parity",195.2 +7917,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,114.0 +7918,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",276.7 +7919,Croatia,2015,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",881.6 +7920,Croatia,2015,8,N-Nervous system,Million of national currency units,812.0 +7921,Croatia,2015,8,B-Blood and blood forming organs,Million of national currency units,355.0 +7922,Croatia,2015,8,N02-Analgesics,Million US$ at exchange rate,205.4 +7923,Croatia,2015,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",52.0 +7924,Croatia,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",84.1 +7925,Croatia,2015,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.3 +7926,Croatia,2015,8,N02-Analgesics,Million of national currency units,187.0 +7927,Croatia,2015,8,N06A-Antidepressants,Million of national currency units,81.0 +7928,Croatia,2015,8,C02-Antihypertensives,Million of national currency units,49.0 +7929,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",682.2 +7930,Croatia,2015,8,C10-Lipid modifying agents,Million of national currency units,166.0 +7931,Croatia,2015,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.5 +7932,Croatia,2015,8,B-Blood and blood forming organs,Million US$ at exchange rate,390.0 +7933,Croatia,2015,8,R03-Drugs for obstructive airway diseases,Million of national currency units,217.0 +7934,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",135.1 +7935,Croatia,2015,8,N06A-Antidepressants,Million US$ at exchange rate,89.0 +7936,Croatia,2015,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",53.3 +7937,Croatia,2015,8,C03-Diuretics,"Million US$, purchasing power parity",103.0 +7938,Croatia,2015,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",46.4 +7939,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",83.0 +7940,Croatia,2015,8,A02A-Antacids,Million US$ at exchange rate,11.0 +7941,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,18.7 +7942,Croatia,2015,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,34.1 +7943,Croatia,2015,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2685.0 +7944,Croatia,2015,8,M-Musculo-skeletal system,Million of national currency units,204.0 +7945,Croatia,2015,8,C02-Antihypertensives,"Million US$, purchasing power parity",105.1 +7946,Croatia,2015,8,N-Nervous system,Million US$ at exchange rate,892.1 +7947,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.4 +7948,Croatia,2015,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",175.4 +7949,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",25.3 +7950,Croatia,2015,8,N02-Analgesics,"/capita, US$ purchasing power parity",95.3 +7951,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",65.8 +7952,Croatia,2015,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",367.0 +7953,Croatia,2015,8,C02-Antihypertensives,Million US$ at exchange rate,53.8 +7954,Croatia,2015,8,R-Respiratory system,"/capita, US$ purchasing power parity",177.4 +7955,Croatia,2015,8,C-Cardiovascular system,Million US$ at exchange rate,859.1 +7956,Croatia,2015,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1375.1 +7957,Croatia,2015,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",104.0 +7958,Croatia,2015,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,238.4 +7959,Croatia,2015,8,C10-Lipid modifying agents,Million US$ at exchange rate,182.4 +7960,Croatia,2015,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.1 +7961,Croatia,2015,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",398.6 +7962,Croatia,2015,8,Total pharmaceutical sales,Million of national currency units,5267.0 +7963,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",58.1 +7964,Croatia,2015,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",77.5 +7965,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,97.0 +7966,Croatia,2015,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",181.0 +7967,Croatia,2015,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",356.1 +7968,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,349.4 +7969,Croatia,2015,8,A02A-Antacids,"/capita, US$ purchasing power parity",5.1 +7970,Croatia,2015,8,C03-Diuretics,Million US$ at exchange rate,52.7 +7971,Croatia,2015,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",89.8 +7972,Croatia,2015,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",107.3 +7973,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0 +7974,Croatia,2015,8,A10-Drugs used in diabetes,% of total sales,6.5 +7975,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +7976,Croatia,2015,8,C01A-Cardiac glycosides,Million US$ at exchange rate,5.5 +7977,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",110.6 +7978,Croatia,2015,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",188.0 +7979,Croatia,2015,8,N02-Analgesics,"Million US$, purchasing power parity",401.1 +7980,Croatia,2015,8,C03-Diuretics,"/capita, US$ exchange rate",12.5 +7981,Croatia,2015,8,C08-Calcium channel blockers,Million of national currency units,102.0 +7982,Croatia,2015,8,C-Cardiovascular system,"Million US$, purchasing power parity",1677.5 +7983,Croatia,2015,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.4 +7984,Croatia,2015,8,N05B-Anxiolytics,Million of national currency units,91.0 +7985,Croatia,2015,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,326.3 +7986,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.7 +7987,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",33.7 +7988,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.1 +7989,Croatia,2015,8,N05B-Anxiolytics,"/capita, US$ exchange rate",23.8 +7990,Croatia,2015,8,G-Genito urinary system and sex hormones,Million of national currency units,165.0 +7991,Croatia,2015,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",15.8 +7992,Croatia,2015,8,M-Musculo-skeletal system,% of total sales,3.9 +7993,Croatia,2015,8,C10-Lipid modifying agents,% of total sales,3.2 +7994,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +7995,Croatia,2015,8,N06A-Antidepressants,% of total sales,1.5 +7996,Croatia,2015,8,C-Cardiovascular system,% of total sales,14.8 +7997,Croatia,2015,8,N02-Analgesics,% of total sales,3.6 +7998,Croatia,2015,8,C02-Antihypertensives,% of total sales,0.9 +7999,Croatia,2015,8,C08-Calcium channel blockers,% of total sales,1.9 +8000,Croatia,2015,8,G-Genito urinary system and sex hormones,% of total sales,3.1 +8001,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +8002,Croatia,2015,8,J-Antiinfectives for systemic use,% of total sales,7.8 +8003,Croatia,2015,8,A-Alimentary tract and metabolism,% of total sales,13.7 +8004,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.2 +8005,Croatia,2015,8,R-Respiratory system,% of total sales,6.6 +8006,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +8007,Croatia,2015,8,B-Blood and blood forming organs,% of total sales,6.7 +8008,Croatia,2015,8,N05B-Anxiolytics,% of total sales,1.7 +8009,Croatia,2015,8,C03-Diuretics,% of total sales,0.9 +8010,Croatia,2015,8,C01A-Cardiac glycosides,% of total sales,0.1 +8011,Croatia,2015,8,N05C-Hypnotics and sedatives,% of total sales,0.6 +8012,Croatia,2015,8,J01-Antibacterials for systemic use,% of total sales,5.6 +8013,Croatia,2015,8,N-Nervous system,% of total sales,15.4 +8014,Croatia,2015,8,R03-Drugs for obstructive airway diseases,% of total sales,4.1 +8015,Croatia,2015,8,C07-Beta blocking agents,% of total sales,1.7 +8016,Croatia,2015,8,A02A-Antacids,% of total sales,0.2 +8017,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",36.5 +8018,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",32.1 +8019,Croatia,2015,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",26.6 +8020,Croatia,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",43.1 +8021,Croatia,2015,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",761.5 +8022,Croatia,2015,8,N05B-Anxiolytics,Million US$ at exchange rate,100.0 +8023,Croatia,2015,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",66.5 +8024,Croatia,2015,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,181.3 +8025,Croatia,2015,8,N02-Analgesics,"/capita, US$ exchange rate",48.8 +8026,Croatia,2015,8,N06A-Antidepressants,"/capita, US$ exchange rate",21.1 +8027,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,141.7 +8028,Croatia,2015,8,C02-Antihypertensives,"/capita, US$ exchange rate",12.8 +8029,Croatia,2015,8,A10-Drugs used in diabetes,Million US$ at exchange rate,377.9 +8030,Croatia,2015,8,N-Nervous system,"/capita, US$ purchasing power parity",413.9 +8031,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,318.0 +8032,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",465.5 +8033,Croatia,2015,8,M-Musculo-skeletal system,Million US$ at exchange rate,224.1 +8034,Croatia,2015,8,C07-Beta blocking agents,"/capita, US$ exchange rate",23.2 +8035,Croatia,2015,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.7 +8036,Croatia,2015,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",151.4 +8037,Croatia,2015,8,R-Respiratory system,Million US$ at exchange rate,382.3 +8038,Croatia,2015,8,J01-Antibacterials for systemic use,Million of national currency units,297.0 +8039,Croatia,2015,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,791.0 +8040,Croatia,2015,8,C07-Beta blocking agents,"Million US$, purchasing power parity",190.9 +8041,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.0 +8042,Croatia,2015,8,N05C-Hypnotics and sedatives,Million of national currency units,31.0 +8043,Croatia,2015,8,Total pharmaceutical sales,"Million US$, purchasing power parity",11298.4 +8044,Croatia,2015,8,A-Alimentary tract and metabolism,Million of national currency units,720.0 +8045,Croatia,2015,8,J-Antiinfectives for systemic use,Million of national currency units,411.0 +8046,Croatia,2015,8,N06A-Antidepressants,"Million US$, purchasing power parity",173.8 +8047,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,69.2 +8048,Croatia,2015,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3 +8049,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",49.4 +8050,Croatia,2015,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",84.6 +8051,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",244.5 +8052,Croatia,2015,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",437.6 +8053,Croatia,2015,8,A10-Drugs used in diabetes,Million of national currency units,344.0 +8054,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,129.0 +8055,Croatia,2015,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",637.1 +8056,Croatia,2015,8,A02A-Antacids,"Million US$, purchasing power parity",21.5 +8057,Croatia,2015,8,C01A-Cardiac glycosides,Million of national currency units,5.0 +8058,Croatia,2015,8,C-Cardiovascular system,"/capita, US$ exchange rate",204.2 +8059,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.8 +8060,Croatia,2015,8,C08-Calcium channel blockers,Million US$ at exchange rate,112.1 +8061,Croatia,2015,8,C03-Diuretics,Million of national currency units,48.0 +8062,Croatia,2015,8,R-Respiratory system,"/capita, US$ exchange rate",90.9 +8063,Croatia,2015,8,R-Respiratory system,Million of national currency units,348.0 +8064,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",162.1 +8065,Croatia,2015,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,451.5 +8066,Croatia,2015,8,C03-Diuretics,"/capita, US$ purchasing power parity",24.5 +8067,Croatia,2015,8,N-Nervous system,"Million US$, purchasing power parity",1741.8 +8068,Croatia,2014,8,C07-Beta blocking agents,Million US$ at exchange rate,119.3 +8069,Croatia,2014,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",26.1 +8070,Croatia,2014,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",674.0 +8071,Croatia,2014,8,N-Nervous system,"/capita, US$ exchange rate",246.0 +8072,Croatia,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",340.2 +8073,Croatia,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",93.8 +8074,Croatia,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1471.4 +8075,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.0 +8076,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,118.0 +8077,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0 +8078,Croatia,2014,8,C07-Beta blocking agents,Million of national currency units,91.0 +8079,Croatia,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",204.8 +8080,Croatia,2014,8,A02A-Antacids,Million of national currency units,10.0 +8081,Croatia,2014,8,R-Respiratory system,"Million US$, purchasing power parity",686.8 +8082,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",65.3 +8083,Croatia,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,6561.7 +8084,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,165.2 +8085,Croatia,2014,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.8 +8086,Croatia,2014,8,C-Cardiovascular system,Million of national currency units,778.0 +8087,Croatia,2014,8,N-Nervous system,Million of national currency units,795.0 +8088,Croatia,2014,8,N05B-Anxiolytics,"Million US$, purchasing power parity",191.4 +8089,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,126.0 +8090,Croatia,2014,8,A02A-Antacids,"/capita, US$ exchange rate",3.1 +8091,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",267.9 +8092,Croatia,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",867.5 +8093,Croatia,2014,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",57.2 +8094,Croatia,2014,8,B-Blood and blood forming organs,Million of national currency units,303.0 +8095,Croatia,2014,8,N02-Analgesics,Million US$ at exchange rate,242.5 +8096,Croatia,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",80.3 +8097,Croatia,2014,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.2 +8098,Croatia,2014,8,N02-Analgesics,Million of national currency units,185.0 +8099,Croatia,2014,8,N06A-Antidepressants,Million of national currency units,82.0 +8100,Croatia,2014,8,C02-Antihypertensives,Million of national currency units,52.0 +8101,Croatia,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",162.1 +8102,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",686.8 +8103,Croatia,2014,8,C10-Lipid modifying agents,Million of national currency units,148.0 +8104,Croatia,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,397.2 +8105,Croatia,2014,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.5 +8106,Croatia,2014,8,R03-Drugs for obstructive airway diseases,Million of national currency units,211.0 +8107,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",129.7 +8108,Croatia,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",61.6 +8109,Croatia,2014,8,C03-Diuretics,"Million US$, purchasing power parity",95.7 +8110,Croatia,2014,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",45.2 +8111,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",99.9 +8112,Croatia,2014,8,A02A-Antacids,Million US$ at exchange rate,13.1 +8113,Croatia,2014,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,39.3 +8114,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.0 +8115,Croatia,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2512.8 +8116,Croatia,2014,8,M-Musculo-skeletal system,Million of national currency units,199.0 +8117,Croatia,2014,8,C02-Antihypertensives,"Million US$, purchasing power parity",110.6 +8118,Croatia,2014,8,N-Nervous system,Million US$ at exchange rate,1042.1 +8119,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",18.9 +8120,Croatia,2014,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",159.1 +8121,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.8 +8122,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",63.2 +8123,Croatia,2014,8,N02-Analgesics,"/capita, US$ purchasing power parity",92.9 +8124,Croatia,2014,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",242.4 +8125,Croatia,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",347.3 +8126,Croatia,2014,8,C02-Antihypertensives,Million US$ at exchange rate,68.2 +8127,Croatia,2014,8,C-Cardiovascular system,Million US$ at exchange rate,1019.8 +8128,Croatia,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1549.0 +8129,Croatia,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",99.9 +8130,Croatia,2014,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,276.6 +8131,Croatia,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.3 +8132,Croatia,2014,8,C10-Lipid modifying agents,Million US$ at exchange rate,194.0 +8133,Croatia,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",390.5 +8134,Croatia,2014,8,Total pharmaceutical sales,Million of national currency units,5006.0 +8135,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",63.2 +8136,Croatia,2014,8,N06A-Antidepressants,Million US$ at exchange rate,107.5 +8137,Croatia,2014,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",89.1 +8138,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,90.0 +8139,Croatia,2014,8,N05C-Hypnotics and sedatives,Million of national currency units,30.0 +8140,Croatia,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",152.1 +8141,Croatia,2014,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",314.7 +8142,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,423.4 +8143,Croatia,2014,8,A02A-Antacids,"/capita, US$ purchasing power parity",5.0 +8144,Croatia,2014,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",98.1 +8145,Croatia,2014,8,C03-Diuretics,Million US$ at exchange rate,59.0 +8146,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.5 +8147,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +8148,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",105.9 +8149,Croatia,2014,8,C01A-Cardiac glycosides,Million US$ at exchange rate,6.6 +8150,Croatia,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",126.2 +8151,Croatia,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",214.1 +8152,Croatia,2014,8,A10-Drugs used in diabetes,% of total sales,6.3 +8153,Croatia,2014,8,N02-Analgesics,"Million US$, purchasing power parity",393.4 +8154,Croatia,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",1654.3 +8155,Croatia,2014,8,C03-Diuretics,"/capita, US$ exchange rate",13.9 +8156,Croatia,2014,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.7 +8157,Croatia,2014,8,N05B-Anxiolytics,Million of national currency units,90.0 +8158,Croatia,2014,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.5 +8159,Croatia,2014,8,C08-Calcium channel blockers,Million of national currency units,114.0 +8160,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.0 +8161,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",191.4 +8162,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",39.0 +8163,Croatia,2014,8,N05B-Anxiolytics,"/capita, US$ exchange rate",27.8 +8164,Croatia,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,160.0 +8165,Croatia,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",15.1 +8166,Croatia,2014,8,M-Musculo-skeletal system,% of total sales,4.0 +8167,Croatia,2014,8,C10-Lipid modifying agents,% of total sales,3.0 +8168,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +8169,Croatia,2014,8,C-Cardiovascular system,% of total sales,15.5 +8170,Croatia,2014,8,N06A-Antidepressants,% of total sales,1.6 +8171,Croatia,2014,8,N02-Analgesics,% of total sales,3.7 +8172,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +8173,Croatia,2014,8,C02-Antihypertensives,% of total sales,1.0 +8174,Croatia,2014,8,G-Genito urinary system and sex hormones,% of total sales,3.2 +8175,Croatia,2014,8,C08-Calcium channel blockers,% of total sales,2.3 +8176,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.5 +8177,Croatia,2014,8,A-Alimentary tract and metabolism,% of total sales,13.8 +8178,Croatia,2014,8,J-Antiinfectives for systemic use,% of total sales,8.2 +8179,Croatia,2014,8,R-Respiratory system,% of total sales,6.5 +8180,Croatia,2014,8,B-Blood and blood forming organs,% of total sales,6.1 +8181,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +8182,Croatia,2014,8,N05B-Anxiolytics,% of total sales,1.8 +8183,Croatia,2014,8,C03-Diuretics,% of total sales,0.9 +8184,Croatia,2014,8,C01A-Cardiac glycosides,% of total sales,0.1 +8185,Croatia,2014,8,N05C-Hypnotics and sedatives,% of total sales,0.6 +8186,Croatia,2014,8,J01-Antibacterials for systemic use,% of total sales,5.8 +8187,Croatia,2014,8,N-Nervous system,% of total sales,15.9 +8188,Croatia,2014,8,R03-Drugs for obstructive airway diseases,% of total sales,4.2 +8189,Croatia,2014,8,C07-Beta blocking agents,% of total sales,1.8 +8190,Croatia,2014,8,A02A-Antacids,% of total sales,0.2 +8191,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",34.0 +8192,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.6 +8193,Croatia,2014,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",35.3 +8194,Croatia,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.5 +8195,Croatia,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",644.3 +8196,Croatia,2014,8,N05B-Anxiolytics,Million US$ at exchange rate,118.0 +8197,Croatia,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,209.7 +8198,Croatia,2014,8,N02-Analgesics,"/capita, US$ exchange rate",57.2 +8199,Croatia,2014,8,N06A-Antidepressants,"/capita, US$ exchange rate",25.4 +8200,Croatia,2014,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",63.8 +8201,Croatia,2014,8,C02-Antihypertensives,"/capita, US$ exchange rate",16.1 +8202,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,165.2 +8203,Croatia,2014,8,A10-Drugs used in diabetes,Million US$ at exchange rate,415.5 +8204,Croatia,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",399.0 +8205,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,323.0 +8206,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",448.6 +8207,Croatia,2014,8,C07-Beta blocking agents,"/capita, US$ exchange rate",28.2 +8208,Croatia,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,260.8 +8209,Croatia,2014,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.6 +8210,Croatia,2014,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",144.6 +8211,Croatia,2014,8,R-Respiratory system,Million US$ at exchange rate,423.4 +8212,Croatia,2014,8,J01-Antibacterials for systemic use,Million of national currency units,288.0 +8213,Croatia,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,907.0 +8214,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0 +8215,Croatia,2014,8,C07-Beta blocking agents,"Million US$, purchasing power parity",193.5 +8216,Croatia,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",10644.2 +8217,Croatia,2014,8,J-Antiinfectives for systemic use,Million of national currency units,408.0 +8218,Croatia,2014,8,A-Alimentary tract and metabolism,Million of national currency units,692.0 +8219,Croatia,2014,8,N06A-Antidepressants,"Million US$, purchasing power parity",174.4 +8220,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,80.0 +8221,Croatia,2014,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.5 +8222,Croatia,2014,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",74.3 +8223,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",45.2 +8224,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",267.9 +8225,Croatia,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",423.1 +8226,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,126.0 +8227,Croatia,2014,8,A10-Drugs used in diabetes,Million of national currency units,317.0 +8228,Croatia,2014,8,R-Respiratory system,"/capita, US$ exchange rate",99.9 +8229,Croatia,2014,8,A02A-Antacids,"Million US$, purchasing power parity",21.3 +8230,Croatia,2014,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",612.4 +8231,Croatia,2014,8,C01A-Cardiac glycosides,Million of national currency units,5.0 +8232,Croatia,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",240.7 +8233,Croatia,2014,8,C08-Calcium channel blockers,Million US$ at exchange rate,149.4 +8234,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",39.0 +8235,Croatia,2014,8,C03-Diuretics,Million of national currency units,45.0 +8236,Croatia,2014,8,R-Respiratory system,Million of national currency units,323.0 +8237,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",162.1 +8238,Croatia,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,534.8 +8239,Croatia,2014,8,C03-Diuretics,"/capita, US$ purchasing power parity",22.6 +8240,Croatia,2014,8,N-Nervous system,"Million US$, purchasing power parity",1690.4 +8241,Croatia,2013,9,C07-Beta blocking agents,Million US$ at exchange rate,124.1 +8242,Croatia,2013,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",26.3 +8243,Croatia,2013,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",636.5 +8244,Croatia,2013,9,N-Nervous system,"/capita, US$ exchange rate",251.8 +8245,Croatia,2013,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",339.3 +8246,Croatia,2013,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",89.1 +8247,Croatia,2013,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1502.6 +8248,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.6 +8249,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,117.5 +8250,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0 +8251,Croatia,2013,9,C07-Beta blocking agents,Million of national currency units,94.0 +8252,Croatia,2013,9,R-Respiratory system,"Million US$, purchasing power parity",699.7 +8253,Croatia,2013,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",212.5 +8254,Croatia,2013,9,A02A-Antacids,Million of national currency units,9.0 +8255,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",63.6 +8256,Croatia,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,6845.2 +8257,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,215.3 +8258,Croatia,2013,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",69.5 +8259,Croatia,2013,9,C-Cardiovascular system,Million of national currency units,946.0 +8260,Croatia,2013,9,N-Nervous system,Million of national currency units,811.0 +8261,Croatia,2013,9,N05B-Anxiolytics,"Million US$, purchasing power parity",185.5 +8262,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,163.0 +8263,Croatia,2013,9,A02A-Antacids,"/capita, US$ exchange rate",2.8 +8264,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",248.7 +8265,Croatia,2013,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",904.1 +8266,Croatia,2013,9,B-Blood and blood forming organs,Million of national currency units,287.0 +8267,Croatia,2013,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",60.9 +8268,Croatia,2013,9,N02-Analgesics,Million US$ at exchange rate,249.6 +8269,Croatia,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",79.8 +8270,Croatia,2013,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.6 +8271,Croatia,2013,9,N02-Analgesics,Million of national currency units,189.0 +8272,Croatia,2013,9,N06A-Antidepressants,Million of national currency units,84.0 +8273,Croatia,2013,9,C02-Antihypertensives,Million of national currency units,53.0 +8274,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",687.0 +8275,Croatia,2013,9,C10-Lipid modifying agents,Million of national currency units,224.0 +8276,Croatia,2013,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.0 +8277,Croatia,2013,9,B-Blood and blood forming organs,Million US$ at exchange rate,379.0 +8278,Croatia,2013,9,R03-Drugs for obstructive airway diseases,Million of national currency units,205.0 +8279,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",130.7 +8280,Croatia,2013,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",64.6 +8281,Croatia,2013,9,C03-Diuretics,"Million US$, purchasing power parity",92.7 +8282,Croatia,2013,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",43.6 +8283,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",101.2 +8284,Croatia,2013,9,A02A-Antacids,Million US$ at exchange rate,11.9 +8285,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,23.8 +8286,Croatia,2013,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,38.3 +8287,Croatia,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2567.4 +8288,Croatia,2013,9,M-Musculo-skeletal system,Million of national currency units,208.0 +8289,Croatia,2013,9,C02-Antihypertensives,"Million US$, purchasing power parity",111.7 +8290,Croatia,2013,9,N-Nervous system,Million US$ at exchange rate,1071.1 +8291,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.2 +8292,Croatia,2013,9,R-Respiratory system,"/capita, US$ purchasing power parity",164.5 +8293,Croatia,2013,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",149.6 +8294,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.6 +8295,Croatia,2013,9,N02-Analgesics,"/capita, US$ purchasing power parity",93.6 +8296,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",58.5 +8297,Croatia,2013,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",259.2 +8298,Croatia,2013,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",353.2 +8299,Croatia,2013,9,C02-Antihypertensives,Million US$ at exchange rate,70.0 +8300,Croatia,2013,9,C-Cardiovascular system,Million US$ at exchange rate,1249.4 +8301,Croatia,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1609.0 +8302,Croatia,2013,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",103.0 +8303,Croatia,2013,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,270.7 +8304,Croatia,2013,9,C10-Lipid modifying agents,Million US$ at exchange rate,295.8 +8305,Croatia,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0 +8306,Croatia,2013,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",468.6 +8307,Croatia,2013,9,Total pharmaceutical sales,Million of national currency units,5183.0 +8308,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",80.7 +8309,Croatia,2013,9,N06A-Antidepressants,Million US$ at exchange rate,110.9 +8310,Croatia,2013,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",91.6 +8311,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,89.0 +8312,Croatia,2013,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",472.1 +8313,Croatia,2013,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",142.2 +8314,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,430.6 +8315,Croatia,2013,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.5 +8316,Croatia,2013,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",93.7 +8317,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3 +8318,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",101.5 +8319,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +8320,Croatia,2013,9,C01A-Cardiac glycosides,Million US$ at exchange rate,5.3 +8321,Croatia,2013,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",133.2 +8322,Croatia,2013,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",221.3 +8323,Croatia,2013,9,N02-Analgesics,"Million US$, purchasing power parity",398.3 +8324,Croatia,2013,9,C-Cardiovascular system,"Million US$, purchasing power parity",1993.7 +8325,Croatia,2013,9,C03-Diuretics,"/capita, US$ exchange rate",13.7 +8326,Croatia,2013,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",46.6 +8327,Croatia,2013,9,N05B-Anxiolytics,Million of national currency units,88.0 +8328,Croatia,2013,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,389.6 +8329,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.9 +8330,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",187.6 +8331,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",36.6 +8332,Croatia,2013,9,C08-Calcium channel blockers,Million of national currency units,123.0 +8333,Croatia,2013,9,G-Genito urinary system and sex hormones,Million of national currency units,161.0 +8334,Croatia,2013,9,N05B-Anxiolytics,"/capita, US$ exchange rate",27.3 +8335,Croatia,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",14.4 +8336,Croatia,2013,9,A10-Drugs used in diabetes,% of total sales,5.8 +8337,Croatia,2013,9,M-Musculo-skeletal system,% of total sales,4.0 +8338,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7 +8339,Croatia,2013,9,C10-Lipid modifying agents,% of total sales,4.3 +8340,Croatia,2013,9,N06A-Antidepressants,% of total sales,1.6 +8341,Croatia,2013,9,C-Cardiovascular system,% of total sales,18.3 +8342,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1 +8343,Croatia,2013,9,N02-Analgesics,% of total sales,3.6 +8344,Croatia,2013,9,C02-Antihypertensives,% of total sales,1.0 +8345,Croatia,2013,9,C08-Calcium channel blockers,% of total sales,2.4 +8346,Croatia,2013,9,G-Genito urinary system and sex hormones,% of total sales,3.1 +8347,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +8348,Croatia,2013,9,A-Alimentary tract and metabolism,% of total sales,13.8 +8349,Croatia,2013,9,J-Antiinfectives for systemic use,% of total sales,8.3 +8350,Croatia,2013,9,R-Respiratory system,% of total sales,6.4 +8351,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +8352,Croatia,2013,9,B-Blood and blood forming organs,% of total sales,5.5 +8353,Croatia,2013,9,N05B-Anxiolytics,% of total sales,1.7 +8354,Croatia,2013,9,C03-Diuretics,% of total sales,0.8 +8355,Croatia,2013,9,C01A-Cardiac glycosides,% of total sales,0.1 +8356,Croatia,2013,9,N05C-Hypnotics and sedatives,% of total sales,0.6 +8357,Croatia,2013,9,J01-Antibacterials for systemic use,% of total sales,5.7 +8358,Croatia,2013,9,N-Nervous system,% of total sales,15.6 +8359,Croatia,2013,9,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +8360,Croatia,2013,9,C07-Beta blocking agents,% of total sales,1.8 +8361,Croatia,2013,9,A02A-Antacids,% of total sales,0.2 +8362,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",37.9 +8363,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.7 +8364,Croatia,2013,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",38.2 +8365,Croatia,2013,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",604.8 +8366,Croatia,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",50.0 +8367,Croatia,2013,9,N05B-Anxiolytics,Million US$ at exchange rate,116.2 +8368,Croatia,2013,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",61.1 +8369,Croatia,2013,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,212.6 +8370,Croatia,2013,9,N02-Analgesics,"/capita, US$ exchange rate",58.7 +8371,Croatia,2013,9,N06A-Antidepressants,"/capita, US$ exchange rate",26.1 +8372,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,155.8 +8373,Croatia,2013,9,C02-Antihypertensives,"/capita, US$ exchange rate",16.5 +8374,Croatia,2013,9,A10-Drugs used in diabetes,Million US$ at exchange rate,398.9 +8375,Croatia,2013,9,N-Nervous system,"/capita, US$ purchasing power parity",401.7 +8376,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",432.0 +8377,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,326.0 +8378,Croatia,2013,9,M-Musculo-skeletal system,Million US$ at exchange rate,274.7 +8379,Croatia,2013,9,C07-Beta blocking agents,"/capita, US$ exchange rate",29.2 +8380,Croatia,2013,9,N05C-Hypnotics and sedatives,Million of national currency units,29.0 +8381,Croatia,2013,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.4 +8382,Croatia,2013,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",146.1 +8383,Croatia,2013,9,J01-Antibacterials for systemic use,Million of national currency units,295.0 +8384,Croatia,2013,9,R-Respiratory system,Million US$ at exchange rate,438.5 +8385,Croatia,2013,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,941.7 +8386,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0 +8387,Croatia,2013,9,C07-Beta blocking agents,"Million US$, purchasing power parity",198.1 +8388,Croatia,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",10923.1 +8389,Croatia,2013,9,J-Antiinfectives for systemic use,Million of national currency units,429.0 +8390,Croatia,2013,9,A-Alimentary tract and metabolism,Million of national currency units,713.0 +8391,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,81.9 +8392,Croatia,2013,9,N06A-Antidepressants,"Million US$, purchasing power parity",177.0 +8393,Croatia,2013,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.2 +8394,Croatia,2013,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",111.0 +8395,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",44.1 +8396,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",343.5 +8397,Croatia,2013,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",438.4 +8398,Croatia,2013,9,A10-Drugs used in diabetes,Million of national currency units,302.0 +8399,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,118.0 +8400,Croatia,2013,9,R-Respiratory system,"/capita, US$ exchange rate",103.1 +8401,Croatia,2013,9,A02A-Antacids,"Million US$, purchasing power parity",19.0 +8402,Croatia,2013,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",621.7 +8403,Croatia,2013,9,C01A-Cardiac glycosides,Million of national currency units,4.0 +8404,Croatia,2013,9,C-Cardiovascular system,"/capita, US$ exchange rate",293.7 +8405,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",50.6 +8406,Croatia,2013,9,C08-Calcium channel blockers,Million US$ at exchange rate,162.4 +8407,Croatia,2013,9,C03-Diuretics,Million of national currency units,44.0 +8408,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",161.5 +8409,Croatia,2013,9,R-Respiratory system,Million of national currency units,332.0 +8410,Croatia,2013,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,566.6 +8411,Croatia,2013,9,C03-Diuretics,"/capita, US$ purchasing power parity",21.8 +8412,Croatia,2013,9,N-Nervous system,"Million US$, purchasing power parity",1709.2 +8413,Croatia,2013,9,C03-Diuretics,Million US$ at exchange rate,58.1 +8414,Croatia,2012,8,C07-Beta blocking agents,Million US$ at exchange rate,124.9 +8415,Croatia,2012,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",571.6 +8416,Croatia,2012,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",24.6 +8417,Croatia,2012,8,N-Nervous system,"/capita, US$ exchange rate",246.2 +8418,Croatia,2012,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",335.2 +8419,Croatia,2012,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.1 +8420,Croatia,2012,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1455.8 +8421,Croatia,2012,8,A02A-Antacids,Million of national currency units,8.0 +8422,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.1 +8423,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,96.6 +8424,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0 +8425,Croatia,2012,8,C07-Beta blocking agents,Million of national currency units,97.0 +8426,Croatia,2012,8,R-Respiratory system,"Million US$, purchasing power parity",664.2 +8427,Croatia,2012,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",206.2 +8428,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",60.6 +8429,Croatia,2012,8,Total pharmaceutical sales,Million US$ at exchange rate,6536.0 +8430,Croatia,2012,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",74.5 +8431,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,258.9 +8432,Croatia,2012,8,C-Cardiovascular system,Million of national currency units,1005.0 +8433,Croatia,2012,8,N-Nervous system,Million of national currency units,816.0 +8434,Croatia,2012,8,N05B-Anxiolytics,"Million US$, purchasing power parity",183.0 +8435,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,201.0 +8436,Croatia,2012,8,A02A-Antacids,"/capita, US$ exchange rate",2.4 +8437,Croatia,2012,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",880.1 +8438,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",232.4 +8439,Croatia,2012,8,B-Blood and blood forming organs,Million of national currency units,282.0 +8440,Croatia,2012,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",66.0 +8441,Croatia,2012,8,N02-Analgesics,Million US$ at exchange rate,246.0 +8442,Croatia,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",78.5 +8443,Croatia,2012,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.4 +8444,Croatia,2012,8,N02-Analgesics,Million of national currency units,191.0 +8445,Croatia,2012,8,N06A-Antidepressants,Million of national currency units,86.0 +8446,Croatia,2012,8,C02-Antihypertensives,Million of national currency units,51.0 +8447,Croatia,2012,8,R-Respiratory system,"/capita, US$ purchasing power parity",155.6 +8448,Croatia,2012,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.4 +8449,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",738.2 +8450,Croatia,2012,8,C10-Lipid modifying agents,Million of national currency units,247.0 +8451,Croatia,2012,8,B-Blood and blood forming organs,Million US$ at exchange rate,363.2 +8452,Croatia,2012,8,R03-Drugs for obstructive airway diseases,Million of national currency units,201.0 +8453,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",129.5 +8454,Croatia,2012,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",61.8 +8455,Croatia,2012,8,C03-Diuretics,"Million US$, purchasing power parity",88.4 +8456,Croatia,2012,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",42.9 +8457,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.9 +8458,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",108.3 +8459,Croatia,2012,8,A02A-Antacids,Million US$ at exchange rate,10.3 +8460,Croatia,2012,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.5 +8461,Croatia,2012,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2444.5 +8462,Croatia,2012,8,M-Musculo-skeletal system,Million of national currency units,205.0 +8463,Croatia,2012,8,C02-Antihypertensives,"Million US$, purchasing power parity",104.9 +8464,Croatia,2012,8,N-Nervous system,Million US$ at exchange rate,1050.9 +8465,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.0 +8466,Croatia,2012,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",133.9 +8467,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",22.6 +8468,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",54.4 +8469,Croatia,2012,8,N02-Analgesics,"/capita, US$ purchasing power parity",92.0 +8470,Croatia,2012,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",281.7 +8471,Croatia,2012,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",341.0 +8472,Croatia,2012,8,C02-Antihypertensives,Million US$ at exchange rate,65.7 +8473,Croatia,2012,8,C-Cardiovascular system,Million US$ at exchange rate,1294.3 +8474,Croatia,2012,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1531.0 +8475,Croatia,2012,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",98.7 +8476,Croatia,2012,8,C10-Lipid modifying agents,Million US$ at exchange rate,318.1 +8477,Croatia,2012,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,258.9 +8478,Croatia,2012,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.8 +8479,Croatia,2012,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",484.1 +8480,Croatia,2012,8,Total pharmaceutical sales,Million of national currency units,5075.0 +8481,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",96.8 +8482,Croatia,2012,8,N06A-Antidepressants,Million US$ at exchange rate,110.8 +8483,Croatia,2012,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",88.4 +8484,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,75.0 +8485,Croatia,2012,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",507.9 +8486,Croatia,2012,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",135.8 +8487,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,462.4 +8488,Croatia,2012,8,A02A-Antacids,"/capita, US$ purchasing power parity",3.9 +8489,Croatia,2012,8,C03-Diuretics,Million US$ at exchange rate,55.4 +8490,Croatia,2012,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",83.9 +8491,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.1 +8492,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",96.8 +8493,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +8494,Croatia,2012,8,C01A-Cardiac glycosides,Million US$ at exchange rate,6.4 +8495,Croatia,2012,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",129.1 +8496,Croatia,2012,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",213.6 +8497,Croatia,2012,8,N02-Analgesics,"Million US$, purchasing power parity",392.7 +8498,Croatia,2012,8,C-Cardiovascular system,"Million US$, purchasing power parity",2066.6 +8499,Croatia,2012,8,C03-Diuretics,"/capita, US$ exchange rate",13.0 +8500,Croatia,2012,8,N05B-Anxiolytics,Million of national currency units,89.0 +8501,Croatia,2012,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",46.7 +8502,Croatia,2012,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.4 +8503,Croatia,2012,8,C08-Calcium channel blockers,Million of national currency units,137.0 +8504,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.2 +8505,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.2 +8506,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",34.1 +8507,Croatia,2012,8,N05B-Anxiolytics,"/capita, US$ exchange rate",26.8 +8508,Croatia,2012,8,G-Genito urinary system and sex hormones,Million of national currency units,163.0 +8509,Croatia,2012,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",12.5 +8510,Croatia,2012,8,A10-Drugs used in diabetes,% of total sales,5.5 +8511,Croatia,2012,8,M-Musculo-skeletal system,% of total sales,4.0 +8512,Croatia,2012,8,N06A-Antidepressants,% of total sales,1.7 +8513,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5 +8514,Croatia,2012,8,C-Cardiovascular system,% of total sales,19.8 +8515,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0 +8516,Croatia,2012,8,N02-Analgesics,% of total sales,3.8 +8517,Croatia,2012,8,C10-Lipid modifying agents,% of total sales,4.9 +8518,Croatia,2012,8,C02-Antihypertensives,% of total sales,1.0 +8519,Croatia,2012,8,G-Genito urinary system and sex hormones,% of total sales,3.2 +8520,Croatia,2012,8,C08-Calcium channel blockers,% of total sales,2.7 +8521,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2 +8522,Croatia,2012,8,A-Alimentary tract and metabolism,% of total sales,14.0 +8523,Croatia,2012,8,J-Antiinfectives for systemic use,% of total sales,8.4 +8524,Croatia,2012,8,R-Respiratory system,% of total sales,6.4 +8525,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +8526,Croatia,2012,8,B-Blood and blood forming organs,% of total sales,5.6 +8527,Croatia,2012,8,C03-Diuretics,% of total sales,0.8 +8528,Croatia,2012,8,N05B-Anxiolytics,% of total sales,1.8 +8529,Croatia,2012,8,C01A-Cardiac glycosides,% of total sales,0.1 +8530,Croatia,2012,8,J01-Antibacterials for systemic use,% of total sales,5.8 +8531,Croatia,2012,8,N05C-Hypnotics and sedatives,% of total sales,0.5 +8532,Croatia,2012,8,N-Nervous system,% of total sales,16.1 +8533,Croatia,2012,8,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +8534,Croatia,2012,8,C07-Beta blocking agents,% of total sales,1.9 +8535,Croatia,2012,8,A02A-Antacids,% of total sales,0.2 +8536,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.0 +8537,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.3 +8538,Croatia,2012,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",41.3 +8539,Croatia,2012,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",579.9 +8540,Croatia,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.2 +8541,Croatia,2012,8,N05B-Anxiolytics,Million US$ at exchange rate,114.6 +8542,Croatia,2012,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,209.9 +8543,Croatia,2012,8,N06A-Antidepressants,"/capita, US$ exchange rate",25.9 +8544,Croatia,2012,8,C02-Antihypertensives,"/capita, US$ exchange rate",15.4 +8545,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,145.5 +8546,Croatia,2012,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",53.5 +8547,Croatia,2012,8,A10-Drugs used in diabetes,Million US$ at exchange rate,358.0 +8548,Croatia,2012,8,N-Nervous system,"/capita, US$ purchasing power parity",393.0 +8549,Croatia,2012,8,M-Musculo-skeletal system,Million US$ at exchange rate,264.0 +8550,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",413.3 +8551,Croatia,2012,8,C07-Beta blocking agents,"/capita, US$ exchange rate",29.3 +8552,Croatia,2012,8,N05C-Hypnotics and sedatives,Million of national currency units,26.0 +8553,Croatia,2012,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.3 +8554,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,359.0 +8555,Croatia,2012,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",141.1 +8556,Croatia,2012,8,R-Respiratory system,Million US$ at exchange rate,416.0 +8557,Croatia,2012,8,J01-Antibacterials for systemic use,Million of national currency units,293.0 +8558,Croatia,2012,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,911.8 +8559,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.0 +8560,Croatia,2012,8,N02-Analgesics,"/capita, US$ exchange rate",57.6 +8561,Croatia,2012,8,C07-Beta blocking agents,"Million US$, purchasing power parity",199.5 +8562,Croatia,2012,8,Total pharmaceutical sales,"Million US$, purchasing power parity",10435.6 +8563,Croatia,2012,8,J-Antiinfectives for systemic use,Million of national currency units,428.0 +8564,Croatia,2012,8,A-Alimentary tract and metabolism,Million of national currency units,708.0 +8565,Croatia,2012,8,N06A-Antidepressants,"Million US$, purchasing power parity",176.8 +8566,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,81.1 +8567,Croatia,2012,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.5 +8568,Croatia,2012,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",119.0 +8569,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",413.3 +8570,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",36.1 +8571,Croatia,2012,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",421.5 +8572,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,113.0 +8573,Croatia,2012,8,A10-Drugs used in diabetes,Million of national currency units,278.0 +8574,Croatia,2012,8,R-Respiratory system,"/capita, US$ exchange rate",97.4 +8575,Croatia,2012,8,A02A-Antacids,"Million US$, purchasing power parity",16.5 +8576,Croatia,2012,8,C01A-Cardiac glycosides,Million of national currency units,5.0 +8577,Croatia,2012,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",602.5 +8578,Croatia,2012,8,C-Cardiovascular system,"/capita, US$ exchange rate",303.2 +8579,Croatia,2012,8,C08-Calcium channel blockers,Million US$ at exchange rate,176.4 +8580,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",60.6 +8581,Croatia,2012,8,C03-Diuretics,Million of national currency units,43.0 +8582,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",172.9 +8583,Croatia,2012,8,R-Respiratory system,Million of national currency units,323.0 +8584,Croatia,2012,8,C03-Diuretics,"/capita, US$ purchasing power parity",20.7 +8585,Croatia,2012,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,551.2 +8586,Croatia,2012,8,N-Nervous system,"Million US$, purchasing power parity",1677.9 +8587,Croatia,2011,9,C07-Beta blocking agents,Million US$ at exchange rate,133.9 +8588,Croatia,2011,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",520.0 +8589,Croatia,2011,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",22.5 +8590,Croatia,2011,9,N-Nervous system,"/capita, US$ exchange rate",267.0 +8591,Croatia,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",333.3 +8592,Croatia,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.3 +8593,Croatia,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1385.4 +8594,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",6.3 +8595,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,98.7 +8596,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0 +8597,Croatia,2011,9,C07-Beta blocking agents,Million of national currency units,95.0 +8598,Croatia,2011,9,R-Respiratory system,"Million US$, purchasing power parity",668.6 +8599,Croatia,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",217.1 +8600,Croatia,2011,9,A02A-Antacids,Million of national currency units,9.0 +8601,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",64.5 +8602,Croatia,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,7145.5 +8603,Croatia,2011,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",82.3 +8604,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,282.0 +8605,Croatia,2011,9,C-Cardiovascular system,Million of national currency units,984.0 +8606,Croatia,2011,9,N-Nervous system,Million of national currency units,811.0 +8607,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,200.0 +8608,Croatia,2011,9,A02A-Antacids,"/capita, US$ exchange rate",3.0 +8609,Croatia,2011,9,N05B-Anxiolytics,"Million US$, purchasing power parity",174.7 +8610,Croatia,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",929.6 +8611,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",220.9 +8612,Croatia,2011,9,B-Blood and blood forming organs,Million of national currency units,259.0 +8613,Croatia,2011,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",68.0 +8614,Croatia,2011,9,N02-Analgesics,Million US$ at exchange rate,273.5 +8615,Croatia,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",77.8 +8616,Croatia,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",156.1 +8617,Croatia,2011,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",40.8 +8618,Croatia,2011,9,N02-Analgesics,Million of national currency units,194.0 +8619,Croatia,2011,9,N06A-Antidepressants,Million of national currency units,87.0 +8620,Croatia,2011,9,C02-Antihypertensives,Million of national currency units,48.0 +8621,Croatia,2011,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",1.9 +8622,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",704.7 +8623,Croatia,2011,9,C10-Lipid modifying agents,Million of national currency units,250.0 +8624,Croatia,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,365.2 +8625,Croatia,2011,9,R03-Drugs for obstructive airway diseases,Million of national currency units,196.0 +8626,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",120.5 +8627,Croatia,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",68.5 +8628,Croatia,2011,9,C03-Diuretics,"Million US$, purchasing power parity",82.3 +8629,Croatia,2011,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",40.8 +8630,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,26.8 +8631,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",115.5 +8632,Croatia,2011,9,A02A-Antacids,Million US$ at exchange rate,12.7 +8633,Croatia,2011,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.8 +8634,Croatia,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2375.8 +8635,Croatia,2011,9,M-Musculo-skeletal system,Million of national currency units,208.0 +8636,Croatia,2011,9,C02-Antihypertensives,"Million US$, purchasing power parity",96.4 +8637,Croatia,2011,9,N-Nervous system,Million US$ at exchange rate,1143.5 +8638,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.8 +8639,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",51.6 +8640,Croatia,2011,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",121.4 +8641,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",23.0 +8642,Croatia,2011,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",291.1 +8643,Croatia,2011,9,N02-Analgesics,"/capita, US$ purchasing power parity",90.9 +8644,Croatia,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",323.5 +8645,Croatia,2011,9,C02-Antihypertensives,Million US$ at exchange rate,67.7 +8646,Croatia,2011,9,C-Cardiovascular system,Million US$ at exchange rate,1387.4 +8647,Croatia,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1668.4 +8648,Croatia,2011,9,C10-Lipid modifying agents,Million US$ at exchange rate,352.5 +8649,Croatia,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",97.5 +8650,Croatia,2011,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,276.3 +8651,Croatia,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.9 +8652,Croatia,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",461.3 +8653,Croatia,2011,9,Total pharmaceutical sales,Million of national currency units,5068.0 +8654,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",93.8 +8655,Croatia,2011,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",95.1 +8656,Croatia,2011,9,N06A-Antidepressants,Million US$ at exchange rate,122.7 +8657,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,70.0 +8658,Croatia,2011,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",501.9 +8659,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,494.9 +8660,Croatia,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",121.4 +8661,Croatia,2011,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.2 +8662,Croatia,2011,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",85.3 +8663,Croatia,2011,9,C03-Diuretics,Million US$ at exchange rate,57.8 +8664,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.9 +8665,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",91.9 +8666,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +8667,Croatia,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",152.4 +8668,Croatia,2011,9,C01A-Cardiac glycosides,Million US$ at exchange rate,5.6 +8669,Croatia,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",227.1 +8670,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",140.5 +8671,Croatia,2011,9,N02-Analgesics,"Million US$, purchasing power parity",389.5 +8672,Croatia,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",1975.7 +8673,Croatia,2011,9,C03-Diuretics,"/capita, US$ exchange rate",13.5 +8674,Croatia,2011,9,N05B-Anxiolytics,Million of national currency units,87.0 +8675,Croatia,2011,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",44.5 +8676,Croatia,2011,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,407.5 +8677,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.9 +8678,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",36.2 +8679,Croatia,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,166.0 +8680,Croatia,2011,9,N05B-Anxiolytics,"/capita, US$ exchange rate",28.6 +8681,Croatia,2011,9,C08-Calcium channel blockers,Million of national currency units,145.0 +8682,Croatia,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",11.3 +8683,Croatia,2011,9,A10-Drugs used in diabetes,% of total sales,5.1 +8684,Croatia,2011,9,M-Musculo-skeletal system,% of total sales,4.1 +8685,Croatia,2011,9,N06A-Antidepressants,% of total sales,1.7 +8686,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +8687,Croatia,2011,9,C-Cardiovascular system,% of total sales,19.4 +8688,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9 +8689,Croatia,2011,9,N02-Analgesics,% of total sales,3.8 +8690,Croatia,2011,9,C02-Antihypertensives,% of total sales,0.9 +8691,Croatia,2011,9,G-Genito urinary system and sex hormones,% of total sales,3.3 +8692,Croatia,2011,9,C08-Calcium channel blockers,% of total sales,2.9 +8693,Croatia,2011,9,C10-Lipid modifying agents,% of total sales,4.9 +8694,Croatia,2011,9,A-Alimentary tract and metabolism,% of total sales,13.6 +8695,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2 +8696,Croatia,2011,9,J-Antiinfectives for systemic use,% of total sales,9.1 +8697,Croatia,2011,9,R-Respiratory system,% of total sales,6.6 +8698,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +8699,Croatia,2011,9,B-Blood and blood forming organs,% of total sales,5.1 +8700,Croatia,2011,9,N05B-Anxiolytics,% of total sales,1.7 +8701,Croatia,2011,9,C03-Diuretics,% of total sales,0.8 +8702,Croatia,2011,9,C01A-Cardiac glycosides,% of total sales,0.1 +8703,Croatia,2011,9,J01-Antibacterials for systemic use,% of total sales,5.7 +8704,Croatia,2011,9,N05C-Hypnotics and sedatives,% of total sales,0.5 +8705,Croatia,2011,9,N-Nervous system,% of total sales,16.0 +8706,Croatia,2011,9,R03-Drugs for obstructive airway diseases,% of total sales,3.9 +8707,Croatia,2011,9,A02A-Antacids,% of total sales,0.2 +8708,Croatia,2011,9,C07-Beta blocking agents,% of total sales,1.9 +8709,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",28.1 +8710,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",38.1 +8711,Croatia,2011,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",47.7 +8712,Croatia,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",520.0 +8713,Croatia,2011,9,N05B-Anxiolytics,Million US$ at exchange rate,122.7 +8714,Croatia,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",54.6 +8715,Croatia,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,234.0 +8716,Croatia,2011,9,C02-Antihypertensives,"/capita, US$ exchange rate",15.8 +8717,Croatia,2011,9,N06A-Antidepressants,"/capita, US$ exchange rate",28.6 +8718,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,155.1 +8719,Croatia,2011,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",48.2 +8720,Croatia,2011,9,A10-Drugs used in diabetes,Million US$ at exchange rate,365.2 +8721,Croatia,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",380.2 +8722,Croatia,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,293.3 +8723,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",393.5 +8724,Croatia,2011,9,C07-Beta blocking agents,"/capita, US$ exchange rate",31.3 +8725,Croatia,2011,9,N05C-Hypnotics and sedatives,Million of national currency units,24.0 +8726,Croatia,2011,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.0 +8727,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,351.0 +8728,Croatia,2011,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",135.5 +8729,Croatia,2011,9,J01-Antibacterials for systemic use,Million of national currency units,289.0 +8730,Croatia,2011,9,R-Respiratory system,Million US$ at exchange rate,469.5 +8731,Croatia,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,972.9 +8732,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,60.0 +8733,Croatia,2011,9,C07-Beta blocking agents,"Million US$, purchasing power parity",190.7 +8734,Croatia,2011,9,N02-Analgesics,"/capita, US$ exchange rate",63.9 +8735,Croatia,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",10175.5 +8736,Croatia,2011,9,A-Alimentary tract and metabolism,Million of national currency units,690.0 +8737,Croatia,2011,9,J-Antiinfectives for systemic use,Million of national currency units,463.0 +8738,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,84.6 +8739,Croatia,2011,9,N06A-Antidepressants,"Million US$, purchasing power parity",174.7 +8740,Croatia,2011,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3 +8741,Croatia,2011,9,R-Respiratory system,"/capita, US$ exchange rate",109.6 +8742,Croatia,2011,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",117.2 +8743,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",32.8 +8744,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",401.6 +8745,Croatia,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",417.6 +8746,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,110.0 +8747,Croatia,2011,9,A10-Drugs used in diabetes,Million of national currency units,259.0 +8748,Croatia,2011,9,A02A-Antacids,"Million US$, purchasing power parity",18.1 +8749,Croatia,2011,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",580.3 +8750,Croatia,2011,9,C01A-Cardiac glycosides,Million of national currency units,4.0 +8751,Croatia,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",323.9 +8752,Croatia,2011,9,C08-Calcium channel blockers,Million US$ at exchange rate,204.4 +8753,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",65.8 +8754,Croatia,2011,9,C03-Diuretics,Million of national currency units,41.0 +8755,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",164.5 +8756,Croatia,2011,9,R-Respiratory system,Million of national currency units,333.0 +8757,Croatia,2011,9,C03-Diuretics,"/capita, US$ purchasing power parity",19.2 +8758,Croatia,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,652.8 +8759,Croatia,2011,9,N-Nervous system,"Million US$, purchasing power parity",1628.3 +8760,Croatia,2010,9,C07-Beta blocking agents,Million US$ at exchange rate,126.1 +8761,Croatia,2010,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",468.8 +8762,Croatia,2010,9,N-Nervous system,"/capita, US$ exchange rate",250.1 +8763,Croatia,2010,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",19.5 +8764,Croatia,2010,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",317.1 +8765,Croatia,2010,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1244.9 +8766,Croatia,2010,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.2 +8767,Croatia,2010,9,A02A-Antacids,Million of national currency units,9.0 +8768,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.7 +8769,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.2 +8770,Croatia,2010,9,C07-Beta blocking agents,Million of national currency units,92.0 +8771,Croatia,2010,9,R-Respiratory system,"/capita, US$ purchasing power parity",152.6 +8772,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0 +8773,Croatia,2010,9,R-Respiratory system,"Million US$, purchasing power parity",655.5 +8774,Croatia,2010,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",215.5 +8775,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",59.0 +8776,Croatia,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,6628.7 +8777,Croatia,2010,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",77.2 +8778,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,270.0 +8779,Croatia,2010,9,N-Nervous system,Million of national currency units,784.0 +8780,Croatia,2010,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",925.9 +8781,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,197.0 +8782,Croatia,2010,9,A02A-Antacids,"/capita, US$ exchange rate",2.9 +8783,Croatia,2010,9,C-Cardiovascular system,Million of national currency units,975.0 +8784,Croatia,2010,9,N05B-Anxiolytics,"Million US$, purchasing power parity",167.3 +8785,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",215.9 +8786,Croatia,2010,9,B-Blood and blood forming organs,Million of national currency units,267.0 +8787,Croatia,2010,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",66.1 +8788,Croatia,2010,9,N02-Analgesics,Million US$ at exchange rate,254.9 +8789,Croatia,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",73.8 +8790,Croatia,2010,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",39.8 +8791,Croatia,2010,9,N02-Analgesics,Million of national currency units,186.0 +8792,Croatia,2010,9,N06A-Antidepressants,Million of national currency units,88.0 +8793,Croatia,2010,9,C02-Antihypertensives,Million of national currency units,43.0 +8794,Croatia,2010,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.3 +8795,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",663.3 +8796,Croatia,2010,9,B-Blood and blood forming organs,Million US$ at exchange rate,365.9 +8797,Croatia,2010,9,R03-Drugs for obstructive airway diseases,Million of national currency units,185.0 +8798,Croatia,2010,9,C10-Lipid modifying agents,Million of national currency units,242.0 +8799,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",120.6 +8800,Croatia,2010,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",67.3 +8801,Croatia,2010,9,C03-Diuretics,"Million US$, purchasing power parity",75.9 +8802,Croatia,2010,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",38.9 +8803,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,24.7 +8804,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",108.8 +8805,Croatia,2010,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,31.5 +8806,Croatia,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2189.9 +8807,Croatia,2010,9,A02A-Antacids,Million US$ at exchange rate,12.3 +8808,Croatia,2010,9,M-Musculo-skeletal system,Million of national currency units,211.0 +8809,Croatia,2010,9,C02-Antihypertensives,"Million US$, purchasing power parity",83.6 +8810,Croatia,2010,9,N-Nervous system,Million US$ at exchange rate,1074.4 +8811,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.8 +8812,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",50.3 +8813,Croatia,2010,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",109.1 +8814,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",19.1 +8815,Croatia,2010,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",284.0 +8816,Croatia,2010,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",289.8 +8817,Croatia,2010,9,C02-Antihypertensives,Million US$ at exchange rate,58.9 +8818,Croatia,2010,9,C-Cardiovascular system,Million US$ at exchange rate,1336.1 +8819,Croatia,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1542.9 +8820,Croatia,2010,9,N02-Analgesics,"/capita, US$ purchasing power parity",84.2 +8821,Croatia,2010,9,C10-Lipid modifying agents,Million US$ at exchange rate,331.6 +8822,Croatia,2010,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",95.5 +8823,Croatia,2010,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,253.5 +8824,Croatia,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.3 +8825,Croatia,2010,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",441.4 +8826,Croatia,2010,9,Total pharmaceutical sales,Million of national currency units,4837.0 +8827,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",89.2 +8828,Croatia,2010,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",90.6 +8829,Croatia,2010,9,N06A-Antidepressants,Million US$ at exchange rate,120.6 +8830,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,60.0 +8831,Croatia,2010,9,C-Cardiovascular system,"/capita, US$ exchange rate",311.0 +8832,Croatia,2010,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",470.7 +8833,Croatia,2010,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",120.9 +8834,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,467.3 +8835,Croatia,2010,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.1 +8836,Croatia,2010,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",76.9 +8837,Croatia,2010,9,C03-Diuretics,Million US$ at exchange rate,53.4 +8838,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.0 +8839,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",83.8 +8840,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.3 +8841,Croatia,2010,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",151.8 +8842,Croatia,2010,9,C01A-Cardiac glycosides,Million US$ at exchange rate,6.9 +8843,Croatia,2010,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",204.1 +8844,Croatia,2010,9,C-Cardiovascular system,"Million US$, purchasing power parity",1896.5 +8845,Croatia,2010,9,N02-Analgesics,"Million US$, purchasing power parity",361.8 +8846,Croatia,2010,9,C03-Diuretics,"/capita, US$ exchange rate",12.4 +8847,Croatia,2010,9,N05B-Anxiolytics,Million of national currency units,86.0 +8848,Croatia,2010,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,389.2 +8849,Croatia,2010,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",41.7 +8850,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",116.7 +8851,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.1 +8852,Croatia,2010,9,G-Genito urinary system and sex hormones,Million of national currency units,163.0 +8853,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",35.4 +8854,Croatia,2010,9,N05B-Anxiolytics,"/capita, US$ exchange rate",27.4 +8855,Croatia,2010,9,C08-Calcium channel blockers,Million of national currency units,146.0 +8856,Croatia,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.4 +8857,Croatia,2010,9,M-Musculo-skeletal system,% of total sales,4.4 +8858,Croatia,2010,9,N06A-Antidepressants,% of total sales,1.8 +8859,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.2 +8860,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.1 +8861,Croatia,2010,9,C-Cardiovascular system,% of total sales,20.2 +8862,Croatia,2010,9,N02-Analgesics,% of total sales,3.8 +8863,Croatia,2010,9,C10-Lipid modifying agents,% of total sales,5.0 +8864,Croatia,2010,9,C02-Antihypertensives,% of total sales,0.9 +8865,Croatia,2010,9,G-Genito urinary system and sex hormones,% of total sales,3.4 +8866,Croatia,2010,9,C08-Calcium channel blockers,% of total sales,3.0 +8867,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +8868,Croatia,2010,9,A-Alimentary tract and metabolism,% of total sales,13.2 +8869,Croatia,2010,9,J-Antiinfectives for systemic use,% of total sales,9.8 +8870,Croatia,2010,9,R-Respiratory system,% of total sales,7.0 +8871,Croatia,2010,9,B-Blood and blood forming organs,% of total sales,5.5 +8872,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +8873,Croatia,2010,9,C03-Diuretics,% of total sales,0.8 +8874,Croatia,2010,9,N05B-Anxiolytics,% of total sales,1.8 +8875,Croatia,2010,9,A10-Drugs used in diabetes,% of total sales,5.0 +8876,Croatia,2010,9,C01A-Cardiac glycosides,% of total sales,0.1 +8877,Croatia,2010,9,J01-Antibacterials for systemic use,% of total sales,5.9 +8878,Croatia,2010,9,N-Nervous system,% of total sales,16.2 +8879,Croatia,2010,9,N05C-Hypnotics and sedatives,% of total sales,0.5 +8880,Croatia,2010,9,R03-Drugs for obstructive airway diseases,% of total sales,3.8 +8881,Croatia,2010,9,A02A-Antacids,% of total sales,0.2 +8882,Croatia,2010,9,C07-Beta blocking agents,% of total sales,1.9 +8883,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",28.1 +8884,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.0 +8885,Croatia,2010,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",46.6 +8886,Croatia,2010,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",519.3 +8887,Croatia,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",52.0 +8888,Croatia,2010,9,N05B-Anxiolytics,Million US$ at exchange rate,117.9 +8889,Croatia,2010,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,223.4 +8890,Croatia,2010,9,C02-Antihypertensives,"/capita, US$ exchange rate",13.7 +8891,Croatia,2010,9,N06A-Antidepressants,"/capita, US$ exchange rate",28.1 +8892,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,152.1 +8893,Croatia,2010,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",44.7 +8894,Croatia,2010,9,A10-Drugs used in diabetes,Million US$ at exchange rate,330.3 +8895,Croatia,2010,9,N-Nervous system,"/capita, US$ purchasing power parity",354.9 +8896,Croatia,2010,9,M-Musculo-skeletal system,Million US$ at exchange rate,289.2 +8897,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",359.8 +8898,Croatia,2010,9,N05C-Hypnotics and sedatives,Million of national currency units,23.0 +8899,Croatia,2010,9,C07-Beta blocking agents,"/capita, US$ exchange rate",29.3 +8900,Croatia,2010,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.7 +8901,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,341.0 +8902,Croatia,2010,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",128.6 +8903,Croatia,2010,9,J01-Antibacterials for systemic use,Million of national currency units,284.0 +8904,Croatia,2010,9,R-Respiratory system,Million US$ at exchange rate,461.8 +8905,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0 +8906,Croatia,2010,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,877.1 +8907,Croatia,2010,9,C07-Beta blocking agents,"Million US$, purchasing power parity",179.0 +8908,Croatia,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",9408.5 +8909,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,85.0 +8910,Croatia,2010,9,A-Alimentary tract and metabolism,Million of national currency units,640.0 +8911,Croatia,2010,9,N06A-Antidepressants,"Million US$, purchasing power parity",171.2 +8912,Croatia,2010,9,R-Respiratory system,"/capita, US$ exchange rate",107.5 +8913,Croatia,2010,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.6 +8914,Croatia,2010,9,J-Antiinfectives for systemic use,Million of national currency units,476.0 +8915,Croatia,2010,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",109.6 +8916,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",383.2 +8917,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",27.2 +8918,Croatia,2010,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",410.4 +8919,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,111.0 +8920,Croatia,2010,9,A10-Drugs used in diabetes,Million of national currency units,241.0 +8921,Croatia,2010,9,A02A-Antacids,"Million US$, purchasing power parity",17.5 +8922,Croatia,2010,9,C01A-Cardiac glycosides,Million of national currency units,5.0 +8923,Croatia,2010,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",552.4 +8924,Croatia,2010,9,C08-Calcium channel blockers,Million US$ at exchange rate,200.1 +8925,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",62.8 +8926,Croatia,2010,9,C03-Diuretics,Million of national currency units,39.0 +8927,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",154.4 +8928,Croatia,2010,9,R-Respiratory system,Million of national currency units,337.0 +8929,Croatia,2010,9,C03-Diuretics,"/capita, US$ purchasing power parity",17.7 +8930,Croatia,2010,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,652.3 +8931,Croatia,2010,9,N-Nervous system,"Million US$, purchasing power parity",1525.0 +8932,Croatia,2010,9,N02-Analgesics,"/capita, US$ exchange rate",59.3 +8933,Croatia,2017,8,C07-Beta blocking agents,Million US$ at exchange rate,99.0 +8934,Croatia,2017,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",924.6 +8935,Croatia,2017,8,N-Nervous system,"/capita, US$ exchange rate",229.7 +8936,Croatia,2017,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",405.7 +8937,Croatia,2017,8,A02A-Antacids,"/capita, US$ exchange rate",2.5 +8938,Croatia,2017,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",136.6 +8939,Croatia,2017,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1810.7 +8940,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.4 +8941,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,129.7 +8942,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0 +8943,Croatia,2017,8,C07-Beta blocking agents,Million of national currency units,87.0 +8944,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",60.6 +8945,Croatia,2017,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",334.2 +8946,Croatia,2017,8,A02A-Antacids,Million of national currency units,9.0 +8947,Croatia,2017,8,Total pharmaceutical sales,Million US$ at exchange rate,6975.1 +8948,Croatia,2017,8,R-Respiratory system,"Million US$, purchasing power parity",811.3 +8949,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,131.9 +8950,Croatia,2017,8,N05B-Anxiolytics,"Million US$, purchasing power parity",204.0 +8951,Croatia,2017,8,C-Cardiovascular system,Million of national currency units,785.0 +8952,Croatia,2017,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.0 +8953,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",315.0 +8954,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,116.0 +8955,Croatia,2017,8,N05C-Hypnotics and sedatives,Million of national currency units,35.0 +8956,Croatia,2017,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1380.1 +8957,Croatia,2017,8,N02-Analgesics,Million US$ at exchange rate,208.2 +8958,Croatia,2017,8,N-Nervous system,Million of national currency units,834.0 +8959,Croatia,2017,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",188.1 +8960,Croatia,2017,8,B-Blood and blood forming organs,Million of national currency units,496.0 +8961,Croatia,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",98.2 +8962,Croatia,2017,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",45.5 +8963,Croatia,2017,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",43.9 +8964,Croatia,2017,8,N02-Analgesics,Million of national currency units,183.0 +8965,Croatia,2017,8,C02-Antihypertensives,Million of national currency units,47.0 +8966,Croatia,2017,8,N06A-Antidepressants,Million of national currency units,80.0 +8967,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",713.9 +8968,Croatia,2017,8,C10-Lipid modifying agents,Million of national currency units,149.0 +8969,Croatia,2017,8,R03-Drugs for obstructive airway diseases,Million of national currency units,220.0 +8970,Croatia,2017,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.7 +8971,Croatia,2017,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",62.8 +8972,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",140.5 +8973,Croatia,2017,8,C03-Diuretics,"Million US$, purchasing power parity",120.1 +8974,Croatia,2017,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",49.4 +8975,Croatia,2017,8,B-Blood and blood forming organs,Million US$ at exchange rate,564.2 +8976,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",86.8 +8977,Croatia,2017,8,A02A-Antacids,Million US$ at exchange rate,10.2 +8978,Croatia,2017,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",3364.9 +8979,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,18.2 +8980,Croatia,2017,8,M-Musculo-skeletal system,Million of national currency units,228.0 +8981,Croatia,2017,8,C02-Antihypertensives,"Million US$, purchasing power parity",106.5 +8982,Croatia,2017,8,N-Nervous system,Million US$ at exchange rate,948.7 +8983,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.1 +8984,Croatia,2017,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",223.9 +8985,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",31.4 +8986,Croatia,2017,8,N02-Analgesics,"/capita, US$ purchasing power parity",100.4 +8987,Croatia,2017,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",25.8 +8988,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",76.3 +8989,Croatia,2017,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,39.8 +8990,Croatia,2017,8,C02-Antihypertensives,Million US$ at exchange rate,53.5 +8991,Croatia,2017,8,R-Respiratory system,"/capita, US$ purchasing power parity",196.5 +8992,Croatia,2017,8,C-Cardiovascular system,Million US$ at exchange rate,892.9 +8993,Croatia,2017,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",438.4 +8994,Croatia,2017,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1688.9 +8995,Croatia,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.6 +8996,Croatia,2017,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",125.1 +8997,Croatia,2017,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,250.2 +8998,Croatia,2017,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",430.8 +8999,Croatia,2017,8,C10-Lipid modifying agents,Million US$ at exchange rate,169.5 +9000,Croatia,2017,8,Total pharmaceutical sales,Million of national currency units,6132.0 +9001,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",63.7 +9002,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114.0 +9003,Croatia,2017,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",85.9 +9004,Croatia,2017,8,N06A-Antidepressants,Million US$ at exchange rate,91.0 +9005,Croatia,2017,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",272.2 +9006,Croatia,2017,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",337.7 +9007,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,358.3 +9008,Croatia,2017,8,C03-Diuretics,Million US$ at exchange rate,60.3 +9009,Croatia,2017,8,A02A-Antacids,"/capita, US$ purchasing power parity",4.9 +9010,Croatia,2017,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",112.4 +9011,Croatia,2017,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",167.7 +9012,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1 +9013,Croatia,2017,8,A10-Drugs used in diabetes,% of total sales,6.7 +9014,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +9015,Croatia,2017,8,C01A-Cardiac glycosides,Million US$ at exchange rate,5.7 +9016,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",120.7 +9017,Croatia,2017,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",220.1 +9018,Croatia,2017,8,N02-Analgesics,"Million US$, purchasing power parity",414.7 +9019,Croatia,2017,8,C08-Calcium channel blockers,Million of national currency units,83.0 +9020,Croatia,2017,8,C03-Diuretics,"/capita, US$ exchange rate",14.6 +9021,Croatia,2017,8,C-Cardiovascular system,"Million US$, purchasing power parity",1779.0 +9022,Croatia,2017,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",47.7 +9023,Croatia,2017,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,354.9 +9024,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.8 +9025,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",38.3 +9026,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",258.4 +9027,Croatia,2017,8,N05B-Anxiolytics,"/capita, US$ exchange rate",24.8 +9028,Croatia,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",19.2 +9029,Croatia,2017,8,G-Genito urinary system and sex hormones,Million of national currency units,179.0 +9030,Croatia,2017,8,M-Musculo-skeletal system,% of total sales,3.7 +9031,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +9032,Croatia,2017,8,C10-Lipid modifying agents,% of total sales,2.4 +9033,Croatia,2017,8,C-Cardiovascular system,% of total sales,12.8 +9034,Croatia,2017,8,N06A-Antidepressants,% of total sales,1.3 +9035,Croatia,2017,8,N02-Analgesics,% of total sales,3.0 +9036,Croatia,2017,8,C08-Calcium channel blockers,% of total sales,1.4 +9037,Croatia,2017,8,C02-Antihypertensives,% of total sales,0.8 +9038,Croatia,2017,8,G-Genito urinary system and sex hormones,% of total sales,2.9 +9039,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +9040,Croatia,2017,8,J-Antiinfectives for systemic use,% of total sales,9.9 +9041,Croatia,2017,8,A-Alimentary tract and metabolism,% of total sales,13.0 +9042,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9 +9043,Croatia,2017,8,R-Respiratory system,% of total sales,5.8 +9044,Croatia,2017,8,B-Blood and blood forming organs,% of total sales,8.1 +9045,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +9046,Croatia,2017,8,N05B-Anxiolytics,% of total sales,1.5 +9047,Croatia,2017,8,C03-Diuretics,% of total sales,0.9 +9048,Croatia,2017,8,C01A-Cardiac glycosides,% of total sales,0.1 +9049,Croatia,2017,8,N05C-Hypnotics and sedatives,% of total sales,0.6 +9050,Croatia,2017,8,N-Nervous system,% of total sales,13.6 +9051,Croatia,2017,8,J01-Antibacterials for systemic use,% of total sales,5.1 +9052,Croatia,2017,8,C07-Beta blocking agents,% of total sales,1.4 +9053,Croatia,2017,8,R03-Drugs for obstructive airway diseases,% of total sales,3.6 +9054,Croatia,2017,8,A02A-Antacids,% of total sales,0.1 +9055,Croatia,2017,8,N05B-Anxiolytics,Million of national currency units,90.0 +9056,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",36.3 +9057,Croatia,2017,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",79.3 +9058,Croatia,2017,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",22.9 +9059,Croatia,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.3 +9060,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",34.0 +9061,Croatia,2017,8,N05B-Anxiolytics,Million US$ at exchange rate,102.4 +9062,Croatia,2017,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1124.1 +9063,Croatia,2017,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,203.6 +9064,Croatia,2017,8,N02-Analgesics,"/capita, US$ exchange rate",50.4 +9065,Croatia,2017,8,N06A-Antidepressants,"/capita, US$ exchange rate",22.0 +9066,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,158.1 +9067,Croatia,2017,8,C02-Antihypertensives,"/capita, US$ exchange rate",12.9 +9068,Croatia,2017,8,A10-Drugs used in diabetes,Million US$ at exchange rate,464.1 +9069,Croatia,2017,8,N-Nervous system,"/capita, US$ purchasing power parity",457.7 +9070,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",498.6 +9071,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,315.0 +9072,Croatia,2017,8,C07-Beta blocking agents,"/capita, US$ exchange rate",24.0 +9073,Croatia,2017,8,M-Musculo-skeletal system,Million US$ at exchange rate,259.3 +9074,Croatia,2017,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.3 +9075,Croatia,2017,8,R-Respiratory system,Million US$ at exchange rate,407.2 +9076,Croatia,2017,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",171.2 +9077,Croatia,2017,8,J01-Antibacterials for systemic use,Million of national currency units,312.0 +9078,Croatia,2017,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,908.8 +9079,Croatia,2017,8,C07-Beta blocking agents,"Million US$, purchasing power parity",197.2 +9080,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0 +9081,Croatia,2017,8,Total pharmaceutical sales,"Million US$, purchasing power parity",13896.6 +9082,Croatia,2017,8,A-Alimentary tract and metabolism,Million of national currency units,799.0 +9083,Croatia,2017,8,J-Antiinfectives for systemic use,Million of national currency units,609.0 +9084,Croatia,2017,8,N06A-Antidepressants,"Million US$, purchasing power parity",181.3 +9085,Croatia,2017,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.4 +9086,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,70.5 +9087,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",62.6 +9088,Croatia,2017,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",81.8 +9089,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",262.9 +9090,Croatia,2017,8,A10-Drugs used in diabetes,Million of national currency units,408.0 +9091,Croatia,2017,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",516.7 +9092,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,139.0 +9093,Croatia,2017,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",707.1 +9094,Croatia,2017,8,A02A-Antacids,"Million US$, purchasing power parity",20.4 +9095,Croatia,2017,8,C01A-Cardiac glycosides,Million of national currency units,5.0 +9096,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",31.9 +9097,Croatia,2017,8,C-Cardiovascular system,"/capita, US$ exchange rate",216.2 +9098,Croatia,2017,8,C08-Calcium channel blockers,Million US$ at exchange rate,94.4 +9099,Croatia,2017,8,C03-Diuretics,"/capita, US$ purchasing power parity",29.1 +9100,Croatia,2017,8,C03-Diuretics,Million of national currency units,53.0 +9101,Croatia,2017,8,R-Respiratory system,"/capita, US$ exchange rate",98.6 +9102,Croatia,2017,8,R-Respiratory system,Million of national currency units,358.0 +9103,Croatia,2017,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,692.7 +9104,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",172.9 +9105,Croatia,2017,8,N-Nervous system,"Million US$, purchasing power parity",1890.0 +9106,Denmark,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,3825.9 +9107,Denmark,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",46.0 +9108,Denmark,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,120.3 +9109,Denmark,2011,5,Total pharmaceutical sales,Million of national currency units,20540.2 +9110,Denmark,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2751.0 +9111,Denmark,2011,5,C-Cardiovascular system,Million US$ at exchange rate,264.2 +9112,Denmark,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",86.5 +9113,Denmark,2011,5,C-Cardiovascular system,Million of national currency units,1418.5 +9114,Denmark,2011,5,R-Respiratory system,% of total sales,9.3 +9115,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.0 +9116,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +9117,Denmark,2011,5,M-Musculo-skeletal system,Million of national currency units,646.0 +9118,Denmark,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2036.3 +9119,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.6 +9120,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,497.6 +9121,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.7 +9122,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.6 +9123,Denmark,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",272.7 +9124,Denmark,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,379.3 +9125,Denmark,2011,5,R-Respiratory system,Million of national currency units,1913.4 +9126,Denmark,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.1 +9127,Denmark,2011,5,R-Respiratory system,"/capita, US$ exchange rate",64.0 +9128,Denmark,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",493.8 +9129,Denmark,2011,5,R-Respiratory system,Million US$ at exchange rate,356.4 +9130,Denmark,2011,5,C-Cardiovascular system,% of total sales,6.9 +9131,Denmark,2011,5,R-Respiratory system,"Million US$, purchasing power parity",256.3 +9132,Denmark,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.6 +9133,Denmark,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5 +9134,Denmark,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",190.0 +9135,Denmark,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",47.4 +9136,Denmark,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",49.0 +9137,Denmark,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",34.1 +9138,Denmark,2011,5,J-Antiinfectives for systemic use,% of total sales,9.9 +9139,Denmark,2011,5,M-Musculo-skeletal system,% of total sales,3.1 +9140,Denmark,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",686.8 +9141,Denmark,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.3 +9142,Denmark,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",161.5 +9143,Denmark,2011,5,Products not elsewhere classified,Million of national currency units,5610.0 +9144,Denmark,2011,5,Products not elsewhere classified,Million US$ at exchange rate,1044.9 +9145,Denmark,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.7 +9146,Denmark,2011,5,G-Genito urinary system and sex hormones,% of total sales,4.6 +9147,Denmark,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.3 +9148,Denmark,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,313.5 +9149,Denmark,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.0 +9150,Denmark,2011,5,A-Alimentary tract and metabolism,Million of national currency units,1682.9 +9151,Denmark,2011,5,N-Nervous system,"/capita, US$ exchange rate",153.3 +9152,Denmark,2011,5,B-Blood and blood forming organs,% of total sales,5.9 +9153,Denmark,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",225.4 +9154,Denmark,2011,5,N-Nervous system,% of total sales,22.3 +9155,Denmark,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",110.2 +9156,Denmark,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.6 +9157,Denmark,2011,5,N-Nervous system,Million US$ at exchange rate,853.7 +9158,Denmark,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,946.1 +9159,Denmark,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,176.2 +9160,Denmark,2011,5,A-Alimentary tract and metabolism,% of total sales,8.2 +9161,Denmark,2011,5,N-Nervous system,Million of national currency units,4583.4 +9162,Denmark,2011,5,N-Nervous system,"Million US$, purchasing power parity",613.9 +9163,Denmark,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.5 +9164,Denmark,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",751.4 +9165,Denmark,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",187.6 +9166,Denmark,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,224.6 +9167,Denmark,2011,5,B-Blood and blood forming organs,Million of national currency units,1206.0 +9168,Denmark,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.9 +9169,Denmark,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",126.7 +9170,Denmark,2011,5,Products not elsewhere classified,% of total sales,27.3 +9171,Denmark,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,3532.1 +9172,Denmark,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",46.8 +9173,Denmark,2012,5,Total pharmaceutical sales,Million of national currency units,20459.8 +9174,Denmark,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,93.9 +9175,Denmark,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2704.8 +9176,Denmark,2012,5,C-Cardiovascular system,Million US$ at exchange rate,219.8 +9177,Denmark,2012,5,C-Cardiovascular system,Million of national currency units,1273.3 +9178,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4 +9179,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +9180,Denmark,2012,5,M-Musculo-skeletal system,Million of national currency units,543.8 +9181,Denmark,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2015.8 +9182,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9 +9183,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,482.7 +9184,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.8 +9185,Denmark,2012,5,R-Respiratory system,% of total sales,9.7 +9186,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,83.3 +9187,Denmark,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",266.5 +9188,Denmark,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,348.0 +9189,Denmark,2012,5,R-Respiratory system,Million of national currency units,1977.5 +9190,Denmark,2012,5,C-Cardiovascular system,% of total sales,6.2 +9191,Denmark,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.2 +9192,Denmark,2012,5,R-Respiratory system,"/capita, US$ exchange rate",61.1 +9193,Denmark,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",483.7 +9194,Denmark,2012,5,R-Respiratory system,Million US$ at exchange rate,341.4 +9195,Denmark,2012,5,R-Respiratory system,"Million US$, purchasing power parity",261.4 +9196,Denmark,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.8 +9197,Denmark,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9 +9198,Denmark,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",168.3 +9199,Denmark,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",39.3 +9200,Denmark,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",71.9 +9201,Denmark,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",631.7 +9202,Denmark,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.7 +9203,Denmark,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",30.1 +9204,Denmark,2012,5,J-Antiinfectives for systemic use,% of total sales,9.9 +9205,Denmark,2012,5,M-Musculo-skeletal system,% of total sales,2.7 +9206,Denmark,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",41.5 +9207,Denmark,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",177.7 +9208,Denmark,2012,5,Products not elsewhere classified,Million of national currency units,5976.8 +9209,Denmark,2012,5,Products not elsewhere classified,Million US$ at exchange rate,1031.8 +9210,Denmark,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.1 +9211,Denmark,2012,5,G-Genito urinary system and sex hormones,% of total sales,4.8 +9212,Denmark,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.9 +9213,Denmark,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,306.8 +9214,Denmark,2012,5,A-Alimentary tract and metabolism,Million of national currency units,1777.0 +9215,Denmark,2012,5,N-Nervous system,"/capita, US$ exchange rate",126.3 +9216,Denmark,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8 +9217,Denmark,2012,5,B-Blood and blood forming organs,% of total sales,6.6 +9218,Denmark,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",234.9 +9219,Denmark,2012,5,N-Nervous system,% of total sales,20.0 +9220,Denmark,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",96.7 +9221,Denmark,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.2 +9222,Denmark,2012,5,N-Nervous system,Million US$ at exchange rate,706.2 +9223,Denmark,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,978.0 +9224,Denmark,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,168.8 +9225,Denmark,2012,5,A-Alimentary tract and metabolism,% of total sales,8.7 +9226,Denmark,2012,5,N-Nervous system,Million of national currency units,4090.7 +9227,Denmark,2012,5,N-Nervous system,"Million US$, purchasing power parity",540.8 +9228,Denmark,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.0 +9229,Denmark,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",790.2 +9230,Denmark,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",184.5 +9231,Denmark,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,232.0 +9232,Denmark,2012,5,B-Blood and blood forming organs,Million of national currency units,1344.1 +9233,Denmark,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",129.3 +9234,Denmark,2012,5,Products not elsewhere classified,% of total sales,29.2 +9235,Denmark,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",141.3 +9236,Denmark,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,3636.2 +9237,Denmark,2013,4,Total pharmaceutical sales,Million of national currency units,20422.2 +9238,Denmark,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",46.2 +9239,Denmark,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2776.7 +9240,Denmark,2013,4,C-Cardiovascular system,Million US$ at exchange rate,200.9 +9241,Denmark,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,98.2 +9242,Denmark,2013,4,C-Cardiovascular system,Million of national currency units,1128.6 +9243,Denmark,2013,4,R-Respiratory system,% of total sales,9.3 +9244,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6 +9245,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9 +9246,Denmark,2013,4,M-Musculo-skeletal system,Million of national currency units,551.8 +9247,Denmark,2013,4,J-Antiinfectives for systemic use,Million of national currency units,2066.2 +9248,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +9249,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,437.0 +9250,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.4 +9251,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,77.8 +9252,Denmark,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",280.9 +9253,Denmark,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.9 +9254,Denmark,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",647.6 +9255,Denmark,2013,4,C-Cardiovascular system,% of total sales,5.5 +9256,Denmark,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.5 +9257,Denmark,2013,4,R-Respiratory system,Million of national currency units,1909.3 +9258,Denmark,2013,4,R-Respiratory system,"/capita, US$ exchange rate",60.5 +9259,Denmark,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",494.5 +9260,Denmark,2013,4,R-Respiratory system,Million US$ at exchange rate,340.0 +9261,Denmark,2013,4,R-Respiratory system,"Million US$, purchasing power parity",259.6 +9262,Denmark,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.5 +9263,Denmark,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.4 +9264,Denmark,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",75.0 +9265,Denmark,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",153.4 +9266,Denmark,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",35.8 +9267,Denmark,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.0 +9268,Denmark,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.3 +9269,Denmark,2013,4,M-Musculo-skeletal system,% of total sales,2.7 +9270,Denmark,2013,4,J-Antiinfectives for systemic use,% of total sales,10.1 +9271,Denmark,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.6 +9272,Denmark,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",191.1 +9273,Denmark,2013,4,Products not elsewhere classified,Million of national currency units,6538.7 +9274,Denmark,2013,4,Products not elsewhere classified,Million US$ at exchange rate,1164.2 +9275,Denmark,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.1 +9276,Denmark,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.9 +9277,Denmark,2013,4,G-Genito urinary system and sex hormones,% of total sales,4.3 +9278,Denmark,2013,4,A-Alimentary tract and metabolism,Million of national currency units,1825.1 +9279,Denmark,2013,4,N-Nervous system,"/capita, US$ exchange rate",117.0 +9280,Denmark,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.0 +9281,Denmark,2013,4,B-Blood and blood forming organs,% of total sales,6.9 +9282,Denmark,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",248.2 +9283,Denmark,2013,4,N-Nervous system,% of total sales,18.1 +9284,Denmark,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",89.3 +9285,Denmark,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,325.0 +9286,Denmark,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6 +9287,Denmark,2013,4,N-Nervous system,Million US$ at exchange rate,657.0 +9288,Denmark,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,155.0 +9289,Denmark,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,870.4 +9290,Denmark,2013,4,A-Alimentary tract and metabolism,% of total sales,8.9 +9291,Denmark,2013,4,N-Nervous system,Million of national currency units,3689.7 +9292,Denmark,2013,4,N-Nervous system,"Million US$, purchasing power parity",501.7 +9293,Denmark,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.2 +9294,Denmark,2013,4,Products not elsewhere classified,% of total sales,32.0 +9295,Denmark,2013,4,Products not elsewhere classified,"Million US$, purchasing power parity",889.0 +9296,Denmark,2013,4,Products not elsewhere classified,"/capita, US$ exchange rate",207.3 +9297,Denmark,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,250.2 +9298,Denmark,2013,4,B-Blood and blood forming organs,Million of national currency units,1405.3 +9299,Denmark,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",118.3 +9300,Denmark,2013,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",158.3 +9301,Denmark,2017,4,Total pharmaceutical sales,Million of national currency units,22941.5 +9302,Denmark,2017,4,M-Musculo-skeletal system,Million of national currency units,598.1 +9303,Denmark,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",48.6 +9304,Denmark,2017,4,R-Respiratory system,"/capita, US$ exchange rate",50.6 +9305,Denmark,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3338.6 +9306,Denmark,2017,4,C-Cardiovascular system,Million US$ at exchange rate,163.5 +9307,Denmark,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,3474.5 +9308,Denmark,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,90.6 +9309,Denmark,2017,4,C-Cardiovascular system,Million of national currency units,1079.3 +9310,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.1 +9311,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6 +9312,Denmark,2017,4,J-Antiinfectives for systemic use,Million of national currency units,1983.3 +9313,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +9314,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,477.8 +9315,Denmark,2017,4,R-Respiratory system,% of total sales,8.4 +9316,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",69.5 +9317,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.4 +9318,Denmark,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",602.7 +9319,Denmark,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",288.6 +9320,Denmark,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,300.4 +9321,Denmark,2017,4,C-Cardiovascular system,% of total sales,4.7 +9322,Denmark,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.1 +9323,Denmark,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",579.1 +9324,Denmark,2017,4,R-Respiratory system,"Million US$, purchasing power parity",280.2 +9325,Denmark,2017,4,R-Respiratory system,Million of national currency units,1925.4 +9326,Denmark,2017,4,R-Respiratory system,Million US$ at exchange rate,291.6 +9327,Denmark,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",87.0 +9328,Denmark,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.7 +9329,Denmark,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.1 +9330,Denmark,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.4 +9331,Denmark,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1 +9332,Denmark,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.2 +9333,Denmark,2017,4,M-Musculo-skeletal system,% of total sales,2.6 +9334,Denmark,2017,4,J-Antiinfectives for systemic use,% of total sales,8.6 +9335,Denmark,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.1 +9336,Denmark,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",52.4 +9337,Denmark,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.1 +9338,Denmark,2017,4,Products not elsewhere classified,Million of national currency units,8416.3 +9339,Denmark,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.0 +9340,Denmark,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.8 +9341,Denmark,2017,4,G-Genito urinary system and sex hormones,% of total sales,3.6 +9342,Denmark,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2320.4 +9343,Denmark,2017,4,B-Blood and blood forming organs,% of total sales,8.7 +9344,Denmark,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",50.3 +9345,Denmark,2017,4,N-Nervous system,"/capita, US$ exchange rate",87.1 +9346,Denmark,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",337.7 +9347,Denmark,2017,4,N-Nervous system,% of total sales,14.5 +9348,Denmark,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",83.7 +9349,Denmark,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,351.4 +9350,Denmark,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.0 +9351,Denmark,2017,4,N-Nervous system,Million US$ at exchange rate,502.3 +9352,Denmark,2017,4,Products not elsewhere classified,% of total sales,36.7 +9353,Denmark,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,830.2 +9354,Denmark,2017,4,N-Nervous system,Million of national currency units,3316.9 +9355,Denmark,2017,4,A-Alimentary tract and metabolism,% of total sales,10.1 +9356,Denmark,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.6 +9357,Denmark,2017,4,N-Nervous system,"Million US$, purchasing power parity",482.7 +9358,Denmark,2017,4,Products not elsewhere classified,"Million US$, purchasing power parity",1224.8 +9359,Denmark,2017,4,Products not elsewhere classified,"/capita, US$ exchange rate",221.1 +9360,Denmark,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,302.0 +9361,Denmark,2017,4,B-Blood and blood forming organs,Million of national currency units,1993.8 +9362,Denmark,2017,4,Products not elsewhere classified,Million US$ at exchange rate,1274.6 +9363,Denmark,2017,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",212.5 +9364,Denmark,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.8 +9365,Denmark,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,125.7 +9366,Denmark,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,3254.8 +9367,Denmark,2015,4,M-Musculo-skeletal system,Million of national currency units,578.9 +9368,Denmark,2015,4,Total pharmaceutical sales,Million of national currency units,21897.7 +9369,Denmark,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",47.4 +9370,Denmark,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2997.5 +9371,Denmark,2015,4,C-Cardiovascular system,Million US$ at exchange rate,171.3 +9372,Denmark,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,86.0 +9373,Denmark,2015,4,C-Cardiovascular system,Million of national currency units,1152.3 +9374,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.1 +9375,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.0 +9376,Denmark,2015,4,J-Antiinfectives for systemic use,Million of national currency units,2220.3 +9377,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +9378,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,459.2 +9379,Denmark,2015,4,R-Respiratory system,% of total sales,9.0 +9380,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",62.9 +9381,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.2 +9382,Denmark,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",303.9 +9383,Denmark,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,330.0 +9384,Denmark,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",572.7 +9385,Denmark,2015,4,C-Cardiovascular system,% of total sales,5.3 +9386,Denmark,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",58.1 +9387,Denmark,2015,4,R-Respiratory system,Million of national currency units,1968.7 +9388,Denmark,2015,4,R-Respiratory system,"/capita, US$ exchange rate",51.5 +9389,Denmark,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",527.4 +9390,Denmark,2015,4,R-Respiratory system,Million US$ at exchange rate,292.6 +9391,Denmark,2015,4,R-Respiratory system,"Million US$, purchasing power parity",269.5 +9392,Denmark,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.1 +9393,Denmark,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9 +9394,Denmark,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",79.2 +9395,Denmark,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.7 +9396,Denmark,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",30.1 +9397,Denmark,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",53.5 +9398,Denmark,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.8 +9399,Denmark,2015,4,M-Musculo-skeletal system,% of total sales,2.6 +9400,Denmark,2015,4,J-Antiinfectives for systemic use,% of total sales,10.1 +9401,Denmark,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.0 +9402,Denmark,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",235.6 +9403,Denmark,2015,4,Products not elsewhere classified,Million of national currency units,7278.8 +9404,Denmark,2015,4,Products not elsewhere classified,Million US$ at exchange rate,1081.9 +9405,Denmark,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.1 +9406,Denmark,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.8 +9407,Denmark,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.6 +9408,Denmark,2015,4,G-Genito urinary system and sex hormones,% of total sales,3.8 +9409,Denmark,2015,4,A-Alimentary tract and metabolism,Million of national currency units,2086.5 +9410,Denmark,2015,4,B-Blood and blood forming organs,% of total sales,7.9 +9411,Denmark,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.5 +9412,Denmark,2015,4,N-Nervous system,"/capita, US$ exchange rate",94.1 +9413,Denmark,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",285.6 +9414,Denmark,2015,4,N-Nervous system,% of total sales,16.4 +9415,Denmark,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",86.6 +9416,Denmark,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,310.1 +9417,Denmark,2015,4,N-Nervous system,Million US$ at exchange rate,534.6 +9418,Denmark,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,834.9 +9419,Denmark,2015,4,N-Nervous system,Million of national currency units,3596.9 +9420,Denmark,2015,4,A-Alimentary tract and metabolism,% of total sales,9.5 +9421,Denmark,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.3 +9422,Denmark,2015,4,N-Nervous system,"Million US$, purchasing power parity",492.4 +9423,Denmark,2015,4,Products not elsewhere classified,% of total sales,33.2 +9424,Denmark,2015,4,Products not elsewhere classified,"Million US$, purchasing power parity",996.4 +9425,Denmark,2015,4,Products not elsewhere classified,"/capita, US$ exchange rate",190.4 +9426,Denmark,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,255.8 +9427,Denmark,2015,4,B-Blood and blood forming organs,Million of national currency units,1721.2 +9428,Denmark,2015,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",175.3 +9429,Denmark,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",114.3 +9430,Denmark,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,124.1 +9431,Denmark,2016,4,M-Musculo-skeletal system,Million of national currency units,593.4 +9432,Denmark,2016,4,Total pharmaceutical sales,Million of national currency units,22110.0 +9433,Denmark,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,3284.5 +9434,Denmark,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",48.2 +9435,Denmark,2016,4,R-Respiratory system,"/capita, US$ exchange rate",50.7 +9436,Denmark,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3122.9 +9437,Denmark,2016,4,C-Cardiovascular system,Million US$ at exchange rate,161.1 +9438,Denmark,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,88.1 +9439,Denmark,2016,4,C-Cardiovascular system,Million of national currency units,1084.4 +9440,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5 +9441,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.1 +9442,Denmark,2016,4,J-Antiinfectives for systemic use,Million of national currency units,2066.0 +9443,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +9444,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,466.9 +9445,Denmark,2016,4,R-Respiratory system,% of total sales,8.8 +9446,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.0 +9447,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,69.4 +9448,Denmark,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",291.8 +9449,Denmark,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,306.9 +9450,Denmark,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",573.4 +9451,Denmark,2016,4,C-Cardiovascular system,% of total sales,4.9 +9452,Denmark,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6 +9453,Denmark,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",545.2 +9454,Denmark,2016,4,R-Respiratory system,"Million US$, purchasing power parity",276.1 +9455,Denmark,2016,4,R-Respiratory system,Million of national currency units,1954.6 +9456,Denmark,2016,4,R-Respiratory system,Million US$ at exchange rate,290.4 +9457,Denmark,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.4 +9458,Denmark,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",83.8 +9459,Denmark,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",153.2 +9460,Denmark,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.6 +9461,Denmark,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.1 +9462,Denmark,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.9 +9463,Denmark,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",26.7 +9464,Denmark,2016,4,M-Musculo-skeletal system,% of total sales,2.7 +9465,Denmark,2016,4,J-Antiinfectives for systemic use,% of total sales,9.3 +9466,Denmark,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.0 +9467,Denmark,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",261.6 +9468,Denmark,2016,4,Products not elsewhere classified,Million of national currency units,7562.7 +9469,Denmark,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.5 +9470,Denmark,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.6 +9471,Denmark,2016,4,G-Genito urinary system and sex hormones,% of total sales,3.8 +9472,Denmark,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2214.3 +9473,Denmark,2016,4,B-Blood and blood forming organs,% of total sales,8.4 +9474,Denmark,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.7 +9475,Denmark,2016,4,N-Nervous system,"/capita, US$ exchange rate",90.4 +9476,Denmark,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",312.8 +9477,Denmark,2016,4,N-Nervous system,% of total sales,15.8 +9478,Denmark,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",85.9 +9479,Denmark,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.9 +9480,Denmark,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.4 +9481,Denmark,2016,4,N-Nervous system,Million US$ at exchange rate,517.6 +9482,Denmark,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,831.7 +9483,Denmark,2016,4,Products not elsewhere classified,% of total sales,34.2 +9484,Denmark,2016,4,A-Alimentary tract and metabolism,% of total sales,10.0 +9485,Denmark,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.6 +9486,Denmark,2016,4,N-Nervous system,"Million US$, purchasing power parity",492.1 +9487,Denmark,2016,4,N-Nervous system,Million of national currency units,3484.1 +9488,Denmark,2016,4,Products not elsewhere classified,"Million US$, purchasing power parity",1068.2 +9489,Denmark,2016,4,Products not elsewhere classified,"/capita, US$ exchange rate",196.1 +9490,Denmark,2016,4,Products not elsewhere classified,Million US$ at exchange rate,1123.4 +9491,Denmark,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,275.1 +9492,Denmark,2016,4,B-Blood and blood forming organs,Million of national currency units,1851.8 +9493,Denmark,2016,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",186.5 +9494,Denmark,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",117.5 +9495,Denmark,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,123.5 +9496,Denmark,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,3764.4 +9497,Denmark,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,109.9 +9498,Denmark,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",45.5 +9499,Denmark,2010,5,Total pharmaceutical sales,Million of national currency units,21171.2 +9500,Denmark,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2788.9 +9501,Denmark,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",678.6 +9502,Denmark,2010,5,R-Respiratory system,% of total sales,9.1 +9503,Denmark,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.5 +9504,Denmark,2010,5,C-Cardiovascular system,Million of national currency units,1722.0 +9505,Denmark,2010,5,C-Cardiovascular system,Million US$ at exchange rate,306.2 +9506,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +9507,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8 +9508,Denmark,2010,5,M-Musculo-skeletal system,Million of national currency units,618.3 +9509,Denmark,2010,5,J-Antiinfectives for systemic use,Million of national currency units,2056.7 +9510,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9 +9511,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,497.6 +9512,Denmark,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,365.7 +9513,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.5 +9514,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.6 +9515,Denmark,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",270.9 +9516,Denmark,2010,5,R-Respiratory system,Million of national currency units,1917.9 +9517,Denmark,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.9 +9518,Denmark,2010,5,R-Respiratory system,"/capita, US$ exchange rate",61.5 +9519,Denmark,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.7 +9520,Denmark,2010,5,R-Respiratory system,Million US$ at exchange rate,341.0 +9521,Denmark,2010,5,R-Respiratory system,"Million US$, purchasing power parity",252.7 +9522,Denmark,2010,5,C-Cardiovascular system,% of total sales,8.1 +9523,Denmark,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.8 +9524,Denmark,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7 +9525,Denmark,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",226.8 +9526,Denmark,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",55.2 +9527,Denmark,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",48.8 +9528,Denmark,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9 +9529,Denmark,2010,5,J-Antiinfectives for systemic use,% of total sales,9.7 +9530,Denmark,2010,5,M-Musculo-skeletal system,% of total sales,2.9 +9531,Denmark,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.9 +9532,Denmark,2010,5,Products not elsewhere classified,Million US$ at exchange rate,1011.3 +9533,Denmark,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.5 +9534,Denmark,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",163.8 +9535,Denmark,2010,5,Products not elsewhere classified,Million of national currency units,5687.4 +9536,Denmark,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.7 +9537,Denmark,2010,5,G-Genito urinary system and sex hormones,% of total sales,4.9 +9538,Denmark,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.8 +9539,Denmark,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,309.4 +9540,Denmark,2010,5,A-Alimentary tract and metabolism,Million of national currency units,1740.0 +9541,Denmark,2010,5,B-Blood and blood forming organs,% of total sales,5.9 +9542,Denmark,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",229.2 +9543,Denmark,2010,5,N-Nervous system,% of total sales,21.9 +9544,Denmark,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",110.3 +9545,Denmark,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.3 +9546,Denmark,2010,5,N-Nervous system,Million US$ at exchange rate,826.1 +9547,Denmark,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,1041.8 +9548,Denmark,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,185.2 +9549,Denmark,2010,5,A-Alimentary tract and metabolism,% of total sales,8.2 +9550,Denmark,2010,5,N-Nervous system,"/capita, US$ exchange rate",148.9 +9551,Denmark,2010,5,N-Nervous system,Million of national currency units,4646.0 +9552,Denmark,2010,5,N-Nervous system,"Million US$, purchasing power parity",612.0 +9553,Denmark,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",749.2 +9554,Denmark,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",182.3 +9555,Denmark,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.4 +9556,Denmark,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,221.1 +9557,Denmark,2010,5,B-Blood and blood forming organs,Million of national currency units,1243.4 +9558,Denmark,2010,5,Products not elsewhere classified,% of total sales,26.9 +9559,Denmark,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.0 +9560,Denmark,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",137.2 +9561,Denmark,2014,4,Total pharmaceutical sales,Million US$ at exchange rate,3816.2 +9562,Denmark,2014,4,M-Musculo-skeletal system,Million of national currency units,534.2 +9563,Denmark,2014,4,R-Respiratory system,"/capita, US$ purchasing power parity",47.0 +9564,Denmark,2014,4,Total pharmaceutical sales,Million of national currency units,21418.1 +9565,Denmark,2014,4,M-Musculo-skeletal system,Million US$ at exchange rate,95.2 +9566,Denmark,2014,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2922.5 +9567,Denmark,2014,4,C-Cardiovascular system,Million US$ at exchange rate,205.5 +9568,Denmark,2014,4,C-Cardiovascular system,Million of national currency units,1153.2 +9569,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.3 +9570,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.7 +9571,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +9572,Denmark,2014,4,J-Antiinfectives for systemic use,Million of national currency units,2107.4 +9573,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,465.8 +9574,Denmark,2014,4,R-Respiratory system,% of total sales,9.1 +9575,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.6 +9576,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,83.0 +9577,Denmark,2014,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",287.6 +9578,Denmark,2014,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,375.5 +9579,Denmark,2014,4,Total pharmaceutical sales,"/capita, US$ exchange rate",676.2 +9580,Denmark,2014,4,C-Cardiovascular system,% of total sales,5.4 +9581,Denmark,2014,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.5 +9582,Denmark,2014,4,R-Respiratory system,Million of national currency units,1944.7 +9583,Denmark,2014,4,R-Respiratory system,"/capita, US$ exchange rate",61.4 +9584,Denmark,2014,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",517.9 +9585,Denmark,2014,4,R-Respiratory system,Million US$ at exchange rate,346.5 +9586,Denmark,2014,4,R-Respiratory system,"Million US$, purchasing power parity",265.4 +9587,Denmark,2014,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.9 +9588,Denmark,2014,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9 +9589,Denmark,2014,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",72.9 +9590,Denmark,2014,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.4 +9591,Denmark,2014,4,C-Cardiovascular system,"/capita, US$ exchange rate",36.4 +9592,Denmark,2014,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.0 +9593,Denmark,2014,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.9 +9594,Denmark,2014,4,M-Musculo-skeletal system,% of total sales,2.5 +9595,Denmark,2014,4,J-Antiinfectives for systemic use,% of total sales,9.8 +9596,Denmark,2014,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.3 +9597,Denmark,2014,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",217.5 +9598,Denmark,2014,4,Products not elsewhere classified,Million of national currency units,7193.0 +9599,Denmark,2014,4,Products not elsewhere classified,Million US$ at exchange rate,1281.6 +9600,Denmark,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.7 +9601,Denmark,2014,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.7 +9602,Denmark,2014,4,G-Genito urinary system and sex hormones,% of total sales,3.8 +9603,Denmark,2014,4,A-Alimentary tract and metabolism,Million of national currency units,1954.7 +9604,Denmark,2014,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5 +9605,Denmark,2014,4,B-Blood and blood forming organs,% of total sales,7.4 +9606,Denmark,2014,4,N-Nervous system,"/capita, US$ exchange rate",115.5 +9607,Denmark,2014,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",266.7 +9608,Denmark,2014,4,N-Nervous system,% of total sales,17.1 +9609,Denmark,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.7 +9610,Denmark,2014,4,N-Nervous system,"/capita, US$ purchasing power parity",88.5 +9611,Denmark,2014,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,348.3 +9612,Denmark,2014,4,N-Nervous system,Million US$ at exchange rate,651.8 +9613,Denmark,2014,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,144.9 +9614,Denmark,2014,4,G-Genito urinary system and sex hormones,Million of national currency units,813.1 +9615,Denmark,2014,4,A-Alimentary tract and metabolism,% of total sales,9.1 +9616,Denmark,2014,4,N-Nervous system,Million of national currency units,3658.3 +9617,Denmark,2014,4,N-Nervous system,"Million US$, purchasing power parity",499.2 +9618,Denmark,2014,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.3 +9619,Denmark,2014,4,Products not elsewhere classified,"Million US$, purchasing power parity",981.5 +9620,Denmark,2014,4,Products not elsewhere classified,"/capita, US$ exchange rate",227.1 +9621,Denmark,2014,4,B-Blood and blood forming organs,Million US$ at exchange rate,284.0 +9622,Denmark,2014,4,B-Blood and blood forming organs,Million of national currency units,1593.7 +9623,Denmark,2014,4,Products not elsewhere classified,% of total sales,33.6 +9624,Denmark,2014,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",173.9 +9625,Denmark,2014,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",110.9 +9626,Estonia,2016,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.4 +9627,Estonia,2016,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.6 +9628,Estonia,2016,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0 +9629,Estonia,2016,11,N05B-Anxiolytics,% of total sales,0.5 +9630,Estonia,2016,11,C02-Antihypertensives,Million US$ at exchange rate,0.8 +9631,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3 +9632,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.6 +9633,Estonia,2016,11,N02-Analgesics,"Million US$, purchasing power parity",14.1 +9634,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.4 +9635,Estonia,2016,11,N02-Analgesics,Million US$ at exchange rate,8.3 +9636,Estonia,2016,11,N05B-Anxiolytics,Million US$ at exchange rate,1.5 +9637,Estonia,2016,11,N05B-Anxiolytics,Million of national currency units,1.4 +9638,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3 +9639,Estonia,2016,11,N02-Analgesics,"/capita, US$ purchasing power parity",10.7 +9640,Estonia,2016,11,N02-Analgesics,"/capita, US$ exchange rate",6.3 +9641,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.9 +9642,Estonia,2016,11,N02-Analgesics,% of total sales,2.6 +9643,Estonia,2016,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +9644,Estonia,2016,11,C-Cardiovascular system,"/capita, US$ exchange rate",25.9 +9645,Estonia,2016,11,C-Cardiovascular system,"Million US$, purchasing power parity",58.3 +9646,Estonia,2016,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +9647,Estonia,2016,11,C02-Antihypertensives,% of total sales,0.3 +9648,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3 +9649,Estonia,2016,11,C-Cardiovascular system,Million US$ at exchange rate,34.1 +9650,Estonia,2016,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +9651,Estonia,2016,11,N02-Analgesics,Million of national currency units,7.5 +9652,Estonia,2016,11,C-Cardiovascular system,Million of national currency units,30.8 +9653,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.7 +9654,Estonia,2016,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.3 +9655,Estonia,2016,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",36.5 +9656,Estonia,2016,11,B-Blood and blood forming organs,Million US$ at exchange rate,28.1 +9657,Estonia,2016,11,B-Blood and blood forming organs,% of total sales,8.7 +9658,Estonia,2016,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",48.0 +9659,Estonia,2016,11,R-Respiratory system,"Million US$, purchasing power parity",40.4 +9660,Estonia,2016,11,R-Respiratory system,"/capita, US$ exchange rate",17.9 +9661,Estonia,2016,11,R-Respiratory system,Million of national currency units,21.3 +9662,Estonia,2016,11,R-Respiratory system,Million US$ at exchange rate,23.6 +9663,Estonia,2016,11,C10-Lipid modifying agents,% of total sales,1.1 +9664,Estonia,2016,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.4 +9665,Estonia,2016,11,A02A-Antacids,Million of national currency units,0.4 +9666,Estonia,2016,11,A02A-Antacids,"Million US$, purchasing power parity",0.7 +9667,Estonia,2016,11,A02A-Antacids,Million US$ at exchange rate,0.4 +9668,Estonia,2016,11,C10-Lipid modifying agents,Million US$ at exchange rate,3.4 +9669,Estonia,2016,11,C10-Lipid modifying agents,Million of national currency units,3.1 +9670,Estonia,2016,11,B-Blood and blood forming organs,Million of national currency units,25.4 +9671,Estonia,2016,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.6 +9672,Estonia,2016,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.8 +9673,Estonia,2016,11,R-Respiratory system,"/capita, US$ purchasing power parity",30.7 +9674,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.6 +9675,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3 +9676,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.2 +9677,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.7 +9678,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.3 +9679,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.5 +9680,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.8 +9681,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.8 +9682,Estonia,2016,11,R03-Drugs for obstructive airway diseases,Million of national currency units,8.9 +9683,Estonia,2016,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.8 +9684,Estonia,2016,11,C08-Calcium channel blockers,Million US$ at exchange rate,2.3 +9685,Estonia,2016,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0 +9686,Estonia,2016,11,R-Respiratory system,% of total sales,7.4 +9687,Estonia,2016,11,C08-Calcium channel blockers,Million of national currency units,2.1 +9688,Estonia,2016,11,R03-Drugs for obstructive airway diseases,% of total sales,3.1 +9689,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2 +9690,Estonia,2016,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.8 +9691,Estonia,2016,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0 +9692,Estonia,2016,11,C08-Calcium channel blockers,% of total sales,0.7 +9693,Estonia,2016,11,N05C-Hypnotics and sedatives,Million of national currency units,1.8 +9694,Estonia,2016,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0 +9695,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.4 +9696,Estonia,2016,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4 +9697,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.8 +9698,Estonia,2016,11,N05C-Hypnotics and sedatives,% of total sales,0.6 +9699,Estonia,2016,11,G-Genito urinary system and sex hormones,% of total sales,4.0 +9700,Estonia,2016,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5 +9701,Estonia,2016,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6 +9702,Estonia,2016,11,C03-Diuretics,"/capita, US$ exchange rate",1.6 +9703,Estonia,2016,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.7 +9704,Estonia,2016,11,C03-Diuretics,"Million US$, purchasing power parity",3.6 +9705,Estonia,2016,11,C03-Diuretics,Million of national currency units,1.9 +9706,Estonia,2016,11,C03-Diuretics,Million US$ at exchange rate,2.1 +9707,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.3 +9708,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.9 +9709,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.0 +9710,Estonia,2016,11,C03-Diuretics,% of total sales,0.7 +9711,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +9712,Estonia,2016,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.7 +9713,Estonia,2016,11,C07-Beta blocking agents,Million US$ at exchange rate,6.0 +9714,Estonia,2016,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.3 +9715,Estonia,2016,11,N06A-Antidepressants,% of total sales,1.1 +9716,Estonia,2016,11,C07-Beta blocking agents,Million of national currency units,5.4 +9717,Estonia,2016,11,A02A-Antacids,% of total sales,0.1 +9718,Estonia,2016,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +9719,Estonia,2016,11,A02A-Antacids,"/capita, US$ exchange rate",0.3 +9720,Estonia,2016,11,C07-Beta blocking agents,% of total sales,1.9 +9721,Estonia,2016,11,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6 +9722,Estonia,2016,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8 +9723,Estonia,2016,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.8 +9724,Estonia,2016,11,G-Genito urinary system and sex hormones,Million of national currency units,11.6 +9725,Estonia,2016,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.8 +9726,Estonia,2016,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",22.0 +9727,Estonia,2016,11,N06A-Antidepressants,"/capita, US$ exchange rate",2.7 +9728,Estonia,2016,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.7 +9729,Estonia,2016,11,N06A-Antidepressants,Million of national currency units,3.3 +9730,Estonia,2016,11,N06A-Antidepressants,Million US$ at exchange rate,3.6 +9731,Estonia,2016,11,N06A-Antidepressants,"Million US$, purchasing power parity",6.2 +9732,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3 +9733,Estonia,2016,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.0 +9734,Estonia,2016,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9 +9735,Estonia,2016,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",65.1 +9736,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3 +9737,Estonia,2016,11,A10-Drugs used in diabetes,% of total sales,6.0 +9738,Estonia,2016,11,A-Alimentary tract and metabolism,Million of national currency units,34.3 +9739,Estonia,2016,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.8 +9740,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1 +9741,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.0 +9742,Estonia,2016,11,N-Nervous system,% of total sales,8.7 +9743,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +9744,Estonia,2016,11,N-Nervous system,"/capita, US$ purchasing power parity",36.4 +9745,Estonia,2016,11,N-Nervous system,"Million US$, purchasing power parity",47.9 +9746,Estonia,2016,11,N-Nervous system,"/capita, US$ exchange rate",21.3 +9747,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +9748,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4 +9749,Estonia,2016,11,A-Alimentary tract and metabolism,% of total sales,11.8 +9750,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8 +9751,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1 +9752,Estonia,2016,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.4 +9753,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +9754,Estonia,2016,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +9755,Estonia,2016,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +9756,Estonia,2016,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +9757,Estonia,2016,11,C01A-Cardiac glycosides,Million of national currency units,0.1 +9758,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.0 +9759,Estonia,2016,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +9760,Estonia,2016,11,Total pharmaceutical sales,Million US$ at exchange rate,320.9 +9761,Estonia,2016,11,Total pharmaceutical sales,Million of national currency units,289.9 +9762,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.3 +9763,Estonia,2016,11,C01A-Cardiac glycosides,% of total sales,0.0 +9764,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.7 +9765,Estonia,2016,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.6 +9766,Estonia,2016,11,M-Musculo-skeletal system,% of total sales,5.6 +9767,Estonia,2016,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.8 +9768,Estonia,2016,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.5 +9769,Estonia,2016,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",32.7 +9770,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.1 +9771,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.5 +9772,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.5 +9773,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",18.0 +9774,Estonia,2016,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.0 +9775,Estonia,2016,11,M-Musculo-skeletal system,Million US$ at exchange rate,18.1 +9776,Estonia,2016,11,M-Musculo-skeletal system,Million of national currency units,16.4 +9777,Estonia,2016,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,49.1 +9778,Estonia,2016,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.0 +9779,Estonia,2016,11,A10-Drugs used in diabetes,Million US$ at exchange rate,19.1 +9780,Estonia,2016,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.8 +9781,Estonia,2016,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",84.0 +9782,Estonia,2016,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.3 +9783,Estonia,2016,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.6 +9784,Estonia,2016,11,Total pharmaceutical sales,"/capita, US$ exchange rate",243.9 +9785,Estonia,2016,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",417.4 +9786,Estonia,2016,11,J-Antiinfectives for systemic use,Million of national currency units,44.3 +9787,Estonia,2016,11,J01-Antibacterials for systemic use,Million of national currency units,6.9 +9788,Estonia,2016,11,A10-Drugs used in diabetes,Million of national currency units,17.3 +9789,Estonia,2016,11,N-Nervous system,Million of national currency units,25.3 +9790,Estonia,2016,11,N-Nervous system,Million US$ at exchange rate,28.0 +9791,Estonia,2016,11,J-Antiinfectives for systemic use,% of total sales,15.3 +9792,Estonia,2016,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",44.3 +9793,Estonia,2016,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9 +9794,Estonia,2016,11,C02-Antihypertensives,Million of national currency units,0.8 +9795,Estonia,2016,11,Total pharmaceutical sales,"Million US$, purchasing power parity",549.2 +9796,Estonia,2016,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8 +9797,Estonia,2016,11,J01-Antibacterials for systemic use,% of total sales,2.4 +9798,Estonia,2016,11,C-Cardiovascular system,% of total sales,10.6 +9799,Estonia,2015,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.5 +9800,Estonia,2015,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.7 +9801,Estonia,2015,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0 +9802,Estonia,2015,10,N05B-Anxiolytics,% of total sales,0.5 +9803,Estonia,2015,10,C02-Antihypertensives,Million US$ at exchange rate,0.9 +9804,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.0 +9805,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3 +9806,Estonia,2015,10,N02-Analgesics,"Million US$, purchasing power parity",12.7 +9807,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.6 +9808,Estonia,2015,10,N05B-Anxiolytics,Million US$ at exchange rate,1.6 +9809,Estonia,2015,10,N05B-Anxiolytics,Million of national currency units,1.4 +9810,Estonia,2015,10,N02-Analgesics,Million US$ at exchange rate,7.6 +9811,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9 +9812,Estonia,2015,10,N02-Analgesics,"/capita, US$ exchange rate",5.8 +9813,Estonia,2015,10,N02-Analgesics,"/capita, US$ purchasing power parity",9.7 +9814,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.5 +9815,Estonia,2015,10,N02-Analgesics,% of total sales,2.6 +9816,Estonia,2015,10,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +9817,Estonia,2015,10,C-Cardiovascular system,"/capita, US$ exchange rate",26.5 +9818,Estonia,2015,10,C-Cardiovascular system,"Million US$, purchasing power parity",58.5 +9819,Estonia,2015,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +9820,Estonia,2015,10,C02-Antihypertensives,% of total sales,0.3 +9821,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0 +9822,Estonia,2015,10,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +9823,Estonia,2015,10,N02-Analgesics,Million of national currency units,6.8 +9824,Estonia,2015,10,C-Cardiovascular system,Million US$ at exchange rate,34.9 +9825,Estonia,2015,10,C-Cardiovascular system,Million of national currency units,31.5 +9826,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.5 +9827,Estonia,2015,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.9 +9828,Estonia,2015,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.1 +9829,Estonia,2015,10,B-Blood and blood forming organs,% of total sales,8.0 +9830,Estonia,2015,10,B-Blood and blood forming organs,Million US$ at exchange rate,23.6 +9831,Estonia,2015,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",39.6 +9832,Estonia,2015,10,R-Respiratory system,"Million US$, purchasing power parity",37.9 +9833,Estonia,2015,10,R-Respiratory system,"/capita, US$ exchange rate",17.2 +9834,Estonia,2015,10,R-Respiratory system,Million of national currency units,20.4 +9835,Estonia,2015,10,R-Respiratory system,Million US$ at exchange rate,22.6 +9836,Estonia,2015,10,C10-Lipid modifying agents,% of total sales,1.2 +9837,Estonia,2015,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.6 +9838,Estonia,2015,10,A02A-Antacids,Million of national currency units,0.4 +9839,Estonia,2015,10,A02A-Antacids,"Million US$, purchasing power parity",0.7 +9840,Estonia,2015,10,A02A-Antacids,Million US$ at exchange rate,0.4 +9841,Estonia,2015,10,C10-Lipid modifying agents,Million US$ at exchange rate,3.6 +9842,Estonia,2015,10,B-Blood and blood forming organs,Million of national currency units,21.3 +9843,Estonia,2015,10,C10-Lipid modifying agents,Million of national currency units,3.2 +9844,Estonia,2015,10,R-Respiratory system,"/capita, US$ purchasing power parity",28.8 +9845,Estonia,2015,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.7 +9846,Estonia,2015,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.0 +9847,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.7 +9848,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3 +9849,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.0 +9850,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.5 +9851,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.4 +9852,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.3 +9853,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.2 +9854,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.0 +9855,Estonia,2015,10,R03-Drugs for obstructive airway diseases,Million of national currency units,8.6 +9856,Estonia,2015,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.6 +9857,Estonia,2015,10,C08-Calcium channel blockers,Million US$ at exchange rate,2.6 +9858,Estonia,2015,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.4 +9859,Estonia,2015,10,R-Respiratory system,% of total sales,7.7 +9860,Estonia,2015,10,C08-Calcium channel blockers,Million of national currency units,2.3 +9861,Estonia,2015,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.0 +9862,Estonia,2015,10,R03-Drugs for obstructive airway diseases,% of total sales,3.3 +9863,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7 +9864,Estonia,2015,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.3 +9865,Estonia,2015,10,C08-Calcium channel blockers,% of total sales,0.9 +9866,Estonia,2015,10,N05C-Hypnotics and sedatives,Million of national currency units,1.8 +9867,Estonia,2015,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.9 +9868,Estonia,2015,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3 +9869,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.6 +9870,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.0 +9871,Estonia,2015,10,N05C-Hypnotics and sedatives,% of total sales,0.7 +9872,Estonia,2015,10,G-Genito urinary system and sex hormones,% of total sales,4.4 +9873,Estonia,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5 +9874,Estonia,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5 +9875,Estonia,2015,10,C03-Diuretics,"/capita, US$ exchange rate",1.5 +9876,Estonia,2015,10,C03-Diuretics,"/capita, US$ purchasing power parity",2.6 +9877,Estonia,2015,10,C03-Diuretics,"Million US$, purchasing power parity",3.4 +9878,Estonia,2015,10,C03-Diuretics,Million of national currency units,1.8 +9879,Estonia,2015,10,C03-Diuretics,Million US$ at exchange rate,2.0 +9880,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.5 +9881,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.1 +9882,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.1 +9883,Estonia,2015,10,C03-Diuretics,% of total sales,0.7 +9884,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.3 +9885,Estonia,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.4 +9886,Estonia,2015,10,C07-Beta blocking agents,Million US$ at exchange rate,6.2 +9887,Estonia,2015,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.4 +9888,Estonia,2015,10,N06A-Antidepressants,% of total sales,1.2 +9889,Estonia,2015,10,A02A-Antacids,% of total sales,0.1 +9890,Estonia,2015,10,C07-Beta blocking agents,Million of national currency units,5.6 +9891,Estonia,2015,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +9892,Estonia,2015,10,A02A-Antacids,"/capita, US$ exchange rate",0.3 +9893,Estonia,2015,10,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7 +9894,Estonia,2015,10,C07-Beta blocking agents,% of total sales,2.1 +9895,Estonia,2015,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9 +9896,Estonia,2015,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.9 +9897,Estonia,2015,10,G-Genito urinary system and sex hormones,Million of national currency units,11.6 +9898,Estonia,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.8 +9899,Estonia,2015,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.6 +9900,Estonia,2015,10,N06A-Antidepressants,Million of national currency units,3.2 +9901,Estonia,2015,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.7 +9902,Estonia,2015,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6 +9903,Estonia,2015,10,N06A-Antidepressants,Million US$ at exchange rate,3.6 +9904,Estonia,2015,10,N06A-Antidepressants,"Million US$, purchasing power parity",6.0 +9905,Estonia,2015,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,36.3 +9906,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3 +9907,Estonia,2015,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.6 +9908,Estonia,2015,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",60.9 +9909,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.9 +9910,Estonia,2015,10,A-Alimentary tract and metabolism,Million of national currency units,32.7 +9911,Estonia,2015,10,A10-Drugs used in diabetes,% of total sales,6.2 +9912,Estonia,2015,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.1 +9913,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9 +9914,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4 +9915,Estonia,2015,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.3 +9916,Estonia,2015,10,N-Nervous system,% of total sales,9.4 +9917,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +9918,Estonia,2015,10,N-Nervous system,"/capita, US$ purchasing power parity",35.3 +9919,Estonia,2015,10,N-Nervous system,"Million US$, purchasing power parity",46.4 +9920,Estonia,2015,10,N-Nervous system,"/capita, US$ exchange rate",21.1 +9921,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +9922,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4 +9923,Estonia,2015,10,A-Alimentary tract and metabolism,% of total sales,12.3 +9924,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.9 +9925,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1 +9926,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +9927,Estonia,2015,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +9928,Estonia,2015,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +9929,Estonia,2015,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +9930,Estonia,2015,10,C01A-Cardiac glycosides,Million of national currency units,0.1 +9931,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8 +9932,Estonia,2015,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +9933,Estonia,2015,10,Total pharmaceutical sales,Million US$ at exchange rate,294.2 +9934,Estonia,2015,10,Total pharmaceutical sales,Million of national currency units,265.2 +9935,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.5 +9936,Estonia,2015,10,C01A-Cardiac glycosides,% of total sales,0.1 +9937,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.1 +9938,Estonia,2015,10,M-Musculo-skeletal system,% of total sales,5.9 +9939,Estonia,2015,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.1 +9940,Estonia,2015,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.2 +9941,Estonia,2015,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.8 +9942,Estonia,2015,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",30.4 +9943,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.8 +9944,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.2 +9945,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.2 +9946,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",17.2 +9947,Estonia,2015,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",29.1 +9948,Estonia,2015,10,M-Musculo-skeletal system,Million of national currency units,15.6 +9949,Estonia,2015,10,M-Musculo-skeletal system,Million US$ at exchange rate,17.3 +9950,Estonia,2015,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,35.3 +9951,Estonia,2015,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.9 +9952,Estonia,2015,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",59.2 +9953,Estonia,2015,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.0 +9954,Estonia,2015,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.8 +9955,Estonia,2015,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7 +9956,Estonia,2015,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",375.0 +9957,Estonia,2015,10,Total pharmaceutical sales,"/capita, US$ exchange rate",223.6 +9958,Estonia,2015,10,J-Antiinfectives for systemic use,Million of national currency units,31.8 +9959,Estonia,2015,10,J01-Antibacterials for systemic use,Million of national currency units,6.9 +9960,Estonia,2015,10,A10-Drugs used in diabetes,Million of national currency units,16.4 +9961,Estonia,2015,10,A10-Drugs used in diabetes,Million US$ at exchange rate,18.2 +9962,Estonia,2015,10,N-Nervous system,Million of national currency units,25.0 +9963,Estonia,2015,10,N-Nervous system,Million US$ at exchange rate,27.7 +9964,Estonia,2015,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",44.5 +9965,Estonia,2015,10,J-Antiinfectives for systemic use,% of total sales,12.0 +9966,Estonia,2015,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.8 +9967,Estonia,2015,10,C02-Antihypertensives,Million of national currency units,0.8 +9968,Estonia,2015,10,Total pharmaceutical sales,"Million US$, purchasing power parity",493.2 +9969,Estonia,2015,10,J01-Antibacterials for systemic use,% of total sales,2.6 +9970,Estonia,2015,10,C-Cardiovascular system,% of total sales,11.9 +9971,Estonia,2015,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.9 +9972,Estonia,2014,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.6 +9973,Estonia,2014,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.8 +9974,Estonia,2014,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0 +9975,Estonia,2014,11,N05B-Anxiolytics,% of total sales,0.6 +9976,Estonia,2014,11,C02-Antihypertensives,Million US$ at exchange rate,1.1 +9977,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.2 +9978,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +9979,Estonia,2014,11,N02-Analgesics,"Million US$, purchasing power parity",12.0 +9980,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.8 +9981,Estonia,2014,11,N05B-Anxiolytics,Million US$ at exchange rate,1.9 +9982,Estonia,2014,11,N05B-Anxiolytics,Million of national currency units,1.4 +9983,Estonia,2014,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7 +9984,Estonia,2014,11,N02-Analgesics,"/capita, US$ exchange rate",6.4 +9985,Estonia,2014,11,N02-Analgesics,"/capita, US$ purchasing power parity",9.1 +9986,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.6 +9987,Estonia,2014,11,N02-Analgesics,% of total sales,2.5 +9988,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.7 +9989,Estonia,2014,11,C-Cardiovascular system,"/capita, US$ exchange rate",32.4 +9990,Estonia,2014,11,C-Cardiovascular system,"Million US$, purchasing power parity",60.8 +9991,Estonia,2014,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2 +9992,Estonia,2014,11,C02-Antihypertensives,% of total sales,0.3 +9993,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.6 +9994,Estonia,2014,11,N02-Analgesics,Million US$ at exchange rate,8.4 +9995,Estonia,2014,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +9996,Estonia,2014,11,C-Cardiovascular system,Million US$ at exchange rate,42.5 +9997,Estonia,2014,11,C-Cardiovascular system,Million of national currency units,32.0 +9998,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.4 +9999,Estonia,2014,11,N02-Analgesics,Million of national currency units,6.3 +10000,Estonia,2014,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1 +10001,Estonia,2014,11,B-Blood and blood forming organs,% of total sales,7.0 +10002,Estonia,2014,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6 +10003,Estonia,2014,11,B-Blood and blood forming organs,Million US$ at exchange rate,23.1 +10004,Estonia,2014,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",33.0 +10005,Estonia,2014,11,R-Respiratory system,"Million US$, purchasing power parity",37.5 +10006,Estonia,2014,11,R-Respiratory system,"/capita, US$ exchange rate",20.0 +10007,Estonia,2014,11,R-Respiratory system,"/capita, US$ purchasing power parity",28.5 +10008,Estonia,2014,11,R-Respiratory system,Million of national currency units,19.7 +10009,Estonia,2014,11,R-Respiratory system,Million US$ at exchange rate,26.2 +10010,Estonia,2014,11,A02A-Antacids,Million of national currency units,0.4 +10011,Estonia,2014,11,C10-Lipid modifying agents,% of total sales,1.3 +10012,Estonia,2014,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.7 +10013,Estonia,2014,11,A02A-Antacids,"Million US$, purchasing power parity",0.7 +10014,Estonia,2014,11,A02A-Antacids,Million US$ at exchange rate,0.5 +10015,Estonia,2014,11,C10-Lipid modifying agents,Million US$ at exchange rate,4.3 +10016,Estonia,2014,11,C10-Lipid modifying agents,Million of national currency units,3.2 +10017,Estonia,2014,11,B-Blood and blood forming organs,Million of national currency units,17.4 +10018,Estonia,2014,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3 +10019,Estonia,2014,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.1 +10020,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,17.1 +10021,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.9 +10022,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",24.4 +10023,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.6 +10024,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.0 +10025,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",8.8 +10026,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.6 +10027,Estonia,2014,11,R03-Drugs for obstructive airway diseases,Million of national currency units,8.7 +10028,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.6 +10029,Estonia,2014,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.6 +10030,Estonia,2014,11,C08-Calcium channel blockers,Million US$ at exchange rate,3.4 +10031,Estonia,2014,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.9 +10032,Estonia,2014,11,R-Respiratory system,% of total sales,7.9 +10033,Estonia,2014,11,C08-Calcium channel blockers,Million of national currency units,2.6 +10034,Estonia,2014,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +10035,Estonia,2014,11,R03-Drugs for obstructive airway diseases,% of total sales,3.5 +10036,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.2 +10037,Estonia,2014,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7 +10038,Estonia,2014,11,C08-Calcium channel blockers,% of total sales,1.0 +10039,Estonia,2014,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.2 +10040,Estonia,2014,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +10041,Estonia,2014,11,N05C-Hypnotics and sedatives,Million of national currency units,1.7 +10042,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.2 +10043,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2 +10044,Estonia,2014,11,N05C-Hypnotics and sedatives,% of total sales,0.7 +10045,Estonia,2014,11,G-Genito urinary system and sex hormones,% of total sales,4.6 +10046,Estonia,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7 +10047,Estonia,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4 +10048,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.7 +10049,Estonia,2014,11,C03-Diuretics,"/capita, US$ exchange rate",1.8 +10050,Estonia,2014,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.5 +10051,Estonia,2014,11,C03-Diuretics,"Million US$, purchasing power parity",3.3 +10052,Estonia,2014,11,C03-Diuretics,Million of national currency units,1.8 +10053,Estonia,2014,11,C03-Diuretics,Million US$ at exchange rate,2.3 +10054,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.9 +10055,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.2 +10056,Estonia,2014,11,C03-Diuretics,% of total sales,0.7 +10057,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,% of total sales,2.5 +10058,Estonia,2014,11,C07-Beta blocking agents,Million US$ at exchange rate,7.4 +10059,Estonia,2014,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.5 +10060,Estonia,2014,11,A02A-Antacids,% of total sales,0.1 +10061,Estonia,2014,11,C07-Beta blocking agents,Million of national currency units,5.5 +10062,Estonia,2014,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +10063,Estonia,2014,11,A02A-Antacids,"/capita, US$ exchange rate",0.4 +10064,Estonia,2014,11,N06A-Antidepressants,% of total sales,1.2 +10065,Estonia,2014,11,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6 +10066,Estonia,2014,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0 +10067,Estonia,2014,11,C07-Beta blocking agents,% of total sales,2.2 +10068,Estonia,2014,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.3 +10069,Estonia,2014,11,G-Genito urinary system and sex hormones,Million of national currency units,11.5 +10070,Estonia,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.6 +10071,Estonia,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.6 +10072,Estonia,2014,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.8 +10073,Estonia,2014,11,N06A-Antidepressants,Million of national currency units,3.0 +10074,Estonia,2014,11,N06A-Antidepressants,"/capita, US$ exchange rate",3.1 +10075,Estonia,2014,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.4 +10076,Estonia,2014,11,N06A-Antidepressants,Million US$ at exchange rate,4.1 +10077,Estonia,2014,11,N06A-Antidepressants,"Million US$, purchasing power parity",5.8 +10078,Estonia,2014,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,40.8 +10079,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3 +10080,Estonia,2014,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",31.1 +10081,Estonia,2014,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",58.3 +10082,Estonia,2014,11,A-Alimentary tract and metabolism,Million of national currency units,30.7 +10083,Estonia,2014,11,A10-Drugs used in diabetes,% of total sales,6.2 +10084,Estonia,2014,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.2 +10085,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.4 +10086,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.8 +10087,Estonia,2014,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.4 +10088,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4 +10089,Estonia,2014,11,N-Nervous system,% of total sales,9.6 +10090,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +10091,Estonia,2014,11,N-Nervous system,"Million US$, purchasing power parity",45.3 +10092,Estonia,2014,11,N-Nervous system,"/capita, US$ exchange rate",24.1 +10093,Estonia,2014,11,N-Nervous system,"/capita, US$ purchasing power parity",34.5 +10094,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.3 +10095,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +10096,Estonia,2014,11,A-Alimentary tract and metabolism,% of total sales,12.3 +10097,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4 +10098,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8 +10099,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +10100,Estonia,2014,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +10101,Estonia,2014,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +10102,Estonia,2014,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +10103,Estonia,2014,11,C01A-Cardiac glycosides,Million of national currency units,0.2 +10104,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.8 +10105,Estonia,2014,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +10106,Estonia,2014,11,Total pharmaceutical sales,Million of national currency units,249.4 +10107,Estonia,2014,11,Total pharmaceutical sales,Million US$ at exchange rate,331.4 +10108,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.5 +10109,Estonia,2014,11,C01A-Cardiac glycosides,% of total sales,0.1 +10110,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.5 +10111,Estonia,2014,11,M-Musculo-skeletal system,% of total sales,5.8 +10112,Estonia,2014,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.7 +10113,Estonia,2014,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.5 +10114,Estonia,2014,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.5 +10115,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.5 +10116,Estonia,2014,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",29.2 +10117,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.7 +10118,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.5 +10119,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",16.5 +10120,Estonia,2014,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",27.2 +10121,Estonia,2014,11,M-Musculo-skeletal system,Million US$ at exchange rate,19.1 +10122,Estonia,2014,11,M-Musculo-skeletal system,Million of national currency units,14.3 +10123,Estonia,2014,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.2 +10124,Estonia,2014,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.4 +10125,Estonia,2014,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.5 +10126,Estonia,2014,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",53.2 +10127,Estonia,2014,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.3 +10128,Estonia,2014,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4 +10129,Estonia,2014,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",360.1 +10130,Estonia,2014,11,Total pharmaceutical sales,"/capita, US$ exchange rate",252.1 +10131,Estonia,2014,11,J-Antiinfectives for systemic use,Million of national currency units,28.0 +10132,Estonia,2014,11,J01-Antibacterials for systemic use,Million of national currency units,7.0 +10133,Estonia,2014,11,A10-Drugs used in diabetes,Million US$ at exchange rate,20.4 +10134,Estonia,2014,11,A10-Drugs used in diabetes,Million of national currency units,15.4 +10135,Estonia,2014,11,N-Nervous system,Million of national currency units,23.9 +10136,Estonia,2014,11,N-Nervous system,Million US$ at exchange rate,31.7 +10137,Estonia,2014,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",46.2 +10138,Estonia,2014,11,J-Antiinfectives for systemic use,% of total sales,11.2 +10139,Estonia,2014,11,C-Cardiovascular system,% of total sales,12.8 +10140,Estonia,2014,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.2 +10141,Estonia,2014,11,C02-Antihypertensives,Million of national currency units,0.8 +10142,Estonia,2014,11,J01-Antibacterials for systemic use,% of total sales,2.8 +10143,Estonia,2014,11,Total pharmaceutical sales,"Million US$, purchasing power parity",473.4 +10144,Estonia,2014,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1 +10145,Estonia,2013,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.6 +10146,Estonia,2013,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +10147,Estonia,2013,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.9 +10148,Estonia,2013,10,N05B-Anxiolytics,% of total sales,0.6 +10149,Estonia,2013,10,C02-Antihypertensives,Million US$ at exchange rate,1.1 +10150,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.8 +10151,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +10152,Estonia,2013,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2 +10153,Estonia,2013,10,N02-Analgesics,"Million US$, purchasing power parity",11.3 +10154,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.3 +10155,Estonia,2013,10,N05B-Anxiolytics,"Million US$, purchasing power parity",2.5 +10156,Estonia,2013,10,N05B-Anxiolytics,Million US$ at exchange rate,1.8 +10157,Estonia,2013,10,N05B-Anxiolytics,Million of national currency units,1.3 +10158,Estonia,2013,10,N02-Analgesics,"/capita, US$ exchange rate",6.0 +10159,Estonia,2013,10,N02-Analgesics,"/capita, US$ purchasing power parity",8.6 +10160,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4 +10161,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.3 +10162,Estonia,2013,10,N02-Analgesics,% of total sales,2.6 +10163,Estonia,2013,10,C-Cardiovascular system,"/capita, US$ exchange rate",31.9 +10164,Estonia,2013,10,C-Cardiovascular system,"Million US$, purchasing power parity",60.7 +10165,Estonia,2013,10,C02-Antihypertensives,% of total sales,0.4 +10166,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3 +10167,Estonia,2013,10,N02-Analgesics,Million US$ at exchange rate,7.8 +10168,Estonia,2013,10,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +10169,Estonia,2013,10,N02-Analgesics,Million of national currency units,5.9 +10170,Estonia,2013,10,C-Cardiovascular system,Million US$ at exchange rate,42.1 +10171,Estonia,2013,10,C-Cardiovascular system,Million of national currency units,31.7 +10172,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.5 +10173,Estonia,2013,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.5 +10174,Estonia,2013,10,B-Blood and blood forming organs,% of total sales,6.1 +10175,Estonia,2013,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.2 +10176,Estonia,2013,10,B-Blood and blood forming organs,Million US$ at exchange rate,18.7 +10177,Estonia,2013,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",27.0 +10178,Estonia,2013,10,R-Respiratory system,"/capita, US$ exchange rate",18.8 +10179,Estonia,2013,10,R-Respiratory system,"/capita, US$ purchasing power parity",27.1 +10180,Estonia,2013,10,R-Respiratory system,"Million US$, purchasing power parity",35.7 +10181,Estonia,2013,10,R-Respiratory system,Million of national currency units,18.6 +10182,Estonia,2013,10,R-Respiratory system,Million US$ at exchange rate,24.8 +10183,Estonia,2013,10,A02A-Antacids,Million of national currency units,0.3 +10184,Estonia,2013,10,C10-Lipid modifying agents,% of total sales,1.5 +10185,Estonia,2013,10,A02A-Antacids,"Million US$, purchasing power parity",0.6 +10186,Estonia,2013,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.0 +10187,Estonia,2013,10,A02A-Antacids,Million US$ at exchange rate,0.4 +10188,Estonia,2013,10,C10-Lipid modifying agents,Million US$ at exchange rate,4.6 +10189,Estonia,2013,10,C10-Lipid modifying agents,Million of national currency units,3.4 +10190,Estonia,2013,10,B-Blood and blood forming organs,Million of national currency units,14.1 +10191,Estonia,2013,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.5 +10192,Estonia,2013,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.6 +10193,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.8 +10194,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,16.5 +10195,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.4 +10196,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1 +10197,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5 +10198,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",8.4 +10199,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.1 +10200,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.0 +10201,Estonia,2013,10,R03-Drugs for obstructive airway diseases,Million of national currency units,8.3 +10202,Estonia,2013,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.1 +10203,Estonia,2013,10,C08-Calcium channel blockers,Million US$ at exchange rate,3.9 +10204,Estonia,2013,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.6 +10205,Estonia,2013,10,R-Respiratory system,% of total sales,8.1 +10206,Estonia,2013,10,C08-Calcium channel blockers,Million of national currency units,2.9 +10207,Estonia,2013,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0 +10208,Estonia,2013,10,R03-Drugs for obstructive airway diseases,% of total sales,3.6 +10209,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4 +10210,Estonia,2013,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3 +10211,Estonia,2013,10,C08-Calcium channel blockers,% of total sales,1.3 +10212,Estonia,2013,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.1 +10213,Estonia,2013,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.0 +10214,Estonia,2013,10,N05C-Hypnotics and sedatives,Million of national currency units,1.5 +10215,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5 +10216,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.4 +10217,Estonia,2013,10,N05C-Hypnotics and sedatives,% of total sales,0.7 +10218,Estonia,2013,10,G-Genito urinary system and sex hormones,% of total sales,5.0 +10219,Estonia,2013,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +10220,Estonia,2013,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2 +10221,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.2 +10222,Estonia,2013,10,C03-Diuretics,"/capita, US$ exchange rate",1.7 +10223,Estonia,2013,10,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +10224,Estonia,2013,10,C03-Diuretics,Million of national currency units,1.6 +10225,Estonia,2013,10,C03-Diuretics,"Million US$, purchasing power parity",3.2 +10226,Estonia,2013,10,C03-Diuretics,Million US$ at exchange rate,2.2 +10227,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.3 +10228,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4 +10229,Estonia,2013,10,C03-Diuretics,% of total sales,0.7 +10230,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.8 +10231,Estonia,2013,10,C07-Beta blocking agents,Million US$ at exchange rate,7.1 +10232,Estonia,2013,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2 +10233,Estonia,2013,10,A02A-Antacids,% of total sales,0.1 +10234,Estonia,2013,10,C07-Beta blocking agents,Million of national currency units,5.3 +10235,Estonia,2013,10,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4 +10236,Estonia,2013,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +10237,Estonia,2013,10,A02A-Antacids,"/capita, US$ exchange rate",0.3 +10238,Estonia,2013,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7 +10239,Estonia,2013,10,C07-Beta blocking agents,% of total sales,2.3 +10240,Estonia,2013,10,N06A-Antidepressants,% of total sales,1.3 +10241,Estonia,2013,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.2 +10242,Estonia,2013,10,G-Genito urinary system and sex hormones,Million of national currency units,11.4 +10243,Estonia,2013,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.6 +10244,Estonia,2013,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.9 +10245,Estonia,2013,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.5 +10246,Estonia,2013,10,N06A-Antidepressants,Million of national currency units,2.9 +10247,Estonia,2013,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.9 +10248,Estonia,2013,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.2 +10249,Estonia,2013,10,N06A-Antidepressants,Million US$ at exchange rate,3.9 +10250,Estonia,2013,10,N06A-Antidepressants,"Million US$, purchasing power parity",5.6 +10251,Estonia,2013,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.1 +10252,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +10253,Estonia,2013,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9 +10254,Estonia,2013,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.7 +10255,Estonia,2013,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",54.9 +10256,Estonia,2013,10,A-Alimentary tract and metabolism,Million of national currency units,28.7 +10257,Estonia,2013,10,A10-Drugs used in diabetes,% of total sales,6.1 +10258,Estonia,2013,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.5 +10259,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.6 +10260,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.1 +10261,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.8 +10262,Estonia,2013,10,N-Nervous system,% of total sales,10.0 +10263,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.9 +10264,Estonia,2013,10,N-Nervous system,"/capita, US$ purchasing power parity",33.6 +10265,Estonia,2013,10,N-Nervous system,"Million US$, purchasing power parity",44.3 +10266,Estonia,2013,10,N-Nervous system,"/capita, US$ exchange rate",23.3 +10267,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.2 +10268,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +10269,Estonia,2013,10,A-Alimentary tract and metabolism,% of total sales,12.4 +10270,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +10271,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +10272,Estonia,2013,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +10273,Estonia,2013,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +10274,Estonia,2013,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +10275,Estonia,2013,10,C01A-Cardiac glycosides,Million of national currency units,0.2 +10276,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.0 +10277,Estonia,2013,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +10278,Estonia,2013,10,Total pharmaceutical sales,Million of national currency units,231.0 +10279,Estonia,2013,10,Total pharmaceutical sales,Million US$ at exchange rate,306.7 +10280,Estonia,2013,10,C01A-Cardiac glycosides,% of total sales,0.1 +10281,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.4 +10282,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.5 +10283,Estonia,2013,10,M-Musculo-skeletal system,% of total sales,5.7 +10284,Estonia,2013,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.2 +10285,Estonia,2013,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.3 +10286,Estonia,2013,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.3 +10287,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.7 +10288,Estonia,2013,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",27.1 +10289,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.6 +10290,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.9 +10291,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",15.2 +10292,Estonia,2013,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",25.3 +10293,Estonia,2013,10,M-Musculo-skeletal system,Million of national currency units,13.2 +10294,Estonia,2013,10,M-Musculo-skeletal system,Million US$ at exchange rate,17.5 +10295,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +10296,Estonia,2013,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.8 +10297,Estonia,2013,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.0 +10298,Estonia,2013,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",45.8 +10299,Estonia,2013,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.7 +10300,Estonia,2013,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.1 +10301,Estonia,2013,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",335.4 +10302,Estonia,2013,10,Total pharmaceutical sales,"/capita, US$ exchange rate",232.7 +10303,Estonia,2013,10,J-Antiinfectives for systemic use,Million of national currency units,23.9 +10304,Estonia,2013,10,J01-Antibacterials for systemic use,Million of national currency units,7.3 +10305,Estonia,2013,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.7 +10306,Estonia,2013,10,A10-Drugs used in diabetes,Million US$ at exchange rate,18.8 +10307,Estonia,2013,10,A10-Drugs used in diabetes,Million of national currency units,14.1 +10308,Estonia,2013,10,N-Nervous system,Million of national currency units,23.2 +10309,Estonia,2013,10,N-Nervous system,Million US$ at exchange rate,30.8 +10310,Estonia,2013,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",46.0 +10311,Estonia,2013,10,C-Cardiovascular system,% of total sales,13.7 +10312,Estonia,2013,10,J-Antiinfectives for systemic use,% of total sales,10.4 +10313,Estonia,2013,10,C02-Antihypertensives,Million of national currency units,0.9 +10314,Estonia,2013,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6 +10315,Estonia,2013,10,J01-Antibacterials for systemic use,% of total sales,3.2 +10316,Estonia,2013,10,Total pharmaceutical sales,"Million US$, purchasing power parity",442.1 +10317,Estonia,2013,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.4 +10318,Estonia,2012,12,C02-Antihypertensives,"Million US$, purchasing power parity",1.8 +10319,Estonia,2012,12,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +10320,Estonia,2012,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8 +10321,Estonia,2012,12,N05B-Anxiolytics,% of total sales,0.6 +10322,Estonia,2012,12,C02-Antihypertensives,Million US$ at exchange rate,1.2 +10323,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.4 +10324,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +10325,Estonia,2012,12,N02-Analgesics,"Million US$, purchasing power parity",10.6 +10326,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8 +10327,Estonia,2012,12,N05B-Anxiolytics,"Million US$, purchasing power parity",2.4 +10328,Estonia,2012,12,N05B-Anxiolytics,Million US$ at exchange rate,1.6 +10329,Estonia,2012,12,N05B-Anxiolytics,Million of national currency units,1.3 +10330,Estonia,2012,12,N02-Analgesics,"/capita, US$ exchange rate",5.4 +10331,Estonia,2012,12,N02-Analgesics,"/capita, US$ purchasing power parity",8.0 +10332,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.0 +10333,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9 +10334,Estonia,2012,12,N02-Analgesics,% of total sales,2.5 +10335,Estonia,2012,12,C-Cardiovascular system,"/capita, US$ exchange rate",31.6 +10336,Estonia,2012,12,C-Cardiovascular system,"Million US$, purchasing power parity",62.5 +10337,Estonia,2012,12,C02-Antihypertensives,% of total sales,0.4 +10338,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9 +10339,Estonia,2012,12,N02-Analgesics,Million US$ at exchange rate,7.1 +10340,Estonia,2012,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +10341,Estonia,2012,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +10342,Estonia,2012,12,C-Cardiovascular system,Million US$ at exchange rate,41.8 +10343,Estonia,2012,12,C-Cardiovascular system,Million of national currency units,32.6 +10344,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.4 +10345,Estonia,2012,12,N02-Analgesics,Million of national currency units,5.5 +10346,Estonia,2012,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.1 +10347,Estonia,2012,12,B-Blood and blood forming organs,% of total sales,5.9 +10348,Estonia,2012,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.8 +10349,Estonia,2012,12,B-Blood and blood forming organs,Million US$ at exchange rate,16.9 +10350,Estonia,2012,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",25.2 +10351,Estonia,2012,12,R-Respiratory system,"/capita, US$ exchange rate",16.2 +10352,Estonia,2012,12,R-Respiratory system,"/capita, US$ purchasing power parity",24.2 +10353,Estonia,2012,12,R-Respiratory system,"Million US$, purchasing power parity",32.0 +10354,Estonia,2012,12,R-Respiratory system,Million of national currency units,16.7 +10355,Estonia,2012,12,R-Respiratory system,Million US$ at exchange rate,21.4 +10356,Estonia,2012,12,A02A-Antacids,Million of national currency units,0.3 +10357,Estonia,2012,12,C10-Lipid modifying agents,% of total sales,1.8 +10358,Estonia,2012,12,A02A-Antacids,"Million US$, purchasing power parity",0.6 +10359,Estonia,2012,12,A02A-Antacids,Million US$ at exchange rate,0.4 +10360,Estonia,2012,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7 +10361,Estonia,2012,12,C10-Lipid modifying agents,Million US$ at exchange rate,5.1 +10362,Estonia,2012,12,C10-Lipid modifying agents,Million of national currency units,4.0 +10363,Estonia,2012,12,B-Blood and blood forming organs,Million of national currency units,13.1 +10364,Estonia,2012,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.8 +10365,Estonia,2012,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",7.6 +10366,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",22.8 +10367,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.2 +10368,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.2 +10369,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.9 +10370,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5 +10371,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.2 +10372,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.7 +10373,Estonia,2012,12,R03-Drugs for obstructive airway diseases,Million of national currency units,7.4 +10374,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",14.2 +10375,Estonia,2012,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.5 +10376,Estonia,2012,12,C08-Calcium channel blockers,Million US$ at exchange rate,4.5 +10377,Estonia,2012,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.7 +10378,Estonia,2012,12,R-Respiratory system,% of total sales,7.5 +10379,Estonia,2012,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4 +10380,Estonia,2012,12,C08-Calcium channel blockers,Million of national currency units,3.5 +10381,Estonia,2012,12,R03-Drugs for obstructive airway diseases,% of total sales,3.3 +10382,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4 +10383,Estonia,2012,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.1 +10384,Estonia,2012,12,C08-Calcium channel blockers,% of total sales,1.6 +10385,Estonia,2012,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0 +10386,Estonia,2012,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.9 +10387,Estonia,2012,12,N05C-Hypnotics and sedatives,Million of national currency units,1.5 +10388,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5 +10389,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.6 +10390,Estonia,2012,12,G-Genito urinary system and sex hormones,% of total sales,5.0 +10391,Estonia,2012,12,N05C-Hypnotics and sedatives,% of total sales,0.7 +10392,Estonia,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5 +10393,Estonia,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2 +10394,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.7 +10395,Estonia,2012,12,C03-Diuretics,"/capita, US$ exchange rate",1.7 +10396,Estonia,2012,12,C03-Diuretics,"/capita, US$ purchasing power parity",2.5 +10397,Estonia,2012,12,C03-Diuretics,Million of national currency units,1.7 +10398,Estonia,2012,12,C03-Diuretics,Million US$ at exchange rate,2.2 +10399,Estonia,2012,12,C03-Diuretics,"Million US$, purchasing power parity",3.3 +10400,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.6 +10401,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4 +10402,Estonia,2012,12,C03-Diuretics,% of total sales,0.8 +10403,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,% of total sales,3.0 +10404,Estonia,2012,12,C07-Beta blocking agents,Million US$ at exchange rate,6.8 +10405,Estonia,2012,12,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2 +10406,Estonia,2012,12,A02A-Antacids,% of total sales,0.1 +10407,Estonia,2012,12,C07-Beta blocking agents,Million of national currency units,5.3 +10408,Estonia,2012,12,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2 +10409,Estonia,2012,12,A02A-Antacids,"/capita, US$ exchange rate",0.3 +10410,Estonia,2012,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +10411,Estonia,2012,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7 +10412,Estonia,2012,12,C07-Beta blocking agents,% of total sales,2.4 +10413,Estonia,2012,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.4 +10414,Estonia,2012,12,G-Genito urinary system and sex hormones,Million of national currency units,11.2 +10415,Estonia,2012,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.5 +10416,Estonia,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.2 +10417,Estonia,2012,12,N06A-Antidepressants,Million of national currency units,2.9 +10418,Estonia,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.9 +10419,Estonia,2012,12,N06A-Antidepressants,"/capita, US$ exchange rate",2.9 +10420,Estonia,2012,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3 +10421,Estonia,2012,12,N06A-Antidepressants,% of total sales,1.3 +10422,Estonia,2012,12,N06A-Antidepressants,Million US$ at exchange rate,3.8 +10423,Estonia,2012,12,N06A-Antidepressants,"Million US$, purchasing power parity",5.6 +10424,Estonia,2012,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,34.5 +10425,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +10426,Estonia,2012,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.1 +10427,Estonia,2012,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0 +10428,Estonia,2012,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",51.6 +10429,Estonia,2012,12,A-Alimentary tract and metabolism,Million of national currency units,26.9 +10430,Estonia,2012,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4 +10431,Estonia,2012,12,A10-Drugs used in diabetes,% of total sales,6.0 +10432,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.0 +10433,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.3 +10434,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.6 +10435,Estonia,2012,12,N-Nervous system,% of total sales,10.3 +10436,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.9 +10437,Estonia,2012,12,N-Nervous system,"Million US$, purchasing power parity",43.9 +10438,Estonia,2012,12,N-Nervous system,"/capita, US$ purchasing power parity",33.2 +10439,Estonia,2012,12,N-Nervous system,"/capita, US$ exchange rate",22.2 +10440,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1 +10441,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +10442,Estonia,2012,12,A-Alimentary tract and metabolism,% of total sales,12.1 +10443,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +10444,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +10445,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +10446,Estonia,2012,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +10447,Estonia,2012,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +10448,Estonia,2012,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +10449,Estonia,2012,12,C01A-Cardiac glycosides,Million of national currency units,0.2 +10450,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.9 +10451,Estonia,2012,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +10452,Estonia,2012,12,Total pharmaceutical sales,Million of national currency units,221.7 +10453,Estonia,2012,12,Total pharmaceutical sales,Million US$ at exchange rate,284.9 +10454,Estonia,2012,12,C01A-Cardiac glycosides,% of total sales,0.1 +10455,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2 +10456,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3 +10457,Estonia,2012,12,M-Musculo-skeletal system,% of total sales,5.5 +10458,Estonia,2012,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.9 +10459,Estonia,2012,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.7 +10460,Estonia,2012,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.0 +10461,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.4 +10462,Estonia,2012,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",25.7 +10463,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.1 +10464,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.1 +10465,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.6 +10466,Estonia,2012,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",23.4 +10467,Estonia,2012,12,M-Musculo-skeletal system,Million of national currency units,12.2 +10468,Estonia,2012,12,M-Musculo-skeletal system,Million US$ at exchange rate,15.7 +10469,Estonia,2012,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.5 +10470,Estonia,2012,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.1 +10471,Estonia,2012,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.2 +10472,Estonia,2012,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.6 +10473,Estonia,2012,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.8 +10474,Estonia,2012,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",321.7 +10475,Estonia,2012,12,Total pharmaceutical sales,"/capita, US$ exchange rate",215.4 +10476,Estonia,2012,12,J-Antiinfectives for systemic use,Million of national currency units,24.5 +10477,Estonia,2012,12,J01-Antibacterials for systemic use,Million of national currency units,7.9 +10478,Estonia,2012,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.2 +10479,Estonia,2012,12,A10-Drugs used in diabetes,Million of national currency units,13.4 +10480,Estonia,2012,12,A10-Drugs used in diabetes,Million US$ at exchange rate,17.2 +10481,Estonia,2012,12,N-Nervous system,Million of national currency units,22.9 +10482,Estonia,2012,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",47.2 +10483,Estonia,2012,12,N-Nervous system,Million US$ at exchange rate,29.4 +10484,Estonia,2012,12,C-Cardiovascular system,% of total sales,14.7 +10485,Estonia,2012,12,C02-Antihypertensives,Million of national currency units,0.9 +10486,Estonia,2012,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5 +10487,Estonia,2012,12,J01-Antibacterials for systemic use,% of total sales,3.6 +10488,Estonia,2012,12,Total pharmaceutical sales,"Million US$, purchasing power parity",425.5 +10489,Estonia,2012,12,J-Antiinfectives for systemic use,% of total sales,11.1 +10490,Estonia,2012,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.7 +10491,Estonia,2011,13,C02-Antihypertensives,"Million US$, purchasing power parity",1.7 +10492,Estonia,2011,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +10493,Estonia,2011,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7 +10494,Estonia,2011,13,N05B-Anxiolytics,% of total sales,0.6 +10495,Estonia,2011,13,C02-Antihypertensives,Million US$ at exchange rate,1.2 +10496,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1 +10497,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +10498,Estonia,2011,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +10499,Estonia,2011,13,N02-Analgesics,"Million US$, purchasing power parity",10.5 +10500,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.5 +10501,Estonia,2011,13,N05B-Anxiolytics,"Million US$, purchasing power parity",2.3 +10502,Estonia,2011,13,N05B-Anxiolytics,Million US$ at exchange rate,1.6 +10503,Estonia,2011,13,N05B-Anxiolytics,Million of national currency units,1.2 +10504,Estonia,2011,13,N02-Analgesics,"/capita, US$ exchange rate",5.6 +10505,Estonia,2011,13,N02-Analgesics,"/capita, US$ purchasing power parity",7.9 +10506,Estonia,2011,13,N02-Analgesics,% of total sales,2.6 +10507,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2.8 +10508,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9 +10509,Estonia,2011,13,C-Cardiovascular system,"/capita, US$ exchange rate",32.7 +10510,Estonia,2011,13,C-Cardiovascular system,"Million US$, purchasing power parity",60.9 +10511,Estonia,2011,13,C02-Antihypertensives,% of total sales,0.4 +10512,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9 +10513,Estonia,2011,13,N02-Analgesics,Million US$ at exchange rate,7.5 +10514,Estonia,2011,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +10515,Estonia,2011,13,C-Cardiovascular system,Million US$ at exchange rate,43.4 +10516,Estonia,2011,13,C-Cardiovascular system,Million of national currency units,31.2 +10517,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.2 +10518,Estonia,2011,13,N02-Analgesics,Million of national currency units,5.4 +10519,Estonia,2011,13,C03-Diuretics,Million of national currency units,1.6 +10520,Estonia,2011,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.7 +10521,Estonia,2011,13,B-Blood and blood forming organs,% of total sales,5.6 +10522,Estonia,2011,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.9 +10523,Estonia,2011,13,B-Blood and blood forming organs,Million US$ at exchange rate,15.8 +10524,Estonia,2011,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",22.2 +10525,Estonia,2011,13,R-Respiratory system,"/capita, US$ exchange rate",15.8 +10526,Estonia,2011,13,R-Respiratory system,"/capita, US$ purchasing power parity",22.2 +10527,Estonia,2011,13,R-Respiratory system,"Million US$, purchasing power parity",29.5 +10528,Estonia,2011,13,R-Respiratory system,Million of national currency units,15.1 +10529,Estonia,2011,13,R-Respiratory system,Million US$ at exchange rate,21.0 +10530,Estonia,2011,13,A02A-Antacids,Million of national currency units,0.3 +10531,Estonia,2011,13,C10-Lipid modifying agents,% of total sales,1.9 +10532,Estonia,2011,13,A02A-Antacids,"Million US$, purchasing power parity",0.6 +10533,Estonia,2011,13,A02A-Antacids,Million US$ at exchange rate,0.4 +10534,Estonia,2011,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.8 +10535,Estonia,2011,13,C10-Lipid modifying agents,Million US$ at exchange rate,5.5 +10536,Estonia,2011,13,C10-Lipid modifying agents,Million of national currency units,3.9 +10537,Estonia,2011,13,B-Blood and blood forming organs,Million of national currency units,11.4 +10538,Estonia,2011,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.1 +10539,Estonia,2011,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",7.7 +10540,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.7 +10541,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.5 +10542,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.4 +10543,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.7 +10544,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.1 +10545,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.0 +10546,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.8 +10547,Estonia,2011,13,R03-Drugs for obstructive airway diseases,Million of national currency units,6.7 +10548,Estonia,2011,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.3 +10549,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",13.1 +10550,Estonia,2011,13,C08-Calcium channel blockers,Million US$ at exchange rate,5.2 +10551,Estonia,2011,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.2 +10552,Estonia,2011,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9 +10553,Estonia,2011,13,R-Respiratory system,% of total sales,7.4 +10554,Estonia,2011,13,C08-Calcium channel blockers,Million of national currency units,3.7 +10555,Estonia,2011,13,R03-Drugs for obstructive airway diseases,% of total sales,3.3 +10556,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4 +10557,Estonia,2011,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4 +10558,Estonia,2011,13,C08-Calcium channel blockers,% of total sales,1.8 +10559,Estonia,2011,13,A02A-Antacids,"/capita, US$ exchange rate",0.3 +10560,Estonia,2011,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0 +10561,Estonia,2011,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.8 +10562,Estonia,2011,13,N05C-Hypnotics and sedatives,Million of national currency units,1.4 +10563,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.1 +10564,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5 +10565,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.8 +10566,Estonia,2011,13,G-Genito urinary system and sex hormones,% of total sales,5.3 +10567,Estonia,2011,13,N05C-Hypnotics and sedatives,% of total sales,0.7 +10568,Estonia,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5 +10569,Estonia,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1 +10570,Estonia,2011,13,C03-Diuretics,"/capita, US$ exchange rate",1.6 +10571,Estonia,2011,13,C03-Diuretics,"/capita, US$ purchasing power parity",2.3 +10572,Estonia,2011,13,C03-Diuretics,Million US$ at exchange rate,2.2 +10573,Estonia,2011,13,C03-Diuretics,"Million US$, purchasing power parity",3.1 +10574,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.6 +10575,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9 +10576,Estonia,2011,13,C03-Diuretics,% of total sales,0.8 +10577,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,% of total sales,3.2 +10578,Estonia,2011,13,C07-Beta blocking agents,Million US$ at exchange rate,6.6 +10579,Estonia,2011,13,C07-Beta blocking agents,"Million US$, purchasing power parity",9.3 +10580,Estonia,2011,13,A02A-Antacids,% of total sales,0.1 +10581,Estonia,2011,13,C07-Beta blocking agents,Million of national currency units,4.8 +10582,Estonia,2011,13,C07-Beta blocking agents,"/capita, US$ exchange rate",5.0 +10583,Estonia,2011,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +10584,Estonia,2011,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.0 +10585,Estonia,2011,13,C07-Beta blocking agents,% of total sales,2.3 +10586,Estonia,2011,13,N06A-Antidepressants,% of total sales,1.4 +10587,Estonia,2011,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.0 +10588,Estonia,2011,13,G-Genito urinary system and sex hormones,Million of national currency units,10.8 +10589,Estonia,2011,13,N06A-Antidepressants,Million of national currency units,2.9 +10590,Estonia,2011,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.1 +10591,Estonia,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.9 +10592,Estonia,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3 +10593,Estonia,2011,13,N06A-Antidepressants,"/capita, US$ exchange rate",3.1 +10594,Estonia,2011,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3 +10595,Estonia,2011,13,N06A-Antidepressants,Million US$ at exchange rate,4.1 +10596,Estonia,2011,13,N06A-Antidepressants,"Million US$, purchasing power parity",5.8 +10597,Estonia,2011,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,33.9 +10598,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6 +10599,Estonia,2011,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.8 +10600,Estonia,2011,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.5 +10601,Estonia,2011,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",47.6 +10602,Estonia,2011,13,A-Alimentary tract and metabolism,Million of national currency units,24.3 +10603,Estonia,2011,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.6 +10604,Estonia,2011,13,A10-Drugs used in diabetes,% of total sales,5.8 +10605,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.7 +10606,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.4 +10607,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.3 +10608,Estonia,2011,13,N-Nervous system,% of total sales,10.8 +10609,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8 +10610,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1 +10611,Estonia,2011,13,N-Nervous system,"Million US$, purchasing power parity",43.3 +10612,Estonia,2011,13,N-Nervous system,"/capita, US$ purchasing power parity",32.6 +10613,Estonia,2011,13,N-Nervous system,"/capita, US$ exchange rate",23.2 +10614,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +10615,Estonia,2011,13,A-Alimentary tract and metabolism,% of total sales,11.9 +10616,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +10617,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5 +10618,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +10619,Estonia,2011,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +10620,Estonia,2011,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +10621,Estonia,2011,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +10622,Estonia,2011,13,C01A-Cardiac glycosides,Million of national currency units,0.2 +10623,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6 +10624,Estonia,2011,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +10625,Estonia,2011,13,Total pharmaceutical sales,"Million US$, purchasing power parity",399.5 +10626,Estonia,2011,13,Total pharmaceutical sales,Million of national currency units,204.4 +10627,Estonia,2011,13,Total pharmaceutical sales,Million US$ at exchange rate,284.5 +10628,Estonia,2011,13,C01A-Cardiac glycosides,% of total sales,0.1 +10629,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.3 +10630,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1 +10631,Estonia,2011,13,M-Musculo-skeletal system,% of total sales,5.4 +10632,Estonia,2011,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.6 +10633,Estonia,2011,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.3 +10634,Estonia,2011,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",12.5 +10635,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.5 +10636,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.7 +10637,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",12.3 +10638,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.3 +10639,Estonia,2011,13,M-Musculo-skeletal system,Million of national currency units,11.1 +10640,Estonia,2011,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",21.6 +10641,Estonia,2011,13,M-Musculo-skeletal system,Million US$ at exchange rate,15.4 +10642,Estonia,2011,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.1 +10643,Estonia,2011,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",43.7 +10644,Estonia,2011,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.8 +10645,Estonia,2011,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",32.9 +10646,Estonia,2011,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.4 +10647,Estonia,2011,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",301.0 +10648,Estonia,2011,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",23.3 +10649,Estonia,2011,13,J-Antiinfectives for systemic use,Million of national currency units,22.4 +10650,Estonia,2011,13,Total pharmaceutical sales,"/capita, US$ exchange rate",214.3 +10651,Estonia,2011,13,J01-Antibacterials for systemic use,Million of national currency units,8.1 +10652,Estonia,2011,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.2 +10653,Estonia,2011,13,A10-Drugs used in diabetes,Million US$ at exchange rate,16.6 +10654,Estonia,2011,13,A10-Drugs used in diabetes,Million of national currency units,11.9 +10655,Estonia,2011,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.5 +10656,Estonia,2011,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.9 +10657,Estonia,2011,13,N-Nervous system,Million of national currency units,22.1 +10658,Estonia,2011,13,N-Nervous system,Million US$ at exchange rate,30.8 +10659,Estonia,2011,13,C-Cardiovascular system,% of total sales,15.3 +10660,Estonia,2011,13,J-Antiinfectives for systemic use,% of total sales,10.9 +10661,Estonia,2011,13,J01-Antibacterials for systemic use,% of total sales,3.9 +10662,Estonia,2011,13,C02-Antihypertensives,Million of national currency units,0.9 +10663,Estonia,2011,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9 +10664,Estonia,2010,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.7 +10665,Estonia,2010,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +10666,Estonia,2010,11,N05B-Anxiolytics,% of total sales,0.6 +10667,Estonia,2010,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7 +10668,Estonia,2010,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +10669,Estonia,2010,11,C02-Antihypertensives,Million US$ at exchange rate,1.2 +10670,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.7 +10671,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3 +10672,Estonia,2010,11,N02-Analgesics,"Million US$, purchasing power parity",10.2 +10673,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.9 +10674,Estonia,2010,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.2 +10675,Estonia,2010,11,N05B-Anxiolytics,Million US$ at exchange rate,1.5 +10676,Estonia,2010,11,N02-Analgesics,"/capita, US$ exchange rate",5.2 +10677,Estonia,2010,11,N02-Analgesics,"/capita, US$ purchasing power parity",7.6 +10678,Estonia,2010,11,N02-Analgesics,% of total sales,2.7 +10679,Estonia,2010,11,N05B-Anxiolytics,Million of national currency units,1.1 +10680,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2.5 +10681,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.3 +10682,Estonia,2010,11,C-Cardiovascular system,"/capita, US$ exchange rate",34.8 +10683,Estonia,2010,11,C-Cardiovascular system,"Million US$, purchasing power parity",68.3 +10684,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5 +10685,Estonia,2010,11,C02-Antihypertensives,% of total sales,0.5 +10686,Estonia,2010,11,N02-Analgesics,Million US$ at exchange rate,6.9 +10687,Estonia,2010,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +10688,Estonia,2010,11,C-Cardiovascular system,Million US$ at exchange rate,46.3 +10689,Estonia,2010,11,C-Cardiovascular system,Million of national currency units,35.0 +10690,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.6 +10691,Estonia,2010,11,N02-Analgesics,Million of national currency units,5.2 +10692,Estonia,2010,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.2 +10693,Estonia,2010,11,B-Blood and blood forming organs,% of total sales,5.3 +10694,Estonia,2010,11,B-Blood and blood forming organs,Million US$ at exchange rate,13.7 +10695,Estonia,2010,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.3 +10696,Estonia,2010,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",20.2 +10697,Estonia,2010,11,R-Respiratory system,"/capita, US$ exchange rate",14.4 +10698,Estonia,2010,11,R-Respiratory system,"/capita, US$ purchasing power parity",21.2 +10699,Estonia,2010,11,R-Respiratory system,"Million US$, purchasing power parity",28.2 +10700,Estonia,2010,11,R-Respiratory system,Million of national currency units,14.5 +10701,Estonia,2010,11,R-Respiratory system,Million US$ at exchange rate,19.2 +10702,Estonia,2010,11,A02A-Antacids,Million of national currency units,0.3 +10703,Estonia,2010,11,C10-Lipid modifying agents,% of total sales,2.7 +10704,Estonia,2010,11,A02A-Antacids,"Million US$, purchasing power parity",0.5 +10705,Estonia,2010,11,A02A-Antacids,Million US$ at exchange rate,0.4 +10706,Estonia,2010,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.8 +10707,Estonia,2010,11,C10-Lipid modifying agents,Million US$ at exchange rate,7.1 +10708,Estonia,2010,11,C10-Lipid modifying agents,Million of national currency units,5.3 +10709,Estonia,2010,11,B-Blood and blood forming organs,Million of national currency units,10.3 +10710,Estonia,2010,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.3 +10711,Estonia,2010,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",10.4 +10712,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",22.8 +10713,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.5 +10714,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.1 +10715,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.6 +10716,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.7 +10717,Estonia,2010,11,R03-Drugs for obstructive airway diseases,Million of national currency units,6.4 +10718,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.4 +10719,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.4 +10720,Estonia,2010,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,8.5 +10721,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.5 +10722,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0 +10723,Estonia,2010,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",9.7 +10724,Estonia,2010,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.9 +10725,Estonia,2010,11,C08-Calcium channel blockers,Million US$ at exchange rate,6.6 +10726,Estonia,2010,11,R-Respiratory system,% of total sales,7.5 +10727,Estonia,2010,11,C08-Calcium channel blockers,Million of national currency units,4.9 +10728,Estonia,2010,11,R03-Drugs for obstructive airway diseases,% of total sales,3.3 +10729,Estonia,2010,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.3 +10730,Estonia,2010,11,C08-Calcium channel blockers,% of total sales,2.6 +10731,Estonia,2010,11,C03-Diuretics,Million of national currency units,1.6 +10732,Estonia,2010,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.8 +10733,Estonia,2010,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.7 +10734,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.7 +10735,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.6 +10736,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5 +10737,Estonia,2010,11,N05C-Hypnotics and sedatives,Million of national currency units,1.4 +10738,Estonia,2010,11,G-Genito urinary system and sex hormones,% of total sales,5.5 +10739,Estonia,2010,11,N05C-Hypnotics and sedatives,% of total sales,0.7 +10740,Estonia,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.4 +10741,Estonia,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0 +10742,Estonia,2010,11,C03-Diuretics,"/capita, US$ exchange rate",1.6 +10743,Estonia,2010,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.3 +10744,Estonia,2010,11,C03-Diuretics,Million US$ at exchange rate,2.1 +10745,Estonia,2010,11,C03-Diuretics,"Million US$, purchasing power parity",3.1 +10746,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.5 +10747,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5 +10748,Estonia,2010,11,C03-Diuretics,% of total sales,0.8 +10749,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.4 +10750,Estonia,2010,11,C07-Beta blocking agents,Million US$ at exchange rate,7.2 +10751,Estonia,2010,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.7 +10752,Estonia,2010,11,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4 +10753,Estonia,2010,11,C07-Beta blocking agents,Million of national currency units,5.5 +10754,Estonia,2010,11,A02A-Antacids,% of total sales,0.1 +10755,Estonia,2010,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +10756,Estonia,2010,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0 +10757,Estonia,2010,11,C07-Beta blocking agents,% of total sales,2.8 +10758,Estonia,2010,11,A02A-Antacids,"/capita, US$ exchange rate",0.3 +10759,Estonia,2010,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.1 +10760,Estonia,2010,11,G-Genito urinary system and sex hormones,Million of national currency units,10.6 +10761,Estonia,2010,11,N06A-Antidepressants,Million of national currency units,3.0 +10762,Estonia,2010,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",20.7 +10763,Estonia,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.6 +10764,Estonia,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.6 +10765,Estonia,2010,11,N06A-Antidepressants,"/capita, US$ exchange rate",3.0 +10766,Estonia,2010,11,N06A-Antidepressants,% of total sales,1.6 +10767,Estonia,2010,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.4 +10768,Estonia,2010,11,N06A-Antidepressants,Million US$ at exchange rate,4.0 +10769,Estonia,2010,11,N06A-Antidepressants,"Million US$, purchasing power parity",5.9 +10770,Estonia,2010,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,31.2 +10771,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9 +10772,Estonia,2010,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.5 +10773,Estonia,2010,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",23.4 +10774,Estonia,2010,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",46.0 +10775,Estonia,2010,11,A-Alimentary tract and metabolism,Million of national currency units,23.5 +10776,Estonia,2010,11,A10-Drugs used in diabetes,% of total sales,5.9 +10777,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3 +10778,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.1 +10779,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.6 +10780,Estonia,2010,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.8 +10781,Estonia,2010,11,N-Nervous system,% of total sales,11.1 +10782,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.0 +10783,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8 +10784,Estonia,2010,11,N-Nervous system,"Million US$, purchasing power parity",42.0 +10785,Estonia,2010,11,N-Nervous system,"/capita, US$ exchange rate",21.4 +10786,Estonia,2010,11,N-Nervous system,"/capita, US$ purchasing power parity",31.5 +10787,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +10788,Estonia,2010,11,A-Alimentary tract and metabolism,% of total sales,12.1 +10789,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5 +10790,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +10791,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +10792,Estonia,2010,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +10793,Estonia,2010,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +10794,Estonia,2010,11,C01A-Cardiac glycosides,Million of national currency units,0.2 +10795,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.1 +10796,Estonia,2010,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +10797,Estonia,2010,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +10798,Estonia,2010,11,C01A-Cardiac glycosides,% of total sales,0.1 +10799,Estonia,2010,11,Total pharmaceutical sales,"Million US$, purchasing power parity",379.0 +10800,Estonia,2010,11,Total pharmaceutical sales,Million of national currency units,194.1 +10801,Estonia,2010,11,Total pharmaceutical sales,Million US$ at exchange rate,257.2 +10802,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2 +10803,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0 +10804,Estonia,2010,11,M-Musculo-skeletal system,% of total sales,5.6 +10805,Estonia,2010,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.8 +10806,Estonia,2010,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.7 +10807,Estonia,2010,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4 +10808,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.8 +10809,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.1 +10810,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",11.9 +10811,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.1 +10812,Estonia,2010,11,M-Musculo-skeletal system,Million of national currency units,10.8 +10813,Estonia,2010,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",21.1 +10814,Estonia,2010,11,M-Musculo-skeletal system,Million US$ at exchange rate,14.3 +10815,Estonia,2010,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,26.3 +10816,Estonia,2010,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",38.7 +10817,Estonia,2010,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.3 +10818,Estonia,2010,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.1 +10819,Estonia,2010,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.7 +10820,Estonia,2010,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",284.6 +10821,Estonia,2010,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",22.4 +10822,Estonia,2010,11,J-Antiinfectives for systemic use,Million of national currency units,19.8 +10823,Estonia,2010,11,J01-Antibacterials for systemic use,Million of national currency units,7.9 +10824,Estonia,2010,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.4 +10825,Estonia,2010,11,A10-Drugs used in diabetes,Million of national currency units,11.5 +10826,Estonia,2010,11,A10-Drugs used in diabetes,Million US$ at exchange rate,15.2 +10827,Estonia,2010,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",51.3 +10828,Estonia,2010,11,N-Nervous system,Million of national currency units,21.5 +10829,Estonia,2010,11,N-Nervous system,Million US$ at exchange rate,28.5 +10830,Estonia,2010,11,C-Cardiovascular system,% of total sales,18.0 +10831,Estonia,2010,11,J-Antiinfectives for systemic use,% of total sales,10.2 +10832,Estonia,2010,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.8 +10833,Estonia,2010,11,Total pharmaceutical sales,"/capita, US$ exchange rate",193.2 +10834,Estonia,2010,11,J01-Antibacterials for systemic use,% of total sales,4.0 +10835,Estonia,2010,11,C02-Antihypertensives,Million of national currency units,0.9 +10836,Estonia,2010,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5 +10837,Estonia,2017,9,C02-Antihypertensives,"Million US$, purchasing power parity",1.7 +10838,Estonia,2017,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.8 +10839,Estonia,2017,9,C02-Antihypertensives,Million US$ at exchange rate,1.0 +10840,Estonia,2017,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0 +10841,Estonia,2017,9,N05B-Anxiolytics,% of total sales,0.5 +10842,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +10843,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.1 +10844,Estonia,2017,9,N02-Analgesics,"/capita, US$ purchasing power parity",11.3 +10845,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.9 +10846,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",8.1 +10847,Estonia,2017,9,N02-Analgesics,Million US$ at exchange rate,9.0 +10848,Estonia,2017,9,N05B-Anxiolytics,Million US$ at exchange rate,1.6 +10849,Estonia,2017,9,N05B-Anxiolytics,Million of national currency units,1.4 +10850,Estonia,2017,9,N02-Analgesics,"Million US$, purchasing power parity",14.9 +10851,Estonia,2017,9,N02-Analgesics,"/capita, US$ exchange rate",6.8 +10852,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.3 +10853,Estonia,2017,9,N02-Analgesics,% of total sales,2.6 +10854,Estonia,2017,9,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +10855,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.7 +10856,Estonia,2017,9,C-Cardiovascular system,"/capita, US$ exchange rate",25.7 +10857,Estonia,2017,9,C-Cardiovascular system,"Million US$, purchasing power parity",56.0 +10858,Estonia,2017,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +10859,Estonia,2017,9,C02-Antihypertensives,% of total sales,0.3 +10860,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7 +10861,Estonia,2017,9,C-Cardiovascular system,Million US$ at exchange rate,33.8 +10862,Estonia,2017,9,N02-Analgesics,Million of national currency units,7.9 +10863,Estonia,2017,9,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2 +10864,Estonia,2017,9,C-Cardiovascular system,Million of national currency units,29.9 +10865,Estonia,2017,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.2 +10866,Estonia,2017,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.7 +10867,Estonia,2017,9,B-Blood and blood forming organs,Million US$ at exchange rate,33.2 +10868,Estonia,2017,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",54.9 +10869,Estonia,2017,9,B-Blood and blood forming organs,% of total sales,9.8 +10870,Estonia,2017,9,R-Respiratory system,"Million US$, purchasing power parity",41.3 +10871,Estonia,2017,9,R-Respiratory system,"/capita, US$ exchange rate",18.9 +10872,Estonia,2017,9,R-Respiratory system,Million of national currency units,22.1 +10873,Estonia,2017,9,R-Respiratory system,Million US$ at exchange rate,25.0 +10874,Estonia,2017,9,C10-Lipid modifying agents,% of total sales,1.0 +10875,Estonia,2017,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.5 +10876,Estonia,2017,9,A02A-Antacids,Million of national currency units,0.4 +10877,Estonia,2017,9,A02A-Antacids,"Million US$, purchasing power parity",0.7 +10878,Estonia,2017,9,A02A-Antacids,Million US$ at exchange rate,0.4 +10879,Estonia,2017,9,C10-Lipid modifying agents,Million of national currency units,3.1 +10880,Estonia,2017,9,C10-Lipid modifying agents,Million US$ at exchange rate,3.5 +10881,Estonia,2017,9,B-Blood and blood forming organs,Million of national currency units,29.4 +10882,Estonia,2017,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.7 +10883,Estonia,2017,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.9 +10884,Estonia,2017,9,R-Respiratory system,"/capita, US$ purchasing power parity",31.4 +10885,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.3 +10886,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.7 +10887,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.9 +10888,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.7 +10889,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.1 +10890,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.2 +10891,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.9 +10892,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.1 +10893,Estonia,2017,9,R03-Drugs for obstructive airway diseases,Million of national currency units,9.2 +10894,Estonia,2017,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.4 +10895,Estonia,2017,9,C08-Calcium channel blockers,Million US$ at exchange rate,2.1 +10896,Estonia,2017,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",3.5 +10897,Estonia,2017,9,R-Respiratory system,% of total sales,7.3 +10898,Estonia,2017,9,C08-Calcium channel blockers,Million of national currency units,1.9 +10899,Estonia,2017,9,R03-Drugs for obstructive airway diseases,% of total sales,3.1 +10900,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9 +10901,Estonia,2017,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.6 +10902,Estonia,2017,9,C08-Calcium channel blockers,% of total sales,0.6 +10903,Estonia,2017,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7 +10904,Estonia,2017,9,N05C-Hypnotics and sedatives,Million of national currency units,2.0 +10905,Estonia,2017,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.2 +10906,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.1 +10907,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.4 +10908,Estonia,2017,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.7 +10909,Estonia,2017,9,N05C-Hypnotics and sedatives,% of total sales,0.7 +10910,Estonia,2017,9,G-Genito urinary system and sex hormones,% of total sales,3.8 +10911,Estonia,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7 +10912,Estonia,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8 +10913,Estonia,2017,9,C03-Diuretics,"/capita, US$ exchange rate",1.6 +10914,Estonia,2017,9,C03-Diuretics,"/capita, US$ purchasing power parity",2.7 +10915,Estonia,2017,9,C03-Diuretics,"Million US$, purchasing power parity",3.6 +10916,Estonia,2017,9,C03-Diuretics,Million of national currency units,1.9 +10917,Estonia,2017,9,C03-Diuretics,Million US$ at exchange rate,2.2 +10918,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.6 +10919,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.6 +10920,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",10.1 +10921,Estonia,2017,9,C03-Diuretics,% of total sales,0.6 +10922,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +10923,Estonia,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.4 +10924,Estonia,2017,9,C07-Beta blocking agents,Million US$ at exchange rate,6.2 +10925,Estonia,2017,9,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2 +10926,Estonia,2017,9,N06A-Antidepressants,% of total sales,1.1 +10927,Estonia,2017,9,A02A-Antacids,% of total sales,0.1 +10928,Estonia,2017,9,C07-Beta blocking agents,Million of national currency units,5.5 +10929,Estonia,2017,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +10930,Estonia,2017,9,A02A-Antacids,"/capita, US$ exchange rate",0.3 +10931,Estonia,2017,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7 +10932,Estonia,2017,9,C07-Beta blocking agents,% of total sales,1.8 +10933,Estonia,2017,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7 +10934,Estonia,2017,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,13.0 +10935,Estonia,2017,9,G-Genito urinary system and sex hormones,Million of national currency units,11.5 +10936,Estonia,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.9 +10937,Estonia,2017,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.6 +10938,Estonia,2017,9,N06A-Antidepressants,"/capita, US$ exchange rate",2.8 +10939,Estonia,2017,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6 +10940,Estonia,2017,9,N06A-Antidepressants,Million of national currency units,3.2 +10941,Estonia,2017,9,N06A-Antidepressants,"Million US$, purchasing power parity",6.0 +10942,Estonia,2017,9,N06A-Antidepressants,Million US$ at exchange rate,3.6 +10943,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +10944,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2 +10945,Estonia,2017,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,40.2 +10946,Estonia,2017,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.5 +10947,Estonia,2017,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",66.5 +10948,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3 +10949,Estonia,2017,9,A10-Drugs used in diabetes,% of total sales,6.0 +10950,Estonia,2017,9,A-Alimentary tract and metabolism,Million of national currency units,35.6 +10951,Estonia,2017,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.5 +10952,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2 +10953,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2 +10954,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.0 +10955,Estonia,2017,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.5 +10956,Estonia,2017,9,N-Nervous system,% of total sales,8.7 +10957,Estonia,2017,9,N-Nervous system,"/capita, US$ purchasing power parity",37.2 +10958,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8 +10959,Estonia,2017,9,N-Nervous system,"Million US$, purchasing power parity",49.0 +10960,Estonia,2017,9,N-Nervous system,"/capita, US$ exchange rate",22.5 +10961,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +10962,Estonia,2017,9,A-Alimentary tract and metabolism,% of total sales,11.8 +10963,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9 +10964,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5 +10965,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +10966,Estonia,2017,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +10967,Estonia,2017,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +10968,Estonia,2017,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +10969,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1 +10970,Estonia,2017,9,C01A-Cardiac glycosides,Million of national currency units,0.1 +10971,Estonia,2017,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +10972,Estonia,2017,9,Total pharmaceutical sales,Million US$ at exchange rate,340.0 +10973,Estonia,2017,9,Total pharmaceutical sales,Million of national currency units,301.0 +10974,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2 +10975,Estonia,2017,9,C01A-Cardiac glycosides,% of total sales,0.0 +10976,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.5 +10977,Estonia,2017,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.9 +10978,Estonia,2017,9,M-Musculo-skeletal system,% of total sales,5.6 +10979,Estonia,2017,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.4 +10980,Estonia,2017,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.4 +10981,Estonia,2017,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.6 +10982,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.5 +10983,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",17.8 +10984,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.7 +10985,Estonia,2017,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.5 +10986,Estonia,2017,9,M-Musculo-skeletal system,Million US$ at exchange rate,19.0 +10987,Estonia,2017,9,M-Musculo-skeletal system,Million of national currency units,16.8 +10988,Estonia,2017,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,49.4 +10989,Estonia,2017,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.4 +10990,Estonia,2017,9,J-Antiinfectives for systemic use,Million of national currency units,43.8 +10991,Estonia,2017,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.5 +10992,Estonia,2017,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",62.1 +10993,Estonia,2017,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",81.8 +10994,Estonia,2017,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.5 +10995,Estonia,2017,9,Total pharmaceutical sales,"/capita, US$ exchange rate",258.1 +10996,Estonia,2017,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",427.1 +10997,Estonia,2017,9,A10-Drugs used in diabetes,Million US$ at exchange rate,20.3 +10998,Estonia,2017,9,J01-Antibacterials for systemic use,Million of national currency units,6.6 +10999,Estonia,2017,9,A10-Drugs used in diabetes,Million of national currency units,18.0 +11000,Estonia,2017,9,N-Nervous system,Million of national currency units,26.2 +11001,Estonia,2017,9,J-Antiinfectives for systemic use,% of total sales,14.5 +11002,Estonia,2017,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",42.5 +11003,Estonia,2017,9,N-Nervous system,Million US$ at exchange rate,29.6 +11004,Estonia,2017,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4 +11005,Estonia,2017,9,C02-Antihypertensives,Million of national currency units,0.9 +11006,Estonia,2017,9,Total pharmaceutical sales,"Million US$, purchasing power parity",562.6 +11007,Estonia,2017,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.7 +11008,Estonia,2017,9,J01-Antibacterials for systemic use,% of total sales,2.2 +11009,Estonia,2017,9,C-Cardiovascular system,% of total sales,9.9 +11010,Finland,2016,3,C01A-Cardiac glycosides,% of total sales,0.1 +11011,Finland,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +11012,Finland,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.1 +11013,Finland,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,29.3 +11014,Finland,2016,3,C07-Beta blocking agents,Million of national currency units,26.5 +11015,Finland,2016,3,C01A-Cardiac glycosides,Million of national currency units,1.2 +11016,Finland,2016,3,C02-Antihypertensives,Million of national currency units,7.6 +11017,Finland,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +11018,Finland,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +11019,Finland,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3 +11020,Finland,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.5 +11021,Finland,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.9 +11022,Finland,2016,3,A-Alimentary tract and metabolism,% of total sales,13.2 +11023,Finland,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,334.7 +11024,Finland,2016,3,A-Alimentary tract and metabolism,Million of national currency units,302.4 +11025,Finland,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",343.3 +11026,Finland,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.7 +11027,Finland,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.4 +11028,Finland,2016,3,N-Nervous system,Million of national currency units,307.0 +11029,Finland,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.4 +11030,Finland,2016,3,N05C-Hypnotics and sedatives,% of total sales,0.5 +11031,Finland,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5 +11032,Finland,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",130.2 +11033,Finland,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,127.0 +11034,Finland,2016,3,C02-Antihypertensives,Million US$ at exchange rate,8.4 +11035,Finland,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",8.6 +11036,Finland,2016,3,G-Genito urinary system and sex hormones,% of total sales,5.0 +11037,Finland,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",23.1 +11038,Finland,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.7 +11039,Finland,2016,3,N-Nervous system,Million US$ at exchange rate,339.8 +11040,Finland,2016,3,N-Nervous system,"Million US$, purchasing power parity",348.5 +11041,Finland,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,114.7 +11042,Finland,2016,3,N-Nervous system,% of total sales,13.4 +11043,Finland,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",63.4 +11044,Finland,2016,3,N-Nervous system,"/capita, US$ exchange rate",61.8 +11045,Finland,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.0 +11046,Finland,2016,3,N06A-Antidepressants,Million US$ at exchange rate,34.1 +11047,Finland,2016,3,N06A-Antidepressants,Million of national currency units,30.8 +11048,Finland,2016,3,N06A-Antidepressants,% of total sales,1.3 +11049,Finland,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.4 +11050,Finland,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.2 +11051,Finland,2016,3,A10-Drugs used in diabetes,Million of national currency units,153.5 +11052,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.1 +11053,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",40.1 +11054,Finland,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",174.3 +11055,Finland,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.9 +11056,Finland,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,169.9 +11057,Finland,2016,3,R-Respiratory system,"/capita, US$ exchange rate",30.3 +11058,Finland,2016,3,M-Musculo-skeletal system,% of total sales,4.3 +11059,Finland,2016,3,R-Respiratory system,Million of national currency units,150.2 +11060,Finland,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",111.0 +11061,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +11062,Finland,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.2 +11063,Finland,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.7 +11064,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.3 +11065,Finland,2016,3,R-Respiratory system,Million US$ at exchange rate,166.3 +11066,Finland,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.7 +11067,Finland,2016,3,R-Respiratory system,"Million US$, purchasing power parity",170.5 +11068,Finland,2016,3,C08-Calcium channel blockers,% of total sales,0.8 +11069,Finland,2016,3,A10-Drugs used in diabetes,% of total sales,6.7 +11070,Finland,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0 +11071,Finland,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,108.3 +11072,Finland,2016,3,M-Musculo-skeletal system,Million of national currency units,97.8 +11073,Finland,2016,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.5 +11074,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +11075,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +11076,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +11077,Finland,2016,3,C07-Beta blocking agents,% of total sales,1.2 +11078,Finland,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3 +11079,Finland,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5 +11080,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2 +11081,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.8 +11082,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.6 +11083,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,35.3 +11084,Finland,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9 +11085,Finland,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.0 +11086,Finland,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.5 +11087,Finland,2016,3,R-Respiratory system,% of total sales,6.6 +11088,Finland,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",31.0 +11089,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.1 +11090,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",65.5 +11091,Finland,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,63.9 +11092,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.6 +11093,Finland,2016,3,C08-Calcium channel blockers,Million of national currency units,19.4 +11094,Finland,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.5 +11095,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.9 +11096,Finland,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7 +11097,Finland,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.1 +11098,Finland,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",209.0 +11099,Finland,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.0 +11100,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.5 +11101,Finland,2016,3,A02A-Antacids,% of total sales,0.1 +11102,Finland,2016,3,J-Antiinfectives for systemic use,Million of national currency units,184.1 +11103,Finland,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,203.8 +11104,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.2 +11105,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.0 +11106,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",61.5 +11107,Finland,2016,3,J-Antiinfectives for systemic use,% of total sales,8.0 +11108,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.8 +11109,Finland,2016,3,C-Cardiovascular system,% of total sales,9.2 +11110,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +11111,Finland,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.2 +11112,Finland,2016,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +11113,Finland,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.7 +11114,Finland,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.7 +11115,Finland,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,90.5 +11116,Finland,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,100.2 +11117,Finland,2016,3,A02A-Antacids,"Million US$, purchasing power parity",3.6 +11118,Finland,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.6 +11119,Finland,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +11120,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.4 +11121,Finland,2016,3,A02A-Antacids,Million US$ at exchange rate,3.5 +11122,Finland,2016,3,A02A-Antacids,Million of national currency units,3.2 +11123,Finland,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",222.4 +11124,Finland,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,216.8 +11125,Finland,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.5 +11126,Finland,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.5 +11127,Finland,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,8.0 +11128,Finland,2016,3,N05B-Anxiolytics,Million of national currency units,7.2 +11129,Finland,2016,3,N02-Analgesics,% of total sales,3.2 +11130,Finland,2016,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2598.3 +11131,Finland,2016,3,Total pharmaceutical sales,Million US$ at exchange rate,2533.5 +11132,Finland,2016,3,Total pharmaceutical sales,Million of national currency units,2288.8 +11133,Finland,2016,3,B-Blood and blood forming organs,% of total sales,8.6 +11134,Finland,2016,3,Total pharmaceutical sales,"/capita, US$ exchange rate",461.0 +11135,Finland,2016,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",472.8 +11136,Finland,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7 +11137,Finland,2016,3,C03-Diuretics,"Million US$, purchasing power parity",9.1 +11138,Finland,2016,3,C03-Diuretics,"/capita, US$ exchange rate",1.6 +11139,Finland,2016,3,C03-Diuretics,% of total sales,0.3 +11140,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.2 +11141,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.9 +11142,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4 +11143,Finland,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5 +11144,Finland,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +11145,Finland,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.2 +11146,Finland,2016,3,C03-Diuretics,Million US$ at exchange rate,8.9 +11147,Finland,2016,3,C03-Diuretics,Million of national currency units,8.0 +11148,Finland,2016,3,N05B-Anxiolytics,% of total sales,0.3 +11149,Finland,2016,3,B-Blood and blood forming organs,Million of national currency units,195.9 +11150,Finland,2016,3,N02-Analgesics,Million US$ at exchange rate,79.9 +11151,Finland,2016,3,N02-Analgesics,"Million US$, purchasing power parity",82.0 +11152,Finland,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,12.1 +11153,Finland,2016,3,C10-Lipid modifying agents,Million of national currency units,66.8 +11154,Finland,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,73.9 +11155,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,50.1 +11156,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,45.3 +11157,Finland,2016,3,N02-Analgesics,"/capita, US$ exchange rate",14.5 +11158,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.1 +11159,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.4 +11160,Finland,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",62.7 +11161,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.4 +11162,Finland,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,61.1 +11163,Finland,2016,3,J01-Antibacterials for systemic use,Million of national currency units,55.2 +11164,Finland,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.4 +11165,Finland,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.1 +11166,Finland,2016,3,N02-Analgesics,Million of national currency units,72.2 +11167,Finland,2016,3,J01-Antibacterials for systemic use,% of total sales,2.4 +11168,Finland,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.5 +11169,Finland,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",42.3 +11170,Finland,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",43.4 +11171,Finland,2016,3,C02-Antihypertensives,% of total sales,0.3 +11172,Finland,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6 +11173,Finland,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.8 +11174,Finland,2016,3,C10-Lipid modifying agents,% of total sales,2.9 +11175,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +11176,Finland,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",75.8 +11177,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,57.9 +11178,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,52.3 +11179,Finland,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.9 +11180,Finland,2016,3,C-Cardiovascular system,Million of national currency units,210.1 +11181,Finland,2016,3,C-Cardiovascular system,Million US$ at exchange rate,232.6 +11182,Finland,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",238.5 +11183,Finland,2015,3,C01A-Cardiac glycosides,% of total sales,0.1 +11184,Finland,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +11185,Finland,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4 +11186,Finland,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,30.6 +11187,Finland,2015,3,C07-Beta blocking agents,Million of national currency units,27.6 +11188,Finland,2015,3,C01A-Cardiac glycosides,Million of national currency units,1.3 +11189,Finland,2015,3,C02-Antihypertensives,Million of national currency units,7.1 +11190,Finland,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4 +11191,Finland,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +11192,Finland,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +11193,Finland,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.9 +11194,Finland,2015,3,A-Alimentary tract and metabolism,% of total sales,13.3 +11195,Finland,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.3 +11196,Finland,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,325.1 +11197,Finland,2015,3,A-Alimentary tract and metabolism,Million of national currency units,293.0 +11198,Finland,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",322.8 +11199,Finland,2015,3,N-Nervous system,Million of national currency units,319.8 +11200,Finland,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.8 +11201,Finland,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.4 +11202,Finland,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.9 +11203,Finland,2015,3,N05C-Hypnotics and sedatives,% of total sales,0.6 +11204,Finland,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.5 +11205,Finland,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5 +11206,Finland,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",123.4 +11207,Finland,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,124.3 +11208,Finland,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.8 +11209,Finland,2015,3,C02-Antihypertensives,Million US$ at exchange rate,7.9 +11210,Finland,2015,3,G-Genito urinary system and sex hormones,% of total sales,5.1 +11211,Finland,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.5 +11212,Finland,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.7 +11213,Finland,2015,3,N-Nervous system,Million US$ at exchange rate,354.8 +11214,Finland,2015,3,N-Nervous system,"Million US$, purchasing power parity",352.3 +11215,Finland,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,112.0 +11216,Finland,2015,3,N-Nervous system,% of total sales,14.5 +11217,Finland,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",64.3 +11218,Finland,2015,3,N-Nervous system,"/capita, US$ exchange rate",64.8 +11219,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6 +11220,Finland,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.4 +11221,Finland,2015,3,N06A-Antidepressants,Million of national currency units,32.1 +11222,Finland,2015,3,N06A-Antidepressants,Million US$ at exchange rate,35.6 +11223,Finland,2015,3,N06A-Antidepressants,% of total sales,1.5 +11224,Finland,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.5 +11225,Finland,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.5 +11226,Finland,2015,3,A10-Drugs used in diabetes,Million of national currency units,148.2 +11227,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.2 +11228,Finland,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.0 +11229,Finland,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",163.3 +11230,Finland,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,164.4 +11231,Finland,2015,3,M-Musculo-skeletal system,% of total sales,4.5 +11232,Finland,2015,3,R-Respiratory system,Million of national currency units,144.4 +11233,Finland,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",108.2 +11234,Finland,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9 +11235,Finland,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.7 +11236,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.1 +11237,Finland,2015,3,R-Respiratory system,Million US$ at exchange rate,160.2 +11238,Finland,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",29.8 +11239,Finland,2015,3,R-Respiratory system,"/capita, US$ exchange rate",29.2 +11240,Finland,2015,3,R-Respiratory system,"Million US$, purchasing power parity",159.1 +11241,Finland,2015,3,C08-Calcium channel blockers,% of total sales,0.9 +11242,Finland,2015,3,A10-Drugs used in diabetes,% of total sales,6.7 +11243,Finland,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8 +11244,Finland,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",29.0 +11245,Finland,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,109.0 +11246,Finland,2015,3,M-Musculo-skeletal system,Million of national currency units,98.2 +11247,Finland,2015,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.7 +11248,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +11249,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +11250,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +11251,Finland,2015,3,C07-Beta blocking agents,% of total sales,1.3 +11252,Finland,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6 +11253,Finland,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5 +11254,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.0 +11255,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.4 +11256,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.4 +11257,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.7 +11258,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,35.4 +11259,Finland,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",20.9 +11260,Finland,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8 +11261,Finland,2015,3,R-Respiratory system,% of total sales,6.6 +11262,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",39.0 +11263,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.3 +11264,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",64.3 +11265,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.8 +11266,Finland,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.8 +11267,Finland,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.1 +11268,Finland,2015,3,C08-Calcium channel blockers,Million of national currency units,19.0 +11269,Finland,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,58.4 +11270,Finland,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.9 +11271,Finland,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",200.6 +11272,Finland,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",36.6 +11273,Finland,2015,3,A02A-Antacids,% of total sales,0.1 +11274,Finland,2015,3,J-Antiinfectives for systemic use,Million of national currency units,182.1 +11275,Finland,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,202.0 +11276,Finland,2015,3,J-Antiinfectives for systemic use,% of total sales,8.3 +11277,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,55.0 +11278,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,61.0 +11279,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",60.6 +11280,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6 +11281,Finland,2015,3,C-Cardiovascular system,% of total sales,9.2 +11282,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +11283,Finland,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",17.7 +11284,Finland,2015,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +11285,Finland,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6 +11286,Finland,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,87.5 +11287,Finland,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",96.4 +11288,Finland,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,97.1 +11289,Finland,2015,3,A02A-Antacids,"Million US$, purchasing power parity",3.5 +11290,Finland,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.6 +11291,Finland,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +11292,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.7 +11293,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.9 +11294,Finland,2015,3,A02A-Antacids,Million of national currency units,3.2 +11295,Finland,2015,3,A02A-Antacids,Million US$ at exchange rate,3.6 +11296,Finland,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",195.4 +11297,Finland,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.7 +11298,Finland,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.9 +11299,Finland,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,196.8 +11300,Finland,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,8.7 +11301,Finland,2015,3,N05B-Anxiolytics,Million of national currency units,7.8 +11302,Finland,2015,3,N02-Analgesics,% of total sales,3.3 +11303,Finland,2015,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2423.7 +11304,Finland,2015,3,Total pharmaceutical sales,Million US$ at exchange rate,2441.0 +11305,Finland,2015,3,Total pharmaceutical sales,Million of national currency units,2200.1 +11306,Finland,2015,3,B-Blood and blood forming organs,% of total sales,8.1 +11307,Finland,2015,3,Total pharmaceutical sales,"/capita, US$ exchange rate",445.5 +11308,Finland,2015,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.3 +11309,Finland,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.8 +11310,Finland,2015,3,C03-Diuretics,% of total sales,0.4 +11311,Finland,2015,3,C03-Diuretics,"/capita, US$ exchange rate",1.8 +11312,Finland,2015,3,C03-Diuretics,"Million US$, purchasing power parity",9.7 +11313,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.1 +11314,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1 +11315,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5 +11316,Finland,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6 +11317,Finland,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.6 +11318,Finland,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6 +11319,Finland,2015,3,C03-Diuretics,Million US$ at exchange rate,9.8 +11320,Finland,2015,3,N05B-Anxiolytics,% of total sales,0.4 +11321,Finland,2015,3,C03-Diuretics,Million of national currency units,8.8 +11322,Finland,2015,3,B-Blood and blood forming organs,Million of national currency units,177.4 +11323,Finland,2015,3,N02-Analgesics,"/capita, US$ exchange rate",14.6 +11324,Finland,2015,3,N02-Analgesics,Million US$ at exchange rate,79.8 +11325,Finland,2015,3,N02-Analgesics,"Million US$, purchasing power parity",79.2 +11326,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +11327,Finland,2015,3,C10-Lipid modifying agents,Million of national currency units,58.7 +11328,Finland,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,65.1 +11329,Finland,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,12.5 +11330,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,46.8 +11331,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,42.2 +11332,Finland,2015,3,N02-Analgesics,Million of national currency units,71.9 +11333,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.5 +11334,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",46.5 +11335,Finland,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",57.1 +11336,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.5 +11337,Finland,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.5 +11338,Finland,2015,3,J01-Antibacterials for systemic use,Million of national currency units,51.8 +11339,Finland,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4 +11340,Finland,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5 +11341,Finland,2015,3,J01-Antibacterials for systemic use,% of total sales,2.4 +11342,Finland,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.9 +11343,Finland,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",41.1 +11344,Finland,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9 +11345,Finland,2015,3,C02-Antihypertensives,% of total sales,0.3 +11346,Finland,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4 +11347,Finland,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8 +11348,Finland,2015,3,C10-Lipid modifying agents,% of total sales,2.7 +11349,Finland,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",64.7 +11350,Finland,2015,3,C-Cardiovascular system,Million of national currency units,203.2 +11351,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,58.4 +11352,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,52.6 +11353,Finland,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.5 +11354,Finland,2015,3,C-Cardiovascular system,Million US$ at exchange rate,225.5 +11355,Finland,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",223.9 +11356,Finland,2014,3,C01A-Cardiac glycosides,% of total sales,0.1 +11357,Finland,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +11358,Finland,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4 +11359,Finland,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,36.7 +11360,Finland,2014,3,C07-Beta blocking agents,Million of national currency units,27.6 +11361,Finland,2014,3,C01A-Cardiac glycosides,Million of national currency units,1.1 +11362,Finland,2014,3,C02-Antihypertensives,Million of national currency units,6.2 +11363,Finland,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +11364,Finland,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2 +11365,Finland,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5 +11366,Finland,2014,3,G-Genito urinary system and sex hormones,% of total sales,5.3 +11367,Finland,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4 +11368,Finland,2014,3,A-Alimentary tract and metabolism,% of total sales,13.3 +11369,Finland,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,371.1 +11370,Finland,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.9 +11371,Finland,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",307.9 +11372,Finland,2014,3,A-Alimentary tract and metabolism,Million of national currency units,279.3 +11373,Finland,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.1 +11374,Finland,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.5 +11375,Finland,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.0 +11376,Finland,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",3.1 +11377,Finland,2014,3,N05C-Hypnotics and sedatives,% of total sales,0.6 +11378,Finland,2014,3,N-Nervous system,Million of national currency units,335.5 +11379,Finland,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6 +11380,Finland,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",122.8 +11381,Finland,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",6.8 +11382,Finland,2014,3,C02-Antihypertensives,Million US$ at exchange rate,8.2 +11383,Finland,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.1 +11384,Finland,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.5 +11385,Finland,2014,3,N-Nervous system,"Million US$, purchasing power parity",369.8 +11386,Finland,2014,3,N-Nervous system,Million US$ at exchange rate,445.7 +11387,Finland,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,148.0 +11388,Finland,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,111.4 +11389,Finland,2014,3,N-Nervous system,% of total sales,16.0 +11390,Finland,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",67.7 +11391,Finland,2014,3,N-Nervous system,"/capita, US$ exchange rate",81.6 +11392,Finland,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7 +11393,Finland,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",36.3 +11394,Finland,2014,3,N06A-Antidepressants,Million US$ at exchange rate,43.7 +11395,Finland,2014,3,N06A-Antidepressants,Million of national currency units,32.9 +11396,Finland,2014,3,N06A-Antidepressants,% of total sales,1.6 +11397,Finland,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.0 +11398,Finland,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.6 +11399,Finland,2014,3,A10-Drugs used in diabetes,Million of national currency units,140.0 +11400,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0 +11401,Finland,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.1 +11402,Finland,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",154.3 +11403,Finland,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,186.0 +11404,Finland,2014,3,M-Musculo-skeletal system,% of total sales,4.7 +11405,Finland,2014,3,R-Respiratory system,Million of national currency units,148.8 +11406,Finland,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.0 +11407,Finland,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.1 +11408,Finland,2014,3,R-Respiratory system,Million US$ at exchange rate,197.7 +11409,Finland,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.3 +11410,Finland,2014,3,R-Respiratory system,"/capita, US$ exchange rate",36.2 +11411,Finland,2014,3,R-Respiratory system,"Million US$, purchasing power parity",164.0 +11412,Finland,2014,3,C08-Calcium channel blockers,% of total sales,0.9 +11413,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.7 +11414,Finland,2014,3,A10-Drugs used in diabetes,% of total sales,6.7 +11415,Finland,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7 +11416,Finland,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",30.0 +11417,Finland,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,131.4 +11418,Finland,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",109.0 +11419,Finland,2014,3,M-Musculo-skeletal system,Million of national currency units,98.9 +11420,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +11421,Finland,2014,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.8 +11422,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +11423,Finland,2014,3,C07-Beta blocking agents,% of total sales,1.3 +11424,Finland,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.6 +11425,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.6 +11426,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.0 +11427,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +11428,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6 +11429,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.8 +11430,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,33.0 +11431,Finland,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.4 +11432,Finland,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",20.0 +11433,Finland,2014,3,R-Respiratory system,% of total sales,7.1 +11434,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.8 +11435,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",36.4 +11436,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",63.6 +11437,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.6 +11438,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.0 +11439,Finland,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,76.7 +11440,Finland,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,24.0 +11441,Finland,2014,3,C08-Calcium channel blockers,Million of national currency units,18.1 +11442,Finland,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7 +11443,Finland,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.4 +11444,Finland,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",160.6 +11445,Finland,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.4 +11446,Finland,2014,3,J-Antiinfectives for systemic use,% of total sales,7.0 +11447,Finland,2014,3,J-Antiinfectives for systemic use,Million of national currency units,145.7 +11448,Finland,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,193.6 +11449,Finland,2014,3,A02A-Antacids,% of total sales,0.1 +11450,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.5 +11451,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.4 +11452,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",60.1 +11453,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9 +11454,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.6 +11455,Finland,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1 +11456,Finland,2014,3,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +11457,Finland,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.3 +11458,Finland,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",100.2 +11459,Finland,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,90.9 +11460,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.5 +11461,Finland,2014,3,C-Cardiovascular system,% of total sales,9.1 +11462,Finland,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,120.8 +11463,Finland,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.8 +11464,Finland,2014,3,A02A-Antacids,"Million US$, purchasing power parity",3.4 +11465,Finland,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +11466,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1 +11467,Finland,2014,3,A02A-Antacids,Million US$ at exchange rate,4.1 +11468,Finland,2014,3,A02A-Antacids,Million of national currency units,3.1 +11469,Finland,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",178.7 +11470,Finland,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.7 +11471,Finland,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.4 +11472,Finland,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,10.5 +11473,Finland,2014,3,N05B-Anxiolytics,Million of national currency units,7.9 +11474,Finland,2014,3,N02-Analgesics,% of total sales,3.4 +11475,Finland,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,215.4 +11476,Finland,2014,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2307.6 +11477,Finland,2014,3,Total pharmaceutical sales,Million US$ at exchange rate,2781.2 +11478,Finland,2014,3,Total pharmaceutical sales,Million of national currency units,2093.5 +11479,Finland,2014,3,B-Blood and blood forming organs,% of total sales,7.7 +11480,Finland,2014,3,Total pharmaceutical sales,"/capita, US$ exchange rate",509.2 +11481,Finland,2014,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",422.5 +11482,Finland,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7 +11483,Finland,2014,3,C03-Diuretics,% of total sales,0.4 +11484,Finland,2014,3,C03-Diuretics,"/capita, US$ exchange rate",2.1 +11485,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.0 +11486,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.3 +11487,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.6 +11488,Finland,2014,3,C03-Diuretics,"Million US$, purchasing power parity",9.4 +11489,Finland,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6 +11490,Finland,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.7 +11491,Finland,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9 +11492,Finland,2014,3,N05B-Anxiolytics,% of total sales,0.4 +11493,Finland,2014,3,C03-Diuretics,Million US$ at exchange rate,11.3 +11494,Finland,2014,3,C03-Diuretics,Million of national currency units,8.5 +11495,Finland,2014,3,B-Blood and blood forming organs,Million of national currency units,162.1 +11496,Finland,2014,3,N02-Analgesics,"/capita, US$ exchange rate",17.1 +11497,Finland,2014,3,N02-Analgesics,Million US$ at exchange rate,93.5 +11498,Finland,2014,3,N02-Analgesics,"Million US$, purchasing power parity",77.6 +11499,Finland,2014,3,C10-Lipid modifying agents,Million of national currency units,49.1 +11500,Finland,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,65.2 +11501,Finland,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,12.8 +11502,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,54.5 +11503,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,41.0 +11504,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.0 +11505,Finland,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",55.4 +11506,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.3 +11507,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +11508,Finland,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,66.8 +11509,Finland,2014,3,J01-Antibacterials for systemic use,Million of national currency units,50.3 +11510,Finland,2014,3,N02-Analgesics,Million of national currency units,70.4 +11511,Finland,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.2 +11512,Finland,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.2 +11513,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",45.2 +11514,Finland,2014,3,J01-Antibacterials for systemic use,% of total sales,2.4 +11515,Finland,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.9 +11516,Finland,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",46.4 +11517,Finland,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",38.5 +11518,Finland,2014,3,C02-Antihypertensives,% of total sales,0.3 +11519,Finland,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +11520,Finland,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.9 +11521,Finland,2014,3,C10-Lipid modifying agents,% of total sales,2.3 +11522,Finland,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.1 +11523,Finland,2014,3,C-Cardiovascular system,Million of national currency units,190.9 +11524,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.7 +11525,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,54.0 +11526,Finland,2014,3,C-Cardiovascular system,Million US$ at exchange rate,253.6 +11527,Finland,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",210.4 +11528,Finland,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.2 +11529,Finland,2013,4,C01A-Cardiac glycosides,% of total sales,0.0 +11530,Finland,2013,4,C07-Beta blocking agents,Million of national currency units,27.1 +11531,Finland,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",29.9 +11532,Finland,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,36.0 +11533,Finland,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +11534,Finland,2013,4,C01A-Cardiac glycosides,Million of national currency units,0.6 +11535,Finland,2013,4,C02-Antihypertensives,Million of national currency units,5.7 +11536,Finland,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +11537,Finland,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +11538,Finland,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7 +11539,Finland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.8 +11540,Finland,2013,4,A-Alimentary tract and metabolism,% of total sales,13.2 +11541,Finland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.7 +11542,Finland,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,352.0 +11543,Finland,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",292.7 +11544,Finland,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.9 +11545,Finland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",3.1 +11546,Finland,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4 +11547,Finland,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.7 +11548,Finland,2013,4,N05C-Hypnotics and sedatives,% of total sales,0.6 +11549,Finland,2013,4,N-Nervous system,Million of national currency units,341.2 +11550,Finland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6 +11551,Finland,2013,4,A-Alimentary tract and metabolism,Million of national currency units,265.0 +11552,Finland,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.3 +11553,Finland,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",6.3 +11554,Finland,2013,4,C02-Antihypertensives,Million US$ at exchange rate,7.6 +11555,Finland,2013,4,G-Genito urinary system and sex hormones,% of total sales,5.4 +11556,Finland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.6 +11557,Finland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.1 +11558,Finland,2013,4,N-Nervous system,"Million US$, purchasing power parity",376.9 +11559,Finland,2013,4,N-Nervous system,Million US$ at exchange rate,453.2 +11560,Finland,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,108.9 +11561,Finland,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,144.6 +11562,Finland,2013,4,N-Nervous system,% of total sales,17.0 +11563,Finland,2013,4,N-Nervous system,"/capita, US$ exchange rate",83.3 +11564,Finland,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",69.3 +11565,Finland,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",34.0 +11566,Finland,2013,4,N06A-Antidepressants,Million of national currency units,30.8 +11567,Finland,2013,4,N06A-Antidepressants,Million US$ at exchange rate,40.9 +11568,Finland,2013,4,N06A-Antidepressants,% of total sales,1.5 +11569,Finland,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.5 +11570,Finland,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.3 +11571,Finland,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4 +11572,Finland,2013,4,A10-Drugs used in diabetes,Million of national currency units,131.0 +11573,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.8 +11574,Finland,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0 +11575,Finland,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,174.0 +11576,Finland,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",144.7 +11577,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6 +11578,Finland,2013,4,M-Musculo-skeletal system,% of total sales,4.8 +11579,Finland,2013,4,R-Respiratory system,Million of national currency units,146.3 +11580,Finland,2013,4,R-Respiratory system,Million US$ at exchange rate,194.3 +11581,Finland,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.6 +11582,Finland,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.6 +11583,Finland,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.6 +11584,Finland,2013,4,R-Respiratory system,"/capita, US$ exchange rate",35.7 +11585,Finland,2013,4,R-Respiratory system,"Million US$, purchasing power parity",161.6 +11586,Finland,2013,4,C08-Calcium channel blockers,% of total sales,0.8 +11587,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.5 +11588,Finland,2013,4,A10-Drugs used in diabetes,% of total sales,6.5 +11589,Finland,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",29.7 +11590,Finland,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",106.8 +11591,Finland,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,128.4 +11592,Finland,2013,4,M-Musculo-skeletal system,Million of national currency units,96.7 +11593,Finland,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.8 +11594,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +11595,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +11596,Finland,2013,4,C07-Beta blocking agents,% of total sales,1.3 +11597,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7 +11598,Finland,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5 +11599,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.1 +11600,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +11601,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9 +11602,Finland,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6 +11603,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,32.0 +11604,Finland,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.7 +11605,Finland,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +11606,Finland,2013,4,R-Respiratory system,% of total sales,7.3 +11607,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,42.5 +11608,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",35.3 +11609,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",62.8 +11610,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.6 +11611,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.9 +11612,Finland,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,75.6 +11613,Finland,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,22.4 +11614,Finland,2013,4,C08-Calcium channel blockers,Million of national currency units,16.9 +11615,Finland,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,56.9 +11616,Finland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.2 +11617,Finland,2013,4,J-Antiinfectives for systemic use,% of total sales,7.2 +11618,Finland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.3 +11619,Finland,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",159.2 +11620,Finland,2013,4,J-Antiinfectives for systemic use,Million of national currency units,144.1 +11621,Finland,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,191.4 +11622,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,75.8 +11623,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,57.1 +11624,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",63.1 +11625,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9 +11626,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7 +11627,Finland,2013,4,A02A-Antacids,% of total sales,0.1 +11628,Finland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.6 +11629,Finland,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,4.6 +11630,Finland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.8 +11631,Finland,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,92.4 +11632,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.5 +11633,Finland,2013,4,C-Cardiovascular system,% of total sales,9.0 +11634,Finland,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.1 +11635,Finland,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,122.7 +11636,Finland,2013,4,A02A-Antacids,"/capita, US$ exchange rate",0.7 +11637,Finland,2013,4,A02A-Antacids,"Million US$, purchasing power parity",3.3 +11638,Finland,2013,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +11639,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.2 +11640,Finland,2013,4,A02A-Antacids,Million of national currency units,3.0 +11641,Finland,2013,4,A02A-Antacids,Million US$ at exchange rate,4.0 +11642,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.9 +11643,Finland,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",172.5 +11644,Finland,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.7 +11645,Finland,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1 +11646,Finland,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,10.5 +11647,Finland,2013,4,N05B-Anxiolytics,Million of national currency units,7.9 +11648,Finland,2013,4,N02-Analgesics,% of total sales,3.5 +11649,Finland,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2223.1 +11650,Finland,2013,4,Total pharmaceutical sales,Million of national currency units,2012.7 +11651,Finland,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,2673.1 +11652,Finland,2013,4,B-Blood and blood forming organs,% of total sales,7.8 +11653,Finland,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",491.5 +11654,Finland,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",408.7 +11655,Finland,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.7 +11656,Finland,2013,4,C03-Diuretics,% of total sales,0.4 +11657,Finland,2013,4,C03-Diuretics,"/capita, US$ exchange rate",2.0 +11658,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.6 +11659,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8 +11660,Finland,2013,4,C03-Diuretics,"Million US$, purchasing power parity",9.2 +11661,Finland,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6 +11662,Finland,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",8.7 +11663,Finland,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9 +11664,Finland,2013,4,N05B-Anxiolytics,% of total sales,0.4 +11665,Finland,2013,4,C03-Diuretics,Million US$ at exchange rate,11.0 +11666,Finland,2013,4,C03-Diuretics,Million of national currency units,8.3 +11667,Finland,2013,4,N02-Analgesics,"/capita, US$ exchange rate",17.0 +11668,Finland,2013,4,B-Blood and blood forming organs,Million of national currency units,156.2 +11669,Finland,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,207.5 +11670,Finland,2013,4,N02-Analgesics,Million US$ at exchange rate,92.6 +11671,Finland,2013,4,N02-Analgesics,"Million US$, purchasing power parity",77.0 +11672,Finland,2013,4,C10-Lipid modifying agents,Million of national currency units,41.9 +11673,Finland,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,55.6 +11674,Finland,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,12.6 +11675,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,51.9 +11676,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,39.1 +11677,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.5 +11678,Finland,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",59.4 +11679,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +11680,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9 +11681,Finland,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,71.5 +11682,Finland,2013,4,J01-Antibacterials for systemic use,Million of national currency units,53.8 +11683,Finland,2013,4,N02-Analgesics,Million of national currency units,69.7 +11684,Finland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.1 +11685,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",43.2 +11686,Finland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9 +11687,Finland,2013,4,J01-Antibacterials for systemic use,% of total sales,2.7 +11688,Finland,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.2 +11689,Finland,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",44.4 +11690,Finland,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.9 +11691,Finland,2013,4,C02-Antihypertensives,% of total sales,0.3 +11692,Finland,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2 +11693,Finland,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5 +11694,Finland,2013,4,C10-Lipid modifying agents,% of total sales,2.1 +11695,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.6 +11696,Finland,2013,4,C-Cardiovascular system,Million of national currency units,181.9 +11697,Finland,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",46.3 +11698,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,53.9 +11699,Finland,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",200.9 +11700,Finland,2013,4,C-Cardiovascular system,Million US$ at exchange rate,241.6 +11701,Finland,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.2 +11702,Finland,2012,4,C01A-Cardiac glycosides,% of total sales,0.0 +11703,Finland,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",28.8 +11704,Finland,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,33.7 +11705,Finland,2012,4,C07-Beta blocking agents,Million of national currency units,26.2 +11706,Finland,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +11707,Finland,2012,4,C01A-Cardiac glycosides,Million of national currency units,0.4 +11708,Finland,2012,4,C02-Antihypertensives,Million of national currency units,5.4 +11709,Finland,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5 +11710,Finland,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +11711,Finland,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +11712,Finland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.8 +11713,Finland,2012,4,A-Alimentary tract and metabolism,% of total sales,13.0 +11714,Finland,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,327.2 +11715,Finland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.4 +11716,Finland,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",280.4 +11717,Finland,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.4 +11718,Finland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.9 +11719,Finland,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3 +11720,Finland,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.7 +11721,Finland,2012,4,N05C-Hypnotics and sedatives,% of total sales,0.6 +11722,Finland,2012,4,N-Nervous system,Million of national currency units,350.6 +11723,Finland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5 +11724,Finland,2012,4,A-Alimentary tract and metabolism,Million of national currency units,254.7 +11725,Finland,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",115.7 +11726,Finland,2012,4,C02-Antihypertensives,Million US$ at exchange rate,6.9 +11727,Finland,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9 +11728,Finland,2012,4,G-Genito urinary system and sex hormones,% of total sales,5.3 +11729,Finland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.9 +11730,Finland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.4 +11731,Finland,2012,4,N-Nervous system,"Million US$, purchasing power parity",385.9 +11732,Finland,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,105.1 +11733,Finland,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,135.0 +11734,Finland,2012,4,N-Nervous system,Million US$ at exchange rate,450.4 +11735,Finland,2012,4,N-Nervous system,% of total sales,17.8 +11736,Finland,2012,4,N-Nervous system,"/capita, US$ exchange rate",83.2 +11737,Finland,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",71.3 +11738,Finland,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.2 +11739,Finland,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",32.5 +11740,Finland,2012,4,N06A-Antidepressants,Million of national currency units,29.5 +11741,Finland,2012,4,N06A-Antidepressants,Million US$ at exchange rate,37.9 +11742,Finland,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.0 +11743,Finland,2012,4,N06A-Antidepressants,% of total sales,1.5 +11744,Finland,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.0 +11745,Finland,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1 +11746,Finland,2012,4,A10-Drugs used in diabetes,Million of national currency units,127.2 +11747,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.3 +11748,Finland,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.2 +11749,Finland,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",140.0 +11750,Finland,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,163.4 +11751,Finland,2012,4,R-Respiratory system,Million of national currency units,154.4 +11752,Finland,2012,4,M-Musculo-skeletal system,% of total sales,4.9 +11753,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6 +11754,Finland,2012,4,R-Respiratory system,Million US$ at exchange rate,198.4 +11755,Finland,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.8 +11756,Finland,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.5 +11757,Finland,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.9 +11758,Finland,2012,4,R-Respiratory system,"Million US$, purchasing power parity",170.0 +11759,Finland,2012,4,R-Respiratory system,"/capita, US$ exchange rate",36.6 +11760,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.2 +11761,Finland,2012,4,C08-Calcium channel blockers,% of total sales,0.8 +11762,Finland,2012,4,A10-Drugs used in diabetes,% of total sales,6.5 +11763,Finland,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",31.4 +11764,Finland,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",105.8 +11765,Finland,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,123.5 +11766,Finland,2012,4,M-Musculo-skeletal system,Million of national currency units,96.1 +11767,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +11768,Finland,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.8 +11769,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +11770,Finland,2012,4,C07-Beta blocking agents,% of total sales,1.3 +11771,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.8 +11772,Finland,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.3 +11773,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2 +11774,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +11775,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9 +11776,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,30.7 +11777,Finland,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.8 +11778,Finland,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6 +11779,Finland,2012,4,R-Respiratory system,% of total sales,7.9 +11780,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.4 +11781,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",33.8 +11782,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",61.2 +11783,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.3 +11784,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.2 +11785,Finland,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,19.7 +11786,Finland,2012,4,C08-Calcium channel blockers,Million of national currency units,15.3 +11787,Finland,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,71.4 +11788,Finland,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,55.6 +11789,Finland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.4 +11790,Finland,2012,4,J-Antiinfectives for systemic use,% of total sales,7.2 +11791,Finland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.6 +11792,Finland,2012,4,J-Antiinfectives for systemic use,Million of national currency units,140.8 +11793,Finland,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",155.0 +11794,Finland,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,180.9 +11795,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.9 +11796,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,63.0 +11797,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",69.3 +11798,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.3 +11799,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8 +11800,Finland,2012,4,A02A-Antacids,% of total sales,0.2 +11801,Finland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.8 +11802,Finland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.5 +11803,Finland,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +11804,Finland,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,95.9 +11805,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",61.2 +11806,Finland,2012,4,C-Cardiovascular system,% of total sales,9.0 +11807,Finland,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",105.6 +11808,Finland,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,123.2 +11809,Finland,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.7 +11810,Finland,2012,4,A02A-Antacids,"Million US$, purchasing power parity",3.3 +11811,Finland,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +11812,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.2 +11813,Finland,2012,4,A02A-Antacids,Million of national currency units,3.0 +11814,Finland,2012,4,A02A-Antacids,Million US$ at exchange rate,3.9 +11815,Finland,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",167.7 +11816,Finland,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.0 +11817,Finland,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.2 +11818,Finland,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,10.4 +11819,Finland,2012,4,N05B-Anxiolytics,Million of national currency units,8.1 +11820,Finland,2012,4,N02-Analgesics,% of total sales,3.6 +11821,Finland,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2162.7 +11822,Finland,2012,4,Total pharmaceutical sales,Million of national currency units,1964.8 +11823,Finland,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,2524.4 +11824,Finland,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",466.3 +11825,Finland,2012,4,B-Blood and blood forming organs,% of total sales,7.8 +11826,Finland,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",399.5 +11827,Finland,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.7 +11828,Finland,2012,4,C03-Diuretics,% of total sales,0.4 +11829,Finland,2012,4,C03-Diuretics,"/capita, US$ exchange rate",1.9 +11830,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.8 +11831,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.2 +11832,Finland,2012,4,C03-Diuretics,"Million US$, purchasing power parity",9.0 +11833,Finland,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6 +11834,Finland,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",8.9 +11835,Finland,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9 +11836,Finland,2012,4,N05B-Anxiolytics,% of total sales,0.4 +11837,Finland,2012,4,C03-Diuretics,Million US$ at exchange rate,10.5 +11838,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.0 +11839,Finland,2012,4,C03-Diuretics,Million of national currency units,8.2 +11840,Finland,2012,4,N02-Analgesics,"/capita, US$ exchange rate",16.8 +11841,Finland,2012,4,B-Blood and blood forming organs,Million of national currency units,152.4 +11842,Finland,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,195.8 +11843,Finland,2012,4,N02-Analgesics,Million US$ at exchange rate,91.0 +11844,Finland,2012,4,N02-Analgesics,"Million US$, purchasing power parity",77.9 +11845,Finland,2012,4,C10-Lipid modifying agents,Million of national currency units,35.2 +11846,Finland,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,45.2 +11847,Finland,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",38.7 +11848,Finland,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,12.2 +11849,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,54.9 +11850,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,42.7 +11851,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.1 +11852,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.7 +11853,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +11854,Finland,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",60.5 +11855,Finland,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,70.7 +11856,Finland,2012,4,J01-Antibacterials for systemic use,Million of national currency units,55.0 +11857,Finland,2012,4,N02-Analgesics,Million of national currency units,70.8 +11858,Finland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.1 +11859,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",47.0 +11860,Finland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +11861,Finland,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.4 +11862,Finland,2012,4,J01-Antibacterials for systemic use,% of total sales,2.8 +11863,Finland,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",41.8 +11864,Finland,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",35.8 +11865,Finland,2012,4,C02-Antihypertensives,% of total sales,0.3 +11866,Finland,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +11867,Finland,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.2 +11868,Finland,2012,4,C10-Lipid modifying agents,% of total sales,1.8 +11869,Finland,2012,4,C-Cardiovascular system,Million of national currency units,176.2 +11870,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.4 +11871,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,55.6 +11872,Finland,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",193.9 +11873,Finland,2012,4,C-Cardiovascular system,Million US$ at exchange rate,226.4 +11874,Finland,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4 +11875,Finland,2011,4,C01A-Cardiac glycosides,% of total sales,0.0 +11876,Finland,2011,4,C07-Beta blocking agents,Million of national currency units,25.0 +11877,Finland,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",27.8 +11878,Finland,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +11879,Finland,2011,4,C01A-Cardiac glycosides,Million of national currency units,0.4 +11880,Finland,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,34.8 +11881,Finland,2011,4,C02-Antihypertensives,Million of national currency units,5.3 +11882,Finland,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +11883,Finland,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +11884,Finland,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4 +11885,Finland,2011,4,A-Alimentary tract and metabolism,Million of national currency units,241.9 +11886,Finland,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.0 +11887,Finland,2011,4,A-Alimentary tract and metabolism,% of total sales,12.5 +11888,Finland,2011,4,N-Nervous system,Million US$ at exchange rate,492.5 +11889,Finland,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,336.7 +11890,Finland,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",62.5 +11891,Finland,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",269.4 +11892,Finland,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.7 +11893,Finland,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.7 +11894,Finland,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4 +11895,Finland,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.6 +11896,Finland,2011,4,N-Nervous system,Million of national currency units,353.8 +11897,Finland,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.5 +11898,Finland,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2 +11899,Finland,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",116.9 +11900,Finland,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9 +11901,Finland,2011,4,C02-Antihypertensives,Million US$ at exchange rate,7.4 +11902,Finland,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.1 +11903,Finland,2011,4,G-Genito urinary system and sex hormones,% of total sales,5.4 +11904,Finland,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5 +11905,Finland,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.7 +11906,Finland,2011,4,N-Nervous system,"Million US$, purchasing power parity",394.0 +11907,Finland,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,105.0 +11908,Finland,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,146.2 +11909,Finland,2011,4,N-Nervous system,% of total sales,18.4 +11910,Finland,2011,4,N-Nervous system,"/capita, US$ exchange rate",91.4 +11911,Finland,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",73.1 +11912,Finland,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",32.7 +11913,Finland,2011,4,N06A-Antidepressants,Million of national currency units,29.4 +11914,Finland,2011,4,N06A-Antidepressants,Million US$ at exchange rate,40.9 +11915,Finland,2011,4,N06A-Antidepressants,% of total sales,1.5 +11916,Finland,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.6 +11917,Finland,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.1 +11918,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.1 +11919,Finland,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1 +11920,Finland,2011,4,A10-Drugs used in diabetes,Million of national currency units,117.1 +11921,Finland,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.7 +11922,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6 +11923,Finland,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.3 +11924,Finland,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,163.0 +11925,Finland,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",130.4 +11926,Finland,2011,4,R-Respiratory system,Million of national currency units,148.7 +11927,Finland,2011,4,M-Musculo-skeletal system,% of total sales,4.7 +11928,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +11929,Finland,2011,4,R-Respiratory system,Million US$ at exchange rate,207.0 +11930,Finland,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5 +11931,Finland,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8 +11932,Finland,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.2 +11933,Finland,2011,4,R-Respiratory system,"/capita, US$ exchange rate",38.4 +11934,Finland,2011,4,R-Respiratory system,"Million US$, purchasing power parity",165.6 +11935,Finland,2011,4,C08-Calcium channel blockers,% of total sales,0.8 +11936,Finland,2011,4,A10-Drugs used in diabetes,% of total sales,6.1 +11937,Finland,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",101.3 +11938,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +11939,Finland,2011,4,M-Musculo-skeletal system,Million of national currency units,91.0 +11940,Finland,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,126.7 +11941,Finland,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9 +11942,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +11943,Finland,2011,4,C07-Beta blocking agents,% of total sales,1.3 +11944,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2 +11945,Finland,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2 +11946,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +11947,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.7 +11948,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.8 +11949,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,29.4 +11950,Finland,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.9 +11951,Finland,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9 +11952,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.9 +11953,Finland,2011,4,R-Respiratory system,% of total sales,7.7 +11954,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.7 +11955,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",62.0 +11956,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.4 +11957,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.5 +11958,Finland,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,21.2 +11959,Finland,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.5 +11960,Finland,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,55.7 +11961,Finland,2011,4,C08-Calcium channel blockers,Million of national currency units,15.2 +11962,Finland,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.5 +11963,Finland,2011,4,J-Antiinfectives for systemic use,% of total sales,7.9 +11964,Finland,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.6 +11965,Finland,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",170.3 +11966,Finland,2011,4,J-Antiinfectives for systemic use,Million of national currency units,152.9 +11967,Finland,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,212.8 +11968,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,99.4 +11969,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,71.4 +11970,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",79.5 +11971,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.0 +11972,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8 +11973,Finland,2011,4,A02A-Antacids,% of total sales,0.1 +11974,Finland,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2 +11975,Finland,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4 +11976,Finland,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +11977,Finland,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,93.8 +11978,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.2 +11979,Finland,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",104.4 +11980,Finland,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,130.6 +11981,Finland,2011,4,A02A-Antacids,"/capita, US$ exchange rate",0.7 +11982,Finland,2011,4,A02A-Antacids,"Million US$, purchasing power parity",3.1 +11983,Finland,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +11984,Finland,2011,4,A02A-Antacids,Million of national currency units,2.8 +11985,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.7 +11986,Finland,2011,4,A02A-Antacids,Million US$ at exchange rate,3.9 +11987,Finland,2011,4,C-Cardiovascular system,% of total sales,9.2 +11988,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.4 +11989,Finland,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",154.2 +11990,Finland,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.8 +11991,Finland,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.6 +11992,Finland,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,11.4 +11993,Finland,2011,4,N02-Analgesics,% of total sales,3.5 +11994,Finland,2011,4,N05B-Anxiolytics,Million of national currency units,8.2 +11995,Finland,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2146.4 +11996,Finland,2011,4,Total pharmaceutical sales,Million of national currency units,1927.6 +11997,Finland,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,2683.1 +11998,Finland,2011,4,B-Blood and blood forming organs,% of total sales,7.2 +11999,Finland,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",498.0 +12000,Finland,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",398.3 +12001,Finland,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",9.1 +12002,Finland,2011,4,C03-Diuretics,% of total sales,0.5 +12003,Finland,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.8 +12004,Finland,2011,4,C03-Diuretics,"/capita, US$ exchange rate",2.3 +12005,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",14.8 +12006,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.7 +12007,Finland,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7 +12008,Finland,2011,4,N05B-Anxiolytics,% of total sales,0.4 +12009,Finland,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1 +12010,Finland,2011,4,C03-Diuretics,Million US$ at exchange rate,12.2 +12011,Finland,2011,4,C03-Diuretics,"Million US$, purchasing power parity",9.8 +12012,Finland,2011,4,C03-Diuretics,Million of national currency units,8.8 +12013,Finland,2011,4,N02-Analgesics,"/capita, US$ exchange rate",17.5 +12014,Finland,2011,4,B-Blood and blood forming organs,Million of national currency units,138.5 +12015,Finland,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,192.8 +12016,Finland,2011,4,N02-Analgesics,Million US$ at exchange rate,94.5 +12017,Finland,2011,4,N02-Analgesics,"Million US$, purchasing power parity",75.6 +12018,Finland,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,41.3 +12019,Finland,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",33.1 +12020,Finland,2011,4,C10-Lipid modifying agents,Million of national currency units,29.7 +12021,Finland,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,10.5 +12022,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,57.8 +12023,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,41.5 +12024,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.6 +12025,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7 +12026,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +12027,Finland,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",73.0 +12028,Finland,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,91.3 +12029,Finland,2011,4,J01-Antibacterials for systemic use,Million of national currency units,65.6 +12030,Finland,2011,4,N02-Analgesics,Million of national currency units,67.9 +12031,Finland,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.9 +12032,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",46.2 +12033,Finland,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.6 +12034,Finland,2011,4,J01-Antibacterials for systemic use,% of total sales,3.4 +12035,Finland,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.7 +12036,Finland,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.0 +12037,Finland,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.8 +12038,Finland,2011,4,C02-Antihypertensives,% of total sales,0.3 +12039,Finland,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +12040,Finland,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.1 +12041,Finland,2011,4,C10-Lipid modifying agents,% of total sales,1.5 +12042,Finland,2011,4,C-Cardiovascular system,Million of national currency units,178.2 +12043,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,53.2 +12044,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,74.1 +12045,Finland,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",198.4 +12046,Finland,2011,4,C-Cardiovascular system,Million US$ at exchange rate,248.0 +12047,Finland,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.0 +12048,Finland,2010,4,C01A-Cardiac glycosides,% of total sales,0.0 +12049,Finland,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",7.4 +12050,Finland,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",33.1 +12051,Finland,2010,4,C07-Beta blocking agents,Million of national currency units,29.8 +12052,Finland,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +12053,Finland,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7 +12054,Finland,2010,4,C01A-Cardiac glycosides,Million of national currency units,0.5 +12055,Finland,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,39.5 +12056,Finland,2010,4,C02-Antihypertensives,Million of national currency units,4.9 +12057,Finland,2010,4,C02-Antihypertensives,Million US$ at exchange rate,6.5 +12058,Finland,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +12059,Finland,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +12060,Finland,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1 +12061,Finland,2010,4,N-Nervous system,Million US$ at exchange rate,456.0 +12062,Finland,2010,4,A-Alimentary tract and metabolism,% of total sales,12.1 +12063,Finland,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,301.6 +12064,Finland,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2 +12065,Finland,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",252.6 +12066,Finland,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",10.9 +12067,Finland,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.4 +12068,Finland,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2 +12069,Finland,2010,4,N-Nervous system,Million of national currency units,344.0 +12070,Finland,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.5 +12071,Finland,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0 +12072,Finland,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,108.1 +12073,Finland,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.0 +12074,Finland,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.4 +12075,Finland,2010,4,G-Genito urinary system and sex hormones,% of total sales,5.7 +12076,Finland,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.7 +12077,Finland,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.4 +12078,Finland,2010,4,N-Nervous system,"Million US$, purchasing power parity",382.0 +12079,Finland,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,143.3 +12080,Finland,2010,4,N-Nervous system,% of total sales,18.3 +12081,Finland,2010,4,N-Nervous system,"/capita, US$ exchange rate",85.0 +12082,Finland,2010,4,A-Alimentary tract and metabolism,Million of national currency units,227.5 +12083,Finland,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",71.2 +12084,Finland,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",35.2 +12085,Finland,2010,4,N06A-Antidepressants,Million US$ at exchange rate,42.0 +12086,Finland,2010,4,N06A-Antidepressants,Million of national currency units,31.7 +12087,Finland,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.8 +12088,Finland,2010,4,N06A-Antidepressants,% of total sales,1.7 +12089,Finland,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.6 +12090,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.9 +12091,Finland,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +12092,Finland,2010,4,A10-Drugs used in diabetes,Million of national currency units,104.6 +12093,Finland,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.6 +12094,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.2 +12095,Finland,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.9 +12096,Finland,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,138.7 +12097,Finland,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",116.2 +12098,Finland,2010,4,R-Respiratory system,Million of national currency units,147.6 +12099,Finland,2010,4,M-Musculo-skeletal system,% of total sales,4.8 +12100,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8 +12101,Finland,2010,4,R-Respiratory system,Million US$ at exchange rate,195.7 +12102,Finland,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.5 +12103,Finland,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8 +12104,Finland,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.7 +12105,Finland,2010,4,R-Respiratory system,"Million US$, purchasing power parity",163.9 +12106,Finland,2010,4,R-Respiratory system,"/capita, US$ exchange rate",36.5 +12107,Finland,2010,4,C08-Calcium channel blockers,% of total sales,0.9 +12108,Finland,2010,4,A10-Drugs used in diabetes,% of total sales,5.6 +12109,Finland,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",101.1 +12110,Finland,2010,4,C08-Calcium channel blockers,Million of national currency units,17.0 +12111,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +12112,Finland,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,120.6 +12113,Finland,2010,4,M-Musculo-skeletal system,Million of national currency units,91.0 +12114,Finland,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9 +12115,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +12116,Finland,2010,4,C07-Beta blocking agents,% of total sales,1.6 +12117,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.2 +12118,Finland,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.2 +12119,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +12120,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6 +12121,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2 +12122,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,33.2 +12123,Finland,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2 +12124,Finland,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.9 +12125,Finland,2010,4,R-Respiratory system,% of total sales,7.9 +12126,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,44.0 +12127,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",36.9 +12128,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",60.7 +12129,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.3 +12130,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.5 +12131,Finland,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,22.5 +12132,Finland,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,72.5 +12133,Finland,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,54.7 +12134,Finland,2010,4,J-Antiinfectives for systemic use,% of total sales,7.9 +12135,Finland,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8 +12136,Finland,2010,4,J-Antiinfectives for systemic use,Million of national currency units,148.9 +12137,Finland,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",165.3 +12138,Finland,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,197.4 +12139,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,103.1 +12140,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,77.8 +12141,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.4 +12142,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6 +12143,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7 +12144,Finland,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.6 +12145,Finland,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.8 +12146,Finland,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,5.1 +12147,Finland,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,95.5 +12148,Finland,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",106.0 +12149,Finland,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,126.6 +12150,Finland,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.7 +12151,Finland,2010,4,A02A-Antacids,% of total sales,0.1 +12152,Finland,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +12153,Finland,2010,4,A02A-Antacids,"Million US$, purchasing power parity",3.0 +12154,Finland,2010,4,A02A-Antacids,Million of national currency units,2.7 +12155,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.7 +12156,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.2 +12157,Finland,2010,4,A02A-Antacids,Million US$ at exchange rate,3.6 +12158,Finland,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",145.8 +12159,Finland,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.5 +12160,Finland,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.2 +12161,Finland,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,11.0 +12162,Finland,2010,4,N02-Analgesics,% of total sales,3.5 +12163,Finland,2010,4,N05B-Anxiolytics,Million of national currency units,8.3 +12164,Finland,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2087.9 +12165,Finland,2010,4,Total pharmaceutical sales,Million of national currency units,1880.2 +12166,Finland,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,2492.6 +12167,Finland,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",464.7 +12168,Finland,2010,4,B-Blood and blood forming organs,% of total sales,7.0 +12169,Finland,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",389.3 +12170,Finland,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",9.2 +12171,Finland,2010,4,C03-Diuretics,% of total sales,0.5 +12172,Finland,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.9 +12173,Finland,2010,4,C03-Diuretics,"/capita, US$ exchange rate",2.2 +12174,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.1 +12175,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.1 +12176,Finland,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7 +12177,Finland,2010,4,N05B-Anxiolytics,% of total sales,0.4 +12178,Finland,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1 +12179,Finland,2010,4,C03-Diuretics,Million US$ at exchange rate,11.9 +12180,Finland,2010,4,C03-Diuretics,"Million US$, purchasing power parity",10.0 +12181,Finland,2010,4,C03-Diuretics,Million of national currency units,9.0 +12182,Finland,2010,4,C-Cardiovascular system,% of total sales,10.4 +12183,Finland,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.8 +12184,Finland,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.9 +12185,Finland,2010,4,B-Blood and blood forming organs,Million of national currency units,131.3 +12186,Finland,2010,4,N02-Analgesics,"/capita, US$ exchange rate",16.3 +12187,Finland,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,174.1 +12188,Finland,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.0 +12189,Finland,2010,4,N02-Analgesics,Million US$ at exchange rate,87.6 +12190,Finland,2010,4,N02-Analgesics,"Million US$, purchasing power parity",73.4 +12191,Finland,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,46.1 +12192,Finland,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",38.6 +12193,Finland,2010,4,C10-Lipid modifying agents,Million of national currency units,34.8 +12194,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,38.7 +12195,Finland,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,9.8 +12196,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,51.3 +12197,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.0 +12198,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.6 +12199,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +12200,Finland,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",74.5 +12201,Finland,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,89.0 +12202,Finland,2010,4,J01-Antibacterials for systemic use,Million of national currency units,67.1 +12203,Finland,2010,4,N02-Analgesics,Million of national currency units,66.1 +12204,Finland,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.6 +12205,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",43.0 +12206,Finland,2010,4,J01-Antibacterials for systemic use,% of total sales,3.6 +12207,Finland,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6 +12208,Finland,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",48.2 +12209,Finland,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.4 +12210,Finland,2010,4,C02-Antihypertensives,% of total sales,0.3 +12211,Finland,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +12212,Finland,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.2 +12213,Finland,2010,4,C10-Lipid modifying agents,% of total sales,1.9 +12214,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,68.1 +12215,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.1 +12216,Finland,2010,4,C-Cardiovascular system,Million of national currency units,195.0 +12217,Finland,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",216.5 +12218,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,51.4 +12219,Finland,2010,4,C-Cardiovascular system,Million US$ at exchange rate,258.5 +12220,Finland,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",13.7 +12221,Finland,2017,3,C07-Beta blocking agents,Million of national currency units,23.5 +12222,Finland,2017,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +12223,Finland,2017,3,C01A-Cardiac glycosides,% of total sales,0.1 +12224,Finland,2017,3,C07-Beta blocking agents,"Million US$, purchasing power parity",27.2 +12225,Finland,2017,3,C07-Beta blocking agents,Million US$ at exchange rate,26.5 +12226,Finland,2017,3,C01A-Cardiac glycosides,Million of national currency units,1.2 +12227,Finland,2017,3,C02-Antihypertensives,Million of national currency units,6.5 +12228,Finland,2017,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +12229,Finland,2017,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +12230,Finland,2017,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4 +12231,Finland,2017,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.0 +12232,Finland,2017,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.5 +12233,Finland,2017,3,A-Alimentary tract and metabolism,% of total sales,12.8 +12234,Finland,2017,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,333.4 +12235,Finland,2017,3,A-Alimentary tract and metabolism,Million of national currency units,295.1 +12236,Finland,2017,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",341.7 +12237,Finland,2017,3,N-Nervous system,Million of national currency units,297.2 +12238,Finland,2017,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8 +12239,Finland,2017,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.5 +12240,Finland,2017,3,N05C-Hypnotics and sedatives,% of total sales,0.6 +12241,Finland,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.6 +12242,Finland,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.7 +12243,Finland,2017,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,127.2 +12244,Finland,2017,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",130.4 +12245,Finland,2017,3,C02-Antihypertensives,Million US$ at exchange rate,7.3 +12246,Finland,2017,3,G-Genito urinary system and sex hormones,% of total sales,4.9 +12247,Finland,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.7 +12248,Finland,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",23.1 +12249,Finland,2017,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.5 +12250,Finland,2017,3,N-Nervous system,Million US$ at exchange rate,335.7 +12251,Finland,2017,3,N-Nervous system,"Million US$, purchasing power parity",344.1 +12252,Finland,2017,3,G-Genito urinary system and sex hormones,Million of national currency units,112.6 +12253,Finland,2017,3,N-Nervous system,% of total sales,12.8 +12254,Finland,2017,3,N-Nervous system,"/capita, US$ purchasing power parity",62.5 +12255,Finland,2017,3,N-Nervous system,"/capita, US$ exchange rate",61.0 +12256,Finland,2017,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.1 +12257,Finland,2017,3,N06A-Antidepressants,Million US$ at exchange rate,34.2 +12258,Finland,2017,3,N06A-Antidepressants,Million of national currency units,30.3 +12259,Finland,2017,3,N06A-Antidepressants,% of total sales,1.3 +12260,Finland,2017,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.2 +12261,Finland,2017,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.4 +12262,Finland,2017,3,A10-Drugs used in diabetes,Million of national currency units,148.0 +12263,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",39.7 +12264,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.0 +12265,Finland,2017,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",171.4 +12266,Finland,2017,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.4 +12267,Finland,2017,3,A10-Drugs used in diabetes,Million US$ at exchange rate,167.2 +12268,Finland,2017,3,R-Respiratory system,"/capita, US$ exchange rate",30.8 +12269,Finland,2017,3,M-Musculo-skeletal system,% of total sales,4.2 +12270,Finland,2017,3,R-Respiratory system,Million of national currency units,150.1 +12271,Finland,2017,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",111.3 +12272,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +12273,Finland,2017,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.2 +12274,Finland,2017,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.7 +12275,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.2 +12276,Finland,2017,3,R-Respiratory system,Million US$ at exchange rate,169.6 +12277,Finland,2017,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.1 +12278,Finland,2017,3,R-Respiratory system,"Million US$, purchasing power parity",173.8 +12279,Finland,2017,3,C08-Calcium channel blockers,% of total sales,0.8 +12280,Finland,2017,3,A10-Drugs used in diabetes,% of total sales,6.4 +12281,Finland,2017,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8 +12282,Finland,2017,3,M-Musculo-skeletal system,Million US$ at exchange rate,108.6 +12283,Finland,2017,3,M-Musculo-skeletal system,Million of national currency units,96.1 +12284,Finland,2017,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.5 +12285,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +12286,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +12287,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +12288,Finland,2017,3,C07-Beta blocking agents,% of total sales,1.0 +12289,Finland,2017,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8 +12290,Finland,2017,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9 +12291,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.9 +12292,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2 +12293,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.7 +12294,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.1 +12295,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,34.3 +12296,Finland,2017,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.7 +12297,Finland,2017,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.1 +12298,Finland,2017,3,R-Respiratory system,% of total sales,6.5 +12299,Finland,2017,3,R-Respiratory system,"/capita, US$ purchasing power parity",31.6 +12300,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,38.7 +12301,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.8 +12302,Finland,2017,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,65.2 +12303,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.8 +12304,Finland,2017,3,C08-Calcium channel blockers,Million of national currency units,18.2 +12305,Finland,2017,3,C08-Calcium channel blockers,Million US$ at exchange rate,20.6 +12306,Finland,2017,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7 +12307,Finland,2017,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.3 +12308,Finland,2017,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",40.4 +12309,Finland,2017,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",228.0 +12310,Finland,2017,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",41.4 +12311,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.1 +12312,Finland,2017,3,A02A-Antacids,% of total sales,0.1 +12313,Finland,2017,3,J-Antiinfectives for systemic use,Million of national currency units,196.9 +12314,Finland,2017,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,222.4 +12315,Finland,2017,3,J-Antiinfectives for systemic use,% of total sales,8.5 +12316,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,50.5 +12317,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,57.0 +12318,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",58.5 +12319,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3 +12320,Finland,2017,3,C-Cardiovascular system,% of total sales,8.5 +12321,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1 +12322,Finland,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.0 +12323,Finland,2017,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",107.0 +12324,Finland,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4 +12325,Finland,2017,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +12326,Finland,2017,3,R03-Drugs for obstructive airway diseases,Million of national currency units,92.4 +12327,Finland,2017,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,104.4 +12328,Finland,2017,3,A02A-Antacids,"Million US$, purchasing power parity",3.9 +12329,Finland,2017,3,A02A-Antacids,"/capita, US$ exchange rate",0.7 +12330,Finland,2017,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +12331,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.0 +12332,Finland,2017,3,A02A-Antacids,Million US$ at exchange rate,3.8 +12333,Finland,2017,3,A02A-Antacids,Million of national currency units,3.4 +12334,Finland,2017,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",251.8 +12335,Finland,2017,3,B-Blood and blood forming organs,Million US$ at exchange rate,245.7 +12336,Finland,2017,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.6 +12337,Finland,2017,3,N05B-Anxiolytics,Million of national currency units,6.6 +12338,Finland,2017,3,N05B-Anxiolytics,Million US$ at exchange rate,7.5 +12339,Finland,2017,3,N02-Analgesics,% of total sales,2.9 +12340,Finland,2017,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.7 +12341,Finland,2017,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2679.0 +12342,Finland,2017,3,Total pharmaceutical sales,Million US$ at exchange rate,2613.7 +12343,Finland,2017,3,Total pharmaceutical sales,Million of national currency units,2313.7 +12344,Finland,2017,3,B-Blood and blood forming organs,% of total sales,9.4 +12345,Finland,2017,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",486.4 +12346,Finland,2017,3,Total pharmaceutical sales,"/capita, US$ exchange rate",474.5 +12347,Finland,2017,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7 +12348,Finland,2017,3,C03-Diuretics,"Million US$, purchasing power parity",9.1 +12349,Finland,2017,3,C03-Diuretics,"/capita, US$ exchange rate",1.6 +12350,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.4 +12351,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.6 +12352,Finland,2017,3,C03-Diuretics,% of total sales,0.3 +12353,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.2 +12354,Finland,2017,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4 +12355,Finland,2017,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +12356,Finland,2017,3,N05B-Anxiolytics,"Million US$, purchasing power parity",7.6 +12357,Finland,2017,3,C03-Diuretics,Million US$ at exchange rate,8.9 +12358,Finland,2017,3,N05B-Anxiolytics,% of total sales,0.3 +12359,Finland,2017,3,C03-Diuretics,Million of national currency units,7.9 +12360,Finland,2017,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.0 +12361,Finland,2017,3,B-Blood and blood forming organs,Million of national currency units,217.5 +12362,Finland,2017,3,N02-Analgesics,Million US$ at exchange rate,75.2 +12363,Finland,2017,3,N02-Analgesics,"Million US$, purchasing power parity",77.1 +12364,Finland,2017,3,C10-Lipid modifying agents,Million of national currency units,65.1 +12365,Finland,2017,3,C10-Lipid modifying agents,Million US$ at exchange rate,73.5 +12366,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,49.9 +12367,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,44.2 +12368,Finland,2017,3,N02-Analgesics,Million of national currency units,66.6 +12369,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.1 +12370,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.2 +12371,Finland,2017,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",60.9 +12372,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +12373,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.3 +12374,Finland,2017,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,59.4 +12375,Finland,2017,3,J01-Antibacterials for systemic use,Million of national currency units,52.6 +12376,Finland,2017,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.8 +12377,Finland,2017,3,N02-Analgesics,"/capita, US$ exchange rate",13.7 +12378,Finland,2017,3,N05C-Hypnotics and sedatives,Million of national currency units,12.8 +12379,Finland,2017,3,J01-Antibacterials for systemic use,% of total sales,2.3 +12380,Finland,2017,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.1 +12381,Finland,2017,3,C-Cardiovascular system,"/capita, US$ exchange rate",40.5 +12382,Finland,2017,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",41.6 +12383,Finland,2017,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.4 +12384,Finland,2017,3,C02-Antihypertensives,% of total sales,0.3 +12385,Finland,2017,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4 +12386,Finland,2017,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.7 +12387,Finland,2017,3,C10-Lipid modifying agents,% of total sales,2.8 +12388,Finland,2017,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",75.4 +12389,Finland,2017,3,C-Cardiovascular system,Million of national currency units,197.7 +12390,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,49.2 +12391,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.6 +12392,Finland,2017,3,C-Cardiovascular system,Million US$ at exchange rate,223.3 +12393,Finland,2017,3,C-Cardiovascular system,"Million US$, purchasing power parity",228.9 +12394,France,2013,9,Total pharmaceutical sales,Million of national currency units,26800.0 +12395,France,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,35593.6 +12396,France,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.0 +12397,France,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",541.2 +12398,France,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",33019.4 +12399,France,2012,9,Total pharmaceutical sales,Million of national currency units,27200.0 +12400,France,2012,9,Total pharmaceutical sales,Million US$ at exchange rate,34946.3 +12401,France,2012,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",492.3 +12402,France,2012,9,Total pharmaceutical sales,"/capita, US$ exchange rate",534.0 +12403,France,2012,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32216.0 +12404,France,2011,9,B-Blood and blood forming organs,% of total sales,7.7 +12405,France,2011,9,N-Nervous system,"Million US$, purchasing power parity",4634.0 +12406,France,2011,9,N-Nervous system,Million US$ at exchange rate,5427.1 +12407,France,2011,9,N-Nervous system,"/capita, US$ exchange rate",83.3 +12408,France,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",71.2 +12409,France,2011,9,N-Nervous system,% of total sales,14.1 +12410,France,2011,9,M-Musculo-skeletal system,% of total sales,3.4 +12411,France,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",84.1 +12412,France,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.1 +12413,France,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.0 +12414,France,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",1111.1 +12415,France,2011,9,M-Musculo-skeletal system,Million of national currency units,934.8 +12416,France,2011,9,N-Nervous system,Million of national currency units,3898.9 +12417,France,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.8 +12418,France,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,1301.2 +12419,France,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.5 +12420,France,2011,9,Total pharmaceutical sales,Million of national currency units,27600.0 +12421,France,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,2963.3 +12422,France,2011,9,B-Blood and blood forming organs,Million of national currency units,2128.9 +12423,France,2011,9,A-Alimentary tract and metabolism,% of total sales,10.7 +12424,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +12425,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.2 +12426,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7 +12427,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",597.7 +12428,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,700.0 +12429,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,502.9 +12430,France,2011,9,A-Alimentary tract and metabolism,Million of national currency units,2952.3 +12431,France,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,4109.5 +12432,France,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3509.0 +12433,France,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.1 +12434,France,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.9 +12435,France,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,38418.0 +12436,France,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",2530.3 +12437,France,2011,9,G-Genito urinary system and sex hormones,% of total sales,3.7 +12438,France,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.9 +12439,France,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.1 +12440,France,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1228.5 +12441,France,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1438.7 +12442,France,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,1033.6 +12443,France,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.9 +12444,France,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",589.9 +12445,France,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32804.0 +12446,France,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",503.7 +12447,France,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",4679.3 +12448,France,2011,9,C-Cardiovascular system,Million of national currency units,3937.0 +12449,France,2011,9,R-Respiratory system,% of total sales,7.3 +12450,France,2011,9,C-Cardiovascular system,% of total sales,14.3 +12451,France,2011,9,J-Antiinfectives for systemic use,Million of national currency units,3056.5 +12452,France,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,4254.5 +12453,France,2011,9,R-Respiratory system,Million of national currency units,2016.0 +12454,France,2011,9,R-Respiratory system,Million US$ at exchange rate,2806.2 +12455,France,2011,9,R-Respiratory system,"/capita, US$ exchange rate",43.1 +12456,France,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3632.8 +12457,France,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.3 +12458,France,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.8 +12459,France,2011,9,J-Antiinfectives for systemic use,% of total sales,11.1 +12460,France,2011,9,R-Respiratory system,"Million US$, purchasing power parity",2396.1 +12461,France,2011,9,C-Cardiovascular system,Million US$ at exchange rate,5480.1 +12462,France,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",36.8 +12463,France,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,36508.9 +12464,France,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32221.6 +12465,France,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",497.1 +12466,France,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",563.2 +12467,France,2010,9,Total pharmaceutical sales,Million of national currency units,27539.0 +12468,Germany,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",5949.9 +12469,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.0 +12470,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0 +12471,Germany,2017,7,C-Cardiovascular system,Million US$ at exchange rate,5006.1 +12472,Germany,2017,7,C08-Calcium channel blockers,Million of national currency units,287.2 +12473,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5 +12474,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",26.1 +12475,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.3 +12476,Germany,2017,7,C-Cardiovascular system,Million of national currency units,4431.4 +12477,Germany,2017,7,N-Nervous system,% of total sales,13.5 +12478,Germany,2017,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2006.7 +12479,Germany,2017,7,N-Nervous system,"/capita, US$ exchange rate",68.4 +12480,Germany,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",81.3 +12481,Germany,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.9 +12482,Germany,2017,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +12483,Germany,2017,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2385.0 +12484,Germany,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.3 +12485,Germany,2017,7,N-Nervous system,Million of national currency units,5004.2 +12486,Germany,2017,7,Products not elsewhere classified,Million US$ at exchange rate,13284.1 +12487,Germany,2017,7,Products not elsewhere classified,Million of national currency units,11759.2 +12488,Germany,2017,7,N-Nervous system,Million US$ at exchange rate,5653.1 +12489,Germany,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.0 +12490,Germany,2017,7,R03-Drugs for obstructive airway diseases,Million of national currency units,1776.3 +12491,Germany,2017,7,N-Nervous system,"Million US$, purchasing power parity",6719.0 +12492,Germany,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",60.6 +12493,Germany,2017,7,R-Respiratory system,Million of national currency units,2146.1 +12494,Germany,2017,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.9 +12495,Germany,2017,7,R-Respiratory system,"/capita, US$ exchange rate",29.3 +12496,Germany,2017,7,R-Respiratory system,"Million US$, purchasing power parity",2881.5 +12497,Germany,2017,7,R-Respiratory system,Million US$ at exchange rate,2424.4 +12498,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,556.5 +12499,Germany,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",604.1 +12500,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,628.7 +12501,Germany,2017,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.0 +12502,Germany,2017,7,C10-Lipid modifying agents,Million US$ at exchange rate,828.7 +12503,Germany,2017,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",985.0 +12504,Germany,2017,7,C10-Lipid modifying agents,% of total sales,2.0 +12505,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +12506,Germany,2017,7,M-Musculo-skeletal system,% of total sales,3.7 +12507,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +12508,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",95.6 +12509,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +12510,Germany,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.6 +12511,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,71.2 +12512,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",747.2 +12513,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.6 +12514,Germany,2017,7,R-Respiratory system,% of total sales,5.8 +12515,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,80.4 +12516,Germany,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",34.9 +12517,Germany,2017,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7 +12518,Germany,2017,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9 +12519,Germany,2017,7,C08-Calcium channel blockers,% of total sales,0.8 +12520,Germany,2017,7,M-Musculo-skeletal system,Million of national currency units,1390.3 +12521,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1609.5 +12522,Germany,2017,7,Products not elsewhere classified,"Million US$, purchasing power parity",15788.8 +12523,Germany,2017,7,C08-Calcium channel blockers,Million US$ at exchange rate,324.4 +12524,Germany,2017,7,Products not elsewhere classified,"/capita, US$ exchange rate",160.7 +12525,Germany,2017,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",385.6 +12526,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2161.0 +12527,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1818.2 +12528,Germany,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,42011.2 +12529,Germany,2017,7,Total pharmaceutical sales,Million of national currency units,37188.6 +12530,Germany,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",49932.1 +12531,Germany,2017,7,C-Cardiovascular system,% of total sales,11.9 +12532,Germany,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",508.3 +12533,Germany,2017,7,C10-Lipid modifying agents,Million of national currency units,733.6 +12534,Germany,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0 +12535,Germany,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,1570.6 +12536,Germany,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",1866.7 +12537,Germany,2017,7,Products not elsewhere classified,% of total sales,31.6 +12538,Germany,2017,7,Products not elsewhere classified,"/capita, US$ purchasing power parity",191.0 +12539,Germany,2017,7,C07-Beta blocking agents,Million of national currency units,654.9 +12540,Germany,2017,7,C01A-Cardiac glycosides,% of total sales,0.1 +12541,Germany,2017,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +12542,Germany,2017,7,J-Antiinfectives for systemic use,% of total sales,7.9 +12543,Germany,2017,7,C07-Beta blocking agents,Million US$ at exchange rate,739.8 +12544,Germany,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.9 +12545,Germany,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.5 +12546,Germany,2017,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +12547,Germany,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3924.2 +12548,Germany,2017,7,J-Antiinfectives for systemic use,Million of national currency units,2922.7 +12549,Germany,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3301.7 +12550,Germany,2017,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",29.1 +12551,Germany,2017,7,C01A-Cardiac glycosides,Million of national currency units,21.7 +12552,Germany,2017,7,C01A-Cardiac glycosides,Million US$ at exchange rate,24.5 +12553,Germany,2017,7,C07-Beta blocking agents,"Million US$, purchasing power parity",879.3 +12554,Germany,2017,7,C03-Diuretics,"/capita, US$ exchange rate",6.1 +12555,Germany,2017,7,C03-Diuretics,"Million US$, purchasing power parity",602.2 +12556,Germany,2017,7,C03-Diuretics,% of total sales,1.2 +12557,Germany,2017,7,C03-Diuretics,"/capita, US$ purchasing power parity",7.3 +12558,Germany,2017,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +12559,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +12560,Germany,2017,7,C03-Diuretics,Million of national currency units,448.5 +12561,Germany,2017,7,C03-Diuretics,Million US$ at exchange rate,506.7 +12562,Germany,2017,7,C07-Beta blocking agents,% of total sales,1.8 +12563,Germany,2017,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6 +12564,Germany,2017,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1 +12565,Germany,2017,7,C07-Beta blocking agents,"/capita, US$ exchange rate",9.0 +12566,Germany,2017,7,N05B-Anxiolytics,Million US$ at exchange rate,74.1 +12567,Germany,2017,7,N05B-Anxiolytics,"Million US$, purchasing power parity",88.1 +12568,Germany,2017,7,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9 +12569,Germany,2017,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.0 +12570,Germany,2017,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9 +12571,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1132.0 +12572,Germany,2017,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",983.9 +12573,Germany,2017,7,C02-Antihypertensives,% of total sales,1.1 +12574,Germany,2017,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.4 +12575,Germany,2017,7,J01-Antibacterials for systemic use,% of total sales,2.0 +12576,Germany,2017,7,N05B-Anxiolytics,% of total sales,0.2 +12577,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0 +12578,Germany,2017,7,J01-Antibacterials for systemic use,Million of national currency units,732.8 +12579,Germany,2017,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,827.8 +12580,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.4 +12581,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1519.9 +12582,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1278.8 +12583,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.5 +12584,Germany,2017,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",120.6 +12585,Germany,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2 +12586,Germany,2017,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,101.4 +12587,Germany,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",4254.1 +12588,Germany,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,3579.3 +12589,Germany,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5 +12590,Germany,2017,7,N05C-Hypnotics and sedatives,% of total sales,0.2 +12591,Germany,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.3 +12592,Germany,2017,7,C02-Antihypertensives,Million US$ at exchange rate,442.0 +12593,Germany,2017,7,C02-Antihypertensives,Million of national currency units,391.3 +12594,Germany,2017,7,C02-Antihypertensives,"/capita, US$ exchange rate",5.3 +12595,Germany,2017,7,C02-Antihypertensives,"Million US$, purchasing power parity",525.4 +12596,Germany,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",51.5 +12597,Germany,2017,7,B-Blood and blood forming organs,% of total sales,8.5 +12598,Germany,2017,7,N05C-Hypnotics and sedatives,Million of national currency units,89.8 +12599,Germany,2017,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",3359.4 +12600,Germany,2017,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.2 +12601,Germany,2017,7,A10-Drugs used in diabetes,Million US$ at exchange rate,2826.5 +12602,Germany,2017,7,G-Genito urinary system and sex hormones,% of total sales,2.0 +12603,Germany,2017,7,A10-Drugs used in diabetes,% of total sales,6.7 +12604,Germany,2017,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",40.6 +12605,Germany,2017,7,A10-Drugs used in diabetes,Million of national currency units,2502.0 +12606,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.5 +12607,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.3 +12608,Germany,2017,7,N02-Analgesics,"/capita, US$ exchange rate",24.1 +12609,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,695.7 +12610,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",934.1 +12611,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,785.9 +12612,Germany,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2 +12613,Germany,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.8 +12614,Germany,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.3 +12615,Germany,2017,7,N02-Analgesics,"/capita, US$ purchasing power parity",28.7 +12616,Germany,2017,7,A-Alimentary tract and metabolism,% of total sales,12.1 +12617,Germany,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,5064.7 +12618,Germany,2017,7,A-Alimentary tract and metabolism,Million of national currency units,4483.3 +12619,Germany,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",6019.6 +12620,Germany,2017,7,N02-Analgesics,% of total sales,4.7 +12621,Germany,2017,7,B-Blood and blood forming organs,Million of national currency units,3168.4 +12622,Germany,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.3 +12623,Germany,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,848.4 +12624,Germany,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,751.0 +12625,Germany,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1008.3 +12626,Germany,2017,7,A02A-Antacids,Million US$ at exchange rate,21.6 +12627,Germany,2017,7,A02A-Antacids,"Million US$, purchasing power parity",25.6 +12628,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",521.4 +12629,Germany,2017,7,A02A-Antacids,% of total sales,0.1 +12630,Germany,2017,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.3 +12631,Germany,2017,7,N06A-Antidepressants,Million of national currency units,702.5 +12632,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9 +12633,Germany,2017,7,N02-Analgesics,Million of national currency units,1763.8 +12634,Germany,2017,7,N02-Analgesics,Million US$ at exchange rate,1992.5 +12635,Germany,2017,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,438.7 +12636,Germany,2017,7,A02A-Antacids,"/capita, US$ exchange rate",0.3 +12637,Germany,2017,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,388.3 +12638,Germany,2017,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.4 +12639,Germany,2017,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.6 +12640,Germany,2017,7,N02-Analgesics,"Million US$, purchasing power parity",2368.2 +12641,Germany,2017,7,N06A-Antidepressants,% of total sales,1.9 +12642,Germany,2017,7,A02A-Antacids,Million of national currency units,19.1 +12643,Germany,2017,7,N06A-Antidepressants,"Million US$, purchasing power parity",943.2 +12644,Germany,2017,7,N05B-Anxiolytics,Million of national currency units,65.6 +12645,Germany,2017,7,N06A-Antidepressants,Million US$ at exchange rate,793.6 +12646,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.3 +12647,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.6 +12648,Germany,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",5492.2 +12649,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5 +12650,Germany,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",58.0 +12651,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.0 +12652,Germany,2015,5,C-Cardiovascular system,Million US$ at exchange rate,4741.6 +12653,Germany,2015,5,C08-Calcium channel blockers,Million of national currency units,284.9 +12654,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +12655,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5 +12656,Germany,2015,5,C-Cardiovascular system,Million of national currency units,4273.6 +12657,Germany,2015,5,N-Nervous system,% of total sales,15.3 +12658,Germany,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1883.2 +12659,Germany,2015,5,N-Nervous system,"/capita, US$ exchange rate",73.4 +12660,Germany,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",85.0 +12661,Germany,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.7 +12662,Germany,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +12663,Germany,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2181.3 +12664,Germany,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.1 +12665,Germany,2015,5,N-Nervous system,Million of national currency units,5401.9 +12666,Germany,2015,5,N-Nervous system,Million US$ at exchange rate,5993.5 +12667,Germany,2015,5,Products not elsewhere classified,Million of national currency units,9719.6 +12668,Germany,2015,5,Products not elsewhere classified,Million US$ at exchange rate,10784.0 +12669,Germany,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",67.2 +12670,Germany,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1697.3 +12671,Germany,2015,5,N-Nervous system,"Million US$, purchasing power parity",6942.2 +12672,Germany,2015,5,R-Respiratory system,Million of national currency units,2054.6 +12673,Germany,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.4 +12674,Germany,2015,5,R-Respiratory system,Million US$ at exchange rate,2279.6 +12675,Germany,2015,5,R-Respiratory system,"/capita, US$ exchange rate",27.9 +12676,Germany,2015,5,R-Respiratory system,"Million US$, purchasing power parity",2640.5 +12677,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,606.3 +12678,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,672.7 +12679,Germany,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.1 +12680,Germany,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",767.1 +12681,Germany,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,662.3 +12682,Germany,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",556.1 +12683,Germany,2015,5,C10-Lipid modifying agents,% of total sales,1.7 +12684,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +12685,Germany,2015,5,M-Musculo-skeletal system,% of total sales,4.0 +12686,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.1 +12687,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +12688,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +12689,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.9 +12690,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.2 +12691,Germany,2015,5,R-Respiratory system,% of total sales,5.8 +12692,Germany,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.3 +12693,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,86.4 +12694,Germany,2015,5,C08-Calcium channel blockers,% of total sales,0.8 +12695,Germany,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5 +12696,Germany,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9 +12697,Germany,2015,5,M-Musculo-skeletal system,Million of national currency units,1397.1 +12698,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1590.0 +12699,Germany,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",132.0 +12700,Germany,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",12491.1 +12701,Germany,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",366.1 +12702,Germany,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,316.1 +12703,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1764.1 +12704,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2043.4 +12705,Germany,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",45429.5 +12706,Germany,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,39221.0 +12707,Germany,2015,5,Total pharmaceutical sales,Million of national currency units,35349.7 +12708,Germany,2015,5,C-Cardiovascular system,% of total sales,12.1 +12709,Germany,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",480.1 +12710,Germany,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0 +12711,Germany,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1795.5 +12712,Germany,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,1550.1 +12713,Germany,2015,5,C10-Lipid modifying agents,Million of national currency units,596.9 +12714,Germany,2015,5,Products not elsewhere classified,% of total sales,27.5 +12715,Germany,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",152.9 +12716,Germany,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.0 +12717,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",779.2 +12718,Germany,2015,5,C07-Beta blocking agents,Million of national currency units,668.9 +12719,Germany,2015,5,C01A-Cardiac glycosides,% of total sales,0.1 +12720,Germany,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +12721,Germany,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,742.2 +12722,Germany,2015,5,J-Antiinfectives for systemic use,% of total sales,10.6 +12723,Germany,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",859.6 +12724,Germany,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.9 +12725,Germany,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",4811.3 +12726,Germany,2015,5,J-Antiinfectives for systemic use,Million of national currency units,3743.8 +12727,Germany,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,4153.8 +12728,Germany,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.9 +12729,Germany,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",33.9 +12730,Germany,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4 +12731,Germany,2015,5,C01A-Cardiac glycosides,Million of national currency units,26.4 +12732,Germany,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,29.3 +12733,Germany,2015,5,C03-Diuretics,"/capita, US$ exchange rate",6.0 +12734,Germany,2015,5,C03-Diuretics,% of total sales,1.3 +12735,Germany,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.0 +12736,Germany,2015,5,C03-Diuretics,"Million US$, purchasing power parity",569.7 +12737,Germany,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +12738,Germany,2015,5,C03-Diuretics,Million of national currency units,443.3 +12739,Germany,2015,5,C03-Diuretics,Million US$ at exchange rate,491.8 +12740,Germany,2015,5,C07-Beta blocking agents,% of total sales,1.9 +12741,Germany,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.1 +12742,Germany,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.5 +12743,Germany,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2 +12744,Germany,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,81.3 +12745,Germany,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",94.2 +12746,Germany,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0 +12747,Germany,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5 +12748,Germany,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.1 +12749,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1111.7 +12750,Germany,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",989.2 +12751,Germany,2015,5,C02-Antihypertensives,% of total sales,1.1 +12752,Germany,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.8 +12753,Germany,2015,5,J01-Antibacterials for systemic use,% of total sales,2.2 +12754,Germany,2015,5,N05B-Anxiolytics,% of total sales,0.2 +12755,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.1 +12756,Germany,2015,5,J01-Antibacterials for systemic use,Million of national currency units,769.7 +12757,Germany,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,854.0 +12758,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1428.7 +12759,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1233.4 +12760,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.5 +12761,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.1 +12762,Germany,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +12763,Germany,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.8 +12764,Germany,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,104.8 +12765,Germany,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",121.4 +12766,Germany,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5 +12767,Germany,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3295.4 +12768,Germany,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,2845.0 +12769,Germany,2015,5,N05C-Hypnotics and sedatives,% of total sales,0.3 +12770,Germany,2015,5,C02-Antihypertensives,Million US$ at exchange rate,412.3 +12771,Germany,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.0 +12772,Germany,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",477.6 +12773,Germany,2015,5,C02-Antihypertensives,Million of national currency units,371.6 +12774,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.4 +12775,Germany,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.3 +12776,Germany,2015,5,B-Blood and blood forming organs,% of total sales,7.3 +12777,Germany,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,94.5 +12778,Germany,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2960.3 +12779,Germany,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",31.3 +12780,Germany,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2555.8 +12781,Germany,2015,5,G-Genito urinary system and sex hormones,% of total sales,2.3 +12782,Germany,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",36.2 +12783,Germany,2015,5,A10-Drugs used in diabetes,% of total sales,6.5 +12784,Germany,2015,5,A10-Drugs used in diabetes,Million of national currency units,2303.5 +12785,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.8 +12786,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5 +12787,Germany,2015,5,N02-Analgesics,"/capita, US$ exchange rate",23.0 +12788,Germany,2015,5,B-Blood and blood forming organs,Million of national currency units,2564.2 +12789,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,796.2 +12790,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1023.2 +12791,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,883.4 +12792,Germany,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.9 +12793,Germany,2015,5,A-Alimentary tract and metabolism,% of total sales,12.0 +12794,Germany,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.8 +12795,Germany,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4719.0 +12796,Germany,2015,5,A-Alimentary tract and metabolism,Million of national currency units,4253.2 +12797,Germany,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5466.0 +12798,Germany,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,829.9 +12799,Germany,2015,5,N02-Analgesics,% of total sales,4.8 +12800,Germany,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.1 +12801,Germany,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3 +12802,Germany,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,920.8 +12803,Germany,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.6 +12804,Germany,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1066.5 +12805,Germany,2015,5,A02A-Antacids,Million US$ at exchange rate,19.7 +12806,Germany,2015,5,A02A-Antacids,"Million US$, purchasing power parity",22.9 +12807,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",523.6 +12808,Germany,2015,5,A02A-Antacids,% of total sales,0.1 +12809,Germany,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3 +12810,Germany,2015,5,N06A-Antidepressants,Million of national currency units,805.8 +12811,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3 +12812,Germany,2015,5,N02-Analgesics,Million US$ at exchange rate,1877.3 +12813,Germany,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,452.0 +12814,Germany,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.2 +12815,Germany,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,407.4 +12816,Germany,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7 +12817,Germany,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.9 +12818,Germany,2015,5,N02-Analgesics,"Million US$, purchasing power parity",2174.5 +12819,Germany,2015,5,N06A-Antidepressants,% of total sales,2.3 +12820,Germany,2015,5,N02-Analgesics,Million of national currency units,1692.0 +12821,Germany,2015,5,N05B-Anxiolytics,Million of national currency units,73.3 +12822,Germany,2015,5,A02A-Antacids,Million of national currency units,17.8 +12823,Germany,2015,5,N06A-Antidepressants,Million US$ at exchange rate,894.0 +12824,Germany,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",1035.6 +12825,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.5 +12826,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.5 +12827,Germany,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",5721.8 +12828,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0 +12829,Germany,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",72.2 +12830,Germany,2014,5,C08-Calcium channel blockers,Million of national currency units,284.7 +12831,Germany,2014,5,C-Cardiovascular system,Million US$ at exchange rate,5845.0 +12832,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +12833,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.2 +12834,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.9 +12835,Germany,2014,5,C-Cardiovascular system,Million of national currency units,4399.7 +12836,Germany,2014,5,N-Nervous system,% of total sales,16.9 +12837,Germany,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2270.1 +12838,Germany,2014,5,N-Nervous system,"/capita, US$ exchange rate",93.1 +12839,Germany,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",91.1 +12840,Germany,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4 +12841,Germany,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1 +12842,Germany,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2222.3 +12843,Germany,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.0 +12844,Germany,2014,5,N-Nervous system,Million of national currency units,5672.9 +12845,Germany,2014,5,N-Nervous system,Million US$ at exchange rate,7536.5 +12846,Germany,2014,5,Products not elsewhere classified,Million of national currency units,8741.3 +12847,Germany,2014,5,Products not elsewhere classified,Million US$ at exchange rate,11612.8 +12848,Germany,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",11368.0 +12849,Germany,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.7 +12850,Germany,2014,5,C-Cardiovascular system,% of total sales,13.1 +12851,Germany,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1708.8 +12852,Germany,2014,5,N-Nervous system,"Million US$, purchasing power parity",7377.6 +12853,Germany,2014,5,R-Respiratory system,Million of national currency units,2047.5 +12854,Germany,2014,5,C10-Lipid modifying agents,% of total sales,1.7 +12855,Germany,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.4 +12856,Germany,2014,5,R-Respiratory system,Million US$ at exchange rate,2720.1 +12857,Germany,2014,5,R-Respiratory system,"/capita, US$ exchange rate",33.6 +12858,Germany,2014,5,R-Respiratory system,"Million US$, purchasing power parity",2662.8 +12859,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,620.4 +12860,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,824.2 +12861,Germany,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.6 +12862,Germany,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",763.4 +12863,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +12864,Germany,2014,5,M-Musculo-skeletal system,% of total sales,4.1 +12865,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",104.6 +12866,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3 +12867,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +12868,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,80.4 +12869,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",806.8 +12870,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2 +12871,Germany,2014,5,R-Respiratory system,% of total sales,6.1 +12872,Germany,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.9 +12873,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,106.8 +12874,Germany,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,779.8 +12875,Germany,2014,5,C08-Calcium channel blockers,% of total sales,0.8 +12876,Germany,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6 +12877,Germany,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7 +12878,Germany,2014,5,M-Musculo-skeletal system,Million of national currency units,1386.0 +12879,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1739.9 +12880,Germany,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",143.4 +12881,Germany,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",370.3 +12882,Germany,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,378.2 +12883,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2311.5 +12884,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2262.7 +12885,Germany,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,1841.3 +12886,Germany,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",43650.9 +12887,Germany,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,44590.9 +12888,Germany,2014,5,Total pharmaceutical sales,Million of national currency units,33564.8 +12889,Germany,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",539.0 +12890,Germany,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",550.6 +12891,Germany,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.7 +12892,Germany,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1802.5 +12893,Germany,2014,5,C10-Lipid modifying agents,Million of national currency units,587.0 +12894,Germany,2014,5,Products not elsewhere classified,% of total sales,26.0 +12895,Germany,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",140.4 +12896,Germany,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.3 +12897,Germany,2014,5,C07-Beta blocking agents,Million of national currency units,669.8 +12898,Germany,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +12899,Germany,2014,5,C01A-Cardiac glycosides,% of total sales,0.1 +12900,Germany,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,889.8 +12901,Germany,2014,5,J-Antiinfectives for systemic use,% of total sales,8.8 +12902,Germany,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",871.1 +12903,Germany,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.6 +12904,Germany,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3857.4 +12905,Germany,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.7 +12906,Germany,2014,5,J-Antiinfectives for systemic use,Million of national currency units,2966.1 +12907,Germany,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3940.5 +12908,Germany,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",37.3 +12909,Germany,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +12910,Germany,2014,5,C01A-Cardiac glycosides,Million of national currency units,28.7 +12911,Germany,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,38.1 +12912,Germany,2014,5,C03-Diuretics,"/capita, US$ exchange rate",7.2 +12913,Germany,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.1 +12914,Germany,2014,5,C03-Diuretics,% of total sales,1.3 +12915,Germany,2014,5,C03-Diuretics,"Million US$, purchasing power parity",572.9 +12916,Germany,2014,5,C03-Diuretics,Million of national currency units,440.5 +12917,Germany,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +12918,Germany,2014,5,C03-Diuretics,Million US$ at exchange rate,585.2 +12919,Germany,2014,5,C07-Beta blocking agents,% of total sales,2.0 +12920,Germany,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8 +12921,Germany,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",11.0 +12922,Germany,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2 +12923,Germany,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",99.9 +12924,Germany,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,102.0 +12925,Germany,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +12926,Germany,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,3079.2 +12927,Germany,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.8 +12928,Germany,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.6 +12929,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1085.5 +12930,Germany,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1017.9 +12931,Germany,2014,5,C02-Antihypertensives,% of total sales,1.1 +12932,Germany,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.7 +12933,Germany,2014,5,J01-Antibacterials for systemic use,% of total sales,2.3 +12934,Germany,2014,5,N05B-Anxiolytics,% of total sales,0.2 +12935,Germany,2014,5,J01-Antibacterials for systemic use,Million of national currency units,782.7 +12936,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.2 +12937,Germany,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,1039.8 +12938,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1411.7 +12939,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1442.1 +12940,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.4 +12941,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.8 +12942,Germany,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +12943,Germany,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",126.9 +12944,Germany,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.0 +12945,Germany,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,129.7 +12946,Germany,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6 +12947,Germany,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3014.3 +12948,Germany,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.3 +12949,Germany,2014,5,C02-Antihypertensives,Million US$ at exchange rate,473.6 +12950,Germany,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.8 +12951,Germany,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",463.6 +12952,Germany,2014,5,C02-Antihypertensives,Million of national currency units,356.5 +12953,Germany,2014,5,B-Blood and blood forming organs,% of total sales,6.9 +12954,Germany,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.2 +12955,Germany,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,97.6 +12956,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +12957,Germany,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2899.6 +12958,Germany,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.6 +12959,Germany,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2962.0 +12960,Germany,2014,5,G-Genito urinary system and sex hormones,% of total sales,2.4 +12961,Germany,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.8 +12962,Germany,2014,5,A10-Drugs used in diabetes,% of total sales,6.6 +12963,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.8 +12964,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.1 +12965,Germany,2014,5,N02-Analgesics,"/capita, US$ exchange rate",27.5 +12966,Germany,2014,5,B-Blood and blood forming organs,Million of national currency units,2317.8 +12967,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,795.5 +12968,Germany,2014,5,A10-Drugs used in diabetes,Million of national currency units,2229.6 +12969,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1034.5 +12970,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1056.8 +12971,Germany,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.4 +12972,Germany,2014,5,A-Alimentary tract and metabolism,% of total sales,12.3 +12973,Germany,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.8 +12974,Germany,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5489.8 +12975,Germany,2014,5,A-Alimentary tract and metabolism,Million of national currency units,4132.3 +12976,Germany,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5374.0 +12977,Germany,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,815.7 +12978,Germany,2014,5,N02-Analgesics,% of total sales,5.0 +12979,Germany,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.1 +12980,Germany,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.4 +12981,Germany,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1083.7 +12982,Germany,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.9 +12983,Germany,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1060.8 +12984,Germany,2014,5,A02A-Antacids,"Million US$, purchasing power parity",22.2 +12985,Germany,2014,5,A02A-Antacids,Million US$ at exchange rate,22.7 +12986,Germany,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3 +12987,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",513.8 +12988,Germany,2014,5,A02A-Antacids,% of total sales,0.1 +12989,Germany,2014,5,N06A-Antidepressants,Million of national currency units,832.6 +12990,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +12991,Germany,2014,5,N02-Analgesics,Million US$ at exchange rate,2226.3 +12992,Germany,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,524.9 +12993,Germany,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.3 +12994,Germany,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,395.1 +12995,Germany,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.4 +12996,Germany,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",13.7 +12997,Germany,2014,5,N02-Analgesics,"Million US$, purchasing power parity",2179.4 +12998,Germany,2014,5,N06A-Antidepressants,% of total sales,2.5 +12999,Germany,2014,5,N02-Analgesics,Million of national currency units,1675.8 +13000,Germany,2014,5,N05B-Anxiolytics,Million of national currency units,76.8 +13001,Germany,2014,5,A02A-Antacids,Million of national currency units,17.1 +13002,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5 +13003,Germany,2014,5,N06A-Antidepressants,Million US$ at exchange rate,1106.1 +13004,Germany,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",1082.8 +13005,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +13006,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.6 +13007,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9 +13008,Germany,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.4 +13009,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.8 +13010,Germany,2013,5,C-Cardiovascular system,Million US$ at exchange rate,5918.0 +13011,Germany,2013,5,C08-Calcium channel blockers,Million of national currency units,283.4 +13012,Germany,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",5751.2 +13013,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9 +13014,Germany,2013,5,C-Cardiovascular system,Million of national currency units,4455.9 +13015,Germany,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",10354.8 +13016,Germany,2013,5,N-Nervous system,% of total sales,17.1 +13017,Germany,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2241.3 +13018,Germany,2013,5,N-Nervous system,"/capita, US$ exchange rate",88.6 +13019,Germany,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",86.1 +13020,Germany,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.0 +13021,Germany,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +13022,Germany,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2178.2 +13023,Germany,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.8 +13024,Germany,2013,5,N-Nervous system,Million of national currency units,5380.2 +13025,Germany,2013,5,N-Nervous system,Million US$ at exchange rate,7145.5 +13026,Germany,2013,5,Products not elsewhere classified,Million of national currency units,8022.7 +13027,Germany,2013,5,Products not elsewhere classified,Million US$ at exchange rate,10655.1 +13028,Germany,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.3 +13029,Germany,2013,5,C-Cardiovascular system,% of total sales,14.1 +13030,Germany,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1687.6 +13031,Germany,2013,5,N-Nervous system,"Million US$, purchasing power parity",6944.1 +13032,Germany,2013,5,R-Respiratory system,Million of national currency units,2036.5 +13033,Germany,2013,5,C10-Lipid modifying agents,% of total sales,1.9 +13034,Germany,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.5 +13035,Germany,2013,5,R-Respiratory system,Million US$ at exchange rate,2704.7 +13036,Germany,2013,5,R-Respiratory system,"/capita, US$ exchange rate",33.5 +13037,Germany,2013,5,R-Respiratory system,"Million US$, purchasing power parity",2628.5 +13038,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,820.5 +13039,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,617.8 +13040,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",797.4 +13041,Germany,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.8 +13042,Germany,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",766.7 +13043,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +13044,Germany,2013,5,M-Musculo-skeletal system,% of total sales,4.3 +13045,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",102.1 +13046,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +13047,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3 +13048,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.1 +13049,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2 +13050,Germany,2013,5,R-Respiratory system,% of total sales,6.5 +13051,Germany,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.6 +13052,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,105.1 +13053,Germany,2013,5,C08-Calcium channel blockers,% of total sales,0.9 +13054,Germany,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5 +13055,Germany,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7 +13056,Germany,2013,5,M-Musculo-skeletal system,Million of national currency units,1361.5 +13057,Germany,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",128.4 +13058,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1860.4 +13059,Germany,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",132.1 +13060,Germany,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,376.4 +13061,Germany,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",365.8 +13062,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2470.8 +13063,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2401.2 +13064,Germany,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,788.9 +13065,Germany,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",40687.6 +13066,Germany,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,41867.7 +13067,Germany,2013,5,Total pharmaceutical sales,Million of national currency units,31524.1 +13068,Germany,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.5 +13069,Germany,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",519.2 +13070,Germany,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.4 +13071,Germany,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1757.3 +13072,Germany,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,1808.2 +13073,Germany,2013,5,C10-Lipid modifying agents,Million of national currency units,594.0 +13074,Germany,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.8 +13075,Germany,2013,5,Products not elsewhere classified,% of total sales,25.4 +13076,Germany,2013,5,C07-Beta blocking agents,Million of national currency units,661.4 +13077,Germany,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,878.4 +13078,Germany,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +13079,Germany,2013,5,C01A-Cardiac glycosides,% of total sales,0.1 +13080,Germany,2013,5,J-Antiinfectives for systemic use,% of total sales,7.6 +13081,Germany,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",853.7 +13082,Germany,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.3 +13083,Germany,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3091.6 +13084,Germany,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.4 +13085,Germany,2013,5,J-Antiinfectives for systemic use,Million of national currency units,2395.3 +13086,Germany,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3181.2 +13087,Germany,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",39.8 +13088,Germany,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +13089,Germany,2013,5,C01A-Cardiac glycosides,Million of national currency units,30.8 +13090,Germany,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,40.9 +13091,Germany,2013,5,C03-Diuretics,"/capita, US$ exchange rate",6.9 +13092,Germany,2013,5,C03-Diuretics,% of total sales,1.3 +13093,Germany,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",6.7 +13094,Germany,2013,5,C03-Diuretics,"Million US$, purchasing power parity",540.7 +13095,Germany,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +13096,Germany,2013,5,C03-Diuretics,Million US$ at exchange rate,556.3 +13097,Germany,2013,5,C07-Beta blocking agents,% of total sales,2.1 +13098,Germany,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.9 +13099,Germany,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6 +13100,Germany,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",99.4 +13101,Germany,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,102.3 +13102,Germany,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2 +13103,Germany,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +13104,Germany,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.6 +13105,Germany,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.3 +13106,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1046.4 +13107,Germany,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1068.9 +13108,Germany,2013,5,C02-Antihypertensives,% of total sales,1.0 +13109,Germany,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.2 +13110,Germany,2013,5,N05B-Anxiolytics,% of total sales,0.2 +13111,Germany,2013,5,J01-Antibacterials for systemic use,% of total sales,2.6 +13112,Germany,2013,5,J01-Antibacterials for systemic use,Million of national currency units,828.2 +13113,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +13114,Germany,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,1099.9 +13115,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1350.6 +13116,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1389.7 +13117,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.7 +13118,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2 +13119,Germany,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +13120,Germany,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,129.4 +13121,Germany,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",125.7 +13122,Germany,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6 +13123,Germany,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",2598.8 +13124,Germany,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.3 +13125,Germany,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.2 +13126,Germany,2013,5,C02-Antihypertensives,Million US$ at exchange rate,433.0 +13127,Germany,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",420.8 +13128,Germany,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.4 +13129,Germany,2013,5,B-Blood and blood forming organs,% of total sales,6.4 +13130,Germany,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.2 +13131,Germany,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,97.4 +13132,Germany,2013,5,C02-Antihypertensives,Million of national currency units,326.0 +13133,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.0 +13134,Germany,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.3 +13135,Germany,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2843.4 +13136,Germany,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2925.8 +13137,Germany,2013,5,G-Genito urinary system and sex hormones,% of total sales,2.5 +13138,Germany,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.3 +13139,Germany,2013,5,A10-Drugs used in diabetes,% of total sales,7.0 +13140,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5 +13141,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.8 +13142,Germany,2013,5,N02-Analgesics,"/capita, US$ exchange rate",27.2 +13143,Germany,2013,5,B-Blood and blood forming organs,Million of national currency units,2013.5 +13144,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,778.8 +13145,Germany,2013,5,A10-Drugs used in diabetes,Million of national currency units,2203.0 +13146,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1005.2 +13147,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1034.3 +13148,Germany,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",64.5 +13149,Germany,2013,5,A-Alimentary tract and metabolism,% of total sales,12.8 +13150,Germany,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5354.4 +13151,Germany,2013,5,A-Alimentary tract and metabolism,Million of national currency units,4031.6 +13152,Germany,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",66.4 +13153,Germany,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5203.5 +13154,Germany,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,780.3 +13155,Germany,2013,5,N02-Analgesics,% of total sales,5.2 +13156,Germany,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.5 +13157,Germany,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.9 +13158,Germany,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,2674.2 +13159,Germany,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1036.3 +13160,Germany,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.5 +13161,Germany,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1007.1 +13162,Germany,2013,5,A02A-Antacids,"Million US$, purchasing power parity",19.5 +13163,Germany,2013,5,A02A-Antacids,Million US$ at exchange rate,20.1 +13164,Germany,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.2 +13165,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.2 +13166,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",487.7 +13167,Germany,2013,5,A02A-Antacids,% of total sales,0.0 +13168,Germany,2013,5,N06A-Antidepressants,Million of national currency units,791.7 +13169,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +13170,Germany,2013,5,N02-Analgesics,Million US$ at exchange rate,2197.1 +13171,Germany,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,501.9 +13172,Germany,2013,5,A02A-Antacids,"/capita, US$ exchange rate",0.2 +13173,Germany,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,377.9 +13174,Germany,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7 +13175,Germany,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",13.0 +13176,Germany,2013,5,N02-Analgesics,"Million US$, purchasing power parity",2135.2 +13177,Germany,2013,5,N06A-Antidepressants,% of total sales,2.5 +13178,Germany,2013,5,N02-Analgesics,Million of national currency units,1654.3 +13179,Germany,2013,5,N05B-Anxiolytics,Million of national currency units,77.0 +13180,Germany,2013,5,N06A-Antidepressants,Million US$ at exchange rate,1051.5 +13181,Germany,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",1021.8 +13182,Germany,2013,5,C03-Diuretics,Million of national currency units,418.9 +13183,Germany,2013,5,A02A-Antacids,Million of national currency units,15.1 +13184,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.7 +13185,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.3 +13186,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +13187,Germany,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",72.4 +13188,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.3 +13189,Germany,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",5753.2 +13190,Germany,2012,5,C08-Calcium channel blockers,Million of national currency units,289.6 +13191,Germany,2012,5,C-Cardiovascular system,Million US$ at exchange rate,5819.1 +13192,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3 +13193,Germany,2012,5,C-Cardiovascular system,Million of national currency units,4529.2 +13194,Germany,2012,5,N-Nervous system,% of total sales,17.9 +13195,Germany,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2088.7 +13196,Germany,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",85.9 +13197,Germany,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2065.0 +13198,Germany,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.3 +13199,Germany,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.7 +13200,Germany,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.0 +13201,Germany,2012,5,N-Nervous system,Million of national currency units,5439.9 +13202,Germany,2012,5,Products not elsewhere classified,Million of national currency units,7344.1 +13203,Germany,2012,5,N-Nervous system,Million US$ at exchange rate,6989.1 +13204,Germany,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",9328.9 +13205,Germany,2012,5,Products not elsewhere classified,Million US$ at exchange rate,9435.6 +13206,Germany,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.5 +13207,Germany,2012,5,C-Cardiovascular system,% of total sales,14.9 +13208,Germany,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1625.7 +13209,Germany,2012,5,N-Nervous system,"Million US$, purchasing power parity",6910.0 +13210,Germany,2012,5,N-Nervous system,"/capita, US$ exchange rate",86.9 +13211,Germany,2012,5,R-Respiratory system,Million US$ at exchange rate,2476.9 +13212,Germany,2012,5,R-Respiratory system,Million of national currency units,1927.9 +13213,Germany,2012,5,C10-Lipid modifying agents,% of total sales,2.1 +13214,Germany,2012,5,R-Respiratory system,"/capita, US$ exchange rate",30.8 +13215,Germany,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.1 +13216,Germany,2012,5,R-Respiratory system,"Million US$, purchasing power parity",2448.9 +13217,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,759.8 +13218,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",751.2 +13219,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,591.4 +13220,Germany,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.3 +13221,Germany,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",815.4 +13222,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +13223,Germany,2012,5,M-Musculo-skeletal system,% of total sales,4.4 +13224,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.7 +13225,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3 +13226,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +13227,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.3 +13228,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.4 +13229,Germany,2012,5,R-Respiratory system,% of total sales,6.3 +13230,Germany,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",30.4 +13231,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,101.9 +13232,Germany,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,824.7 +13233,Germany,2012,5,C08-Calcium channel blockers,% of total sales,1.0 +13234,Germany,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6 +13235,Germany,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.6 +13236,Germany,2012,5,M-Musculo-skeletal system,Million of national currency units,1338.2 +13237,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1919.1 +13238,Germany,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",116.0 +13239,Germany,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",117.3 +13240,Germany,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",367.9 +13241,Germany,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,372.1 +13242,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2465.6 +13243,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2437.7 +13244,Germany,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,1719.3 +13245,Germany,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",38669.0 +13246,Germany,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,39111.5 +13247,Germany,2012,5,Total pharmaceutical sales,Million of national currency units,30442.0 +13248,Germany,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",480.8 +13249,Germany,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",486.3 +13250,Germany,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.4 +13251,Germany,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1699.8 +13252,Germany,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.1 +13253,Germany,2012,5,C10-Lipid modifying agents,Million of national currency units,641.9 +13254,Germany,2012,5,Products not elsewhere classified,% of total sales,24.1 +13255,Germany,2012,5,A-Alimentary tract and metabolism,Million of national currency units,3894.1 +13256,Germany,2012,5,C07-Beta blocking agents,Million of national currency units,654.5 +13257,Germany,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,840.9 +13258,Germany,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +13259,Germany,2012,5,C01A-Cardiac glycosides,% of total sales,0.1 +13260,Germany,2012,5,J-Antiinfectives for systemic use,% of total sales,7.9 +13261,Germany,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",831.4 +13262,Germany,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.1 +13263,Germany,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3062.8 +13264,Germany,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",38.5 +13265,Germany,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2411.2 +13266,Germany,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3097.9 +13267,Germany,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",42.7 +13268,Germany,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +13269,Germany,2012,5,C01A-Cardiac glycosides,Million of national currency units,33.6 +13270,Germany,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,43.2 +13271,Germany,2012,5,A02A-Antacids,Million of national currency units,14.9 +13272,Germany,2012,5,C03-Diuretics,"/capita, US$ exchange rate",6.4 +13273,Germany,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",6.3 +13274,Germany,2012,5,C03-Diuretics,% of total sales,1.3 +13275,Germany,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.3 +13276,Germany,2012,5,C03-Diuretics,"Million US$, purchasing power parity",509.8 +13277,Germany,2012,5,C03-Diuretics,Million US$ at exchange rate,515.6 +13278,Germany,2012,5,C07-Beta blocking agents,% of total sales,2.1 +13279,Germany,2012,5,N05B-Anxiolytics,% of total sales,0.3 +13280,Germany,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.5 +13281,Germany,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.3 +13282,Germany,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",100.2 +13283,Germany,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,101.4 +13284,Germany,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2 +13285,Germany,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +13286,Germany,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3 +13287,Germany,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.2 +13288,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1019.3 +13289,Germany,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",981.8 +13290,Germany,2012,5,C02-Antihypertensives,% of total sales,1.0 +13291,Germany,2012,5,J01-Antibacterials for systemic use,% of total sales,2.5 +13292,Germany,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.9 +13293,Germany,2012,5,J01-Antibacterials for systemic use,Million of national currency units,772.9 +13294,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +13295,Germany,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,993.0 +13296,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1294.8 +13297,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1309.6 +13298,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.1 +13299,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.3 +13300,Germany,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +13301,Germany,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6 +13302,Germany,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,127.6 +13303,Germany,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",126.1 +13304,Germany,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",2233.2 +13305,Germany,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",28.1 +13306,Germany,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.3 +13307,Germany,2012,5,C02-Antihypertensives,Million US$ at exchange rate,399.4 +13308,Germany,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",394.9 +13309,Germany,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.0 +13310,Germany,2012,5,C02-Antihypertensives,Million of national currency units,310.9 +13311,Germany,2012,5,B-Blood and blood forming organs,% of total sales,5.8 +13312,Germany,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8 +13313,Germany,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,99.3 +13314,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1 +13315,Germany,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.0 +13316,Germany,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2658.0 +13317,Germany,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2627.9 +13318,Germany,2012,5,G-Genito urinary system and sex hormones,% of total sales,2.6 +13319,Germany,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",32.7 +13320,Germany,2012,5,A10-Drugs used in diabetes,% of total sales,6.8 +13321,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.7 +13322,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9 +13323,Germany,2012,5,N02-Analgesics,"/capita, US$ exchange rate",26.0 +13324,Germany,2012,5,B-Blood and blood forming organs,Million of national currency units,1758.1 +13325,Germany,2012,5,A10-Drugs used in diabetes,Million of national currency units,2068.8 +13326,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,805.4 +13327,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1034.8 +13328,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1023.1 +13329,Germany,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",61.5 +13330,Germany,2012,5,A-Alimentary tract and metabolism,% of total sales,12.8 +13331,Germany,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5003.1 +13332,Germany,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",62.2 +13333,Germany,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4946.5 +13334,Germany,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,779.7 +13335,Germany,2012,5,N02-Analgesics,% of total sales,5.4 +13336,Germany,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,2258.8 +13337,Germany,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3 +13338,Germany,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.5 +13339,Germany,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1001.7 +13340,Germany,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",25.7 +13341,Germany,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",990.4 +13342,Germany,2012,5,A02A-Antacids,"Million US$, purchasing power parity",18.9 +13343,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.1 +13344,Germany,2012,5,A02A-Antacids,% of total sales,0.0 +13345,Germany,2012,5,N06A-Antidepressants,Million of national currency units,746.5 +13346,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",487.1 +13347,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +13348,Germany,2012,5,N02-Analgesics,Million US$ at exchange rate,2093.0 +13349,Germany,2012,5,A02A-Antacids,"/capita, US$ exchange rate",0.2 +13350,Germany,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,492.7 +13351,Germany,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,383.5 +13352,Germany,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.8 +13353,Germany,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.9 +13354,Germany,2012,5,N06A-Antidepressants,% of total sales,2.5 +13355,Germany,2012,5,N02-Analgesics,"Million US$, purchasing power parity",2069.4 +13356,Germany,2012,5,A02A-Antacids,Million US$ at exchange rate,19.1 +13357,Germany,2012,5,N05B-Anxiolytics,Million of national currency units,78.9 +13358,Germany,2012,5,N02-Analgesics,Million of national currency units,1629.1 +13359,Germany,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.2 +13360,Germany,2012,5,N06A-Antidepressants,Million US$ at exchange rate,959.1 +13361,Germany,2012,5,C03-Diuretics,Million of national currency units,401.3 +13362,Germany,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",948.2 +13363,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.3 +13364,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.0 +13365,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +13366,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8 +13367,Germany,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",83.1 +13368,Germany,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",6078.4 +13369,Germany,2011,6,C08-Calcium channel blockers,Million of national currency units,292.0 +13370,Germany,2011,6,C-Cardiovascular system,Million US$ at exchange rate,6673.5 +13371,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.2 +13372,Germany,2011,6,C-Cardiovascular system,Million of national currency units,4794.3 +13373,Germany,2011,6,N-Nervous system,% of total sales,19.1 +13374,Germany,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2325.3 +13375,Germany,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",89.7 +13376,Germany,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2117.9 +13377,Germany,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,5.6 +13378,Germany,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.4 +13379,Germany,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.0 +13380,Germany,2011,6,Products not elsewhere classified,Million of national currency units,6791.6 +13381,Germany,2011,6,N-Nervous system,Million of national currency units,5679.2 +13382,Germany,2011,6,N-Nervous system,Million US$ at exchange rate,7905.2 +13383,Germany,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",8610.7 +13384,Germany,2011,6,Products not elsewhere classified,Million US$ at exchange rate,9453.6 +13385,Germany,2011,6,C-Cardiovascular system,% of total sales,16.1 +13386,Germany,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.7 +13387,Germany,2011,6,N-Nervous system,"Million US$, purchasing power parity",7200.4 +13388,Germany,2011,6,N-Nervous system,"/capita, US$ exchange rate",98.5 +13389,Germany,2011,6,R-Respiratory system,Million US$ at exchange rate,2766.2 +13390,Germany,2011,6,R-Respiratory system,Million of national currency units,1987.3 +13391,Germany,2011,6,C10-Lipid modifying agents,% of total sales,2.3 +13392,Germany,2011,6,R-Respiratory system,"/capita, US$ exchange rate",34.5 +13393,Germany,2011,6,R-Respiratory system,"Million US$, purchasing power parity",2519.6 +13394,Germany,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.6 +13395,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,772.5 +13396,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",703.7 +13397,Germany,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",31.4 +13398,Germany,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.7 +13399,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,555.0 +13400,Germany,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",852.8 +13401,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +13402,Germany,2011,6,M-Musculo-skeletal system,% of total sales,4.3 +13403,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",111.2 +13404,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +13405,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4 +13406,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,87.7 +13407,Germany,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,1670.5 +13408,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.6 +13409,Germany,2011,6,R-Respiratory system,% of total sales,6.7 +13410,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,122.1 +13411,Germany,2011,6,C08-Calcium channel blockers,% of total sales,1.0 +13412,Germany,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6 +13413,Germany,2011,6,M-Musculo-skeletal system,Million of national currency units,1285.2 +13414,Germany,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1 +13415,Germany,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",107.3 +13416,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,2149.7 +13417,Germany,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",117.8 +13418,Germany,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",370.2 +13419,Germany,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,406.5 +13420,Germany,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,1788.9 +13421,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2992.3 +13422,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2725.5 +13423,Germany,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",37675.6 +13424,Germany,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,41363.6 +13425,Germany,2011,6,Total pharmaceutical sales,Million of national currency units,29716.2 +13426,Germany,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,936.2 +13427,Germany,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",469.3 +13428,Germany,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",515.3 +13429,Germany,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.3 +13430,Germany,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",1629.4 +13431,Germany,2011,6,C10-Lipid modifying agents,Million of national currency units,672.6 +13432,Germany,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.3 +13433,Germany,2011,6,Products not elsewhere classified,% of total sales,22.9 +13434,Germany,2011,6,C07-Beta blocking agents,Million of national currency units,647.2 +13435,Germany,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,900.9 +13436,Germany,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.6 +13437,Germany,2011,6,C01A-Cardiac glycosides,% of total sales,0.1 +13438,Germany,2011,6,J-Antiinfectives for systemic use,% of total sales,7.1 +13439,Germany,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",820.6 +13440,Germany,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.1 +13441,Germany,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2661.1 +13442,Germany,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.4 +13443,Germany,2011,6,J-Antiinfectives for systemic use,Million of national currency units,2098.9 +13444,Germany,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2921.6 +13445,Germany,2011,6,C01A-Cardiac glycosides,Million of national currency units,35.8 +13446,Germany,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",45.4 +13447,Germany,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6 +13448,Germany,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,49.8 +13449,Germany,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.1 +13450,Germany,2011,6,C03-Diuretics,"/capita, US$ exchange rate",6.7 +13451,Germany,2011,6,C03-Diuretics,% of total sales,1.3 +13452,Germany,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.3 +13453,Germany,2011,6,C03-Diuretics,"Million US$, purchasing power parity",493.3 +13454,Germany,2011,6,C03-Diuretics,Million US$ at exchange rate,541.6 +13455,Germany,2011,6,C07-Beta blocking agents,% of total sales,2.2 +13456,Germany,2011,6,N05B-Anxiolytics,% of total sales,0.3 +13457,Germany,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.2 +13458,Germany,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.2 +13459,Germany,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",101.6 +13460,Germany,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,111.5 +13461,Germany,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3 +13462,Germany,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +13463,Germany,2011,6,A02A-Antacids,Million of national currency units,14.7 +13464,Germany,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +13465,Germany,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.4 +13466,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,994.0 +13467,Germany,2011,6,C02-Antihypertensives,% of total sales,1.0 +13468,Germany,2011,6,J01-Antibacterials for systemic use,% of total sales,2.4 +13469,Germany,2011,6,J01-Antibacterials for systemic use,Million of national currency units,712.3 +13470,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +13471,Germany,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",903.1 +13472,Germany,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,991.5 +13473,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1260.2 +13474,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1383.6 +13475,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.7 +13476,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2 +13477,Germany,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7 +13478,Germany,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8 +13479,Germany,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6 +13480,Germany,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,144.3 +13481,Germany,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",131.5 +13482,Germany,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",2019.3 +13483,Germany,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.6 +13484,Germany,2011,6,N05C-Hypnotics and sedatives,% of total sales,0.3 +13485,Germany,2011,6,C02-Antihypertensives,Million US$ at exchange rate,416.5 +13486,Germany,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",379.3 +13487,Germany,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.2 +13488,Germany,2011,6,B-Blood and blood forming organs,% of total sales,5.4 +13489,Germany,2011,6,A-Alimentary tract and metabolism,Million of national currency units,3704.0 +13490,Germany,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.2 +13491,Germany,2011,6,C02-Antihypertensives,Million of national currency units,299.2 +13492,Germany,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,103.7 +13493,Germany,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.8 +13494,Germany,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2468.6 +13495,Germany,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,2710.3 +13496,Germany,2011,6,G-Genito urinary system and sex hormones,% of total sales,2.7 +13497,Germany,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.8 +13498,Germany,2011,6,A10-Drugs used in diabetes,% of total sales,6.6 +13499,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.6 +13500,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.8 +13501,Germany,2011,6,N02-Analgesics,"/capita, US$ exchange rate",27.3 +13502,Germany,2011,6,B-Blood and blood forming organs,Million of national currency units,1592.7 +13503,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,796.7 +13504,Germany,2011,6,A10-Drugs used in diabetes,Million of national currency units,1947.1 +13505,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1109.0 +13506,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1010.1 +13507,Germany,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.5 +13508,Germany,2011,6,A-Alimentary tract and metabolism,% of total sales,12.5 +13509,Germany,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,788.7 +13510,Germany,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,5155.8 +13511,Germany,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.2 +13512,Germany,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4696.1 +13513,Germany,2011,6,N02-Analgesics,% of total sales,5.3 +13514,Germany,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,2217.0 +13515,Germany,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.5 +13516,Germany,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.7 +13517,Germany,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1097.8 +13518,Germany,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1000.0 +13519,Germany,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",24.9 +13520,Germany,2011,6,A02A-Antacids,"Million US$, purchasing power parity",18.6 +13521,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9 +13522,Germany,2011,6,A02A-Antacids,% of total sales,0.0 +13523,Germany,2011,6,N06A-Antidepressants,Million US$ at exchange rate,1065.4 +13524,Germany,2011,6,N06A-Antidepressants,Million of national currency units,765.4 +13525,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7 +13526,Germany,2011,6,N02-Analgesics,Million US$ at exchange rate,2192.2 +13527,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",501.3 +13528,Germany,2011,6,A02A-Antacids,"/capita, US$ exchange rate",0.3 +13529,Germany,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,395.4 +13530,Germany,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,550.4 +13531,Germany,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.2 +13532,Germany,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.1 +13533,Germany,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.3 +13534,Germany,2011,6,N06A-Antidepressants,% of total sales,2.6 +13535,Germany,2011,6,N02-Analgesics,"Million US$, purchasing power parity",1996.7 +13536,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.2 +13537,Germany,2011,6,A02A-Antacids,Million US$ at exchange rate,20.5 +13538,Germany,2011,6,N02-Analgesics,Million of national currency units,1574.9 +13539,Germany,2011,6,N05B-Anxiolytics,Million of national currency units,80.1 +13540,Germany,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",970.4 +13541,Germany,2011,6,C03-Diuretics,Million of national currency units,389.1 +13542,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.8 +13543,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",32.6 +13544,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +13545,Germany,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",78.9 +13546,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4 +13547,Germany,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",6048.6 +13548,Germany,2010,6,C08-Calcium channel blockers,Million of national currency units,308.0 +13549,Germany,2010,6,C-Cardiovascular system,Million US$ at exchange rate,6455.7 +13550,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.2 +13551,Germany,2010,6,C-Cardiovascular system,Million of national currency units,4869.6 +13552,Germany,2010,6,N-Nervous system,% of total sales,19.1 +13553,Germany,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2284.2 +13554,Germany,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",86.4 +13555,Germany,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2140.2 +13556,Germany,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,5.8 +13557,Germany,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.2 +13558,Germany,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.9 +13559,Germany,2010,6,Products not elsewhere classified,Million of national currency units,6585.2 +13560,Germany,2010,6,N-Nervous system,Million of national currency units,5688.1 +13561,Germany,2010,6,N-Nervous system,Million US$ at exchange rate,7540.8 +13562,Germany,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",8179.5 +13563,Germany,2010,6,Products not elsewhere classified,Million US$ at exchange rate,8730.1 +13564,Germany,2010,6,C-Cardiovascular system,% of total sales,16.4 +13565,Germany,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.0 +13566,Germany,2010,6,N-Nervous system,"Million US$, purchasing power parity",7065.3 +13567,Germany,2010,6,N-Nervous system,"/capita, US$ exchange rate",92.2 +13568,Germany,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,408.3 +13569,Germany,2010,6,R-Respiratory system,Million US$ at exchange rate,2719.7 +13570,Germany,2010,6,R-Respiratory system,Million of national currency units,2051.5 +13571,Germany,2010,6,C10-Lipid modifying agents,% of total sales,2.4 +13572,Germany,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",31.2 +13573,Germany,2010,6,R-Respiratory system,"/capita, US$ exchange rate",33.3 +13574,Germany,2010,6,R-Respiratory system,"Million US$, purchasing power parity",2548.2 +13575,Germany,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.8 +13576,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,735.9 +13577,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",689.5 +13578,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,555.1 +13579,Germany,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.5 +13580,Germany,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",880.3 +13581,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +13582,Germany,2010,6,M-Musculo-skeletal system,% of total sales,4.5 +13583,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",94.5 +13584,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.2 +13585,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +13586,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,76.1 +13587,Germany,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,1723.0 +13588,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.0 +13589,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,100.9 +13590,Germany,2010,6,R-Respiratory system,% of total sales,6.9 +13591,Germany,2010,6,C08-Calcium channel blockers,% of total sales,1.0 +13592,Germany,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7 +13593,Germany,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,1771.4 +13594,Germany,2010,6,M-Musculo-skeletal system,Million of national currency units,1336.2 +13595,Germany,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",100.0 +13596,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,2144.2 +13597,Germany,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0 +13598,Germany,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",106.8 +13599,Germany,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",382.6 +13600,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2842.6 +13601,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2663.3 +13602,Germany,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",36921.4 +13603,Germany,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,39406.5 +13604,Germany,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,939.5 +13605,Germany,2010,6,Total pharmaceutical sales,Million of national currency units,29724.7 +13606,Germany,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",481.9 +13607,Germany,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",451.5 +13608,Germany,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.7 +13609,Germany,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",1659.7 +13610,Germany,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.3 +13611,Germany,2010,6,C10-Lipid modifying agents,Million of national currency units,708.7 +13612,Germany,2010,6,Products not elsewhere classified,% of total sales,22.2 +13613,Germany,2010,6,A-Alimentary tract and metabolism,Million of national currency units,3714.8 +13614,Germany,2010,6,C07-Beta blocking agents,Million of national currency units,666.0 +13615,Germany,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,882.9 +13616,Germany,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.6 +13617,Germany,2010,6,C01A-Cardiac glycosides,% of total sales,0.1 +13618,Germany,2010,6,J-Antiinfectives for systemic use,% of total sales,6.8 +13619,Germany,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",827.2 +13620,Germany,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8 +13621,Germany,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2520.2 +13622,Germany,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",32.9 +13623,Germany,2010,6,J-Antiinfectives for systemic use,Million of national currency units,2029.0 +13624,Germany,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2689.9 +13625,Germany,2010,6,C01A-Cardiac glycosides,Million of national currency units,39.3 +13626,Germany,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",48.8 +13627,Germany,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6 +13628,Germany,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,52.1 +13629,Germany,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.0 +13630,Germany,2010,6,C03-Diuretics,"/capita, US$ exchange rate",6.4 +13631,Germany,2010,6,C03-Diuretics,% of total sales,1.3 +13632,Germany,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4 +13633,Germany,2010,6,C03-Diuretics,"Million US$, purchasing power parity",487.5 +13634,Germany,2010,6,C03-Diuretics,Million US$ at exchange rate,520.3 +13635,Germany,2010,6,C07-Beta blocking agents,% of total sales,2.2 +13636,Germany,2010,6,N05B-Anxiolytics,% of total sales,0.3 +13637,Germany,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",10.8 +13638,Germany,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.1 +13639,Germany,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",105.6 +13640,Germany,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,112.7 +13641,Germany,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3 +13642,Germany,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +13643,Germany,2010,6,A02A-Antacids,Million of national currency units,14.5 +13644,Germany,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +13645,Germany,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0 +13646,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,987.2 +13647,Germany,2010,6,J01-Antibacterials for systemic use,% of total sales,2.5 +13648,Germany,2010,6,C02-Antihypertensives,% of total sales,1.0 +13649,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1308.7 +13650,Germany,2010,6,J01-Antibacterials for systemic use,Million of national currency units,740.2 +13651,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +13652,Germany,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",919.4 +13653,Germany,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,981.3 +13654,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1226.2 +13655,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.0 +13656,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0 +13657,Germany,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7 +13658,Germany,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8 +13659,Germany,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.7 +13660,Germany,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",137.0 +13661,Germany,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",2050.1 +13662,Germany,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.8 +13663,Germany,2010,6,N05C-Hypnotics and sedatives,% of total sales,0.4 +13664,Germany,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",381.0 +13665,Germany,2010,6,C02-Antihypertensives,Million US$ at exchange rate,406.6 +13666,Germany,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.0 +13667,Germany,2010,6,B-Blood and blood forming organs,% of total sales,5.6 +13668,Germany,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1 +13669,Germany,2010,6,C02-Antihypertensives,Million of national currency units,306.7 +13670,Germany,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,110.3 +13671,Germany,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,146.2 +13672,Germany,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,2504.1 +13673,Germany,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2346.2 +13674,Germany,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.7 +13675,Germany,2010,6,G-Genito urinary system and sex hormones,% of total sales,2.7 +13676,Germany,2010,6,A10-Drugs used in diabetes,% of total sales,6.4 +13677,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9 +13678,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.8 +13679,Germany,2010,6,N02-Analgesics,"/capita, US$ exchange rate",25.3 +13680,Germany,2010,6,B-Blood and blood forming organs,Million of national currency units,1650.5 +13681,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,912.0 +13682,Germany,2010,6,A10-Drugs used in diabetes,Million of national currency units,1888.9 +13683,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1209.1 +13684,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1132.8 +13685,Germany,2010,6,A-Alimentary tract and metabolism,% of total sales,12.5 +13686,Germany,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4 +13687,Germany,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,812.2 +13688,Germany,2010,6,N02-Analgesics,% of total sales,5.3 +13689,Germany,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,4924.8 +13690,Germany,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.2 +13691,Germany,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4614.2 +13692,Germany,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,2188.1 +13693,Germany,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3 +13694,Germany,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",23.7 +13695,Germany,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1076.7 +13696,Germany,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1008.8 +13697,Germany,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.2 +13698,Germany,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.6 +13699,Germany,2010,6,A02A-Antacids,"Million US$, purchasing power parity",18.0 +13700,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8 +13701,Germany,2010,6,A02A-Antacids,% of total sales,0.0 +13702,Germany,2010,6,N06A-Antidepressants,Million of national currency units,798.5 +13703,Germany,2010,6,N06A-Antidepressants,Million US$ at exchange rate,1058.6 +13704,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",521.4 +13705,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1 +13706,Germany,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.2 +13707,Germany,2010,6,N02-Analgesics,Million US$ at exchange rate,2069.6 +13708,Germany,2010,6,A02A-Antacids,"/capita, US$ exchange rate",0.2 +13709,Germany,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,556.5 +13710,Germany,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,419.8 +13711,Germany,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.1 +13712,Germany,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",12.9 +13713,Germany,2010,6,N06A-Antidepressants,% of total sales,2.7 +13714,Germany,2010,6,N02-Analgesics,"Million US$, purchasing power parity",1939.1 +13715,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.4 +13716,Germany,2010,6,A02A-Antacids,Million US$ at exchange rate,19.2 +13717,Germany,2010,6,N02-Analgesics,Million of national currency units,1561.1 +13718,Germany,2010,6,N05B-Anxiolytics,Million of national currency units,85.0 +13719,Germany,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",991.8 +13720,Germany,2010,6,C03-Diuretics,Million of national currency units,392.5 +13721,Germany,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",5802.0 +13722,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.6 +13723,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5 +13724,Germany,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",58.7 +13725,Germany,2016,5,C-Cardiovascular system,Million US$ at exchange rate,4833.4 +13726,Germany,2016,5,C08-Calcium channel blockers,Million of national currency units,285.0 +13727,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6 +13728,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.9 +13729,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4 +13730,Germany,2016,5,C-Cardiovascular system,Million of national currency units,4366.6 +13731,Germany,2016,5,N-Nervous system,% of total sales,14.6 +13732,Germany,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1929.4 +13733,Germany,2016,5,N-Nervous system,"/capita, US$ exchange rate",70.7 +13734,Germany,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",84.9 +13735,Germany,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.1 +13736,Germany,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +13737,Germany,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2316.1 +13738,Germany,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.4 +13739,Germany,2016,5,N-Nervous system,Million of national currency units,5260.4 +13740,Germany,2016,5,Products not elsewhere classified,Million US$ at exchange rate,11702.7 +13741,Germany,2016,5,Products not elsewhere classified,Million of national currency units,10572.5 +13742,Germany,2016,5,N-Nervous system,Million US$ at exchange rate,5822.8 +13743,Germany,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.5 +13744,Germany,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1743.1 +13745,Germany,2016,5,N-Nervous system,"Million US$, purchasing power parity",6989.6 +13746,Germany,2016,5,R-Respiratory system,Million of national currency units,2134.3 +13747,Germany,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.7 +13748,Germany,2016,5,R-Respiratory system,Million US$ at exchange rate,2362.5 +13749,Germany,2016,5,R-Respiratory system,"/capita, US$ exchange rate",28.7 +13750,Germany,2016,5,R-Respiratory system,"Million US$, purchasing power parity",2835.9 +13751,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,588.8 +13752,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,651.7 +13753,Germany,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",582.8 +13754,Germany,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.9 +13755,Germany,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",884.4 +13756,Germany,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,736.8 +13757,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +13758,Germany,2016,5,M-Musculo-skeletal system,% of total sales,3.9 +13759,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +13760,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.3 +13761,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +13762,Germany,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7 +13763,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.5 +13764,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",782.3 +13765,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.9 +13766,Germany,2016,5,C10-Lipid modifying agents,% of total sales,1.8 +13767,Germany,2016,5,R-Respiratory system,% of total sales,5.9 +13768,Germany,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",34.4 +13769,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,83.6 +13770,Germany,2016,5,C08-Calcium channel blockers,% of total sales,0.8 +13771,Germany,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6 +13772,Germany,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8 +13773,Germany,2016,5,M-Musculo-skeletal system,Million of national currency units,1405.1 +13774,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1604.2 +13775,Germany,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",14047.8 +13776,Germany,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",142.1 +13777,Germany,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,315.5 +13778,Germany,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",378.7 +13779,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1775.7 +13780,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2131.5 +13781,Germany,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,39979.8 +13782,Germany,2016,5,Total pharmaceutical sales,Million of national currency units,36118.6 +13783,Germany,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",47991.3 +13784,Germany,2016,5,C-Cardiovascular system,% of total sales,12.1 +13785,Germany,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",485.5 +13786,Germany,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.9 +13787,Germany,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1867.0 +13788,Germany,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,1555.3 +13789,Germany,2016,5,C10-Lipid modifying agents,Million of national currency units,665.6 +13790,Germany,2016,5,Products not elsewhere classified,% of total sales,29.3 +13791,Germany,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",170.6 +13792,Germany,2016,5,C07-Beta blocking agents,Million of national currency units,659.7 +13793,Germany,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +13794,Germany,2016,5,C01A-Cardiac glycosides,% of total sales,0.1 +13795,Germany,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,730.2 +13796,Germany,2016,5,J-Antiinfectives for systemic use,% of total sales,9.0 +13797,Germany,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",43.5 +13798,Germany,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.3 +13799,Germany,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",876.6 +13800,Germany,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",4302.8 +13801,Germany,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3584.5 +13802,Germany,2016,5,J-Antiinfectives for systemic use,Million of national currency units,3238.3 +13803,Germany,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",31.4 +13804,Germany,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +13805,Germany,2016,5,C01A-Cardiac glycosides,Million of national currency units,23.6 +13806,Germany,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,26.1 +13807,Germany,2016,5,C03-Diuretics,"/capita, US$ exchange rate",6.0 +13808,Germany,2016,5,C03-Diuretics,"Million US$, purchasing power parity",597.8 +13809,Germany,2016,5,C03-Diuretics,% of total sales,1.2 +13810,Germany,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.3 +13811,Germany,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.1 +13812,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.5 +13813,Germany,2016,5,C03-Diuretics,Million of national currency units,449.9 +13814,Germany,2016,5,C03-Diuretics,Million US$ at exchange rate,498.0 +13815,Germany,2016,5,C07-Beta blocking agents,% of total sales,1.8 +13816,Germany,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6 +13817,Germany,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9 +13818,Germany,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1 +13819,Germany,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,76.2 +13820,Germany,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9 +13821,Germany,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.1 +13822,Germany,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.2 +13823,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1115.3 +13824,Germany,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1002.6 +13825,Germany,2016,5,C02-Antihypertensives,% of total sales,1.1 +13826,Germany,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3 +13827,Germany,2016,5,J01-Antibacterials for systemic use,% of total sales,2.1 +13828,Germany,2016,5,N05B-Anxiolytics,% of total sales,0.2 +13829,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.1 +13830,Germany,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,835.3 +13831,Germany,2016,5,J01-Antibacterials for systemic use,Million of national currency units,754.6 +13832,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.0 +13833,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1481.9 +13834,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1234.5 +13835,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0 +13836,Germany,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2 +13837,Germany,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",120.2 +13838,Germany,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1 +13839,Germany,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.2 +13840,Germany,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3770.0 +13841,Germany,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,3140.6 +13842,Germany,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5 +13843,Germany,2016,5,N05C-Hypnotics and sedatives,% of total sales,0.3 +13844,Germany,2016,5,C02-Antihypertensives,Million US$ at exchange rate,431.8 +13845,Germany,2016,5,C02-Antihypertensives,Million of national currency units,390.1 +13846,Germany,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.2 +13847,Germany,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",518.3 +13848,Germany,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.8 +13849,Germany,2016,5,B-Blood and blood forming organs,% of total sales,7.9 +13850,Germany,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,90.5 +13851,Germany,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",91.4 +13852,Germany,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",3211.4 +13853,Germany,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.5 +13854,Germany,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2675.3 +13855,Germany,2016,5,G-Genito urinary system and sex hormones,% of total sales,2.2 +13856,Germany,2016,5,A10-Drugs used in diabetes,% of total sales,6.7 +13857,Germany,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",39.0 +13858,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.4 +13859,Germany,2016,5,N02-Analgesics,"/capita, US$ exchange rate",23.3 +13860,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5 +13861,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,772.4 +13862,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1026.3 +13863,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,855.0 +13864,Germany,2016,5,A10-Drugs used in diabetes,Million of national currency units,2416.9 +13865,Germany,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.7 +13866,Germany,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",71.1 +13867,Germany,2016,5,A-Alimentary tract and metabolism,% of total sales,12.2 +13868,Germany,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.2 +13869,Germany,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4875.1 +13870,Germany,2016,5,A-Alimentary tract and metabolism,Million of national currency units,4404.3 +13871,Germany,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5852.1 +13872,Germany,2016,5,N02-Analgesics,% of total sales,4.8 +13873,Germany,2016,5,B-Blood and blood forming organs,Million of national currency units,2837.3 +13874,Germany,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.5 +13875,Germany,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,868.3 +13876,Germany,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,784.4 +13877,Germany,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",28.0 +13878,Germany,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1042.2 +13879,Germany,2016,5,A02A-Antacids,Million US$ at exchange rate,21.1 +13880,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",533.1 +13881,Germany,2016,5,A02A-Antacids,"Million US$, purchasing power parity",25.4 +13882,Germany,2016,5,N02-Analgesics,Million of national currency units,1735.8 +13883,Germany,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3 +13884,Germany,2016,5,A02A-Antacids,% of total sales,0.1 +13885,Germany,2016,5,N06A-Antidepressants,Million of national currency units,759.1 +13886,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.1 +13887,Germany,2016,5,N02-Analgesics,Million US$ at exchange rate,1921.4 +13888,Germany,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.3 +13889,Germany,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,444.1 +13890,Germany,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,401.2 +13891,Germany,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.2 +13892,Germany,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.2 +13893,Germany,2016,5,N02-Analgesics,"Million US$, purchasing power parity",2306.4 +13894,Germany,2016,5,N06A-Antidepressants,% of total sales,2.1 +13895,Germany,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",1008.6 +13896,Germany,2016,5,A02A-Antacids,Million of national currency units,19.1 +13897,Germany,2016,5,N05B-Anxiolytics,Million of national currency units,68.8 +13898,Germany,2016,5,N06A-Antidepressants,Million US$ at exchange rate,840.3 +13899,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.4 +13900,Greece,2016,3,N02-Analgesics,Million of national currency units,143.3 +13901,Greece,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,23.7 +13902,Greece,2016,3,N05B-Anxiolytics,Million of national currency units,21.4 +13903,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,66.5 +13904,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,73.6 +13905,Greece,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4 +13906,Greece,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",36.4 +13907,Greece,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2 +13908,Greece,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.1 +13909,Greece,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1076.6 +13910,Greece,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,288.1 +13911,Greece,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,260.3 +13912,Greece,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",99.9 +13913,Greece,2016,3,N02-Analgesics,"/capita, US$ exchange rate",14.7 +13914,Greece,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",22.6 +13915,Greece,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,701.4 +13916,Greece,2016,3,J-Antiinfectives for systemic use,Million of national currency units,633.7 +13917,Greece,2016,3,N02-Analgesics,"Million US$, purchasing power parity",243.4 +13918,Greece,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,1883.7 +13919,Greece,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",2891.3 +13920,Greece,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",268.3 +13921,Greece,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",174.8 +13922,Greece,2016,3,N02-Analgesics,Million US$ at exchange rate,158.6 +13923,Greece,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",442.2 +13924,Greece,2016,3,B-Blood and blood forming organs,Million of national currency units,1701.7 +13925,Greece,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.7 +13926,Greece,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",41.0 +13927,Greece,2016,3,M-Musculo-skeletal system,Million of national currency units,215.5 +13928,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.3 +13929,Greece,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",366.1 +13930,Greece,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,238.5 +13931,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,184.6 +13932,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1 +13933,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",283.4 +13934,Greece,2016,3,R-Respiratory system,Million of national currency units,405.5 +13935,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.9 +13936,Greece,2016,3,R-Respiratory system,"Million US$, purchasing power parity",688.9 +13937,Greece,2016,3,R-Respiratory system,Million US$ at exchange rate,448.8 +13938,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,166.8 +13939,Greece,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,41.3 +13940,Greece,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,37.3 +13941,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.8 +13942,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",63.3 +13943,Greece,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,155.4 +13944,Greece,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",107.3 +13945,Greece,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",264.1 +13946,Greece,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,172.1 +13947,Greece,2016,3,N-Nervous system,Million US$ at exchange rate,753.0 +13948,Greece,2016,3,N-Nervous system,"/capita, US$ exchange rate",69.9 +13949,Greece,2016,3,N-Nervous system,"Million US$, purchasing power parity",1155.8 +13950,Greece,2016,3,N-Nervous system,Million of national currency units,680.3 +13951,Greece,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",182.8 +13952,Greece,2016,3,N06A-Antidepressants,Million of national currency units,107.6 +13953,Greece,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",11.1 +13954,Greece,2016,3,N06A-Antidepressants,Million US$ at exchange rate,119.1 +13955,Greece,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.0 +13956,Greece,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.5 +13957,Greece,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.0 +13958,Greece,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",393.4 +13959,Greece,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8 +13960,Greece,2016,3,J01-Antibacterials for systemic use,Million of national currency units,231.5 +13961,Greece,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,256.3 +13962,Greece,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",40.9 +13963,Greece,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",676.5 +13964,Greece,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",36.5 +13965,Greece,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",62.8 +13966,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5 +13967,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",19.3 +13968,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",112.9 +13969,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.8 +13970,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,135.8 +13971,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,122.7 +13972,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6 +13973,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.4 +13974,Greece,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",35.4 +13975,Greece,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",54.4 +13976,Greece,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,381.6 +13977,Greece,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",585.7 +13978,Greece,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",63.9 +13979,Greece,2016,3,R-Respiratory system,"/capita, US$ exchange rate",41.7 +13980,Greece,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.0 +13981,Greece,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.1 +13982,Greece,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,8.2 +13983,Greece,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,9.1 +13984,Greece,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,440.7 +13985,Greece,2016,3,A10-Drugs used in diabetes,Million of national currency units,398.2 +13986,Greece,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +13987,Greece,2016,3,C10-Lipid modifying agents,Million of national currency units,344.7 +13988,Greece,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.9 +13989,Greece,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +13990,Greece,2016,3,C-Cardiovascular system,Million US$ at exchange rate,1039.8 +13991,Greece,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",1596.1 +13992,Greece,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",96.5 +13993,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,362.6 +13994,Greece,2016,3,C-Cardiovascular system,Million of national currency units,939.4 +13995,Greece,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +13996,Greece,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.4 +13997,Greece,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",148.1 +13998,Greece,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +13999,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.5 +14000,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +14001,Greece,2016,3,A-Alimentary tract and metabolism,Million of national currency units,749.2 +14002,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.2 +14003,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +14004,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",616.1 +14005,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,401.4 +14006,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",57.2 +14007,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.2 +14008,Greece,2016,3,C03-Diuretics,"/capita, US$ exchange rate",3.5 +14009,Greece,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +14010,Greece,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,829.3 +14011,Greece,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1272.9 +14012,Greece,2016,3,C07-Beta blocking agents,Million of national currency units,59.7 +14013,Greece,2016,3,C02-Antihypertensives,Million of national currency units,26.0 +14014,Greece,2016,3,C01A-Cardiac glycosides,Million of national currency units,0.7 +14015,Greece,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +14016,Greece,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",101.5 +14017,Greece,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2 +14018,Greece,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,66.1 +14019,Greece,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",44.2 +14020,Greece,2016,3,C02-Antihypertensives,Million US$ at exchange rate,28.8 +14021,Greece,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.1 +14022,Greece,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +14023,Greece,2016,3,A02A-Antacids,"Million US$, purchasing power parity",7.3 +14024,Greece,2016,3,A02A-Antacids,Million US$ at exchange rate,4.8 +14025,Greece,2016,3,A02A-Antacids,Million of national currency units,4.3 +14026,Greece,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.4 +14027,Greece,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.0 +14028,Greece,2016,3,C03-Diuretics,"Million US$, purchasing power parity",58.6 +14029,Greece,2016,3,C03-Diuretics,Million US$ at exchange rate,38.2 +14030,Greece,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9 +14031,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.4 +14032,Greece,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1 +14033,Greece,2016,3,C03-Diuretics,Million of national currency units,34.5 +14034,Greece,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",118.1 +14035,Greece,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.4 +14036,Greece,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.6 +14037,Greece,2016,3,C08-Calcium channel blockers,Million of national currency units,50.2 +14038,Greece,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",85.3 +14039,Greece,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2 +14040,Greece,2015,3,N02-Analgesics,Million of national currency units,84.1 +14041,Greece,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,23.0 +14042,Greece,2015,3,N05B-Anxiolytics,Million of national currency units,20.7 +14043,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,62.4 +14044,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,69.3 +14045,Greece,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1 +14046,Greece,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",34.0 +14047,Greece,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1 +14048,Greece,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",55.2 +14049,Greece,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",883.7 +14050,Greece,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",81.7 +14051,Greece,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,234.7 +14052,Greece,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,211.5 +14053,Greece,2015,3,N02-Analgesics,"Million US$, purchasing power parity",138.1 +14054,Greece,2015,3,N02-Analgesics,"/capita, US$ exchange rate",8.6 +14055,Greece,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",12.8 +14056,Greece,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,597.2 +14057,Greece,2015,3,J-Antiinfectives for systemic use,Million of national currency units,538.2 +14058,Greece,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,498.4 +14059,Greece,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",737.5 +14060,Greece,2015,3,N02-Analgesics,Million US$ at exchange rate,93.4 +14061,Greece,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",68.2 +14062,Greece,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",46.1 +14063,Greece,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",347.3 +14064,Greece,2015,3,B-Blood and blood forming organs,Million of national currency units,449.2 +14065,Greece,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.7 +14066,Greece,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.1 +14067,Greece,2015,3,M-Musculo-skeletal system,Million of national currency units,187.1 +14068,Greece,2015,3,R-Respiratory system,Million of national currency units,331.4 +14069,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.5 +14070,Greece,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",307.1 +14071,Greece,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,207.5 +14072,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,172.0 +14073,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",254.6 +14074,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.9 +14075,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.1 +14076,Greece,2015,3,R-Respiratory system,Million US$ at exchange rate,367.7 +14077,Greece,2015,3,R-Respiratory system,"Million US$, purchasing power parity",544.2 +14078,Greece,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.5 +14079,Greece,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,33.8 +14080,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5 +14081,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",55.5 +14082,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,155.1 +14083,Greece,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,125.6 +14084,Greece,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",85.7 +14085,Greece,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",206.2 +14086,Greece,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,139.4 +14087,Greece,2015,3,N-Nervous system,Million US$ at exchange rate,626.3 +14088,Greece,2015,3,N-Nervous system,"Million US$, purchasing power parity",926.8 +14089,Greece,2015,3,N-Nervous system,"/capita, US$ exchange rate",57.9 +14090,Greece,2015,3,N-Nervous system,Million of national currency units,564.5 +14091,Greece,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",172.9 +14092,Greece,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",10.8 +14093,Greece,2015,3,N06A-Antidepressants,Million of national currency units,105.3 +14094,Greece,2015,3,N06A-Antidepressants,Million US$ at exchange rate,116.8 +14095,Greece,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.1 +14096,Greece,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.9 +14097,Greece,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0 +14098,Greece,2015,3,R-Respiratory system,"/capita, US$ exchange rate",34.0 +14099,Greece,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",375.1 +14100,Greece,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.4 +14101,Greece,2015,3,J01-Antibacterials for systemic use,Million of national currency units,228.5 +14102,Greece,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,253.5 +14103,Greece,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.1 +14104,Greece,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",465.9 +14105,Greece,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",34.7 +14106,Greece,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",43.1 +14107,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5 +14108,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.1 +14109,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",102.5 +14110,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4 +14111,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,110.3 +14112,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,99.5 +14113,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2 +14114,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",163.3 +14115,Greece,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",31.2 +14116,Greece,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",46.2 +14117,Greece,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,337.8 +14118,Greece,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",499.9 +14119,Greece,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",50.3 +14120,Greece,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4 +14121,Greece,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.2 +14122,Greece,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,7.4 +14123,Greece,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,8.3 +14124,Greece,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,314.8 +14125,Greece,2015,3,A10-Drugs used in diabetes,Million of national currency units,283.8 +14126,Greece,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.1 +14127,Greece,2015,3,C10-Lipid modifying agents,Million of national currency units,304.5 +14128,Greece,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",12.2 +14129,Greece,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8 +14130,Greece,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",1454.5 +14131,Greece,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",90.8 +14132,Greece,2015,3,C-Cardiovascular system,Million US$ at exchange rate,982.9 +14133,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,331.1 +14134,Greece,2015,3,C-Cardiovascular system,Million of national currency units,885.9 +14135,Greece,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14136,Greece,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.7 +14137,Greece,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",134.4 +14138,Greece,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +14139,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.9 +14140,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +14141,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3 +14142,Greece,2015,3,A-Alimentary tract and metabolism,Million of national currency units,594.7 +14143,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",543.6 +14144,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,367.4 +14145,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +14146,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.0 +14147,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",50.2 +14148,Greece,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,659.8 +14149,Greece,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",976.4 +14150,Greece,2015,3,C07-Beta blocking agents,Million of national currency units,57.5 +14151,Greece,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,63.8 +14152,Greece,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +14153,Greece,2015,3,C02-Antihypertensives,Million of national currency units,25.1 +14154,Greece,2015,3,C01A-Cardiac glycosides,Million of national currency units,0.7 +14155,Greece,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",94.4 +14156,Greece,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2 +14157,Greece,2015,3,A02A-Antacids,Million of national currency units,5.2 +14158,Greece,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",41.3 +14159,Greece,2015,3,C02-Antihypertensives,Million US$ at exchange rate,27.9 +14160,Greece,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +14161,Greece,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.8 +14162,Greece,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +14163,Greece,2015,3,A02A-Antacids,"Million US$, purchasing power parity",8.5 +14164,Greece,2015,3,A02A-Antacids,Million US$ at exchange rate,5.7 +14165,Greece,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.5 +14166,Greece,2015,3,C03-Diuretics,"/capita, US$ exchange rate",3.2 +14167,Greece,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.0 +14168,Greece,2015,3,C03-Diuretics,"Million US$, purchasing power parity",50.6 +14169,Greece,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.6 +14170,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.6 +14171,Greece,2015,3,C03-Diuretics,Million US$ at exchange rate,34.2 +14172,Greece,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.9 +14173,Greece,2015,3,C03-Diuretics,Million of national currency units,30.8 +14174,Greece,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.7 +14175,Greece,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",90.2 +14176,Greece,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.9 +14177,Greece,2015,3,C08-Calcium channel blockers,Million of national currency units,50.4 +14178,Greece,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",82.7 +14179,Greece,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2 +14180,Greece,2014,3,N02-Analgesics,Million of national currency units,89.8 +14181,Greece,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,26.8 +14182,Greece,2014,3,N05B-Anxiolytics,Million of national currency units,20.2 +14183,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,66.0 +14184,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,87.7 +14185,Greece,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",33.1 +14186,Greece,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.5 +14187,Greece,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.0 +14188,Greece,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.9 +14189,Greece,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",897.0 +14190,Greece,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",82.4 +14191,Greece,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,328.5 +14192,Greece,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,247.3 +14193,Greece,2014,3,N02-Analgesics,"Million US$, purchasing power parity",146.9 +14194,Greece,2014,3,N02-Analgesics,"/capita, US$ exchange rate",10.9 +14195,Greece,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",13.5 +14196,Greece,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,728.3 +14197,Greece,2014,3,J-Antiinfectives for systemic use,Million of national currency units,548.2 +14198,Greece,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",805.1 +14199,Greece,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,653.6 +14200,Greece,2014,3,N02-Analgesics,Million US$ at exchange rate,119.2 +14201,Greece,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",73.9 +14202,Greece,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",60.0 +14203,Greece,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",404.6 +14204,Greece,2014,3,B-Blood and blood forming organs,Million of national currency units,492.0 +14205,Greece,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.2 +14206,Greece,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",37.1 +14207,Greece,2014,3,M-Musculo-skeletal system,Million of national currency units,211.4 +14208,Greece,2014,3,R-Respiratory system,Million of national currency units,365.1 +14209,Greece,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",345.8 +14210,Greece,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,280.8 +14211,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.3 +14212,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,214.6 +14213,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",264.3 +14214,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",19.7 +14215,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1 +14216,Greece,2014,3,R-Respiratory system,Million US$ at exchange rate,485.1 +14217,Greece,2014,3,R-Respiratory system,"Million US$, purchasing power parity",597.5 +14218,Greece,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,53.9 +14219,Greece,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,40.6 +14220,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.9 +14221,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.4 +14222,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,161.5 +14223,Greece,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,152.6 +14224,Greece,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",99.9 +14225,Greece,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",249.7 +14226,Greece,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,202.7 +14227,Greece,2014,3,N-Nervous system,Million US$ at exchange rate,883.7 +14228,Greece,2014,3,N-Nervous system,"Million US$, purchasing power parity",1088.5 +14229,Greece,2014,3,N-Nervous system,"/capita, US$ exchange rate",81.1 +14230,Greece,2014,3,N-Nervous system,Million of national currency units,665.2 +14231,Greece,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",195.1 +14232,Greece,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",14.5 +14233,Greece,2014,3,N06A-Antidepressants,Million of national currency units,119.2 +14234,Greece,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.9 +14235,Greece,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.6 +14236,Greece,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.9 +14237,Greece,2014,3,R-Respiratory system,"/capita, US$ exchange rate",44.5 +14238,Greece,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",385.9 +14239,Greece,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",28.8 +14240,Greece,2014,3,J01-Antibacterials for systemic use,Million of national currency units,235.9 +14241,Greece,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,313.3 +14242,Greece,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.3 +14243,Greece,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",500.8 +14244,Greece,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",46.0 +14245,Greece,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",35.4 +14246,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9 +14247,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.4 +14248,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",108.1 +14249,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1 +14250,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,153.7 +14251,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,115.7 +14252,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.1 +14253,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",189.3 +14254,Greece,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",42.5 +14255,Greece,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.4 +14256,Greece,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,463.0 +14257,Greece,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",570.3 +14258,Greece,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",54.9 +14259,Greece,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.7 +14260,Greece,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.8 +14261,Greece,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.9 +14262,Greece,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,8.9 +14263,Greece,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,406.6 +14264,Greece,2014,3,A10-Drugs used in diabetes,Million of national currency units,306.1 +14265,Greece,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +14266,Greece,2014,3,C10-Lipid modifying agents,Million of national currency units,348.5 +14267,Greece,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6 +14268,Greece,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1 +14269,Greece,2014,3,N06A-Antidepressants,Million US$ at exchange rate,158.4 +14270,Greece,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",1560.8 +14271,Greece,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",116.3 +14272,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,364.8 +14273,Greece,2014,3,C-Cardiovascular system,Million US$ at exchange rate,1267.2 +14274,Greece,2014,3,C-Cardiovascular system,Million of national currency units,953.9 +14275,Greece,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14276,Greece,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.5 +14277,Greece,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",143.3 +14278,Greece,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +14279,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.4 +14280,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +14281,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.4 +14282,Greece,2014,3,A-Alimentary tract and metabolism,Million of national currency units,634.9 +14283,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +14284,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",596.9 +14285,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,484.6 +14286,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",44.5 +14287,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",54.8 +14288,Greece,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1038.9 +14289,Greece,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,843.5 +14290,Greece,2014,3,C07-Beta blocking agents,Million of national currency units,58.7 +14291,Greece,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,78.0 +14292,Greece,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2 +14293,Greece,2014,3,C01A-Cardiac glycosides,Million of national currency units,0.9 +14294,Greece,2014,3,C02-Antihypertensives,Million of national currency units,25.2 +14295,Greece,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",96.0 +14296,Greece,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +14297,Greece,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",41.2 +14298,Greece,2014,3,C02-Antihypertensives,Million US$ at exchange rate,33.5 +14299,Greece,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +14300,Greece,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.8 +14301,Greece,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.1 +14302,Greece,2014,3,A02A-Antacids,Million of national currency units,5.5 +14303,Greece,2014,3,A02A-Antacids,"Million US$, purchasing power parity",8.9 +14304,Greece,2014,3,A02A-Antacids,Million US$ at exchange rate,7.2 +14305,Greece,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.7 +14306,Greece,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.4 +14307,Greece,2014,3,C03-Diuretics,"Million US$, purchasing power parity",59.5 +14308,Greece,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.4 +14309,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.4 +14310,Greece,2014,3,C03-Diuretics,Million US$ at exchange rate,48.3 +14311,Greece,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2 +14312,Greece,2014,3,C03-Diuretics,"/capita, US$ exchange rate",4.4 +14313,Greece,2014,3,C03-Diuretics,Million of national currency units,36.3 +14314,Greece,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.8 +14315,Greece,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",95.4 +14316,Greece,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,74.3 +14317,Greece,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",91.6 +14318,Greece,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8 +14319,Greece,2014,3,C08-Calcium channel blockers,Million of national currency units,56.0 +14320,Greece,2013,3,N02-Analgesics,Million of national currency units,82.9 +14321,Greece,2013,3,N05B-Anxiolytics,Million of national currency units,21.8 +14322,Greece,2013,3,N05B-Anxiolytics,Million US$ at exchange rate,29.0 +14323,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,67.6 +14324,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.8 +14325,Greece,2013,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.2 +14326,Greece,2013,3,N05B-Anxiolytics,"Million US$, purchasing power parity",34.6 +14327,Greece,2013,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.6 +14328,Greece,2013,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",74.9 +14329,Greece,2013,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.8 +14330,Greece,2013,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",821.3 +14331,Greece,2013,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,328.4 +14332,Greece,2013,3,R03-Drugs for obstructive airway diseases,Million of national currency units,247.3 +14333,Greece,2013,3,N02-Analgesics,"Million US$, purchasing power parity",131.4 +14334,Greece,2013,3,N02-Analgesics,"/capita, US$ exchange rate",10.0 +14335,Greece,2013,3,N02-Analgesics,"/capita, US$ purchasing power parity",12.0 +14336,Greece,2013,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,688.6 +14337,Greece,2013,3,J-Antiinfectives for systemic use,Million of national currency units,518.5 +14338,Greece,2013,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",734.5 +14339,Greece,2013,3,B-Blood and blood forming organs,Million US$ at exchange rate,615.8 +14340,Greece,2013,3,N02-Analgesics,Million US$ at exchange rate,110.1 +14341,Greece,2013,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.0 +14342,Greece,2013,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",56.2 +14343,Greece,2013,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",391.7 +14344,Greece,2013,3,B-Blood and blood forming organs,Million of national currency units,463.7 +14345,Greece,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.9 +14346,Greece,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.7 +14347,Greece,2013,3,M-Musculo-skeletal system,Million of national currency units,221.0 +14348,Greece,2013,3,R-Respiratory system,Million of national currency units,359.2 +14349,Greece,2013,3,M-Musculo-skeletal system,Million US$ at exchange rate,293.6 +14350,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.0 +14351,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,239.0 +14352,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",285.1 +14353,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.8 +14354,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.6 +14355,Greece,2013,3,R-Respiratory system,Million US$ at exchange rate,477.0 +14356,Greece,2013,3,R-Respiratory system,"Million US$, purchasing power parity",568.9 +14357,Greece,2013,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,51.3 +14358,Greece,2013,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,38.6 +14359,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7 +14360,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",61.2 +14361,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,180.0 +14362,Greece,2013,3,G-Genito urinary system and sex hormones,Million of national currency units,149.0 +14363,Greece,2013,3,N-Nervous system,"/capita, US$ purchasing power parity",102.1 +14364,Greece,2013,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",236.0 +14365,Greece,2013,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,197.9 +14366,Greece,2013,3,N-Nervous system,Million US$ at exchange rate,938.7 +14367,Greece,2013,3,N-Nervous system,"Million US$, purchasing power parity",1119.6 +14368,Greece,2013,3,N-Nervous system,"/capita, US$ exchange rate",85.6 +14369,Greece,2013,3,N-Nervous system,Million of national currency units,706.8 +14370,Greece,2013,3,N06A-Antidepressants,"Million US$, purchasing power parity",213.8 +14371,Greece,2013,3,N06A-Antidepressants,"/capita, US$ exchange rate",16.3 +14372,Greece,2013,3,N06A-Antidepressants,Million of national currency units,134.9 +14373,Greece,2013,3,N06A-Antidepressants,Million US$ at exchange rate,179.2 +14374,Greece,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.5 +14375,Greece,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.0 +14376,Greece,2013,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.5 +14377,Greece,2013,3,R-Respiratory system,"/capita, US$ exchange rate",43.5 +14378,Greece,2013,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",360.1 +14379,Greece,2013,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",27.5 +14380,Greece,2013,3,J01-Antibacterials for systemic use,Million of national currency units,227.4 +14381,Greece,2013,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,301.9 +14382,Greece,2013,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.7 +14383,Greece,2013,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",453.7 +14384,Greece,2013,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",41.4 +14385,Greece,2013,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",32.8 +14386,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8 +14387,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.6 +14388,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",107.1 +14389,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.2 +14390,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,152.3 +14391,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114.7 +14392,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9 +14393,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",181.7 +14394,Greece,2013,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",43.8 +14395,Greece,2013,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.3 +14396,Greece,2013,3,C10-Lipid modifying agents,Million US$ at exchange rate,480.8 +14397,Greece,2013,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",573.4 +14398,Greece,2013,3,R-Respiratory system,"/capita, US$ purchasing power parity",51.9 +14399,Greece,2013,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.9 +14400,Greece,2013,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",26.8 +14401,Greece,2013,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,10.9 +14402,Greece,2013,3,N05C-Hypnotics and sedatives,Million of national currency units,8.2 +14403,Greece,2013,3,A10-Drugs used in diabetes,Million US$ at exchange rate,380.4 +14404,Greece,2013,3,A10-Drugs used in diabetes,Million of national currency units,286.4 +14405,Greece,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2 +14406,Greece,2013,3,C10-Lipid modifying agents,Million of national currency units,362.0 +14407,Greece,2013,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.0 +14408,Greece,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0 +14409,Greece,2013,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",350.1 +14410,Greece,2013,3,C-Cardiovascular system,"Million US$, purchasing power parity",1612.5 +14411,Greece,2013,3,C-Cardiovascular system,"/capita, US$ exchange rate",123.3 +14412,Greece,2013,3,C-Cardiovascular system,Million US$ at exchange rate,1352.0 +14413,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,400.1 +14414,Greece,2013,3,C-Cardiovascular system,Million of national currency units,1018.0 +14415,Greece,2013,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14416,Greece,2013,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.5 +14417,Greece,2013,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",147.1 +14418,Greece,2013,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +14419,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.3 +14420,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +14421,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +14422,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.6 +14423,Greece,2013,3,A-Alimentary tract and metabolism,Million of national currency units,630.1 +14424,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",633.7 +14425,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,531.3 +14426,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",48.5 +14427,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",57.8 +14428,Greece,2013,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",998.1 +14429,Greece,2013,3,C08-Calcium channel blockers,Million of national currency units,61.0 +14430,Greece,2013,3,C07-Beta blocking agents,Million of national currency units,64.2 +14431,Greece,2013,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,836.8 +14432,Greece,2013,3,C07-Beta blocking agents,Million US$ at exchange rate,85.2 +14433,Greece,2013,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3 +14434,Greece,2013,3,C02-Antihypertensives,Million of national currency units,27.0 +14435,Greece,2013,3,C01A-Cardiac glycosides,Million of national currency units,1.0 +14436,Greece,2013,3,C07-Beta blocking agents,"Million US$, purchasing power parity",101.7 +14437,Greece,2013,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +14438,Greece,2013,3,A02A-Antacids,Million of national currency units,5.6 +14439,Greece,2013,3,C02-Antihypertensives,"Million US$, purchasing power parity",42.8 +14440,Greece,2013,3,C02-Antihypertensives,Million US$ at exchange rate,35.9 +14441,Greece,2013,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +14442,Greece,2013,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.9 +14443,Greece,2013,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.3 +14444,Greece,2013,3,A02A-Antacids,"Million US$, purchasing power parity",8.9 +14445,Greece,2013,3,A02A-Antacids,Million US$ at exchange rate,7.4 +14446,Greece,2013,3,A02A-Antacids,"/capita, US$ exchange rate",0.7 +14447,Greece,2013,3,C03-Diuretics,"/capita, US$ exchange rate",4.6 +14448,Greece,2013,3,C03-Diuretics,"Million US$, purchasing power parity",60.5 +14449,Greece,2013,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.3 +14450,Greece,2013,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.8 +14451,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.5 +14452,Greece,2013,3,C03-Diuretics,Million US$ at exchange rate,50.7 +14453,Greece,2013,3,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8 +14454,Greece,2013,3,C03-Diuretics,Million of national currency units,38.2 +14455,Greece,2013,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.3 +14456,Greece,2013,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.0 +14457,Greece,2013,3,C08-Calcium channel blockers,Million US$ at exchange rate,81.0 +14458,Greece,2013,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",96.7 +14459,Greece,2013,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.4 +14460,Greece,2012,3,N05B-Anxiolytics,Million of national currency units,21.1 +14461,Greece,2012,3,N02-Analgesics,Million of national currency units,84.3 +14462,Greece,2012,3,N05B-Anxiolytics,Million US$ at exchange rate,27.1 +14463,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,74.2 +14464,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,95.3 +14465,Greece,2012,3,N05B-Anxiolytics,"Million US$, purchasing power parity",30.8 +14466,Greece,2012,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8 +14467,Greece,2012,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.5 +14468,Greece,2012,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",79.4 +14469,Greece,2012,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.9 +14470,Greece,2012,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",877.1 +14471,Greece,2012,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,356.9 +14472,Greece,2012,3,R03-Drugs for obstructive airway diseases,Million of national currency units,277.8 +14473,Greece,2012,3,N02-Analgesics,"Million US$, purchasing power parity",123.2 +14474,Greece,2012,3,N02-Analgesics,"/capita, US$ exchange rate",9.8 +14475,Greece,2012,3,N02-Analgesics,"/capita, US$ purchasing power parity",11.2 +14476,Greece,2012,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,771.6 +14477,Greece,2012,3,J-Antiinfectives for systemic use,Million of national currency units,600.5 +14478,Greece,2012,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",744.8 +14479,Greece,2012,3,B-Blood and blood forming organs,Million US$ at exchange rate,655.1 +14480,Greece,2012,3,N02-Analgesics,Million US$ at exchange rate,108.4 +14481,Greece,2012,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.4 +14482,Greece,2012,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.3 +14483,Greece,2012,3,B-Blood and blood forming organs,Million of national currency units,509.9 +14484,Greece,2012,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",405.7 +14485,Greece,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.3 +14486,Greece,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",36.7 +14487,Greece,2012,3,A10-Drugs used in diabetes,Million US$ at exchange rate,361.1 +14488,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",108.4 +14489,Greece,2012,3,M-Musculo-skeletal system,Million of national currency units,245.0 +14490,Greece,2012,3,R-Respiratory system,Million of national currency units,398.3 +14491,Greece,2012,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",357.8 +14492,Greece,2012,3,M-Musculo-skeletal system,Million US$ at exchange rate,314.8 +14493,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",29.5 +14494,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,286.4 +14495,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",325.6 +14496,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.9 +14497,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.6 +14498,Greece,2012,3,R-Respiratory system,Million US$ at exchange rate,511.7 +14499,Greece,2012,3,R-Respiratory system,"Million US$, purchasing power parity",581.7 +14500,Greece,2012,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.5 +14501,Greece,2012,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,50.2 +14502,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.8 +14503,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",73.3 +14504,Greece,2012,3,G-Genito urinary system and sex hormones,Million of national currency units,161.3 +14505,Greece,2012,3,N-Nervous system,"/capita, US$ purchasing power parity",104.5 +14506,Greece,2012,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",235.6 +14507,Greece,2012,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,207.3 +14508,Greece,2012,3,N-Nervous system,Million US$ at exchange rate,1015.0 +14509,Greece,2012,3,N-Nervous system,"Million US$, purchasing power parity",1153.9 +14510,Greece,2012,3,N-Nervous system,"/capita, US$ exchange rate",91.9 +14511,Greece,2012,3,N-Nervous system,Million of national currency units,790.0 +14512,Greece,2012,3,R-Respiratory system,"/capita, US$ exchange rate",46.3 +14513,Greece,2012,3,N06A-Antidepressants,"Million US$, purchasing power parity",200.0 +14514,Greece,2012,3,N06A-Antidepressants,"/capita, US$ exchange rate",15.9 +14515,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,222.9 +14516,Greece,2012,3,N06A-Antidepressants,Million of national currency units,137.0 +14517,Greece,2012,3,N06A-Antidepressants,Million US$ at exchange rate,176.0 +14518,Greece,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3 +14519,Greece,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.8 +14520,Greece,2012,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.1 +14521,Greece,2012,3,A10-Drugs used in diabetes,Million of national currency units,281.1 +14522,Greece,2012,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",34.2 +14523,Greece,2012,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",429.6 +14524,Greece,2012,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.9 +14525,Greece,2012,3,J01-Antibacterials for systemic use,Million of national currency units,294.1 +14526,Greece,2012,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.7 +14527,Greece,2012,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.2 +14528,Greece,2012,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",38.9 +14529,Greece,2012,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",410.6 +14530,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.0 +14531,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8 +14532,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.6 +14533,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,175.2 +14534,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,136.4 +14535,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9 +14536,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",199.2 +14537,Greece,2012,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",50.6 +14538,Greece,2012,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",57.5 +14539,Greece,2012,3,C10-Lipid modifying agents,Million US$ at exchange rate,558.8 +14540,Greece,2012,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",635.2 +14541,Greece,2012,3,R-Respiratory system,"/capita, US$ purchasing power parity",52.7 +14542,Greece,2012,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.4 +14543,Greece,2012,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.5 +14544,Greece,2012,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.4 +14545,Greece,2012,3,N05C-Hypnotics and sedatives,Million of national currency units,8.9 +14546,Greece,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2 +14547,Greece,2012,3,C10-Lipid modifying agents,Million of national currency units,434.9 +14548,Greece,2012,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.0 +14549,Greece,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0 +14550,Greece,2012,3,C08-Calcium channel blockers,Million of national currency units,68.8 +14551,Greece,2012,3,C-Cardiovascular system,"Million US$, purchasing power parity",1748.1 +14552,Greece,2012,3,C-Cardiovascular system,"/capita, US$ exchange rate",139.2 +14553,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,473.3 +14554,Greece,2012,3,C-Cardiovascular system,Million of national currency units,1196.9 +14555,Greece,2012,3,C-Cardiovascular system,Million US$ at exchange rate,1537.7 +14556,Greece,2012,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14557,Greece,2012,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.9 +14558,Greece,2012,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",158.3 +14559,Greece,2012,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +14560,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.5 +14561,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +14562,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +14563,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5 +14564,Greece,2012,3,A-Alimentary tract and metabolism,Million of national currency units,678.3 +14565,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",691.2 +14566,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,608.0 +14567,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",55.1 +14568,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",62.6 +14569,Greece,2012,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",990.7 +14570,Greece,2012,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,871.5 +14571,Greece,2012,3,C07-Beta blocking agents,Million of national currency units,79.9 +14572,Greece,2012,3,C07-Beta blocking agents,Million US$ at exchange rate,102.6 +14573,Greece,2012,3,A02A-Antacids,Million of national currency units,5.3 +14574,Greece,2012,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5 +14575,Greece,2012,3,C02-Antihypertensives,Million of national currency units,32.3 +14576,Greece,2012,3,C01A-Cardiac glycosides,Million of national currency units,1.2 +14577,Greece,2012,3,C07-Beta blocking agents,"Million US$, purchasing power parity",116.7 +14578,Greece,2012,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7 +14579,Greece,2012,3,C02-Antihypertensives,"Million US$, purchasing power parity",47.2 +14580,Greece,2012,3,C02-Antihypertensives,Million US$ at exchange rate,41.5 +14581,Greece,2012,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +14582,Greece,2012,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3 +14583,Greece,2012,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.8 +14584,Greece,2012,3,A02A-Antacids,"Million US$, purchasing power parity",7.8 +14585,Greece,2012,3,A02A-Antacids,Million US$ at exchange rate,6.9 +14586,Greece,2012,3,A02A-Antacids,"/capita, US$ exchange rate",0.6 +14587,Greece,2012,3,C03-Diuretics,"Million US$, purchasing power parity",53.9 +14588,Greece,2012,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",78.9 +14589,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.8 +14590,Greece,2012,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6 +14591,Greece,2012,3,C03-Diuretics,Million of national currency units,36.9 +14592,Greece,2012,3,C07-Beta blocking agents,"/capita, US$ exchange rate",9.3 +14593,Greece,2012,3,C03-Diuretics,Million US$ at exchange rate,47.4 +14594,Greece,2012,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",89.7 +14595,Greece,2012,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",9.1 +14596,Greece,2012,3,C08-Calcium channel blockers,Million US$ at exchange rate,88.4 +14597,Greece,2012,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",100.5 +14598,Greece,2012,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.0 +14599,Greece,2012,3,C03-Diuretics,"/capita, US$ exchange rate",4.3 +14600,Greece,2011,3,N02-Analgesics,Million of national currency units,80.9 +14601,Greece,2011,3,N05B-Anxiolytics,Million US$ at exchange rate,31.4 +14602,Greece,2011,3,N05B-Anxiolytics,Million of national currency units,22.6 +14603,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,83.3 +14604,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,115.9 +14605,Greece,2011,3,N05B-Anxiolytics,"Million US$, purchasing power parity",31.7 +14606,Greece,2011,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.9 +14607,Greece,2011,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8 +14608,Greece,2011,3,N02-Analgesics,Million US$ at exchange rate,112.7 +14609,Greece,2011,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",87.6 +14610,Greece,2011,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",86.9 +14611,Greece,2011,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,438.4 +14612,Greece,2011,3,R03-Drugs for obstructive airway diseases,Million of national currency units,315.0 +14613,Greece,2011,3,N02-Analgesics,"Million US$, purchasing power parity",113.5 +14614,Greece,2011,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",972.4 +14615,Greece,2011,3,N02-Analgesics,"/capita, US$ exchange rate",10.1 +14616,Greece,2011,3,N02-Analgesics,"/capita, US$ purchasing power parity",10.2 +14617,Greece,2011,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,965.3 +14618,Greece,2011,3,J-Antiinfectives for systemic use,Million of national currency units,693.5 +14619,Greece,2011,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",812.5 +14620,Greece,2011,3,B-Blood and blood forming organs,Million US$ at exchange rate,806.5 +14621,Greece,2011,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",73.2 +14622,Greece,2011,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",72.6 +14623,Greece,2011,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.5 +14624,Greece,2011,3,B-Blood and blood forming organs,Million of national currency units,579.4 +14625,Greece,2011,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",441.7 +14626,Greece,2011,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",39.8 +14627,Greece,2011,3,M-Musculo-skeletal system,Million of national currency units,275.8 +14628,Greece,2011,3,R-Respiratory system,Million of national currency units,451.6 +14629,Greece,2011,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",386.7 +14630,Greece,2011,3,M-Musculo-skeletal system,Million US$ at exchange rate,383.9 +14631,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",371.2 +14632,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,368.5 +14633,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",33.4 +14634,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",33.2 +14635,Greece,2011,3,R-Respiratory system,Million US$ at exchange rate,628.6 +14636,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.2 +14637,Greece,2011,3,R-Respiratory system,"/capita, US$ exchange rate",56.6 +14638,Greece,2011,3,R-Respiratory system,"Million US$, purchasing power parity",633.2 +14639,Greece,2011,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,90.9 +14640,Greece,2011,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,65.3 +14641,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.2 +14642,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",91.6 +14643,Greece,2011,3,G-Genito urinary system and sex hormones,Million of national currency units,191.1 +14644,Greece,2011,3,N-Nervous system,"/capita, US$ purchasing power parity",115.4 +14645,Greece,2011,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",268.0 +14646,Greece,2011,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,266.0 +14647,Greece,2011,3,N-Nervous system,Million US$ at exchange rate,1272.3 +14648,Greece,2011,3,N-Nervous system,"Million US$, purchasing power parity",1281.7 +14649,Greece,2011,3,N-Nervous system,"/capita, US$ exchange rate",114.6 +14650,Greece,2011,3,N-Nervous system,Million of national currency units,914.1 +14651,Greece,2011,3,N06A-Antidepressants,"Million US$, purchasing power parity",218.9 +14652,Greece,2011,3,N06A-Antidepressants,"/capita, US$ exchange rate",19.6 +14653,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,264.7 +14654,Greece,2011,3,N06A-Antidepressants,Million of national currency units,156.1 +14655,Greece,2011,3,N06A-Antidepressants,Million US$ at exchange rate,217.3 +14656,Greece,2011,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.1 +14657,Greece,2011,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.0 +14658,Greece,2011,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.7 +14659,Greece,2011,3,A10-Drugs used in diabetes,Million of national currency units,277.3 +14660,Greece,2011,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",42.7 +14661,Greece,2011,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",477.7 +14662,Greece,2011,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,474.2 +14663,Greece,2011,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.8 +14664,Greece,2011,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.0 +14665,Greece,2011,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",43.0 +14666,Greece,2011,3,J01-Antibacterials for systemic use,Million of national currency units,340.7 +14667,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",19.8 +14668,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5 +14669,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4 +14670,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,218.8 +14671,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,157.2 +14672,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",19.7 +14673,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",220.4 +14674,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",116.8 +14675,Greece,2011,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",388.9 +14676,Greece,2011,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",60.2 +14677,Greece,2011,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",60.6 +14678,Greece,2011,3,C10-Lipid modifying agents,Million US$ at exchange rate,668.5 +14679,Greece,2011,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",673.5 +14680,Greece,2011,3,R-Respiratory system,"/capita, US$ purchasing power parity",57.0 +14681,Greece,2011,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",34.6 +14682,Greece,2011,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.8 +14683,Greece,2011,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.2 +14684,Greece,2011,3,N05C-Hypnotics and sedatives,Million of national currency units,10.2 +14685,Greece,2011,3,A10-Drugs used in diabetes,Million US$ at exchange rate,386.1 +14686,Greece,2011,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +14687,Greece,2011,3,C10-Lipid modifying agents,Million of national currency units,480.3 +14688,Greece,2011,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.3 +14689,Greece,2011,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +14690,Greece,2011,3,C-Cardiovascular system,"Million US$, purchasing power parity",1843.2 +14691,Greece,2011,3,C-Cardiovascular system,"/capita, US$ exchange rate",164.8 +14692,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,523.1 +14693,Greece,2011,3,C-Cardiovascular system,Million of national currency units,1314.5 +14694,Greece,2011,3,C-Cardiovascular system,Million US$ at exchange rate,1829.7 +14695,Greece,2011,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.5 +14696,Greece,2011,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +14697,Greece,2011,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",166.0 +14698,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +14699,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +14700,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.7 +14701,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.7 +14702,Greece,2011,3,A-Alimentary tract and metabolism,Million of national currency units,743.9 +14703,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",65.6 +14704,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",733.5 +14705,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,728.2 +14706,Greece,2011,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1043.1 +14707,Greece,2011,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",93.2 +14708,Greece,2011,3,A02A-Antacids,Million of national currency units,6.0 +14709,Greece,2011,3,C07-Beta blocking agents,Million of national currency units,81.7 +14710,Greece,2011,3,C07-Beta blocking agents,Million US$ at exchange rate,113.7 +14711,Greece,2011,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,1035.5 +14712,Greece,2011,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6 +14713,Greece,2011,3,C02-Antihypertensives,Million of national currency units,39.3 +14714,Greece,2011,3,C01A-Cardiac glycosides,Million of national currency units,1.2 +14715,Greece,2011,3,C07-Beta blocking agents,"Million US$, purchasing power parity",114.5 +14716,Greece,2011,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +14717,Greece,2011,3,C02-Antihypertensives,"Million US$, purchasing power parity",55.1 +14718,Greece,2011,3,C02-Antihypertensives,Million US$ at exchange rate,54.7 +14719,Greece,2011,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +14720,Greece,2011,3,C02-Antihypertensives,"/capita, US$ exchange rate",4.9 +14721,Greece,2011,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.0 +14722,Greece,2011,3,A02A-Antacids,"Million US$, purchasing power parity",8.4 +14723,Greece,2011,3,A02A-Antacids,Million US$ at exchange rate,8.4 +14724,Greece,2011,3,A02A-Antacids,"/capita, US$ exchange rate",0.8 +14725,Greece,2011,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14726,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",66.1 +14727,Greece,2011,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",93.9 +14728,Greece,2011,3,C03-Diuretics,"Million US$, purchasing power parity",50.1 +14729,Greece,2011,3,C08-Calcium channel blockers,Million of national currency units,77.7 +14730,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.2 +14731,Greece,2011,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.3 +14732,Greece,2011,3,C07-Beta blocking agents,"/capita, US$ exchange rate",10.2 +14733,Greece,2011,3,C03-Diuretics,Million of national currency units,35.7 +14734,Greece,2011,3,C03-Diuretics,Million US$ at exchange rate,49.7 +14735,Greece,2011,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",9.8 +14736,Greece,2011,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",9.7 +14737,Greece,2011,3,C08-Calcium channel blockers,Million US$ at exchange rate,108.1 +14738,Greece,2011,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",108.9 +14739,Greece,2011,3,C03-Diuretics,"/capita, US$ exchange rate",4.5 +14740,Greece,2010,3,N02-Analgesics,Million of national currency units,76.5 +14741,Greece,2010,3,N05B-Anxiolytics,Million US$ at exchange rate,29.5 +14742,Greece,2010,3,N05B-Anxiolytics,Million of national currency units,22.3 +14743,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,101.4 +14744,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,134.5 +14745,Greece,2010,3,N05B-Anxiolytics,"Million US$, purchasing power parity",30.8 +14746,Greece,2010,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +14747,Greece,2010,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8 +14748,Greece,2010,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",93.2 +14749,Greece,2010,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",89.2 +14750,Greece,2010,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,427.1 +14751,Greece,2010,3,R03-Drugs for obstructive airway diseases,Million of national currency units,322.2 +14752,Greece,2010,3,N02-Analgesics,"Million US$, purchasing power parity",106.0 +14753,Greece,2010,3,N02-Analgesics,"/capita, US$ exchange rate",9.1 +14754,Greece,2010,3,N02-Analgesics,"/capita, US$ purchasing power parity",9.5 +14755,Greece,2010,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1036.8 +14756,Greece,2010,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,992.4 +14757,Greece,2010,3,J-Antiinfectives for systemic use,Million of national currency units,748.6 +14758,Greece,2010,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",891.6 +14759,Greece,2010,3,B-Blood and blood forming organs,Million US$ at exchange rate,853.4 +14760,Greece,2010,3,N02-Analgesics,Million US$ at exchange rate,101.4 +14761,Greece,2010,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",80.2 +14762,Greece,2010,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",76.7 +14763,Greece,2010,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.4 +14764,Greece,2010,3,B-Blood and blood forming organs,Million of national currency units,643.7 +14765,Greece,2010,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",446.2 +14766,Greece,2010,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",40.1 +14767,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",140.5 +14768,Greece,2010,3,M-Musculo-skeletal system,Million of national currency units,317.4 +14769,Greece,2010,3,R-Respiratory system,Million of national currency units,459.6 +14770,Greece,2010,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",439.6 +14771,Greece,2010,3,M-Musculo-skeletal system,Million US$ at exchange rate,420.8 +14772,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",444.8 +14773,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,425.8 +14774,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",40.0 +14775,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",38.3 +14776,Greece,2010,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,67.5 +14777,Greece,2010,3,R-Respiratory system,Million US$ at exchange rate,609.3 +14778,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.4 +14779,Greece,2010,3,R-Respiratory system,"/capita, US$ exchange rate",54.8 +14780,Greece,2010,3,R-Respiratory system,"Million US$, purchasing power parity",636.5 +14781,Greece,2010,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,89.4 +14782,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.0 +14783,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",93.4 +14784,Greece,2010,3,G-Genito urinary system and sex hormones,Million of national currency units,211.3 +14785,Greece,2010,3,N-Nervous system,"/capita, US$ purchasing power parity",130.0 +14786,Greece,2010,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.6 +14787,Greece,2010,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,280.1 +14788,Greece,2010,3,N-Nervous system,Million US$ at exchange rate,1383.9 +14789,Greece,2010,3,N-Nervous system,"Million US$, purchasing power parity",1445.8 +14790,Greece,2010,3,N-Nervous system,"/capita, US$ exchange rate",124.4 +14791,Greece,2010,3,N-Nervous system,Million of national currency units,1043.9 +14792,Greece,2010,3,N06A-Antidepressants,"Million US$, purchasing power parity",258.4 +14793,Greece,2010,3,N06A-Antidepressants,"/capita, US$ exchange rate",22.2 +14794,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,321.2 +14795,Greece,2010,3,N06A-Antidepressants,Million of national currency units,186.6 +14796,Greece,2010,3,N06A-Antidepressants,Million US$ at exchange rate,247.4 +14797,Greece,2010,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3 +14798,Greece,2010,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.2 +14799,Greece,2010,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",23.2 +14800,Greece,2010,3,A10-Drugs used in diabetes,Million of national currency units,303.2 +14801,Greece,2010,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",43.6 +14802,Greece,2010,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",507.1 +14803,Greece,2010,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,485.4 +14804,Greece,2010,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.1 +14805,Greece,2010,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",45.6 +14806,Greece,2010,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.8 +14807,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,169.2 +14808,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",21.1 +14809,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6 +14810,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.1 +14811,Greece,2010,3,J01-Antibacterials for systemic use,Million of national currency units,366.1 +14812,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,224.2 +14813,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",20.2 +14814,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",234.3 +14815,Greece,2010,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",64.8 +14816,Greece,2010,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",67.7 +14817,Greece,2010,3,C10-Lipid modifying agents,Million US$ at exchange rate,720.2 +14818,Greece,2010,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",752.5 +14819,Greece,2010,3,R-Respiratory system,"/capita, US$ purchasing power parity",57.2 +14820,Greece,2010,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",37.8 +14821,Greece,2010,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",39.5 +14822,Greece,2010,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",419.9 +14823,Greece,2010,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.2 +14824,Greece,2010,3,A10-Drugs used in diabetes,Million US$ at exchange rate,401.9 +14825,Greece,2010,3,N05C-Hypnotics and sedatives,Million of national currency units,10.7 +14826,Greece,2010,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +14827,Greece,2010,3,C10-Lipid modifying agents,Million of national currency units,543.3 +14828,Greece,2010,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8 +14829,Greece,2010,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +14830,Greece,2010,3,C-Cardiovascular system,"Million US$, purchasing power parity",1974.4 +14831,Greece,2010,3,C-Cardiovascular system,"/capita, US$ exchange rate",169.9 +14832,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,539.5 +14833,Greece,2010,3,C-Cardiovascular system,Million of national currency units,1425.5 +14834,Greece,2010,3,C-Cardiovascular system,Million US$ at exchange rate,1889.8 +14835,Greece,2010,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.6 +14836,Greece,2010,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",177.5 +14837,Greece,2010,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +14838,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,715.2 +14839,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +14840,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +14841,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.6 +14842,Greece,2010,3,A-Alimentary tract and metabolism,Million of national currency units,856.0 +14843,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",64.3 +14844,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",747.1 +14845,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",67.2 +14846,Greece,2010,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1185.5 +14847,Greece,2010,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",102.0 +14848,Greece,2010,3,C07-Beta blocking agents,"/capita, US$ exchange rate",9.7 +14849,Greece,2010,3,A02A-Antacids,Million of national currency units,5.8 +14850,Greece,2010,3,C07-Beta blocking agents,Million of national currency units,81.2 +14851,Greece,2010,3,C07-Beta blocking agents,Million US$ at exchange rate,107.7 +14852,Greece,2010,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,1134.8 +14853,Greece,2010,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6 +14854,Greece,2010,3,C02-Antihypertensives,Million of national currency units,41.5 +14855,Greece,2010,3,C01A-Cardiac glycosides,Million of national currency units,1.2 +14856,Greece,2010,3,C07-Beta blocking agents,"Million US$, purchasing power parity",112.5 +14857,Greece,2010,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7 +14858,Greece,2010,3,C02-Antihypertensives,"Million US$, purchasing power parity",57.5 +14859,Greece,2010,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +14860,Greece,2010,3,C02-Antihypertensives,"/capita, US$ exchange rate",5.0 +14861,Greece,2010,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.2 +14862,Greece,2010,3,A02A-Antacids,"Million US$, purchasing power parity",8.0 +14863,Greece,2010,3,A02A-Antacids,Million US$ at exchange rate,7.7 +14864,Greece,2010,3,A02A-Antacids,"/capita, US$ exchange rate",0.7 +14865,Greece,2010,3,C02-Antihypertensives,Million US$ at exchange rate,55.1 +14866,Greece,2010,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14867,Greece,2010,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",106.6 +14868,Greece,2010,3,C03-Diuretics,"Million US$, purchasing power parity",50.8 +14869,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3 +14870,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.5 +14871,Greece,2010,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.1 +14872,Greece,2010,3,C03-Diuretics,Million of national currency units,36.7 +14873,Greece,2010,3,C03-Diuretics,Million US$ at exchange rate,48.7 +14874,Greece,2010,3,C08-Calcium channel blockers,Million of national currency units,94.3 +14875,Greece,2010,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.2 +14876,Greece,2010,3,C08-Calcium channel blockers,Million US$ at exchange rate,125.0 +14877,Greece,2010,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",130.6 +14878,Greece,2010,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",11.7 +14879,Greece,2010,3,C03-Diuretics,"/capita, US$ exchange rate",4.4 +14880,Greece,2017,3,N02-Analgesics,Million of national currency units,141.8 +14881,Greece,2017,3,N05B-Anxiolytics,Million of national currency units,22.2 +14882,Greece,2017,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6 +14883,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,64.2 +14884,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,72.5 +14885,Greece,2017,3,N05B-Anxiolytics,Million US$ at exchange rate,25.1 +14886,Greece,2017,3,N05B-Anxiolytics,"Million US$, purchasing power parity",38.7 +14887,Greece,2017,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3 +14888,Greece,2017,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.6 +14889,Greece,2017,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1135.8 +14890,Greece,2017,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",105.6 +14891,Greece,2017,3,R03-Drugs for obstructive airway diseases,Million of national currency units,267.2 +14892,Greece,2017,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,301.8 +14893,Greece,2017,3,N02-Analgesics,"/capita, US$ exchange rate",14.9 +14894,Greece,2017,3,N02-Analgesics,"/capita, US$ purchasing power parity",22.9 +14895,Greece,2017,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,737.8 +14896,Greece,2017,3,J-Antiinfectives for systemic use,Million of national currency units,653.1 +14897,Greece,2017,3,N02-Analgesics,"Million US$, purchasing power parity",246.7 +14898,Greece,2017,3,B-Blood and blood forming organs,Million US$ at exchange rate,1157.5 +14899,Greece,2017,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",165.7 +14900,Greece,2017,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",107.6 +14901,Greece,2017,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",1781.9 +14902,Greece,2017,3,N02-Analgesics,Million US$ at exchange rate,160.2 +14903,Greece,2017,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",464.6 +14904,Greece,2017,3,B-Blood and blood forming organs,Million of national currency units,1024.6 +14905,Greece,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",43.2 +14906,Greece,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.1 +14907,Greece,2017,3,M-Musculo-skeletal system,Million of national currency units,212.1 +14908,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.7 +14909,Greece,2017,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",368.9 +14910,Greece,2017,3,M-Musculo-skeletal system,Million US$ at exchange rate,239.6 +14911,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,172.3 +14912,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,152.5 +14913,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.0 +14914,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",265.3 +14915,Greece,2017,3,R-Respiratory system,Million of national currency units,410.4 +14916,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1 +14917,Greece,2017,3,R-Respiratory system,"Million US$, purchasing power parity",713.8 +14918,Greece,2017,3,R-Respiratory system,Million US$ at exchange rate,463.7 +14919,Greece,2017,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,42.9 +14920,Greece,2017,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,38.0 +14921,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0 +14922,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.1 +14923,Greece,2017,3,N-Nervous system,"/capita, US$ purchasing power parity",104.6 +14924,Greece,2017,3,G-Genito urinary system and sex hormones,Million of national currency units,166.8 +14925,Greece,2017,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,188.4 +14926,Greece,2017,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",290.0 +14927,Greece,2017,3,N-Nervous system,Million US$ at exchange rate,730.9 +14928,Greece,2017,3,N-Nervous system,Million of national currency units,647.0 +14929,Greece,2017,3,N-Nervous system,"/capita, US$ exchange rate",68.0 +14930,Greece,2017,3,N-Nervous system,"Million US$, purchasing power parity",1125.1 +14931,Greece,2017,3,N06A-Antidepressants,"Million US$, purchasing power parity",173.8 +14932,Greece,2017,3,N06A-Antidepressants,Million US$ at exchange rate,112.9 +14933,Greece,2017,3,N06A-Antidepressants,Million of national currency units,100.0 +14934,Greece,2017,3,N06A-Antidepressants,"/capita, US$ exchange rate",10.5 +14935,Greece,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.5 +14936,Greece,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.0 +14937,Greece,2017,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2 +14938,Greece,2017,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",393.3 +14939,Greece,2017,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8 +14940,Greece,2017,3,J01-Antibacterials for systemic use,Million of national currency units,226.2 +14941,Greece,2017,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,255.5 +14942,Greece,2017,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",710.7 +14943,Greece,2017,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",36.6 +14944,Greece,2017,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",66.1 +14945,Greece,2017,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",42.9 +14946,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.4 +14947,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",20.9 +14948,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",111.6 +14949,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7 +14950,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,146.0 +14951,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,129.2 +14952,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6 +14953,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",224.7 +14954,Greece,2017,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.8 +14955,Greece,2017,3,C10-Lipid modifying agents,Million US$ at exchange rate,352.4 +14956,Greece,2017,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.4 +14957,Greece,2017,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",542.4 +14958,Greece,2017,3,R-Respiratory system,"/capita, US$ purchasing power parity",66.4 +14959,Greece,2017,3,R-Respiratory system,"/capita, US$ exchange rate",43.1 +14960,Greece,2017,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.3 +14961,Greece,2017,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.3 +14962,Greece,2017,3,N05C-Hypnotics and sedatives,Million of national currency units,8.4 +14963,Greece,2017,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,9.5 +14964,Greece,2017,3,A10-Drugs used in diabetes,Million US$ at exchange rate,461.7 +14965,Greece,2017,3,A10-Drugs used in diabetes,Million of national currency units,408.7 +14966,Greece,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.4 +14967,Greece,2017,3,C10-Lipid modifying agents,Million of national currency units,311.9 +14968,Greece,2017,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6 +14969,Greece,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +14970,Greece,2017,3,C-Cardiovascular system,Million US$ at exchange rate,987.0 +14971,Greece,2017,3,C-Cardiovascular system,"Million US$, purchasing power parity",1519.4 +14972,Greece,2017,3,C-Cardiovascular system,"/capita, US$ exchange rate",91.8 +14973,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,334.4 +14974,Greece,2017,3,C-Cardiovascular system,Million of national currency units,873.7 +14975,Greece,2017,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +14976,Greece,2017,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.6 +14977,Greece,2017,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",141.3 +14978,Greece,2017,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +14979,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.2 +14980,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +14981,Greece,2017,3,C03-Diuretics,"/capita, US$ exchange rate",3.6 +14982,Greece,2017,3,A-Alimentary tract and metabolism,Million of national currency units,760.9 +14983,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.6 +14984,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",581.5 +14985,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,377.7 +14986,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +14987,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",54.1 +14988,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.1 +14989,Greece,2017,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,859.6 +14990,Greece,2017,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1323.2 +14991,Greece,2017,3,C07-Beta blocking agents,Million of national currency units,57.6 +14992,Greece,2017,3,C07-Beta blocking agents,"Million US$, purchasing power parity",100.1 +14993,Greece,2017,3,C02-Antihypertensives,Million of national currency units,24.9 +14994,Greece,2017,3,C01A-Cardiac glycosides,Million of national currency units,0.6 +14995,Greece,2017,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7 +14996,Greece,2017,3,C07-Beta blocking agents,Million US$ at exchange rate,65.0 +14997,Greece,2017,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.0 +14998,Greece,2017,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +14999,Greece,2017,3,C02-Antihypertensives,"Million US$, purchasing power parity",43.2 +15000,Greece,2017,3,C02-Antihypertensives,Million US$ at exchange rate,28.1 +15001,Greece,2017,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.0 +15002,Greece,2017,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +15003,Greece,2017,3,A02A-Antacids,Million US$ at exchange rate,5.0 +15004,Greece,2017,3,A02A-Antacids,Million of national currency units,4.4 +15005,Greece,2017,3,A02A-Antacids,"Million US$, purchasing power parity",7.6 +15006,Greece,2017,3,A02A-Antacids,"/capita, US$ exchange rate",0.5 +15007,Greece,2017,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9 +15008,Greece,2017,3,C03-Diuretics,"Million US$, purchasing power parity",60.3 +15009,Greece,2017,3,C03-Diuretics,Million US$ at exchange rate,39.2 +15010,Greece,2017,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9 +15011,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.6 +15012,Greece,2017,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.0 +15013,Greece,2017,3,C03-Diuretics,Million of national currency units,34.7 +15014,Greece,2017,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",123.0 +15015,Greece,2017,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.3 +15016,Greece,2017,3,C08-Calcium channel blockers,Million of national currency units,49.1 +15017,Greece,2017,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.5 +15018,Greece,2017,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",85.5 +15019,Greece,2017,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2 +15020,Hungary,2017,12,A-Alimentary tract and metabolism,Million of national currency units,78667.7 +15021,Hungary,2017,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.4 +15022,Hungary,2017,12,C10-Lipid modifying agents,% of total sales,3.9 +15023,Hungary,2017,12,A10-Drugs used in diabetes,Million US$ at exchange rate,182.3 +15024,Hungary,2017,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",367.8 +15025,Hungary,2017,12,A10-Drugs used in diabetes,Million of national currency units,50037.2 +15026,Hungary,2017,12,C03-Diuretics,"/capita, US$ exchange rate",1.7 +15027,Hungary,2017,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.4 +15028,Hungary,2017,12,C03-Diuretics,% of total sales,0.9 +15029,Hungary,2017,12,C03-Diuretics,Million US$ at exchange rate,16.6 +15030,Hungary,2017,12,C03-Diuretics,"Million US$, purchasing power parity",33.4 +15031,Hungary,2017,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",140.7 +15032,Hungary,2017,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",578.3 +15033,Hungary,2017,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,286.7 +15034,Hungary,2017,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.1 +15035,Hungary,2017,12,N06A-Antidepressants,% of total sales,1.6 +15036,Hungary,2017,12,C08-Calcium channel blockers,Million of national currency units,2649.1 +15037,Hungary,2017,12,N-Nervous system,"/capita, US$ purchasing power parity",44.9 +15038,Hungary,2017,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",19.5 +15039,Hungary,2017,12,C08-Calcium channel blockers,Million US$ at exchange rate,9.7 +15040,Hungary,2017,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.0 +15041,Hungary,2017,12,N06A-Antidepressants,Million US$ at exchange rate,29.2 +15042,Hungary,2017,12,N06A-Antidepressants,Million of national currency units,8013.6 +15043,Hungary,2017,12,N06A-Antidepressants,"/capita, US$ exchange rate",3.0 +15044,Hungary,2017,12,N06A-Antidepressants,"Million US$, purchasing power parity",58.9 +15045,Hungary,2017,12,A10-Drugs used in diabetes,% of total sales,10.1 +15046,Hungary,2017,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +15047,Hungary,2017,12,C01A-Cardiac glycosides,% of total sales,0.0 +15048,Hungary,2017,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.6 +15049,Hungary,2017,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.6 +15050,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +15051,Hungary,2017,12,N-Nervous system,% of total sales,12.1 +15052,Hungary,2017,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.0 +15053,Hungary,2017,12,C08-Calcium channel blockers,% of total sales,0.5 +15054,Hungary,2017,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0 +15055,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.1 +15056,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +15057,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1380.3 +15058,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0 +15059,Hungary,2017,12,A02A-Antacids,"/capita, US$ exchange rate",0.0 +15060,Hungary,2017,12,A02A-Antacids,"Million US$, purchasing power parity",0.0 +15061,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +15062,Hungary,2017,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +15063,Hungary,2017,12,A02A-Antacids,% of total sales,0.0 +15064,Hungary,2017,12,A-Alimentary tract and metabolism,% of total sales,16.0 +15065,Hungary,2017,12,R-Respiratory system,"/capita, US$ exchange rate",12.8 +15066,Hungary,2017,12,R-Respiratory system,"Million US$, purchasing power parity",253.6 +15067,Hungary,2017,12,N02-Analgesics,Million of national currency units,5346.6 +15068,Hungary,2017,12,R-Respiratory system,Million of national currency units,34496.8 +15069,Hungary,2017,12,R-Respiratory system,Million US$ at exchange rate,125.7 +15070,Hungary,2017,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",59.1 +15071,Hungary,2017,12,N02-Analgesics,Million US$ at exchange rate,19.5 +15072,Hungary,2017,12,R-Respiratory system,"/capita, US$ purchasing power parity",25.9 +15073,Hungary,2017,12,N02-Analgesics,"Million US$, purchasing power parity",39.3 +15074,Hungary,2017,12,R-Respiratory system,% of total sales,7.0 +15075,Hungary,2017,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",216.0 +15076,Hungary,2017,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +15077,Hungary,2017,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0 +15078,Hungary,2017,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.9 +15079,Hungary,2017,12,C01A-Cardiac glycosides,Million of national currency units,162.2 +15080,Hungary,2017,12,J-Antiinfectives for systemic use,Million of national currency units,29379.9 +15081,Hungary,2017,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.3 +15082,Hungary,2017,12,C03-Diuretics,Million of national currency units,4545.2 +15083,Hungary,2017,12,A02A-Antacids,Million US$ at exchange rate,0.0 +15084,Hungary,2017,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,107.1 +15085,Hungary,2017,12,A02A-Antacids,Million of national currency units,0.0 +15086,Hungary,2017,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",22.1 +15087,Hungary,2017,12,N02-Analgesics,"/capita, US$ exchange rate",2.0 +15088,Hungary,2017,12,J-Antiinfectives for systemic use,% of total sales,6.0 +15089,Hungary,2017,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +15090,Hungary,2017,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2 +15091,Hungary,2017,12,M-Musculo-skeletal system,% of total sales,3.6 +15092,Hungary,2017,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",130.3 +15093,Hungary,2017,12,M-Musculo-skeletal system,Million of national currency units,17723.5 +15094,Hungary,2017,12,M-Musculo-skeletal system,Million US$ at exchange rate,64.6 +15095,Hungary,2017,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.3 +15096,Hungary,2017,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.6 +15097,Hungary,2017,12,N05C-Hypnotics and sedatives,% of total sales,0.0 +15098,Hungary,2017,12,C07-Beta blocking agents,% of total sales,2.0 +15099,Hungary,2017,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4 +15100,Hungary,2017,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +15101,Hungary,2017,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +15102,Hungary,2017,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +15103,Hungary,2017,12,C07-Beta blocking agents,Million US$ at exchange rate,35.9 +15104,Hungary,2017,12,C07-Beta blocking agents,"Million US$, purchasing power parity",72.4 +15105,Hungary,2017,12,C07-Beta blocking agents,Million of national currency units,9854.4 +15106,Hungary,2017,12,N05B-Anxiolytics,Million of national currency units,2831.3 +15107,Hungary,2017,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.7 +15108,Hungary,2017,12,N05B-Anxiolytics,Million US$ at exchange rate,10.3 +15109,Hungary,2017,12,C02-Antihypertensives,% of total sales,2.0 +15110,Hungary,2017,12,N05C-Hypnotics and sedatives,Million of national currency units,1.0 +15111,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.6 +15112,Hungary,2017,12,N02-Analgesics,% of total sales,1.1 +15113,Hungary,2017,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.4 +15114,Hungary,2017,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29875.7 +15115,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.4 +15116,Hungary,2017,12,R03-Drugs for obstructive airway diseases,% of total sales,6.1 +15117,Hungary,2017,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +15118,Hungary,2017,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,108.9 +15119,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.1 +15120,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",219.6 +15121,Hungary,2017,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",87.7 +15122,Hungary,2017,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",9.0 +15123,Hungary,2017,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.4 +15124,Hungary,2017,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,43.5 +15125,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.3 +15126,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +15127,Hungary,2017,12,G-Genito urinary system and sex hormones,Million of national currency units,11937.0 +15128,Hungary,2017,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3624.2 +15129,Hungary,2017,12,Total pharmaceutical sales,Million US$ at exchange rate,1796.5 +15130,Hungary,2017,12,Total pharmaceutical sales,Million of national currency units,493022.1 +15131,Hungary,2017,12,G-Genito urinary system and sex hormones,% of total sales,2.4 +15132,Hungary,2017,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.3 +15133,Hungary,2017,12,Total pharmaceutical sales,"/capita, US$ exchange rate",183.5 +15134,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,20.5 +15135,Hungary,2017,12,N05B-Anxiolytics,"Million US$, purchasing power parity",20.8 +15136,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5629.9 +15137,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2 +15138,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.4 +15139,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.1 +15140,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,20.9 +15141,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1 +15142,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.2 +15143,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,5743.2 +15144,Hungary,2017,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.1 +15145,Hungary,2017,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +15146,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1 +15147,Hungary,2017,12,N05B-Anxiolytics,% of total sales,0.6 +15148,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.0 +15149,Hungary,2017,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",93.5 +15150,Hungary,2017,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,46.3 +15151,Hungary,2017,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.7 +15152,Hungary,2017,12,J01-Antibacterials for systemic use,% of total sales,2.6 +15153,Hungary,2017,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5 +15154,Hungary,2017,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",370.0 +15155,Hungary,2017,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.7 +15156,Hungary,2017,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.8 +15157,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +15158,Hungary,2017,12,J01-Antibacterials for systemic use,Million of national currency units,12714.9 +15159,Hungary,2017,12,B-Blood and blood forming organs,Million of national currency units,50338.2 +15160,Hungary,2017,12,B-Blood and blood forming organs,Million US$ at exchange rate,183.4 +15161,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,39.7 +15162,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",80.2 +15163,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10907.7 +15164,Hungary,2017,12,C10-Lipid modifying agents,Million US$ at exchange rate,69.7 +15165,Hungary,2017,12,C10-Lipid modifying agents,Million of national currency units,19139.1 +15166,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.1 +15167,Hungary,2017,12,N-Nervous system,Million of national currency units,59790.5 +15168,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.2 +15169,Hungary,2017,12,N-Nervous system,Million US$ at exchange rate,217.9 +15170,Hungary,2017,12,N-Nervous system,"/capita, US$ exchange rate",22.3 +15171,Hungary,2017,12,N-Nervous system,"Million US$, purchasing power parity",439.5 +15172,Hungary,2017,12,C-Cardiovascular system,"Million US$, purchasing power parity",683.4 +15173,Hungary,2017,12,C-Cardiovascular system,Million US$ at exchange rate,338.8 +15174,Hungary,2017,12,C-Cardiovascular system,% of total sales,18.9 +15175,Hungary,2017,12,C-Cardiovascular system,"/capita, US$ exchange rate",34.6 +15176,Hungary,2017,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.8 +15177,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",274.2 +15178,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.9 +15179,Hungary,2017,12,C-Cardiovascular system,Million of national currency units,92973.4 +15180,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,37305.6 +15181,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,135.9 +15182,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.6 +15183,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.3 +15184,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8825.9 +15185,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8 +15186,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,32.2 +15187,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.9 +15188,Hungary,2017,12,C02-Antihypertensives,Million of national currency units,9804.7 +15189,Hungary,2017,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.7 +15190,Hungary,2017,12,B-Blood and blood forming organs,% of total sales,10.2 +15191,Hungary,2017,12,C02-Antihypertensives,Million US$ at exchange rate,35.7 +15192,Hungary,2017,12,C02-Antihypertensives,"Million US$, purchasing power parity",72.1 +15193,Hungary,2016,12,A-Alimentary tract and metabolism,Million of national currency units,73066.7 +15194,Hungary,2016,12,C10-Lipid modifying agents,% of total sales,3.8 +15195,Hungary,2016,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.7 +15196,Hungary,2016,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",342.9 +15197,Hungary,2016,12,A10-Drugs used in diabetes,Million US$ at exchange rate,160.8 +15198,Hungary,2016,12,A10-Drugs used in diabetes,Million of national currency units,45267.9 +15199,Hungary,2016,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.5 +15200,Hungary,2016,12,C03-Diuretics,% of total sales,0.9 +15201,Hungary,2016,12,C03-Diuretics,"/capita, US$ exchange rate",1.6 +15202,Hungary,2016,12,C03-Diuretics,Million US$ at exchange rate,16.1 +15203,Hungary,2016,12,C03-Diuretics,"Million US$, purchasing power parity",34.3 +15204,Hungary,2016,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",553.4 +15205,Hungary,2016,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,259.5 +15206,Hungary,2016,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.9 +15207,Hungary,2016,12,C08-Calcium channel blockers,Million of national currency units,2787.9 +15208,Hungary,2016,12,N-Nervous system,"/capita, US$ purchasing power parity",46.1 +15209,Hungary,2016,12,N06A-Antidepressants,% of total sales,1.6 +15210,Hungary,2016,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.1 +15211,Hungary,2016,12,C08-Calcium channel blockers,Million US$ at exchange rate,9.9 +15212,Hungary,2016,12,N06A-Antidepressants,Million US$ at exchange rate,28.6 +15213,Hungary,2016,12,N06A-Antidepressants,Million of national currency units,8047.7 +15214,Hungary,2016,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.2 +15215,Hungary,2016,12,N06A-Antidepressants,"/capita, US$ exchange rate",2.9 +15216,Hungary,2016,12,N06A-Antidepressants,"Million US$, purchasing power parity",61.0 +15217,Hungary,2016,12,A10-Drugs used in diabetes,% of total sales,9.1 +15218,Hungary,2016,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +15219,Hungary,2016,12,C01A-Cardiac glycosides,% of total sales,0.0 +15220,Hungary,2016,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.4 +15221,Hungary,2016,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",34.9 +15222,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +15223,Hungary,2016,12,N-Nervous system,% of total sales,12.0 +15224,Hungary,2016,12,C08-Calcium channel blockers,% of total sales,0.6 +15225,Hungary,2016,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.2 +15226,Hungary,2016,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.0 +15227,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.5 +15228,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +15229,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9 +15230,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1384.4 +15231,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +15232,Hungary,2016,12,A02A-Antacids,"/capita, US$ exchange rate",0.0 +15233,Hungary,2016,12,A02A-Antacids,"Million US$, purchasing power parity",0.0 +15234,Hungary,2016,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +15235,Hungary,2016,12,A02A-Antacids,% of total sales,0.0 +15236,Hungary,2016,12,N02-Analgesics,"Million US$, purchasing power parity",39.7 +15237,Hungary,2016,12,A-Alimentary tract and metabolism,% of total sales,14.6 +15238,Hungary,2016,12,R-Respiratory system,"Million US$, purchasing power parity",258.8 +15239,Hungary,2016,12,R-Respiratory system,"/capita, US$ exchange rate",12.4 +15240,Hungary,2016,12,N02-Analgesics,Million of national currency units,5247.3 +15241,Hungary,2016,12,R-Respiratory system,Million of national currency units,34173.3 +15242,Hungary,2016,12,R-Respiratory system,Million US$ at exchange rate,121.4 +15243,Hungary,2016,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4 +15244,Hungary,2016,12,N02-Analgesics,Million US$ at exchange rate,18.6 +15245,Hungary,2016,12,R-Respiratory system,"/capita, US$ purchasing power parity",26.4 +15246,Hungary,2016,12,R-Respiratory system,% of total sales,6.9 +15247,Hungary,2016,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",297.0 +15248,Hungary,2016,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +15249,Hungary,2016,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.3 +15250,Hungary,2016,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.2 +15251,Hungary,2016,12,J-Antiinfectives for systemic use,Million of national currency units,39211.2 +15252,Hungary,2016,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.4 +15253,Hungary,2016,12,C03-Diuretics,Million of national currency units,4527.3 +15254,Hungary,2016,12,C01A-Cardiac glycosides,Million of national currency units,174.1 +15255,Hungary,2016,12,A02A-Antacids,Million US$ at exchange rate,0.0 +15256,Hungary,2016,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,139.3 +15257,Hungary,2016,12,A02A-Antacids,Million of national currency units,0.0 +15258,Hungary,2016,12,N02-Analgesics,"/capita, US$ exchange rate",1.9 +15259,Hungary,2016,12,J-Antiinfectives for systemic use,% of total sales,7.9 +15260,Hungary,2016,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",144.1 +15261,Hungary,2016,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0 +15262,Hungary,2016,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +15263,Hungary,2016,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.3 +15264,Hungary,2016,12,M-Musculo-skeletal system,% of total sales,3.5 +15265,Hungary,2016,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",133.8 +15266,Hungary,2016,12,M-Musculo-skeletal system,Million US$ at exchange rate,62.7 +15267,Hungary,2016,12,M-Musculo-skeletal system,Million of national currency units,17665.2 +15268,Hungary,2016,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.6 +15269,Hungary,2016,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.4 +15270,Hungary,2016,12,N05C-Hypnotics and sedatives,% of total sales,0.0 +15271,Hungary,2016,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6 +15272,Hungary,2016,12,C07-Beta blocking agents,% of total sales,2.0 +15273,Hungary,2016,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +15274,Hungary,2016,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +15275,Hungary,2016,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +15276,Hungary,2016,12,C07-Beta blocking agents,Million US$ at exchange rate,34.8 +15277,Hungary,2016,12,C07-Beta blocking agents,"Million US$, purchasing power parity",74.2 +15278,Hungary,2016,12,C07-Beta blocking agents,Million of national currency units,9800.0 +15279,Hungary,2016,12,N05B-Anxiolytics,Million of national currency units,2872.5 +15280,Hungary,2016,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5 +15281,Hungary,2016,12,N05B-Anxiolytics,Million US$ at exchange rate,10.2 +15282,Hungary,2016,12,C02-Antihypertensives,% of total sales,1.9 +15283,Hungary,2016,12,N05C-Hypnotics and sedatives,Million of national currency units,0.9 +15284,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.3 +15285,Hungary,2016,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.2 +15286,Hungary,2016,12,N02-Analgesics,% of total sales,1.1 +15287,Hungary,2016,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29620.8 +15288,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9 +15289,Hungary,2016,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +15290,Hungary,2016,12,R03-Drugs for obstructive airway diseases,% of total sales,5.9 +15291,Hungary,2016,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,105.2 +15292,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",10.7 +15293,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",224.3 +15294,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1 +15295,Hungary,2016,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",85.2 +15296,Hungary,2016,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.7 +15297,Hungary,2016,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1 +15298,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.2 +15299,Hungary,2016,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,40.0 +15300,Hungary,2016,12,G-Genito urinary system and sex hormones,Million of national currency units,11251.9 +15301,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.1 +15302,Hungary,2016,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3778.3 +15303,Hungary,2016,12,Total pharmaceutical sales,Million US$ at exchange rate,1772.0 +15304,Hungary,2016,12,Total pharmaceutical sales,Million of national currency units,498866.9 +15305,Hungary,2016,12,G-Genito urinary system and sex hormones,% of total sales,2.3 +15306,Hungary,2016,12,Total pharmaceutical sales,"/capita, US$ exchange rate",180.6 +15307,Hungary,2016,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",385.0 +15308,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,19.9 +15309,Hungary,2016,12,N05B-Anxiolytics,"Million US$, purchasing power parity",21.8 +15310,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5595.1 +15311,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",42.4 +15312,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.3 +15313,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.0 +15314,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3 +15315,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0 +15316,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.1 +15317,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,5426.8 +15318,Hungary,2016,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +15319,Hungary,2016,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0 +15320,Hungary,2016,12,N05B-Anxiolytics,% of total sales,0.6 +15321,Hungary,2016,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",97.4 +15322,Hungary,2016,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,45.7 +15323,Hungary,2016,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.7 +15324,Hungary,2016,12,J01-Antibacterials for systemic use,% of total sales,2.6 +15325,Hungary,2016,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9 +15326,Hungary,2016,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",402.8 +15327,Hungary,2016,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.3 +15328,Hungary,2016,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.0 +15329,Hungary,2016,12,B-Blood and blood forming organs,Million of national currency units,53187.8 +15330,Hungary,2016,12,J01-Antibacterials for systemic use,Million of national currency units,12865.7 +15331,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.1 +15332,Hungary,2016,12,B-Blood and blood forming organs,Million US$ at exchange rate,188.9 +15333,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +15334,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,37.7 +15335,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",80.4 +15336,Hungary,2016,12,C10-Lipid modifying agents,Million US$ at exchange rate,67.6 +15337,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10611.0 +15338,Hungary,2016,12,C10-Lipid modifying agents,Million of national currency units,19032.0 +15339,Hungary,2016,12,N-Nervous system,Million of national currency units,59756.4 +15340,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.2 +15341,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8 +15342,Hungary,2016,12,N-Nervous system,"/capita, US$ exchange rate",21.6 +15343,Hungary,2016,12,N-Nervous system,Million US$ at exchange rate,212.3 +15344,Hungary,2016,12,N-Nervous system,"Million US$, purchasing power parity",452.6 +15345,Hungary,2016,12,C-Cardiovascular system,"Million US$, purchasing power parity",698.1 +15346,Hungary,2016,12,C-Cardiovascular system,Million US$ at exchange rate,327.4 +15347,Hungary,2016,12,C-Cardiovascular system,"/capita, US$ exchange rate",33.4 +15348,Hungary,2016,12,C-Cardiovascular system,% of total sales,18.5 +15349,Hungary,2016,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.1 +15350,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",275.7 +15351,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.2 +15352,Hungary,2016,12,C-Cardiovascular system,Million of national currency units,92167.6 +15353,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,36400.5 +15354,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,129.3 +15355,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.6 +15356,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1 +15357,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8548.3 +15358,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7 +15359,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,30.4 +15360,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.7 +15361,Hungary,2016,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.4 +15362,Hungary,2016,12,B-Blood and blood forming organs,% of total sales,10.7 +15363,Hungary,2016,12,C02-Antihypertensives,Million US$ at exchange rate,33.1 +15364,Hungary,2016,12,C02-Antihypertensives,Million of national currency units,9311.8 +15365,Hungary,2016,12,C02-Antihypertensives,"Million US$, purchasing power parity",70.5 +15366,Hungary,2015,12,C10-Lipid modifying agents,% of total sales,4.1 +15367,Hungary,2015,12,A-Alimentary tract and metabolism,Million of national currency units,67533.0 +15368,Hungary,2015,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",305.9 +15369,Hungary,2015,12,A10-Drugs used in diabetes,Million US$ at exchange rate,145.2 +15370,Hungary,2015,12,A10-Drugs used in diabetes,Million of national currency units,40546.0 +15371,Hungary,2015,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.4 +15372,Hungary,2015,12,C03-Diuretics,% of total sales,1.0 +15373,Hungary,2015,12,C03-Diuretics,Million US$ at exchange rate,16.1 +15374,Hungary,2015,12,C03-Diuretics,"/capita, US$ exchange rate",1.6 +15375,Hungary,2015,12,C03-Diuretics,"Million US$, purchasing power parity",33.9 +15376,Hungary,2015,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",509.5 +15377,Hungary,2015,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,241.8 +15378,Hungary,2015,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.9 +15379,Hungary,2015,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.5 +15380,Hungary,2015,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.7 +15381,Hungary,2015,12,C08-Calcium channel blockers,Million of national currency units,2946.5 +15382,Hungary,2015,12,N-Nervous system,"/capita, US$ purchasing power parity",46.7 +15383,Hungary,2015,12,N06A-Antidepressants,% of total sales,2.0 +15384,Hungary,2015,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2 +15385,Hungary,2015,12,C08-Calcium channel blockers,Million US$ at exchange rate,10.5 +15386,Hungary,2015,12,N06A-Antidepressants,Million US$ at exchange rate,33.7 +15387,Hungary,2015,12,N06A-Antidepressants,Million of national currency units,9404.9 +15388,Hungary,2015,12,N06A-Antidepressants,"Million US$, purchasing power parity",71.0 +15389,Hungary,2015,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.2 +15390,Hungary,2015,12,N06A-Antidepressants,"/capita, US$ exchange rate",3.4 +15391,Hungary,2015,12,A10-Drugs used in diabetes,% of total sales,8.7 +15392,Hungary,2015,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +15393,Hungary,2015,12,C01A-Cardiac glycosides,% of total sales,0.0 +15394,Hungary,2015,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.1 +15395,Hungary,2015,12,N-Nervous system,% of total sales,13.1 +15396,Hungary,2015,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.1 +15397,Hungary,2015,12,C08-Calcium channel blockers,% of total sales,0.6 +15398,Hungary,2015,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +15399,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.5 +15400,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +15401,Hungary,2015,12,N02-Analgesics,"/capita, US$ exchange rate",1.9 +15402,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1391.1 +15403,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0 +15404,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +15405,Hungary,2015,12,A02A-Antacids,"/capita, US$ exchange rate",0.0 +15406,Hungary,2015,12,A02A-Antacids,"Million US$, purchasing power parity",0.0 +15407,Hungary,2015,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +15408,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +15409,Hungary,2015,12,A02A-Antacids,% of total sales,0.0 +15410,Hungary,2015,12,A-Alimentary tract and metabolism,% of total sales,14.5 +15411,Hungary,2015,12,R-Respiratory system,"Million US$, purchasing power parity",252.8 +15412,Hungary,2015,12,R-Respiratory system,"/capita, US$ exchange rate",12.2 +15413,Hungary,2015,12,N02-Analgesics,Million of national currency units,5270.6 +15414,Hungary,2015,12,R-Respiratory system,Million of national currency units,33515.8 +15415,Hungary,2015,12,R-Respiratory system,Million US$ at exchange rate,120.0 +15416,Hungary,2015,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.8 +15417,Hungary,2015,12,N02-Analgesics,Million US$ at exchange rate,18.9 +15418,Hungary,2015,12,N02-Analgesics,"Million US$, purchasing power parity",39.8 +15419,Hungary,2015,12,R-Respiratory system,"/capita, US$ purchasing power parity",25.7 +15420,Hungary,2015,12,R-Respiratory system,% of total sales,7.2 +15421,Hungary,2015,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",236.2 +15422,Hungary,2015,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7 +15423,Hungary,2015,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.0 +15424,Hungary,2015,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.4 +15425,Hungary,2015,12,J-Antiinfectives for systemic use,Million of national currency units,31313.2 +15426,Hungary,2015,12,C03-Diuretics,Million of national currency units,4496.7 +15427,Hungary,2015,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.6 +15428,Hungary,2015,12,C01A-Cardiac glycosides,Million of national currency units,188.4 +15429,Hungary,2015,12,A02A-Antacids,Million US$ at exchange rate,0.0 +15430,Hungary,2015,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,112.1 +15431,Hungary,2015,12,A02A-Antacids,Million of national currency units,0.0 +15432,Hungary,2015,12,M-Musculo-skeletal system,Million of national currency units,17492.2 +15433,Hungary,2015,12,J-Antiinfectives for systemic use,% of total sales,6.7 +15434,Hungary,2015,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0 +15435,Hungary,2015,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +15436,Hungary,2015,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +15437,Hungary,2015,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.0 +15438,Hungary,2015,12,M-Musculo-skeletal system,Million US$ at exchange rate,62.6 +15439,Hungary,2015,12,M-Musculo-skeletal system,% of total sales,3.8 +15440,Hungary,2015,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.4 +15441,Hungary,2015,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.4 +15442,Hungary,2015,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",142.8 +15443,Hungary,2015,12,G-Genito urinary system and sex hormones,Million of national currency units,10463.8 +15444,Hungary,2015,12,N05C-Hypnotics and sedatives,% of total sales,0.0 +15445,Hungary,2015,12,C07-Beta blocking agents,% of total sales,2.1 +15446,Hungary,2015,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5 +15447,Hungary,2015,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +15448,Hungary,2015,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +15449,Hungary,2015,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +15450,Hungary,2015,12,C07-Beta blocking agents,Million US$ at exchange rate,34.9 +15451,Hungary,2015,12,C07-Beta blocking agents,"Million US$, purchasing power parity",73.5 +15452,Hungary,2015,12,C07-Beta blocking agents,Million of national currency units,9746.0 +15453,Hungary,2015,12,N05B-Anxiolytics,Million of national currency units,2888.3 +15454,Hungary,2015,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5 +15455,Hungary,2015,12,N05B-Anxiolytics,Million US$ at exchange rate,10.3 +15456,Hungary,2015,12,N05B-Anxiolytics,"Million US$, purchasing power parity",21.8 +15457,Hungary,2015,12,C02-Antihypertensives,% of total sales,1.9 +15458,Hungary,2015,12,N05C-Hypnotics and sedatives,Million of national currency units,1.1 +15459,Hungary,2015,12,R03-Drugs for obstructive airway diseases,Million of national currency units,28986.7 +15460,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.5 +15461,Hungary,2015,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.6 +15462,Hungary,2015,12,N02-Analgesics,% of total sales,1.1 +15463,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2 +15464,Hungary,2015,12,R03-Drugs for obstructive airway diseases,% of total sales,6.2 +15465,Hungary,2015,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +15466,Hungary,2015,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,103.8 +15467,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",10.5 +15468,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",218.7 +15469,Hungary,2015,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",78.9 +15470,Hungary,2015,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.0 +15471,Hungary,2015,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8 +15472,Hungary,2015,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,37.5 +15473,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8 +15474,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.1 +15475,Hungary,2015,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3518.7 +15476,Hungary,2015,12,Total pharmaceutical sales,Million of national currency units,466411.6 +15477,Hungary,2015,12,Total pharmaceutical sales,Million US$ at exchange rate,1669.7 +15478,Hungary,2015,12,G-Genito urinary system and sex hormones,% of total sales,2.2 +15479,Hungary,2015,12,Total pharmaceutical sales,"/capita, US$ exchange rate",169.6 +15480,Hungary,2015,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",357.5 +15481,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,19.8 +15482,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5542.3 +15483,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2 +15484,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +15485,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.8 +15486,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.0 +15487,Hungary,2015,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1 +15488,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.7 +15489,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.8 +15490,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",37.4 +15491,Hungary,2015,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +15492,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4957.9 +15493,Hungary,2015,12,N05B-Anxiolytics,% of total sales,0.6 +15494,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.0 +15495,Hungary,2015,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.3 +15496,Hungary,2015,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.9 +15497,Hungary,2015,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,48.6 +15498,Hungary,2015,12,J01-Antibacterials for systemic use,% of total sales,2.9 +15499,Hungary,2015,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4 +15500,Hungary,2015,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6 +15501,Hungary,2015,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",364.9 +15502,Hungary,2015,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.1 +15503,Hungary,2015,12,B-Blood and blood forming organs,Million of national currency units,48375.2 +15504,Hungary,2015,12,J01-Antibacterials for systemic use,Million of national currency units,13565.6 +15505,Hungary,2015,12,B-Blood and blood forming organs,Million US$ at exchange rate,173.2 +15506,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +15507,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,35.7 +15508,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",75.2 +15509,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9969.4 +15510,Hungary,2015,12,C10-Lipid modifying agents,Million US$ at exchange rate,67.8 +15511,Hungary,2015,12,C10-Lipid modifying agents,Million of national currency units,18929.3 +15512,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.6 +15513,Hungary,2015,12,N-Nervous system,Million of national currency units,60933.7 +15514,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6 +15515,Hungary,2015,12,N-Nervous system,Million US$ at exchange rate,218.1 +15516,Hungary,2015,12,N-Nervous system,"Million US$, purchasing power parity",459.7 +15517,Hungary,2015,12,C-Cardiovascular system,"Million US$, purchasing power parity",683.3 +15518,Hungary,2015,12,C-Cardiovascular system,Million US$ at exchange rate,324.3 +15519,Hungary,2015,12,C-Cardiovascular system,"/capita, US$ exchange rate",32.9 +15520,Hungary,2015,12,C-Cardiovascular system,% of total sales,19.4 +15521,Hungary,2015,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.4 +15522,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",265.3 +15523,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.8 +15524,Hungary,2015,12,C-Cardiovascular system,Million of national currency units,90577.6 +15525,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35167.2 +15526,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,125.9 +15527,Hungary,2015,12,N-Nervous system,"/capita, US$ exchange rate",22.2 +15528,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",67.2 +15529,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.8 +15530,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2 +15531,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9 +15532,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,31.9 +15533,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8905.5 +15534,Hungary,2015,12,C02-Antihypertensives,Million of national currency units,8633.8 +15535,Hungary,2015,12,C02-Antihypertensives,Million US$ at exchange rate,30.9 +15536,Hungary,2015,12,B-Blood and blood forming organs,% of total sales,10.4 +15537,Hungary,2015,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.1 +15538,Hungary,2015,12,C02-Antihypertensives,"Million US$, purchasing power parity",65.1 +15539,Hungary,2014,12,C10-Lipid modifying agents,% of total sales,4.5 +15540,Hungary,2014,12,A-Alimentary tract and metabolism,Million of national currency units,64320.4 +15541,Hungary,2014,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",297.4 +15542,Hungary,2014,12,A10-Drugs used in diabetes,Million US$ at exchange rate,165.5 +15543,Hungary,2014,12,A10-Drugs used in diabetes,Million of national currency units,38486.2 +15544,Hungary,2014,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.5 +15545,Hungary,2014,12,C03-Diuretics,% of total sales,1.0 +15546,Hungary,2014,12,C03-Diuretics,"/capita, US$ exchange rate",2.0 +15547,Hungary,2014,12,C03-Diuretics,"Million US$, purchasing power parity",34.8 +15548,Hungary,2014,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.0 +15549,Hungary,2014,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",497.0 +15550,Hungary,2014,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,276.5 +15551,Hungary,2014,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6 +15552,Hungary,2014,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.5 +15553,Hungary,2014,12,A02A-Antacids,Million of national currency units,0.0 +15554,Hungary,2014,12,C08-Calcium channel blockers,Million of national currency units,3109.2 +15555,Hungary,2014,12,N-Nervous system,"/capita, US$ purchasing power parity",46.8 +15556,Hungary,2014,12,N06A-Antidepressants,% of total sales,2.4 +15557,Hungary,2014,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",24.0 +15558,Hungary,2014,12,C08-Calcium channel blockers,Million US$ at exchange rate,13.4 +15559,Hungary,2014,12,N06A-Antidepressants,Million US$ at exchange rate,45.1 +15560,Hungary,2014,12,N06A-Antidepressants,Million of national currency units,10500.3 +15561,Hungary,2014,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.2 +15562,Hungary,2014,12,N06A-Antidepressants,"/capita, US$ exchange rate",4.6 +15563,Hungary,2014,12,N06A-Antidepressants,"Million US$, purchasing power parity",81.1 +15564,Hungary,2014,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +15565,Hungary,2014,12,C01A-Cardiac glycosides,% of total sales,0.0 +15566,Hungary,2014,12,C03-Diuretics,Million US$ at exchange rate,19.4 +15567,Hungary,2014,12,A10-Drugs used in diabetes,% of total sales,8.7 +15568,Hungary,2014,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8 +15569,Hungary,2014,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.1 +15570,Hungary,2014,12,N-Nervous system,% of total sales,13.5 +15571,Hungary,2014,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4 +15572,Hungary,2014,12,C08-Calcium channel blockers,% of total sales,0.7 +15573,Hungary,2014,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4 +15574,Hungary,2014,12,J-Antiinfectives for systemic use,Million of national currency units,26838.3 +15575,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.9 +15576,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +15577,Hungary,2014,12,N02-Analgesics,"/capita, US$ exchange rate",2.3 +15578,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1405.0 +15579,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.0 +15580,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +15581,Hungary,2014,12,A02A-Antacids,"/capita, US$ exchange rate",0.0 +15582,Hungary,2014,12,A02A-Antacids,"Million US$, purchasing power parity",0.0 +15583,Hungary,2014,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +15584,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +15585,Hungary,2014,12,A02A-Antacids,% of total sales,0.0 +15586,Hungary,2014,12,A-Alimentary tract and metabolism,% of total sales,14.5 +15587,Hungary,2014,12,R-Respiratory system,"Million US$, purchasing power parity",264.3 +15588,Hungary,2014,12,R-Respiratory system,"/capita, US$ exchange rate",14.9 +15589,Hungary,2014,12,R-Respiratory system,Million of national currency units,34198.5 +15590,Hungary,2014,12,R-Respiratory system,Million US$ at exchange rate,147.0 +15591,Hungary,2014,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.4 +15592,Hungary,2014,12,N02-Analgesics,"Million US$, purchasing power parity",41.0 +15593,Hungary,2014,12,N02-Analgesics,Million US$ at exchange rate,22.8 +15594,Hungary,2014,12,R-Respiratory system,"/capita, US$ purchasing power parity",26.8 +15595,Hungary,2014,12,N02-Analgesics,Million of national currency units,5304.8 +15596,Hungary,2014,12,R-Respiratory system,% of total sales,7.7 +15597,Hungary,2014,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",207.4 +15598,Hungary,2014,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9 +15599,Hungary,2014,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.0 +15600,Hungary,2014,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.7 +15601,Hungary,2014,12,C03-Diuretics,Million of national currency units,4504.9 +15602,Hungary,2014,12,C01A-Cardiac glycosides,Million of national currency units,204.0 +15603,Hungary,2014,12,A02A-Antacids,Million US$ at exchange rate,0.0 +15604,Hungary,2014,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,115.4 +15605,Hungary,2014,12,J-Antiinfectives for systemic use,% of total sales,6.1 +15606,Hungary,2014,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2 +15607,Hungary,2014,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +15608,Hungary,2014,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +15609,Hungary,2014,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.2 +15610,Hungary,2014,12,M-Musculo-skeletal system,Million US$ at exchange rate,76.3 +15611,Hungary,2014,12,M-Musculo-skeletal system,% of total sales,4.0 +15612,Hungary,2014,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9 +15613,Hungary,2014,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.7 +15614,Hungary,2014,12,M-Musculo-skeletal system,Million of national currency units,17751.8 +15615,Hungary,2014,12,G-Genito urinary system and sex hormones,Million of national currency units,9549.9 +15616,Hungary,2014,12,N05C-Hypnotics and sedatives,% of total sales,0.0 +15617,Hungary,2014,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6 +15618,Hungary,2014,12,C07-Beta blocking agents,% of total sales,2.2 +15619,Hungary,2014,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +15620,Hungary,2014,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +15621,Hungary,2014,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +15622,Hungary,2014,12,C07-Beta blocking agents,"Million US$, purchasing power parity",75.1 +15623,Hungary,2014,12,C07-Beta blocking agents,Million US$ at exchange rate,41.8 +15624,Hungary,2014,12,C07-Beta blocking agents,Million of national currency units,9722.1 +15625,Hungary,2014,12,N05B-Anxiolytics,Million of national currency units,2958.9 +15626,Hungary,2014,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2 +15627,Hungary,2014,12,N05B-Anxiolytics,"Million US$, purchasing power parity",22.9 +15628,Hungary,2014,12,N05B-Anxiolytics,Million US$ at exchange rate,12.7 +15629,Hungary,2014,12,C02-Antihypertensives,% of total sales,1.8 +15630,Hungary,2014,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29679.1 +15631,Hungary,2014,12,N05C-Hypnotics and sedatives,Million of national currency units,1.1 +15632,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8 +15633,Hungary,2014,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3 +15634,Hungary,2014,12,N02-Analgesics,% of total sales,1.2 +15635,Hungary,2014,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",153.2 +15636,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.2 +15637,Hungary,2014,12,R03-Drugs for obstructive airway diseases,% of total sales,6.7 +15638,Hungary,2014,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +15639,Hungary,2014,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,127.6 +15640,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",12.9 +15641,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",229.3 +15642,Hungary,2014,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",73.8 +15643,Hungary,2014,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.5 +15644,Hungary,2014,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.2 +15645,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4 +15646,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +15647,Hungary,2014,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,41.1 +15648,Hungary,2014,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3422.7 +15649,Hungary,2014,12,Total pharmaceutical sales,Million US$ at exchange rate,1904.3 +15650,Hungary,2014,12,Total pharmaceutical sales,Million of national currency units,442945.7 +15651,Hungary,2014,12,G-Genito urinary system and sex hormones,% of total sales,2.2 +15652,Hungary,2014,12,Total pharmaceutical sales,"/capita, US$ exchange rate",193.0 +15653,Hungary,2014,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",346.9 +15654,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.9 +15655,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5568.3 +15656,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",43.0 +15657,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.4 +15658,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3 +15659,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.4 +15660,Hungary,2014,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +15661,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.6 +15662,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",33.4 +15663,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9 +15664,Hungary,2014,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +15665,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4324.3 +15666,Hungary,2014,12,N05B-Anxiolytics,% of total sales,0.7 +15667,Hungary,2014,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.3 +15668,Hungary,2014,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8 +15669,Hungary,2014,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,56.9 +15670,Hungary,2014,12,J01-Antibacterials for systemic use,% of total sales,3.0 +15671,Hungary,2014,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4 +15672,Hungary,2014,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.0 +15673,Hungary,2014,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",337.4 +15674,Hungary,2014,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.2 +15675,Hungary,2014,12,B-Blood and blood forming organs,Million of national currency units,43658.2 +15676,Hungary,2014,12,J01-Antibacterials for systemic use,Million of national currency units,13239.1 +15677,Hungary,2014,12,B-Blood and blood forming organs,Million US$ at exchange rate,187.7 +15678,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +15679,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,38.9 +15680,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.0 +15681,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9 +15682,Hungary,2014,12,C10-Lipid modifying agents,Million US$ at exchange rate,85.3 +15683,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9057.8 +15684,Hungary,2014,12,C10-Lipid modifying agents,Million of national currency units,19830.2 +15685,Hungary,2014,12,N-Nervous system,Million of national currency units,59797.2 +15686,Hungary,2014,12,N-Nervous system,Million US$ at exchange rate,257.1 +15687,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.1 +15688,Hungary,2014,12,N-Nervous system,"/capita, US$ exchange rate",26.1 +15689,Hungary,2014,12,N-Nervous system,"Million US$, purchasing power parity",462.1 +15690,Hungary,2014,12,C-Cardiovascular system,"/capita, US$ exchange rate",39.5 +15691,Hungary,2014,12,C-Cardiovascular system,"Million US$, purchasing power parity",700.4 +15692,Hungary,2014,12,C-Cardiovascular system,Million US$ at exchange rate,389.7 +15693,Hungary,2014,12,C-Cardiovascular system,% of total sales,20.5 +15694,Hungary,2014,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.0 +15695,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",265.4 +15696,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",26.9 +15697,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.0 +15698,Hungary,2014,12,C-Cardiovascular system,Million of national currency units,90647.4 +15699,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34341.3 +15700,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,147.6 +15701,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.9 +15702,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8814.9 +15703,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0 +15704,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.8 +15705,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,37.9 +15706,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.1 +15707,Hungary,2014,12,C02-Antihypertensives,Million US$ at exchange rate,34.8 +15708,Hungary,2014,12,C02-Antihypertensives,Million of national currency units,8102.4 +15709,Hungary,2014,12,B-Blood and blood forming organs,% of total sales,9.9 +15710,Hungary,2014,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.5 +15711,Hungary,2014,12,C02-Antihypertensives,"Million US$, purchasing power parity",62.6 +15712,Hungary,2013,12,C10-Lipid modifying agents,% of total sales,5.3 +15713,Hungary,2013,12,A-Alimentary tract and metabolism,Million of national currency units,60613.7 +15714,Hungary,2013,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",284.5 +15715,Hungary,2013,12,A10-Drugs used in diabetes,Million US$ at exchange rate,159.0 +15716,Hungary,2013,12,A10-Drugs used in diabetes,Million of national currency units,35559.7 +15717,Hungary,2013,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,271.0 +15718,Hungary,2013,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.8 +15719,Hungary,2013,12,C03-Diuretics,% of total sales,1.1 +15720,Hungary,2013,12,C03-Diuretics,"Million US$, purchasing power parity",37.1 +15721,Hungary,2013,12,C03-Diuretics,"/capita, US$ exchange rate",2.1 +15722,Hungary,2013,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.4 +15723,Hungary,2013,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",485.0 +15724,Hungary,2013,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.3 +15725,Hungary,2013,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.5 +15726,Hungary,2013,12,A02A-Antacids,Million of national currency units,0.0 +15727,Hungary,2013,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.1 +15728,Hungary,2013,12,C08-Calcium channel blockers,Million of national currency units,3769.8 +15729,Hungary,2013,12,N-Nervous system,"/capita, US$ purchasing power parity",47.6 +15730,Hungary,2013,12,N06A-Antidepressants,% of total sales,2.5 +15731,Hungary,2013,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",30.2 +15732,Hungary,2013,12,C08-Calcium channel blockers,Million US$ at exchange rate,16.9 +15733,Hungary,2013,12,N06A-Antidepressants,Million US$ at exchange rate,47.9 +15734,Hungary,2013,12,N06A-Antidepressants,"Million US$, purchasing power parity",85.8 +15735,Hungary,2013,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.7 +15736,Hungary,2013,12,N06A-Antidepressants,"/capita, US$ exchange rate",4.8 +15737,Hungary,2013,12,C01A-Cardiac glycosides,% of total sales,0.1 +15738,Hungary,2013,12,N06A-Antidepressants,Million of national currency units,10723.6 +15739,Hungary,2013,12,A10-Drugs used in diabetes,% of total sales,8.3 +15740,Hungary,2013,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.8 +15741,Hungary,2013,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +15742,Hungary,2013,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.7 +15743,Hungary,2013,12,N-Nervous system,% of total sales,13.7 +15744,Hungary,2013,12,C08-Calcium channel blockers,% of total sales,0.9 +15745,Hungary,2013,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0 +15746,Hungary,2013,12,C03-Diuretics,Million US$ at exchange rate,20.8 +15747,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3 +15748,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +15749,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +15750,Hungary,2013,12,N02-Analgesics,"/capita, US$ exchange rate",2.4 +15751,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1406.9 +15752,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.3 +15753,Hungary,2013,12,A02A-Antacids,"/capita, US$ exchange rate",0.0 +15754,Hungary,2013,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +15755,Hungary,2013,12,A02A-Antacids,"Million US$, purchasing power parity",0.0 +15756,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +15757,Hungary,2013,12,A02A-Antacids,% of total sales,0.0 +15758,Hungary,2013,12,A-Alimentary tract and metabolism,% of total sales,14.1 +15759,Hungary,2013,12,R-Respiratory system,"Million US$, purchasing power parity",274.3 +15760,Hungary,2013,12,R-Respiratory system,"/capita, US$ exchange rate",15.5 +15761,Hungary,2013,12,R-Respiratory system,Million of national currency units,34278.8 +15762,Hungary,2013,12,R-Respiratory system,Million US$ at exchange rate,153.2 +15763,Hungary,2013,12,N02-Analgesics,Million US$ at exchange rate,23.4 +15764,Hungary,2013,12,N02-Analgesics,"Million US$, purchasing power parity",41.8 +15765,Hungary,2013,12,R-Respiratory system,"/capita, US$ purchasing power parity",27.7 +15766,Hungary,2013,12,R-Respiratory system,% of total sales,8.0 +15767,Hungary,2013,12,N02-Analgesics,Million of national currency units,5228.6 +15768,Hungary,2013,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",192.7 +15769,Hungary,2013,12,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0 +15770,Hungary,2013,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.9 +15771,Hungary,2013,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5 +15772,Hungary,2013,12,J-Antiinfectives for systemic use,Million of national currency units,24081.3 +15773,Hungary,2013,12,C03-Diuretics,Million of national currency units,4641.7 +15774,Hungary,2013,12,C01A-Cardiac glycosides,Million of national currency units,219.9 +15775,Hungary,2013,12,A02A-Antacids,Million US$ at exchange rate,0.0 +15776,Hungary,2013,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,107.7 +15777,Hungary,2013,12,M-Musculo-skeletal system,Million of national currency units,18632.7 +15778,Hungary,2013,12,J-Antiinfectives for systemic use,% of total sales,5.6 +15779,Hungary,2013,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2 +15780,Hungary,2013,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +15781,Hungary,2013,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8 +15782,Hungary,2013,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",149.1 +15783,Hungary,2013,12,M-Musculo-skeletal system,Million US$ at exchange rate,83.3 +15784,Hungary,2013,12,M-Musculo-skeletal system,% of total sales,4.3 +15785,Hungary,2013,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1 +15786,Hungary,2013,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4 +15787,Hungary,2013,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0 +15788,Hungary,2013,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",182.7 +15789,Hungary,2013,12,G-Genito urinary system and sex hormones,Million of national currency units,9141.6 +15790,Hungary,2013,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1 +15791,Hungary,2013,12,C07-Beta blocking agents,% of total sales,2.3 +15792,Hungary,2013,12,N05C-Hypnotics and sedatives,% of total sales,0.0 +15793,Hungary,2013,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +15794,Hungary,2013,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +15795,Hungary,2013,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +15796,Hungary,2013,12,C07-Beta blocking agents,"Million US$, purchasing power parity",79.6 +15797,Hungary,2013,12,C07-Beta blocking agents,Million US$ at exchange rate,44.5 +15798,Hungary,2013,12,C07-Beta blocking agents,Million of national currency units,9953.6 +15799,Hungary,2013,12,N05B-Anxiolytics,Million US$ at exchange rate,13.3 +15800,Hungary,2013,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5 +15801,Hungary,2013,12,N05B-Anxiolytics,"Million US$, purchasing power parity",23.8 +15802,Hungary,2013,12,N02-Analgesics,% of total sales,1.2 +15803,Hungary,2013,12,C02-Antihypertensives,% of total sales,1.8 +15804,Hungary,2013,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29536.7 +15805,Hungary,2013,12,N05C-Hypnotics and sedatives,Million of national currency units,0.8 +15806,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.2 +15807,Hungary,2013,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.1 +15808,Hungary,2013,12,R03-Drugs for obstructive airway diseases,% of total sales,6.9 +15809,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9 +15810,Hungary,2013,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +15811,Hungary,2013,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,132.0 +15812,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.3 +15813,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3 +15814,Hungary,2013,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",73.1 +15815,Hungary,2013,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1 +15816,Hungary,2013,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.4 +15817,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.0 +15818,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3 +15819,Hungary,2013,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,40.9 +15820,Hungary,2013,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3441.9 +15821,Hungary,2013,12,Total pharmaceutical sales,Million of national currency units,430163.5 +15822,Hungary,2013,12,Total pharmaceutical sales,Million US$ at exchange rate,1923.0 +15823,Hungary,2013,12,G-Genito urinary system and sex hormones,% of total sales,2.1 +15824,Hungary,2013,12,Total pharmaceutical sales,"/capita, US$ exchange rate",194.4 +15825,Hungary,2013,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",347.9 +15826,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.5 +15827,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",42.0 +15828,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5250.0 +15829,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2 +15830,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +15831,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.4 +15832,Hungary,2013,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +15833,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.4 +15834,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9 +15835,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",32.9 +15836,Hungary,2013,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +15837,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4108.8 +15838,Hungary,2013,12,N05B-Anxiolytics,% of total sales,0.7 +15839,Hungary,2013,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8 +15840,Hungary,2013,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",103.5 +15841,Hungary,2013,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.8 +15842,Hungary,2013,12,J01-Antibacterials for systemic use,% of total sales,3.0 +15843,Hungary,2013,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.5 +15844,Hungary,2013,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6 +15845,Hungary,2013,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.8 +15846,Hungary,2013,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.5 +15847,Hungary,2013,12,B-Blood and blood forming organs,Million of national currency units,38973.8 +15848,Hungary,2013,12,J01-Antibacterials for systemic use,Million of national currency units,12938.1 +15849,Hungary,2013,12,B-Blood and blood forming organs,Million US$ at exchange rate,174.2 +15850,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,37.1 +15851,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8 +15852,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.5 +15853,Hungary,2013,12,C10-Lipid modifying agents,Million US$ at exchange rate,102.1 +15854,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8307.2 +15855,Hungary,2013,12,C10-Lipid modifying agents,Million of national currency units,22838.1 +15856,Hungary,2013,12,N-Nervous system,Million of national currency units,58867.3 +15857,Hungary,2013,12,N-Nervous system,Million US$ at exchange rate,263.2 +15858,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +15859,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.7 +15860,Hungary,2013,12,N-Nervous system,"/capita, US$ exchange rate",26.6 +15861,Hungary,2013,12,N-Nervous system,"Million US$, purchasing power parity",471.0 +15862,Hungary,2013,12,C-Cardiovascular system,"/capita, US$ exchange rate",43.1 +15863,Hungary,2013,12,C-Cardiovascular system,"Million US$, purchasing power parity",763.3 +15864,Hungary,2013,12,C-Cardiovascular system,Million US$ at exchange rate,426.5 +15865,Hungary,2013,12,C-Cardiovascular system,% of total sales,22.2 +15866,Hungary,2013,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.2 +15867,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",281.9 +15868,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.9 +15869,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.5 +15870,Hungary,2013,12,C-Cardiovascular system,Million of national currency units,95396.2 +15871,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35227.6 +15872,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,157.5 +15873,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.3 +15874,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,9057.7 +15875,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.1 +15876,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",4.1 +15877,Hungary,2013,12,N05B-Anxiolytics,Million of national currency units,2974.6 +15878,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.5 +15879,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",72.5 +15880,Hungary,2013,12,C02-Antihypertensives,Million US$ at exchange rate,33.9 +15881,Hungary,2013,12,B-Blood and blood forming organs,% of total sales,9.1 +15882,Hungary,2013,12,C02-Antihypertensives,Million of national currency units,7583.8 +15883,Hungary,2013,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.4 +15884,Hungary,2013,12,C02-Antihypertensives,"Million US$, purchasing power parity",60.7 +15885,Hungary,2012,12,A-Alimentary tract and metabolism,Million of national currency units,64446.7 +15886,Hungary,2012,12,C10-Lipid modifying agents,% of total sales,6.3 +15887,Hungary,2012,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",273.7 +15888,Hungary,2012,12,A10-Drugs used in diabetes,Million of national currency units,34389.1 +15889,Hungary,2012,12,A10-Drugs used in diabetes,Million US$ at exchange rate,152.8 +15890,Hungary,2012,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +15891,Hungary,2012,12,C03-Diuretics,% of total sales,1.1 +15892,Hungary,2012,12,C03-Diuretics,"Million US$, purchasing power parity",38.5 +15893,Hungary,2012,12,C03-Diuretics,"/capita, US$ exchange rate",2.2 +15894,Hungary,2012,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9 +15895,Hungary,2012,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",513.0 +15896,Hungary,2012,12,A02A-Antacids,Million of national currency units,0.0 +15897,Hungary,2012,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.5 +15898,Hungary,2012,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.4 +15899,Hungary,2012,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,286.3 +15900,Hungary,2012,12,N-Nervous system,"/capita, US$ purchasing power parity",47.0 +15901,Hungary,2012,12,N06A-Antidepressants,% of total sales,2.5 +15902,Hungary,2012,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",44.0 +15903,Hungary,2012,12,C08-Calcium channel blockers,Million US$ at exchange rate,24.6 +15904,Hungary,2012,12,C08-Calcium channel blockers,Million of national currency units,5530.2 +15905,Hungary,2012,12,N06A-Antidepressants,Million US$ at exchange rate,49.2 +15906,Hungary,2012,12,N06A-Antidepressants,"Million US$, purchasing power parity",88.1 +15907,Hungary,2012,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.9 +15908,Hungary,2012,12,N06A-Antidepressants,"/capita, US$ exchange rate",5.0 +15909,Hungary,2012,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.4 +15910,Hungary,2012,12,C01A-Cardiac glycosides,% of total sales,0.1 +15911,Hungary,2012,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",27.6 +15912,Hungary,2012,12,N06A-Antidepressants,Million of national currency units,11070.4 +15913,Hungary,2012,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +15914,Hungary,2012,12,A10-Drugs used in diabetes,% of total sales,7.7 +15915,Hungary,2012,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5 +15916,Hungary,2012,12,N-Nervous system,% of total sales,13.2 +15917,Hungary,2012,12,C08-Calcium channel blockers,% of total sales,1.2 +15918,Hungary,2012,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4 +15919,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.4 +15920,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +15921,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1 +15922,Hungary,2012,12,N02-Analgesics,"/capita, US$ exchange rate",2.4 +15923,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1427.3 +15924,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.3 +15925,Hungary,2012,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +15926,Hungary,2012,12,A02A-Antacids,"/capita, US$ exchange rate",0.0 +15927,Hungary,2012,12,A02A-Antacids,"Million US$, purchasing power parity",0.0 +15928,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +15929,Hungary,2012,12,A02A-Antacids,% of total sales,0.0 +15930,Hungary,2012,12,A-Alimentary tract and metabolism,% of total sales,14.5 +15931,Hungary,2012,12,R-Respiratory system,"Million US$, purchasing power parity",268.8 +15932,Hungary,2012,12,R-Respiratory system,"/capita, US$ exchange rate",15.1 +15933,Hungary,2012,12,R-Respiratory system,Million of national currency units,33762.7 +15934,Hungary,2012,12,R-Respiratory system,Million US$ at exchange rate,150.0 +15935,Hungary,2012,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.7 +15936,Hungary,2012,12,N02-Analgesics,Million US$ at exchange rate,23.4 +15937,Hungary,2012,12,N02-Analgesics,"Million US$, purchasing power parity",42.0 +15938,Hungary,2012,12,R-Respiratory system,"/capita, US$ purchasing power parity",27.1 +15939,Hungary,2012,12,R-Respiratory system,% of total sales,7.6 +15940,Hungary,2012,12,N02-Analgesics,Million of national currency units,5276.2 +15941,Hungary,2012,12,C03-Diuretics,Million US$ at exchange rate,21.5 +15942,Hungary,2012,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",169.0 +15943,Hungary,2012,12,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0 +15944,Hungary,2012,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.0 +15945,Hungary,2012,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.5 +15946,Hungary,2012,12,J-Antiinfectives for systemic use,Million of national currency units,21233.6 +15947,Hungary,2012,12,C03-Diuretics,Million of national currency units,4833.0 +15948,Hungary,2012,12,C01A-Cardiac glycosides,Million of national currency units,234.3 +15949,Hungary,2012,12,A02A-Antacids,Million US$ at exchange rate,0.0 +15950,Hungary,2012,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,94.3 +15951,Hungary,2012,12,M-Musculo-skeletal system,Million of national currency units,19341.8 +15952,Hungary,2012,12,J-Antiinfectives for systemic use,% of total sales,4.8 +15953,Hungary,2012,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2 +15954,Hungary,2012,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +15955,Hungary,2012,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9 +15956,Hungary,2012,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",154.0 +15957,Hungary,2012,12,M-Musculo-skeletal system,Million US$ at exchange rate,85.9 +15958,Hungary,2012,12,M-Musculo-skeletal system,% of total sales,4.4 +15959,Hungary,2012,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5 +15960,Hungary,2012,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.7 +15961,Hungary,2012,12,G-Genito urinary system and sex hormones,Million of national currency units,8098.7 +15962,Hungary,2012,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3 +15963,Hungary,2012,12,C07-Beta blocking agents,% of total sales,2.3 +15964,Hungary,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +15965,Hungary,2012,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +15966,Hungary,2012,12,N05C-Hypnotics and sedatives,% of total sales,0.0 +15967,Hungary,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +15968,Hungary,2012,12,C07-Beta blocking agents,"Million US$, purchasing power parity",82.6 +15969,Hungary,2012,12,C07-Beta blocking agents,Million of national currency units,10376.8 +15970,Hungary,2012,12,C07-Beta blocking agents,Million US$ at exchange rate,46.1 +15971,Hungary,2012,12,N05B-Anxiolytics,Million US$ at exchange rate,13.1 +15972,Hungary,2012,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6 +15973,Hungary,2012,12,N05B-Anxiolytics,"Million US$, purchasing power parity",23.5 +15974,Hungary,2012,12,N02-Analgesics,% of total sales,1.2 +15975,Hungary,2012,12,C02-Antihypertensives,% of total sales,1.7 +15976,Hungary,2012,12,R03-Drugs for obstructive airway diseases,Million of national currency units,28440.2 +15977,Hungary,2012,12,N05C-Hypnotics and sedatives,Million of national currency units,0.5 +15978,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.5 +15979,Hungary,2012,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.9 +15980,Hungary,2012,12,R03-Drugs for obstructive airway diseases,% of total sales,6.4 +15981,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8 +15982,Hungary,2012,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +15983,Hungary,2012,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,126.3 +15984,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",226.4 +15985,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",12.7 +15986,Hungary,2012,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",64.5 +15987,Hungary,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.5 +15988,Hungary,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.6 +15989,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,% of total sales,0.8 +15990,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.7 +15991,Hungary,2012,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,36.0 +15992,Hungary,2012,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3538.7 +15993,Hungary,2012,12,Total pharmaceutical sales,Million of national currency units,444548.6 +15994,Hungary,2012,12,Total pharmaceutical sales,Million US$ at exchange rate,1974.9 +15995,Hungary,2012,12,Total pharmaceutical sales,"/capita, US$ exchange rate",199.1 +15996,Hungary,2012,12,G-Genito urinary system and sex hormones,% of total sales,1.8 +15997,Hungary,2012,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",356.7 +15998,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.0 +15999,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.2 +16000,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5181.6 +16001,Hungary,2012,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +16002,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2 +16003,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +16004,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.3 +16005,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,15.2 +16006,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",27.3 +16007,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.5 +16008,Hungary,2012,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +16009,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,3423.8 +16010,Hungary,2012,12,N05B-Anxiolytics,% of total sales,0.7 +16011,Hungary,2012,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8 +16012,Hungary,2012,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.9 +16013,Hungary,2012,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.4 +16014,Hungary,2012,12,J01-Antibacterials for systemic use,% of total sales,2.9 +16015,Hungary,2012,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4 +16016,Hungary,2012,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.5 +16017,Hungary,2012,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.4 +16018,Hungary,2012,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.0 +16019,Hungary,2012,12,B-Blood and blood forming organs,Million of national currency units,39070.0 +16020,Hungary,2012,12,J01-Antibacterials for systemic use,Million of national currency units,12925.5 +16021,Hungary,2012,12,B-Blood and blood forming organs,Million US$ at exchange rate,173.6 +16022,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,36.4 +16023,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7 +16024,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.2 +16025,Hungary,2012,12,C10-Lipid modifying agents,Million US$ at exchange rate,124.2 +16026,Hungary,2012,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",222.6 +16027,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8192.9 +16028,Hungary,2012,12,C10-Lipid modifying agents,Million of national currency units,27959.9 +16029,Hungary,2012,12,N-Nervous system,Million of national currency units,58615.1 +16030,Hungary,2012,12,N-Nervous system,Million US$ at exchange rate,260.4 +16031,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +16032,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6 +16033,Hungary,2012,12,N-Nervous system,"/capita, US$ exchange rate",26.2 +16034,Hungary,2012,12,N-Nervous system,"Million US$, purchasing power parity",466.6 +16035,Hungary,2012,12,B-Blood and blood forming organs,% of total sales,8.8 +16036,Hungary,2012,12,C-Cardiovascular system,"/capita, US$ exchange rate",47.4 +16037,Hungary,2012,12,C-Cardiovascular system,"Million US$, purchasing power parity",843.0 +16038,Hungary,2012,12,C-Cardiovascular system,Million US$ at exchange rate,470.4 +16039,Hungary,2012,12,C-Cardiovascular system,% of total sales,23.8 +16040,Hungary,2012,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.0 +16041,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",302.3 +16042,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",17.0 +16043,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.5 +16044,Hungary,2012,12,C-Cardiovascular system,Million of national currency units,105895.0 +16045,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,37976.3 +16046,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,168.7 +16047,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.2 +16048,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,12740.4 +16049,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9 +16050,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7 +16051,Hungary,2012,12,N05B-Anxiolytics,Million of national currency units,2947.0 +16052,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,56.6 +16053,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",101.4 +16054,Hungary,2012,12,C02-Antihypertensives,Million US$ at exchange rate,32.8 +16055,Hungary,2012,12,C02-Antihypertensives,Million of national currency units,7380.4 +16056,Hungary,2012,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.3 +16057,Hungary,2012,12,C02-Antihypertensives,"Million US$, purchasing power parity",58.8 +16058,Hungary,2010,13,A-Alimentary tract and metabolism,Million of national currency units,64095.7 +16059,Hungary,2010,13,C10-Lipid modifying agents,% of total sales,7.5 +16060,Hungary,2010,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",241.8 +16061,Hungary,2010,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,308.2 +16062,Hungary,2010,13,A10-Drugs used in diabetes,Million of national currency units,30573.8 +16063,Hungary,2010,13,A10-Drugs used in diabetes,Million US$ at exchange rate,147.0 +16064,Hungary,2010,13,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +16065,Hungary,2010,13,C03-Diuretics,% of total sales,0.9 +16066,Hungary,2010,13,C03-Diuretics,"Million US$, purchasing power parity",36.7 +16067,Hungary,2010,13,C03-Diuretics,"/capita, US$ exchange rate",2.2 +16068,Hungary,2010,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.8 +16069,Hungary,2010,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",507.0 +16070,Hungary,2010,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.7 +16071,Hungary,2010,13,A02A-Antacids,Million of national currency units,0.0 +16072,Hungary,2010,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.9 +16073,Hungary,2010,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.4 +16074,Hungary,2010,13,N-Nervous system,"/capita, US$ purchasing power parity",49.1 +16075,Hungary,2010,13,N06A-Antidepressants,% of total sales,2.4 +16076,Hungary,2010,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",55.1 +16077,Hungary,2010,13,C08-Calcium channel blockers,Million US$ at exchange rate,33.5 +16078,Hungary,2010,13,N06A-Antidepressants,"Million US$, purchasing power parity",94.5 +16079,Hungary,2010,13,N06A-Antidepressants,Million US$ at exchange rate,57.5 +16080,Hungary,2010,13,C08-Calcium channel blockers,Million of national currency units,6967.9 +16081,Hungary,2010,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.5 +16082,Hungary,2010,13,N06A-Antidepressants,"/capita, US$ exchange rate",5.7 +16083,Hungary,2010,13,C01A-Cardiac glycosides,% of total sales,0.1 +16084,Hungary,2010,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.2 +16085,Hungary,2010,13,N06A-Antidepressants,Million of national currency units,11947.1 +16086,Hungary,2010,13,A10-Drugs used in diabetes,% of total sales,6.1 +16087,Hungary,2010,13,N-Nervous system,% of total sales,12.5 +16088,Hungary,2010,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4 +16089,Hungary,2010,13,C08-Calcium channel blockers,% of total sales,1.4 +16090,Hungary,2010,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5 +16091,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.0 +16092,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +16093,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +16094,Hungary,2010,13,N02-Analgesics,"/capita, US$ exchange rate",2.6 +16095,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1511.2 +16096,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3 +16097,Hungary,2010,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +16098,Hungary,2010,13,A02A-Antacids,"Million US$, purchasing power parity",0.0 +16099,Hungary,2010,13,A02A-Antacids,"/capita, US$ exchange rate",0.0 +16100,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +16101,Hungary,2010,13,A02A-Antacids,% of total sales,0.0 +16102,Hungary,2010,13,R-Respiratory system,"Million US$, purchasing power parity",269.1 +16103,Hungary,2010,13,R-Respiratory system,"/capita, US$ exchange rate",16.4 +16104,Hungary,2010,13,R-Respiratory system,Million of national currency units,34020.0 +16105,Hungary,2010,13,R-Respiratory system,Million US$ at exchange rate,163.6 +16106,Hungary,2010,13,N02-Analgesics,Million US$ at exchange rate,25.8 +16107,Hungary,2010,13,N02-Analgesics,"Million US$, purchasing power parity",42.4 +16108,Hungary,2010,13,A-Alimentary tract and metabolism,% of total sales,12.9 +16109,Hungary,2010,13,R-Respiratory system,"/capita, US$ purchasing power parity",26.9 +16110,Hungary,2010,13,R-Respiratory system,% of total sales,6.8 +16111,Hungary,2010,13,N02-Analgesics,Million of national currency units,5356.6 +16112,Hungary,2010,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",175.0 +16113,Hungary,2010,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.2 +16114,Hungary,2010,13,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3 +16115,Hungary,2010,13,M-Musculo-skeletal system,Million of national currency units,22271.6 +16116,Hungary,2010,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.7 +16117,Hungary,2010,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.6 +16118,Hungary,2010,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.5 +16119,Hungary,2010,13,J-Antiinfectives for systemic use,Million of national currency units,22127.8 +16120,Hungary,2010,13,C03-Diuretics,Million of national currency units,4641.1 +16121,Hungary,2010,13,C03-Diuretics,Million US$ at exchange rate,22.3 +16122,Hungary,2010,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,106.4 +16123,Hungary,2010,13,C01A-Cardiac glycosides,Million of national currency units,279.1 +16124,Hungary,2010,13,A02A-Antacids,Million US$ at exchange rate,0.0 +16125,Hungary,2010,13,J-Antiinfectives for systemic use,% of total sales,4.4 +16126,Hungary,2010,13,N02-Analgesics,"/capita, US$ purchasing power parity",4.2 +16127,Hungary,2010,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +16128,Hungary,2010,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +16129,Hungary,2010,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",176.2 +16130,Hungary,2010,13,M-Musculo-skeletal system,Million US$ at exchange rate,107.1 +16131,Hungary,2010,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.7 +16132,Hungary,2010,13,M-Musculo-skeletal system,% of total sales,4.5 +16133,Hungary,2010,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.6 +16134,Hungary,2010,13,G-Genito urinary system and sex hormones,Million of national currency units,7875.0 +16135,Hungary,2010,13,C07-Beta blocking agents,% of total sales,2.4 +16136,Hungary,2010,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.5 +16137,Hungary,2010,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +16138,Hungary,2010,13,N05C-Hypnotics and sedatives,% of total sales,0.0 +16139,Hungary,2010,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +16140,Hungary,2010,13,C07-Beta blocking agents,"Million US$, purchasing power parity",95.5 +16141,Hungary,2010,13,C07-Beta blocking agents,Million of national currency units,12071.4 +16142,Hungary,2010,13,C07-Beta blocking agents,Million US$ at exchange rate,58.1 +16143,Hungary,2010,13,N05B-Anxiolytics,Million US$ at exchange rate,14.0 +16144,Hungary,2010,13,C07-Beta blocking agents,"/capita, US$ exchange rate",5.8 +16145,Hungary,2010,13,N05B-Anxiolytics,"Million US$, purchasing power parity",23.0 +16146,Hungary,2010,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.1 +16147,Hungary,2010,13,N02-Analgesics,% of total sales,1.1 +16148,Hungary,2010,13,C02-Antihypertensives,% of total sales,1.5 +16149,Hungary,2010,13,R03-Drugs for obstructive airway diseases,Million of national currency units,27620.8 +16150,Hungary,2010,13,N05C-Hypnotics and sedatives,Million of national currency units,9.8 +16151,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.7 +16152,Hungary,2010,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.8 +16153,Hungary,2010,13,R03-Drugs for obstructive airway diseases,% of total sales,5.5 +16154,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.8 +16155,Hungary,2010,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +16156,Hungary,2010,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,132.8 +16157,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",218.5 +16158,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3 +16159,Hungary,2010,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",62.3 +16160,Hungary,2010,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8 +16161,Hungary,2010,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.2 +16162,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,% of total sales,0.7 +16163,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.7 +16164,Hungary,2010,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,37.9 +16165,Hungary,2010,13,Total pharmaceutical sales,"Million US$, purchasing power parity",3940.5 +16166,Hungary,2010,13,Total pharmaceutical sales,Million of national currency units,498140.3 +16167,Hungary,2010,13,Total pharmaceutical sales,Million US$ at exchange rate,2395.5 +16168,Hungary,2010,13,Total pharmaceutical sales,"/capita, US$ exchange rate",239.6 +16169,Hungary,2010,13,G-Genito urinary system and sex hormones,% of total sales,1.6 +16170,Hungary,2010,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",394.0 +16171,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,31.0 +16172,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.0 +16173,Hungary,2010,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +16174,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6442.7 +16175,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3 +16176,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1 +16177,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.1 +16178,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",26.5 +16179,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,16.1 +16180,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.6 +16181,Hungary,2010,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +16182,Hungary,2010,13,N05B-Anxiolytics,% of total sales,0.6 +16183,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,3352.5 +16184,Hungary,2010,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.9 +16185,Hungary,2010,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.0 +16186,Hungary,2010,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",113.4 +16187,Hungary,2010,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3 +16188,Hungary,2010,13,J01-Antibacterials for systemic use,% of total sales,2.9 +16189,Hungary,2010,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.9 +16190,Hungary,2010,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.1 +16191,Hungary,2010,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.2 +16192,Hungary,2010,13,B-Blood and blood forming organs,Million of national currency units,39342.1 +16193,Hungary,2010,13,J01-Antibacterials for systemic use,Million of national currency units,14338.6 +16194,Hungary,2010,13,B-Blood and blood forming organs,Million US$ at exchange rate,189.2 +16195,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,33.4 +16196,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3 +16197,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",54.9 +16198,Hungary,2010,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",294.2 +16199,Hungary,2010,13,C10-Lipid modifying agents,Million US$ at exchange rate,178.8 +16200,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6945.0 +16201,Hungary,2010,13,C10-Lipid modifying agents,Million of national currency units,37190.0 +16202,Hungary,2010,13,N-Nervous system,Million US$ at exchange rate,298.7 +16203,Hungary,2010,13,N-Nervous system,Million of national currency units,62105.9 +16204,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +16205,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.5 +16206,Hungary,2010,13,N-Nervous system,"/capita, US$ exchange rate",29.9 +16207,Hungary,2010,13,N-Nervous system,"Million US$, purchasing power parity",491.3 +16208,Hungary,2010,13,B-Blood and blood forming organs,% of total sales,7.9 +16209,Hungary,2010,13,C-Cardiovascular system,"/capita, US$ exchange rate",62.5 +16210,Hungary,2010,13,C-Cardiovascular system,Million US$ at exchange rate,625.1 +16211,Hungary,2010,13,C-Cardiovascular system,"Million US$, purchasing power parity",1028.2 +16212,Hungary,2010,13,C-Cardiovascular system,% of total sales,26.1 +16213,Hungary,2010,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.8 +16214,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",380.3 +16215,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.1 +16216,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",38.0 +16217,Hungary,2010,13,C-Cardiovascular system,Million of national currency units,129978.7 +16218,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,48076.5 +16219,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,231.2 +16220,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.8 +16221,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8 +16222,Hungary,2010,13,N05B-Anxiolytics,Million of national currency units,2903.2 +16223,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,89.9 +16224,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.0 +16225,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",147.8 +16226,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,18687.7 +16227,Hungary,2010,13,C02-Antihypertensives,Million US$ at exchange rate,35.3 +16228,Hungary,2010,13,C02-Antihypertensives,Million of national currency units,7338.5 +16229,Hungary,2010,13,C02-Antihypertensives,"/capita, US$ exchange rate",3.5 +16230,Hungary,2010,13,C02-Antihypertensives,"Million US$, purchasing power parity",58.0 +16231,Hungary,2011,13,A-Alimentary tract and metabolism,Million of national currency units,68963.5 +16232,Hungary,2011,13,C10-Lipid modifying agents,% of total sales,7.2 +16233,Hungary,2011,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",268.9 +16234,Hungary,2011,13,A10-Drugs used in diabetes,Million of national currency units,33416.2 +16235,Hungary,2011,13,A10-Drugs used in diabetes,Million US$ at exchange rate,166.2 +16236,Hungary,2011,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,343.0 +16237,Hungary,2011,13,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +16238,Hungary,2011,13,C03-Diuretics,% of total sales,0.9 +16239,Hungary,2011,13,C03-Diuretics,"Million US$, purchasing power parity",39.1 +16240,Hungary,2011,13,C03-Diuretics,"/capita, US$ exchange rate",2.4 +16241,Hungary,2011,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.4 +16242,Hungary,2011,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",554.9 +16243,Hungary,2011,13,A02A-Antacids,Million of national currency units,0.0 +16244,Hungary,2011,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5 +16245,Hungary,2011,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.9 +16246,Hungary,2011,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.7 +16247,Hungary,2011,13,N-Nervous system,"/capita, US$ purchasing power parity",52.0 +16248,Hungary,2011,13,N06A-Antidepressants,% of total sales,2.4 +16249,Hungary,2011,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",54.7 +16250,Hungary,2011,13,C08-Calcium channel blockers,Million US$ at exchange rate,33.8 +16251,Hungary,2011,13,N06A-Antidepressants,"Million US$, purchasing power parity",101.1 +16252,Hungary,2011,13,N06A-Antidepressants,Million US$ at exchange rate,62.5 +16253,Hungary,2011,13,C08-Calcium channel blockers,Million of national currency units,6798.9 +16254,Hungary,2011,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",10.1 +16255,Hungary,2011,13,N06A-Antidepressants,"/capita, US$ exchange rate",6.3 +16256,Hungary,2011,13,N-Nervous system,% of total sales,12.5 +16257,Hungary,2011,13,C01A-Cardiac glycosides,% of total sales,0.1 +16258,Hungary,2011,13,A10-Drugs used in diabetes,% of total sales,6.5 +16259,Hungary,2011,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",27.0 +16260,Hungary,2011,13,N06A-Antidepressants,Million of national currency units,12569.5 +16261,Hungary,2011,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4 +16262,Hungary,2011,13,C08-Calcium channel blockers,% of total sales,1.3 +16263,Hungary,2011,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5 +16264,Hungary,2011,13,C03-Diuretics,Million US$ at exchange rate,24.2 +16265,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.3 +16266,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +16267,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +16268,Hungary,2011,13,N02-Analgesics,"/capita, US$ exchange rate",2.7 +16269,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1522.8 +16270,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.6 +16271,Hungary,2011,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +16272,Hungary,2011,13,A02A-Antacids,"/capita, US$ exchange rate",0.0 +16273,Hungary,2011,13,A02A-Antacids,"Million US$, purchasing power parity",0.0 +16274,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +16275,Hungary,2011,13,A02A-Antacids,% of total sales,0.0 +16276,Hungary,2011,13,A-Alimentary tract and metabolism,% of total sales,13.4 +16277,Hungary,2011,13,R-Respiratory system,"Million US$, purchasing power parity",287.5 +16278,Hungary,2011,13,R-Respiratory system,"/capita, US$ exchange rate",17.8 +16279,Hungary,2011,13,R-Respiratory system,Million of national currency units,35728.1 +16280,Hungary,2011,13,R-Respiratory system,Million US$ at exchange rate,177.7 +16281,Hungary,2011,13,N02-Analgesics,Million US$ at exchange rate,27.1 +16282,Hungary,2011,13,N02-Analgesics,"Million US$, purchasing power parity",43.8 +16283,Hungary,2011,13,R-Respiratory system,"/capita, US$ purchasing power parity",28.8 +16284,Hungary,2011,13,R-Respiratory system,% of total sales,6.9 +16285,Hungary,2011,13,N02-Analgesics,Million of national currency units,5439.1 +16286,Hungary,2011,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",180.3 +16287,Hungary,2011,13,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3 +16288,Hungary,2011,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.2 +16289,Hungary,2011,13,M-Musculo-skeletal system,Million of national currency units,21144.6 +16290,Hungary,2011,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.7 +16291,Hungary,2011,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.1 +16292,Hungary,2011,13,J-Antiinfectives for systemic use,Million of national currency units,22409.7 +16293,Hungary,2011,13,C03-Diuretics,Million of national currency units,4864.6 +16294,Hungary,2011,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,111.5 +16295,Hungary,2011,13,C01A-Cardiac glycosides,Million of national currency units,260.8 +16296,Hungary,2011,13,A02A-Antacids,Million US$ at exchange rate,0.0 +16297,Hungary,2011,13,J-Antiinfectives for systemic use,% of total sales,4.3 +16298,Hungary,2011,13,N02-Analgesics,"/capita, US$ purchasing power parity",4.4 +16299,Hungary,2011,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +16300,Hungary,2011,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +16301,Hungary,2011,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.1 +16302,Hungary,2011,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",170.1 +16303,Hungary,2011,13,M-Musculo-skeletal system,Million US$ at exchange rate,105.2 +16304,Hungary,2011,13,M-Musculo-skeletal system,% of total sales,4.1 +16305,Hungary,2011,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5 +16306,Hungary,2011,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.1 +16307,Hungary,2011,13,G-Genito urinary system and sex hormones,Million of national currency units,8316.0 +16308,Hungary,2011,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.8 +16309,Hungary,2011,13,C07-Beta blocking agents,% of total sales,2.4 +16310,Hungary,2011,13,N05C-Hypnotics and sedatives,% of total sales,0.0 +16311,Hungary,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0 +16312,Hungary,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0 +16313,Hungary,2011,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0 +16314,Hungary,2011,13,C07-Beta blocking agents,"Million US$, purchasing power parity",98.1 +16315,Hungary,2011,13,C07-Beta blocking agents,Million US$ at exchange rate,60.6 +16316,Hungary,2011,13,C07-Beta blocking agents,Million of national currency units,12185.1 +16317,Hungary,2011,13,N05B-Anxiolytics,Million US$ at exchange rate,15.2 +16318,Hungary,2011,13,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1 +16319,Hungary,2011,13,N05B-Anxiolytics,"Million US$, purchasing power parity",24.6 +16320,Hungary,2011,13,N02-Analgesics,% of total sales,1.1 +16321,Hungary,2011,13,C02-Antihypertensives,% of total sales,1.5 +16322,Hungary,2011,13,R03-Drugs for obstructive airway diseases,Million of national currency units,29340.5 +16323,Hungary,2011,13,N05C-Hypnotics and sedatives,Million of national currency units,3.3 +16324,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.9 +16325,Hungary,2011,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.2 +16326,Hungary,2011,13,R03-Drugs for obstructive airway diseases,% of total sales,5.7 +16327,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.7 +16328,Hungary,2011,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0 +16329,Hungary,2011,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,145.9 +16330,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.1 +16331,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.6 +16332,Hungary,2011,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",66.9 +16333,Hungary,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1 +16334,Hungary,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7 +16335,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,% of total sales,0.7 +16336,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.8 +16337,Hungary,2011,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,41.4 +16338,Hungary,2011,13,Total pharmaceutical sales,"Million US$, purchasing power parity",4146.5 +16339,Hungary,2011,13,Total pharmaceutical sales,Million of national currency units,515299.2 +16340,Hungary,2011,13,Total pharmaceutical sales,Million US$ at exchange rate,2563.0 +16341,Hungary,2011,13,G-Genito urinary system and sex hormones,% of total sales,1.6 +16342,Hungary,2011,13,Total pharmaceutical sales,"/capita, US$ exchange rate",257.0 +16343,Hungary,2011,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",415.8 +16344,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,28.2 +16345,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",45.6 +16346,Hungary,2011,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +16347,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5672.5 +16348,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1 +16349,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.6 +16350,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.8 +16351,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.3 +16352,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",28.0 +16353,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7 +16354,Hungary,2011,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +16355,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,3483.0 +16356,Hungary,2011,13,N05B-Anxiolytics,% of total sales,0.6 +16357,Hungary,2011,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1 +16358,Hungary,2011,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",114.9 +16359,Hungary,2011,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,71.0 +16360,Hungary,2011,13,J01-Antibacterials for systemic use,% of total sales,2.8 +16361,Hungary,2011,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5 +16362,Hungary,2011,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1 +16363,Hungary,2011,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.5 +16364,Hungary,2011,13,B-Blood and blood forming organs,Million of national currency units,40274.7 +16365,Hungary,2011,13,J01-Antibacterials for systemic use,Million of national currency units,14278.5 +16366,Hungary,2011,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",324.1 +16367,Hungary,2011,13,B-Blood and blood forming organs,Million US$ at exchange rate,200.3 +16368,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,39.2 +16369,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.4 +16370,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9 +16371,Hungary,2011,13,C10-Lipid modifying agents,Million US$ at exchange rate,184.0 +16372,Hungary,2011,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",297.7 +16373,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,7875.2 +16374,Hungary,2011,13,C10-Lipid modifying agents,Million of national currency units,37000.6 +16375,Hungary,2011,13,N-Nervous system,Million US$ at exchange rate,320.4 +16376,Hungary,2011,13,N-Nervous system,Million of national currency units,64409.0 +16377,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4 +16378,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5 +16379,Hungary,2011,13,N-Nervous system,"/capita, US$ exchange rate",32.1 +16380,Hungary,2011,13,N-Nervous system,"Million US$, purchasing power parity",518.3 +16381,Hungary,2011,13,C-Cardiovascular system,"/capita, US$ exchange rate",63.6 +16382,Hungary,2011,13,C-Cardiovascular system,"Million US$, purchasing power parity",1025.6 +16383,Hungary,2011,13,C-Cardiovascular system,Million US$ at exchange rate,633.9 +16384,Hungary,2011,13,C-Cardiovascular system,% of total sales,24.7 +16385,Hungary,2011,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.9 +16386,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",367.8 +16387,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.8 +16388,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.9 +16389,Hungary,2011,13,C-Cardiovascular system,Million of national currency units,127453.0 +16390,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,45712.3 +16391,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,227.4 +16392,Hungary,2011,13,B-Blood and blood forming organs,% of total sales,7.8 +16393,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.9 +16394,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6 +16395,Hungary,2011,13,N05B-Anxiolytics,Million of national currency units,3057.1 +16396,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,92.1 +16397,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.2 +16398,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",148.9 +16399,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,18507.6 +16400,Hungary,2011,13,C02-Antihypertensives,Million US$ at exchange rate,38.3 +16401,Hungary,2011,13,C02-Antihypertensives,Million of national currency units,7703.6 +16402,Hungary,2011,13,C02-Antihypertensives,"/capita, US$ exchange rate",3.8 +16403,Hungary,2011,13,C02-Antihypertensives,"Million US$, purchasing power parity",62.0 +16404,Iceland,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,461.2 +16405,Iceland,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",35.4 +16406,Iceland,2010,5,G-Genito urinary system and sex hormones,% of total sales,6.0 +16407,Iceland,2010,5,N-Nervous system,"Million US$, purchasing power parity",51.0 +16408,Iceland,2010,5,N-Nervous system,Million US$ at exchange rate,55.5 +16409,Iceland,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.9 +16410,Iceland,2010,5,N-Nervous system,"/capita, US$ exchange rate",174.5 +16411,Iceland,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5 +16412,Iceland,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8 +16413,Iceland,2010,5,N-Nervous system,Million of national currency units,6783.8 +16414,Iceland,2010,5,N05C-Hypnotics and sedatives,% of total sales,1.8 +16415,Iceland,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.9 +16416,Iceland,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9 +16417,Iceland,2010,5,C02-Antihypertensives,Million of national currency units,37.6 +16418,Iceland,2010,5,C02-Antihypertensives,% of total sales,0.2 +16419,Iceland,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4 +16420,Iceland,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7 +16421,Iceland,2010,5,C07-Beta blocking agents,% of total sales,1.3 +16422,Iceland,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.1 +16423,Iceland,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7 +16424,Iceland,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",24.2 +16425,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.0 +16426,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4 +16427,Iceland,2010,5,J01-Antibacterials for systemic use,Million of national currency units,942.2 +16428,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,853.4 +16429,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.4 +16430,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",20.0 +16431,Iceland,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.0 +16432,Iceland,2010,5,C02-Antihypertensives,Million US$ at exchange rate,0.3 +16433,Iceland,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.3 +16434,Iceland,2010,5,C07-Beta blocking agents,Million of national currency units,327.2 +16435,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,846.9 +16436,Iceland,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,2.7 +16437,Iceland,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5 +16438,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.8 +16439,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.4 +16440,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9 +16441,Iceland,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0 +16442,Iceland,2010,5,A-Alimentary tract and metabolism,% of total sales,8.3 +16443,Iceland,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.3 +16444,Iceland,2010,5,A02A-Antacids,"Million US$, purchasing power parity",0.4 +16445,Iceland,2010,5,A02A-Antacids,Million US$ at exchange rate,0.4 +16446,Iceland,2010,5,A02A-Antacids,"/capita, US$ exchange rate",1.4 +16447,Iceland,2010,5,N-Nervous system,% of total sales,27.1 +16448,Iceland,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",160.5 +16449,Iceland,2010,5,A-Alimentary tract and metabolism,Million of national currency units,2071.3 +16450,Iceland,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.9 +16451,Iceland,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6 +16452,Iceland,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.3 +16453,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",20.2 +16454,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.4 +16455,Iceland,2010,5,N06A-Antidepressants,Million of national currency units,1101.8 +16456,Iceland,2010,5,J01-Antibacterials for systemic use,% of total sales,3.8 +16457,Iceland,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.3 +16458,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.0 +16459,Iceland,2010,5,N06A-Antidepressants,% of total sales,4.4 +16460,Iceland,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",26.1 +16461,Iceland,2010,5,A02A-Antacids,Million of national currency units,53.9 +16462,Iceland,2010,5,N06A-Antidepressants,Million US$ at exchange rate,9.0 +16463,Iceland,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",8.3 +16464,Iceland,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",28.3 +16465,Iceland,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.7 +16466,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8 +16467,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.4 +16468,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9 +16469,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.1 +16470,Iceland,2010,5,Products not elsewhere classified,Million of national currency units,5683.3 +16471,Iceland,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",146.2 +16472,Iceland,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",42.8 +16473,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,585.4 +16474,Iceland,2010,5,Products not elsewhere classified,Million US$ at exchange rate,46.5 +16475,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6 +16476,Iceland,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.8 +16477,Iceland,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.1 +16478,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",21.4 +16479,Iceland,2010,5,B-Blood and blood forming organs,Million of national currency units,1316.0 +16480,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +16481,Iceland,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.5 +16482,Iceland,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.9 +16483,Iceland,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,10.8 +16484,Iceland,2010,5,A10-Drugs used in diabetes,% of total sales,2.4 +16485,Iceland,2010,5,C03-Diuretics,"/capita, US$ exchange rate",5.3 +16486,Iceland,2010,5,C03-Diuretics,% of total sales,0.8 +16487,Iceland,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",4.8 +16488,Iceland,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,5.0 +16489,Iceland,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.6 +16490,Iceland,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.5 +16491,Iceland,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.8 +16492,Iceland,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,2.7 +16493,Iceland,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.5 +16494,Iceland,2010,5,Products not elsewhere classified,% of total sales,22.7 +16495,Iceland,2010,5,C10-Lipid modifying agents,Million of national currency units,335.4 +16496,Iceland,2010,5,C10-Lipid modifying agents,% of total sales,1.3 +16497,Iceland,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6 +16498,Iceland,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9 +16499,Iceland,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,2.1 +16500,Iceland,2010,5,N05B-Anxiolytics,Million of national currency units,262.1 +16501,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,903.3 +16502,Iceland,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.7 +16503,Iceland,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0 +16504,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",23.2 +16505,Iceland,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,4.5 +16506,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.4 +16507,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.8 +16508,Iceland,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",643.3 +16509,Iceland,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",188.2 +16510,Iceland,2010,5,Total pharmaceutical sales,Million of national currency units,25011.6 +16511,Iceland,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,204.6 +16512,Iceland,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",591.8 +16513,Iceland,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",6.2 +16514,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.2 +16515,Iceland,2010,5,N05B-Anxiolytics,% of total sales,1.0 +16516,Iceland,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",14.3 +16517,Iceland,2010,5,C-Cardiovascular system,Million US$ at exchange rate,15.6 +16518,Iceland,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.0 +16519,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,543.8 +16520,Iceland,2010,5,C-Cardiovascular system,Million of national currency units,1906.8 +16521,Iceland,2010,5,B-Blood and blood forming organs,% of total sales,5.3 +16522,Iceland,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.1 +16523,Iceland,2010,5,C-Cardiovascular system,% of total sales,7.6 +16524,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.4 +16525,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.4 +16526,Iceland,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.1 +16527,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.4 +16528,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.7 +16529,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.0 +16530,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.1 +16531,Iceland,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1114.5 +16532,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.9 +16533,Iceland,2010,5,A10-Drugs used in diabetes,Million of national currency units,612.6 +16534,Iceland,2010,5,C01A-Cardiac glycosides,Million of national currency units,9.4 +16535,Iceland,2010,5,C08-Calcium channel blockers,% of total sales,0.9 +16536,Iceland,2010,5,M-Musculo-skeletal system,Million of national currency units,1220.1 +16537,Iceland,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,10.0 +16538,Iceland,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3 +16539,Iceland,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,1.8 +16540,Iceland,2010,5,C08-Calcium channel blockers,Million of national currency units,223.5 +16541,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,61.4 +16542,Iceland,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.7 +16543,Iceland,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",9.2 +16544,Iceland,2010,5,R-Respiratory system,"Million US$, purchasing power parity",13.3 +16545,Iceland,2010,5,R-Respiratory system,Million US$ at exchange rate,14.4 +16546,Iceland,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.7 +16547,Iceland,2010,5,R-Respiratory system,"/capita, US$ exchange rate",45.3 +16548,Iceland,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.9 +16549,Iceland,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.4 +16550,Iceland,2010,5,R-Respiratory system,Million of national currency units,1762.5 +16551,Iceland,2010,5,M-Musculo-skeletal system,% of total sales,4.9 +16552,Iceland,2010,5,N02-Analgesics,"Million US$, purchasing power parity",7.6 +16553,Iceland,2010,5,N02-Analgesics,Million US$ at exchange rate,8.3 +16554,Iceland,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.9 +16555,Iceland,2010,5,N02-Analgesics,"/capita, US$ exchange rate",26.0 +16556,Iceland,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",11.3 +16557,Iceland,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.5 +16558,Iceland,2010,5,N02-Analgesics,Million of national currency units,1011.6 +16559,Iceland,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,1497.1 +16560,Iceland,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.2 +16561,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6 +16562,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5 +16563,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5 +16564,Iceland,2010,5,N02-Analgesics,% of total sales,4.0 +16565,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.5 +16566,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +16567,Iceland,2010,5,A02A-Antacids,% of total sales,0.2 +16568,Iceland,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +16569,Iceland,2010,5,J-Antiinfectives for systemic use,Million of national currency units,2185.2 +16570,Iceland,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +16571,Iceland,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +16572,Iceland,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +16573,Iceland,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,17.9 +16574,Iceland,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.7 +16575,Iceland,2010,5,J-Antiinfectives for systemic use,% of total sales,8.7 +16576,Iceland,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",16.4 +16577,Iceland,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.2 +16578,Iceland,2010,5,C01A-Cardiac glycosides,% of total sales,0.0 +16579,Iceland,2010,5,C03-Diuretics,"Million US$, purchasing power parity",1.5 +16580,Iceland,2010,5,C03-Diuretics,Million of national currency units,204.5 +16581,Iceland,2010,5,R-Respiratory system,% of total sales,7.0 +16582,Iceland,2010,5,C03-Diuretics,Million US$ at exchange rate,1.7 +16583,Iceland,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.5 +16584,Iceland,2017,4,G-Genito urinary system and sex hormones,% of total sales,4.9 +16585,Iceland,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,509.2 +16586,Iceland,2017,4,N-Nervous system,Million US$ at exchange rate,49.3 +16587,Iceland,2017,4,N-Nervous system,Million of national currency units,5265.0 +16588,Iceland,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",13.9 +16589,Iceland,2017,4,N-Nervous system,"Million US$, purchasing power parity",38.1 +16590,Iceland,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.8 +16591,Iceland,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.7 +16592,Iceland,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.7 +16593,Iceland,2017,4,N05C-Hypnotics and sedatives,% of total sales,1.9 +16594,Iceland,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +16595,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.5 +16596,Iceland,2017,4,C02-Antihypertensives,% of total sales,0.2 +16597,Iceland,2017,4,C07-Beta blocking agents,% of total sales,1.3 +16598,Iceland,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",9.5 +16599,Iceland,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4 +16600,Iceland,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.0 +16601,Iceland,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.7 +16602,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9 +16603,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,626.3 +16604,Iceland,2017,4,J01-Antibacterials for systemic use,Million of national currency units,1066.3 +16605,Iceland,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5 +16606,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.7 +16607,Iceland,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4 +16608,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.9 +16609,Iceland,2017,4,C02-Antihypertensives,Million of national currency units,51.0 +16610,Iceland,2017,4,C02-Antihypertensives,Million US$ at exchange rate,0.5 +16611,Iceland,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4 +16612,Iceland,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",29.1 +16613,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.2 +16614,Iceland,2017,4,C07-Beta blocking agents,Million of national currency units,349.6 +16615,Iceland,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,3.3 +16616,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,705.6 +16617,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.1 +16618,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.6 +16619,Iceland,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.5 +16620,Iceland,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6 +16621,Iceland,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.9 +16622,Iceland,2017,4,A02A-Antacids,Million US$ at exchange rate,0.0 +16623,Iceland,2017,4,A-Alimentary tract and metabolism,% of total sales,8.1 +16624,Iceland,2017,4,A02A-Antacids,"Million US$, purchasing power parity",0.0 +16625,Iceland,2017,4,N-Nervous system,% of total sales,19.9 +16626,Iceland,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",110.9 +16627,Iceland,2017,4,N-Nervous system,"/capita, US$ exchange rate",143.5 +16628,Iceland,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,20.2 +16629,Iceland,2017,4,A02A-Antacids,"/capita, US$ exchange rate",0.0 +16630,Iceland,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2159.5 +16631,Iceland,2017,4,A02A-Antacids,Million of national currency units,0.0 +16632,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.2 +16633,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +16634,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1 +16635,Iceland,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.5 +16636,Iceland,2017,4,J01-Antibacterials for systemic use,% of total sales,4.0 +16637,Iceland,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2 +16638,Iceland,2017,4,N06A-Antidepressants,% of total sales,2.9 +16639,Iceland,2017,4,N06A-Antidepressants,Million of national currency units,769.4 +16640,Iceland,2017,4,N06A-Antidepressants,Million US$ at exchange rate,7.2 +16641,Iceland,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.6 +16642,Iceland,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",21.0 +16643,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.5 +16644,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,690.2 +16645,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",18.8 +16646,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.0 +16647,Iceland,2017,4,Products not elsewhere classified,"Million US$, purchasing power parity",58.1 +16648,Iceland,2017,4,Products not elsewhere classified,"/capita, US$ exchange rate",218.8 +16649,Iceland,2017,4,Products not elsewhere classified,Million of national currency units,8027.6 +16650,Iceland,2017,4,Products not elsewhere classified,Million US$ at exchange rate,75.1 +16651,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.1 +16652,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6 +16653,Iceland,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.2 +16654,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.8 +16655,Iceland,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",12.8 +16656,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +16657,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5 +16658,Iceland,2017,4,B-Blood and blood forming organs,Million of national currency units,1768.1 +16659,Iceland,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,16.5 +16660,Iceland,2017,4,A10-Drugs used in diabetes,% of total sales,3.2 +16661,Iceland,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.8 +16662,Iceland,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.6 +16663,Iceland,2017,4,C03-Diuretics,"/capita, US$ exchange rate",5.9 +16664,Iceland,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9 +16665,Iceland,2017,4,A10-Drugs used in diabetes,Million of national currency units,845.8 +16666,Iceland,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.1 +16667,Iceland,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",6.1 +16668,Iceland,2017,4,C10-Lipid modifying agents,Million of national currency units,344.3 +16669,Iceland,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,3.2 +16670,Iceland,2017,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",169.1 +16671,Iceland,2017,4,Products not elsewhere classified,% of total sales,30.3 +16672,Iceland,2017,4,C10-Lipid modifying agents,% of total sales,1.3 +16673,Iceland,2017,4,C03-Diuretics,% of total sales,0.8 +16674,Iceland,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.3 +16675,Iceland,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.4 +16676,Iceland,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.2 +16677,Iceland,2017,4,N05B-Anxiolytics,Million of national currency units,276.7 +16678,Iceland,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,2.6 +16679,Iceland,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0 +16680,Iceland,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",7.5 +16681,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,431.6 +16682,Iceland,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +16683,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.1 +16684,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.0 +16685,Iceland,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",191.8 +16686,Iceland,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",722.9 +16687,Iceland,2017,4,Total pharmaceutical sales,Million of national currency units,26522.3 +16688,Iceland,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,248.2 +16689,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7 +16690,Iceland,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8 +16691,Iceland,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",558.5 +16692,Iceland,2017,4,N05B-Anxiolytics,% of total sales,1.0 +16693,Iceland,2017,4,C-Cardiovascular system,Million US$ at exchange rate,17.1 +16694,Iceland,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.2 +16695,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,454.9 +16696,Iceland,2017,4,C-Cardiovascular system,Million of national currency units,1827.3 +16697,Iceland,2017,4,C-Cardiovascular system,% of total sales,6.9 +16698,Iceland,2017,4,B-Blood and blood forming organs,% of total sales,6.7 +16699,Iceland,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",49.8 +16700,Iceland,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",38.5 +16701,Iceland,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.6 +16702,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.2 +16703,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9 +16704,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.0 +16705,Iceland,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1136.8 +16706,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.3 +16707,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.3 +16708,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.6 +16709,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.4 +16710,Iceland,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.5 +16711,Iceland,2017,4,C03-Diuretics,"Million US$, purchasing power parity",1.6 +16712,Iceland,2017,4,C08-Calcium channel blockers,% of total sales,0.6 +16713,Iceland,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +16714,Iceland,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,6.5 +16715,Iceland,2017,4,M-Musculo-skeletal system,Million of national currency units,698.3 +16716,Iceland,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.5 +16717,Iceland,2017,4,C08-Calcium channel blockers,Million of national currency units,164.6 +16718,Iceland,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5 +16719,Iceland,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.2 +16720,Iceland,2017,4,R-Respiratory system,Million US$ at exchange rate,14.3 +16721,Iceland,2017,4,R-Respiratory system,Million of national currency units,1532.7 +16722,Iceland,2017,4,R-Respiratory system,"Million US$, purchasing power parity",11.1 +16723,Iceland,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",32.3 +16724,Iceland,2017,4,R-Respiratory system,"/capita, US$ exchange rate",41.8 +16725,Iceland,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0 +16726,Iceland,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.1 +16727,Iceland,2017,4,M-Musculo-skeletal system,% of total sales,2.6 +16728,Iceland,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7 +16729,Iceland,2017,4,N02-Analgesics,Million US$ at exchange rate,8.5 +16730,Iceland,2017,4,N02-Analgesics,Million of national currency units,903.0 +16731,Iceland,2017,4,N02-Analgesics,"Million US$, purchasing power parity",6.5 +16732,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +16733,Iceland,2017,4,N02-Analgesics,"/capita, US$ exchange rate",24.6 +16734,Iceland,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.5 +16735,Iceland,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",35.7 +16736,Iceland,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.2 +16737,Iceland,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,1308.1 +16738,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +16739,Iceland,2017,4,N02-Analgesics,% of total sales,3.4 +16740,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,83.5 +16741,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +16742,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",2.3 +16743,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8 +16744,Iceland,2017,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +16745,Iceland,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",19.0 +16746,Iceland,2017,4,A02A-Antacids,% of total sales,0.0 +16747,Iceland,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +16748,Iceland,2017,4,C01A-Cardiac glycosides,Million of national currency units,11.3 +16749,Iceland,2017,4,J-Antiinfectives for systemic use,Million of national currency units,3067.9 +16750,Iceland,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +16751,Iceland,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +16752,Iceland,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +16753,Iceland,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.6 +16754,Iceland,2017,4,J-Antiinfectives for systemic use,% of total sales,11.6 +16755,Iceland,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",83.6 +16756,Iceland,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.7 +16757,Iceland,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",22.2 +16758,Iceland,2017,4,C01A-Cardiac glycosides,% of total sales,0.0 +16759,Iceland,2017,4,R-Respiratory system,% of total sales,5.8 +16760,Iceland,2017,4,C03-Diuretics,Million US$ at exchange rate,2.0 +16761,Iceland,2017,4,C03-Diuretics,Million of national currency units,216.6 +16762,Iceland,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",28.4 +16763,Iceland,2016,4,G-Genito urinary system and sex hormones,% of total sales,5.3 +16764,Iceland,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,471.8 +16765,Iceland,2016,4,N-Nervous system,Million US$ at exchange rate,46.0 +16766,Iceland,2016,4,N-Nervous system,Million of national currency units,5561.3 +16767,Iceland,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.6 +16768,Iceland,2016,4,N-Nervous system,"Million US$, purchasing power parity",39.7 +16769,Iceland,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4 +16770,Iceland,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9 +16771,Iceland,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.0 +16772,Iceland,2016,4,N05C-Hypnotics and sedatives,% of total sales,1.9 +16773,Iceland,2016,4,N06A-Antidepressants,Million US$ at exchange rate,6.2 +16774,Iceland,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +16775,Iceland,2016,4,C02-Antihypertensives,% of total sales,0.2 +16776,Iceland,2016,4,C07-Beta blocking agents,% of total sales,1.3 +16777,Iceland,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4 +16778,Iceland,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2 +16779,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.3 +16780,Iceland,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.8 +16781,Iceland,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.2 +16782,Iceland,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.6 +16783,Iceland,2016,4,J01-Antibacterials for systemic use,Million of national currency units,1062.7 +16784,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.9 +16785,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,596.9 +16786,Iceland,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.4 +16787,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9 +16788,Iceland,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2 +16789,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.5 +16790,Iceland,2016,4,C02-Antihypertensives,Million of national currency units,49.0 +16791,Iceland,2016,4,C02-Antihypertensives,Million US$ at exchange rate,0.4 +16792,Iceland,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.3 +16793,Iceland,2016,4,C07-Beta blocking agents,Million of national currency units,340.2 +16794,Iceland,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,2.8 +16795,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",18.0 +16796,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.2 +16797,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.0 +16798,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,729.9 +16799,Iceland,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.6 +16800,Iceland,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6 +16801,Iceland,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.0 +16802,Iceland,2016,4,A-Alimentary tract and metabolism,% of total sales,8.6 +16803,Iceland,2016,4,A02A-Antacids,Million US$ at exchange rate,0.0 +16804,Iceland,2016,4,A02A-Antacids,"Million US$, purchasing power parity",0.0 +16805,Iceland,2016,4,N-Nervous system,% of total sales,21.9 +16806,Iceland,2016,4,N-Nervous system,"/capita, US$ exchange rate",137.2 +16807,Iceland,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",118.4 +16808,Iceland,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,18.1 +16809,Iceland,2016,4,A02A-Antacids,"/capita, US$ exchange rate",0.0 +16810,Iceland,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2188.8 +16811,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.7 +16812,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +16813,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.7 +16814,Iceland,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.6 +16815,Iceland,2016,4,J01-Antibacterials for systemic use,% of total sales,4.2 +16816,Iceland,2016,4,N06A-Antidepressants,Million of national currency units,744.1 +16817,Iceland,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.8 +16818,Iceland,2016,4,A02A-Antacids,Million of national currency units,0.0 +16819,Iceland,2016,4,N06A-Antidepressants,% of total sales,2.9 +16820,Iceland,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",18.4 +16821,Iceland,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.3 +16822,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.5 +16823,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,670.4 +16824,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.5 +16825,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.8 +16826,Iceland,2016,4,Products not elsewhere classified,"Million US$, purchasing power parity",52.4 +16827,Iceland,2016,4,Products not elsewhere classified,"/capita, US$ exchange rate",181.2 +16828,Iceland,2016,4,Products not elsewhere classified,Million of national currency units,7341.2 +16829,Iceland,2016,4,Products not elsewhere classified,Million US$ at exchange rate,60.8 +16830,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +16831,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2 +16832,Iceland,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",47.4 +16833,Iceland,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",13.7 +16834,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +16835,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.3 +16836,Iceland,2016,4,B-Blood and blood forming organs,Million of national currency units,1922.6 +16837,Iceland,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,15.9 +16838,Iceland,2016,4,A10-Drugs used in diabetes,% of total sales,3.3 +16839,Iceland,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.8 +16840,Iceland,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.4 +16841,Iceland,2016,4,C03-Diuretics,"/capita, US$ exchange rate",5.1 +16842,Iceland,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,6.9 +16843,Iceland,2016,4,A10-Drugs used in diabetes,Million of national currency units,838.3 +16844,Iceland,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.7 +16845,Iceland,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",6.0 +16846,Iceland,2016,4,C10-Lipid modifying agents,Million of national currency units,326.4 +16847,Iceland,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.7 +16848,Iceland,2016,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",156.3 +16849,Iceland,2016,4,Products not elsewhere classified,% of total sales,28.9 +16850,Iceland,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.3 +16851,Iceland,2016,4,C10-Lipid modifying agents,% of total sales,1.3 +16852,Iceland,2016,4,C03-Diuretics,% of total sales,0.8 +16853,Iceland,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.9 +16854,Iceland,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.1 +16855,Iceland,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.9 +16856,Iceland,2016,4,N05B-Anxiolytics,Million of national currency units,265.2 +16857,Iceland,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,2.2 +16858,Iceland,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.5 +16859,Iceland,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9 +16860,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.7 +16861,Iceland,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,4.5 +16862,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.1 +16863,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,431.9 +16864,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.6 +16865,Iceland,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",181.3 +16866,Iceland,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",626.4 +16867,Iceland,2016,4,Total pharmaceutical sales,Million of national currency units,25384.8 +16868,Iceland,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,210.1 +16869,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8 +16870,Iceland,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.6 +16871,Iceland,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",540.4 +16872,Iceland,2016,4,N05B-Anxiolytics,% of total sales,1.0 +16873,Iceland,2016,4,C-Cardiovascular system,Million US$ at exchange rate,14.4 +16874,Iceland,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",12.4 +16875,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,448.0 +16876,Iceland,2016,4,C-Cardiovascular system,Million of national currency units,1734.6 +16877,Iceland,2016,4,C-Cardiovascular system,% of total sales,6.8 +16878,Iceland,2016,4,B-Blood and blood forming organs,% of total sales,7.6 +16879,Iceland,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",42.8 +16880,Iceland,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.9 +16881,Iceland,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.4 +16882,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.1 +16883,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.3 +16884,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.2 +16885,Iceland,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1141.2 +16886,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2 +16887,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.7 +16888,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.5 +16889,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1 +16890,Iceland,2016,4,C08-Calcium channel blockers,% of total sales,0.7 +16891,Iceland,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +16892,Iceland,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,5.8 +16893,Iceland,2016,4,M-Musculo-skeletal system,Million of national currency units,697.1 +16894,Iceland,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.4 +16895,Iceland,2016,4,C08-Calcium channel blockers,Million of national currency units,165.6 +16896,Iceland,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +16897,Iceland,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.2 +16898,Iceland,2016,4,R-Respiratory system,"Million US$, purchasing power parity",10.8 +16899,Iceland,2016,4,R-Respiratory system,Million US$ at exchange rate,12.5 +16900,Iceland,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",32.1 +16901,Iceland,2016,4,R-Respiratory system,"/capita, US$ exchange rate",37.2 +16902,Iceland,2016,4,R-Respiratory system,Million of national currency units,1508.4 +16903,Iceland,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.2 +16904,Iceland,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.0 +16905,Iceland,2016,4,M-Musculo-skeletal system,% of total sales,2.7 +16906,Iceland,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.8 +16907,Iceland,2016,4,N02-Analgesics,"Million US$, purchasing power parity",6.2 +16908,Iceland,2016,4,N02-Analgesics,Million US$ at exchange rate,7.2 +16909,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +16910,Iceland,2016,4,N02-Analgesics,"/capita, US$ exchange rate",21.6 +16911,Iceland,2016,4,N02-Analgesics,Million of national currency units,873.8 +16912,Iceland,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.5 +16913,Iceland,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.9 +16914,Iceland,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.1 +16915,Iceland,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,1335.0 +16916,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +16917,Iceland,2016,4,N02-Analgesics,% of total sales,3.4 +16918,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9 +16919,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.9 +16920,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +16921,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +16922,Iceland,2016,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +16923,Iceland,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",18.6 +16924,Iceland,2016,4,A02A-Antacids,% of total sales,0.0 +16925,Iceland,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +16926,Iceland,2016,4,C01A-Cardiac glycosides,Million of national currency units,11.5 +16927,Iceland,2016,4,J-Antiinfectives for systemic use,Million of national currency units,3055.4 +16928,Iceland,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +16929,Iceland,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +16930,Iceland,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +16931,Iceland,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",65.0 +16932,Iceland,2016,4,J-Antiinfectives for systemic use,% of total sales,12.0 +16933,Iceland,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.3 +16934,Iceland,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",75.4 +16935,Iceland,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",21.8 +16936,Iceland,2016,4,C01A-Cardiac glycosides,% of total sales,0.0 +16937,Iceland,2016,4,R-Respiratory system,% of total sales,5.9 +16938,Iceland,2016,4,C03-Diuretics,"Million US$, purchasing power parity",1.5 +16939,Iceland,2016,4,C03-Diuretics,Million US$ at exchange rate,1.7 +16940,Iceland,2016,4,C03-Diuretics,Million of national currency units,205.6 +16941,Iceland,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",28.0 +16942,Iceland,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,460.4 +16943,Iceland,2015,4,G-Genito urinary system and sex hormones,% of total sales,5.4 +16944,Iceland,2015,4,N-Nervous system,Million US$ at exchange rate,40.5 +16945,Iceland,2015,4,N-Nervous system,Million of national currency units,5341.2 +16946,Iceland,2015,4,N-Nervous system,"Million US$, purchasing power parity",37.6 +16947,Iceland,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",10.5 +16948,Iceland,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +16949,Iceland,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5 +16950,Iceland,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",9.8 +16951,Iceland,2015,4,N05C-Hypnotics and sedatives,% of total sales,1.9 +16952,Iceland,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +16953,Iceland,2015,4,C02-Antihypertensives,% of total sales,0.2 +16954,Iceland,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8 +16955,Iceland,2015,4,C07-Beta blocking agents,% of total sales,1.4 +16956,Iceland,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2 +16957,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.0 +16958,Iceland,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.9 +16959,Iceland,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8 +16960,Iceland,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.3 +16961,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.3 +16962,Iceland,2015,4,J01-Antibacterials for systemic use,Million of national currency units,1040.8 +16963,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,561.1 +16964,Iceland,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.4 +16965,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.0 +16966,Iceland,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2 +16967,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.4 +16968,Iceland,2015,4,C02-Antihypertensives,Million US$ at exchange rate,0.4 +16969,Iceland,2015,4,C02-Antihypertensives,Million of national currency units,50.5 +16970,Iceland,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4 +16971,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.6 +16972,Iceland,2015,4,C07-Beta blocking agents,Million of national currency units,339.2 +16973,Iceland,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,2.6 +16974,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,723.6 +16975,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.1 +16976,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,5.5 +16977,Iceland,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.7 +16978,Iceland,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",45.9 +16979,Iceland,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",14.1 +16980,Iceland,2015,4,A02A-Antacids,Million US$ at exchange rate,0.0 +16981,Iceland,2015,4,A02A-Antacids,"Million US$, purchasing power parity",0.0 +16982,Iceland,2015,4,A-Alimentary tract and metabolism,% of total sales,8.2 +16983,Iceland,2015,4,N-Nervous system,% of total sales,21.9 +16984,Iceland,2015,4,N-Nervous system,"/capita, US$ exchange rate",122.4 +16985,Iceland,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",113.7 +16986,Iceland,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,15.2 +16987,Iceland,2015,4,A02A-Antacids,"/capita, US$ exchange rate",0.0 +16988,Iceland,2015,4,A-Alimentary tract and metabolism,Million of national currency units,2003.7 +16989,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.9 +16990,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3 +16991,Iceland,2015,4,N06A-Antidepressants,Million of national currency units,759.2 +16992,Iceland,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.2 +16993,Iceland,2015,4,J01-Antibacterials for systemic use,% of total sales,4.3 +16994,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9 +16995,Iceland,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2 +16996,Iceland,2015,4,A02A-Antacids,Million of national currency units,0.0 +16997,Iceland,2015,4,N06A-Antidepressants,% of total sales,3.1 +16998,Iceland,2015,4,N06A-Antidepressants,Million US$ at exchange rate,5.8 +16999,Iceland,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",17.4 +17000,Iceland,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.3 +17001,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8 +17002,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,636.0 +17003,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.6 +17004,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.5 +17005,Iceland,2015,4,Products not elsewhere classified,"Million US$, purchasing power parity",48.4 +17006,Iceland,2015,4,Products not elsewhere classified,"/capita, US$ exchange rate",157.4 +17007,Iceland,2015,4,Products not elsewhere classified,Million of national currency units,6869.4 +17008,Iceland,2015,4,Products not elsewhere classified,Million US$ at exchange rate,52.1 +17009,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.5 +17010,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +17011,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2 +17012,Iceland,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.1 +17013,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +17014,Iceland,2015,4,B-Blood and blood forming organs,Million of national currency units,1575.9 +17015,Iceland,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.1 +17016,Iceland,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,11.9 +17017,Iceland,2015,4,A10-Drugs used in diabetes,% of total sales,3.0 +17018,Iceland,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.6 +17019,Iceland,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.0 +17020,Iceland,2015,4,C03-Diuretics,"/capita, US$ exchange rate",4.3 +17021,Iceland,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,5.5 +17022,Iceland,2015,4,A10-Drugs used in diabetes,Million of national currency units,731.1 +17023,Iceland,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8 +17024,Iceland,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.1 +17025,Iceland,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.3 +17026,Iceland,2015,4,C10-Lipid modifying agents,Million of national currency units,308.6 +17027,Iceland,2015,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",146.3 +17028,Iceland,2015,4,Products not elsewhere classified,% of total sales,28.1 +17029,Iceland,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.2 +17030,Iceland,2015,4,C10-Lipid modifying agents,% of total sales,1.3 +17031,Iceland,2015,4,C03-Diuretics,% of total sales,0.8 +17032,Iceland,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6 +17033,Iceland,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.1 +17034,Iceland,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.6 +17035,Iceland,2015,4,N05B-Anxiolytics,Million of national currency units,268.0 +17036,Iceland,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,2.0 +17037,Iceland,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.1 +17038,Iceland,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9 +17039,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,430.1 +17040,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.9 +17041,Iceland,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,4.4 +17042,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.3 +17043,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.0 +17044,Iceland,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",171.9 +17045,Iceland,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",559.2 +17046,Iceland,2015,4,Total pharmaceutical sales,Million of national currency units,24403.4 +17047,Iceland,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,185.0 +17048,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8 +17049,Iceland,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.7 +17050,Iceland,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",519.6 +17051,Iceland,2015,4,N05B-Anxiolytics,% of total sales,1.1 +17052,Iceland,2015,4,C-Cardiovascular system,Million US$ at exchange rate,13.0 +17053,Iceland,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",12.1 +17054,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,438.0 +17055,Iceland,2015,4,C-Cardiovascular system,Million of national currency units,1713.3 +17056,Iceland,2015,4,C-Cardiovascular system,% of total sales,7.0 +17057,Iceland,2015,4,B-Blood and blood forming organs,% of total sales,6.5 +17058,Iceland,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",39.3 +17059,Iceland,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.5 +17060,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",7.6 +17061,Iceland,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,8.2 +17062,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.1 +17063,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.9 +17064,Iceland,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1085.7 +17065,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.1 +17066,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.3 +17067,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.3 +17068,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0 +17069,Iceland,2015,4,C08-Calcium channel blockers,% of total sales,0.6 +17070,Iceland,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.3 +17071,Iceland,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,4.9 +17072,Iceland,2015,4,M-Musculo-skeletal system,Million of national currency units,645.8 +17073,Iceland,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.2 +17074,Iceland,2015,4,C08-Calcium channel blockers,Million of national currency units,156.8 +17075,Iceland,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6 +17076,Iceland,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.1 +17077,Iceland,2015,4,R-Respiratory system,"Million US$, purchasing power parity",10.2 +17078,Iceland,2015,4,R-Respiratory system,Million US$ at exchange rate,11.0 +17079,Iceland,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.8 +17080,Iceland,2015,4,R-Respiratory system,"/capita, US$ exchange rate",33.1 +17081,Iceland,2015,4,R-Respiratory system,Million of national currency units,1444.8 +17082,Iceland,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.8 +17083,Iceland,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",4.5 +17084,Iceland,2015,4,M-Musculo-skeletal system,% of total sales,2.6 +17085,Iceland,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.7 +17086,Iceland,2015,4,N02-Analgesics,"Million US$, purchasing power parity",5.9 +17087,Iceland,2015,4,N02-Analgesics,Million US$ at exchange rate,6.4 +17088,Iceland,2015,4,N02-Analgesics,"/capita, US$ exchange rate",19.3 +17089,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +17090,Iceland,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.3 +17091,Iceland,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.1 +17092,Iceland,2015,4,N02-Analgesics,Million of national currency units,841.5 +17093,Iceland,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,1315.4 +17094,Iceland,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.0 +17095,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6 +17096,Iceland,2015,4,N02-Analgesics,% of total sales,3.4 +17097,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5 +17098,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,69.1 +17099,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5 +17100,Iceland,2015,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +17101,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.5 +17102,Iceland,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",17.9 +17103,Iceland,2015,4,A02A-Antacids,% of total sales,0.0 +17104,Iceland,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +17105,Iceland,2015,4,C01A-Cardiac glycosides,Million of national currency units,11.7 +17106,Iceland,2015,4,J-Antiinfectives for systemic use,Million of national currency units,2857.9 +17107,Iceland,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +17108,Iceland,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +17109,Iceland,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +17110,Iceland,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",60.8 +17111,Iceland,2015,4,J-Antiinfectives for systemic use,% of total sales,11.7 +17112,Iceland,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.5 +17113,Iceland,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,21.7 +17114,Iceland,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",20.1 +17115,Iceland,2015,4,C01A-Cardiac glycosides,% of total sales,0.0 +17116,Iceland,2015,4,R-Respiratory system,% of total sales,5.9 +17117,Iceland,2015,4,C03-Diuretics,"Million US$, purchasing power parity",1.3 +17118,Iceland,2015,4,C03-Diuretics,Million US$ at exchange rate,1.4 +17119,Iceland,2015,4,C03-Diuretics,Million of national currency units,186.4 +17120,Iceland,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,451.9 +17121,Iceland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",29.6 +17122,Iceland,2014,5,G-Genito urinary system and sex hormones,% of total sales,5.7 +17123,Iceland,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.8 +17124,Iceland,2014,5,N-Nervous system,Million US$ at exchange rate,45.5 +17125,Iceland,2014,5,N-Nervous system,Million of national currency units,5314.4 +17126,Iceland,2014,5,N-Nervous system,"Million US$, purchasing power parity",38.4 +17127,Iceland,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3 +17128,Iceland,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9 +17129,Iceland,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.0 +17130,Iceland,2014,5,N05C-Hypnotics and sedatives,% of total sales,1.9 +17131,Iceland,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +17132,Iceland,2014,5,C02-Antihypertensives,% of total sales,0.2 +17133,Iceland,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9 +17134,Iceland,2014,5,C07-Beta blocking agents,% of total sales,1.4 +17135,Iceland,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5 +17136,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.1 +17137,Iceland,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.5 +17138,Iceland,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1 +17139,Iceland,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.2 +17140,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.9 +17141,Iceland,2014,5,J01-Antibacterials for systemic use,Million of national currency units,997.1 +17142,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,569.9 +17143,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.2 +17144,Iceland,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.2 +17145,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",16.6 +17146,Iceland,2014,5,C02-Antihypertensives,Million US$ at exchange rate,0.4 +17147,Iceland,2014,5,C02-Antihypertensives,Million of national currency units,45.3 +17148,Iceland,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.3 +17149,Iceland,2014,5,C07-Beta blocking agents,Million of national currency units,342.1 +17150,Iceland,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5 +17151,Iceland,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,2.9 +17152,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,754.3 +17153,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.4 +17154,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.7 +17155,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.5 +17156,Iceland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8 +17157,Iceland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.6 +17158,Iceland,2014,5,A-Alimentary tract and metabolism,% of total sales,8.0 +17159,Iceland,2014,5,A02A-Antacids,Million US$ at exchange rate,0.0 +17160,Iceland,2014,5,A02A-Antacids,"Million US$, purchasing power parity",0.0 +17161,Iceland,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",13.7 +17162,Iceland,2014,5,N-Nervous system,% of total sales,22.4 +17163,Iceland,2014,5,N-Nervous system,"/capita, US$ exchange rate",139.0 +17164,Iceland,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",117.2 +17165,Iceland,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.2 +17166,Iceland,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +17167,Iceland,2014,5,A-Alimentary tract and metabolism,Million of national currency units,1897.2 +17168,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.6 +17169,Iceland,2014,5,N06A-Antidepressants,Million of national currency units,730.7 +17170,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +17171,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.9 +17172,Iceland,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.0 +17173,Iceland,2014,5,J01-Antibacterials for systemic use,% of total sales,4.2 +17174,Iceland,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.1 +17175,Iceland,2014,5,A02A-Antacids,Million of national currency units,0.0 +17176,Iceland,2014,5,N06A-Antidepressants,% of total sales,3.1 +17177,Iceland,2014,5,N06A-Antidepressants,Million US$ at exchange rate,6.3 +17178,Iceland,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",19.1 +17179,Iceland,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",5.3 +17180,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.6 +17181,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,656.6 +17182,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2 +17183,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.7 +17184,Iceland,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",45.4 +17185,Iceland,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",164.5 +17186,Iceland,2014,5,Products not elsewhere classified,Million of national currency units,6288.7 +17187,Iceland,2014,5,Products not elsewhere classified,Million US$ at exchange rate,53.9 +17188,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5 +17189,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +17190,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8 +17191,Iceland,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.9 +17192,Iceland,2014,5,B-Blood and blood forming organs,Million of national currency units,1526.6 +17193,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8 +17194,Iceland,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.0 +17195,Iceland,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,13.1 +17196,Iceland,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.7 +17197,Iceland,2014,5,A10-Drugs used in diabetes,% of total sales,3.1 +17198,Iceland,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",4.6 +17199,Iceland,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.0 +17200,Iceland,2014,5,C03-Diuretics,"/capita, US$ exchange rate",5.4 +17201,Iceland,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,6.2 +17202,Iceland,2014,5,A10-Drugs used in diabetes,Million of national currency units,726.7 +17203,Iceland,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0 +17204,Iceland,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.2 +17205,Iceland,2014,5,C03-Diuretics,% of total sales,0.9 +17206,Iceland,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,2.9 +17207,Iceland,2014,5,C10-Lipid modifying agents,Million of national currency units,333.6 +17208,Iceland,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",138.6 +17209,Iceland,2014,5,Products not elsewhere classified,% of total sales,26.5 +17210,Iceland,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.4 +17211,Iceland,2014,5,C10-Lipid modifying agents,% of total sales,1.4 +17212,Iceland,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.7 +17213,Iceland,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.4 +17214,Iceland,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,2.3 +17215,Iceland,2014,5,N05B-Anxiolytics,Million of national currency units,263.5 +17216,Iceland,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9 +17217,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,446.0 +17218,Iceland,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9 +17219,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.7 +17220,Iceland,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +17221,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.8 +17222,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.2 +17223,Iceland,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",171.0 +17224,Iceland,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",619.7 +17225,Iceland,2014,5,Total pharmaceutical sales,Million of national currency units,23689.8 +17226,Iceland,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,202.9 +17227,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.9 +17228,Iceland,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8 +17229,Iceland,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.3 +17230,Iceland,2014,5,N05B-Anxiolytics,% of total sales,1.1 +17231,Iceland,2014,5,C-Cardiovascular system,Million US$ at exchange rate,15.3 +17232,Iceland,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",12.9 +17233,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,439.8 +17234,Iceland,2014,5,C-Cardiovascular system,Million of national currency units,1783.8 +17235,Iceland,2014,5,B-Blood and blood forming organs,% of total sales,6.4 +17236,Iceland,2014,5,C-Cardiovascular system,% of total sales,7.5 +17237,Iceland,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",46.7 +17238,Iceland,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",39.3 +17239,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.4 +17240,Iceland,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.0 +17241,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.7 +17242,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5 +17243,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2 +17244,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.8 +17245,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5 +17246,Iceland,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1164.2 +17247,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.7 +17248,Iceland,2014,5,C08-Calcium channel blockers,% of total sales,0.8 +17249,Iceland,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1 +17250,Iceland,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,6.0 +17251,Iceland,2014,5,C01A-Cardiac glycosides,Million of national currency units,11.6 +17252,Iceland,2014,5,M-Musculo-skeletal system,Million of national currency units,699.9 +17253,Iceland,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,1.6 +17254,Iceland,2014,5,C08-Calcium channel blockers,Million of national currency units,185.1 +17255,Iceland,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.8 +17256,Iceland,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.3 +17257,Iceland,2014,5,R-Respiratory system,"Million US$, purchasing power parity",10.9 +17258,Iceland,2014,5,R-Respiratory system,Million US$ at exchange rate,13.0 +17259,Iceland,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",33.4 +17260,Iceland,2014,5,R-Respiratory system,"/capita, US$ exchange rate",39.7 +17261,Iceland,2014,5,R-Respiratory system,Million of national currency units,1516.1 +17262,Iceland,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.3 +17263,Iceland,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.1 +17264,Iceland,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.4 +17265,Iceland,2014,5,M-Musculo-skeletal system,% of total sales,3.0 +17266,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.0 +17267,Iceland,2014,5,N02-Analgesics,"Million US$, purchasing power parity",6.1 +17268,Iceland,2014,5,N02-Analgesics,Million US$ at exchange rate,7.2 +17269,Iceland,2014,5,N02-Analgesics,"/capita, US$ exchange rate",22.1 +17270,Iceland,2014,5,N02-Analgesics,Million of national currency units,843.8 +17271,Iceland,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.7 +17272,Iceland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",35.1 +17273,Iceland,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,1343.4 +17274,Iceland,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.5 +17275,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +17276,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9 +17277,Iceland,2014,5,N02-Analgesics,% of total sales,3.6 +17278,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5 +17279,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +17280,Iceland,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +17281,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6 +17282,Iceland,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",18.6 +17283,Iceland,2014,5,A02A-Antacids,% of total sales,0.0 +17284,Iceland,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +17285,Iceland,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +17286,Iceland,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +17287,Iceland,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +17288,Iceland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.7 +17289,Iceland,2014,5,J-Antiinfectives for systemic use,% of total sales,11.2 +17290,Iceland,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.8 +17291,Iceland,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.2 +17292,Iceland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.7 +17293,Iceland,2014,5,J-Antiinfectives for systemic use,Million of national currency units,2663.1 +17294,Iceland,2014,5,C01A-Cardiac glycosides,% of total sales,0.0 +17295,Iceland,2014,5,R-Respiratory system,% of total sales,6.4 +17296,Iceland,2014,5,C03-Diuretics,"Million US$, purchasing power parity",1.5 +17297,Iceland,2014,5,C03-Diuretics,Million US$ at exchange rate,1.8 +17298,Iceland,2014,5,C03-Diuretics,Million of national currency units,206.8 +17299,Iceland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.8 +17300,Iceland,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,449.1 +17301,Iceland,2013,4,G-Genito urinary system and sex hormones,% of total sales,5.8 +17302,Iceland,2013,4,N-Nervous system,Million US$ at exchange rate,52.6 +17303,Iceland,2013,4,N-Nervous system,"Million US$, purchasing power parity",46.9 +17304,Iceland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.4 +17305,Iceland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.1 +17306,Iceland,2013,4,N-Nervous system,Million of national currency units,6429.3 +17307,Iceland,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3 +17308,Iceland,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7 +17309,Iceland,2013,4,N05C-Hypnotics and sedatives,% of total sales,1.7 +17310,Iceland,2013,4,N-Nervous system,"/capita, US$ exchange rate",162.5 +17311,Iceland,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +17312,Iceland,2013,4,C02-Antihypertensives,% of total sales,0.2 +17313,Iceland,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9 +17314,Iceland,2013,4,C07-Beta blocking agents,% of total sales,1.4 +17315,Iceland,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0 +17316,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.5 +17317,Iceland,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.6 +17318,Iceland,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.6 +17319,Iceland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.5 +17320,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.1 +17321,Iceland,2013,4,J01-Antibacterials for systemic use,Million of national currency units,1047.8 +17322,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,621.0 +17323,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.3 +17324,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.2 +17325,Iceland,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3 +17326,Iceland,2013,4,C02-Antihypertensives,Million US$ at exchange rate,0.4 +17327,Iceland,2013,4,C02-Antihypertensives,Million of national currency units,50.8 +17328,Iceland,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4 +17329,Iceland,2013,4,C07-Beta blocking agents,Million of national currency units,353.3 +17330,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,853.4 +17331,Iceland,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.6 +17332,Iceland,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,2.9 +17333,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.2 +17334,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.6 +17335,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.0 +17336,Iceland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.1 +17337,Iceland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.9 +17338,Iceland,2013,4,A-Alimentary tract and metabolism,% of total sales,8.2 +17339,Iceland,2013,4,A02A-Antacids,Million US$ at exchange rate,0.0 +17340,Iceland,2013,4,A02A-Antacids,"Million US$, purchasing power parity",0.0 +17341,Iceland,2013,4,N-Nervous system,% of total sales,24.7 +17342,Iceland,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",144.9 +17343,Iceland,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6 +17344,Iceland,2013,4,A-Alimentary tract and metabolism,Million of national currency units,2134.0 +17345,Iceland,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,17.5 +17346,Iceland,2013,4,A02A-Antacids,"/capita, US$ exchange rate",0.0 +17347,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0 +17348,Iceland,2013,4,N06A-Antidepressants,Million of national currency units,767.5 +17349,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +17350,Iceland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.6 +17351,Iceland,2013,4,J01-Antibacterials for systemic use,% of total sales,4.0 +17352,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.7 +17353,Iceland,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.3 +17354,Iceland,2013,4,N06A-Antidepressants,% of total sales,2.9 +17355,Iceland,2013,4,A02A-Antacids,Million of national currency units,0.0 +17356,Iceland,2013,4,N06A-Antidepressants,Million US$ at exchange rate,6.3 +17357,Iceland,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",19.4 +17358,Iceland,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.6 +17359,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4 +17360,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,665.0 +17361,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.9 +17362,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.8 +17363,Iceland,2013,4,Products not elsewhere classified,"Million US$, purchasing power parity",47.6 +17364,Iceland,2013,4,Products not elsewhere classified,"/capita, US$ exchange rate",164.9 +17365,Iceland,2013,4,Products not elsewhere classified,Million of national currency units,6524.4 +17366,Iceland,2013,4,Products not elsewhere classified,Million US$ at exchange rate,53.4 +17367,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.0 +17368,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.5 +17369,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",14.4 +17370,Iceland,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.1 +17371,Iceland,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.4 +17372,Iceland,2013,4,B-Blood and blood forming organs,Million of national currency units,1557.0 +17373,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +17374,Iceland,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.4 +17375,Iceland,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,12.7 +17376,Iceland,2013,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",147.1 +17377,Iceland,2013,4,A10-Drugs used in diabetes,% of total sales,2.8 +17378,Iceland,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",5.1 +17379,Iceland,2013,4,C03-Diuretics,"/capita, US$ exchange rate",5.7 +17380,Iceland,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.6 +17381,Iceland,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,6.0 +17382,Iceland,2013,4,A10-Drugs used in diabetes,Million of national currency units,738.0 +17383,Iceland,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.7 +17384,Iceland,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.4 +17385,Iceland,2013,4,C03-Diuretics,% of total sales,0.9 +17386,Iceland,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.5 +17387,Iceland,2013,4,C10-Lipid modifying agents,Million of national currency units,308.7 +17388,Iceland,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.3 +17389,Iceland,2013,4,Products not elsewhere classified,% of total sales,25.1 +17390,Iceland,2013,4,C10-Lipid modifying agents,% of total sales,1.2 +17391,Iceland,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.8 +17392,Iceland,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.0 +17393,Iceland,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,2.2 +17394,Iceland,2013,4,N05B-Anxiolytics,Million of national currency units,270.4 +17395,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,638.8 +17396,Iceland,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.8 +17397,Iceland,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0 +17398,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.1 +17399,Iceland,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,4.7 +17400,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.2 +17401,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7 +17402,Iceland,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",189.9 +17403,Iceland,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",657.9 +17404,Iceland,2013,4,Total pharmaceutical sales,Million of national currency units,26023.1 +17405,Iceland,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,213.0 +17406,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.6 +17407,Iceland,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",6.1 +17408,Iceland,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",586.6 +17409,Iceland,2013,4,N05B-Anxiolytics,% of total sales,1.0 +17410,Iceland,2013,4,C-Cardiovascular system,Million US$ at exchange rate,14.8 +17411,Iceland,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.2 +17412,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,417.9 +17413,Iceland,2013,4,C-Cardiovascular system,Million of national currency units,1814.0 +17414,Iceland,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",45.9 +17415,Iceland,2013,4,B-Blood and blood forming organs,% of total sales,6.0 +17416,Iceland,2013,4,C-Cardiovascular system,% of total sales,7.0 +17417,Iceland,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9 +17418,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.9 +17419,Iceland,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.9 +17420,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4 +17421,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.7 +17422,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.0 +17423,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.4 +17424,Iceland,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1215.5 +17425,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.6 +17426,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.4 +17427,Iceland,2013,4,C08-Calcium channel blockers,% of total sales,0.8 +17428,Iceland,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5 +17429,Iceland,2013,4,C01A-Cardiac glycosides,Million of national currency units,11.3 +17430,Iceland,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,7.7 +17431,Iceland,2013,4,M-Musculo-skeletal system,Million of national currency units,945.5 +17432,Iceland,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.6 +17433,Iceland,2013,4,C08-Calcium channel blockers,Million of national currency units,198.8 +17434,Iceland,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0 +17435,Iceland,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.5 +17436,Iceland,2013,4,R-Respiratory system,"Million US$, purchasing power parity",13.4 +17437,Iceland,2013,4,R-Respiratory system,Million US$ at exchange rate,15.0 +17438,Iceland,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",41.4 +17439,Iceland,2013,4,R-Respiratory system,"/capita, US$ exchange rate",46.4 +17440,Iceland,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.9 +17441,Iceland,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",6.9 +17442,Iceland,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.3 +17443,Iceland,2013,4,R-Respiratory system,Million of national currency units,1836.6 +17444,Iceland,2013,4,M-Musculo-skeletal system,% of total sales,3.6 +17445,Iceland,2013,4,N02-Analgesics,"Million US$, purchasing power parity",7.3 +17446,Iceland,2013,4,N02-Analgesics,Million US$ at exchange rate,8.2 +17447,Iceland,2013,4,N02-Analgesics,"/capita, US$ exchange rate",25.3 +17448,Iceland,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.9 +17449,Iceland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",37.9 +17450,Iceland,2013,4,N02-Analgesics,Million of national currency units,998.9 +17451,Iceland,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,1498.7 +17452,Iceland,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.3 +17453,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +17454,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",2.0 +17455,Iceland,2013,4,N02-Analgesics,% of total sales,3.8 +17456,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +17457,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +17458,Iceland,2013,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +17459,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8 +17460,Iceland,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",22.5 +17461,Iceland,2013,4,A02A-Antacids,% of total sales,0.0 +17462,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.2 +17463,Iceland,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +17464,Iceland,2013,4,J-Antiinfectives for systemic use,Million of national currency units,2618.6 +17465,Iceland,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +17466,Iceland,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +17467,Iceland,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +17468,Iceland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",59.0 +17469,Iceland,2013,4,J-Antiinfectives for systemic use,% of total sales,10.1 +17470,Iceland,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,21.4 +17471,Iceland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.2 +17472,Iceland,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.1 +17473,Iceland,2013,4,R-Respiratory system,% of total sales,7.1 +17474,Iceland,2013,4,C01A-Cardiac glycosides,% of total sales,0.0 +17475,Iceland,2013,4,C03-Diuretics,Million US$ at exchange rate,1.8 +17476,Iceland,2013,4,C03-Diuretics,"Million US$, purchasing power parity",1.6 +17477,Iceland,2013,4,C03-Diuretics,Million of national currency units,225.0 +17478,Iceland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.6 +17479,Iceland,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,463.9 +17480,Iceland,2012,4,G-Genito urinary system and sex hormones,% of total sales,6.1 +17481,Iceland,2012,4,N-Nervous system,Million US$ at exchange rate,45.3 +17482,Iceland,2012,4,N-Nervous system,"Million US$, purchasing power parity",41.4 +17483,Iceland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.6 +17484,Iceland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.6 +17485,Iceland,2012,4,N-Nervous system,Million of national currency units,5666.6 +17486,Iceland,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4 +17487,Iceland,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7 +17488,Iceland,2012,4,N05C-Hypnotics and sedatives,% of total sales,1.9 +17489,Iceland,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +17490,Iceland,2012,4,C02-Antihypertensives,Million of national currency units,57.7 +17491,Iceland,2012,4,C02-Antihypertensives,% of total sales,0.2 +17492,Iceland,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.6 +17493,Iceland,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9 +17494,Iceland,2012,4,C07-Beta blocking agents,% of total sales,1.4 +17495,Iceland,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.2 +17496,Iceland,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.5 +17497,Iceland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",25.7 +17498,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.6 +17499,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.2 +17500,Iceland,2012,4,J01-Antibacterials for systemic use,Million of national currency units,1031.1 +17501,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,581.0 +17502,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.6 +17503,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.7 +17504,Iceland,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4 +17505,Iceland,2012,4,C02-Antihypertensives,Million US$ at exchange rate,0.5 +17506,Iceland,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4 +17507,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,865.6 +17508,Iceland,2012,4,C07-Beta blocking agents,Million of national currency units,345.8 +17509,Iceland,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5 +17510,Iceland,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,2.8 +17511,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.3 +17512,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.6 +17513,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9 +17514,Iceland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",38.7 +17515,Iceland,2012,4,A-Alimentary tract and metabolism,% of total sales,7.0 +17516,Iceland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.4 +17517,Iceland,2012,4,A02A-Antacids,Million US$ at exchange rate,0.0 +17518,Iceland,2012,4,A02A-Antacids,"Million US$, purchasing power parity",0.0 +17519,Iceland,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.0 +17520,Iceland,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",12.4 +17521,Iceland,2012,4,N-Nervous system,% of total sales,23.3 +17522,Iceland,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",129.0 +17523,Iceland,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,13.6 +17524,Iceland,2012,4,A-Alimentary tract and metabolism,Million of national currency units,1700.3 +17525,Iceland,2012,4,N-Nervous system,"/capita, US$ exchange rate",141.3 +17526,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.2 +17527,Iceland,2012,4,N06A-Antidepressants,Million of national currency units,842.3 +17528,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +17529,Iceland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.5 +17530,Iceland,2012,4,J01-Antibacterials for systemic use,% of total sales,4.2 +17531,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.5 +17532,Iceland,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.2 +17533,Iceland,2012,4,N06A-Antidepressants,% of total sales,3.5 +17534,Iceland,2012,4,A02A-Antacids,Million of national currency units,0.0 +17535,Iceland,2012,4,N06A-Antidepressants,Million US$ at exchange rate,6.7 +17536,Iceland,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",6.1 +17537,Iceland,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",21.0 +17538,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.9 +17539,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.5 +17540,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,617.7 +17541,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.4 +17542,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.1 +17543,Iceland,2012,4,Products not elsewhere classified,"/capita, US$ exchange rate",174.1 +17544,Iceland,2012,4,Products not elsewhere classified,"Million US$, purchasing power parity",51.0 +17545,Iceland,2012,4,Products not elsewhere classified,Million of national currency units,6983.5 +17546,Iceland,2012,4,Products not elsewhere classified,Million US$ at exchange rate,55.8 +17547,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +17548,Iceland,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.2 +17549,Iceland,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.0 +17550,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.0 +17551,Iceland,2012,4,B-Blood and blood forming organs,Million of national currency units,1325.5 +17552,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +17553,Iceland,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.7 +17554,Iceland,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,10.6 +17555,Iceland,2012,4,A10-Drugs used in diabetes,% of total sales,2.8 +17556,Iceland,2012,4,C03-Diuretics,"/capita, US$ exchange rate",5.5 +17557,Iceland,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",5.0 +17558,Iceland,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,5.4 +17559,Iceland,2012,4,A10-Drugs used in diabetes,Million of national currency units,673.1 +17560,Iceland,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.9 +17561,Iceland,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3 +17562,Iceland,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8 +17563,Iceland,2012,4,C03-Diuretics,% of total sales,0.9 +17564,Iceland,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.9 +17565,Iceland,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.7 +17566,Iceland,2012,4,C10-Lipid modifying agents,Million of national currency units,367.8 +17567,Iceland,2012,4,Products not elsewhere classified,% of total sales,28.8 +17568,Iceland,2012,4,C10-Lipid modifying agents,% of total sales,1.5 +17569,Iceland,2012,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",159.0 +17570,Iceland,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.2 +17571,Iceland,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.4 +17572,Iceland,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,2.1 +17573,Iceland,2012,4,N05B-Anxiolytics,Million of national currency units,256.8 +17574,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,482.3 +17575,Iceland,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.4 +17576,Iceland,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9 +17577,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.0 +17578,Iceland,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +17579,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.9 +17580,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.5 +17581,Iceland,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",177.3 +17582,Iceland,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",605.2 +17583,Iceland,2012,4,Total pharmaceutical sales,Million of national currency units,24278.0 +17584,Iceland,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,194.1 +17585,Iceland,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",552.7 +17586,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8 +17587,Iceland,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8 +17588,Iceland,2012,4,N05B-Anxiolytics,% of total sales,1.1 +17589,Iceland,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.6 +17590,Iceland,2012,4,C-Cardiovascular system,Million US$ at exchange rate,14.9 +17591,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,435.6 +17592,Iceland,2012,4,C-Cardiovascular system,Million of national currency units,1866.2 +17593,Iceland,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.5 +17594,Iceland,2012,4,B-Blood and blood forming organs,% of total sales,5.5 +17595,Iceland,2012,4,C-Cardiovascular system,% of total sales,7.7 +17596,Iceland,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",42.5 +17597,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.5 +17598,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.7 +17599,Iceland,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.6 +17600,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.2 +17601,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8 +17602,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2 +17603,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.9 +17604,Iceland,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1196.5 +17605,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.9 +17606,Iceland,2012,4,C08-Calcium channel blockers,% of total sales,0.9 +17607,Iceland,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,6.1 +17608,Iceland,2012,4,M-Musculo-skeletal system,Million of national currency units,765.0 +17609,Iceland,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8 +17610,Iceland,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.7 +17611,Iceland,2012,4,C08-Calcium channel blockers,Million of national currency units,211.5 +17612,Iceland,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.3 +17613,Iceland,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.5 +17614,Iceland,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.6 +17615,Iceland,2012,4,R-Respiratory system,"Million US$, purchasing power parity",11.6 +17616,Iceland,2012,4,R-Respiratory system,Million US$ at exchange rate,12.7 +17617,Iceland,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",36.0 +17618,Iceland,2012,4,R-Respiratory system,"/capita, US$ exchange rate",39.5 +17619,Iceland,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.1 +17620,Iceland,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4 +17621,Iceland,2012,4,R-Respiratory system,Million of national currency units,1582.6 +17622,Iceland,2012,4,M-Musculo-skeletal system,% of total sales,3.2 +17623,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.4 +17624,Iceland,2012,4,N02-Analgesics,"Million US$, purchasing power parity",5.7 +17625,Iceland,2012,4,N02-Analgesics,Million US$ at exchange rate,6.3 +17626,Iceland,2012,4,N02-Analgesics,"/capita, US$ exchange rate",19.6 +17627,Iceland,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.8 +17628,Iceland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",36.8 +17629,Iceland,2012,4,N02-Analgesics,Million of national currency units,787.5 +17630,Iceland,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,1476.1 +17631,Iceland,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.8 +17632,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +17633,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9 +17634,Iceland,2012,4,N02-Analgesics,% of total sales,3.2 +17635,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +17636,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +17637,Iceland,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +17638,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8 +17639,Iceland,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",17.9 +17640,Iceland,2012,4,A02A-Antacids,% of total sales,0.0 +17641,Iceland,2012,4,C01A-Cardiac glycosides,Million of national currency units,10.6 +17642,Iceland,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +17643,Iceland,2012,4,J-Antiinfectives for systemic use,Million of national currency units,2794.5 +17644,Iceland,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +17645,Iceland,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +17646,Iceland,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +17647,Iceland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.6 +17648,Iceland,2012,4,J-Antiinfectives for systemic use,% of total sales,11.5 +17649,Iceland,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.3 +17650,Iceland,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",20.4 +17651,Iceland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.7 +17652,Iceland,2012,4,C03-Diuretics,Million of national currency units,221.6 +17653,Iceland,2012,4,C01A-Cardiac glycosides,% of total sales,0.0 +17654,Iceland,2012,4,C03-Diuretics,Million US$ at exchange rate,1.8 +17655,Iceland,2012,4,R-Respiratory system,% of total sales,6.5 +17656,Iceland,2012,4,C03-Diuretics,"Million US$, purchasing power parity",1.6 +17657,Iceland,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,466.6 +17658,Iceland,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.3 +17659,Iceland,2011,5,G-Genito urinary system and sex hormones,% of total sales,5.5 +17660,Iceland,2011,5,N-Nervous system,"Million US$, purchasing power parity",42.2 +17661,Iceland,2011,5,N-Nervous system,Million US$ at exchange rate,49.2 +17662,Iceland,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.8 +17663,Iceland,2011,5,N-Nervous system,"/capita, US$ exchange rate",154.2 +17664,Iceland,2011,5,N-Nervous system,Million of national currency units,5703.4 +17665,Iceland,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5 +17666,Iceland,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0 +17667,Iceland,2011,5,N05C-Hypnotics and sedatives,% of total sales,1.8 +17668,Iceland,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",12.6 +17669,Iceland,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1 +17670,Iceland,2011,5,C02-Antihypertensives,% of total sales,0.2 +17671,Iceland,2011,5,C02-Antihypertensives,Million of national currency units,48.9 +17672,Iceland,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.4 +17673,Iceland,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0 +17674,Iceland,2011,5,C07-Beta blocking agents,% of total sales,1.3 +17675,Iceland,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.3 +17676,Iceland,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.2 +17677,Iceland,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1 +17678,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.0 +17679,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.0 +17680,Iceland,2011,5,J01-Antibacterials for systemic use,Million of national currency units,966.8 +17681,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,808.1 +17682,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.2 +17683,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.6 +17684,Iceland,2011,5,C02-Antihypertensives,Million US$ at exchange rate,0.4 +17685,Iceland,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.4 +17686,Iceland,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.3 +17687,Iceland,2011,5,C07-Beta blocking agents,Million of national currency units,346.8 +17688,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,845.0 +17689,Iceland,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,3.0 +17690,Iceland,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.6 +17691,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",22.8 +17692,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.3 +17693,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.3 +17694,Iceland,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.9 +17695,Iceland,2011,5,A-Alimentary tract and metabolism,% of total sales,7.3 +17696,Iceland,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.2 +17697,Iceland,2011,5,A02A-Antacids,"Million US$, purchasing power parity",0.0 +17698,Iceland,2011,5,A02A-Antacids,Million US$ at exchange rate,0.0 +17699,Iceland,2011,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +17700,Iceland,2011,5,N-Nervous system,% of total sales,21.9 +17701,Iceland,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",132.3 +17702,Iceland,2011,5,A-Alimentary tract and metabolism,Million of national currency units,1894.8 +17703,Iceland,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.3 +17704,Iceland,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",14.0 +17705,Iceland,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +17706,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.7 +17707,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1 +17708,Iceland,2011,5,N06A-Antidepressants,Million of national currency units,865.8 +17709,Iceland,2011,5,J01-Antibacterials for systemic use,% of total sales,3.7 +17710,Iceland,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.4 +17711,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.8 +17712,Iceland,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.1 +17713,Iceland,2011,5,N06A-Antidepressants,% of total sales,3.3 +17714,Iceland,2011,5,A02A-Antacids,Million of national currency units,0.0 +17715,Iceland,2011,5,N06A-Antidepressants,Million US$ at exchange rate,7.5 +17716,Iceland,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.4 +17717,Iceland,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",23.4 +17718,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4 +17719,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.6 +17720,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5 +17721,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.9 +17722,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,623.4 +17723,Iceland,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",223.3 +17724,Iceland,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",61.1 +17725,Iceland,2011,5,Products not elsewhere classified,Million of national currency units,8260.8 +17726,Iceland,2011,5,Products not elsewhere classified,Million US$ at exchange rate,71.2 +17727,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +17728,Iceland,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.7 +17729,Iceland,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.8 +17730,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.3 +17731,Iceland,2011,5,B-Blood and blood forming organs,Million of national currency units,1283.9 +17732,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +17733,Iceland,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.5 +17734,Iceland,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,11.1 +17735,Iceland,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",191.6 +17736,Iceland,2011,5,A10-Drugs used in diabetes,% of total sales,2.5 +17737,Iceland,2011,5,C03-Diuretics,"/capita, US$ exchange rate",5.9 +17738,Iceland,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",5.1 +17739,Iceland,2011,5,C03-Diuretics,% of total sales,0.8 +17740,Iceland,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.0 +17741,Iceland,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,5.6 +17742,Iceland,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.8 +17743,Iceland,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.4 +17744,Iceland,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,3.2 +17745,Iceland,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.7 +17746,Iceland,2011,5,Products not elsewhere classified,% of total sales,31.7 +17747,Iceland,2011,5,C10-Lipid modifying agents,Million of national currency units,366.0 +17748,Iceland,2011,5,C10-Lipid modifying agents,% of total sales,1.4 +17749,Iceland,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.9 +17750,Iceland,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5 +17751,Iceland,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,1.9 +17752,Iceland,2011,5,N05B-Anxiolytics,Million of national currency units,214.7 +17753,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,485.5 +17754,Iceland,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.8 +17755,Iceland,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",1.6 +17756,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1 +17757,Iceland,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,4.5 +17758,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.2 +17759,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.6 +17760,Iceland,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",705.1 +17761,Iceland,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",193.0 +17762,Iceland,2011,5,Total pharmaceutical sales,Million of national currency units,26083.5 +17763,Iceland,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,224.9 +17764,Iceland,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",605.0 +17765,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.0 +17766,Iceland,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.0 +17767,Iceland,2011,5,N05B-Anxiolytics,% of total sales,0.8 +17768,Iceland,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",14.4 +17769,Iceland,2011,5,C-Cardiovascular system,Million US$ at exchange rate,16.8 +17770,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,520.4 +17771,Iceland,2011,5,C-Cardiovascular system,Million of national currency units,1946.3 +17772,Iceland,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",52.6 +17773,Iceland,2011,5,B-Blood and blood forming organs,% of total sales,4.9 +17774,Iceland,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.1 +17775,Iceland,2011,5,C-Cardiovascular system,% of total sales,7.5 +17776,Iceland,2011,5,A10-Drugs used in diabetes,Million of national currency units,645.2 +17777,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.7 +17778,Iceland,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.2 +17779,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4 +17780,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.9 +17781,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.1 +17782,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.9 +17783,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.5 +17784,Iceland,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1180.2 +17785,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.1 +17786,Iceland,2011,5,C01A-Cardiac glycosides,Million of national currency units,10.0 +17787,Iceland,2011,5,C08-Calcium channel blockers,% of total sales,0.9 +17788,Iceland,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,6.6 +17789,Iceland,2011,5,M-Musculo-skeletal system,Million of national currency units,760.9 +17790,Iceland,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0 +17791,Iceland,2011,5,C08-Calcium channel blockers,Million of national currency units,229.8 +17792,Iceland,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3 +17793,Iceland,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.2 +17794,Iceland,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.7 +17795,Iceland,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.6 +17796,Iceland,2011,5,R-Respiratory system,"Million US$, purchasing power parity",11.5 +17797,Iceland,2011,5,R-Respiratory system,Million US$ at exchange rate,13.4 +17798,Iceland,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",36.1 +17799,Iceland,2011,5,R-Respiratory system,"/capita, US$ exchange rate",42.1 +17800,Iceland,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.6 +17801,Iceland,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.6 +17802,Iceland,2011,5,R-Respiratory system,Million of national currency units,1558.2 +17803,Iceland,2011,5,M-Musculo-skeletal system,% of total sales,2.9 +17804,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,69.6 +17805,Iceland,2011,5,N02-Analgesics,"Million US$, purchasing power parity",5.8 +17806,Iceland,2011,5,N02-Analgesics,Million US$ at exchange rate,6.8 +17807,Iceland,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",18.3 +17808,Iceland,2011,5,N02-Analgesics,"/capita, US$ exchange rate",21.4 +17809,Iceland,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.6 +17810,Iceland,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.8 +17811,Iceland,2011,5,N02-Analgesics,Million of national currency units,789.8 +17812,Iceland,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,1436.1 +17813,Iceland,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.4 +17814,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9 +17815,Iceland,2011,5,N02-Analgesics,% of total sales,3.0 +17816,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +17817,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5 +17818,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6 +17819,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +17820,Iceland,2011,5,A02A-Antacids,% of total sales,0.0 +17821,Iceland,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +17822,Iceland,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2615.7 +17823,Iceland,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +17824,Iceland,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +17825,Iceland,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +17826,Iceland,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",60.7 +17827,Iceland,2011,5,J-Antiinfectives for systemic use,% of total sales,10.0 +17828,Iceland,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.6 +17829,Iceland,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.4 +17830,Iceland,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",70.7 +17831,Iceland,2011,5,C01A-Cardiac glycosides,% of total sales,0.0 +17832,Iceland,2011,5,C03-Diuretics,"Million US$, purchasing power parity",1.6 +17833,Iceland,2011,5,C03-Diuretics,Million of national currency units,219.2 +17834,Iceland,2011,5,R-Respiratory system,% of total sales,6.0 +17835,Iceland,2011,5,C03-Diuretics,Million US$ at exchange rate,1.9 +17836,Ireland,2017,5,N02-Analgesics,"Million US$, purchasing power parity",69.0 +17837,Ireland,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.4 +17838,Ireland,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.6 +17839,Ireland,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.6 +17840,Ireland,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",142.4 +17841,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.5 +17842,Ireland,2017,5,N05B-Anxiolytics,% of total sales,0.4 +17843,Ireland,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +17844,Ireland,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +17845,Ireland,2017,5,B-Blood and blood forming organs,% of total sales,5.3 +17846,Ireland,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1 +17847,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +17848,Ireland,2017,5,C02-Antihypertensives,Million of national currency units,17.8 +17849,Ireland,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,10.2 +17850,Ireland,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",11.3 +17851,Ireland,2017,5,N05B-Anxiolytics,Million of national currency units,9.0 +17852,Ireland,2017,5,N02-Analgesics,Million of national currency units,54.8 +17853,Ireland,2017,5,N02-Analgesics,Million US$ at exchange rate,61.9 +17854,Ireland,2017,5,C03-Diuretics,Million of national currency units,14.3 +17855,Ireland,2017,5,C03-Diuretics,Million US$ at exchange rate,16.1 +17856,Ireland,2017,5,C03-Diuretics,"Million US$, purchasing power parity",18.0 +17857,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +17858,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,51.7 +17859,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0 +17860,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5 +17861,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.1 +17862,Ireland,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",143.0 +17863,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.5 +17864,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.4 +17865,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",65.1 +17866,Ireland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.7 +17867,Ireland,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7 +17868,Ireland,2017,5,C02-Antihypertensives,% of total sales,0.8 +17869,Ireland,2017,5,J-Antiinfectives for systemic use,% of total sales,5.3 +17870,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,62.7 +17871,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",69.9 +17872,Ireland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.7 +17873,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.5 +17874,Ireland,2017,5,N02-Analgesics,% of total sales,2.6 +17875,Ireland,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.1 +17876,Ireland,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.7 +17877,Ireland,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8 +17878,Ireland,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3 +17879,Ireland,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",22.4 +17880,Ireland,2017,5,C02-Antihypertensives,Million US$ at exchange rate,20.1 +17881,Ireland,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,18.3 +17882,Ireland,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",4.2 +17883,Ireland,2017,5,N05C-Hypnotics and sedatives,% of total sales,0.9 +17884,Ireland,2017,5,B-Blood and blood forming organs,Million of national currency units,113.1 +17885,Ireland,2017,5,N02-Analgesics,"/capita, US$ exchange rate",12.9 +17886,Ireland,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",14.4 +17887,Ireland,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,127.8 +17888,Ireland,2017,5,C03-Diuretics,% of total sales,0.7 +17889,Ireland,2017,5,J-Antiinfectives for systemic use,Million of national currency units,113.6 +17890,Ireland,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,128.3 +17891,Ireland,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +17892,Ireland,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +17893,Ireland,2017,5,C01A-Cardiac glycosides,% of total sales,0.1 +17894,Ireland,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +17895,Ireland,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2 +17896,Ireland,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.7 +17897,Ireland,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.9 +17898,Ireland,2017,5,C01A-Cardiac glycosides,Million of national currency units,1.1 +17899,Ireland,2017,5,M-Musculo-skeletal system,% of total sales,3.2 +17900,Ireland,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,74.8 +17901,Ireland,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",83.3 +17902,Ireland,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",205.2 +17903,Ireland,2017,5,Products not elsewhere classified,% of total sales,36.9 +17904,Ireland,2017,5,C10-Lipid modifying agents,Million of national currency units,66.2 +17905,Ireland,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,110.5 +17906,Ireland,2017,5,A10-Drugs used in diabetes,Million of national currency units,97.8 +17907,Ireland,2017,5,C10-Lipid modifying agents,% of total sales,3.1 +17908,Ireland,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.6 +17909,Ireland,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.3 +17910,Ireland,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",85.0 +17911,Ireland,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,19.9 +17912,Ireland,2017,5,C08-Calcium channel blockers,Million of national currency units,17.6 +17913,Ireland,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2 +17914,Ireland,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6 +17915,Ireland,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +17916,Ireland,2017,5,A02A-Antacids,Million US$ at exchange rate,0.0 +17917,Ireland,2017,5,A02A-Antacids,Million of national currency units,0.0 +17918,Ireland,2017,5,A02A-Antacids,"Million US$, purchasing power parity",0.0 +17919,Ireland,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +17920,Ireland,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.0 +17921,Ireland,2017,5,R-Respiratory system,"/capita, US$ exchange rate",42.7 +17922,Ireland,2017,5,R-Respiratory system,% of total sales,8.6 +17923,Ireland,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",47.6 +17924,Ireland,2017,5,M-Musculo-skeletal system,Million of national currency units,67.5 +17925,Ireland,2017,5,C08-Calcium channel blockers,% of total sales,0.8 +17926,Ireland,2017,5,R-Respiratory system,Million US$ at exchange rate,205.3 +17927,Ireland,2017,5,R-Respiratory system,Million of national currency units,181.8 +17928,Ireland,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,76.2 +17929,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.9 +17930,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2 +17931,Ireland,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",556.3 +17932,Ireland,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +17933,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",129.4 +17934,Ireland,2017,5,C-Cardiovascular system,Million of national currency units,211.3 +17935,Ireland,2017,5,C-Cardiovascular system,Million US$ at exchange rate,238.7 +17936,Ireland,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,116.1 +17937,Ireland,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,102.8 +17938,Ireland,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",499.2 +17939,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5 +17940,Ireland,2017,5,Total pharmaceutical sales,Million of national currency units,2124.4 +17941,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",13.9 +17942,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5 +17943,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",66.9 +17944,Ireland,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,2399.9 +17945,Ireland,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2674.3 +17946,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.0 +17947,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,53.1 +17948,Ireland,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",123.2 +17949,Ireland,2017,5,A02A-Antacids,% of total sales,0.0 +17950,Ireland,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.0 +17951,Ireland,2017,5,A10-Drugs used in diabetes,% of total sales,4.6 +17952,Ireland,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.6 +17953,Ireland,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",986.5 +17954,Ireland,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",184.2 +17955,Ireland,2017,5,Products not elsewhere classified,Million of national currency units,783.7 +17956,Ireland,2017,5,Products not elsewhere classified,Million US$ at exchange rate,885.3 +17957,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,17.8 +17958,Ireland,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",266.0 +17959,Ireland,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.7 +17960,Ireland,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",55.3 +17961,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.7 +17962,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +17963,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.2 +17964,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,20.1 +17965,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.4 +17966,Ireland,2017,5,C-Cardiovascular system,% of total sales,9.9 +17967,Ireland,2017,5,R-Respiratory system,"Million US$, purchasing power parity",228.8 +17968,Ireland,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",81.5 +17969,Ireland,2017,5,J01-Antibacterials for systemic use,Million of national currency units,42.9 +17970,Ireland,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.1 +17971,Ireland,2017,5,N-Nervous system,% of total sales,14.7 +17972,Ireland,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",54.0 +17973,Ireland,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +17974,Ireland,2017,5,N-Nervous system,"/capita, US$ exchange rate",73.1 +17975,Ireland,2017,5,G-Genito urinary system and sex hormones,% of total sales,3.3 +17976,Ireland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.7 +17977,Ireland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.6 +17978,Ireland,2017,5,N-Nervous system,"Million US$, purchasing power parity",391.8 +17979,Ireland,2017,5,N-Nervous system,Million of national currency units,311.2 +17980,Ireland,2017,5,N-Nervous system,Million US$ at exchange rate,351.6 +17981,Ireland,2017,5,N06A-Antidepressants,Million US$ at exchange rate,50.1 +17982,Ireland,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",55.8 +17983,Ireland,2017,5,A-Alimentary tract and metabolism,% of total sales,10.1 +17984,Ireland,2017,5,N06A-Antidepressants,Million of national currency units,44.4 +17985,Ireland,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.4 +17986,Ireland,2017,5,N06A-Antidepressants,% of total sales,2.1 +17987,Ireland,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.6 +17988,Ireland,2017,5,A-Alimentary tract and metabolism,Million of national currency units,215.6 +17989,Ireland,2017,5,J01-Antibacterials for systemic use,% of total sales,2.0 +17990,Ireland,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,243.5 +17991,Ireland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.7 +17992,Ireland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4 +17993,Ireland,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",271.4 +17994,Ireland,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,48.5 +17995,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.3 +17996,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.0 +17997,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.7 +17998,Ireland,2017,5,C07-Beta blocking agents,Million of national currency units,22.5 +17999,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,32.8 +18000,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6 +18001,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +18002,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +18003,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1 +18004,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4 +18005,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.8 +18006,Ireland,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,25.4 +18007,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +18008,Ireland,2017,5,C07-Beta blocking agents,% of total sales,1.1 +18009,Ireland,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3 +18010,Ireland,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,80.4 +18011,Ireland,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",89.6 +18012,Ireland,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,71.2 +18013,Ireland,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.9 +18014,Ireland,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",28.3 +18015,Ireland,2016,6,N02-Analgesics,"Million US$, purchasing power parity",73.0 +18016,Ireland,2016,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8 +18017,Ireland,2016,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.4 +18018,Ireland,2016,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",132.1 +18019,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +18020,Ireland,2016,6,C02-Antihypertensives,Million of national currency units,18.3 +18021,Ireland,2016,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +18022,Ireland,2016,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +18023,Ireland,2016,6,N05B-Anxiolytics,% of total sales,0.4 +18024,Ireland,2016,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2 +18025,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +18026,Ireland,2016,6,N05B-Anxiolytics,Million US$ at exchange rate,10.3 +18027,Ireland,2016,6,N05B-Anxiolytics,Million of national currency units,9.3 +18028,Ireland,2016,6,B-Blood and blood forming organs,% of total sales,5.1 +18029,Ireland,2016,6,C03-Diuretics,"/capita, US$ exchange rate",3.4 +18030,Ireland,2016,6,N02-Analgesics,Million of national currency units,58.0 +18031,Ireland,2016,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.8 +18032,Ireland,2016,6,N02-Analgesics,Million US$ at exchange rate,64.2 +18033,Ireland,2016,6,C03-Diuretics,Million of national currency units,14.7 +18034,Ireland,2016,6,C03-Diuretics,Million US$ at exchange rate,16.3 +18035,Ireland,2016,6,C03-Diuretics,"Million US$, purchasing power parity",18.6 +18036,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +18037,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,52.4 +18038,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0 +18039,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.8 +18040,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9 +18041,Ireland,2016,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",129.4 +18042,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.2 +18043,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.0 +18044,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",66.0 +18045,Ireland,2016,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.2 +18046,Ireland,2016,6,J-Antiinfectives for systemic use,% of total sales,5.0 +18047,Ireland,2016,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.9 +18048,Ireland,2016,6,C02-Antihypertensives,% of total sales,0.9 +18049,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,61.7 +18050,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.2 +18051,Ireland,2016,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.9 +18052,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.7 +18053,Ireland,2016,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6 +18054,Ireland,2016,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.8 +18055,Ireland,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.4 +18056,Ireland,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0 +18057,Ireland,2016,6,C02-Antihypertensives,"Million US$, purchasing power parity",23.1 +18058,Ireland,2016,6,C02-Antihypertensives,Million US$ at exchange rate,20.3 +18059,Ireland,2016,6,N05C-Hypnotics and sedatives,Million of national currency units,18.8 +18060,Ireland,2016,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.3 +18061,Ireland,2016,6,N05C-Hypnotics and sedatives,% of total sales,0.9 +18062,Ireland,2016,6,B-Blood and blood forming organs,Million of national currency units,104.9 +18063,Ireland,2016,6,B-Blood and blood forming organs,Million US$ at exchange rate,116.1 +18064,Ireland,2016,6,N02-Analgesics,"/capita, US$ exchange rate",13.5 +18065,Ireland,2016,6,N02-Analgesics,% of total sales,2.8 +18066,Ireland,2016,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.4 +18067,Ireland,2016,6,C03-Diuretics,% of total sales,0.7 +18068,Ireland,2016,6,J-Antiinfectives for systemic use,Million of national currency units,102.8 +18069,Ireland,2016,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,113.8 +18070,Ireland,2016,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +18071,Ireland,2016,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +18072,Ireland,2016,6,C01A-Cardiac glycosides,% of total sales,0.1 +18073,Ireland,2016,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +18074,Ireland,2016,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4 +18075,Ireland,2016,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9 +18076,Ireland,2016,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.7 +18077,Ireland,2016,6,C01A-Cardiac glycosides,Million of national currency units,1.2 +18078,Ireland,2016,6,M-Musculo-skeletal system,% of total sales,3.2 +18079,Ireland,2016,6,C10-Lipid modifying agents,Million US$ at exchange rate,72.4 +18080,Ireland,2016,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",82.3 +18081,Ireland,2016,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",194.1 +18082,Ireland,2016,6,Products not elsewhere classified,% of total sales,35.3 +18083,Ireland,2016,6,C10-Lipid modifying agents,Million of national currency units,65.4 +18084,Ireland,2016,6,A10-Drugs used in diabetes,Million US$ at exchange rate,104.0 +18085,Ireland,2016,6,A10-Drugs used in diabetes,Million of national currency units,94.0 +18086,Ireland,2016,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.2 +18087,Ireland,2016,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.3 +18088,Ireland,2016,6,C10-Lipid modifying agents,% of total sales,3.1 +18089,Ireland,2016,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",84.9 +18090,Ireland,2016,6,C08-Calcium channel blockers,Million US$ at exchange rate,20.0 +18091,Ireland,2016,6,C08-Calcium channel blockers,Million of national currency units,18.1 +18092,Ireland,2016,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.7 +18093,Ireland,2016,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8 +18094,Ireland,2016,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2 +18095,Ireland,2016,6,A02A-Antacids,Million US$ at exchange rate,0.0 +18096,Ireland,2016,6,A02A-Antacids,Million of national currency units,0.0 +18097,Ireland,2016,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +18098,Ireland,2016,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +18099,Ireland,2016,6,A02A-Antacids,"Million US$, purchasing power parity",0.1 +18100,Ireland,2016,6,R-Respiratory system,"/capita, US$ exchange rate",39.1 +18101,Ireland,2016,6,R-Respiratory system,"Million US$, purchasing power parity",211.3 +18102,Ireland,2016,6,R-Respiratory system,% of total sales,8.1 +18103,Ireland,2016,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.4 +18104,Ireland,2016,6,R-Respiratory system,Million US$ at exchange rate,185.7 +18105,Ireland,2016,6,M-Musculo-skeletal system,Million of national currency units,67.5 +18106,Ireland,2016,6,C08-Calcium channel blockers,% of total sales,0.9 +18107,Ireland,2016,6,M-Musculo-skeletal system,Million US$ at exchange rate,74.7 +18108,Ireland,2016,6,R-Respiratory system,Million of national currency units,167.8 +18109,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",29.5 +18110,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.9 +18111,Ireland,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",549.6 +18112,Ireland,2016,6,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +18113,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",140.2 +18114,Ireland,2016,6,C-Cardiovascular system,Million of national currency units,218.3 +18115,Ireland,2016,6,C-Cardiovascular system,Million US$ at exchange rate,241.6 +18116,Ireland,2016,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,123.2 +18117,Ireland,2016,6,R03-Drugs for obstructive airway diseases,Million of national currency units,111.3 +18118,Ireland,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",483.2 +18119,Ireland,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,2298.0 +18120,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.8 +18121,Ireland,2016,6,Total pharmaceutical sales,Million of national currency units,2076.0 +18122,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.7 +18123,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.9 +18124,Ireland,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2613.7 +18125,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",74.5 +18126,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,65.5 +18127,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,59.2 +18128,Ireland,2016,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.9 +18129,Ireland,2016,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",118.3 +18130,Ireland,2016,6,A10-Drugs used in diabetes,% of total sales,4.5 +18131,Ireland,2016,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.9 +18132,Ireland,2016,6,A02A-Antacids,% of total sales,0.0 +18133,Ireland,2016,6,Products not elsewhere classified,"Million US$, purchasing power parity",923.2 +18134,Ireland,2016,6,Products not elsewhere classified,"/capita, US$ exchange rate",170.7 +18135,Ireland,2016,6,Products not elsewhere classified,Million US$ at exchange rate,811.7 +18136,Ireland,2016,6,Products not elsewhere classified,Million of national currency units,733.3 +18137,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.2 +18138,Ireland,2016,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.8 +18139,Ireland,2016,6,C-Cardiovascular system,"Million US$, purchasing power parity",274.8 +18140,Ireland,2016,6,C-Cardiovascular system,"/capita, US$ exchange rate",50.8 +18141,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,21.2 +18142,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1 +18143,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9 +18144,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.5 +18145,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.1 +18146,Ireland,2016,6,C-Cardiovascular system,% of total sales,10.5 +18147,Ireland,2016,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,49.7 +18148,Ireland,2016,6,N-Nervous system,"/capita, US$ purchasing power parity",89.7 +18149,Ireland,2016,6,J01-Antibacterials for systemic use,Million of national currency units,44.9 +18150,Ireland,2016,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.4 +18151,Ireland,2016,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9 +18152,Ireland,2016,6,N-Nervous system,% of total sales,16.3 +18153,Ireland,2016,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",56.5 +18154,Ireland,2016,6,G-Genito urinary system and sex hormones,% of total sales,3.7 +18155,Ireland,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.3 +18156,Ireland,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.8 +18157,Ireland,2016,6,N-Nervous system,"Million US$, purchasing power parity",426.5 +18158,Ireland,2016,6,N-Nervous system,"/capita, US$ exchange rate",78.9 +18159,Ireland,2016,6,N-Nervous system,Million of national currency units,338.8 +18160,Ireland,2016,6,N-Nervous system,Million US$ at exchange rate,375.0 +18161,Ireland,2016,6,N06A-Antidepressants,Million US$ at exchange rate,55.0 +18162,Ireland,2016,6,N06A-Antidepressants,"Million US$, purchasing power parity",62.5 +18163,Ireland,2016,6,A-Alimentary tract and metabolism,% of total sales,10.1 +18164,Ireland,2016,6,N06A-Antidepressants,Million of national currency units,49.7 +18165,Ireland,2016,6,N06A-Antidepressants,"/capita, US$ exchange rate",11.6 +18166,Ireland,2016,6,N06A-Antidepressants,% of total sales,2.4 +18167,Ireland,2016,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.2 +18168,Ireland,2016,6,A-Alimentary tract and metabolism,Million of national currency units,210.4 +18169,Ireland,2016,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,232.9 +18170,Ireland,2016,6,J01-Antibacterials for systemic use,% of total sales,2.2 +18171,Ireland,2016,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.0 +18172,Ireland,2016,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.7 +18173,Ireland,2016,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",264.9 +18174,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",44.4 +18175,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,39.0 +18176,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.2 +18177,Ireland,2016,6,C07-Beta blocking agents,Million of national currency units,22.9 +18178,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,35.3 +18179,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +18180,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.3 +18181,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +18182,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +18183,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4 +18184,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1 +18185,Ireland,2016,6,C07-Beta blocking agents,Million US$ at exchange rate,25.4 +18186,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9 +18187,Ireland,2016,6,C07-Beta blocking agents,% of total sales,1.1 +18188,Ireland,2016,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1 +18189,Ireland,2016,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3 +18190,Ireland,2016,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",96.5 +18191,Ireland,2016,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,84.8 +18192,Ireland,2016,6,G-Genito urinary system and sex hormones,Million of national currency units,76.6 +18193,Ireland,2016,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.9 +18194,Ireland,2015,6,N02-Analgesics,"Million US$, purchasing power parity",71.0 +18195,Ireland,2015,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.0 +18196,Ireland,2015,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",117.5 +18197,Ireland,2015,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.5 +18198,Ireland,2015,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.6 +18199,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +18200,Ireland,2015,6,C02-Antihypertensives,Million of national currency units,17.2 +18201,Ireland,2015,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0 +18202,Ireland,2015,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +18203,Ireland,2015,6,N05B-Anxiolytics,% of total sales,0.5 +18204,Ireland,2015,6,B-Blood and blood forming organs,% of total sales,4.8 +18205,Ireland,2015,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2 +18206,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.8 +18207,Ireland,2015,6,N05B-Anxiolytics,Million US$ at exchange rate,10.4 +18208,Ireland,2015,6,N05B-Anxiolytics,Million of national currency units,9.4 +18209,Ireland,2015,6,C03-Diuretics,"/capita, US$ exchange rate",3.6 +18210,Ireland,2015,6,N02-Analgesics,Million of national currency units,57.5 +18211,Ireland,2015,6,N02-Analgesics,Million US$ at exchange rate,63.7 +18212,Ireland,2015,6,C03-Diuretics,Million of national currency units,15.4 +18213,Ireland,2015,6,C03-Diuretics,Million US$ at exchange rate,17.1 +18214,Ireland,2015,6,C03-Diuretics,"Million US$, purchasing power parity",19.0 +18215,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +18216,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,55.6 +18217,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6 +18218,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.0 +18219,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,61.7 +18220,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.6 +18221,Ireland,2015,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",110.7 +18222,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.1 +18223,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.6 +18224,Ireland,2015,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.5 +18225,Ireland,2015,6,J-Antiinfectives for systemic use,% of total sales,4.5 +18226,Ireland,2015,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.5 +18227,Ireland,2015,6,C02-Antihypertensives,% of total sales,0.9 +18228,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,59.2 +18229,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.9 +18230,Ireland,2015,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.2 +18231,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,53.4 +18232,Ireland,2015,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.6 +18233,Ireland,2015,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.3 +18234,Ireland,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3 +18235,Ireland,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8 +18236,Ireland,2015,6,N05C-Hypnotics and sedatives,% of total sales,0.9 +18237,Ireland,2015,6,C02-Antihypertensives,"Million US$, purchasing power parity",21.2 +18238,Ireland,2015,6,C02-Antihypertensives,Million US$ at exchange rate,19.1 +18239,Ireland,2015,6,N05C-Hypnotics and sedatives,Million of national currency units,18.3 +18240,Ireland,2015,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.1 +18241,Ireland,2015,6,B-Blood and blood forming organs,Million of national currency units,95.2 +18242,Ireland,2015,6,N02-Analgesics,"/capita, US$ exchange rate",13.6 +18243,Ireland,2015,6,B-Blood and blood forming organs,Million US$ at exchange rate,105.6 +18244,Ireland,2015,6,N02-Analgesics,% of total sales,2.9 +18245,Ireland,2015,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.1 +18246,Ireland,2015,6,C03-Diuretics,% of total sales,0.8 +18247,Ireland,2015,6,J-Antiinfectives for systemic use,Million of national currency units,89.6 +18248,Ireland,2015,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,99.5 +18249,Ireland,2015,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3 +18250,Ireland,2015,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7 +18251,Ireland,2015,6,C01A-Cardiac glycosides,% of total sales,0.1 +18252,Ireland,2015,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +18253,Ireland,2015,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5 +18254,Ireland,2015,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4 +18255,Ireland,2015,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6 +18256,Ireland,2015,6,C01A-Cardiac glycosides,Million of national currency units,1.3 +18257,Ireland,2015,6,M-Musculo-skeletal system,% of total sales,3.3 +18258,Ireland,2015,6,C10-Lipid modifying agents,Million US$ at exchange rate,72.7 +18259,Ireland,2015,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",80.9 +18260,Ireland,2015,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",174.4 +18261,Ireland,2015,6,Products not elsewhere classified,% of total sales,33.4 +18262,Ireland,2015,6,C10-Lipid modifying agents,Million of national currency units,65.5 +18263,Ireland,2015,6,A10-Drugs used in diabetes,Million US$ at exchange rate,99.1 +18264,Ireland,2015,6,A10-Drugs used in diabetes,Million of national currency units,89.3 +18265,Ireland,2015,6,C10-Lipid modifying agents,% of total sales,3.3 +18266,Ireland,2015,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.5 +18267,Ireland,2015,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.2 +18268,Ireland,2015,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2 +18269,Ireland,2015,6,C08-Calcium channel blockers,Million US$ at exchange rate,20.0 +18270,Ireland,2015,6,C08-Calcium channel blockers,Million of national currency units,18.0 +18271,Ireland,2015,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7 +18272,Ireland,2015,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2 +18273,Ireland,2015,6,A02A-Antacids,Million US$ at exchange rate,0.1 +18274,Ireland,2015,6,A02A-Antacids,Million of national currency units,0.1 +18275,Ireland,2015,6,A02A-Antacids,"Million US$, purchasing power parity",0.1 +18276,Ireland,2015,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +18277,Ireland,2015,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +18278,Ireland,2015,6,R-Respiratory system,"/capita, US$ exchange rate",40.0 +18279,Ireland,2015,6,R-Respiratory system,"Million US$, purchasing power parity",209.4 +18280,Ireland,2015,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.8 +18281,Ireland,2015,6,R-Respiratory system,% of total sales,8.5 +18282,Ireland,2015,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.5 +18283,Ireland,2015,6,M-Musculo-skeletal system,Million of national currency units,66.2 +18284,Ireland,2015,6,C08-Calcium channel blockers,% of total sales,0.9 +18285,Ireland,2015,6,R-Respiratory system,Million US$ at exchange rate,188.1 +18286,Ireland,2015,6,R-Respiratory system,Million of national currency units,169.5 +18287,Ireland,2015,6,M-Musculo-skeletal system,Million US$ at exchange rate,73.5 +18288,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.3 +18289,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.2 +18290,Ireland,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",521.4 +18291,Ireland,2015,6,R03-Drugs for obstructive airway diseases,% of total sales,5.8 +18292,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",142.5 +18293,Ireland,2015,6,C-Cardiovascular system,Million of national currency units,217.8 +18294,Ireland,2015,6,C-Cardiovascular system,Million US$ at exchange rate,241.7 +18295,Ireland,2015,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,128.0 +18296,Ireland,2015,6,R03-Drugs for obstructive airway diseases,Million of national currency units,115.4 +18297,Ireland,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,2202.5 +18298,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.0 +18299,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.6 +18300,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.0 +18301,Ireland,2015,6,Total pharmaceutical sales,Million of national currency units,1985.1 +18302,Ireland,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2451.7 +18303,Ireland,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",468.4 +18304,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,59.5 +18305,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",73.4 +18306,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,66.0 +18307,Ireland,2015,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1 +18308,Ireland,2015,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",110.3 +18309,Ireland,2015,6,A10-Drugs used in diabetes,% of total sales,4.5 +18310,Ireland,2015,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.5 +18311,Ireland,2015,6,A02A-Antacids,% of total sales,0.0 +18312,Ireland,2015,6,Products not elsewhere classified,"Million US$, purchasing power parity",819.8 +18313,Ireland,2015,6,Products not elsewhere classified,"/capita, US$ exchange rate",156.6 +18314,Ireland,2015,6,Products not elsewhere classified,Million of national currency units,663.8 +18315,Ireland,2015,6,Products not elsewhere classified,Million US$ at exchange rate,736.5 +18316,Ireland,2015,6,C-Cardiovascular system,% of total sales,11.0 +18317,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.7 +18318,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,21.9 +18319,Ireland,2015,6,C-Cardiovascular system,"Million US$, purchasing power parity",269.0 +18320,Ireland,2015,6,C-Cardiovascular system,"/capita, US$ exchange rate",51.4 +18321,Ireland,2015,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.2 +18322,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2 +18323,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0 +18324,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.4 +18325,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.7 +18326,Ireland,2015,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,53.0 +18327,Ireland,2015,6,N-Nervous system,"/capita, US$ purchasing power parity",91.7 +18328,Ireland,2015,6,J01-Antibacterials for systemic use,Million of national currency units,47.7 +18329,Ireland,2015,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.3 +18330,Ireland,2015,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.5 +18331,Ireland,2015,6,N-Nervous system,% of total sales,17.6 +18332,Ireland,2015,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",58.9 +18333,Ireland,2015,6,G-Genito urinary system and sex hormones,% of total sales,3.7 +18334,Ireland,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.5 +18335,Ireland,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5 +18336,Ireland,2015,6,N-Nervous system,Million of national currency units,349.3 +18337,Ireland,2015,6,N-Nervous system,"Million US$, purchasing power parity",431.4 +18338,Ireland,2015,6,N-Nervous system,"/capita, US$ exchange rate",82.4 +18339,Ireland,2015,6,N-Nervous system,Million US$ at exchange rate,387.5 +18340,Ireland,2015,6,N06A-Antidepressants,Million US$ at exchange rate,62.3 +18341,Ireland,2015,6,N06A-Antidepressants,"Million US$, purchasing power parity",69.4 +18342,Ireland,2015,6,A-Alimentary tract and metabolism,% of total sales,10.4 +18343,Ireland,2015,6,N06A-Antidepressants,Million of national currency units,56.2 +18344,Ireland,2015,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.3 +18345,Ireland,2015,6,N06A-Antidepressants,% of total sales,2.8 +18346,Ireland,2015,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.8 +18347,Ireland,2015,6,A-Alimentary tract and metabolism,Million of national currency units,206.0 +18348,Ireland,2015,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,228.6 +18349,Ireland,2015,6,J01-Antibacterials for systemic use,% of total sales,2.4 +18350,Ireland,2015,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.1 +18351,Ireland,2015,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.6 +18352,Ireland,2015,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",254.4 +18353,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.4 +18354,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,38.1 +18355,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.1 +18356,Ireland,2015,6,C07-Beta blocking agents,Million of national currency units,22.7 +18357,Ireland,2015,6,C07-Beta blocking agents,Million US$ at exchange rate,25.2 +18358,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.3 +18359,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +18360,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0 +18361,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +18362,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +18363,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3 +18364,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.0 +18365,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.7 +18366,Ireland,2015,6,C07-Beta blocking agents,% of total sales,1.1 +18367,Ireland,2015,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.0 +18368,Ireland,2015,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4 +18369,Ireland,2015,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",91.7 +18370,Ireland,2015,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,82.4 +18371,Ireland,2015,6,G-Genito urinary system and sex hormones,Million of national currency units,74.3 +18372,Ireland,2015,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.0 +18373,Ireland,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.7 +18374,Ireland,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.5 +18375,Ireland,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.8 +18376,Ireland,2014,6,N02-Analgesics,"Million US$, purchasing power parity",67.1 +18377,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +18378,Ireland,2014,6,C02-Antihypertensives,Million of national currency units,16.6 +18379,Ireland,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.2 +18380,Ireland,2014,6,B-Blood and blood forming organs,% of total sales,4.7 +18381,Ireland,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +18382,Ireland,2014,6,N05B-Anxiolytics,% of total sales,0.5 +18383,Ireland,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.6 +18384,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.5 +18385,Ireland,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.3 +18386,Ireland,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,12.3 +18387,Ireland,2014,6,N05B-Anxiolytics,Million of national currency units,9.3 +18388,Ireland,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.5 +18389,Ireland,2014,6,N02-Analgesics,Million of national currency units,54.9 +18390,Ireland,2014,6,N02-Analgesics,Million US$ at exchange rate,73.0 +18391,Ireland,2014,6,C03-Diuretics,Million of national currency units,15.9 +18392,Ireland,2014,6,C03-Diuretics,Million US$ at exchange rate,21.2 +18393,Ireland,2014,6,C03-Diuretics,"Million US$, purchasing power parity",19.5 +18394,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,66.3 +18395,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +18396,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.7 +18397,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.5 +18398,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.4 +18399,Ireland,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",83.6 +18400,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,88.1 +18401,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.9 +18402,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",81.0 +18403,Ireland,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.0 +18404,Ireland,2014,6,J-Antiinfectives for systemic use,% of total sales,3.6 +18405,Ireland,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3 +18406,Ireland,2014,6,C02-Antihypertensives,% of total sales,0.9 +18407,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.4 +18408,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",62.9 +18409,Ireland,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.5 +18410,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,51.5 +18411,Ireland,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.9 +18412,Ireland,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.9 +18413,Ireland,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.4 +18414,Ireland,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.0 +18415,Ireland,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.9 +18416,Ireland,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",20.2 +18417,Ireland,2014,6,C02-Antihypertensives,Million US$ at exchange rate,22.0 +18418,Ireland,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,18.8 +18419,Ireland,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.7 +18420,Ireland,2014,6,N02-Analgesics,"/capita, US$ exchange rate",15.7 +18421,Ireland,2014,6,B-Blood and blood forming organs,Million of national currency units,90.5 +18422,Ireland,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,120.2 +18423,Ireland,2014,6,N02-Analgesics,% of total sales,2.9 +18424,Ireland,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.4 +18425,Ireland,2014,6,C03-Diuretics,% of total sales,0.8 +18426,Ireland,2014,6,J-Antiinfectives for systemic use,Million of national currency units,68.5 +18427,Ireland,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,91.0 +18428,Ireland,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4 +18429,Ireland,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7 +18430,Ireland,2014,6,C01A-Cardiac glycosides,% of total sales,0.1 +18431,Ireland,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +18432,Ireland,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.9 +18433,Ireland,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.3 +18434,Ireland,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.8 +18435,Ireland,2014,6,C01A-Cardiac glycosides,Million of national currency units,1.4 +18436,Ireland,2014,6,M-Musculo-skeletal system,% of total sales,3.4 +18437,Ireland,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,92.2 +18438,Ireland,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",84.7 +18439,Ireland,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",158.5 +18440,Ireland,2014,6,Products not elsewhere classified,% of total sales,31.6 +18441,Ireland,2014,6,C10-Lipid modifying agents,Million of national currency units,69.4 +18442,Ireland,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,111.1 +18443,Ireland,2014,6,A10-Drugs used in diabetes,Million of national currency units,83.6 +18444,Ireland,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.8 +18445,Ireland,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.2 +18446,Ireland,2014,6,C10-Lipid modifying agents,% of total sales,3.6 +18447,Ireland,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",27.3 +18448,Ireland,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,29.7 +18449,Ireland,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.9 +18450,Ireland,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.4 +18451,Ireland,2014,6,C08-Calcium channel blockers,Million of national currency units,22.3 +18452,Ireland,2014,6,A02A-Antacids,Million US$ at exchange rate,0.1 +18453,Ireland,2014,6,A02A-Antacids,Million of national currency units,0.1 +18454,Ireland,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.1 +18455,Ireland,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +18456,Ireland,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +18457,Ireland,2014,6,R-Respiratory system,"/capita, US$ exchange rate",47.1 +18458,Ireland,2014,6,R-Respiratory system,"Million US$, purchasing power parity",201.5 +18459,Ireland,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",80.5 +18460,Ireland,2014,6,R-Respiratory system,% of total sales,8.6 +18461,Ireland,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",43.3 +18462,Ireland,2014,6,M-Musculo-skeletal system,Million of national currency units,66.0 +18463,Ireland,2014,6,C08-Calcium channel blockers,% of total sales,1.2 +18464,Ireland,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,87.6 +18465,Ireland,2014,6,R-Respiratory system,Million US$ at exchange rate,219.3 +18466,Ireland,2014,6,R-Respiratory system,Million of national currency units,165.0 +18467,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",29.7 +18468,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.4 +18469,Ireland,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",501.7 +18470,Ireland,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.9 +18471,Ireland,2014,6,C-Cardiovascular system,Million of national currency units,233.7 +18472,Ireland,2014,6,C-Cardiovascular system,Million US$ at exchange rate,310.5 +18473,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",138.5 +18474,Ireland,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,150.7 +18475,Ireland,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,113.5 +18476,Ireland,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,2542.4 +18477,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.2 +18478,Ireland,2014,6,Total pharmaceutical sales,Million of national currency units,1913.8 +18479,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.6 +18480,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.5 +18481,Ireland,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2336.6 +18482,Ireland,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",545.9 +18483,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",82.0 +18484,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,89.2 +18485,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,67.2 +18486,Ireland,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",285.4 +18487,Ireland,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.8 +18488,Ireland,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",102.1 +18489,Ireland,2014,6,A10-Drugs used in diabetes,% of total sales,4.4 +18490,Ireland,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.9 +18491,Ireland,2014,6,A02A-Antacids,% of total sales,0.0 +18492,Ireland,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",738.3 +18493,Ireland,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",172.5 +18494,Ireland,2014,6,Products not elsewhere classified,Million of national currency units,604.7 +18495,Ireland,2014,6,Products not elsewhere classified,Million US$ at exchange rate,803.3 +18496,Ireland,2014,6,C-Cardiovascular system,% of total sales,12.2 +18497,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.9 +18498,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,26.4 +18499,Ireland,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",66.7 +18500,Ireland,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",61.3 +18501,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2 +18502,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0 +18503,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7 +18504,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.3 +18505,Ireland,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,63.8 +18506,Ireland,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",92.4 +18507,Ireland,2014,6,J01-Antibacterials for systemic use,Million of national currency units,48.0 +18508,Ireland,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.7 +18509,Ireland,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.6 +18510,Ireland,2014,6,N-Nervous system,% of total sales,18.4 +18511,Ireland,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",58.6 +18512,Ireland,2014,6,G-Genito urinary system and sex hormones,% of total sales,3.9 +18513,Ireland,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.2 +18514,Ireland,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.4 +18515,Ireland,2014,6,N-Nervous system,Million of national currency units,352.3 +18516,Ireland,2014,6,N-Nervous system,"Million US$, purchasing power parity",430.2 +18517,Ireland,2014,6,N-Nervous system,"/capita, US$ exchange rate",100.5 +18518,Ireland,2014,6,N-Nervous system,Million US$ at exchange rate,468.1 +18519,Ireland,2014,6,N06A-Antidepressants,Million US$ at exchange rate,93.1 +18520,Ireland,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",85.6 +18521,Ireland,2014,6,A-Alimentary tract and metabolism,% of total sales,10.8 +18522,Ireland,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.0 +18523,Ireland,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.4 +18524,Ireland,2014,6,N06A-Antidepressants,% of total sales,3.7 +18525,Ireland,2014,6,A-Alimentary tract and metabolism,Million of national currency units,207.4 +18526,Ireland,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,275.5 +18527,Ireland,2014,6,J01-Antibacterials for systemic use,% of total sales,2.5 +18528,Ireland,2014,6,N06A-Antidepressants,Million of national currency units,70.1 +18529,Ireland,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.4 +18530,Ireland,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.1 +18531,Ireland,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",253.2 +18532,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",40.0 +18533,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.3 +18534,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,43.5 +18535,Ireland,2014,6,C07-Beta blocking agents,Million of national currency units,23.4 +18536,Ireland,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,31.0 +18537,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,32.8 +18538,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +18539,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +18540,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +18541,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6 +18542,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0 +18543,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2.3 +18544,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.8 +18545,Ireland,2014,6,C07-Beta blocking agents,% of total sales,1.2 +18546,Ireland,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7 +18547,Ireland,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1 +18548,Ireland,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",90.6 +18549,Ireland,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,74.2 +18550,Ireland,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,98.6 +18551,Ireland,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.5 +18552,Ireland,2013,6,N02-Analgesics,"Million US$, purchasing power parity",67.5 +18553,Ireland,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.9 +18554,Ireland,2013,6,B-Blood and blood forming organs,% of total sales,4.6 +18555,Ireland,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.8 +18556,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +18557,Ireland,2013,6,C02-Antihypertensives,Million of national currency units,16.9 +18558,Ireland,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.4 +18559,Ireland,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +18560,Ireland,2013,6,N05B-Anxiolytics,% of total sales,0.5 +18561,Ireland,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +18562,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.8 +18563,Ireland,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.7 +18564,Ireland,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,12.6 +18565,Ireland,2013,6,N05B-Anxiolytics,Million of national currency units,9.5 +18566,Ireland,2013,6,C03-Diuretics,Million of national currency units,16.4 +18567,Ireland,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.7 +18568,Ireland,2013,6,N02-Analgesics,Million of national currency units,54.7 +18569,Ireland,2013,6,N02-Analgesics,Million US$ at exchange rate,72.7 +18570,Ireland,2013,6,C03-Diuretics,Million US$ at exchange rate,21.8 +18571,Ireland,2013,6,C03-Diuretics,"Million US$, purchasing power parity",20.2 +18572,Ireland,2013,6,C02-Antihypertensives,Million US$ at exchange rate,22.4 +18573,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,95.0 +18574,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +18575,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4 +18576,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.4 +18577,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,126.2 +18578,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",25.3 +18579,Ireland,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",79.3 +18580,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",117.2 +18581,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",27.3 +18582,Ireland,2013,6,J-Antiinfectives for systemic use,% of total sales,3.3 +18583,Ireland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.2 +18584,Ireland,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.5 +18585,Ireland,2013,6,C02-Antihypertensives,% of total sales,0.9 +18586,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.6 +18587,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",61.8 +18588,Ireland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.5 +18589,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50.1 +18590,Ireland,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.2 +18591,Ireland,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.5 +18592,Ireland,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.9 +18593,Ireland,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.9 +18594,Ireland,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.2 +18595,Ireland,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",20.8 +18596,Ireland,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,18.2 +18597,Ireland,2013,6,J-Antiinfectives for systemic use,Million of national currency units,64.3 +18598,Ireland,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.8 +18599,Ireland,2013,6,N02-Analgesics,"/capita, US$ exchange rate",15.7 +18600,Ireland,2013,6,B-Blood and blood forming organs,Million of national currency units,89.7 +18601,Ireland,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,119.2 +18602,Ireland,2013,6,N02-Analgesics,% of total sales,2.8 +18603,Ireland,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.6 +18604,Ireland,2013,6,C03-Diuretics,% of total sales,0.8 +18605,Ireland,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.6 +18606,Ireland,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,85.4 +18607,Ireland,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4 +18608,Ireland,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9 +18609,Ireland,2013,6,C01A-Cardiac glycosides,% of total sales,0.1 +18610,Ireland,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +18611,Ireland,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9 +18612,Ireland,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.3 +18613,Ireland,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0 +18614,Ireland,2013,6,C01A-Cardiac glycosides,Million of national currency units,1.5 +18615,Ireland,2013,6,M-Musculo-skeletal system,% of total sales,3.4 +18616,Ireland,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,149.2 +18617,Ireland,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",138.5 +18618,Ireland,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",150.8 +18619,Ireland,2013,6,Products not elsewhere classified,% of total sales,28.9 +18620,Ireland,2013,6,C10-Lipid modifying agents,Million of national currency units,112.4 +18621,Ireland,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.3 +18622,Ireland,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,108.9 +18623,Ireland,2013,6,A10-Drugs used in diabetes,Million of national currency units,82.0 +18624,Ireland,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.0 +18625,Ireland,2013,6,C10-Lipid modifying agents,% of total sales,5.7 +18626,Ireland,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",29.6 +18627,Ireland,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,31.8 +18628,Ireland,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4 +18629,Ireland,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.9 +18630,Ireland,2013,6,C08-Calcium channel blockers,Million of national currency units,24.0 +18631,Ireland,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.1 +18632,Ireland,2013,6,A02A-Antacids,Million US$ at exchange rate,0.1 +18633,Ireland,2013,6,A02A-Antacids,Million of national currency units,0.1 +18634,Ireland,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +18635,Ireland,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +18636,Ireland,2013,6,R-Respiratory system,"/capita, US$ exchange rate",47.0 +18637,Ireland,2013,6,R-Respiratory system,"Million US$, purchasing power parity",201.5 +18638,Ireland,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",82.7 +18639,Ireland,2013,6,R-Respiratory system,% of total sales,8.3 +18640,Ireland,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",43.6 +18641,Ireland,2013,6,M-Musculo-skeletal system,Million of national currency units,67.1 +18642,Ireland,2013,6,C08-Calcium channel blockers,% of total sales,1.2 +18643,Ireland,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,89.1 +18644,Ireland,2013,6,R-Respiratory system,Million US$ at exchange rate,217.1 +18645,Ireland,2013,6,R-Respiratory system,Million of national currency units,163.5 +18646,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.7 +18647,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.2 +18648,Ireland,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.4 +18649,Ireland,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,6.1 +18650,Ireland,2013,6,C-Cardiovascular system,Million of national currency units,288.4 +18651,Ireland,2013,6,C-Cardiovascular system,Million US$ at exchange rate,383.0 +18652,Ireland,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,119.0 +18653,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",146.7 +18654,Ireland,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,158.1 +18655,Ireland,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,2602.6 +18656,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.1 +18657,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",20.5 +18658,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9 +18659,Ireland,2013,6,Total pharmaceutical sales,Million of national currency units,1959.6 +18660,Ireland,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2415.6 +18661,Ireland,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",562.9 +18662,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,76.8 +18663,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",94.7 +18664,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,102.0 +18665,Ireland,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.5 +18666,Ireland,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",101.0 +18667,Ireland,2013,6,A10-Drugs used in diabetes,% of total sales,4.2 +18668,Ireland,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.9 +18669,Ireland,2013,6,A02A-Antacids,% of total sales,0.0 +18670,Ireland,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",697.2 +18671,Ireland,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",162.5 +18672,Ireland,2013,6,Products not elsewhere classified,Million of national currency units,565.6 +18673,Ireland,2013,6,Products not elsewhere classified,Million US$ at exchange rate,751.2 +18674,Ireland,2013,6,C-Cardiovascular system,% of total sales,14.7 +18675,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,21.3 +18676,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,28.3 +18677,Ireland,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",82.8 +18678,Ireland,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",76.9 +18679,Ireland,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",355.5 +18680,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.7 +18681,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1 +18682,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",26.3 +18683,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.1 +18684,Ireland,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,63.8 +18685,Ireland,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",95.4 +18686,Ireland,2013,6,J01-Antibacterials for systemic use,Million of national currency units,48.1 +18687,Ireland,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.8 +18688,Ireland,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.8 +18689,Ireland,2013,6,N-Nervous system,% of total sales,18.3 +18690,Ireland,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",59.2 +18691,Ireland,2013,6,G-Genito urinary system and sex hormones,% of total sales,4.1 +18692,Ireland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.9 +18693,Ireland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.2 +18694,Ireland,2013,6,N-Nervous system,Million of national currency units,357.7 +18695,Ireland,2013,6,N-Nervous system,"Million US$, purchasing power parity",441.0 +18696,Ireland,2013,6,N-Nervous system,"/capita, US$ exchange rate",102.8 +18697,Ireland,2013,6,N-Nervous system,Million US$ at exchange rate,475.1 +18698,Ireland,2013,6,N06A-Antidepressants,Million US$ at exchange rate,96.6 +18699,Ireland,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",89.7 +18700,Ireland,2013,6,A-Alimentary tract and metabolism,% of total sales,11.9 +18701,Ireland,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.9 +18702,Ireland,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.4 +18703,Ireland,2013,6,N06A-Antidepressants,% of total sales,3.7 +18704,Ireland,2013,6,A-Alimentary tract and metabolism,Million of national currency units,233.4 +18705,Ireland,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,310.0 +18706,Ireland,2013,6,N06A-Antidepressants,Million of national currency units,72.7 +18707,Ireland,2013,6,J01-Antibacterials for systemic use,% of total sales,2.5 +18708,Ireland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.2 +18709,Ireland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.0 +18710,Ireland,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",287.7 +18711,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.8 +18712,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.7 +18713,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,45.0 +18714,Ireland,2013,6,C07-Beta blocking agents,Million of national currency units,23.6 +18715,Ireland,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,31.3 +18716,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,33.9 +18717,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0 +18718,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.0 +18719,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +18720,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +18721,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +18722,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9 +18723,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6 +18724,Ireland,2013,6,C07-Beta blocking agents,% of total sales,1.2 +18725,Ireland,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.3 +18726,Ireland,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.8 +18727,Ireland,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",98.2 +18728,Ireland,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,105.8 +18729,Ireland,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,79.7 +18730,Ireland,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",29.0 +18731,Ireland,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.2 +18732,Ireland,2012,6,B-Blood and blood forming organs,% of total sales,4.5 +18733,Ireland,2012,6,N02-Analgesics,"Million US$, purchasing power parity",71.9 +18734,Ireland,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.6 +18735,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +18736,Ireland,2012,6,J-Antiinfectives for systemic use,Million of national currency units,69.6 +18737,Ireland,2012,6,C02-Antihypertensives,Million of national currency units,21.1 +18738,Ireland,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.3 +18739,Ireland,2012,6,N05B-Anxiolytics,% of total sales,0.5 +18740,Ireland,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +18741,Ireland,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6 +18742,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.3 +18743,Ireland,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.8 +18744,Ireland,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,12.5 +18745,Ireland,2012,6,N05B-Anxiolytics,Million of national currency units,9.7 +18746,Ireland,2012,6,N02-Analgesics,Million of national currency units,59.2 +18747,Ireland,2012,6,C03-Diuretics,"/capita, US$ exchange rate",4.6 +18748,Ireland,2012,6,N02-Analgesics,Million US$ at exchange rate,76.0 +18749,Ireland,2012,6,C03-Diuretics,Million US$ at exchange rate,21.1 +18750,Ireland,2012,6,C03-Diuretics,Million of national currency units,16.4 +18751,Ireland,2012,6,C03-Diuretics,"Million US$, purchasing power parity",20.0 +18752,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,108.5 +18753,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,139.4 +18754,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +18755,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.8 +18756,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.7 +18757,Ireland,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",84.6 +18758,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",131.8 +18759,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",30.3 +18760,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6 +18761,Ireland,2012,6,J-Antiinfectives for systemic use,% of total sales,3.4 +18762,Ireland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.4 +18763,Ireland,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6 +18764,Ireland,2012,6,C02-Antihypertensives,% of total sales,1.0 +18765,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,62.4 +18766,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.0 +18767,Ireland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.5 +18768,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,48.6 +18769,Ireland,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.9 +18770,Ireland,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.5 +18771,Ireland,2012,6,N05C-Hypnotics and sedatives,% of total sales,0.9 +18772,Ireland,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.7 +18773,Ireland,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",25.7 +18774,Ireland,2012,6,C02-Antihypertensives,Million US$ at exchange rate,27.1 +18775,Ireland,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.7 +18776,Ireland,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,17.7 +18777,Ireland,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.9 +18778,Ireland,2012,6,N02-Analgesics,"/capita, US$ exchange rate",16.5 +18779,Ireland,2012,6,B-Blood and blood forming organs,Million of national currency units,91.6 +18780,Ireland,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,117.7 +18781,Ireland,2012,6,N02-Analgesics,% of total sales,2.9 +18782,Ireland,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.6 +18783,Ireland,2012,6,C03-Diuretics,% of total sales,0.8 +18784,Ireland,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",111.3 +18785,Ireland,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,89.5 +18786,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.6 +18787,Ireland,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4 +18788,Ireland,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9 +18789,Ireland,2012,6,C01A-Cardiac glycosides,% of total sales,0.1 +18790,Ireland,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +18791,Ireland,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.8 +18792,Ireland,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.9 +18793,Ireland,2012,6,M-Musculo-skeletal system,% of total sales,3.7 +18794,Ireland,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0 +18795,Ireland,2012,6,C01A-Cardiac glycosides,Million of national currency units,1.5 +18796,Ireland,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,187.3 +18797,Ireland,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",177.2 +18798,Ireland,2012,6,Products not elsewhere classified,% of total sales,26.6 +18799,Ireland,2012,6,C10-Lipid modifying agents,Million of national currency units,145.8 +18800,Ireland,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",40.7 +18801,Ireland,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,104.5 +18802,Ireland,2012,6,A10-Drugs used in diabetes,Million of national currency units,81.4 +18803,Ireland,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.5 +18804,Ireland,2012,6,C10-Lipid modifying agents,% of total sales,7.1 +18805,Ireland,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",30.6 +18806,Ireland,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,32.4 +18807,Ireland,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7 +18808,Ireland,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.0 +18809,Ireland,2012,6,C08-Calcium channel blockers,Million of national currency units,25.2 +18810,Ireland,2012,6,A02A-Antacids,"Million US$, purchasing power parity",0.1 +18811,Ireland,2012,6,A02A-Antacids,Million US$ at exchange rate,0.1 +18812,Ireland,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +18813,Ireland,2012,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +18814,Ireland,2012,6,R-Respiratory system,"/capita, US$ exchange rate",43.6 +18815,Ireland,2012,6,R-Respiratory system,"Million US$, purchasing power parity",189.5 +18816,Ireland,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",41.2 +18817,Ireland,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",90.9 +18818,Ireland,2012,6,R-Respiratory system,% of total sales,7.6 +18819,Ireland,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",143.7 +18820,Ireland,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,96.2 +18821,Ireland,2012,6,M-Musculo-skeletal system,Million of national currency units,74.9 +18822,Ireland,2012,6,C08-Calcium channel blockers,% of total sales,1.2 +18823,Ireland,2012,6,R-Respiratory system,Million US$ at exchange rate,200.4 +18824,Ireland,2012,6,R-Respiratory system,Million of national currency units,156.0 +18825,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.0 +18826,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",37.0 +18827,Ireland,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",540.1 +18828,Ireland,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,6.5 +18829,Ireland,2012,6,C-Cardiovascular system,Million of national currency units,337.5 +18830,Ireland,2012,6,C-Cardiovascular system,Million US$ at exchange rate,433.6 +18831,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",161.0 +18832,Ireland,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,170.2 +18833,Ireland,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,132.5 +18834,Ireland,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,2627.1 +18835,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.9 +18836,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2 +18837,Ireland,2012,6,Total pharmaceutical sales,Million of national currency units,2044.7 +18838,Ireland,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2484.3 +18839,Ireland,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",571.2 +18840,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,85.7 +18841,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",104.1 +18842,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,110.1 +18843,Ireland,2012,6,A02A-Antacids,Million of national currency units,0.1 +18844,Ireland,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",410.0 +18845,Ireland,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.7 +18846,Ireland,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",98.8 +18847,Ireland,2012,6,A10-Drugs used in diabetes,% of total sales,4.0 +18848,Ireland,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.5 +18849,Ireland,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",661.1 +18850,Ireland,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",152.0 +18851,Ireland,2012,6,A02A-Antacids,% of total sales,0.0 +18852,Ireland,2012,6,Products not elsewhere classified,Million of national currency units,544.1 +18853,Ireland,2012,6,Products not elsewhere classified,Million US$ at exchange rate,699.1 +18854,Ireland,2012,6,C-Cardiovascular system,% of total sales,16.5 +18855,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,27.8 +18856,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,35.7 +18857,Ireland,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",94.3 +18858,Ireland,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.1 +18859,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.3 +18860,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4 +18861,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",33.8 +18862,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8 +18863,Ireland,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.6 +18864,Ireland,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",65.8 +18865,Ireland,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",102.5 +18866,Ireland,2012,6,J01-Antibacterials for systemic use,Million of national currency units,54.2 +18867,Ireland,2012,6,N-Nervous system,% of total sales,19.0 +18868,Ireland,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.1 +18869,Ireland,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.3 +18870,Ireland,2012,6,G-Genito urinary system and sex hormones,% of total sales,4.2 +18871,Ireland,2012,6,N-Nervous system,Million of national currency units,387.9 +18872,Ireland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.0 +18873,Ireland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.7 +18874,Ireland,2012,6,N-Nervous system,"Million US$, purchasing power parity",471.3 +18875,Ireland,2012,6,N-Nervous system,"/capita, US$ exchange rate",108.4 +18876,Ireland,2012,6,N-Nervous system,Million US$ at exchange rate,498.4 +18877,Ireland,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",88.5 +18878,Ireland,2012,6,N06A-Antidepressants,Million US$ at exchange rate,93.6 +18879,Ireland,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.3 +18880,Ireland,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.2 +18881,Ireland,2012,6,N06A-Antidepressants,% of total sales,3.6 +18882,Ireland,2012,6,A-Alimentary tract and metabolism,% of total sales,12.2 +18883,Ireland,2012,6,A-Alimentary tract and metabolism,Million of national currency units,248.8 +18884,Ireland,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,319.6 +18885,Ireland,2012,6,J01-Antibacterials for systemic use,% of total sales,2.6 +18886,Ireland,2012,6,N06A-Antidepressants,Million of national currency units,72.8 +18887,Ireland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.7 +18888,Ireland,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",302.3 +18889,Ireland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",69.5 +18890,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.2 +18891,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.7 +18892,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.2 +18893,Ireland,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,30.4 +18894,Ireland,2012,6,C07-Beta blocking agents,Million of national currency units,23.7 +18895,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.7 +18896,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,44.6 +18897,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1 +18898,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +18899,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +18900,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +18901,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9 +18902,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.7 +18903,Ireland,2012,6,C07-Beta blocking agents,% of total sales,1.2 +18904,Ireland,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6 +18905,Ireland,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.2 +18906,Ireland,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",104.2 +18907,Ireland,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,85.8 +18908,Ireland,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,110.2 +18909,Ireland,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.7 +18910,Ireland,2010,6,N02-Analgesics,"Million US$, purchasing power parity",64.9 +18911,Ireland,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.2 +18912,Ireland,2010,6,B-Blood and blood forming organs,% of total sales,4.6 +18913,Ireland,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.3 +18914,Ireland,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0 +18915,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +18916,Ireland,2010,6,J-Antiinfectives for systemic use,Million of national currency units,66.1 +18917,Ireland,2010,6,C02-Antihypertensives,Million of national currency units,21.1 +18918,Ireland,2010,6,N05B-Anxiolytics,% of total sales,0.5 +18919,Ireland,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +18920,Ireland,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8 +18921,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,6.6 +18922,Ireland,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.5 +18923,Ireland,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,12.9 +18924,Ireland,2010,6,N05B-Anxiolytics,Million of national currency units,9.7 +18925,Ireland,2010,6,C03-Diuretics,Million of national currency units,15.7 +18926,Ireland,2010,6,N02-Analgesics,Million of national currency units,55.1 +18927,Ireland,2010,6,N02-Analgesics,Million US$ at exchange rate,73.1 +18928,Ireland,2010,6,C03-Diuretics,"/capita, US$ exchange rate",4.6 +18929,Ireland,2010,6,C03-Diuretics,Million US$ at exchange rate,20.8 +18930,Ireland,2010,6,C03-Diuretics,"Million US$, purchasing power parity",18.4 +18931,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,135.0 +18932,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,178.9 +18933,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4 +18934,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +18935,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",34.8 +18936,Ireland,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",77.8 +18937,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",158.9 +18938,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",39.2 +18939,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.9 +18940,Ireland,2010,6,J-Antiinfectives for systemic use,% of total sales,3.2 +18941,Ireland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.1 +18942,Ireland,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.4 +18943,Ireland,2010,6,C02-Antihypertensives,% of total sales,1.0 +18944,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.1 +18945,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,58.7 +18946,Ireland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.2 +18947,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,44.3 +18948,Ireland,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.9 +18949,Ireland,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.7 +18950,Ireland,2010,6,N05C-Hypnotics and sedatives,% of total sales,0.8 +18951,Ireland,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3 +18952,Ireland,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.8 +18953,Ireland,2010,6,C02-Antihypertensives,Million US$ at exchange rate,28.0 +18954,Ireland,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.2 +18955,Ireland,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",6.1 +18956,Ireland,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,16.8 +18957,Ireland,2010,6,B-Blood and blood forming organs,Million of national currency units,93.9 +18958,Ireland,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,124.5 +18959,Ireland,2010,6,N02-Analgesics,% of total sales,2.7 +18960,Ireland,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.2 +18961,Ireland,2010,6,C03-Diuretics,% of total sales,0.8 +18962,Ireland,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.6 +18963,Ireland,2010,6,N02-Analgesics,"/capita, US$ exchange rate",16.0 +18964,Ireland,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,87.7 +18965,Ireland,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +18966,Ireland,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8 +18967,Ireland,2010,6,C01A-Cardiac glycosides,% of total sales,0.1 +18968,Ireland,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +18969,Ireland,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7 +18970,Ireland,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.6 +18971,Ireland,2010,6,M-Musculo-skeletal system,% of total sales,4.3 +18972,Ireland,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.1 +18973,Ireland,2010,6,C01A-Cardiac glycosides,Million of national currency units,1.6 +18974,Ireland,2010,6,A10-Drugs used in diabetes,Million of national currency units,68.0 +18975,Ireland,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,256.6 +18976,Ireland,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",227.8 +18977,Ireland,2010,6,Products not elsewhere classified,% of total sales,24.8 +18978,Ireland,2010,6,C10-Lipid modifying agents,Million of national currency units,193.6 +18979,Ireland,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",56.3 +18980,Ireland,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,90.1 +18981,Ireland,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.0 +18982,Ireland,2010,6,C10-Lipid modifying agents,% of total sales,9.4 +18983,Ireland,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",31.5 +18984,Ireland,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,35.5 +18985,Ireland,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.9 +18986,Ireland,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.8 +18987,Ireland,2010,6,A02A-Antacids,"Million US$, purchasing power parity",0.2 +18988,Ireland,2010,6,A02A-Antacids,Million US$ at exchange rate,0.2 +18989,Ireland,2010,6,C08-Calcium channel blockers,Million of national currency units,26.8 +18990,Ireland,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +18991,Ireland,2010,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +18992,Ireland,2010,6,C08-Calcium channel blockers,% of total sales,1.3 +18993,Ireland,2010,6,R-Respiratory system,"/capita, US$ exchange rate",46.1 +18994,Ireland,2010,6,R-Respiratory system,"Million US$, purchasing power parity",186.6 +18995,Ireland,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",40.9 +18996,Ireland,2010,6,R-Respiratory system,% of total sales,7.7 +18997,Ireland,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,116.8 +18998,Ireland,2010,6,M-Musculo-skeletal system,Million of national currency units,88.1 +18999,Ireland,2010,6,R-Respiratory system,Million US$ at exchange rate,210.2 +19000,Ireland,2010,6,R-Respiratory system,Million of national currency units,158.6 +19001,Ireland,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",103.7 +19002,Ireland,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",131.1 +19003,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",34.8 +19004,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.1 +19005,Ireland,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,6.6 +19006,Ireland,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",529.1 +19007,Ireland,2010,6,C-Cardiovascular system,Million of national currency units,398.5 +19008,Ireland,2010,6,C-Cardiovascular system,Million US$ at exchange rate,528.2 +19009,Ireland,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",469.0 +19010,Ireland,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,134.6 +19011,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",158.5 +19012,Ireland,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,178.5 +19013,Ireland,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,2717.7 +19014,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.7 +19015,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.9 +19016,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7 +19017,Ireland,2010,6,Total pharmaceutical sales,Million of national currency units,2050.0 +19018,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,95.8 +19019,Ireland,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2413.0 +19020,Ireland,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",596.0 +19021,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",112.8 +19022,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,127.0 +19023,Ireland,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.8 +19024,Ireland,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",80.0 +19025,Ireland,2010,6,A10-Drugs used in diabetes,% of total sales,3.3 +19026,Ireland,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.5 +19027,Ireland,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",597.6 +19028,Ireland,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",147.6 +19029,Ireland,2010,6,A02A-Antacids,% of total sales,0.0 +19030,Ireland,2010,6,Products not elsewhere classified,Million of national currency units,507.7 +19031,Ireland,2010,6,Products not elsewhere classified,Million US$ at exchange rate,673.1 +19032,Ireland,2010,6,C-Cardiovascular system,% of total sales,19.4 +19033,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,34.3 +19034,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,45.4 +19035,Ireland,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.8 +19036,Ireland,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.9 +19037,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8 +19038,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +19039,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",40.4 +19040,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.0 +19041,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2.6 +19042,Ireland,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",56.8 +19043,Ireland,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,64.0 +19044,Ireland,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",89.1 +19045,Ireland,2010,6,N-Nervous system,% of total sales,16.8 +19046,Ireland,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.5 +19047,Ireland,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.0 +19048,Ireland,2010,6,G-Genito urinary system and sex hormones,% of total sales,4.1 +19049,Ireland,2010,6,N-Nervous system,Million of national currency units,345.2 +19050,Ireland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.7 +19051,Ireland,2010,6,N-Nervous system,"/capita, US$ exchange rate",100.4 +19052,Ireland,2010,6,N-Nervous system,"Million US$, purchasing power parity",406.3 +19053,Ireland,2010,6,N-Nervous system,Million US$ at exchange rate,457.6 +19054,Ireland,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",79.1 +19055,Ireland,2010,6,N06A-Antidepressants,Million US$ at exchange rate,89.1 +19056,Ireland,2010,6,A02A-Antacids,Million of national currency units,0.1 +19057,Ireland,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.4 +19058,Ireland,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",19.5 +19059,Ireland,2010,6,N06A-Antidepressants,% of total sales,3.3 +19060,Ireland,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,349.2 +19061,Ireland,2010,6,A-Alimentary tract and metabolism,Million of national currency units,263.4 +19062,Ireland,2010,6,J01-Antibacterials for systemic use,% of total sales,2.4 +19063,Ireland,2010,6,N06A-Antidepressants,Million of national currency units,67.2 +19064,Ireland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",68.0 +19065,Ireland,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",310.0 +19066,Ireland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.6 +19067,Ireland,2010,6,A-Alimentary tract and metabolism,% of total sales,12.8 +19068,Ireland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.5 +19069,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.3 +19070,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0 +19071,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.2 +19072,Ireland,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,36.3 +19073,Ireland,2010,6,C07-Beta blocking agents,Million of national currency units,27.4 +19074,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,46.5 +19075,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,35.1 +19076,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +19077,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +19078,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4 +19079,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +19080,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1 +19081,Ireland,2010,6,C07-Beta blocking agents,% of total sales,1.3 +19082,Ireland,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",8.0 +19083,Ireland,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1 +19084,Ireland,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.1 +19085,Ireland,2010,6,J01-Antibacterials for systemic use,Million of national currency units,48.2 +19086,Ireland,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,84.2 +19087,Ireland,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,111.6 +19088,Ireland,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",32.2 +19089,Ireland,2011,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.6 +19090,Ireland,2011,7,B-Blood and blood forming organs,% of total sales,4.6 +19091,Ireland,2011,7,N02-Analgesics,"Million US$, purchasing power parity",68.6 +19092,Ireland,2011,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.3 +19093,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +19094,Ireland,2011,7,J-Antiinfectives for systemic use,Million of national currency units,60.3 +19095,Ireland,2011,7,C02-Antihypertensives,Million of national currency units,21.4 +19096,Ireland,2011,7,C03-Diuretics,"/capita, US$ purchasing power parity",4.1 +19097,Ireland,2011,7,N05B-Anxiolytics,% of total sales,0.5 +19098,Ireland,2011,7,N02-Analgesics,Million US$ at exchange rate,79.4 +19099,Ireland,2011,7,N05B-Anxiolytics,"/capita, US$ exchange rate",2.9 +19100,Ireland,2011,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +19101,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.5 +19102,Ireland,2011,7,N05B-Anxiolytics,"Million US$, purchasing power parity",11.5 +19103,Ireland,2011,7,N05B-Anxiolytics,Million US$ at exchange rate,13.4 +19104,Ireland,2011,7,N05B-Anxiolytics,Million of national currency units,9.6 +19105,Ireland,2011,7,C03-Diuretics,Million of national currency units,15.8 +19106,Ireland,2011,7,N02-Analgesics,Million of national currency units,57.1 +19107,Ireland,2011,7,C03-Diuretics,"/capita, US$ exchange rate",4.8 +19108,Ireland,2011,7,C03-Diuretics,Million US$ at exchange rate,22.0 +19109,Ireland,2011,7,C03-Diuretics,"Million US$, purchasing power parity",19.0 +19110,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.4 +19111,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,107.7 +19112,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,150.0 +19113,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.0 +19114,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +19115,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.3 +19116,Ireland,2011,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",72.5 +19117,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",129.6 +19118,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",32.7 +19119,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9 +19120,Ireland,2011,7,J-Antiinfectives for systemic use,% of total sales,3.1 +19121,Ireland,2011,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.8 +19122,Ireland,2011,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6 +19123,Ireland,2011,7,C02-Antihypertensives,% of total sales,1.1 +19124,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.8 +19125,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.1 +19126,Ireland,2011,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.3 +19127,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,45.8 +19128,Ireland,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.2 +19129,Ireland,2011,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",20.4 +19130,Ireland,2011,7,N05C-Hypnotics and sedatives,% of total sales,0.9 +19131,Ireland,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.5 +19132,Ireland,2011,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,23.6 +19133,Ireland,2011,7,C02-Antihypertensives,"Million US$, purchasing power parity",25.7 +19134,Ireland,2011,7,C02-Antihypertensives,Million US$ at exchange rate,29.8 +19135,Ireland,2011,7,C02-Antihypertensives,"/capita, US$ exchange rate",6.5 +19136,Ireland,2011,7,N05C-Hypnotics and sedatives,Million of national currency units,17.0 +19137,Ireland,2011,7,N02-Analgesics,"/capita, US$ exchange rate",17.3 +19138,Ireland,2011,7,B-Blood and blood forming organs,Million of national currency units,89.8 +19139,Ireland,2011,7,B-Blood and blood forming organs,Million US$ at exchange rate,124.9 +19140,Ireland,2011,7,N02-Analgesics,% of total sales,2.9 +19141,Ireland,2011,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.0 +19142,Ireland,2011,7,C03-Diuretics,% of total sales,0.8 +19143,Ireland,2011,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",107.9 +19144,Ireland,2011,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,83.9 +19145,Ireland,2011,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +19146,Ireland,2011,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9 +19147,Ireland,2011,7,C01A-Cardiac glycosides,% of total sales,0.1 +19148,Ireland,2011,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +19149,Ireland,2011,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.7 +19150,Ireland,2011,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.8 +19151,Ireland,2011,7,C01A-Cardiac glycosides,Million US$ at exchange rate,2.1 +19152,Ireland,2011,7,C01A-Cardiac glycosides,Million of national currency units,1.5 +19153,Ireland,2011,7,M-Musculo-skeletal system,% of total sales,3.8 +19154,Ireland,2011,7,C10-Lipid modifying agents,Million US$ at exchange rate,209.8 +19155,Ireland,2011,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",181.3 +19156,Ireland,2011,7,Products not elsewhere classified,% of total sales,26.3 +19157,Ireland,2011,7,C10-Lipid modifying agents,Million of national currency units,150.8 +19158,Ireland,2011,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.8 +19159,Ireland,2011,7,A10-Drugs used in diabetes,Million US$ at exchange rate,102.2 +19160,Ireland,2011,7,A10-Drugs used in diabetes,Million of national currency units,73.5 +19161,Ireland,2011,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",39.6 +19162,Ireland,2011,7,C10-Lipid modifying agents,% of total sales,7.7 +19163,Ireland,2011,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",29.8 +19164,Ireland,2011,7,C08-Calcium channel blockers,Million US$ at exchange rate,34.5 +19165,Ireland,2011,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.5 +19166,Ireland,2011,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.5 +19167,Ireland,2011,7,C08-Calcium channel blockers,Million of national currency units,24.8 +19168,Ireland,2011,7,A02A-Antacids,"Million US$, purchasing power parity",0.1 +19169,Ireland,2011,7,A02A-Antacids,Million US$ at exchange rate,0.2 +19170,Ireland,2011,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +19171,Ireland,2011,7,A02A-Antacids,"/capita, US$ exchange rate",0.0 +19172,Ireland,2011,7,C08-Calcium channel blockers,% of total sales,1.3 +19173,Ireland,2011,7,R-Respiratory system,"/capita, US$ exchange rate",45.9 +19174,Ireland,2011,7,R-Respiratory system,"Million US$, purchasing power parity",181.6 +19175,Ireland,2011,7,R-Respiratory system,% of total sales,7.7 +19176,Ireland,2011,7,R-Respiratory system,"/capita, US$ purchasing power parity",39.7 +19177,Ireland,2011,7,M-Musculo-skeletal system,Million US$ at exchange rate,104.3 +19178,Ireland,2011,7,M-Musculo-skeletal system,Million of national currency units,74.9 +19179,Ireland,2011,7,R-Respiratory system,Million US$ at exchange rate,210.2 +19180,Ireland,2011,7,R-Respiratory system,Million of national currency units,151.0 +19181,Ireland,2011,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",90.1 +19182,Ireland,2011,7,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.2 +19183,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.9 +19184,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.3 +19185,Ireland,2011,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",513.8 +19186,Ireland,2011,7,R03-Drugs for obstructive airway diseases,% of total sales,6.6 +19187,Ireland,2011,7,C-Cardiovascular system,Million of national currency units,339.9 +19188,Ireland,2011,7,C-Cardiovascular system,Million US$ at exchange rate,473.1 +19189,Ireland,2011,7,R03-Drugs for obstructive airway diseases,Million of national currency units,129.2 +19190,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",155.4 +19191,Ireland,2011,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,179.8 +19192,Ireland,2011,7,Total pharmaceutical sales,Million US$ at exchange rate,2723.5 +19193,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.9 +19194,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4 +19195,Ireland,2011,7,Total pharmaceutical sales,Million of national currency units,1956.6 +19196,Ireland,2011,7,C-Cardiovascular system,"Million US$, purchasing power parity",408.7 +19197,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,85.1 +19198,Ireland,2011,7,Total pharmaceutical sales,"Million US$, purchasing power parity",2353.1 +19199,Ireland,2011,7,Total pharmaceutical sales,"/capita, US$ exchange rate",594.6 +19200,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",102.4 +19201,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,118.5 +19202,Ireland,2011,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.3 +19203,Ireland,2011,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",88.3 +19204,Ireland,2011,7,A10-Drugs used in diabetes,% of total sales,3.8 +19205,Ireland,2011,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.3 +19206,Ireland,2011,7,Products not elsewhere classified,"Million US$, purchasing power parity",619.1 +19207,Ireland,2011,7,Products not elsewhere classified,"/capita, US$ exchange rate",156.4 +19208,Ireland,2011,7,A02A-Antacids,% of total sales,0.0 +19209,Ireland,2011,7,Products not elsewhere classified,Million of national currency units,514.8 +19210,Ireland,2011,7,Products not elsewhere classified,Million US$ at exchange rate,716.6 +19211,Ireland,2011,7,C-Cardiovascular system,% of total sales,17.4 +19212,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,29.9 +19213,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,41.6 +19214,Ireland,2011,7,C-Cardiovascular system,"/capita, US$ exchange rate",103.3 +19215,Ireland,2011,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.2 +19216,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.9 +19217,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5 +19218,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",36.0 +19219,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.1 +19220,Ireland,2011,7,A02A-Antacids,Million of national currency units,0.1 +19221,Ireland,2011,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,61.6 +19222,Ireland,2011,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",53.2 +19223,Ireland,2011,7,N-Nervous system,"/capita, US$ purchasing power parity",94.1 +19224,Ireland,2011,7,N-Nervous system,% of total sales,18.3 +19225,Ireland,2011,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.6 +19226,Ireland,2011,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.5 +19227,Ireland,2011,7,G-Genito urinary system and sex hormones,% of total sales,4.2 +19228,Ireland,2011,7,N-Nervous system,Million of national currency units,358.3 +19229,Ireland,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.8 +19230,Ireland,2011,7,N-Nervous system,"/capita, US$ exchange rate",108.9 +19231,Ireland,2011,7,N-Nervous system,"Million US$, purchasing power parity",430.9 +19232,Ireland,2011,7,N-Nervous system,Million US$ at exchange rate,498.7 +19233,Ireland,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.2 +19234,Ireland,2011,7,N06A-Antidepressants,"Million US$, purchasing power parity",80.6 +19235,Ireland,2011,7,N06A-Antidepressants,Million US$ at exchange rate,93.3 +19236,Ireland,2011,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.6 +19237,Ireland,2011,7,N06A-Antidepressants,"/capita, US$ exchange rate",20.4 +19238,Ireland,2011,7,N06A-Antidepressants,% of total sales,3.4 +19239,Ireland,2011,7,A-Alimentary tract and metabolism,% of total sales,12.2 +19240,Ireland,2011,7,A-Alimentary tract and metabolism,Million of national currency units,239.0 +19241,Ireland,2011,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,332.6 +19242,Ireland,2011,7,J01-Antibacterials for systemic use,% of total sales,2.3 +19243,Ireland,2011,7,N06A-Antidepressants,Million of national currency units,67.1 +19244,Ireland,2011,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.7 +19245,Ireland,2011,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",287.4 +19246,Ireland,2011,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",72.6 +19247,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.1 +19248,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0 +19249,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.4 +19250,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,47.6 +19251,Ireland,2011,7,C07-Beta blocking agents,Million US$ at exchange rate,32.4 +19252,Ireland,2011,7,C07-Beta blocking agents,Million of national currency units,23.3 +19253,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.3 +19254,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.2 +19255,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +19256,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +19257,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.6 +19258,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +19259,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9 +19260,Ireland,2011,7,C07-Beta blocking agents,% of total sales,1.2 +19261,Ireland,2011,7,C07-Beta blocking agents,"/capita, US$ exchange rate",7.1 +19262,Ireland,2011,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1 +19263,Ireland,2011,7,J01-Antibacterials for systemic use,Million of national currency units,44.3 +19264,Ireland,2011,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.7 +19265,Ireland,2011,7,G-Genito urinary system and sex hormones,Million of national currency units,82.9 +19266,Ireland,2011,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,115.4 +19267,Ireland,2011,7,C07-Beta blocking agents,"Million US$, purchasing power parity",28.0 +19268,Italy,2016,2,C03-Diuretics,"/capita, US$ exchange rate",2.0 +19269,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,195.1 +19270,Italy,2016,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6 +19271,Italy,2016,2,C02-Antihypertensives,"Million US$, purchasing power parity",324.7 +19272,Italy,2016,2,C02-Antihypertensives,Million of national currency units,227.5 +19273,Italy,2016,2,C02-Antihypertensives,Million US$ at exchange rate,251.8 +19274,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",278.5 +19275,Italy,2016,2,C03-Diuretics,Million US$ at exchange rate,121.7 +19276,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.6 +19277,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.6 +19278,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,216.0 +19279,Italy,2016,2,C03-Diuretics,"Million US$, purchasing power parity",156.9 +19280,Italy,2016,2,C03-Diuretics,% of total sales,0.5 +19281,Italy,2016,2,B-Blood and blood forming organs,Million of national currency units,2027.0 +19282,Italy,2016,2,B-Blood and blood forming organs,Million US$ at exchange rate,2243.7 +19283,Italy,2016,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,978.7 +19284,Italy,2016,2,J01-Antibacterials for systemic use,Million of national currency units,884.2 +19285,Italy,2016,2,Total pharmaceutical sales,Million US$ at exchange rate,25215.9 +19286,Italy,2016,2,Total pharmaceutical sales,Million of national currency units,22780.6 +19287,Italy,2016,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",536.4 +19288,Italy,2016,2,Total pharmaceutical sales,"/capita, US$ exchange rate",415.9 +19289,Italy,2016,2,Total pharmaceutical sales,"Million US$, purchasing power parity",32518.4 +19290,Italy,2016,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.3 +19291,Italy,2016,2,N05B-Anxiolytics,Million US$ at exchange rate,3.4 +19292,Italy,2016,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +19293,Italy,2016,2,N05B-Anxiolytics,% of total sales,0.0 +19294,Italy,2016,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +19295,Italy,2016,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.1 +19296,Italy,2016,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1262.1 +19297,Italy,2016,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",20.8 +19298,Italy,2016,2,N05B-Anxiolytics,Million of national currency units,3.0 +19299,Italy,2016,2,J01-Antibacterials for systemic use,% of total sales,3.9 +19300,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9 +19301,Italy,2016,2,J-Antiinfectives for systemic use,Million of national currency units,4413.6 +19302,Italy,2016,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,4885.4 +19303,Italy,2016,2,M-Musculo-skeletal system,Million of national currency units,467.9 +19304,Italy,2016,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",103.9 +19305,Italy,2016,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",80.6 +19306,Italy,2016,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",6300.2 +19307,Italy,2016,2,M-Musculo-skeletal system,% of total sales,2.1 +19308,Italy,2016,2,N-Nervous system,Million US$ at exchange rate,2000.6 +19309,Italy,2016,2,N-Nervous system,Million of national currency units,1807.4 +19310,Italy,2016,2,M-Musculo-skeletal system,Million US$ at exchange rate,517.9 +19311,Italy,2016,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",667.9 +19312,Italy,2016,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.0 +19313,Italy,2016,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.5 +19314,Italy,2016,2,N02-Analgesics,"Million US$, purchasing power parity",511.2 +19315,Italy,2016,2,N02-Analgesics,Million US$ at exchange rate,396.4 +19316,Italy,2016,2,N02-Analgesics,"/capita, US$ exchange rate",6.5 +19317,Italy,2016,2,N02-Analgesics,"/capita, US$ purchasing power parity",8.4 +19318,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.7 +19319,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,86.0 +19320,Italy,2016,2,N02-Analgesics,Million of national currency units,358.1 +19321,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8 +19322,Italy,2016,2,J-Antiinfectives for systemic use,% of total sales,19.4 +19323,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +19324,Italy,2016,2,N02-Analgesics,% of total sales,1.6 +19325,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4 +19326,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",110.9 +19327,Italy,2016,2,C02-Antihypertensives,% of total sales,1.0 +19328,Italy,2016,2,A-Alimentary tract and metabolism,% of total sales,11.8 +19329,Italy,2016,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.4 +19330,Italy,2016,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3847.5 +19331,Italy,2016,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.2 +19332,Italy,2016,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.5 +19333,Italy,2016,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2 +19334,Italy,2016,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.1 +19335,Italy,2016,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.4 +19336,Italy,2016,2,A10-Drugs used in diabetes,% of total sales,3.9 +19337,Italy,2016,2,A10-Drugs used in diabetes,Million US$ at exchange rate,994.2 +19338,Italy,2016,2,A10-Drugs used in diabetes,Million of national currency units,898.2 +19339,Italy,2016,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1282.1 +19340,Italy,2016,2,C01A-Cardiac glycosides,Million US$ at exchange rate,7.2 +19341,Italy,2016,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +19342,Italy,2016,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.3 +19343,Italy,2016,2,C01A-Cardiac glycosides,Million of national currency units,6.5 +19344,Italy,2016,2,N-Nervous system,"Million US$, purchasing power parity",2579.9 +19345,Italy,2016,2,N-Nervous system,"/capita, US$ exchange rate",33.0 +19346,Italy,2016,2,N-Nervous system,"/capita, US$ purchasing power parity",42.6 +19347,Italy,2016,2,A-Alimentary tract and metabolism,Million of national currency units,2695.4 +19348,Italy,2016,2,C03-Diuretics,Million of national currency units,109.9 +19349,Italy,2016,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,2983.5 +19350,Italy,2016,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +19351,Italy,2016,2,C01A-Cardiac glycosides,% of total sales,0.0 +19352,Italy,2016,2,N-Nervous system,% of total sales,7.9 +19353,Italy,2016,2,R-Respiratory system,"/capita, US$ purchasing power parity",26.1 +19354,Italy,2016,2,R-Respiratory system,% of total sales,4.9 +19355,Italy,2016,2,R-Respiratory system,"Million US$, purchasing power parity",1580.8 +19356,Italy,2016,2,R-Respiratory system,"/capita, US$ exchange rate",20.2 +19357,Italy,2016,2,B-Blood and blood forming organs,% of total sales,8.9 +19358,Italy,2016,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2893.5 +19359,Italy,2016,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",37.0 +19360,Italy,2016,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",47.7 +19361,Italy,2016,2,C10-Lipid modifying agents,% of total sales,4.6 +19362,Italy,2016,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",423.1 +19363,Italy,2016,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4 +19364,Italy,2016,2,C08-Calcium channel blockers,Million US$ at exchange rate,328.1 +19365,Italy,2016,2,N05C-Hypnotics and sedatives,Million of national currency units,7.1 +19366,Italy,2016,2,C08-Calcium channel blockers,Million of national currency units,296.4 +19367,Italy,2016,2,R-Respiratory system,Million of national currency units,1107.4 +19368,Italy,2016,2,R-Respiratory system,Million US$ at exchange rate,1225.8 +19369,Italy,2016,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0 +19370,Italy,2016,2,C08-Calcium channel blockers,% of total sales,1.3 +19371,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,489.7 +19372,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,542.1 +19373,Italy,2016,2,A02A-Antacids,% of total sales,0.1 +19374,Italy,2016,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +19375,Italy,2016,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +19376,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5 +19377,Italy,2016,2,C-Cardiovascular system,% of total sales,15.9 +19378,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",699.0 +19379,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.9 +19380,Italy,2016,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1483.7 +19381,Italy,2016,2,C10-Lipid modifying agents,Million US$ at exchange rate,1150.5 +19382,Italy,2016,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.5 +19383,Italy,2016,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.0 +19384,Italy,2016,2,A02A-Antacids,Million US$ at exchange rate,28.0 +19385,Italy,2016,2,A02A-Antacids,"Million US$, purchasing power parity",36.1 +19386,Italy,2016,2,C10-Lipid modifying agents,Million of national currency units,1039.4 +19387,Italy,2016,2,A02A-Antacids,Million of national currency units,25.3 +19388,Italy,2016,2,G-Genito urinary system and sex hormones,Million of national currency units,560.9 +19389,Italy,2016,2,C07-Beta blocking agents,% of total sales,1.5 +19390,Italy,2016,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,620.9 +19391,Italy,2016,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",800.7 +19392,Italy,2016,2,C07-Beta blocking agents,"Million US$, purchasing power parity",489.9 +19393,Italy,2016,2,C07-Beta blocking agents,Million US$ at exchange rate,379.9 +19394,Italy,2016,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1 +19395,Italy,2016,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3 +19396,Italy,2016,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.2 +19397,Italy,2016,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.6 +19398,Italy,2016,2,N06A-Antidepressants,"Million US$, purchasing power parity",512.7 +19399,Italy,2016,2,N06A-Antidepressants,% of total sales,1.6 +19400,Italy,2016,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.5 +19401,Italy,2016,2,G-Genito urinary system and sex hormones,% of total sales,2.5 +19402,Italy,2016,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.2 +19403,Italy,2016,2,N06A-Antidepressants,Million US$ at exchange rate,397.6 +19404,Italy,2016,2,N06A-Antidepressants,Million of national currency units,359.2 +19405,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.4 +19406,Italy,2016,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +19407,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1294.9 +19408,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.6 +19409,Italy,2016,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",10.2 +19410,Italy,2016,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,7.9 +19411,Italy,2016,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +19412,Italy,2016,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +19413,Italy,2016,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,150.6 +19414,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",194.3 +19415,Italy,2016,2,C07-Beta blocking agents,Million of national currency units,343.2 +19416,Italy,2016,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,136.1 +19417,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.5 +19418,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,907.1 +19419,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1004.1 +19420,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.2 +19421,Italy,2016,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.6 +19422,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +19423,Italy,2016,2,R03-Drugs for obstructive airway diseases,Million of national currency units,991.3 +19424,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9 +19425,Italy,2016,2,C-Cardiovascular system,"Million US$, purchasing power parity",5181.0 +19426,Italy,2016,2,C-Cardiovascular system,Million US$ at exchange rate,4017.5 +19427,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1916.4 +19428,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1486.1 +19429,Italy,2016,2,C-Cardiovascular system,Million of national currency units,3629.5 +19430,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.6 +19431,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",24.5 +19432,Italy,2016,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.3 +19433,Italy,2016,2,R03-Drugs for obstructive airway diseases,% of total sales,4.4 +19434,Italy,2016,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.3 +19435,Italy,2016,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.5 +19436,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0 +19437,Italy,2016,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.1 +19438,Italy,2016,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1415.1 +19439,Italy,2016,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1097.3 +19440,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1342.6 +19441,Italy,2015,2,C03-Diuretics,"/capita, US$ exchange rate",2.1 +19442,Italy,2015,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.1 +19443,Italy,2015,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6 +19444,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,209.1 +19445,Italy,2015,2,C02-Antihypertensives,Million of national currency units,224.1 +19446,Italy,2015,2,C02-Antihypertensives,"Million US$, purchasing power parity",303.3 +19447,Italy,2015,2,C02-Antihypertensives,Million US$ at exchange rate,248.6 +19448,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",283.1 +19449,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.8 +19450,Italy,2015,2,C03-Diuretics,Million US$ at exchange rate,127.0 +19451,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.7 +19452,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,232.0 +19453,Italy,2015,2,C03-Diuretics,"Million US$, purchasing power parity",155.0 +19454,Italy,2015,2,C03-Diuretics,% of total sales,0.5 +19455,Italy,2015,2,B-Blood and blood forming organs,Million of national currency units,1981.9 +19456,Italy,2015,2,B-Blood and blood forming organs,Million US$ at exchange rate,2198.9 +19457,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9 +19458,Italy,2015,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1060.9 +19459,Italy,2015,2,J01-Antibacterials for systemic use,Million of national currency units,956.2 +19460,Italy,2015,2,Total pharmaceutical sales,Million US$ at exchange rate,25092.0 +19461,Italy,2015,2,Total pharmaceutical sales,Million of national currency units,22615.3 +19462,Italy,2015,2,Total pharmaceutical sales,"Million US$, purchasing power parity",30615.3 +19463,Italy,2015,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.1 +19464,Italy,2015,2,Total pharmaceutical sales,"/capita, US$ exchange rate",413.2 +19465,Italy,2015,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.1 +19466,Italy,2015,2,N05B-Anxiolytics,Million US$ at exchange rate,3.4 +19467,Italy,2015,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +19468,Italy,2015,2,N05B-Anxiolytics,% of total sales,0.0 +19469,Italy,2015,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +19470,Italy,2015,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.3 +19471,Italy,2015,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",17.5 +19472,Italy,2015,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1294.4 +19473,Italy,2015,2,N05B-Anxiolytics,Million of national currency units,3.0 +19474,Italy,2015,2,J01-Antibacterials for systemic use,% of total sales,4.2 +19475,Italy,2015,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,4852.6 +19476,Italy,2015,2,J-Antiinfectives for systemic use,Million of national currency units,4373.6 +19477,Italy,2015,2,M-Musculo-skeletal system,Million of national currency units,485.2 +19478,Italy,2015,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",97.5 +19479,Italy,2015,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",79.9 +19480,Italy,2015,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",5920.7 +19481,Italy,2015,2,M-Musculo-skeletal system,Million US$ at exchange rate,538.4 +19482,Italy,2015,2,M-Musculo-skeletal system,% of total sales,2.1 +19483,Italy,2015,2,N-Nervous system,Million of national currency units,1902.0 +19484,Italy,2015,2,N-Nervous system,Million US$ at exchange rate,2110.3 +19485,Italy,2015,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",656.9 +19486,Italy,2015,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.8 +19487,Italy,2015,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.9 +19488,Italy,2015,2,N02-Analgesics,"Million US$, purchasing power parity",456.4 +19489,Italy,2015,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.5 +19490,Italy,2015,2,N02-Analgesics,"/capita, US$ exchange rate",6.2 +19491,Italy,2015,2,N02-Analgesics,Million US$ at exchange rate,374.0 +19492,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.1 +19493,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,85.5 +19494,Italy,2015,2,N02-Analgesics,Million of national currency units,337.1 +19495,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +19496,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +19497,Italy,2015,2,J-Antiinfectives for systemic use,% of total sales,19.3 +19498,Italy,2015,2,N02-Analgesics,% of total sales,1.5 +19499,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4 +19500,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",104.3 +19501,Italy,2015,2,C02-Antihypertensives,% of total sales,1.0 +19502,Italy,2015,2,A-Alimentary tract and metabolism,% of total sales,11.7 +19503,Italy,2015,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.0 +19504,Italy,2015,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3594.0 +19505,Italy,2015,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.5 +19506,Italy,2015,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",59.2 +19507,Italy,2015,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4 +19508,Italy,2015,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.9 +19509,Italy,2015,2,A10-Drugs used in diabetes,% of total sales,3.8 +19510,Italy,2015,2,A10-Drugs used in diabetes,Million US$ at exchange rate,965.1 +19511,Italy,2015,2,A10-Drugs used in diabetes,Million of national currency units,869.9 +19512,Italy,2015,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1177.6 +19513,Italy,2015,2,C01A-Cardiac glycosides,Million US$ at exchange rate,8.0 +19514,Italy,2015,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +19515,Italy,2015,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.8 +19516,Italy,2015,2,N-Nervous system,"Million US$, purchasing power parity",2574.8 +19517,Italy,2015,2,N-Nervous system,"/capita, US$ exchange rate",34.7 +19518,Italy,2015,2,C01A-Cardiac glycosides,Million of national currency units,7.2 +19519,Italy,2015,2,N-Nervous system,"/capita, US$ purchasing power parity",42.4 +19520,Italy,2015,2,A-Alimentary tract and metabolism,Million of national currency units,2654.9 +19521,Italy,2015,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,2945.6 +19522,Italy,2015,2,C03-Diuretics,Million of national currency units,114.5 +19523,Italy,2015,2,C01A-Cardiac glycosides,% of total sales,0.0 +19524,Italy,2015,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +19525,Italy,2015,2,N-Nervous system,% of total sales,8.4 +19526,Italy,2015,2,R-Respiratory system,"/capita, US$ purchasing power parity",25.1 +19527,Italy,2015,2,R-Respiratory system,% of total sales,5.0 +19528,Italy,2015,2,R-Respiratory system,"Million US$, purchasing power parity",1523.6 +19529,Italy,2015,2,R-Respiratory system,"/capita, US$ exchange rate",20.6 +19530,Italy,2015,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2683.0 +19531,Italy,2015,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.2 +19532,Italy,2015,2,B-Blood and blood forming organs,% of total sales,8.8 +19533,Italy,2015,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",44.2 +19534,Italy,2015,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",408.7 +19535,Italy,2015,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5 +19536,Italy,2015,2,N05C-Hypnotics and sedatives,Million of national currency units,4.1 +19537,Italy,2015,2,C08-Calcium channel blockers,Million US$ at exchange rate,335.0 +19538,Italy,2015,2,C08-Calcium channel blockers,Million of national currency units,301.9 +19539,Italy,2015,2,R-Respiratory system,Million of national currency units,1125.4 +19540,Italy,2015,2,R-Respiratory system,Million US$ at exchange rate,1248.7 +19541,Italy,2015,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7 +19542,Italy,2015,2,C08-Calcium channel blockers,% of total sales,1.3 +19543,Italy,2015,2,C10-Lipid modifying agents,% of total sales,4.5 +19544,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,481.1 +19545,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,533.8 +19546,Italy,2015,2,A02A-Antacids,% of total sales,0.1 +19547,Italy,2015,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +19548,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7 +19549,Italy,2015,2,C-Cardiovascular system,% of total sales,16.0 +19550,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",651.3 +19551,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.8 +19552,Italy,2015,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +19553,Italy,2015,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1370.3 +19554,Italy,2015,2,C10-Lipid modifying agents,Million US$ at exchange rate,1123.1 +19555,Italy,2015,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.6 +19556,Italy,2015,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5 +19557,Italy,2015,2,A02A-Antacids,Million US$ at exchange rate,27.3 +19558,Italy,2015,2,A02A-Antacids,"Million US$, purchasing power parity",33.4 +19559,Italy,2015,2,C10-Lipid modifying agents,Million of national currency units,1012.2 +19560,Italy,2015,2,A02A-Antacids,Million of national currency units,24.6 +19561,Italy,2015,2,G-Genito urinary system and sex hormones,Million of national currency units,548.0 +19562,Italy,2015,2,C07-Beta blocking agents,% of total sales,1.5 +19563,Italy,2015,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,608.1 +19564,Italy,2015,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",741.9 +19565,Italy,2015,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.0 +19566,Italy,2015,2,C07-Beta blocking agents,"Million US$, purchasing power parity",451.2 +19567,Italy,2015,2,C07-Beta blocking agents,Million US$ at exchange rate,369.8 +19568,Italy,2015,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4 +19569,Italy,2015,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1 +19570,Italy,2015,2,N06A-Antidepressants,"/capita, US$ exchange rate",7.4 +19571,Italy,2015,2,N06A-Antidepressants,"Million US$, purchasing power parity",550.0 +19572,Italy,2015,2,N06A-Antidepressants,% of total sales,1.8 +19573,Italy,2015,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.1 +19574,Italy,2015,2,G-Genito urinary system and sex hormones,% of total sales,2.4 +19575,Italy,2015,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2 +19576,Italy,2015,2,N06A-Antidepressants,Million US$ at exchange rate,450.8 +19577,Italy,2015,2,N06A-Antidepressants,Million of national currency units,406.3 +19578,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.9 +19579,Italy,2015,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +19580,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1328.9 +19581,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.9 +19582,Italy,2015,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.5 +19583,Italy,2015,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.5 +19584,Italy,2015,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +19585,Italy,2015,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +19586,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",202.4 +19587,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.7 +19588,Italy,2015,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.9 +19589,Italy,2015,2,C07-Beta blocking agents,Million of national currency units,333.3 +19590,Italy,2015,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,149.5 +19591,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,981.7 +19592,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1089.2 +19593,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3 +19594,Italy,2015,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.7 +19595,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +19596,Italy,2015,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1020.1 +19597,Italy,2015,2,C-Cardiovascular system,"Million US$, purchasing power parity",4897.1 +19598,Italy,2015,2,C-Cardiovascular system,Million US$ at exchange rate,4013.6 +19599,Italy,2015,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.1 +19600,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.1 +19601,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1865.8 +19602,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1529.2 +19603,Italy,2015,2,C-Cardiovascular system,Million of national currency units,3617.5 +19604,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.7 +19605,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.2 +19606,Italy,2015,2,R03-Drugs for obstructive airway diseases,% of total sales,4.5 +19607,Italy,2015,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.7 +19608,Italy,2015,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.6 +19609,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.3 +19610,Italy,2015,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1380.9 +19611,Italy,2015,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.6 +19612,Italy,2015,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1131.8 +19613,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1378.2 +19614,Italy,2014,2,C03-Diuretics,"/capita, US$ exchange rate",2.5 +19615,Italy,2014,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.3 +19616,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,232.6 +19617,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +19618,Italy,2014,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6 +19619,Italy,2014,2,C02-Antihypertensives,Million of national currency units,197.8 +19620,Italy,2014,2,C02-Antihypertensives,Million US$ at exchange rate,262.8 +19621,Italy,2014,2,C02-Antihypertensives,"Million US$, purchasing power parity",267.4 +19622,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",314.5 +19623,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.1 +19624,Italy,2014,2,C03-Diuretics,Million US$ at exchange rate,153.9 +19625,Italy,2014,2,C03-Diuretics,"Million US$, purchasing power parity",156.7 +19626,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2 +19627,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,309.0 +19628,Italy,2014,2,C03-Diuretics,% of total sales,0.6 +19629,Italy,2014,2,B-Blood and blood forming organs,Million US$ at exchange rate,2462.9 +19630,Italy,2014,2,B-Blood and blood forming organs,Million of national currency units,1853.9 +19631,Italy,2014,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1294.3 +19632,Italy,2014,2,J01-Antibacterials for systemic use,Million of national currency units,974.3 +19633,Italy,2014,2,Total pharmaceutical sales,Million of national currency units,19887.5 +19634,Italy,2014,2,Total pharmaceutical sales,Million US$ at exchange rate,26420.6 +19635,Italy,2014,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.3 +19636,Italy,2014,2,Total pharmaceutical sales,"/capita, US$ exchange rate",434.6 +19637,Italy,2014,2,Total pharmaceutical sales,"Million US$, purchasing power parity",26888.0 +19638,Italy,2014,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1317.2 +19639,Italy,2014,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +19640,Italy,2014,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7 +19641,Italy,2014,2,N05B-Anxiolytics,Million US$ at exchange rate,4.7 +19642,Italy,2014,2,N05B-Anxiolytics,% of total sales,0.0 +19643,Italy,2014,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +19644,Italy,2014,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.7 +19645,Italy,2014,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.3 +19646,Italy,2014,2,N05B-Anxiolytics,Million of national currency units,3.5 +19647,Italy,2014,2,J01-Antibacterials for systemic use,% of total sales,4.9 +19648,Italy,2014,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3251.5 +19649,Italy,2014,2,J-Antiinfectives for systemic use,Million of national currency units,2447.5 +19650,Italy,2014,2,M-Musculo-skeletal system,Million of national currency units,505.9 +19651,Italy,2014,2,M-Musculo-skeletal system,Million US$ at exchange rate,672.1 +19652,Italy,2014,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.4 +19653,Italy,2014,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3309.0 +19654,Italy,2014,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.5 +19655,Italy,2014,2,M-Musculo-skeletal system,% of total sales,2.5 +19656,Italy,2014,2,N-Nervous system,Million of national currency units,1881.8 +19657,Italy,2014,2,N-Nervous system,Million US$ at exchange rate,2499.9 +19658,Italy,2014,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",683.9 +19659,Italy,2014,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3 +19660,Italy,2014,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.1 +19661,Italy,2014,2,N02-Analgesics,"Million US$, purchasing power parity",468.5 +19662,Italy,2014,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.7 +19663,Italy,2014,2,N02-Analgesics,"/capita, US$ exchange rate",7.6 +19664,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.7 +19665,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,100.5 +19666,Italy,2014,2,N02-Analgesics,Million US$ at exchange rate,460.3 +19667,Italy,2014,2,N02-Analgesics,Million of national currency units,346.5 +19668,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +19669,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +19670,Italy,2014,2,J-Antiinfectives for systemic use,% of total sales,12.3 +19671,Italy,2014,2,N02-Analgesics,% of total sales,1.7 +19672,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.7 +19673,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",102.3 +19674,Italy,2014,2,C02-Antihypertensives,% of total sales,1.0 +19675,Italy,2014,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4 +19676,Italy,2014,2,A-Alimentary tract and metabolism,% of total sales,13.0 +19677,Italy,2014,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.5 +19678,Italy,2014,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3494.1 +19679,Italy,2014,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",57.5 +19680,Italy,2014,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.0 +19681,Italy,2014,2,A10-Drugs used in diabetes,% of total sales,4.1 +19682,Italy,2014,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.7 +19683,Italy,2014,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1075.6 +19684,Italy,2014,2,A10-Drugs used in diabetes,Million of national currency units,809.7 +19685,Italy,2014,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1094.7 +19686,Italy,2014,2,C01A-Cardiac glycosides,Million US$ at exchange rate,10.7 +19687,Italy,2014,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.9 +19688,Italy,2014,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +19689,Italy,2014,2,N-Nervous system,"/capita, US$ exchange rate",41.1 +19690,Italy,2014,2,N-Nervous system,"Million US$, purchasing power parity",2544.1 +19691,Italy,2014,2,C01A-Cardiac glycosides,Million of national currency units,8.1 +19692,Italy,2014,2,N-Nervous system,"/capita, US$ purchasing power parity",41.9 +19693,Italy,2014,2,A-Alimentary tract and metabolism,Million of national currency units,2584.4 +19694,Italy,2014,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3433.3 +19695,Italy,2014,2,C03-Diuretics,Million of national currency units,115.9 +19696,Italy,2014,2,C01A-Cardiac glycosides,% of total sales,0.0 +19697,Italy,2014,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +19698,Italy,2014,2,N-Nervous system,% of total sales,9.5 +19699,Italy,2014,2,R-Respiratory system,% of total sales,5.5 +19700,Italy,2014,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.5 +19701,Italy,2014,2,R-Respiratory system,"Million US$, purchasing power parity",1491.4 +19702,Italy,2014,2,R-Respiratory system,"/capita, US$ exchange rate",24.1 +19703,Italy,2014,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.5 +19704,Italy,2014,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2506.4 +19705,Italy,2014,2,B-Blood and blood forming organs,% of total sales,9.3 +19706,Italy,2014,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.2 +19707,Italy,2014,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",430.3 +19708,Italy,2014,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.0 +19709,Italy,2014,2,C08-Calcium channel blockers,Million US$ at exchange rate,422.8 +19710,Italy,2014,2,N05C-Hypnotics and sedatives,Million of national currency units,2.5 +19711,Italy,2014,2,C08-Calcium channel blockers,Million of national currency units,318.3 +19712,Italy,2014,2,R-Respiratory system,Million of national currency units,1103.1 +19713,Italy,2014,2,R-Respiratory system,Million US$ at exchange rate,1465.4 +19714,Italy,2014,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.1 +19715,Italy,2014,2,C08-Calcium channel blockers,% of total sales,1.6 +19716,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,488.9 +19717,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,649.5 +19718,Italy,2014,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +19719,Italy,2014,2,A02A-Antacids,% of total sales,0.1 +19720,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9 +19721,Italy,2014,2,C-Cardiovascular system,% of total sales,18.2 +19722,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",661.0 +19723,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7 +19724,Italy,2014,2,C10-Lipid modifying agents,% of total sales,5.1 +19725,Italy,2014,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1363.1 +19726,Italy,2014,2,C10-Lipid modifying agents,Million US$ at exchange rate,1339.4 +19727,Italy,2014,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.0 +19728,Italy,2014,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.4 +19729,Italy,2014,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +19730,Italy,2014,2,A02A-Antacids,Million US$ at exchange rate,32.2 +19731,Italy,2014,2,A02A-Antacids,"Million US$, purchasing power parity",32.7 +19732,Italy,2014,2,C10-Lipid modifying agents,Million of national currency units,1008.2 +19733,Italy,2014,2,A02A-Antacids,Million of national currency units,24.2 +19734,Italy,2014,2,G-Genito urinary system and sex hormones,Million of national currency units,532.6 +19735,Italy,2014,2,C07-Beta blocking agents,% of total sales,1.6 +19736,Italy,2014,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,707.6 +19737,Italy,2014,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.6 +19738,Italy,2014,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",720.1 +19739,Italy,2014,2,C07-Beta blocking agents,"Million US$, purchasing power parity",437.1 +19740,Italy,2014,2,C07-Beta blocking agents,Million US$ at exchange rate,429.5 +19741,Italy,2014,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2 +19742,Italy,2014,2,C07-Beta blocking agents,"/capita, US$ exchange rate",7.1 +19743,Italy,2014,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.2 +19744,Italy,2014,2,N06A-Antidepressants,"Million US$, purchasing power parity",628.0 +19745,Italy,2014,2,N06A-Antidepressants,% of total sales,2.3 +19746,Italy,2014,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",10.3 +19747,Italy,2014,2,G-Genito urinary system and sex hormones,% of total sales,2.7 +19748,Italy,2014,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.8 +19749,Italy,2014,2,N06A-Antidepressants,Million US$ at exchange rate,617.1 +19750,Italy,2014,2,N06A-Antidepressants,Million of national currency units,464.5 +19751,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.1 +19752,Italy,2014,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +19753,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1402.0 +19754,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.7 +19755,Italy,2014,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4 +19756,Italy,2014,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +19757,Italy,2014,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +19758,Italy,2014,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +19759,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",209.1 +19760,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4 +19761,Italy,2014,2,C07-Beta blocking agents,Million of national currency units,323.3 +19762,Italy,2014,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,205.5 +19763,Italy,2014,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,154.7 +19764,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1037.0 +19765,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1377.7 +19766,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4 +19767,Italy,2014,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.8 +19768,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +19769,Italy,2014,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1009.2 +19770,Italy,2014,2,C-Cardiovascular system,"/capita, US$ exchange rate",79.2 +19771,Italy,2014,2,C-Cardiovascular system,"Million US$, purchasing power parity",4899.6 +19772,Italy,2014,2,C-Cardiovascular system,Million US$ at exchange rate,4814.5 +19773,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1890.3 +19774,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1857.5 +19775,Italy,2014,2,C-Cardiovascular system,Million of national currency units,3624.0 +19776,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.0 +19777,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.1 +19778,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.6 +19779,Italy,2014,2,R03-Drugs for obstructive airway diseases,% of total sales,5.1 +19780,Italy,2014,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.4 +19781,Italy,2014,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.6 +19782,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.2 +19783,Italy,2014,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1364.4 +19784,Italy,2014,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1340.7 +19785,Italy,2014,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1 +19786,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1398.2 +19787,Italy,2013,2,C03-Diuretics,"/capita, US$ exchange rate",2.4 +19788,Italy,2013,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2 +19789,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,235.2 +19790,Italy,2013,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.5 +19791,Italy,2013,2,C02-Antihypertensives,Million US$ at exchange rate,251.4 +19792,Italy,2013,2,C02-Antihypertensives,"Million US$, purchasing power parity",256.7 +19793,Italy,2013,2,C03-Diuretics,"Million US$, purchasing power parity",149.4 +19794,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",319.0 +19795,Italy,2013,2,C03-Diuretics,Million US$ at exchange rate,146.3 +19796,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.3 +19797,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +19798,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,312.4 +19799,Italy,2013,2,C03-Diuretics,% of total sales,0.6 +19800,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.2 +19801,Italy,2013,2,B-Blood and blood forming organs,Million US$ at exchange rate,2280.7 +19802,Italy,2013,2,C02-Antihypertensives,Million of national currency units,189.3 +19803,Italy,2013,2,B-Blood and blood forming organs,Million of national currency units,1717.3 +19804,Italy,2013,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1300.7 +19805,Italy,2013,2,J01-Antibacterials for systemic use,Million of national currency units,979.4 +19806,Italy,2013,2,Total pharmaceutical sales,Million of national currency units,19445.0 +19807,Italy,2013,2,Total pharmaceutical sales,Million US$ at exchange rate,25825.3 +19808,Italy,2013,2,Total pharmaceutical sales,"Million US$, purchasing power parity",26373.3 +19809,Italy,2013,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",437.8 +19810,Italy,2013,2,Total pharmaceutical sales,"/capita, US$ exchange rate",428.7 +19811,Italy,2013,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +19812,Italy,2013,2,N05B-Anxiolytics,"Million US$, purchasing power parity",5.4 +19813,Italy,2013,2,N05B-Anxiolytics,% of total sales,0.0 +19814,Italy,2013,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +19815,Italy,2013,2,N05B-Anxiolytics,Million US$ at exchange rate,5.3 +19816,Italy,2013,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.1 +19817,Italy,2013,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.6 +19818,Italy,2013,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1328.3 +19819,Italy,2013,2,N05B-Anxiolytics,Million of national currency units,4.0 +19820,Italy,2013,2,J01-Antibacterials for systemic use,% of total sales,5.0 +19821,Italy,2013,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3234.2 +19822,Italy,2013,2,J-Antiinfectives for systemic use,Million of national currency units,2435.2 +19823,Italy,2013,2,M-Musculo-skeletal system,Million US$ at exchange rate,732.0 +19824,Italy,2013,2,M-Musculo-skeletal system,Million of national currency units,551.2 +19825,Italy,2013,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.8 +19826,Italy,2013,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3302.9 +19827,Italy,2013,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.7 +19828,Italy,2013,2,M-Musculo-skeletal system,% of total sales,2.8 +19829,Italy,2013,2,N-Nervous system,Million of national currency units,1897.9 +19830,Italy,2013,2,N-Nervous system,Million US$ at exchange rate,2520.6 +19831,Italy,2013,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",747.6 +19832,Italy,2013,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.4 +19833,Italy,2013,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2 +19834,Italy,2013,2,J-Antiinfectives for systemic use,% of total sales,12.5 +19835,Italy,2013,2,N02-Analgesics,"Million US$, purchasing power parity",442.8 +19836,Italy,2013,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.4 +19837,Italy,2013,2,N02-Analgesics,"/capita, US$ exchange rate",7.2 +19838,Italy,2013,2,N02-Analgesics,Million US$ at exchange rate,433.6 +19839,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,99.3 +19840,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.8 +19841,Italy,2013,2,N02-Analgesics,Million of national currency units,326.5 +19842,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +19843,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +19844,Italy,2013,2,N02-Analgesics,% of total sales,1.7 +19845,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6 +19846,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",101.4 +19847,Italy,2013,2,C02-Antihypertensives,% of total sales,1.0 +19848,Italy,2013,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3 +19849,Italy,2013,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.7 +19850,Italy,2013,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3361.9 +19851,Italy,2013,2,A-Alimentary tract and metabolism,% of total sales,12.7 +19852,Italy,2013,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.8 +19853,Italy,2013,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.3 +19854,Italy,2013,2,A10-Drugs used in diabetes,% of total sales,4.2 +19855,Italy,2013,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.9 +19856,Italy,2013,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1078.4 +19857,Italy,2013,2,A10-Drugs used in diabetes,Million of national currency units,812.0 +19858,Italy,2013,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1101.3 +19859,Italy,2013,2,C01A-Cardiac glycosides,Million US$ at exchange rate,11.7 +19860,Italy,2013,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.9 +19861,Italy,2013,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +19862,Italy,2013,2,N-Nervous system,"/capita, US$ exchange rate",41.8 +19863,Italy,2013,2,N-Nervous system,"Million US$, purchasing power parity",2574.1 +19864,Italy,2013,2,C01A-Cardiac glycosides,Million of national currency units,8.8 +19865,Italy,2013,2,N-Nervous system,"/capita, US$ purchasing power parity",42.7 +19866,Italy,2013,2,A-Alimentary tract and metabolism,Million of national currency units,2478.7 +19867,Italy,2013,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3292.0 +19868,Italy,2013,2,C03-Diuretics,Million of national currency units,110.2 +19869,Italy,2013,2,C01A-Cardiac glycosides,% of total sales,0.0 +19870,Italy,2013,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +19871,Italy,2013,2,N-Nervous system,% of total sales,9.8 +19872,Italy,2013,2,R-Respiratory system,% of total sales,5.5 +19873,Italy,2013,2,R-Respiratory system,"Million US$, purchasing power parity",1459.8 +19874,Italy,2013,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.2 +19875,Italy,2013,2,R-Respiratory system,"/capita, US$ exchange rate",23.7 +19876,Italy,2013,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",37.9 +19877,Italy,2013,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2329.1 +19878,Italy,2013,2,B-Blood and blood forming organs,% of total sales,8.8 +19879,Italy,2013,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.7 +19880,Italy,2013,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",438.5 +19881,Italy,2013,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.1 +19882,Italy,2013,2,N05C-Hypnotics and sedatives,Million of national currency units,3.1 +19883,Italy,2013,2,C08-Calcium channel blockers,Million of national currency units,323.3 +19884,Italy,2013,2,C08-Calcium channel blockers,Million US$ at exchange rate,429.4 +19885,Italy,2013,2,R-Respiratory system,Million of national currency units,1076.3 +19886,Italy,2013,2,R-Respiratory system,Million US$ at exchange rate,1429.5 +19887,Italy,2013,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.3 +19888,Italy,2013,2,C08-Calcium channel blockers,% of total sales,1.7 +19889,Italy,2013,2,C10-Lipid modifying agents,% of total sales,5.3 +19890,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,484.7 +19891,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,643.7 +19892,Italy,2013,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +19893,Italy,2013,2,A02A-Antacids,% of total sales,0.1 +19894,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9 +19895,Italy,2013,2,C-Cardiovascular system,% of total sales,19.4 +19896,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",657.4 +19897,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7 +19898,Italy,2013,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +19899,Italy,2013,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1401.2 +19900,Italy,2013,2,C10-Lipid modifying agents,Million US$ at exchange rate,1372.1 +19901,Italy,2013,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.8 +19902,Italy,2013,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.3 +19903,Italy,2013,2,A02A-Antacids,"Million US$, purchasing power parity",30.0 +19904,Italy,2013,2,A02A-Antacids,Million US$ at exchange rate,29.4 +19905,Italy,2013,2,C10-Lipid modifying agents,Million of national currency units,1033.1 +19906,Italy,2013,2,A02A-Antacids,Million of national currency units,22.1 +19907,Italy,2013,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,686.0 +19908,Italy,2013,2,G-Genito urinary system and sex hormones,Million of national currency units,516.5 +19909,Italy,2013,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.4 +19910,Italy,2013,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",700.6 +19911,Italy,2013,2,C07-Beta blocking agents,% of total sales,1.6 +19912,Italy,2013,2,C07-Beta blocking agents,"Million US$, purchasing power parity",410.7 +19913,Italy,2013,2,C07-Beta blocking agents,Million US$ at exchange rate,402.1 +19914,Italy,2013,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8 +19915,Italy,2013,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7 +19916,Italy,2013,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.9 +19917,Italy,2013,2,N06A-Antidepressants,"Million US$, purchasing power parity",668.9 +19918,Italy,2013,2,N06A-Antidepressants,% of total sales,2.5 +19919,Italy,2013,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1 +19920,Italy,2013,2,G-Genito urinary system and sex hormones,% of total sales,2.7 +19921,Italy,2013,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.6 +19922,Italy,2013,2,N06A-Antidepressants,Million US$ at exchange rate,655.0 +19923,Italy,2013,2,N06A-Antidepressants,Million of national currency units,493.2 +19924,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.5 +19925,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1 +19926,Italy,2013,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +19927,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1352.6 +19928,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.0 +19929,Italy,2013,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.2 +19930,Italy,2013,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.1 +19931,Italy,2013,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +19932,Italy,2013,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +19933,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",222.1 +19934,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6 +19935,Italy,2013,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,217.5 +19936,Italy,2013,2,C07-Beta blocking agents,Million of national currency units,302.8 +19937,Italy,2013,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,163.8 +19938,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,997.3 +19939,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1324.5 +19940,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7 +19941,Italy,2013,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.8 +19942,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +19943,Italy,2013,2,R03-Drugs for obstructive airway diseases,Million of national currency units,986.1 +19944,Italy,2013,2,C-Cardiovascular system,Million of national currency units,3769.3 +19945,Italy,2013,2,C-Cardiovascular system,"Million US$, purchasing power parity",5112.3 +19946,Italy,2013,2,C-Cardiovascular system,Million US$ at exchange rate,5006.1 +19947,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.0 +19948,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2104.9 +19949,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2061.2 +19950,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.9 +19951,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.2 +19952,Italy,2013,2,C-Cardiovascular system,"/capita, US$ exchange rate",83.1 +19953,Italy,2013,2,R03-Drugs for obstructive airway diseases,% of total sales,5.1 +19954,Italy,2013,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2 +19955,Italy,2013,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.9 +19956,Italy,2013,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1337.4 +19957,Italy,2013,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1309.6 +19958,Italy,2013,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.7 +19959,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1551.9 +19960,Italy,2012,2,C03-Diuretics,"/capita, US$ exchange rate",2.3 +19961,Italy,2012,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2 +19962,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,234.5 +19963,Italy,2012,2,C02-Antihypertensives,Million US$ at exchange rate,249.9 +19964,Italy,2012,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +19965,Italy,2012,2,C02-Antihypertensives,"Million US$, purchasing power parity",260.2 +19966,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,301.3 +19967,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.1 +19968,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",313.6 +19969,Italy,2012,2,C03-Diuretics,"Million US$, purchasing power parity",145.0 +19970,Italy,2012,2,C03-Diuretics,Million US$ at exchange rate,139.3 +19971,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.3 +19972,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2 +19973,Italy,2012,2,C03-Diuretics,% of total sales,0.6 +19974,Italy,2012,2,B-Blood and blood forming organs,Million US$ at exchange rate,2267.4 +19975,Italy,2012,2,C02-Antihypertensives,Million of national currency units,194.5 +19976,Italy,2012,2,B-Blood and blood forming organs,Million of national currency units,1764.8 +19977,Italy,2012,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1282.4 +19978,Italy,2012,2,J01-Antibacterials for systemic use,Million of national currency units,998.1 +19979,Italy,2012,2,Total pharmaceutical sales,Million of national currency units,19077.9 +19980,Italy,2012,2,Total pharmaceutical sales,Million US$ at exchange rate,24511.0 +19981,Italy,2012,2,Total pharmaceutical sales,"Million US$, purchasing power parity",25514.3 +19982,Italy,2012,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",428.5 +19983,Italy,2012,2,Total pharmaceutical sales,"/capita, US$ exchange rate",411.7 +19984,Italy,2012,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1334.9 +19985,Italy,2012,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +19986,Italy,2012,2,N05B-Anxiolytics,"Million US$, purchasing power parity",5.2 +19987,Italy,2012,2,N05B-Anxiolytics,% of total sales,0.0 +19988,Italy,2012,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +19989,Italy,2012,2,N05B-Anxiolytics,Million US$ at exchange rate,5.0 +19990,Italy,2012,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.4 +19991,Italy,2012,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.5 +19992,Italy,2012,2,N05B-Anxiolytics,Million of national currency units,3.9 +19993,Italy,2012,2,J01-Antibacterials for systemic use,% of total sales,5.2 +19994,Italy,2012,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3027.7 +19995,Italy,2012,2,J-Antiinfectives for systemic use,Million of national currency units,2356.5 +19996,Italy,2012,2,M-Musculo-skeletal system,Million US$ at exchange rate,757.3 +19997,Italy,2012,2,M-Musculo-skeletal system,Million of national currency units,589.4 +19998,Italy,2012,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.9 +19999,Italy,2012,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3151.6 +20000,Italy,2012,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.9 +20001,Italy,2012,2,M-Musculo-skeletal system,% of total sales,3.1 +20002,Italy,2012,2,N-Nervous system,Million of national currency units,1936.9 +20003,Italy,2012,2,N-Nervous system,Million US$ at exchange rate,2488.5 +20004,Italy,2012,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",788.3 +20005,Italy,2012,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.7 +20006,Italy,2012,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.2 +20007,Italy,2012,2,J-Antiinfectives for systemic use,% of total sales,12.4 +20008,Italy,2012,2,N02-Analgesics,"Million US$, purchasing power parity",409.5 +20009,Italy,2012,2,N02-Analgesics,"/capita, US$ purchasing power parity",6.9 +20010,Italy,2012,2,N02-Analgesics,"/capita, US$ exchange rate",6.6 +20011,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,94.3 +20012,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.4 +20013,Italy,2012,2,N02-Analgesics,Million US$ at exchange rate,393.4 +20014,Italy,2012,2,N02-Analgesics,Million of national currency units,306.2 +20015,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6 +20016,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +20017,Italy,2012,2,N02-Analgesics,% of total sales,1.6 +20018,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",98.1 +20019,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6 +20020,Italy,2012,2,C02-Antihypertensives,% of total sales,1.0 +20021,Italy,2012,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4 +20022,Italy,2012,2,A-Alimentary tract and metabolism,% of total sales,12.4 +20023,Italy,2012,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.0 +20024,Italy,2012,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3160.4 +20025,Italy,2012,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.1 +20026,Italy,2012,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.5 +20027,Italy,2012,2,A10-Drugs used in diabetes,% of total sales,4.1 +20028,Italy,2012,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8 +20029,Italy,2012,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1001.8 +20030,Italy,2012,2,A10-Drugs used in diabetes,Million of national currency units,779.7 +20031,Italy,2012,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1042.8 +20032,Italy,2012,2,C01A-Cardiac glycosides,Million US$ at exchange rate,12.5 +20033,Italy,2012,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",13.0 +20034,Italy,2012,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +20035,Italy,2012,2,N-Nervous system,"/capita, US$ exchange rate",41.8 +20036,Italy,2012,2,N-Nervous system,"Million US$, purchasing power parity",2590.3 +20037,Italy,2012,2,C01A-Cardiac glycosides,Million of national currency units,9.7 +20038,Italy,2012,2,N-Nervous system,"/capita, US$ purchasing power parity",43.5 +20039,Italy,2012,2,A-Alimentary tract and metabolism,Million of national currency units,2363.1 +20040,Italy,2012,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3036.1 +20041,Italy,2012,2,C03-Diuretics,Million of national currency units,108.5 +20042,Italy,2012,2,C01A-Cardiac glycosides,% of total sales,0.1 +20043,Italy,2012,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +20044,Italy,2012,2,N-Nervous system,% of total sales,10.2 +20045,Italy,2012,2,R-Respiratory system,% of total sales,5.8 +20046,Italy,2012,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.9 +20047,Italy,2012,2,R-Respiratory system,"/capita, US$ exchange rate",23.9 +20048,Italy,2012,2,R-Respiratory system,"Million US$, purchasing power parity",1484.1 +20049,Italy,2012,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1 +20050,Italy,2012,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2360.2 +20051,Italy,2012,2,B-Blood and blood forming organs,% of total sales,9.3 +20052,Italy,2012,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.6 +20053,Italy,2012,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",444.8 +20054,Italy,2012,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.2 +20055,Italy,2012,2,N05C-Hypnotics and sedatives,Million of national currency units,3.8 +20056,Italy,2012,2,C08-Calcium channel blockers,Million of national currency units,332.6 +20057,Italy,2012,2,C08-Calcium channel blockers,Million US$ at exchange rate,427.3 +20058,Italy,2012,2,R-Respiratory system,Million of national currency units,1109.7 +20059,Italy,2012,2,R-Respiratory system,Million US$ at exchange rate,1425.7 +20060,Italy,2012,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.5 +20061,Italy,2012,2,C08-Calcium channel blockers,% of total sales,1.7 +20062,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,478.2 +20063,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,614.3 +20064,Italy,2012,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +20065,Italy,2012,2,A02A-Antacids,% of total sales,0.1 +20066,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7 +20067,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",639.5 +20068,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.3 +20069,Italy,2012,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1531.3 +20070,Italy,2012,2,C10-Lipid modifying agents,Million US$ at exchange rate,1471.1 +20071,Italy,2012,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",24.7 +20072,Italy,2012,2,C10-Lipid modifying agents,% of total sales,6.0 +20073,Italy,2012,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.7 +20074,Italy,2012,2,A02A-Antacids,"Million US$, purchasing power parity",29.1 +20075,Italy,2012,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +20076,Italy,2012,2,C10-Lipid modifying agents,Million of national currency units,1145.0 +20077,Italy,2012,2,A02A-Antacids,Million US$ at exchange rate,27.9 +20078,Italy,2012,2,A02A-Antacids,Million of national currency units,21.7 +20079,Italy,2012,2,C-Cardiovascular system,% of total sales,20.8 +20080,Italy,2012,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,643.1 +20081,Italy,2012,2,G-Genito urinary system and sex hormones,Million of national currency units,500.5 +20082,Italy,2012,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.8 +20083,Italy,2012,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",669.4 +20084,Italy,2012,2,C07-Beta blocking agents,"Million US$, purchasing power parity",387.4 +20085,Italy,2012,2,C07-Beta blocking agents,Million US$ at exchange rate,372.2 +20086,Italy,2012,2,C07-Beta blocking agents,% of total sales,1.5 +20087,Italy,2012,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3 +20088,Italy,2012,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.5 +20089,Italy,2012,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.6 +20090,Italy,2012,2,N06A-Antidepressants,"Million US$, purchasing power parity",659.4 +20091,Italy,2012,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1 +20092,Italy,2012,2,N06A-Antidepressants,% of total sales,2.6 +20093,Italy,2012,2,G-Genito urinary system and sex hormones,% of total sales,2.6 +20094,Italy,2012,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2 +20095,Italy,2012,2,N06A-Antidepressants,Million US$ at exchange rate,633.4 +20096,Italy,2012,2,N06A-Antidepressants,Million of national currency units,493.0 +20097,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.0 +20098,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1 +20099,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1310.5 +20100,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.1 +20101,Italy,2012,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +20102,Italy,2012,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.1 +20103,Italy,2012,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.9 +20104,Italy,2012,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +20105,Italy,2012,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +20106,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",227.0 +20107,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.7 +20108,Italy,2012,2,C07-Beta blocking agents,Million of national currency units,289.7 +20109,Italy,2012,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,169.7 +20110,Italy,2012,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,218.0 +20111,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,979.9 +20112,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1259.0 +20113,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8 +20114,Italy,2012,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +20115,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +20116,Italy,2012,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1008.3 +20117,Italy,2012,2,C-Cardiovascular system,Million of national currency units,3968.6 +20118,Italy,2012,2,C-Cardiovascular system,"/capita, US$ exchange rate",85.6 +20119,Italy,2012,2,C-Cardiovascular system,"Million US$, purchasing power parity",5307.5 +20120,Italy,2012,2,C-Cardiovascular system,Million US$ at exchange rate,5098.8 +20121,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2201.1 +20122,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.6 +20123,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",37.0 +20124,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5 +20125,Italy,2012,2,R03-Drugs for obstructive airway diseases,% of total sales,5.3 +20126,Italy,2012,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.6 +20127,Italy,2012,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.1 +20128,Italy,2012,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1348.5 +20129,Italy,2012,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1295.5 +20130,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2114.6 +20131,Italy,2012,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.8 +20132,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1645.8 +20133,Italy,2017,2,C03-Diuretics,"/capita, US$ exchange rate",2.1 +20134,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.3 +20135,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,174.7 +20136,Italy,2017,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.7 +20137,Italy,2017,2,C02-Antihypertensives,Million of national currency units,221.7 +20138,Italy,2017,2,C02-Antihypertensives,"Million US$, purchasing power parity",321.3 +20139,Italy,2017,2,C02-Antihypertensives,Million US$ at exchange rate,250.4 +20140,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",253.2 +20141,Italy,2017,2,C03-Diuretics,Million US$ at exchange rate,127.7 +20142,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,197.3 +20143,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2 +20144,Italy,2017,2,C03-Diuretics,"Million US$, purchasing power parity",163.8 +20145,Italy,2017,2,C03-Diuretics,% of total sales,0.5 +20146,Italy,2017,2,J01-Antibacterials for systemic use,% of total sales,3.9 +20147,Italy,2017,2,B-Blood and blood forming organs,Million of national currency units,2088.3 +20148,Italy,2017,2,B-Blood and blood forming organs,Million US$ at exchange rate,2359.1 +20149,Italy,2017,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,983.9 +20150,Italy,2017,2,J01-Antibacterials for systemic use,Million of national currency units,871.0 +20151,Italy,2017,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",541.6 +20152,Italy,2017,2,Total pharmaceutical sales,Million US$ at exchange rate,25552.0 +20153,Italy,2017,2,Total pharmaceutical sales,Million of national currency units,22618.8 +20154,Italy,2017,2,Total pharmaceutical sales,"/capita, US$ exchange rate",422.1 +20155,Italy,2017,2,Total pharmaceutical sales,"Million US$, purchasing power parity",32785.9 +20156,Italy,2017,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8 +20157,Italy,2017,2,N05B-Anxiolytics,Million US$ at exchange rate,3.7 +20158,Italy,2017,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +20159,Italy,2017,2,N05B-Anxiolytics,% of total sales,0.0 +20160,Italy,2017,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +20161,Italy,2017,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.3 +20162,Italy,2017,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1262.5 +20163,Italy,2017,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",20.9 +20164,Italy,2017,2,N05B-Anxiolytics,Million of national currency units,3.3 +20165,Italy,2017,2,J-Antiinfectives for systemic use,Million of national currency units,3501.5 +20166,Italy,2017,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3955.6 +20167,Italy,2017,2,M-Musculo-skeletal system,Million of national currency units,462.0 +20168,Italy,2017,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",83.8 +20169,Italy,2017,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.3 +20170,Italy,2017,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",5075.4 +20171,Italy,2017,2,M-Musculo-skeletal system,Million US$ at exchange rate,521.9 +20172,Italy,2017,2,M-Musculo-skeletal system,% of total sales,2.0 +20173,Italy,2017,2,N-Nervous system,Million US$ at exchange rate,2019.4 +20174,Italy,2017,2,N-Nervous system,Million of national currency units,1787.6 +20175,Italy,2017,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.1 +20176,Italy,2017,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",669.7 +20177,Italy,2017,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.6 +20178,Italy,2017,2,N02-Analgesics,"Million US$, purchasing power parity",540.3 +20179,Italy,2017,2,N02-Analgesics,Million US$ at exchange rate,421.1 +20180,Italy,2017,2,N02-Analgesics,"/capita, US$ exchange rate",7.0 +20181,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.0 +20182,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,89.2 +20183,Italy,2017,2,N02-Analgesics,Million of national currency units,372.7 +20184,Italy,2017,2,N02-Analgesics,"/capita, US$ purchasing power parity",8.9 +20185,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.9 +20186,Italy,2017,2,J-Antiinfectives for systemic use,% of total sales,15.5 +20187,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +20188,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +20189,Italy,2017,2,N02-Analgesics,% of total sales,1.6 +20190,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",114.5 +20191,Italy,2017,2,C02-Antihypertensives,% of total sales,1.0 +20192,Italy,2017,2,A-Alimentary tract and metabolism,% of total sales,12.2 +20193,Italy,2017,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.3 +20194,Italy,2017,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3992.0 +20195,Italy,2017,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.4 +20196,Italy,2017,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.9 +20197,Italy,2017,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.1 +20198,Italy,2017,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.6 +20199,Italy,2017,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.9 +20200,Italy,2017,2,A10-Drugs used in diabetes,% of total sales,4.0 +20201,Italy,2017,2,A10-Drugs used in diabetes,Million of national currency units,904.1 +20202,Italy,2017,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1021.3 +20203,Italy,2017,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1310.5 +20204,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +20205,Italy,2017,2,C01A-Cardiac glycosides,Million US$ at exchange rate,6.7 +20206,Italy,2017,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +20207,Italy,2017,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.6 +20208,Italy,2017,2,N-Nervous system,"Million US$, purchasing power parity",2591.1 +20209,Italy,2017,2,N-Nervous system,"/capita, US$ exchange rate",33.4 +20210,Italy,2017,2,C01A-Cardiac glycosides,Million of national currency units,5.9 +20211,Italy,2017,2,A-Alimentary tract and metabolism,Million of national currency units,2754.0 +20212,Italy,2017,2,C03-Diuretics,Million of national currency units,113.0 +20213,Italy,2017,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3111.2 +20214,Italy,2017,2,N-Nervous system,% of total sales,7.9 +20215,Italy,2017,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +20216,Italy,2017,2,C01A-Cardiac glycosides,% of total sales,0.0 +20217,Italy,2017,2,N-Nervous system,"/capita, US$ purchasing power parity",42.8 +20218,Italy,2017,2,R-Respiratory system,"/capita, US$ purchasing power parity",26.8 +20219,Italy,2017,2,R-Respiratory system,% of total sales,5.0 +20220,Italy,2017,2,R-Respiratory system,"Million US$, purchasing power parity",1623.1 +20221,Italy,2017,2,R-Respiratory system,"/capita, US$ exchange rate",20.9 +20222,Italy,2017,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",3027.0 +20223,Italy,2017,2,C10-Lipid modifying agents,% of total sales,4.8 +20224,Italy,2017,2,B-Blood and blood forming organs,% of total sales,9.2 +20225,Italy,2017,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.0 +20226,Italy,2017,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",50.0 +20227,Italy,2017,2,C08-Calcium channel blockers,Million US$ at exchange rate,323.9 +20228,Italy,2017,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",415.5 +20229,Italy,2017,2,N05C-Hypnotics and sedatives,Million of national currency units,10.1 +20230,Italy,2017,2,C08-Calcium channel blockers,Million of national currency units,286.7 +20231,Italy,2017,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.3 +20232,Italy,2017,2,R-Respiratory system,Million of national currency units,1119.8 +20233,Italy,2017,2,R-Respiratory system,Million US$ at exchange rate,1265.0 +20234,Italy,2017,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.9 +20235,Italy,2017,2,C08-Calcium channel blockers,% of total sales,1.3 +20236,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,509.2 +20237,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,575.2 +20238,Italy,2017,2,A02A-Antacids,% of total sales,0.1 +20239,Italy,2017,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +20240,Italy,2017,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +20241,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.2 +20242,Italy,2017,2,C-Cardiovascular system,% of total sales,15.7 +20243,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",738.0 +20244,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.5 +20245,Italy,2017,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1583.1 +20246,Italy,2017,2,C10-Lipid modifying agents,Million US$ at exchange rate,1233.8 +20247,Italy,2017,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.2 +20248,Italy,2017,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.4 +20249,Italy,2017,2,A02A-Antacids,Million US$ at exchange rate,28.7 +20250,Italy,2017,2,A02A-Antacids,"Million US$, purchasing power parity",36.9 +20251,Italy,2017,2,C10-Lipid modifying agents,Million of national currency units,1092.2 +20252,Italy,2017,2,A02A-Antacids,Million of national currency units,25.4 +20253,Italy,2017,2,G-Genito urinary system and sex hormones,Million of national currency units,514.6 +20254,Italy,2017,2,C07-Beta blocking agents,% of total sales,1.5 +20255,Italy,2017,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",746.0 +20256,Italy,2017,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,581.4 +20257,Italy,2017,2,C07-Beta blocking agents,"Million US$, purchasing power parity",504.0 +20258,Italy,2017,2,C07-Beta blocking agents,Million US$ at exchange rate,392.8 +20259,Italy,2017,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3 +20260,Italy,2017,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5 +20261,Italy,2017,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.9 +20262,Italy,2017,2,N06A-Antidepressants,"Million US$, purchasing power parity",534.9 +20263,Italy,2017,2,N06A-Antidepressants,% of total sales,1.6 +20264,Italy,2017,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.8 +20265,Italy,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.6 +20266,Italy,2017,2,G-Genito urinary system and sex hormones,% of total sales,2.3 +20267,Italy,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3 +20268,Italy,2017,2,N06A-Antidepressants,Million US$ at exchange rate,416.9 +20269,Italy,2017,2,N06A-Antidepressants,Million of national currency units,369.0 +20270,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.3 +20271,Italy,2017,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +20272,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1289.8 +20273,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.6 +20274,Italy,2017,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6 +20275,Italy,2017,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.4 +20276,Italy,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +20277,Italy,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2 +20278,Italy,2017,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,139.8 +20279,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.3 +20280,Italy,2017,2,C07-Beta blocking agents,Million of national currency units,347.7 +20281,Italy,2017,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,123.7 +20282,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,889.8 +20283,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1005.2 +20284,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3 +20285,Italy,2017,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.5 +20286,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0 +20287,Italy,2017,2,R03-Drugs for obstructive airway diseases,Million of national currency units,988.2 +20288,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +20289,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4 +20290,Italy,2017,2,C-Cardiovascular system,"Million US$, purchasing power parity",5145.2 +20291,Italy,2017,2,C-Cardiovascular system,Million US$ at exchange rate,4010.0 +20292,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1757.8 +20293,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1370.0 +20294,Italy,2017,2,C-Cardiovascular system,Million of national currency units,3549.6 +20295,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.0 +20296,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.6 +20297,Italy,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.7 +20298,Italy,2017,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.2 +20299,Italy,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.4 +20300,Italy,2017,2,R03-Drugs for obstructive airway diseases,% of total sales,4.4 +20301,Italy,2017,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.0 +20302,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9 +20303,Italy,2017,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1432.4 +20304,Italy,2017,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1116.4 +20305,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1212.7 +20306,Italy,2011,2,C03-Diuretics,"/capita, US$ exchange rate",2.5 +20307,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,250.0 +20308,Italy,2011,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.6 +20309,Italy,2011,2,C02-Antihypertensives,Million US$ at exchange rate,274.6 +20310,Italy,2011,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +20311,Italy,2011,2,C02-Antihypertensives,"Million US$, purchasing power parity",260.1 +20312,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,347.9 +20313,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.9 +20314,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",329.5 +20315,Italy,2011,2,C03-Diuretics,Million US$ at exchange rate,151.3 +20316,Italy,2011,2,C03-Diuretics,"Million US$, purchasing power parity",143.3 +20317,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.5 +20318,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3 +20319,Italy,2011,2,C03-Diuretics,% of total sales,0.6 +20320,Italy,2011,2,B-Blood and blood forming organs,Million US$ at exchange rate,2471.4 +20321,Italy,2011,2,C02-Antihypertensives,Million of national currency units,197.3 +20322,Italy,2011,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1565.3 +20323,Italy,2011,2,J01-Antibacterials for systemic use,Million of national currency units,1124.5 +20324,Italy,2011,2,B-Blood and blood forming organs,Million of national currency units,1775.5 +20325,Italy,2011,2,Total pharmaceutical sales,"Million US$, purchasing power parity",25720.8 +20326,Italy,2011,2,Total pharmaceutical sales,Million of national currency units,19514.0 +20327,Italy,2011,2,Total pharmaceutical sales,Million US$ at exchange rate,27162.7 +20328,Italy,2011,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1482.2 +20329,Italy,2011,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",433.2 +20330,Italy,2011,2,Total pharmaceutical sales,"/capita, US$ exchange rate",457.4 +20331,Italy,2011,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +20332,Italy,2011,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8 +20333,Italy,2011,2,N05B-Anxiolytics,% of total sales,0.0 +20334,Italy,2011,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +20335,Italy,2011,2,N05B-Anxiolytics,Million US$ at exchange rate,5.1 +20336,Italy,2011,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",25.0 +20337,Italy,2011,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.4 +20338,Italy,2011,2,N05B-Anxiolytics,Million of national currency units,3.7 +20339,Italy,2011,2,J01-Antibacterials for systemic use,% of total sales,5.8 +20340,Italy,2011,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3335.7 +20341,Italy,2011,2,M-Musculo-skeletal system,Million US$ at exchange rate,891.0 +20342,Italy,2011,2,M-Musculo-skeletal system,Million of national currency units,640.1 +20343,Italy,2011,2,J-Antiinfectives for systemic use,Million of national currency units,2396.4 +20344,Italy,2011,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",53.2 +20345,Italy,2011,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3158.6 +20346,Italy,2011,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.2 +20347,Italy,2011,2,N-Nervous system,Million of national currency units,1995.7 +20348,Italy,2011,2,M-Musculo-skeletal system,% of total sales,3.3 +20349,Italy,2011,2,N-Nervous system,Million US$ at exchange rate,2778.0 +20350,Italy,2011,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",843.7 +20351,Italy,2011,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.0 +20352,Italy,2011,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.2 +20353,Italy,2011,2,J-Antiinfectives for systemic use,% of total sales,12.3 +20354,Italy,2011,2,N02-Analgesics,"Million US$, purchasing power parity",375.6 +20355,Italy,2011,2,N02-Analgesics,"/capita, US$ exchange rate",6.7 +20356,Italy,2011,2,N02-Analgesics,"/capita, US$ purchasing power parity",6.3 +20357,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,104.8 +20358,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.3 +20359,Italy,2011,2,N02-Analgesics,Million US$ at exchange rate,396.7 +20360,Italy,2011,2,N02-Analgesics,Million of national currency units,285.0 +20361,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +20362,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7 +20363,Italy,2011,2,N02-Analgesics,% of total sales,1.5 +20364,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8 +20365,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",99.2 +20366,Italy,2011,2,N-Nervous system,"Million US$, purchasing power parity",2630.5 +20367,Italy,2011,2,C02-Antihypertensives,% of total sales,1.0 +20368,Italy,2011,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4 +20369,Italy,2011,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.5 +20370,Italy,2011,2,A-Alimentary tract and metabolism,% of total sales,11.7 +20371,Italy,2011,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.7 +20372,Italy,2011,2,A10-Drugs used in diabetes,Million of national currency units,742.4 +20373,Italy,2011,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.5 +20374,Italy,2011,2,A10-Drugs used in diabetes,% of total sales,3.8 +20375,Italy,2011,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1033.4 +20376,Italy,2011,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.4 +20377,Italy,2011,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",978.5 +20378,Italy,2011,2,C01A-Cardiac glycosides,Million US$ at exchange rate,14.7 +20379,Italy,2011,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",14.0 +20380,Italy,2011,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +20381,Italy,2011,2,N-Nervous system,"/capita, US$ exchange rate",46.8 +20382,Italy,2011,2,C01A-Cardiac glycosides,Million of national currency units,10.6 +20383,Italy,2011,2,N-Nervous system,"/capita, US$ purchasing power parity",44.3 +20384,Italy,2011,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3176.3 +20385,Italy,2011,2,A-Alimentary tract and metabolism,Million of national currency units,2281.9 +20386,Italy,2011,2,C03-Diuretics,Million of national currency units,108.7 +20387,Italy,2011,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3007.7 +20388,Italy,2011,2,C01A-Cardiac glycosides,% of total sales,0.1 +20389,Italy,2011,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +20390,Italy,2011,2,N-Nervous system,% of total sales,10.2 +20391,Italy,2011,2,R-Respiratory system,Million of national currency units,1136.7 +20392,Italy,2011,2,R-Respiratory system,% of total sales,5.8 +20393,Italy,2011,2,R-Respiratory system,"/capita, US$ exchange rate",26.6 +20394,Italy,2011,2,R-Respiratory system,"/capita, US$ purchasing power parity",25.2 +20395,Italy,2011,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",41.6 +20396,Italy,2011,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2340.2 +20397,Italy,2011,2,B-Blood and blood forming organs,% of total sales,9.1 +20398,Italy,2011,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.4 +20399,Italy,2011,2,R-Respiratory system,"Million US$, purchasing power parity",1498.3 +20400,Italy,2011,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",512.7 +20401,Italy,2011,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",9.1 +20402,Italy,2011,2,N05C-Hypnotics and sedatives,Million of national currency units,3.1 +20403,Italy,2011,2,C08-Calcium channel blockers,Million of national currency units,389.0 +20404,Italy,2011,2,C08-Calcium channel blockers,Million US$ at exchange rate,541.5 +20405,Italy,2011,2,R-Respiratory system,Million US$ at exchange rate,1582.3 +20406,Italy,2011,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.6 +20407,Italy,2011,2,C08-Calcium channel blockers,% of total sales,2.0 +20408,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,462.9 +20409,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,644.4 +20410,Italy,2011,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +20411,Italy,2011,2,A02A-Antacids,% of total sales,0.1 +20412,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.3 +20413,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +20414,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",610.2 +20415,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.9 +20416,Italy,2011,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.3 +20417,Italy,2011,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1815.3 +20418,Italy,2011,2,C10-Lipid modifying agents,% of total sales,7.1 +20419,Italy,2011,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.6 +20420,Italy,2011,2,C10-Lipid modifying agents,Million US$ at exchange rate,1917.0 +20421,Italy,2011,2,A02A-Antacids,"Million US$, purchasing power parity",28.9 +20422,Italy,2011,2,A02A-Antacids,"/capita, US$ exchange rate",0.5 +20423,Italy,2011,2,A02A-Antacids,Million US$ at exchange rate,30.5 +20424,Italy,2011,2,C10-Lipid modifying agents,Million of national currency units,1377.2 +20425,Italy,2011,2,A02A-Antacids,Million of national currency units,21.9 +20426,Italy,2011,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,700.8 +20427,Italy,2011,2,G-Genito urinary system and sex hormones,Million of national currency units,503.5 +20428,Italy,2011,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.8 +20429,Italy,2011,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",663.6 +20430,Italy,2011,2,C07-Beta blocking agents,% of total sales,1.5 +20431,Italy,2011,2,C07-Beta blocking agents,"Million US$, purchasing power parity",375.0 +20432,Italy,2011,2,C07-Beta blocking agents,Million US$ at exchange rate,396.0 +20433,Italy,2011,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7 +20434,Italy,2011,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.3 +20435,Italy,2011,2,N06A-Antidepressants,"/capita, US$ exchange rate",11.7 +20436,Italy,2011,2,N06A-Antidepressants,"Million US$, purchasing power parity",655.6 +20437,Italy,2011,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.0 +20438,Italy,2011,2,N06A-Antidepressants,% of total sales,2.5 +20439,Italy,2011,2,G-Genito urinary system and sex hormones,% of total sales,2.6 +20440,Italy,2011,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2 +20441,Italy,2011,2,N06A-Antidepressants,Million US$ at exchange rate,692.4 +20442,Italy,2011,2,N06A-Antidepressants,Million of national currency units,497.4 +20443,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1 +20444,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.9 +20445,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1301.5 +20446,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.1 +20447,Italy,2011,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1 +20448,Italy,2011,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.3 +20449,Italy,2011,2,N05C-Hypnotics and sedatives,% of total sales,0.0 +20450,Italy,2011,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1 +20451,Italy,2011,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1 +20452,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",232.5 +20453,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1 +20454,Italy,2011,2,C07-Beta blocking agents,Million of national currency units,284.5 +20455,Italy,2011,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,176.4 +20456,Italy,2011,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,245.5 +20457,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,987.4 +20458,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1374.5 +20459,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.9 +20460,Italy,2011,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +20461,Italy,2011,2,C-Cardiovascular system,% of total sales,23.3 +20462,Italy,2011,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1030.5 +20463,Italy,2011,2,C-Cardiovascular system,Million of national currency units,4542.7 +20464,Italy,2011,2,C-Cardiovascular system,"/capita, US$ exchange rate",106.5 +20465,Italy,2011,2,C-Cardiovascular system,"Million US$, purchasing power parity",5987.5 +20466,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2546.9 +20467,Italy,2011,2,C-Cardiovascular system,Million US$ at exchange rate,6323.2 +20468,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.9 +20469,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",42.9 +20470,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",45.3 +20471,Italy,2011,2,R03-Drugs for obstructive airway diseases,% of total sales,5.3 +20472,Italy,2011,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9 +20473,Italy,2011,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",100.8 +20474,Italy,2011,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1358.2 +20475,Italy,2011,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1434.4 +20476,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2689.7 +20477,Italy,2011,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2 +20478,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1932.3 +20479,Japan,2016,5,Products not elsewhere classified,% of total sales,50.4 +20480,Japan,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",62773.8 +20481,Japan,2016,5,Products not elsewhere classified,Million US$ at exchange rate,30673.2 +20482,Japan,2016,5,Products not elsewhere classified,Million of national currency units,3337024.0 +20483,Japan,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",241.6 +20484,Japan,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",31624.7 +20485,Japan,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.2 +20486,Japan,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1989.1 +20487,Japan,2016,5,J-Antiinfectives for systemic use,% of total sales,3.2 +20488,Japan,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.7 +20489,Japan,2016,5,R-Respiratory system,"Million US$, purchasing power parity",1133.6 +20490,Japan,2016,5,R-Respiratory system,Million US$ at exchange rate,1099.5 +20491,Japan,2016,5,R-Respiratory system,Million of national currency units,119619.0 +20492,Japan,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",479.7 +20493,Japan,2016,5,R-Respiratory system,% of total sales,1.8 +20494,Japan,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",249.1 +20495,Japan,2016,5,R-Respiratory system,"/capita, US$ exchange rate",8.7 +20496,Japan,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",8.9 +20497,Japan,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3793.9 +20498,Japan,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3679.7 +20499,Japan,2016,5,A-Alimentary tract and metabolism,Million of national currency units,400328.0 +20500,Japan,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.0 +20501,Japan,2016,5,G-Genito urinary system and sex hormones,% of total sales,2.0 +20502,Japan,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.0 +20503,Japan,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",29.9 +20504,Japan,2016,5,N-Nervous system,"Million US$, purchasing power parity",7865.8 +20505,Japan,2016,5,N-Nervous system,"/capita, US$ exchange rate",60.1 +20506,Japan,2016,5,N-Nervous system,Million US$ at exchange rate,7629.2 +20507,Japan,2016,5,N-Nervous system,% of total sales,12.5 +20508,Japan,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",62.0 +20509,Japan,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,60885.0 +20510,Japan,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",9550.3 +20511,Japan,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.2 +20512,Japan,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.0 +20513,Japan,2016,5,Total pharmaceutical sales,Million of national currency units,6623860.0 +20514,Japan,2016,5,C-Cardiovascular system,Million US$ at exchange rate,9263.0 +20515,Japan,2016,5,C-Cardiovascular system,Million of national currency units,1007745.0 +20516,Japan,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1274.6 +20517,Japan,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1236.2 +20518,Japan,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.7 +20519,Japan,2016,5,A-Alimentary tract and metabolism,% of total sales,6.0 +20520,Japan,2016,5,C-Cardiovascular system,% of total sales,15.2 +20521,Japan,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,134491.0 +20522,Japan,2016,5,N-Nervous system,Million of national currency units,830000.0 +20523,Japan,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",494.5 +20524,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,159150.0 +20525,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1508.3 +20526,Japan,2016,5,B-Blood and blood forming organs,Million of national currency units,425618.0 +20527,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +20528,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.9 +20529,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.5 +20530,Japan,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8 +20531,Japan,2016,5,B-Blood and blood forming organs,% of total sales,6.4 +20532,Japan,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.8 +20533,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1462.9 +20534,Japan,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1929.2 +20535,Japan,2016,5,J-Antiinfectives for systemic use,Million of national currency units,209885.0 +20536,Japan,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,3912.2 +20537,Japan,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4033.5 +20538,Japan,2015,5,Products not elsewhere classified,% of total sales,48.2 +20539,Japan,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",65218.5 +20540,Japan,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",438.6 +20541,Japan,2015,5,Products not elsewhere classified,Million US$ at exchange rate,26853.0 +20542,Japan,2015,5,Products not elsewhere classified,Million of national currency units,3250399.0 +20543,Japan,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",211.3 +20544,Japan,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",31414.1 +20545,Japan,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3 +20546,Japan,2015,5,J-Antiinfectives for systemic use,% of total sales,3.3 +20547,Japan,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.7 +20548,Japan,2015,5,R-Respiratory system,"Million US$, purchasing power parity",1150.3 +20549,Japan,2015,5,R-Respiratory system,Million US$ at exchange rate,983.3 +20550,Japan,2015,5,R-Respiratory system,Million of national currency units,119017.0 +20551,Japan,2015,5,R-Respiratory system,"/capita, US$ exchange rate",7.7 +20552,Japan,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",247.2 +20553,Japan,2015,5,R-Respiratory system,% of total sales,1.8 +20554,Japan,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.1 +20555,Japan,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,55749.3 +20556,Japan,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4485.1 +20557,Japan,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.2 +20558,Japan,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3833.9 +20559,Japan,2015,5,G-Genito urinary system and sex hormones,% of total sales,2.2 +20560,Japan,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.3 +20561,Japan,2015,5,A-Alimentary tract and metabolism,Million of national currency units,464073.0 +20562,Japan,2015,5,N-Nervous system,"Million US$, purchasing power parity",7869.6 +20563,Japan,2015,5,N-Nervous system,"/capita, US$ exchange rate",52.9 +20564,Japan,2015,5,N-Nervous system,Million US$ at exchange rate,6727.0 +20565,Japan,2015,5,N-Nervous system,Million of national currency units,814267.0 +20566,Japan,2015,5,N-Nervous system,% of total sales,12.1 +20567,Japan,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2 +20568,Japan,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",61.9 +20569,Japan,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",10519.8 +20570,Japan,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",70.8 +20571,Japan,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8 +20572,Japan,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2121.2 +20573,Japan,2015,5,Total pharmaceutical sales,Million of national currency units,6748121.0 +20574,Japan,2015,5,C-Cardiovascular system,Million of national currency units,1088475.0 +20575,Japan,2015,5,C-Cardiovascular system,Million US$ at exchange rate,8992.4 +20576,Japan,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1427.3 +20577,Japan,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1220.1 +20578,Japan,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.6 +20579,Japan,2015,5,C-Cardiovascular system,% of total sales,16.1 +20580,Japan,2015,5,A-Alimentary tract and metabolism,% of total sales,6.9 +20581,Japan,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,147680.0 +20582,Japan,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",513.1 +20583,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1767.7 +20584,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,182902.0 +20585,Japan,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.1 +20586,Japan,2015,5,B-Blood and blood forming organs,Million of national currency units,461825.0 +20587,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +20588,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9 +20589,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9 +20590,Japan,2015,5,B-Blood and blood forming organs,% of total sales,6.8 +20591,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1511.0 +20592,Japan,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1813.2 +20593,Japan,2015,5,J-Antiinfectives for systemic use,Million of national currency units,219483.0 +20594,Japan,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,3815.3 +20595,Japan,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.0 +20596,Japan,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4463.4 +20597,Japan,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",488.9 +20598,Japan,2014,5,Products not elsewhere classified,% of total sales,46.0 +20599,Japan,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",63945.9 +20600,Japan,2014,5,R-Respiratory system,"Million US$, purchasing power parity",951.6 +20601,Japan,2014,5,Products not elsewhere classified,Million US$ at exchange rate,28623.7 +20602,Japan,2014,5,Products not elsewhere classified,Million of national currency units,3032529.0 +20603,Japan,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",225.0 +20604,Japan,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",29427.2 +20605,Japan,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.5 +20606,Japan,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.0 +20607,Japan,2014,5,J-Antiinfectives for systemic use,% of total sales,3.6 +20608,Japan,2014,5,R-Respiratory system,Million US$ at exchange rate,925.6 +20609,Japan,2014,5,R-Respiratory system,Million of national currency units,98066.0 +20610,Japan,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",231.3 +20611,Japan,2014,5,R-Respiratory system,% of total sales,1.5 +20612,Japan,2014,5,R-Respiratory system,"/capita, US$ exchange rate",7.3 +20613,Japan,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",7.5 +20614,Japan,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4699.9 +20615,Japan,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",35.9 +20616,Japan,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4571.5 +20617,Japan,2014,5,G-Genito urinary system and sex hormones,% of total sales,2.3 +20618,Japan,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",36.9 +20619,Japan,2014,5,A-Alimentary tract and metabolism,Million of national currency units,484331.0 +20620,Japan,2014,5,N-Nervous system,"Million US$, purchasing power parity",7970.7 +20621,Japan,2014,5,N-Nervous system,"/capita, US$ exchange rate",60.9 +20622,Japan,2014,5,N-Nervous system,Million US$ at exchange rate,7753.0 +20623,Japan,2014,5,N-Nervous system,Million of national currency units,821393.0 +20624,Japan,2014,5,N-Nervous system,% of total sales,12.5 +20625,Japan,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",62.6 +20626,Japan,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.6 +20627,Japan,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",11229.5 +20628,Japan,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",85.8 +20629,Japan,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",88.3 +20630,Japan,2014,5,Total pharmaceutical sales,Million of national currency units,6589762.0 +20631,Japan,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,62200.0 +20632,Japan,2014,5,C-Cardiovascular system,Million US$ at exchange rate,10922.9 +20633,Japan,2014,5,C-Cardiovascular system,Million of national currency units,1157221.0 +20634,Japan,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1477.3 +20635,Japan,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1437.0 +20636,Japan,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3 +20637,Japan,2014,5,C-Cardiovascular system,% of total sales,17.6 +20638,Japan,2014,5,A-Alimentary tract and metabolism,% of total sales,7.3 +20639,Japan,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,152239.0 +20640,Japan,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2293.1 +20641,Japan,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.6 +20642,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,158691.0 +20643,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1539.9 +20644,Japan,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.2 +20645,Japan,2014,5,B-Blood and blood forming organs,Million of national currency units,448987.0 +20646,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +20647,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.1 +20648,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.8 +20649,Japan,2014,5,B-Blood and blood forming organs,% of total sales,6.8 +20650,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1497.9 +20651,Japan,2014,5,J-Antiinfectives for systemic use,Million of national currency units,236305.0 +20652,Japan,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,2230.5 +20653,Japan,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,4237.9 +20654,Japan,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4356.9 +20655,Japan,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.3 +20656,Japan,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",554.4 +20657,Japan,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",68053.6 +20658,Japan,2013,5,Products not elsewhere classified,Million US$ at exchange rate,31664.9 +20659,Japan,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",30506.2 +20660,Japan,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",248.5 +20661,Japan,2013,5,Products not elsewhere classified,Million of national currency units,3090356.0 +20662,Japan,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.9 +20663,Japan,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.2 +20664,Japan,2013,5,J-Antiinfectives for systemic use,% of total sales,3.4 +20665,Japan,2013,5,R-Respiratory system,"Million US$, purchasing power parity",1168.8 +20666,Japan,2013,5,R-Respiratory system,Million US$ at exchange rate,1213.2 +20667,Japan,2013,5,R-Respiratory system,Million of national currency units,118406.0 +20668,Japan,2013,5,R-Respiratory system,"/capita, US$ exchange rate",9.5 +20669,Japan,2013,5,Products not elsewhere classified,% of total sales,44.8 +20670,Japan,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",239.4 +20671,Japan,2013,5,R-Respiratory system,% of total sales,1.7 +20672,Japan,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.2 +20673,Japan,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5257.4 +20674,Japan,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.8 +20675,Japan,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5457.1 +20676,Japan,2013,5,G-Genito urinary system and sex hormones,% of total sales,2.4 +20677,Japan,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.3 +20678,Japan,2013,5,A-Alimentary tract and metabolism,Million of national currency units,532593.0 +20679,Japan,2013,5,N-Nervous system,"Million US$, purchasing power parity",8200.2 +20680,Japan,2013,5,N-Nervous system,"/capita, US$ exchange rate",66.8 +20681,Japan,2013,5,N-Nervous system,Million US$ at exchange rate,8511.7 +20682,Japan,2013,5,N-Nervous system,Million of national currency units,830706.0 +20683,Japan,2013,5,N-Nervous system,% of total sales,12.0 +20684,Japan,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",64.4 +20685,Japan,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",100.9 +20686,Japan,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",12388.8 +20687,Japan,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",97.2 +20688,Japan,2013,5,Total pharmaceutical sales,Million of national currency units,6894014.0 +20689,Japan,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,70638.5 +20690,Japan,2013,5,C-Cardiovascular system,Million of national currency units,1255017.0 +20691,Japan,2013,5,C-Cardiovascular system,Million US$ at exchange rate,12859.4 +20692,Japan,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1658.5 +20693,Japan,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1721.5 +20694,Japan,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.5 +20695,Japan,2013,5,C-Cardiovascular system,% of total sales,18.2 +20696,Japan,2013,5,A-Alimentary tract and metabolism,% of total sales,7.7 +20697,Japan,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.0 +20698,Japan,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,168011.0 +20699,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,166912.0 +20700,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1647.7 +20701,Japan,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",534.1 +20702,Japan,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5 +20703,Japan,2013,5,B-Blood and blood forming organs,Million of national currency units,497196.0 +20704,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +20705,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.9 +20706,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.4 +20707,Japan,2013,5,B-Blood and blood forming organs,% of total sales,7.2 +20708,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1710.2 +20709,Japan,2013,5,J-Antiinfectives for systemic use,Million of national currency units,234817.0 +20710,Japan,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,2406.0 +20711,Japan,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4908.0 +20712,Japan,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,5094.4 +20713,Japan,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.0 +20714,Japan,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2318.0 +20715,Japan,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",685.3 +20716,Japan,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",66907.5 +20717,Japan,2012,5,Products not elsewhere classified,Million US$ at exchange rate,37641.3 +20718,Japan,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",295.0 +20719,Japan,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",28803.1 +20720,Japan,2012,5,Products not elsewhere classified,Million of national currency units,3003413.0 +20721,Japan,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.7 +20722,Japan,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.9 +20723,Japan,2012,5,J-Antiinfectives for systemic use,% of total sales,3.6 +20724,Japan,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",225.7 +20725,Japan,2012,5,R-Respiratory system,"Million US$, purchasing power parity",1221.6 +20726,Japan,2012,5,R-Respiratory system,Million of national currency units,127386.0 +20727,Japan,2012,5,R-Respiratory system,"/capita, US$ exchange rate",12.5 +20728,Japan,2012,5,R-Respiratory system,Million US$ at exchange rate,1596.5 +20729,Japan,2012,5,Products not elsewhere classified,% of total sales,43.0 +20730,Japan,2012,5,R-Respiratory system,% of total sales,1.8 +20731,Japan,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.6 +20732,Japan,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5488.9 +20733,Japan,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2 +20734,Japan,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,7173.2 +20735,Japan,2012,5,G-Genito urinary system and sex hormones,% of total sales,2.5 +20736,Japan,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0 +20737,Japan,2012,5,N-Nervous system,"/capita, US$ exchange rate",86.9 +20738,Japan,2012,5,N-Nervous system,"Million US$, purchasing power parity",8481.0 +20739,Japan,2012,5,N-Nervous system,Million US$ at exchange rate,11083.3 +20740,Japan,2012,5,N-Nervous system,Million of national currency units,884343.0 +20741,Japan,2012,5,A-Alimentary tract and metabolism,Million of national currency units,572354.0 +20742,Japan,2012,5,N-Nervous system,% of total sales,12.7 +20743,Japan,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",66.5 +20744,Japan,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.3 +20745,Japan,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",127.4 +20746,Japan,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",12438.7 +20747,Japan,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",97.5 +20748,Japan,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,87437.9 +20749,Japan,2012,5,C-Cardiovascular system,Million of national currency units,1297037.0 +20750,Japan,2012,5,C-Cardiovascular system,Million US$ at exchange rate,16255.5 +20751,Japan,2012,5,C-Cardiovascular system,% of total sales,18.6 +20752,Japan,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1695.6 +20753,Japan,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.4 +20754,Japan,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,2215.9 +20755,Japan,2012,5,A-Alimentary tract and metabolism,% of total sales,8.2 +20756,Japan,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,176807.0 +20757,Japan,2012,5,Total pharmaceutical sales,Million of national currency units,6976712.0 +20758,Japan,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2412.6 +20759,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,152914.0 +20760,Japan,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.4 +20761,Japan,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",524.4 +20762,Japan,2012,5,B-Blood and blood forming organs,Million of national currency units,510891.0 +20763,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0 +20764,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +20765,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5 +20766,Japan,2012,5,B-Blood and blood forming organs,% of total sales,7.3 +20767,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1916.4 +20768,Japan,2012,5,J-Antiinfectives for systemic use,Million of national currency units,251567.0 +20769,Japan,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3152.8 +20770,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1466.5 +20771,Japan,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4899.5 +20772,Japan,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,6402.9 +20773,Japan,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.2 +20774,Japan,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",684.9 +20775,Japan,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",65026.4 +20776,Japan,2011,6,Products not elsewhere classified,Million US$ at exchange rate,37960.1 +20777,Japan,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",28193.3 +20778,Japan,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",296.9 +20779,Japan,2011,6,Products not elsewhere classified,Million of national currency units,3029486.0 +20780,Japan,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.1 +20781,Japan,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.4 +20782,Japan,2011,6,J-Antiinfectives for systemic use,% of total sales,3.8 +20783,Japan,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",220.5 +20784,Japan,2011,6,R-Respiratory system,"Million US$, purchasing power parity",1152.4 +20785,Japan,2011,6,R-Respiratory system,"/capita, US$ exchange rate",12.1 +20786,Japan,2011,6,R-Respiratory system,Million of national currency units,123835.0 +20787,Japan,2011,6,R-Respiratory system,Million US$ at exchange rate,1551.7 +20788,Japan,2011,6,Products not elsewhere classified,% of total sales,43.4 +20789,Japan,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",9.0 +20790,Japan,2011,6,R-Respiratory system,% of total sales,1.8 +20791,Japan,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.9 +20792,Japan,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5305.8 +20793,Japan,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,7143.9 +20794,Japan,2011,6,G-Genito urinary system and sex hormones,% of total sales,2.2 +20795,Japan,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.5 +20796,Japan,2011,6,N-Nervous system,"/capita, US$ exchange rate",87.2 +20797,Japan,2011,6,N-Nervous system,"Million US$, purchasing power parity",8282.7 +20798,Japan,2011,6,N-Nervous system,Million US$ at exchange rate,11152.0 +20799,Japan,2011,6,N-Nervous system,Million of national currency units,890011.0 +20800,Japan,2011,6,A-Alimentary tract and metabolism,Million of national currency units,570135.0 +20801,Japan,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",64.8 +20802,Japan,2011,6,N-Nervous system,% of total sales,12.7 +20803,Japan,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",132.1 +20804,Japan,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",12544.8 +20805,Japan,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.1 +20806,Japan,2011,6,C-Cardiovascular system,Million of national currency units,1347996.0 +20807,Japan,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,87553.3 +20808,Japan,2011,6,C-Cardiovascular system,Million US$ at exchange rate,16890.7 +20809,Japan,2011,6,C-Cardiovascular system,% of total sales,19.3 +20810,Japan,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1452.9 +20811,Japan,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.4 +20812,Japan,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.3 +20813,Japan,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1956.2 +20814,Japan,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,156118.0 +20815,Japan,2011,6,Total pharmaceutical sales,Million of national currency units,6987367.0 +20816,Japan,2011,6,A-Alimentary tract and metabolism,% of total sales,8.2 +20817,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,139935.0 +20818,Japan,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",508.7 +20819,Japan,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.8 +20820,Japan,2011,6,B-Blood and blood forming organs,Million of national currency units,463919.0 +20821,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.7 +20822,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +20823,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.2 +20824,Japan,2011,6,B-Blood and blood forming organs,% of total sales,6.6 +20825,Japan,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,5813.0 +20826,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1753.4 +20827,Japan,2011,6,J-Antiinfectives for systemic use,Million of national currency units,265932.0 +20828,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1302.3 +20829,Japan,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2474.8 +20830,Japan,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,3332.2 +20831,Japan,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",4317.4 +20832,Japan,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.5 +20833,Japan,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",603.1 +20834,Japan,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",60685.0 +20835,Japan,2010,6,C-Cardiovascular system,Million of national currency units,1401736.0 +20836,Japan,2010,6,Products not elsewhere classified,Million US$ at exchange rate,33031.6 +20837,Japan,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",25955.8 +20838,Japan,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",257.9 +20839,Japan,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.8 +20840,Japan,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.4 +20841,Japan,2010,6,Products not elsewhere classified,Million of national currency units,2899512.0 +20842,Japan,2010,6,J-Antiinfectives for systemic use,% of total sales,3.5 +20843,Japan,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",202.7 +20844,Japan,2010,6,R-Respiratory system,"Million US$, purchasing power parity",1102.5 +20845,Japan,2010,6,R-Respiratory system,"/capita, US$ exchange rate",11.0 +20846,Japan,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",473.9 +20847,Japan,2010,6,R-Respiratory system,Million of national currency units,123160.0 +20848,Japan,2010,6,R-Respiratory system,Million US$ at exchange rate,1403.1 +20849,Japan,2010,6,Products not elsewhere classified,% of total sales,42.8 +20850,Japan,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",8.6 +20851,Japan,2010,6,R-Respiratory system,% of total sales,1.8 +20852,Japan,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.8 +20853,Japan,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5209.6 +20854,Japan,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,6629.8 +20855,Japan,2010,6,G-Genito urinary system and sex hormones,% of total sales,2.3 +20856,Japan,2010,6,A-Alimentary tract and metabolism,% of total sales,8.6 +20857,Japan,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.7 +20858,Japan,2010,6,N-Nervous system,"/capita, US$ exchange rate",72.3 +20859,Japan,2010,6,N-Nervous system,Million US$ at exchange rate,9253.3 +20860,Japan,2010,6,N-Nervous system,"Million US$, purchasing power parity",7271.1 +20861,Japan,2010,6,N-Nervous system,Million of national currency units,812255.0 +20862,Japan,2010,6,A-Alimentary tract and metabolism,Million of national currency units,581966.0 +20863,Japan,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",56.8 +20864,Japan,2010,6,N-Nervous system,% of total sales,12.0 +20865,Japan,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",124.7 +20866,Japan,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",12548.0 +20867,Japan,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.0 +20868,Japan,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,77228.4 +20869,Japan,2010,6,C-Cardiovascular system,Million US$ at exchange rate,15968.8 +20870,Japan,2010,6,C-Cardiovascular system,% of total sales,20.7 +20871,Japan,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1419.4 +20872,Japan,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.1 +20873,Japan,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.1 +20874,Japan,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1806.3 +20875,Japan,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,158560.0 +20876,Japan,2010,6,Total pharmaceutical sales,Million of national currency units,6779099.0 +20877,Japan,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.2 +20878,Japan,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,5088.9 +20879,Japan,2010,6,B-Blood and blood forming organs,Million of national currency units,446699.0 +20880,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2 +20881,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7 +20882,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.0 +20883,Japan,2010,6,B-Blood and blood forming organs,% of total sales,6.6 +20884,Japan,2010,6,J-Antiinfectives for systemic use,Million of national currency units,240226.0 +20885,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114985.0 +20886,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1309.9 +20887,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1029.3 +20888,Japan,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2150.5 +20889,Japan,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2736.7 +20890,Japan,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",3998.8 +20891,Japan,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.7 +20892,Japan,2017,5,N-Nervous system,Million of national currency units,779318.0 +20893,Japan,2017,5,Products not elsewhere classified,% of total sales,52.7 +20894,Japan,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",63950.5 +20895,Japan,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",472.9 +20896,Japan,2017,5,Products not elsewhere classified,Million US$ at exchange rate,31572.7 +20897,Japan,2017,5,Products not elsewhere classified,Million of national currency units,3541392.0 +20898,Japan,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",249.2 +20899,Japan,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",33694.8 +20900,Japan,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.9 +20901,Japan,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1609.2 +20902,Japan,2017,5,J-Antiinfectives for systemic use,% of total sales,2.5 +20903,Japan,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",12.7 +20904,Japan,2017,5,R-Respiratory system,Million US$ at exchange rate,1204.0 +20905,Japan,2017,5,R-Respiratory system,"Million US$, purchasing power parity",1285.0 +20906,Japan,2017,5,R-Respiratory system,Million of national currency units,135053.0 +20907,Japan,2017,5,R-Respiratory system,% of total sales,2.0 +20908,Japan,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",265.9 +20909,Japan,2017,5,R-Respiratory system,"/capita, US$ exchange rate",9.5 +20910,Japan,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",10.1 +20911,Japan,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,59922.9 +20912,Japan,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3839.1 +20913,Japan,2017,5,A-Alimentary tract and metabolism,Million of national currency units,403493.0 +20914,Japan,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3597.3 +20915,Japan,2017,5,G-Genito urinary system and sex hormones,% of total sales,2.4 +20916,Japan,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2 +20917,Japan,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4 +20918,Japan,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",30.3 +20919,Japan,2017,5,N-Nervous system,"Million US$, purchasing power parity",7414.9 +20920,Japan,2017,5,N-Nervous system,Million US$ at exchange rate,6947.9 +20921,Japan,2017,5,N-Nervous system,"/capita, US$ exchange rate",54.8 +20922,Japan,2017,5,N-Nervous system,% of total sales,11.6 +20923,Japan,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",58.5 +20924,Japan,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",8890.8 +20925,Japan,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",65.7 +20926,Japan,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.2 +20927,Japan,2017,5,Total pharmaceutical sales,Million of national currency units,6721317.0 +20928,Japan,2017,5,C-Cardiovascular system,Million US$ at exchange rate,8330.8 +20929,Japan,2017,5,C-Cardiovascular system,Million of national currency units,934437.0 +20930,Japan,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1448.0 +20931,Japan,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1545.3 +20932,Japan,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.4 +20933,Japan,2017,5,A-Alimentary tract and metabolism,% of total sales,6.0 +20934,Japan,2017,5,C-Cardiovascular system,% of total sales,13.9 +20935,Japan,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,162419.0 +20936,Japan,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.7 +20937,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,175173.0 +20938,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1666.7 +20939,Japan,2017,5,B-Blood and blood forming organs,Million of national currency units,420896.0 +20940,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +20941,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.2 +20942,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3 +20943,Japan,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.6 +20944,Japan,2017,5,B-Blood and blood forming organs,% of total sales,6.3 +20945,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1561.7 +20946,Japan,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1507.9 +20947,Japan,2017,5,J-Antiinfectives for systemic use,Million of national currency units,169135.0 +20948,Japan,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6 +20949,Japan,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,3752.4 +20950,Japan,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4004.6 +20951,Latvia,2010,26,A-Alimentary tract and metabolism,Million of national currency units,35.8 +20952,Latvia,2010,26,A02A-Antacids,Million of national currency units,0.4 +20953,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.5 +20954,Latvia,2010,26,C01A-Cardiac glycosides,% of total sales,0.0 +20955,Latvia,2010,26,Total pharmaceutical sales,Million of national currency units,276.2 +20956,Latvia,2010,26,N05B-Anxiolytics,% of total sales,0.8 +20957,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,% of total sales,2.1 +20958,Latvia,2010,26,N-Nervous system,% of total sales,12.0 +20959,Latvia,2010,26,M-Musculo-skeletal system,% of total sales,6.6 +20960,Latvia,2010,26,A02A-Antacids,% of total sales,0.1 +20961,Latvia,2010,26,J01-Antibacterials for systemic use,% of total sales,3.4 +20962,Latvia,2010,26,R03-Drugs for obstructive airway diseases,% of total sales,3.1 +20963,Latvia,2010,26,B-Blood and blood forming organs,% of total sales,6.8 +20964,Latvia,2010,26,N02-Analgesics,% of total sales,2.6 +20965,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7 +20966,Latvia,2010,26,C-Cardiovascular system,% of total sales,18.9 +20967,Latvia,2010,26,C10-Lipid modifying agents,% of total sales,2.6 +20968,Latvia,2010,26,N05C-Hypnotics and sedatives,% of total sales,0.9 +20969,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +20970,Latvia,2010,26,C07-Beta blocking agents,% of total sales,2.4 +20971,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +20972,Latvia,2010,26,N06A-Antidepressants,% of total sales,0.8 +20973,Latvia,2010,26,R-Respiratory system,% of total sales,7.4 +20974,Latvia,2010,26,C03-Diuretics,% of total sales,0.8 +20975,Latvia,2010,26,A-Alimentary tract and metabolism,% of total sales,13.0 +20976,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7 +20977,Latvia,2010,26,A10-Drugs used in diabetes,% of total sales,5.5 +20978,Latvia,2010,26,C02-Antihypertensives,% of total sales,0.9 +20979,Latvia,2010,26,C08-Calcium channel blockers,% of total sales,1.5 +20980,Latvia,2010,26,J-Antiinfectives for systemic use,% of total sales,9.3 +20981,Latvia,2010,26,G-Genito urinary system and sex hormones,% of total sales,4.5 +20982,Latvia,2010,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.8 +20983,Latvia,2010,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.6 +20984,Latvia,2010,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +20985,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6 +20986,Latvia,2010,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4 +20987,Latvia,2010,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0 +20988,Latvia,2010,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.1 +20989,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4 +20990,Latvia,2010,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5 +20991,Latvia,2010,26,R-Respiratory system,Million US$ at exchange rate,27.3 +20992,Latvia,2010,26,N06A-Antidepressants,Million US$ at exchange rate,3.0 +20993,Latvia,2010,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.2 +20994,Latvia,2010,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",73.5 +20995,Latvia,2010,26,Total pharmaceutical sales,"Million US$, purchasing power parity",567.2 +20996,Latvia,2010,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.3 +20997,Latvia,2010,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.9 +20998,Latvia,2010,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",51.2 +20999,Latvia,2010,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +21000,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.1 +21001,Latvia,2010,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2 +21002,Latvia,2010,26,Total pharmaceutical sales,"/capita, US$ exchange rate",174.5 +21003,Latvia,2010,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",22.6 +21004,Latvia,2010,26,A02A-Antacids,"/capita, US$ exchange rate",0.2 +21005,Latvia,2010,26,N05B-Anxiolytics,Million US$ at exchange rate,2.8 +21006,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,13.7 +21007,Latvia,2010,26,M-Musculo-skeletal system,Million US$ at exchange rate,24.1 +21008,Latvia,2010,26,N02-Analgesics,Million US$ at exchange rate,9.5 +21009,Latvia,2010,26,N-Nervous system,Million US$ at exchange rate,43.8 +21010,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.6 +21011,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.5 +21012,Latvia,2010,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2 +21013,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.6 +21014,Latvia,2010,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.1 +21015,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.4 +21016,Latvia,2010,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +21017,Latvia,2010,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1 +21018,Latvia,2010,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.0 +21019,Latvia,2010,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +21020,Latvia,2010,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4 +21021,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.3 +21022,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5 +21023,Latvia,2010,26,N-Nervous system,"/capita, US$ exchange rate",20.9 +21024,Latvia,2010,26,N02-Analgesics,"Million US$, purchasing power parity",14.7 +21025,Latvia,2010,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3 +21026,Latvia,2010,26,N02-Analgesics,"/capita, US$ exchange rate",4.5 +21027,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",21.2 +21028,Latvia,2010,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",37.4 +21029,Latvia,2010,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.5 +21030,Latvia,2010,26,N-Nervous system,"Million US$, purchasing power parity",67.9 +21031,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.3 +21032,Latvia,2010,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",270.4 +21033,Latvia,2010,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5 +21034,Latvia,2010,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.4 +21035,Latvia,2010,26,R-Respiratory system,"/capita, US$ exchange rate",13.0 +21036,Latvia,2010,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.0 +21037,Latvia,2010,26,N05B-Anxiolytics,"Million US$, purchasing power parity",4.3 +21038,Latvia,2010,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.0 +21039,Latvia,2010,26,R-Respiratory system,"Million US$, purchasing power parity",42.3 +21040,Latvia,2010,26,N06A-Antidepressants,"Million US$, purchasing power parity",4.7 +21041,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.8 +21042,Latvia,2010,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +21043,Latvia,2010,26,C02-Antihypertensives,"Million US$, purchasing power parity",5.3 +21044,Latvia,2010,26,C07-Beta blocking agents,"Million US$, purchasing power parity",13.4 +21045,Latvia,2010,26,C03-Diuretics,"Million US$, purchasing power parity",4.4 +21046,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.7 +21047,Latvia,2010,26,A02A-Antacids,"Million US$, purchasing power parity",0.8 +21048,Latvia,2010,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",31.2 +21049,Latvia,2010,26,C-Cardiovascular system,"Million US$, purchasing power parity",107.3 +21050,Latvia,2010,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.5 +21051,Latvia,2010,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.9 +21052,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.7 +21053,Latvia,2010,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2 +21054,Latvia,2010,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",52.5 +21055,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",9.4 +21056,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",36.9 +21057,Latvia,2010,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",8.3 +21058,Latvia,2010,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.9 +21059,Latvia,2010,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",25.5 +21060,Latvia,2010,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",16.2 +21061,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9 +21062,Latvia,2010,26,N02-Analgesics,Million of national currency units,7.2 +21063,Latvia,2010,26,N-Nervous system,Million of national currency units,33.1 +21064,Latvia,2010,26,N05C-Hypnotics and sedatives,Million of national currency units,2.4 +21065,Latvia,2010,26,N05B-Anxiolytics,Million of national currency units,2.1 +21066,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,10.3 +21067,Latvia,2010,26,J-Antiinfectives for systemic use,Million of national currency units,25.6 +21068,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.6 +21069,Latvia,2010,26,M-Musculo-skeletal system,Million of national currency units,18.2 +21070,Latvia,2010,26,J01-Antibacterials for systemic use,Million of national currency units,9.4 +21071,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.6 +21072,Latvia,2010,26,A02A-Antacids,Million US$ at exchange rate,0.5 +21073,Latvia,2010,26,A10-Drugs used in diabetes,Million US$ at exchange rate,20.1 +21074,Latvia,2010,26,C-Cardiovascular system,Million US$ at exchange rate,69.2 +21075,Latvia,2010,26,B-Blood and blood forming organs,Million US$ at exchange rate,24.8 +21076,Latvia,2010,26,R-Respiratory system,Million of national currency units,20.6 +21077,Latvia,2010,26,N06A-Antidepressants,Million of national currency units,2.3 +21078,Latvia,2010,26,R03-Drugs for obstructive airway diseases,Million of national currency units,8.4 +21079,Latvia,2010,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,47.4 +21080,Latvia,2010,26,Total pharmaceutical sales,Million US$ at exchange rate,365.9 +21081,Latvia,2010,26,C03-Diuretics,"/capita, US$ exchange rate",1.3 +21082,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.4 +21083,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3 +21084,Latvia,2010,26,C02-Antihypertensives,"/capita, US$ exchange rate",1.6 +21085,Latvia,2010,26,A10-Drugs used in diabetes,Million of national currency units,15.2 +21086,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.2 +21087,Latvia,2010,26,C01A-Cardiac glycosides,Million of national currency units,0.1 +21088,Latvia,2010,26,C-Cardiovascular system,Million of national currency units,52.3 +21089,Latvia,2010,26,B-Blood and blood forming organs,Million of national currency units,18.7 +21090,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.0 +21091,Latvia,2010,26,C08-Calcium channel blockers,Million of national currency units,4.0 +21092,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.7 +21093,Latvia,2010,26,G-Genito urinary system and sex hormones,Million of national currency units,12.4 +21094,Latvia,2010,26,C10-Lipid modifying agents,Million of national currency units,7.3 +21095,Latvia,2010,26,C-Cardiovascular system,"/capita, US$ exchange rate",33.0 +21096,Latvia,2010,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +21097,Latvia,2010,26,C02-Antihypertensives,Million of national currency units,2.6 +21098,Latvia,2010,26,C07-Beta blocking agents,Million of national currency units,6.5 +21099,Latvia,2010,26,C03-Diuretics,Million of national currency units,2.1 +21100,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.7 +21101,Latvia,2010,26,C02-Antihypertensives,Million US$ at exchange rate,3.4 +21102,Latvia,2010,26,R-Respiratory system,"/capita, US$ purchasing power parity",20.1 +21103,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.3 +21104,Latvia,2010,26,C07-Beta blocking agents,Million US$ at exchange rate,8.7 +21105,Latvia,2010,26,C03-Diuretics,Million US$ at exchange rate,2.8 +21106,Latvia,2010,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",9.6 +21107,Latvia,2010,26,N-Nervous system,"/capita, US$ purchasing power parity",32.4 +21108,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.1 +21109,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5 +21110,Latvia,2010,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.8 +21111,Latvia,2010,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4 +21112,Latvia,2010,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2 +21113,Latvia,2010,26,N02-Analgesics,"/capita, US$ purchasing power parity",7.0 +21114,Latvia,2010,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0 +21115,Latvia,2010,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,33.9 +21116,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0 +21117,Latvia,2010,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.8 +21118,Latvia,2010,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +21119,Latvia,2010,26,C10-Lipid modifying agents,Million US$ at exchange rate,9.6 +21120,Latvia,2010,26,C08-Calcium channel blockers,Million US$ at exchange rate,5.4 +21121,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,23.8 +21122,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.6 +21123,Latvia,2010,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.5 +21124,Latvia,2016,26,A-Alimentary tract and metabolism,Million of national currency units,49.1 +21125,Latvia,2016,26,A02A-Antacids,% of total sales,0.1 +21126,Latvia,2016,26,A02A-Antacids,Million of national currency units,0.4 +21127,Latvia,2016,26,Total pharmaceutical sales,Million of national currency units,369.2 +21128,Latvia,2016,26,C01A-Cardiac glycosides,% of total sales,0.0 +21129,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1 +21130,Latvia,2016,26,N05B-Anxiolytics,% of total sales,0.8 +21131,Latvia,2016,26,N-Nervous system,% of total sales,9.6 +21132,Latvia,2016,26,N06A-Antidepressants,% of total sales,0.7 +21133,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +21134,Latvia,2016,26,J01-Antibacterials for systemic use,% of total sales,2.7 +21135,Latvia,2016,26,N05C-Hypnotics and sedatives,% of total sales,0.8 +21136,Latvia,2016,26,R03-Drugs for obstructive airway diseases,% of total sales,2.5 +21137,Latvia,2016,26,B-Blood and blood forming organs,% of total sales,6.7 +21138,Latvia,2016,26,A-Alimentary tract and metabolism,% of total sales,13.3 +21139,Latvia,2016,26,C10-Lipid modifying agents,% of total sales,1.5 +21140,Latvia,2016,26,N02-Analgesics,% of total sales,2.1 +21141,Latvia,2016,26,C-Cardiovascular system,% of total sales,14.9 +21142,Latvia,2016,26,M-Musculo-skeletal system,% of total sales,6.2 +21143,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4 +21144,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6 +21145,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +21146,Latvia,2016,26,C07-Beta blocking agents,% of total sales,2.1 +21147,Latvia,2016,26,C03-Diuretics,% of total sales,0.6 +21148,Latvia,2016,26,A10-Drugs used in diabetes,% of total sales,5.7 +21149,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0 +21150,Latvia,2016,26,R-Respiratory system,% of total sales,7.0 +21151,Latvia,2016,26,C02-Antihypertensives,% of total sales,1.0 +21152,Latvia,2016,26,C08-Calcium channel blockers,% of total sales,0.7 +21153,Latvia,2016,26,J-Antiinfectives for systemic use,% of total sales,15.0 +21154,Latvia,2016,26,G-Genito urinary system and sex hormones,% of total sales,3.8 +21155,Latvia,2016,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.0 +21156,Latvia,2016,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.1 +21157,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",19.1 +21158,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5 +21159,Latvia,2016,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +21160,Latvia,2016,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.9 +21161,Latvia,2016,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +21162,Latvia,2016,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3 +21163,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +21164,Latvia,2016,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.7 +21165,Latvia,2016,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7 +21166,Latvia,2016,26,R-Respiratory system,Million US$ at exchange rate,28.4 +21167,Latvia,2016,26,N06A-Antidepressants,Million US$ at exchange rate,2.9 +21168,Latvia,2016,26,Total pharmaceutical sales,"Million US$, purchasing power parity",762.0 +21169,Latvia,2016,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.3 +21170,Latvia,2016,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.7 +21171,Latvia,2016,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.2 +21172,Latvia,2016,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.0 +21173,Latvia,2016,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +21174,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.4 +21175,Latvia,2016,26,A02A-Antacids,"/capita, US$ exchange rate",0.2 +21176,Latvia,2016,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +21177,Latvia,2016,26,N05B-Anxiolytics,Million US$ at exchange rate,3.1 +21178,Latvia,2016,26,Total pharmaceutical sales,"/capita, US$ exchange rate",208.6 +21179,Latvia,2016,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.7 +21180,Latvia,2016,26,M-Musculo-skeletal system,Million US$ at exchange rate,25.3 +21181,Latvia,2016,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.1 +21182,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,16.4 +21183,Latvia,2016,26,N02-Analgesics,Million US$ at exchange rate,8.8 +21184,Latvia,2016,26,N-Nervous system,Million US$ at exchange rate,39.1 +21185,Latvia,2016,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.9 +21186,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.6 +21187,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.8 +21188,Latvia,2016,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.9 +21189,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4 +21190,Latvia,2016,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.5 +21191,Latvia,2016,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5 +21192,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.6 +21193,Latvia,2016,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.5 +21194,Latvia,2016,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6 +21195,Latvia,2016,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",101.3 +21196,Latvia,2016,26,N-Nervous system,"/capita, US$ exchange rate",19.9 +21197,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.4 +21198,Latvia,2016,26,R-Respiratory system,"Million US$, purchasing power parity",53.0 +21199,Latvia,2016,26,N02-Analgesics,"/capita, US$ exchange rate",4.5 +21200,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",30.7 +21201,Latvia,2016,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",47.1 +21202,Latvia,2016,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",20.8 +21203,Latvia,2016,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.9 +21204,Latvia,2016,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.7 +21205,Latvia,2016,26,N-Nervous system,"Million US$, purchasing power parity",72.8 +21206,Latvia,2016,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6 +21207,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.2 +21208,Latvia,2016,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.5 +21209,Latvia,2016,26,R-Respiratory system,"/capita, US$ exchange rate",14.5 +21210,Latvia,2016,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7 +21211,Latvia,2016,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",6.2 +21212,Latvia,2016,26,N05B-Anxiolytics,"Million US$, purchasing power parity",5.8 +21213,Latvia,2016,26,N02-Analgesics,"Million US$, purchasing power parity",16.4 +21214,Latvia,2016,26,N06A-Antidepressants,"Million US$, purchasing power parity",5.4 +21215,Latvia,2016,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",388.9 +21216,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.6 +21217,Latvia,2016,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +21218,Latvia,2016,26,C03-Diuretics,"Million US$, purchasing power parity",4.8 +21219,Latvia,2016,26,C02-Antihypertensives,"Million US$, purchasing power parity",7.3 +21220,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.5 +21221,Latvia,2016,26,A02A-Antacids,"Million US$, purchasing power parity",0.8 +21222,Latvia,2016,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",50.9 +21223,Latvia,2016,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",43.6 +21224,Latvia,2016,26,C-Cardiovascular system,"Million US$, purchasing power parity",113.4 +21225,Latvia,2016,26,C07-Beta blocking agents,"Million US$, purchasing power parity",16.3 +21226,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.9 +21227,Latvia,2016,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",31.4 +21228,Latvia,2016,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",114.6 +21229,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.5 +21230,Latvia,2016,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",29.2 +21231,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",38.9 +21232,Latvia,2016,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.3 +21233,Latvia,2016,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.5 +21234,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4 +21235,Latvia,2016,26,N-Nervous system,Million of national currency units,35.3 +21236,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,14.9 +21237,Latvia,2016,26,N02-Analgesics,Million of national currency units,7.9 +21238,Latvia,2016,26,N05C-Hypnotics and sedatives,Million of national currency units,3.0 +21239,Latvia,2016,26,N05B-Anxiolytics,Million of national currency units,2.8 +21240,Latvia,2016,26,J-Antiinfectives for systemic use,Million of national currency units,55.5 +21241,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.0 +21242,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.3 +21243,Latvia,2016,26,M-Musculo-skeletal system,Million of national currency units,22.8 +21244,Latvia,2016,26,J01-Antibacterials for systemic use,Million of national currency units,10.1 +21245,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.6 +21246,Latvia,2016,26,A02A-Antacids,Million US$ at exchange rate,0.5 +21247,Latvia,2016,26,B-Blood and blood forming organs,Million US$ at exchange rate,27.3 +21248,Latvia,2016,26,A10-Drugs used in diabetes,Million US$ at exchange rate,23.4 +21249,Latvia,2016,26,R-Respiratory system,Million of national currency units,25.7 +21250,Latvia,2016,26,N06A-Antidepressants,Million of national currency units,2.6 +21251,Latvia,2016,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,54.4 +21252,Latvia,2016,26,Total pharmaceutical sales,Million US$ at exchange rate,408.7 +21253,Latvia,2016,26,R03-Drugs for obstructive airway diseases,Million of national currency units,9.3 +21254,Latvia,2016,26,C03-Diuretics,"/capita, US$ exchange rate",1.3 +21255,Latvia,2016,26,C01A-Cardiac glycosides,Million of national currency units,0.1 +21256,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +21257,Latvia,2016,26,C02-Antihypertensives,"/capita, US$ exchange rate",2.0 +21258,Latvia,2016,26,A10-Drugs used in diabetes,Million of national currency units,21.1 +21259,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.1 +21260,Latvia,2016,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +21261,Latvia,2016,26,C-Cardiovascular system,Million of national currency units,54.9 +21262,Latvia,2016,26,B-Blood and blood forming organs,Million of national currency units,24.6 +21263,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.8 +21264,Latvia,2016,26,C08-Calcium channel blockers,Million of national currency units,2.6 +21265,Latvia,2016,26,G-Genito urinary system and sex hormones,Million of national currency units,14.2 +21266,Latvia,2016,26,C10-Lipid modifying agents,Million of national currency units,5.6 +21267,Latvia,2016,26,C07-Beta blocking agents,Million of national currency units,7.9 +21268,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8 +21269,Latvia,2016,26,C-Cardiovascular system,"/capita, US$ exchange rate",31.0 +21270,Latvia,2016,26,C03-Diuretics,Million of national currency units,2.3 +21271,Latvia,2016,26,C02-Antihypertensives,Million of national currency units,3.6 +21272,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.8 +21273,Latvia,2016,26,C02-Antihypertensives,Million US$ at exchange rate,3.9 +21274,Latvia,2016,26,R-Respiratory system,"/capita, US$ purchasing power parity",27.0 +21275,Latvia,2016,26,C03-Diuretics,Million US$ at exchange rate,2.6 +21276,Latvia,2016,26,C07-Beta blocking agents,Million US$ at exchange rate,8.7 +21277,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9 +21278,Latvia,2016,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.9 +21279,Latvia,2016,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.7 +21280,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",15.7 +21281,Latvia,2016,26,N-Nervous system,"/capita, US$ purchasing power parity",37.2 +21282,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +21283,Latvia,2016,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",24.0 +21284,Latvia,2016,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2 +21285,Latvia,2016,26,N02-Analgesics,"/capita, US$ purchasing power parity",8.4 +21286,Latvia,2016,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.9 +21287,Latvia,2016,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,61.5 +21288,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.7 +21289,Latvia,2016,26,C-Cardiovascular system,Million US$ at exchange rate,60.8 +21290,Latvia,2016,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +21291,Latvia,2016,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.9 +21292,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.8 +21293,Latvia,2016,26,C08-Calcium channel blockers,Million US$ at exchange rate,2.9 +21294,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9 +21295,Latvia,2016,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.7 +21296,Latvia,2016,26,C10-Lipid modifying agents,Million US$ at exchange rate,6.2 +21297,Latvia,2015,23,A-Alimentary tract and metabolism,Million of national currency units,45.6 +21298,Latvia,2015,23,A02A-Antacids,% of total sales,0.1 +21299,Latvia,2015,23,A02A-Antacids,Million of national currency units,0.4 +21300,Latvia,2015,23,C01A-Cardiac glycosides,% of total sales,0.0 +21301,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6 +21302,Latvia,2015,23,N05B-Anxiolytics,% of total sales,0.8 +21303,Latvia,2015,23,Total pharmaceutical sales,Million of national currency units,331.6 +21304,Latvia,2015,23,N-Nervous system,% of total sales,10.5 +21305,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,% of total sales,1.9 +21306,Latvia,2015,23,N06A-Antidepressants,% of total sales,0.8 +21307,Latvia,2015,23,J01-Antibacterials for systemic use,% of total sales,3.0 +21308,Latvia,2015,23,N05C-Hypnotics and sedatives,% of total sales,0.9 +21309,Latvia,2015,23,R03-Drugs for obstructive airway diseases,% of total sales,2.8 +21310,Latvia,2015,23,B-Blood and blood forming organs,% of total sales,7.0 +21311,Latvia,2015,23,C10-Lipid modifying agents,% of total sales,1.6 +21312,Latvia,2015,23,N02-Analgesics,% of total sales,2.3 +21313,Latvia,2015,23,C-Cardiovascular system,% of total sales,16.2 +21314,Latvia,2015,23,M-Musculo-skeletal system,% of total sales,6.6 +21315,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +21316,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +21317,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +21318,Latvia,2015,23,C07-Beta blocking agents,% of total sales,2.3 +21319,Latvia,2015,23,C03-Diuretics,% of total sales,0.7 +21320,Latvia,2015,23,A10-Drugs used in diabetes,% of total sales,6.0 +21321,Latvia,2015,23,R-Respiratory system,% of total sales,7.3 +21322,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.2 +21323,Latvia,2015,23,C02-Antihypertensives,% of total sales,1.0 +21324,Latvia,2015,23,C08-Calcium channel blockers,% of total sales,0.9 +21325,Latvia,2015,23,J-Antiinfectives for systemic use,% of total sales,10.6 +21326,Latvia,2015,23,G-Genito urinary system and sex hormones,% of total sales,4.3 +21327,Latvia,2015,23,A-Alimentary tract and metabolism,% of total sales,13.7 +21328,Latvia,2015,23,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.9 +21329,Latvia,2015,23,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0 +21330,Latvia,2015,23,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +21331,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.4 +21332,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5 +21333,Latvia,2015,23,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +21334,Latvia,2015,23,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.9 +21335,Latvia,2015,23,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7 +21336,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +21337,Latvia,2015,23,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.3 +21338,Latvia,2015,23,C-Cardiovascular system,"/capita, US$ purchasing power parity",54.5 +21339,Latvia,2015,23,R-Respiratory system,Million US$ at exchange rate,26.9 +21340,Latvia,2015,23,N06A-Antidepressants,Million US$ at exchange rate,2.8 +21341,Latvia,2015,23,Total pharmaceutical sales,"Million US$, purchasing power parity",666.4 +21342,Latvia,2015,23,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.2 +21343,Latvia,2015,23,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.1 +21344,Latvia,2015,23,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.5 +21345,Latvia,2015,23,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +21346,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.0 +21347,Latvia,2015,23,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.3 +21348,Latvia,2015,23,A02A-Antacids,"/capita, US$ exchange rate",0.2 +21349,Latvia,2015,23,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2 +21350,Latvia,2015,23,N05B-Anxiolytics,Million US$ at exchange rate,3.0 +21351,Latvia,2015,23,Total pharmaceutical sales,"/capita, US$ exchange rate",186.0 +21352,Latvia,2015,23,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.6 +21353,Latvia,2015,23,M-Musculo-skeletal system,Million US$ at exchange rate,24.1 +21354,Latvia,2015,23,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.0 +21355,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,15.5 +21356,Latvia,2015,23,N02-Analgesics,Million US$ at exchange rate,8.5 +21357,Latvia,2015,23,N-Nervous system,Million US$ at exchange rate,38.5 +21358,Latvia,2015,23,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.4 +21359,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.0 +21360,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +21361,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.0 +21362,Latvia,2015,23,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.4 +21363,Latvia,2015,23,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.6 +21364,Latvia,2015,23,C07-Beta blocking agents,"/capita, US$ exchange rate",4.3 +21365,Latvia,2015,23,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",91.6 +21366,Latvia,2015,23,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.9 +21367,Latvia,2015,23,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1 +21368,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.5 +21369,Latvia,2015,23,N-Nervous system,"/capita, US$ exchange rate",19.5 +21370,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8 +21371,Latvia,2015,23,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +21372,Latvia,2015,23,N02-Analgesics,"/capita, US$ exchange rate",4.3 +21373,Latvia,2015,23,R-Respiratory system,"Million US$, purchasing power parity",48.8 +21374,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",28.0 +21375,Latvia,2015,23,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.9 +21376,Latvia,2015,23,M-Musculo-skeletal system,"Million US$, purchasing power parity",43.7 +21377,Latvia,2015,23,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2 +21378,Latvia,2015,23,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.6 +21379,Latvia,2015,23,N-Nervous system,"Million US$, purchasing power parity",69.8 +21380,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.1 +21381,Latvia,2015,23,N06A-Antidepressants,"/capita, US$ exchange rate",1.4 +21382,Latvia,2015,23,R-Respiratory system,"/capita, US$ exchange rate",13.6 +21383,Latvia,2015,23,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +21384,Latvia,2015,23,Total pharmaceutical sales,"/capita, US$ purchasing power parity",337.0 +21385,Latvia,2015,23,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.7 +21386,Latvia,2015,23,N02-Analgesics,"Million US$, purchasing power parity",15.4 +21387,Latvia,2015,23,N05B-Anxiolytics,"Million US$, purchasing power parity",5.5 +21388,Latvia,2015,23,N06A-Antidepressants,"Million US$, purchasing power parity",5.0 +21389,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.4 +21390,Latvia,2015,23,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +21391,Latvia,2015,23,C03-Diuretics,"Million US$, purchasing power parity",4.4 +21392,Latvia,2015,23,C02-Antihypertensives,"Million US$, purchasing power parity",6.6 +21393,Latvia,2015,23,C07-Beta blocking agents,"Million US$, purchasing power parity",15.3 +21394,Latvia,2015,23,C-Cardiovascular system,"Million US$, purchasing power parity",107.7 +21395,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.9 +21396,Latvia,2015,23,A02A-Antacids,"Million US$, purchasing power parity",0.8 +21397,Latvia,2015,23,B-Blood and blood forming organs,"Million US$, purchasing power parity",46.5 +21398,Latvia,2015,23,A10-Drugs used in diabetes,"Million US$, purchasing power parity",39.8 +21399,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.5 +21400,Latvia,2015,23,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.8 +21401,Latvia,2015,23,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",70.9 +21402,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",11.8 +21403,Latvia,2015,23,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",28.4 +21404,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",37.6 +21405,Latvia,2015,23,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.8 +21406,Latvia,2015,23,C10-Lipid modifying agents,"Million US$, purchasing power parity",10.7 +21407,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3 +21408,Latvia,2015,23,N-Nervous system,Million of national currency units,34.7 +21409,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,13.9 +21410,Latvia,2015,23,N02-Analgesics,Million of national currency units,7.7 +21411,Latvia,2015,23,N05C-Hypnotics and sedatives,Million of national currency units,2.8 +21412,Latvia,2015,23,N05B-Anxiolytics,Million of national currency units,2.7 +21413,Latvia,2015,23,J-Antiinfectives for systemic use,Million of national currency units,35.3 +21414,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.9 +21415,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2 +21416,Latvia,2015,23,M-Musculo-skeletal system,Million of national currency units,21.7 +21417,Latvia,2015,23,J01-Antibacterials for systemic use,Million of national currency units,9.9 +21418,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.5 +21419,Latvia,2015,23,A02A-Antacids,Million US$ at exchange rate,0.5 +21420,Latvia,2015,23,B-Blood and blood forming organs,Million US$ at exchange rate,25.7 +21421,Latvia,2015,23,A10-Drugs used in diabetes,Million US$ at exchange rate,22.0 +21422,Latvia,2015,23,A-Alimentary tract and metabolism,Million US$ at exchange rate,50.6 +21423,Latvia,2015,23,R-Respiratory system,Million of national currency units,24.3 +21424,Latvia,2015,23,N06A-Antidepressants,Million of national currency units,2.5 +21425,Latvia,2015,23,Total pharmaceutical sales,Million US$ at exchange rate,367.9 +21426,Latvia,2015,23,R03-Drugs for obstructive airway diseases,Million of national currency units,9.2 +21427,Latvia,2015,23,C03-Diuretics,"/capita, US$ exchange rate",1.2 +21428,Latvia,2015,23,C01A-Cardiac glycosides,Million of national currency units,0.1 +21429,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +21430,Latvia,2015,23,C02-Antihypertensives,"/capita, US$ exchange rate",1.8 +21431,Latvia,2015,23,A10-Drugs used in diabetes,Million of national currency units,19.8 +21432,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.9 +21433,Latvia,2015,23,C-Cardiovascular system,Million of national currency units,53.6 +21434,Latvia,2015,23,B-Blood and blood forming organs,Million of national currency units,23.1 +21435,Latvia,2015,23,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +21436,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.7 +21437,Latvia,2015,23,C08-Calcium channel blockers,Million of national currency units,2.9 +21438,Latvia,2015,23,G-Genito urinary system and sex hormones,Million of national currency units,14.2 +21439,Latvia,2015,23,C10-Lipid modifying agents,Million of national currency units,5.3 +21440,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.7 +21441,Latvia,2015,23,C-Cardiovascular system,"/capita, US$ exchange rate",30.1 +21442,Latvia,2015,23,C07-Beta blocking agents,Million of national currency units,7.6 +21443,Latvia,2015,23,C03-Diuretics,Million of national currency units,2.2 +21444,Latvia,2015,23,C02-Antihypertensives,Million of national currency units,3.3 +21445,Latvia,2015,23,C02-Antihypertensives,Million US$ at exchange rate,3.6 +21446,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.3 +21447,Latvia,2015,23,R-Respiratory system,"/capita, US$ purchasing power parity",24.7 +21448,Latvia,2015,23,C03-Diuretics,Million US$ at exchange rate,2.4 +21449,Latvia,2015,23,C07-Beta blocking agents,Million US$ at exchange rate,8.4 +21450,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.8 +21451,Latvia,2015,23,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.1 +21452,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",14.2 +21453,Latvia,2015,23,N-Nervous system,"/capita, US$ purchasing power parity",35.3 +21454,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +21455,Latvia,2015,23,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.1 +21456,Latvia,2015,23,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.9 +21457,Latvia,2015,23,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.5 +21458,Latvia,2015,23,N02-Analgesics,"/capita, US$ purchasing power parity",7.8 +21459,Latvia,2015,23,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8 +21460,Latvia,2015,23,J-Antiinfectives for systemic use,Million US$ at exchange rate,39.1 +21461,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.5 +21462,Latvia,2015,23,C-Cardiovascular system,Million US$ at exchange rate,59.5 +21463,Latvia,2015,23,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +21464,Latvia,2015,23,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.0 +21465,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9 +21466,Latvia,2015,23,C08-Calcium channel blockers,Million US$ at exchange rate,3.2 +21467,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.7 +21468,Latvia,2015,23,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.7 +21469,Latvia,2015,23,C10-Lipid modifying agents,Million US$ at exchange rate,5.9 +21470,Latvia,2014,24,A-Alimentary tract and metabolism,Million of national currency units,42.6 +21471,Latvia,2014,24,A02A-Antacids,% of total sales,0.1 +21472,Latvia,2014,24,A02A-Antacids,Million of national currency units,0.4 +21473,Latvia,2014,24,Total pharmaceutical sales,Million of national currency units,315.9 +21474,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.1 +21475,Latvia,2014,24,C01A-Cardiac glycosides,% of total sales,0.0 +21476,Latvia,2014,24,N05B-Anxiolytics,% of total sales,0.8 +21477,Latvia,2014,24,N-Nervous system,% of total sales,10.7 +21478,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +21479,Latvia,2014,24,N06A-Antidepressants,% of total sales,0.7 +21480,Latvia,2014,24,J01-Antibacterials for systemic use,% of total sales,3.1 +21481,Latvia,2014,24,N05C-Hypnotics and sedatives,% of total sales,0.9 +21482,Latvia,2014,24,R03-Drugs for obstructive airway diseases,% of total sales,3.0 +21483,Latvia,2014,24,B-Blood and blood forming organs,% of total sales,7.0 +21484,Latvia,2014,24,A-Alimentary tract and metabolism,% of total sales,13.5 +21485,Latvia,2014,24,C10-Lipid modifying agents,% of total sales,1.8 +21486,Latvia,2014,24,N02-Analgesics,% of total sales,2.3 +21487,Latvia,2014,24,C-Cardiovascular system,% of total sales,17.2 +21488,Latvia,2014,24,M-Musculo-skeletal system,% of total sales,6.6 +21489,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +21490,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8 +21491,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +21492,Latvia,2014,24,C07-Beta blocking agents,% of total sales,2.4 +21493,Latvia,2014,24,C03-Diuretics,% of total sales,0.7 +21494,Latvia,2014,24,A10-Drugs used in diabetes,% of total sales,5.7 +21495,Latvia,2014,24,R-Respiratory system,% of total sales,7.6 +21496,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1 +21497,Latvia,2014,24,C02-Antihypertensives,% of total sales,1.0 +21498,Latvia,2014,24,C08-Calcium channel blockers,% of total sales,1.0 +21499,Latvia,2014,24,J-Antiinfectives for systemic use,% of total sales,9.9 +21500,Latvia,2014,24,G-Genito urinary system and sex hormones,% of total sales,4.5 +21501,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,17.3 +21502,Latvia,2014,24,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.5 +21503,Latvia,2014,24,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.7 +21504,Latvia,2014,24,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +21505,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",19.2 +21506,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1 +21507,Latvia,2014,24,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +21508,Latvia,2014,24,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6 +21509,Latvia,2014,24,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.2 +21510,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +21511,Latvia,2014,24,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.2 +21512,Latvia,2014,24,R-Respiratory system,Million US$ at exchange rate,31.8 +21513,Latvia,2014,24,N06A-Antidepressants,Million US$ at exchange rate,3.0 +21514,Latvia,2014,24,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",85.7 +21515,Latvia,2014,24,Total pharmaceutical sales,"Million US$, purchasing power parity",634.9 +21516,Latvia,2014,24,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.7 +21517,Latvia,2014,24,C-Cardiovascular system,"/capita, US$ purchasing power parity",54.6 +21518,Latvia,2014,24,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0 +21519,Latvia,2014,24,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.2 +21520,Latvia,2014,24,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.3 +21521,Latvia,2014,24,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +21522,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.9 +21523,Latvia,2014,24,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.6 +21524,Latvia,2014,24,A02A-Antacids,"/capita, US$ exchange rate",0.3 +21525,Latvia,2014,24,N05B-Anxiolytics,Million US$ at exchange rate,3.4 +21526,Latvia,2014,24,Total pharmaceutical sales,"/capita, US$ exchange rate",210.5 +21527,Latvia,2014,24,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4 +21528,Latvia,2014,24,M-Musculo-skeletal system,Million US$ at exchange rate,27.6 +21529,Latvia,2014,24,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.0 +21530,Latvia,2014,24,N02-Analgesics,Million US$ at exchange rate,9.8 +21531,Latvia,2014,24,N-Nervous system,Million US$ at exchange rate,44.8 +21532,Latvia,2014,24,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.4 +21533,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +21534,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.8 +21535,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.3 +21536,Latvia,2014,24,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7 +21537,Latvia,2014,24,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.1 +21538,Latvia,2014,24,C07-Beta blocking agents,"/capita, US$ exchange rate",5.0 +21539,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.7 +21540,Latvia,2014,24,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.4 +21541,Latvia,2014,24,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9 +21542,Latvia,2014,24,N-Nervous system,"/capita, US$ exchange rate",22.5 +21543,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.7 +21544,Latvia,2014,24,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7 +21545,Latvia,2014,24,N02-Analgesics,"/capita, US$ exchange rate",4.9 +21546,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",26.1 +21547,Latvia,2014,24,M-Musculo-skeletal system,"Million US$, purchasing power parity",41.8 +21548,Latvia,2014,24,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.9 +21549,Latvia,2014,24,N-Nervous system,"Million US$, purchasing power parity",67.7 +21550,Latvia,2014,24,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.7 +21551,Latvia,2014,24,N02-Analgesics,"Million US$, purchasing power parity",14.9 +21552,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.4 +21553,Latvia,2014,24,N06A-Antidepressants,"/capita, US$ exchange rate",1.5 +21554,Latvia,2014,24,R-Respiratory system,"/capita, US$ exchange rate",16.0 +21555,Latvia,2014,24,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8 +21556,Latvia,2014,24,Total pharmaceutical sales,"/capita, US$ purchasing power parity",318.5 +21557,Latvia,2014,24,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.5 +21558,Latvia,2014,24,N05B-Anxiolytics,"Million US$, purchasing power parity",5.2 +21559,Latvia,2014,24,R-Respiratory system,"Million US$, purchasing power parity",48.2 +21560,Latvia,2014,24,N06A-Antidepressants,"Million US$, purchasing power parity",4.6 +21561,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.3 +21562,Latvia,2014,24,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +21563,Latvia,2014,24,C07-Beta blocking agents,"Million US$, purchasing power parity",15.1 +21564,Latvia,2014,24,C03-Diuretics,"Million US$, purchasing power parity",4.4 +21565,Latvia,2014,24,C02-Antihypertensives,"Million US$, purchasing power parity",6.3 +21566,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.8 +21567,Latvia,2014,24,A02A-Antacids,"Million US$, purchasing power parity",0.8 +21568,Latvia,2014,24,C-Cardiovascular system,"Million US$, purchasing power parity",108.9 +21569,Latvia,2014,24,B-Blood and blood forming organs,"Million US$, purchasing power parity",44.4 +21570,Latvia,2014,24,A10-Drugs used in diabetes,"Million US$, purchasing power parity",36.3 +21571,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.5 +21572,Latvia,2014,24,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5 +21573,Latvia,2014,24,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.7 +21574,Latvia,2014,24,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",62.6 +21575,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",11.5 +21576,Latvia,2014,24,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",28.7 +21577,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",38.4 +21578,Latvia,2014,24,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.4 +21579,Latvia,2014,24,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.3 +21580,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8 +21581,Latvia,2014,24,N-Nervous system,Million of national currency units,33.7 +21582,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,13.0 +21583,Latvia,2014,24,N02-Analgesics,Million of national currency units,7.4 +21584,Latvia,2014,24,N05C-Hypnotics and sedatives,Million of national currency units,2.7 +21585,Latvia,2014,24,N05B-Anxiolytics,Million of national currency units,2.6 +21586,Latvia,2014,24,J-Antiinfectives for systemic use,Million of national currency units,31.1 +21587,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.7 +21588,Latvia,2014,24,M-Musculo-skeletal system,Million of national currency units,20.8 +21589,Latvia,2014,24,J01-Antibacterials for systemic use,Million of national currency units,9.8 +21590,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.4 +21591,Latvia,2014,24,A02A-Antacids,Million US$ at exchange rate,0.5 +21592,Latvia,2014,24,B-Blood and blood forming organs,Million US$ at exchange rate,29.3 +21593,Latvia,2014,24,A10-Drugs used in diabetes,Million US$ at exchange rate,24.0 +21594,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2 +21595,Latvia,2014,24,R-Respiratory system,Million of national currency units,24.0 +21596,Latvia,2014,24,N06A-Antidepressants,Million of national currency units,2.3 +21597,Latvia,2014,24,A-Alimentary tract and metabolism,Million US$ at exchange rate,56.6 +21598,Latvia,2014,24,Total pharmaceutical sales,Million US$ at exchange rate,419.7 +21599,Latvia,2014,24,R03-Drugs for obstructive airway diseases,Million of national currency units,9.6 +21600,Latvia,2014,24,C03-Diuretics,"/capita, US$ exchange rate",1.5 +21601,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +21602,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +21603,Latvia,2014,24,C02-Antihypertensives,"/capita, US$ exchange rate",2.1 +21604,Latvia,2014,24,C01A-Cardiac glycosides,Million of national currency units,0.1 +21605,Latvia,2014,24,A10-Drugs used in diabetes,Million of national currency units,18.1 +21606,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.9 +21607,Latvia,2014,24,C-Cardiovascular system,Million of national currency units,54.2 +21608,Latvia,2014,24,B-Blood and blood forming organs,Million of national currency units,22.1 +21609,Latvia,2014,24,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +21610,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.1 +21611,Latvia,2014,24,C08-Calcium channel blockers,Million of national currency units,3.2 +21612,Latvia,2014,24,G-Genito urinary system and sex hormones,Million of national currency units,14.3 +21613,Latvia,2014,24,C10-Lipid modifying agents,Million of national currency units,5.6 +21614,Latvia,2014,24,C07-Beta blocking agents,Million of national currency units,7.5 +21615,Latvia,2014,24,C-Cardiovascular system,"/capita, US$ exchange rate",36.1 +21616,Latvia,2014,24,C03-Diuretics,Million of national currency units,2.2 +21617,Latvia,2014,24,C02-Antihypertensives,Million of national currency units,3.1 +21618,Latvia,2014,24,C02-Antihypertensives,Million US$ at exchange rate,4.2 +21619,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2 +21620,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.6 +21621,Latvia,2014,24,R-Respiratory system,"/capita, US$ purchasing power parity",24.2 +21622,Latvia,2014,24,C03-Diuretics,Million US$ at exchange rate,2.9 +21623,Latvia,2014,24,C07-Beta blocking agents,Million US$ at exchange rate,10.0 +21624,Latvia,2014,24,A10-Drugs used in diabetes,"/capita, US$ exchange rate",12.0 +21625,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.1 +21626,Latvia,2014,24,N-Nervous system,"/capita, US$ purchasing power parity",34.0 +21627,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9 +21628,Latvia,2014,24,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.0 +21629,Latvia,2014,24,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8 +21630,Latvia,2014,24,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.3 +21631,Latvia,2014,24,N02-Analgesics,"/capita, US$ purchasing power parity",7.4 +21632,Latvia,2014,24,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6 +21633,Latvia,2014,24,J-Antiinfectives for systemic use,Million US$ at exchange rate,41.4 +21634,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.6 +21635,Latvia,2014,24,C-Cardiovascular system,Million US$ at exchange rate,72.0 +21636,Latvia,2014,24,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.7 +21637,Latvia,2014,24,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +21638,Latvia,2014,24,C08-Calcium channel blockers,Million US$ at exchange rate,4.2 +21639,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.4 +21640,Latvia,2014,24,G-Genito urinary system and sex hormones,Million US$ at exchange rate,19.0 +21641,Latvia,2014,24,C10-Lipid modifying agents,Million US$ at exchange rate,7.5 +21642,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.3 +21643,Latvia,2013,27,A-Alimentary tract and metabolism,Million of national currency units,40.5 +21644,Latvia,2013,27,A02A-Antacids,% of total sales,0.1 +21645,Latvia,2013,27,A02A-Antacids,Million of national currency units,0.4 +21646,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3 +21647,Latvia,2013,27,C01A-Cardiac glycosides,% of total sales,0.0 +21648,Latvia,2013,27,Total pharmaceutical sales,Million of national currency units,307.6 +21649,Latvia,2013,27,N05B-Anxiolytics,% of total sales,0.8 +21650,Latvia,2013,27,N05C-Hypnotics and sedatives,% of total sales,0.8 +21651,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +21652,Latvia,2013,27,N-Nervous system,% of total sales,10.8 +21653,Latvia,2013,27,J01-Antibacterials for systemic use,% of total sales,3.1 +21654,Latvia,2013,27,R03-Drugs for obstructive airway diseases,% of total sales,3.0 +21655,Latvia,2013,27,B-Blood and blood forming organs,% of total sales,6.7 +21656,Latvia,2013,27,C10-Lipid modifying agents,% of total sales,2.2 +21657,Latvia,2013,27,N02-Analgesics,% of total sales,2.4 +21658,Latvia,2013,27,C-Cardiovascular system,% of total sales,18.0 +21659,Latvia,2013,27,M-Musculo-skeletal system,% of total sales,6.5 +21660,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +21661,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +21662,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +21663,Latvia,2013,27,N06A-Antidepressants,% of total sales,0.7 +21664,Latvia,2013,27,C07-Beta blocking agents,% of total sales,2.4 +21665,Latvia,2013,27,C03-Diuretics,% of total sales,0.7 +21666,Latvia,2013,27,A10-Drugs used in diabetes,% of total sales,5.6 +21667,Latvia,2013,27,R-Respiratory system,% of total sales,7.6 +21668,Latvia,2013,27,A-Alimentary tract and metabolism,% of total sales,13.2 +21669,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0 +21670,Latvia,2013,27,C02-Antihypertensives,% of total sales,1.0 +21671,Latvia,2013,27,C08-Calcium channel blockers,% of total sales,1.1 +21672,Latvia,2013,27,J-Antiinfectives for systemic use,% of total sales,10.4 +21673,Latvia,2013,27,G-Genito urinary system and sex hormones,% of total sales,4.5 +21674,Latvia,2013,27,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.1 +21675,Latvia,2013,27,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.5 +21676,Latvia,2013,27,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +21677,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0 +21678,Latvia,2013,27,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2 +21679,Latvia,2013,27,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +21680,Latvia,2013,27,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4 +21681,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +21682,Latvia,2013,27,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.0 +21683,Latvia,2013,27,C-Cardiovascular system,"/capita, US$ purchasing power parity",55.0 +21684,Latvia,2013,27,R-Respiratory system,Million US$ at exchange rate,30.9 +21685,Latvia,2013,27,N06A-Antidepressants,Million US$ at exchange rate,3.0 +21686,Latvia,2013,27,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",81.2 +21687,Latvia,2013,27,Total pharmaceutical sales,"Million US$, purchasing power parity",616.0 +21688,Latvia,2013,27,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.4 +21689,Latvia,2013,27,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.2 +21690,Latvia,2013,27,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.4 +21691,Latvia,2013,27,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +21692,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.6 +21693,Latvia,2013,27,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5 +21694,Latvia,2013,27,N05B-Anxiolytics,Million US$ at exchange rate,3.2 +21695,Latvia,2013,27,A02A-Antacids,"/capita, US$ exchange rate",0.3 +21696,Latvia,2013,27,Total pharmaceutical sales,"/capita, US$ exchange rate",202.9 +21697,Latvia,2013,27,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.7 +21698,Latvia,2013,27,M-Musculo-skeletal system,Million US$ at exchange rate,26.7 +21699,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,16.4 +21700,Latvia,2013,27,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.7 +21701,Latvia,2013,27,N02-Analgesics,Million US$ at exchange rate,9.9 +21702,Latvia,2013,27,N-Nervous system,Million US$ at exchange rate,44.2 +21703,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1 +21704,Latvia,2013,27,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.8 +21705,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.1 +21706,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.4 +21707,Latvia,2013,27,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.8 +21708,Latvia,2013,27,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.3 +21709,Latvia,2013,27,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8 +21710,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.8 +21711,Latvia,2013,27,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.8 +21712,Latvia,2013,27,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5 +21713,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.7 +21714,Latvia,2013,27,N-Nervous system,"/capita, US$ exchange rate",22.0 +21715,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1 +21716,Latvia,2013,27,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6 +21717,Latvia,2013,27,N02-Analgesics,"/capita, US$ exchange rate",4.9 +21718,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.7 +21719,Latvia,2013,27,M-Musculo-skeletal system,"Million US$, purchasing power parity",40.2 +21720,Latvia,2013,27,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.2 +21721,Latvia,2013,27,N-Nervous system,"Million US$, purchasing power parity",66.7 +21722,Latvia,2013,27,Total pharmaceutical sales,"/capita, US$ purchasing power parity",306.1 +21723,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.2 +21724,Latvia,2013,27,N06A-Antidepressants,"/capita, US$ exchange rate",1.5 +21725,Latvia,2013,27,R-Respiratory system,"/capita, US$ exchange rate",15.3 +21726,Latvia,2013,27,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7 +21727,Latvia,2013,27,N02-Analgesics,"Million US$, purchasing power parity",14.9 +21728,Latvia,2013,27,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.2 +21729,Latvia,2013,27,N05B-Anxiolytics,"Million US$, purchasing power parity",4.9 +21730,Latvia,2013,27,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.3 +21731,Latvia,2013,27,R-Respiratory system,"Million US$, purchasing power parity",46.6 +21732,Latvia,2013,27,N06A-Antidepressants,"Million US$, purchasing power parity",4.5 +21733,Latvia,2013,27,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.1 +21734,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.2 +21735,Latvia,2013,27,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +21736,Latvia,2013,27,C07-Beta blocking agents,"Million US$, purchasing power parity",14.5 +21737,Latvia,2013,27,C03-Diuretics,"Million US$, purchasing power parity",4.4 +21738,Latvia,2013,27,C02-Antihypertensives,"Million US$, purchasing power parity",6.1 +21739,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.3 +21740,Latvia,2013,27,A02A-Antacids,"Million US$, purchasing power parity",0.8 +21741,Latvia,2013,27,C-Cardiovascular system,"Million US$, purchasing power parity",110.6 +21742,Latvia,2013,27,B-Blood and blood forming organs,"Million US$, purchasing power parity",41.1 +21743,Latvia,2013,27,A10-Drugs used in diabetes,"Million US$, purchasing power parity",34.5 +21744,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.2 +21745,Latvia,2013,27,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.3 +21746,Latvia,2013,27,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.1 +21747,Latvia,2013,27,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",64.0 +21748,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.3 +21749,Latvia,2013,27,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",27.7 +21750,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",39.0 +21751,Latvia,2013,27,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.9 +21752,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.0 +21753,Latvia,2013,27,C10-Lipid modifying agents,"Million US$, purchasing power parity",13.7 +21754,Latvia,2013,27,N02-Analgesics,Million of national currency units,7.4 +21755,Latvia,2013,27,N-Nervous system,Million of national currency units,33.3 +21756,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,12.3 +21757,Latvia,2013,27,N05C-Hypnotics and sedatives,Million of national currency units,2.6 +21758,Latvia,2013,27,N05B-Anxiolytics,Million of national currency units,2.4 +21759,Latvia,2013,27,J-Antiinfectives for systemic use,Million of national currency units,32.0 +21760,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.1 +21761,Latvia,2013,27,M-Musculo-skeletal system,Million of national currency units,20.1 +21762,Latvia,2013,27,J01-Antibacterials for systemic use,Million of national currency units,9.5 +21763,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.2 +21764,Latvia,2013,27,A02A-Antacids,Million US$ at exchange rate,0.5 +21765,Latvia,2013,27,B-Blood and blood forming organs,Million US$ at exchange rate,27.2 +21766,Latvia,2013,27,A10-Drugs used in diabetes,Million US$ at exchange rate,22.9 +21767,Latvia,2013,27,R-Respiratory system,Million of national currency units,23.3 +21768,Latvia,2013,27,N06A-Antidepressants,Million of national currency units,2.2 +21769,Latvia,2013,27,R03-Drugs for obstructive airway diseases,Million of national currency units,9.3 +21770,Latvia,2013,27,A-Alimentary tract and metabolism,Million US$ at exchange rate,53.8 +21771,Latvia,2013,27,Total pharmaceutical sales,Million US$ at exchange rate,408.3 +21772,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.1 +21773,Latvia,2013,27,C03-Diuretics,"/capita, US$ exchange rate",1.4 +21774,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +21775,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +21776,Latvia,2013,27,C02-Antihypertensives,"/capita, US$ exchange rate",2.0 +21777,Latvia,2013,27,C01A-Cardiac glycosides,Million of national currency units,0.1 +21778,Latvia,2013,27,A10-Drugs used in diabetes,Million of national currency units,17.2 +21779,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.7 +21780,Latvia,2013,27,C-Cardiovascular system,Million of national currency units,55.2 +21781,Latvia,2013,27,B-Blood and blood forming organs,Million of national currency units,20.5 +21782,Latvia,2013,27,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +21783,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.5 +21784,Latvia,2013,27,C08-Calcium channel blockers,Million of national currency units,3.4 +21785,Latvia,2013,27,G-Genito urinary system and sex hormones,Million of national currency units,13.8 +21786,Latvia,2013,27,C10-Lipid modifying agents,Million of national currency units,6.9 +21787,Latvia,2013,27,C-Cardiovascular system,"/capita, US$ exchange rate",36.4 +21788,Latvia,2013,27,C07-Beta blocking agents,Million of national currency units,7.2 +21789,Latvia,2013,27,C03-Diuretics,Million of national currency units,2.2 +21790,Latvia,2013,27,C02-Antihypertensives,Million of national currency units,3.0 +21791,Latvia,2013,27,C-Cardiovascular system,Million US$ at exchange rate,73.3 +21792,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1 +21793,Latvia,2013,27,C02-Antihypertensives,Million US$ at exchange rate,4.0 +21794,Latvia,2013,27,R-Respiratory system,"/capita, US$ purchasing power parity",23.2 +21795,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.3 +21796,Latvia,2013,27,C03-Diuretics,Million US$ at exchange rate,2.9 +21797,Latvia,2013,27,C07-Beta blocking agents,Million US$ at exchange rate,9.6 +21798,Latvia,2013,27,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4 +21799,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3 +21800,Latvia,2013,27,N-Nervous system,"/capita, US$ purchasing power parity",33.1 +21801,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +21802,Latvia,2013,27,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.0 +21803,Latvia,2013,27,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6 +21804,Latvia,2013,27,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2 +21805,Latvia,2013,27,N02-Analgesics,"/capita, US$ purchasing power parity",7.4 +21806,Latvia,2013,27,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +21807,Latvia,2013,27,J-Antiinfectives for systemic use,Million US$ at exchange rate,42.4 +21808,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,8.1 +21809,Latvia,2013,27,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +21810,Latvia,2013,27,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.5 +21811,Latvia,2013,27,C08-Calcium channel blockers,Million US$ at exchange rate,4.6 +21812,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.8 +21813,Latvia,2013,27,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.4 +21814,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.1 +21815,Latvia,2013,27,C10-Lipid modifying agents,Million US$ at exchange rate,9.1 +21816,Latvia,2012,23,A-Alimentary tract and metabolism,Million of national currency units,38.9 +21817,Latvia,2012,23,A02A-Antacids,Million of national currency units,0.4 +21818,Latvia,2012,23,A02A-Antacids,% of total sales,0.1 +21819,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.4 +21820,Latvia,2012,23,C01A-Cardiac glycosides,% of total sales,0.0 +21821,Latvia,2012,23,Total pharmaceutical sales,Million of national currency units,295.4 +21822,Latvia,2012,23,N05B-Anxiolytics,% of total sales,0.8 +21823,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +21824,Latvia,2012,23,N-Nervous system,% of total sales,11.3 +21825,Latvia,2012,23,N05C-Hypnotics and sedatives,% of total sales,0.8 +21826,Latvia,2012,23,J01-Antibacterials for systemic use,% of total sales,3.2 +21827,Latvia,2012,23,R03-Drugs for obstructive airway diseases,% of total sales,3.1 +21828,Latvia,2012,23,B-Blood and blood forming organs,% of total sales,6.6 +21829,Latvia,2012,23,C10-Lipid modifying agents,% of total sales,2.6 +21830,Latvia,2012,23,N02-Analgesics,% of total sales,2.5 +21831,Latvia,2012,23,C-Cardiovascular system,% of total sales,18.6 +21832,Latvia,2012,23,M-Musculo-skeletal system,% of total sales,6.6 +21833,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6 +21834,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +21835,Latvia,2012,23,C07-Beta blocking agents,% of total sales,2.4 +21836,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +21837,Latvia,2012,23,N06A-Antidepressants,% of total sales,0.8 +21838,Latvia,2012,23,R-Respiratory system,% of total sales,7.6 +21839,Latvia,2012,23,C03-Diuretics,% of total sales,0.7 +21840,Latvia,2012,23,A-Alimentary tract and metabolism,% of total sales,13.2 +21841,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9 +21842,Latvia,2012,23,A10-Drugs used in diabetes,% of total sales,5.7 +21843,Latvia,2012,23,C02-Antihypertensives,% of total sales,1.0 +21844,Latvia,2012,23,C08-Calcium channel blockers,% of total sales,1.2 +21845,Latvia,2012,23,J-Antiinfectives for systemic use,% of total sales,9.9 +21846,Latvia,2012,23,G-Genito urinary system and sex hormones,% of total sales,4.4 +21847,Latvia,2012,23,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.3 +21848,Latvia,2012,23,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.8 +21849,Latvia,2012,23,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +21850,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.7 +21851,Latvia,2012,23,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8 +21852,Latvia,2012,23,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6 +21853,Latvia,2012,23,C03-Diuretics,"/capita, US$ purchasing power parity",2.1 +21854,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5 +21855,Latvia,2012,23,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9 +21856,Latvia,2012,23,R-Respiratory system,Million US$ at exchange rate,28.7 +21857,Latvia,2012,23,N06A-Antidepressants,Million US$ at exchange rate,2.9 +21858,Latvia,2012,23,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",76.8 +21859,Latvia,2012,23,Total pharmaceutical sales,"Million US$, purchasing power parity",583.5 +21860,Latvia,2012,23,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.7 +21861,Latvia,2012,23,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.2 +21862,Latvia,2012,23,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.5 +21863,Latvia,2012,23,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.0 +21864,Latvia,2012,23,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +21865,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.5 +21866,Latvia,2012,23,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2 +21867,Latvia,2012,23,N05B-Anxiolytics,Million US$ at exchange rate,3.0 +21868,Latvia,2012,23,A02A-Antacids,"/capita, US$ exchange rate",0.3 +21869,Latvia,2012,23,Total pharmaceutical sales,"/capita, US$ exchange rate",186.6 +21870,Latvia,2012,23,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.6 +21871,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,14.8 +21872,Latvia,2012,23,M-Musculo-skeletal system,Million US$ at exchange rate,24.9 +21873,Latvia,2012,23,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.2 +21874,Latvia,2012,23,N02-Analgesics,Million US$ at exchange rate,9.4 +21875,Latvia,2012,23,N-Nervous system,Million US$ at exchange rate,43.0 +21876,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7 +21877,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.3 +21878,Latvia,2012,23,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.8 +21879,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.5 +21880,Latvia,2012,23,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.4 +21881,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.0 +21882,Latvia,2012,23,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.3 +21883,Latvia,2012,23,C07-Beta blocking agents,"/capita, US$ exchange rate",4.4 +21884,Latvia,2012,23,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.4 +21885,Latvia,2012,23,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +21886,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.0 +21887,Latvia,2012,23,N-Nervous system,"/capita, US$ exchange rate",21.2 +21888,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.3 +21889,Latvia,2012,23,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +21890,Latvia,2012,23,N02-Analgesics,"/capita, US$ exchange rate",4.6 +21891,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.8 +21892,Latvia,2012,23,M-Musculo-skeletal system,"Million US$, purchasing power parity",38.3 +21893,Latvia,2012,23,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2 +21894,Latvia,2012,23,N-Nervous system,"Million US$, purchasing power parity",66.2 +21895,Latvia,2012,23,N02-Analgesics,"Million US$, purchasing power parity",14.5 +21896,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.7 +21897,Latvia,2012,23,Total pharmaceutical sales,"/capita, US$ purchasing power parity",286.8 +21898,Latvia,2012,23,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +21899,Latvia,2012,23,N06A-Antidepressants,"/capita, US$ exchange rate",1.4 +21900,Latvia,2012,23,R-Respiratory system,"/capita, US$ exchange rate",14.1 +21901,Latvia,2012,23,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.9 +21902,Latvia,2012,23,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7 +21903,Latvia,2012,23,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.7 +21904,Latvia,2012,23,R-Respiratory system,"Million US$, purchasing power parity",44.1 +21905,Latvia,2012,23,N06A-Antidepressants,"Million US$, purchasing power parity",4.5 +21906,Latvia,2012,23,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8 +21907,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.0 +21908,Latvia,2012,23,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +21909,Latvia,2012,23,C07-Beta blocking agents,"Million US$, purchasing power parity",13.9 +21910,Latvia,2012,23,C03-Diuretics,"Million US$, purchasing power parity",4.3 +21911,Latvia,2012,23,C02-Antihypertensives,"Million US$, purchasing power parity",5.8 +21912,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.1 +21913,Latvia,2012,23,A02A-Antacids,"Million US$, purchasing power parity",0.8 +21914,Latvia,2012,23,C-Cardiovascular system,"Million US$, purchasing power parity",108.8 +21915,Latvia,2012,23,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.6 +21916,Latvia,2012,23,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.0 +21917,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.6 +21918,Latvia,2012,23,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0 +21919,Latvia,2012,23,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",57.8 +21920,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",10.8 +21921,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",37.6 +21922,Latvia,2012,23,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.3 +21923,Latvia,2012,23,C10-Lipid modifying agents,"Million US$, purchasing power parity",15.0 +21924,Latvia,2012,23,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",25.9 +21925,Latvia,2012,23,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.5 +21926,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.5 +21927,Latvia,2012,23,N02-Analgesics,Million of national currency units,7.3 +21928,Latvia,2012,23,N-Nervous system,Million of national currency units,33.5 +21929,Latvia,2012,23,N05C-Hypnotics and sedatives,Million of national currency units,2.5 +21930,Latvia,2012,23,N05B-Anxiolytics,Million of national currency units,2.4 +21931,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,11.6 +21932,Latvia,2012,23,J-Antiinfectives for systemic use,Million of national currency units,29.3 +21933,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.5 +21934,Latvia,2012,23,M-Musculo-skeletal system,Million of national currency units,19.4 +21935,Latvia,2012,23,J01-Antibacterials for systemic use,Million of national currency units,9.5 +21936,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9 +21937,Latvia,2012,23,A02A-Antacids,Million US$ at exchange rate,0.5 +21938,Latvia,2012,23,B-Blood and blood forming organs,Million US$ at exchange rate,25.1 +21939,Latvia,2012,23,A10-Drugs used in diabetes,Million US$ at exchange rate,21.5 +21940,Latvia,2012,23,R-Respiratory system,Million of national currency units,22.3 +21941,Latvia,2012,23,N06A-Antidepressants,Million of national currency units,2.3 +21942,Latvia,2012,23,A-Alimentary tract and metabolism,Million US$ at exchange rate,49.9 +21943,Latvia,2012,23,Total pharmaceutical sales,Million US$ at exchange rate,379.6 +21944,Latvia,2012,23,R03-Drugs for obstructive airway diseases,Million of national currency units,9.1 +21945,Latvia,2012,23,C-Cardiovascular system,Million US$ at exchange rate,70.8 +21946,Latvia,2012,23,C03-Diuretics,"/capita, US$ exchange rate",1.4 +21947,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5 +21948,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3 +21949,Latvia,2012,23,C02-Antihypertensives,"/capita, US$ exchange rate",1.9 +21950,Latvia,2012,23,C01A-Cardiac glycosides,Million of national currency units,0.1 +21951,Latvia,2012,23,A10-Drugs used in diabetes,Million of national currency units,16.7 +21952,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.6 +21953,Latvia,2012,23,C-Cardiovascular system,Million of national currency units,55.1 +21954,Latvia,2012,23,B-Blood and blood forming organs,Million of national currency units,19.5 +21955,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.0 +21956,Latvia,2012,23,C08-Calcium channel blockers,Million of national currency units,3.7 +21957,Latvia,2012,23,G-Genito urinary system and sex hormones,Million of national currency units,13.1 +21958,Latvia,2012,23,C10-Lipid modifying agents,Million of national currency units,7.6 +21959,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.9 +21960,Latvia,2012,23,C-Cardiovascular system,"/capita, US$ exchange rate",34.8 +21961,Latvia,2012,23,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +21962,Latvia,2012,23,C02-Antihypertensives,Million of national currency units,3.0 +21963,Latvia,2012,23,C07-Beta blocking agents,Million of national currency units,7.0 +21964,Latvia,2012,23,C03-Diuretics,Million of national currency units,2.2 +21965,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9 +21966,Latvia,2012,23,C02-Antihypertensives,Million US$ at exchange rate,3.8 +21967,Latvia,2012,23,R-Respiratory system,"/capita, US$ purchasing power parity",21.7 +21968,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.8 +21969,Latvia,2012,23,C03-Diuretics,Million US$ at exchange rate,2.8 +21970,Latvia,2012,23,C07-Beta blocking agents,Million US$ at exchange rate,9.0 +21971,Latvia,2012,23,A10-Drugs used in diabetes,"/capita, US$ exchange rate",10.6 +21972,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.2 +21973,Latvia,2012,23,N-Nervous system,"/capita, US$ purchasing power parity",32.5 +21974,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7 +21975,Latvia,2012,23,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8 +21976,Latvia,2012,23,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4 +21977,Latvia,2012,23,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2 +21978,Latvia,2012,23,N02-Analgesics,"/capita, US$ purchasing power parity",7.1 +21979,Latvia,2012,23,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +21980,Latvia,2012,23,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.6 +21981,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.0 +21982,Latvia,2012,23,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +21983,Latvia,2012,23,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.3 +21984,Latvia,2012,23,C10-Lipid modifying agents,Million US$ at exchange rate,9.8 +21985,Latvia,2012,23,C08-Calcium channel blockers,Million US$ at exchange rate,4.7 +21986,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,24.5 +21987,Latvia,2012,23,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.9 +21988,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.5 +21989,Latvia,2011,26,A-Alimentary tract and metabolism,Million of national currency units,38.1 +21990,Latvia,2011,26,A02A-Antacids,Million of national currency units,0.4 +21991,Latvia,2011,26,C01A-Cardiac glycosides,% of total sales,0.0 +21992,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3 +21993,Latvia,2011,26,Total pharmaceutical sales,Million of national currency units,289.9 +21994,Latvia,2011,26,N05B-Anxiolytics,% of total sales,0.8 +21995,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +21996,Latvia,2011,26,N-Nervous system,% of total sales,11.6 +21997,Latvia,2011,26,A02A-Antacids,% of total sales,0.1 +21998,Latvia,2011,26,J01-Antibacterials for systemic use,% of total sales,3.3 +21999,Latvia,2011,26,R03-Drugs for obstructive airway diseases,% of total sales,3.1 +22000,Latvia,2011,26,B-Blood and blood forming organs,% of total sales,6.5 +22001,Latvia,2011,26,J-Antiinfectives for systemic use,% of total sales,9.2 +22002,Latvia,2011,26,N02-Analgesics,% of total sales,2.6 +22003,Latvia,2011,26,N05C-Hypnotics and sedatives,% of total sales,0.9 +22004,Latvia,2011,26,C10-Lipid modifying agents,% of total sales,2.7 +22005,Latvia,2011,26,C-Cardiovascular system,% of total sales,18.6 +22006,Latvia,2011,26,M-Musculo-skeletal system,% of total sales,6.6 +22007,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +22008,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7 +22009,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +22010,Latvia,2011,26,C07-Beta blocking agents,% of total sales,2.4 +22011,Latvia,2011,26,N06A-Antidepressants,% of total sales,0.8 +22012,Latvia,2011,26,R-Respiratory system,% of total sales,7.4 +22013,Latvia,2011,26,C03-Diuretics,% of total sales,0.7 +22014,Latvia,2011,26,A-Alimentary tract and metabolism,% of total sales,13.1 +22015,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9 +22016,Latvia,2011,26,A10-Drugs used in diabetes,% of total sales,5.8 +22017,Latvia,2011,26,C02-Antihypertensives,% of total sales,1.0 +22018,Latvia,2011,26,C08-Calcium channel blockers,% of total sales,1.3 +22019,Latvia,2011,26,G-Genito urinary system and sex hormones,% of total sales,4.5 +22020,Latvia,2011,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.8 +22021,Latvia,2011,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.2 +22022,Latvia,2011,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +22023,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0 +22024,Latvia,2011,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.7 +22025,Latvia,2011,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8 +22026,Latvia,2011,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.1 +22027,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4 +22028,Latvia,2011,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8 +22029,Latvia,2011,26,R-Respiratory system,Million US$ at exchange rate,30.0 +22030,Latvia,2011,26,N06A-Antidepressants,Million US$ at exchange rate,3.2 +22031,Latvia,2011,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.5 +22032,Latvia,2011,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",76.4 +22033,Latvia,2011,26,Total pharmaceutical sales,"Million US$, purchasing power parity",581.5 +22034,Latvia,2011,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.4 +22035,Latvia,2011,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.5 +22036,Latvia,2011,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",52.5 +22037,Latvia,2011,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +22038,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.3 +22039,Latvia,2011,26,N05B-Anxiolytics,Million US$ at exchange rate,3.1 +22040,Latvia,2011,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5 +22041,Latvia,2011,26,A02A-Antacids,"/capita, US$ exchange rate",0.3 +22042,Latvia,2011,26,Total pharmaceutical sales,"/capita, US$ exchange rate",197.3 +22043,Latvia,2011,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.9 +22044,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,15.8 +22045,Latvia,2011,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.4 +22046,Latvia,2011,26,M-Musculo-skeletal system,Million US$ at exchange rate,26.8 +22047,Latvia,2011,26,N02-Analgesics,Million US$ at exchange rate,10.4 +22048,Latvia,2011,26,N-Nervous system,Million US$ at exchange rate,47.0 +22049,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7 +22050,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.9 +22051,Latvia,2011,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.7 +22052,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.9 +22053,Latvia,2011,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.5 +22054,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5 +22055,Latvia,2011,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +22056,Latvia,2011,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7 +22057,Latvia,2011,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",26.1 +22058,Latvia,2011,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3 +22059,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.9 +22060,Latvia,2011,26,N-Nervous system,"/capita, US$ exchange rate",22.8 +22061,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.7 +22062,Latvia,2011,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +22063,Latvia,2011,26,N02-Analgesics,"/capita, US$ exchange rate",5.0 +22064,Latvia,2011,26,N02-Analgesics,"Million US$, purchasing power parity",14.8 +22065,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.5 +22066,Latvia,2011,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",38.3 +22067,Latvia,2011,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.0 +22068,Latvia,2011,26,N-Nervous system,"Million US$, purchasing power parity",67.3 +22069,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.1 +22070,Latvia,2011,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",282.3 +22071,Latvia,2011,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7 +22072,Latvia,2011,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.6 +22073,Latvia,2011,26,R-Respiratory system,"/capita, US$ exchange rate",14.6 +22074,Latvia,2011,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.0 +22075,Latvia,2011,26,N05B-Anxiolytics,"Million US$, purchasing power parity",4.5 +22076,Latvia,2011,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.1 +22077,Latvia,2011,26,R-Respiratory system,"Million US$, purchasing power parity",43.0 +22078,Latvia,2011,26,N06A-Antidepressants,"Million US$, purchasing power parity",4.6 +22079,Latvia,2011,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2 +22080,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.9 +22081,Latvia,2011,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +22082,Latvia,2011,26,C02-Antihypertensives,"Million US$, purchasing power parity",5.7 +22083,Latvia,2011,26,C07-Beta blocking agents,"Million US$, purchasing power parity",13.9 +22084,Latvia,2011,26,C03-Diuretics,"Million US$, purchasing power parity",4.2 +22085,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.8 +22086,Latvia,2011,26,A02A-Antacids,"Million US$, purchasing power parity",0.8 +22087,Latvia,2011,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.7 +22088,Latvia,2011,26,C-Cardiovascular system,"Million US$, purchasing power parity",108.2 +22089,Latvia,2011,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.0 +22090,Latvia,2011,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5 +22091,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.8 +22092,Latvia,2011,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",53.7 +22093,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",10.0 +22094,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",36.8 +22095,Latvia,2011,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.7 +22096,Latvia,2011,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",26.1 +22097,Latvia,2011,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.2 +22098,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4 +22099,Latvia,2011,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",15.4 +22100,Latvia,2011,26,N02-Analgesics,Million of national currency units,7.4 +22101,Latvia,2011,26,N-Nervous system,Million of national currency units,33.5 +22102,Latvia,2011,26,N05C-Hypnotics and sedatives,Million of national currency units,2.5 +22103,Latvia,2011,26,N05B-Anxiolytics,Million of national currency units,2.2 +22104,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,11.2 +22105,Latvia,2011,26,J-Antiinfectives for systemic use,Million of national currency units,26.8 +22106,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.0 +22107,Latvia,2011,26,M-Musculo-skeletal system,Million of national currency units,19.1 +22108,Latvia,2011,26,J01-Antibacterials for systemic use,Million of national currency units,9.6 +22109,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.2 +22110,Latvia,2011,26,A02A-Antacids,Million US$ at exchange rate,0.5 +22111,Latvia,2011,26,C-Cardiovascular system,Million US$ at exchange rate,75.6 +22112,Latvia,2011,26,B-Blood and blood forming organs,Million US$ at exchange rate,26.6 +22113,Latvia,2011,26,A10-Drugs used in diabetes,Million US$ at exchange rate,23.5 +22114,Latvia,2011,26,R-Respiratory system,Million of national currency units,21.4 +22115,Latvia,2011,26,N06A-Antidepressants,Million of national currency units,2.3 +22116,Latvia,2011,26,R03-Drugs for obstructive airway diseases,Million of national currency units,8.9 +22117,Latvia,2011,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,53.4 +22118,Latvia,2011,26,Total pharmaceutical sales,Million US$ at exchange rate,406.4 +22119,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.9 +22120,Latvia,2011,26,C03-Diuretics,"/capita, US$ exchange rate",1.4 +22121,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5 +22122,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3 +22123,Latvia,2011,26,C02-Antihypertensives,"/capita, US$ exchange rate",1.9 +22124,Latvia,2011,26,C01A-Cardiac glycosides,Million of national currency units,0.1 +22125,Latvia,2011,26,A10-Drugs used in diabetes,Million of national currency units,16.8 +22126,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.4 +22127,Latvia,2011,26,C-Cardiovascular system,Million of national currency units,53.9 +22128,Latvia,2011,26,B-Blood and blood forming organs,Million of national currency units,18.9 +22129,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.4 +22130,Latvia,2011,26,C08-Calcium channel blockers,Million of national currency units,3.9 +22131,Latvia,2011,26,G-Genito urinary system and sex hormones,Million of national currency units,13.0 +22132,Latvia,2011,26,C10-Lipid modifying agents,Million of national currency units,7.7 +22133,Latvia,2011,26,C-Cardiovascular system,"/capita, US$ exchange rate",36.7 +22134,Latvia,2011,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +22135,Latvia,2011,26,C07-Beta blocking agents,Million of national currency units,6.9 +22136,Latvia,2011,26,C03-Diuretics,Million of national currency units,2.1 +22137,Latvia,2011,26,C02-Antihypertensives,Million of national currency units,2.9 +22138,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.0 +22139,Latvia,2011,26,C02-Antihypertensives,Million US$ at exchange rate,4.0 +22140,Latvia,2011,26,R-Respiratory system,"/capita, US$ purchasing power parity",20.9 +22141,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.7 +22142,Latvia,2011,26,C03-Diuretics,Million US$ at exchange rate,3.0 +22143,Latvia,2011,26,C07-Beta blocking agents,Million US$ at exchange rate,9.7 +22144,Latvia,2011,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4 +22145,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9 +22146,Latvia,2011,26,N-Nervous system,"/capita, US$ purchasing power parity",32.7 +22147,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +22148,Latvia,2011,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.6 +22149,Latvia,2011,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4 +22150,Latvia,2011,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2 +22151,Latvia,2011,26,N02-Analgesics,"/capita, US$ purchasing power parity",7.2 +22152,Latvia,2011,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +22153,Latvia,2011,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.5 +22154,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.0 +22155,Latvia,2011,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +22156,Latvia,2011,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.9 +22157,Latvia,2011,26,C10-Lipid modifying agents,Million US$ at exchange rate,10.8 +22158,Latvia,2011,26,C08-Calcium channel blockers,Million US$ at exchange rate,5.4 +22159,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.7 +22160,Latvia,2011,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.2 +22161,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.2 +22162,Latvia,2017,19,A-Alimentary tract and metabolism,Million of national currency units,50.4 +22163,Latvia,2017,19,A02A-Antacids,Million of national currency units,0.4 +22164,Latvia,2017,19,Total pharmaceutical sales,Million of national currency units,392.8 +22165,Latvia,2017,19,C01A-Cardiac glycosides,% of total sales,0.0 +22166,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.0 +22167,Latvia,2017,19,N05B-Anxiolytics,% of total sales,0.7 +22168,Latvia,2017,19,N-Nervous system,% of total sales,9.5 +22169,Latvia,2017,19,A-Alimentary tract and metabolism,% of total sales,12.8 +22170,Latvia,2017,19,N06A-Antidepressants,% of total sales,0.7 +22171,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +22172,Latvia,2017,19,R03-Drugs for obstructive airway diseases,% of total sales,2.5 +22173,Latvia,2017,19,J01-Antibacterials for systemic use,% of total sales,2.7 +22174,Latvia,2017,19,N05C-Hypnotics and sedatives,% of total sales,0.8 +22175,Latvia,2017,19,B-Blood and blood forming organs,% of total sales,7.2 +22176,Latvia,2017,19,C10-Lipid modifying agents,% of total sales,1.6 +22177,Latvia,2017,19,N02-Analgesics,% of total sales,2.1 +22178,Latvia,2017,19,A02A-Antacids,% of total sales,0.1 +22179,Latvia,2017,19,M-Musculo-skeletal system,% of total sales,6.3 +22180,Latvia,2017,19,C-Cardiovascular system,% of total sales,14.5 +22181,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3 +22182,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6 +22183,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +22184,Latvia,2017,19,C07-Beta blocking agents,% of total sales,2.0 +22185,Latvia,2017,19,C03-Diuretics,% of total sales,0.6 +22186,Latvia,2017,19,A10-Drugs used in diabetes,% of total sales,5.7 +22187,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9 +22188,Latvia,2017,19,R-Respiratory system,% of total sales,7.1 +22189,Latvia,2017,19,C02-Antihypertensives,% of total sales,1.0 +22190,Latvia,2017,19,C08-Calcium channel blockers,% of total sales,0.6 +22191,Latvia,2017,19,J-Antiinfectives for systemic use,% of total sales,15.4 +22192,Latvia,2017,19,G-Genito urinary system and sex hormones,% of total sales,3.8 +22193,Latvia,2017,19,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.7 +22194,Latvia,2017,19,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.6 +22195,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5 +22196,Latvia,2017,19,C-Cardiovascular system,"/capita, US$ purchasing power parity",60.3 +22197,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",20.1 +22198,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.8 +22199,Latvia,2017,19,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +22200,Latvia,2017,19,C03-Diuretics,"/capita, US$ purchasing power parity",2.6 +22201,Latvia,2017,19,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3 +22202,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +22203,Latvia,2017,19,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.0 +22204,Latvia,2017,19,R-Respiratory system,Million US$ at exchange rate,31.3 +22205,Latvia,2017,19,N06A-Antidepressants,Million US$ at exchange rate,3.2 +22206,Latvia,2017,19,Total pharmaceutical sales,"Million US$, purchasing power parity",810.6 +22207,Latvia,2017,19,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.0 +22208,Latvia,2017,19,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.8 +22209,Latvia,2017,19,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.1 +22210,Latvia,2017,19,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.6 +22211,Latvia,2017,19,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +22212,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.5 +22213,Latvia,2017,19,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.5 +22214,Latvia,2017,19,A02A-Antacids,"/capita, US$ exchange rate",0.3 +22215,Latvia,2017,19,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5 +22216,Latvia,2017,19,N05B-Anxiolytics,Million US$ at exchange rate,3.3 +22217,Latvia,2017,19,Total pharmaceutical sales,"/capita, US$ exchange rate",228.5 +22218,Latvia,2017,19,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.3 +22219,Latvia,2017,19,M-Musculo-skeletal system,Million US$ at exchange rate,27.7 +22220,Latvia,2017,19,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.0 +22221,Latvia,2017,19,N02-Analgesics,Million US$ at exchange rate,9.4 +22222,Latvia,2017,19,N-Nervous system,Million US$ at exchange rate,42.2 +22223,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,17.4 +22224,Latvia,2017,19,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.9 +22225,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.9 +22226,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.1 +22227,Latvia,2017,19,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6 +22228,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.5 +22229,Latvia,2017,19,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4 +22230,Latvia,2017,19,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6 +22231,Latvia,2017,19,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.3 +22232,Latvia,2017,19,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3 +22233,Latvia,2017,19,N-Nervous system,"/capita, US$ exchange rate",21.7 +22234,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.0 +22235,Latvia,2017,19,R-Respiratory system,"Million US$, purchasing power parity",57.2 +22236,Latvia,2017,19,N02-Analgesics,"/capita, US$ exchange rate",4.9 +22237,Latvia,2017,19,M-Musculo-skeletal system,"Million US$, purchasing power parity",50.7 +22238,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",31.8 +22239,Latvia,2017,19,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",21.9 +22240,Latvia,2017,19,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.3 +22241,Latvia,2017,19,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2 +22242,Latvia,2017,19,N-Nervous system,"Million US$, purchasing power parity",77.1 +22243,Latvia,2017,19,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7 +22244,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.7 +22245,Latvia,2017,19,N06A-Antidepressants,"/capita, US$ exchange rate",1.7 +22246,Latvia,2017,19,R-Respiratory system,"/capita, US$ exchange rate",16.1 +22247,Latvia,2017,19,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8 +22248,Latvia,2017,19,Total pharmaceutical sales,"/capita, US$ purchasing power parity",417.4 +22249,Latvia,2017,19,N05B-Anxiolytics,"Million US$, purchasing power parity",6.0 +22250,Latvia,2017,19,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",6.4 +22251,Latvia,2017,19,N02-Analgesics,"Million US$, purchasing power parity",17.2 +22252,Latvia,2017,19,N06A-Antidepressants,"Million US$, purchasing power parity",5.9 +22253,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +22254,Latvia,2017,19,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +22255,Latvia,2017,19,C03-Diuretics,"Million US$, purchasing power parity",5.1 +22256,Latvia,2017,19,C02-Antihypertensives,"Million US$, purchasing power parity",7.7 +22257,Latvia,2017,19,C-Cardiovascular system,"Million US$, purchasing power parity",117.2 +22258,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.7 +22259,Latvia,2017,19,A02A-Antacids,"Million US$, purchasing power parity",0.9 +22260,Latvia,2017,19,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.4 +22261,Latvia,2017,19,A10-Drugs used in diabetes,"Million US$, purchasing power parity",46.1 +22262,Latvia,2017,19,C07-Beta blocking agents,"Million US$, purchasing power parity",16.2 +22263,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.5 +22264,Latvia,2017,19,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.2 +22265,Latvia,2017,19,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",30.8 +22266,Latvia,2017,19,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",124.9 +22267,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.6 +22268,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",40.9 +22269,Latvia,2017,19,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.0 +22270,Latvia,2017,19,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",104.0 +22271,Latvia,2017,19,C10-Lipid modifying agents,"Million US$, purchasing power parity",12.9 +22272,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.5 +22273,Latvia,2017,19,N-Nervous system,Million of national currency units,37.4 +22274,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,15.4 +22275,Latvia,2017,19,N05C-Hypnotics and sedatives,Million of national currency units,3.1 +22276,Latvia,2017,19,N05B-Anxiolytics,Million of national currency units,2.9 +22277,Latvia,2017,19,N02-Analgesics,Million of national currency units,8.3 +22278,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.1 +22279,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5 +22280,Latvia,2017,19,J-Antiinfectives for systemic use,Million of national currency units,60.5 +22281,Latvia,2017,19,M-Musculo-skeletal system,Million of national currency units,24.6 +22282,Latvia,2017,19,J01-Antibacterials for systemic use,Million of national currency units,10.6 +22283,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9 +22284,Latvia,2017,19,A02A-Antacids,Million US$ at exchange rate,0.5 +22285,Latvia,2017,19,B-Blood and blood forming organs,Million US$ at exchange rate,32.0 +22286,Latvia,2017,19,A10-Drugs used in diabetes,Million US$ at exchange rate,25.3 +22287,Latvia,2017,19,A-Alimentary tract and metabolism,Million US$ at exchange rate,57.0 +22288,Latvia,2017,19,R-Respiratory system,Million of national currency units,27.7 +22289,Latvia,2017,19,N06A-Antidepressants,Million of national currency units,2.8 +22290,Latvia,2017,19,Total pharmaceutical sales,Million US$ at exchange rate,443.7 +22291,Latvia,2017,19,R03-Drugs for obstructive airway diseases,Million of national currency units,9.8 +22292,Latvia,2017,19,C03-Diuretics,"/capita, US$ exchange rate",1.4 +22293,Latvia,2017,19,C01A-Cardiac glycosides,Million of national currency units,0.1 +22294,Latvia,2017,19,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +22295,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +22296,Latvia,2017,19,C02-Antihypertensives,"/capita, US$ exchange rate",2.2 +22297,Latvia,2017,19,A10-Drugs used in diabetes,Million of national currency units,22.4 +22298,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.2 +22299,Latvia,2017,19,C-Cardiovascular system,Million of national currency units,56.8 +22300,Latvia,2017,19,B-Blood and blood forming organs,Million of national currency units,28.3 +22301,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.8 +22302,Latvia,2017,19,C08-Calcium channel blockers,Million of national currency units,2.4 +22303,Latvia,2017,19,C07-Beta blocking agents,Million of national currency units,7.9 +22304,Latvia,2017,19,G-Genito urinary system and sex hormones,Million of national currency units,14.9 +22305,Latvia,2017,19,C10-Lipid modifying agents,Million of national currency units,6.2 +22306,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8 +22307,Latvia,2017,19,C-Cardiovascular system,"/capita, US$ exchange rate",33.0 +22308,Latvia,2017,19,C03-Diuretics,Million of national currency units,2.5 +22309,Latvia,2017,19,C02-Antihypertensives,Million of national currency units,3.8 +22310,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.4 +22311,Latvia,2017,19,R-Respiratory system,"/capita, US$ purchasing power parity",29.4 +22312,Latvia,2017,19,C02-Antihypertensives,Million US$ at exchange rate,4.2 +22313,Latvia,2017,19,C03-Diuretics,Million US$ at exchange rate,2.8 +22314,Latvia,2017,19,C07-Beta blocking agents,Million US$ at exchange rate,8.9 +22315,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.0 +22316,Latvia,2017,19,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.0 +22317,Latvia,2017,19,N06A-Antidepressants,"/capita, US$ purchasing power parity",3.0 +22318,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4 +22319,Latvia,2017,19,N-Nervous system,"/capita, US$ purchasing power parity",39.7 +22320,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9 +22321,Latvia,2017,19,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",26.1 +22322,Latvia,2017,19,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.3 +22323,Latvia,2017,19,N02-Analgesics,"/capita, US$ purchasing power parity",8.9 +22324,Latvia,2017,19,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1 +22325,Latvia,2017,19,J-Antiinfectives for systemic use,Million US$ at exchange rate,68.4 +22326,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.9 +22327,Latvia,2017,19,C-Cardiovascular system,Million US$ at exchange rate,64.2 +22328,Latvia,2017,19,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +22329,Latvia,2017,19,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.5 +22330,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.4 +22331,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,22.4 +22332,Latvia,2017,19,C08-Calcium channel blockers,Million US$ at exchange rate,2.7 +22333,Latvia,2017,19,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.9 +22334,Latvia,2017,19,C10-Lipid modifying agents,Million US$ at exchange rate,7.0 +22335,Luxembourg,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,2.8 +22336,Luxembourg,2016,5,N05B-Anxiolytics,Million of national currency units,2.5 +22337,Luxembourg,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5 +22338,Luxembourg,2016,5,N05B-Anxiolytics,% of total sales,1.3 +22339,Luxembourg,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.9 +22340,Luxembourg,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.2 +22341,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.3 +22342,Luxembourg,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +22343,Luxembourg,2016,5,A02A-Antacids,% of total sales,0.2 +22344,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.2 +22345,Luxembourg,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.8 +22346,Luxembourg,2016,5,A02A-Antacids,"Million US$, purchasing power parity",0.4 +22347,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2 +22348,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7 +22349,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.3 +22350,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,8.1 +22351,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1 +22352,Luxembourg,2016,5,A02A-Antacids,Million US$ at exchange rate,0.4 +22353,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.5 +22354,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.7 +22355,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.9 +22356,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,10.0 +22357,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.0 +22358,Luxembourg,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6 +22359,Luxembourg,2016,5,N05C-Hypnotics and sedatives,% of total sales,1.8 +22360,Luxembourg,2016,5,A-Alimentary tract and metabolism,% of total sales,17.6 +22361,Luxembourg,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",72.2 +22362,Luxembourg,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.0 +22363,Luxembourg,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",40.3 +22364,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.2 +22365,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.0 +22366,Luxembourg,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8 +22367,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7 +22368,Luxembourg,2016,5,A-Alimentary tract and metabolism,Million of national currency units,34.4 +22369,Luxembourg,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",70.9 +22370,Luxembourg,2016,5,N-Nervous system,"/capita, US$ exchange rate",66.8 +22371,Luxembourg,2016,5,N-Nervous system,% of total sales,16.3 +22372,Luxembourg,2016,5,N-Nervous system,Million of national currency units,31.8 +22373,Luxembourg,2016,5,N-Nervous system,Million US$ at exchange rate,35.2 +22374,Luxembourg,2016,5,N-Nervous system,"Million US$, purchasing power parity",37.3 +22375,Luxembourg,2016,5,N06A-Antidepressants,Million US$ at exchange rate,5.9 +22376,Luxembourg,2016,5,N06A-Antidepressants,Million of national currency units,5.4 +22377,Luxembourg,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.3 +22378,Luxembourg,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9 +22379,Luxembourg,2016,5,N06A-Antidepressants,% of total sales,2.7 +22380,Luxembourg,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.2 +22381,Luxembourg,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,215.7 +22382,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0 +22383,Luxembourg,2016,5,Total pharmaceutical sales,Million of national currency units,194.9 +22384,Luxembourg,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",434.3 +22385,Luxembourg,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",228.8 +22386,Luxembourg,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",409.6 +22387,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.6 +22388,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.9 +22389,Luxembourg,2016,5,A02A-Antacids,Million of national currency units,0.4 +22390,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.2 +22391,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.5 +22392,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",7.0 +22393,Luxembourg,2016,5,R-Respiratory system,% of total sales,7.2 +22394,Luxembourg,2016,5,N02-Analgesics,"/capita, US$ exchange rate",16.3 +22395,Luxembourg,2016,5,N02-Analgesics,"Million US$, purchasing power parity",9.1 +22396,Luxembourg,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",17.3 +22397,Luxembourg,2016,5,N02-Analgesics,Million of national currency units,7.8 +22398,Luxembourg,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4 +22399,Luxembourg,2016,5,N02-Analgesics,Million US$ at exchange rate,8.6 +22400,Luxembourg,2016,5,R-Respiratory system,"/capita, US$ exchange rate",29.6 +22401,Luxembourg,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",31.4 +22402,Luxembourg,2016,5,R-Respiratory system,"Million US$, purchasing power parity",16.5 +22403,Luxembourg,2016,5,R-Respiratory system,Million of national currency units,14.1 +22404,Luxembourg,2016,5,N02-Analgesics,% of total sales,4.0 +22405,Luxembourg,2016,5,R-Respiratory system,Million US$ at exchange rate,15.6 +22406,Luxembourg,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",16.9 +22407,Luxembourg,2016,5,B-Blood and blood forming organs,Million of national currency units,14.4 +22408,Luxembourg,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,15.9 +22409,Luxembourg,2016,5,B-Blood and blood forming organs,% of total sales,7.4 +22410,Luxembourg,2016,5,C02-Antihypertensives,% of total sales,0.2 +22411,Luxembourg,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.3 +22412,Luxembourg,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.1 +22413,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7 +22414,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.1 +22415,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +22416,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3 +22417,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.8 +22418,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.2 +22419,Luxembourg,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +22420,Luxembourg,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0 +22421,Luxembourg,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5 +22422,Luxembourg,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0 +22423,Luxembourg,2016,5,M-Musculo-skeletal system,% of total sales,5.7 +22424,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.5 +22425,Luxembourg,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",25.0 +22426,Luxembourg,2016,5,J-Antiinfectives for systemic use,% of total sales,4.6 +22427,Luxembourg,2016,5,M-Musculo-skeletal system,Million of national currency units,11.2 +22428,Luxembourg,2016,5,C10-Lipid modifying agents,% of total sales,6.5 +22429,Luxembourg,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.0 +22430,Luxembourg,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,12.4 +22431,Luxembourg,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",13.1 +22432,Luxembourg,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +22433,Luxembourg,2016,5,C10-Lipid modifying agents,Million of national currency units,12.6 +22434,Luxembourg,2016,5,C03-Diuretics,Million of national currency units,1.6 +22435,Luxembourg,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,13.9 +22436,Luxembourg,2016,5,C03-Diuretics,"/capita, US$ exchange rate",3.3 +22437,Luxembourg,2016,5,C03-Diuretics,Million US$ at exchange rate,1.7 +22438,Luxembourg,2016,5,C03-Diuretics,"Million US$, purchasing power parity",1.8 +22439,Luxembourg,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.5 +22440,Luxembourg,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +22441,Luxembourg,2016,5,C02-Antihypertensives,Million of national currency units,0.5 +22442,Luxembourg,2016,5,C02-Antihypertensives,Million US$ at exchange rate,0.5 +22443,Luxembourg,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.8 +22444,Luxembourg,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.5 +22445,Luxembourg,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +22446,Luxembourg,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.1 +22447,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +22448,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +22449,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +22450,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5 +22451,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +22452,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +22453,Luxembourg,2016,5,J-Antiinfectives for systemic use,Million of national currency units,9.0 +22454,Luxembourg,2016,5,C03-Diuretics,% of total sales,0.8 +22455,Luxembourg,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.0 +22456,Luxembourg,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.0 +22457,Luxembourg,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.1 +22458,Luxembourg,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.6 +22459,Luxembourg,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.4 +22460,Luxembourg,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.7 +22461,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.8 +22462,Luxembourg,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +22463,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +22464,Luxembourg,2016,5,J01-Antibacterials for systemic use,Million of national currency units,5.8 +22465,Luxembourg,2016,5,C01A-Cardiac glycosides,% of total sales,0.0 +22466,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.5 +22467,Luxembourg,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.1 +22468,Luxembourg,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.8 +22469,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.1 +22470,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.4 +22471,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.9 +22472,Luxembourg,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.3 +22473,Luxembourg,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.3 +22474,Luxembourg,2016,5,A10-Drugs used in diabetes,% of total sales,8.1 +22475,Luxembourg,2016,5,A10-Drugs used in diabetes,Million of national currency units,15.8 +22476,Luxembourg,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,17.5 +22477,Luxembourg,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",18.6 +22478,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.2 +22479,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.2 +22480,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3 +22481,Luxembourg,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,8.7 +22482,Luxembourg,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.6 +22483,Luxembourg,2016,5,C-Cardiovascular system,% of total sales,16.7 +22484,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.5 +22485,Luxembourg,2016,5,C07-Beta blocking agents,% of total sales,1.9 +22486,Luxembourg,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.2 +22487,Luxembourg,2016,5,C08-Calcium channel blockers,% of total sales,0.9 +22488,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,10.7 +22489,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,11.8 +22490,Luxembourg,2016,5,C07-Beta blocking agents,Million of national currency units,3.7 +22491,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.4 +22492,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.7 +22493,Luxembourg,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.3 +22494,Luxembourg,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.7 +22495,Luxembourg,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,4.1 +22496,Luxembourg,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1 +22497,Luxembourg,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",38.1 +22498,Luxembourg,2016,5,C-Cardiovascular system,Million US$ at exchange rate,36.0 +22499,Luxembourg,2016,5,C-Cardiovascular system,Million of national currency units,32.5 +22500,Luxembourg,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",68.3 +22501,Luxembourg,2016,5,G-Genito urinary system and sex hormones,% of total sales,4.4 +22502,Luxembourg,2016,5,J01-Antibacterials for systemic use,% of total sales,3.0 +22503,Luxembourg,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.4 +22504,Luxembourg,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0 +22505,Luxembourg,2016,5,C08-Calcium channel blockers,Million of national currency units,1.8 +22506,Luxembourg,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8 +22507,Luxembourg,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.1 +22508,Luxembourg,2015,5,N05B-Anxiolytics,Million of national currency units,2.4 +22509,Luxembourg,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,2.7 +22510,Luxembourg,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7 +22511,Luxembourg,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2 +22512,Luxembourg,2015,5,N05B-Anxiolytics,% of total sales,1.2 +22513,Luxembourg,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.1 +22514,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5 +22515,Luxembourg,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +22516,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.9 +22517,Luxembourg,2015,5,A02A-Antacids,% of total sales,0.2 +22518,Luxembourg,2015,5,A02A-Antacids,"Million US$, purchasing power parity",0.4 +22519,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9 +22520,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8 +22521,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.2 +22522,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.2 +22523,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,8.0 +22524,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +22525,Luxembourg,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.8 +22526,Luxembourg,2015,5,A02A-Antacids,Million US$ at exchange rate,0.4 +22527,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.4 +22528,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.9 +22529,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,10.5 +22530,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.6 +22531,Luxembourg,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.9 +22532,Luxembourg,2015,5,A-Alimentary tract and metabolism,% of total sales,17.3 +22533,Luxembourg,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,36.9 +22534,Luxembourg,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",71.2 +22535,Luxembourg,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",37.8 +22536,Luxembourg,2015,5,N05C-Hypnotics and sedatives,% of total sales,1.8 +22537,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.3 +22538,Luxembourg,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8 +22539,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.9 +22540,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.5 +22541,Luxembourg,2015,5,A-Alimentary tract and metabolism,Million of national currency units,33.3 +22542,Luxembourg,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",72.7 +22543,Luxembourg,2015,5,N-Nervous system,"/capita, US$ exchange rate",71.1 +22544,Luxembourg,2015,5,N-Nervous system,% of total sales,17.2 +22545,Luxembourg,2015,5,N-Nervous system,Million US$ at exchange rate,36.8 +22546,Luxembourg,2015,5,N-Nervous system,Million of national currency units,33.2 +22547,Luxembourg,2015,5,N-Nervous system,"Million US$, purchasing power parity",37.7 +22548,Luxembourg,2015,5,N06A-Antidepressants,Million US$ at exchange rate,6.3 +22549,Luxembourg,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.5 +22550,Luxembourg,2015,5,N06A-Antidepressants,Million of national currency units,5.7 +22551,Luxembourg,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.5 +22552,Luxembourg,2015,5,N06A-Antidepressants,% of total sales,3.0 +22553,Luxembourg,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.2 +22554,Luxembourg,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,213.7 +22555,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1 +22556,Luxembourg,2015,5,Total pharmaceutical sales,Million of national currency units,192.6 +22557,Luxembourg,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",421.8 +22558,Luxembourg,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",218.6 +22559,Luxembourg,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",412.5 +22560,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.5 +22561,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.9 +22562,Luxembourg,2015,5,A02A-Antacids,Million of national currency units,0.4 +22563,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.9 +22564,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.7 +22565,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6 +22566,Luxembourg,2015,5,N02-Analgesics,"/capita, US$ exchange rate",16.6 +22567,Luxembourg,2015,5,N02-Analgesics,"Million US$, purchasing power parity",8.8 +22568,Luxembourg,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",16.9 +22569,Luxembourg,2015,5,N02-Analgesics,Million of national currency units,7.7 +22570,Luxembourg,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4 +22571,Luxembourg,2015,5,N02-Analgesics,Million US$ at exchange rate,8.6 +22572,Luxembourg,2015,5,N02-Analgesics,% of total sales,4.0 +22573,Luxembourg,2015,5,R-Respiratory system,"/capita, US$ exchange rate",31.1 +22574,Luxembourg,2015,5,R-Respiratory system,% of total sales,7.5 +22575,Luxembourg,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",31.8 +22576,Luxembourg,2015,5,R-Respiratory system,Million of national currency units,14.5 +22577,Luxembourg,2015,5,R-Respiratory system,Million US$ at exchange rate,16.1 +22578,Luxembourg,2015,5,R-Respiratory system,"Million US$, purchasing power parity",16.5 +22579,Luxembourg,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",14.8 +22580,Luxembourg,2015,5,B-Blood and blood forming organs,Million of national currency units,13.0 +22581,Luxembourg,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,14.5 +22582,Luxembourg,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.9 +22583,Luxembourg,2015,5,B-Blood and blood forming organs,% of total sales,6.8 +22584,Luxembourg,2015,5,C02-Antihypertensives,% of total sales,0.2 +22585,Luxembourg,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.6 +22586,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.2 +22587,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0 +22588,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +22589,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.1 +22590,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.7 +22591,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8 +22592,Luxembourg,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +22593,Luxembourg,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.0 +22594,Luxembourg,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0 +22595,Luxembourg,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0 +22596,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.7 +22597,Luxembourg,2015,5,M-Musculo-skeletal system,% of total sales,5.6 +22598,Luxembourg,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.5 +22599,Luxembourg,2015,5,J-Antiinfectives for systemic use,% of total sales,4.9 +22600,Luxembourg,2015,5,M-Musculo-skeletal system,Million of national currency units,10.8 +22601,Luxembourg,2015,5,C10-Lipid modifying agents,% of total sales,6.6 +22602,Luxembourg,2015,5,C01A-Cardiac glycosides,Million of national currency units,0.0 +22603,Luxembourg,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,11.9 +22604,Luxembourg,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.2 +22605,Luxembourg,2015,5,C03-Diuretics,Million of national currency units,1.6 +22606,Luxembourg,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,14.1 +22607,Luxembourg,2015,5,C03-Diuretics,Million US$ at exchange rate,1.8 +22608,Luxembourg,2015,5,C03-Diuretics,"/capita, US$ exchange rate",3.4 +22609,Luxembourg,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.5 +22610,Luxembourg,2015,5,C03-Diuretics,"Million US$, purchasing power parity",1.8 +22611,Luxembourg,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.4 +22612,Luxembourg,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +22613,Luxembourg,2015,5,C02-Antihypertensives,Million of national currency units,0.4 +22614,Luxembourg,2015,5,C02-Antihypertensives,Million US$ at exchange rate,0.5 +22615,Luxembourg,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +22616,Luxembourg,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",27.1 +22617,Luxembourg,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.7 +22618,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +22619,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.2 +22620,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +22621,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +22622,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +22623,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +22624,Luxembourg,2015,5,J-Antiinfectives for systemic use,Million of national currency units,9.4 +22625,Luxembourg,2015,5,C03-Diuretics,% of total sales,0.8 +22626,Luxembourg,2015,5,C10-Lipid modifying agents,Million of national currency units,12.7 +22627,Luxembourg,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.4 +22628,Luxembourg,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.0 +22629,Luxembourg,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.5 +22630,Luxembourg,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9 +22631,Luxembourg,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.6 +22632,Luxembourg,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.4 +22633,Luxembourg,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.6 +22634,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.5 +22635,Luxembourg,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +22636,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +22637,Luxembourg,2015,5,J01-Antibacterials for systemic use,Million of national currency units,5.8 +22638,Luxembourg,2015,5,C01A-Cardiac glycosides,% of total sales,0.0 +22639,Luxembourg,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.4 +22640,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.4 +22641,Luxembourg,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.7 +22642,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9 +22643,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.3 +22644,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.8 +22645,Luxembourg,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",33.1 +22646,Luxembourg,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.4 +22647,Luxembourg,2015,5,A10-Drugs used in diabetes,% of total sales,7.8 +22648,Luxembourg,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,16.8 +22649,Luxembourg,2015,5,A10-Drugs used in diabetes,Million of national currency units,15.1 +22650,Luxembourg,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",17.2 +22651,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.8 +22652,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.4 +22653,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.2 +22654,Luxembourg,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,8.3 +22655,Luxembourg,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.2 +22656,Luxembourg,2015,5,C-Cardiovascular system,% of total sales,17.1 +22657,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.5 +22658,Luxembourg,2015,5,C07-Beta blocking agents,% of total sales,1.9 +22659,Luxembourg,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9 +22660,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,12.2 +22661,Luxembourg,2015,5,C08-Calcium channel blockers,% of total sales,1.0 +22662,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.0 +22663,Luxembourg,2015,5,C07-Beta blocking agents,Million of national currency units,3.6 +22664,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.6 +22665,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.1 +22666,Luxembourg,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.7 +22667,Luxembourg,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1 +22668,Luxembourg,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,4.0 +22669,Luxembourg,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",37.4 +22670,Luxembourg,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2 +22671,Luxembourg,2015,5,C-Cardiovascular system,Million US$ at exchange rate,36.6 +22672,Luxembourg,2015,5,G-Genito urinary system and sex hormones,% of total sales,4.3 +22673,Luxembourg,2015,5,J01-Antibacterials for systemic use,% of total sales,3.0 +22674,Luxembourg,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",70.6 +22675,Luxembourg,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.2 +22676,Luxembourg,2015,5,C-Cardiovascular system,Million of national currency units,33.0 +22677,Luxembourg,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.1 +22678,Luxembourg,2015,5,C08-Calcium channel blockers,Million of national currency units,1.9 +22679,Luxembourg,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.2 +22680,Luxembourg,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +22681,Luxembourg,2014,6,N05B-Anxiolytics,Million of national currency units,2.4 +22682,Luxembourg,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,3.2 +22683,Luxembourg,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.3 +22684,Luxembourg,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7 +22685,Luxembourg,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",6.2 +22686,Luxembourg,2014,6,N05B-Anxiolytics,% of total sales,1.2 +22687,Luxembourg,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.9 +22688,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.6 +22689,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.4 +22690,Luxembourg,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +22691,Luxembourg,2014,6,A02A-Antacids,% of total sales,0.2 +22692,Luxembourg,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.4 +22693,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.4 +22694,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.5 +22695,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.3 +22696,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.1 +22697,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.5 +22698,Luxembourg,2014,6,A02A-Antacids,Million US$ at exchange rate,0.5 +22699,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.5 +22700,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.4 +22701,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.0 +22702,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,10.6 +22703,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.1 +22704,Luxembourg,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.8 +22705,Luxembourg,2014,6,A-Alimentary tract and metabolism,% of total sales,17.2 +22706,Luxembourg,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,43.7 +22707,Luxembourg,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",85.5 +22708,Luxembourg,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",37.2 +22709,Luxembourg,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.6 +22710,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.2 +22711,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.6 +22712,Luxembourg,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.2 +22713,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.0 +22714,Luxembourg,2014,6,A-Alimentary tract and metabolism,Million of national currency units,32.9 +22715,Luxembourg,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",70.5 +22716,Luxembourg,2014,6,N-Nervous system,"/capita, US$ exchange rate",82.8 +22717,Luxembourg,2014,6,N-Nervous system,% of total sales,16.6 +22718,Luxembourg,2014,6,N-Nervous system,Million US$ at exchange rate,42.3 +22719,Luxembourg,2014,6,N-Nervous system,Million of national currency units,31.8 +22720,Luxembourg,2014,6,N-Nervous system,"Million US$, purchasing power parity",36.0 +22721,Luxembourg,2014,6,N06A-Antidepressants,Million US$ at exchange rate,8.3 +22722,Luxembourg,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",7.1 +22723,Luxembourg,2014,6,N06A-Antidepressants,Million of national currency units,6.3 +22724,Luxembourg,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.8 +22725,Luxembourg,2014,6,N06A-Antidepressants,% of total sales,3.3 +22726,Luxembourg,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",16.3 +22727,Luxembourg,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,254.1 +22728,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2 +22729,Luxembourg,2014,6,Total pharmaceutical sales,Million of national currency units,191.3 +22730,Luxembourg,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",216.3 +22731,Luxembourg,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",423.6 +22732,Luxembourg,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",497.5 +22733,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.1 +22734,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.1 +22735,Luxembourg,2014,6,A02A-Antacids,Million of national currency units,0.4 +22736,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.6 +22737,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.9 +22738,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.9 +22739,Luxembourg,2014,6,N02-Analgesics,"/capita, US$ exchange rate",19.8 +22740,Luxembourg,2014,6,N02-Analgesics,"Million US$, purchasing power parity",8.6 +22741,Luxembourg,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",16.8 +22742,Luxembourg,2014,6,N02-Analgesics,Million of national currency units,7.6 +22743,Luxembourg,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,3.1 +22744,Luxembourg,2014,6,N02-Analgesics,Million US$ at exchange rate,10.1 +22745,Luxembourg,2014,6,N02-Analgesics,% of total sales,4.0 +22746,Luxembourg,2014,6,R-Respiratory system,"/capita, US$ exchange rate",38.4 +22747,Luxembourg,2014,6,R-Respiratory system,% of total sales,7.7 +22748,Luxembourg,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",32.7 +22749,Luxembourg,2014,6,R-Respiratory system,"Million US$, purchasing power parity",16.7 +22750,Luxembourg,2014,6,R-Respiratory system,Million of national currency units,14.8 +22751,Luxembourg,2014,6,R-Respiratory system,Million US$ at exchange rate,19.6 +22752,Luxembourg,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",13.4 +22753,Luxembourg,2014,6,B-Blood and blood forming organs,Million of national currency units,11.9 +22754,Luxembourg,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.8 +22755,Luxembourg,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,15.7 +22756,Luxembourg,2014,6,B-Blood and blood forming organs,% of total sales,6.2 +22757,Luxembourg,2014,6,C02-Antihypertensives,% of total sales,0.2 +22758,Luxembourg,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2 +22759,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8 +22760,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.8 +22761,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8 +22762,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3 +22763,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.1 +22764,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.0 +22765,Luxembourg,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +22766,Luxembourg,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +22767,Luxembourg,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0 +22768,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0 +22769,Luxembourg,2014,6,M-Musculo-skeletal system,% of total sales,5.6 +22770,Luxembourg,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.7 +22771,Luxembourg,2014,6,J-Antiinfectives for systemic use,% of total sales,4.9 +22772,Luxembourg,2014,6,C10-Lipid modifying agents,% of total sales,6.9 +22773,Luxembourg,2014,6,M-Musculo-skeletal system,Million of national currency units,10.7 +22774,Luxembourg,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.9 +22775,Luxembourg,2014,6,C01A-Cardiac glycosides,Million of national currency units,0.0 +22776,Luxembourg,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,14.2 +22777,Luxembourg,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.1 +22778,Luxembourg,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +22779,Luxembourg,2014,6,C03-Diuretics,Million of national currency units,1.7 +22780,Luxembourg,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,17.4 +22781,Luxembourg,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.8 +22782,Luxembourg,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.3 +22783,Luxembourg,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +22784,Luxembourg,2014,6,C03-Diuretics,Million US$ at exchange rate,2.2 +22785,Luxembourg,2014,6,C03-Diuretics,"Million US$, purchasing power parity",1.9 +22786,Luxembourg,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +22787,Luxembourg,2014,6,C02-Antihypertensives,Million of national currency units,0.4 +22788,Luxembourg,2014,6,C02-Antihypertensives,Million US$ at exchange rate,0.6 +22789,Luxembourg,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",34.1 +22790,Luxembourg,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",1.1 +22791,Luxembourg,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.1 +22792,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +22793,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +22794,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +22795,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +22796,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +22797,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +22798,Luxembourg,2014,6,J-Antiinfectives for systemic use,Million of national currency units,9.4 +22799,Luxembourg,2014,6,C03-Diuretics,% of total sales,0.9 +22800,Luxembourg,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,12.5 +22801,Luxembourg,2014,6,C10-Lipid modifying agents,Million of national currency units,13.1 +22802,Luxembourg,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.6 +22803,Luxembourg,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.9 +22804,Luxembourg,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.7 +22805,Luxembourg,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.7 +22806,Luxembourg,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.9 +22807,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.6 +22808,Luxembourg,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +22809,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +22810,Luxembourg,2014,6,C01A-Cardiac glycosides,% of total sales,0.0 +22811,Luxembourg,2014,6,J01-Antibacterials for systemic use,Million of national currency units,6.0 +22812,Luxembourg,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.5 +22813,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.4 +22814,Luxembourg,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.2 +22815,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.9 +22816,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9 +22817,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.5 +22818,Luxembourg,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.7 +22819,Luxembourg,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.0 +22820,Luxembourg,2014,6,A10-Drugs used in diabetes,% of total sales,7.2 +22821,Luxembourg,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,18.4 +22822,Luxembourg,2014,6,A10-Drugs used in diabetes,Million of national currency units,13.8 +22823,Luxembourg,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",15.7 +22824,Luxembourg,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,8.2 +22825,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.4 +22826,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.3 +22827,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.2 +22828,Luxembourg,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.9 +22829,Luxembourg,2014,6,C-Cardiovascular system,% of total sales,17.9 +22830,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.9 +22831,Luxembourg,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0 +22832,Luxembourg,2014,6,C07-Beta blocking agents,% of total sales,1.9 +22833,Luxembourg,2014,6,C08-Calcium channel blockers,% of total sales,1.1 +22834,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.1 +22835,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.4 +22836,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.6 +22837,Luxembourg,2014,6,C07-Beta blocking agents,Million of national currency units,3.6 +22838,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.2 +22839,Luxembourg,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",9.4 +22840,Luxembourg,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1 +22841,Luxembourg,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,4.8 +22842,Luxembourg,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7 +22843,Luxembourg,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",38.7 +22844,Luxembourg,2014,6,C-Cardiovascular system,Million US$ at exchange rate,45.4 +22845,Luxembourg,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",88.9 +22846,Luxembourg,2014,6,G-Genito urinary system and sex hormones,% of total sales,4.3 +22847,Luxembourg,2014,6,J01-Antibacterials for systemic use,% of total sales,3.1 +22848,Luxembourg,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.7 +22849,Luxembourg,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,2.8 +22850,Luxembourg,2014,6,C-Cardiovascular system,Million of national currency units,34.2 +22851,Luxembourg,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.4 +22852,Luxembourg,2014,6,C08-Calcium channel blockers,Million of national currency units,2.1 +22853,Luxembourg,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5 +22854,Luxembourg,2013,6,N05B-Anxiolytics,Million of national currency units,2.3 +22855,Luxembourg,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,3.1 +22856,Luxembourg,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +22857,Luxembourg,2013,6,N05B-Anxiolytics,% of total sales,1.2 +22858,Luxembourg,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2 +22859,Luxembourg,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",6.2 +22860,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.6 +22861,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.9 +22862,Luxembourg,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +22863,Luxembourg,2013,6,A02A-Antacids,% of total sales,0.2 +22864,Luxembourg,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.8 +22865,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.6 +22866,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.4 +22867,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.9 +22868,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.8 +22869,Luxembourg,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.4 +22870,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,5.9 +22871,Luxembourg,2013,6,A02A-Antacids,Million US$ at exchange rate,0.4 +22872,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,11.4 +22873,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.2 +22874,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.0 +22875,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.7 +22876,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,15.2 +22877,Luxembourg,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.3 +22878,Luxembourg,2013,6,A-Alimentary tract and metabolism,% of total sales,16.2 +22879,Luxembourg,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,42.0 +22880,Luxembourg,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",83.6 +22881,Luxembourg,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",35.3 +22882,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.0 +22883,Luxembourg,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0 +22884,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4 +22885,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.7 +22886,Luxembourg,2013,6,N05C-Hypnotics and sedatives,% of total sales,1.6 +22887,Luxembourg,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",70.4 +22888,Luxembourg,2013,6,N-Nervous system,"/capita, US$ exchange rate",83.7 +22889,Luxembourg,2013,6,N-Nervous system,% of total sales,16.2 +22890,Luxembourg,2013,6,N-Nervous system,Million US$ at exchange rate,42.0 +22891,Luxembourg,2013,6,N-Nervous system,Million of national currency units,31.7 +22892,Luxembourg,2013,6,N-Nervous system,"Million US$, purchasing power parity",35.4 +22893,Luxembourg,2013,6,N06A-Antidepressants,Million US$ at exchange rate,8.7 +22894,Luxembourg,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",7.3 +22895,Luxembourg,2013,6,A-Alimentary tract and metabolism,Million of national currency units,31.6 +22896,Luxembourg,2013,6,N06A-Antidepressants,Million of national currency units,6.5 +22897,Luxembourg,2013,6,N06A-Antidepressants,% of total sales,3.3 +22898,Luxembourg,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.5 +22899,Luxembourg,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",17.3 +22900,Luxembourg,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,258.9 +22901,Luxembourg,2013,6,Total pharmaceutical sales,Million of national currency units,194.9 +22902,Luxembourg,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",217.7 +22903,Luxembourg,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",433.8 +22904,Luxembourg,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",515.8 +22905,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2 +22906,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.2 +22907,Luxembourg,2013,6,A02A-Antacids,Million of national currency units,0.3 +22908,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.2 +22909,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.7 +22910,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.9 +22911,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.3 +22912,Luxembourg,2013,6,N02-Analgesics,"/capita, US$ exchange rate",20.2 +22913,Luxembourg,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",17.0 +22914,Luxembourg,2013,6,N02-Analgesics,"Million US$, purchasing power parity",8.5 +22915,Luxembourg,2013,6,N02-Analgesics,Million of national currency units,7.6 +22916,Luxembourg,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,3.0 +22917,Luxembourg,2013,6,N02-Analgesics,Million US$ at exchange rate,10.1 +22918,Luxembourg,2013,6,N02-Analgesics,% of total sales,3.9 +22919,Luxembourg,2013,6,R-Respiratory system,"/capita, US$ exchange rate",41.4 +22920,Luxembourg,2013,6,R-Respiratory system,% of total sales,8.0 +22921,Luxembourg,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",34.8 +22922,Luxembourg,2013,6,R-Respiratory system,Million of national currency units,15.6 +22923,Luxembourg,2013,6,R-Respiratory system,"Million US$, purchasing power parity",17.5 +22924,Luxembourg,2013,6,R-Respiratory system,Million US$ at exchange rate,20.8 +22925,Luxembourg,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +22926,Luxembourg,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",12.1 +22927,Luxembourg,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",28.6 +22928,Luxembourg,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,14.4 +22929,Luxembourg,2013,6,B-Blood and blood forming organs,Million of national currency units,10.8 +22930,Luxembourg,2013,6,C02-Antihypertensives,% of total sales,0.2 +22931,Luxembourg,2013,6,B-Blood and blood forming organs,% of total sales,5.6 +22932,Luxembourg,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.1 +22933,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5 +22934,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6 +22935,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +22936,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.8 +22937,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.2 +22938,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8 +22939,Luxembourg,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +22940,Luxembourg,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +22941,Luxembourg,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +22942,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.8 +22943,Luxembourg,2013,6,M-Musculo-skeletal system,% of total sales,5.4 +22944,Luxembourg,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.4 +22945,Luxembourg,2013,6,J-Antiinfectives for systemic use,% of total sales,5.4 +22946,Luxembourg,2013,6,C10-Lipid modifying agents,% of total sales,8.0 +22947,Luxembourg,2013,6,M-Musculo-skeletal system,Million of national currency units,10.5 +22948,Luxembourg,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.8 +22949,Luxembourg,2013,6,C01A-Cardiac glycosides,Million of national currency units,0.1 +22950,Luxembourg,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,13.9 +22951,Luxembourg,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",11.7 +22952,Luxembourg,2013,6,C03-Diuretics,Million of national currency units,1.6 +22953,Luxembourg,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",17.4 +22954,Luxembourg,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,20.7 +22955,Luxembourg,2013,6,C03-Diuretics,Million US$ at exchange rate,2.2 +22956,Luxembourg,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.3 +22957,Luxembourg,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.6 +22958,Luxembourg,2013,6,C03-Diuretics,"Million US$, purchasing power parity",1.8 +22959,Luxembourg,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +22960,Luxembourg,2013,6,C02-Antihypertensives,Million of national currency units,0.4 +22961,Luxembourg,2013,6,C02-Antihypertensives,Million US$ at exchange rate,0.5 +22962,Luxembourg,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",1.1 +22963,Luxembourg,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.3 +22964,Luxembourg,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.7 +22965,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +22966,Luxembourg,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9 +22967,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +22968,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +22969,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +22970,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +22971,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +22972,Luxembourg,2013,6,J-Antiinfectives for systemic use,Million of national currency units,10.4 +22973,Luxembourg,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,13.9 +22974,Luxembourg,2013,6,C10-Lipid modifying agents,Million of national currency units,15.6 +22975,Luxembourg,2013,6,C03-Diuretics,% of total sales,0.8 +22976,Luxembourg,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.6 +22977,Luxembourg,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.2 +22978,Luxembourg,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.7 +22979,Luxembourg,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.0 +22980,Luxembourg,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.4 +22981,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.4 +22982,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +22983,Luxembourg,2013,6,C01A-Cardiac glycosides,% of total sales,0.0 +22984,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.3 +22985,Luxembourg,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.0 +22986,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.8 +22987,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.7 +22988,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.4 +22989,Luxembourg,2013,6,J01-Antibacterials for systemic use,Million of national currency units,6.3 +22990,Luxembourg,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.9 +22991,Luxembourg,2013,6,A10-Drugs used in diabetes,% of total sales,6.2 +22992,Luxembourg,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0 +22993,Luxembourg,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,16.1 +22994,Luxembourg,2013,6,A10-Drugs used in diabetes,Million of national currency units,12.1 +22995,Luxembourg,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",13.5 +22996,Luxembourg,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,8.0 +22997,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.2 +22998,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.0 +22999,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",17.9 +23000,Luxembourg,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.7 +23001,Luxembourg,2013,6,C-Cardiovascular system,% of total sales,19.8 +23002,Luxembourg,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.6 +23003,Luxembourg,2013,6,J01-Antibacterials for systemic use,% of total sales,3.2 +23004,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",14.8 +23005,Luxembourg,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1 +23006,Luxembourg,2013,6,C07-Beta blocking agents,% of total sales,1.9 +23007,Luxembourg,2013,6,C08-Calcium channel blockers,% of total sales,1.2 +23008,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,17.6 +23009,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,13.3 +23010,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.1 +23011,Luxembourg,2013,6,C07-Beta blocking agents,Million of national currency units,3.7 +23012,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.5 +23013,Luxembourg,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",9.7 +23014,Luxembourg,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,4.9 +23015,Luxembourg,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1 +23016,Luxembourg,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",43.2 +23017,Luxembourg,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",102.4 +23018,Luxembourg,2013,6,C-Cardiovascular system,Million US$ at exchange rate,51.4 +23019,Luxembourg,2013,6,G-Genito urinary system and sex hormones,% of total sales,4.1 +23020,Luxembourg,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",86.1 +23021,Luxembourg,2013,6,C-Cardiovascular system,Million of national currency units,38.7 +23022,Luxembourg,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,3.0 +23023,Luxembourg,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.5 +23024,Luxembourg,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0 +23025,Luxembourg,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.0 +23026,Luxembourg,2013,6,C08-Calcium channel blockers,Million of national currency units,2.3 +23027,Luxembourg,2012,7,N05B-Anxiolytics,Million of national currency units,2.3 +23028,Luxembourg,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +23029,Luxembourg,2012,7,N05B-Anxiolytics,% of total sales,1.2 +23030,Luxembourg,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",6.1 +23031,Luxembourg,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2 +23032,Luxembourg,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +23033,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.8 +23034,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.6 +23035,Luxembourg,2012,7,A02A-Antacids,% of total sales,0.2 +23036,Luxembourg,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.9 +23037,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5 +23038,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.0 +23039,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.2 +23040,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.8 +23041,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,5.7 +23042,Luxembourg,2012,7,A02A-Antacids,Million US$ at exchange rate,0.4 +23043,Luxembourg,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.4 +23044,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.2 +23045,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.6 +23046,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.3 +23047,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,11.2 +23048,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.4 +23049,Luxembourg,2012,7,R-Respiratory system,"Million US$, purchasing power parity",16.7 +23050,Luxembourg,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.9 +23051,Luxembourg,2012,7,A-Alimentary tract and metabolism,% of total sales,15.3 +23052,Luxembourg,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.4 +23053,Luxembourg,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",78.0 +23054,Luxembourg,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",33.0 +23055,Luxembourg,2012,7,N05C-Hypnotics and sedatives,% of total sales,1.5 +23056,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.8 +23057,Luxembourg,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9 +23058,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3 +23059,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.7 +23060,Luxembourg,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",73.6 +23061,Luxembourg,2012,7,N-Nervous system,% of total sales,16.8 +23062,Luxembourg,2012,7,N-Nervous system,"/capita, US$ exchange rate",85.7 +23063,Luxembourg,2012,7,N-Nervous system,Million US$ at exchange rate,42.2 +23064,Luxembourg,2012,7,N-Nervous system,Million of national currency units,32.9 +23065,Luxembourg,2012,7,N-Nervous system,"Million US$, purchasing power parity",36.2 +23066,Luxembourg,2012,7,N06A-Antidepressants,Million US$ at exchange rate,8.6 +23067,Luxembourg,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",7.4 +23068,Luxembourg,2012,7,A-Alimentary tract and metabolism,Million of national currency units,29.9 +23069,Luxembourg,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0 +23070,Luxembourg,2012,7,N06A-Antidepressants,Million of national currency units,6.7 +23071,Luxembourg,2012,7,N06A-Antidepressants,% of total sales,3.4 +23072,Luxembourg,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.1 +23073,Luxembourg,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",17.6 +23074,Luxembourg,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,251.5 +23075,Luxembourg,2012,7,Total pharmaceutical sales,Million of national currency units,195.8 +23076,Luxembourg,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",215.9 +23077,Luxembourg,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",438.3 +23078,Luxembourg,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",510.7 +23079,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1 +23080,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.7 +23081,Luxembourg,2012,7,A02A-Antacids,Million of national currency units,0.3 +23082,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.0 +23083,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.4 +23084,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.6 +23085,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.7 +23086,Luxembourg,2012,7,N02-Analgesics,"/capita, US$ exchange rate",19.5 +23087,Luxembourg,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",16.7 +23088,Luxembourg,2012,7,N02-Analgesics,"Million US$, purchasing power parity",8.2 +23089,Luxembourg,2012,7,N02-Analgesics,Million of national currency units,7.5 +23090,Luxembourg,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,3.0 +23091,Luxembourg,2012,7,N02-Analgesics,Million US$ at exchange rate,9.6 +23092,Luxembourg,2012,7,N02-Analgesics,% of total sales,3.8 +23093,Luxembourg,2012,7,R-Respiratory system,"/capita, US$ exchange rate",39.4 +23094,Luxembourg,2012,7,R-Respiratory system,% of total sales,7.7 +23095,Luxembourg,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",33.9 +23096,Luxembourg,2012,7,R-Respiratory system,Million of national currency units,15.1 +23097,Luxembourg,2012,7,R-Respiratory system,Million US$ at exchange rate,19.4 +23098,Luxembourg,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.1 +23099,Luxembourg,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.2 +23100,Luxembourg,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,12.9 +23101,Luxembourg,2012,7,C02-Antihypertensives,% of total sales,0.2 +23102,Luxembourg,2012,7,B-Blood and blood forming organs,% of total sales,5.1 +23103,Luxembourg,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.5 +23104,Luxembourg,2012,7,B-Blood and blood forming organs,Million of national currency units,10.1 +23105,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9 +23106,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +23107,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.7 +23108,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.2 +23109,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.9 +23110,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.3 +23111,Luxembourg,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +23112,Luxembourg,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +23113,Luxembourg,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +23114,Luxembourg,2012,7,M-Musculo-skeletal system,% of total sales,5.0 +23115,Luxembourg,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.9 +23116,Luxembourg,2012,7,J-Antiinfectives for systemic use,% of total sales,5.6 +23117,Luxembourg,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +23118,Luxembourg,2012,7,M-Musculo-skeletal system,Million of national currency units,9.8 +23119,Luxembourg,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.6 +23120,Luxembourg,2012,7,C01A-Cardiac glycosides,Million of national currency units,0.1 +23121,Luxembourg,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,12.6 +23122,Luxembourg,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.8 +23123,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.4 +23124,Luxembourg,2012,7,C03-Diuretics,Million of national currency units,1.6 +23125,Luxembourg,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",19.3 +23126,Luxembourg,2012,7,C03-Diuretics,Million US$ at exchange rate,2.0 +23127,Luxembourg,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,22.4 +23128,Luxembourg,2012,7,C03-Diuretics,"/capita, US$ exchange rate",4.1 +23129,Luxembourg,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",3.5 +23130,Luxembourg,2012,7,C03-Diuretics,"Million US$, purchasing power parity",1.7 +23131,Luxembourg,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",0.4 +23132,Luxembourg,2012,7,C02-Antihypertensives,Million of national currency units,0.4 +23133,Luxembourg,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.0 +23134,Luxembourg,2012,7,C02-Antihypertensives,Million US$ at exchange rate,0.5 +23135,Luxembourg,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.5 +23136,Luxembourg,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",39.1 +23137,Luxembourg,2012,7,C10-Lipid modifying agents,% of total sales,8.9 +23138,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +23139,Luxembourg,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9 +23140,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +23141,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5 +23142,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7 +23143,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +23144,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +23145,Luxembourg,2012,7,J-Antiinfectives for systemic use,Million of national currency units,11.1 +23146,Luxembourg,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.2 +23147,Luxembourg,2012,7,C10-Lipid modifying agents,Million of national currency units,17.5 +23148,Luxembourg,2012,7,C03-Diuretics,% of total sales,0.8 +23149,Luxembourg,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.8 +23150,Luxembourg,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.8 +23151,Luxembourg,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",12.2 +23152,Luxembourg,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.1 +23153,Luxembourg,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.3 +23154,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.9 +23155,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +23156,Luxembourg,2012,7,C01A-Cardiac glycosides,% of total sales,0.0 +23157,Luxembourg,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.9 +23158,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.5 +23159,Luxembourg,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.5 +23160,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.2 +23161,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9 +23162,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.5 +23163,Luxembourg,2012,7,J01-Antibacterials for systemic use,Million of national currency units,6.5 +23164,Luxembourg,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.7 +23165,Luxembourg,2012,7,A10-Drugs used in diabetes,% of total sales,5.6 +23166,Luxembourg,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",28.8 +23167,Luxembourg,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,14.2 +23168,Luxembourg,2012,7,A10-Drugs used in diabetes,Million of national currency units,11.0 +23169,Luxembourg,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.2 +23170,Luxembourg,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,8.1 +23171,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.0 +23172,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.0 +23173,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",8.9 +23174,Luxembourg,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.3 +23175,Luxembourg,2012,7,C-Cardiovascular system,% of total sales,21.3 +23176,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",15.9 +23177,Luxembourg,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9 +23178,Luxembourg,2012,7,C07-Beta blocking agents,% of total sales,1.8 +23179,Luxembourg,2012,7,C08-Calcium channel blockers,% of total sales,1.2 +23180,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,18.6 +23181,Luxembourg,2012,7,J01-Antibacterials for systemic use,% of total sales,3.3 +23182,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.4 +23183,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.7 +23184,Luxembourg,2012,7,C07-Beta blocking agents,Million of national currency units,3.5 +23185,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",32.3 +23186,Luxembourg,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",9.2 +23187,Luxembourg,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",3.9 +23188,Luxembourg,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,4.5 +23189,Luxembourg,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",46.0 +23190,Luxembourg,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",108.8 +23191,Luxembourg,2012,7,C-Cardiovascular system,Million US$ at exchange rate,53.6 +23192,Luxembourg,2012,7,G-Genito urinary system and sex hormones,% of total sales,4.1 +23193,Luxembourg,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.4 +23194,Luxembourg,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,3.1 +23195,Luxembourg,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.6 +23196,Luxembourg,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4 +23197,Luxembourg,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.2 +23198,Luxembourg,2012,7,C-Cardiovascular system,Million of national currency units,41.7 +23199,Luxembourg,2012,7,C08-Calcium channel blockers,Million of national currency units,2.4 +23200,Luxembourg,2011,8,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +23201,Luxembourg,2011,8,N05B-Anxiolytics,Million of national currency units,2.4 +23202,Luxembourg,2011,8,N05B-Anxiolytics,% of total sales,1.3 +23203,Luxembourg,2011,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5 +23204,Luxembourg,2011,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9 +23205,Luxembourg,2011,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +23206,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.0 +23207,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.8 +23208,Luxembourg,2011,8,A02A-Antacids,% of total sales,0.2 +23209,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,% of total sales,5.8 +23210,Luxembourg,2011,8,A02A-Antacids,"/capita, US$ exchange rate",0.9 +23211,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5 +23212,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.1 +23213,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,12.0 +23214,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.6 +23215,Luxembourg,2011,8,A02A-Antacids,"Million US$, purchasing power parity",0.3 +23216,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,Million of national currency units,11.0 +23217,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.6 +23218,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.5 +23219,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,15.2 +23220,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.1 +23221,Luxembourg,2011,8,N-Nervous system,Million of national currency units,33.5 +23222,Luxembourg,2011,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.1 +23223,Luxembourg,2011,8,A-Alimentary tract and metabolism,% of total sales,14.9 +23224,Luxembourg,2011,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,39.5 +23225,Luxembourg,2011,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",31.4 +23226,Luxembourg,2011,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",82.0 +23227,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.7 +23228,Luxembourg,2011,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.2 +23229,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3 +23230,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.9 +23231,Luxembourg,2011,8,N05C-Hypnotics and sedatives,% of total sales,1.6 +23232,Luxembourg,2011,8,N-Nervous system,"/capita, US$ purchasing power parity",76.8 +23233,Luxembourg,2011,8,N-Nervous system,% of total sales,17.6 +23234,Luxembourg,2011,8,N-Nervous system,"/capita, US$ exchange rate",96.8 +23235,Luxembourg,2011,8,N-Nervous system,Million US$ at exchange rate,46.6 +23236,Luxembourg,2011,8,N-Nervous system,"Million US$, purchasing power parity",37.0 +23237,Luxembourg,2011,8,N06A-Antidepressants,"Million US$, purchasing power parity",7.5 +23238,Luxembourg,2011,8,N06A-Antidepressants,Million US$ at exchange rate,9.5 +23239,Luxembourg,2011,8,A-Alimentary tract and metabolism,Million of national currency units,28.4 +23240,Luxembourg,2011,8,N06A-Antidepressants,Million of national currency units,6.8 +23241,Luxembourg,2011,8,N06A-Antidepressants,% of total sales,3.6 +23242,Luxembourg,2011,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.6 +23243,Luxembourg,2011,8,N06A-Antidepressants,"/capita, US$ exchange rate",19.6 +23244,Luxembourg,2011,8,Total pharmaceutical sales,Million US$ at exchange rate,265.0 +23245,Luxembourg,2011,8,Total pharmaceutical sales,"Million US$, purchasing power parity",210.4 +23246,Luxembourg,2011,8,Total pharmaceutical sales,Million of national currency units,190.4 +23247,Luxembourg,2011,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",436.5 +23248,Luxembourg,2011,8,Total pharmaceutical sales,"/capita, US$ exchange rate",549.9 +23249,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.9 +23250,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.7 +23251,Luxembourg,2011,8,A02A-Antacids,Million of national currency units,0.3 +23252,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5 +23253,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.1 +23254,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6 +23255,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.9 +23256,Luxembourg,2011,8,A02A-Antacids,Million US$ at exchange rate,0.4 +23257,Luxembourg,2011,8,N02-Analgesics,"/capita, US$ exchange rate",21.0 +23258,Luxembourg,2011,8,N02-Analgesics,% of total sales,3.8 +23259,Luxembourg,2011,8,N02-Analgesics,"/capita, US$ purchasing power parity",16.7 +23260,Luxembourg,2011,8,N02-Analgesics,"Million US$, purchasing power parity",8.0 +23261,Luxembourg,2011,8,N02-Analgesics,Million of national currency units,7.3 +23262,Luxembourg,2011,8,N05C-Hypnotics and sedatives,Million of national currency units,3.0 +23263,Luxembourg,2011,8,N02-Analgesics,Million US$ at exchange rate,10.1 +23264,Luxembourg,2011,8,R-Respiratory system,"/capita, US$ exchange rate",43.2 +23265,Luxembourg,2011,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.3 +23266,Luxembourg,2011,8,R-Respiratory system,% of total sales,7.9 +23267,Luxembourg,2011,8,R-Respiratory system,Million of national currency units,15.0 +23268,Luxembourg,2011,8,R-Respiratory system,"Million US$, purchasing power parity",16.5 +23269,Luxembourg,2011,8,R-Respiratory system,Million US$ at exchange rate,20.8 +23270,Luxembourg,2011,8,N05B-Anxiolytics,Million US$ at exchange rate,3.3 +23271,Luxembourg,2011,8,A10-Drugs used in diabetes,Million of national currency units,10.3 +23272,Luxembourg,2011,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",10.1 +23273,Luxembourg,2011,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.4 +23274,Luxembourg,2011,8,B-Blood and blood forming organs,Million US$ at exchange rate,12.7 +23275,Luxembourg,2011,8,C02-Antihypertensives,% of total sales,0.2 +23276,Luxembourg,2011,8,B-Blood and blood forming organs,% of total sales,4.8 +23277,Luxembourg,2011,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.0 +23278,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.9 +23279,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +23280,Luxembourg,2011,8,B-Blood and blood forming organs,Million of national currency units,9.2 +23281,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0 +23282,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.3 +23283,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.4 +23284,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.8 +23285,Luxembourg,2011,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +23286,Luxembourg,2011,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1 +23287,Luxembourg,2011,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1 +23288,Luxembourg,2011,8,C02-Antihypertensives,Million of national currency units,0.4 +23289,Luxembourg,2011,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.2 +23290,Luxembourg,2011,8,M-Musculo-skeletal system,% of total sales,4.8 +23291,Luxembourg,2011,8,J-Antiinfectives for systemic use,% of total sales,5.6 +23292,Luxembourg,2011,8,M-Musculo-skeletal system,Million of national currency units,9.2 +23293,Luxembourg,2011,8,M-Musculo-skeletal system,Million US$ at exchange rate,12.8 +23294,Luxembourg,2011,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",26.7 +23295,Luxembourg,2011,8,C01A-Cardiac glycosides,Million of national currency units,0.1 +23296,Luxembourg,2011,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.2 +23297,Luxembourg,2011,8,C03-Diuretics,Million of national currency units,1.6 +23298,Luxembourg,2011,8,C03-Diuretics,Million US$ at exchange rate,2.3 +23299,Luxembourg,2011,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",19.3 +23300,Luxembourg,2011,8,C10-Lipid modifying agents,Million US$ at exchange rate,24.3 +23301,Luxembourg,2011,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +23302,Luxembourg,2011,8,C03-Diuretics,"/capita, US$ exchange rate",4.7 +23303,Luxembourg,2011,8,C03-Diuretics,"Million US$, purchasing power parity",1.8 +23304,Luxembourg,2011,8,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +23305,Luxembourg,2011,8,C02-Antihypertensives,"/capita, US$ exchange rate",1.2 +23306,Luxembourg,2011,8,C02-Antihypertensives,Million US$ at exchange rate,0.6 +23307,Luxembourg,2011,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",50.3 +23308,Luxembourg,2011,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",40.0 +23309,Luxembourg,2011,8,C10-Lipid modifying agents,% of total sales,9.2 +23310,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +23311,Luxembourg,2011,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +23312,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +23313,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8 +23314,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +23315,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6 +23316,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +23317,Luxembourg,2011,8,J-Antiinfectives for systemic use,Million of national currency units,10.6 +23318,Luxembourg,2011,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.8 +23319,Luxembourg,2011,8,C10-Lipid modifying agents,Million of national currency units,17.4 +23320,Luxembourg,2011,8,C03-Diuretics,% of total sales,0.9 +23321,Luxembourg,2011,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.3 +23322,Luxembourg,2011,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.7 +23323,Luxembourg,2011,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.6 +23324,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.7 +23325,Luxembourg,2011,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.5 +23326,Luxembourg,2011,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.5 +23327,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7 +23328,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.3 +23329,Luxembourg,2011,8,C01A-Cardiac glycosides,% of total sales,0.0 +23330,Luxembourg,2011,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.7 +23331,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,2.5 +23332,Luxembourg,2011,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.6 +23333,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.1 +23334,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.4 +23335,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",2.7 +23336,Luxembourg,2011,8,J01-Antibacterials for systemic use,Million of national currency units,6.8 +23337,Luxembourg,2011,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.6 +23338,Luxembourg,2011,8,A10-Drugs used in diabetes,% of total sales,5.4 +23339,Luxembourg,2011,8,G-Genito urinary system and sex hormones,Million of national currency units,6.8 +23340,Luxembourg,2011,8,A10-Drugs used in diabetes,Million US$ at exchange rate,14.4 +23341,Luxembourg,2011,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",11.4 +23342,Luxembourg,2011,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.8 +23343,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.7 +23344,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.6 +23345,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",7.5 +23346,Luxembourg,2011,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.5 +23347,Luxembourg,2011,8,C-Cardiovascular system,% of total sales,22.0 +23348,Luxembourg,2011,8,J01-Antibacterials for systemic use,% of total sales,3.6 +23349,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",16.1 +23350,Luxembourg,2011,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6 +23351,Luxembourg,2011,8,C07-Beta blocking agents,% of total sales,1.7 +23352,Luxembourg,2011,8,C08-Calcium channel blockers,% of total sales,1.4 +23353,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.6 +23354,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.3 +23355,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",42.2 +23356,Luxembourg,2011,8,C07-Beta blocking agents,Million of national currency units,3.3 +23357,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",33.5 +23358,Luxembourg,2011,8,C07-Beta blocking agents,"/capita, US$ exchange rate",9.6 +23359,Luxembourg,2011,8,C07-Beta blocking agents,Million US$ at exchange rate,4.6 +23360,Luxembourg,2011,8,C07-Beta blocking agents,"Million US$, purchasing power parity",3.7 +23361,Luxembourg,2011,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +23362,Luxembourg,2011,8,C-Cardiovascular system,"Million US$, purchasing power parity",46.3 +23363,Luxembourg,2011,8,C-Cardiovascular system,"/capita, US$ exchange rate",121.2 +23364,Luxembourg,2011,8,C-Cardiovascular system,Million US$ at exchange rate,58.4 +23365,Luxembourg,2011,8,G-Genito urinary system and sex hormones,% of total sales,3.6 +23366,Luxembourg,2011,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.2 +23367,Luxembourg,2011,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.9 +23368,Luxembourg,2011,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.9 +23369,Luxembourg,2011,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.5 +23370,Luxembourg,2011,8,C08-Calcium channel blockers,Million US$ at exchange rate,3.6 +23371,Luxembourg,2011,8,C-Cardiovascular system,Million of national currency units,42.0 +23372,Luxembourg,2011,8,C08-Calcium channel blockers,Million of national currency units,2.6 +23373,Luxembourg,2010,8,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6 +23374,Luxembourg,2010,8,N05B-Anxiolytics,Million of national currency units,2.4 +23375,Luxembourg,2010,8,N05B-Anxiolytics,Million US$ at exchange rate,3.2 +23376,Luxembourg,2010,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.7 +23377,Luxembourg,2010,8,N05B-Anxiolytics,% of total sales,1.3 +23378,Luxembourg,2010,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5 +23379,Luxembourg,2010,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +23380,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.1 +23381,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.6 +23382,Luxembourg,2010,8,A02A-Antacids,% of total sales,0.1 +23383,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,% of total sales,5.6 +23384,Luxembourg,2010,8,A02A-Antacids,"/capita, US$ exchange rate",0.8 +23385,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.6 +23386,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.3 +23387,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,14.0 +23388,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.6 +23389,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,Million of national currency units,10.7 +23390,Luxembourg,2010,8,A02A-Antacids,"Million US$, purchasing power parity",0.3 +23391,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8 +23392,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",11.4 +23393,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.1 +23394,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.5 +23395,Luxembourg,2010,8,A02A-Antacids,Million US$ at exchange rate,0.4 +23396,Luxembourg,2010,8,A-Alimentary tract and metabolism,% of total sales,15.1 +23397,Luxembourg,2010,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.1 +23398,Luxembourg,2010,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,37.8 +23399,Luxembourg,2010,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",30.8 +23400,Luxembourg,2010,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9 +23401,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.4 +23402,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2 +23403,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.8 +23404,Luxembourg,2010,8,N05C-Hypnotics and sedatives,% of total sales,1.6 +23405,Luxembourg,2010,8,N-Nervous system,"/capita, US$ purchasing power parity",74.7 +23406,Luxembourg,2010,8,N-Nervous system,% of total sales,17.3 +23407,Luxembourg,2010,8,N-Nervous system,"/capita, US$ exchange rate",91.7 +23408,Luxembourg,2010,8,N-Nervous system,Million US$ at exchange rate,43.4 +23409,Luxembourg,2010,8,N-Nervous system,"Million US$, purchasing power parity",35.3 +23410,Luxembourg,2010,8,N06A-Antidepressants,"Million US$, purchasing power parity",7.6 +23411,Luxembourg,2010,8,N06A-Antidepressants,Million US$ at exchange rate,9.4 +23412,Luxembourg,2010,8,A-Alimentary tract and metabolism,Million of national currency units,28.5 +23413,Luxembourg,2010,8,N06A-Antidepressants,Million of national currency units,7.1 +23414,Luxembourg,2010,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0 +23415,Luxembourg,2010,8,N06A-Antidepressants,% of total sales,3.7 +23416,Luxembourg,2010,8,N06A-Antidepressants,"/capita, US$ exchange rate",19.8 +23417,Luxembourg,2010,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2 +23418,Luxembourg,2010,8,Total pharmaceutical sales,Million US$ at exchange rate,251.1 +23419,Luxembourg,2010,8,Total pharmaceutical sales,"Million US$, purchasing power parity",204.6 +23420,Luxembourg,2010,8,Total pharmaceutical sales,Million of national currency units,189.4 +23421,Luxembourg,2010,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",432.5 +23422,Luxembourg,2010,8,Total pharmaceutical sales,"/capita, US$ exchange rate",530.7 +23423,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.9 +23424,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.3 +23425,Luxembourg,2010,8,A02A-Antacids,Million of national currency units,0.3 +23426,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5 +23427,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6 +23428,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.5 +23429,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.0 +23430,Luxembourg,2010,8,N02-Analgesics,"/capita, US$ exchange rate",19.1 +23431,Luxembourg,2010,8,N02-Analgesics,% of total sales,3.6 +23432,Luxembourg,2010,8,N02-Analgesics,"/capita, US$ purchasing power parity",15.6 +23433,Luxembourg,2010,8,N02-Analgesics,Million of national currency units,6.8 +23434,Luxembourg,2010,8,N05C-Hypnotics and sedatives,Million of national currency units,3.0 +23435,Luxembourg,2010,8,N02-Analgesics,"Million US$, purchasing power parity",7.4 +23436,Luxembourg,2010,8,N02-Analgesics,Million US$ at exchange rate,9.0 +23437,Luxembourg,2010,8,R-Respiratory system,"/capita, US$ exchange rate",42.9 +23438,Luxembourg,2010,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.9 +23439,Luxembourg,2010,8,R-Respiratory system,% of total sales,8.1 +23440,Luxembourg,2010,8,R-Respiratory system,Million of national currency units,15.3 +23441,Luxembourg,2010,8,N-Nervous system,Million of national currency units,32.7 +23442,Luxembourg,2010,8,R-Respiratory system,"Million US$, purchasing power parity",16.5 +23443,Luxembourg,2010,8,R-Respiratory system,Million US$ at exchange rate,20.3 +23444,Luxembourg,2010,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",10.4 +23445,Luxembourg,2010,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.9 +23446,Luxembourg,2010,8,B-Blood and blood forming organs,Million US$ at exchange rate,12.7 +23447,Luxembourg,2010,8,C02-Antihypertensives,% of total sales,0.2 +23448,Luxembourg,2010,8,B-Blood and blood forming organs,% of total sales,5.1 +23449,Luxembourg,2010,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.9 +23450,Luxembourg,2010,8,B-Blood and blood forming organs,Million of national currency units,9.6 +23451,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.4 +23452,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +23453,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.5 +23454,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4 +23455,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.1 +23456,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.4 +23457,Luxembourg,2010,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +23458,Luxembourg,2010,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +23459,Luxembourg,2010,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0 +23460,Luxembourg,2010,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.0 +23461,Luxembourg,2010,8,M-Musculo-skeletal system,% of total sales,5.1 +23462,Luxembourg,2010,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0 +23463,Luxembourg,2010,8,J-Antiinfectives for systemic use,% of total sales,5.6 +23464,Luxembourg,2010,8,M-Musculo-skeletal system,Million of national currency units,9.7 +23465,Luxembourg,2010,8,M-Musculo-skeletal system,Million US$ at exchange rate,12.8 +23466,Luxembourg,2010,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.0 +23467,Luxembourg,2010,8,C01A-Cardiac glycosides,Million of national currency units,0.0 +23468,Luxembourg,2010,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.4 +23469,Luxembourg,2010,8,C03-Diuretics,Million of national currency units,1.7 +23470,Luxembourg,2010,8,C03-Diuretics,Million US$ at exchange rate,2.3 +23471,Luxembourg,2010,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",17.1 +23472,Luxembourg,2010,8,C10-Lipid modifying agents,Million US$ at exchange rate,21.0 +23473,Luxembourg,2010,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.9 +23474,Luxembourg,2010,8,C03-Diuretics,"/capita, US$ exchange rate",4.8 +23475,Luxembourg,2010,8,C03-Diuretics,"Million US$, purchasing power parity",1.8 +23476,Luxembourg,2010,8,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +23477,Luxembourg,2010,8,C02-Antihypertensives,"/capita, US$ exchange rate",1.3 +23478,Luxembourg,2010,8,C02-Antihypertensives,Million US$ at exchange rate,0.6 +23479,Luxembourg,2010,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",44.4 +23480,Luxembourg,2010,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",36.1 +23481,Luxembourg,2010,8,C10-Lipid modifying agents,% of total sales,8.4 +23482,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3 +23483,Luxembourg,2010,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +23484,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +23485,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6 +23486,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7 +23487,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6 +23488,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +23489,Luxembourg,2010,8,J-Antiinfectives for systemic use,Million of national currency units,10.7 +23490,Luxembourg,2010,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.1 +23491,Luxembourg,2010,8,C10-Lipid modifying agents,Million of national currency units,15.8 +23492,Luxembourg,2010,8,C03-Diuretics,% of total sales,0.9 +23493,Luxembourg,2010,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.3 +23494,Luxembourg,2010,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",29.8 +23495,Luxembourg,2010,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.5 +23496,Luxembourg,2010,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.7 +23497,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.5 +23498,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.3 +23499,Luxembourg,2010,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4 +23500,Luxembourg,2010,8,C01A-Cardiac glycosides,% of total sales,0.0 +23501,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9 +23502,Luxembourg,2010,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.9 +23503,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,2.4 +23504,Luxembourg,2010,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",16.2 +23505,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8 +23506,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.2 +23507,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",2.6 +23508,Luxembourg,2010,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.9 +23509,Luxembourg,2010,8,G-Genito urinary system and sex hormones,Million of national currency units,6.8 +23510,Luxembourg,2010,8,A10-Drugs used in diabetes,Million of national currency units,9.1 +23511,Luxembourg,2010,8,A10-Drugs used in diabetes,% of total sales,4.8 +23512,Luxembourg,2010,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.6 +23513,Luxembourg,2010,8,A10-Drugs used in diabetes,Million US$ at exchange rate,12.1 +23514,Luxembourg,2010,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",9.9 +23515,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.1 +23516,Luxembourg,2010,8,J01-Antibacterials for systemic use,Million of national currency units,7.1 +23517,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.5 +23518,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",7.3 +23519,Luxembourg,2010,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.0 +23520,Luxembourg,2010,8,C-Cardiovascular system,% of total sales,21.7 +23521,Luxembourg,2010,8,J01-Antibacterials for systemic use,% of total sales,3.7 +23522,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",16.1 +23523,Luxembourg,2010,8,C07-Beta blocking agents,% of total sales,1.8 +23524,Luxembourg,2010,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8 +23525,Luxembourg,2010,8,C08-Calcium channel blockers,% of total sales,1.5 +23526,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.9 +23527,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,19.8 +23528,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",41.8 +23529,Luxembourg,2010,8,C07-Beta blocking agents,Million of national currency units,3.4 +23530,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.0 +23531,Luxembourg,2010,8,C07-Beta blocking agents,"/capita, US$ exchange rate",9.6 +23532,Luxembourg,2010,8,C07-Beta blocking agents,Million US$ at exchange rate,4.5 +23533,Luxembourg,2010,8,C07-Beta blocking agents,"Million US$, purchasing power parity",3.7 +23534,Luxembourg,2010,8,C-Cardiovascular system,"Million US$, purchasing power parity",44.4 +23535,Luxembourg,2010,8,C-Cardiovascular system,"/capita, US$ exchange rate",115.1 +23536,Luxembourg,2010,8,C-Cardiovascular system,Million US$ at exchange rate,54.4 +23537,Luxembourg,2010,8,G-Genito urinary system and sex hormones,% of total sales,3.6 +23538,Luxembourg,2010,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.8 +23539,Luxembourg,2010,8,C02-Antihypertensives,Million of national currency units,0.5 +23540,Luxembourg,2010,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",3.0 +23541,Luxembourg,2010,8,C08-Calcium channel blockers,Million US$ at exchange rate,3.6 +23542,Luxembourg,2010,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.3 +23543,Luxembourg,2010,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.7 +23544,Luxembourg,2010,8,C08-Calcium channel blockers,Million of national currency units,2.8 +23545,Luxembourg,2010,8,C-Cardiovascular system,Million of national currency units,41.1 +23546,Luxembourg,2017,5,N05B-Anxiolytics,Million of national currency units,2.6 +23547,Luxembourg,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,2.9 +23548,Luxembourg,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.6 +23549,Luxembourg,2017,5,N05B-Anxiolytics,% of total sales,1.3 +23550,Luxembourg,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",3.0 +23551,Luxembourg,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.4 +23552,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.8 +23553,Luxembourg,2017,5,A02A-Antacids,% of total sales,0.2 +23554,Luxembourg,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +23555,Luxembourg,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.8 +23556,Luxembourg,2017,5,A02A-Antacids,"Million US$, purchasing power parity",0.4 +23557,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.7 +23558,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.4 +23559,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6 +23560,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.3 +23561,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.0 +23562,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.9 +23563,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +23564,Luxembourg,2017,5,A02A-Antacids,Million US$ at exchange rate,0.4 +23565,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.1 +23566,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.9 +23567,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,9.4 +23568,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.6 +23569,Luxembourg,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.5 +23570,Luxembourg,2017,5,N05C-Hypnotics and sedatives,% of total sales,1.8 +23571,Luxembourg,2017,5,A-Alimentary tract and metabolism,% of total sales,18.2 +23572,Luxembourg,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",74.3 +23573,Luxembourg,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,39.8 +23574,Luxembourg,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",41.5 +23575,Luxembourg,2017,5,A-Alimentary tract and metabolism,Million of national currency units,35.2 +23576,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.0 +23577,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.2 +23578,Luxembourg,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9 +23579,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.5 +23580,Luxembourg,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",69.3 +23581,Luxembourg,2017,5,N-Nervous system,"/capita, US$ exchange rate",66.4 +23582,Luxembourg,2017,5,N-Nervous system,% of total sales,16.2 +23583,Luxembourg,2017,5,N-Nervous system,Million of national currency units,31.5 +23584,Luxembourg,2017,5,N-Nervous system,Million US$ at exchange rate,35.6 +23585,Luxembourg,2017,5,N-Nervous system,"Million US$, purchasing power parity",37.2 +23586,Luxembourg,2017,5,N06A-Antidepressants,Million US$ at exchange rate,5.8 +23587,Luxembourg,2017,5,N06A-Antidepressants,Million of national currency units,5.1 +23588,Luxembourg,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.0 +23589,Luxembourg,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.3 +23590,Luxembourg,2017,5,N06A-Antidepressants,% of total sales,2.6 +23591,Luxembourg,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8 +23592,Luxembourg,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,219.2 +23593,Luxembourg,2017,5,Total pharmaceutical sales,Million of national currency units,194.1 +23594,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8 +23595,Luxembourg,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",426.8 +23596,Luxembourg,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",228.8 +23597,Luxembourg,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",409.0 +23598,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5 +23599,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.2 +23600,Luxembourg,2017,5,A02A-Antacids,Million of national currency units,0.4 +23601,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.0 +23602,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5 +23603,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.4 +23604,Luxembourg,2017,5,N02-Analgesics,"/capita, US$ exchange rate",16.3 +23605,Luxembourg,2017,5,N02-Analgesics,"Million US$, purchasing power parity",9.1 +23606,Luxembourg,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",17.0 +23607,Luxembourg,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4 +23608,Luxembourg,2017,5,N02-Analgesics,Million of national currency units,7.7 +23609,Luxembourg,2017,5,N02-Analgesics,Million US$ at exchange rate,8.7 +23610,Luxembourg,2017,5,R-Respiratory system,"/capita, US$ exchange rate",27.7 +23611,Luxembourg,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",28.9 +23612,Luxembourg,2017,5,R-Respiratory system,"Million US$, purchasing power parity",15.5 +23613,Luxembourg,2017,5,R-Respiratory system,% of total sales,6.8 +23614,Luxembourg,2017,5,R-Respiratory system,Million of national currency units,13.2 +23615,Luxembourg,2017,5,N02-Analgesics,% of total sales,4.0 +23616,Luxembourg,2017,5,R-Respiratory system,Million US$ at exchange rate,14.9 +23617,Luxembourg,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",18.4 +23618,Luxembourg,2017,5,B-Blood and blood forming organs,Million of national currency units,15.6 +23619,Luxembourg,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,17.6 +23620,Luxembourg,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.9 +23621,Luxembourg,2017,5,B-Blood and blood forming organs,% of total sales,8.0 +23622,Luxembourg,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.4 +23623,Luxembourg,2017,5,C02-Antihypertensives,% of total sales,0.2 +23624,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7 +23625,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.3 +23626,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8 +23627,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3 +23628,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0 +23629,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.3 +23630,Luxembourg,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +23631,Luxembourg,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0 +23632,Luxembourg,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0 +23633,Luxembourg,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.5 +23634,Luxembourg,2017,5,M-Musculo-skeletal system,% of total sales,5.5 +23635,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.0 +23636,Luxembourg,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.5 +23637,Luxembourg,2017,5,J-Antiinfectives for systemic use,% of total sales,4.6 +23638,Luxembourg,2017,5,M-Musculo-skeletal system,Million of national currency units,10.7 +23639,Luxembourg,2017,5,C10-Lipid modifying agents,% of total sales,6.0 +23640,Luxembourg,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.0 +23641,Luxembourg,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0 +23642,Luxembourg,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.6 +23643,Luxembourg,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,12.1 +23644,Luxembourg,2017,5,C10-Lipid modifying agents,Million of national currency units,11.6 +23645,Luxembourg,2017,5,C03-Diuretics,Million of national currency units,1.4 +23646,Luxembourg,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,13.1 +23647,Luxembourg,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.0 +23648,Luxembourg,2017,5,C03-Diuretics,Million US$ at exchange rate,1.6 +23649,Luxembourg,2017,5,C03-Diuretics,"Million US$, purchasing power parity",1.7 +23650,Luxembourg,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",13.7 +23651,Luxembourg,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5 +23652,Luxembourg,2017,5,C02-Antihypertensives,Million US$ at exchange rate,0.5 +23653,Luxembourg,2017,5,C02-Antihypertensives,Million of national currency units,0.4 +23654,Luxembourg,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",24.5 +23655,Luxembourg,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9 +23656,Luxembourg,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.5 +23657,Luxembourg,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1 +23658,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +23659,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1 +23660,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +23661,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5 +23662,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6 +23663,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6 +23664,Luxembourg,2017,5,J-Antiinfectives for systemic use,Million of national currency units,8.9 +23665,Luxembourg,2017,5,C03-Diuretics,% of total sales,0.7 +23666,Luxembourg,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.0 +23667,Luxembourg,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.7 +23668,Luxembourg,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5 +23669,Luxembourg,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.4 +23670,Luxembourg,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.2 +23671,Luxembourg,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.4 +23672,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.0 +23673,Luxembourg,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +23674,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.9 +23675,Luxembourg,2017,5,J01-Antibacterials for systemic use,Million of national currency units,5.5 +23676,Luxembourg,2017,5,C01A-Cardiac glycosides,% of total sales,0.0 +23677,Luxembourg,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5 +23678,Luxembourg,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.0 +23679,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.6 +23680,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.3 +23681,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.7 +23682,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.1 +23683,Luxembourg,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.6 +23684,Luxembourg,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.0 +23685,Luxembourg,2017,5,A10-Drugs used in diabetes,% of total sales,8.8 +23686,Luxembourg,2017,5,A10-Drugs used in diabetes,Million of national currency units,17.1 +23687,Luxembourg,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,19.3 +23688,Luxembourg,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",20.1 +23689,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.4 +23690,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.7 +23691,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5 +23692,Luxembourg,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,8.9 +23693,Luxembourg,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.0 +23694,Luxembourg,2017,5,C-Cardiovascular system,% of total sales,15.6 +23695,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",11.5 +23696,Luxembourg,2017,5,C07-Beta blocking agents,% of total sales,1.8 +23697,Luxembourg,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9 +23698,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,11.0 +23699,Luxembourg,2017,5,C08-Calcium channel blockers,% of total sales,0.9 +23700,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,9.8 +23701,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.6 +23702,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.5 +23703,Luxembourg,2017,5,C07-Beta blocking agents,Million of national currency units,3.6 +23704,Luxembourg,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.2 +23705,Luxembourg,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.6 +23706,Luxembourg,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8 +23707,Luxembourg,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,4.1 +23708,Luxembourg,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",35.6 +23709,Luxembourg,2017,5,C-Cardiovascular system,Million of national currency units,30.2 +23710,Luxembourg,2017,5,C-Cardiovascular system,Million US$ at exchange rate,34.2 +23711,Luxembourg,2017,5,G-Genito urinary system and sex hormones,% of total sales,4.6 +23712,Luxembourg,2017,5,J01-Antibacterials for systemic use,% of total sales,2.8 +23713,Luxembourg,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",63.7 +23714,Luxembourg,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.5 +23715,Luxembourg,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0 +23716,Luxembourg,2017,5,C08-Calcium channel blockers,Million of national currency units,1.7 +23717,Luxembourg,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6 +23718,Luxembourg,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.0 +23719,Mexico,2016,34,M-Musculo-skeletal system,Million of national currency units,2604.0 +23720,Mexico,2016,34,R-Respiratory system,Million of national currency units,6149.0 +23721,Mexico,2016,34,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.1 +23722,Mexico,2016,34,M-Musculo-skeletal system,Million US$ at exchange rate,139.5 +23723,Mexico,2016,34,M-Musculo-skeletal system,"Million US$, purchasing power parity",308.3 +23724,Mexico,2016,34,C-Cardiovascular system,"/capita, US$ exchange rate",5.2 +23725,Mexico,2016,34,C-Cardiovascular system,"Million US$, purchasing power parity",1402.6 +23726,Mexico,2016,34,C-Cardiovascular system,Million US$ at exchange rate,634.7 +23727,Mexico,2016,34,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.2 +23728,Mexico,2016,34,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.4 +23729,Mexico,2016,34,Products not elsewhere classified,"/capita, US$ exchange rate",8.4 +23730,Mexico,2016,34,Products not elsewhere classified,"Million US$, purchasing power parity",2270.2 +23731,Mexico,2016,34,Products not elsewhere classified,"/capita, US$ purchasing power parity",18.5 +23732,Mexico,2016,34,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.1 +23733,Mexico,2016,34,Products not elsewhere classified,Million of national currency units,19174.5 +23734,Mexico,2016,34,C-Cardiovascular system,Million of national currency units,11846.0 +23735,Mexico,2016,34,Products not elsewhere classified,Million US$ at exchange rate,1027.3 +23736,Mexico,2016,34,N-Nervous system,Million of national currency units,15668.0 +23737,Mexico,2016,34,N-Nervous system,Million US$ at exchange rate,839.5 +23738,Mexico,2016,34,R-Respiratory system,"/capita, US$ purchasing power parity",5.9 +23739,Mexico,2016,34,R-Respiratory system,"Million US$, purchasing power parity",728.0 +23740,Mexico,2016,34,R-Respiratory system,Million US$ at exchange rate,329.5 +23741,Mexico,2016,34,R-Respiratory system,"/capita, US$ exchange rate",2.7 +23742,Mexico,2016,34,N-Nervous system,"Million US$, purchasing power parity",1855.1 +23743,Mexico,2016,34,J-Antiinfectives for systemic use,Million US$ at exchange rate,1122.0 +23744,Mexico,2016,34,J-Antiinfectives for systemic use,Million of national currency units,20942.0 +23745,Mexico,2016,34,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2479.5 +23746,Mexico,2016,34,N-Nervous system,"/capita, US$ exchange rate",6.8 +23747,Mexico,2016,34,N-Nervous system,"/capita, US$ purchasing power parity",15.1 +23748,Mexico,2016,34,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",2.5 +23749,Mexico,2016,34,B-Blood and blood forming organs,Million of national currency units,1766.0 +23750,Mexico,2016,34,B-Blood and blood forming organs,Million US$ at exchange rate,94.6 +23751,Mexico,2016,34,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",1.7 +23752,Mexico,2016,34,B-Blood and blood forming organs,"Million US$, purchasing power parity",209.1 +23753,Mexico,2016,34,B-Blood and blood forming organs,"/capita, US$ exchange rate",0.8 +23754,Mexico,2015,36,M-Musculo-skeletal system,Million of national currency units,3283.0 +23755,Mexico,2015,36,R-Respiratory system,Million of national currency units,5656.0 +23756,Mexico,2015,36,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.7 +23757,Mexico,2015,36,M-Musculo-skeletal system,Million US$ at exchange rate,207.2 +23758,Mexico,2015,36,M-Musculo-skeletal system,"Million US$, purchasing power parity",394.2 +23759,Mexico,2015,36,R-Respiratory system,Million US$ at exchange rate,356.9 +23760,Mexico,2015,36,C-Cardiovascular system,"/capita, US$ exchange rate",5.0 +23761,Mexico,2015,36,C-Cardiovascular system,"Million US$, purchasing power parity",1150.8 +23762,Mexico,2015,36,C-Cardiovascular system,Million US$ at exchange rate,604.7 +23763,Mexico,2015,36,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.8 +23764,Mexico,2015,36,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.5 +23765,Mexico,2015,36,Products not elsewhere classified,"/capita, US$ exchange rate",9.1 +23766,Mexico,2015,36,Products not elsewhere classified,"Million US$, purchasing power parity",2108.6 +23767,Mexico,2015,36,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.4 +23768,Mexico,2015,36,Products not elsewhere classified,Million of national currency units,17559.7 +23769,Mexico,2015,36,C-Cardiovascular system,Million of national currency units,9583.0 +23770,Mexico,2015,36,Products not elsewhere classified,Million US$ at exchange rate,1108.0 +23771,Mexico,2015,36,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.9 +23772,Mexico,2015,36,N-Nervous system,Million of national currency units,14984.0 +23773,Mexico,2015,36,N-Nervous system,Million US$ at exchange rate,945.5 +23774,Mexico,2015,36,R-Respiratory system,"Million US$, purchasing power parity",679.2 +23775,Mexico,2015,36,R-Respiratory system,"/capita, US$ purchasing power parity",5.6 +23776,Mexico,2015,36,R-Respiratory system,"/capita, US$ exchange rate",2.9 +23777,Mexico,2015,36,J-Antiinfectives for systemic use,Million US$ at exchange rate,1200.3 +23778,Mexico,2015,36,J-Antiinfectives for systemic use,Million of national currency units,19023.0 +23779,Mexico,2015,36,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2284.3 +23780,Mexico,2015,36,N-Nervous system,"Million US$, purchasing power parity",1799.3 +23781,Mexico,2015,36,N-Nervous system,"/capita, US$ exchange rate",7.8 +23782,Mexico,2015,36,N-Nervous system,"/capita, US$ purchasing power parity",14.8 +23783,Mexico,2015,36,B-Blood and blood forming organs,Million of national currency units,2320.0 +23784,Mexico,2015,36,B-Blood and blood forming organs,Million US$ at exchange rate,146.4 +23785,Mexico,2015,36,B-Blood and blood forming organs,"Million US$, purchasing power parity",278.6 +23786,Mexico,2015,36,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.2 +23787,Mexico,2015,36,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.3 +23788,Mexico,2015,36,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2 +23789,Mexico,2014,38,M-Musculo-skeletal system,Million of national currency units,3091.0 +23790,Mexico,2014,38,R-Respiratory system,Million of national currency units,6950.0 +23791,Mexico,2014,38,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.9 +23792,Mexico,2014,38,M-Musculo-skeletal system,Million US$ at exchange rate,232.5 +23793,Mexico,2014,38,M-Musculo-skeletal system,"Million US$, purchasing power parity",384.2 +23794,Mexico,2014,38,C-Cardiovascular system,"/capita, US$ exchange rate",5.3 +23795,Mexico,2014,38,C-Cardiovascular system,"Million US$, purchasing power parity",1042.6 +23796,Mexico,2014,38,C-Cardiovascular system,Million US$ at exchange rate,631.0 +23797,Mexico,2014,38,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.4 +23798,Mexico,2014,38,C-Cardiovascular system,"/capita, US$ purchasing power parity",8.7 +23799,Mexico,2014,38,Products not elsewhere classified,"/capita, US$ exchange rate",10.7 +23800,Mexico,2014,38,Products not elsewhere classified,"Million US$, purchasing power parity",2126.5 +23801,Mexico,2014,38,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.7 +23802,Mexico,2014,38,Products not elsewhere classified,Million of national currency units,17108.4 +23803,Mexico,2014,38,C-Cardiovascular system,Million of national currency units,8388.0 +23804,Mexico,2014,38,Products not elsewhere classified,Million US$ at exchange rate,1287.1 +23805,Mexico,2014,38,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.1 +23806,Mexico,2014,38,N-Nervous system,Million of national currency units,14128.0 +23807,Mexico,2014,38,N-Nervous system,Million US$ at exchange rate,1062.9 +23808,Mexico,2014,38,R-Respiratory system,"/capita, US$ purchasing power parity",7.2 +23809,Mexico,2014,38,R-Respiratory system,"Million US$, purchasing power parity",863.9 +23810,Mexico,2014,38,R-Respiratory system,"/capita, US$ exchange rate",4.4 +23811,Mexico,2014,38,R-Respiratory system,Million US$ at exchange rate,522.9 +23812,Mexico,2014,38,N-Nervous system,"Million US$, purchasing power parity",1756.1 +23813,Mexico,2014,38,J-Antiinfectives for systemic use,Million US$ at exchange rate,1333.1 +23814,Mexico,2014,38,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2202.5 +23815,Mexico,2014,38,J-Antiinfectives for systemic use,Million of national currency units,17720.0 +23816,Mexico,2014,38,N-Nervous system,"/capita, US$ exchange rate",8.9 +23817,Mexico,2014,38,N-Nervous system,"/capita, US$ purchasing power parity",14.6 +23818,Mexico,2014,38,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2 +23819,Mexico,2014,38,B-Blood and blood forming organs,"Million US$, purchasing power parity",270.5 +23820,Mexico,2014,38,B-Blood and blood forming organs,Million US$ at exchange rate,163.7 +23821,Mexico,2014,38,B-Blood and blood forming organs,Million of national currency units,2176.0 +23822,Mexico,2014,38,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.3 +23823,Mexico,2014,38,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.4 +23824,Mexico,2013,39,M-Musculo-skeletal system,Million of national currency units,3553.0 +23825,Mexico,2013,39,R-Respiratory system,Million of national currency units,7254.0 +23826,Mexico,2013,39,R-Respiratory system,Million US$ at exchange rate,568.0 +23827,Mexico,2013,39,M-Musculo-skeletal system,Million US$ at exchange rate,278.2 +23828,Mexico,2013,39,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.3 +23829,Mexico,2013,39,M-Musculo-skeletal system,"Million US$, purchasing power parity",450.6 +23830,Mexico,2013,39,C-Cardiovascular system,"/capita, US$ exchange rate",6.6 +23831,Mexico,2013,39,C-Cardiovascular system,"Million US$, purchasing power parity",1258.9 +23832,Mexico,2013,39,C-Cardiovascular system,Million US$ at exchange rate,777.2 +23833,Mexico,2013,39,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5 +23834,Mexico,2013,39,J-Antiinfectives for systemic use,% of total sales,12.8 +23835,Mexico,2013,39,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.6 +23836,Mexico,2013,39,C-Cardiovascular system,% of total sales,7.0 +23837,Mexico,2013,39,Products not elsewhere classified,"/capita, US$ exchange rate",11.8 +23838,Mexico,2013,39,Products not elsewhere classified,% of total sales,12.6 +23839,Mexico,2013,39,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.1 +23840,Mexico,2013,39,Products not elsewhere classified,"Million US$, purchasing power parity",2258.6 +23841,Mexico,2013,39,Products not elsewhere classified,Million of national currency units,17807.7 +23842,Mexico,2013,39,C-Cardiovascular system,Million of national currency units,9926.0 +23843,Mexico,2013,39,Products not elsewhere classified,Million US$ at exchange rate,1394.3 +23844,Mexico,2013,39,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.0 +23845,Mexico,2013,39,N-Nervous system,Million of national currency units,13836.0 +23846,Mexico,2013,39,R-Respiratory system,% of total sales,5.1 +23847,Mexico,2013,39,N-Nervous system,Million US$ at exchange rate,1083.3 +23848,Mexico,2013,39,N-Nervous system,"Million US$, purchasing power parity",1754.9 +23849,Mexico,2013,39,R-Respiratory system,"Million US$, purchasing power parity",920.0 +23850,Mexico,2013,39,R-Respiratory system,"/capita, US$ purchasing power parity",7.8 +23851,Mexico,2013,39,R-Respiratory system,"/capita, US$ exchange rate",4.8 +23852,Mexico,2013,39,J-Antiinfectives for systemic use,Million US$ at exchange rate,1426.0 +23853,Mexico,2013,39,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2310.0 +23854,Mexico,2013,39,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8 +23855,Mexico,2013,39,N-Nervous system,"/capita, US$ exchange rate",9.1 +23856,Mexico,2013,39,J-Antiinfectives for systemic use,Million of national currency units,18213.0 +23857,Mexico,2013,39,N-Nervous system,% of total sales,9.8 +23858,Mexico,2013,39,N-Nervous system,"/capita, US$ purchasing power parity",14.8 +23859,Mexico,2013,39,B-Blood and blood forming organs,"Million US$, purchasing power parity",281.3 +23860,Mexico,2013,39,B-Blood and blood forming organs,Million US$ at exchange rate,173.7 +23861,Mexico,2013,39,Total pharmaceutical sales,"/capita, US$ purchasing power parity",151.8 +23862,Mexico,2013,39,Total pharmaceutical sales,"/capita, US$ exchange rate",93.7 +23863,Mexico,2013,39,Total pharmaceutical sales,"Million US$, purchasing power parity",17978.4 +23864,Mexico,2013,39,Total pharmaceutical sales,Million US$ at exchange rate,11098.4 +23865,Mexico,2013,39,Total pharmaceutical sales,Million of national currency units,141748.4 +23866,Mexico,2013,39,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.4 +23867,Mexico,2013,39,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.5 +23868,Mexico,2013,39,B-Blood and blood forming organs,Million of national currency units,2218.0 +23869,Mexico,2013,39,B-Blood and blood forming organs,% of total sales,1.6 +23870,Mexico,2013,39,M-Musculo-skeletal system,% of total sales,2.5 +23871,Mexico,2012,41,M-Musculo-skeletal system,Million of national currency units,4445.0 +23872,Mexico,2012,41,R-Respiratory system,Million US$ at exchange rate,607.4 +23873,Mexico,2012,41,R-Respiratory system,Million of national currency units,7999.0 +23874,Mexico,2012,41,M-Musculo-skeletal system,Million US$ at exchange rate,337.5 +23875,Mexico,2012,41,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.9 +23876,Mexico,2012,41,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.8 +23877,Mexico,2012,41,M-Musculo-skeletal system,"Million US$, purchasing power parity",565.6 +23878,Mexico,2012,41,C-Cardiovascular system,"/capita, US$ exchange rate",6.3 +23879,Mexico,2012,41,C-Cardiovascular system,Million US$ at exchange rate,740.1 +23880,Mexico,2012,41,C-Cardiovascular system,"Million US$, purchasing power parity",1240.3 +23881,Mexico,2012,41,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",13.2 +23882,Mexico,2012,41,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.6 +23883,Mexico,2012,41,Products not elsewhere classified,"/capita, US$ exchange rate",10.4 +23884,Mexico,2012,41,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.4 +23885,Mexico,2012,41,Products not elsewhere classified,Million of national currency units,15972.0 +23886,Mexico,2012,41,C-Cardiovascular system,Million of national currency units,9747.0 +23887,Mexico,2012,41,Products not elsewhere classified,"Million US$, purchasing power parity",2032.4 +23888,Mexico,2012,41,Products not elsewhere classified,Million US$ at exchange rate,1212.8 +23889,Mexico,2012,41,N-Nervous system,Million of national currency units,12804.0 +23890,Mexico,2012,41,N-Nervous system,"Million US$, purchasing power parity",1629.3 +23891,Mexico,2012,41,N-Nervous system,Million US$ at exchange rate,972.2 +23892,Mexico,2012,41,R-Respiratory system,"Million US$, purchasing power parity",1017.9 +23893,Mexico,2012,41,R-Respiratory system,"/capita, US$ purchasing power parity",8.7 +23894,Mexico,2012,41,R-Respiratory system,"/capita, US$ exchange rate",5.2 +23895,Mexico,2012,41,J-Antiinfectives for systemic use,Million US$ at exchange rate,924.3 +23896,Mexico,2012,41,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.9 +23897,Mexico,2012,41,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1549.0 +23898,Mexico,2012,41,J-Antiinfectives for systemic use,Million of national currency units,12173.0 +23899,Mexico,2012,41,N-Nervous system,"/capita, US$ exchange rate",8.3 +23900,Mexico,2012,41,N-Nervous system,"/capita, US$ purchasing power parity",13.9 +23901,Mexico,2012,41,B-Blood and blood forming organs,"Million US$, purchasing power parity",530.9 +23902,Mexico,2012,41,B-Blood and blood forming organs,Million US$ at exchange rate,316.8 +23903,Mexico,2012,41,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.5 +23904,Mexico,2012,41,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.7 +23905,Mexico,2012,41,B-Blood and blood forming organs,Million of national currency units,4172.0 +23906,Mexico,2011,43,M-Musculo-skeletal system,Million of national currency units,4208.0 +23907,Mexico,2011,43,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.8 +23908,Mexico,2011,43,R-Respiratory system,Million of national currency units,7354.0 +23909,Mexico,2011,43,R-Respiratory system,Million US$ at exchange rate,592.0 +23910,Mexico,2011,43,M-Musculo-skeletal system,Million US$ at exchange rate,338.7 +23911,Mexico,2011,43,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.9 +23912,Mexico,2011,43,M-Musculo-skeletal system,"Million US$, purchasing power parity",548.4 +23913,Mexico,2011,43,C-Cardiovascular system,"/capita, US$ exchange rate",7.2 +23914,Mexico,2011,43,C-Cardiovascular system,Million US$ at exchange rate,827.2 +23915,Mexico,2011,43,C-Cardiovascular system,"Million US$, purchasing power parity",1339.4 +23916,Mexico,2011,43,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.0 +23917,Mexico,2011,43,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.6 +23918,Mexico,2011,43,Products not elsewhere classified,"/capita, US$ exchange rate",11.9 +23919,Mexico,2011,43,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.2 +23920,Mexico,2011,43,Products not elsewhere classified,"Million US$, purchasing power parity",2217.4 +23921,Mexico,2011,43,Products not elsewhere classified,Million of national currency units,17014.0 +23922,Mexico,2011,43,C-Cardiovascular system,Million of national currency units,10277.0 +23923,Mexico,2011,43,Products not elsewhere classified,Million US$ at exchange rate,1369.5 +23924,Mexico,2011,43,N-Nervous system,Million of national currency units,12584.0 +23925,Mexico,2011,43,N-Nervous system,"Million US$, purchasing power parity",1640.0 +23926,Mexico,2011,43,N-Nervous system,Million US$ at exchange rate,1012.9 +23927,Mexico,2011,43,R-Respiratory system,"Million US$, purchasing power parity",958.4 +23928,Mexico,2011,43,R-Respiratory system,"/capita, US$ purchasing power parity",8.3 +23929,Mexico,2011,43,R-Respiratory system,"/capita, US$ exchange rate",5.1 +23930,Mexico,2011,43,J-Antiinfectives for systemic use,Million US$ at exchange rate,638.8 +23931,Mexico,2011,43,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",5.5 +23932,Mexico,2011,43,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1034.3 +23933,Mexico,2011,43,N-Nervous system,"/capita, US$ exchange rate",8.8 +23934,Mexico,2011,43,J-Antiinfectives for systemic use,Million of national currency units,7936.0 +23935,Mexico,2011,43,N-Nervous system,"/capita, US$ purchasing power parity",14.2 +23936,Mexico,2011,43,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.8 +23937,Mexico,2011,43,B-Blood and blood forming organs,Million US$ at exchange rate,179.6 +23938,Mexico,2011,43,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.6 +23939,Mexico,2011,43,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.5 +23940,Mexico,2011,43,B-Blood and blood forming organs,Million of national currency units,2231.0 +23941,Mexico,2010,46,M-Musculo-skeletal system,Million of national currency units,5495.0 +23942,Mexico,2010,46,M-Musculo-skeletal system,Million US$ at exchange rate,434.9 +23943,Mexico,2010,46,R-Respiratory system,Million of national currency units,8936.0 +23944,Mexico,2010,46,R-Respiratory system,Million US$ at exchange rate,707.2 +23945,Mexico,2010,46,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.8 +23946,Mexico,2010,46,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",6.3 +23947,Mexico,2010,46,M-Musculo-skeletal system,"Million US$, purchasing power parity",715.5 +23948,Mexico,2010,46,C-Cardiovascular system,"/capita, US$ exchange rate",7.0 +23949,Mexico,2010,46,C-Cardiovascular system,Million US$ at exchange rate,801.1 +23950,Mexico,2010,46,C-Cardiovascular system,"Million US$, purchasing power parity",1318.2 +23951,Mexico,2010,46,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.6 +23952,Mexico,2010,46,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.6 +23953,Mexico,2010,46,Products not elsewhere classified,"/capita, US$ exchange rate",12.0 +23954,Mexico,2010,46,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.7 +23955,Mexico,2010,46,Products not elsewhere classified,Million of national currency units,17216.0 +23956,Mexico,2010,46,C-Cardiovascular system,Million of national currency units,10123.0 +23957,Mexico,2010,46,Products not elsewhere classified,"Million US$, purchasing power parity",2241.8 +23958,Mexico,2010,46,Products not elsewhere classified,Million US$ at exchange rate,1362.5 +23959,Mexico,2010,46,N-Nervous system,Million of national currency units,14077.0 +23960,Mexico,2010,46,N-Nervous system,"Million US$, purchasing power parity",1833.0 +23961,Mexico,2010,46,N-Nervous system,Million US$ at exchange rate,1114.0 +23962,Mexico,2010,46,R-Respiratory system,"Million US$, purchasing power parity",1163.6 +23963,Mexico,2010,46,R-Respiratory system,"/capita, US$ exchange rate",6.2 +23964,Mexico,2010,46,R-Respiratory system,"/capita, US$ purchasing power parity",10.2 +23965,Mexico,2010,46,J-Antiinfectives for systemic use,Million US$ at exchange rate,591.8 +23966,Mexico,2010,46,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",5.2 +23967,Mexico,2010,46,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",973.7 +23968,Mexico,2010,46,N-Nervous system,"/capita, US$ exchange rate",9.8 +23969,Mexico,2010,46,N-Nervous system,"/capita, US$ purchasing power parity",16.1 +23970,Mexico,2010,46,J-Antiinfectives for systemic use,Million of national currency units,7478.0 +23971,Mexico,2010,46,B-Blood and blood forming organs,"Million US$, purchasing power parity",511.7 +23972,Mexico,2010,46,B-Blood and blood forming organs,Million US$ at exchange rate,311.0 +23973,Mexico,2010,46,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.7 +23974,Mexico,2010,46,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.5 +23975,Mexico,2010,46,B-Blood and blood forming organs,Million of national currency units,3930.0 +23976,Mexico,2017,33,M-Musculo-skeletal system,Million of national currency units,2708.0 +23977,Mexico,2017,33,R-Respiratory system,Million of national currency units,5570.0 +23978,Mexico,2017,33,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.2 +23979,Mexico,2017,33,M-Musculo-skeletal system,Million US$ at exchange rate,143.1 +23980,Mexico,2017,33,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.8 +23981,Mexico,2017,33,N-Nervous system,"/capita, US$ exchange rate",7.1 +23982,Mexico,2017,33,C-Cardiovascular system,"Million US$, purchasing power parity",1176.9 +23983,Mexico,2017,33,C-Cardiovascular system,"/capita, US$ exchange rate",4.5 +23984,Mexico,2017,33,C-Cardiovascular system,Million US$ at exchange rate,554.2 +23985,Mexico,2017,33,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.4 +23986,Mexico,2017,33,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.6 +23987,Mexico,2017,33,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.5 +23988,Mexico,2017,33,Products not elsewhere classified,"/capita, US$ exchange rate",8.4 +23989,Mexico,2017,33,Products not elsewhere classified,"Million US$, purchasing power parity",2221.4 +23990,Mexico,2017,33,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.9 +23991,Mexico,2017,33,Products not elsewhere classified,Million of national currency units,19800.8 +23992,Mexico,2017,33,C-Cardiovascular system,Million of national currency units,10490.0 +23993,Mexico,2017,33,Products not elsewhere classified,Million US$ at exchange rate,1046.2 +23994,Mexico,2017,33,N-Nervous system,Million of national currency units,16565.0 +23995,Mexico,2017,33,R-Respiratory system,"/capita, US$ purchasing power parity",5.0 +23996,Mexico,2017,33,N-Nervous system,Million US$ at exchange rate,875.2 +23997,Mexico,2017,33,R-Respiratory system,"Million US$, purchasing power parity",624.9 +23998,Mexico,2017,33,R-Respiratory system,Million US$ at exchange rate,294.3 +23999,Mexico,2017,33,R-Respiratory system,"/capita, US$ exchange rate",2.4 +24000,Mexico,2017,33,J-Antiinfectives for systemic use,Million US$ at exchange rate,1192.2 +24001,Mexico,2017,33,J-Antiinfectives for systemic use,Million of national currency units,22564.0 +24002,Mexico,2017,33,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2531.4 +24003,Mexico,2017,33,N-Nervous system,"Million US$, purchasing power parity",1858.4 +24004,Mexico,2017,33,N-Nervous system,"/capita, US$ purchasing power parity",15.0 +24005,Mexico,2017,33,B-Blood and blood forming organs,Million US$ at exchange rate,86.7 +24006,Mexico,2017,33,B-Blood and blood forming organs,Million of national currency units,1640.0 +24007,Mexico,2017,33,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",1.5 +24008,Mexico,2017,33,B-Blood and blood forming organs,"Million US$, purchasing power parity",184.0 +24009,Mexico,2017,33,B-Blood and blood forming organs,"/capita, US$ exchange rate",0.7 +24010,Mexico,2017,33,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",2.4 +24011,Netherlands,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",334.6 +24012,Netherlands,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5697.7 +24013,Netherlands,2016,6,Total pharmaceutical sales,Million of national currency units,4532.2 +24014,Netherlands,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,5016.8 +24015,Netherlands,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",294.6 +24016,Netherlands,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",325.3 +24017,Netherlands,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5510.4 +24018,Netherlands,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,4952.1 +24019,Netherlands,2015,6,Total pharmaceutical sales,Million of national currency units,4463.3 +24020,Netherlands,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",292.3 +24021,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.4 +24022,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.6 +24023,Netherlands,2014,6,J-Antiinfectives for systemic use,Million of national currency units,387.7 +24024,Netherlands,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,515.0 +24025,Netherlands,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",479.3 +24026,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,9.6 +24027,Netherlands,2014,6,B-Blood and blood forming organs,Million of national currency units,267.6 +24028,Netherlands,2014,6,N06A-Antidepressants,% of total sales,2.3 +24029,Netherlands,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.6 +24030,Netherlands,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1 +24031,Netherlands,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",330.9 +24032,Netherlands,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,355.5 +24033,Netherlands,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.5 +24034,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,141.1 +24035,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",512.0 +24036,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,550.2 +24037,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,414.1 +24038,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,187.5 +24039,Netherlands,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.4 +24040,Netherlands,2014,6,J-Antiinfectives for systemic use,% of total sales,9.0 +24041,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.3 +24042,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.3 +24043,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1 +24044,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",174.5 +24045,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.6 +24046,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.8 +24047,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.9 +24048,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,129.9 +24049,Netherlands,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",317.3 +24050,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2 +24051,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.5 +24052,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0 +24053,Netherlands,2014,6,C03-Diuretics,% of total sales,1.9 +24054,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.6 +24055,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +24056,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +24057,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +24058,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,172.6 +24059,Netherlands,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5351.6 +24060,Netherlands,2014,6,Total pharmaceutical sales,Million of national currency units,4328.4 +24061,Netherlands,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.3 +24062,Netherlands,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,5750.2 +24063,Netherlands,2014,6,N-Nervous system,% of total sales,13.2 +24064,Netherlands,2014,6,N-Nervous system,Million of national currency units,571.7 +24065,Netherlands,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",341.0 +24066,Netherlands,2014,6,N-Nervous system,Million US$ at exchange rate,759.6 +24067,Netherlands,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",41.9 +24068,Netherlands,2014,6,N-Nervous system,"Million US$, purchasing power parity",706.9 +24069,Netherlands,2014,6,N-Nervous system,"/capita, US$ exchange rate",45.0 +24070,Netherlands,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.5 +24071,Netherlands,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1 +24072,Netherlands,2014,6,C-Cardiovascular system,Million US$ at exchange rate,906.2 +24073,Netherlands,2014,6,C-Cardiovascular system,Million of national currency units,682.1 +24074,Netherlands,2014,6,C01A-Cardiac glycosides,% of total sales,0.1 +24075,Netherlands,2014,6,B-Blood and blood forming organs,% of total sales,6.2 +24076,Netherlands,2014,6,J01-Antibacterials for systemic use,Million of national currency units,102.9 +24077,Netherlands,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,136.7 +24078,Netherlands,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",127.2 +24079,Netherlands,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",843.4 +24080,Netherlands,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.0 +24081,Netherlands,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1 +24082,Netherlands,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",17.2 +24083,Netherlands,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.5 +24084,Netherlands,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",53.7 +24085,Netherlands,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",50.0 +24086,Netherlands,2014,6,C-Cardiovascular system,% of total sales,15.8 +24087,Netherlands,2014,6,J01-Antibacterials for systemic use,% of total sales,2.4 +24088,Netherlands,2014,6,N05C-Hypnotics and sedatives,% of total sales,0.3 +24089,Netherlands,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.7 +24090,Netherlands,2014,6,A10-Drugs used in diabetes,% of total sales,6.2 +24091,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,0.6 +24092,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1 +24093,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.2 +24094,Netherlands,2014,6,A10-Drugs used in diabetes,Million of national currency units,268.1 +24095,Netherlands,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1 +24096,Netherlands,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",331.5 +24097,Netherlands,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,356.2 +24098,Netherlands,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,7.9 +24099,Netherlands,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.4 +24100,Netherlands,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +24101,Netherlands,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +24102,Netherlands,2014,6,C01A-Cardiac glycosides,Million of national currency units,6.0 +24103,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",34.7 +24104,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.3 +24105,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,28.1 +24106,Netherlands,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,13.9 +24107,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,69.0 +24108,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,91.6 +24109,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",85.3 +24110,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.4 +24111,Netherlands,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",123.3 +24112,Netherlands,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.0 +24113,Netherlands,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +24114,Netherlands,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +24115,Netherlands,2014,6,A02A-Antacids,% of total sales,0.0 +24116,Netherlands,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,123.9 +24117,Netherlands,2014,6,C07-Beta blocking agents,Million of national currency units,93.3 +24118,Netherlands,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",7.9 +24119,Netherlands,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",115.3 +24120,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1 +24121,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6 +24122,Netherlands,2014,6,C07-Beta blocking agents,% of total sales,2.2 +24123,Netherlands,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8 +24124,Netherlands,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",7.3 +24125,Netherlands,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,87.5 +24126,Netherlands,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.4 +24127,Netherlands,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2 +24128,Netherlands,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8 +24129,Netherlands,2014,6,C08-Calcium channel blockers,Million of national currency units,65.8 +24130,Netherlands,2014,6,N06A-Antidepressants,Million of national currency units,99.7 +24131,Netherlands,2014,6,N06A-Antidepressants,Million US$ at exchange rate,132.4 +24132,Netherlands,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",10.5 +24133,Netherlands,2014,6,N02-Analgesics,% of total sales,3.3 +24134,Netherlands,2014,6,A02A-Antacids,Million of national currency units,0.0 +24135,Netherlands,2014,6,A02A-Antacids,Million US$ at exchange rate,0.0 +24136,Netherlands,2014,6,N02-Analgesics,"/capita, US$ exchange rate",11.3 +24137,Netherlands,2014,6,C08-Calcium channel blockers,% of total sales,1.5 +24138,Netherlands,2014,6,N02-Analgesics,Million of national currency units,143.6 +24139,Netherlands,2014,6,N02-Analgesics,Million US$ at exchange rate,190.8 +24140,Netherlands,2014,6,N02-Analgesics,"Million US$, purchasing power parity",177.6 +24141,Netherlands,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",5.9 +24142,Netherlands,2014,6,N05B-Anxiolytics,Million of national currency units,20.4 +24143,Netherlands,2014,6,R-Respiratory system,Million US$ at exchange rate,686.1 +24144,Netherlands,2014,6,R-Respiratory system,Million of national currency units,516.5 +24145,Netherlands,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5 +24146,Netherlands,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6 +24147,Netherlands,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",25.2 +24148,Netherlands,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,27.1 +24149,Netherlands,2014,6,G-Genito urinary system and sex hormones,% of total sales,2.4 +24150,Netherlands,2014,6,R-Respiratory system,% of total sales,11.9 +24151,Netherlands,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",129.8 +24152,Netherlands,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",37.9 +24153,Netherlands,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,139.5 +24154,Netherlands,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,105.0 +24155,Netherlands,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.7 +24156,Netherlands,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.3 +24157,Netherlands,2014,6,R-Respiratory system,"Million US$, purchasing power parity",638.6 +24158,Netherlands,2014,6,R-Respiratory system,"/capita, US$ exchange rate",40.7 +24159,Netherlands,2014,6,N05B-Anxiolytics,% of total sales,0.5 +24160,Netherlands,2014,6,C02-Antihypertensives,% of total sales,0.8 +24161,Netherlands,2014,6,C10-Lipid modifying agents,Million of national currency units,213.7 +24162,Netherlands,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6 +24163,Netherlands,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,283.9 +24164,Netherlands,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",264.2 +24165,Netherlands,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",43.3 +24166,Netherlands,2014,6,C02-Antihypertensives,Million US$ at exchange rate,46.6 +24167,Netherlands,2014,6,C02-Antihypertensives,Million of national currency units,35.0 +24168,Netherlands,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.8 +24169,Netherlands,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",805.6 +24170,Netherlands,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,865.6 +24171,Netherlands,2014,6,A-Alimentary tract and metabolism,Million of national currency units,651.6 +24172,Netherlands,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.3 +24173,Netherlands,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",16.8 +24174,Netherlands,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.7 +24175,Netherlands,2014,6,C10-Lipid modifying agents,% of total sales,4.9 +24176,Netherlands,2014,6,A-Alimentary tract and metabolism,% of total sales,15.1 +24177,Netherlands,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.8 +24178,Netherlands,2014,6,M-Musculo-skeletal system,Million of national currency units,121.1 +24179,Netherlands,2014,6,C03-Diuretics,"/capita, US$ exchange rate",6.3 +24180,Netherlands,2014,6,C03-Diuretics,"Million US$, purchasing power parity",99.5 +24181,Netherlands,2014,6,C03-Diuretics,Million US$ at exchange rate,106.9 +24182,Netherlands,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,160.9 +24183,Netherlands,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9 +24184,Netherlands,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.5 +24185,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",144.8 +24186,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.2 +24187,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.6 +24188,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7 +24189,Netherlands,2014,6,C03-Diuretics,Million of national currency units,80.5 +24190,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,117.1 +24191,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,155.6 +24192,Netherlands,2014,6,M-Musculo-skeletal system,% of total sales,2.8 +24193,Netherlands,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",149.7 +24194,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.1 +24195,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.0 +24196,Netherlands,2013,6,J-Antiinfectives for systemic use,Million of national currency units,393.7 +24197,Netherlands,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,522.8 +24198,Netherlands,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",493.2 +24199,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,10.0 +24200,Netherlands,2013,6,B-Blood and blood forming organs,Million of national currency units,258.1 +24201,Netherlands,2013,6,N06A-Antidepressants,% of total sales,2.3 +24202,Netherlands,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.2 +24203,Netherlands,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.4 +24204,Netherlands,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",323.4 +24205,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,222.7 +24206,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,167.6 +24207,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",538.9 +24208,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,571.3 +24209,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,430.1 +24210,Netherlands,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",31.1 +24211,Netherlands,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,342.8 +24212,Netherlands,2013,6,J-Antiinfectives for systemic use,% of total sales,9.2 +24213,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9 +24214,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.5 +24215,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.2 +24216,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",210.0 +24217,Netherlands,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.3 +24218,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.7 +24219,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.9 +24220,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.2 +24221,Netherlands,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",320.7 +24222,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,127.9 +24223,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +24224,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.1 +24225,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.5 +24226,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0 +24227,Netherlands,2013,6,C03-Diuretics,% of total sales,1.9 +24228,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.2 +24229,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +24230,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +24231,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,169.8 +24232,Netherlands,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5388.7 +24233,Netherlands,2013,6,Total pharmaceutical sales,Million of national currency units,4301.1 +24234,Netherlands,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,5712.3 +24235,Netherlands,2013,6,N-Nervous system,% of total sales,13.2 +24236,Netherlands,2013,6,N-Nervous system,Million of national currency units,568.2 +24237,Netherlands,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",339.9 +24238,Netherlands,2013,6,N-Nervous system,Million US$ at exchange rate,754.7 +24239,Netherlands,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",42.4 +24240,Netherlands,2013,6,N-Nervous system,"/capita, US$ exchange rate",44.9 +24241,Netherlands,2013,6,N-Nervous system,"Million US$, purchasing power parity",711.9 +24242,Netherlands,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.3 +24243,Netherlands,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",7.8 +24244,Netherlands,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0 +24245,Netherlands,2013,6,C-Cardiovascular system,Million of national currency units,714.1 +24246,Netherlands,2013,6,C-Cardiovascular system,Million US$ at exchange rate,948.4 +24247,Netherlands,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",894.7 +24248,Netherlands,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.5 +24249,Netherlands,2013,6,J01-Antibacterials for systemic use,Million of national currency units,120.2 +24250,Netherlands,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,159.6 +24251,Netherlands,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",150.6 +24252,Netherlands,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9 +24253,Netherlands,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0 +24254,Netherlands,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",16.0 +24255,Netherlands,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.9 +24256,Netherlands,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.3 +24257,Netherlands,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",56.4 +24258,Netherlands,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.2 +24259,Netherlands,2013,6,C-Cardiovascular system,% of total sales,16.6 +24260,Netherlands,2013,6,J01-Antibacterials for systemic use,% of total sales,2.8 +24261,Netherlands,2013,6,C01A-Cardiac glycosides,% of total sales,0.1 +24262,Netherlands,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.1 +24263,Netherlands,2013,6,A10-Drugs used in diabetes,% of total sales,6.3 +24264,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.5 +24265,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4 +24266,Netherlands,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.3 +24267,Netherlands,2013,6,A10-Drugs used in diabetes,Million of national currency units,269.8 +24268,Netherlands,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,358.3 +24269,Netherlands,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",338.0 +24270,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7 +24271,Netherlands,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,8.6 +24272,Netherlands,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.1 +24273,Netherlands,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +24274,Netherlands,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +24275,Netherlands,2013,6,C01A-Cardiac glycosides,Million of national currency units,6.4 +24276,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",75.1 +24277,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,79.6 +24278,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,59.9 +24279,Netherlands,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,12.7 +24280,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,80.9 +24281,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.5 +24282,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",101.4 +24283,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4 +24284,Netherlands,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.0 +24285,Netherlands,2013,6,A02A-Antacids,% of total sales,0.0 +24286,Netherlands,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",123.2 +24287,Netherlands,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +24288,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.0 +24289,Netherlands,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,124.7 +24290,Netherlands,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",117.7 +24291,Netherlands,2013,6,C07-Beta blocking agents,Million of national currency units,93.9 +24292,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +24293,Netherlands,2013,6,C07-Beta blocking agents,% of total sales,2.2 +24294,Netherlands,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.0 +24295,Netherlands,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",7.4 +24296,Netherlands,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.0 +24297,Netherlands,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,86.2 +24298,Netherlands,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.3 +24299,Netherlands,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1 +24300,Netherlands,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8 +24301,Netherlands,2013,6,C08-Calcium channel blockers,Million of national currency units,64.9 +24302,Netherlands,2013,6,B-Blood and blood forming organs,% of total sales,6.0 +24303,Netherlands,2013,6,N06A-Antidepressants,Million of national currency units,98.3 +24304,Netherlands,2013,6,N06A-Antidepressants,Million US$ at exchange rate,130.6 +24305,Netherlands,2013,6,C08-Calcium channel blockers,% of total sales,1.5 +24306,Netherlands,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",11.1 +24307,Netherlands,2013,6,N02-Analgesics,% of total sales,3.5 +24308,Netherlands,2013,6,A02A-Antacids,Million of national currency units,0.0 +24309,Netherlands,2013,6,A02A-Antacids,Million US$ at exchange rate,0.0 +24310,Netherlands,2013,6,N02-Analgesics,"/capita, US$ exchange rate",11.8 +24311,Netherlands,2013,6,N02-Analgesics,Million of national currency units,148.9 +24312,Netherlands,2013,6,N02-Analgesics,Million US$ at exchange rate,197.7 +24313,Netherlands,2013,6,N02-Analgesics,"Million US$, purchasing power parity",186.5 +24314,Netherlands,2013,6,N05B-Anxiolytics,Million of national currency units,20.1 +24315,Netherlands,2013,6,R-Respiratory system,Million of national currency units,540.6 +24316,Netherlands,2013,6,R-Respiratory system,Million US$ at exchange rate,718.0 +24317,Netherlands,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,26.7 +24318,Netherlands,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5 +24319,Netherlands,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6 +24320,Netherlands,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",25.2 +24321,Netherlands,2013,6,R-Respiratory system,"Million US$, purchasing power parity",677.3 +24322,Netherlands,2013,6,N05B-Anxiolytics,% of total sales,0.5 +24323,Netherlands,2013,6,R-Respiratory system,% of total sales,12.6 +24324,Netherlands,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",171.4 +24325,Netherlands,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,181.7 +24326,Netherlands,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,136.8 +24327,Netherlands,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",40.3 +24328,Netherlands,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.2 +24329,Netherlands,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.8 +24330,Netherlands,2013,6,R-Respiratory system,"/capita, US$ exchange rate",42.7 +24331,Netherlands,2013,6,G-Genito urinary system and sex hormones,% of total sales,3.2 +24332,Netherlands,2013,6,C02-Antihypertensives,% of total sales,0.8 +24333,Netherlands,2013,6,C10-Lipid modifying agents,Million of national currency units,213.2 +24334,Netherlands,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,283.2 +24335,Netherlands,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",267.1 +24336,Netherlands,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6 +24337,Netherlands,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",42.9 +24338,Netherlands,2013,6,C02-Antihypertensives,Million US$ at exchange rate,45.5 +24339,Netherlands,2013,6,C02-Antihypertensives,Million of national currency units,34.2 +24340,Netherlands,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +24341,Netherlands,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",16.9 +24342,Netherlands,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",816.6 +24343,Netherlands,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,865.6 +24344,Netherlands,2013,6,A-Alimentary tract and metabolism,Million of national currency units,651.8 +24345,Netherlands,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.5 +24346,Netherlands,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.9 +24347,Netherlands,2013,6,C10-Lipid modifying agents,% of total sales,5.0 +24348,Netherlands,2013,6,A-Alimentary tract and metabolism,% of total sales,15.2 +24349,Netherlands,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.6 +24350,Netherlands,2013,6,M-Musculo-skeletal system,Million of national currency units,133.3 +24351,Netherlands,2013,6,C03-Diuretics,"/capita, US$ exchange rate",6.4 +24352,Netherlands,2013,6,C03-Diuretics,"Million US$, purchasing power parity",102.2 +24353,Netherlands,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,177.1 +24354,Netherlands,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.9 +24355,Netherlands,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5 +24356,Netherlands,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",167.1 +24357,Netherlands,2013,6,C03-Diuretics,Million US$ at exchange rate,108.3 +24358,Netherlands,2013,6,M-Musculo-skeletal system,% of total sales,3.1 +24359,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.4 +24360,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",148.3 +24361,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.8 +24362,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.8 +24363,Netherlands,2013,6,C03-Diuretics,Million of national currency units,81.5 +24364,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,118.4 +24365,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,157.3 +24366,Netherlands,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.1 +24367,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.2 +24368,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.2 +24369,Netherlands,2012,7,J-Antiinfectives for systemic use,Million of national currency units,375.5 +24370,Netherlands,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,482.5 +24371,Netherlands,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",455.5 +24372,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,9.7 +24373,Netherlands,2012,7,B-Blood and blood forming organs,Million of national currency units,244.3 +24374,Netherlands,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,313.9 +24375,Netherlands,2012,7,N06A-Antidepressants,% of total sales,2.1 +24376,Netherlands,2012,7,B-Blood and blood forming organs,% of total sales,5.3 +24377,Netherlands,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.7 +24378,Netherlands,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.7 +24379,Netherlands,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.8 +24380,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,265.6 +24381,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,206.8 +24382,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",540.2 +24383,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,572.2 +24384,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,445.4 +24385,Netherlands,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",296.4 +24386,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",250.8 +24387,Netherlands,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.2 +24388,Netherlands,2012,7,J-Antiinfectives for systemic use,% of total sales,8.1 +24389,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5 +24390,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.0 +24391,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.9 +24392,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.7 +24393,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.5 +24394,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.8 +24395,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,223.8 +24396,Netherlands,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",333.6 +24397,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,174.2 +24398,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +24399,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.4 +24400,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.6 +24401,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.8 +24402,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +24403,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",211.3 +24404,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +24405,Netherlands,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",5589.9 +24406,Netherlands,2012,7,Total pharmaceutical sales,Million of national currency units,4608.3 +24407,Netherlands,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,5920.7 +24408,Netherlands,2012,7,N-Nervous system,Million US$ at exchange rate,761.8 +24409,Netherlands,2012,7,N-Nervous system,Million of national currency units,592.9 +24410,Netherlands,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",353.4 +24411,Netherlands,2012,7,N-Nervous system,% of total sales,12.9 +24412,Netherlands,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",42.9 +24413,Netherlands,2012,7,N-Nervous system,"/capita, US$ exchange rate",45.5 +24414,Netherlands,2012,7,N-Nervous system,"Million US$, purchasing power parity",719.2 +24415,Netherlands,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.7 +24416,Netherlands,2012,7,C-Cardiovascular system,Million of national currency units,776.6 +24417,Netherlands,2012,7,C-Cardiovascular system,Million US$ at exchange rate,997.8 +24418,Netherlands,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",942.0 +24419,Netherlands,2012,7,J01-Antibacterials for systemic use,Million of national currency units,120.6 +24420,Netherlands,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.3 +24421,Netherlands,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",146.3 +24422,Netherlands,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,155.0 +24423,Netherlands,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9 +24424,Netherlands,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0 +24425,Netherlands,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",15.1 +24426,Netherlands,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.0 +24427,Netherlands,2012,7,N05C-Hypnotics and sedatives,% of total sales,0.3 +24428,Netherlands,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",59.6 +24429,Netherlands,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",56.2 +24430,Netherlands,2012,7,C-Cardiovascular system,% of total sales,16.9 +24431,Netherlands,2012,7,J01-Antibacterials for systemic use,% of total sales,2.6 +24432,Netherlands,2012,7,C01A-Cardiac glycosides,% of total sales,0.1 +24433,Netherlands,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.8 +24434,Netherlands,2012,7,A10-Drugs used in diabetes,% of total sales,5.6 +24435,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.5 +24436,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.9 +24437,Netherlands,2012,7,A10-Drugs used in diabetes,Million of national currency units,260.2 +24438,Netherlands,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,334.2 +24439,Netherlands,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",315.6 +24440,Netherlands,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9 +24441,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.2 +24442,Netherlands,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,8.3 +24443,Netherlands,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.8 +24444,Netherlands,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +24445,Netherlands,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +24446,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",82.7 +24447,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,87.6 +24448,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,68.2 +24449,Netherlands,2012,7,C01A-Cardiac glycosides,Million of national currency units,6.5 +24450,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,83.9 +24451,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.8 +24452,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",101.8 +24453,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4 +24454,Netherlands,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.0 +24455,Netherlands,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +24456,Netherlands,2012,7,A02A-Antacids,% of total sales,0.0 +24457,Netherlands,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",115.1 +24458,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1 +24459,Netherlands,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",113.9 +24460,Netherlands,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,120.7 +24461,Netherlands,2012,7,C07-Beta blocking agents,Million of national currency units,93.9 +24462,Netherlands,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",7.3 +24463,Netherlands,2012,7,C03-Diuretics,% of total sales,1.7 +24464,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +24465,Netherlands,2012,7,C07-Beta blocking agents,% of total sales,2.0 +24466,Netherlands,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8 +24467,Netherlands,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2 +24468,Netherlands,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.0 +24469,Netherlands,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,78.2 +24470,Netherlands,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",73.9 +24471,Netherlands,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7 +24472,Netherlands,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4 +24473,Netherlands,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,12.4 +24474,Netherlands,2012,7,N06A-Antidepressants,Million of national currency units,94.9 +24475,Netherlands,2012,7,N06A-Antidepressants,Million US$ at exchange rate,121.9 +24476,Netherlands,2012,7,C08-Calcium channel blockers,Million of national currency units,60.9 +24477,Netherlands,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.9 +24478,Netherlands,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",11.8 +24479,Netherlands,2012,7,N02-Analgesics,% of total sales,3.5 +24480,Netherlands,2012,7,A02A-Antacids,Million of national currency units,0.0 +24481,Netherlands,2012,7,A02A-Antacids,Million US$ at exchange rate,0.0 +24482,Netherlands,2012,7,N02-Analgesics,Million of national currency units,162.5 +24483,Netherlands,2012,7,N02-Analgesics,Million US$ at exchange rate,208.8 +24484,Netherlands,2012,7,N02-Analgesics,"Million US$, purchasing power parity",197.1 +24485,Netherlands,2012,7,N02-Analgesics,"/capita, US$ exchange rate",12.5 +24486,Netherlands,2012,7,C08-Calcium channel blockers,% of total sales,1.3 +24487,Netherlands,2012,7,N05B-Anxiolytics,Million of national currency units,19.6 +24488,Netherlands,2012,7,R-Respiratory system,Million of national currency units,559.6 +24489,Netherlands,2012,7,R-Respiratory system,Million US$ at exchange rate,719.0 +24490,Netherlands,2012,7,R-Respiratory system,"Million US$, purchasing power parity",678.8 +24491,Netherlands,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,25.1 +24492,Netherlands,2012,7,N05B-Anxiolytics,% of total sales,0.4 +24493,Netherlands,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4 +24494,Netherlands,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +24495,Netherlands,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",23.7 +24496,Netherlands,2012,7,G-Genito urinary system and sex hormones,% of total sales,3.2 +24497,Netherlands,2012,7,R-Respiratory system,% of total sales,12.1 +24498,Netherlands,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",179.2 +24499,Netherlands,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,189.8 +24500,Netherlands,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,147.7 +24501,Netherlands,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",40.5 +24502,Netherlands,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.7 +24503,Netherlands,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3 +24504,Netherlands,2012,7,R-Respiratory system,"/capita, US$ exchange rate",42.9 +24505,Netherlands,2012,7,C10-Lipid modifying agents,Million of national currency units,242.3 +24506,Netherlands,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,311.4 +24507,Netherlands,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",294.0 +24508,Netherlands,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5 +24509,Netherlands,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",42.1 +24510,Netherlands,2012,7,C02-Antihypertensives,Million US$ at exchange rate,44.6 +24511,Netherlands,2012,7,C02-Antihypertensives,Million of national currency units,34.7 +24512,Netherlands,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +24513,Netherlands,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.6 +24514,Netherlands,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.6 +24515,Netherlands,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",784.3 +24516,Netherlands,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,830.8 +24517,Netherlands,2012,7,A-Alimentary tract and metabolism,Million of national currency units,646.6 +24518,Netherlands,2012,7,C02-Antihypertensives,% of total sales,0.8 +24519,Netherlands,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.5 +24520,Netherlands,2012,7,C10-Lipid modifying agents,% of total sales,5.3 +24521,Netherlands,2012,7,A-Alimentary tract and metabolism,% of total sales,14.0 +24522,Netherlands,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.8 +24523,Netherlands,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,175.4 +24524,Netherlands,2012,7,C03-Diuretics,"/capita, US$ exchange rate",6.1 +24525,Netherlands,2012,7,C03-Diuretics,"Million US$, purchasing power parity",95.9 +24526,Netherlands,2012,7,M-Musculo-skeletal system,% of total sales,3.0 +24527,Netherlands,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.9 +24528,Netherlands,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5 +24529,Netherlands,2012,7,M-Musculo-skeletal system,Million of national currency units,136.5 +24530,Netherlands,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",165.6 +24531,Netherlands,2012,7,C03-Diuretics,Million US$ at exchange rate,101.5 +24532,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.6 +24533,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7 +24534,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.1 +24535,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",152.6 +24536,Netherlands,2012,7,C03-Diuretics,Million of national currency units,79.0 +24537,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,125.8 +24538,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,161.7 +24539,Netherlands,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.7 +24540,Netherlands,2011,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.3 +24541,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.8 +24542,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.1 +24543,Netherlands,2011,7,J-Antiinfectives for systemic use,Million of national currency units,358.2 +24544,Netherlands,2011,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,498.6 +24545,Netherlands,2011,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",428.5 +24546,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,% of total sales,8.8 +24547,Netherlands,2011,7,B-Blood and blood forming organs,Million of national currency units,242.7 +24548,Netherlands,2011,7,B-Blood and blood forming organs,Million US$ at exchange rate,337.8 +24549,Netherlands,2011,7,N06A-Antidepressants,% of total sales,1.8 +24550,Netherlands,2011,7,B-Blood and blood forming organs,% of total sales,4.7 +24551,Netherlands,2011,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.4 +24552,Netherlands,2011,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.2 +24553,Netherlands,2011,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",29.9 +24554,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,356.5 +24555,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,256.1 +24556,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",546.7 +24557,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,636.3 +24558,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,Million of national currency units,457.1 +24559,Netherlands,2011,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.7 +24560,Netherlands,2011,7,J-Antiinfectives for systemic use,% of total sales,6.9 +24561,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.9 +24562,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.4 +24563,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.4 +24564,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",306.4 +24565,Netherlands,2011,7,Total pharmaceutical sales,Million of national currency units,5210.0 +24566,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,10.2 +24567,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.3 +24568,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.3 +24569,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,242.8 +24570,Netherlands,2011,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",373.3 +24571,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,174.4 +24572,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +24573,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.5 +24574,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +24575,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.5 +24576,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +24577,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +24578,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.6 +24579,Netherlands,2011,7,Total pharmaceutical sales,"Million US$, purchasing power parity",6231.5 +24580,Netherlands,2011,7,Total pharmaceutical sales,Million US$ at exchange rate,7252.1 +24581,Netherlands,2011,7,Total pharmaceutical sales,"/capita, US$ exchange rate",434.4 +24582,Netherlands,2011,7,N-Nervous system,Million US$ at exchange rate,877.2 +24583,Netherlands,2011,7,N-Nervous system,Million of national currency units,630.2 +24584,Netherlands,2011,7,N-Nervous system,"Million US$, purchasing power parity",753.8 +24585,Netherlands,2011,7,N-Nervous system,% of total sales,12.1 +24586,Netherlands,2011,7,N-Nervous system,"/capita, US$ purchasing power parity",45.2 +24587,Netherlands,2011,7,N-Nervous system,"/capita, US$ exchange rate",52.6 +24588,Netherlands,2011,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.9 +24589,Netherlands,2011,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.1 +24590,Netherlands,2011,7,C-Cardiovascular system,Million of national currency units,896.2 +24591,Netherlands,2011,7,C-Cardiovascular system,Million US$ at exchange rate,1247.4 +24592,Netherlands,2011,7,C-Cardiovascular system,"Million US$, purchasing power parity",1071.9 +24593,Netherlands,2011,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.6 +24594,Netherlands,2011,7,J01-Antibacterials for systemic use,Million of national currency units,126.9 +24595,Netherlands,2011,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,176.7 +24596,Netherlands,2011,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",151.8 +24597,Netherlands,2011,7,C-Cardiovascular system,"/capita, US$ exchange rate",74.7 +24598,Netherlands,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9 +24599,Netherlands,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0 +24600,Netherlands,2011,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8 +24601,Netherlands,2011,7,N05C-Hypnotics and sedatives,% of total sales,0.2 +24602,Netherlands,2011,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.2 +24603,Netherlands,2011,7,C-Cardiovascular system,% of total sales,17.2 +24604,Netherlands,2011,7,J01-Antibacterials for systemic use,% of total sales,2.4 +24605,Netherlands,2011,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.3 +24606,Netherlands,2011,7,A10-Drugs used in diabetes,% of total sales,4.8 +24607,Netherlands,2011,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1 +24608,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.4 +24609,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.2 +24610,Netherlands,2011,7,A10-Drugs used in diabetes,Million of national currency units,252.0 +24611,Netherlands,2011,7,A10-Drugs used in diabetes,Million US$ at exchange rate,350.8 +24612,Netherlands,2011,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",301.5 +24613,Netherlands,2011,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.0 +24614,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.0 +24615,Netherlands,2011,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.7 +24616,Netherlands,2011,7,C01A-Cardiac glycosides,Million US$ at exchange rate,9.0 +24617,Netherlands,2011,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5 +24618,Netherlands,2011,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +24619,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",86.3 +24620,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,100.4 +24621,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,72.2 +24622,Netherlands,2011,7,C01A-Cardiac glycosides,Million of national currency units,6.5 +24623,Netherlands,2011,7,C01A-Cardiac glycosides,% of total sales,0.1 +24624,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,127.6 +24625,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,91.7 +24626,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.6 +24627,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",109.6 +24628,Netherlands,2011,7,A02A-Antacids,"/capita, US$ exchange rate",0.0 +24629,Netherlands,2011,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +24630,Netherlands,2011,7,A02A-Antacids,% of total sales,0.0 +24631,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.6 +24632,Netherlands,2011,7,C07-Beta blocking agents,"Million US$, purchasing power parity",115.5 +24633,Netherlands,2011,7,C07-Beta blocking agents,Million US$ at exchange rate,134.4 +24634,Netherlands,2011,7,C07-Beta blocking agents,Million of national currency units,96.6 +24635,Netherlands,2011,7,N06A-Antidepressants,"/capita, US$ exchange rate",8.0 +24636,Netherlands,2011,7,C07-Beta blocking agents,"/capita, US$ exchange rate",8.1 +24637,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +24638,Netherlands,2011,7,C07-Beta blocking agents,% of total sales,1.9 +24639,Netherlands,2011,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.9 +24640,Netherlands,2011,7,A02A-Antacids,"Million US$, purchasing power parity",0.0 +24641,Netherlands,2011,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",72.8 +24642,Netherlands,2011,7,C08-Calcium channel blockers,Million US$ at exchange rate,84.7 +24643,Netherlands,2011,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4 +24644,Netherlands,2011,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1 +24645,Netherlands,2011,7,N05C-Hypnotics and sedatives,Million of national currency units,12.4 +24646,Netherlands,2011,7,N06A-Antidepressants,Million of national currency units,95.7 +24647,Netherlands,2011,7,N06A-Antidepressants,Million US$ at exchange rate,133.3 +24648,Netherlands,2011,7,N06A-Antidepressants,"Million US$, purchasing power parity",114.5 +24649,Netherlands,2011,7,C08-Calcium channel blockers,Million of national currency units,60.9 +24650,Netherlands,2011,7,C08-Calcium channel blockers,% of total sales,1.2 +24651,Netherlands,2011,7,N02-Analgesics,% of total sales,3.1 +24652,Netherlands,2011,7,N02-Analgesics,"/capita, US$ purchasing power parity",11.4 +24653,Netherlands,2011,7,A02A-Antacids,Million US$ at exchange rate,0.0 +24654,Netherlands,2011,7,A02A-Antacids,Million of national currency units,0.0 +24655,Netherlands,2011,7,N02-Analgesics,Million of national currency units,159.7 +24656,Netherlands,2011,7,N02-Analgesics,Million US$ at exchange rate,222.3 +24657,Netherlands,2011,7,N02-Analgesics,"Million US$, purchasing power parity",191.1 +24658,Netherlands,2011,7,N02-Analgesics,"/capita, US$ exchange rate",13.3 +24659,Netherlands,2011,7,C03-Diuretics,% of total sales,1.5 +24660,Netherlands,2011,7,N05B-Anxiolytics,Million of national currency units,20.3 +24661,Netherlands,2011,7,R-Respiratory system,Million of national currency units,586.7 +24662,Netherlands,2011,7,R-Respiratory system,Million US$ at exchange rate,816.7 +24663,Netherlands,2011,7,R-Respiratory system,"Million US$, purchasing power parity",701.8 +24664,Netherlands,2011,7,N05B-Anxiolytics,Million US$ at exchange rate,28.3 +24665,Netherlands,2011,7,N05B-Anxiolytics,% of total sales,0.4 +24666,Netherlands,2011,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5 +24667,Netherlands,2011,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7 +24668,Netherlands,2011,7,N05B-Anxiolytics,"Million US$, purchasing power parity",24.3 +24669,Netherlands,2011,7,R-Respiratory system,% of total sales,11.3 +24670,Netherlands,2011,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",179.2 +24671,Netherlands,2011,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,208.5 +24672,Netherlands,2011,7,R-Respiratory system,"/capita, US$ purchasing power parity",42.0 +24673,Netherlands,2011,7,G-Genito urinary system and sex hormones,% of total sales,2.9 +24674,Netherlands,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.7 +24675,Netherlands,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.5 +24676,Netherlands,2011,7,R-Respiratory system,"/capita, US$ exchange rate",48.9 +24677,Netherlands,2011,7,C02-Antihypertensives,% of total sales,0.7 +24678,Netherlands,2011,7,C10-Lipid modifying agents,Million of national currency units,309.8 +24679,Netherlands,2011,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",370.5 +24680,Netherlands,2011,7,C10-Lipid modifying agents,Million US$ at exchange rate,431.2 +24681,Netherlands,2011,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5 +24682,Netherlands,2011,7,C02-Antihypertensives,"Million US$, purchasing power parity",41.4 +24683,Netherlands,2011,7,C02-Antihypertensives,Million US$ at exchange rate,48.2 +24684,Netherlands,2011,7,C02-Antihypertensives,Million of national currency units,34.6 +24685,Netherlands,2011,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.8 +24686,Netherlands,2011,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.1 +24687,Netherlands,2011,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",818.5 +24688,Netherlands,2011,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,952.6 +24689,Netherlands,2011,7,A-Alimentary tract and metabolism,Million of national currency units,684.3 +24690,Netherlands,2011,7,G-Genito urinary system and sex hormones,Million of national currency units,149.8 +24691,Netherlands,2011,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0 +24692,Netherlands,2011,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.2 +24693,Netherlands,2011,7,C10-Lipid modifying agents,% of total sales,5.9 +24694,Netherlands,2011,7,A-Alimentary tract and metabolism,% of total sales,13.1 +24695,Netherlands,2011,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.9 +24696,Netherlands,2011,7,M-Musculo-skeletal system,Million US$ at exchange rate,206.6 +24697,Netherlands,2011,7,C03-Diuretics,"Million US$, purchasing power parity",93.2 +24698,Netherlands,2011,7,C03-Diuretics,"/capita, US$ exchange rate",6.5 +24699,Netherlands,2011,7,M-Musculo-skeletal system,% of total sales,2.8 +24700,Netherlands,2011,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.6 +24701,Netherlands,2011,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.4 +24702,Netherlands,2011,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",177.5 +24703,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.4 +24704,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.3 +24705,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6 +24706,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",221.5 +24707,Netherlands,2011,7,C03-Diuretics,Million of national currency units,78.0 +24708,Netherlands,2011,7,M-Musculo-skeletal system,Million of national currency units,148.4 +24709,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,185.2 +24710,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,257.8 +24711,Netherlands,2011,7,C03-Diuretics,Million US$ at exchange rate,108.5 +24712,Netherlands,2011,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.6 +24713,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,% of total sales,8.4 +24714,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.7 +24715,Netherlands,2010,7,J-Antiinfectives for systemic use,Million of national currency units,350.8 +24716,Netherlands,2010,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,465.1 +24717,Netherlands,2010,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",410.8 +24718,Netherlands,2010,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.0 +24719,Netherlands,2010,7,B-Blood and blood forming organs,Million US$ at exchange rate,325.8 +24720,Netherlands,2010,7,N06A-Antidepressants,% of total sales,1.8 +24721,Netherlands,2010,7,B-Blood and blood forming organs,% of total sales,4.7 +24722,Netherlands,2010,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.3 +24723,Netherlands,2010,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.6 +24724,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,352.0 +24725,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,265.5 +24726,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.8 +24727,Netherlands,2010,7,B-Blood and blood forming organs,Million of national currency units,245.7 +24728,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",510.5 +24729,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,578.0 +24730,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,Million of national currency units,436.0 +24731,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",310.9 +24732,Netherlands,2010,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.7 +24733,Netherlands,2010,7,J-Antiinfectives for systemic use,% of total sales,6.7 +24734,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1 +24735,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.7 +24736,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.2 +24737,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,10.7 +24738,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.1 +24739,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.5 +24740,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +24741,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,169.1 +24742,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,224.1 +24743,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.9 +24744,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.2 +24745,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.5 +24746,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +24747,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +24748,Netherlands,2010,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.4 +24749,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",197.9 +24750,Netherlands,2010,7,Total pharmaceutical sales,Million of national currency units,5213.1 +24751,Netherlands,2010,7,Total pharmaceutical sales,"Million US$, purchasing power parity",6103.7 +24752,Netherlands,2010,7,Total pharmaceutical sales,"/capita, US$ exchange rate",415.9 +24753,Netherlands,2010,7,Total pharmaceutical sales,Million US$ at exchange rate,6911.1 +24754,Netherlands,2010,7,N-Nervous system,Million US$ at exchange rate,793.6 +24755,Netherlands,2010,7,N-Nervous system,Million of national currency units,598.6 +24756,Netherlands,2010,7,N-Nervous system,"Million US$, purchasing power parity",700.9 +24757,Netherlands,2010,7,N-Nervous system,% of total sales,11.5 +24758,Netherlands,2010,7,N-Nervous system,"/capita, US$ purchasing power parity",42.2 +24759,Netherlands,2010,7,N-Nervous system,"/capita, US$ exchange rate",47.8 +24760,Netherlands,2010,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3 +24761,Netherlands,2010,7,C-Cardiovascular system,Million of national currency units,906.4 +24762,Netherlands,2010,7,C-Cardiovascular system,Million US$ at exchange rate,1201.6 +24763,Netherlands,2010,7,C-Cardiovascular system,"Million US$, purchasing power parity",1061.2 +24764,Netherlands,2010,7,J01-Antibacterials for systemic use,Million of national currency units,131.9 +24765,Netherlands,2010,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,174.8 +24766,Netherlands,2010,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",154.4 +24767,Netherlands,2010,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5 +24768,Netherlands,2010,7,C-Cardiovascular system,"/capita, US$ exchange rate",72.3 +24769,Netherlands,2010,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8 +24770,Netherlands,2010,7,N05C-Hypnotics and sedatives,% of total sales,0.2 +24771,Netherlands,2010,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.7 +24772,Netherlands,2010,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9 +24773,Netherlands,2010,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.9 +24774,Netherlands,2010,7,C-Cardiovascular system,% of total sales,17.4 +24775,Netherlands,2010,7,J01-Antibacterials for systemic use,% of total sales,2.5 +24776,Netherlands,2010,7,C01A-Cardiac glycosides,% of total sales,0.1 +24777,Netherlands,2010,7,A10-Drugs used in diabetes,% of total sales,4.6 +24778,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +24779,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6 +24780,Netherlands,2010,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.1 +24781,Netherlands,2010,7,A10-Drugs used in diabetes,Million of national currency units,242.2 +24782,Netherlands,2010,7,A10-Drugs used in diabetes,Million US$ at exchange rate,321.1 +24783,Netherlands,2010,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",283.6 +24784,Netherlands,2010,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.3 +24785,Netherlands,2010,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.4 +24786,Netherlands,2010,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5 +24787,Netherlands,2010,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4 +24788,Netherlands,2010,7,C01A-Cardiac glycosides,Million US$ at exchange rate,8.4 +24789,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.8 +24790,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",143.7 +24791,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,162.7 +24792,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,122.7 +24793,Netherlands,2010,7,C01A-Cardiac glycosides,Million of national currency units,6.4 +24794,Netherlands,2010,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.5 +24795,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,125.0 +24796,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",110.4 +24797,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.5 +24798,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.6 +24799,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,94.3 +24800,Netherlands,2010,7,A02A-Antacids,"/capita, US$ exchange rate",0.0 +24801,Netherlands,2010,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +24802,Netherlands,2010,7,N06A-Antidepressants,"/capita, US$ exchange rate",7.3 +24803,Netherlands,2010,7,A02A-Antacids,% of total sales,0.0 +24804,Netherlands,2010,7,C07-Beta blocking agents,"Million US$, purchasing power parity",129.3 +24805,Netherlands,2010,7,C07-Beta blocking agents,Million US$ at exchange rate,146.4 +24806,Netherlands,2010,7,C07-Beta blocking agents,Million of national currency units,110.5 +24807,Netherlands,2010,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.5 +24808,Netherlands,2010,7,C07-Beta blocking agents,"/capita, US$ exchange rate",8.8 +24809,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +24810,Netherlands,2010,7,C07-Beta blocking agents,% of total sales,2.1 +24811,Netherlands,2010,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8 +24812,Netherlands,2010,7,A02A-Antacids,"Million US$, purchasing power parity",0.0 +24813,Netherlands,2010,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",72.9 +24814,Netherlands,2010,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0 +24815,Netherlands,2010,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4 +24816,Netherlands,2010,7,C08-Calcium channel blockers,Million US$ at exchange rate,82.5 +24817,Netherlands,2010,7,N05C-Hypnotics and sedatives,Million of national currency units,11.7 +24818,Netherlands,2010,7,N06A-Antidepressants,Million of national currency units,91.7 +24819,Netherlands,2010,7,N06A-Antidepressants,Million US$ at exchange rate,121.6 +24820,Netherlands,2010,7,N06A-Antidepressants,"Million US$, purchasing power parity",107.4 +24821,Netherlands,2010,7,C08-Calcium channel blockers,Million of national currency units,62.2 +24822,Netherlands,2010,7,C08-Calcium channel blockers,% of total sales,1.2 +24823,Netherlands,2010,7,N02-Analgesics,% of total sales,2.8 +24824,Netherlands,2010,7,A02A-Antacids,Million of national currency units,0.0 +24825,Netherlands,2010,7,A02A-Antacids,Million US$ at exchange rate,0.0 +24826,Netherlands,2010,7,N02-Analgesics,"/capita, US$ purchasing power parity",10.3 +24827,Netherlands,2010,7,N02-Analgesics,Million of national currency units,146.5 +24828,Netherlands,2010,7,N02-Analgesics,Million US$ at exchange rate,194.2 +24829,Netherlands,2010,7,N02-Analgesics,"Million US$, purchasing power parity",171.5 +24830,Netherlands,2010,7,N02-Analgesics,"/capita, US$ exchange rate",11.7 +24831,Netherlands,2010,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",287.7 +24832,Netherlands,2010,7,N05B-Anxiolytics,Million of national currency units,21.3 +24833,Netherlands,2010,7,R-Respiratory system,Million of national currency units,566.5 +24834,Netherlands,2010,7,N05B-Anxiolytics,Million US$ at exchange rate,28.3 +24835,Netherlands,2010,7,R-Respiratory system,Million US$ at exchange rate,751.0 +24836,Netherlands,2010,7,R-Respiratory system,"Million US$, purchasing power parity",663.2 +24837,Netherlands,2010,7,N05B-Anxiolytics,% of total sales,0.4 +24838,Netherlands,2010,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5 +24839,Netherlands,2010,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7 +24840,Netherlands,2010,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.8 +24841,Netherlands,2010,7,R-Respiratory system,% of total sales,10.9 +24842,Netherlands,2010,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,273.1 +24843,Netherlands,2010,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",241.2 +24844,Netherlands,2010,7,G-Genito urinary system and sex hormones,% of total sales,4.0 +24845,Netherlands,2010,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.5 +24846,Netherlands,2010,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.4 +24847,Netherlands,2010,7,R-Respiratory system,"/capita, US$ exchange rate",45.2 +24848,Netherlands,2010,7,R-Respiratory system,"/capita, US$ purchasing power parity",39.9 +24849,Netherlands,2010,7,C02-Antihypertensives,% of total sales,0.7 +24850,Netherlands,2010,7,C03-Diuretics,% of total sales,1.4 +24851,Netherlands,2010,7,C10-Lipid modifying agents,Million of national currency units,298.9 +24852,Netherlands,2010,7,C10-Lipid modifying agents,Million US$ at exchange rate,396.2 +24853,Netherlands,2010,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",349.9 +24854,Netherlands,2010,7,C02-Antihypertensives,"Million US$, purchasing power parity",41.6 +24855,Netherlands,2010,7,C02-Antihypertensives,Million US$ at exchange rate,47.1 +24856,Netherlands,2010,7,C02-Antihypertensives,Million of national currency units,35.6 +24857,Netherlands,2010,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5 +24858,Netherlands,2010,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",23.8 +24859,Netherlands,2010,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.3 +24860,Netherlands,2010,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",782.1 +24861,Netherlands,2010,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,885.6 +24862,Netherlands,2010,7,A-Alimentary tract and metabolism,Million of national currency units,668.0 +24863,Netherlands,2010,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",21.1 +24864,Netherlands,2010,7,C10-Lipid modifying agents,% of total sales,5.7 +24865,Netherlands,2010,7,A-Alimentary tract and metabolism,% of total sales,12.8 +24866,Netherlands,2010,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1 +24867,Netherlands,2010,7,G-Genito urinary system and sex hormones,Million of national currency units,206.0 +24868,Netherlands,2010,7,N05B-Anxiolytics,"Million US$, purchasing power parity",25.0 +24869,Netherlands,2010,7,M-Musculo-skeletal system,Million US$ at exchange rate,212.2 +24870,Netherlands,2010,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3 +24871,Netherlands,2010,7,C03-Diuretics,"/capita, US$ exchange rate",5.9 +24872,Netherlands,2010,7,C03-Diuretics,"Million US$, purchasing power parity",87.3 +24873,Netherlands,2010,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",187.4 +24874,Netherlands,2010,7,M-Musculo-skeletal system,% of total sales,3.1 +24875,Netherlands,2010,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3 +24876,Netherlands,2010,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.8 +24877,Netherlands,2010,7,C03-Diuretics,Million US$ at exchange rate,98.8 +24878,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.1 +24879,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.2 +24880,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9 +24881,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",236.7 +24882,Netherlands,2010,7,C03-Diuretics,Million of national currency units,74.5 +24883,Netherlands,2010,7,M-Musculo-skeletal system,Million of national currency units,160.1 +24884,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,202.1 +24885,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,268.0 +24886,Netherlands,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",340.4 +24887,Netherlands,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5831.7 +24888,Netherlands,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,5152.7 +24889,Netherlands,2017,5,Total pharmaceutical sales,Million of national currency units,4561.2 +24890,Netherlands,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",300.8 +24891,New Zealand,2011,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.6 +24892,New Zealand,2011,10,N05C-Hypnotics and sedatives,Million of national currency units,1.7 +24893,New Zealand,2011,10,Products not elsewhere classified,Million US$ at exchange rate,160.0 +24894,New Zealand,2011,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3 +24895,New Zealand,2011,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.0 +24896,New Zealand,2011,10,C08-Calcium channel blockers,Million US$ at exchange rate,11.7 +24897,New Zealand,2011,10,Products not elsewhere classified,"/capita, US$ exchange rate",36.5 +24898,New Zealand,2011,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",36.0 +24899,New Zealand,2011,10,C10-Lipid modifying agents,Million US$ at exchange rate,42.3 +24900,New Zealand,2011,10,Products not elsewhere classified,"Million US$, purchasing power parity",136.3 +24901,New Zealand,2011,10,C10-Lipid modifying agents,Million of national currency units,53.5 +24902,New Zealand,2011,10,C08-Calcium channel blockers,Million of national currency units,14.8 +24903,New Zealand,2011,10,N02-Analgesics,"/capita, US$ purchasing power parity",4.6 +24904,New Zealand,2011,10,N02-Analgesics,"Million US$, purchasing power parity",20.1 +24905,New Zealand,2011,10,N02-Analgesics,"/capita, US$ exchange rate",5.4 +24906,New Zealand,2011,10,Products not elsewhere classified,% of total sales,24.8 +24907,New Zealand,2011,10,N02-Analgesics,% of total sales,3.7 +24908,New Zealand,2011,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +24909,New Zealand,2011,10,C08-Calcium channel blockers,% of total sales,1.8 +24910,New Zealand,2011,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7 +24911,New Zealand,2011,10,N02-Analgesics,Million US$ at exchange rate,23.6 +24912,New Zealand,2011,10,N02-Analgesics,Million of national currency units,29.8 +24913,New Zealand,2011,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",31.1 +24914,New Zealand,2011,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.8 +24915,New Zealand,2011,10,B-Blood and blood forming organs,Million of national currency units,26.3 +24916,New Zealand,2011,10,G-Genito urinary system and sex hormones,Million of national currency units,21.3 +24917,New Zealand,2011,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.7 +24918,New Zealand,2011,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",17.7 +24919,New Zealand,2011,10,B-Blood and blood forming organs,Million US$ at exchange rate,20.7 +24920,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.6 +24921,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.9 +24922,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.4 +24923,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0 +24924,New Zealand,2011,10,C10-Lipid modifying agents,% of total sales,6.6 +24925,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.2 +24926,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.5 +24927,New Zealand,2011,10,N05C-Hypnotics and sedatives,% of total sales,0.2 +24928,New Zealand,2011,10,B-Blood and blood forming organs,% of total sales,3.2 +24929,New Zealand,2011,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +24930,New Zealand,2011,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1 +24931,New Zealand,2011,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.3 +24932,New Zealand,2011,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.0 +24933,New Zealand,2011,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.3 +24934,New Zealand,2011,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8 +24935,New Zealand,2011,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.2 +24936,New Zealand,2011,10,Products not elsewhere classified,Million of national currency units,202.6 +24937,New Zealand,2011,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3 +24938,New Zealand,2011,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",33.6 +24939,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.3 +24940,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2 +24941,New Zealand,2011,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,39.5 +24942,New Zealand,2011,10,R-Respiratory system,Million US$ at exchange rate,65.7 +24943,New Zealand,2011,10,R-Respiratory system,"Million US$, purchasing power parity",56.0 +24944,New Zealand,2011,10,J-Antiinfectives for systemic use,Million of national currency units,50.0 +24945,New Zealand,2011,10,R-Respiratory system,Million of national currency units,83.2 +24946,New Zealand,2011,10,N05B-Anxiolytics,Million of national currency units,1.2 +24947,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +24948,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,Million of national currency units,73.3 +24949,New Zealand,2011,10,N05B-Anxiolytics,Million US$ at exchange rate,0.9 +24950,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34.6 +24951,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",6.2 +24952,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.3 +24953,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,27.3 +24954,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.9 +24955,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +24956,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,11.9 +24957,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,14.7 +24958,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4 +24959,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.6 +24960,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18.7 +24961,New Zealand,2011,10,R-Respiratory system,% of total sales,10.2 +24962,New Zealand,2011,10,R-Respiratory system,"/capita, US$ purchasing power parity",12.8 +24963,New Zealand,2011,10,R-Respiratory system,"/capita, US$ exchange rate",15.0 +24964,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.0 +24965,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,9.4 +24966,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.8 +24967,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.1 +24968,New Zealand,2011,10,N06A-Antidepressants,Million US$ at exchange rate,25.4 +24969,New Zealand,2011,10,N06A-Antidepressants,"Million US$, purchasing power parity",21.7 +24970,New Zealand,2011,10,N06A-Antidepressants,Million of national currency units,32.2 +24971,New Zealand,2011,10,N06A-Antidepressants,% of total sales,3.9 +24972,New Zealand,2011,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2 +24973,New Zealand,2011,10,N06A-Antidepressants,"/capita, US$ exchange rate",5.8 +24974,New Zealand,2011,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.9 +24975,New Zealand,2011,10,G-Genito urinary system and sex hormones,% of total sales,2.6 +24976,New Zealand,2011,10,A02A-Antacids,Million of national currency units,0.3 +24977,New Zealand,2011,10,A02A-Antacids,Million US$ at exchange rate,0.2 +24978,New Zealand,2011,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +24979,New Zealand,2011,10,N05B-Anxiolytics,% of total sales,0.1 +24980,New Zealand,2011,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8 +24981,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,% of total sales,9.0 +24982,New Zealand,2011,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",7.7 +24983,New Zealand,2011,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.0 +24984,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",49.4 +24985,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,57.9 +24986,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",11.3 +24987,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.2 +24988,New Zealand,2011,10,A02A-Antacids,"/capita, US$ exchange rate",0.0 +24989,New Zealand,2011,10,A02A-Antacids,"Million US$, purchasing power parity",0.2 +24990,New Zealand,2011,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +24991,New Zealand,2011,10,J-Antiinfectives for systemic use,% of total sales,6.1 +24992,New Zealand,2011,10,A02A-Antacids,% of total sales,0.0 +24993,New Zealand,2011,10,C07-Beta blocking agents,Million US$ at exchange rate,14.4 +24994,New Zealand,2011,10,C07-Beta blocking agents,Million of national currency units,18.2 +24995,New Zealand,2011,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",20.7 +24996,New Zealand,2011,10,C07-Beta blocking agents,"/capita, US$ exchange rate",3.3 +24997,New Zealand,2011,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.8 +24998,New Zealand,2011,10,C07-Beta blocking agents,"Million US$, purchasing power parity",12.3 +24999,New Zealand,2011,10,M-Musculo-skeletal system,% of total sales,3.2 +25000,New Zealand,2011,10,C03-Diuretics,Million US$ at exchange rate,1.8 +25001,New Zealand,2011,10,C-Cardiovascular system,% of total sales,16.5 +25002,New Zealand,2011,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.7 +25003,New Zealand,2011,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.0 +25004,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.4 +25005,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2 +25006,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.2 +25007,New Zealand,2011,10,M-Musculo-skeletal system,Million of national currency units,26.2 +25008,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.5 +25009,New Zealand,2011,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.6 +25010,New Zealand,2011,10,C07-Beta blocking agents,% of total sales,2.2 +25011,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +25012,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0 +25013,New Zealand,2011,10,M-Musculo-skeletal system,Million US$ at exchange rate,20.7 +25014,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.8 +25015,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.8 +25016,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2 +25017,New Zealand,2011,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",125.4 +25018,New Zealand,2011,10,Total pharmaceutical sales,"/capita, US$ exchange rate",147.2 +25019,New Zealand,2011,10,N-Nervous system,% of total sales,22.3 +25020,New Zealand,2011,10,C02-Antihypertensives,Million US$ at exchange rate,2.4 +25021,New Zealand,2011,10,C02-Antihypertensives,Million of national currency units,3.0 +25022,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.6 +25023,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +25024,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +25025,New Zealand,2011,10,N-Nervous system,Million of national currency units,182.6 +25026,New Zealand,2011,10,C03-Diuretics,% of total sales,0.3 +25027,New Zealand,2011,10,Total pharmaceutical sales,Million of national currency units,817.0 +25028,New Zealand,2011,10,C03-Diuretics,"Million US$, purchasing power parity",1.5 +25029,New Zealand,2011,10,C03-Diuretics,"/capita, US$ exchange rate",0.4 +25030,New Zealand,2011,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.4 +25031,New Zealand,2011,10,Total pharmaceutical sales,Million US$ at exchange rate,645.4 +25032,New Zealand,2011,10,N-Nervous system,"/capita, US$ purchasing power parity",28.0 +25033,New Zealand,2011,10,Total pharmaceutical sales,"Million US$, purchasing power parity",549.8 +25034,New Zealand,2011,10,N-Nervous system,"Million US$, purchasing power parity",122.9 +25035,New Zealand,2011,10,N-Nervous system,Million US$ at exchange rate,144.2 +25036,New Zealand,2011,10,N-Nervous system,"/capita, US$ exchange rate",32.9 +25037,New Zealand,2011,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",3.4 +25038,New Zealand,2011,10,J01-Antibacterials for systemic use,% of total sales,2.3 +25039,New Zealand,2011,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9 +25040,New Zealand,2011,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.9 +25041,New Zealand,2011,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.7 +25042,New Zealand,2011,10,C-Cardiovascular system,"/capita, US$ exchange rate",24.2 +25043,New Zealand,2011,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +25044,New Zealand,2011,10,C01A-Cardiac glycosides,Million of national currency units,0.4 +25045,New Zealand,2011,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +25046,New Zealand,2011,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +25047,New Zealand,2011,10,A10-Drugs used in diabetes,Million US$ at exchange rate,25.6 +25048,New Zealand,2011,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",21.8 +25049,New Zealand,2011,10,C02-Antihypertensives,% of total sales,0.4 +25050,New Zealand,2011,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +25051,New Zealand,2011,10,A10-Drugs used in diabetes,Million of national currency units,32.4 +25052,New Zealand,2011,10,J01-Antibacterials for systemic use,Million of national currency units,18.9 +25053,New Zealand,2011,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",5.8 +25054,New Zealand,2011,10,C-Cardiovascular system,Million of national currency units,134.6 +25055,New Zealand,2011,10,C-Cardiovascular system,"Million US$, purchasing power parity",90.6 +25056,New Zealand,2011,10,C-Cardiovascular system,Million US$ at exchange rate,106.3 +25057,New Zealand,2011,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.0 +25058,New Zealand,2011,10,A10-Drugs used in diabetes,% of total sales,4.0 +25059,New Zealand,2011,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",12.9 +25060,New Zealand,2011,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",48.2 +25061,New Zealand,2011,10,A-Alimentary tract and metabolism,% of total sales,8.8 +25062,New Zealand,2011,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",11.0 +25063,New Zealand,2011,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +25064,New Zealand,2011,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.0 +25065,New Zealand,2011,10,C03-Diuretics,Million of national currency units,2.3 +25066,New Zealand,2011,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,56.6 +25067,New Zealand,2011,10,A-Alimentary tract and metabolism,Million of national currency units,71.7 +25068,New Zealand,2011,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +25069,New Zealand,2011,10,C01A-Cardiac glycosides,% of total sales,0.0 +25070,New Zealand,2017,9,C08-Calcium channel blockers,Million of national currency units,5.8 +25071,New Zealand,2017,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.4 +25072,New Zealand,2017,9,N05C-Hypnotics and sedatives,Million of national currency units,1.1 +25073,New Zealand,2017,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.8 +25074,New Zealand,2017,9,C08-Calcium channel blockers,Million US$ at exchange rate,4.1 +25075,New Zealand,2017,9,Products not elsewhere classified,"Million US$, purchasing power parity",456.5 +25076,New Zealand,2017,9,C10-Lipid modifying agents,Million US$ at exchange rate,6.5 +25077,New Zealand,2017,9,Products not elsewhere classified,Million US$ at exchange rate,464.1 +25078,New Zealand,2017,9,C10-Lipid modifying agents,Million of national currency units,9.1 +25079,New Zealand,2017,9,N02-Analgesics,"/capita, US$ exchange rate",2.5 +25080,New Zealand,2017,9,N02-Analgesics,"/capita, US$ purchasing power parity",2.5 +25081,New Zealand,2017,9,N02-Analgesics,"Million US$, purchasing power parity",11.8 +25082,New Zealand,2017,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",94.8 +25083,New Zealand,2017,9,Products not elsewhere classified,% of total sales,51.7 +25084,New Zealand,2017,9,N02-Analgesics,% of total sales,1.3 +25085,New Zealand,2017,9,N02-Analgesics,Million US$ at exchange rate,12.0 +25086,New Zealand,2017,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8 +25087,New Zealand,2017,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0 +25088,New Zealand,2017,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.8 +25089,New Zealand,2017,9,N02-Analgesics,Million of national currency units,16.9 +25090,New Zealand,2017,9,C08-Calcium channel blockers,% of total sales,0.5 +25091,New Zealand,2017,9,Products not elsewhere classified,"/capita, US$ exchange rate",96.4 +25092,New Zealand,2017,9,G-Genito urinary system and sex hormones,Million of national currency units,20.2 +25093,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +25094,New Zealand,2017,9,B-Blood and blood forming organs,Million of national currency units,68.3 +25095,New Zealand,2017,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",47.7 +25096,New Zealand,2017,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.3 +25097,New Zealand,2017,9,B-Blood and blood forming organs,Million US$ at exchange rate,48.5 +25098,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.9 +25099,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7 +25100,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.1 +25101,New Zealand,2017,9,C10-Lipid modifying agents,% of total sales,0.7 +25102,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.6 +25103,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.4 +25104,New Zealand,2017,9,N05C-Hypnotics and sedatives,% of total sales,0.1 +25105,New Zealand,2017,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.3 +25106,New Zealand,2017,9,B-Blood and blood forming organs,% of total sales,5.4 +25107,New Zealand,2017,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.8 +25108,New Zealand,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +25109,New Zealand,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2 +25110,New Zealand,2017,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.1 +25111,New Zealand,2017,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.1 +25112,New Zealand,2017,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.9 +25113,New Zealand,2017,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3 +25114,New Zealand,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.0 +25115,New Zealand,2017,9,Products not elsewhere classified,Million of national currency units,653.2 +25116,New Zealand,2017,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,121.0 +25117,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,0.9 +25118,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.7 +25119,New Zealand,2017,9,R-Respiratory system,Million US$ at exchange rate,69.3 +25120,New Zealand,2017,9,R-Respiratory system,Million of national currency units,97.6 +25121,New Zealand,2017,9,J-Antiinfectives for systemic use,Million of national currency units,170.3 +25122,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9 +25123,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,Million of national currency units,89.1 +25124,New Zealand,2017,9,N05B-Anxiolytics,Million of national currency units,1.2 +25125,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",8.2 +25126,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",1.7 +25127,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.8 +25128,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,8.4 +25129,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6 +25130,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7 +25131,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.9 +25132,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +25133,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,25.0 +25134,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,17.8 +25135,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",17.5 +25136,New Zealand,2017,9,R-Respiratory system,"/capita, US$ purchasing power parity",14.2 +25137,New Zealand,2017,9,R-Respiratory system,% of total sales,7.7 +25138,New Zealand,2017,9,R-Respiratory system,"Million US$, purchasing power parity",68.2 +25139,New Zealand,2017,9,R-Respiratory system,"/capita, US$ exchange rate",14.4 +25140,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2 +25141,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.1 +25142,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.9 +25143,New Zealand,2017,9,N06A-Antidepressants,Million US$ at exchange rate,9.6 +25144,New Zealand,2017,9,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9 +25145,New Zealand,2017,9,N06A-Antidepressants,Million of national currency units,13.5 +25146,New Zealand,2017,9,N06A-Antidepressants,"Million US$, purchasing power parity",9.4 +25147,New Zealand,2017,9,N06A-Antidepressants,% of total sales,1.1 +25148,New Zealand,2017,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.0 +25149,New Zealand,2017,9,N06A-Antidepressants,"/capita, US$ exchange rate",2.0 +25150,New Zealand,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",2.9 +25151,New Zealand,2017,9,G-Genito urinary system and sex hormones,% of total sales,1.6 +25152,New Zealand,2017,9,A02A-Antacids,Million of national currency units,0.3 +25153,New Zealand,2017,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +25154,New Zealand,2017,9,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2 +25155,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.5 +25156,New Zealand,2017,9,N05B-Anxiolytics,% of total sales,0.1 +25157,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,% of total sales,7.1 +25158,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.9 +25159,New Zealand,2017,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",119.0 +25160,New Zealand,2017,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.1 +25161,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,63.3 +25162,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",62.2 +25163,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.1 +25164,New Zealand,2017,9,A02A-Antacids,"Million US$, purchasing power parity",0.2 +25165,New Zealand,2017,9,A02A-Antacids,"/capita, US$ exchange rate",0.0 +25166,New Zealand,2017,9,N05B-Anxiolytics,Million US$ at exchange rate,0.9 +25167,New Zealand,2017,9,A02A-Antacids,Million US$ at exchange rate,0.2 +25168,New Zealand,2017,9,J-Antiinfectives for systemic use,% of total sales,13.5 +25169,New Zealand,2017,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.7 +25170,New Zealand,2017,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +25171,New Zealand,2017,9,A02A-Antacids,% of total sales,0.0 +25172,New Zealand,2017,9,C07-Beta blocking agents,Million of national currency units,12.1 +25173,New Zealand,2017,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",7.5 +25174,New Zealand,2017,9,C07-Beta blocking agents,Million US$ at exchange rate,8.6 +25175,New Zealand,2017,9,C07-Beta blocking agents,"/capita, US$ exchange rate",1.8 +25176,New Zealand,2017,9,C07-Beta blocking agents,"Million US$, purchasing power parity",8.5 +25177,New Zealand,2017,9,M-Musculo-skeletal system,% of total sales,1.7 +25178,New Zealand,2017,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.1 +25179,New Zealand,2017,9,C03-Diuretics,Million of national currency units,2.3 +25180,New Zealand,2017,9,C-Cardiovascular system,% of total sales,4.1 +25181,New Zealand,2017,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.2 +25182,New Zealand,2017,9,C03-Diuretics,Million US$ at exchange rate,1.7 +25183,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.0 +25184,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.9 +25185,New Zealand,2017,9,C02-Antihypertensives,Million US$ at exchange rate,1.6 +25186,New Zealand,2017,9,M-Musculo-skeletal system,Million of national currency units,21.7 +25187,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.0 +25188,New Zealand,2017,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.2 +25189,New Zealand,2017,9,C07-Beta blocking agents,% of total sales,1.0 +25190,New Zealand,2017,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.8 +25191,New Zealand,2017,9,M-Musculo-skeletal system,Million US$ at exchange rate,15.4 +25192,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0 +25193,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.6 +25194,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.1 +25195,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.9 +25196,New Zealand,2017,9,N-Nervous system,% of total sales,13.3 +25197,New Zealand,2017,9,Total pharmaceutical sales,"/capita, US$ exchange rate",186.3 +25198,New Zealand,2017,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",183.2 +25199,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +25200,New Zealand,2017,9,C02-Antihypertensives,Million of national currency units,2.2 +25201,New Zealand,2017,9,C03-Diuretics,% of total sales,0.2 +25202,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +25203,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.9 +25204,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +25205,New Zealand,2017,9,N-Nervous system,Million of national currency units,167.6 +25206,New Zealand,2017,9,Total pharmaceutical sales,Million of national currency units,1262.2 +25207,New Zealand,2017,9,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +25208,New Zealand,2017,9,C03-Diuretics,"Million US$, purchasing power parity",1.6 +25209,New Zealand,2017,9,C03-Diuretics,"/capita, US$ exchange rate",0.3 +25210,New Zealand,2017,9,N-Nervous system,"/capita, US$ purchasing power parity",24.3 +25211,New Zealand,2017,9,Total pharmaceutical sales,"Million US$, purchasing power parity",882.1 +25212,New Zealand,2017,9,Total pharmaceutical sales,Million US$ at exchange rate,896.8 +25213,New Zealand,2017,9,N-Nervous system,Million US$ at exchange rate,119.1 +25214,New Zealand,2017,9,N-Nervous system,"/capita, US$ exchange rate",24.7 +25215,New Zealand,2017,9,N-Nervous system,"Million US$, purchasing power parity",117.1 +25216,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.0 +25217,New Zealand,2017,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.3 +25218,New Zealand,2017,9,J01-Antibacterials for systemic use,Million of national currency units,15.3 +25219,New Zealand,2017,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.9 +25220,New Zealand,2017,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",10.7 +25221,New Zealand,2017,9,C-Cardiovascular system,"Million US$, purchasing power parity",36.1 +25222,New Zealand,2017,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +25223,New Zealand,2017,9,C-Cardiovascular system,"/capita, US$ exchange rate",7.6 +25224,New Zealand,2017,9,J01-Antibacterials for systemic use,% of total sales,1.2 +25225,New Zealand,2017,9,C01A-Cardiac glycosides,Million of national currency units,0.4 +25226,New Zealand,2017,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +25227,New Zealand,2017,9,A10-Drugs used in diabetes,Million US$ at exchange rate,37.8 +25228,New Zealand,2017,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",37.2 +25229,New Zealand,2017,9,A10-Drugs used in diabetes,Million of national currency units,53.2 +25230,New Zealand,2017,9,C02-Antihypertensives,% of total sales,0.2 +25231,New Zealand,2017,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3 +25232,New Zealand,2017,9,C-Cardiovascular system,Million of national currency units,51.6 +25233,New Zealand,2017,9,C-Cardiovascular system,Million US$ at exchange rate,36.7 +25234,New Zealand,2017,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.9 +25235,New Zealand,2017,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",7.7 +25236,New Zealand,2017,9,A10-Drugs used in diabetes,% of total sales,4.2 +25237,New Zealand,2017,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.2 +25238,New Zealand,2017,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.1 +25239,New Zealand,2017,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",62.0 +25240,New Zealand,2017,9,A-Alimentary tract and metabolism,% of total sales,7.0 +25241,New Zealand,2017,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",12.9 +25242,New Zealand,2017,9,C02-Antihypertensives,"Million US$, purchasing power parity",1.6 +25243,New Zealand,2017,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +25244,New Zealand,2017,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,63.0 +25245,New Zealand,2017,9,A-Alimentary tract and metabolism,Million of national currency units,88.7 +25246,New Zealand,2017,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +25247,New Zealand,2017,9,C01A-Cardiac glycosides,% of total sales,0.0 +25248,New Zealand,2017,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +25249,New Zealand,2016,10,N05C-Hypnotics and sedatives,Million of national currency units,1.8 +25250,New Zealand,2016,10,C08-Calcium channel blockers,Million of national currency units,5.7 +25251,New Zealand,2016,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",8.1 +25252,New Zealand,2016,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2 +25253,New Zealand,2016,10,C08-Calcium channel blockers,Million US$ at exchange rate,4.0 +25254,New Zealand,2016,10,C10-Lipid modifying agents,Million US$ at exchange rate,8.1 +25255,New Zealand,2016,10,Products not elsewhere classified,"Million US$, purchasing power parity",266.2 +25256,New Zealand,2016,10,Products not elsewhere classified,Million US$ at exchange rate,267.0 +25257,New Zealand,2016,10,C10-Lipid modifying agents,Million of national currency units,11.7 +25258,New Zealand,2016,10,N02-Analgesics,"/capita, US$ exchange rate",2.9 +25259,New Zealand,2016,10,N02-Analgesics,"/capita, US$ purchasing power parity",2.9 +25260,New Zealand,2016,10,N02-Analgesics,"Million US$, purchasing power parity",13.6 +25261,New Zealand,2016,10,Products not elsewhere classified,% of total sales,35.8 +25262,New Zealand,2016,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",56.5 +25263,New Zealand,2016,10,N02-Analgesics,% of total sales,1.8 +25264,New Zealand,2016,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8 +25265,New Zealand,2016,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0 +25266,New Zealand,2016,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.8 +25267,New Zealand,2016,10,N02-Analgesics,Million of national currency units,19.6 +25268,New Zealand,2016,10,N02-Analgesics,Million US$ at exchange rate,13.7 +25269,New Zealand,2016,10,C08-Calcium channel blockers,% of total sales,0.5 +25270,New Zealand,2016,10,Products not elsewhere classified,"/capita, US$ exchange rate",56.6 +25271,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +25272,New Zealand,2016,10,G-Genito urinary system and sex hormones,Million of national currency units,21.6 +25273,New Zealand,2016,10,B-Blood and blood forming organs,Million of national currency units,84.8 +25274,New Zealand,2016,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.8 +25275,New Zealand,2016,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.0 +25276,New Zealand,2016,10,B-Blood and blood forming organs,Million US$ at exchange rate,59.0 +25277,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.8 +25278,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9 +25279,New Zealand,2016,10,C10-Lipid modifying agents,% of total sales,1.1 +25280,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.8 +25281,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.6 +25282,New Zealand,2016,10,N05C-Hypnotics and sedatives,% of total sales,0.2 +25283,New Zealand,2016,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.7 +25284,New Zealand,2016,10,B-Blood and blood forming organs,% of total sales,7.9 +25285,New Zealand,2016,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.2 +25286,New Zealand,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +25287,New Zealand,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.3 +25288,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9 +25289,New Zealand,2016,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.5 +25290,New Zealand,2016,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.5 +25291,New Zealand,2016,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.0 +25292,New Zealand,2016,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.7 +25293,New Zealand,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.2 +25294,New Zealand,2016,10,Products not elsewhere classified,Million of national currency units,383.6 +25295,New Zealand,2016,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,80.0 +25296,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.1 +25297,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.8 +25298,New Zealand,2016,10,R-Respiratory system,Million US$ at exchange rate,71.9 +25299,New Zealand,2016,10,J-Antiinfectives for systemic use,Million of national currency units,114.9 +25300,New Zealand,2016,10,R-Respiratory system,Million of national currency units,103.2 +25301,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9 +25302,New Zealand,2016,10,N05B-Anxiolytics,Million of national currency units,2.7 +25303,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,Million of national currency units,92.7 +25304,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",8.5 +25305,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",1.8 +25306,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3 +25307,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,8.6 +25308,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1 +25309,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.0 +25310,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +25311,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.2 +25312,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,28.2 +25313,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,19.6 +25314,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.6 +25315,New Zealand,2016,10,R-Respiratory system,"/capita, US$ purchasing power parity",15.2 +25316,New Zealand,2016,10,R-Respiratory system,% of total sales,9.6 +25317,New Zealand,2016,10,R-Respiratory system,"Million US$, purchasing power parity",71.6 +25318,New Zealand,2016,10,R-Respiratory system,"/capita, US$ exchange rate",15.2 +25319,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2 +25320,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.2 +25321,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.9 +25322,New Zealand,2016,10,N06A-Antidepressants,Million US$ at exchange rate,9.5 +25323,New Zealand,2016,10,N06A-Antidepressants,"Million US$, purchasing power parity",9.5 +25324,New Zealand,2016,10,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9 +25325,New Zealand,2016,10,N06A-Antidepressants,Million of national currency units,13.7 +25326,New Zealand,2016,10,N06A-Antidepressants,% of total sales,1.3 +25327,New Zealand,2016,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.0 +25328,New Zealand,2016,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.0 +25329,New Zealand,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.2 +25330,New Zealand,2016,10,G-Genito urinary system and sex hormones,% of total sales,2.0 +25331,New Zealand,2016,10,A02A-Antacids,Million US$ at exchange rate,0.3 +25332,New Zealand,2016,10,A02A-Antacids,Million of national currency units,0.4 +25333,New Zealand,2016,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.4 +25334,New Zealand,2016,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.4 +25335,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.6 +25336,New Zealand,2016,10,N05B-Anxiolytics,% of total sales,0.3 +25337,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,% of total sales,8.7 +25338,New Zealand,2016,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",79.8 +25339,New Zealand,2016,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.0 +25340,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.7 +25341,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,64.6 +25342,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",64.4 +25343,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7 +25344,New Zealand,2016,10,A02A-Antacids,"/capita, US$ exchange rate",0.1 +25345,New Zealand,2016,10,A02A-Antacids,"Million US$, purchasing power parity",0.3 +25346,New Zealand,2016,10,N05B-Anxiolytics,Million US$ at exchange rate,1.9 +25347,New Zealand,2016,10,J-Antiinfectives for systemic use,% of total sales,10.7 +25348,New Zealand,2016,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.9 +25349,New Zealand,2016,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +25350,New Zealand,2016,10,A02A-Antacids,% of total sales,0.0 +25351,New Zealand,2016,10,C07-Beta blocking agents,Million of national currency units,7.9 +25352,New Zealand,2016,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",7.5 +25353,New Zealand,2016,10,C07-Beta blocking agents,Million US$ at exchange rate,5.5 +25354,New Zealand,2016,10,C07-Beta blocking agents,"/capita, US$ exchange rate",1.2 +25355,New Zealand,2016,10,C07-Beta blocking agents,"Million US$, purchasing power parity",5.5 +25356,New Zealand,2016,10,M-Musculo-skeletal system,% of total sales,2.0 +25357,New Zealand,2016,10,C03-Diuretics,Million US$ at exchange rate,1.6 +25358,New Zealand,2016,10,C03-Diuretics,Million of national currency units,2.2 +25359,New Zealand,2016,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2 +25360,New Zealand,2016,10,C-Cardiovascular system,% of total sales,4.8 +25361,New Zealand,2016,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.2 +25362,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.5 +25363,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2 +25364,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5 +25365,New Zealand,2016,10,C02-Antihypertensives,Million US$ at exchange rate,1.8 +25366,New Zealand,2016,10,M-Musculo-skeletal system,Million of national currency units,21.7 +25367,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.9 +25368,New Zealand,2016,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.1 +25369,New Zealand,2016,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.2 +25370,New Zealand,2016,10,C07-Beta blocking agents,% of total sales,0.7 +25371,New Zealand,2016,10,M-Musculo-skeletal system,Million US$ at exchange rate,15.1 +25372,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.2 +25373,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.7 +25374,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.7 +25375,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3 +25376,New Zealand,2016,10,N-Nervous system,% of total sales,16.0 +25377,New Zealand,2016,10,Total pharmaceutical sales,"/capita, US$ exchange rate",158.3 +25378,New Zealand,2016,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",157.8 +25379,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.3 +25380,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4 +25381,New Zealand,2016,10,C03-Diuretics,% of total sales,0.2 +25382,New Zealand,2016,10,C02-Antihypertensives,Million of national currency units,2.6 +25383,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +25384,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +25385,New Zealand,2016,10,N-Nervous system,Million of national currency units,171.8 +25386,New Zealand,2016,10,Total pharmaceutical sales,Million of national currency units,1072.1 +25387,New Zealand,2016,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +25388,New Zealand,2016,10,C03-Diuretics,"Million US$, purchasing power parity",1.6 +25389,New Zealand,2016,10,C03-Diuretics,"/capita, US$ exchange rate",0.3 +25390,New Zealand,2016,10,N-Nervous system,"/capita, US$ purchasing power parity",25.3 +25391,New Zealand,2016,10,Total pharmaceutical sales,Million US$ at exchange rate,746.3 +25392,New Zealand,2016,10,Total pharmaceutical sales,"Million US$, purchasing power parity",744.0 +25393,New Zealand,2016,10,N-Nervous system,Million US$ at exchange rate,119.6 +25394,New Zealand,2016,10,N-Nervous system,"/capita, US$ exchange rate",25.4 +25395,New Zealand,2016,10,N-Nervous system,"Million US$, purchasing power parity",119.2 +25396,New Zealand,2016,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.7 +25397,New Zealand,2016,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.7 +25398,New Zealand,2016,10,J01-Antibacterials for systemic use,Million of national currency units,18.5 +25399,New Zealand,2016,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.8 +25400,New Zealand,2016,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.9 +25401,New Zealand,2016,10,J01-Antibacterials for systemic use,% of total sales,1.7 +25402,New Zealand,2016,10,C-Cardiovascular system,"Million US$, purchasing power parity",35.4 +25403,New Zealand,2016,10,C-Cardiovascular system,"/capita, US$ exchange rate",7.5 +25404,New Zealand,2016,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +25405,New Zealand,2016,10,C01A-Cardiac glycosides,Million of national currency units,0.3 +25406,New Zealand,2016,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +25407,New Zealand,2016,10,A10-Drugs used in diabetes,Million US$ at exchange rate,34.8 +25408,New Zealand,2016,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",34.7 +25409,New Zealand,2016,10,C02-Antihypertensives,% of total sales,0.2 +25410,New Zealand,2016,10,A10-Drugs used in diabetes,Million of national currency units,50.0 +25411,New Zealand,2016,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4 +25412,New Zealand,2016,10,C-Cardiovascular system,Million of national currency units,51.0 +25413,New Zealand,2016,10,C-Cardiovascular system,Million US$ at exchange rate,35.5 +25414,New Zealand,2016,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.4 +25415,New Zealand,2016,10,A10-Drugs used in diabetes,% of total sales,4.7 +25416,New Zealand,2016,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",7.4 +25417,New Zealand,2016,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.5 +25418,New Zealand,2016,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",63.2 +25419,New Zealand,2016,10,A-Alimentary tract and metabolism,% of total sales,8.5 +25420,New Zealand,2016,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",13.4 +25421,New Zealand,2016,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.4 +25422,New Zealand,2016,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.8 +25423,New Zealand,2016,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,63.4 +25424,New Zealand,2016,10,A-Alimentary tract and metabolism,Million of national currency units,91.1 +25425,New Zealand,2016,10,C01A-Cardiac glycosides,% of total sales,0.0 +25426,New Zealand,2016,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0 +25427,New Zealand,2016,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0 +25428,New Zealand,2015,10,N05C-Hypnotics and sedatives,Million of national currency units,1.7 +25429,New Zealand,2015,10,C08-Calcium channel blockers,Million of national currency units,8.2 +25430,New Zealand,2015,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.8 +25431,New Zealand,2015,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2 +25432,New Zealand,2015,10,C08-Calcium channel blockers,Million US$ at exchange rate,5.7 +25433,New Zealand,2015,10,C10-Lipid modifying agents,Million US$ at exchange rate,12.2 +25434,New Zealand,2015,10,Products not elsewhere classified,Million US$ at exchange rate,239.3 +25435,New Zealand,2015,10,Products not elsewhere classified,"Million US$, purchasing power parity",232.1 +25436,New Zealand,2015,10,Products not elsewhere classified,"/capita, US$ exchange rate",51.9 +25437,New Zealand,2015,10,C10-Lipid modifying agents,Million of national currency units,17.4 +25438,New Zealand,2015,10,N02-Analgesics,"/capita, US$ exchange rate",3.1 +25439,New Zealand,2015,10,N02-Analgesics,"/capita, US$ purchasing power parity",3.0 +25440,New Zealand,2015,10,N02-Analgesics,"Million US$, purchasing power parity",13.8 +25441,New Zealand,2015,10,Products not elsewhere classified,% of total sales,34.7 +25442,New Zealand,2015,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",50.4 +25443,New Zealand,2015,10,N02-Analgesics,% of total sales,2.1 +25444,New Zealand,2015,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.2 +25445,New Zealand,2015,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.5 +25446,New Zealand,2015,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.2 +25447,New Zealand,2015,10,C08-Calcium channel blockers,% of total sales,0.8 +25448,New Zealand,2015,10,N02-Analgesics,Million of national currency units,20.4 +25449,New Zealand,2015,10,N02-Analgesics,Million US$ at exchange rate,14.2 +25450,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9 +25451,New Zealand,2015,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.6 +25452,New Zealand,2015,10,B-Blood and blood forming organs,Million of national currency units,99.0 +25453,New Zealand,2015,10,G-Genito urinary system and sex hormones,Million of national currency units,22.4 +25454,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.3 +25455,New Zealand,2015,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",67.0 +25456,New Zealand,2015,10,B-Blood and blood forming organs,Million US$ at exchange rate,69.1 +25457,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.7 +25458,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9 +25459,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.0 +25460,New Zealand,2015,10,C10-Lipid modifying agents,% of total sales,1.8 +25461,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.9 +25462,New Zealand,2015,10,N05C-Hypnotics and sedatives,% of total sales,0.2 +25463,New Zealand,2015,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.6 +25464,New Zealand,2015,10,B-Blood and blood forming organs,% of total sales,10.0 +25465,New Zealand,2015,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1 +25466,New Zealand,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +25467,New Zealand,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +25468,New Zealand,2015,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.0 +25469,New Zealand,2015,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.5 +25470,New Zealand,2015,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.2 +25471,New Zealand,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.4 +25472,New Zealand,2015,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",2.6 +25473,New Zealand,2015,10,Products not elsewhere classified,Million of national currency units,343.1 +25474,New Zealand,2015,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",74.4 +25475,New Zealand,2015,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,76.7 +25476,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.4 +25477,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.0 +25478,New Zealand,2015,10,R-Respiratory system,Million US$ at exchange rate,70.2 +25479,New Zealand,2015,10,R-Respiratory system,Million of national currency units,100.6 +25480,New Zealand,2015,10,J-Antiinfectives for systemic use,Million of national currency units,109.9 +25481,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9 +25482,New Zealand,2015,10,N05B-Anxiolytics,Million of national currency units,2.5 +25483,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,Million of national currency units,90.5 +25484,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",9.1 +25485,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",2.0 +25486,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,13.4 +25487,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,9.4 +25488,New Zealand,2015,10,R-Respiratory system,"Million US$, purchasing power parity",68.1 +25489,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.2 +25490,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.3 +25491,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.9 +25492,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.3 +25493,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,28.5 +25494,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,19.9 +25495,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.3 +25496,New Zealand,2015,10,R-Respiratory system,"/capita, US$ purchasing power parity",14.8 +25497,New Zealand,2015,10,R-Respiratory system,% of total sales,10.2 +25498,New Zealand,2015,10,R-Respiratory system,"/capita, US$ exchange rate",15.2 +25499,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.3 +25500,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.4 +25501,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.0 +25502,New Zealand,2015,10,N06A-Antidepressants,Million US$ at exchange rate,10.8 +25503,New Zealand,2015,10,N06A-Antidepressants,"Million US$, purchasing power parity",10.5 +25504,New Zealand,2015,10,N06A-Antidepressants,Million of national currency units,15.6 +25505,New Zealand,2015,10,N06A-Antidepressants,% of total sales,1.6 +25506,New Zealand,2015,10,N05B-Anxiolytics,"Million US$, purchasing power parity",1.7 +25507,New Zealand,2015,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.4 +25508,New Zealand,2015,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.3 +25509,New Zealand,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3 +25510,New Zealand,2015,10,G-Genito urinary system and sex hormones,% of total sales,2.3 +25511,New Zealand,2015,10,A02A-Antacids,Million US$ at exchange rate,0.3 +25512,New Zealand,2015,10,A02A-Antacids,Million of national currency units,0.4 +25513,New Zealand,2015,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.4 +25514,New Zealand,2015,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.4 +25515,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.6 +25516,New Zealand,2015,10,N05B-Anxiolytics,% of total sales,0.3 +25517,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,% of total sales,9.2 +25518,New Zealand,2015,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",16.6 +25519,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.3 +25520,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",61.2 +25521,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,63.1 +25522,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7 +25523,New Zealand,2015,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.1 +25524,New Zealand,2015,10,A02A-Antacids,"/capita, US$ exchange rate",0.1 +25525,New Zealand,2015,10,A02A-Antacids,"Million US$, purchasing power parity",0.3 +25526,New Zealand,2015,10,N05B-Anxiolytics,Million US$ at exchange rate,1.8 +25527,New Zealand,2015,10,J-Antiinfectives for systemic use,% of total sales,11.1 +25528,New Zealand,2015,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.1 +25529,New Zealand,2015,10,A02A-Antacids,% of total sales,0.0 +25530,New Zealand,2015,10,C07-Beta blocking agents,Million of national currency units,14.1 +25531,New Zealand,2015,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.8 +25532,New Zealand,2015,10,C07-Beta blocking agents,Million US$ at exchange rate,9.9 +25533,New Zealand,2015,10,C07-Beta blocking agents,"/capita, US$ exchange rate",2.1 +25534,New Zealand,2015,10,C07-Beta blocking agents,"Million US$, purchasing power parity",9.6 +25535,New Zealand,2015,10,M-Musculo-skeletal system,% of total sales,2.2 +25536,New Zealand,2015,10,C03-Diuretics,Million US$ at exchange rate,1.5 +25537,New Zealand,2015,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2 +25538,New Zealand,2015,10,C-Cardiovascular system,% of total sales,6.7 +25539,New Zealand,2015,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.3 +25540,New Zealand,2015,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.1 +25541,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.4 +25542,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.2 +25543,New Zealand,2015,10,C03-Diuretics,% of total sales,0.2 +25544,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2 +25545,New Zealand,2015,10,M-Musculo-skeletal system,Million of national currency units,21.9 +25546,New Zealand,2015,10,C02-Antihypertensives,Million US$ at exchange rate,2.5 +25547,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.7 +25548,New Zealand,2015,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",14.8 +25549,New Zealand,2015,10,C07-Beta blocking agents,% of total sales,1.4 +25550,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +25551,New Zealand,2015,10,M-Musculo-skeletal system,Million US$ at exchange rate,15.3 +25552,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +25553,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.6 +25554,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.2 +25555,New Zealand,2015,10,Total pharmaceutical sales,"/capita, US$ exchange rate",149.4 +25556,New Zealand,2015,10,N-Nervous system,% of total sales,17.0 +25557,New Zealand,2015,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",145.0 +25558,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5 +25559,New Zealand,2015,10,C02-Antihypertensives,Million of national currency units,3.5 +25560,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +25561,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +25562,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1 +25563,New Zealand,2015,10,N-Nervous system,Million of national currency units,167.5 +25564,New Zealand,2015,10,Total pharmaceutical sales,Million of national currency units,987.6 +25565,New Zealand,2015,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +25566,New Zealand,2015,10,C03-Diuretics,"Million US$, purchasing power parity",1.5 +25567,New Zealand,2015,10,C03-Diuretics,"/capita, US$ exchange rate",0.3 +25568,New Zealand,2015,10,N-Nervous system,"/capita, US$ purchasing power parity",24.6 +25569,New Zealand,2015,10,Total pharmaceutical sales,Million US$ at exchange rate,688.7 +25570,New Zealand,2015,10,Total pharmaceutical sales,"Million US$, purchasing power parity",668.2 +25571,New Zealand,2015,10,N-Nervous system,Million US$ at exchange rate,116.8 +25572,New Zealand,2015,10,N-Nervous system,"Million US$, purchasing power parity",113.4 +25573,New Zealand,2015,10,N-Nervous system,"/capita, US$ exchange rate",25.3 +25574,New Zealand,2015,10,C03-Diuretics,Million of national currency units,2.2 +25575,New Zealand,2015,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.6 +25576,New Zealand,2015,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.5 +25577,New Zealand,2015,10,J01-Antibacterials for systemic use,Million of national currency units,17.0 +25578,New Zealand,2015,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.9 +25579,New Zealand,2015,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.5 +25580,New Zealand,2015,10,C-Cardiovascular system,"Million US$, purchasing power parity",45.1 +25581,New Zealand,2015,10,C-Cardiovascular system,"/capita, US$ exchange rate",10.1 +25582,New Zealand,2015,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2 +25583,New Zealand,2015,10,J01-Antibacterials for systemic use,% of total sales,1.7 +25584,New Zealand,2015,10,C01A-Cardiac glycosides,Million of national currency units,0.4 +25585,New Zealand,2015,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2 +25586,New Zealand,2015,10,A10-Drugs used in diabetes,Million US$ at exchange rate,32.3 +25587,New Zealand,2015,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",31.4 +25588,New Zealand,2015,10,A10-Drugs used in diabetes,Million of national currency units,46.4 +25589,New Zealand,2015,10,C02-Antihypertensives,% of total sales,0.4 +25590,New Zealand,2015,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +25591,New Zealand,2015,10,C-Cardiovascular system,Million of national currency units,66.6 +25592,New Zealand,2015,10,C-Cardiovascular system,Million US$ at exchange rate,46.5 +25593,New Zealand,2015,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.0 +25594,New Zealand,2015,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.8 +25595,New Zealand,2015,10,A10-Drugs used in diabetes,% of total sales,4.7 +25596,New Zealand,2015,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.6 +25597,New Zealand,2015,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",61.0 +25598,New Zealand,2015,10,A-Alimentary tract and metabolism,% of total sales,9.1 +25599,New Zealand,2015,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",13.2 +25600,New Zealand,2015,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +25601,New Zealand,2015,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.4 +25602,New Zealand,2015,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,62.9 +25603,New Zealand,2015,10,A-Alimentary tract and metabolism,Million of national currency units,90.2 +25604,New Zealand,2015,10,C01A-Cardiac glycosides,% of total sales,0.0 +25605,New Zealand,2015,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +25606,New Zealand,2015,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +25607,New Zealand,2014,10,N05C-Hypnotics and sedatives,Million of national currency units,1.6 +25608,New Zealand,2014,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",12.1 +25609,New Zealand,2014,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3 +25610,New Zealand,2014,10,C08-Calcium channel blockers,Million US$ at exchange rate,6.8 +25611,New Zealand,2014,10,C10-Lipid modifying agents,Million US$ at exchange rate,14.5 +25612,New Zealand,2014,10,Products not elsewhere classified,Million US$ at exchange rate,268.0 +25613,New Zealand,2014,10,Products not elsewhere classified,"/capita, US$ exchange rate",59.3 +25614,New Zealand,2014,10,Products not elsewhere classified,"Million US$, purchasing power parity",224.3 +25615,New Zealand,2014,10,C08-Calcium channel blockers,Million of national currency units,8.3 +25616,New Zealand,2014,10,C10-Lipid modifying agents,Million of national currency units,17.5 +25617,New Zealand,2014,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.7 +25618,New Zealand,2014,10,N02-Analgesics,"/capita, US$ exchange rate",3.9 +25619,New Zealand,2014,10,N02-Analgesics,"/capita, US$ purchasing power parity",3.3 +25620,New Zealand,2014,10,N02-Analgesics,"Million US$, purchasing power parity",14.7 +25621,New Zealand,2014,10,Products not elsewhere classified,% of total sales,33.7 +25622,New Zealand,2014,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",49.7 +25623,New Zealand,2014,10,N02-Analgesics,% of total sales,2.2 +25624,New Zealand,2014,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.3 +25625,New Zealand,2014,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.5 +25626,New Zealand,2014,10,N02-Analgesics,Million of national currency units,21.2 +25627,New Zealand,2014,10,N02-Analgesics,Million US$ at exchange rate,17.6 +25628,New Zealand,2014,10,C08-Calcium channel blockers,% of total sales,0.9 +25629,New Zealand,2014,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,17.5 +25630,New Zealand,2014,10,B-Blood and blood forming organs,Million of national currency units,87.1 +25631,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +25632,New Zealand,2014,10,G-Genito urinary system and sex hormones,Million of national currency units,21.1 +25633,New Zealand,2014,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",60.5 +25634,New Zealand,2014,10,B-Blood and blood forming organs,Million US$ at exchange rate,72.3 +25635,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.7 +25636,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.7 +25637,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0 +25638,New Zealand,2014,10,C10-Lipid modifying agents,% of total sales,1.8 +25639,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.2 +25640,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.1 +25641,New Zealand,2014,10,N05C-Hypnotics and sedatives,% of total sales,0.2 +25642,New Zealand,2014,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.2 +25643,New Zealand,2014,10,B-Blood and blood forming organs,% of total sales,9.1 +25644,New Zealand,2014,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1 +25645,New Zealand,2014,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +25646,New Zealand,2014,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +25647,New Zealand,2014,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.0 +25648,New Zealand,2014,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.4 +25649,New Zealand,2014,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.9 +25650,New Zealand,2014,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.6 +25651,New Zealand,2014,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",2.7 +25652,New Zealand,2014,10,Products not elsewhere classified,Million of national currency units,323.1 +25653,New Zealand,2014,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",70.6 +25654,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.3 +25655,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.5 +25656,New Zealand,2014,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,84.4 +25657,New Zealand,2014,10,R-Respiratory system,Million US$ at exchange rate,76.4 +25658,New Zealand,2014,10,J-Antiinfectives for systemic use,Million of national currency units,101.7 +25659,New Zealand,2014,10,R-Respiratory system,Million of national currency units,92.1 +25660,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1 +25661,New Zealand,2014,10,N05B-Anxiolytics,Million of national currency units,1.3 +25662,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,Million of national currency units,84.7 +25663,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.7 +25664,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",10.2 +25665,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",2.7 +25666,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,12.2 +25667,New Zealand,2014,10,R-Respiratory system,"Million US$, purchasing power parity",63.9 +25668,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.8 +25669,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.0 +25670,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +25671,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.5 +25672,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.5 +25673,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,20.3 +25674,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",17.0 +25675,New Zealand,2014,10,R-Respiratory system,"/capita, US$ purchasing power parity",14.2 +25676,New Zealand,2014,10,R-Respiratory system,% of total sales,9.6 +25677,New Zealand,2014,10,R-Respiratory system,"/capita, US$ exchange rate",16.9 +25678,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.8 +25679,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.8 +25680,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.3 +25681,New Zealand,2014,10,N06A-Antidepressants,Million US$ at exchange rate,14.5 +25682,New Zealand,2014,10,N06A-Antidepressants,"Million US$, purchasing power parity",12.1 +25683,New Zealand,2014,10,N06A-Antidepressants,Million of national currency units,17.5 +25684,New Zealand,2014,10,N06A-Antidepressants,% of total sales,1.8 +25685,New Zealand,2014,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.7 +25686,New Zealand,2014,10,N06A-Antidepressants,"/capita, US$ exchange rate",3.2 +25687,New Zealand,2014,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9 +25688,New Zealand,2014,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2 +25689,New Zealand,2014,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.2 +25690,New Zealand,2014,10,G-Genito urinary system and sex hormones,% of total sales,2.2 +25691,New Zealand,2014,10,A02A-Antacids,Million US$ at exchange rate,0.2 +25692,New Zealand,2014,10,A02A-Antacids,Million of national currency units,0.3 +25693,New Zealand,2014,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +25694,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.7 +25695,New Zealand,2014,10,N05B-Anxiolytics,% of total sales,0.1 +25696,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,% of total sales,8.8 +25697,New Zealand,2014,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.7 +25698,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.0 +25699,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",58.8 +25700,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,70.3 +25701,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.6 +25702,New Zealand,2014,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.6 +25703,New Zealand,2014,10,A02A-Antacids,"/capita, US$ exchange rate",0.1 +25704,New Zealand,2014,10,N05B-Anxiolytics,Million US$ at exchange rate,1.1 +25705,New Zealand,2014,10,A02A-Antacids,"Million US$, purchasing power parity",0.2 +25706,New Zealand,2014,10,J-Antiinfectives for systemic use,% of total sales,10.6 +25707,New Zealand,2014,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +25708,New Zealand,2014,10,A02A-Antacids,% of total sales,0.0 +25709,New Zealand,2014,10,C07-Beta blocking agents,Million of national currency units,14.7 +25710,New Zealand,2014,10,C07-Beta blocking agents,Million US$ at exchange rate,12.2 +25711,New Zealand,2014,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.7 +25712,New Zealand,2014,10,C07-Beta blocking agents,"/capita, US$ exchange rate",2.7 +25713,New Zealand,2014,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2 +25714,New Zealand,2014,10,M-Musculo-skeletal system,% of total sales,2.6 +25715,New Zealand,2014,10,C03-Diuretics,Million US$ at exchange rate,1.8 +25716,New Zealand,2014,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8 +25717,New Zealand,2014,10,C-Cardiovascular system,% of total sales,7.3 +25718,New Zealand,2014,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.6 +25719,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.2 +25720,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.2 +25721,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.4 +25722,New Zealand,2014,10,M-Musculo-skeletal system,Million of national currency units,24.8 +25723,New Zealand,2014,10,C02-Antihypertensives,Million US$ at exchange rate,3.2 +25724,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.5 +25725,New Zealand,2014,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.3 +25726,New Zealand,2014,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.2 +25727,New Zealand,2014,10,C07-Beta blocking agents,% of total sales,1.5 +25728,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +25729,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +25730,New Zealand,2014,10,M-Musculo-skeletal system,Million US$ at exchange rate,20.6 +25731,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.1 +25732,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2 +25733,New Zealand,2014,10,Total pharmaceutical sales,"/capita, US$ exchange rate",176.2 +25734,New Zealand,2014,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",147.5 +25735,New Zealand,2014,10,N-Nervous system,% of total sales,14.2 +25736,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.5 +25737,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5 +25738,New Zealand,2014,10,C02-Antihypertensives,Million of national currency units,3.9 +25739,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +25740,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +25741,New Zealand,2014,10,N-Nervous system,Million of national currency units,136.0 +25742,New Zealand,2014,10,Total pharmaceutical sales,Million of national currency units,959.5 +25743,New Zealand,2014,10,C03-Diuretics,"Million US$, purchasing power parity",1.5 +25744,New Zealand,2014,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +25745,New Zealand,2014,10,C03-Diuretics,"/capita, US$ exchange rate",0.4 +25746,New Zealand,2014,10,N-Nervous system,"/capita, US$ purchasing power parity",20.9 +25747,New Zealand,2014,10,Total pharmaceutical sales,Million US$ at exchange rate,796.0 +25748,New Zealand,2014,10,Total pharmaceutical sales,"Million US$, purchasing power parity",666.0 +25749,New Zealand,2014,10,N-Nervous system,Million US$ at exchange rate,112.9 +25750,New Zealand,2014,10,N-Nervous system,"Million US$, purchasing power parity",94.4 +25751,New Zealand,2014,10,N-Nervous system,"/capita, US$ exchange rate",25.0 +25752,New Zealand,2014,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.8 +25753,New Zealand,2014,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.3 +25754,New Zealand,2014,10,C03-Diuretics,Million of national currency units,2.2 +25755,New Zealand,2014,10,J01-Antibacterials for systemic use,Million of national currency units,15.0 +25756,New Zealand,2014,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4 +25757,New Zealand,2014,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",10.4 +25758,New Zealand,2014,10,J01-Antibacterials for systemic use,% of total sales,1.6 +25759,New Zealand,2014,10,C-Cardiovascular system,"/capita, US$ exchange rate",12.8 +25760,New Zealand,2014,10,C-Cardiovascular system,"Million US$, purchasing power parity",48.5 +25761,New Zealand,2014,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +25762,New Zealand,2014,10,C01A-Cardiac glycosides,Million of national currency units,0.4 +25763,New Zealand,2014,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +25764,New Zealand,2014,10,A10-Drugs used in diabetes,Million US$ at exchange rate,35.3 +25765,New Zealand,2014,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",29.5 +25766,New Zealand,2014,10,C02-Antihypertensives,% of total sales,0.4 +25767,New Zealand,2014,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +25768,New Zealand,2014,10,A10-Drugs used in diabetes,Million of national currency units,42.5 +25769,New Zealand,2014,10,C-Cardiovascular system,Million of national currency units,69.9 +25770,New Zealand,2014,10,C-Cardiovascular system,Million US$ at exchange rate,58.0 +25771,New Zealand,2014,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.8 +25772,New Zealand,2014,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.5 +25773,New Zealand,2014,10,A10-Drugs used in diabetes,% of total sales,4.4 +25774,New Zealand,2014,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +25775,New Zealand,2014,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",14.5 +25776,New Zealand,2014,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",55.0 +25777,New Zealand,2014,10,A-Alimentary tract and metabolism,% of total sales,8.3 +25778,New Zealand,2014,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",12.2 +25779,New Zealand,2014,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.7 +25780,New Zealand,2014,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.7 +25781,New Zealand,2014,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,65.7 +25782,New Zealand,2014,10,A-Alimentary tract and metabolism,Million of national currency units,79.2 +25783,New Zealand,2014,10,C03-Diuretics,% of total sales,0.2 +25784,New Zealand,2014,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +25785,New Zealand,2014,10,C01A-Cardiac glycosides,% of total sales,0.0 +25786,New Zealand,2013,9,C10-Lipid modifying agents,Million US$ at exchange rate,24.7 +25787,New Zealand,2013,9,N05C-Hypnotics and sedatives,Million of national currency units,1.5 +25788,New Zealand,2013,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3 +25789,New Zealand,2013,9,C08-Calcium channel blockers,Million US$ at exchange rate,7.8 +25790,New Zealand,2013,9,Products not elsewhere classified,"/capita, US$ exchange rate",57.5 +25791,New Zealand,2013,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",20.8 +25792,New Zealand,2013,9,Products not elsewhere classified,Million US$ at exchange rate,255.2 +25793,New Zealand,2013,9,C08-Calcium channel blockers,Million of national currency units,9.6 +25794,New Zealand,2013,9,C10-Lipid modifying agents,Million of national currency units,30.1 +25795,New Zealand,2013,9,Products not elsewhere classified,"Million US$, purchasing power parity",215.2 +25796,New Zealand,2013,9,N02-Analgesics,"/capita, US$ exchange rate",4.4 +25797,New Zealand,2013,9,N02-Analgesics,"/capita, US$ purchasing power parity",3.7 +25798,New Zealand,2013,9,N02-Analgesics,"Million US$, purchasing power parity",16.5 +25799,New Zealand,2013,9,Products not elsewhere classified,% of total sales,33.7 +25800,New Zealand,2013,9,N02-Analgesics,% of total sales,2.6 +25801,New Zealand,2013,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",48.5 +25802,New Zealand,2013,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.6 +25803,New Zealand,2013,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.5 +25804,New Zealand,2013,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.8 +25805,New Zealand,2013,9,C08-Calcium channel blockers,% of total sales,1.0 +25806,New Zealand,2013,9,N02-Analgesics,Million of national currency units,23.9 +25807,New Zealand,2013,9,N02-Analgesics,Million US$ at exchange rate,19.6 +25808,New Zealand,2013,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,17.2 +25809,New Zealand,2013,9,B-Blood and blood forming organs,Million of national currency units,48.2 +25810,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2 +25811,New Zealand,2013,9,G-Genito urinary system and sex hormones,Million of national currency units,21.0 +25812,New Zealand,2013,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",33.3 +25813,New Zealand,2013,9,B-Blood and blood forming organs,Million US$ at exchange rate,39.5 +25814,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.9 +25815,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.8 +25816,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1 +25817,New Zealand,2013,9,C10-Lipid modifying agents,% of total sales,3.3 +25818,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.4 +25819,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.4 +25820,New Zealand,2013,9,N05C-Hypnotics and sedatives,% of total sales,0.2 +25821,New Zealand,2013,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.6 +25822,New Zealand,2013,9,B-Blood and blood forming organs,% of total sales,5.2 +25823,New Zealand,2013,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1 +25824,New Zealand,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +25825,New Zealand,2013,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.5 +25826,New Zealand,2013,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.9 +25827,New Zealand,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.9 +25828,New Zealand,2013,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.5 +25829,New Zealand,2013,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.7 +25830,New Zealand,2013,9,Products not elsewhere classified,Million of national currency units,311.2 +25831,New Zealand,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +25832,New Zealand,2013,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",67.9 +25833,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.8 +25834,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.9 +25835,New Zealand,2013,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,80.5 +25836,New Zealand,2013,9,R-Respiratory system,Million US$ at exchange rate,73.8 +25837,New Zealand,2013,9,J-Antiinfectives for systemic use,Million of national currency units,98.1 +25838,New Zealand,2013,9,R-Respiratory system,Million of national currency units,90.0 +25839,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.7 +25840,New Zealand,2013,9,N05B-Anxiolytics,Million of national currency units,1.2 +25841,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1 +25842,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,Million of national currency units,79.6 +25843,New Zealand,2013,9,N05B-Anxiolytics,Million US$ at exchange rate,1.0 +25844,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,17.8 +25845,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.3 +25846,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.3 +25847,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,14.6 +25848,New Zealand,2013,9,R-Respiratory system,"Million US$, purchasing power parity",62.3 +25849,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.5 +25850,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.9 +25851,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +25852,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.2 +25853,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,18.6 +25854,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,22.7 +25855,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.7 +25856,New Zealand,2013,9,R-Respiratory system,"/capita, US$ purchasing power parity",14.0 +25857,New Zealand,2013,9,R-Respiratory system,% of total sales,9.8 +25858,New Zealand,2013,9,R-Respiratory system,"/capita, US$ exchange rate",16.6 +25859,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.8 +25860,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.7 +25861,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.3 +25862,New Zealand,2013,9,N06A-Antidepressants,Million US$ at exchange rate,24.0 +25863,New Zealand,2013,9,N06A-Antidepressants,"Million US$, purchasing power parity",20.2 +25864,New Zealand,2013,9,N06A-Antidepressants,Million of national currency units,29.2 +25865,New Zealand,2013,9,N06A-Antidepressants,% of total sales,3.2 +25866,New Zealand,2013,9,N06A-Antidepressants,"/capita, US$ exchange rate",5.4 +25867,New Zealand,2013,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.5 +25868,New Zealand,2013,9,G-Genito urinary system and sex hormones,% of total sales,2.3 +25869,New Zealand,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3 +25870,New Zealand,2013,9,A02A-Antacids,Million of national currency units,0.3 +25871,New Zealand,2013,9,A02A-Antacids,Million US$ at exchange rate,0.2 +25872,New Zealand,2013,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +25873,New Zealand,2013,9,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2 +25874,New Zealand,2013,9,N05B-Anxiolytics,% of total sales,0.1 +25875,New Zealand,2013,9,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9 +25876,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,% of total sales,8.6 +25877,New Zealand,2013,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.1 +25878,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.4 +25879,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",55.0 +25880,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,65.2 +25881,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.7 +25882,New Zealand,2013,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.3 +25883,New Zealand,2013,9,A02A-Antacids,"/capita, US$ exchange rate",0.1 +25884,New Zealand,2013,9,A02A-Antacids,"Million US$, purchasing power parity",0.2 +25885,New Zealand,2013,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +25886,New Zealand,2013,9,J-Antiinfectives for systemic use,% of total sales,10.6 +25887,New Zealand,2013,9,A02A-Antacids,% of total sales,0.0 +25888,New Zealand,2013,9,C07-Beta blocking agents,Million of national currency units,14.4 +25889,New Zealand,2013,9,C07-Beta blocking agents,Million US$ at exchange rate,11.8 +25890,New Zealand,2013,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",13.5 +25891,New Zealand,2013,9,C07-Beta blocking agents,"/capita, US$ exchange rate",2.7 +25892,New Zealand,2013,9,C07-Beta blocking agents,"Million US$, purchasing power parity",10.0 +25893,New Zealand,2013,9,M-Musculo-skeletal system,% of total sales,2.6 +25894,New Zealand,2013,9,C03-Diuretics,Million US$ at exchange rate,1.8 +25895,New Zealand,2013,9,C-Cardiovascular system,% of total sales,9.4 +25896,New Zealand,2013,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8 +25897,New Zealand,2013,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.5 +25898,New Zealand,2013,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.2 +25899,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.1 +25900,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.0 +25901,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.4 +25902,New Zealand,2013,9,M-Musculo-skeletal system,Million of national currency units,24.3 +25903,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.3 +25904,New Zealand,2013,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",16.8 +25905,New Zealand,2013,9,C07-Beta blocking agents,% of total sales,1.6 +25906,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +25907,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +25908,New Zealand,2013,9,M-Musculo-skeletal system,Million US$ at exchange rate,19.9 +25909,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.0 +25910,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1 +25911,New Zealand,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",170.4 +25912,New Zealand,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",143.7 +25913,New Zealand,2013,9,N-Nervous system,% of total sales,16.0 +25914,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.5 +25915,New Zealand,2013,9,C02-Antihypertensives,Million US$ at exchange rate,3.1 +25916,New Zealand,2013,9,C02-Antihypertensives,Million of national currency units,3.8 +25917,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5 +25918,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +25919,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +25920,New Zealand,2013,9,N-Nervous system,Million of national currency units,147.4 +25921,New Zealand,2013,9,C03-Diuretics,% of total sales,0.2 +25922,New Zealand,2013,9,Total pharmaceutical sales,Million of national currency units,922.9 +25923,New Zealand,2013,9,C03-Diuretics,"Million US$, purchasing power parity",1.5 +25924,New Zealand,2013,9,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +25925,New Zealand,2013,9,C03-Diuretics,"/capita, US$ exchange rate",0.4 +25926,New Zealand,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,756.8 +25927,New Zealand,2013,9,N-Nervous system,"/capita, US$ purchasing power parity",22.9 +25928,New Zealand,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",638.2 +25929,New Zealand,2013,9,N-Nervous system,Million US$ at exchange rate,120.9 +25930,New Zealand,2013,9,N-Nervous system,"Million US$, purchasing power parity",101.9 +25931,New Zealand,2013,9,N-Nervous system,"/capita, US$ exchange rate",27.2 +25932,New Zealand,2013,9,C03-Diuretics,Million of national currency units,2.2 +25933,New Zealand,2013,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.9 +25934,New Zealand,2013,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.5 +25935,New Zealand,2013,9,J01-Antibacterials for systemic use,% of total sales,1.7 +25936,New Zealand,2013,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.0 +25937,New Zealand,2013,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.0 +25938,New Zealand,2013,9,J01-Antibacterials for systemic use,Million of national currency units,15.9 +25939,New Zealand,2013,9,C-Cardiovascular system,"/capita, US$ exchange rate",16.0 +25940,New Zealand,2013,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +25941,New Zealand,2013,9,C-Cardiovascular system,"Million US$, purchasing power parity",59.8 +25942,New Zealand,2013,9,C01A-Cardiac glycosides,Million of national currency units,0.4 +25943,New Zealand,2013,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +25944,New Zealand,2013,9,A10-Drugs used in diabetes,Million US$ at exchange rate,32.1 +25945,New Zealand,2013,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",27.0 +25946,New Zealand,2013,9,C02-Antihypertensives,% of total sales,0.4 +25947,New Zealand,2013,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +25948,New Zealand,2013,9,A10-Drugs used in diabetes,Million of national currency units,39.1 +25949,New Zealand,2013,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.2 +25950,New Zealand,2013,9,C-Cardiovascular system,Million of national currency units,86.4 +25951,New Zealand,2013,9,C-Cardiovascular system,Million US$ at exchange rate,70.9 +25952,New Zealand,2013,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.1 +25953,New Zealand,2013,9,A10-Drugs used in diabetes,% of total sales,4.2 +25954,New Zealand,2013,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.9 +25955,New Zealand,2013,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",52.0 +25956,New Zealand,2013,9,A-Alimentary tract and metabolism,% of total sales,8.1 +25957,New Zealand,2013,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",11.7 +25958,New Zealand,2013,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +25959,New Zealand,2013,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.7 +25960,New Zealand,2013,9,C02-Antihypertensives,"Million US$, purchasing power parity",2.6 +25961,New Zealand,2013,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,61.7 +25962,New Zealand,2013,9,A-Alimentary tract and metabolism,Million of national currency units,75.2 +25963,New Zealand,2013,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +25964,New Zealand,2013,9,C01A-Cardiac glycosides,% of total sales,0.0 +25965,New Zealand,2012,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.1 +25966,New Zealand,2012,10,N05C-Hypnotics and sedatives,Million of national currency units,1.4 +25967,New Zealand,2012,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2 +25968,New Zealand,2012,10,C08-Calcium channel blockers,Million US$ at exchange rate,10.9 +25969,New Zealand,2012,10,Products not elsewhere classified,Million US$ at exchange rate,234.9 +25970,New Zealand,2012,10,Products not elsewhere classified,"/capita, US$ exchange rate",53.3 +25971,New Zealand,2012,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.2 +25972,New Zealand,2012,10,C10-Lipid modifying agents,Million US$ at exchange rate,62.0 +25973,New Zealand,2012,10,Products not elsewhere classified,"Million US$, purchasing power parity",193.9 +25974,New Zealand,2012,10,C08-Calcium channel blockers,Million of national currency units,13.5 +25975,New Zealand,2012,10,C10-Lipid modifying agents,Million of national currency units,76.5 +25976,New Zealand,2012,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",9.0 +25977,New Zealand,2012,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0 +25978,New Zealand,2012,10,N02-Analgesics,"/capita, US$ purchasing power parity",4.4 +25979,New Zealand,2012,10,N02-Analgesics,"/capita, US$ exchange rate",5.3 +25980,New Zealand,2012,10,N02-Analgesics,"Million US$, purchasing power parity",19.2 +25981,New Zealand,2012,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",44.0 +25982,New Zealand,2012,10,Products not elsewhere classified,% of total sales,31.4 +25983,New Zealand,2012,10,N02-Analgesics,% of total sales,3.1 +25984,New Zealand,2012,10,C08-Calcium channel blockers,% of total sales,1.5 +25985,New Zealand,2012,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5 +25986,New Zealand,2012,10,N02-Analgesics,Million US$ at exchange rate,23.2 +25987,New Zealand,2012,10,N02-Analgesics,Million of national currency units,28.7 +25988,New Zealand,2012,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.5 +25989,New Zealand,2012,10,B-Blood and blood forming organs,Million of national currency units,42.8 +25990,New Zealand,2012,10,G-Genito urinary system and sex hormones,Million of national currency units,22.8 +25991,New Zealand,2012,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.9 +25992,New Zealand,2012,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",28.6 +25993,New Zealand,2012,10,B-Blood and blood forming organs,Million US$ at exchange rate,34.7 +25994,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.5 +25995,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",9.1 +25996,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1 +25997,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.5 +25998,New Zealand,2012,10,C10-Lipid modifying agents,% of total sales,8.3 +25999,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,11.0 +26000,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.6 +26001,New Zealand,2012,10,N05C-Hypnotics and sedatives,% of total sales,0.2 +26002,New Zealand,2012,10,B-Blood and blood forming organs,% of total sales,4.6 +26003,New Zealand,2012,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3 +26004,New Zealand,2012,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.0 +26005,New Zealand,2012,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +26006,New Zealand,2012,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",6.5 +26007,New Zealand,2012,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.2 +26008,New Zealand,2012,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.2 +26009,New Zealand,2012,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.6 +26010,New Zealand,2012,10,Products not elsewhere classified,Million of national currency units,290.0 +26011,New Zealand,2012,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",35.5 +26012,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.8 +26013,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4 +26014,New Zealand,2012,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,43.1 +26015,New Zealand,2012,10,R-Respiratory system,Million US$ at exchange rate,71.9 +26016,New Zealand,2012,10,J-Antiinfectives for systemic use,Million of national currency units,53.1 +26017,New Zealand,2012,10,R-Respiratory system,Million of national currency units,88.7 +26018,New Zealand,2012,10,R-Respiratory system,"Million US$, purchasing power parity",59.3 +26019,New Zealand,2012,10,N05B-Anxiolytics,Million of national currency units,1.3 +26020,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.8 +26021,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,Million of national currency units,77.2 +26022,New Zealand,2012,10,N05B-Anxiolytics,Million US$ at exchange rate,1.0 +26023,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,31.7 +26024,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.2 +26025,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.8 +26026,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.7 +26027,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.2 +26028,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +26029,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.8 +26030,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,17.2 +26031,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,21.2 +26032,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9 +26033,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.2 +26034,New Zealand,2012,10,R-Respiratory system,% of total sales,9.6 +26035,New Zealand,2012,10,R-Respiratory system,"/capita, US$ purchasing power parity",13.5 +26036,New Zealand,2012,10,R-Respiratory system,"/capita, US$ exchange rate",16.3 +26037,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",5.2 +26038,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.3 +26039,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.2 +26040,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.4 +26041,New Zealand,2012,10,N06A-Antidepressants,Million US$ at exchange rate,26.6 +26042,New Zealand,2012,10,N06A-Antidepressants,"Million US$, purchasing power parity",22.0 +26043,New Zealand,2012,10,N06A-Antidepressants,Million of national currency units,32.9 +26044,New Zealand,2012,10,N06A-Antidepressants,% of total sales,3.6 +26045,New Zealand,2012,10,N06A-Antidepressants,"/capita, US$ exchange rate",6.0 +26046,New Zealand,2012,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.0 +26047,New Zealand,2012,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2 +26048,New Zealand,2012,10,G-Genito urinary system and sex hormones,% of total sales,2.5 +26049,New Zealand,2012,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.5 +26050,New Zealand,2012,10,A02A-Antacids,Million of national currency units,0.3 +26051,New Zealand,2012,10,A02A-Antacids,Million US$ at exchange rate,0.2 +26052,New Zealand,2012,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2 +26053,New Zealand,2012,10,N05B-Anxiolytics,% of total sales,0.1 +26054,New Zealand,2012,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9 +26055,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,% of total sales,8.3 +26056,New Zealand,2012,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.8 +26057,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",51.6 +26058,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,62.5 +26059,New Zealand,2012,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.1 +26060,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",11.7 +26061,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.2 +26062,New Zealand,2012,10,A02A-Antacids,"/capita, US$ exchange rate",0.1 +26063,New Zealand,2012,10,A02A-Antacids,"Million US$, purchasing power parity",0.2 +26064,New Zealand,2012,10,J-Antiinfectives for systemic use,% of total sales,5.8 +26065,New Zealand,2012,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +26066,New Zealand,2012,10,A02A-Antacids,% of total sales,0.0 +26067,New Zealand,2012,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",140.2 +26068,New Zealand,2012,10,C07-Beta blocking agents,Million of national currency units,18.5 +26069,New Zealand,2012,10,C07-Beta blocking agents,Million US$ at exchange rate,15.0 +26070,New Zealand,2012,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",23.3 +26071,New Zealand,2012,10,C07-Beta blocking agents,"/capita, US$ exchange rate",3.4 +26072,New Zealand,2012,10,C07-Beta blocking agents,"Million US$, purchasing power parity",12.4 +26073,New Zealand,2012,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.8 +26074,New Zealand,2012,10,M-Musculo-skeletal system,% of total sales,2.5 +26075,New Zealand,2012,10,C03-Diuretics,Million US$ at exchange rate,1.9 +26076,New Zealand,2012,10,C-Cardiovascular system,% of total sales,16.6 +26077,New Zealand,2012,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.5 +26078,New Zealand,2012,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.3 +26079,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.8 +26080,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.8 +26081,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.3 +26082,New Zealand,2012,10,M-Musculo-skeletal system,Million of national currency units,23.3 +26083,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.2 +26084,New Zealand,2012,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.6 +26085,New Zealand,2012,10,C07-Beta blocking agents,% of total sales,2.0 +26086,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1 +26087,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8 +26088,New Zealand,2012,10,M-Musculo-skeletal system,Million US$ at exchange rate,18.9 +26089,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.9 +26090,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.3 +26091,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9 +26092,New Zealand,2012,10,Total pharmaceutical sales,"/capita, US$ exchange rate",169.8 +26093,New Zealand,2012,10,N-Nervous system,% of total sales,17.0 +26094,New Zealand,2012,10,C02-Antihypertensives,Million US$ at exchange rate,2.3 +26095,New Zealand,2012,10,C02-Antihypertensives,Million of national currency units,2.9 +26096,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5 +26097,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +26098,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +26099,New Zealand,2012,10,N-Nervous system,Million of national currency units,156.7 +26100,New Zealand,2012,10,C03-Diuretics,% of total sales,0.2 +26101,New Zealand,2012,10,Total pharmaceutical sales,Million of national currency units,924.1 +26102,New Zealand,2012,10,C03-Diuretics,"Million US$, purchasing power parity",1.5 +26103,New Zealand,2012,10,C03-Diuretics,"/capita, US$ exchange rate",0.4 +26104,New Zealand,2012,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3 +26105,New Zealand,2012,10,Total pharmaceutical sales,Million US$ at exchange rate,748.7 +26106,New Zealand,2012,10,N-Nervous system,"/capita, US$ purchasing power parity",23.8 +26107,New Zealand,2012,10,Total pharmaceutical sales,"Million US$, purchasing power parity",617.9 +26108,New Zealand,2012,10,N-Nervous system,"Million US$, purchasing power parity",104.8 +26109,New Zealand,2012,10,N-Nervous system,Million US$ at exchange rate,126.9 +26110,New Zealand,2012,10,N-Nervous system,"/capita, US$ exchange rate",28.8 +26111,New Zealand,2012,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",3.5 +26112,New Zealand,2012,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9 +26113,New Zealand,2012,10,J01-Antibacterials for systemic use,% of total sales,2.0 +26114,New Zealand,2012,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.3 +26115,New Zealand,2012,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.6 +26116,New Zealand,2012,10,C-Cardiovascular system,"/capita, US$ exchange rate",28.2 +26117,New Zealand,2012,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +26118,New Zealand,2012,10,C01A-Cardiac glycosides,Million of national currency units,0.4 +26119,New Zealand,2012,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +26120,New Zealand,2012,10,J01-Antibacterials for systemic use,Million of national currency units,18.8 +26121,New Zealand,2012,10,A10-Drugs used in diabetes,Million US$ at exchange rate,28.7 +26122,New Zealand,2012,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",23.7 +26123,New Zealand,2012,10,C02-Antihypertensives,% of total sales,0.3 +26124,New Zealand,2012,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4 +26125,New Zealand,2012,10,A10-Drugs used in diabetes,Million of national currency units,35.5 +26126,New Zealand,2012,10,C-Cardiovascular system,Million of national currency units,153.7 +26127,New Zealand,2012,10,C-Cardiovascular system,Million US$ at exchange rate,124.5 +26128,New Zealand,2012,10,C-Cardiovascular system,"Million US$, purchasing power parity",102.8 +26129,New Zealand,2012,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",6.5 +26130,New Zealand,2012,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.4 +26131,New Zealand,2012,10,A10-Drugs used in diabetes,% of total sales,3.8 +26132,New Zealand,2012,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +26133,New Zealand,2012,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.2 +26134,New Zealand,2012,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",48.0 +26135,New Zealand,2012,10,A-Alimentary tract and metabolism,% of total sales,7.8 +26136,New Zealand,2012,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",10.9 +26137,New Zealand,2012,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +26138,New Zealand,2012,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.9 +26139,New Zealand,2012,10,C03-Diuretics,Million of national currency units,2.3 +26140,New Zealand,2012,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,58.1 +26141,New Zealand,2012,10,A-Alimentary tract and metabolism,Million of national currency units,71.7 +26142,New Zealand,2012,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +26143,New Zealand,2012,10,C01A-Cardiac glycosides,% of total sales,0.0 +26144,New Zealand,2010,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.3 +26145,New Zealand,2010,11,N05C-Hypnotics and sedatives,Million of national currency units,1.5 +26146,New Zealand,2010,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.0 +26147,New Zealand,2010,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",8.9 +26148,New Zealand,2010,11,C08-Calcium channel blockers,Million US$ at exchange rate,9.6 +26149,New Zealand,2010,11,Products not elsewhere classified,"/capita, US$ exchange rate",30.9 +26150,New Zealand,2010,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",25.3 +26151,New Zealand,2010,11,C10-Lipid modifying agents,Million US$ at exchange rate,27.3 +26152,New Zealand,2010,11,Products not elsewhere classified,"Million US$, purchasing power parity",124.5 +26153,New Zealand,2010,11,C08-Calcium channel blockers,Million of national currency units,13.3 +26154,New Zealand,2010,11,C10-Lipid modifying agents,Million of national currency units,37.9 +26155,New Zealand,2010,11,N02-Analgesics,"/capita, US$ purchasing power parity",4.6 +26156,New Zealand,2010,11,N02-Analgesics,"/capita, US$ exchange rate",4.9 +26157,New Zealand,2010,11,N02-Analgesics,"Million US$, purchasing power parity",19.9 +26158,New Zealand,2010,11,Products not elsewhere classified,% of total sales,24.9 +26159,New Zealand,2010,11,N02-Analgesics,% of total sales,4.0 +26160,New Zealand,2010,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0 +26161,New Zealand,2010,11,C08-Calcium channel blockers,% of total sales,1.8 +26162,New Zealand,2010,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.2 +26163,New Zealand,2010,11,N02-Analgesics,Million US$ at exchange rate,21.4 +26164,New Zealand,2010,11,N02-Analgesics,Million of national currency units,29.7 +26165,New Zealand,2010,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",28.6 +26166,New Zealand,2010,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.0 +26167,New Zealand,2010,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,13.0 +26168,New Zealand,2010,11,B-Blood and blood forming organs,Million of national currency units,26.2 +26169,New Zealand,2010,11,G-Genito urinary system and sex hormones,Million of national currency units,18.0 +26170,New Zealand,2010,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.3 +26171,New Zealand,2010,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",17.5 +26172,New Zealand,2010,11,B-Blood and blood forming organs,Million US$ at exchange rate,18.9 +26173,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,% of total sales,1.6 +26174,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.1 +26175,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0 +26176,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9 +26177,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.1 +26178,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.7 +26179,New Zealand,2010,11,B-Blood and blood forming organs,% of total sales,3.5 +26180,New Zealand,2010,11,N05C-Hypnotics and sedatives,% of total sales,0.2 +26181,New Zealand,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2 +26182,New Zealand,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2 +26183,New Zealand,2010,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.0 +26184,New Zealand,2010,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",12.0 +26185,New Zealand,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.0 +26186,New Zealand,2010,11,Products not elsewhere classified,Million US$ at exchange rate,134.3 +26187,New Zealand,2010,11,C10-Lipid modifying agents,% of total sales,5.1 +26188,New Zealand,2010,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.8 +26189,New Zealand,2010,11,Products not elsewhere classified,Million of national currency units,186.3 +26190,New Zealand,2010,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",28.8 +26191,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.3 +26192,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.6 +26193,New Zealand,2010,11,R-Respiratory system,Million US$ at exchange rate,54.4 +26194,New Zealand,2010,11,R-Respiratory system,"Million US$, purchasing power parity",50.4 +26195,New Zealand,2010,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.1 +26196,New Zealand,2010,11,J-Antiinfectives for systemic use,Million of national currency units,43.2 +26197,New Zealand,2010,11,R-Respiratory system,Million of national currency units,75.5 +26198,New Zealand,2010,11,N05B-Anxiolytics,Million of national currency units,0.9 +26199,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7 +26200,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34.5 +26201,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,Million of national currency units,68.3 +26202,New Zealand,2010,11,N05B-Anxiolytics,Million US$ at exchange rate,0.6 +26203,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.7 +26204,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.0 +26205,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,24.8 +26206,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.9 +26207,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +26208,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,12.5 +26209,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,13.4 +26210,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18.7 +26211,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.1 +26212,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.5 +26213,New Zealand,2010,11,R-Respiratory system,% of total sales,10.1 +26214,New Zealand,2010,11,R-Respiratory system,"/capita, US$ exchange rate",12.5 +26215,New Zealand,2010,11,R-Respiratory system,"/capita, US$ purchasing power parity",11.6 +26216,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.4 +26217,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,9.0 +26218,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.9 +26219,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.1 +26220,New Zealand,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",2.8 +26221,New Zealand,2010,11,N06A-Antidepressants,"Million US$, purchasing power parity",19.7 +26222,New Zealand,2010,11,N06A-Antidepressants,Million US$ at exchange rate,21.2 +26223,New Zealand,2010,11,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1 +26224,New Zealand,2010,11,N06A-Antidepressants,Million of national currency units,29.5 +26225,New Zealand,2010,11,N06A-Antidepressants,% of total sales,3.9 +26226,New Zealand,2010,11,N06A-Antidepressants,"/capita, US$ exchange rate",4.9 +26227,New Zealand,2010,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.5 +26228,New Zealand,2010,11,G-Genito urinary system and sex hormones,% of total sales,2.4 +26229,New Zealand,2010,11,A02A-Antacids,Million of national currency units,0.2 +26230,New Zealand,2010,11,A02A-Antacids,Million US$ at exchange rate,0.2 +26231,New Zealand,2010,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1 +26232,New Zealand,2010,11,N05B-Anxiolytics,% of total sales,0.1 +26233,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,% of total sales,9.1 +26234,New Zealand,2010,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",6.6 +26235,New Zealand,2010,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1 +26236,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",45.6 +26237,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,49.2 +26238,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.5 +26239,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.3 +26240,New Zealand,2010,11,A02A-Antacids,"/capita, US$ exchange rate",0.0 +26241,New Zealand,2010,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0 +26242,New Zealand,2010,11,N05B-Anxiolytics,"Million US$, purchasing power parity",0.6 +26243,New Zealand,2010,11,A02A-Antacids,"Million US$, purchasing power parity",0.2 +26244,New Zealand,2010,11,J-Antiinfectives for systemic use,% of total sales,5.8 +26245,New Zealand,2010,11,A02A-Antacids,% of total sales,0.0 +26246,New Zealand,2010,11,C07-Beta blocking agents,Million US$ at exchange rate,16.8 +26247,New Zealand,2010,11,C07-Beta blocking agents,Million of national currency units,23.3 +26248,New Zealand,2010,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",18.8 +26249,New Zealand,2010,11,C07-Beta blocking agents,"/capita, US$ exchange rate",3.9 +26250,New Zealand,2010,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6 +26251,New Zealand,2010,11,C07-Beta blocking agents,"Million US$, purchasing power parity",15.6 +26252,New Zealand,2010,11,C-Cardiovascular system,% of total sales,16.3 +26253,New Zealand,2010,11,M-Musculo-skeletal system,% of total sales,3.4 +26254,New Zealand,2010,11,C03-Diuretics,Million US$ at exchange rate,2.0 +26255,New Zealand,2010,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.3 +26256,New Zealand,2010,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.0 +26257,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.4 +26258,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.1 +26259,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.7 +26260,New Zealand,2010,11,M-Musculo-skeletal system,Million of national currency units,25.8 +26261,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.5 +26262,New Zealand,2010,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.2 +26263,New Zealand,2010,11,C07-Beta blocking agents,% of total sales,3.1 +26264,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9 +26265,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0 +26266,New Zealand,2010,11,M-Musculo-skeletal system,Million US$ at exchange rate,18.6 +26267,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.6 +26268,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1 +26269,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3 +26270,New Zealand,2010,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",115.0 +26271,New Zealand,2010,11,Total pharmaceutical sales,"/capita, US$ exchange rate",124.0 +26272,New Zealand,2010,11,N-Nervous system,% of total sales,22.0 +26273,New Zealand,2010,11,C02-Antihypertensives,Million US$ at exchange rate,2.0 +26274,New Zealand,2010,11,C02-Antihypertensives,Million of national currency units,2.8 +26275,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +26276,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.6 +26277,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +26278,New Zealand,2010,11,N-Nervous system,Million of national currency units,164.5 +26279,New Zealand,2010,11,Total pharmaceutical sales,Million of national currency units,748.7 +26280,New Zealand,2010,11,C03-Diuretics,% of total sales,0.4 +26281,New Zealand,2010,11,Total pharmaceutical sales,Million US$ at exchange rate,539.5 +26282,New Zealand,2010,11,C03-Diuretics,"Million US$, purchasing power parity",1.8 +26283,New Zealand,2010,11,C03-Diuretics,"/capita, US$ exchange rate",0.5 +26284,New Zealand,2010,11,C03-Diuretics,"/capita, US$ purchasing power parity",0.4 +26285,New Zealand,2010,11,N-Nervous system,Million US$ at exchange rate,118.5 +26286,New Zealand,2010,11,N-Nervous system,"/capita, US$ purchasing power parity",25.3 +26287,New Zealand,2010,11,Total pharmaceutical sales,"Million US$, purchasing power parity",500.2 +26288,New Zealand,2010,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.9 +26289,New Zealand,2010,11,N-Nervous system,"Million US$, purchasing power parity",109.9 +26290,New Zealand,2010,11,N-Nervous system,"/capita, US$ exchange rate",27.2 +26291,New Zealand,2010,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.8 +26292,New Zealand,2010,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.6 +26293,New Zealand,2010,11,J01-Antibacterials for systemic use,% of total sales,2.2 +26294,New Zealand,2010,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.0 +26295,New Zealand,2010,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.1 +26296,New Zealand,2010,11,C-Cardiovascular system,"/capita, US$ exchange rate",20.3 +26297,New Zealand,2010,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +26298,New Zealand,2010,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +26299,New Zealand,2010,11,C01A-Cardiac glycosides,Million of national currency units,0.4 +26300,New Zealand,2010,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +26301,New Zealand,2010,11,J01-Antibacterials for systemic use,Million of national currency units,16.7 +26302,New Zealand,2010,11,A10-Drugs used in diabetes,Million US$ at exchange rate,21.4 +26303,New Zealand,2010,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",19.8 +26304,New Zealand,2010,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.9 +26305,New Zealand,2010,11,C02-Antihypertensives,% of total sales,0.4 +26306,New Zealand,2010,11,A10-Drugs used in diabetes,Million of national currency units,29.7 +26307,New Zealand,2010,11,C-Cardiovascular system,Million of national currency units,122.4 +26308,New Zealand,2010,11,C-Cardiovascular system,Million US$ at exchange rate,88.2 +26309,New Zealand,2010,11,C-Cardiovascular system,"Million US$, purchasing power parity",81.8 +26310,New Zealand,2010,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",4.6 +26311,New Zealand,2010,11,A10-Drugs used in diabetes,% of total sales,4.0 +26312,New Zealand,2010,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",11.3 +26313,New Zealand,2010,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",45.6 +26314,New Zealand,2010,11,A-Alimentary tract and metabolism,% of total sales,9.1 +26315,New Zealand,2010,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",10.5 +26316,New Zealand,2010,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +26317,New Zealand,2010,11,C03-Diuretics,Million of national currency units,2.7 +26318,New Zealand,2010,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,49.2 +26319,New Zealand,2010,11,A-Alimentary tract and metabolism,Million of national currency units,68.2 +26320,New Zealand,2010,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4 +26321,New Zealand,2010,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +26322,New Zealand,2010,11,C01A-Cardiac glycosides,% of total sales,0.1 +26323,Norway,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",69.4 +26324,Norway,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,112.4 +26325,Norway,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,72.3 +26326,Norway,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",44.6 +26327,Norway,2011,4,C10-Lipid modifying agents,Million of national currency units,405.0 +26328,Norway,2011,4,A-Alimentary tract and metabolism,% of total sales,10.4 +26329,Norway,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.9 +26330,Norway,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,925.0 +26331,Norway,2011,4,C02-Antihypertensives,Million of national currency units,56.0 +26332,Norway,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,165.0 +26333,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,79.8 +26334,Norway,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.0 +26335,Norway,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.7 +26336,Norway,2011,4,M-Musculo-skeletal system,% of total sales,3.5 +26337,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +26338,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",49.2 +26339,Norway,2011,4,C10-Lipid modifying agents,% of total sales,2.2 +26340,Norway,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",4.3 +26341,Norway,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.9 +26342,Norway,2011,4,M-Musculo-skeletal system,Million of national currency units,630.0 +26343,Norway,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",207.6 +26344,Norway,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,21.1 +26345,Norway,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",13.0 +26346,Norway,2011,4,A-Alimentary tract and metabolism,Million of national currency units,1886.0 +26347,Norway,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,336.5 +26348,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.9 +26349,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +26350,Norway,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.6 +26351,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.1 +26352,Norway,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6 +26353,Norway,2011,4,N05B-Anxiolytics,Million of national currency units,118.0 +26354,Norway,2011,4,N05B-Anxiolytics,% of total sales,0.6 +26355,Norway,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.0 +26356,Norway,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.9 +26357,Norway,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8 +26358,Norway,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.2 +26359,Norway,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",18.9 +26360,Norway,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.3 +26361,Norway,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.7 +26362,Norway,2011,4,B-Blood and blood forming organs,% of total sales,6.6 +26363,Norway,2011,4,C01A-Cardiac glycosides,% of total sales,0.0 +26364,Norway,2011,4,N06A-Antidepressants,Million of national currency units,266.0 +26365,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,437.0 +26366,Norway,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,30.7 +26367,Norway,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,172.0 +26368,Norway,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +26369,Norway,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +26370,Norway,2011,4,A10-Drugs used in diabetes,Million of national currency units,556.0 +26371,Norway,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,436.0 +26372,Norway,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +26373,Norway,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",61.2 +26374,Norway,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,99.2 +26375,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",48.0 +26376,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7 +26377,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.7 +26378,Norway,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",132.4 +26379,Norway,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +26380,Norway,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5 +26381,Norway,2011,4,B-Blood and blood forming organs,Million of national currency units,1203.0 +26382,Norway,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,214.6 +26383,Norway,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.4 +26384,Norway,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.0 +26385,Norway,2011,4,C01A-Cardiac glycosides,Million of national currency units,3.0 +26386,Norway,2011,4,A10-Drugs used in diabetes,% of total sales,3.1 +26387,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.2 +26388,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0 +26389,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,79.4 +26390,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,445.0 +26391,Norway,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2003.8 +26392,Norway,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,3247.3 +26393,Norway,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",404.6 +26394,Norway,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",655.6 +26395,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +26396,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +26397,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,447.0 +26398,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +26399,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0 +26400,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",49.0 +26401,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2 +26402,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.9 +26403,Norway,2011,4,N06A-Antidepressants,% of total sales,1.5 +26404,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,78.0 +26405,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",48.1 +26406,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.7 +26407,Norway,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.9 +26408,Norway,2011,4,N06A-Antidepressants,Million US$ at exchange rate,47.5 +26409,Norway,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",29.3 +26410,Norway,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",9.6 +26411,Norway,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.3 +26412,Norway,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6 +26413,Norway,2011,4,Total pharmaceutical sales,Million of national currency units,18200.0 +26414,Norway,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",101.8 +26415,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.7 +26416,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +26417,Norway,2011,4,G-Genito urinary system and sex hormones,% of total sales,5.1 +26418,Norway,2011,4,C02-Antihypertensives,Million US$ at exchange rate,10.0 +26419,Norway,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,6.2 +26420,Norway,2011,4,A02A-Antacids,Million US$ at exchange rate,5.0 +26421,Norway,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.4 +26422,Norway,2011,4,A02A-Antacids,Million of national currency units,28.0 +26423,Norway,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",125.1 +26424,Norway,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.3 +26425,Norway,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",40.9 +26426,Norway,2011,4,C07-Beta blocking agents,Million of national currency units,166.0 +26427,Norway,2011,4,C-Cardiovascular system,Million of national currency units,1797.0 +26428,Norway,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1 +26429,Norway,2011,4,C08-Calcium channel blockers,% of total sales,0.8 +26430,Norway,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",64.7 +26431,Norway,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",39.9 +26432,Norway,2011,4,C-Cardiovascular system,Million US$ at exchange rate,320.6 +26433,Norway,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",197.8 +26434,Norway,2011,4,C03-Diuretics,Million US$ at exchange rate,18.2 +26435,Norway,2011,4,C03-Diuretics,Million of national currency units,102.0 +26436,Norway,2011,4,C03-Diuretics,"/capita, US$ exchange rate",3.7 +26437,Norway,2011,4,C03-Diuretics,"Million US$, purchasing power parity",11.2 +26438,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.1 +26439,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,139.5 +26440,Norway,2011,4,N-Nervous system,% of total sales,19.0 +26441,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,782.0 +26442,Norway,2011,4,J-Antiinfectives for systemic use,Million of national currency units,1426.0 +26443,Norway,2011,4,C-Cardiovascular system,% of total sales,9.9 +26444,Norway,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,254.4 +26445,Norway,2011,4,C03-Diuretics,% of total sales,0.6 +26446,Norway,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.3 +26447,Norway,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,202.7 +26448,Norway,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1136.0 +26449,Norway,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",157.0 +26450,Norway,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.0 +26451,Norway,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.8 +26452,Norway,2011,4,C08-Calcium channel blockers,Million of national currency units,141.0 +26453,Norway,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",49.3 +26454,Norway,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.1 +26455,Norway,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1 +26456,Norway,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,25.2 +26457,Norway,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",15.5 +26458,Norway,2011,4,Products not elsewhere classified,"Million US$, purchasing power parity",495.2 +26459,Norway,2011,4,Products not elsewhere classified,"/capita, US$ exchange rate",162.0 +26460,Norway,2011,4,Products not elsewhere classified,Million of national currency units,4498.0 +26461,Norway,2011,4,Products not elsewhere classified,Million US$ at exchange rate,802.6 +26462,Norway,2011,4,J01-Antibacterials for systemic use,Million of national currency units,448.0 +26463,Norway,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,79.9 +26464,Norway,2011,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",100.0 +26465,Norway,2011,4,Products not elsewhere classified,% of total sales,24.7 +26466,Norway,2011,4,J-Antiinfectives for systemic use,% of total sales,7.8 +26467,Norway,2011,4,N02-Analgesics,Million US$ at exchange rate,217.5 +26468,Norway,2011,4,N02-Analgesics,"Million US$, purchasing power parity",134.2 +26469,Norway,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,29.6 +26470,Norway,2011,4,N02-Analgesics,Million of national currency units,1219.0 +26471,Norway,2011,4,N02-Analgesics,% of total sales,6.7 +26472,Norway,2011,4,N02-Analgesics,"/capita, US$ exchange rate",43.9 +26473,Norway,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",27.1 +26474,Norway,2011,4,J01-Antibacterials for systemic use,% of total sales,2.5 +26475,Norway,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.7 +26476,Norway,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.0 +26477,Norway,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",18.3 +26478,Norway,2011,4,C07-Beta blocking agents,% of total sales,0.9 +26479,Norway,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.7 +26480,Norway,2011,4,R-Respiratory system,Million US$ at exchange rate,339.4 +26481,Norway,2011,4,R-Respiratory system,Million of national currency units,1902.0 +26482,Norway,2011,4,R-Respiratory system,"/capita, US$ exchange rate",68.5 +26483,Norway,2011,4,R-Respiratory system,"Million US$, purchasing power parity",209.4 +26484,Norway,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2 +26485,Norway,2011,4,N-Nervous system,"Million US$, purchasing power parity",380.7 +26486,Norway,2011,4,N-Nervous system,Million US$ at exchange rate,617.0 +26487,Norway,2011,4,C02-Antihypertensives,% of total sales,0.3 +26488,Norway,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +26489,Norway,2011,4,A02A-Antacids,"/capita, US$ exchange rate",1.0 +26490,Norway,2011,4,A02A-Antacids,% of total sales,0.2 +26491,Norway,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",42.3 +26492,Norway,2011,4,N-Nervous system,Million of national currency units,3458.0 +26493,Norway,2011,4,R-Respiratory system,% of total sales,10.5 +26494,Norway,2011,4,A02A-Antacids,"Million US$, purchasing power parity",3.1 +26495,Norway,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",76.9 +26496,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.2 +26497,Norway,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.0 +26498,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.3 +26499,Norway,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",6.2 +26500,Norway,2011,4,N-Nervous system,"/capita, US$ exchange rate",124.6 +26501,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.4 +26502,Norway,2012,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",73.1 +26503,Norway,2012,3,M-Musculo-skeletal system,Million US$ at exchange rate,113.6 +26504,Norway,2012,3,C10-Lipid modifying agents,Million US$ at exchange rate,64.5 +26505,Norway,2012,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.5 +26506,Norway,2012,3,N05B-Anxiolytics,% of total sales,0.6 +26507,Norway,2012,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.1 +26508,Norway,2012,3,C10-Lipid modifying agents,Million of national currency units,375.0 +26509,Norway,2012,3,A-Alimentary tract and metabolism,% of total sales,10.2 +26510,Norway,2012,3,N05B-Anxiolytics,"Million US$, purchasing power parity",12.8 +26511,Norway,2012,3,G-Genito urinary system and sex hormones,Million of national currency units,948.0 +26512,Norway,2012,3,C02-Antihypertensives,Million of national currency units,61.0 +26513,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,71.2 +26514,Norway,2012,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,163.0 +26515,Norway,2012,3,M-Musculo-skeletal system,% of total sales,3.5 +26516,Norway,2012,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.6 +26517,Norway,2012,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.6 +26518,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +26519,Norway,2012,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",211.4 +26520,Norway,2012,3,C10-Lipid modifying agents,% of total sales,2.0 +26521,Norway,2012,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",65.4 +26522,Norway,2012,3,N05B-Anxiolytics,"/capita, US$ exchange rate",4.0 +26523,Norway,2012,3,M-Musculo-skeletal system,Million of national currency units,661.0 +26524,Norway,2012,3,N05B-Anxiolytics,Million US$ at exchange rate,19.9 +26525,Norway,2012,3,A-Alimentary tract and metabolism,Million of national currency units,1910.0 +26526,Norway,2012,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.3 +26527,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.1 +26528,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.2 +26529,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",45.8 +26530,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.2 +26531,Norway,2012,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6 +26532,Norway,2012,3,N05B-Anxiolytics,Million of national currency units,116.0 +26533,Norway,2012,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.8 +26534,Norway,2012,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.3 +26535,Norway,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3 +26536,Norway,2012,3,N05C-Hypnotics and sedatives,% of total sales,1.0 +26537,Norway,2012,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.5 +26538,Norway,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.6 +26539,Norway,2012,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.6 +26540,Norway,2012,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.1 +26541,Norway,2012,3,B-Blood and blood forming organs,% of total sales,6.8 +26542,Norway,2012,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.3 +26543,Norway,2012,3,C01A-Cardiac glycosides,% of total sales,0.0 +26544,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,446.0 +26545,Norway,2012,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +26546,Norway,2012,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.3 +26547,Norway,2012,3,N05C-Hypnotics and sedatives,Million of national currency units,194.0 +26548,Norway,2012,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +26549,Norway,2012,3,N06A-Antidepressants,Million of national currency units,266.0 +26550,Norway,2012,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",141.0 +26551,Norway,2012,3,A10-Drugs used in diabetes,Million of national currency units,596.0 +26552,Norway,2012,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,441.0 +26553,Norway,2012,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",66.0 +26554,Norway,2012,3,A10-Drugs used in diabetes,Million US$ at exchange rate,102.4 +26555,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",48.8 +26556,Norway,2012,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,75.8 +26557,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7 +26558,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.1 +26559,Norway,2012,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3 +26560,Norway,2012,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5 +26561,Norway,2012,3,B-Blood and blood forming organs,Million of national currency units,1274.0 +26562,Norway,2012,3,B-Blood and blood forming organs,Million US$ at exchange rate,219.0 +26563,Norway,2012,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.1 +26564,Norway,2012,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.4 +26565,Norway,2012,3,C01A-Cardiac glycosides,Million of national currency units,3.0 +26566,Norway,2012,3,A10-Drugs used in diabetes,% of total sales,3.2 +26567,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0 +26568,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0 +26569,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,80.4 +26570,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,468.0 +26571,Norway,2012,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2080.3 +26572,Norway,2012,3,Total pharmaceutical sales,Million US$ at exchange rate,3231.6 +26573,Norway,2012,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",414.5 +26574,Norway,2012,3,Total pharmaceutical sales,"/capita, US$ exchange rate",643.9 +26575,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +26576,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +26577,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,414.0 +26578,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +26579,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0 +26580,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.8 +26581,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2 +26582,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.3 +26583,Norway,2012,3,N06A-Antidepressants,% of total sales,1.4 +26584,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,76.7 +26585,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",49.4 +26586,Norway,2012,3,N06A-Antidepressants,Million US$ at exchange rate,45.7 +26587,Norway,2012,3,N06A-Antidepressants,"Million US$, purchasing power parity",29.4 +26588,Norway,2012,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.9 +26589,Norway,2012,3,N06A-Antidepressants,"/capita, US$ exchange rate",9.1 +26590,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.3 +26591,Norway,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.5 +26592,Norway,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.9 +26593,Norway,2012,3,Total pharmaceutical sales,Million of national currency units,18800.0 +26594,Norway,2012,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",104.9 +26595,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8 +26596,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +26597,Norway,2012,3,G-Genito urinary system and sex hormones,% of total sales,5.0 +26598,Norway,2012,3,R03-Drugs for obstructive airway diseases,% of total sales,6.0 +26599,Norway,2012,3,A02A-Antacids,Million of national currency units,28.0 +26600,Norway,2012,3,A02A-Antacids,Million US$ at exchange rate,4.8 +26601,Norway,2012,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",123.8 +26602,Norway,2012,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,192.4 +26603,Norway,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.7 +26604,Norway,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.3 +26605,Norway,2012,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.0 +26606,Norway,2012,3,C07-Beta blocking agents,Million of national currency units,165.0 +26607,Norway,2012,3,C-Cardiovascular system,Million of national currency units,1631.0 +26608,Norway,2012,3,C08-Calcium channel blockers,% of total sales,0.7 +26609,Norway,2012,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.9 +26610,Norway,2012,3,C-Cardiovascular system,"/capita, US$ exchange rate",55.9 +26611,Norway,2012,3,C-Cardiovascular system,Million US$ at exchange rate,280.4 +26612,Norway,2012,3,C-Cardiovascular system,"Million US$, purchasing power parity",180.5 +26613,Norway,2012,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",169.7 +26614,Norway,2012,3,C03-Diuretics,Million US$ at exchange rate,17.0 +26615,Norway,2012,3,C03-Diuretics,Million of national currency units,99.0 +26616,Norway,2012,3,C03-Diuretics,"/capita, US$ exchange rate",3.4 +26617,Norway,2012,3,C03-Diuretics,"Million US$, purchasing power parity",11.0 +26618,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,111.2 +26619,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",71.6 +26620,Norway,2012,3,N-Nervous system,% of total sales,19.1 +26621,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,647.0 +26622,Norway,2012,3,J-Antiinfectives for systemic use,Million of national currency units,1534.0 +26623,Norway,2012,3,C-Cardiovascular system,% of total sales,8.7 +26624,Norway,2012,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,263.7 +26625,Norway,2012,3,C03-Diuretics,% of total sales,0.5 +26626,Norway,2012,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +26627,Norway,2012,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1119.0 +26628,Norway,2012,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5 +26629,Norway,2012,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1 +26630,Norway,2012,3,C08-Calcium channel blockers,Million of national currency units,132.0 +26631,Norway,2012,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.7 +26632,Norway,2012,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",50.7 +26633,Norway,2012,3,J-Antiinfectives for systemic use,% of total sales,8.2 +26634,Norway,2012,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.6 +26635,Norway,2012,3,C08-Calcium channel blockers,Million US$ at exchange rate,22.7 +26636,Norway,2012,3,Products not elsewhere classified,"Million US$, purchasing power parity",535.8 +26637,Norway,2012,3,Products not elsewhere classified,"/capita, US$ exchange rate",165.8 +26638,Norway,2012,3,Products not elsewhere classified,Million of national currency units,4842.0 +26639,Norway,2012,3,Products not elsewhere classified,Million US$ at exchange rate,832.3 +26640,Norway,2012,3,J01-Antibacterials for systemic use,Million of national currency units,458.0 +26641,Norway,2012,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,78.7 +26642,Norway,2012,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.8 +26643,Norway,2012,3,Products not elsewhere classified,% of total sales,25.8 +26644,Norway,2012,3,N02-Analgesics,Million US$ at exchange rate,215.9 +26645,Norway,2012,3,N02-Analgesics,"Million US$, purchasing power parity",139.0 +26646,Norway,2012,3,C07-Beta blocking agents,Million US$ at exchange rate,28.4 +26647,Norway,2012,3,N02-Analgesics,Million of national currency units,1256.0 +26648,Norway,2012,3,N02-Analgesics,% of total sales,6.7 +26649,Norway,2012,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.7 +26650,Norway,2012,3,N02-Analgesics,"/capita, US$ exchange rate",43.0 +26651,Norway,2012,3,J01-Antibacterials for systemic use,% of total sales,2.4 +26652,Norway,2012,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.8 +26653,Norway,2012,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.5 +26654,Norway,2012,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7 +26655,Norway,2012,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.3 +26656,Norway,2012,3,C07-Beta blocking agents,% of total sales,0.9 +26657,Norway,2012,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6 +26658,Norway,2012,3,R-Respiratory system,Million US$ at exchange rate,331.4 +26659,Norway,2012,3,R-Respiratory system,Million of national currency units,1928.0 +26660,Norway,2012,3,R-Respiratory system,"/capita, US$ exchange rate",66.0 +26661,Norway,2012,3,R-Respiratory system,"Million US$, purchasing power parity",213.3 +26662,Norway,2012,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +26663,Norway,2012,3,N-Nervous system,Million US$ at exchange rate,618.7 +26664,Norway,2012,3,C02-Antihypertensives,% of total sales,0.3 +26665,Norway,2012,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +26666,Norway,2012,3,A02A-Antacids,"/capita, US$ exchange rate",1.0 +26667,Norway,2012,3,A02A-Antacids,% of total sales,0.1 +26668,Norway,2012,3,N-Nervous system,"Million US$, purchasing power parity",398.2 +26669,Norway,2012,3,R-Respiratory system,"/capita, US$ purchasing power parity",42.5 +26670,Norway,2012,3,N-Nervous system,Million of national currency units,3599.0 +26671,Norway,2012,3,A02A-Antacids,"Million US$, purchasing power parity",3.1 +26672,Norway,2012,3,R-Respiratory system,% of total sales,10.3 +26673,Norway,2012,3,N-Nervous system,"/capita, US$ purchasing power parity",79.4 +26674,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.2 +26675,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4 +26676,Norway,2012,3,C02-Antihypertensives,"Million US$, purchasing power parity",6.7 +26677,Norway,2012,3,N-Nervous system,"/capita, US$ exchange rate",123.3 +26678,Norway,2012,3,C02-Antihypertensives,Million US$ at exchange rate,10.5 +26679,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",14.3 +26680,Norway,2012,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.1 +26681,Norway,2013,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",79.1 +26682,Norway,2013,3,M-Musculo-skeletal system,Million US$ at exchange rate,121.5 +26683,Norway,2013,3,N05B-Anxiolytics,% of total sales,0.6 +26684,Norway,2013,3,C10-Lipid modifying agents,Million US$ at exchange rate,66.6 +26685,Norway,2013,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",43.3 +26686,Norway,2013,3,C10-Lipid modifying agents,Million of national currency units,391.0 +26687,Norway,2013,3,A-Alimentary tract and metabolism,% of total sales,9.9 +26688,Norway,2013,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8 +26689,Norway,2013,3,G-Genito urinary system and sex hormones,Million of national currency units,983.0 +26690,Norway,2013,3,C02-Antihypertensives,Million of national currency units,69.0 +26691,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,65.9 +26692,Norway,2013,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,167.3 +26693,Norway,2013,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6 +26694,Norway,2013,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.9 +26695,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +26696,Norway,2013,3,M-Musculo-skeletal system,% of total sales,3.7 +26697,Norway,2013,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",212.1 +26698,Norway,2013,3,C10-Lipid modifying agents,% of total sales,2.0 +26699,Norway,2013,3,N05B-Anxiolytics,"/capita, US$ exchange rate",3.8 +26700,Norway,2013,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.2 +26701,Norway,2013,3,M-Musculo-skeletal system,Million of national currency units,714.0 +26702,Norway,2013,3,N05B-Anxiolytics,Million US$ at exchange rate,19.4 +26703,Norway,2013,3,A-Alimentary tract and metabolism,Million of national currency units,1915.0 +26704,Norway,2013,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,326.0 +26705,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.4 +26706,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0 +26707,Norway,2013,3,N05B-Anxiolytics,"Million US$, purchasing power parity",12.6 +26708,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",42.9 +26709,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.0 +26710,Norway,2013,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +26711,Norway,2013,3,N05B-Anxiolytics,Million of national currency units,114.0 +26712,Norway,2013,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.1 +26713,Norway,2013,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5 +26714,Norway,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.2 +26715,Norway,2013,3,N05C-Hypnotics and sedatives,% of total sales,1.0 +26716,Norway,2013,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.2 +26717,Norway,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.4 +26718,Norway,2013,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.2 +26719,Norway,2013,3,B-Blood and blood forming organs,% of total sales,7.8 +26720,Norway,2013,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.7 +26721,Norway,2013,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",165.9 +26722,Norway,2013,3,C01A-Cardiac glycosides,% of total sales,0.0 +26723,Norway,2013,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +26724,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,464.0 +26725,Norway,2013,3,N05C-Hypnotics and sedatives,Million of national currency units,191.0 +26726,Norway,2013,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,32.5 +26727,Norway,2013,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +26728,Norway,2013,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +26729,Norway,2013,3,A10-Drugs used in diabetes,Million of national currency units,601.0 +26730,Norway,2013,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,454.0 +26731,Norway,2013,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",66.6 +26732,Norway,2013,3,A10-Drugs used in diabetes,Million US$ at exchange rate,102.3 +26733,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",50.3 +26734,Norway,2013,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.3 +26735,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9 +26736,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.2 +26737,Norway,2013,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +26738,Norway,2013,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9 +26739,Norway,2013,3,B-Blood and blood forming organs,Million of national currency units,1498.0 +26740,Norway,2013,3,B-Blood and blood forming organs,Million US$ at exchange rate,255.0 +26741,Norway,2013,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.1 +26742,Norway,2013,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.1 +26743,Norway,2013,3,C01A-Cardiac glycosides,Million of national currency units,5.0 +26744,Norway,2013,3,A10-Drugs used in diabetes,% of total sales,3.1 +26745,Norway,2013,3,N06A-Antidepressants,Million of national currency units,261.0 +26746,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.3 +26747,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.0 +26748,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.6 +26749,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,485.0 +26750,Norway,2013,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2137.5 +26751,Norway,2013,3,Total pharmaceutical sales,Million US$ at exchange rate,3285.1 +26752,Norway,2013,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",420.8 +26753,Norway,2013,3,Total pharmaceutical sales,"/capita, US$ exchange rate",646.7 +26754,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +26755,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +26756,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,387.0 +26757,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +26758,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.3 +26759,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",53.7 +26760,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.4 +26761,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6 +26762,Norway,2013,3,N06A-Antidepressants,% of total sales,1.4 +26763,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,79.0 +26764,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.4 +26765,Norway,2013,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.7 +26766,Norway,2013,3,N06A-Antidepressants,Million US$ at exchange rate,44.4 +26767,Norway,2013,3,N06A-Antidepressants,"Million US$, purchasing power parity",28.9 +26768,Norway,2013,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.7 +26769,Norway,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.9 +26770,Norway,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.4 +26771,Norway,2013,3,Total pharmaceutical sales,Million of national currency units,19300.0 +26772,Norway,2013,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",108.9 +26773,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.5 +26774,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.1 +26775,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +26776,Norway,2013,3,G-Genito urinary system and sex hormones,% of total sales,5.1 +26777,Norway,2013,3,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +26778,Norway,2013,3,A02A-Antacids,Million of national currency units,29.0 +26779,Norway,2013,3,A02A-Antacids,Million US$ at exchange rate,4.9 +26780,Norway,2013,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",115.7 +26781,Norway,2013,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,177.9 +26782,Norway,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8 +26783,Norway,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",35.0 +26784,Norway,2013,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",32.3 +26785,Norway,2013,3,C08-Calcium channel blockers,% of total sales,0.7 +26786,Norway,2013,3,C07-Beta blocking agents,Million of national currency units,167.0 +26787,Norway,2013,3,C-Cardiovascular system,Million of national currency units,1481.0 +26788,Norway,2013,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.8 +26789,Norway,2013,3,C-Cardiovascular system,"/capita, US$ exchange rate",49.6 +26790,Norway,2013,3,C-Cardiovascular system,Million US$ at exchange rate,252.1 +26791,Norway,2013,3,C-Cardiovascular system,"Million US$, purchasing power parity",164.0 +26792,Norway,2013,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",167.7 +26793,Norway,2013,3,C03-Diuretics,Million US$ at exchange rate,16.7 +26794,Norway,2013,3,C03-Diuretics,Million of national currency units,98.0 +26795,Norway,2013,3,C03-Diuretics,"/capita, US$ exchange rate",3.3 +26796,Norway,2013,3,C03-Diuretics,"Million US$, purchasing power parity",10.9 +26797,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.2 +26798,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",52.2 +26799,Norway,2013,3,N-Nervous system,% of total sales,18.5 +26800,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,471.0 +26801,Norway,2013,3,C-Cardiovascular system,% of total sales,7.7 +26802,Norway,2013,3,J-Antiinfectives for systemic use,Million of national currency units,1514.0 +26803,Norway,2013,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,257.7 +26804,Norway,2013,3,C03-Diuretics,% of total sales,0.5 +26805,Norway,2013,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1 +26806,Norway,2013,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1045.0 +26807,Norway,2013,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3 +26808,Norway,2013,3,C08-Calcium channel blockers,Million of national currency units,128.0 +26809,Norway,2013,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +26810,Norway,2013,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.8 +26811,Norway,2013,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.2 +26812,Norway,2013,3,J-Antiinfectives for systemic use,% of total sales,7.8 +26813,Norway,2013,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.8 +26814,Norway,2013,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.2 +26815,Norway,2013,3,Products not elsewhere classified,"Million US$, purchasing power parity",580.7 +26816,Norway,2013,3,Products not elsewhere classified,"/capita, US$ exchange rate",175.7 +26817,Norway,2013,3,Products not elsewhere classified,Million of national currency units,5243.0 +26818,Norway,2013,3,Products not elsewhere classified,Million US$ at exchange rate,892.4 +26819,Norway,2013,3,J01-Antibacterials for systemic use,Million of national currency units,423.0 +26820,Norway,2013,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.0 +26821,Norway,2013,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",114.3 +26822,Norway,2013,3,Products not elsewhere classified,% of total sales,27.2 +26823,Norway,2013,3,N02-Analgesics,Million US$ at exchange rate,213.6 +26824,Norway,2013,3,N02-Analgesics,"Million US$, purchasing power parity",139.0 +26825,Norway,2013,3,C07-Beta blocking agents,Million US$ at exchange rate,28.4 +26826,Norway,2013,3,N02-Analgesics,Million of national currency units,1255.0 +26827,Norway,2013,3,N02-Analgesics,% of total sales,6.5 +26828,Norway,2013,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.4 +26829,Norway,2013,3,N02-Analgesics,"/capita, US$ exchange rate",42.1 +26830,Norway,2013,3,J01-Antibacterials for systemic use,% of total sales,2.2 +26831,Norway,2013,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.7 +26832,Norway,2013,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.0 +26833,Norway,2013,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6 +26834,Norway,2013,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.5 +26835,Norway,2013,3,C07-Beta blocking agents,% of total sales,0.9 +26836,Norway,2013,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6 +26837,Norway,2013,3,R-Respiratory system,Million US$ at exchange rate,316.4 +26838,Norway,2013,3,R-Respiratory system,Million of national currency units,1859.0 +26839,Norway,2013,3,R-Respiratory system,"Million US$, purchasing power parity",205.9 +26840,Norway,2013,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.5 +26841,Norway,2013,3,N-Nervous system,Million US$ at exchange rate,607.7 +26842,Norway,2013,3,C02-Antihypertensives,% of total sales,0.4 +26843,Norway,2013,3,R-Respiratory system,"/capita, US$ exchange rate",62.3 +26844,Norway,2013,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +26845,Norway,2013,3,A02A-Antacids,"/capita, US$ exchange rate",1.0 +26846,Norway,2013,3,A02A-Antacids,% of total sales,0.2 +26847,Norway,2013,3,R-Respiratory system,"/capita, US$ purchasing power parity",40.5 +26848,Norway,2013,3,N-Nervous system,Million of national currency units,3570.0 +26849,Norway,2013,3,A02A-Antacids,"Million US$, purchasing power parity",3.2 +26850,Norway,2013,3,R-Respiratory system,% of total sales,9.6 +26851,Norway,2013,3,N-Nervous system,"Million US$, purchasing power parity",395.4 +26852,Norway,2013,3,N-Nervous system,"/capita, US$ purchasing power parity",77.8 +26853,Norway,2013,3,N-Nervous system,"/capita, US$ exchange rate",119.6 +26854,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.8 +26855,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4 +26856,Norway,2013,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.6 +26857,Norway,2013,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +26858,Norway,2013,3,C02-Antihypertensives,Million US$ at exchange rate,11.7 +26859,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.3 +26860,Norway,2017,2,N05B-Anxiolytics,% of total sales,0.4 +26861,Norway,2017,2,M-Musculo-skeletal system,Million of national currency units,998.0 +26862,Norway,2017,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",102.4 +26863,Norway,2017,2,M-Musculo-skeletal system,Million US$ at exchange rate,120.7 +26864,Norway,2017,2,C10-Lipid modifying agents,Million of national currency units,504.0 +26865,Norway,2017,2,C10-Lipid modifying agents,Million US$ at exchange rate,60.9 +26866,Norway,2017,2,A-Alimentary tract and metabolism,% of total sales,10.4 +26867,Norway,2017,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.9 +26868,Norway,2017,2,G-Genito urinary system and sex hormones,Million of national currency units,1228.0 +26869,Norway,2017,2,M-Musculo-skeletal system,% of total sales,3.7 +26870,Norway,2017,2,C02-Antihypertensives,Million of national currency units,110.0 +26871,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.9 +26872,Norway,2017,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,148.5 +26873,Norway,2017,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.4 +26874,Norway,2017,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.9 +26875,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6 +26876,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +26877,Norway,2017,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.7 +26878,Norway,2017,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",284.6 +26879,Norway,2017,2,C10-Lipid modifying agents,% of total sales,1.9 +26880,Norway,2017,2,N05B-Anxiolytics,Million of national currency units,116.0 +26881,Norway,2017,2,N05B-Anxiolytics,Million US$ at exchange rate,14.0 +26882,Norway,2017,2,N05B-Anxiolytics,"Million US$, purchasing power parity",11.9 +26883,Norway,2017,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,335.5 +26884,Norway,2017,2,A-Alimentary tract and metabolism,Million of national currency units,2775.0 +26885,Norway,2017,2,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +26886,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.4 +26887,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2 +26888,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6 +26889,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",33.8 +26890,Norway,2017,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +26891,Norway,2017,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.6 +26892,Norway,2017,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.5 +26893,Norway,2017,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.8 +26894,Norway,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0 +26895,Norway,2017,2,N05C-Hypnotics and sedatives,% of total sales,1.0 +26896,Norway,2017,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",26.4 +26897,Norway,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.9 +26898,Norway,2017,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",53.4 +26899,Norway,2017,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",239.0 +26900,Norway,2017,2,B-Blood and blood forming organs,% of total sales,8.7 +26901,Norway,2017,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.3 +26902,Norway,2017,2,C01A-Cardiac glycosides,% of total sales,0.0 +26903,Norway,2017,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +26904,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,550.0 +26905,Norway,2017,2,G03-Sex hormones and modulators of the genital system,% of total sales,2.1 +26906,Norway,2017,2,N05C-Hypnotics and sedatives,Million of national currency units,257.0 +26907,Norway,2017,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,31.1 +26908,Norway,2017,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +26909,Norway,2017,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +26910,Norway,2017,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,562.0 +26911,Norway,2017,2,A10-Drugs used in diabetes,Million of national currency units,1001.0 +26912,Norway,2017,2,A10-Drugs used in diabetes,Million US$ at exchange rate,121.0 +26913,Norway,2017,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",102.7 +26914,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",57.6 +26915,Norway,2017,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.9 +26916,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.9 +26917,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.9 +26918,Norway,2017,2,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +26919,Norway,2017,2,B-Blood and blood forming organs,Million US$ at exchange rate,281.7 +26920,Norway,2017,2,B-Blood and blood forming organs,Million of national currency units,2330.0 +26921,Norway,2017,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.9 +26922,Norway,2017,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.5 +26923,Norway,2017,2,C01A-Cardiac glycosides,Million of national currency units,5.0 +26924,Norway,2017,2,A10-Drugs used in diabetes,% of total sales,3.8 +26925,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,41.0 +26926,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0 +26927,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,65.6 +26928,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,543.0 +26929,Norway,2017,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",518.0 +26930,Norway,2017,2,Total pharmaceutical sales,Million US$ at exchange rate,3221.8 +26931,Norway,2017,2,Total pharmaceutical sales,"Million US$, purchasing power parity",2733.4 +26932,Norway,2017,2,Total pharmaceutical sales,"/capita, US$ exchange rate",610.5 +26933,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +26934,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +26935,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,330.0 +26936,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +26937,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.7 +26938,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.4 +26939,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2 +26940,Norway,2017,2,N06A-Antidepressants,% of total sales,1.0 +26941,Norway,2017,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.4 +26942,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",56.4 +26943,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,66.5 +26944,Norway,2017,2,N06A-Antidepressants,Million US$ at exchange rate,33.5 +26945,Norway,2017,2,N06A-Antidepressants,Million of national currency units,277.0 +26946,Norway,2017,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.3 +26947,Norway,2017,2,N06A-Antidepressants,"Million US$, purchasing power parity",28.4 +26948,Norway,2017,2,Total pharmaceutical sales,Million of national currency units,26650.0 +26949,Norway,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",28.1 +26950,Norway,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.9 +26951,Norway,2017,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",126.0 +26952,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.7 +26953,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6 +26954,Norway,2017,2,G-Genito urinary system and sex hormones,% of total sales,4.6 +26955,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1 +26956,Norway,2017,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",241.2 +26957,Norway,2017,2,R03-Drugs for obstructive airway diseases,% of total sales,4.6 +26958,Norway,2017,2,A02A-Antacids,Million of national currency units,29.0 +26959,Norway,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.6 +26960,Norway,2017,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",124.5 +26961,Norway,2017,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,146.8 +26962,Norway,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.8 +26963,Norway,2017,2,C08-Calcium channel blockers,% of total sales,0.5 +26964,Norway,2017,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9 +26965,Norway,2017,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.5 +26966,Norway,2017,2,C-Cardiovascular system,Million of national currency units,1708.0 +26967,Norway,2017,2,C-Cardiovascular system,"Million US$, purchasing power parity",175.2 +26968,Norway,2017,2,C-Cardiovascular system,"/capita, US$ exchange rate",39.1 +26969,Norway,2017,2,C-Cardiovascular system,Million US$ at exchange rate,206.5 +26970,Norway,2017,2,C03-Diuretics,Million US$ at exchange rate,14.7 +26971,Norway,2017,2,C03-Diuretics,Million of national currency units,122.0 +26972,Norway,2017,2,C03-Diuretics,"Million US$, purchasing power parity",12.5 +26973,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,54.5 +26974,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",46.3 +26975,Norway,2017,2,N-Nervous system,% of total sales,16.0 +26976,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,451.0 +26977,Norway,2017,2,C03-Diuretics,"/capita, US$ exchange rate",2.8 +26978,Norway,2017,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",33.2 +26979,Norway,2017,2,C-Cardiovascular system,% of total sales,6.4 +26980,Norway,2017,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,284.3 +26981,Norway,2017,2,J-Antiinfectives for systemic use,Million of national currency units,2352.0 +26982,Norway,2017,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4 +26983,Norway,2017,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1214.0 +26984,Norway,2017,2,C03-Diuretics,% of total sales,0.5 +26985,Norway,2017,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.9 +26986,Norway,2017,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.4 +26987,Norway,2017,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",44.5 +26988,Norway,2017,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,52.5 +26989,Norway,2017,2,C08-Calcium channel blockers,Million of national currency units,128.0 +26990,Norway,2017,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.1 +26991,Norway,2017,2,J-Antiinfectives for systemic use,% of total sales,8.8 +26992,Norway,2017,2,C08-Calcium channel blockers,Million US$ at exchange rate,15.5 +26993,Norway,2017,2,Products not elsewhere classified,"Million US$, purchasing power parity",822.4 +26994,Norway,2017,2,Products not elsewhere classified,"/capita, US$ exchange rate",183.7 +26995,Norway,2017,2,Products not elsewhere classified,Million of national currency units,8018.0 +26996,Norway,2017,2,Products not elsewhere classified,Million US$ at exchange rate,969.3 +26997,Norway,2017,2,J01-Antibacterials for systemic use,Million of national currency units,434.0 +26998,Norway,2017,2,Products not elsewhere classified,% of total sales,30.1 +26999,Norway,2017,2,Products not elsewhere classified,"/capita, US$ purchasing power parity",155.8 +27000,Norway,2017,2,N02-Analgesics,Million US$ at exchange rate,179.2 +27001,Norway,2017,2,N02-Analgesics,Million of national currency units,1482.0 +27002,Norway,2017,2,C07-Beta blocking agents,Million US$ at exchange rate,22.1 +27003,Norway,2017,2,C07-Beta blocking agents,Million of national currency units,183.0 +27004,Norway,2017,2,N02-Analgesics,"/capita, US$ purchasing power parity",28.8 +27005,Norway,2017,2,N02-Analgesics,% of total sales,5.6 +27006,Norway,2017,2,N02-Analgesics,"Million US$, purchasing power parity",152.0 +27007,Norway,2017,2,N02-Analgesics,"/capita, US$ exchange rate",34.0 +27008,Norway,2017,2,J01-Antibacterials for systemic use,% of total sales,1.6 +27009,Norway,2017,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.7 +27010,Norway,2017,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.9 +27011,Norway,2017,2,C07-Beta blocking agents,% of total sales,0.7 +27012,Norway,2017,2,C07-Beta blocking agents,"Million US$, purchasing power parity",18.8 +27013,Norway,2017,2,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2 +27014,Norway,2017,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6 +27015,Norway,2017,2,R-Respiratory system,Million of national currency units,2421.0 +27016,Norway,2017,2,R-Respiratory system,Million US$ at exchange rate,292.7 +27017,Norway,2017,2,R-Respiratory system,"Million US$, purchasing power parity",248.3 +27018,Norway,2017,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1 +27019,Norway,2017,2,N-Nervous system,Million US$ at exchange rate,517.1 +27020,Norway,2017,2,N-Nervous system,Million of national currency units,4277.0 +27021,Norway,2017,2,C02-Antihypertensives,% of total sales,0.4 +27022,Norway,2017,2,A02A-Antacids,"/capita, US$ exchange rate",0.7 +27023,Norway,2017,2,A02A-Antacids,% of total sales,0.1 +27024,Norway,2017,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +27025,Norway,2017,2,A02A-Antacids,"Million US$, purchasing power parity",3.0 +27026,Norway,2017,2,R-Respiratory system,"/capita, US$ purchasing power parity",47.1 +27027,Norway,2017,2,R-Respiratory system,"/capita, US$ exchange rate",55.5 +27028,Norway,2017,2,A02A-Antacids,Million US$ at exchange rate,3.5 +27029,Norway,2017,2,R-Respiratory system,% of total sales,9.1 +27030,Norway,2017,2,N-Nervous system,"/capita, US$ purchasing power parity",83.1 +27031,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.3 +27032,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7 +27033,Norway,2017,2,N-Nervous system,"/capita, US$ exchange rate",98.0 +27034,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.8 +27035,Norway,2017,2,C02-Antihypertensives,"Million US$, purchasing power parity",11.3 +27036,Norway,2017,2,C02-Antihypertensives,"/capita, US$ exchange rate",2.5 +27037,Norway,2017,2,N-Nervous system,"Million US$, purchasing power parity",438.7 +27038,Norway,2017,2,C02-Antihypertensives,Million US$ at exchange rate,13.3 +27039,Norway,2015,3,N05B-Anxiolytics,% of total sales,0.5 +27040,Norway,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",83.9 +27041,Norway,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,103.3 +27042,Norway,2015,3,C10-Lipid modifying agents,Million of national currency units,406.0 +27043,Norway,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,50.3 +27044,Norway,2015,3,A-Alimentary tract and metabolism,% of total sales,9.8 +27045,Norway,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.2 +27046,Norway,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,1082.0 +27047,Norway,2015,3,C02-Antihypertensives,Million of national currency units,91.0 +27048,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.7 +27049,Norway,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,134.2 +27050,Norway,2015,3,M-Musculo-skeletal system,% of total sales,3.7 +27051,Norway,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.2 +27052,Norway,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9 +27053,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +27054,Norway,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",40.9 +27055,Norway,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",223.9 +27056,Norway,2015,3,C10-Lipid modifying agents,% of total sales,1.8 +27057,Norway,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +27058,Norway,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.2 +27059,Norway,2015,3,M-Musculo-skeletal system,Million of national currency units,833.0 +27060,Norway,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,14.3 +27061,Norway,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",11.6 +27062,Norway,2015,3,A-Alimentary tract and metabolism,Million of national currency units,2224.0 +27063,Norway,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,275.8 +27064,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.2 +27065,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4 +27066,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6 +27067,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.2 +27068,Norway,2015,3,N05B-Anxiolytics,Million of national currency units,115.0 +27069,Norway,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +27070,Norway,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.7 +27071,Norway,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9 +27072,Norway,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3 +27073,Norway,2015,3,N05C-Hypnotics and sedatives,% of total sales,1.0 +27074,Norway,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.4 +27075,Norway,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.3 +27076,Norway,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.1 +27077,Norway,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",185.9 +27078,Norway,2015,3,B-Blood and blood forming organs,% of total sales,8.1 +27079,Norway,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.8 +27080,Norway,2015,3,C01A-Cardiac glycosides,% of total sales,0.0 +27081,Norway,2015,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2 +27082,Norway,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +27083,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,515.0 +27084,Norway,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,222.0 +27085,Norway,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,27.5 +27086,Norway,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +27087,Norway,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +27088,Norway,2015,3,A10-Drugs used in diabetes,Million of national currency units,786.0 +27089,Norway,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,512.0 +27090,Norway,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",79.1 +27091,Norway,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,97.5 +27092,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",51.5 +27093,Norway,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,63.5 +27094,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9 +27095,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.2 +27096,Norway,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +27097,Norway,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,228.9 +27098,Norway,2015,3,B-Blood and blood forming organs,Million of national currency units,1846.0 +27099,Norway,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3 +27100,Norway,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.8 +27101,Norway,2015,3,C01A-Cardiac glycosides,Million of national currency units,5.0 +27102,Norway,2015,3,A10-Drugs used in diabetes,% of total sales,3.5 +27103,Norway,2015,3,N06A-Antidepressants,Million of national currency units,264.0 +27104,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.0 +27105,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.5 +27106,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.1 +27107,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,549.0 +27108,Norway,2015,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",441.8 +27109,Norway,2015,3,Total pharmaceutical sales,Million US$ at exchange rate,2823.5 +27110,Norway,2015,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2292.4 +27111,Norway,2015,3,Total pharmaceutical sales,"/capita, US$ exchange rate",544.2 +27112,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +27113,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +27114,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,320.0 +27115,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +27116,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.1 +27117,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.3 +27118,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6 +27119,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7 +27120,Norway,2015,3,N06A-Antidepressants,% of total sales,1.2 +27121,Norway,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.1 +27122,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.8 +27123,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,63.9 +27124,Norway,2015,3,N06A-Antidepressants,Million US$ at exchange rate,32.7 +27125,Norway,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.3 +27126,Norway,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",26.6 +27127,Norway,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.9 +27128,Norway,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.0 +27129,Norway,2015,3,Total pharmaceutical sales,Million of national currency units,22769.0 +27130,Norway,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",108.9 +27131,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0 +27132,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.3 +27133,Norway,2015,3,G-Genito urinary system and sex hormones,% of total sales,4.8 +27134,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +27135,Norway,2015,3,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +27136,Norway,2015,3,A02A-Antacids,Million of national currency units,28.0 +27137,Norway,2015,3,A02A-Antacids,Million US$ at exchange rate,3.5 +27138,Norway,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.5 +27139,Norway,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",111.6 +27140,Norway,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,137.4 +27141,Norway,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",222.9 +27142,Norway,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.5 +27143,Norway,2015,3,C08-Calcium channel blockers,% of total sales,0.5 +27144,Norway,2015,3,C07-Beta blocking agents,Million of national currency units,174.0 +27145,Norway,2015,3,C-Cardiovascular system,Million of national currency units,1508.0 +27146,Norway,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +27147,Norway,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",36.0 +27148,Norway,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",151.8 +27149,Norway,2015,3,C-Cardiovascular system,Million US$ at exchange rate,187.0 +27150,Norway,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9 +27151,Norway,2015,3,C03-Diuretics,Million US$ at exchange rate,13.6 +27152,Norway,2015,3,C03-Diuretics,Million of national currency units,110.0 +27153,Norway,2015,3,C03-Diuretics,"Million US$, purchasing power parity",11.1 +27154,Norway,2015,3,C03-Diuretics,"/capita, US$ exchange rate",2.6 +27155,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,52.1 +27156,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",42.3 +27157,Norway,2015,3,N-Nervous system,% of total sales,17.3 +27158,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,420.0 +27159,Norway,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",29.3 +27160,Norway,2015,3,C-Cardiovascular system,% of total sales,6.6 +27161,Norway,2015,3,J-Antiinfectives for systemic use,Million of national currency units,2214.0 +27162,Norway,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,274.5 +27163,Norway,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1 +27164,Norway,2015,3,C03-Diuretics,% of total sales,0.5 +27165,Norway,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1108.0 +27166,Norway,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.0 +27167,Norway,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.9 +27168,Norway,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.3 +27169,Norway,2015,3,C08-Calcium channel blockers,Million of national currency units,121.0 +27170,Norway,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",12.2 +27171,Norway,2015,3,J-Antiinfectives for systemic use,% of total sales,9.7 +27172,Norway,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,15.0 +27173,Norway,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.0 +27174,Norway,2015,3,Products not elsewhere classified,"Million US$, purchasing power parity",653.5 +27175,Norway,2015,3,Products not elsewhere classified,"/capita, US$ exchange rate",155.1 +27176,Norway,2015,3,Products not elsewhere classified,Million of national currency units,6491.0 +27177,Norway,2015,3,Products not elsewhere classified,Million US$ at exchange rate,804.9 +27178,Norway,2015,3,J01-Antibacterials for systemic use,Million of national currency units,460.0 +27179,Norway,2015,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.0 +27180,Norway,2015,3,Products not elsewhere classified,% of total sales,28.5 +27181,Norway,2015,3,N02-Analgesics,Million US$ at exchange rate,172.5 +27182,Norway,2015,3,N02-Analgesics,Million of national currency units,1391.0 +27183,Norway,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,21.6 +27184,Norway,2015,3,N02-Analgesics,"Million US$, purchasing power parity",140.0 +27185,Norway,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.0 +27186,Norway,2015,3,N02-Analgesics,% of total sales,6.1 +27187,Norway,2015,3,N02-Analgesics,"/capita, US$ exchange rate",33.2 +27188,Norway,2015,3,J01-Antibacterials for systemic use,% of total sales,2.0 +27189,Norway,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.0 +27190,Norway,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.9 +27191,Norway,2015,3,C07-Beta blocking agents,% of total sales,0.8 +27192,Norway,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2 +27193,Norway,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",17.5 +27194,Norway,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.4 +27195,Norway,2015,3,R-Respiratory system,Million US$ at exchange rate,259.5 +27196,Norway,2015,3,R-Respiratory system,Million of national currency units,2093.0 +27197,Norway,2015,3,R-Respiratory system,"Million US$, purchasing power parity",210.7 +27198,Norway,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8 +27199,Norway,2015,3,N-Nervous system,Million of national currency units,3929.0 +27200,Norway,2015,3,N-Nervous system,Million US$ at exchange rate,487.2 +27201,Norway,2015,3,C02-Antihypertensives,% of total sales,0.4 +27202,Norway,2015,3,R-Respiratory system,"/capita, US$ exchange rate",50.0 +27203,Norway,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.7 +27204,Norway,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +27205,Norway,2015,3,A02A-Antacids,% of total sales,0.1 +27206,Norway,2015,3,A02A-Antacids,"Million US$, purchasing power parity",2.8 +27207,Norway,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",40.6 +27208,Norway,2015,3,R-Respiratory system,% of total sales,9.2 +27209,Norway,2015,3,N-Nervous system,"Million US$, purchasing power parity",395.6 +27210,Norway,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",76.2 +27211,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0 +27212,Norway,2015,3,N-Nervous system,"/capita, US$ exchange rate",93.9 +27213,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8 +27214,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.1 +27215,Norway,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",9.2 +27216,Norway,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.2 +27217,Norway,2015,3,C02-Antihypertensives,Million US$ at exchange rate,11.3 +27218,Norway,2016,3,N05B-Anxiolytics,% of total sales,0.5 +27219,Norway,2016,3,M-Musculo-skeletal system,Million of national currency units,922.0 +27220,Norway,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",91.8 +27221,Norway,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,109.8 +27222,Norway,2016,3,C10-Lipid modifying agents,Million of national currency units,473.0 +27223,Norway,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,56.3 +27224,Norway,2016,3,A-Alimentary tract and metabolism,% of total sales,10.3 +27225,Norway,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.7 +27226,Norway,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,1162.0 +27227,Norway,2016,3,M-Musculo-skeletal system,% of total sales,3.7 +27228,Norway,2016,3,C02-Antihypertensives,Million of national currency units,103.0 +27229,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.2 +27230,Norway,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,138.3 +27231,Norway,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.5 +27232,Norway,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.0 +27233,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.8 +27234,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +27235,Norway,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",254.8 +27236,Norway,2016,3,C10-Lipid modifying agents,% of total sales,1.9 +27237,Norway,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +27238,Norway,2016,3,N05B-Anxiolytics,Million of national currency units,119.0 +27239,Norway,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,14.2 +27240,Norway,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,304.6 +27241,Norway,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",11.9 +27242,Norway,2016,3,A-Alimentary tract and metabolism,Million of national currency units,2559.0 +27243,Norway,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",47.1 +27244,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.3 +27245,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3 +27246,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.5 +27247,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.8 +27248,Norway,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +27249,Norway,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.2 +27250,Norway,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.0 +27251,Norway,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.8 +27252,Norway,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8 +27253,Norway,2016,3,N05C-Hypnotics and sedatives,% of total sales,1.0 +27254,Norway,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",25.3 +27255,Norway,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.8 +27256,Norway,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.4 +27257,Norway,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",211.8 +27258,Norway,2016,3,B-Blood and blood forming organs,% of total sales,8.6 +27259,Norway,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.5 +27260,Norway,2016,3,C01A-Cardiac glycosides,% of total sales,0.0 +27261,Norway,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +27262,Norway,2016,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2 +27263,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,537.0 +27264,Norway,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,254.0 +27265,Norway,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,30.2 +27266,Norway,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +27267,Norway,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +27268,Norway,2016,3,A10-Drugs used in diabetes,Million of national currency units,913.0 +27269,Norway,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,545.0 +27270,Norway,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",90.9 +27271,Norway,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,108.7 +27272,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",54.3 +27273,Norway,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.9 +27274,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4 +27275,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.4 +27276,Norway,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6 +27277,Norway,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,253.2 +27278,Norway,2016,3,B-Blood and blood forming organs,Million of national currency units,2127.0 +27279,Norway,2016,3,C01A-Cardiac glycosides,Million of national currency units,5.0 +27280,Norway,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.8 +27281,Norway,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.4 +27282,Norway,2016,3,A10-Drugs used in diabetes,% of total sales,3.7 +27283,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,38.0 +27284,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.5 +27285,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.9 +27286,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,570.0 +27287,Norway,2016,3,Total pharmaceutical sales,Million US$ at exchange rate,2948.7 +27288,Norway,2016,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2466.6 +27289,Norway,2016,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",471.2 +27290,Norway,2016,3,Total pharmaceutical sales,"/capita, US$ exchange rate",563.3 +27291,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +27292,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +27293,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,329.0 +27294,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +27295,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0 +27296,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.8 +27297,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.8 +27298,Norway,2016,3,Total pharmaceutical sales,Million of national currency units,24769.0 +27299,Norway,2016,3,N06A-Antidepressants,% of total sales,1.1 +27300,Norway,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.1 +27301,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.5 +27302,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,63.9 +27303,Norway,2016,3,N06A-Antidepressants,Million US$ at exchange rate,31.8 +27304,Norway,2016,3,N06A-Antidepressants,Million of national currency units,267.0 +27305,Norway,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.1 +27306,Norway,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",26.6 +27307,Norway,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.4 +27308,Norway,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.1 +27309,Norway,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",115.7 +27310,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.2 +27311,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.2 +27312,Norway,2016,3,G-Genito urinary system and sex hormones,% of total sales,4.7 +27313,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2 +27314,Norway,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",226.9 +27315,Norway,2016,3,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +27316,Norway,2016,3,A02A-Antacids,Million of national currency units,30.0 +27317,Norway,2016,3,A02A-Antacids,Million US$ at exchange rate,3.6 +27318,Norway,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",118.1 +27319,Norway,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,141.2 +27320,Norway,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.6 +27321,Norway,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.0 +27322,Norway,2016,3,C08-Calcium channel blockers,% of total sales,0.5 +27323,Norway,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9 +27324,Norway,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4 +27325,Norway,2016,3,C-Cardiovascular system,Million of national currency units,1632.0 +27326,Norway,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",37.1 +27327,Norway,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",162.5 +27328,Norway,2016,3,C-Cardiovascular system,Million US$ at exchange rate,194.3 +27329,Norway,2016,3,C03-Diuretics,Million US$ at exchange rate,13.3 +27330,Norway,2016,3,C03-Diuretics,Million of national currency units,112.0 +27331,Norway,2016,3,C03-Diuretics,"Million US$, purchasing power parity",11.2 +27332,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,52.4 +27333,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",43.8 +27334,Norway,2016,3,N-Nervous system,% of total sales,16.7 +27335,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,440.0 +27336,Norway,2016,3,C03-Diuretics,"/capita, US$ exchange rate",2.5 +27337,Norway,2016,3,C-Cardiovascular system,% of total sales,6.6 +27338,Norway,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,271.3 +27339,Norway,2016,3,J-Antiinfectives for systemic use,Million of national currency units,2279.0 +27340,Norway,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1 +27341,Norway,2016,3,C03-Diuretics,% of total sales,0.5 +27342,Norway,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1186.0 +27343,Norway,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.7 +27344,Norway,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.9 +27345,Norway,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.7 +27346,Norway,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",12.5 +27347,Norway,2016,3,J-Antiinfectives for systemic use,% of total sales,9.2 +27348,Norway,2016,3,C08-Calcium channel blockers,Million of national currency units,126.0 +27349,Norway,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,15.0 +27350,Norway,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,55.8 +27351,Norway,2016,3,Products not elsewhere classified,"Million US$, purchasing power parity",708.2 +27352,Norway,2016,3,Products not elsewhere classified,"/capita, US$ exchange rate",161.7 +27353,Norway,2016,3,Products not elsewhere classified,Million of national currency units,7112.0 +27354,Norway,2016,3,Products not elsewhere classified,Million US$ at exchange rate,846.7 +27355,Norway,2016,3,J01-Antibacterials for systemic use,Million of national currency units,469.0 +27356,Norway,2016,3,Products not elsewhere classified,% of total sales,28.7 +27357,Norway,2016,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.3 +27358,Norway,2016,3,N02-Analgesics,Million US$ at exchange rate,174.4 +27359,Norway,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,21.4 +27360,Norway,2016,3,N02-Analgesics,Million of national currency units,1465.0 +27361,Norway,2016,3,C07-Beta blocking agents,Million of national currency units,180.0 +27362,Norway,2016,3,N02-Analgesics,"Million US$, purchasing power parity",145.9 +27363,Norway,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.9 +27364,Norway,2016,3,N02-Analgesics,% of total sales,5.9 +27365,Norway,2016,3,N02-Analgesics,"/capita, US$ exchange rate",33.3 +27366,Norway,2016,3,J01-Antibacterials for systemic use,% of total sales,1.9 +27367,Norway,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.4 +27368,Norway,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.8 +27369,Norway,2016,3,C07-Beta blocking agents,% of total sales,0.7 +27370,Norway,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1 +27371,Norway,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",17.9 +27372,Norway,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.4 +27373,Norway,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",31.0 +27374,Norway,2016,3,R-Respiratory system,Million US$ at exchange rate,270.6 +27375,Norway,2016,3,R-Respiratory system,Million of national currency units,2273.0 +27376,Norway,2016,3,R-Respiratory system,"Million US$, purchasing power parity",226.4 +27377,Norway,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.0 +27378,Norway,2016,3,N-Nervous system,Million US$ at exchange rate,492.0 +27379,Norway,2016,3,N-Nervous system,Million of national currency units,4133.0 +27380,Norway,2016,3,C02-Antihypertensives,% of total sales,0.4 +27381,Norway,2016,3,R-Respiratory system,"/capita, US$ exchange rate",51.7 +27382,Norway,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.7 +27383,Norway,2016,3,A02A-Antacids,% of total sales,0.1 +27384,Norway,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +27385,Norway,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",43.2 +27386,Norway,2016,3,R-Respiratory system,% of total sales,9.2 +27387,Norway,2016,3,A02A-Antacids,"Million US$, purchasing power parity",3.0 +27388,Norway,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",78.6 +27389,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0 +27390,Norway,2016,3,N-Nervous system,"/capita, US$ exchange rate",94.0 +27391,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8 +27392,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.4 +27393,Norway,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",10.3 +27394,Norway,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +27395,Norway,2016,3,N-Nervous system,"Million US$, purchasing power parity",411.6 +27396,Norway,2016,3,C02-Antihypertensives,Million US$ at exchange rate,12.3 +27397,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",50.2 +27398,Norway,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",66.5 +27399,Norway,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,100.8 +27400,Norway,2010,4,C10-Lipid modifying agents,Million of national currency units,440.0 +27401,Norway,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,72.8 +27402,Norway,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",48.1 +27403,Norway,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.9 +27404,Norway,2010,4,A-Alimentary tract and metabolism,% of total sales,10.2 +27405,Norway,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,914.0 +27406,Norway,2010,4,C02-Antihypertensives,Million of national currency units,54.0 +27407,Norway,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,151.2 +27408,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,75.9 +27409,Norway,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.6 +27410,Norway,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.6 +27411,Norway,2010,4,M-Musculo-skeletal system,% of total sales,3.4 +27412,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +27413,Norway,2010,4,C10-Lipid modifying agents,% of total sales,2.5 +27414,Norway,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.9 +27415,Norway,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",4.1 +27416,Norway,2010,4,M-Musculo-skeletal system,Million of national currency units,609.0 +27417,Norway,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,20.2 +27418,Norway,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",13.3 +27419,Norway,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",199.9 +27420,Norway,2010,4,A-Alimentary tract and metabolism,Million of national currency units,1829.0 +27421,Norway,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,302.6 +27422,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.3 +27423,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +27424,Norway,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.9 +27425,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5 +27426,Norway,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.7 +27427,Norway,2010,4,N05B-Anxiolytics,Million of national currency units,122.0 +27428,Norway,2010,4,N05B-Anxiolytics,% of total sales,0.7 +27429,Norway,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.8 +27430,Norway,2010,4,N05C-Hypnotics and sedatives,% of total sales,1.0 +27431,Norway,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8 +27432,Norway,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.8 +27433,Norway,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.2 +27434,Norway,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.6 +27435,Norway,2010,4,B-Blood and blood forming organs,% of total sales,6.6 +27436,Norway,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",18.8 +27437,Norway,2010,4,C01A-Cardiac glycosides,% of total sales,0.0 +27438,Norway,2010,4,N06A-Antidepressants,Million of national currency units,324.0 +27439,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,70.3 +27440,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,425.0 +27441,Norway,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,28.5 +27442,Norway,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,172.0 +27443,Norway,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +27444,Norway,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +27445,Norway,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",129.8 +27446,Norway,2010,4,A10-Drugs used in diabetes,Million of national currency units,517.0 +27447,Norway,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,433.0 +27448,Norway,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",56.5 +27449,Norway,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +27450,Norway,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,85.5 +27451,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",47.3 +27452,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.7 +27453,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7 +27454,Norway,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +27455,Norway,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +27456,Norway,2010,4,B-Blood and blood forming organs,Million of national currency units,1188.0 +27457,Norway,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,196.6 +27458,Norway,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",11.6 +27459,Norway,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.5 +27460,Norway,2010,4,C01A-Cardiac glycosides,Million of national currency units,5.0 +27461,Norway,2010,4,A10-Drugs used in diabetes,% of total sales,2.9 +27462,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1 +27463,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,25.0 +27464,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.8 +27465,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,440.0 +27466,Norway,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",1954.8 +27467,Norway,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,2959.9 +27468,Norway,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",399.8 +27469,Norway,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",605.4 +27470,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +27471,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,459.0 +27472,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +27473,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +27474,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9 +27475,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",48.1 +27476,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.7 +27477,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.8 +27478,Norway,2010,4,N06A-Antidepressants,% of total sales,1.8 +27479,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.4 +27480,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",46.4 +27481,Norway,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",35.4 +27482,Norway,2010,4,N06A-Antidepressants,Million US$ at exchange rate,53.6 +27483,Norway,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.2 +27484,Norway,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.0 +27485,Norway,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.4 +27486,Norway,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.9 +27487,Norway,2010,4,Total pharmaceutical sales,Million of national currency units,17890.0 +27488,Norway,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.9 +27489,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5 +27490,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +27491,Norway,2010,4,G-Genito urinary system and sex hormones,% of total sales,5.1 +27492,Norway,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,71.6 +27493,Norway,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,6.5 +27494,Norway,2010,4,A02A-Antacids,Million US$ at exchange rate,4.6 +27495,Norway,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.5 +27496,Norway,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",126.3 +27497,Norway,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.8 +27498,Norway,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.1 +27499,Norway,2010,4,A02A-Antacids,Million of national currency units,28.0 +27500,Norway,2010,4,C07-Beta blocking agents,Million of national currency units,168.0 +27501,Norway,2010,4,C-Cardiovascular system,Million of national currency units,1869.0 +27502,Norway,2010,4,C08-Calcium channel blockers,% of total sales,0.9 +27503,Norway,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6 +27504,Norway,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",63.2 +27505,Norway,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",41.8 +27506,Norway,2010,4,C-Cardiovascular system,Million US$ at exchange rate,309.2 +27507,Norway,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",204.2 +27508,Norway,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",137.2 +27509,Norway,2010,4,C03-Diuretics,Million US$ at exchange rate,16.4 +27510,Norway,2010,4,C03-Diuretics,Million of national currency units,99.0 +27511,Norway,2010,4,C03-Diuretics,"/capita, US$ exchange rate",3.4 +27512,Norway,2010,4,C03-Diuretics,"Million US$, purchasing power parity",10.8 +27513,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",88.3 +27514,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,808.0 +27515,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,133.7 +27516,Norway,2010,4,J-Antiinfectives for systemic use,Million of national currency units,1256.0 +27517,Norway,2010,4,C02-Antihypertensives,Million US$ at exchange rate,8.9 +27518,Norway,2010,4,C-Cardiovascular system,% of total sales,10.4 +27519,Norway,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,207.8 +27520,Norway,2010,4,C03-Diuretics,% of total sales,0.6 +27521,Norway,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +27522,Norway,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,191.3 +27523,Norway,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1156.0 +27524,Norway,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1 +27525,Norway,2010,4,C08-Calcium channel blockers,Million of national currency units,159.0 +27526,Norway,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",49.6 +27527,Norway,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.4 +27528,Norway,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4 +27529,Norway,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,26.3 +27530,Norway,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.4 +27531,Norway,2010,4,Products not elsewhere classified,"Million US$, purchasing power parity",481.1 +27532,Norway,2010,4,Products not elsewhere classified,"/capita, US$ exchange rate",149.0 +27533,Norway,2010,4,Products not elsewhere classified,Million of national currency units,4403.0 +27534,Norway,2010,4,Products not elsewhere classified,Million US$ at exchange rate,728.5 +27535,Norway,2010,4,J01-Antibacterials for systemic use,Million of national currency units,454.0 +27536,Norway,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,75.1 +27537,Norway,2010,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",98.4 +27538,Norway,2010,4,Products not elsewhere classified,% of total sales,24.6 +27539,Norway,2010,4,J-Antiinfectives for systemic use,% of total sales,7.0 +27540,Norway,2010,4,N02-Analgesics,Million US$ at exchange rate,197.5 +27541,Norway,2010,4,N02-Analgesics,"Million US$, purchasing power parity",130.5 +27542,Norway,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,27.8 +27543,Norway,2010,4,N02-Analgesics,Million of national currency units,1194.0 +27544,Norway,2010,4,N02-Analgesics,% of total sales,6.7 +27545,Norway,2010,4,N02-Analgesics,"/capita, US$ exchange rate",40.4 +27546,Norway,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",26.7 +27547,Norway,2010,4,J01-Antibacterials for systemic use,% of total sales,2.5 +27548,Norway,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.1 +27549,Norway,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7 +27550,Norway,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",18.4 +27551,Norway,2010,4,C07-Beta blocking agents,% of total sales,0.9 +27552,Norway,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.8 +27553,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.3 +27554,Norway,2010,4,R-Respiratory system,Million US$ at exchange rate,317.2 +27555,Norway,2010,4,R-Respiratory system,Million of national currency units,1917.0 +27556,Norway,2010,4,R-Respiratory system,"/capita, US$ exchange rate",64.9 +27557,Norway,2010,4,R-Respiratory system,"Million US$, purchasing power parity",209.5 +27558,Norway,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2 +27559,Norway,2010,4,N-Nervous system,"Million US$, purchasing power parity",378.4 +27560,Norway,2010,4,C02-Antihypertensives,% of total sales,0.3 +27561,Norway,2010,4,N-Nervous system,Million US$ at exchange rate,572.9 +27562,Norway,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +27563,Norway,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.9 +27564,Norway,2010,4,A02A-Antacids,% of total sales,0.2 +27565,Norway,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",42.8 +27566,Norway,2010,4,N-Nervous system,Million of national currency units,3463.0 +27567,Norway,2010,4,A02A-Antacids,"Million US$, purchasing power parity",3.1 +27568,Norway,2010,4,R-Respiratory system,% of total sales,10.7 +27569,Norway,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",77.4 +27570,Norway,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.8 +27571,Norway,2010,4,N-Nervous system,% of total sales,19.4 +27572,Norway,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9 +27573,Norway,2010,4,N-Nervous system,"/capita, US$ exchange rate",117.2 +27574,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5 +27575,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1 +27576,Norway,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,119.7 +27577,Norway,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.3 +27578,Norway,2014,3,N05B-Anxiolytics,% of total sales,0.6 +27579,Norway,2014,3,C10-Lipid modifying agents,Million of national currency units,377.0 +27580,Norway,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,59.8 +27581,Norway,2014,3,A-Alimentary tract and metabolism,% of total sales,9.8 +27582,Norway,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.2 +27583,Norway,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,1015.0 +27584,Norway,2014,3,C02-Antihypertensives,Million of national currency units,74.0 +27585,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,59.2 +27586,Norway,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,161.1 +27587,Norway,2014,3,M-Musculo-skeletal system,% of total sales,3.6 +27588,Norway,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.8 +27589,Norway,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",40.6 +27590,Norway,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.3 +27591,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +27592,Norway,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",222.1 +27593,Norway,2014,3,C10-Lipid modifying agents,% of total sales,1.8 +27594,Norway,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",3.7 +27595,Norway,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.7 +27596,Norway,2014,3,M-Musculo-skeletal system,Million of national currency units,754.0 +27597,Norway,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,19.2 +27598,Norway,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",13.0 +27599,Norway,2014,3,A-Alimentary tract and metabolism,Million of national currency units,2061.0 +27600,Norway,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,327.1 +27601,Norway,2014,3,N05B-Anxiolytics,Million of national currency units,121.0 +27602,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.8 +27603,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8 +27604,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",40.2 +27605,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",11.5 +27606,Norway,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5 +27607,Norway,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.6 +27608,Norway,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9 +27609,Norway,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.4 +27610,Norway,2014,3,N05C-Hypnotics and sedatives,% of total sales,1.0 +27611,Norway,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.7 +27612,Norway,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.5 +27613,Norway,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.1 +27614,Norway,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",178.3 +27615,Norway,2014,3,B-Blood and blood forming organs,% of total sales,7.8 +27616,Norway,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.7 +27617,Norway,2014,3,C01A-Cardiac glycosides,% of total sales,0.0 +27618,Norway,2014,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2 +27619,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,474.0 +27620,Norway,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +27621,Norway,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,211.0 +27622,Norway,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.5 +27623,Norway,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +27624,Norway,2014,3,A10-Drugs used in diabetes,Million of national currency units,683.0 +27625,Norway,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,471.0 +27626,Norway,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",73.6 +27627,Norway,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,108.4 +27628,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",50.8 +27629,Norway,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,74.7 +27630,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9 +27631,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.5 +27632,Norway,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +27633,Norway,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +27634,Norway,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,262.5 +27635,Norway,2014,3,B-Blood and blood forming organs,Million of national currency units,1654.0 +27636,Norway,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.3 +27637,Norway,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1 +27638,Norway,2014,3,C01A-Cardiac glycosides,Million of national currency units,5.0 +27639,Norway,2014,3,A10-Drugs used in diabetes,% of total sales,3.2 +27640,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,33.0 +27641,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.2 +27642,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,81.9 +27643,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,516.0 +27644,Norway,2014,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2271.6 +27645,Norway,2014,3,Total pharmaceutical sales,Million US$ at exchange rate,3344.7 +27646,Norway,2014,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.2 +27647,Norway,2014,3,Total pharmaceutical sales,"/capita, US$ exchange rate",651.1 +27648,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +27649,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +27650,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,373.0 +27651,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +27652,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9 +27653,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.6 +27654,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6 +27655,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.8 +27656,Norway,2014,3,N06A-Antidepressants,Million of national currency units,263.0 +27657,Norway,2014,3,N06A-Antidepressants,% of total sales,1.2 +27658,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,75.2 +27659,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.1 +27660,Norway,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.5 +27661,Norway,2014,3,N06A-Antidepressants,Million US$ at exchange rate,41.7 +27662,Norway,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",28.3 +27663,Norway,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.1 +27664,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.6 +27665,Norway,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.4 +27666,Norway,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3 +27667,Norway,2014,3,Total pharmaceutical sales,Million of national currency units,21077.0 +27668,Norway,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",109.4 +27669,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9 +27670,Norway,2014,3,G-Genito urinary system and sex hormones,% of total sales,4.8 +27671,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2 +27672,Norway,2014,3,R03-Drugs for obstructive airway diseases,% of total sales,5.2 +27673,Norway,2014,3,A02A-Antacids,Million of national currency units,28.0 +27674,Norway,2014,3,A02A-Antacids,Million US$ at exchange rate,4.4 +27675,Norway,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",118.3 +27676,Norway,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,174.2 +27677,Norway,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",197.2 +27678,Norway,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.0 +27679,Norway,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",33.9 +27680,Norway,2014,3,C08-Calcium channel blockers,% of total sales,0.6 +27681,Norway,2014,3,C-Cardiovascular system,Million of national currency units,1477.0 +27682,Norway,2014,3,C07-Beta blocking agents,Million of national currency units,172.0 +27683,Norway,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7 +27684,Norway,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",45.6 +27685,Norway,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",159.2 +27686,Norway,2014,3,C-Cardiovascular system,Million US$ at exchange rate,234.4 +27687,Norway,2014,3,C03-Diuretics,Million US$ at exchange rate,16.7 +27688,Norway,2014,3,C03-Diuretics,Million of national currency units,105.0 +27689,Norway,2014,3,C03-Diuretics,"/capita, US$ exchange rate",3.2 +27690,Norway,2014,3,C03-Diuretics,"Million US$, purchasing power parity",11.3 +27691,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,70.3 +27692,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.7 +27693,Norway,2014,3,N-Nervous system,% of total sales,17.8 +27694,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,443.0 +27695,Norway,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",31.0 +27696,Norway,2014,3,C-Cardiovascular system,% of total sales,7.0 +27697,Norway,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,290.4 +27698,Norway,2014,3,J-Antiinfectives for systemic use,Million of national currency units,1830.0 +27699,Norway,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.2 +27700,Norway,2014,3,C03-Diuretics,% of total sales,0.5 +27701,Norway,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1098.0 +27702,Norway,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.0 +27703,Norway,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5 +27704,Norway,2014,3,C08-Calcium channel blockers,Million of national currency units,130.0 +27705,Norway,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.0 +27706,Norway,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",48.9 +27707,Norway,2014,3,J-Antiinfectives for systemic use,% of total sales,8.7 +27708,Norway,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.0 +27709,Norway,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,20.6 +27710,Norway,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.0 +27711,Norway,2014,3,Products not elsewhere classified,"Million US$, purchasing power parity",648.2 +27712,Norway,2014,3,Products not elsewhere classified,"/capita, US$ exchange rate",185.8 +27713,Norway,2014,3,Products not elsewhere classified,Million of national currency units,6014.0 +27714,Norway,2014,3,Products not elsewhere classified,Million US$ at exchange rate,954.4 +27715,Norway,2014,3,J01-Antibacterials for systemic use,Million of national currency units,454.0 +27716,Norway,2014,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.2 +27717,Norway,2014,3,Products not elsewhere classified,% of total sales,28.5 +27718,Norway,2014,3,N02-Analgesics,Million US$ at exchange rate,209.0 +27719,Norway,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,27.3 +27720,Norway,2014,3,N02-Analgesics,Million of national currency units,1317.0 +27721,Norway,2014,3,N02-Analgesics,"Million US$, purchasing power parity",141.9 +27722,Norway,2014,3,N02-Analgesics,% of total sales,6.2 +27723,Norway,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.6 +27724,Norway,2014,3,N02-Analgesics,"/capita, US$ exchange rate",40.7 +27725,Norway,2014,3,J01-Antibacterials for systemic use,% of total sales,2.2 +27726,Norway,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.4 +27727,Norway,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.5 +27728,Norway,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3 +27729,Norway,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.5 +27730,Norway,2014,3,C07-Beta blocking agents,% of total sales,0.8 +27731,Norway,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6 +27732,Norway,2014,3,R-Respiratory system,Million US$ at exchange rate,317.5 +27733,Norway,2014,3,R-Respiratory system,Million of national currency units,2001.0 +27734,Norway,2014,3,R-Respiratory system,"Million US$, purchasing power parity",215.7 +27735,Norway,2014,3,N-Nervous system,Million of national currency units,3753.0 +27736,Norway,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6 +27737,Norway,2014,3,N-Nervous system,Million US$ at exchange rate,595.6 +27738,Norway,2014,3,C02-Antihypertensives,% of total sales,0.4 +27739,Norway,2014,3,R-Respiratory system,"/capita, US$ exchange rate",61.8 +27740,Norway,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.9 +27741,Norway,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +27742,Norway,2014,3,A02A-Antacids,% of total sales,0.1 +27743,Norway,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",42.0 +27744,Norway,2014,3,A02A-Antacids,"Million US$, purchasing power parity",3.0 +27745,Norway,2014,3,R-Respiratory system,% of total sales,9.5 +27746,Norway,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",78.7 +27747,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.7 +27748,Norway,2014,3,N-Nervous system,"/capita, US$ exchange rate",115.9 +27749,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.1 +27750,Norway,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",8.0 +27751,Norway,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +27752,Norway,2014,3,N-Nervous system,"Million US$, purchasing power parity",404.5 +27753,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.3 +27754,Norway,2014,3,C02-Antihypertensives,Million US$ at exchange rate,11.7 +27755,Portugal,2011,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +27756,Portugal,2011,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3 +27757,Portugal,2011,9,C01A-Cardiac glycosides,Million of national currency units,0.9 +27758,Portugal,2011,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.6 +27759,Portugal,2011,9,R-Respiratory system,% of total sales,7.3 +27760,Portugal,2011,9,C02-Antihypertensives,% of total sales,0.1 +27761,Portugal,2011,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +27762,Portugal,2011,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +27763,Portugal,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.2 +27764,Portugal,2011,9,G-Genito urinary system and sex hormones,% of total sales,5.9 +27765,Portugal,2011,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9 +27766,Portugal,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.7 +27767,Portugal,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",276.6 +27768,Portugal,2011,9,C01A-Cardiac glycosides,% of total sales,0.0 +27769,Portugal,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",32.4 +27770,Portugal,2011,9,A02A-Antacids,% of total sales,0.2 +27771,Portugal,2011,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +27772,Portugal,2011,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +27773,Portugal,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",169.6 +27774,Portugal,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.1 +27775,Portugal,2011,9,B-Blood and blood forming organs,% of total sales,3.6 +27776,Portugal,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.9 +27777,Portugal,2011,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1 +27778,Portugal,2011,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +27779,Portugal,2011,9,C07-Beta blocking agents,% of total sales,1.1 +27780,Portugal,2011,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8 +27781,Portugal,2011,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +27782,Portugal,2011,9,C02-Antihypertensives,Million of national currency units,4.1 +27783,Portugal,2011,9,C07-Beta blocking agents,"Million US$, purchasing power parity",50.3 +27784,Portugal,2011,9,Products not elsewhere classified,% of total sales,0.0 +27785,Portugal,2011,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +27786,Portugal,2011,9,A-Alimentary tract and metabolism,Million of national currency units,455.8 +27787,Portugal,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,634.4 +27788,Portugal,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",731.5 +27789,Portugal,2011,9,R-Respiratory system,Million US$ at exchange rate,297.0 +27790,Portugal,2011,9,B-Blood and blood forming organs,Million of national currency units,105.7 +27791,Portugal,2011,9,C07-Beta blocking agents,Million of national currency units,31.4 +27792,Portugal,2011,9,R-Respiratory system,Million of national currency units,213.4 +27793,Portugal,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,147.1 +27794,Portugal,2011,9,R-Respiratory system,"/capita, US$ exchange rate",28.1 +27795,Portugal,2011,9,R-Respiratory system,"Million US$, purchasing power parity",342.5 +27796,Portugal,2011,9,Products not elsewhere classified,Million of national currency units,0.0 +27797,Portugal,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.1 +27798,Portugal,2011,9,C02-Antihypertensives,Million US$ at exchange rate,5.8 +27799,Portugal,2011,9,Products not elsewhere classified,Million US$ at exchange rate,0.0 +27800,Portugal,2011,9,C07-Beta blocking agents,Million US$ at exchange rate,43.6 +27801,Portugal,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",69.3 +27802,Portugal,2011,9,A-Alimentary tract and metabolism,% of total sales,15.5 +27803,Portugal,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",1254.5 +27804,Portugal,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",388.0 +27805,Portugal,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",447.3 +27806,Portugal,2011,9,C-Cardiovascular system,% of total sales,26.6 +27807,Portugal,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",103.1 +27808,Portugal,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",118.8 +27809,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",56.9 +27810,Portugal,2011,9,C-Cardiovascular system,Million of national currency units,781.6 +27811,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.7 +27812,Portugal,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,4096.0 +27813,Portugal,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4722.6 +27814,Portugal,2011,9,C-Cardiovascular system,Million US$ at exchange rate,1088.0 +27815,Portugal,2011,9,Total pharmaceutical sales,Million of national currency units,2942.6 +27816,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +27817,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9 +27818,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.9 +27819,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +27820,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,521.2 +27821,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,374.4 +27822,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +27823,Portugal,2011,9,C03-Diuretics,"/capita, US$ exchange rate",3.3 +27824,Portugal,2011,9,C03-Diuretics,"Million US$, purchasing power parity",39.9 +27825,Portugal,2011,9,C03-Diuretics,% of total sales,0.8 +27826,Portugal,2011,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.8 +27827,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.3 +27828,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",600.9 +27829,Portugal,2011,9,C03-Diuretics,Million US$ at exchange rate,34.6 +27830,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",49.4 +27831,Portugal,2011,9,C03-Diuretics,Million of national currency units,24.9 +27832,Portugal,2011,9,A02A-Antacids,Million of national currency units,6.0 +27833,Portugal,2011,9,C10-Lipid modifying agents,Million of national currency units,202.3 +27834,Portugal,2011,9,N06A-Antidepressants,Million of national currency units,140.4 +27835,Portugal,2011,9,A02A-Antacids,"Million US$, purchasing power parity",9.7 +27836,Portugal,2011,9,A02A-Antacids,Million US$ at exchange rate,8.4 +27837,Portugal,2011,9,N06A-Antidepressants,"/capita, US$ exchange rate",18.5 +27838,Portugal,2011,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",21.3 +27839,Portugal,2011,9,N06A-Antidepressants,Million US$ at exchange rate,195.4 +27840,Portugal,2011,9,N06A-Antidepressants,"Million US$, purchasing power parity",225.3 +27841,Portugal,2011,9,C08-Calcium channel blockers,Million US$ at exchange rate,61.8 +27842,Portugal,2011,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.2 +27843,Portugal,2011,9,A02A-Antacids,"/capita, US$ exchange rate",0.8 +27844,Portugal,2011,9,C08-Calcium channel blockers,Million of national currency units,44.4 +27845,Portugal,2011,9,C08-Calcium channel blockers,% of total sales,1.5 +27846,Portugal,2011,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7 +27847,Portugal,2011,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.9 +27848,Portugal,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,172.4 +27849,Portugal,2011,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,183.9 +27850,Portugal,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,239.9 +27851,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.0 +27852,Portugal,2011,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.8 +27853,Portugal,2011,9,C10-Lipid modifying agents,% of total sales,6.9 +27854,Portugal,2011,9,R03-Drugs for obstructive airway diseases,Million of national currency units,132.1 +27855,Portugal,2011,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.7 +27856,Portugal,2011,9,C10-Lipid modifying agents,Million US$ at exchange rate,281.6 +27857,Portugal,2011,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",324.7 +27858,Portugal,2011,9,N06A-Antidepressants,% of total sales,4.8 +27859,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",17.4 +27860,Portugal,2011,9,R03-Drugs for obstructive airway diseases,% of total sales,4.5 +27861,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.1 +27862,Portugal,2011,9,N02-Analgesics,% of total sales,3.7 +27863,Portugal,2011,9,J01-Antibacterials for systemic use,Million of national currency units,91.4 +27864,Portugal,2011,9,N-Nervous system,"/capita, US$ exchange rate",85.1 +27865,Portugal,2011,9,N02-Analgesics,"/capita, US$ exchange rate",14.3 +27866,Portugal,2011,9,N02-Analgesics,"/capita, US$ purchasing power parity",16.4 +27867,Portugal,2011,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,127.2 +27868,Portugal,2011,9,N05B-Anxiolytics,Million US$ at exchange rate,80.1 +27869,Portugal,2011,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.4 +27870,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,112.3 +27871,Portugal,2011,9,N05B-Anxiolytics,Million of national currency units,57.6 +27872,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8 +27873,Portugal,2011,9,N-Nervous system,"Million US$, purchasing power parity",1035.5 +27874,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2 +27875,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.8 +27876,Portugal,2011,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.3 +27877,Portugal,2011,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",33.8 +27878,Portugal,2011,9,A10-Drugs used in diabetes,% of total sales,7.6 +27879,Portugal,2011,9,J-Antiinfectives for systemic use,Million of national currency units,163.6 +27880,Portugal,2011,9,N-Nervous system,Million of national currency units,645.2 +27881,Portugal,2011,9,N-Nervous system,Million US$ at exchange rate,898.1 +27882,Portugal,2011,9,N02-Analgesics,Million of national currency units,108.1 +27883,Portugal,2011,9,N02-Analgesics,Million US$ at exchange rate,150.5 +27884,Portugal,2011,9,N02-Analgesics,"Million US$, purchasing power parity",173.5 +27885,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,156.3 +27886,Portugal,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",98.1 +27887,Portugal,2011,9,N-Nervous system,% of total sales,21.9 +27888,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.4 +27889,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",199.9 +27890,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",17.1 +27891,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",180.2 +27892,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.8 +27893,Portugal,2011,9,J01-Antibacterials for systemic use,% of total sales,3.1 +27894,Portugal,2011,9,N05B-Anxiolytics,% of total sales,2.0 +27895,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.9 +27896,Portugal,2011,9,N05B-Anxiolytics,"/capita, US$ exchange rate",7.6 +27897,Portugal,2011,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.8 +27898,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.7 +27899,Portugal,2011,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.9 +27900,Portugal,2011,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",146.6 +27901,Portugal,2011,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0 +27902,Portugal,2011,9,M-Musculo-skeletal system,Million of national currency units,226.7 +27903,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0 +27904,Portugal,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,315.5 +27905,Portugal,2011,9,N05C-Hypnotics and sedatives,% of total sales,0.6 +27906,Portugal,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",262.5 +27907,Portugal,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,227.7 +27908,Portugal,2011,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",28.5 +27909,Portugal,2011,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.7 +27910,Portugal,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.7 +27911,Portugal,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3 +27912,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.5 +27913,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,173.4 +27914,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,124.6 +27915,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,22.7 +27916,Portugal,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.6 +27917,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",36.5 +27918,Portugal,2011,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",356.8 +27919,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,31.7 +27920,Portugal,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",363.8 +27921,Portugal,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.5 +27922,Portugal,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.9 +27923,Portugal,2011,9,A10-Drugs used in diabetes,Million US$ at exchange rate,309.5 +27924,Portugal,2011,9,A10-Drugs used in diabetes,Million of national currency units,222.3 +27925,Portugal,2011,9,M-Musculo-skeletal system,% of total sales,7.7 +27926,Portugal,2011,9,J-Antiinfectives for systemic use,% of total sales,5.6 +27927,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.9 +27928,Portugal,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",29.9 +27929,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.9 +27930,Portugal,2011,9,N05C-Hypnotics and sedatives,Million of national currency units,17.8 +27931,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,78.3 +27932,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.3 +27933,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",125.6 +27934,Portugal,2012,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +27935,Portugal,2012,9,C01A-Cardiac glycosides,Million of national currency units,0.9 +27936,Portugal,2012,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1 +27937,Portugal,2012,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.4 +27938,Portugal,2012,9,R-Respiratory system,"/capita, US$ purchasing power parity",33.7 +27939,Portugal,2012,9,R-Respiratory system,% of total sales,8.2 +27940,Portugal,2012,9,C02-Antihypertensives,% of total sales,0.1 +27941,Portugal,2012,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +27942,Portugal,2012,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +27943,Portugal,2012,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.0 +27944,Portugal,2012,9,G-Genito urinary system and sex hormones,% of total sales,6.1 +27945,Portugal,2012,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.4 +27946,Portugal,2012,9,A02A-Antacids,"/capita, US$ purchasing power parity",1.0 +27947,Portugal,2012,9,C01A-Cardiac glycosides,% of total sales,0.0 +27948,Portugal,2012,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",262.9 +27949,Portugal,2012,9,A02A-Antacids,% of total sales,0.2 +27950,Portugal,2012,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +27951,Portugal,2012,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +27952,Portugal,2012,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",144.4 +27953,Portugal,2012,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.7 +27954,Portugal,2012,9,B-Blood and blood forming organs,% of total sales,3.3 +27955,Portugal,2012,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.7 +27956,Portugal,2012,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.6 +27957,Portugal,2012,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +27958,Portugal,2012,9,C07-Beta blocking agents,% of total sales,1.1 +27959,Portugal,2012,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.6 +27960,Portugal,2012,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +27961,Portugal,2012,9,C02-Antihypertensives,Million of national currency units,3.9 +27962,Portugal,2012,9,C07-Beta blocking agents,"Million US$, purchasing power parity",48.6 +27963,Portugal,2012,9,Products not elsewhere classified,% of total sales,0.0 +27964,Portugal,2012,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +27965,Portugal,2012,9,A-Alimentary tract and metabolism,Million of national currency units,400.8 +27966,Portugal,2012,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",662.1 +27967,Portugal,2012,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,515.0 +27968,Portugal,2012,9,R-Respiratory system,Million US$ at exchange rate,275.9 +27969,Portugal,2012,9,B-Blood and blood forming organs,Million of national currency units,87.4 +27970,Portugal,2012,9,C07-Beta blocking agents,Million of national currency units,29.4 +27971,Portugal,2012,9,R-Respiratory system,Million of national currency units,214.8 +27972,Portugal,2012,9,B-Blood and blood forming organs,Million US$ at exchange rate,112.3 +27973,Portugal,2012,9,R-Respiratory system,"/capita, US$ exchange rate",26.2 +27974,Portugal,2012,9,R-Respiratory system,"Million US$, purchasing power parity",354.8 +27975,Portugal,2012,9,Products not elsewhere classified,Million of national currency units,0.0 +27976,Portugal,2012,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.0 +27977,Portugal,2012,9,C02-Antihypertensives,Million US$ at exchange rate,5.0 +27978,Portugal,2012,9,Products not elsewhere classified,Million US$ at exchange rate,0.0 +27979,Portugal,2012,9,C07-Beta blocking agents,Million US$ at exchange rate,37.8 +27980,Portugal,2012,9,A-Alimentary tract and metabolism,% of total sales,15.3 +27981,Portugal,2012,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.0 +27982,Portugal,2012,9,C-Cardiovascular system,"Million US$, purchasing power parity",1104.8 +27983,Portugal,2012,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.6 +27984,Portugal,2012,9,Total pharmaceutical sales,"/capita, US$ exchange rate",319.4 +27985,Portugal,2012,9,C-Cardiovascular system,% of total sales,25.6 +27986,Portugal,2012,9,C-Cardiovascular system,"/capita, US$ exchange rate",81.7 +27987,Portugal,2012,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",105.1 +27988,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",50.3 +27989,Portugal,2012,9,C-Cardiovascular system,Million of national currency units,668.8 +27990,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.3 +27991,Portugal,2012,9,Total pharmaceutical sales,Million US$ at exchange rate,3358.4 +27992,Portugal,2012,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4317.7 +27993,Portugal,2012,9,C-Cardiovascular system,Million US$ at exchange rate,859.3 +27994,Portugal,2012,9,Total pharmaceutical sales,Million of national currency units,2614.0 +27995,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +27996,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.3 +27997,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9 +27998,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +27999,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +28000,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,411.4 +28001,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,320.2 +28002,Portugal,2012,9,C03-Diuretics,"/capita, US$ exchange rate",2.9 +28003,Portugal,2012,9,C03-Diuretics,"Million US$, purchasing power parity",39.3 +28004,Portugal,2012,9,C03-Diuretics,% of total sales,0.9 +28005,Portugal,2012,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +28006,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",529.0 +28007,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2 +28008,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",39.1 +28009,Portugal,2012,9,C03-Diuretics,Million US$ at exchange rate,30.6 +28010,Portugal,2012,9,C03-Diuretics,Million of national currency units,23.8 +28011,Portugal,2012,9,A02A-Antacids,Million of national currency units,6.1 +28012,Portugal,2012,9,C10-Lipid modifying agents,Million of national currency units,163.9 +28013,Portugal,2012,9,N06A-Antidepressants,Million of national currency units,116.6 +28014,Portugal,2012,9,A02A-Antacids,"Million US$, purchasing power parity",10.0 +28015,Portugal,2012,9,A02A-Antacids,Million US$ at exchange rate,7.8 +28016,Portugal,2012,9,N06A-Antidepressants,"/capita, US$ exchange rate",14.3 +28017,Portugal,2012,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.3 +28018,Portugal,2012,9,N06A-Antidepressants,Million US$ at exchange rate,149.9 +28019,Portugal,2012,9,N06A-Antidepressants,"Million US$, purchasing power parity",192.7 +28020,Portugal,2012,9,C08-Calcium channel blockers,Million US$ at exchange rate,45.1 +28021,Portugal,2012,9,A02A-Antacids,"/capita, US$ exchange rate",0.7 +28022,Portugal,2012,9,C08-Calcium channel blockers,Million of national currency units,35.1 +28023,Portugal,2012,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",58.0 +28024,Portugal,2012,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5 +28025,Portugal,2012,9,C08-Calcium channel blockers,% of total sales,1.3 +28026,Portugal,2012,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3 +28027,Portugal,2012,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,167.9 +28028,Portugal,2012,9,G-Genito urinary system and sex hormones,Million of national currency units,159.2 +28029,Portugal,2012,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",270.7 +28030,Portugal,2012,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,204.5 +28031,Portugal,2012,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.7 +28032,Portugal,2012,9,C10-Lipid modifying agents,% of total sales,6.3 +28033,Portugal,2012,9,R03-Drugs for obstructive airway diseases,Million of national currency units,130.7 +28034,Portugal,2012,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.0 +28035,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",215.9 +28036,Portugal,2012,9,C10-Lipid modifying agents,Million US$ at exchange rate,210.6 +28037,Portugal,2012,9,N06A-Antidepressants,% of total sales,4.5 +28038,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",16.0 +28039,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.5 +28040,Portugal,2012,9,R03-Drugs for obstructive airway diseases,% of total sales,5.0 +28041,Portugal,2012,9,N02-Analgesics,% of total sales,4.3 +28042,Portugal,2012,9,J01-Antibacterials for systemic use,Million of national currency units,75.9 +28043,Portugal,2012,9,N02-Analgesics,"/capita, US$ exchange rate",13.7 +28044,Portugal,2012,9,N02-Analgesics,"/capita, US$ purchasing power parity",17.6 +28045,Portugal,2012,9,N05B-Anxiolytics,Million US$ at exchange rate,72.1 +28046,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,105.0 +28047,Portugal,2012,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,97.5 +28048,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8 +28049,Portugal,2012,9,N05B-Anxiolytics,Million of national currency units,56.1 +28050,Portugal,2012,9,N-Nervous system,"Million US$, purchasing power parity",944.4 +28051,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +28052,Portugal,2012,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",27.4 +28053,Portugal,2012,9,J-Antiinfectives for systemic use,Million of national currency units,130.0 +28054,Portugal,2012,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.2 +28055,Portugal,2012,9,A10-Drugs used in diabetes,% of total sales,8.6 +28056,Portugal,2012,9,N-Nervous system,Million of national currency units,571.7 +28057,Portugal,2012,9,N-Nervous system,Million US$ at exchange rate,734.5 +28058,Portugal,2012,9,N02-Analgesics,Million of national currency units,111.8 +28059,Portugal,2012,9,N02-Analgesics,Million US$ at exchange rate,143.7 +28060,Portugal,2012,9,N02-Analgesics,"Million US$, purchasing power parity",184.7 +28061,Portugal,2012,9,N-Nervous system,"/capita, US$ exchange rate",69.9 +28062,Portugal,2012,9,N-Nervous system,"/capita, US$ purchasing power parity",89.8 +28063,Portugal,2012,9,N-Nervous system,% of total sales,21.9 +28064,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.2 +28065,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",110.5 +28066,Portugal,2012,9,J01-Antibacterials for systemic use,% of total sales,2.9 +28067,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.5 +28068,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.8 +28069,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",173.5 +28070,Portugal,2012,9,N05B-Anxiolytics,% of total sales,2.1 +28071,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.5 +28072,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,135.0 +28073,Portugal,2012,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.7 +28074,Portugal,2012,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.8 +28075,Portugal,2012,9,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9 +28076,Portugal,2012,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9 +28077,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.9 +28078,Portugal,2012,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",125.3 +28079,Portugal,2012,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.3 +28080,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0 +28081,Portugal,2012,9,M-Musculo-skeletal system,Million US$ at exchange rate,262.5 +28082,Portugal,2012,9,N05C-Hypnotics and sedatives,% of total sales,0.7 +28083,Portugal,2012,9,M-Musculo-skeletal system,Million of national currency units,204.3 +28084,Portugal,2012,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,167.0 +28085,Portugal,2012,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.9 +28086,Portugal,2012,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.0 +28087,Portugal,2012,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.9 +28088,Portugal,2012,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3 +28089,Portugal,2012,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",214.7 +28090,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5 +28091,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,86.0 +28092,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,66.9 +28093,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.2 +28094,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,20.6 +28095,Portugal,2012,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.9 +28096,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",34.1 +28097,Portugal,2012,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",370.4 +28098,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,26.5 +28099,Portugal,2012,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.1 +28100,Portugal,2012,9,A10-Drugs used in diabetes,Million US$ at exchange rate,288.1 +28101,Portugal,2012,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.4 +28102,Portugal,2012,9,A10-Drugs used in diabetes,Million of national currency units,224.2 +28103,Portugal,2012,9,M-Musculo-skeletal system,% of total sales,7.8 +28104,Portugal,2012,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.0 +28105,Portugal,2012,9,J-Antiinfectives for systemic use,% of total sales,5.0 +28106,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.7 +28107,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,95.9 +28108,Portugal,2012,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",337.5 +28109,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,74.7 +28110,Portugal,2012,9,N05C-Hypnotics and sedatives,Million of national currency units,18.7 +28111,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.1 +28112,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",123.3 +28113,Portugal,2013,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +28114,Portugal,2013,8,C01A-Cardiac glycosides,Million of national currency units,0.8 +28115,Portugal,2013,8,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1 +28116,Portugal,2013,8,C02-Antihypertensives,Million US$ at exchange rate,4.8 +28117,Portugal,2013,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.1 +28118,Portugal,2013,8,R-Respiratory system,"/capita, US$ purchasing power parity",33.1 +28119,Portugal,2013,8,R-Respiratory system,% of total sales,8.4 +28120,Portugal,2013,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +28121,Portugal,2013,8,C02-Antihypertensives,% of total sales,0.1 +28122,Portugal,2013,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +28123,Portugal,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.5 +28124,Portugal,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.0 +28125,Portugal,2013,8,G-Genito urinary system and sex hormones,% of total sales,6.2 +28126,Portugal,2013,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +28127,Portugal,2013,8,C01A-Cardiac glycosides,% of total sales,0.0 +28128,Portugal,2013,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",255.8 +28129,Portugal,2013,8,A02A-Antacids,% of total sales,0.2 +28130,Portugal,2013,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +28131,Portugal,2013,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +28132,Portugal,2013,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.0 +28133,Portugal,2013,8,B-Blood and blood forming organs,% of total sales,3.8 +28134,Portugal,2013,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",157.3 +28135,Portugal,2013,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.7 +28136,Portugal,2013,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.8 +28137,Portugal,2013,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +28138,Portugal,2013,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9 +28139,Portugal,2013,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +28140,Portugal,2013,8,C02-Antihypertensives,Million of national currency units,3.6 +28141,Portugal,2013,8,C07-Beta blocking agents,"Million US$, purchasing power parity",51.6 +28142,Portugal,2013,8,C07-Beta blocking agents,% of total sales,1.2 +28143,Portugal,2013,8,Products not elsewhere classified,% of total sales,0.0 +28144,Portugal,2013,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +28145,Portugal,2013,8,A-Alimentary tract and metabolism,Million of national currency units,396.1 +28146,Portugal,2013,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",678.6 +28147,Portugal,2013,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,526.0 +28148,Portugal,2013,8,R-Respiratory system,Million US$ at exchange rate,268.2 +28149,Portugal,2013,8,B-Blood and blood forming organs,Million of national currency units,91.8 +28150,Portugal,2013,8,C07-Beta blocking agents,Million of national currency units,30.1 +28151,Portugal,2013,8,R-Respiratory system,Million of national currency units,201.9 +28152,Portugal,2013,8,B-Blood and blood forming organs,Million US$ at exchange rate,121.9 +28153,Portugal,2013,8,R-Respiratory system,"/capita, US$ exchange rate",25.6 +28154,Portugal,2013,8,R-Respiratory system,"Million US$, purchasing power parity",346.0 +28155,Portugal,2013,8,Products not elsewhere classified,Million of national currency units,0.0 +28156,Portugal,2013,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.3 +28157,Portugal,2013,8,Products not elsewhere classified,Million US$ at exchange rate,0.0 +28158,Portugal,2013,8,C07-Beta blocking agents,Million US$ at exchange rate,40.0 +28159,Portugal,2013,8,A-Alimentary tract and metabolism,% of total sales,16.4 +28160,Portugal,2013,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",64.9 +28161,Portugal,2013,8,C-Cardiovascular system,"Million US$, purchasing power parity",1013.0 +28162,Portugal,2013,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",394.8 +28163,Portugal,2013,8,Total pharmaceutical sales,"/capita, US$ exchange rate",306.0 +28164,Portugal,2013,8,C-Cardiovascular system,% of total sales,24.5 +28165,Portugal,2013,8,C-Cardiovascular system,"/capita, US$ exchange rate",75.1 +28166,Portugal,2013,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.9 +28167,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",44.0 +28168,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.1 +28169,Portugal,2013,8,C-Cardiovascular system,Million of national currency units,591.2 +28170,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.1 +28171,Portugal,2013,8,Total pharmaceutical sales,Million US$ at exchange rate,3200.1 +28172,Portugal,2013,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4128.6 +28173,Portugal,2013,8,C-Cardiovascular system,Million US$ at exchange rate,785.2 +28174,Portugal,2013,8,Total pharmaceutical sales,Million of national currency units,2409.5 +28175,Portugal,2013,8,C03-Diuretics,% of total sales,0.9 +28176,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +28177,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.6 +28178,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.1 +28179,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +28180,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,356.4 +28181,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +28182,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,268.4 +28183,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.8 +28184,Portugal,2013,8,C03-Diuretics,"/capita, US$ exchange rate",2.9 +28185,Portugal,2013,8,C03-Diuretics,"Million US$, purchasing power parity",38.8 +28186,Portugal,2013,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +28187,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",459.8 +28188,Portugal,2013,8,C03-Diuretics,Million US$ at exchange rate,30.0 +28189,Portugal,2013,8,C03-Diuretics,Million of national currency units,22.6 +28190,Portugal,2013,8,A02A-Antacids,Million of national currency units,5.1 +28191,Portugal,2013,8,C10-Lipid modifying agents,Million of national currency units,153.4 +28192,Portugal,2013,8,N06A-Antidepressants,Million of national currency units,97.7 +28193,Portugal,2013,8,A02A-Antacids,"Million US$, purchasing power parity",8.8 +28194,Portugal,2013,8,A02A-Antacids,Million US$ at exchange rate,6.8 +28195,Portugal,2013,8,N06A-Antidepressants,"/capita, US$ exchange rate",12.4 +28196,Portugal,2013,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0 +28197,Portugal,2013,8,N06A-Antidepressants,Million US$ at exchange rate,129.8 +28198,Portugal,2013,8,N06A-Antidepressants,"Million US$, purchasing power parity",167.4 +28199,Portugal,2013,8,C08-Calcium channel blockers,Million US$ at exchange rate,38.9 +28200,Portugal,2013,8,C08-Calcium channel blockers,Million of national currency units,29.3 +28201,Portugal,2013,8,A02A-Antacids,"/capita, US$ exchange rate",0.7 +28202,Portugal,2013,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8 +28203,Portugal,2013,8,C08-Calcium channel blockers,% of total sales,1.2 +28204,Portugal,2013,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",50.2 +28205,Portugal,2013,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.7 +28206,Portugal,2013,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,165.1 +28207,Portugal,2013,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",262.8 +28208,Portugal,2013,8,G-Genito urinary system and sex hormones,Million of national currency units,149.3 +28209,Portugal,2013,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,198.3 +28210,Portugal,2013,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.1 +28211,Portugal,2013,8,C10-Lipid modifying agents,% of total sales,6.4 +28212,Portugal,2013,8,R03-Drugs for obstructive airway diseases,Million of national currency units,124.3 +28213,Portugal,2013,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.5 +28214,Portugal,2013,8,C10-Lipid modifying agents,Million US$ at exchange rate,203.7 +28215,Portugal,2013,8,N06A-Antidepressants,% of total sales,4.1 +28216,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.9 +28217,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.8 +28218,Portugal,2013,8,R03-Drugs for obstructive airway diseases,% of total sales,5.2 +28219,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.4 +28220,Portugal,2013,8,N02-Analgesics,% of total sales,4.5 +28221,Portugal,2013,8,J01-Antibacterials for systemic use,Million of national currency units,68.6 +28222,Portugal,2013,8,N02-Analgesics,"/capita, US$ exchange rate",13.8 +28223,Portugal,2013,8,N02-Analgesics,"/capita, US$ purchasing power parity",17.8 +28224,Portugal,2013,8,N-Nervous system,"Million US$, purchasing power parity",877.7 +28225,Portugal,2013,8,N05B-Anxiolytics,Million US$ at exchange rate,71.8 +28226,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,99.8 +28227,Portugal,2013,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,91.1 +28228,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8 +28229,Portugal,2013,8,N05B-Anxiolytics,Million of national currency units,54.1 +28230,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +28231,Portugal,2013,8,J-Antiinfectives for systemic use,Million of national currency units,116.1 +28232,Portugal,2013,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.0 +28233,Portugal,2013,8,A10-Drugs used in diabetes,% of total sales,9.5 +28234,Portugal,2013,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.4 +28235,Portugal,2013,8,N-Nervous system,Million of national currency units,512.2 +28236,Portugal,2013,8,N-Nervous system,Million US$ at exchange rate,680.3 +28237,Portugal,2013,8,N02-Analgesics,Million of national currency units,108.8 +28238,Portugal,2013,8,N02-Analgesics,"Million US$, purchasing power parity",186.5 +28239,Portugal,2013,8,N02-Analgesics,Million US$ at exchange rate,144.5 +28240,Portugal,2013,8,N-Nervous system,"/capita, US$ exchange rate",65.1 +28241,Portugal,2013,8,N-Nervous system,"/capita, US$ purchasing power parity",83.9 +28242,Portugal,2013,8,N-Nervous system,% of total sales,21.3 +28243,Portugal,2013,8,J01-Antibacterials for systemic use,% of total sales,2.8 +28244,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.9 +28245,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.2 +28246,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1 +28247,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4 +28248,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",171.0 +28249,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.7 +28250,Portugal,2013,8,N05B-Anxiolytics,% of total sales,2.2 +28251,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.3 +28252,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,132.6 +28253,Portugal,2013,8,N05B-Anxiolytics,"Million US$, purchasing power parity",92.6 +28254,Portugal,2013,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9 +28255,Portugal,2013,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.9 +28256,Portugal,2013,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +28257,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.8 +28258,Portugal,2013,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",117.5 +28259,Portugal,2013,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.7 +28260,Portugal,2013,8,N05C-Hypnotics and sedatives,% of total sales,0.8 +28261,Portugal,2013,8,M-Musculo-skeletal system,Million US$ at exchange rate,245.5 +28262,Portugal,2013,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,154.2 +28263,Portugal,2013,8,M-Musculo-skeletal system,Million of national currency units,184.9 +28264,Portugal,2013,8,A10-Drugs used in diabetes,Million US$ at exchange rate,303.4 +28265,Portugal,2013,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.5 +28266,Portugal,2013,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,26.7 +28267,Portugal,2013,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.3 +28268,Portugal,2013,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.6 +28269,Portugal,2013,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",198.9 +28270,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5 +28271,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,83.1 +28272,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.6 +28273,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.3 +28274,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,20.0 +28275,Portugal,2013,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.7 +28276,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",34.3 +28277,Portugal,2013,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",391.4 +28278,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,26.6 +28279,Portugal,2013,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",30.3 +28280,Portugal,2013,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5 +28281,Portugal,2013,8,A10-Drugs used in diabetes,Million of national currency units,228.4 +28282,Portugal,2013,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.0 +28283,Portugal,2013,8,M-Musculo-skeletal system,% of total sales,7.7 +28284,Portugal,2013,8,J-Antiinfectives for systemic use,% of total sales,4.8 +28285,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.0 +28286,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,88.9 +28287,Portugal,2013,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",316.7 +28288,Portugal,2013,8,N05C-Hypnotics and sedatives,Million of national currency units,20.1 +28289,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,66.9 +28290,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.5 +28291,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",114.6 +28292,Portugal,2017,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8 +28293,Portugal,2017,8,C01A-Cardiac glycosides,Million of national currency units,0.7 +28294,Portugal,2017,8,C02-Antihypertensives,% of total sales,0.1 +28295,Portugal,2017,8,C02-Antihypertensives,Million US$ at exchange rate,3.5 +28296,Portugal,2017,8,R-Respiratory system,"/capita, US$ purchasing power parity",37.5 +28297,Portugal,2017,8,R-Respiratory system,% of total sales,8.7 +28298,Portugal,2017,8,C02-Antihypertensives,"Million US$, purchasing power parity",5.4 +28299,Portugal,2017,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +28300,Portugal,2017,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +28301,Portugal,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.8 +28302,Portugal,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.4 +28303,Portugal,2017,8,G-Genito urinary system and sex hormones,% of total sales,6.2 +28304,Portugal,2017,8,B-Blood and blood forming organs,% of total sales,7.5 +28305,Portugal,2017,8,C01A-Cardiac glycosides,% of total sales,0.0 +28306,Portugal,2017,8,A02A-Antacids,"/capita, US$ purchasing power parity",1.0 +28307,Portugal,2017,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",276.2 +28308,Portugal,2017,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +28309,Portugal,2017,8,A02A-Antacids,% of total sales,0.2 +28310,Portugal,2017,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +28311,Portugal,2017,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.4 +28312,Portugal,2017,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",333.6 +28313,Portugal,2017,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1 +28314,Portugal,2017,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.3 +28315,Portugal,2017,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.6 +28316,Portugal,2017,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5 +28317,Portugal,2017,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +28318,Portugal,2017,8,C02-Antihypertensives,Million of national currency units,3.1 +28319,Portugal,2017,8,C07-Beta blocking agents,Million US$ at exchange rate,37.0 +28320,Portugal,2017,8,C07-Beta blocking agents,"Million US$, purchasing power parity",56.9 +28321,Portugal,2017,8,Products not elsewhere classified,% of total sales,0.0 +28322,Portugal,2017,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +28323,Portugal,2017,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +28324,Portugal,2017,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",830.4 +28325,Portugal,2017,8,A-Alimentary tract and metabolism,Million of national currency units,478.0 +28326,Portugal,2017,8,C07-Beta blocking agents,% of total sales,1.3 +28327,Portugal,2017,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,540.0 +28328,Portugal,2017,8,B-Blood and blood forming organs,Million of national currency units,192.1 +28329,Portugal,2017,8,R-Respiratory system,Million of national currency units,222.4 +28330,Portugal,2017,8,R-Respiratory system,"Million US$, purchasing power parity",386.3 +28331,Portugal,2017,8,R-Respiratory system,"/capita, US$ exchange rate",24.4 +28332,Portugal,2017,8,B-Blood and blood forming organs,Million US$ at exchange rate,217.0 +28333,Portugal,2017,8,R-Respiratory system,Million US$ at exchange rate,251.2 +28334,Portugal,2017,8,C07-Beta blocking agents,Million of national currency units,32.8 +28335,Portugal,2017,8,Products not elsewhere classified,Million of national currency units,0.0 +28336,Portugal,2017,8,Products not elsewhere classified,Million US$ at exchange rate,0.0 +28337,Portugal,2017,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.4 +28338,Portugal,2017,8,A-Alimentary tract and metabolism,% of total sales,18.7 +28339,Portugal,2017,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",80.6 +28340,Portugal,2017,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",430.9 +28341,Portugal,2017,8,C-Cardiovascular system,"Million US$, purchasing power parity",902.5 +28342,Portugal,2017,8,Total pharmaceutical sales,"/capita, US$ exchange rate",280.2 +28343,Portugal,2017,8,C-Cardiovascular system,% of total sales,20.3 +28344,Portugal,2017,8,C03-Diuretics,% of total sales,0.9 +28345,Portugal,2017,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4438.6 +28346,Portugal,2017,8,C-Cardiovascular system,"/capita, US$ exchange rate",57.0 +28347,Portugal,2017,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.6 +28348,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.2 +28349,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.2 +28350,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9 +28351,Portugal,2017,8,C-Cardiovascular system,Million of national currency units,519.6 +28352,Portugal,2017,8,Total pharmaceutical sales,Million US$ at exchange rate,2886.6 +28353,Portugal,2017,8,Total pharmaceutical sales,Million of national currency units,2555.3 +28354,Portugal,2017,8,C-Cardiovascular system,Million US$ at exchange rate,587.0 +28355,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.4 +28356,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +28357,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7 +28358,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2 +28359,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,228.9 +28360,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +28361,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +28362,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,202.7 +28363,Portugal,2017,8,C03-Diuretics,"Million US$, purchasing power parity",37.8 +28364,Portugal,2017,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +28365,Portugal,2017,8,C03-Diuretics,"/capita, US$ exchange rate",2.4 +28366,Portugal,2017,8,C03-Diuretics,Million US$ at exchange rate,24.6 +28367,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",352.0 +28368,Portugal,2017,8,C03-Diuretics,Million of national currency units,21.8 +28369,Portugal,2017,8,C10-Lipid modifying agents,% of total sales,6.3 +28370,Portugal,2017,8,N06A-Antidepressants,Million of national currency units,96.0 +28371,Portugal,2017,8,A02A-Antacids,Million of national currency units,6.0 +28372,Portugal,2017,8,A02A-Antacids,Million US$ at exchange rate,6.8 +28373,Portugal,2017,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.5 +28374,Portugal,2017,8,N06A-Antidepressants,Million US$ at exchange rate,108.4 +28375,Portugal,2017,8,N06A-Antidepressants,"Million US$, purchasing power parity",166.8 +28376,Portugal,2017,8,C08-Calcium channel blockers,Million of national currency units,24.3 +28377,Portugal,2017,8,C08-Calcium channel blockers,Million US$ at exchange rate,27.5 +28378,Portugal,2017,8,A02A-Antacids,"/capita, US$ exchange rate",0.7 +28379,Portugal,2017,8,A02A-Antacids,"Million US$, purchasing power parity",10.5 +28380,Portugal,2017,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1 +28381,Portugal,2017,8,C08-Calcium channel blockers,% of total sales,1.0 +28382,Portugal,2017,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",42.2 +28383,Portugal,2017,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7 +28384,Portugal,2017,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2 +28385,Portugal,2017,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,148.9 +28386,Portugal,2017,8,R03-Drugs for obstructive airway diseases,Million of national currency units,131.8 +28387,Portugal,2017,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,179.6 +28388,Portugal,2017,8,G-Genito urinary system and sex hormones,Million of national currency units,159.0 +28389,Portugal,2017,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",278.4 +28390,Portugal,2017,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.0 +28391,Portugal,2017,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.6 +28392,Portugal,2017,8,C10-Lipid modifying agents,Million of national currency units,160.3 +28393,Portugal,2017,8,C10-Lipid modifying agents,Million US$ at exchange rate,181.0 +28394,Portugal,2017,8,N06A-Antidepressants,% of total sales,3.8 +28395,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.5 +28396,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",228.9 +28397,Portugal,2017,8,R03-Drugs for obstructive airway diseases,% of total sales,5.2 +28398,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2 +28399,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",107.0 +28400,Portugal,2017,8,N02-Analgesics,% of total sales,4.9 +28401,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4 +28402,Portugal,2017,8,J01-Antibacterials for systemic use,Million of national currency units,59.9 +28403,Portugal,2017,8,N02-Analgesics,"/capita, US$ purchasing power parity",21.1 +28404,Portugal,2017,8,N-Nervous system,"Million US$, purchasing power parity",898.4 +28405,Portugal,2017,8,N02-Analgesics,"/capita, US$ exchange rate",13.7 +28406,Portugal,2017,8,N05B-Anxiolytics,Million US$ at exchange rate,58.0 +28407,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,93.0 +28408,Portugal,2017,8,N05B-Anxiolytics,Million of national currency units,51.4 +28409,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.0 +28410,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.3 +28411,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +28412,Portugal,2017,8,J-Antiinfectives for systemic use,Million of national currency units,116.6 +28413,Portugal,2017,8,A10-Drugs used in diabetes,% of total sales,11.4 +28414,Portugal,2017,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0 +28415,Portugal,2017,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.2 +28416,Portugal,2017,8,N-Nervous system,Million of national currency units,517.2 +28417,Portugal,2017,8,N-Nervous system,Million US$ at exchange rate,584.3 +28418,Portugal,2017,8,N02-Analgesics,"Million US$, purchasing power parity",217.1 +28419,Portugal,2017,8,N02-Analgesics,Million of national currency units,125.0 +28420,Portugal,2017,8,N02-Analgesics,Million US$ at exchange rate,141.2 +28421,Portugal,2017,8,N-Nervous system,"/capita, US$ exchange rate",56.7 +28422,Portugal,2017,8,N-Nervous system,"/capita, US$ purchasing power parity",87.2 +28423,Portugal,2017,8,J01-Antibacterials for systemic use,% of total sales,2.3 +28424,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.0 +28425,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6 +28426,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",15.7 +28427,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2 +28428,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,105.1 +28429,Portugal,2017,8,N-Nervous system,% of total sales,20.2 +28430,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",161.6 +28431,Portugal,2017,8,N05B-Anxiolytics,% of total sales,2.0 +28432,Portugal,2017,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,67.7 +28433,Portugal,2017,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.7 +28434,Portugal,2017,8,N05B-Anxiolytics,"Million US$, purchasing power parity",89.2 +28435,Portugal,2017,8,N05B-Anxiolytics,"/capita, US$ exchange rate",5.6 +28436,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.8 +28437,Portugal,2017,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1 +28438,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4 +28439,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +28440,Portugal,2017,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",104.1 +28441,Portugal,2017,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.6 +28442,Portugal,2017,8,M-Musculo-skeletal system,Million of national currency units,161.1 +28443,Portugal,2017,8,N05C-Hypnotics and sedatives,% of total sales,0.7 +28444,Portugal,2017,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,131.8 +28445,Portugal,2017,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,21.4 +28446,Portugal,2017,8,M-Musculo-skeletal system,Million US$ at exchange rate,182.0 +28447,Portugal,2017,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",32.9 +28448,Portugal,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2 +28449,Portugal,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.1 +28450,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.8 +28451,Portugal,2017,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",506.9 +28452,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.6 +28453,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,61.6 +28454,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",44.6 +28455,Portugal,2017,8,A10-Drugs used in diabetes,Million US$ at exchange rate,329.7 +28456,Portugal,2017,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",202.6 +28457,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,25.7 +28458,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,29.0 +28459,Portugal,2017,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.2 +28460,Portugal,2017,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.8 +28461,Portugal,2017,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.7 +28462,Portugal,2017,8,A10-Drugs used in diabetes,Million of national currency units,291.8 +28463,Portugal,2017,8,J-Antiinfectives for systemic use,% of total sales,4.6 +28464,Portugal,2017,8,M-Musculo-skeletal system,% of total sales,6.3 +28465,Portugal,2017,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.7 +28466,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8 +28467,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,69.6 +28468,Portugal,2017,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",279.8 +28469,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.6 +28470,Portugal,2017,8,N05C-Hypnotics and sedatives,Million of national currency units,19.0 +28471,Portugal,2015,9,C01A-Cardiac glycosides,Million of national currency units,0.9 +28472,Portugal,2015,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0 +28473,Portugal,2015,9,C02-Antihypertensives,Million US$ at exchange rate,4.0 +28474,Portugal,2015,9,R-Respiratory system,"/capita, US$ purchasing power parity",35.4 +28475,Portugal,2015,9,R-Respiratory system,% of total sales,8.6 +28476,Portugal,2015,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.1 +28477,Portugal,2015,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +28478,Portugal,2015,9,C02-Antihypertensives,% of total sales,0.1 +28479,Portugal,2015,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +28480,Portugal,2015,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.4 +28481,Portugal,2015,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.0 +28482,Portugal,2015,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.2 +28483,Portugal,2015,9,G-Genito urinary system and sex hormones,% of total sales,6.1 +28484,Portugal,2015,9,C01A-Cardiac glycosides,% of total sales,0.0 +28485,Portugal,2015,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9 +28486,Portugal,2015,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",259.0 +28487,Portugal,2015,9,B-Blood and blood forming organs,% of total sales,5.6 +28488,Portugal,2015,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +28489,Portugal,2015,9,A02A-Antacids,% of total sales,0.2 +28490,Portugal,2015,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +28491,Portugal,2015,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.2 +28492,Portugal,2015,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",240.3 +28493,Portugal,2015,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.1 +28494,Portugal,2015,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.4 +28495,Portugal,2015,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2 +28496,Portugal,2015,9,C07-Beta blocking agents,Million US$ at exchange rate,35.0 +28497,Portugal,2015,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +28498,Portugal,2015,9,C02-Antihypertensives,Million of national currency units,3.6 +28499,Portugal,2015,9,C07-Beta blocking agents,"Million US$, purchasing power parity",53.9 +28500,Portugal,2015,9,Products not elsewhere classified,% of total sales,0.0 +28501,Portugal,2015,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +28502,Portugal,2015,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +28503,Portugal,2015,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",752.2 +28504,Portugal,2015,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,488.2 +28505,Portugal,2015,9,C07-Beta blocking agents,% of total sales,1.3 +28506,Portugal,2015,9,B-Blood and blood forming organs,Million of national currency units,140.5 +28507,Portugal,2015,9,C07-Beta blocking agents,Million of national currency units,31.5 +28508,Portugal,2015,9,R-Respiratory system,Million of national currency units,214.3 +28509,Portugal,2015,9,R-Respiratory system,"/capita, US$ exchange rate",23.0 +28510,Portugal,2015,9,R-Respiratory system,"Million US$, purchasing power parity",366.4 +28511,Portugal,2015,9,B-Blood and blood forming organs,Million US$ at exchange rate,155.9 +28512,Portugal,2015,9,R-Respiratory system,Million US$ at exchange rate,237.8 +28513,Portugal,2015,9,Products not elsewhere classified,Million of national currency units,0.0 +28514,Portugal,2015,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",47.1 +28515,Portugal,2015,9,Products not elsewhere classified,Million US$ at exchange rate,0.0 +28516,Portugal,2015,9,A-Alimentary tract and metabolism,% of total sales,17.7 +28517,Portugal,2015,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.6 +28518,Portugal,2015,9,C-Cardiovascular system,"Million US$, purchasing power parity",947.9 +28519,Portugal,2015,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",411.2 +28520,Portugal,2015,9,Total pharmaceutical sales,"/capita, US$ exchange rate",266.9 +28521,Portugal,2015,9,C-Cardiovascular system,% of total sales,22.3 +28522,Portugal,2015,9,C-Cardiovascular system,"/capita, US$ exchange rate",59.4 +28523,Portugal,2015,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.5 +28524,Portugal,2015,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4259.0 +28525,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.0 +28526,Portugal,2015,9,C-Cardiovascular system,Million of national currency units,554.5 +28527,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",38.5 +28528,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4 +28529,Portugal,2015,9,Total pharmaceutical sales,Million US$ at exchange rate,2764.1 +28530,Portugal,2015,9,C-Cardiovascular system,Million US$ at exchange rate,615.2 +28531,Portugal,2015,9,Total pharmaceutical sales,Million of national currency units,2491.3 +28532,Portugal,2015,9,C03-Diuretics,% of total sales,0.9 +28533,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.3 +28534,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +28535,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1 +28536,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,258.7 +28537,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +28538,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +28539,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,233.2 +28540,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7 +28541,Portugal,2015,9,C03-Diuretics,"/capita, US$ exchange rate",2.4 +28542,Portugal,2015,9,C03-Diuretics,"Million US$, purchasing power parity",38.0 +28543,Portugal,2015,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +28544,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",398.6 +28545,Portugal,2015,9,C03-Diuretics,Million US$ at exchange rate,24.7 +28546,Portugal,2015,9,C03-Diuretics,Million of national currency units,22.3 +28547,Portugal,2015,9,A02A-Antacids,Million of national currency units,5.6 +28548,Portugal,2015,9,C10-Lipid modifying agents,Million of national currency units,161.0 +28549,Portugal,2015,9,N06A-Antidepressants,Million of national currency units,92.9 +28550,Portugal,2015,9,A02A-Antacids,Million US$ at exchange rate,6.2 +28551,Portugal,2015,9,N06A-Antidepressants,"/capita, US$ exchange rate",10.0 +28552,Portugal,2015,9,N06A-Antidepressants,Million US$ at exchange rate,103.1 +28553,Portugal,2015,9,N06A-Antidepressants,"Million US$, purchasing power parity",158.8 +28554,Portugal,2015,9,A02A-Antacids,"Million US$, purchasing power parity",9.6 +28555,Portugal,2015,9,C08-Calcium channel blockers,Million US$ at exchange rate,28.8 +28556,Portugal,2015,9,C08-Calcium channel blockers,Million of national currency units,26.0 +28557,Portugal,2015,9,A02A-Antacids,"/capita, US$ exchange rate",0.6 +28558,Portugal,2015,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3 +28559,Portugal,2015,9,C08-Calcium channel blockers,% of total sales,1.0 +28560,Portugal,2015,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",44.4 +28561,Portugal,2015,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.8 +28562,Portugal,2015,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.3 +28563,Portugal,2015,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,138.0 +28564,Portugal,2015,9,G-Genito urinary system and sex hormones,Million of national currency units,151.5 +28565,Portugal,2015,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,168.1 +28566,Portugal,2015,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",275.3 +28567,Portugal,2015,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.6 +28568,Portugal,2015,9,C10-Lipid modifying agents,% of total sales,6.5 +28569,Portugal,2015,9,R03-Drugs for obstructive airway diseases,Million of national currency units,124.4 +28570,Portugal,2015,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.3 +28571,Portugal,2015,9,C10-Lipid modifying agents,Million US$ at exchange rate,178.7 +28572,Portugal,2015,9,N06A-Antidepressants,% of total sales,3.7 +28573,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3 +28574,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.7 +28575,Portugal,2015,9,R03-Drugs for obstructive airway diseases,% of total sales,5.0 +28576,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.5 +28577,Portugal,2015,9,A-Alimentary tract and metabolism,Million of national currency units,440.0 +28578,Portugal,2015,9,N02-Analgesics,% of total sales,4.9 +28579,Portugal,2015,9,J01-Antibacterials for systemic use,Million of national currency units,66.8 +28580,Portugal,2015,9,N-Nervous system,"Million US$, purchasing power parity",870.6 +28581,Portugal,2015,9,N02-Analgesics,"/capita, US$ exchange rate",13.1 +28582,Portugal,2015,9,N02-Analgesics,"/capita, US$ purchasing power parity",20.2 +28583,Portugal,2015,9,N05B-Anxiolytics,Million US$ at exchange rate,60.3 +28584,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,97.4 +28585,Portugal,2015,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,74.1 +28586,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9 +28587,Portugal,2015,9,N05B-Anxiolytics,Million of national currency units,54.4 +28588,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +28589,Portugal,2015,9,J-Antiinfectives for systemic use,Million of national currency units,133.5 +28590,Portugal,2015,9,A10-Drugs used in diabetes,% of total sales,10.6 +28591,Portugal,2015,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",28.4 +28592,Portugal,2015,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",43.7 +28593,Portugal,2015,9,N-Nervous system,Million of national currency units,509.2 +28594,Portugal,2015,9,N-Nervous system,Million US$ at exchange rate,565.0 +28595,Portugal,2015,9,N02-Analgesics,"Million US$, purchasing power parity",209.1 +28596,Portugal,2015,9,N02-Analgesics,Million of national currency units,122.3 +28597,Portugal,2015,9,N02-Analgesics,Million US$ at exchange rate,135.7 +28598,Portugal,2015,9,N-Nervous system,"/capita, US$ exchange rate",54.5 +28599,Portugal,2015,9,N-Nervous system,"/capita, US$ purchasing power parity",84.0 +28600,Portugal,2015,9,J01-Antibacterials for systemic use,% of total sales,2.7 +28601,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.7 +28602,Portugal,2015,9,N-Nervous system,% of total sales,20.4 +28603,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.3 +28604,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9 +28605,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.1 +28606,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4 +28607,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,108.1 +28608,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",166.5 +28609,Portugal,2015,9,N05B-Anxiolytics,% of total sales,2.2 +28610,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4 +28611,Portugal,2015,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.0 +28612,Portugal,2015,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.9 +28613,Portugal,2015,9,N05B-Anxiolytics,"/capita, US$ exchange rate",5.8 +28614,Portugal,2015,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.0 +28615,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.1 +28616,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +28617,Portugal,2015,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",114.1 +28618,Portugal,2015,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2 +28619,Portugal,2015,9,N05C-Hypnotics and sedatives,% of total sales,0.8 +28620,Portugal,2015,9,M-Musculo-skeletal system,Million of national currency units,169.1 +28621,Portugal,2015,9,A10-Drugs used in diabetes,Million US$ at exchange rate,294.0 +28622,Portugal,2015,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,148.1 +28623,Portugal,2015,9,M-Musculo-skeletal system,Million US$ at exchange rate,187.6 +28624,Portugal,2015,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",35.5 +28625,Portugal,2015,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,23.1 +28626,Portugal,2015,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4 +28627,Portugal,2015,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.2 +28628,Portugal,2015,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",228.3 +28629,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5 +28630,Portugal,2015,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",453.0 +28631,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.6 +28632,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.8 +28633,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.9 +28634,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,23.4 +28635,Portugal,2015,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3 +28636,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,25.9 +28637,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",39.9 +28638,Portugal,2015,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.9 +28639,Portugal,2015,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.1 +28640,Portugal,2015,9,A10-Drugs used in diabetes,Million of national currency units,265.0 +28641,Portugal,2015,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",22.0 +28642,Portugal,2015,9,J-Antiinfectives for systemic use,% of total sales,5.4 +28643,Portugal,2015,9,M-Musculo-skeletal system,% of total sales,6.8 +28644,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5 +28645,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.6 +28646,Portugal,2015,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",289.1 +28647,Portugal,2015,9,N05C-Hypnotics and sedatives,Million of national currency units,20.8 +28648,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,60.9 +28649,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.1 +28650,Portugal,2016,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9 +28651,Portugal,2016,9,C01A-Cardiac glycosides,Million of national currency units,0.8 +28652,Portugal,2016,9,C02-Antihypertensives,% of total sales,0.1 +28653,Portugal,2016,9,C02-Antihypertensives,Million US$ at exchange rate,3.5 +28654,Portugal,2016,9,R-Respiratory system,% of total sales,8.8 +28655,Portugal,2016,9,R-Respiratory system,"/capita, US$ purchasing power parity",37.8 +28656,Portugal,2016,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5 +28657,Portugal,2016,9,C02-Antihypertensives,"Million US$, purchasing power parity",5.5 +28658,Portugal,2016,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.3 +28659,Portugal,2016,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +28660,Portugal,2016,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.7 +28661,Portugal,2016,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.9 +28662,Portugal,2016,9,G-Genito urinary system and sex hormones,% of total sales,6.2 +28663,Portugal,2016,9,C01A-Cardiac glycosides,% of total sales,0.0 +28664,Portugal,2016,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9 +28665,Portugal,2016,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",275.6 +28666,Portugal,2016,9,B-Blood and blood forming organs,% of total sales,6.9 +28667,Portugal,2016,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +28668,Portugal,2016,9,A02A-Antacids,% of total sales,0.2 +28669,Portugal,2016,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +28670,Portugal,2016,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.7 +28671,Portugal,2016,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",307.2 +28672,Portugal,2016,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.8 +28673,Portugal,2016,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5 +28674,Portugal,2016,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5 +28675,Portugal,2016,9,C07-Beta blocking agents,Million US$ at exchange rate,36.0 +28676,Portugal,2016,9,C02-Antihypertensives,Million of national currency units,3.1 +28677,Portugal,2016,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +28678,Portugal,2016,9,C07-Beta blocking agents,"Million US$, purchasing power parity",57.0 +28679,Portugal,2016,9,C07-Beta blocking agents,% of total sales,1.3 +28680,Portugal,2016,9,Products not elsewhere classified,% of total sales,0.0 +28681,Portugal,2016,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +28682,Portugal,2016,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +28683,Portugal,2016,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",806.0 +28684,Portugal,2016,9,A-Alimentary tract and metabolism,Million of national currency units,460.6 +28685,Portugal,2016,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,509.8 +28686,Portugal,2016,9,B-Blood and blood forming organs,Million of national currency units,175.5 +28687,Portugal,2016,9,R-Respiratory system,Million of national currency units,222.8 +28688,Portugal,2016,9,R-Respiratory system,"/capita, US$ exchange rate",23.9 +28689,Portugal,2016,9,R-Respiratory system,"Million US$, purchasing power parity",389.8 +28690,Portugal,2016,9,B-Blood and blood forming organs,Million US$ at exchange rate,194.3 +28691,Portugal,2016,9,R-Respiratory system,Million US$ at exchange rate,246.6 +28692,Portugal,2016,9,C07-Beta blocking agents,Million of national currency units,32.5 +28693,Portugal,2016,9,Products not elsewhere classified,Million of national currency units,0.0 +28694,Portugal,2016,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.4 +28695,Portugal,2016,9,Products not elsewhere classified,Million US$ at exchange rate,0.0 +28696,Portugal,2016,9,A-Alimentary tract and metabolism,% of total sales,18.2 +28697,Portugal,2016,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",78.1 +28698,Portugal,2016,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",428.9 +28699,Portugal,2016,9,C-Cardiovascular system,"Million US$, purchasing power parity",944.9 +28700,Portugal,2016,9,Total pharmaceutical sales,"/capita, US$ exchange rate",271.3 +28701,Portugal,2016,9,C-Cardiovascular system,% of total sales,21.3 +28702,Portugal,2016,9,C-Cardiovascular system,"/capita, US$ exchange rate",57.9 +28703,Portugal,2016,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.5 +28704,Portugal,2016,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4428.3 +28705,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.3 +28706,Portugal,2016,9,C-Cardiovascular system,Million of national currency units,539.9 +28707,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.6 +28708,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.8 +28709,Portugal,2016,9,C03-Diuretics,% of total sales,0.9 +28710,Portugal,2016,9,Total pharmaceutical sales,Million US$ at exchange rate,2800.9 +28711,Portugal,2016,9,Total pharmaceutical sales,Million of national currency units,2530.4 +28712,Portugal,2016,9,C-Cardiovascular system,Million US$ at exchange rate,597.6 +28713,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.5 +28714,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4 +28715,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1 +28716,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7 +28717,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +28718,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +28719,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,240.2 +28720,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,217.0 +28721,Portugal,2016,9,C03-Diuretics,"Million US$, purchasing power parity",38.4 +28722,Portugal,2016,9,C03-Diuretics,"/capita, US$ exchange rate",2.4 +28723,Portugal,2016,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +28724,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",379.7 +28725,Portugal,2016,9,C03-Diuretics,Million US$ at exchange rate,24.3 +28726,Portugal,2016,9,C03-Diuretics,Million of national currency units,21.9 +28727,Portugal,2016,9,A02A-Antacids,Million of national currency units,5.3 +28728,Portugal,2016,9,N06A-Antidepressants,Million of national currency units,93.6 +28729,Portugal,2016,9,A02A-Antacids,Million US$ at exchange rate,5.9 +28730,Portugal,2016,9,N06A-Antidepressants,"/capita, US$ exchange rate",10.0 +28731,Portugal,2016,9,N06A-Antidepressants,"Million US$, purchasing power parity",163.7 +28732,Portugal,2016,9,N06A-Antidepressants,Million US$ at exchange rate,103.6 +28733,Portugal,2016,9,C08-Calcium channel blockers,Million of national currency units,25.1 +28734,Portugal,2016,9,C08-Calcium channel blockers,Million US$ at exchange rate,27.8 +28735,Portugal,2016,9,A02A-Antacids,"/capita, US$ exchange rate",0.6 +28736,Portugal,2016,9,A02A-Antacids,"Million US$, purchasing power parity",9.3 +28737,Portugal,2016,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3 +28738,Portugal,2016,9,C08-Calcium channel blockers,% of total sales,1.0 +28739,Portugal,2016,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",43.9 +28740,Portugal,2016,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7 +28741,Portugal,2016,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,144.6 +28742,Portugal,2016,9,R03-Drugs for obstructive airway diseases,Million of national currency units,130.7 +28743,Portugal,2016,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,174.3 +28744,Portugal,2016,9,G-Genito urinary system and sex hormones,Million of national currency units,157.5 +28745,Portugal,2016,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.2 +28746,Portugal,2016,9,C10-Lipid modifying agents,% of total sales,6.6 +28747,Portugal,2016,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",291.0 +28748,Portugal,2016,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.8 +28749,Portugal,2016,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9 +28750,Portugal,2016,9,C10-Lipid modifying agents,Million of national currency units,166.3 +28751,Portugal,2016,9,C10-Lipid modifying agents,Million US$ at exchange rate,184.0 +28752,Portugal,2016,9,N06A-Antidepressants,% of total sales,3.7 +28753,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.0 +28754,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",228.7 +28755,Portugal,2016,9,R03-Drugs for obstructive airway diseases,% of total sales,5.2 +28756,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.1 +28757,Portugal,2016,9,N02-Analgesics,% of total sales,4.7 +28758,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.0 +28759,Portugal,2016,9,J01-Antibacterials for systemic use,Million of national currency units,63.4 +28760,Portugal,2016,9,N02-Analgesics,"/capita, US$ purchasing power parity",20.2 +28761,Portugal,2016,9,N-Nervous system,"Million US$, purchasing power parity",887.0 +28762,Portugal,2016,9,N02-Analgesics,"/capita, US$ exchange rate",12.8 +28763,Portugal,2016,9,N05B-Anxiolytics,Million US$ at exchange rate,58.2 +28764,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,96.9 +28765,Portugal,2016,9,N05B-Anxiolytics,Million of national currency units,52.6 +28766,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.0 +28767,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1 +28768,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +28769,Portugal,2016,9,J-Antiinfectives for systemic use,Million of national currency units,118.1 +28770,Portugal,2016,9,A10-Drugs used in diabetes,% of total sales,11.0 +28771,Portugal,2016,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.9 +28772,Portugal,2016,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",47.3 +28773,Portugal,2016,9,N-Nervous system,Million of national currency units,506.8 +28774,Portugal,2016,9,N-Nervous system,Million US$ at exchange rate,561.0 +28775,Portugal,2016,9,N02-Analgesics,Million of national currency units,119.1 +28776,Portugal,2016,9,N02-Analgesics,"Million US$, purchasing power parity",208.5 +28777,Portugal,2016,9,N02-Analgesics,Million US$ at exchange rate,131.9 +28778,Portugal,2016,9,N-Nervous system,"/capita, US$ exchange rate",54.3 +28779,Portugal,2016,9,N-Nervous system,"/capita, US$ purchasing power parity",85.9 +28780,Portugal,2016,9,J01-Antibacterials for systemic use,% of total sales,2.5 +28781,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",113.4 +28782,Portugal,2016,9,N-Nervous system,% of total sales,20.0 +28783,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.8 +28784,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4 +28785,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4 +28786,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.2 +28787,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",169.5 +28788,Portugal,2016,9,N05B-Anxiolytics,% of total sales,2.1 +28789,Portugal,2016,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,70.2 +28790,Portugal,2016,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.9 +28791,Portugal,2016,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.0 +28792,Portugal,2016,9,N05B-Anxiolytics,"/capita, US$ exchange rate",5.6 +28793,Portugal,2016,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.7 +28794,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.3 +28795,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +28796,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.9 +28797,Portugal,2016,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",110.9 +28798,Portugal,2016,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8 +28799,Portugal,2016,9,M-Musculo-skeletal system,Million of national currency units,167.0 +28800,Portugal,2016,9,N05C-Hypnotics and sedatives,% of total sales,0.8 +28801,Portugal,2016,9,A10-Drugs used in diabetes,Million US$ at exchange rate,309.1 +28802,Portugal,2016,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,130.7 +28803,Portugal,2016,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.0 +28804,Portugal,2016,9,M-Musculo-skeletal system,Million US$ at exchange rate,184.8 +28805,Portugal,2016,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.7 +28806,Portugal,2016,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4 +28807,Portugal,2016,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.1 +28808,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.6 +28809,Portugal,2016,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",488.7 +28810,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,71.7 +28811,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,64.8 +28812,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",42.8 +28813,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.5 +28814,Portugal,2016,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",206.6 +28815,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,27.1 +28816,Portugal,2016,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.3 +28817,Portugal,2016,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.7 +28818,Portugal,2016,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.9 +28819,Portugal,2016,9,A10-Drugs used in diabetes,Million of national currency units,279.2 +28820,Portugal,2016,9,J-Antiinfectives for systemic use,% of total sales,4.7 +28821,Portugal,2016,9,M-Musculo-skeletal system,% of total sales,6.6 +28822,Portugal,2016,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.0 +28823,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5 +28824,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.5 +28825,Portugal,2016,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",292.2 +28826,Portugal,2016,9,N05C-Hypnotics and sedatives,Million of national currency units,19.8 +28827,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0 +28828,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",106.8 +28829,Portugal,2010,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +28830,Portugal,2010,9,C01A-Cardiac glycosides,Million of national currency units,1.0 +28831,Portugal,2010,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3 +28832,Portugal,2010,9,C02-Antihypertensives,"Million US$, purchasing power parity",7.2 +28833,Portugal,2010,9,R-Respiratory system,% of total sales,6.6 +28834,Portugal,2010,9,C02-Antihypertensives,% of total sales,0.1 +28835,Portugal,2010,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.6 +28836,Portugal,2010,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.7 +28837,Portugal,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.3 +28838,Portugal,2010,9,G-Genito urinary system and sex hormones,% of total sales,5.6 +28839,Portugal,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.6 +28840,Portugal,2010,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",289.1 +28841,Portugal,2010,9,C01A-Cardiac glycosides,% of total sales,0.0 +28842,Portugal,2010,9,A02A-Antacids,% of total sales,0.2 +28843,Portugal,2010,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +28844,Portugal,2010,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +28845,Portugal,2010,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",193.4 +28846,Portugal,2010,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.3 +28847,Portugal,2010,9,B-Blood and blood forming organs,% of total sales,3.7 +28848,Portugal,2010,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.1 +28849,Portugal,2010,9,R-Respiratory system,"/capita, US$ purchasing power parity",32.6 +28850,Portugal,2010,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +28851,Portugal,2010,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.3 +28852,Portugal,2010,9,C07-Beta blocking agents,% of total sales,1.1 +28853,Portugal,2010,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2 +28854,Portugal,2010,9,C02-Antihypertensives,Million of national currency units,4.5 +28855,Portugal,2010,9,C07-Beta blocking agents,"Million US$, purchasing power parity",55.2 +28856,Portugal,2010,9,Products not elsewhere classified,% of total sales,0.0 +28857,Portugal,2010,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +28858,Portugal,2010,9,A-Alimentary tract and metabolism,Million of national currency units,511.4 +28859,Portugal,2010,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,677.9 +28860,Portugal,2010,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",820.6 +28861,Portugal,2010,9,C02-Antihypertensives,Million US$ at exchange rate,6.0 +28862,Portugal,2010,9,B-Blood and blood forming organs,Million of national currency units,120.5 +28863,Portugal,2010,9,R-Respiratory system,Million US$ at exchange rate,284.6 +28864,Portugal,2010,9,B-Blood and blood forming organs,Million US$ at exchange rate,159.8 +28865,Portugal,2010,9,C07-Beta blocking agents,Million of national currency units,34.4 +28866,Portugal,2010,9,R-Respiratory system,Million of national currency units,214.6 +28867,Portugal,2010,9,R-Respiratory system,"/capita, US$ exchange rate",26.9 +28868,Portugal,2010,9,R-Respiratory system,"Million US$, purchasing power parity",344.5 +28869,Portugal,2010,9,Products not elsewhere classified,Million of national currency units,0.0 +28870,Portugal,2010,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.1 +28871,Portugal,2010,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +28872,Portugal,2010,9,Products not elsewhere classified,Million US$ at exchange rate,0.0 +28873,Portugal,2010,9,A02A-Antacids,"/capita, US$ purchasing power parity",1.0 +28874,Portugal,2010,9,C07-Beta blocking agents,Million US$ at exchange rate,45.6 +28875,Portugal,2010,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.6 +28876,Portugal,2010,9,A-Alimentary tract and metabolism,% of total sales,15.8 +28877,Portugal,2010,9,C-Cardiovascular system,"Million US$, purchasing power parity",1431.7 +28878,Portugal,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",406.0 +28879,Portugal,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",491.4 +28880,Portugal,2010,9,C-Cardiovascular system,"/capita, US$ exchange rate",111.9 +28881,Portugal,2010,9,C-Cardiovascular system,% of total sales,27.6 +28882,Portugal,2010,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",135.4 +28883,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",60.4 +28884,Portugal,2010,9,C-Cardiovascular system,Million of national currency units,892.1 +28885,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.3 +28886,Portugal,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,4292.5 +28887,Portugal,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",5195.9 +28888,Portugal,2010,9,C-Cardiovascular system,Million US$ at exchange rate,1182.7 +28889,Portugal,2010,9,Total pharmaceutical sales,Million of national currency units,3237.9 +28890,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +28891,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.4 +28892,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.7 +28893,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +28894,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,527.3 +28895,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,397.7 +28896,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +28897,Portugal,2010,9,C03-Diuretics,"/capita, US$ exchange rate",3.6 +28898,Portugal,2010,9,C03-Diuretics,"Million US$, purchasing power parity",46.3 +28899,Portugal,2010,9,C03-Diuretics,% of total sales,0.9 +28900,Portugal,2010,9,C03-Diuretics,"/capita, US$ purchasing power parity",4.4 +28901,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",638.2 +28902,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.8 +28903,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",49.9 +28904,Portugal,2010,9,C03-Diuretics,Million US$ at exchange rate,38.3 +28905,Portugal,2010,9,C03-Diuretics,Million of national currency units,28.9 +28906,Portugal,2010,9,A02A-Antacids,Million of national currency units,6.4 +28907,Portugal,2010,9,C10-Lipid modifying agents,Million of national currency units,256.5 +28908,Portugal,2010,9,N06A-Antidepressants,Million of national currency units,158.3 +28909,Portugal,2010,9,A02A-Antacids,"Million US$, purchasing power parity",10.2 +28910,Portugal,2010,9,A02A-Antacids,Million US$ at exchange rate,8.5 +28911,Portugal,2010,9,N06A-Antidepressants,"/capita, US$ exchange rate",19.9 +28912,Portugal,2010,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",24.0 +28913,Portugal,2010,9,N06A-Antidepressants,Million US$ at exchange rate,209.9 +28914,Portugal,2010,9,N06A-Antidepressants,"Million US$, purchasing power parity",254.1 +28915,Portugal,2010,9,C08-Calcium channel blockers,Million US$ at exchange rate,72.1 +28916,Portugal,2010,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",87.2 +28917,Portugal,2010,9,A02A-Antacids,"/capita, US$ exchange rate",0.8 +28918,Portugal,2010,9,C08-Calcium channel blockers,Million of national currency units,54.4 +28919,Portugal,2010,9,C08-Calcium channel blockers,% of total sales,1.7 +28920,Portugal,2010,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8 +28921,Portugal,2010,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.3 +28922,Portugal,2010,9,G-Genito urinary system and sex hormones,Million of national currency units,180.2 +28923,Portugal,2010,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,174.3 +28924,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",211.0 +28925,Portugal,2010,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,238.8 +28926,Portugal,2010,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.9 +28927,Portugal,2010,9,C10-Lipid modifying agents,% of total sales,7.9 +28928,Portugal,2010,9,R03-Drugs for obstructive airway diseases,Million of national currency units,131.5 +28929,Portugal,2010,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.2 +28930,Portugal,2010,9,C10-Lipid modifying agents,Million US$ at exchange rate,340.1 +28931,Portugal,2010,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",411.6 +28932,Portugal,2010,9,N06A-Antidepressants,% of total sales,4.9 +28933,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",16.5 +28934,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.0 +28935,Portugal,2010,9,R03-Drugs for obstructive airway diseases,% of total sales,4.1 +28936,Portugal,2010,9,N02-Analgesics,% of total sales,3.4 +28937,Portugal,2010,9,J01-Antibacterials for systemic use,Million of national currency units,102.5 +28938,Portugal,2010,9,N-Nervous system,"/capita, US$ exchange rate",87.8 +28939,Portugal,2010,9,N02-Analgesics,"/capita, US$ exchange rate",13.8 +28940,Portugal,2010,9,N02-Analgesics,"/capita, US$ purchasing power parity",16.7 +28941,Portugal,2010,9,N05B-Anxiolytics,Million US$ at exchange rate,81.2 +28942,Portugal,2010,9,N05B-Anxiolytics,"Million US$, purchasing power parity",98.3 +28943,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,127.9 +28944,Portugal,2010,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,135.8 +28945,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.7 +28946,Portugal,2010,9,N05B-Anxiolytics,Million of national currency units,61.2 +28947,Portugal,2010,9,N-Nervous system,"Million US$, purchasing power parity",1124.0 +28948,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.8 +28949,Portugal,2010,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.7 +28950,Portugal,2010,9,A10-Drugs used in diabetes,% of total sales,6.4 +28951,Portugal,2010,9,J-Antiinfectives for systemic use,Million of national currency units,182.1 +28952,Portugal,2010,9,N02-Analgesics,Million of national currency units,110.3 +28953,Portugal,2010,9,N-Nervous system,Million of national currency units,700.4 +28954,Portugal,2010,9,N-Nervous system,Million US$ at exchange rate,928.6 +28955,Portugal,2010,9,N02-Analgesics,Million US$ at exchange rate,146.2 +28956,Portugal,2010,9,N02-Analgesics,"Million US$, purchasing power parity",176.9 +28957,Portugal,2010,9,M-Musculo-skeletal system,Million of national currency units,252.5 +28958,Portugal,2010,9,N-Nervous system,"/capita, US$ purchasing power parity",106.3 +28959,Portugal,2010,9,N-Nervous system,% of total sales,21.6 +28960,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",299.3 +28961,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.4 +28962,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",19.4 +28963,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9 +28964,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",205.2 +28965,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.0 +28966,Portugal,2010,9,N05B-Anxiolytics,% of total sales,1.9 +28967,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.3 +28968,Portugal,2010,9,N05B-Anxiolytics,"/capita, US$ exchange rate",7.7 +28969,Portugal,2010,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.3 +28970,Portugal,2010,9,J01-Antibacterials for systemic use,% of total sales,3.2 +28971,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.5 +28972,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,169.5 +28973,Portugal,2010,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",164.4 +28974,Portugal,2010,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.6 +28975,Portugal,2010,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.8 +28976,Portugal,2010,9,M-Musculo-skeletal system,Million US$ at exchange rate,334.8 +28977,Portugal,2010,9,N05C-Hypnotics and sedatives,% of total sales,0.6 +28978,Portugal,2010,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",292.3 +28979,Portugal,2010,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,241.5 +28980,Portugal,2010,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",29.6 +28981,Portugal,2010,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.4 +28982,Portugal,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8 +28983,Portugal,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3 +28984,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0 +28985,Portugal,2010,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",26.2 +28986,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6 +28987,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,247.2 +28988,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,186.5 +28989,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.0 +28990,Portugal,2010,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",22.8 +28991,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",38.5 +28992,Portugal,2010,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",334.7 +28993,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,31.8 +28994,Portugal,2010,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",38.3 +28995,Portugal,2010,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.6 +28996,Portugal,2010,9,A10-Drugs used in diabetes,Million US$ at exchange rate,276.5 +28997,Portugal,2010,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",405.2 +28998,Portugal,2010,9,A10-Drugs used in diabetes,Million of national currency units,208.6 +28999,Portugal,2010,9,M-Musculo-skeletal system,% of total sales,7.8 +29000,Portugal,2010,9,J-Antiinfectives for systemic use,% of total sales,5.6 +29001,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.4 +29002,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.0 +29003,Portugal,2010,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.7 +29004,Portugal,2010,9,N05C-Hypnotics and sedatives,Million of national currency units,18.4 +29005,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,81.5 +29006,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.2 +29007,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",130.7 +29008,Portugal,2014,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +29009,Portugal,2014,8,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2 +29010,Portugal,2014,8,C01A-Cardiac glycosides,Million of national currency units,0.9 +29011,Portugal,2014,8,C02-Antihypertensives,Million US$ at exchange rate,4.8 +29012,Portugal,2014,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.3 +29013,Portugal,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",31.9 +29014,Portugal,2014,8,R-Respiratory system,% of total sales,8.0 +29015,Portugal,2014,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6 +29016,Portugal,2014,8,C02-Antihypertensives,% of total sales,0.2 +29017,Portugal,2014,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.5 +29018,Portugal,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.1 +29019,Portugal,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.3 +29020,Portugal,2014,8,G-Genito urinary system and sex hormones,% of total sales,6.3 +29021,Portugal,2014,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +29022,Portugal,2014,8,C01A-Cardiac glycosides,% of total sales,0.0 +29023,Portugal,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",261.1 +29024,Portugal,2014,8,B-Blood and blood forming organs,% of total sales,4.6 +29025,Portugal,2014,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +29026,Portugal,2014,8,A02A-Antacids,% of total sales,0.2 +29027,Portugal,2014,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +29028,Portugal,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.4 +29029,Portugal,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",191.7 +29030,Portugal,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.2 +29031,Portugal,2014,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.9 +29032,Portugal,2014,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0 +29033,Portugal,2014,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.1 +29034,Portugal,2014,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0 +29035,Portugal,2014,8,C02-Antihypertensives,Million of national currency units,3.6 +29036,Portugal,2014,8,C07-Beta blocking agents,"Million US$, purchasing power parity",52.5 +29037,Portugal,2014,8,C07-Beta blocking agents,% of total sales,1.3 +29038,Portugal,2014,8,Products not elsewhere classified,% of total sales,0.0 +29039,Portugal,2014,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0 +29040,Portugal,2014,8,A-Alimentary tract and metabolism,Million of national currency units,404.8 +29041,Portugal,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",699.3 +29042,Portugal,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,537.8 +29043,Portugal,2014,8,R-Respiratory system,Million US$ at exchange rate,255.4 +29044,Portugal,2014,8,B-Blood and blood forming organs,Million of national currency units,110.9 +29045,Portugal,2014,8,C07-Beta blocking agents,Million of national currency units,30.4 +29046,Portugal,2014,8,R-Respiratory system,Million of national currency units,192.3 +29047,Portugal,2014,8,R-Respiratory system,"/capita, US$ exchange rate",24.6 +29048,Portugal,2014,8,R-Respiratory system,"Million US$, purchasing power parity",332.1 +29049,Portugal,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,147.4 +29050,Portugal,2014,8,Products not elsewhere classified,Million of national currency units,0.0 +29051,Portugal,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.7 +29052,Portugal,2014,8,Products not elsewhere classified,Million US$ at exchange rate,0.0 +29053,Portugal,2014,8,C07-Beta blocking agents,Million US$ at exchange rate,40.4 +29054,Portugal,2014,8,A-Alimentary tract and metabolism,% of total sales,16.9 +29055,Portugal,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",67.2 +29056,Portugal,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",981.9 +29057,Portugal,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",398.2 +29058,Portugal,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",306.2 +29059,Portugal,2014,8,C-Cardiovascular system,% of total sales,23.7 +29060,Portugal,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",72.6 +29061,Portugal,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",94.4 +29062,Portugal,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4141.9 +29063,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",41.5 +29064,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",31.9 +29065,Portugal,2014,8,C-Cardiovascular system,Million of national currency units,568.4 +29066,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,10.4 +29067,Portugal,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,3185.2 +29068,Portugal,2014,8,C-Cardiovascular system,Million US$ at exchange rate,755.1 +29069,Portugal,2014,8,Total pharmaceutical sales,Million of national currency units,2397.6 +29070,Portugal,2014,8,C03-Diuretics,% of total sales,0.9 +29071,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.5 +29072,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +29073,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0 +29074,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +29075,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +29076,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,332.1 +29077,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,250.0 +29078,Portugal,2014,8,C03-Diuretics,"/capita, US$ exchange rate",2.9 +29079,Portugal,2014,8,C03-Diuretics,"Million US$, purchasing power parity",38.8 +29080,Portugal,2014,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +29081,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7 +29082,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",431.9 +29083,Portugal,2014,8,C03-Diuretics,Million US$ at exchange rate,29.8 +29084,Portugal,2014,8,C03-Diuretics,Million of national currency units,22.5 +29085,Portugal,2014,8,A02A-Antacids,Million of national currency units,4.7 +29086,Portugal,2014,8,N06A-Antidepressants,Million of national currency units,95.4 +29087,Portugal,2014,8,C10-Lipid modifying agents,Million of national currency units,157.8 +29088,Portugal,2014,8,A02A-Antacids,Million US$ at exchange rate,6.2 +29089,Portugal,2014,8,A02A-Antacids,"Million US$, purchasing power parity",8.1 +29090,Portugal,2014,8,N06A-Antidepressants,"/capita, US$ exchange rate",12.2 +29091,Portugal,2014,8,N06A-Antidepressants,Million US$ at exchange rate,126.7 +29092,Portugal,2014,8,N06A-Antidepressants,"Million US$, purchasing power parity",164.8 +29093,Portugal,2014,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.8 +29094,Portugal,2014,8,C08-Calcium channel blockers,Million US$ at exchange rate,35.8 +29095,Portugal,2014,8,A02A-Antacids,"/capita, US$ exchange rate",0.6 +29096,Portugal,2014,8,C08-Calcium channel blockers,Million of national currency units,27.0 +29097,Portugal,2014,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",46.6 +29098,Portugal,2014,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5 +29099,Portugal,2014,8,C08-Calcium channel blockers,% of total sales,1.1 +29100,Portugal,2014,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4 +29101,Portugal,2014,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,155.6 +29102,Portugal,2014,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",272.7 +29103,Portugal,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,200.8 +29104,Portugal,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,151.1 +29105,Portugal,2014,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.2 +29106,Portugal,2014,8,C10-Lipid modifying agents,% of total sales,6.6 +29107,Portugal,2014,8,R03-Drugs for obstructive airway diseases,Million of national currency units,117.1 +29108,Portugal,2014,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.2 +29109,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",202.3 +29110,Portugal,2014,8,C10-Lipid modifying agents,Million US$ at exchange rate,209.7 +29111,Portugal,2014,8,N06A-Antidepressants,% of total sales,4.0 +29112,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.0 +29113,Portugal,2014,8,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +29114,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4 +29115,Portugal,2014,8,N02-Analgesics,% of total sales,5.1 +29116,Portugal,2014,8,J01-Antibacterials for systemic use,Million of national currency units,64.8 +29117,Portugal,2014,8,N-Nervous system,"Million US$, purchasing power parity",882.9 +29118,Portugal,2014,8,N02-Analgesics,"/capita, US$ purchasing power parity",20.2 +29119,Portugal,2014,8,N02-Analgesics,"/capita, US$ exchange rate",15.5 +29120,Portugal,2014,8,N05B-Anxiolytics,Million US$ at exchange rate,72.8 +29121,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,98.3 +29122,Portugal,2014,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,86.1 +29123,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9 +29124,Portugal,2014,8,N05B-Anxiolytics,Million of national currency units,54.8 +29125,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +29126,Portugal,2014,8,J-Antiinfectives for systemic use,Million of national currency units,119.0 +29127,Portugal,2014,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.5 +29128,Portugal,2014,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",39.7 +29129,Portugal,2014,8,A10-Drugs used in diabetes,% of total sales,10.0 +29130,Portugal,2014,8,N-Nervous system,Million of national currency units,511.1 +29131,Portugal,2014,8,N-Nervous system,Million US$ at exchange rate,678.9 +29132,Portugal,2014,8,N02-Analgesics,Million of national currency units,121.6 +29133,Portugal,2014,8,N02-Analgesics,Million US$ at exchange rate,161.5 +29134,Portugal,2014,8,N02-Analgesics,"Million US$, purchasing power parity",210.0 +29135,Portugal,2014,8,N-Nervous system,"/capita, US$ exchange rate",65.3 +29136,Portugal,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",84.9 +29137,Portugal,2014,8,N-Nervous system,% of total sales,21.3 +29138,Portugal,2014,8,J01-Antibacterials for systemic use,% of total sales,2.7 +29139,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0 +29140,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",108.4 +29141,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1 +29142,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.3 +29143,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6 +29144,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,130.6 +29145,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",169.9 +29146,Portugal,2014,8,N05B-Anxiolytics,% of total sales,2.3 +29147,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4 +29148,Portugal,2014,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.1 +29149,Portugal,2014,8,N05B-Anxiolytics,"Million US$, purchasing power parity",94.6 +29150,Portugal,2014,8,N05B-Anxiolytics,"/capita, US$ exchange rate",7.0 +29151,Portugal,2014,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.8 +29152,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.6 +29153,Portugal,2014,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",112.0 +29154,Portugal,2014,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.3 +29155,Portugal,2014,8,N05C-Hypnotics and sedatives,% of total sales,0.9 +29156,Portugal,2014,8,M-Musculo-skeletal system,Million of national currency units,172.5 +29157,Portugal,2014,8,A10-Drugs used in diabetes,Million US$ at exchange rate,317.3 +29158,Portugal,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,158.1 +29159,Portugal,2014,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",36.7 +29160,Portugal,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,229.1 +29161,Portugal,2014,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,28.3 +29162,Portugal,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.5 +29163,Portugal,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.7 +29164,Portugal,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",205.6 +29165,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.7 +29166,Portugal,2014,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",412.6 +29167,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,83.3 +29168,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.7 +29169,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6 +29170,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",37.1 +29171,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,21.5 +29172,Portugal,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.2 +29173,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,28.6 +29174,Portugal,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.6 +29175,Portugal,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.0 +29176,Portugal,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.8 +29177,Portugal,2014,8,J-Antiinfectives for systemic use,% of total sales,5.0 +29178,Portugal,2014,8,M-Musculo-skeletal system,% of total sales,7.2 +29179,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.5 +29180,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.1 +29181,Portugal,2014,8,A10-Drugs used in diabetes,Million of national currency units,238.9 +29182,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,84.1 +29183,Portugal,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",298.0 +29184,Portugal,2014,8,N05C-Hypnotics and sedatives,Million of national currency units,21.3 +29185,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.3 +29186,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",109.3 +29187,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",38.5 +29188,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.2 +29189,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,24.6 +29190,Slovenia,2016,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7 +29191,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.9 +29192,Slovenia,2016,7,C-Cardiovascular system,Million US$ at exchange rate,83.7 +29193,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.6 +29194,Slovenia,2016,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.6 +29195,Slovenia,2016,7,N02-Analgesics,% of total sales,4.0 +29196,Slovenia,2016,7,N02-Analgesics,"Million US$, purchasing power parity",32.2 +29197,Slovenia,2016,7,N02-Analgesics,"/capita, US$ exchange rate",10.0 +29198,Slovenia,2016,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.5 +29199,Slovenia,2016,7,C08-Calcium channel blockers,% of total sales,1.3 +29200,Slovenia,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",130.9 +29201,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +29202,Slovenia,2016,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.7 +29203,Slovenia,2016,7,R-Respiratory system,Million US$ at exchange rate,30.1 +29204,Slovenia,2016,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.6 +29205,Slovenia,2016,7,R-Respiratory system,"/capita, US$ exchange rate",14.6 +29206,Slovenia,2016,7,R-Respiratory system,"Million US$, purchasing power parity",47.1 +29207,Slovenia,2016,7,R-Respiratory system,Million of national currency units,27.2 +29208,Slovenia,2016,7,C02-Antihypertensives,Million US$ at exchange rate,3.5 +29209,Slovenia,2016,7,C08-Calcium channel blockers,Million of national currency units,6.0 +29210,Slovenia,2016,7,C02-Antihypertensives,Million of national currency units,3.2 +29211,Slovenia,2016,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0 +29212,Slovenia,2016,7,C-Cardiovascular system,Million of national currency units,75.6 +29213,Slovenia,2016,7,J01-Antibacterials for systemic use,% of total sales,2.4 +29214,Slovenia,2016,7,R-Respiratory system,% of total sales,5.8 +29215,Slovenia,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.8 +29216,Slovenia,2016,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2 +29217,Slovenia,2016,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.3 +29218,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10.8 +29219,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.9 +29220,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.0 +29221,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3 +29222,Slovenia,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.6 +29223,Slovenia,2016,7,B-Blood and blood forming organs,% of total sales,8.6 +29224,Slovenia,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",69.3 +29225,Slovenia,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4 +29226,Slovenia,2016,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.5 +29227,Slovenia,2016,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4 +29228,Slovenia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4 +29229,Slovenia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0 +29230,Slovenia,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,44.3 +29231,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.8 +29232,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",18.7 +29233,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",48.8 +29234,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,31.2 +29235,Slovenia,2016,7,A-Alimentary tract and metabolism,% of total sales,12.0 +29236,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.1 +29237,Slovenia,2016,7,N02-Analgesics,Million of national currency units,18.6 +29238,Slovenia,2016,7,N02-Analgesics,Million US$ at exchange rate,20.6 +29239,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28.2 +29240,Slovenia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1 +29241,Slovenia,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",40.5 +29242,Slovenia,2016,7,A-Alimentary tract and metabolism,Million of national currency units,56.1 +29243,Slovenia,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,62.1 +29244,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0 +29245,Slovenia,2016,7,J01-Antibacterials for systemic use,Million of national currency units,11.2 +29246,Slovenia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.1 +29247,Slovenia,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",97.3 +29248,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.6 +29249,Slovenia,2016,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +29250,Slovenia,2016,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7 +29251,Slovenia,2016,7,N05B-Anxiolytics,% of total sales,0.6 +29252,Slovenia,2016,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +29253,Slovenia,2016,7,N06A-Antidepressants,Million of national currency units,11.2 +29254,Slovenia,2016,7,N06A-Antidepressants,Million US$ at exchange rate,12.4 +29255,Slovenia,2016,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0 +29256,Slovenia,2016,7,N05B-Anxiolytics,Million of national currency units,2.7 +29257,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.5 +29258,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.3 +29259,Slovenia,2016,7,N-Nervous system,"/capita, US$ exchange rate",34.9 +29260,Slovenia,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",54.7 +29261,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +29262,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.6 +29263,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.0 +29264,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0 +29265,Slovenia,2016,7,A02A-Antacids,Million of national currency units,0.7 +29266,Slovenia,2016,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +29267,Slovenia,2016,7,A02A-Antacids,Million US$ at exchange rate,0.8 +29268,Slovenia,2016,7,A02A-Antacids,"Million US$, purchasing power parity",1.3 +29269,Slovenia,2016,7,C10-Lipid modifying agents,% of total sales,3.0 +29270,Slovenia,2016,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8 +29271,Slovenia,2016,7,C01A-Cardiac glycosides,% of total sales,0.1 +29272,Slovenia,2016,7,Total pharmaceutical sales,Million of national currency units,466.7 +29273,Slovenia,2016,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.4 +29274,Slovenia,2016,7,N06A-Antidepressants,% of total sales,2.4 +29275,Slovenia,2016,7,N06A-Antidepressants,"Million US$, purchasing power parity",19.4 +29276,Slovenia,2016,7,N06A-Antidepressants,"/capita, US$ exchange rate",6.0 +29277,Slovenia,2016,7,A02A-Antacids,"/capita, US$ exchange rate",0.4 +29278,Slovenia,2016,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +29279,Slovenia,2016,7,A02A-Antacids,% of total sales,0.2 +29280,Slovenia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0 +29281,Slovenia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +29282,Slovenia,2016,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1 +29283,Slovenia,2016,7,N05C-Hypnotics and sedatives,% of total sales,0.5 +29284,Slovenia,2016,7,C03-Diuretics,Million US$ at exchange rate,7.0 +29285,Slovenia,2016,7,C03-Diuretics,"Million US$, purchasing power parity",11.0 +29286,Slovenia,2016,7,C03-Diuretics,Million of national currency units,6.4 +29287,Slovenia,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4 +29288,Slovenia,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",27.0 +29289,Slovenia,2016,7,M-Musculo-skeletal system,% of total sales,3.3 +29290,Slovenia,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.1 +29291,Slovenia,2016,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.6 +29292,Slovenia,2016,7,N05C-Hypnotics and sedatives,Million of national currency units,2.4 +29293,Slovenia,2016,7,M-Musculo-skeletal system,Million of national currency units,15.6 +29294,Slovenia,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,17.3 +29295,Slovenia,2016,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +29296,Slovenia,2016,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +29297,Slovenia,2016,7,C03-Diuretics,% of total sales,1.4 +29298,Slovenia,2016,7,C01A-Cardiac glycosides,Million of national currency units,0.3 +29299,Slovenia,2016,7,N-Nervous system,Million US$ at exchange rate,72.1 +29300,Slovenia,2016,7,N-Nervous system,"Million US$, purchasing power parity",112.9 +29301,Slovenia,2016,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +29302,Slovenia,2016,7,N-Nervous system,Million of national currency units,65.1 +29303,Slovenia,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,23.5 +29304,Slovenia,2016,7,G-Genito urinary system and sex hormones,% of total sales,5.0 +29305,Slovenia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.7 +29306,Slovenia,2016,7,C03-Diuretics,"/capita, US$ exchange rate",3.4 +29307,Slovenia,2016,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3 +29308,Slovenia,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,26.0 +29309,Slovenia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.6 +29310,Slovenia,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.7 +29311,Slovenia,2016,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.4 +29312,Slovenia,2016,7,C07-Beta blocking agents,% of total sales,2.2 +29313,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.5 +29314,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.9 +29315,Slovenia,2016,7,A10-Drugs used in diabetes,Million of national currency units,30.4 +29316,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.6 +29317,Slovenia,2016,7,C07-Beta blocking agents,Million US$ at exchange rate,11.1 +29318,Slovenia,2016,7,C07-Beta blocking agents,Million of national currency units,10.1 +29319,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.7 +29320,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.6 +29321,Slovenia,2016,7,C07-Beta blocking agents,"Million US$, purchasing power parity",17.4 +29322,Slovenia,2016,7,A10-Drugs used in diabetes,Million US$ at exchange rate,33.6 +29323,Slovenia,2016,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4 +29324,Slovenia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.8 +29325,Slovenia,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.7 +29326,Slovenia,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",51.1 +29327,Slovenia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.8 +29328,Slovenia,2016,7,A10-Drugs used in diabetes,% of total sales,6.5 +29329,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +29330,Slovenia,2016,7,J-Antiinfectives for systemic use,% of total sales,6.3 +29331,Slovenia,2016,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.3 +29332,Slovenia,2016,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.5 +29333,Slovenia,2016,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",52.6 +29334,Slovenia,2016,7,J-Antiinfectives for systemic use,Million of national currency units,29.5 +29335,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.2 +29336,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.6 +29337,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.3 +29338,Slovenia,2016,7,C-Cardiovascular system,% of total sales,16.2 +29339,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +29340,Slovenia,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.4 +29341,Slovenia,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",808.7 +29342,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +29343,Slovenia,2016,7,C10-Lipid modifying agents,Million US$ at exchange rate,15.6 +29344,Slovenia,2016,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.5 +29345,Slovenia,2016,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",24.4 +29346,Slovenia,2016,7,B-Blood and blood forming organs,Million of national currency units,40.0 +29347,Slovenia,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,516.6 +29348,Slovenia,2016,7,C10-Lipid modifying agents,Million of national currency units,14.1 +29349,Slovenia,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",250.2 +29350,Slovenia,2016,7,N-Nervous system,% of total sales,14.0 +29351,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3 +29352,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7 +29353,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.9 +29354,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1 +29355,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +29356,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +29357,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +29358,Slovenia,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",391.6 +29359,Slovenia,2016,7,C02-Antihypertensives,% of total sales,0.7 +29360,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",35.8 +29361,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,Million of national currency units,21.3 +29362,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,23.6 +29363,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +29364,Slovenia,2015,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8 +29365,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.5 +29366,Slovenia,2015,7,C-Cardiovascular system,Million US$ at exchange rate,85.5 +29367,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.3 +29368,Slovenia,2015,7,C-Cardiovascular system,"Million US$, purchasing power parity",129.4 +29369,Slovenia,2015,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.0 +29370,Slovenia,2015,7,N02-Analgesics,% of total sales,4.1 +29371,Slovenia,2015,7,N02-Analgesics,"Million US$, purchasing power parity",30.9 +29372,Slovenia,2015,7,N02-Analgesics,"/capita, US$ exchange rate",9.9 +29373,Slovenia,2015,7,C08-Calcium channel blockers,% of total sales,1.4 +29374,Slovenia,2015,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.8 +29375,Slovenia,2015,7,R-Respiratory system,Million US$ at exchange rate,29.3 +29376,Slovenia,2015,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.8 +29377,Slovenia,2015,7,R-Respiratory system,"/capita, US$ exchange rate",14.2 +29378,Slovenia,2015,7,R-Respiratory system,"Million US$, purchasing power parity",44.4 +29379,Slovenia,2015,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.7 +29380,Slovenia,2015,7,C02-Antihypertensives,Million US$ at exchange rate,3.8 +29381,Slovenia,2015,7,C08-Calcium channel blockers,Million of national currency units,6.2 +29382,Slovenia,2015,7,C-Cardiovascular system,Million of national currency units,77.0 +29383,Slovenia,2015,7,C02-Antihypertensives,Million of national currency units,3.4 +29384,Slovenia,2015,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0 +29385,Slovenia,2015,7,R-Respiratory system,Million of national currency units,26.4 +29386,Slovenia,2015,7,J01-Antibacterials for systemic use,% of total sales,2.6 +29387,Slovenia,2015,7,R-Respiratory system,% of total sales,5.9 +29388,Slovenia,2015,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.5 +29389,Slovenia,2015,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.3 +29390,Slovenia,2015,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.3 +29391,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.0 +29392,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.9 +29393,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1 +29394,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +29395,Slovenia,2015,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.5 +29396,Slovenia,2015,7,B-Blood and blood forming organs,% of total sales,7.8 +29397,Slovenia,2015,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.8 +29398,Slovenia,2015,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.8 +29399,Slovenia,2015,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2 +29400,Slovenia,2015,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.1 +29401,Slovenia,2015,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3 +29402,Slovenia,2015,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.6 +29403,Slovenia,2015,7,B-Blood and blood forming organs,Million US$ at exchange rate,38.8 +29404,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.3 +29405,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",16.7 +29406,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",50.4 +29407,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,33.3 +29408,Slovenia,2015,7,A-Alimentary tract and metabolism,% of total sales,11.8 +29409,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",16.1 +29410,Slovenia,2015,7,N02-Analgesics,Million of national currency units,18.4 +29411,Slovenia,2015,7,N02-Analgesics,Million US$ at exchange rate,20.4 +29412,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,30.0 +29413,Slovenia,2015,7,C-Cardiovascular system,"/capita, US$ exchange rate",41.4 +29414,Slovenia,2015,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0 +29415,Slovenia,2015,7,A-Alimentary tract and metabolism,Million of national currency units,52.8 +29416,Slovenia,2015,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,58.5 +29417,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.7 +29418,Slovenia,2015,7,J01-Antibacterials for systemic use,Million of national currency units,11.4 +29419,Slovenia,2015,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4 +29420,Slovenia,2015,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",88.6 +29421,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.4 +29422,Slovenia,2015,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5 +29423,Slovenia,2015,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.6 +29424,Slovenia,2015,7,N05B-Anxiolytics,% of total sales,0.6 +29425,Slovenia,2015,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +29426,Slovenia,2015,7,N06A-Antidepressants,Million of national currency units,11.7 +29427,Slovenia,2015,7,N06A-Antidepressants,Million US$ at exchange rate,13.0 +29428,Slovenia,2015,7,N05B-Anxiolytics,Million of national currency units,2.7 +29429,Slovenia,2015,7,N05B-Anxiolytics,Million US$ at exchange rate,3.1 +29430,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.7 +29431,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5 +29432,Slovenia,2015,7,N-Nervous system,"/capita, US$ exchange rate",35.4 +29433,Slovenia,2015,7,N-Nervous system,"/capita, US$ purchasing power parity",53.7 +29434,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +29435,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.7 +29436,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.9 +29437,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1 +29438,Slovenia,2015,7,A02A-Antacids,Million of national currency units,0.7 +29439,Slovenia,2015,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +29440,Slovenia,2015,7,A02A-Antacids,"Million US$, purchasing power parity",1.1 +29441,Slovenia,2015,7,A02A-Antacids,Million US$ at exchange rate,0.7 +29442,Slovenia,2015,7,C10-Lipid modifying agents,% of total sales,3.1 +29443,Slovenia,2015,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.4 +29444,Slovenia,2015,7,C01A-Cardiac glycosides,% of total sales,0.1 +29445,Slovenia,2015,7,Total pharmaceutical sales,Million of national currency units,446.0 +29446,Slovenia,2015,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.5 +29447,Slovenia,2015,7,N06A-Antidepressants,% of total sales,2.6 +29448,Slovenia,2015,7,N06A-Antidepressants,"Million US$, purchasing power parity",19.6 +29449,Slovenia,2015,7,N06A-Antidepressants,"/capita, US$ exchange rate",6.3 +29450,Slovenia,2015,7,A02A-Antacids,"/capita, US$ exchange rate",0.4 +29451,Slovenia,2015,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +29452,Slovenia,2015,7,A02A-Antacids,% of total sales,0.1 +29453,Slovenia,2015,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0 +29454,Slovenia,2015,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1 +29455,Slovenia,2015,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +29456,Slovenia,2015,7,C03-Diuretics,"Million US$, purchasing power parity",10.5 +29457,Slovenia,2015,7,C03-Diuretics,Million US$ at exchange rate,7.0 +29458,Slovenia,2015,7,N05C-Hypnotics and sedatives,% of total sales,0.6 +29459,Slovenia,2015,7,C03-Diuretics,Million of national currency units,6.3 +29460,Slovenia,2015,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.7 +29461,Slovenia,2015,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4 +29462,Slovenia,2015,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",26.3 +29463,Slovenia,2015,7,M-Musculo-skeletal system,% of total sales,3.5 +29464,Slovenia,2015,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.8 +29465,Slovenia,2015,7,N05C-Hypnotics and sedatives,Million of national currency units,2.5 +29466,Slovenia,2015,7,M-Musculo-skeletal system,Million US$ at exchange rate,17.4 +29467,Slovenia,2015,7,M-Musculo-skeletal system,Million of national currency units,15.7 +29468,Slovenia,2015,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3 +29469,Slovenia,2015,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +29470,Slovenia,2015,7,C03-Diuretics,% of total sales,1.4 +29471,Slovenia,2015,7,C01A-Cardiac glycosides,Million of national currency units,0.3 +29472,Slovenia,2015,7,N-Nervous system,Million US$ at exchange rate,73.2 +29473,Slovenia,2015,7,N-Nervous system,"Million US$, purchasing power parity",110.8 +29474,Slovenia,2015,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +29475,Slovenia,2015,7,N-Nervous system,Million of national currency units,65.9 +29476,Slovenia,2015,7,G-Genito urinary system and sex hormones,Million of national currency units,22.6 +29477,Slovenia,2015,7,G-Genito urinary system and sex hormones,% of total sales,5.1 +29478,Slovenia,2015,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.4 +29479,Slovenia,2015,7,C03-Diuretics,"/capita, US$ exchange rate",3.4 +29480,Slovenia,2015,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.1 +29481,Slovenia,2015,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,25.1 +29482,Slovenia,2015,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",38.0 +29483,Slovenia,2015,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.2 +29484,Slovenia,2015,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7 +29485,Slovenia,2015,7,C07-Beta blocking agents,% of total sales,2.1 +29486,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.9 +29487,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",15.0 +29488,Slovenia,2015,7,A10-Drugs used in diabetes,Million of national currency units,28.8 +29489,Slovenia,2015,7,A10-Drugs used in diabetes,Million US$ at exchange rate,32.0 +29490,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.7 +29491,Slovenia,2015,7,C07-Beta blocking agents,Million US$ at exchange rate,10.5 +29492,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.9 +29493,Slovenia,2015,7,C07-Beta blocking agents,Million of national currency units,9.5 +29494,Slovenia,2015,7,C07-Beta blocking agents,"Million US$, purchasing power parity",15.9 +29495,Slovenia,2015,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.1 +29496,Slovenia,2015,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3 +29497,Slovenia,2015,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",44.7 +29498,Slovenia,2015,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.6 +29499,Slovenia,2015,7,A10-Drugs used in diabetes,% of total sales,6.5 +29500,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +29501,Slovenia,2015,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,29.5 +29502,Slovenia,2015,7,J-Antiinfectives for systemic use,% of total sales,6.0 +29503,Slovenia,2015,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.5 +29504,Slovenia,2015,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.5 +29505,Slovenia,2015,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",48.4 +29506,Slovenia,2015,7,J-Antiinfectives for systemic use,Million of national currency units,26.6 +29507,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.3 +29508,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.8 +29509,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.9 +29510,Slovenia,2015,7,C-Cardiovascular system,% of total sales,17.3 +29511,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +29512,Slovenia,2015,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",62.7 +29513,Slovenia,2015,7,Total pharmaceutical sales,"Million US$, purchasing power parity",749.3 +29514,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +29515,Slovenia,2015,7,C10-Lipid modifying agents,Million US$ at exchange rate,15.5 +29516,Slovenia,2015,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",23.5 +29517,Slovenia,2015,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.5 +29518,Slovenia,2015,7,B-Blood and blood forming organs,Million of national currency units,35.0 +29519,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.0 +29520,Slovenia,2015,7,C10-Lipid modifying agents,Million of national currency units,14.0 +29521,Slovenia,2015,7,Total pharmaceutical sales,Million US$ at exchange rate,494.9 +29522,Slovenia,2015,7,Total pharmaceutical sales,"/capita, US$ exchange rate",239.8 +29523,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4 +29524,Slovenia,2015,7,N-Nervous system,% of total sales,14.8 +29525,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7 +29526,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.7 +29527,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.2 +29528,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +29529,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +29530,Slovenia,2015,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",363.1 +29531,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +29532,Slovenia,2015,7,C02-Antihypertensives,% of total sales,0.8 +29533,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.1 +29534,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,Million of national currency units,21.3 +29535,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,28.3 +29536,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7 +29537,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +29538,Slovenia,2014,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.3 +29539,Slovenia,2014,7,C-Cardiovascular system,Million US$ at exchange rate,107.8 +29540,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.5 +29541,Slovenia,2014,7,N02-Analgesics,"/capita, US$ purchasing power parity",14.6 +29542,Slovenia,2014,7,N02-Analgesics,% of total sales,4.1 +29543,Slovenia,2014,7,N02-Analgesics,"Million US$, purchasing power parity",30.1 +29544,Slovenia,2014,7,N02-Analgesics,"/capita, US$ exchange rate",11.5 +29545,Slovenia,2014,7,C08-Calcium channel blockers,% of total sales,1.5 +29546,Slovenia,2014,7,C-Cardiovascular system,"Million US$, purchasing power parity",137.3 +29547,Slovenia,2014,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +29548,Slovenia,2014,7,R-Respiratory system,Million US$ at exchange rate,35.4 +29549,Slovenia,2014,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.8 +29550,Slovenia,2014,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.5 +29551,Slovenia,2014,7,R-Respiratory system,"/capita, US$ exchange rate",17.2 +29552,Slovenia,2014,7,R-Respiratory system,"Million US$, purchasing power parity",45.1 +29553,Slovenia,2014,7,C02-Antihypertensives,"Million US$, purchasing power parity",6.8 +29554,Slovenia,2014,7,C08-Calcium channel blockers,Million of national currency units,6.4 +29555,Slovenia,2014,7,C02-Antihypertensives,Million US$ at exchange rate,5.3 +29556,Slovenia,2014,7,C-Cardiovascular system,Million of national currency units,81.2 +29557,Slovenia,2014,7,C02-Antihypertensives,Million of national currency units,4.0 +29558,Slovenia,2014,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.2 +29559,Slovenia,2014,7,J01-Antibacterials for systemic use,% of total sales,2.6 +29560,Slovenia,2014,7,R-Respiratory system,% of total sales,6.2 +29561,Slovenia,2014,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.9 +29562,Slovenia,2014,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1 +29563,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.3 +29564,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.3 +29565,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6 +29566,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +29567,Slovenia,2014,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.6 +29568,Slovenia,2014,7,B-Blood and blood forming organs,% of total sales,7.2 +29569,Slovenia,2014,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",52.9 +29570,Slovenia,2014,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1 +29571,Slovenia,2014,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.9 +29572,Slovenia,2014,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +29573,Slovenia,2014,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2 +29574,Slovenia,2014,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.8 +29575,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.7 +29576,Slovenia,2014,7,B-Blood and blood forming organs,Million US$ at exchange rate,41.5 +29577,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0 +29578,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",57.1 +29579,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.8 +29580,Slovenia,2014,7,A-Alimentary tract and metabolism,% of total sales,11.6 +29581,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,44.9 +29582,Slovenia,2014,7,N02-Analgesics,Million of national currency units,17.8 +29583,Slovenia,2014,7,N02-Analgesics,Million US$ at exchange rate,23.6 +29584,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,33.8 +29585,Slovenia,2014,7,C-Cardiovascular system,"/capita, US$ exchange rate",52.3 +29586,Slovenia,2014,7,A-Alimentary tract and metabolism,Million of national currency units,50.1 +29587,Slovenia,2014,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.6 +29588,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8 +29589,Slovenia,2014,7,J01-Antibacterials for systemic use,Million of national currency units,11.2 +29590,Slovenia,2014,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.3 +29591,Slovenia,2014,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",84.8 +29592,Slovenia,2014,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.1 +29593,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7 +29594,Slovenia,2014,7,R-Respiratory system,Million of national currency units,26.6 +29595,Slovenia,2014,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.8 +29596,Slovenia,2014,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8 +29597,Slovenia,2014,7,N05B-Anxiolytics,% of total sales,0.7 +29598,Slovenia,2014,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +29599,Slovenia,2014,7,N06A-Antidepressants,Million of national currency units,13.5 +29600,Slovenia,2014,7,N06A-Antidepressants,Million US$ at exchange rate,17.9 +29601,Slovenia,2014,7,N05B-Anxiolytics,Million US$ at exchange rate,3.7 +29602,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,8.1 +29603,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.8 +29604,Slovenia,2014,7,N-Nervous system,"/capita, US$ exchange rate",44.9 +29605,Slovenia,2014,7,N-Nervous system,"/capita, US$ purchasing power parity",57.1 +29606,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.7 +29607,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.9 +29608,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.7 +29609,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.2 +29610,Slovenia,2014,7,A02A-Antacids,Million of national currency units,0.6 +29611,Slovenia,2014,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +29612,Slovenia,2014,7,A02A-Antacids,"Million US$, purchasing power parity",1.0 +29613,Slovenia,2014,7,A02A-Antacids,Million US$ at exchange rate,0.8 +29614,Slovenia,2014,7,C10-Lipid modifying agents,% of total sales,3.3 +29615,Slovenia,2014,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8 +29616,Slovenia,2014,7,C01A-Cardiac glycosides,% of total sales,0.1 +29617,Slovenia,2014,7,Total pharmaceutical sales,Million of national currency units,432.3 +29618,Slovenia,2014,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1 +29619,Slovenia,2014,7,N06A-Antidepressants,% of total sales,3.1 +29620,Slovenia,2014,7,N06A-Antidepressants,"Million US$, purchasing power parity",22.8 +29621,Slovenia,2014,7,N06A-Antidepressants,"/capita, US$ exchange rate",8.7 +29622,Slovenia,2014,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +29623,Slovenia,2014,7,A02A-Antacids,"/capita, US$ exchange rate",0.4 +29624,Slovenia,2014,7,N05B-Anxiolytics,Million of national currency units,2.8 +29625,Slovenia,2014,7,A02A-Antacids,% of total sales,0.1 +29626,Slovenia,2014,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0 +29627,Slovenia,2014,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +29628,Slovenia,2014,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1 +29629,Slovenia,2014,7,N05C-Hypnotics and sedatives,% of total sales,0.6 +29630,Slovenia,2014,7,C03-Diuretics,"Million US$, purchasing power parity",10.3 +29631,Slovenia,2014,7,C03-Diuretics,Million US$ at exchange rate,8.1 +29632,Slovenia,2014,7,C03-Diuretics,Million of national currency units,6.1 +29633,Slovenia,2014,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.1 +29634,Slovenia,2014,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9 +29635,Slovenia,2014,7,M-Musculo-skeletal system,% of total sales,3.6 +29636,Slovenia,2014,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",26.6 +29637,Slovenia,2014,7,N05C-Hypnotics and sedatives,Million of national currency units,2.4 +29638,Slovenia,2014,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2 +29639,Slovenia,2014,7,M-Musculo-skeletal system,Million of national currency units,15.7 +29640,Slovenia,2014,7,M-Musculo-skeletal system,Million US$ at exchange rate,20.9 +29641,Slovenia,2014,7,C03-Diuretics,"/capita, US$ exchange rate",3.9 +29642,Slovenia,2014,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +29643,Slovenia,2014,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +29644,Slovenia,2014,7,C01A-Cardiac glycosides,Million of national currency units,0.3 +29645,Slovenia,2014,7,N-Nervous system,Million US$ at exchange rate,92.5 +29646,Slovenia,2014,7,N-Nervous system,"Million US$, purchasing power parity",117.8 +29647,Slovenia,2014,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +29648,Slovenia,2014,7,N-Nervous system,Million of national currency units,69.6 +29649,Slovenia,2014,7,G-Genito urinary system and sex hormones,Million of national currency units,23.8 +29650,Slovenia,2014,7,C03-Diuretics,% of total sales,1.4 +29651,Slovenia,2014,7,G-Genito urinary system and sex hormones,% of total sales,5.5 +29652,Slovenia,2014,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.0 +29653,Slovenia,2014,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5 +29654,Slovenia,2014,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.6 +29655,Slovenia,2014,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.2 +29656,Slovenia,2014,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.3 +29657,Slovenia,2014,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.3 +29658,Slovenia,2014,7,C07-Beta blocking agents,% of total sales,2.1 +29659,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.5 +29660,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.4 +29661,Slovenia,2014,7,A10-Drugs used in diabetes,Million of national currency units,28.3 +29662,Slovenia,2014,7,A10-Drugs used in diabetes,Million US$ at exchange rate,37.6 +29663,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,14.5 +29664,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.9 +29665,Slovenia,2014,7,C07-Beta blocking agents,Million US$ at exchange rate,11.9 +29666,Slovenia,2014,7,C07-Beta blocking agents,Million of national currency units,8.9 +29667,Slovenia,2014,7,C07-Beta blocking agents,"Million US$, purchasing power parity",15.1 +29668,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.5 +29669,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +29670,Slovenia,2014,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.8 +29671,Slovenia,2014,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.8 +29672,Slovenia,2014,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.3 +29673,Slovenia,2014,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",33.6 +29674,Slovenia,2014,7,A10-Drugs used in diabetes,% of total sales,6.5 +29675,Slovenia,2014,7,J-Antiinfectives for systemic use,% of total sales,4.6 +29676,Slovenia,2014,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,26.4 +29677,Slovenia,2014,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.2 +29678,Slovenia,2014,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.2 +29679,Slovenia,2014,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",47.9 +29680,Slovenia,2014,7,J-Antiinfectives for systemic use,Million of national currency units,19.9 +29681,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.5 +29682,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.0 +29683,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.5 +29684,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +29685,Slovenia,2014,7,C-Cardiovascular system,% of total sales,18.8 +29686,Slovenia,2014,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.6 +29687,Slovenia,2014,7,Total pharmaceutical sales,"Million US$, purchasing power parity",731.2 +29688,Slovenia,2014,7,Total pharmaceutical sales,"/capita, US$ exchange rate",278.5 +29689,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +29690,Slovenia,2014,7,C10-Lipid modifying agents,Million US$ at exchange rate,19.1 +29691,Slovenia,2014,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.3 +29692,Slovenia,2014,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",24.3 +29693,Slovenia,2014,7,B-Blood and blood forming organs,Million of national currency units,31.3 +29694,Slovenia,2014,7,C10-Lipid modifying agents,Million of national currency units,14.4 +29695,Slovenia,2014,7,Total pharmaceutical sales,Million US$ at exchange rate,574.3 +29696,Slovenia,2014,7,N-Nervous system,% of total sales,16.1 +29697,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5 +29698,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.0 +29699,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.9 +29700,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4 +29701,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8 +29702,Slovenia,2014,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",354.6 +29703,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +29704,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +29705,Slovenia,2014,7,C02-Antihypertensives,% of total sales,0.9 +29706,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",37.4 +29707,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.1 +29708,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.3 +29709,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +29710,Slovenia,2013,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.6 +29711,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.2 +29712,Slovenia,2013,7,C-Cardiovascular system,Million US$ at exchange rate,133.7 +29713,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.2 +29714,Slovenia,2013,7,N02-Analgesics,"/capita, US$ purchasing power parity",14.2 +29715,Slovenia,2013,7,N02-Analgesics,% of total sales,3.8 +29716,Slovenia,2013,7,N02-Analgesics,"Million US$, purchasing power parity",29.2 +29717,Slovenia,2013,7,N02-Analgesics,"/capita, US$ exchange rate",11.1 +29718,Slovenia,2013,7,C08-Calcium channel blockers,% of total sales,1.5 +29719,Slovenia,2013,7,C-Cardiovascular system,"Million US$, purchasing power parity",170.5 +29720,Slovenia,2013,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.8 +29721,Slovenia,2013,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",11.2 +29722,Slovenia,2013,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.8 +29723,Slovenia,2013,7,R-Respiratory system,"/capita, US$ exchange rate",17.6 +29724,Slovenia,2013,7,R-Respiratory system,"Million US$, purchasing power parity",46.1 +29725,Slovenia,2013,7,C02-Antihypertensives,"Million US$, purchasing power parity",7.4 +29726,Slovenia,2013,7,R-Respiratory system,Million US$ at exchange rate,36.2 +29727,Slovenia,2013,7,C08-Calcium channel blockers,Million of national currency units,6.6 +29728,Slovenia,2013,7,C02-Antihypertensives,Million US$ at exchange rate,5.8 +29729,Slovenia,2013,7,C-Cardiovascular system,Million of national currency units,100.7 +29730,Slovenia,2013,7,C02-Antihypertensives,Million of national currency units,4.4 +29731,Slovenia,2013,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5 +29732,Slovenia,2013,7,J01-Antibacterials for systemic use,% of total sales,2.6 +29733,Slovenia,2013,7,R-Respiratory system,% of total sales,6.0 +29734,Slovenia,2013,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.4 +29735,Slovenia,2013,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3 +29736,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.7 +29737,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8.8 +29738,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3 +29739,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +29740,Slovenia,2013,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.6 +29741,Slovenia,2013,7,B-Blood and blood forming organs,% of total sales,6.4 +29742,Slovenia,2013,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",48.5 +29743,Slovenia,2013,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.5 +29744,Slovenia,2013,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.6 +29745,Slovenia,2013,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.5 +29746,Slovenia,2013,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5 +29747,Slovenia,2013,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.4 +29748,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.0 +29749,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.7 +29750,Slovenia,2013,7,B-Blood and blood forming organs,Million US$ at exchange rate,38.1 +29751,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",72.0 +29752,Slovenia,2013,7,A-Alimentary tract and metabolism,% of total sales,11.1 +29753,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.4 +29754,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,56.5 +29755,Slovenia,2013,7,N02-Analgesics,Million US$ at exchange rate,22.9 +29756,Slovenia,2013,7,N02-Analgesics,Million of national currency units,17.2 +29757,Slovenia,2013,7,C-Cardiovascular system,"/capita, US$ exchange rate",64.9 +29758,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,42.5 +29759,Slovenia,2013,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.0 +29760,Slovenia,2013,7,A-Alimentary tract and metabolism,Million of national currency units,49.9 +29761,Slovenia,2013,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.3 +29762,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4 +29763,Slovenia,2013,7,J01-Antibacterials for systemic use,Million of national currency units,11.6 +29764,Slovenia,2013,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.2 +29765,Slovenia,2013,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",84.5 +29766,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",35.0 +29767,Slovenia,2013,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9 +29768,Slovenia,2013,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +29769,Slovenia,2013,7,N05B-Anxiolytics,% of total sales,0.7 +29770,Slovenia,2013,7,N05B-Anxiolytics,"Million US$, purchasing power parity",5.0 +29771,Slovenia,2013,7,N06A-Antidepressants,Million of national currency units,14.5 +29772,Slovenia,2013,7,N06A-Antidepressants,Million US$ at exchange rate,19.3 +29773,Slovenia,2013,7,N05B-Anxiolytics,Million US$ at exchange rate,3.9 +29774,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.9 +29775,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,8.2 +29776,Slovenia,2013,7,N-Nervous system,"/capita, US$ exchange rate",46.3 +29777,Slovenia,2013,7,N-Nervous system,"/capita, US$ purchasing power parity",59.1 +29778,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.8 +29779,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.8 +29780,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",14.0 +29781,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.3 +29782,Slovenia,2013,7,A02A-Antacids,Million of national currency units,0.5 +29783,Slovenia,2013,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +29784,Slovenia,2013,7,A02A-Antacids,"Million US$, purchasing power parity",0.9 +29785,Slovenia,2013,7,A02A-Antacids,Million US$ at exchange rate,0.7 +29786,Slovenia,2013,7,C10-Lipid modifying agents,% of total sales,5.5 +29787,Slovenia,2013,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.3 +29788,Slovenia,2013,7,C01A-Cardiac glycosides,% of total sales,0.1 +29789,Slovenia,2013,7,Total pharmaceutical sales,Million of national currency units,451.1 +29790,Slovenia,2013,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9 +29791,Slovenia,2013,7,N06A-Antidepressants,% of total sales,3.2 +29792,Slovenia,2013,7,N06A-Antidepressants,"Million US$, purchasing power parity",24.6 +29793,Slovenia,2013,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.3 +29794,Slovenia,2013,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +29795,Slovenia,2013,7,A02A-Antacids,"/capita, US$ exchange rate",0.4 +29796,Slovenia,2013,7,N05B-Anxiolytics,Million of national currency units,3.0 +29797,Slovenia,2013,7,A02A-Antacids,% of total sales,0.1 +29798,Slovenia,2013,7,R-Respiratory system,Million of national currency units,27.2 +29799,Slovenia,2013,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1 +29800,Slovenia,2013,7,N05C-Hypnotics and sedatives,% of total sales,0.6 +29801,Slovenia,2013,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.3 +29802,Slovenia,2013,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +29803,Slovenia,2013,7,C03-Diuretics,"Million US$, purchasing power parity",10.5 +29804,Slovenia,2013,7,C03-Diuretics,Million of national currency units,6.2 +29805,Slovenia,2013,7,C03-Diuretics,Million US$ at exchange rate,8.2 +29806,Slovenia,2013,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.2 +29807,Slovenia,2013,7,M-Musculo-skeletal system,% of total sales,3.9 +29808,Slovenia,2013,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.3 +29809,Slovenia,2013,7,N05C-Hypnotics and sedatives,Million of national currency units,2.5 +29810,Slovenia,2013,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +29811,Slovenia,2013,7,M-Musculo-skeletal system,Million of national currency units,17.4 +29812,Slovenia,2013,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",29.4 +29813,Slovenia,2013,7,M-Musculo-skeletal system,Million US$ at exchange rate,23.1 +29814,Slovenia,2013,7,C03-Diuretics,"/capita, US$ exchange rate",4.0 +29815,Slovenia,2013,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +29816,Slovenia,2013,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +29817,Slovenia,2013,7,C01A-Cardiac glycosides,Million of national currency units,0.3 +29818,Slovenia,2013,7,G-Genito urinary system and sex hormones,Million of national currency units,23.5 +29819,Slovenia,2013,7,N-Nervous system,Million US$ at exchange rate,95.5 +29820,Slovenia,2013,7,N-Nervous system,"Million US$, purchasing power parity",121.8 +29821,Slovenia,2013,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +29822,Slovenia,2013,7,N-Nervous system,Million of national currency units,71.9 +29823,Slovenia,2013,7,G-Genito urinary system and sex hormones,% of total sales,5.2 +29824,Slovenia,2013,7,C03-Diuretics,% of total sales,1.4 +29825,Slovenia,2013,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.1 +29826,Slovenia,2013,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3 +29827,Slovenia,2013,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.1 +29828,Slovenia,2013,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",39.7 +29829,Slovenia,2013,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.1 +29830,Slovenia,2013,7,C07-Beta blocking agents,% of total sales,1.9 +29831,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.9 +29832,Slovenia,2013,7,A10-Drugs used in diabetes,Million of national currency units,28.0 +29833,Slovenia,2013,7,A10-Drugs used in diabetes,Million US$ at exchange rate,37.1 +29834,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,15.5 +29835,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,11.7 +29836,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.9 +29837,Slovenia,2013,7,C07-Beta blocking agents,Million US$ at exchange rate,11.6 +29838,Slovenia,2013,7,C07-Beta blocking agents,Million of national currency units,8.7 +29839,Slovenia,2013,7,C07-Beta blocking agents,"Million US$, purchasing power parity",14.7 +29840,Slovenia,2013,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2 +29841,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.2 +29842,Slovenia,2013,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6 +29843,Slovenia,2013,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",13.7 +29844,Slovenia,2013,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.5 +29845,Slovenia,2013,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",36.0 +29846,Slovenia,2013,7,A10-Drugs used in diabetes,% of total sales,6.2 +29847,Slovenia,2013,7,J-Antiinfectives for systemic use,% of total sales,4.7 +29848,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",19.8 +29849,Slovenia,2013,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.0 +29850,Slovenia,2013,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0 +29851,Slovenia,2013,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",47.4 +29852,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3 +29853,Slovenia,2013,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.2 +29854,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.8 +29855,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +29856,Slovenia,2013,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8 +29857,Slovenia,2013,7,C-Cardiovascular system,% of total sales,22.3 +29858,Slovenia,2013,7,Total pharmaceutical sales,"Million US$, purchasing power parity",764.0 +29859,Slovenia,2013,7,Total pharmaceutical sales,"/capita, US$ exchange rate",290.8 +29860,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +29861,Slovenia,2013,7,C10-Lipid modifying agents,Million US$ at exchange rate,32.8 +29862,Slovenia,2013,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.8 +29863,Slovenia,2013,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.9 +29864,Slovenia,2013,7,B-Blood and blood forming organs,Million of national currency units,28.7 +29865,Slovenia,2013,7,C10-Lipid modifying agents,Million of national currency units,24.7 +29866,Slovenia,2013,7,Total pharmaceutical sales,Million US$ at exchange rate,599.1 +29867,Slovenia,2013,7,N-Nervous system,% of total sales,15.9 +29868,Slovenia,2013,7,J-Antiinfectives for systemic use,Million of national currency units,21.2 +29869,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6 +29870,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.5 +29871,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.6 +29872,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +29873,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8 +29874,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.5 +29875,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +29876,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1 +29877,Slovenia,2013,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.9 +29878,Slovenia,2013,7,C02-Antihypertensives,% of total sales,1.0 +29879,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.3 +29880,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",37.6 +29881,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.3 +29882,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,5.0 +29883,Slovenia,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.5 +29884,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.8 +29885,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.3 +29886,Slovenia,2012,7,C-Cardiovascular system,Million US$ at exchange rate,135.4 +29887,Slovenia,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",12.8 +29888,Slovenia,2012,7,N02-Analgesics,% of total sales,3.5 +29889,Slovenia,2012,7,N02-Analgesics,"/capita, US$ exchange rate",10.0 +29890,Slovenia,2012,7,C08-Calcium channel blockers,% of total sales,1.5 +29891,Slovenia,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",173.6 +29892,Slovenia,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +29893,Slovenia,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",11.0 +29894,Slovenia,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.6 +29895,Slovenia,2012,7,R-Respiratory system,"/capita, US$ exchange rate",17.6 +29896,Slovenia,2012,7,R-Respiratory system,"Million US$, purchasing power parity",46.5 +29897,Slovenia,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",7.1 +29898,Slovenia,2012,7,R-Respiratory system,Million US$ at exchange rate,36.2 +29899,Slovenia,2012,7,C08-Calcium channel blockers,Million of national currency units,6.7 +29900,Slovenia,2012,7,C02-Antihypertensives,Million US$ at exchange rate,5.5 +29901,Slovenia,2012,7,C-Cardiovascular system,Million of national currency units,105.4 +29902,Slovenia,2012,7,C02-Antihypertensives,Million of national currency units,4.3 +29903,Slovenia,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3 +29904,Slovenia,2012,7,J01-Antibacterials for systemic use,% of total sales,2.5 +29905,Slovenia,2012,7,N02-Analgesics,"Million US$, purchasing power parity",26.4 +29906,Slovenia,2012,7,R-Respiratory system,% of total sales,6.2 +29907,Slovenia,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.6 +29908,Slovenia,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2 +29909,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.5 +29910,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8.9 +29911,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.2 +29912,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +29913,Slovenia,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.3 +29914,Slovenia,2012,7,B-Blood and blood forming organs,% of total sales,5.6 +29915,Slovenia,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",41.9 +29916,Slovenia,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.9 +29917,Slovenia,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8 +29918,Slovenia,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1 +29919,Slovenia,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +29920,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.7 +29921,Slovenia,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.7 +29922,Slovenia,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,32.6 +29923,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.6 +29924,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",77.4 +29925,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.3 +29926,Slovenia,2012,7,A-Alimentary tract and metabolism,% of total sales,11.4 +29927,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.3 +29928,Slovenia,2012,7,N02-Analgesics,Million US$ at exchange rate,20.6 +29929,Slovenia,2012,7,N02-Analgesics,Million of national currency units,16.0 +29930,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,47.0 +29931,Slovenia,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",65.8 +29932,Slovenia,2012,7,A-Alimentary tract and metabolism,Million of national currency units,51.8 +29933,Slovenia,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.6 +29934,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,10.3 +29935,Slovenia,2012,7,J01-Antibacterials for systemic use,Million of national currency units,11.4 +29936,Slovenia,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.4 +29937,Slovenia,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.5 +29938,Slovenia,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",85.4 +29939,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",37.6 +29940,Slovenia,2012,7,R-Respiratory system,Million of national currency units,28.2 +29941,Slovenia,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.8 +29942,Slovenia,2012,7,N05B-Anxiolytics,% of total sales,0.6 +29943,Slovenia,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +29944,Slovenia,2012,7,N06A-Antidepressants,Million US$ at exchange rate,18.8 +29945,Slovenia,2012,7,N06A-Antidepressants,Million of national currency units,14.6 +29946,Slovenia,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7 +29947,Slovenia,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,3.7 +29948,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,11.6 +29949,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,9.1 +29950,Slovenia,2012,7,N-Nervous system,"/capita, US$ exchange rate",46.3 +29951,Slovenia,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",59.4 +29952,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",14.9 +29953,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.3 +29954,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,2.0 +29955,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.7 +29956,Slovenia,2012,7,A02A-Antacids,Million of national currency units,0.5 +29957,Slovenia,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +29958,Slovenia,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.8 +29959,Slovenia,2012,7,A02A-Antacids,Million US$ at exchange rate,0.6 +29960,Slovenia,2012,7,C01A-Cardiac glycosides,% of total sales,0.1 +29961,Slovenia,2012,7,C10-Lipid modifying agents,% of total sales,5.6 +29962,Slovenia,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.3 +29963,Slovenia,2012,7,Total pharmaceutical sales,Million of national currency units,454.4 +29964,Slovenia,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.7 +29965,Slovenia,2012,7,N06A-Antidepressants,% of total sales,3.2 +29966,Slovenia,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",24.1 +29967,Slovenia,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.1 +29968,Slovenia,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +29969,Slovenia,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.3 +29970,Slovenia,2012,7,N05B-Anxiolytics,Million of national currency units,2.9 +29971,Slovenia,2012,7,A02A-Antacids,% of total sales,0.1 +29972,Slovenia,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1 +29973,Slovenia,2012,7,N05C-Hypnotics and sedatives,% of total sales,0.6 +29974,Slovenia,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.2 +29975,Slovenia,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6 +29976,Slovenia,2012,7,C03-Diuretics,"Million US$, purchasing power parity",10.0 +29977,Slovenia,2012,7,C03-Diuretics,Million US$ at exchange rate,7.8 +29978,Slovenia,2012,7,C03-Diuretics,Million of national currency units,6.0 +29979,Slovenia,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.6 +29980,Slovenia,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.9 +29981,Slovenia,2012,7,M-Musculo-skeletal system,% of total sales,4.1 +29982,Slovenia,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",30.6 +29983,Slovenia,2012,7,M-Musculo-skeletal system,Million of national currency units,18.6 +29984,Slovenia,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,2.6 +29985,Slovenia,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3 +29986,Slovenia,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,23.9 +29987,Slovenia,2012,7,C03-Diuretics,"/capita, US$ exchange rate",3.8 +29988,Slovenia,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +29989,Slovenia,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +29990,Slovenia,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,24.7 +29991,Slovenia,2012,7,C01A-Cardiac glycosides,Million of national currency units,0.3 +29992,Slovenia,2012,7,N-Nervous system,Million US$ at exchange rate,95.2 +29993,Slovenia,2012,7,N-Nervous system,"Million US$, purchasing power parity",122.2 +29994,Slovenia,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +29995,Slovenia,2012,7,N-Nervous system,Million of national currency units,74.1 +29996,Slovenia,2012,7,G-Genito urinary system and sex hormones,% of total sales,5.4 +29997,Slovenia,2012,7,C03-Diuretics,% of total sales,1.3 +29998,Slovenia,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",4.8 +29999,Slovenia,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.8 +30000,Slovenia,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.7 +30001,Slovenia,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.7 +30002,Slovenia,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.4 +30003,Slovenia,2012,7,C07-Beta blocking agents,% of total sales,1.8 +30004,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",12.9 +30005,Slovenia,2012,7,A10-Drugs used in diabetes,Million of national currency units,28.2 +30006,Slovenia,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,36.2 +30007,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,17.3 +30008,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,13.4 +30009,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.1 +30010,Slovenia,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,10.7 +30011,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",22.1 +30012,Slovenia,2012,7,C07-Beta blocking agents,Million of national currency units,8.3 +30013,Slovenia,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",13.8 +30014,Slovenia,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.7 +30015,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.8 +30016,Slovenia,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2 +30017,Slovenia,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.4 +30018,Slovenia,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.9 +30019,Slovenia,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",32.7 +30020,Slovenia,2012,7,A10-Drugs used in diabetes,% of total sales,6.2 +30021,Slovenia,2012,7,J-Antiinfectives for systemic use,% of total sales,4.4 +30022,Slovenia,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.5 +30023,Slovenia,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.6 +30024,Slovenia,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",46.4 +30025,Slovenia,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.6 +30026,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +30027,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.9 +30028,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.3 +30029,Slovenia,2012,7,C-Cardiovascular system,% of total sales,23.2 +30030,Slovenia,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.4 +30031,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +30032,Slovenia,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",748.8 +30033,Slovenia,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",283.8 +30034,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +30035,Slovenia,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.8 +30036,Slovenia,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,32.6 +30037,Slovenia,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.8 +30038,Slovenia,2012,7,B-Blood and blood forming organs,Million of national currency units,25.4 +30039,Slovenia,2012,7,C10-Lipid modifying agents,Million of national currency units,25.3 +30040,Slovenia,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,583.8 +30041,Slovenia,2012,7,J-Antiinfectives for systemic use,Million of national currency units,19.9 +30042,Slovenia,2012,7,N-Nervous system,% of total sales,16.3 +30043,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.4 +30044,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.8 +30045,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.0 +30046,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4 +30047,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +30048,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.9 +30049,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1 +30050,Slovenia,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",364.0 +30051,Slovenia,2012,7,C02-Antihypertensives,% of total sales,0.9 +30052,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.9 +30053,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.6 +30054,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,32.0 +30055,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,% of total sales,4.9 +30056,Slovenia,2011,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.5 +30057,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.0 +30058,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,Million of national currency units,23.0 +30059,Slovenia,2011,8,N02-Analgesics,"/capita, US$ purchasing power parity",13.0 +30060,Slovenia,2011,8,N02-Analgesics,% of total sales,3.5 +30061,Slovenia,2011,8,N02-Analgesics,"/capita, US$ exchange rate",11.3 +30062,Slovenia,2011,8,C-Cardiovascular system,"Million US$, purchasing power parity",182.1 +30063,Slovenia,2011,8,C08-Calcium channel blockers,% of total sales,1.7 +30064,Slovenia,2011,8,C02-Antihypertensives,"/capita, US$ exchange rate",3.0 +30065,Slovenia,2011,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.1 +30066,Slovenia,2011,8,C08-Calcium channel blockers,Million US$ at exchange rate,11.4 +30067,Slovenia,2011,8,R-Respiratory system,"/capita, US$ exchange rate",19.8 +30068,Slovenia,2011,8,R-Respiratory system,"Million US$, purchasing power parity",46.8 +30069,Slovenia,2011,8,C02-Antihypertensives,"Million US$, purchasing power parity",7.2 +30070,Slovenia,2011,8,R-Respiratory system,Million US$ at exchange rate,40.6 +30071,Slovenia,2011,8,C08-Calcium channel blockers,Million of national currency units,8.2 +30072,Slovenia,2011,8,C02-Antihypertensives,Million US$ at exchange rate,6.2 +30073,Slovenia,2011,8,C-Cardiovascular system,Million of national currency units,113.7 +30074,Slovenia,2011,8,C02-Antihypertensives,Million of national currency units,4.5 +30075,Slovenia,2011,8,C-Cardiovascular system,Million US$ at exchange rate,158.2 +30076,Slovenia,2011,8,J01-Antibacterials for systemic use,% of total sales,2.5 +30077,Slovenia,2011,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4 +30078,Slovenia,2011,8,R-Respiratory system,% of total sales,6.2 +30079,Slovenia,2011,8,R-Respiratory system,"/capita, US$ purchasing power parity",22.8 +30080,Slovenia,2011,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5 +30081,Slovenia,2011,8,N02-Analgesics,"Million US$, purchasing power parity",26.7 +30082,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.8 +30083,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.2 +30084,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.2 +30085,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +30086,Slovenia,2011,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.6 +30087,Slovenia,2011,8,B-Blood and blood forming organs,% of total sales,5.4 +30088,Slovenia,2011,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",40.3 +30089,Slovenia,2011,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.1 +30090,Slovenia,2011,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.0 +30091,Slovenia,2011,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8 +30092,Slovenia,2011,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2 +30093,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.7 +30094,Slovenia,2011,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,16.4 +30095,Slovenia,2011,8,B-Blood and blood forming organs,Million US$ at exchange rate,35.0 +30096,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.2 +30097,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",82.6 +30098,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.0 +30099,Slovenia,2011,8,A-Alimentary tract and metabolism,% of total sales,11.7 +30100,Slovenia,2011,8,N02-Analgesics,Million US$ at exchange rate,23.1 +30101,Slovenia,2011,8,N02-Analgesics,Million of national currency units,16.6 +30102,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,71.8 +30103,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,51.6 +30104,Slovenia,2011,8,C-Cardiovascular system,"/capita, US$ exchange rate",77.1 +30105,Slovenia,2011,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,76.8 +30106,Slovenia,2011,8,A-Alimentary tract and metabolism,Million of national currency units,55.2 +30107,Slovenia,2011,8,J01-Antibacterials for systemic use,Million of national currency units,11.7 +30108,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.0 +30109,Slovenia,2011,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",37.4 +30110,Slovenia,2011,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.1 +30111,Slovenia,2011,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",88.4 +30112,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",40.2 +30113,Slovenia,2011,8,N05B-Anxiolytics,"/capita, US$ exchange rate",2.0 +30114,Slovenia,2011,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +30115,Slovenia,2011,8,N05B-Anxiolytics,% of total sales,0.6 +30116,Slovenia,2011,8,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7 +30117,Slovenia,2011,8,N06A-Antidepressants,Million US$ at exchange rate,22.1 +30118,Slovenia,2011,8,N06A-Antidepressants,Million of national currency units,15.9 +30119,Slovenia,2011,8,N05B-Anxiolytics,Million US$ at exchange rate,4.1 +30120,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,13.7 +30121,Slovenia,2011,8,N-Nervous system,"/capita, US$ exchange rate",54.2 +30122,Slovenia,2011,8,N-Nervous system,"/capita, US$ purchasing power parity",62.4 +30123,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,9.8 +30124,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.1 +30125,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.7 +30126,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",15.7 +30127,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.7 +30128,Slovenia,2011,8,N06A-Antidepressants,"Million US$, purchasing power parity",25.5 +30129,Slovenia,2011,8,A02A-Antacids,Million of national currency units,0.4 +30130,Slovenia,2011,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +30131,Slovenia,2011,8,A02A-Antacids,"Million US$, purchasing power parity",0.7 +30132,Slovenia,2011,8,A02A-Antacids,Million US$ at exchange rate,0.6 +30133,Slovenia,2011,8,C10-Lipid modifying agents,% of total sales,5.9 +30134,Slovenia,2011,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",21.7 +30135,Slovenia,2011,8,C01A-Cardiac glycosides,% of total sales,0.1 +30136,Slovenia,2011,8,Total pharmaceutical sales,Million of national currency units,470.0 +30137,Slovenia,2011,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.4 +30138,Slovenia,2011,8,N06A-Antidepressants,% of total sales,3.4 +30139,Slovenia,2011,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.8 +30140,Slovenia,2011,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.3 +30141,Slovenia,2011,8,A02A-Antacids,"/capita, US$ exchange rate",0.3 +30142,Slovenia,2011,8,N05B-Anxiolytics,Million of national currency units,2.9 +30143,Slovenia,2011,8,A02A-Antacids,% of total sales,0.1 +30144,Slovenia,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1 +30145,Slovenia,2011,8,N05C-Hypnotics and sedatives,% of total sales,0.6 +30146,Slovenia,2011,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.3 +30147,Slovenia,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8 +30148,Slovenia,2011,8,C03-Diuretics,"Million US$, purchasing power parity",9.8 +30149,Slovenia,2011,8,C03-Diuretics,Million of national currency units,6.1 +30150,Slovenia,2011,8,C03-Diuretics,Million US$ at exchange rate,8.5 +30151,Slovenia,2011,8,C03-Diuretics,"/capita, US$ exchange rate",4.1 +30152,Slovenia,2011,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.1 +30153,Slovenia,2011,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1 +30154,Slovenia,2011,8,M-Musculo-skeletal system,% of total sales,4.1 +30155,Slovenia,2011,8,M-Musculo-skeletal system,Million of national currency units,19.3 +30156,Slovenia,2011,8,N05C-Hypnotics and sedatives,Million of national currency units,2.7 +30157,Slovenia,2011,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8 +30158,Slovenia,2011,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.0 +30159,Slovenia,2011,8,M-Musculo-skeletal system,Million US$ at exchange rate,26.9 +30160,Slovenia,2011,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +30161,Slovenia,2011,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +30162,Slovenia,2011,8,G-Genito urinary system and sex hormones,Million of national currency units,26.3 +30163,Slovenia,2011,8,C01A-Cardiac glycosides,Million of national currency units,0.3 +30164,Slovenia,2011,8,N-Nervous system,Million US$ at exchange rate,111.2 +30165,Slovenia,2011,8,N-Nervous system,"Million US$, purchasing power parity",128.1 +30166,Slovenia,2011,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +30167,Slovenia,2011,8,N-Nervous system,Million of national currency units,79.9 +30168,Slovenia,2011,8,G-Genito urinary system and sex hormones,% of total sales,5.6 +30169,Slovenia,2011,8,C03-Diuretics,"/capita, US$ purchasing power parity",4.8 +30170,Slovenia,2011,8,C03-Diuretics,% of total sales,1.3 +30171,Slovenia,2011,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",42.2 +30172,Slovenia,2011,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,36.7 +30173,Slovenia,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6 +30174,Slovenia,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.9 +30175,Slovenia,2011,8,C07-Beta blocking agents,% of total sales,1.7 +30176,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.3 +30177,Slovenia,2011,8,A10-Drugs used in diabetes,Million US$ at exchange rate,37.5 +30178,Slovenia,2011,8,A10-Drugs used in diabetes,Million of national currency units,26.9 +30179,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,17.9 +30180,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,24.9 +30181,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.6 +30182,Slovenia,2011,8,C07-Beta blocking agents,Million US$ at exchange rate,10.9 +30183,Slovenia,2011,8,C07-Beta blocking agents,"Million US$, purchasing power parity",12.6 +30184,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",28.7 +30185,Slovenia,2011,8,C07-Beta blocking agents,Million of national currency units,7.8 +30186,Slovenia,2011,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1 +30187,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.3 +30188,Slovenia,2011,8,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3 +30189,Slovenia,2011,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",13.3 +30190,Slovenia,2011,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.3 +30191,Slovenia,2011,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",31.5 +30192,Slovenia,2011,8,A10-Drugs used in diabetes,% of total sales,5.7 +30193,Slovenia,2011,8,J-Antiinfectives for systemic use,% of total sales,4.2 +30194,Slovenia,2011,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.0 +30195,Slovenia,2011,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.3 +30196,Slovenia,2011,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",43.2 +30197,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8 +30198,Slovenia,2011,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,27.3 +30199,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.6 +30200,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.5 +30201,Slovenia,2011,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",88.7 +30202,Slovenia,2011,8,C-Cardiovascular system,% of total sales,24.2 +30203,Slovenia,2011,8,Total pharmaceutical sales,"Million US$, purchasing power parity",753.3 +30204,Slovenia,2011,8,Total pharmaceutical sales,"/capita, US$ exchange rate",318.7 +30205,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +30206,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +30207,Slovenia,2011,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",44.5 +30208,Slovenia,2011,8,C10-Lipid modifying agents,Million US$ at exchange rate,38.7 +30209,Slovenia,2011,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.8 +30210,Slovenia,2011,8,R-Respiratory system,Million of national currency units,29.2 +30211,Slovenia,2011,8,C10-Lipid modifying agents,Million of national currency units,27.8 +30212,Slovenia,2011,8,Total pharmaceutical sales,Million US$ at exchange rate,654.3 +30213,Slovenia,2011,8,B-Blood and blood forming organs,Million of national currency units,25.2 +30214,Slovenia,2011,8,J-Antiinfectives for systemic use,Million of national currency units,19.6 +30215,Slovenia,2011,8,N-Nervous system,% of total sales,17.0 +30216,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8 +30217,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.1 +30218,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0 +30219,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.0 +30220,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.7 +30221,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +30222,Slovenia,2011,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.0 +30223,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.2 +30224,Slovenia,2011,8,C02-Antihypertensives,% of total sales,1.0 +30225,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.9 +30226,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,30.5 +30227,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.0 +30228,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,% of total sales,4.8 +30229,Slovenia,2010,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.2 +30230,Slovenia,2010,8,C02-Antihypertensives,% of total sales,0.9 +30231,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6 +30232,Slovenia,2010,8,N02-Analgesics,% of total sales,3.6 +30233,Slovenia,2010,8,N02-Analgesics,"/capita, US$ purchasing power parity",13.1 +30234,Slovenia,2010,8,N02-Analgesics,"/capita, US$ exchange rate",11.1 +30235,Slovenia,2010,8,C-Cardiovascular system,"Million US$, purchasing power parity",192.0 +30236,Slovenia,2010,8,C08-Calcium channel blockers,% of total sales,2.1 +30237,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,Million of national currency units,23.0 +30238,Slovenia,2010,8,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +30239,Slovenia,2010,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",15.8 +30240,Slovenia,2010,8,R-Respiratory system,"/capita, US$ exchange rate",18.9 +30241,Slovenia,2010,8,R-Respiratory system,"Million US$, purchasing power parity",45.9 +30242,Slovenia,2010,8,C08-Calcium channel blockers,Million US$ at exchange rate,13.3 +30243,Slovenia,2010,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.5 +30244,Slovenia,2010,8,R-Respiratory system,Million US$ at exchange rate,38.8 +30245,Slovenia,2010,8,C08-Calcium channel blockers,Million of national currency units,10.0 +30246,Slovenia,2010,8,C02-Antihypertensives,Million US$ at exchange rate,5.5 +30247,Slovenia,2010,8,C-Cardiovascular system,Million of national currency units,122.5 +30248,Slovenia,2010,8,C02-Antihypertensives,Million of national currency units,4.1 +30249,Slovenia,2010,8,C-Cardiovascular system,Million US$ at exchange rate,162.4 +30250,Slovenia,2010,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.7 +30251,Slovenia,2010,8,R-Respiratory system,% of total sales,6.2 +30252,Slovenia,2010,8,R-Respiratory system,"/capita, US$ purchasing power parity",22.4 +30253,Slovenia,2010,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.5 +30254,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.9 +30255,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.0 +30256,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.9 +30257,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +30258,Slovenia,2010,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.5 +30259,Slovenia,2010,8,B-Blood and blood forming organs,% of total sales,5.4 +30260,Slovenia,2010,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",39.9 +30261,Slovenia,2010,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.5 +30262,Slovenia,2010,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.6 +30263,Slovenia,2010,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.5 +30264,Slovenia,2010,8,J01-Antibacterials for systemic use,% of total sales,2.5 +30265,Slovenia,2010,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0 +30266,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.1 +30267,Slovenia,2010,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.6 +30268,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.8 +30269,Slovenia,2010,8,B-Blood and blood forming organs,Million US$ at exchange rate,33.8 +30270,Slovenia,2010,8,N02-Analgesics,"Million US$, purchasing power parity",26.9 +30271,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5 +30272,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.1 +30273,Slovenia,2010,8,A-Alimentary tract and metabolism,% of total sales,11.7 +30274,Slovenia,2010,8,N02-Analgesics,Million US$ at exchange rate,22.7 +30275,Slovenia,2010,8,N02-Analgesics,Million of national currency units,17.2 +30276,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.8 +30277,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.9 +30278,Slovenia,2010,8,C-Cardiovascular system,"/capita, US$ exchange rate",79.3 +30279,Slovenia,2010,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,73.5 +30280,Slovenia,2010,8,A-Alimentary tract and metabolism,Million of national currency units,55.5 +30281,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.6 +30282,Slovenia,2010,8,J01-Antibacterials for systemic use,Million of national currency units,11.8 +30283,Slovenia,2010,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",86.9 +30284,Slovenia,2010,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",35.9 +30285,Slovenia,2010,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.4 +30286,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",42.0 +30287,Slovenia,2010,8,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9 +30288,Slovenia,2010,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +30289,Slovenia,2010,8,N05B-Anxiolytics,% of total sales,0.6 +30290,Slovenia,2010,8,N06A-Antidepressants,Million US$ at exchange rate,20.6 +30291,Slovenia,2010,8,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7 +30292,Slovenia,2010,8,N05B-Anxiolytics,Million US$ at exchange rate,4.0 +30293,Slovenia,2010,8,N06A-Antidepressants,Million of national currency units,15.6 +30294,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,13.4 +30295,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,10.1 +30296,Slovenia,2010,8,N-Nervous system,"/capita, US$ exchange rate",52.0 +30297,Slovenia,2010,8,N-Nervous system,"/capita, US$ purchasing power parity",61.5 +30298,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",15.9 +30299,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.1 +30300,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.8 +30301,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.6 +30302,Slovenia,2010,8,N06A-Antidepressants,"Million US$, purchasing power parity",24.4 +30303,Slovenia,2010,8,A02A-Antacids,Million of national currency units,0.3 +30304,Slovenia,2010,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +30305,Slovenia,2010,8,A02A-Antacids,"Million US$, purchasing power parity",0.5 +30306,Slovenia,2010,8,A02A-Antacids,Million US$ at exchange rate,0.5 +30307,Slovenia,2010,8,C01A-Cardiac glycosides,% of total sales,0.1 +30308,Slovenia,2010,8,C10-Lipid modifying agents,% of total sales,6.5 +30309,Slovenia,2010,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.7 +30310,Slovenia,2010,8,Total pharmaceutical sales,Million of national currency units,474.4 +30311,Slovenia,2010,8,N06A-Antidepressants,% of total sales,3.3 +30312,Slovenia,2010,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9 +30313,Slovenia,2010,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.1 +30314,Slovenia,2010,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.3 +30315,Slovenia,2010,8,A02A-Antacids,"/capita, US$ exchange rate",0.2 +30316,Slovenia,2010,8,N05B-Anxiolytics,Million of national currency units,3.0 +30317,Slovenia,2010,8,A02A-Antacids,% of total sales,0.1 +30318,Slovenia,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2 +30319,Slovenia,2010,8,N05C-Hypnotics and sedatives,% of total sales,0.6 +30320,Slovenia,2010,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.5 +30321,Slovenia,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.9 +30322,Slovenia,2010,8,C03-Diuretics,"Million US$, purchasing power parity",9.9 +30323,Slovenia,2010,8,C03-Diuretics,"/capita, US$ exchange rate",4.1 +30324,Slovenia,2010,8,C03-Diuretics,Million of national currency units,6.3 +30325,Slovenia,2010,8,C03-Diuretics,Million US$ at exchange rate,8.4 +30326,Slovenia,2010,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.1 +30327,Slovenia,2010,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.6 +30328,Slovenia,2010,8,M-Musculo-skeletal system,% of total sales,4.4 +30329,Slovenia,2010,8,M-Musculo-skeletal system,Million of national currency units,21.0 +30330,Slovenia,2010,8,N05C-Hypnotics and sedatives,Million of national currency units,2.9 +30331,Slovenia,2010,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8 +30332,Slovenia,2010,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",32.9 +30333,Slovenia,2010,8,M-Musculo-skeletal system,Million US$ at exchange rate,27.8 +30334,Slovenia,2010,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5 +30335,Slovenia,2010,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +30336,Slovenia,2010,8,G-Genito urinary system and sex hormones,Million of national currency units,26.3 +30337,Slovenia,2010,8,C01A-Cardiac glycosides,Million of national currency units,0.3 +30338,Slovenia,2010,8,N-Nervous system,"Million US$, purchasing power parity",126.0 +30339,Slovenia,2010,8,N-Nervous system,Million US$ at exchange rate,106.5 +30340,Slovenia,2010,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +30341,Slovenia,2010,8,N-Nervous system,Million of national currency units,80.4 +30342,Slovenia,2010,8,G-Genito urinary system and sex hormones,% of total sales,5.5 +30343,Slovenia,2010,8,C03-Diuretics,% of total sales,1.3 +30344,Slovenia,2010,8,C03-Diuretics,"/capita, US$ purchasing power parity",4.8 +30345,Slovenia,2010,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",41.2 +30346,Slovenia,2010,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,34.9 +30347,Slovenia,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.1 +30348,Slovenia,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.0 +30349,Slovenia,2010,8,C07-Beta blocking agents,% of total sales,1.8 +30350,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.5 +30351,Slovenia,2010,8,A10-Drugs used in diabetes,Million US$ at exchange rate,34.0 +30352,Slovenia,2010,8,A10-Drugs used in diabetes,Million of national currency units,25.6 +30353,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,26.4 +30354,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,19.9 +30355,Slovenia,2010,8,C07-Beta blocking agents,Million US$ at exchange rate,11.1 +30356,Slovenia,2010,8,C07-Beta blocking agents,"Million US$, purchasing power parity",13.1 +30357,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",31.2 +30358,Slovenia,2010,8,C07-Beta blocking agents,Million of national currency units,8.4 +30359,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.2 +30360,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,12.2 +30361,Slovenia,2010,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4 +30362,Slovenia,2010,8,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4 +30363,Slovenia,2010,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.3 +30364,Slovenia,2010,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",14.6 +30365,Slovenia,2010,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",29.8 +30366,Slovenia,2010,8,A10-Drugs used in diabetes,% of total sales,5.4 +30367,Slovenia,2010,8,J-Antiinfectives for systemic use,% of total sales,4.0 +30368,Slovenia,2010,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.6 +30369,Slovenia,2010,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",40.2 +30370,Slovenia,2010,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.6 +30371,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +30372,Slovenia,2010,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.2 +30373,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0 +30374,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.1 +30375,Slovenia,2010,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.7 +30376,Slovenia,2010,8,C-Cardiovascular system,% of total sales,25.8 +30377,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +30378,Slovenia,2010,8,Total pharmaceutical sales,"/capita, US$ exchange rate",307.0 +30379,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +30380,Slovenia,2010,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",48.6 +30381,Slovenia,2010,8,C10-Lipid modifying agents,Million US$ at exchange rate,41.1 +30382,Slovenia,2010,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.1 +30383,Slovenia,2010,8,Total pharmaceutical sales,"Million US$, purchasing power parity",743.6 +30384,Slovenia,2010,8,R-Respiratory system,Million of national currency units,29.3 +30385,Slovenia,2010,8,B-Blood and blood forming organs,Million of national currency units,25.5 +30386,Slovenia,2010,8,C10-Lipid modifying agents,Million of national currency units,31.0 +30387,Slovenia,2010,8,Total pharmaceutical sales,Million US$ at exchange rate,628.9 +30388,Slovenia,2010,8,J-Antiinfectives for systemic use,Million of national currency units,19.0 +30389,Slovenia,2010,8,N-Nervous system,% of total sales,16.9 +30390,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9 +30391,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2 +30392,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.2 +30393,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +30394,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4 +30395,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +30396,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1 +30397,Slovenia,2010,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",363.0 +30398,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.2 +30399,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,Million of national currency units,20.6 +30400,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,23.3 +30401,Slovenia,2017,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7 +30402,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.3 +30403,Slovenia,2017,7,C-Cardiovascular system,Million US$ at exchange rate,85.7 +30404,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.5 +30405,Slovenia,2017,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.5 +30406,Slovenia,2017,7,N02-Analgesics,% of total sales,3.8 +30407,Slovenia,2017,7,N02-Analgesics,"Million US$, purchasing power parity",32.1 +30408,Slovenia,2017,7,N02-Analgesics,"/capita, US$ exchange rate",10.0 +30409,Slovenia,2017,7,C08-Calcium channel blockers,% of total sales,1.2 +30410,Slovenia,2017,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.6 +30411,Slovenia,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",133.1 +30412,Slovenia,2017,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.7 +30413,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,% of total sales,4.3 +30414,Slovenia,2017,7,R-Respiratory system,Million US$ at exchange rate,28.9 +30415,Slovenia,2017,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.6 +30416,Slovenia,2017,7,R-Respiratory system,"/capita, US$ exchange rate",14.0 +30417,Slovenia,2017,7,R-Respiratory system,"Million US$, purchasing power parity",44.8 +30418,Slovenia,2017,7,R-Respiratory system,Million of national currency units,25.6 +30419,Slovenia,2017,7,C02-Antihypertensives,Million US$ at exchange rate,3.6 +30420,Slovenia,2017,7,C08-Calcium channel blockers,Million of national currency units,5.8 +30421,Slovenia,2017,7,C02-Antihypertensives,Million of national currency units,3.2 +30422,Slovenia,2017,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9 +30423,Slovenia,2017,7,C-Cardiovascular system,Million of national currency units,75.9 +30424,Slovenia,2017,7,J01-Antibacterials for systemic use,% of total sales,2.3 +30425,Slovenia,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.7 +30426,Slovenia,2017,7,R-Respiratory system,% of total sales,5.3 +30427,Slovenia,2017,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2 +30428,Slovenia,2017,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.2 +30429,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10.8 +30430,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.2 +30431,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2 +30432,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.2 +30433,Slovenia,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.6 +30434,Slovenia,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",81.8 +30435,Slovenia,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.5 +30436,Slovenia,2017,7,B-Blood and blood forming organs,% of total sales,9.6 +30437,Slovenia,2017,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.8 +30438,Slovenia,2017,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.7 +30439,Slovenia,2017,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.6 +30440,Slovenia,2017,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2 +30441,Slovenia,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,52.7 +30442,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.9 +30443,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.0 +30444,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",49.8 +30445,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,32.1 +30446,Slovenia,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0 +30447,Slovenia,2017,7,A-Alimentary tract and metabolism,% of total sales,11.9 +30448,Slovenia,2017,7,N02-Analgesics,Million of national currency units,18.3 +30449,Slovenia,2017,7,N02-Analgesics,Million US$ at exchange rate,20.7 +30450,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28.4 +30451,Slovenia,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",41.5 +30452,Slovenia,2017,7,A-Alimentary tract and metabolism,Million of national currency units,57.8 +30453,Slovenia,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,65.3 +30454,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9 +30455,Slovenia,2017,7,J01-Antibacterials for systemic use,Million of national currency units,11.3 +30456,Slovenia,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",31.6 +30457,Slovenia,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",101.3 +30458,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.1 +30459,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.5 +30460,Slovenia,2017,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4 +30461,Slovenia,2017,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.6 +30462,Slovenia,2017,7,N05B-Anxiolytics,% of total sales,0.5 +30463,Slovenia,2017,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +30464,Slovenia,2017,7,N06A-Antidepressants,Million of national currency units,10.6 +30465,Slovenia,2017,7,N06A-Antidepressants,Million US$ at exchange rate,11.9 +30466,Slovenia,2017,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0 +30467,Slovenia,2017,7,N05B-Anxiolytics,Million of national currency units,2.6 +30468,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.5 +30469,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.4 +30470,Slovenia,2017,7,N-Nervous system,"/capita, US$ exchange rate",34.6 +30471,Slovenia,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",53.7 +30472,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3 +30473,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.5 +30474,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.1 +30475,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1 +30476,Slovenia,2017,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3 +30477,Slovenia,2017,7,A02A-Antacids,Million of national currency units,0.8 +30478,Slovenia,2017,7,A02A-Antacids,Million US$ at exchange rate,0.9 +30479,Slovenia,2017,7,C10-Lipid modifying agents,% of total sales,3.0 +30480,Slovenia,2017,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",12.1 +30481,Slovenia,2017,7,C01A-Cardiac glycosides,% of total sales,0.1 +30482,Slovenia,2017,7,Total pharmaceutical sales,Million of national currency units,484.2 +30483,Slovenia,2017,7,A02A-Antacids,"Million US$, purchasing power parity",1.3 +30484,Slovenia,2017,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.0 +30485,Slovenia,2017,7,N06A-Antidepressants,% of total sales,2.2 +30486,Slovenia,2017,7,N06A-Antidepressants,"Million US$, purchasing power parity",18.5 +30487,Slovenia,2017,7,N06A-Antidepressants,"/capita, US$ exchange rate",5.8 +30488,Slovenia,2017,7,A02A-Antacids,"/capita, US$ exchange rate",0.4 +30489,Slovenia,2017,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +30490,Slovenia,2017,7,A02A-Antacids,% of total sales,0.2 +30491,Slovenia,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0 +30492,Slovenia,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +30493,Slovenia,2017,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1 +30494,Slovenia,2017,7,C03-Diuretics,Million US$ at exchange rate,7.1 +30495,Slovenia,2017,7,C03-Diuretics,"Million US$, purchasing power parity",11.0 +30496,Slovenia,2017,7,N05C-Hypnotics and sedatives,% of total sales,0.5 +30497,Slovenia,2017,7,C03-Diuretics,Million of national currency units,6.3 +30498,Slovenia,2017,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.6 +30499,Slovenia,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.0 +30500,Slovenia,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",28.7 +30501,Slovenia,2017,7,M-Musculo-skeletal system,% of total sales,3.4 +30502,Slovenia,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9 +30503,Slovenia,2017,7,N05C-Hypnotics and sedatives,Million of national currency units,2.3 +30504,Slovenia,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,18.5 +30505,Slovenia,2017,7,M-Musculo-skeletal system,Million of national currency units,16.4 +30506,Slovenia,2017,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4 +30507,Slovenia,2017,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6 +30508,Slovenia,2017,7,C03-Diuretics,% of total sales,1.3 +30509,Slovenia,2017,7,C01A-Cardiac glycosides,Million of national currency units,0.3 +30510,Slovenia,2017,7,N-Nervous system,Million US$ at exchange rate,71.4 +30511,Slovenia,2017,7,N-Nervous system,"Million US$, purchasing power parity",110.9 +30512,Slovenia,2017,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +30513,Slovenia,2017,7,N-Nervous system,Million of national currency units,63.2 +30514,Slovenia,2017,7,G-Genito urinary system and sex hormones,% of total sales,4.9 +30515,Slovenia,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.2 +30516,Slovenia,2017,7,C03-Diuretics,"/capita, US$ exchange rate",3.4 +30517,Slovenia,2017,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3 +30518,Slovenia,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,26.9 +30519,Slovenia,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,23.8 +30520,Slovenia,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.0 +30521,Slovenia,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",41.7 +30522,Slovenia,2017,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.7 +30523,Slovenia,2017,7,C07-Beta blocking agents,% of total sales,2.1 +30524,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.5 +30525,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.7 +30526,Slovenia,2017,7,A10-Drugs used in diabetes,Million of national currency units,31.5 +30527,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,9.5 +30528,Slovenia,2017,7,C07-Beta blocking agents,Million US$ at exchange rate,11.5 +30529,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,10.8 +30530,Slovenia,2017,7,C07-Beta blocking agents,Million of national currency units,10.2 +30531,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.4 +30532,Slovenia,2017,7,C07-Beta blocking agents,"Million US$, purchasing power parity",17.9 +30533,Slovenia,2017,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6 +30534,Slovenia,2017,7,A10-Drugs used in diabetes,Million US$ at exchange rate,35.6 +30535,Slovenia,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.9 +30536,Slovenia,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,30.8 +30537,Slovenia,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.8 +30538,Slovenia,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.1 +30539,Slovenia,2017,7,A10-Drugs used in diabetes,% of total sales,6.5 +30540,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +30541,Slovenia,2017,7,J-Antiinfectives for systemic use,% of total sales,5.6 +30542,Slovenia,2017,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.2 +30543,Slovenia,2017,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.7 +30544,Slovenia,2017,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",55.2 +30545,Slovenia,2017,7,J-Antiinfectives for systemic use,Million of national currency units,27.2 +30546,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.1 +30547,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.6 +30548,Slovenia,2017,7,C-Cardiovascular system,% of total sales,15.7 +30549,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +30550,Slovenia,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.4 +30551,Slovenia,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",849.3 +30552,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +30553,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +30554,Slovenia,2017,7,C10-Lipid modifying agents,Million US$ at exchange rate,16.1 +30555,Slovenia,2017,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.8 +30556,Slovenia,2017,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",25.1 +30557,Slovenia,2017,7,B-Blood and blood forming organs,Million of national currency units,46.7 +30558,Slovenia,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,547.0 +30559,Slovenia,2017,7,C10-Lipid modifying agents,Million of national currency units,14.3 +30560,Slovenia,2017,7,N-Nervous system,% of total sales,13.1 +30561,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0 +30562,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.2 +30563,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",16.7 +30564,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.1 +30565,Slovenia,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",264.7 +30566,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1 +30567,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0 +30568,Slovenia,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",411.0 +30569,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7 +30570,Slovenia,2017,7,C02-Antihypertensives,% of total sales,0.7 +30571,Spain,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.8 +30572,Spain,2011,4,J01-Antibacterials for systemic use,Million of national currency units,260.9 +30573,Spain,2011,4,J01-Antibacterials for systemic use,% of total sales,2.1 +30574,Spain,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,363.1 +30575,Spain,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",365.3 +30576,Spain,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.8 +30577,Spain,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",63.1 +30578,Spain,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +30579,Spain,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3 +30580,Spain,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.6 +30581,Spain,2011,4,C02-Antihypertensives,% of total sales,0.4 +30582,Spain,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.6 +30583,Spain,2011,4,C08-Calcium channel blockers,% of total sales,1.5 +30584,Spain,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",3628.2 +30585,Spain,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.3 +30586,Spain,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.3 +30587,Spain,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,433.6 +30588,Spain,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",436.2 +30589,Spain,2011,4,C03-Diuretics,Million US$ at exchange rate,167.4 +30590,Spain,2011,4,C03-Diuretics,"Million US$, purchasing power parity",168.4 +30591,Spain,2011,4,J-Antiinfectives for systemic use,% of total sales,2.5 +30592,Spain,2011,4,C03-Diuretics,Million of national currency units,120.2 +30593,Spain,2011,4,C07-Beta blocking agents,% of total sales,0.7 +30594,Spain,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.5 +30595,Spain,2011,4,N-Nervous system,Million of national currency units,3080.3 +30596,Spain,2011,4,N-Nervous system,Million US$ at exchange rate,4287.7 +30597,Spain,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,118.1 +30598,Spain,2011,4,C07-Beta blocking agents,Million of national currency units,84.9 +30599,Spain,2011,4,J-Antiinfectives for systemic use,Million of national currency units,311.5 +30600,Spain,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.5 +30601,Spain,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",118.8 +30602,Spain,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",92.3 +30603,Spain,2011,4,N-Nervous system,"/capita, US$ exchange rate",91.7 +30604,Spain,2011,4,N-Nervous system,% of total sales,24.9 +30605,Spain,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",261.8 +30606,Spain,2011,4,C-Cardiovascular system,Million US$ at exchange rate,3606.5 +30607,Spain,2011,4,C-Cardiovascular system,Million of national currency units,2591.0 +30608,Spain,2011,4,N-Nervous system,"Million US$, purchasing power parity",4313.4 +30609,Spain,2011,4,C03-Diuretics,% of total sales,1.0 +30610,Spain,2011,4,C03-Diuretics,"/capita, US$ exchange rate",3.6 +30611,Spain,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.6 +30612,Spain,2011,4,C-Cardiovascular system,% of total sales,21.0 +30613,Spain,2011,4,C08-Calcium channel blockers,Million of national currency units,187.0 +30614,Spain,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,260.2 +30615,Spain,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",77.2 +30616,Spain,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.6 +30617,Spain,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1051.7 +30618,Spain,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,1045.5 +30619,Spain,2011,4,C10-Lipid modifying agents,Million of national currency units,751.1 +30620,Spain,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.5 +30621,Spain,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.4 +30622,Spain,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.6 +30623,Spain,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",1063.0 +30624,Spain,2011,4,M-Musculo-skeletal system,% of total sales,6.1 +30625,Spain,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7 +30626,Spain,2011,4,Total pharmaceutical sales,Million of national currency units,12356.1 +30627,Spain,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,17199.1 +30628,Spain,2011,4,B-Blood and blood forming organs,% of total sales,4.3 +30629,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1 +30630,Spain,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.2 +30631,Spain,2011,4,C10-Lipid modifying agents,% of total sales,6.1 +30632,Spain,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17302.4 +30633,Spain,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",368.0 +30634,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.5 +30635,Spain,2011,4,M-Musculo-skeletal system,Million of national currency units,759.1 +30636,Spain,2011,4,R-Respiratory system,Million of national currency units,1311.5 +30637,Spain,2011,4,R-Respiratory system,Million US$ at exchange rate,1825.5 +30638,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +30639,Spain,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,1056.6 +30640,Spain,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.3 +30641,Spain,2011,4,R-Respiratory system,% of total sales,10.6 +30642,Spain,2011,4,R-Respiratory system,"Million US$, purchasing power parity",1836.5 +30643,Spain,2011,4,R-Respiratory system,"/capita, US$ exchange rate",39.1 +30644,Spain,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",158.8 +30645,Spain,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,157.9 +30646,Spain,2011,4,N05B-Anxiolytics,% of total sales,0.9 +30647,Spain,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4 +30648,Spain,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4 +30649,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",362.5 +30650,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.7 +30651,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.8 +30652,Spain,2011,4,N05B-Anxiolytics,Million of national currency units,113.4 +30653,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,258.9 +30654,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,360.3 +30655,Spain,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",5.2 +30656,Spain,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +30657,Spain,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.9 +30658,Spain,2011,4,C01A-Cardiac glycosides,Million of national currency units,3.7 +30659,Spain,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,5.2 +30660,Spain,2011,4,G-Genito urinary system and sex hormones,% of total sales,4.1 +30661,Spain,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1 +30662,Spain,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +30663,Spain,2011,4,C01A-Cardiac glycosides,% of total sales,0.0 +30664,Spain,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2 +30665,Spain,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.6 +30666,Spain,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.3 +30667,Spain,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2 +30668,Spain,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",741.7 +30669,Spain,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.8 +30670,Spain,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,737.2 +30671,Spain,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,57.3 +30672,Spain,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,41.2 +30673,Spain,2011,4,B-Blood and blood forming organs,Million of national currency units,529.6 +30674,Spain,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",17.6 +30675,Spain,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.7 +30676,Spain,2011,4,N06A-Antidepressants,Million US$ at exchange rate,821.9 +30677,Spain,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",826.8 +30678,Spain,2011,4,N06A-Antidepressants,% of total sales,4.8 +30679,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",539.0 +30680,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5 +30681,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,385.0 +30682,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,535.8 +30683,Spain,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,502.5 +30684,Spain,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,114.8 +30685,Spain,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,159.7 +30686,Spain,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.0 +30687,Spain,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,699.4 +30688,Spain,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",703.6 +30689,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4 +30690,Spain,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +30691,Spain,2011,4,N06A-Antidepressants,Million of national currency units,590.4 +30692,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",160.7 +30693,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4 +30694,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,33.6 +30695,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.9 +30696,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.6 +30697,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",788.1 +30698,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.8 +30699,Spain,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2489.0 +30700,Spain,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.9 +30701,Spain,2011,4,A-Alimentary tract and metabolism,Million of national currency units,1777.5 +30702,Spain,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2474.2 +30703,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",33.9 +30704,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.1 +30705,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.2 +30706,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1592.6 +30707,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,562.8 +30708,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,783.4 +30709,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1137.3 +30710,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1583.1 +30711,Spain,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4 +30712,Spain,2011,4,N02-Analgesics,"/capita, US$ exchange rate",14.4 +30713,Spain,2011,4,N02-Analgesics,% of total sales,3.9 +30714,Spain,2011,4,N02-Analgesics,Million of national currency units,482.3 +30715,Spain,2011,4,C02-Antihypertensives,Million of national currency units,45.0 +30716,Spain,2011,4,C02-Antihypertensives,Million US$ at exchange rate,62.7 +30717,Spain,2011,4,N02-Analgesics,"Million US$, purchasing power parity",675.4 +30718,Spain,2011,4,N02-Analgesics,Million US$ at exchange rate,671.3 +30719,Spain,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1063.0 +30720,Spain,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1479.7 +30721,Spain,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.2 +30722,Spain,2011,4,A-Alimentary tract and metabolism,% of total sales,14.4 +30723,Spain,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.8 +30724,Spain,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,8.6 +30725,Spain,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1488.5 +30726,Spain,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.7 +30727,Spain,2011,4,A02A-Antacids,Million US$ at exchange rate,24.9 +30728,Spain,2011,4,A02A-Antacids,Million of national currency units,17.9 +30729,Spain,2011,4,A10-Drugs used in diabetes,Million of national currency units,890.8 +30730,Spain,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1239.9 +30731,Spain,2011,4,A02A-Antacids,"Million US$, purchasing power parity",25.0 +30732,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +30733,Spain,2011,4,A02A-Antacids,% of total sales,0.1 +30734,Spain,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.5 +30735,Spain,2011,4,A02A-Antacids,"/capita, US$ exchange rate",0.5 +30736,Spain,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.7 +30737,Spain,2011,4,A10-Drugs used in diabetes,% of total sales,7.2 +30738,Spain,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1247.4 +30739,Spain,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",26.5 +30740,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.1 +30741,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +30742,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,46.8 +30743,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +30744,Spain,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.0 +30745,Spain,2012,4,J01-Antibacterials for systemic use,% of total sales,2.1 +30746,Spain,2012,4,J01-Antibacterials for systemic use,Million of national currency units,227.4 +30747,Spain,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2 +30748,Spain,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,292.1 +30749,Spain,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",327.1 +30750,Spain,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.5 +30751,Spain,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",58.4 +30752,Spain,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2 +30753,Spain,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1 +30754,Spain,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.9 +30755,Spain,2012,4,C02-Antihypertensives,% of total sales,0.4 +30756,Spain,2012,4,C08-Calcium channel blockers,% of total sales,1.1 +30757,Spain,2012,4,C03-Diuretics,"/capita, US$ exchange rate",3.1 +30758,Spain,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.5 +30759,Spain,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.5 +30760,Spain,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,353.1 +30761,Spain,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",395.5 +30762,Spain,2012,4,C03-Diuretics,Million US$ at exchange rate,143.3 +30763,Spain,2012,4,C03-Diuretics,"Million US$, purchasing power parity",160.5 +30764,Spain,2012,4,J-Antiinfectives for systemic use,% of total sales,2.5 +30765,Spain,2012,4,C03-Diuretics,Million of national currency units,111.6 +30766,Spain,2012,4,C07-Beta blocking agents,% of total sales,0.7 +30767,Spain,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.4 +30768,Spain,2012,4,N-Nervous system,Million of national currency units,2838.9 +30769,Spain,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.2 +30770,Spain,2012,4,J-Antiinfectives for systemic use,Million of national currency units,274.8 +30771,Spain,2012,4,C07-Beta blocking agents,Million of national currency units,79.1 +30772,Spain,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,101.6 +30773,Spain,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",113.8 +30774,Spain,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",87.3 +30775,Spain,2012,4,N-Nervous system,"/capita, US$ exchange rate",78.0 +30776,Spain,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",182.3 +30777,Spain,2012,4,N-Nervous system,% of total sales,25.6 +30778,Spain,2012,4,C-Cardiovascular system,Million US$ at exchange rate,2838.9 +30779,Spain,2012,4,C-Cardiovascular system,Million of national currency units,2209.6 +30780,Spain,2012,4,N-Nervous system,"Million US$, purchasing power parity",4084.9 +30781,Spain,2012,4,N-Nervous system,Million US$ at exchange rate,3647.4 +30782,Spain,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",3179.4 +30783,Spain,2012,4,C03-Diuretics,% of total sales,1.0 +30784,Spain,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.4 +30785,Spain,2012,4,C-Cardiovascular system,% of total sales,20.0 +30786,Spain,2012,4,C08-Calcium channel blockers,Million of national currency units,126.7 +30787,Spain,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,162.8 +30788,Spain,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",60.7 +30789,Spain,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",68.0 +30790,Spain,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",952.6 +30791,Spain,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,850.6 +30792,Spain,2012,4,C10-Lipid modifying agents,Million of national currency units,662.0 +30793,Spain,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.4 +30794,Spain,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.2 +30795,Spain,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.5 +30796,Spain,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",914.2 +30797,Spain,2012,4,M-Musculo-skeletal system,% of total sales,5.7 +30798,Spain,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.5 +30799,Spain,2012,4,B-Blood and blood forming organs,% of total sales,4.5 +30800,Spain,2012,4,Total pharmaceutical sales,Million of national currency units,11072.0 +30801,Spain,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,14225.2 +30802,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.8 +30803,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2 +30804,Spain,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",340.6 +30805,Spain,2012,4,C10-Lipid modifying agents,% of total sales,6.0 +30806,Spain,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",15931.5 +30807,Spain,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",304.1 +30808,Spain,2012,4,M-Musculo-skeletal system,Million of national currency units,635.4 +30809,Spain,2012,4,R-Respiratory system,Million of national currency units,1201.6 +30810,Spain,2012,4,R-Respiratory system,Million US$ at exchange rate,1543.8 +30811,Spain,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,816.3 +30812,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +30813,Spain,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",37.0 +30814,Spain,2012,4,R-Respiratory system,% of total sales,10.9 +30815,Spain,2012,4,R-Respiratory system,"Million US$, purchasing power parity",1729.0 +30816,Spain,2012,4,R-Respiratory system,"/capita, US$ exchange rate",33.0 +30817,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3 +30818,Spain,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",141.3 +30819,Spain,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,126.2 +30820,Spain,2012,4,N05B-Anxiolytics,% of total sales,0.9 +30821,Spain,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.0 +30822,Spain,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7 +30823,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",339.1 +30824,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5 +30825,Spain,2012,4,N05B-Anxiolytics,Million of national currency units,98.2 +30826,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,235.7 +30827,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,302.8 +30828,Spain,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.8 +30829,Spain,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +30830,Spain,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.4 +30831,Spain,2012,4,C01A-Cardiac glycosides,Million of national currency units,3.4 +30832,Spain,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.3 +30833,Spain,2012,4,G-Genito urinary system and sex hormones,% of total sales,4.3 +30834,Spain,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.7 +30835,Spain,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +30836,Spain,2012,4,C01A-Cardiac glycosides,% of total sales,0.0 +30837,Spain,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1 +30838,Spain,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.7 +30839,Spain,2012,4,N05C-Hypnotics and sedatives,% of total sales,0.4 +30840,Spain,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2 +30841,Spain,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,51.5 +30842,Spain,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",722.0 +30843,Spain,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.8 +30844,Spain,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,644.7 +30845,Spain,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,40.1 +30846,Spain,2012,4,B-Blood and blood forming organs,Million of national currency units,501.8 +30847,Spain,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",13.4 +30848,Spain,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.0 +30849,Spain,2012,4,N06A-Antidepressants,Million US$ at exchange rate,627.9 +30850,Spain,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",703.2 +30851,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",507.1 +30852,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.7 +30853,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,352.4 +30854,Spain,2012,4,N06A-Antidepressants,% of total sales,4.4 +30855,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,452.8 +30856,Spain,2012,4,N06A-Antidepressants,Million of national currency units,488.7 +30857,Spain,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,478.2 +30858,Spain,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,125.1 +30859,Spain,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,160.7 +30860,Spain,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.1 +30861,Spain,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",688.0 +30862,Spain,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,614.3 +30863,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8 +30864,Spain,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,1.1 +30865,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.9 +30866,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4 +30867,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.8 +30868,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.1 +30869,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",646.3 +30870,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.3 +30871,Spain,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2415.6 +30872,Spain,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",46.1 +30873,Spain,2012,4,A-Alimentary tract and metabolism,Million of national currency units,1678.8 +30874,Spain,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2156.9 +30875,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.5 +30876,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.2 +30877,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.7 +30878,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1385.6 +30879,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6 +30880,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,449.2 +30881,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,577.1 +30882,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,963.0 +30883,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1237.2 +30884,Spain,2012,4,N02-Analgesics,"/capita, US$ exchange rate",12.9 +30885,Spain,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4 +30886,Spain,2012,4,N02-Analgesics,% of total sales,4.2 +30887,Spain,2012,4,N02-Analgesics,Million of national currency units,468.8 +30888,Spain,2012,4,C02-Antihypertensives,Million of national currency units,40.6 +30889,Spain,2012,4,C02-Antihypertensives,Million US$ at exchange rate,52.2 +30890,Spain,2012,4,N02-Analgesics,"Million US$, purchasing power parity",674.6 +30891,Spain,2012,4,N02-Analgesics,Million US$ at exchange rate,602.3 +30892,Spain,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1009.0 +30893,Spain,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1296.3 +30894,Spain,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.6 +30895,Spain,2012,4,A-Alimentary tract and metabolism,% of total sales,15.2 +30896,Spain,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.0 +30897,Spain,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,9.1 +30898,Spain,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1451.8 +30899,Spain,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.7 +30900,Spain,2012,4,A02A-Antacids,Million US$ at exchange rate,15.0 +30901,Spain,2012,4,A02A-Antacids,Million of national currency units,11.7 +30902,Spain,2012,4,A10-Drugs used in diabetes,Million of national currency units,941.9 +30903,Spain,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1210.1 +30904,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +30905,Spain,2012,4,A02A-Antacids,% of total sales,0.1 +30906,Spain,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.4 +30907,Spain,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.3 +30908,Spain,2012,4,A02A-Antacids,"Million US$, purchasing power parity",16.8 +30909,Spain,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",29.0 +30910,Spain,2012,4,A10-Drugs used in diabetes,% of total sales,8.5 +30911,Spain,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1355.3 +30912,Spain,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.9 +30913,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",44.9 +30914,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +30915,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,40.1 +30916,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +30917,Spain,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.2 +30918,Spain,2013,4,J01-Antibacterials for systemic use,% of total sales,2.1 +30919,Spain,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,302.5 +30920,Spain,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",337.5 +30921,Spain,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5 +30922,Spain,2013,4,J01-Antibacterials for systemic use,Million of national currency units,227.8 +30923,Spain,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",3080.4 +30924,Spain,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",59.4 +30925,Spain,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +30926,Spain,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +30927,Spain,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2 +30928,Spain,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1 +30929,Spain,2013,4,C02-Antihypertensives,% of total sales,0.4 +30930,Spain,2013,4,C08-Calcium channel blockers,% of total sales,1.0 +30931,Spain,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.8 +30932,Spain,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,364.5 +30933,Spain,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",406.7 +30934,Spain,2013,4,C03-Diuretics,Million US$ at exchange rate,135.0 +30935,Spain,2013,4,C03-Diuretics,"Million US$, purchasing power parity",150.6 +30936,Spain,2013,4,J-Antiinfectives for systemic use,% of total sales,2.6 +30937,Spain,2013,4,C03-Diuretics,Million of national currency units,101.6 +30938,Spain,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6 +30939,Spain,2013,4,C07-Beta blocking agents,% of total sales,0.8 +30940,Spain,2013,4,N-Nervous system,Million of national currency units,2862.9 +30941,Spain,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.3 +30942,Spain,2013,4,C07-Beta blocking agents,Million of national currency units,80.7 +30943,Spain,2013,4,J-Antiinfectives for systemic use,Million of national currency units,274.4 +30944,Spain,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,107.2 +30945,Spain,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",119.6 +30946,Spain,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",91.0 +30947,Spain,2013,4,N-Nervous system,"/capita, US$ exchange rate",81.6 +30948,Spain,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",164.3 +30949,Spain,2013,4,N-Nervous system,% of total sales,26.8 +30950,Spain,2013,4,C-Cardiovascular system,Million US$ at exchange rate,2760.7 +30951,Spain,2013,4,C-Cardiovascular system,Million of national currency units,2078.7 +30952,Spain,2013,4,N-Nervous system,"Million US$, purchasing power parity",4242.6 +30953,Spain,2013,4,N-Nervous system,Million US$ at exchange rate,3802.2 +30954,Spain,2013,4,C03-Diuretics,% of total sales,1.0 +30955,Spain,2013,4,C-Cardiovascular system,% of total sales,19.5 +30956,Spain,2013,4,C03-Diuretics,"/capita, US$ exchange rate",2.9 +30957,Spain,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2 +30958,Spain,2013,4,C08-Calcium channel blockers,Million of national currency units,110.8 +30959,Spain,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,147.2 +30960,Spain,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.1 +30961,Spain,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",59.2 +30962,Spain,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.7 +30963,Spain,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,864.0 +30964,Spain,2013,4,C10-Lipid modifying agents,Million of national currency units,650.6 +30965,Spain,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",964.1 +30966,Spain,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.7 +30967,Spain,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5 +30968,Spain,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6 +30969,Spain,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",812.4 +30970,Spain,2013,4,M-Musculo-skeletal system,% of total sales,5.1 +30971,Spain,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4 +30972,Spain,2013,4,B-Blood and blood forming organs,% of total sales,4.9 +30973,Spain,2013,4,Total pharmaceutical sales,Million of national currency units,10669.9 +30974,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6 +30975,Spain,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,14170.8 +30976,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1 +30977,Spain,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",339.2 +30978,Spain,2013,4,C10-Lipid modifying agents,% of total sales,6.1 +30979,Spain,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",15811.9 +30980,Spain,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",304.0 +30981,Spain,2013,4,N05B-Anxiolytics,% of total sales,0.9 +30982,Spain,2013,4,M-Musculo-skeletal system,Million of national currency units,548.2 +30983,Spain,2013,4,R-Respiratory system,Million of national currency units,1092.6 +30984,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +30985,Spain,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,728.1 +30986,Spain,2013,4,R-Respiratory system,Million US$ at exchange rate,1451.1 +30987,Spain,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",34.7 +30988,Spain,2013,4,R-Respiratory system,% of total sales,10.2 +30989,Spain,2013,4,R-Respiratory system,"Million US$, purchasing power parity",1619.2 +30990,Spain,2013,4,R-Respiratory system,"/capita, US$ exchange rate",31.1 +30991,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6 +30992,Spain,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",145.6 +30993,Spain,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,130.5 +30994,Spain,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1 +30995,Spain,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8 +30996,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",305.5 +30997,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.9 +30998,Spain,2013,4,N05B-Anxiolytics,Million of national currency units,98.3 +30999,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,206.1 +31000,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,273.8 +31001,Spain,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.6 +31002,Spain,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31003,Spain,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1 +31004,Spain,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.7 +31005,Spain,2013,4,C01A-Cardiac glycosides,Million of national currency units,3.1 +31006,Spain,2013,4,G-Genito urinary system and sex hormones,% of total sales,4.6 +31007,Spain,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.5 +31008,Spain,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31009,Spain,2013,4,C01A-Cardiac glycosides,% of total sales,0.0 +31010,Spain,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2 +31011,Spain,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",62.1 +31012,Spain,2013,4,N05C-Hypnotics and sedatives,% of total sales,0.4 +31013,Spain,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3 +31014,Spain,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",780.7 +31015,Spain,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.0 +31016,Spain,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,699.7 +31017,Spain,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,41.9 +31018,Spain,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,55.7 +31019,Spain,2013,4,B-Blood and blood forming organs,Million of national currency units,526.8 +31020,Spain,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.9 +31021,Spain,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",14.3 +31022,Spain,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9 +31023,Spain,2013,4,N06A-Antidepressants,Million US$ at exchange rate,664.9 +31024,Spain,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",741.9 +31025,Spain,2013,4,N06A-Antidepressants,% of total sales,4.7 +31026,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",493.0 +31027,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.5 +31028,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,332.7 +31029,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,441.9 +31030,Spain,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,487.0 +31031,Spain,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,121.7 +31032,Spain,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,161.7 +31033,Spain,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",721.6 +31034,Spain,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,646.7 +31035,Spain,2013,4,N06A-Antidepressants,Million of national currency units,500.6 +31036,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.9 +31037,Spain,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,1.1 +31038,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",180.4 +31039,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5 +31040,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.7 +31041,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.3 +31042,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9 +31043,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",621.4 +31044,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",11.9 +31045,Spain,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2497.4 +31046,Spain,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.0 +31047,Spain,2013,4,A-Alimentary tract and metabolism,Million of national currency units,1685.3 +31048,Spain,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2238.2 +31049,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.3 +31050,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1367.8 +31051,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.7 +31052,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.3 +31053,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,419.3 +31054,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,556.9 +31055,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1225.8 +31056,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,923.0 +31057,Spain,2013,4,N02-Analgesics,"/capita, US$ exchange rate",13.9 +31058,Spain,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",15.6 +31059,Spain,2013,4,N02-Analgesics,% of total sales,4.6 +31060,Spain,2013,4,N02-Analgesics,"Million US$, purchasing power parity",725.0 +31061,Spain,2013,4,C02-Antihypertensives,Million of national currency units,40.1 +31062,Spain,2013,4,C02-Antihypertensives,Million US$ at exchange rate,53.2 +31063,Spain,2013,4,N02-Analgesics,Million of national currency units,489.2 +31064,Spain,2013,4,N02-Analgesics,Million US$ at exchange rate,649.7 +31065,Spain,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,945.0 +31066,Spain,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1255.1 +31067,Spain,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.6 +31068,Spain,2013,4,A-Alimentary tract and metabolism,% of total sales,15.8 +31069,Spain,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.0 +31070,Spain,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,8.9 +31071,Spain,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1400.5 +31072,Spain,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.9 +31073,Spain,2013,4,A10-Drugs used in diabetes,Million of national currency units,1024.7 +31074,Spain,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1361.0 +31075,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +31076,Spain,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",32.6 +31077,Spain,2013,4,A10-Drugs used in diabetes,% of total sales,9.6 +31078,Spain,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1518.6 +31079,Spain,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.2 +31080,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.0 +31081,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +31082,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,42.1 +31083,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +31084,Spain,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0 +31085,Spain,2010,4,J01-Antibacterials for systemic use,Million of national currency units,305.1 +31086,Spain,2010,4,J01-Antibacterials for systemic use,% of total sales,2.3 +31087,Spain,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,404.5 +31088,Spain,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",419.7 +31089,Spain,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.7 +31090,Spain,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8 +31091,Spain,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",81.5 +31092,Spain,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7 +31093,Spain,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.7 +31094,Spain,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0 +31095,Spain,2010,4,C02-Antihypertensives,% of total sales,0.4 +31096,Spain,2010,4,C08-Calcium channel blockers,% of total sales,1.8 +31097,Spain,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.4 +31098,Spain,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.8 +31099,Spain,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,485.0 +31100,Spain,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",503.3 +31101,Spain,2010,4,C03-Diuretics,Million US$ at exchange rate,165.2 +31102,Spain,2010,4,C03-Diuretics,"Million US$, purchasing power parity",171.4 +31103,Spain,2010,4,J-Antiinfectives for systemic use,% of total sales,2.8 +31104,Spain,2010,4,C03-Diuretics,Million of national currency units,124.6 +31105,Spain,2010,4,C07-Beta blocking agents,% of total sales,0.7 +31106,Spain,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.9 +31107,Spain,2010,4,N-Nervous system,Million of national currency units,3140.7 +31108,Spain,2010,4,N-Nervous system,Million US$ at exchange rate,4163.7 +31109,Spain,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,131.3 +31110,Spain,2010,4,C07-Beta blocking agents,Million of national currency units,99.0 +31111,Spain,2010,4,J-Antiinfectives for systemic use,Million of national currency units,365.9 +31112,Spain,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.8 +31113,Spain,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",136.2 +31114,Spain,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",92.8 +31115,Spain,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",327.9 +31116,Spain,2010,4,N-Nervous system,% of total sales,23.7 +31117,Spain,2010,4,N-Nervous system,"/capita, US$ exchange rate",89.4 +31118,Spain,2010,4,C-Cardiovascular system,Million US$ at exchange rate,4080.1 +31119,Spain,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",4233.6 +31120,Spain,2010,4,N-Nervous system,"Million US$, purchasing power parity",4320.3 +31121,Spain,2010,4,C-Cardiovascular system,Million of national currency units,3077.7 +31122,Spain,2010,4,C03-Diuretics,% of total sales,0.9 +31123,Spain,2010,4,C03-Diuretics,"/capita, US$ exchange rate",3.5 +31124,Spain,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.7 +31125,Spain,2010,4,C-Cardiovascular system,% of total sales,23.2 +31126,Spain,2010,4,C08-Calcium channel blockers,Million of national currency units,238.3 +31127,Spain,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,316.0 +31128,Spain,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",87.6 +31129,Spain,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.9 +31130,Spain,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1408.7 +31131,Spain,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,1357.6 +31132,Spain,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.2 +31133,Spain,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",29.1 +31134,Spain,2010,4,C10-Lipid modifying agents,Million of national currency units,1024.0 +31135,Spain,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.1 +31136,Spain,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",1163.2 +31137,Spain,2010,4,M-Musculo-skeletal system,% of total sales,6.4 +31138,Spain,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",25.0 +31139,Spain,2010,4,Total pharmaceutical sales,Million of national currency units,13238.8 +31140,Spain,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,17550.9 +31141,Spain,2010,4,B-Blood and blood forming organs,% of total sales,4.6 +31142,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0 +31143,Spain,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",391.0 +31144,Spain,2010,4,C10-Lipid modifying agents,% of total sales,7.7 +31145,Spain,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",18211.2 +31146,Spain,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",376.8 +31147,Spain,2010,4,M-Musculo-skeletal system,Million of national currency units,845.6 +31148,Spain,2010,4,R-Respiratory system,Million of national currency units,1304.6 +31149,Spain,2010,4,R-Respiratory system,Million US$ at exchange rate,1729.5 +31150,Spain,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,1121.0 +31151,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9 +31152,Spain,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.5 +31153,Spain,2010,4,R-Respiratory system,% of total sales,9.9 +31154,Spain,2010,4,R-Respiratory system,"Million US$, purchasing power parity",1794.5 +31155,Spain,2010,4,R-Respiratory system,"/capita, US$ exchange rate",37.1 +31156,Spain,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",167.9 +31157,Spain,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.5 +31158,Spain,2010,4,N05B-Anxiolytics,% of total sales,0.9 +31159,Spain,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6 +31160,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3 +31161,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6 +31162,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",353.3 +31163,Spain,2010,4,N05B-Anxiolytics,Million of national currency units,122.0 +31164,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,256.8 +31165,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,340.5 +31166,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.9 +31167,Spain,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",5.4 +31168,Spain,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31169,Spain,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.1 +31170,Spain,2010,4,C01A-Cardiac glycosides,Million of national currency units,4.0 +31171,Spain,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,5.2 +31172,Spain,2010,4,G-Genito urinary system and sex hormones,% of total sales,3.9 +31173,Spain,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1 +31174,Spain,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31175,Spain,2010,4,C01A-Cardiac glycosides,% of total sales,0.0 +31176,Spain,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2 +31177,Spain,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.9 +31178,Spain,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.3 +31179,Spain,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2 +31180,Spain,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",842.7 +31181,Spain,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.4 +31182,Spain,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,812.1 +31183,Spain,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,55.8 +31184,Spain,2010,4,B-Blood and blood forming organs,Million of national currency units,612.6 +31185,Spain,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,42.1 +31186,Spain,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",19.6 +31187,Spain,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.3 +31188,Spain,2010,4,N06A-Antidepressants,Million US$ at exchange rate,911.0 +31189,Spain,2010,4,N06A-Antidepressants,% of total sales,5.2 +31190,Spain,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",945.2 +31191,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",554.4 +31192,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5 +31193,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,403.0 +31194,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,534.3 +31195,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,22.8 +31196,Spain,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,512.2 +31197,Spain,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,124.8 +31198,Spain,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.5 +31199,Spain,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,679.0 +31200,Spain,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.6 +31201,Spain,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",704.5 +31202,Spain,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +31203,Spain,2010,4,N06A-Antidepressants,Million of national currency units,687.2 +31204,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7 +31205,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",171.7 +31206,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6 +31207,Spain,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,161.8 +31208,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.0 +31209,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.4 +31210,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.7 +31211,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",901.5 +31212,Spain,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2446.7 +31213,Spain,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.6 +31214,Spain,2010,4,A-Alimentary tract and metabolism,Million of national currency units,1778.6 +31215,Spain,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2358.0 +31216,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5 +31217,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4 +31218,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1714.3 +31219,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,655.4 +31220,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,868.9 +31221,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1246.3 +31222,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1652.2 +31223,Spain,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.3 +31224,Spain,2010,4,N02-Analgesics,"/capita, US$ exchange rate",13.8 +31225,Spain,2010,4,N02-Analgesics,% of total sales,3.7 +31226,Spain,2010,4,N02-Analgesics,Million of national currency units,485.0 +31227,Spain,2010,4,C02-Antihypertensives,Million of national currency units,59.2 +31228,Spain,2010,4,C02-Antihypertensives,Million US$ at exchange rate,78.5 +31229,Spain,2010,4,N02-Analgesics,"Million US$, purchasing power parity",667.2 +31230,Spain,2010,4,N02-Analgesics,Million US$ at exchange rate,643.0 +31231,Spain,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1043.8 +31232,Spain,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1383.8 +31233,Spain,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",52.5 +31234,Spain,2010,4,A-Alimentary tract and metabolism,% of total sales,13.4 +31235,Spain,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.8 +31236,Spain,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,7.9 +31237,Spain,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1435.9 +31238,Spain,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.7 +31239,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.8 +31240,Spain,2010,4,A02A-Antacids,Million US$ at exchange rate,25.6 +31241,Spain,2010,4,A02A-Antacids,Million of national currency units,19.3 +31242,Spain,2010,4,A10-Drugs used in diabetes,Million of national currency units,802.4 +31243,Spain,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1063.8 +31244,Spain,2010,4,A02A-Antacids,"Million US$, purchasing power parity",26.6 +31245,Spain,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.6 +31246,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +31247,Spain,2010,4,A02A-Antacids,% of total sales,0.1 +31248,Spain,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6 +31249,Spain,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.7 +31250,Spain,2010,4,A10-Drugs used in diabetes,% of total sales,6.1 +31251,Spain,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1103.8 +31252,Spain,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.8 +31253,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",31.4 +31254,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6 +31255,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +31256,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,30.2 +31257,Spain,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1 +31258,Spain,2015,4,J01-Antibacterials for systemic use,% of total sales,2.2 +31259,Spain,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0 +31260,Spain,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,277.1 +31261,Spain,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",375.7 +31262,Spain,2015,4,J01-Antibacterials for systemic use,Million of national currency units,249.7 +31263,Spain,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",61.6 +31264,Spain,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +31265,Spain,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",3237.1 +31266,Spain,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.0 +31267,Spain,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5 +31268,Spain,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +31269,Spain,2015,4,C02-Antihypertensives,% of total sales,0.4 +31270,Spain,2015,4,C08-Calcium channel blockers,% of total sales,0.9 +31271,Spain,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.2 +31272,Spain,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.8 +31273,Spain,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,335.6 +31274,Spain,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",455.0 +31275,Spain,2015,4,C03-Diuretics,Million US$ at exchange rate,102.8 +31276,Spain,2015,4,C03-Diuretics,"Million US$, purchasing power parity",139.4 +31277,Spain,2015,4,J-Antiinfectives for systemic use,% of total sales,2.7 +31278,Spain,2015,4,C03-Diuretics,Million of national currency units,92.6 +31279,Spain,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.7 +31280,Spain,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.0 +31281,Spain,2015,4,C07-Beta blocking agents,% of total sales,0.7 +31282,Spain,2015,4,N-Nervous system,Million of national currency units,2946.2 +31283,Spain,2015,4,C07-Beta blocking agents,Million of national currency units,82.9 +31284,Spain,2015,4,J-Antiinfectives for systemic use,Million of national currency units,302.5 +31285,Spain,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",124.6 +31286,Spain,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,91.9 +31287,Spain,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",95.4 +31288,Spain,2015,4,N-Nervous system,"/capita, US$ exchange rate",70.4 +31289,Spain,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",162.8 +31290,Spain,2015,4,N-Nervous system,% of total sales,25.8 +31291,Spain,2015,4,C-Cardiovascular system,Million of national currency units,2151.8 +31292,Spain,2015,4,C-Cardiovascular system,Million US$ at exchange rate,2387.5 +31293,Spain,2015,4,N-Nervous system,"Million US$, purchasing power parity",4432.1 +31294,Spain,2015,4,N-Nervous system,Million US$ at exchange rate,3268.8 +31295,Spain,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,120.1 +31296,Spain,2015,4,C03-Diuretics,% of total sales,0.8 +31297,Spain,2015,4,C-Cardiovascular system,% of total sales,18.9 +31298,Spain,2015,4,C03-Diuretics,"/capita, US$ exchange rate",2.2 +31299,Spain,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.0 +31300,Spain,2015,4,C08-Calcium channel blockers,Million of national currency units,108.2 +31301,Spain,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.7 +31302,Spain,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",51.4 +31303,Spain,2015,4,C02-Antihypertensives,Million US$ at exchange rate,45.4 +31304,Spain,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,849.1 +31305,Spain,2015,4,C10-Lipid modifying agents,Million of national currency units,765.3 +31306,Spain,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.8 +31307,Spain,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.3 +31308,Spain,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1151.3 +31309,Spain,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",694.3 +31310,Spain,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.0 +31311,Spain,2015,4,M-Musculo-skeletal system,% of total sales,4.0 +31312,Spain,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.9 +31313,Spain,2015,4,B-Blood and blood forming organs,% of total sales,5.7 +31314,Spain,2015,4,Total pharmaceutical sales,Million of national currency units,11403.6 +31315,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8 +31316,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4 +31317,Spain,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",369.4 +31318,Spain,2015,4,C10-Lipid modifying agents,% of total sales,6.7 +31319,Spain,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17155.0 +31320,Spain,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,12652.5 +31321,Spain,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",272.4 +31322,Spain,2015,4,N05B-Anxiolytics,% of total sales,0.9 +31323,Spain,2015,4,M-Musculo-skeletal system,Million of national currency units,461.5 +31324,Spain,2015,4,R-Respiratory system,Million of national currency units,1182.8 +31325,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +31326,Spain,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,512.1 +31327,Spain,2015,4,R-Respiratory system,Million US$ at exchange rate,1312.3 +31328,Spain,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.3 +31329,Spain,2015,4,R-Respiratory system,% of total sales,10.4 +31330,Spain,2015,4,R-Respiratory system,"Million US$, purchasing power parity",1779.3 +31331,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.4 +31332,Spain,2015,4,R-Respiratory system,"/capita, US$ exchange rate",28.3 +31333,Spain,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",151.4 +31334,Spain,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,111.7 +31335,Spain,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.3 +31336,Spain,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4 +31337,Spain,2015,4,N05B-Anxiolytics,Million of national currency units,100.7 +31338,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",343.8 +31339,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.5 +31340,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,228.5 +31341,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,253.5 +31342,Spain,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.5 +31343,Spain,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31344,Spain,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,3.3 +31345,Spain,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.1 +31346,Spain,2015,4,C01A-Cardiac glycosides,Million of national currency units,3.0 +31347,Spain,2015,4,G-Genito urinary system and sex hormones,% of total sales,4.7 +31348,Spain,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",17.3 +31349,Spain,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31350,Spain,2015,4,C01A-Cardiac glycosides,% of total sales,0.0 +31351,Spain,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.6 +31352,Spain,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1 +31353,Spain,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",68.6 +31354,Spain,2015,4,N05C-Hypnotics and sedatives,% of total sales,0.4 +31355,Spain,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,50.6 +31356,Spain,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5 +31357,Spain,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,724.3 +31358,Spain,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",982.0 +31359,Spain,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,45.6 +31360,Spain,2015,4,B-Blood and blood forming organs,Million of national currency units,652.8 +31361,Spain,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.8 +31362,Spain,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.6 +31363,Spain,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.7 +31364,Spain,2015,4,N06A-Antidepressants,Million US$ at exchange rate,537.7 +31365,Spain,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",729.0 +31366,Spain,2015,4,N06A-Antidepressants,Million of national currency units,484.6 +31367,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",409.4 +31368,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5 +31369,Spain,2015,4,N06A-Antidepressants,% of total sales,4.2 +31370,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,302.0 +31371,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,272.2 +31372,Spain,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,534.8 +31373,Spain,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,96.6 +31374,Spain,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",804.6 +31375,Spain,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,593.4 +31376,Spain,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,107.1 +31377,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.1 +31378,Spain,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.8 +31379,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",145.3 +31380,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3 +31381,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.4 +31382,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6 +31383,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",623.5 +31384,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.9 +31385,Spain,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2945.5 +31386,Spain,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",46.8 +31387,Spain,2015,4,A-Alimentary tract and metabolism,Million of national currency units,1958.0 +31388,Spain,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2172.4 +31389,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.8 +31390,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1308.9 +31391,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.6 +31392,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.2 +31393,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,414.5 +31394,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,459.8 +31395,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,965.3 +31396,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,870.1 +31397,Spain,2015,4,N02-Analgesics,"/capita, US$ exchange rate",14.8 +31398,Spain,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",20.1 +31399,Spain,2015,4,N02-Analgesics,% of total sales,5.4 +31400,Spain,2015,4,N02-Analgesics,"Million US$, purchasing power parity",932.7 +31401,Spain,2015,4,C02-Antihypertensives,Million of national currency units,40.9 +31402,Spain,2015,4,N02-Analgesics,Million of national currency units,620.0 +31403,Spain,2015,4,N02-Analgesics,Million US$ at exchange rate,687.9 +31404,Spain,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1007.5 +31405,Spain,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1117.9 +31406,Spain,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.4 +31407,Spain,2015,4,A-Alimentary tract and metabolism,% of total sales,17.2 +31408,Spain,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.6 +31409,Spain,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,8.8 +31410,Spain,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1515.7 +31411,Spain,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.1 +31412,Spain,2015,4,A10-Drugs used in diabetes,Million of national currency units,1269.7 +31413,Spain,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1408.7 +31414,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +31415,Spain,2015,4,A10-Drugs used in diabetes,% of total sales,11.1 +31416,Spain,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",41.1 +31417,Spain,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1910.0 +31418,Spain,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.3 +31419,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,40.7 +31420,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",55.2 +31421,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.7 +31422,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +31423,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +31424,Spain,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1 +31425,Spain,2016,4,J01-Antibacterials for systemic use,% of total sales,2.1 +31426,Spain,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,268.9 +31427,Spain,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",378.1 +31428,Spain,2016,4,J01-Antibacterials for systemic use,Million of national currency units,243.0 +31429,Spain,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8 +31430,Spain,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",64.0 +31431,Spain,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4 +31432,Spain,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",3478.8 +31433,Spain,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.0 +31434,Spain,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6 +31435,Spain,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +31436,Spain,2016,4,C02-Antihypertensives,% of total sales,0.3 +31437,Spain,2016,4,C08-Calcium channel blockers,% of total sales,0.9 +31438,Spain,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1 +31439,Spain,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0 +31440,Spain,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,329.7 +31441,Spain,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",463.5 +31442,Spain,2016,4,C03-Diuretics,Million US$ at exchange rate,104.6 +31443,Spain,2016,4,C03-Diuretics,"Million US$, purchasing power parity",147.1 +31444,Spain,2016,4,J-Antiinfectives for systemic use,% of total sales,2.5 +31445,Spain,2016,4,C03-Diuretics,Million of national currency units,94.5 +31446,Spain,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.9 +31447,Spain,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.0 +31448,Spain,2016,4,N-Nervous system,Million of national currency units,3022.3 +31449,Spain,2016,4,C07-Beta blocking agents,% of total sales,0.7 +31450,Spain,2016,4,C07-Beta blocking agents,Million of national currency units,85.9 +31451,Spain,2016,4,J-Antiinfectives for systemic use,Million of national currency units,297.9 +31452,Spain,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",133.7 +31453,Spain,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,95.1 +31454,Spain,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",101.2 +31455,Spain,2016,4,N-Nervous system,"/capita, US$ exchange rate",72.0 +31456,Spain,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",168.9 +31457,Spain,2016,4,N-Nervous system,% of total sales,25.5 +31458,Spain,2016,4,C-Cardiovascular system,Million of national currency units,2235.6 +31459,Spain,2016,4,C-Cardiovascular system,Million US$ at exchange rate,2474.6 +31460,Spain,2016,4,N-Nervous system,"Million US$, purchasing power parity",4702.9 +31461,Spain,2016,4,N-Nervous system,Million US$ at exchange rate,3345.4 +31462,Spain,2016,4,C03-Diuretics,% of total sales,0.8 +31463,Spain,2016,4,C-Cardiovascular system,% of total sales,18.9 +31464,Spain,2016,4,C03-Diuretics,"/capita, US$ exchange rate",2.3 +31465,Spain,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2 +31466,Spain,2016,4,C08-Calcium channel blockers,Million of national currency units,108.6 +31467,Spain,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.8 +31468,Spain,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",53.2 +31469,Spain,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,120.2 +31470,Spain,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,915.8 +31471,Spain,2016,4,C10-Lipid modifying agents,Million of national currency units,827.3 +31472,Spain,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1287.4 +31473,Spain,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.7 +31474,Spain,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.7 +31475,Spain,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",724.2 +31476,Spain,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.1 +31477,Spain,2016,4,M-Musculo-skeletal system,% of total sales,3.9 +31478,Spain,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6 +31479,Spain,2016,4,B-Blood and blood forming organs,% of total sales,6.2 +31480,Spain,2016,4,Total pharmaceutical sales,Million of national currency units,11833.0 +31481,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0 +31482,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3 +31483,Spain,2016,4,N05B-Anxiolytics,% of total sales,0.9 +31484,Spain,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,13098.0 +31485,Spain,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",396.1 +31486,Spain,2016,4,C10-Lipid modifying agents,% of total sales,7.0 +31487,Spain,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",18412.9 +31488,Spain,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",281.8 +31489,Spain,2016,4,M-Musculo-skeletal system,Million of national currency units,465.4 +31490,Spain,2016,4,R-Respiratory system,Million of national currency units,1161.6 +31491,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9 +31492,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +31493,Spain,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,515.2 +31494,Spain,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.9 +31495,Spain,2016,4,R-Respiratory system,% of total sales,9.8 +31496,Spain,2016,4,R-Respiratory system,Million US$ at exchange rate,1285.8 +31497,Spain,2016,4,R-Respiratory system,"Million US$, purchasing power parity",1807.6 +31498,Spain,2016,4,R-Respiratory system,"/capita, US$ exchange rate",27.7 +31499,Spain,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",157.0 +31500,Spain,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,111.7 +31501,Spain,2016,4,C02-Antihypertensives,Million US$ at exchange rate,45.5 +31502,Spain,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4 +31503,Spain,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4 +31504,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",368.2 +31505,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.6 +31506,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,236.6 +31507,Spain,2016,4,N05B-Anxiolytics,Million of national currency units,100.9 +31508,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,261.9 +31509,Spain,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.3 +31510,Spain,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31511,Spain,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,3.1 +31512,Spain,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.4 +31513,Spain,2016,4,C01A-Cardiac glycosides,Million of national currency units,2.8 +31514,Spain,2016,4,G-Genito urinary system and sex hormones,% of total sales,4.8 +31515,Spain,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.1 +31516,Spain,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31517,Spain,2016,4,C01A-Cardiac glycosides,% of total sales,0.0 +31518,Spain,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.4 +31519,Spain,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1 +31520,Spain,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",73.0 +31521,Spain,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,51.9 +31522,Spain,2016,4,N05C-Hypnotics and sedatives,% of total sales,0.4 +31523,Spain,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6 +31524,Spain,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.6 +31525,Spain,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,806.9 +31526,Spain,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",1134.4 +31527,Spain,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,46.9 +31528,Spain,2016,4,B-Blood and blood forming organs,Million of national currency units,729.0 +31529,Spain,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.5 +31530,Spain,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2 +31531,Spain,2016,4,N06A-Antidepressants,Million of national currency units,483.9 +31532,Spain,2016,4,N06A-Antidepressants,Million US$ at exchange rate,535.6 +31533,Spain,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",753.0 +31534,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",420.0 +31535,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4 +31536,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,298.7 +31537,Spain,2016,4,N06A-Antidepressants,% of total sales,4.1 +31538,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,269.9 +31539,Spain,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,571.4 +31540,Spain,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,99.3 +31541,Spain,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",889.2 +31542,Spain,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,632.5 +31543,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3 +31544,Spain,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.8 +31545,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",154.6 +31546,Spain,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,110.0 +31547,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.4 +31548,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.2 +31549,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6 +31550,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",657.9 +31551,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.1 +31552,Spain,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3274.4 +31553,Spain,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.1 +31554,Spain,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2104.3 +31555,Spain,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2329.2 +31556,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.1 +31557,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1375.6 +31558,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.5 +31559,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6 +31560,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,422.8 +31561,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,468.0 +31562,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,978.5 +31563,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,884.0 +31564,Spain,2016,4,N02-Analgesics,"/capita, US$ exchange rate",16.4 +31565,Spain,2016,4,N02-Analgesics,% of total sales,5.8 +31566,Spain,2016,4,N02-Analgesics,"Million US$, purchasing power parity",1069.4 +31567,Spain,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.0 +31568,Spain,2016,4,C02-Antihypertensives,Million of national currency units,41.1 +31569,Spain,2016,4,N02-Analgesics,Million of national currency units,687.3 +31570,Spain,2016,4,N02-Analgesics,Million US$ at exchange rate,760.7 +31571,Spain,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,981.7 +31572,Spain,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1086.6 +31573,Spain,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.4 +31574,Spain,2016,4,A-Alimentary tract and metabolism,% of total sales,17.8 +31575,Spain,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.9 +31576,Spain,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,8.3 +31577,Spain,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1527.5 +31578,Spain,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.4 +31579,Spain,2016,4,A10-Drugs used in diabetes,Million of national currency units,1383.9 +31580,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +31581,Spain,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1531.8 +31582,Spain,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",46.3 +31583,Spain,2016,4,A10-Drugs used in diabetes,% of total sales,11.7 +31584,Spain,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2153.4 +31585,Spain,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.0 +31586,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +31587,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,39.2 +31588,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",55.1 +31589,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,35.4 +31590,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +31591,Spain,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1 +31592,Spain,2017,4,J01-Antibacterials for systemic use,% of total sales,2.0 +31593,Spain,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8 +31594,Spain,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,268.2 +31595,Spain,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",376.3 +31596,Spain,2017,4,J01-Antibacterials for systemic use,Million of national currency units,237.4 +31597,Spain,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",71.7 +31598,Spain,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.5 +31599,Spain,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",3491.4 +31600,Spain,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1 +31601,Spain,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7 +31602,Spain,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6 +31603,Spain,2017,4,C02-Antihypertensives,% of total sales,0.4 +31604,Spain,2017,4,C08-Calcium channel blockers,% of total sales,0.9 +31605,Spain,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1 +31606,Spain,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0 +31607,Spain,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,331.2 +31608,Spain,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",464.8 +31609,Spain,2017,4,C03-Diuretics,Million US$ at exchange rate,108.5 +31610,Spain,2017,4,C03-Diuretics,"Million US$, purchasing power parity",152.2 +31611,Spain,2017,4,J-Antiinfectives for systemic use,% of total sales,2.4 +31612,Spain,2017,4,C03-Diuretics,Million of national currency units,96.0 +31613,Spain,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.0 +31614,Spain,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.1 +31615,Spain,2017,4,N-Nervous system,Million of national currency units,3070.2 +31616,Spain,2017,4,C07-Beta blocking agents,% of total sales,0.7 +31617,Spain,2017,4,C07-Beta blocking agents,Million of national currency units,88.5 +31618,Spain,2017,4,J-Antiinfectives for systemic use,Million of national currency units,293.2 +31619,Spain,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",140.4 +31620,Spain,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,100.0 +31621,Spain,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",104.5 +31622,Spain,2017,4,N-Nervous system,"/capita, US$ exchange rate",74.4 +31623,Spain,2017,4,N-Nervous system,% of total sales,25.4 +31624,Spain,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",170.7 +31625,Spain,2017,4,C-Cardiovascular system,Million of national currency units,2202.5 +31626,Spain,2017,4,C-Cardiovascular system,Million US$ at exchange rate,2488.1 +31627,Spain,2017,4,N-Nervous system,"Million US$, purchasing power parity",4866.9 +31628,Spain,2017,4,N-Nervous system,Million US$ at exchange rate,3468.4 +31629,Spain,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,121.6 +31630,Spain,2017,4,C03-Diuretics,% of total sales,0.8 +31631,Spain,2017,4,C-Cardiovascular system,% of total sales,18.3 +31632,Spain,2017,4,C03-Diuretics,"/capita, US$ exchange rate",2.3 +31633,Spain,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.3 +31634,Spain,2017,4,C08-Calcium channel blockers,Million of national currency units,107.7 +31635,Spain,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.9 +31636,Spain,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",53.4 +31637,Spain,2017,4,C02-Antihypertensives,Million US$ at exchange rate,51.1 +31638,Spain,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,969.4 +31639,Spain,2017,4,C10-Lipid modifying agents,Million of national currency units,858.1 +31640,Spain,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.2 +31641,Spain,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.8 +31642,Spain,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1360.3 +31643,Spain,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",710.4 +31644,Spain,2017,4,N05B-Anxiolytics,% of total sales,0.8 +31645,Spain,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.9 +31646,Spain,2017,4,M-Musculo-skeletal system,% of total sales,3.7 +31647,Spain,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.2 +31648,Spain,2017,4,B-Blood and blood forming organs,% of total sales,6.7 +31649,Spain,2017,4,Total pharmaceutical sales,Million of national currency units,12064.9 +31650,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4 +31651,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +31652,Spain,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.4 +31653,Spain,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.5 +31654,Spain,2017,4,C10-Lipid modifying agents,% of total sales,7.1 +31655,Spain,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,13629.5 +31656,Spain,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",19125.2 +31657,Spain,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",292.5 +31658,Spain,2017,4,M-Musculo-skeletal system,Million of national currency units,448.2 +31659,Spain,2017,4,R-Respiratory system,Million of national currency units,1134.8 +31660,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.4 +31661,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1 +31662,Spain,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,506.3 +31663,Spain,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.6 +31664,Spain,2017,4,R-Respiratory system,% of total sales,9.4 +31665,Spain,2017,4,R-Respiratory system,Million US$ at exchange rate,1281.9 +31666,Spain,2017,4,R-Respiratory system,"/capita, US$ exchange rate",27.5 +31667,Spain,2017,4,R-Respiratory system,"Million US$, purchasing power parity",1798.8 +31668,Spain,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",159.1 +31669,Spain,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,113.4 +31670,Spain,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4 +31671,Spain,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4 +31672,Spain,2017,4,N05B-Anxiolytics,Million of national currency units,100.4 +31673,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",392.1 +31674,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0 +31675,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,247.3 +31676,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,279.4 +31677,Spain,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,2.9 +31678,Spain,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.0 +31679,Spain,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31680,Spain,2017,4,C01A-Cardiac glycosides,Million of national currency units,2.5 +31681,Spain,2017,4,G-Genito urinary system and sex hormones,% of total sales,5.0 +31682,Spain,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.4 +31683,Spain,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.5 +31684,Spain,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31685,Spain,2017,4,C01A-Cardiac glycosides,% of total sales,0.0 +31686,Spain,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.5 +31687,Spain,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",75.5 +31688,Spain,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,53.8 +31689,Spain,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2 +31690,Spain,2017,4,N05C-Hypnotics and sedatives,% of total sales,0.4 +31691,Spain,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6 +31692,Spain,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,910.7 +31693,Spain,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",1277.9 +31694,Spain,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,47.6 +31695,Spain,2017,4,B-Blood and blood forming organs,Million of national currency units,806.2 +31696,Spain,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",12.1 +31697,Spain,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.0 +31698,Spain,2017,4,N06A-Antidepressants,Million of national currency units,500.8 +31699,Spain,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",793.8 +31700,Spain,2017,4,N06A-Antidepressants,Million US$ at exchange rate,565.7 +31701,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",391.1 +31702,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0 +31703,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,278.7 +31704,Spain,2017,4,N06A-Antidepressants,% of total sales,4.2 +31705,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,246.7 +31706,Spain,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,600.1 +31707,Spain,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,107.7 +31708,Spain,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",951.3 +31709,Spain,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,677.9 +31710,Spain,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,121.7 +31711,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7 +31712,Spain,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +31713,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",170.7 +31714,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.6 +31715,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.4 +31716,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.5 +31717,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",671.5 +31718,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.3 +31719,Spain,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3512.0 +31720,Spain,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.7 +31721,Spain,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2215.5 +31722,Spain,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2502.8 +31723,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.3 +31724,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1328.0 +31725,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.9 +31726,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.5 +31727,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,423.6 +31728,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,478.6 +31729,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,946.4 +31730,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,837.8 +31731,Spain,2017,4,N02-Analgesics,"/capita, US$ exchange rate",17.4 +31732,Spain,2017,4,N02-Analgesics,"Million US$, purchasing power parity",1138.5 +31733,Spain,2017,4,N02-Analgesics,% of total sales,6.0 +31734,Spain,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",24.4 +31735,Spain,2017,4,C02-Antihypertensives,Million of national currency units,45.2 +31736,Spain,2017,4,N02-Analgesics,Million US$ at exchange rate,811.4 +31737,Spain,2017,4,N02-Analgesics,Million of national currency units,718.2 +31738,Spain,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,8.0 +31739,Spain,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,961.2 +31740,Spain,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",75.4 +31741,Spain,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1085.8 +31742,Spain,2017,4,A-Alimentary tract and metabolism,% of total sales,18.4 +31743,Spain,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.7 +31744,Spain,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.3 +31745,Spain,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1523.6 +31746,Spain,2017,4,A10-Drugs used in diabetes,Million of national currency units,1467.1 +31747,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +31748,Spain,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.9 +31749,Spain,2017,4,A10-Drugs used in diabetes,% of total sales,12.2 +31750,Spain,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1657.4 +31751,Spain,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2325.7 +31752,Spain,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",35.6 +31753,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,33.5 +31754,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.0 +31755,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0 +31756,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7 +31757,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.6 +31758,Spain,2014,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1 +31759,Spain,2014,4,J01-Antibacterials for systemic use,% of total sales,2.2 +31760,Spain,2014,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.1 +31761,Spain,2014,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",378.6 +31762,Spain,2014,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2 +31763,Spain,2014,4,J01-Antibacterials for systemic use,Million of national currency units,250.8 +31764,Spain,2014,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2 +31765,Spain,2014,4,C02-Antihypertensives,"Million US$, purchasing power parity",62.4 +31766,Spain,2014,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3 +31767,Spain,2014,4,C-Cardiovascular system,"Million US$, purchasing power parity",3232.1 +31768,Spain,2014,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7 +31769,Spain,2014,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2 +31770,Spain,2014,4,C02-Antihypertensives,% of total sales,0.4 +31771,Spain,2014,4,C08-Calcium channel blockers,% of total sales,1.0 +31772,Spain,2014,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",8.6 +31773,Spain,2014,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.8 +31774,Spain,2014,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,401.5 +31775,Spain,2014,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",456.2 +31776,Spain,2014,4,C03-Diuretics,Million US$ at exchange rate,136.6 +31777,Spain,2014,4,C03-Diuretics,"Million US$, purchasing power parity",155.2 +31778,Spain,2014,4,J-Antiinfectives for systemic use,% of total sales,2.7 +31779,Spain,2014,4,C03-Diuretics,Million of national currency units,102.8 +31780,Spain,2014,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.7 +31781,Spain,2014,4,N-Nervous system,Million of national currency units,3043.9 +31782,Spain,2014,4,C07-Beta blocking agents,% of total sales,0.7 +31783,Spain,2014,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.4 +31784,Spain,2014,4,C07-Beta blocking agents,Million of national currency units,84.4 +31785,Spain,2014,4,J-Antiinfectives for systemic use,Million of national currency units,302.2 +31786,Spain,2014,4,C07-Beta blocking agents,Million US$ at exchange rate,112.1 +31787,Spain,2014,4,C07-Beta blocking agents,"Million US$, purchasing power parity",127.4 +31788,Spain,2014,4,N-Nervous system,"/capita, US$ purchasing power parity",98.9 +31789,Spain,2014,4,N-Nervous system,"/capita, US$ exchange rate",87.0 +31790,Spain,2014,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",169.9 +31791,Spain,2014,4,N-Nervous system,% of total sales,26.9 +31792,Spain,2014,4,C-Cardiovascular system,Million of national currency units,2140.8 +31793,Spain,2014,4,C-Cardiovascular system,Million US$ at exchange rate,2844.1 +31794,Spain,2014,4,N-Nervous system,"Million US$, purchasing power parity",4595.6 +31795,Spain,2014,4,N-Nervous system,Million US$ at exchange rate,4043.9 +31796,Spain,2014,4,C03-Diuretics,% of total sales,0.9 +31797,Spain,2014,4,C-Cardiovascular system,% of total sales,18.9 +31798,Spain,2014,4,C03-Diuretics,"/capita, US$ exchange rate",2.9 +31799,Spain,2014,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.3 +31800,Spain,2014,4,C08-Calcium channel blockers,Million of national currency units,112.6 +31801,Spain,2014,4,C08-Calcium channel blockers,Million US$ at exchange rate,149.5 +31802,Spain,2014,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.5 +31803,Spain,2014,4,C-Cardiovascular system,"/capita, US$ exchange rate",61.2 +31804,Spain,2014,4,C10-Lipid modifying agents,Million US$ at exchange rate,950.3 +31805,Spain,2014,4,C10-Lipid modifying agents,Million of national currency units,715.3 +31806,Spain,2014,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1080.0 +31807,Spain,2014,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.2 +31808,Spain,2014,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.4 +31809,Spain,2014,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.6 +31810,Spain,2014,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",769.1 +31811,Spain,2014,4,M-Musculo-skeletal system,% of total sales,4.5 +31812,Spain,2014,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.5 +31813,Spain,2014,4,B-Blood and blood forming organs,% of total sales,5.3 +31814,Spain,2014,4,Total pharmaceutical sales,Million of national currency units,11302.6 +31815,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0 +31816,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7 +31817,Spain,2014,4,Total pharmaceutical sales,Million US$ at exchange rate,15015.6 +31818,Spain,2014,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.1 +31819,Spain,2014,4,C10-Lipid modifying agents,% of total sales,6.3 +31820,Spain,2014,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17064.2 +31821,Spain,2014,4,Total pharmaceutical sales,"/capita, US$ exchange rate",323.0 +31822,Spain,2014,4,M-Musculo-skeletal system,Million of national currency units,509.4 +31823,Spain,2014,4,R-Respiratory system,Million of national currency units,1150.2 +31824,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0 +31825,Spain,2014,4,M-Musculo-skeletal system,Million US$ at exchange rate,676.7 +31826,Spain,2014,4,R-Respiratory system,Million US$ at exchange rate,1528.0 +31827,Spain,2014,4,R-Respiratory system,"/capita, US$ purchasing power parity",37.4 +31828,Spain,2014,4,R-Respiratory system,% of total sales,10.2 +31829,Spain,2014,4,R-Respiratory system,"Million US$, purchasing power parity",1736.5 +31830,Spain,2014,4,R-Respiratory system,"/capita, US$ exchange rate",32.9 +31831,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3 +31832,Spain,2014,4,N05B-Anxiolytics,"Million US$, purchasing power parity",156.8 +31833,Spain,2014,4,N05B-Anxiolytics,Million US$ at exchange rate,137.9 +31834,Spain,2014,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4 +31835,Spain,2014,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0 +31836,Spain,2014,4,N05B-Anxiolytics,% of total sales,0.9 +31837,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",338.9 +31838,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.4 +31839,Spain,2014,4,N05B-Anxiolytics,Million of national currency units,103.8 +31840,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,224.5 +31841,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,298.2 +31842,Spain,2014,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.8 +31843,Spain,2014,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31844,Spain,2014,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.3 +31845,Spain,2014,4,C01A-Cardiac glycosides,Million of national currency units,3.2 +31846,Spain,2014,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.2 +31847,Spain,2014,4,G-Genito urinary system and sex hormones,% of total sales,4.6 +31848,Spain,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.7 +31849,Spain,2014,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31850,Spain,2014,4,C01A-Cardiac glycosides,% of total sales,0.0 +31851,Spain,2014,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3 +31852,Spain,2014,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",67.6 +31853,Spain,2014,4,N05C-Hypnotics and sedatives,% of total sales,0.4 +31854,Spain,2014,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5 +31855,Spain,2014,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,59.4 +31856,Spain,2014,4,B-Blood and blood forming organs,Million US$ at exchange rate,788.8 +31857,Spain,2014,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",896.4 +31858,Spain,2014,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.0 +31859,Spain,2014,4,N05C-Hypnotics and sedatives,Million of national currency units,44.7 +31860,Spain,2014,4,B-Blood and blood forming organs,Million of national currency units,593.7 +31861,Spain,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.7 +31862,Spain,2014,4,N06A-Antidepressants,"/capita, US$ exchange rate",15.3 +31863,Spain,2014,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.4 +31864,Spain,2014,4,N06A-Antidepressants,Million US$ at exchange rate,711.2 +31865,Spain,2014,4,N06A-Antidepressants,"Million US$, purchasing power parity",808.2 +31866,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",467.0 +31867,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.8 +31868,Spain,2014,4,N06A-Antidepressants,% of total sales,4.7 +31869,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,309.3 +31870,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,410.9 +31871,Spain,2014,4,N06A-Antidepressants,Million of national currency units,535.3 +31872,Spain,2014,4,G-Genito urinary system and sex hormones,Million of national currency units,515.1 +31873,Spain,2014,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,103.4 +31874,Spain,2014,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",777.6 +31875,Spain,2014,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,137.4 +31876,Spain,2014,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,684.3 +31877,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4 +31878,Spain,2014,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9 +31879,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",156.1 +31880,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.0 +31881,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.7 +31882,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7 +31883,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",635.4 +31884,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.0 +31885,Spain,2014,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2796.7 +31886,Spain,2014,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.9 +31887,Spain,2014,4,A-Alimentary tract and metabolism,Million of national currency units,1852.4 +31888,Spain,2014,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2460.9 +31889,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.6 +31890,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1350.6 +31891,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9 +31892,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.1 +31893,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,420.8 +31894,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,559.1 +31895,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1188.4 +31896,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,894.6 +31897,Spain,2014,4,N02-Analgesics,"/capita, US$ exchange rate",16.3 +31898,Spain,2014,4,N02-Analgesics,"/capita, US$ purchasing power parity",18.5 +31899,Spain,2014,4,N02-Analgesics,% of total sales,5.0 +31900,Spain,2014,4,C02-Antihypertensives,Million of national currency units,41.3 +31901,Spain,2014,4,C02-Antihypertensives,Million US$ at exchange rate,54.9 +31902,Spain,2014,4,N02-Analgesics,Million of national currency units,570.2 +31903,Spain,2014,4,N02-Analgesics,"Million US$, purchasing power parity",860.9 +31904,Spain,2014,4,N02-Analgesics,Million US$ at exchange rate,757.6 +31905,Spain,2014,4,R03-Drugs for obstructive airway diseases,Million of national currency units,985.8 +31906,Spain,2014,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1309.6 +31907,Spain,2014,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",60.2 +31908,Spain,2014,4,A-Alimentary tract and metabolism,% of total sales,16.4 +31909,Spain,2014,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.0 +31910,Spain,2014,4,R03-Drugs for obstructive airway diseases,% of total sales,8.7 +31911,Spain,2014,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1488.3 +31912,Spain,2014,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.2 +31913,Spain,2014,4,A10-Drugs used in diabetes,Million of national currency units,1167.2 +31914,Spain,2014,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1550.7 +31915,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3 +31916,Spain,2014,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.9 +31917,Spain,2014,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1762.2 +31918,Spain,2014,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.4 +31919,Spain,2014,4,A10-Drugs used in diabetes,% of total sales,10.3 +31920,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",53.5 +31921,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,47.1 +31922,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,35.5 +31923,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0 +31924,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2 +31925,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9 +31926,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +31927,Sweden,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",78.4 +31928,Sweden,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",521.7 +31929,Sweden,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,81.2 +31930,Sweden,2017,4,C03-Diuretics,"Million US$, purchasing power parity",25.0 +31931,Sweden,2017,4,C03-Diuretics,Million US$ at exchange rate,25.9 +31932,Sweden,2017,4,C03-Diuretics,Million of national currency units,221.4 +31933,Sweden,2017,4,C03-Diuretics,% of total sales,0.5 +31934,Sweden,2017,4,C-Cardiovascular system,Million US$ at exchange rate,294.2 +31935,Sweden,2017,4,C03-Diuretics,"/capita, US$ exchange rate",2.6 +31936,Sweden,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.5 +31937,Sweden,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.9 +31938,Sweden,2017,4,A-Alimentary tract and metabolism,% of total sales,10.6 +31939,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,80.9 +31940,Sweden,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.7 +31941,Sweden,2017,4,C02-Antihypertensives,Million of national currency units,226.1 +31942,Sweden,2017,4,J01-Antibacterials for systemic use,Million of national currency units,694.2 +31943,Sweden,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",25.5 +31944,Sweden,2017,4,C02-Antihypertensives,Million US$ at exchange rate,26.5 +31945,Sweden,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +31946,Sweden,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +31947,Sweden,2017,4,C-Cardiovascular system,Million of national currency units,2515.4 +31948,Sweden,2017,4,C01A-Cardiac glycosides,% of total sales,0.0 +31949,Sweden,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +31950,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.1 +31951,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.5 +31952,Sweden,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5 +31953,Sweden,2017,4,C01A-Cardiac glycosides,Million of national currency units,12.5 +31954,Sweden,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5 +31955,Sweden,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,217.0 +31956,Sweden,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +31957,Sweden,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,5112.2 +31958,Sweden,2017,4,Total pharmaceutical sales,Million of national currency units,43703.1 +31959,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7 +31960,Sweden,2017,4,C02-Antihypertensives,% of total sales,0.5 +31961,Sweden,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",209.6 +31962,Sweden,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.6 +31963,Sweden,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",180.2 +31964,Sweden,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.6 +31965,Sweden,2017,4,M-Musculo-skeletal system,Million of national currency units,1595.2 +31966,Sweden,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,186.6 +31967,Sweden,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9 +31968,Sweden,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",508.3 +31969,Sweden,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4937.0 +31970,Sweden,2017,4,M-Musculo-skeletal system,% of total sales,3.7 +31971,Sweden,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",490.9 +31972,Sweden,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",29.3 +31973,Sweden,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",284.2 +31974,Sweden,2017,4,A10-Drugs used in diabetes,% of total sales,4.2 +31975,Sweden,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.3 +31976,Sweden,2017,4,J01-Antibacterials for systemic use,% of total sales,1.6 +31977,Sweden,2017,4,A-Alimentary tract and metabolism,Million of national currency units,4618.1 +31978,Sweden,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.8 +31979,Sweden,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1 +31980,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",86.0 +31981,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.0 +31982,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.9 +31983,Sweden,2017,4,A10-Drugs used in diabetes,Million of national currency units,1855.0 +31984,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.6 +31985,Sweden,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,540.2 +31986,Sweden,2017,4,C-Cardiovascular system,% of total sales,5.8 +31987,Sweden,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.8 +31988,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,761.3 +31989,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +31990,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0 +31991,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9 +31992,Sweden,2017,4,A02A-Antacids,Million of national currency units,98.3 +31993,Sweden,2017,4,A02A-Antacids,"Million US$, purchasing power parity",11.1 +31994,Sweden,2017,4,A02A-Antacids,Million US$ at exchange rate,11.5 +31995,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,440.6 +31996,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,56.5 +31997,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,482.8 +31998,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",49.8 +31999,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.1 +32000,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,51.5 +32001,Sweden,2017,4,A02A-Antacids,"/capita, US$ exchange rate",1.1 +32002,Sweden,2017,4,R-Respiratory system,Million of national currency units,3523.8 +32003,Sweden,2017,4,R-Respiratory system,Million US$ at exchange rate,412.2 +32004,Sweden,2017,4,R-Respiratory system,"Million US$, purchasing power parity",398.1 +32005,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3 +32006,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8 +32007,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +32008,Sweden,2017,4,A02A-Antacids,% of total sales,0.2 +32009,Sweden,2017,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1 +32010,Sweden,2017,4,R-Respiratory system,% of total sales,8.1 +32011,Sweden,2017,4,R-Respiratory system,"/capita, US$ exchange rate",41.0 +32012,Sweden,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.6 +32013,Sweden,2017,4,N02-Analgesics,Million US$ at exchange rate,230.4 +32014,Sweden,2017,4,C08-Calcium channel blockers,% of total sales,0.5 +32015,Sweden,2017,4,N02-Analgesics,Million of national currency units,1969.4 +32016,Sweden,2017,4,N02-Analgesics,"/capita, US$ exchange rate",22.9 +32017,Sweden,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",22.1 +32018,Sweden,2017,4,N02-Analgesics,"Million US$, purchasing power parity",222.5 +32019,Sweden,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,23.6 +32020,Sweden,2017,4,C08-Calcium channel blockers,Million of national currency units,202.1 +32021,Sweden,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +32022,Sweden,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.8 +32023,Sweden,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.4 +32024,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.1 +32025,Sweden,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1731.2 +32026,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.4 +32027,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",54.5 +32028,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.6 +32029,Sweden,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,202.5 +32030,Sweden,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,4.0 +32031,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4 +32032,Sweden,2017,4,N02-Analgesics,% of total sales,4.5 +32033,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",195.6 +32034,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.1 +32035,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.7 +32036,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4 +32037,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.8 +32038,Sweden,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,1719.5 +32039,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,927.0 +32040,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.4 +32041,Sweden,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",69.9 +32042,Sweden,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.2 +32043,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.1 +32044,Sweden,2017,4,N06A-Antidepressants,Million of national currency units,618.9 +32045,Sweden,2017,4,N06A-Antidepressants,Million US$ at exchange rate,72.4 +32046,Sweden,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",59.2 +32047,Sweden,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,61.3 +32048,Sweden,2017,4,N05C-Hypnotics and sedatives,% of total sales,1.2 +32049,Sweden,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.1 +32050,Sweden,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.9 +32051,Sweden,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,523.8 +32052,Sweden,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",194.2 +32053,Sweden,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,201.1 +32054,Sweden,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",20.0 +32055,Sweden,2017,4,G-Genito urinary system and sex hormones,% of total sales,3.9 +32056,Sweden,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3 +32057,Sweden,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.0 +32058,Sweden,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +32059,Sweden,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3 +32060,Sweden,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,68.7 +32061,Sweden,2017,4,C10-Lipid modifying agents,Million of national currency units,587.3 +32062,Sweden,2017,4,N05B-Anxiolytics,% of total sales,0.5 +32063,Sweden,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.3 +32064,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,123.4 +32065,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1054.6 +32066,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",119.1 +32067,Sweden,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,23.0 +32068,Sweden,2017,4,N05B-Anxiolytics,Million of national currency units,197.0 +32069,Sweden,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",485.1 +32070,Sweden,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,502.3 +32071,Sweden,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",49.9 +32072,Sweden,2017,4,N06A-Antidepressants,% of total sales,1.4 +32073,Sweden,2017,4,B-Blood and blood forming organs,Million of national currency units,4294.4 +32074,Sweden,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6 +32075,Sweden,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.8 +32076,Sweden,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",66.3 +32077,Sweden,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",48.2 +32078,Sweden,2017,4,B-Blood and blood forming organs,% of total sales,9.8 +32079,Sweden,2017,4,C10-Lipid modifying agents,% of total sales,1.3 +32080,Sweden,2017,4,J-Antiinfectives for systemic use,Million of national currency units,3285.5 +32081,Sweden,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",38.2 +32082,Sweden,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",36.9 +32083,Sweden,2017,4,N-Nervous system,"/capita, US$ exchange rate",88.1 +32084,Sweden,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",85.1 +32085,Sweden,2017,4,C07-Beta blocking agents,Million of national currency units,397.1 +32086,Sweden,2017,4,N-Nervous system,% of total sales,17.3 +32087,Sweden,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,46.4 +32088,Sweden,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6 +32089,Sweden,2017,4,J-Antiinfectives for systemic use,% of total sales,7.5 +32090,Sweden,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",44.9 +32091,Sweden,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5 +32092,Sweden,2017,4,C07-Beta blocking agents,% of total sales,0.9 +32093,Sweden,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,384.3 +32094,Sweden,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",371.1 +32095,Sweden,2017,4,N-Nervous system,Million of national currency units,7573.2 +32096,Sweden,2017,4,N-Nervous system,Million US$ at exchange rate,885.9 +32097,Sweden,2017,4,N-Nervous system,"Million US$, purchasing power parity",855.5 +32098,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +32099,Sweden,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",415.6 +32100,Sweden,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",105.6 +32101,Sweden,2011,5,C03-Diuretics,"Million US$, purchasing power parity",30.0 +32102,Sweden,2011,5,C03-Diuretics,Million of national currency units,265.3 +32103,Sweden,2011,5,C03-Diuretics,"/capita, US$ exchange rate",4.3 +32104,Sweden,2011,5,C03-Diuretics,Million US$ at exchange rate,40.9 +32105,Sweden,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",343.3 +32106,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +32107,Sweden,2011,5,C03-Diuretics,% of total sales,0.7 +32108,Sweden,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.2 +32109,Sweden,2011,5,A-Alimentary tract and metabolism,% of total sales,10.0 +32110,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,49.4 +32111,Sweden,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.9 +32112,Sweden,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.0 +32113,Sweden,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.4 +32114,Sweden,2011,5,C02-Antihypertensives,Million of national currency units,145.3 +32115,Sweden,2011,5,J01-Antibacterials for systemic use,Million of national currency units,934.3 +32116,Sweden,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,143.9 +32117,Sweden,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",16.4 +32118,Sweden,2011,5,C02-Antihypertensives,Million US$ at exchange rate,22.4 +32119,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.6 +32120,Sweden,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +32121,Sweden,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +32122,Sweden,2011,5,C-Cardiovascular system,Million US$ at exchange rate,467.5 +32123,Sweden,2011,5,C-Cardiovascular system,Million of national currency units,3035.7 +32124,Sweden,2011,5,C01A-Cardiac glycosides,% of total sales,0.0 +32125,Sweden,2011,5,C01A-Cardiac glycosides,Million of national currency units,13.1 +32126,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.6 +32127,Sweden,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +32128,Sweden,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0 +32129,Sweden,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7 +32130,Sweden,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,5664.4 +32131,Sweden,2011,5,Total pharmaceutical sales,Million of national currency units,36781.9 +32132,Sweden,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",149.5 +32133,Sweden,2011,5,C02-Antihypertensives,% of total sales,0.4 +32134,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +32135,Sweden,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.6 +32136,Sweden,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.8 +32137,Sweden,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.3 +32138,Sweden,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.1 +32139,Sweden,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,182.0 +32140,Sweden,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",133.6 +32141,Sweden,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",440.1 +32142,Sweden,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",599.5 +32143,Sweden,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4158.9 +32144,Sweden,2011,5,M-Musculo-skeletal system,% of total sales,3.2 +32145,Sweden,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,203.7 +32146,Sweden,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.5 +32147,Sweden,2011,5,A10-Drugs used in diabetes,% of total sales,3.6 +32148,Sweden,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.3 +32149,Sweden,2011,5,A-Alimentary tract and metabolism,Million of national currency units,3675.8 +32150,Sweden,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,566.1 +32151,Sweden,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.2 +32152,Sweden,2011,5,J01-Antibacterials for systemic use,% of total sales,2.5 +32153,Sweden,2011,5,M-Musculo-skeletal system,Million of national currency units,1181.9 +32154,Sweden,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2 +32155,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.6 +32156,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",80.3 +32157,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5 +32158,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.3 +32159,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +32160,Sweden,2011,5,C-Cardiovascular system,% of total sales,8.3 +32161,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,710.0 +32162,Sweden,2011,5,A10-Drugs used in diabetes,Million of national currency units,1322.4 +32163,Sweden,2011,5,N-Nervous system,Million of national currency units,7595.8 +32164,Sweden,2011,5,A02A-Antacids,Million of national currency units,70.7 +32165,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4 +32166,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.6 +32167,Sweden,2011,5,A02A-Antacids,"/capita, US$ exchange rate",1.2 +32168,Sweden,2011,5,A02A-Antacids,"Million US$, purchasing power parity",8.0 +32169,Sweden,2011,5,A02A-Antacids,Million US$ at exchange rate,10.9 +32170,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,560.8 +32171,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,885.6 +32172,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,86.4 +32173,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,136.4 +32174,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.4 +32175,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",100.1 +32176,Sweden,2011,5,R-Respiratory system,Million US$ at exchange rate,530.9 +32177,Sweden,2011,5,R-Respiratory system,"Million US$, purchasing power parity",389.8 +32178,Sweden,2011,5,R-Respiratory system,Million of national currency units,3447.6 +32179,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.2 +32180,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +32181,Sweden,2011,5,A02A-Antacids,% of total sales,0.2 +32182,Sweden,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.3 +32183,Sweden,2011,5,R-Respiratory system,"/capita, US$ exchange rate",56.2 +32184,Sweden,2011,5,R-Respiratory system,% of total sales,9.4 +32185,Sweden,2011,5,N02-Analgesics,Million US$ at exchange rate,310.5 +32186,Sweden,2011,5,N02-Analgesics,Million of national currency units,2016.5 +32187,Sweden,2011,5,N02-Analgesics,"Million US$, purchasing power parity",228.0 +32188,Sweden,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",24.1 +32189,Sweden,2011,5,N02-Analgesics,"/capita, US$ exchange rate",32.9 +32190,Sweden,2011,5,C08-Calcium channel blockers,% of total sales,0.5 +32191,Sweden,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,30.2 +32192,Sweden,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.1 +32193,Sweden,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2551.0 +32194,Sweden,2011,5,C08-Calcium channel blockers,Million of national currency units,195.8 +32195,Sweden,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +32196,Sweden,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2 +32197,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +32198,Sweden,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,308.0 +32199,Sweden,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1999.8 +32200,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.1 +32201,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",63.4 +32202,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.7 +32203,Sweden,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +32204,Sweden,2011,5,N02-Analgesics,% of total sales,5.5 +32205,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",226.1 +32206,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9 +32207,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.6 +32208,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.2 +32209,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.6 +32210,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",101.6 +32211,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.8 +32212,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,898.8 +32213,Sweden,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,1722.7 +32214,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,138.4 +32215,Sweden,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",74.7 +32216,Sweden,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8 +32217,Sweden,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.9 +32218,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +32219,Sweden,2011,5,N06A-Antidepressants,Million of national currency units,660.8 +32220,Sweden,2011,5,N06A-Antidepressants,Million US$ at exchange rate,101.8 +32221,Sweden,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",31.7 +32222,Sweden,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.6 +32223,Sweden,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,43.2 +32224,Sweden,2011,5,N05C-Hypnotics and sedatives,% of total sales,0.8 +32225,Sweden,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4 +32226,Sweden,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",28.1 +32227,Sweden,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,265.3 +32228,Sweden,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",194.8 +32229,Sweden,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,280.4 +32230,Sweden,2011,5,G-Genito urinary system and sex hormones,% of total sales,4.7 +32231,Sweden,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6 +32232,Sweden,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +32233,Sweden,2011,5,N05B-Anxiolytics,% of total sales,0.5 +32234,Sweden,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.1 +32235,Sweden,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,118.2 +32236,Sweden,2011,5,C10-Lipid modifying agents,Million of national currency units,767.3 +32237,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,144.0 +32238,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",105.7 +32239,Sweden,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",21.5 +32240,Sweden,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,29.3 +32241,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,934.9 +32242,Sweden,2011,5,N05B-Anxiolytics,Million of national currency units,190.1 +32243,Sweden,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",86.8 +32244,Sweden,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",358.4 +32245,Sweden,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.7 +32246,Sweden,2011,5,N06A-Antidepressants,% of total sales,1.8 +32247,Sweden,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,488.1 +32248,Sweden,2011,5,B-Blood and blood forming organs,Million of national currency units,3169.6 +32249,Sweden,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.9 +32250,Sweden,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.2 +32251,Sweden,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.5 +32252,Sweden,2011,5,B-Blood and blood forming organs,% of total sales,8.6 +32253,Sweden,2011,5,C10-Lipid modifying agents,% of total sales,2.1 +32254,Sweden,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8 +32255,Sweden,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.5 +32256,Sweden,2011,5,N-Nervous system,% of total sales,20.7 +32257,Sweden,2011,5,J-Antiinfectives for systemic use,% of total sales,6.9 +32258,Sweden,2011,5,N-Nervous system,"/capita, US$ exchange rate",123.8 +32259,Sweden,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",90.9 +32260,Sweden,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.6 +32261,Sweden,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,62.1 +32262,Sweden,2011,5,C07-Beta blocking agents,Million of national currency units,403.0 +32263,Sweden,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6 +32264,Sweden,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",45.6 +32265,Sweden,2011,5,C07-Beta blocking agents,% of total sales,1.1 +32266,Sweden,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8 +32267,Sweden,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",288.4 +32268,Sweden,2011,5,N-Nervous system,Million US$ at exchange rate,1169.7 +32269,Sweden,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,392.9 +32270,Sweden,2011,5,N-Nervous system,"Million US$, purchasing power parity",858.9 +32271,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6 +32272,Sweden,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",431.2 +32273,Sweden,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",98.3 +32274,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +32275,Sweden,2012,5,C03-Diuretics,"Million US$, purchasing power parity",29.9 +32276,Sweden,2012,5,C03-Diuretics,Million of national currency units,259.0 +32277,Sweden,2012,5,C03-Diuretics,Million US$ at exchange rate,38.2 +32278,Sweden,2012,5,C03-Diuretics,"/capita, US$ exchange rate",4.0 +32279,Sweden,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",293.9 +32280,Sweden,2012,5,C03-Diuretics,% of total sales,0.7 +32281,Sweden,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1 +32282,Sweden,2012,5,A-Alimentary tract and metabolism,% of total sales,10.3 +32283,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,50.6 +32284,Sweden,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.3 +32285,Sweden,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.3 +32286,Sweden,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.9 +32287,Sweden,2012,5,C02-Antihypertensives,Million of national currency units,147.5 +32288,Sweden,2012,5,J01-Antibacterials for systemic use,Million of national currency units,850.4 +32289,Sweden,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,125.5 +32290,Sweden,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",17.0 +32291,Sweden,2012,5,C02-Antihypertensives,Million US$ at exchange rate,21.8 +32292,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5 +32293,Sweden,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +32294,Sweden,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +32295,Sweden,2012,5,C-Cardiovascular system,Million US$ at exchange rate,375.4 +32296,Sweden,2012,5,C-Cardiovascular system,Million of national currency units,2543.6 +32297,Sweden,2012,5,C01A-Cardiac glycosides,% of total sales,0.0 +32298,Sweden,2012,5,C01A-Cardiac glycosides,Million of national currency units,13.4 +32299,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.8 +32300,Sweden,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +32301,Sweden,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0 +32302,Sweden,2012,5,M-Musculo-skeletal system,Million of national currency units,1188.3 +32303,Sweden,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8 +32304,Sweden,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,5330.8 +32305,Sweden,2012,5,Total pharmaceutical sales,Million of national currency units,36116.2 +32306,Sweden,2012,5,C02-Antihypertensives,% of total sales,0.4 +32307,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +32308,Sweden,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",159.9 +32309,Sweden,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.5 +32310,Sweden,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4173.0 +32311,Sweden,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.4 +32312,Sweden,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.4 +32313,Sweden,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.3 +32314,Sweden,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,175.4 +32315,Sweden,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",560.0 +32316,Sweden,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",438.4 +32317,Sweden,2012,5,M-Musculo-skeletal system,% of total sales,3.3 +32318,Sweden,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,204.3 +32319,Sweden,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",39.4 +32320,Sweden,2012,5,A10-Drugs used in diabetes,% of total sales,3.8 +32321,Sweden,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",30.9 +32322,Sweden,2012,5,A-Alimentary tract and metabolism,Million of national currency units,3732.0 +32323,Sweden,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,550.8 +32324,Sweden,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.2 +32325,Sweden,2012,5,J01-Antibacterials for systemic use,% of total sales,2.4 +32326,Sweden,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3 +32327,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.2 +32328,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",83.4 +32329,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8 +32330,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +32331,Sweden,2012,5,C-Cardiovascular system,% of total sales,7.0 +32332,Sweden,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.8 +32333,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,106.6 +32334,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,722.2 +32335,Sweden,2012,5,A10-Drugs used in diabetes,Million of national currency units,1384.0 +32336,Sweden,2012,5,A02A-Antacids,Million of national currency units,70.3 +32337,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6 +32338,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7 +32339,Sweden,2012,5,A02A-Antacids,"Million US$, purchasing power parity",8.1 +32340,Sweden,2012,5,A02A-Antacids,"/capita, US$ exchange rate",1.1 +32341,Sweden,2012,5,A02A-Antacids,Million US$ at exchange rate,10.4 +32342,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,536.8 +32343,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,627.9 +32344,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,79.2 +32345,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",9.7 +32346,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,92.7 +32347,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",72.5 +32348,Sweden,2012,5,R-Respiratory system,Million US$ at exchange rate,527.3 +32349,Sweden,2012,5,R-Respiratory system,Million of national currency units,3572.8 +32350,Sweden,2012,5,R-Respiratory system,"Million US$, purchasing power parity",412.8 +32351,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7 +32352,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +32353,Sweden,2012,5,A02A-Antacids,% of total sales,0.2 +32354,Sweden,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.9 +32355,Sweden,2012,5,R-Respiratory system,"/capita, US$ exchange rate",55.4 +32356,Sweden,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",43.4 +32357,Sweden,2012,5,R-Respiratory system,% of total sales,9.9 +32358,Sweden,2012,5,N02-Analgesics,Million US$ at exchange rate,285.8 +32359,Sweden,2012,5,N02-Analgesics,Million of national currency units,1936.1 +32360,Sweden,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.5 +32361,Sweden,2012,5,N02-Analgesics,"Million US$, purchasing power parity",223.7 +32362,Sweden,2012,5,N02-Analgesics,"/capita, US$ exchange rate",30.0 +32363,Sweden,2012,5,C08-Calcium channel blockers,% of total sales,0.5 +32364,Sweden,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,28.5 +32365,Sweden,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.3 +32366,Sweden,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2540.3 +32367,Sweden,2012,5,C08-Calcium channel blockers,Million of national currency units,193.0 +32368,Sweden,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +32369,Sweden,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0 +32370,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5 +32371,Sweden,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,2058.9 +32372,Sweden,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,303.9 +32373,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",62.0 +32374,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.3 +32375,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.5 +32376,Sweden,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.7 +32377,Sweden,2012,5,N02-Analgesics,% of total sales,5.4 +32378,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.0 +32379,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",237.9 +32380,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.9 +32381,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0 +32382,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.3 +32383,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",106.6 +32384,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.2 +32385,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,922.9 +32386,Sweden,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,1757.1 +32387,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,136.2 +32388,Sweden,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",78.4 +32389,Sweden,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.2 +32390,Sweden,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.5 +32391,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.6 +32392,Sweden,2012,5,N06A-Antidepressants,Million of national currency units,678.8 +32393,Sweden,2012,5,N06A-Antidepressants,Million US$ at exchange rate,100.2 +32394,Sweden,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.5 +32395,Sweden,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.6 +32396,Sweden,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,44.0 +32397,Sweden,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.8 +32398,Sweden,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.6 +32399,Sweden,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.2 +32400,Sweden,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",203.0 +32401,Sweden,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,259.3 +32402,Sweden,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,298.3 +32403,Sweden,2012,5,G-Genito urinary system and sex hormones,% of total sales,4.9 +32404,Sweden,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3 +32405,Sweden,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +32406,Sweden,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0 +32407,Sweden,2012,5,N05B-Anxiolytics,% of total sales,0.5 +32408,Sweden,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,82.4 +32409,Sweden,2012,5,C10-Lipid modifying agents,Million of national currency units,558.3 +32410,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,142.5 +32411,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.6 +32412,Sweden,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,28.3 +32413,Sweden,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",22.1 +32414,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,965.5 +32415,Sweden,2012,5,N05B-Anxiolytics,Million of national currency units,191.6 +32416,Sweden,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",64.5 +32417,Sweden,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",366.5 +32418,Sweden,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",49.2 +32419,Sweden,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,468.2 +32420,Sweden,2012,5,N06A-Antidepressants,% of total sales,1.9 +32421,Sweden,2012,5,B-Blood and blood forming organs,Million of national currency units,3172.3 +32422,Sweden,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.8 +32423,Sweden,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.7 +32424,Sweden,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5 +32425,Sweden,2012,5,B-Blood and blood forming organs,% of total sales,8.8 +32426,Sweden,2012,5,C10-Lipid modifying agents,% of total sales,1.5 +32427,Sweden,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8 +32428,Sweden,2012,5,N-Nervous system,% of total sales,20.0 +32429,Sweden,2012,5,J-Antiinfectives for systemic use,% of total sales,7.0 +32430,Sweden,2012,5,N-Nervous system,"/capita, US$ exchange rate",112.2 +32431,Sweden,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",87.8 +32432,Sweden,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.4 +32433,Sweden,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,58.0 +32434,Sweden,2012,5,C07-Beta blocking agents,Million of national currency units,393.0 +32435,Sweden,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1 +32436,Sweden,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",45.4 +32437,Sweden,2012,5,C07-Beta blocking agents,% of total sales,1.1 +32438,Sweden,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8 +32439,Sweden,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",293.5 +32440,Sweden,2012,5,N-Nervous system,Million US$ at exchange rate,1067.8 +32441,Sweden,2012,5,N-Nervous system,Million of national currency units,7234.7 +32442,Sweden,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,374.9 +32443,Sweden,2012,5,N-Nervous system,"Million US$, purchasing power parity",835.9 +32444,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +32445,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +32446,Sweden,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,84.6 +32447,Sweden,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",82.1 +32448,Sweden,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",498.4 +32449,Sweden,2016,4,C03-Diuretics,"Million US$, purchasing power parity",25.3 +32450,Sweden,2016,4,C03-Diuretics,Million US$ at exchange rate,26.0 +32451,Sweden,2016,4,C03-Diuretics,Million of national currency units,223.0 +32452,Sweden,2016,4,C03-Diuretics,% of total sales,0.5 +32453,Sweden,2016,4,C03-Diuretics,"/capita, US$ exchange rate",2.6 +32454,Sweden,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.5 +32455,Sweden,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.2 +32456,Sweden,2016,4,A-Alimentary tract and metabolism,% of total sales,10.4 +32457,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.4 +32458,Sweden,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.8 +32459,Sweden,2016,4,C02-Antihypertensives,Million of national currency units,211.9 +32460,Sweden,2016,4,J01-Antibacterials for systemic use,Million of national currency units,724.5 +32461,Sweden,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",24.0 +32462,Sweden,2016,4,C02-Antihypertensives,Million US$ at exchange rate,24.7 +32463,Sweden,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1 +32464,Sweden,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1 +32465,Sweden,2016,4,C-Cardiovascular system,Million of national currency units,2398.2 +32466,Sweden,2016,4,C01A-Cardiac glycosides,% of total sales,0.0 +32467,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.4 +32468,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.7 +32469,Sweden,2016,4,C-Cardiovascular system,Million US$ at exchange rate,280.1 +32470,Sweden,2016,4,C01A-Cardiac glycosides,Million of national currency units,12.7 +32471,Sweden,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4 +32472,Sweden,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5 +32473,Sweden,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,513.6 +32474,Sweden,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.4 +32475,Sweden,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.5 +32476,Sweden,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,197.1 +32477,Sweden,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,4945.8 +32478,Sweden,2016,4,Total pharmaceutical sales,Million of national currency units,42346.3 +32479,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +32480,Sweden,2016,4,C02-Antihypertensives,% of total sales,0.5 +32481,Sweden,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",191.3 +32482,Sweden,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9 +32483,Sweden,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",170.3 +32484,Sweden,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.7 +32485,Sweden,2016,4,M-Musculo-skeletal system,Million of national currency units,1502.6 +32486,Sweden,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,175.5 +32487,Sweden,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.2 +32488,Sweden,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",498.4 +32489,Sweden,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4799.8 +32490,Sweden,2016,4,M-Musculo-skeletal system,% of total sales,3.5 +32491,Sweden,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",483.7 +32492,Sweden,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.2 +32493,Sweden,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",271.8 +32494,Sweden,2016,4,A10-Drugs used in diabetes,% of total sales,4.0 +32495,Sweden,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.4 +32496,Sweden,2016,4,J01-Antibacterials for systemic use,% of total sales,1.7 +32497,Sweden,2016,4,A-Alimentary tract and metabolism,Million of national currency units,4397.3 +32498,Sweden,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.3 +32499,Sweden,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.5 +32500,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",90.7 +32501,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,93.5 +32502,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.1 +32503,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.4 +32504,Sweden,2016,4,C-Cardiovascular system,% of total sales,5.7 +32505,Sweden,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.3 +32506,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +32507,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,800.6 +32508,Sweden,2016,4,A10-Drugs used in diabetes,Million of national currency units,1687.7 +32509,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0 +32510,Sweden,2016,4,A02A-Antacids,Million of national currency units,95.9 +32511,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.7 +32512,Sweden,2016,4,A02A-Antacids,"Million US$, purchasing power parity",10.9 +32513,Sweden,2016,4,A02A-Antacids,Million US$ at exchange rate,11.2 +32514,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,414.0 +32515,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,493.9 +32516,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,57.7 +32517,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.9 +32518,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",46.9 +32519,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,48.4 +32520,Sweden,2016,4,R-Respiratory system,Million of national currency units,3456.4 +32521,Sweden,2016,4,R-Respiratory system,"Million US$, purchasing power parity",391.8 +32522,Sweden,2016,4,R-Respiratory system,Million US$ at exchange rate,403.7 +32523,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7 +32524,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.1 +32525,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +32526,Sweden,2016,4,A02A-Antacids,% of total sales,0.2 +32527,Sweden,2016,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1 +32528,Sweden,2016,4,A02A-Antacids,"/capita, US$ exchange rate",1.1 +32529,Sweden,2016,4,R-Respiratory system,"/capita, US$ exchange rate",40.7 +32530,Sweden,2016,4,R-Respiratory system,% of total sales,8.2 +32531,Sweden,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.5 +32532,Sweden,2016,4,N02-Analgesics,Million US$ at exchange rate,235.9 +32533,Sweden,2016,4,N02-Analgesics,Million of national currency units,2020.0 +32534,Sweden,2016,4,C08-Calcium channel blockers,% of total sales,0.5 +32535,Sweden,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.1 +32536,Sweden,2016,4,N02-Analgesics,"/capita, US$ exchange rate",23.8 +32537,Sweden,2016,4,N02-Analgesics,"Million US$, purchasing power parity",229.0 +32538,Sweden,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,23.4 +32539,Sweden,2016,4,C08-Calcium channel blockers,Million of national currency units,200.3 +32540,Sweden,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.7 +32541,Sweden,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +32542,Sweden,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.4 +32543,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2 +32544,Sweden,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1741.7 +32545,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",56.0 +32546,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.6 +32547,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.8 +32548,Sweden,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,203.4 +32549,Sweden,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,4.1 +32550,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.9 +32551,Sweden,2016,4,N02-Analgesics,% of total sales,4.8 +32552,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",197.4 +32553,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.5 +32554,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.8 +32555,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.9 +32556,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.6 +32557,Sweden,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,1693.7 +32558,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,924.5 +32559,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.0 +32560,Sweden,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",66.9 +32561,Sweden,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",6.9 +32562,Sweden,2016,4,N06A-Antidepressants,Million US$ at exchange rate,68.9 +32563,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.2 +32564,Sweden,2016,4,N06A-Antidepressants,Million of national currency units,590.1 +32565,Sweden,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",49.1 +32566,Sweden,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,50.6 +32567,Sweden,2016,4,N05C-Hypnotics and sedatives,% of total sales,1.0 +32568,Sweden,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1 +32569,Sweden,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0 +32570,Sweden,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,433.4 +32571,Sweden,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",192.0 +32572,Sweden,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.9 +32573,Sweden,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,197.8 +32574,Sweden,2016,4,G-Genito urinary system and sex hormones,% of total sales,4.0 +32575,Sweden,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3 +32576,Sweden,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.7 +32577,Sweden,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +32578,Sweden,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3 +32579,Sweden,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,61.0 +32580,Sweden,2016,4,N05B-Anxiolytics,% of total sales,0.5 +32581,Sweden,2016,4,C10-Lipid modifying agents,Million of national currency units,522.1 +32582,Sweden,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.5 +32583,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,119.9 +32584,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",116.4 +32585,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1026.8 +32586,Sweden,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,23.2 +32587,Sweden,2016,4,N05B-Anxiolytics,Million of national currency units,198.3 +32588,Sweden,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",440.6 +32589,Sweden,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,454.0 +32590,Sweden,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.8 +32591,Sweden,2016,4,N06A-Antidepressants,% of total sales,1.4 +32592,Sweden,2016,4,B-Blood and blood forming organs,Million of national currency units,3887.5 +32593,Sweden,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.0 +32594,Sweden,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.1 +32595,Sweden,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",59.2 +32596,Sweden,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",44.4 +32597,Sweden,2016,4,B-Blood and blood forming organs,% of total sales,9.2 +32598,Sweden,2016,4,C10-Lipid modifying agents,% of total sales,1.2 +32599,Sweden,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",44.4 +32600,Sweden,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",45.8 +32601,Sweden,2016,4,N-Nervous system,"/capita, US$ exchange rate",87.2 +32602,Sweden,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",84.7 +32603,Sweden,2016,4,J-Antiinfectives for systemic use,% of total sales,9.2 +32604,Sweden,2016,4,C07-Beta blocking agents,Million of national currency units,394.3 +32605,Sweden,2016,4,N-Nervous system,% of total sales,17.5 +32606,Sweden,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,46.0 +32607,Sweden,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6 +32608,Sweden,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",44.7 +32609,Sweden,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5 +32610,Sweden,2016,4,C07-Beta blocking agents,% of total sales,0.9 +32611,Sweden,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,454.2 +32612,Sweden,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",440.8 +32613,Sweden,2016,4,J-Antiinfectives for systemic use,Million of national currency units,3888.6 +32614,Sweden,2016,4,N-Nervous system,Million of national currency units,7411.8 +32615,Sweden,2016,4,N-Nervous system,"Million US$, purchasing power parity",840.1 +32616,Sweden,2016,4,N-Nervous system,Million US$ at exchange rate,865.7 +32617,Sweden,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",81.4 +32618,Sweden,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,103.5 +32619,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +32620,Sweden,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",440.2 +32621,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +32622,Sweden,2014,5,C03-Diuretics,"Million US$, purchasing power parity",29.2 +32623,Sweden,2014,5,C03-Diuretics,Million US$ at exchange rate,37.2 +32624,Sweden,2014,5,C03-Diuretics,Million of national currency units,255.1 +32625,Sweden,2014,5,C03-Diuretics,"/capita, US$ exchange rate",3.8 +32626,Sweden,2014,5,C03-Diuretics,% of total sales,0.7 +32627,Sweden,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.0 +32628,Sweden,2014,5,A-Alimentary tract and metabolism,% of total sales,10.2 +32629,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,60.5 +32630,Sweden,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.4 +32631,Sweden,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.8 +32632,Sweden,2014,5,C02-Antihypertensives,Million of national currency units,181.4 +32633,Sweden,2014,5,J01-Antibacterials for systemic use,Million of national currency units,710.3 +32634,Sweden,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",20.8 +32635,Sweden,2014,5,C02-Antihypertensives,Million US$ at exchange rate,26.4 +32636,Sweden,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +32637,Sweden,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +32638,Sweden,2014,5,C-Cardiovascular system,Million US$ at exchange rate,340.8 +32639,Sweden,2014,5,C01A-Cardiac glycosides,% of total sales,0.0 +32640,Sweden,2014,5,C-Cardiovascular system,Million of national currency units,2338.4 +32641,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9 +32642,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.8 +32643,Sweden,2014,5,C01A-Cardiac glycosides,Million of national currency units,15.9 +32644,Sweden,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8 +32645,Sweden,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.3 +32646,Sweden,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1 +32647,Sweden,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.7 +32648,Sweden,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,205.6 +32649,Sweden,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,5510.9 +32650,Sweden,2014,5,Total pharmaceutical sales,Million of national currency units,37808.8 +32651,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +32652,Sweden,2014,5,C02-Antihypertensives,% of total sales,0.5 +32653,Sweden,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",161.7 +32654,Sweden,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.2 +32655,Sweden,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.4 +32656,Sweden,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",147.5 +32657,Sweden,2014,5,M-Musculo-skeletal system,Million of national currency units,1287.3 +32658,Sweden,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,187.6 +32659,Sweden,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.2 +32660,Sweden,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",568.4 +32661,Sweden,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4332.3 +32662,Sweden,2014,5,M-Musculo-skeletal system,% of total sales,3.4 +32663,Sweden,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",446.8 +32664,Sweden,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",35.2 +32665,Sweden,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",267.9 +32666,Sweden,2014,5,A10-Drugs used in diabetes,% of total sales,3.7 +32667,Sweden,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.6 +32668,Sweden,2014,5,J01-Antibacterials for systemic use,% of total sales,1.9 +32669,Sweden,2014,5,A-Alimentary tract and metabolism,Million of national currency units,3841.9 +32670,Sweden,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,560.0 +32671,Sweden,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.7 +32672,Sweden,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.4 +32673,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",82.4 +32674,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.8 +32675,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,104.8 +32676,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5 +32677,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +32678,Sweden,2014,5,C-Cardiovascular system,% of total sales,6.2 +32679,Sweden,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.7 +32680,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,718.9 +32681,Sweden,2014,5,A10-Drugs used in diabetes,Million of national currency units,1410.9 +32682,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.1 +32683,Sweden,2014,5,A02A-Antacids,Million of national currency units,81.7 +32684,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9 +32685,Sweden,2014,5,A02A-Antacids,"Million US$, purchasing power parity",9.4 +32686,Sweden,2014,5,A02A-Antacids,Million US$ at exchange rate,11.9 +32687,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,413.6 +32688,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,474.1 +32689,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.1 +32690,Sweden,2014,5,A02A-Antacids,"/capita, US$ exchange rate",1.2 +32691,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",6.2 +32692,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.4 +32693,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.3 +32694,Sweden,2014,5,R-Respiratory system,Million US$ at exchange rate,515.1 +32695,Sweden,2014,5,R-Respiratory system,Million of national currency units,3534.1 +32696,Sweden,2014,5,R-Respiratory system,"Million US$, purchasing power parity",405.0 +32697,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4 +32698,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6 +32699,Sweden,2014,5,A02A-Antacids,% of total sales,0.2 +32700,Sweden,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.0 +32701,Sweden,2014,5,R-Respiratory system,"/capita, US$ exchange rate",53.1 +32702,Sweden,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.8 +32703,Sweden,2014,5,R-Respiratory system,% of total sales,9.3 +32704,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.5 +32705,Sweden,2014,5,N02-Analgesics,Million US$ at exchange rate,289.5 +32706,Sweden,2014,5,N02-Analgesics,Million of national currency units,1985.9 +32707,Sweden,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.5 +32708,Sweden,2014,5,N02-Analgesics,"/capita, US$ exchange rate",29.9 +32709,Sweden,2014,5,N02-Analgesics,"Million US$, purchasing power parity",227.6 +32710,Sweden,2014,5,C08-Calcium channel blockers,% of total sales,0.5 +32711,Sweden,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,29.4 +32712,Sweden,2014,5,C08-Calcium channel blockers,Million of national currency units,202.0 +32713,Sweden,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.1 +32714,Sweden,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4 +32715,Sweden,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0 +32716,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3 +32717,Sweden,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1982.6 +32718,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",54.3 +32719,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.1 +32720,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.6 +32721,Sweden,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,289.0 +32722,Sweden,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.2 +32723,Sweden,2014,5,N02-Analgesics,% of total sales,5.3 +32724,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.4 +32725,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",227.2 +32726,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8 +32727,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",105.8 +32728,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.9 +32729,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.9 +32730,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,923.3 +32731,Sweden,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,1684.8 +32732,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,134.6 +32733,Sweden,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",82.7 +32734,Sweden,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8 +32735,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.4 +32736,Sweden,2014,5,N06A-Antidepressants,Million US$ at exchange rate,105.1 +32737,Sweden,2014,5,N06A-Antidepressants,Million of national currency units,721.3 +32738,Sweden,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.5 +32739,Sweden,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",39.3 +32740,Sweden,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,49.9 +32741,Sweden,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1 +32742,Sweden,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.9 +32743,Sweden,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.0 +32744,Sweden,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.3 +32745,Sweden,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",193.0 +32746,Sweden,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,245.6 +32747,Sweden,2014,5,G-Genito urinary system and sex hormones,% of total sales,4.5 +32748,Sweden,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,342.5 +32749,Sweden,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.9 +32750,Sweden,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +32751,Sweden,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0 +32752,Sweden,2014,5,N05B-Anxiolytics,% of total sales,0.5 +32753,Sweden,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,70.1 +32754,Sweden,2014,5,C10-Lipid modifying agents,Million of national currency units,480.8 +32755,Sweden,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",23.1 +32756,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,141.0 +32757,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",110.9 +32758,Sweden,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,29.4 +32759,Sweden,2014,5,N05B-Anxiolytics,Million of national currency units,201.4 +32760,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,967.4 +32761,Sweden,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",369.3 +32762,Sweden,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.4 +32763,Sweden,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,469.8 +32764,Sweden,2014,5,N06A-Antidepressants,% of total sales,1.9 +32765,Sweden,2014,5,B-Blood and blood forming organs,Million of national currency units,3223.0 +32766,Sweden,2014,5,J-Antiinfectives for systemic use,Million of national currency units,3029.8 +32767,Sweden,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7 +32768,Sweden,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",55.1 +32769,Sweden,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.2 +32770,Sweden,2014,5,B-Blood and blood forming organs,% of total sales,8.5 +32771,Sweden,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.1 +32772,Sweden,2014,5,C10-Lipid modifying agents,% of total sales,1.3 +32773,Sweden,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.8 +32774,Sweden,2014,5,J-Antiinfectives for systemic use,% of total sales,8.0 +32775,Sweden,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",45.5 +32776,Sweden,2014,5,N-Nervous system,"/capita, US$ exchange rate",110.4 +32777,Sweden,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",86.8 +32778,Sweden,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,61.1 +32779,Sweden,2014,5,C07-Beta blocking agents,Million of national currency units,419.1 +32780,Sweden,2014,5,N-Nervous system,% of total sales,19.4 +32781,Sweden,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3 +32782,Sweden,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",48.0 +32783,Sweden,2014,5,C07-Beta blocking agents,% of total sales,1.1 +32784,Sweden,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.0 +32785,Sweden,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,441.6 +32786,Sweden,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",347.2 +32787,Sweden,2014,5,N-Nervous system,Million of national currency units,7342.3 +32788,Sweden,2014,5,N-Nervous system,Million US$ at exchange rate,1070.2 +32789,Sweden,2014,5,N-Nervous system,"Million US$, purchasing power parity",841.3 +32790,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8 +32791,Sweden,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,88.9 +32792,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8 +32793,Sweden,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",464.8 +32794,Sweden,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",84.6 +32795,Sweden,2015,4,C03-Diuretics,"Million US$, purchasing power parity",27.3 +32796,Sweden,2015,4,C03-Diuretics,Million US$ at exchange rate,28.7 +32797,Sweden,2015,4,C03-Diuretics,Million of national currency units,241.9 +32798,Sweden,2015,4,C03-Diuretics,% of total sales,0.6 +32799,Sweden,2015,4,C03-Diuretics,"/capita, US$ exchange rate",2.9 +32800,Sweden,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.8 +32801,Sweden,2015,4,C-Cardiovascular system,Million US$ at exchange rate,285.0 +32802,Sweden,2015,4,A-Alimentary tract and metabolism,% of total sales,10.1 +32803,Sweden,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.4 +32804,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,66.6 +32805,Sweden,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.8 +32806,Sweden,2015,4,C02-Antihypertensives,Million of national currency units,214.2 +32807,Sweden,2015,4,J01-Antibacterials for systemic use,Million of national currency units,749.5 +32808,Sweden,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",24.2 +32809,Sweden,2015,4,C02-Antihypertensives,Million US$ at exchange rate,25.4 +32810,Sweden,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +32811,Sweden,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +32812,Sweden,2015,4,C-Cardiovascular system,Million of national currency units,2404.2 +32813,Sweden,2015,4,C01A-Cardiac glycosides,% of total sales,0.0 +32814,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.5 +32815,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.9 +32816,Sweden,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5 +32817,Sweden,2015,4,C01A-Cardiac glycosides,Million of national currency units,13.2 +32818,Sweden,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6 +32819,Sweden,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5 +32820,Sweden,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.6 +32821,Sweden,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,182.1 +32822,Sweden,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,4808.3 +32823,Sweden,2015,4,Total pharmaceutical sales,Million of national currency units,40557.2 +32824,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9 +32825,Sweden,2015,4,C02-Antihypertensives,% of total sales,0.5 +32826,Sweden,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",173.4 +32827,Sweden,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.6 +32828,Sweden,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",155.3 +32829,Sweden,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.6 +32830,Sweden,2015,4,M-Musculo-skeletal system,Million of national currency units,1375.3 +32831,Sweden,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,163.0 +32832,Sweden,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.9 +32833,Sweden,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",490.7 +32834,Sweden,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4580.5 +32835,Sweden,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",467.4 +32836,Sweden,2015,4,M-Musculo-skeletal system,% of total sales,3.4 +32837,Sweden,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",29.1 +32838,Sweden,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",271.5 +32839,Sweden,2015,4,A10-Drugs used in diabetes,% of total sales,3.8 +32840,Sweden,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.7 +32841,Sweden,2015,4,J01-Antibacterials for systemic use,% of total sales,1.8 +32842,Sweden,2015,4,A-Alimentary tract and metabolism,Million of national currency units,4115.1 +32843,Sweden,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,487.9 +32844,Sweden,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.6 +32845,Sweden,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.1 +32846,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",85.0 +32847,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.2 +32848,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.1 +32849,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7 +32850,Sweden,2015,4,C-Cardiovascular system,% of total sales,5.9 +32851,Sweden,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.7 +32852,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2 +32853,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,752.3 +32854,Sweden,2015,4,A10-Drugs used in diabetes,Million of national currency units,1535.6 +32855,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0 +32856,Sweden,2015,4,A02A-Antacids,Million of national currency units,92.4 +32857,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9 +32858,Sweden,2015,4,A02A-Antacids,"Million US$, purchasing power parity",10.4 +32859,Sweden,2015,4,A02A-Antacids,Million US$ at exchange rate,11.0 +32860,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,422.0 +32861,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,493.7 +32862,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.5 +32863,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.1 +32864,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.7 +32865,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,50.0 +32866,Sweden,2015,4,A02A-Antacids,"/capita, US$ exchange rate",1.1 +32867,Sweden,2015,4,R-Respiratory system,Million of national currency units,3332.4 +32868,Sweden,2015,4,R-Respiratory system,Million US$ at exchange rate,395.1 +32869,Sweden,2015,4,R-Respiratory system,"Million US$, purchasing power parity",376.4 +32870,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.3 +32871,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9 +32872,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4 +32873,Sweden,2015,4,A02A-Antacids,% of total sales,0.2 +32874,Sweden,2015,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1 +32875,Sweden,2015,4,R-Respiratory system,"/capita, US$ exchange rate",40.3 +32876,Sweden,2015,4,R-Respiratory system,% of total sales,8.2 +32877,Sweden,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.4 +32878,Sweden,2015,4,N02-Analgesics,Million US$ at exchange rate,242.4 +32879,Sweden,2015,4,C08-Calcium channel blockers,% of total sales,0.5 +32880,Sweden,2015,4,N02-Analgesics,Million of national currency units,2044.8 +32881,Sweden,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.6 +32882,Sweden,2015,4,N02-Analgesics,"/capita, US$ exchange rate",24.7 +32883,Sweden,2015,4,N02-Analgesics,"Million US$, purchasing power parity",230.9 +32884,Sweden,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,24.1 +32885,Sweden,2015,4,C08-Calcium channel blockers,Million of national currency units,203.5 +32886,Sweden,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3 +32887,Sweden,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5 +32888,Sweden,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.0 +32889,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2 +32890,Sweden,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1702.5 +32891,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",55.8 +32892,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.7 +32893,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.0 +32894,Sweden,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,201.8 +32895,Sweden,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,4.2 +32896,Sweden,2015,4,N02-Analgesics,% of total sales,5.0 +32897,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.6 +32898,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",192.3 +32899,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.6 +32900,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.5 +32901,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.7 +32902,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.2 +32903,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,925.1 +32904,Sweden,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,1676.9 +32905,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,109.7 +32906,Sweden,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",75.5 +32907,Sweden,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",8.1 +32908,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.3 +32909,Sweden,2015,4,N06A-Antidepressants,Million US$ at exchange rate,79.2 +32910,Sweden,2015,4,N06A-Antidepressants,Million of national currency units,668.4 +32911,Sweden,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",41.1 +32912,Sweden,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,43.2 +32913,Sweden,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.4 +32914,Sweden,2015,4,N05C-Hypnotics and sedatives,% of total sales,0.9 +32915,Sweden,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.2 +32916,Sweden,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,364.1 +32917,Sweden,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",189.4 +32918,Sweden,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",20.3 +32919,Sweden,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,198.8 +32920,Sweden,2015,4,G-Genito urinary system and sex hormones,% of total sales,4.1 +32921,Sweden,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3 +32922,Sweden,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.7 +32923,Sweden,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3 +32924,Sweden,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4 +32925,Sweden,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,57.2 +32926,Sweden,2015,4,N05B-Anxiolytics,% of total sales,0.5 +32927,Sweden,2015,4,C10-Lipid modifying agents,Million of national currency units,482.1 +32928,Sweden,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.6 +32929,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,116.6 +32930,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.1 +32931,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,983.4 +32932,Sweden,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,23.7 +32933,Sweden,2015,4,N05B-Anxiolytics,Million of national currency units,199.8 +32934,Sweden,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",397.6 +32935,Sweden,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",42.6 +32936,Sweden,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,417.4 +32937,Sweden,2015,4,N06A-Antidepressants,% of total sales,1.6 +32938,Sweden,2015,4,B-Blood and blood forming organs,Million of national currency units,3520.9 +32939,Sweden,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.6 +32940,Sweden,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.8 +32941,Sweden,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.5 +32942,Sweden,2015,4,B-Blood and blood forming organs,% of total sales,8.7 +32943,Sweden,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.6 +32944,Sweden,2015,4,C10-Lipid modifying agents,% of total sales,1.2 +32945,Sweden,2015,4,J-Antiinfectives for systemic use,Million of national currency units,3983.5 +32946,Sweden,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.9 +32947,Sweden,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.2 +32948,Sweden,2015,4,N-Nervous system,"/capita, US$ exchange rate",90.6 +32949,Sweden,2015,4,J-Antiinfectives for systemic use,% of total sales,9.8 +32950,Sweden,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",86.3 +32951,Sweden,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,50.9 +32952,Sweden,2015,4,C07-Beta blocking agents,Million of national currency units,429.4 +32953,Sweden,2015,4,N-Nervous system,% of total sales,18.5 +32954,Sweden,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2 +32955,Sweden,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",48.5 +32956,Sweden,2015,4,C07-Beta blocking agents,% of total sales,1.1 +32957,Sweden,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9 +32958,Sweden,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,472.3 +32959,Sweden,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",449.9 +32960,Sweden,2015,4,N-Nervous system,Million of national currency units,7485.8 +32961,Sweden,2015,4,N-Nervous system,Million US$ at exchange rate,887.5 +32962,Sweden,2015,4,N-Nervous system,"Million US$, purchasing power parity",845.4 +32963,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +32964,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4 +32965,Sweden,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",111.1 +32966,Sweden,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",414.0 +32967,Sweden,2010,4,C03-Diuretics,"Million US$, purchasing power parity",29.8 +32968,Sweden,2010,4,C03-Diuretics,"/capita, US$ exchange rate",4.0 +32969,Sweden,2010,4,C03-Diuretics,Million of national currency units,269.1 +32970,Sweden,2010,4,C03-Diuretics,Million US$ at exchange rate,37.3 +32971,Sweden,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",345.5 +32972,Sweden,2010,4,C03-Diuretics,% of total sales,0.7 +32973,Sweden,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2 +32974,Sweden,2010,4,A-Alimentary tract and metabolism,% of total sales,10.4 +32975,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.1 +32976,Sweden,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.3 +32977,Sweden,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.1 +32978,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0 +32979,Sweden,2010,4,C02-Antihypertensives,Million of national currency units,137.8 +32980,Sweden,2010,4,J01-Antibacterials for systemic use,Million of national currency units,1003.0 +32981,Sweden,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,139.2 +32982,Sweden,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",15.3 +32983,Sweden,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.0 +32984,Sweden,2010,4,C02-Antihypertensives,Million US$ at exchange rate,19.1 +32985,Sweden,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +32986,Sweden,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +32987,Sweden,2010,4,C01A-Cardiac glycosides,% of total sales,0.0 +32988,Sweden,2010,4,C-Cardiovascular system,Million US$ at exchange rate,432.6 +32989,Sweden,2010,4,C-Cardiovascular system,Million of national currency units,3118.3 +32990,Sweden,2010,4,C01A-Cardiac glycosides,Million of national currency units,14.1 +32991,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5 +32992,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.0 +32993,Sweden,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6 +32994,Sweden,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0 +32995,Sweden,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6 +32996,Sweden,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,5003.0 +32997,Sweden,2010,4,Total pharmaceutical sales,Million of national currency units,36059.4 +32998,Sweden,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",143.3 +32999,Sweden,2010,4,C02-Antihypertensives,% of total sales,0.4 +33000,Sweden,2010,4,M-Musculo-skeletal system,Million of national currency units,1241.2 +33001,Sweden,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3 +33002,Sweden,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.1 +33003,Sweden,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3995.5 +33004,Sweden,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.4 +33005,Sweden,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7 +33006,Sweden,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,172.2 +33007,Sweden,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.5 +33008,Sweden,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",426.0 +33009,Sweden,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",533.5 +33010,Sweden,2010,4,M-Musculo-skeletal system,% of total sales,3.4 +33011,Sweden,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,179.4 +33012,Sweden,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.1 +33013,Sweden,2010,4,A10-Drugs used in diabetes,% of total sales,3.6 +33014,Sweden,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.8 +33015,Sweden,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.8 +33016,Sweden,2010,4,A-Alimentary tract and metabolism,Million of national currency units,3736.4 +33017,Sweden,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,518.4 +33018,Sweden,2010,4,J01-Antibacterials for systemic use,% of total sales,2.8 +33019,Sweden,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9 +33020,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.9 +33021,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",82.0 +33022,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1 +33023,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7 +33024,Sweden,2010,4,C-Cardiovascular system,% of total sales,8.6 +33025,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,102.6 +33026,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,739.8 +33027,Sweden,2010,4,A10-Drugs used in diabetes,Million of national currency units,1293.3 +33028,Sweden,2010,4,A02A-Antacids,Million of national currency units,62.4 +33029,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.8 +33030,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8 +33031,Sweden,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.9 +33032,Sweden,2010,4,A02A-Antacids,"Million US$, purchasing power parity",6.9 +33033,Sweden,2010,4,A02A-Antacids,Million US$ at exchange rate,8.7 +33034,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,727.7 +33035,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,998.7 +33036,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,101.0 +33037,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.8 +33038,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",110.7 +33039,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,138.6 +33040,Sweden,2010,4,R-Respiratory system,Million US$ at exchange rate,461.2 +33041,Sweden,2010,4,R-Respiratory system,"Million US$, purchasing power parity",368.3 +33042,Sweden,2010,4,R-Respiratory system,Million of national currency units,3323.9 +33043,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9 +33044,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +33045,Sweden,2010,4,A02A-Antacids,% of total sales,0.2 +33046,Sweden,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.7 +33047,Sweden,2010,4,N-Nervous system,Million of national currency units,7256.9 +33048,Sweden,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.3 +33049,Sweden,2010,4,R-Respiratory system,"/capita, US$ exchange rate",49.2 +33050,Sweden,2010,4,R-Respiratory system,% of total sales,9.2 +33051,Sweden,2010,4,N02-Analgesics,Million US$ at exchange rate,280.4 +33052,Sweden,2010,4,N02-Analgesics,Million of national currency units,2021.1 +33053,Sweden,2010,4,N02-Analgesics,"Million US$, purchasing power parity",223.9 +33054,Sweden,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.9 +33055,Sweden,2010,4,N02-Analgesics,"/capita, US$ exchange rate",29.9 +33056,Sweden,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.9 +33057,Sweden,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,28.7 +33058,Sweden,2010,4,J-Antiinfectives for systemic use,Million of national currency units,2649.2 +33059,Sweden,2010,4,C08-Calcium channel blockers,Million of national currency units,206.8 +33060,Sweden,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4 +33061,Sweden,2010,4,C08-Calcium channel blockers,% of total sales,0.6 +33062,Sweden,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.1 +33063,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0 +33064,Sweden,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1932.4 +33065,Sweden,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,268.1 +33066,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.8 +33067,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",80.6 +33068,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.6 +33069,Sweden,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,5.4 +33070,Sweden,2010,4,N02-Analgesics,% of total sales,5.6 +33071,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",214.1 +33072,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8 +33073,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.6 +33074,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.2 +33075,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.6 +33076,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",99.2 +33077,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,895.5 +33078,Sweden,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,1715.4 +33079,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,124.2 +33080,Sweden,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",69.3 +33081,Sweden,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",9.3 +33082,Sweden,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.4 +33083,Sweden,2010,4,N06A-Antidepressants,Million of national currency units,625.7 +33084,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.5 +33085,Sweden,2010,4,N06A-Antidepressants,Million US$ at exchange rate,86.8 +33086,Sweden,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.1 +33087,Sweden,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.0 +33088,Sweden,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,37.7 +33089,Sweden,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.8 +33090,Sweden,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2 +33091,Sweden,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.4 +33092,Sweden,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,238.0 +33093,Sweden,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",190.1 +33094,Sweden,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,271.6 +33095,Sweden,2010,4,G-Genito urinary system and sex hormones,% of total sales,4.8 +33096,Sweden,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.3 +33097,Sweden,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2 +33098,Sweden,2010,4,N05B-Anxiolytics,% of total sales,0.5 +33099,Sweden,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8 +33100,Sweden,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,100.3 +33101,Sweden,2010,4,C10-Lipid modifying agents,Million of national currency units,722.6 +33102,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,127.6 +33103,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6 +33104,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",101.9 +33105,Sweden,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",20.8 +33106,Sweden,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,26.0 +33107,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,919.4 +33108,Sweden,2010,4,N05B-Anxiolytics,Million of national currency units,187.6 +33109,Sweden,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",80.1 +33110,Sweden,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",341.2 +33111,Sweden,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.6 +33112,Sweden,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",36.4 +33113,Sweden,2010,4,N06A-Antidepressants,% of total sales,1.7 +33114,Sweden,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,427.3 +33115,Sweden,2010,4,B-Blood and blood forming organs,Million of national currency units,3079.7 +33116,Sweden,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5 +33117,Sweden,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.7 +33118,Sweden,2010,4,C10-Lipid modifying agents,% of total sales,2.0 +33119,Sweden,2010,4,B-Blood and blood forming organs,% of total sales,8.5 +33120,Sweden,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.3 +33121,Sweden,2010,4,N-Nervous system,% of total sales,20.1 +33122,Sweden,2010,4,J-Antiinfectives for systemic use,% of total sales,7.3 +33123,Sweden,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",85.7 +33124,Sweden,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.2 +33125,Sweden,2010,4,N-Nervous system,"/capita, US$ exchange rate",107.4 +33126,Sweden,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,59.7 +33127,Sweden,2010,4,C07-Beta blocking agents,Million of national currency units,430.0 +33128,Sweden,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.4 +33129,Sweden,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",47.6 +33130,Sweden,2010,4,C07-Beta blocking agents,% of total sales,1.2 +33131,Sweden,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.1 +33132,Sweden,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",293.5 +33133,Sweden,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.6 +33134,Sweden,2010,4,N-Nervous system,Million US$ at exchange rate,1006.9 +33135,Sweden,2010,4,N-Nervous system,"Million US$, purchasing power parity",804.1 +33136,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7 +33137,Sweden,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",436.2 +33138,Sweden,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",83.8 +33139,Sweden,2013,5,C03-Diuretics,"Million US$, purchasing power parity",29.9 +33140,Sweden,2013,5,C03-Diuretics,Million of national currency units,257.0 +33141,Sweden,2013,5,C03-Diuretics,Million US$ at exchange rate,39.5 +33142,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9 +33143,Sweden,2013,5,C03-Diuretics,% of total sales,0.7 +33144,Sweden,2013,5,C03-Diuretics,"/capita, US$ exchange rate",4.1 +33145,Sweden,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1 +33146,Sweden,2013,5,A-Alimentary tract and metabolism,% of total sales,10.3 +33147,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,54.1 +33148,Sweden,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.4 +33149,Sweden,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.0 +33150,Sweden,2013,5,C02-Antihypertensives,Million of national currency units,154.1 +33151,Sweden,2013,5,J01-Antibacterials for systemic use,Million of national currency units,720.8 +33152,Sweden,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,110.7 +33153,Sweden,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",17.9 +33154,Sweden,2013,5,C02-Antihypertensives,Million US$ at exchange rate,23.7 +33155,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.3 +33156,Sweden,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2 +33157,Sweden,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2 +33158,Sweden,2013,5,C-Cardiovascular system,Million US$ at exchange rate,352.4 +33159,Sweden,2013,5,C-Cardiovascular system,Million of national currency units,2295.4 +33160,Sweden,2013,5,C01A-Cardiac glycosides,% of total sales,0.0 +33161,Sweden,2013,5,C01A-Cardiac glycosides,Million of national currency units,14.5 +33162,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.3 +33163,Sweden,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7 +33164,Sweden,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.2 +33165,Sweden,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9 +33166,Sweden,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,209.8 +33167,Sweden,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,5578.4 +33168,Sweden,2013,5,Total pharmaceutical sales,Million of national currency units,36337.4 +33169,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0 +33170,Sweden,2013,5,C02-Antihypertensives,% of total sales,0.4 +33171,Sweden,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",159.0 +33172,Sweden,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.5 +33173,Sweden,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.9 +33174,Sweden,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.0 +33175,Sweden,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1 +33176,Sweden,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",145.4 +33177,Sweden,2013,5,M-Musculo-skeletal system,Million of national currency units,1249.9 +33178,Sweden,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,191.9 +33179,Sweden,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",581.1 +33180,Sweden,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4226.4 +33181,Sweden,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",440.2 +33182,Sweden,2013,5,M-Musculo-skeletal system,% of total sales,3.4 +33183,Sweden,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",36.7 +33184,Sweden,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",267.0 +33185,Sweden,2013,5,A10-Drugs used in diabetes,% of total sales,3.8 +33186,Sweden,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.8 +33187,Sweden,2013,5,A-Alimentary tract and metabolism,Million of national currency units,3749.9 +33188,Sweden,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,575.7 +33189,Sweden,2013,5,J01-Antibacterials for systemic use,% of total sales,2.0 +33190,Sweden,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.7 +33191,Sweden,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5 +33192,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.4 +33193,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",83.2 +33194,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7 +33195,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.8 +33196,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1 +33197,Sweden,2013,5,C-Cardiovascular system,% of total sales,6.3 +33198,Sweden,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.6 +33199,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,715.4 +33200,Sweden,2013,5,A10-Drugs used in diabetes,Million of national currency units,1366.8 +33201,Sweden,2013,5,A02A-Antacids,Million of national currency units,75.9 +33202,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.3 +33203,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.5 +33204,Sweden,2013,5,A02A-Antacids,"Million US$, purchasing power parity",8.8 +33205,Sweden,2013,5,A02A-Antacids,"/capita, US$ exchange rate",1.2 +33206,Sweden,2013,5,A02A-Antacids,Million US$ at exchange rate,11.7 +33207,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,500.4 +33208,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,457.3 +33209,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,76.8 +33210,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",7.3 +33211,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,70.2 +33212,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",53.2 +33213,Sweden,2013,5,R-Respiratory system,Million US$ at exchange rate,545.2 +33214,Sweden,2013,5,R-Respiratory system,Million of national currency units,3551.1 +33215,Sweden,2013,5,R-Respiratory system,"Million US$, purchasing power parity",413.0 +33216,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8 +33217,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +33218,Sweden,2013,5,A02A-Antacids,% of total sales,0.2 +33219,Sweden,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.9 +33220,Sweden,2013,5,R-Respiratory system,"/capita, US$ exchange rate",56.8 +33221,Sweden,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",43.0 +33222,Sweden,2013,5,R-Respiratory system,% of total sales,9.8 +33223,Sweden,2013,5,N02-Analgesics,Million US$ at exchange rate,302.7 +33224,Sweden,2013,5,N02-Analgesics,Million of national currency units,1972.0 +33225,Sweden,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.9 +33226,Sweden,2013,5,N02-Analgesics,"Million US$, purchasing power parity",229.4 +33227,Sweden,2013,5,N02-Analgesics,"/capita, US$ exchange rate",31.5 +33228,Sweden,2013,5,C08-Calcium channel blockers,% of total sales,0.5 +33229,Sweden,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,30.5 +33230,Sweden,2013,5,J-Antiinfectives for systemic use,Million of national currency units,2367.4 +33231,Sweden,2013,5,C08-Calcium channel blockers,Million of national currency units,198.7 +33232,Sweden,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.1 +33233,Sweden,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4 +33234,Sweden,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2 +33235,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4 +33236,Sweden,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,311.5 +33237,Sweden,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,2029.1 +33238,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",58.2 +33239,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0 +33240,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.1 +33241,Sweden,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.6 +33242,Sweden,2013,5,N02-Analgesics,% of total sales,5.4 +33243,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.0 +33244,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.4 +33245,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.6 +33246,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.6 +33247,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.8 +33248,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",108.0 +33249,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.2 +33250,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,928.4 +33251,Sweden,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,1729.0 +33252,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,142.5 +33253,Sweden,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",86.6 +33254,Sweden,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.0 +33255,Sweden,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.9 +33256,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.6 +33257,Sweden,2013,5,N06A-Antidepressants,Million of national currency units,744.4 +33258,Sweden,2013,5,N06A-Antidepressants,Million US$ at exchange rate,114.3 +33259,Sweden,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",36.6 +33260,Sweden,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,48.3 +33261,Sweden,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.0 +33262,Sweden,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.9 +33263,Sweden,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8 +33264,Sweden,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6 +33265,Sweden,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",201.1 +33266,Sweden,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,265.4 +33267,Sweden,2013,5,G-Genito urinary system and sex hormones,% of total sales,4.8 +33268,Sweden,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,314.9 +33269,Sweden,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.9 +33270,Sweden,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4 +33271,Sweden,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.2 +33272,Sweden,2013,5,N05B-Anxiolytics,% of total sales,0.6 +33273,Sweden,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,67.7 +33274,Sweden,2013,5,C10-Lipid modifying agents,Million of national currency units,440.8 +33275,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,149.4 +33276,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",113.2 +33277,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,973.5 +33278,Sweden,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,30.8 +33279,Sweden,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",23.3 +33280,Sweden,2013,5,N05B-Anxiolytics,Million of national currency units,200.7 +33281,Sweden,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",366.2 +33282,Sweden,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.3 +33283,Sweden,2013,5,N06A-Antidepressants,% of total sales,2.0 +33284,Sweden,2013,5,B-Blood and blood forming organs,Million of national currency units,3148.6 +33285,Sweden,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,483.4 +33286,Sweden,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.1 +33287,Sweden,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.3 +33288,Sweden,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.3 +33289,Sweden,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.0 +33290,Sweden,2013,5,B-Blood and blood forming organs,% of total sales,8.7 +33291,Sweden,2013,5,C10-Lipid modifying agents,% of total sales,1.2 +33292,Sweden,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.7 +33293,Sweden,2013,5,J-Antiinfectives for systemic use,% of total sales,6.5 +33294,Sweden,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.9 +33295,Sweden,2013,5,N-Nervous system,"/capita, US$ exchange rate",116.7 +33296,Sweden,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",88.4 +33297,Sweden,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,63.1 +33298,Sweden,2013,5,C07-Beta blocking agents,Million of national currency units,411.0 +33299,Sweden,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6 +33300,Sweden,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",47.8 +33301,Sweden,2013,5,N-Nervous system,% of total sales,20.1 +33302,Sweden,2013,5,C07-Beta blocking agents,% of total sales,1.1 +33303,Sweden,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.0 +33304,Sweden,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,363.4 +33305,Sweden,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",275.3 +33306,Sweden,2013,5,N-Nervous system,Million US$ at exchange rate,1119.9 +33307,Sweden,2013,5,N-Nervous system,Million of national currency units,7295.0 +33308,Sweden,2013,5,N-Nervous system,"Million US$, purchasing power parity",848.5 +33309,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.3 +33310,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +33311,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.2 +33312,Switzerland,2017,5,B-Blood and blood forming organs,Million of national currency units,354.0 +33313,Switzerland,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,359.5 +33314,Switzerland,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",298.0 +33315,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",78.3 +33316,Switzerland,2017,5,C-Cardiovascular system,Million of national currency units,792.0 +33317,Switzerland,2017,5,N-Nervous system,"/capita, US$ exchange rate",145.9 +33318,Switzerland,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",120.9 +33319,Switzerland,2017,5,N-Nervous system,"Million US$, purchasing power parity",1022.1 +33320,Switzerland,2017,5,N-Nervous system,Million of national currency units,1214.0 +33321,Switzerland,2017,5,N-Nervous system,Million US$ at exchange rate,1232.9 +33322,Switzerland,2017,5,N-Nervous system,% of total sales,18.6 +33323,Switzerland,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",666.8 +33324,Switzerland,2017,5,C-Cardiovascular system,Million US$ at exchange rate,804.3 +33325,Switzerland,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",95.2 +33326,Switzerland,2017,5,C-Cardiovascular system,% of total sales,12.1 +33327,Switzerland,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",78.9 +33328,Switzerland,2017,5,Products not elsewhere classified,Million of national currency units,1298.0 +33329,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,94.4 +33330,Switzerland,2017,5,M-Musculo-skeletal system,Million of national currency units,427.0 +33331,Switzerland,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,433.6 +33332,Switzerland,2017,5,R-Respiratory system,Million of national currency units,507.0 +33333,Switzerland,2017,5,R-Respiratory system,Million US$ at exchange rate,514.9 +33334,Switzerland,2017,5,Products not elsewhere classified,% of total sales,19.9 +33335,Switzerland,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",129.3 +33336,Switzerland,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",156.0 +33337,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,93.0 +33338,Switzerland,2017,5,Products not elsewhere classified,Million US$ at exchange rate,1318.2 +33339,Switzerland,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",1092.8 +33340,Switzerland,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,6621.4 +33341,Switzerland,2017,5,Total pharmaceutical sales,Million of national currency units,6520.0 +33342,Switzerland,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5489.5 +33343,Switzerland,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",42.5 +33344,Switzerland,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.3 +33345,Switzerland,2017,5,B-Blood and blood forming organs,% of total sales,5.4 +33346,Switzerland,2017,5,R-Respiratory system,"/capita, US$ exchange rate",60.9 +33347,Switzerland,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",50.5 +33348,Switzerland,2017,5,R-Respiratory system,"Million US$, purchasing power parity",426.9 +33349,Switzerland,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",783.4 +33350,Switzerland,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",649.5 +33351,Switzerland,2017,5,R-Respiratory system,% of total sales,7.8 +33352,Switzerland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",93.0 +33353,Switzerland,2017,5,A-Alimentary tract and metabolism,% of total sales,14.3 +33354,Switzerland,2017,5,M-Musculo-skeletal system,% of total sales,6.5 +33355,Switzerland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",112.2 +33356,Switzerland,2017,5,J-Antiinfectives for systemic use,% of total sales,8.5 +33357,Switzerland,2017,5,A-Alimentary tract and metabolism,Million of national currency units,934.0 +33358,Switzerland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.2 +33359,Switzerland,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,948.5 +33360,Switzerland,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",51.3 +33361,Switzerland,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",42.5 +33362,Switzerland,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",786.4 +33363,Switzerland,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",359.5 +33364,Switzerland,2017,5,J-Antiinfectives for systemic use,Million of national currency units,554.0 +33365,Switzerland,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,347.0 +33366,Switzerland,2017,5,G-Genito urinary system and sex hormones,% of total sales,5.3 +33367,Switzerland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.6 +33368,Switzerland,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,562.6 +33369,Switzerland,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",466.4 +33370,Switzerland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.6 +33371,Switzerland,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,352.4 +33372,Switzerland,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.2 +33373,Switzerland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",41.7 +33374,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.0 +33375,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +33376,Switzerland,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,324.7 +33377,Switzerland,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",266.2 +33378,Switzerland,2016,5,B-Blood and blood forming organs,Million of national currency units,320.0 +33379,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0 +33380,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",75.7 +33381,Switzerland,2016,5,C-Cardiovascular system,Million of national currency units,799.0 +33382,Switzerland,2016,5,N-Nervous system,"/capita, US$ exchange rate",148.0 +33383,Switzerland,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",121.3 +33384,Switzerland,2016,5,N-Nervous system,Million of national currency units,1221.0 +33385,Switzerland,2016,5,N-Nervous system,"Million US$, purchasing power parity",1015.8 +33386,Switzerland,2016,5,N-Nervous system,Million US$ at exchange rate,1239.1 +33387,Switzerland,2016,5,N-Nervous system,% of total sales,19.1 +33388,Switzerland,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",664.7 +33389,Switzerland,2016,5,C-Cardiovascular system,Million US$ at exchange rate,810.8 +33390,Switzerland,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",96.8 +33391,Switzerland,2016,5,C-Cardiovascular system,% of total sales,12.5 +33392,Switzerland,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",79.4 +33393,Switzerland,2016,5,Products not elsewhere classified,Million of national currency units,1218.0 +33394,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.3 +33395,Switzerland,2016,5,M-Musculo-skeletal system,Million of national currency units,416.0 +33396,Switzerland,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,422.2 +33397,Switzerland,2016,5,R-Respiratory system,Million of national currency units,497.0 +33398,Switzerland,2016,5,R-Respiratory system,Million US$ at exchange rate,504.4 +33399,Switzerland,2016,5,Products not elsewhere classified,% of total sales,19.1 +33400,Switzerland,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",147.6 +33401,Switzerland,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",121.0 +33402,Switzerland,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1236.1 +33403,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,91.0 +33404,Switzerland,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",1013.3 +33405,Switzerland,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,6474.6 +33406,Switzerland,2016,5,Total pharmaceutical sales,Million of national currency units,6380.0 +33407,Switzerland,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5308.0 +33408,Switzerland,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8 +33409,Switzerland,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.8 +33410,Switzerland,2016,5,B-Blood and blood forming organs,% of total sales,5.0 +33411,Switzerland,2016,5,R-Respiratory system,"/capita, US$ exchange rate",60.2 +33412,Switzerland,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",49.4 +33413,Switzerland,2016,5,R-Respiratory system,"Million US$, purchasing power parity",413.5 +33414,Switzerland,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",633.9 +33415,Switzerland,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",773.2 +33416,Switzerland,2016,5,R-Respiratory system,% of total sales,7.8 +33417,Switzerland,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.7 +33418,Switzerland,2016,5,A-Alimentary tract and metabolism,% of total sales,14.5 +33419,Switzerland,2016,5,M-Musculo-skeletal system,% of total sales,6.5 +33420,Switzerland,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",111.9 +33421,Switzerland,2016,5,J-Antiinfectives for systemic use,% of total sales,8.6 +33422,Switzerland,2016,5,A-Alimentary tract and metabolism,Million of national currency units,923.0 +33423,Switzerland,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.3 +33424,Switzerland,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,936.7 +33425,Switzerland,2016,5,J-Antiinfectives for systemic use,Million of national currency units,546.0 +33426,Switzerland,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",50.4 +33427,Switzerland,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",41.3 +33428,Switzerland,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",346.1 +33429,Switzerland,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",767.9 +33430,Switzerland,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,351.0 +33431,Switzerland,2016,5,G-Genito urinary system and sex hormones,% of total sales,5.5 +33432,Switzerland,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.9 +33433,Switzerland,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,554.1 +33434,Switzerland,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",454.3 +33435,Switzerland,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.2 +33436,Switzerland,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,356.2 +33437,Switzerland,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.0 +33438,Switzerland,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",42.5 +33439,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1 +33440,Switzerland,2014,5,C-Cardiovascular system,Million of national currency units,770.0 +33441,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +33442,Switzerland,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,287.1 +33443,Switzerland,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",205.2 +33444,Switzerland,2014,5,B-Blood and blood forming organs,Million of national currency units,263.0 +33445,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.3 +33446,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.3 +33447,Switzerland,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",600.7 +33448,Switzerland,2014,5,N-Nervous system,"/capita, US$ exchange rate",137.0 +33449,Switzerland,2014,5,N-Nervous system,% of total sales,17.3 +33450,Switzerland,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",97.9 +33451,Switzerland,2014,5,N-Nervous system,Million of national currency units,1028.0 +33452,Switzerland,2014,5,N-Nervous system,Million US$ at exchange rate,1122.1 +33453,Switzerland,2014,5,N-Nervous system,"Million US$, purchasing power parity",802.0 +33454,Switzerland,2014,5,C-Cardiovascular system,Million US$ at exchange rate,840.5 +33455,Switzerland,2014,5,C-Cardiovascular system,% of total sales,13.0 +33456,Switzerland,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",73.4 +33457,Switzerland,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.1 +33458,Switzerland,2014,5,Products not elsewhere classified,Million of national currency units,1258.0 +33459,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.8 +33460,Switzerland,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,418.1 +33461,Switzerland,2014,5,M-Musculo-skeletal system,Million of national currency units,383.0 +33462,Switzerland,2014,5,R-Respiratory system,Million of national currency units,476.0 +33463,Switzerland,2014,5,R-Respiratory system,Million US$ at exchange rate,519.6 +33464,Switzerland,2014,5,Products not elsewhere classified,% of total sales,21.2 +33465,Switzerland,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",167.7 +33466,Switzerland,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",119.9 +33467,Switzerland,2014,5,Products not elsewhere classified,Million US$ at exchange rate,1373.1 +33468,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,85.0 +33469,Switzerland,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",981.5 +33470,Switzerland,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,6473.8 +33471,Switzerland,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4627.2 +33472,Switzerland,2014,5,Total pharmaceutical sales,Million of national currency units,5931.0 +33473,Switzerland,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1 +33474,Switzerland,2014,5,B-Blood and blood forming organs,% of total sales,4.4 +33475,Switzerland,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",790.6 +33476,Switzerland,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",45.4 +33477,Switzerland,2014,5,R-Respiratory system,"/capita, US$ exchange rate",63.4 +33478,Switzerland,2014,5,R-Respiratory system,"Million US$, purchasing power parity",371.4 +33479,Switzerland,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",565.1 +33480,Switzerland,2014,5,R-Respiratory system,% of total sales,8.0 +33481,Switzerland,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",102.6 +33482,Switzerland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",82.2 +33483,Switzerland,2014,5,A-Alimentary tract and metabolism,% of total sales,14.6 +33484,Switzerland,2014,5,M-Musculo-skeletal system,% of total sales,6.5 +33485,Switzerland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",115.0 +33486,Switzerland,2014,5,J-Antiinfectives for systemic use,% of total sales,7.7 +33487,Switzerland,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",51.1 +33488,Switzerland,2014,5,A-Alimentary tract and metabolism,Million of national currency units,863.0 +33489,Switzerland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.7 +33490,Switzerland,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,346.0 +33491,Switzerland,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,942.0 +33492,Switzerland,2014,5,J-Antiinfectives for systemic use,Million of national currency units,459.0 +33493,Switzerland,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",36.5 +33494,Switzerland,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",673.3 +33495,Switzerland,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",298.8 +33496,Switzerland,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,501.0 +33497,Switzerland,2014,5,G-Genito urinary system and sex hormones,% of total sales,5.8 +33498,Switzerland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.0 +33499,Switzerland,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",358.1 +33500,Switzerland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",61.2 +33501,Switzerland,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,377.7 +33502,Switzerland,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",269.9 +33503,Switzerland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",46.1 +33504,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9 +33505,Switzerland,2013,6,C-Cardiovascular system,Million of national currency units,791.0 +33506,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +33507,Switzerland,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,264.3 +33508,Switzerland,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",186.7 +33509,Switzerland,2013,6,B-Blood and blood forming organs,Million of national currency units,245.0 +33510,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.2 +33511,Switzerland,2013,6,M-Musculo-skeletal system,Million of national currency units,355.0 +33512,Switzerland,2013,6,N-Nervous system,"/capita, US$ exchange rate",139.4 +33513,Switzerland,2013,6,N-Nervous system,% of total sales,17.6 +33514,Switzerland,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",98.4 +33515,Switzerland,2013,6,N-Nervous system,Million of national currency units,1045.0 +33516,Switzerland,2013,6,N-Nervous system,Million US$ at exchange rate,1127.4 +33517,Switzerland,2013,6,N-Nervous system,"Million US$, purchasing power parity",796.2 +33518,Switzerland,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",602.7 +33519,Switzerland,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",105.5 +33520,Switzerland,2013,6,C-Cardiovascular system,Million US$ at exchange rate,853.4 +33521,Switzerland,2013,6,C-Cardiovascular system,% of total sales,13.3 +33522,Switzerland,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.5 +33523,Switzerland,2013,6,Products not elsewhere classified,Million of national currency units,1238.0 +33524,Switzerland,2013,6,Products not elsewhere classified,Million US$ at exchange rate,1335.6 +33525,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,90.6 +33526,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",64.0 +33527,Switzerland,2013,6,R-Respiratory system,Million of national currency units,513.0 +33528,Switzerland,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,383.0 +33529,Switzerland,2013,6,R-Respiratory system,Million US$ at exchange rate,553.5 +33530,Switzerland,2013,6,Products not elsewhere classified,% of total sales,20.9 +33531,Switzerland,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",165.1 +33532,Switzerland,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",116.6 +33533,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,84.0 +33534,Switzerland,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",943.3 +33535,Switzerland,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,6398.7 +33536,Switzerland,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4518.9 +33537,Switzerland,2013,6,Total pharmaceutical sales,Million of national currency units,5931.0 +33538,Switzerland,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.1 +33539,Switzerland,2013,6,B-Blood and blood forming organs,% of total sales,4.1 +33540,Switzerland,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.7 +33541,Switzerland,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",48.3 +33542,Switzerland,2013,6,R-Respiratory system,"Million US$, purchasing power parity",390.9 +33543,Switzerland,2013,6,R-Respiratory system,"/capita, US$ exchange rate",68.4 +33544,Switzerland,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",558.6 +33545,Switzerland,2013,6,R-Respiratory system,% of total sales,8.6 +33546,Switzerland,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",791.0 +33547,Switzerland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",80.8 +33548,Switzerland,2013,6,A-Alimentary tract and metabolism,% of total sales,14.5 +33549,Switzerland,2013,6,M-Musculo-skeletal system,% of total sales,6.0 +33550,Switzerland,2013,6,J-Antiinfectives for systemic use,% of total sales,7.6 +33551,Switzerland,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,353.0 +33552,Switzerland,2013,6,A-Alimentary tract and metabolism,Million of national currency units,858.0 +33553,Switzerland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.3 +33554,Switzerland,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,925.7 +33555,Switzerland,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",653.7 +33556,Switzerland,2013,6,J-Antiinfectives for systemic use,Million of national currency units,449.0 +33557,Switzerland,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",33.4 +33558,Switzerland,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",270.5 +33559,Switzerland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",114.4 +33560,Switzerland,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,484.4 +33561,Switzerland,2013,6,G-Genito urinary system and sex hormones,% of total sales,6.0 +33562,Switzerland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.2 +33563,Switzerland,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",342.1 +33564,Switzerland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",59.9 +33565,Switzerland,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",47.3 +33566,Switzerland,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,380.8 +33567,Switzerland,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",269.0 +33568,Switzerland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",47.1 +33569,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.7 +33570,Switzerland,2012,6,C-Cardiovascular system,Million of national currency units,876.0 +33571,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +33572,Switzerland,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,236.8 +33573,Switzerland,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",163.9 +33574,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.1 +33575,Switzerland,2012,6,M-Musculo-skeletal system,Million of national currency units,356.0 +33576,Switzerland,2012,6,B-Blood and blood forming organs,Million of national currency units,222.0 +33577,Switzerland,2012,6,N-Nervous system,"/capita, US$ exchange rate",141.4 +33578,Switzerland,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",97.9 +33579,Switzerland,2012,6,N-Nervous system,% of total sales,17.9 +33580,Switzerland,2012,6,N-Nervous system,Million of national currency units,1060.0 +33581,Switzerland,2012,6,N-Nervous system,Million US$ at exchange rate,1130.4 +33582,Switzerland,2012,6,N-Nervous system,"Million US$, purchasing power parity",782.8 +33583,Switzerland,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",646.9 +33584,Switzerland,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",116.8 +33585,Switzerland,2012,6,C-Cardiovascular system,Million US$ at exchange rate,934.2 +33586,Switzerland,2012,6,C-Cardiovascular system,% of total sales,14.8 +33587,Switzerland,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.9 +33588,Switzerland,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6 +33589,Switzerland,2012,6,Products not elsewhere classified,Million of national currency units,1180.0 +33590,Switzerland,2012,6,R-Respiratory system,Million of national currency units,494.0 +33591,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",61.3 +33592,Switzerland,2012,6,Products not elsewhere classified,Million US$ at exchange rate,1258.4 +33593,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.5 +33594,Switzerland,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,379.7 +33595,Switzerland,2012,6,R-Respiratory system,Million US$ at exchange rate,526.8 +33596,Switzerland,2012,6,Products not elsewhere classified,% of total sales,19.9 +33597,Switzerland,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",109.0 +33598,Switzerland,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",157.4 +33599,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,83.0 +33600,Switzerland,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",871.4 +33601,Switzerland,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,6331.6 +33602,Switzerland,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4384.6 +33603,Switzerland,2012,6,Total pharmaceutical sales,Million of national currency units,5937.0 +33604,Switzerland,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.5 +33605,Switzerland,2012,6,B-Blood and blood forming organs,% of total sales,3.7 +33606,Switzerland,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",791.8 +33607,Switzerland,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",45.6 +33608,Switzerland,2012,6,R-Respiratory system,"/capita, US$ exchange rate",65.9 +33609,Switzerland,2012,6,R-Respiratory system,"Million US$, purchasing power parity",364.8 +33610,Switzerland,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",548.3 +33611,Switzerland,2012,6,R-Respiratory system,% of total sales,8.3 +33612,Switzerland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",78.6 +33613,Switzerland,2012,6,A-Alimentary tract and metabolism,% of total sales,14.3 +33614,Switzerland,2012,6,J-Antiinfectives for systemic use,% of total sales,7.8 +33615,Switzerland,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,353.0 +33616,Switzerland,2012,6,A-Alimentary tract and metabolism,Million of national currency units,851.0 +33617,Switzerland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.8 +33618,Switzerland,2012,6,M-Musculo-skeletal system,% of total sales,6.0 +33619,Switzerland,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,907.6 +33620,Switzerland,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",628.5 +33621,Switzerland,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.9 +33622,Switzerland,2012,6,J-Antiinfectives for systemic use,Million of national currency units,463.0 +33623,Switzerland,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",262.9 +33624,Switzerland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",113.5 +33625,Switzerland,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,493.8 +33626,Switzerland,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",47.5 +33627,Switzerland,2012,6,G-Genito urinary system and sex hormones,% of total sales,5.9 +33628,Switzerland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",32.6 +33629,Switzerland,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",341.9 +33630,Switzerland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",61.7 +33631,Switzerland,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",260.7 +33632,Switzerland,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,376.5 +33633,Switzerland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",47.1 +33634,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6 +33635,Switzerland,2011,6,C-Cardiovascular system,Million of national currency units,929.0 +33636,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3 +33637,Switzerland,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,234.2 +33638,Switzerland,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",148.8 +33639,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4 +33640,Switzerland,2011,6,M-Musculo-skeletal system,Million of national currency units,345.0 +33641,Switzerland,2011,6,B-Blood and blood forming organs,Million of national currency units,208.0 +33642,Switzerland,2011,6,N-Nervous system,"/capita, US$ exchange rate",151.3 +33643,Switzerland,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",96.1 +33644,Switzerland,2011,6,N-Nervous system,% of total sales,18.4 +33645,Switzerland,2011,6,N-Nervous system,Million US$ at exchange rate,1197.0 +33646,Switzerland,2011,6,N-Nervous system,Million of national currency units,1063.0 +33647,Switzerland,2011,6,N-Nervous system,"Million US$, purchasing power parity",760.6 +33648,Switzerland,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6 +33649,Switzerland,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",132.2 +33650,Switzerland,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",664.8 +33651,Switzerland,2011,6,C-Cardiovascular system,Million US$ at exchange rate,1046.1 +33652,Switzerland,2011,6,C-Cardiovascular system,% of total sales,16.1 +33653,Switzerland,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.0 +33654,Switzerland,2011,6,Products not elsewhere classified,Million of national currency units,1030.0 +33655,Switzerland,2011,6,R-Respiratory system,Million of national currency units,487.0 +33656,Switzerland,2011,6,Products not elsewhere classified,Million US$ at exchange rate,1159.9 +33657,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.2 +33658,Switzerland,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,388.5 +33659,Switzerland,2011,6,R-Respiratory system,Million US$ at exchange rate,548.4 +33660,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.2 +33661,Switzerland,2011,6,Products not elsewhere classified,% of total sales,17.8 +33662,Switzerland,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",93.1 +33663,Switzerland,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",146.6 +33664,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,73.0 +33665,Switzerland,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",737.0 +33666,Switzerland,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,6504.2 +33667,Switzerland,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4133.1 +33668,Switzerland,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.8 +33669,Switzerland,2011,6,Total pharmaceutical sales,Million of national currency units,5776.0 +33670,Switzerland,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",822.0 +33671,Switzerland,2011,6,B-Blood and blood forming organs,% of total sales,3.6 +33672,Switzerland,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.0 +33673,Switzerland,2011,6,R-Respiratory system,"Million US$, purchasing power parity",348.5 +33674,Switzerland,2011,6,R-Respiratory system,"/capita, US$ exchange rate",69.3 +33675,Switzerland,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.4 +33676,Switzerland,2011,6,R-Respiratory system,% of total sales,8.4 +33677,Switzerland,2011,6,A-Alimentary tract and metabolism,% of total sales,14.7 +33678,Switzerland,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6 +33679,Switzerland,2011,6,J-Antiinfectives for systemic use,% of total sales,7.7 +33680,Switzerland,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,349.0 +33681,Switzerland,2011,6,A-Alimentary tract and metabolism,Million of national currency units,847.0 +33682,Switzerland,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,953.8 +33683,Switzerland,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",606.1 +33684,Switzerland,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.2 +33685,Switzerland,2011,6,J-Antiinfectives for systemic use,Million of national currency units,445.0 +33686,Switzerland,2011,6,M-Musculo-skeletal system,% of total sales,6.0 +33687,Switzerland,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",246.9 +33688,Switzerland,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",120.5 +33689,Switzerland,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,501.1 +33690,Switzerland,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",49.1 +33691,Switzerland,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.2 +33692,Switzerland,2011,6,G-Genito urinary system and sex hormones,% of total sales,6.0 +33693,Switzerland,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",31.6 +33694,Switzerland,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",318.4 +33695,Switzerland,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",63.3 +33696,Switzerland,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,393.0 +33697,Switzerland,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",249.7 +33698,Switzerland,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.7 +33699,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.2 +33700,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.2 +33701,Switzerland,2010,6,C-Cardiovascular system,Million of national currency units,946.1 +33702,Switzerland,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,206.6 +33703,Switzerland,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",147.0 +33704,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.8 +33705,Switzerland,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.4 +33706,Switzerland,2010,6,M-Musculo-skeletal system,Million of national currency units,346.2 +33707,Switzerland,2010,6,B-Blood and blood forming organs,Million of national currency units,215.5 +33708,Switzerland,2010,6,N-Nervous system,"/capita, US$ exchange rate",127.7 +33709,Switzerland,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",90.9 +33710,Switzerland,2010,6,N-Nervous system,% of total sales,18.1 +33711,Switzerland,2010,6,N-Nervous system,Million US$ at exchange rate,999.4 +33712,Switzerland,2010,6,N-Nervous system,Million of national currency units,1042.3 +33713,Switzerland,2010,6,N-Nervous system,"Million US$, purchasing power parity",710.9 +33714,Switzerland,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.9 +33715,Switzerland,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",645.3 +33716,Switzerland,2010,6,C-Cardiovascular system,Million US$ at exchange rate,907.2 +33717,Switzerland,2010,6,C-Cardiovascular system,% of total sales,16.5 +33718,Switzerland,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.5 +33719,Switzerland,2010,6,Products not elsewhere classified,Million of national currency units,980.6 +33720,Switzerland,2010,6,R-Respiratory system,Million of national currency units,484.8 +33721,Switzerland,2010,6,Products not elsewhere classified,Million US$ at exchange rate,940.2 +33722,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",48.7 +33723,Switzerland,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,331.9 +33724,Switzerland,2010,6,R-Respiratory system,Million US$ at exchange rate,464.8 +33725,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.5 +33726,Switzerland,2010,6,Products not elsewhere classified,% of total sales,17.1 +33727,Switzerland,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",85.5 +33728,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,71.4 +33729,Switzerland,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",120.2 +33730,Switzerland,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",668.8 +33731,Switzerland,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,5507.8 +33732,Switzerland,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",703.9 +33733,Switzerland,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",3917.9 +33734,Switzerland,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.8 +33735,Switzerland,2010,6,Total pharmaceutical sales,Million of national currency units,5744.2 +33736,Switzerland,2010,6,B-Blood and blood forming organs,% of total sales,3.8 +33737,Switzerland,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",42.3 +33738,Switzerland,2010,6,R-Respiratory system,"Million US$, purchasing power parity",330.6 +33739,Switzerland,2010,6,R-Respiratory system,"/capita, US$ exchange rate",59.4 +33740,Switzerland,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",500.7 +33741,Switzerland,2010,6,R-Respiratory system,% of total sales,8.4 +33742,Switzerland,2010,6,A-Alimentary tract and metabolism,% of total sales,15.2 +33743,Switzerland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.3 +33744,Switzerland,2010,6,J-Antiinfectives for systemic use,% of total sales,7.6 +33745,Switzerland,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,344.2 +33746,Switzerland,2010,6,A-Alimentary tract and metabolism,Million of national currency units,875.8 +33747,Switzerland,2010,6,M-Musculo-skeletal system,% of total sales,6.0 +33748,Switzerland,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,839.8 +33749,Switzerland,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",597.4 +33750,Switzerland,2010,6,J-Antiinfectives for systemic use,Million of national currency units,437.3 +33751,Switzerland,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",30.2 +33752,Switzerland,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",236.1 +33753,Switzerland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",107.3 +33754,Switzerland,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,419.3 +33755,Switzerland,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",42.4 +33756,Switzerland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.1 +33757,Switzerland,2010,6,G-Genito urinary system and sex hormones,% of total sales,6.0 +33758,Switzerland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",30.0 +33759,Switzerland,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",298.3 +33760,Switzerland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6 +33761,Switzerland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",42.2 +33762,Switzerland,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",234.8 +33763,Switzerland,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,330.0 +33764,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.5 +33765,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4 +33766,Switzerland,2015,5,C-Cardiovascular system,Million of national currency units,777.0 +33767,Switzerland,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,296.1 +33768,Switzerland,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",230.6 +33769,Switzerland,2015,5,B-Blood and blood forming organs,Million of national currency units,285.0 +33770,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.9 +33771,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.4 +33772,Switzerland,2015,5,N-Nervous system,"/capita, US$ exchange rate",130.0 +33773,Switzerland,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",101.2 +33774,Switzerland,2015,5,N-Nervous system,% of total sales,16.8 +33775,Switzerland,2015,5,N-Nervous system,Million of national currency units,1036.0 +33776,Switzerland,2015,5,N-Nervous system,"Million US$, purchasing power parity",838.3 +33777,Switzerland,2015,5,N-Nervous system,Million US$ at exchange rate,1076.5 +33778,Switzerland,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",628.7 +33779,Switzerland,2015,5,C-Cardiovascular system,Million US$ at exchange rate,807.4 +33780,Switzerland,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",97.5 +33781,Switzerland,2015,5,C-Cardiovascular system,% of total sales,12.6 +33782,Switzerland,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.9 +33783,Switzerland,2015,5,Products not elsewhere classified,Million of national currency units,1291.0 +33784,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,90.4 +33785,Switzerland,2015,5,R-Respiratory system,Million of national currency units,503.0 +33786,Switzerland,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,413.6 +33787,Switzerland,2015,5,M-Musculo-skeletal system,Million of national currency units,398.0 +33788,Switzerland,2015,5,R-Respiratory system,Million US$ at exchange rate,522.7 +33789,Switzerland,2015,5,Products not elsewhere classified,% of total sales,20.9 +33790,Switzerland,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",162.0 +33791,Switzerland,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.1 +33792,Switzerland,2015,5,Products not elsewhere classified,Million US$ at exchange rate,1341.5 +33793,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,87.0 +33794,Switzerland,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1044.7 +33795,Switzerland,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,6425.7 +33796,Switzerland,2015,5,Total pharmaceutical sales,Million of national currency units,6184.0 +33797,Switzerland,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5004.1 +33798,Switzerland,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8 +33799,Switzerland,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.8 +33800,Switzerland,2015,5,B-Blood and blood forming organs,% of total sales,4.6 +33801,Switzerland,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",49.1 +33802,Switzerland,2015,5,R-Respiratory system,"/capita, US$ exchange rate",63.1 +33803,Switzerland,2015,5,R-Respiratory system,"Million US$, purchasing power parity",407.0 +33804,Switzerland,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",604.2 +33805,Switzerland,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",775.8 +33806,Switzerland,2015,5,R-Respiratory system,% of total sales,8.1 +33807,Switzerland,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",87.0 +33808,Switzerland,2015,5,A-Alimentary tract and metabolism,% of total sales,14.4 +33809,Switzerland,2015,5,M-Musculo-skeletal system,% of total sales,6.4 +33810,Switzerland,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",111.7 +33811,Switzerland,2015,5,J-Antiinfectives for systemic use,% of total sales,9.2 +33812,Switzerland,2015,5,A-Alimentary tract and metabolism,Million of national currency units,890.0 +33813,Switzerland,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.6 +33814,Switzerland,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,924.8 +33815,Switzerland,2015,5,J-Antiinfectives for systemic use,Million of national currency units,569.0 +33816,Switzerland,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",49.9 +33817,Switzerland,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",38.9 +33818,Switzerland,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",720.2 +33819,Switzerland,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",322.1 +33820,Switzerland,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,348.0 +33821,Switzerland,2015,5,G-Genito urinary system and sex hormones,% of total sales,5.6 +33822,Switzerland,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.0 +33823,Switzerland,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,591.2 +33824,Switzerland,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",460.4 +33825,Switzerland,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",71.4 +33826,Switzerland,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,361.6 +33827,Switzerland,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",281.6 +33828,Switzerland,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",43.7 +33829,United Kingdom,2012,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.8 +33830,United Kingdom,2012,8,M-Musculo-skeletal system,Million US$ at exchange rate,568.4 +33831,United Kingdom,2012,8,M-Musculo-skeletal system,Million of national currency units,359.8 +33832,United Kingdom,2012,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.4 +33833,United Kingdom,2012,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.0 +33834,United Kingdom,2012,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.9 +33835,United Kingdom,2012,8,N-Nervous system,% of total sales,18.7 +33836,United Kingdom,2012,8,N-Nervous system,"/capita, US$ purchasing power parity",57.8 +33837,United Kingdom,2012,8,B-Blood and blood forming organs,% of total sales,4.2 +33838,United Kingdom,2012,8,J-Antiinfectives for systemic use,% of total sales,11.7 +33839,United Kingdom,2012,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",512.8 +33840,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5 +33841,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,338.3 +33842,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6 +33843,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,534.4 +33844,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",482.2 +33845,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.4 +33846,United Kingdom,2012,8,N-Nervous system,"/capita, US$ exchange rate",64.0 +33847,United Kingdom,2012,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.0 +33848,United Kingdom,2012,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.9 +33849,United Kingdom,2012,8,M-Musculo-skeletal system,% of total sales,2.6 +33850,United Kingdom,2012,8,N-Nervous system,Million US$ at exchange rate,4078.4 +33851,United Kingdom,2012,8,N-Nervous system,Million of national currency units,2581.8 +33852,United Kingdom,2012,8,N-Nervous system,"Million US$, purchasing power parity",3679.7 +33853,United Kingdom,2012,8,A-Alimentary tract and metabolism,Million of national currency units,1384.3 +33854,United Kingdom,2012,8,C-Cardiovascular system,Million of national currency units,1332.3 +33855,United Kingdom,2012,8,C-Cardiovascular system,Million US$ at exchange rate,2104.6 +33856,United Kingdom,2012,8,C-Cardiovascular system,"Million US$, purchasing power parity",1898.9 +33857,United Kingdom,2012,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2186.7 +33858,United Kingdom,2012,8,A-Alimentary tract and metabolism,% of total sales,10.1 +33859,United Kingdom,2012,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",31.0 +33860,United Kingdom,2012,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.3 +33861,United Kingdom,2012,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1973.0 +33862,United Kingdom,2012,8,R-Respiratory system,% of total sales,10.5 +33863,United Kingdom,2012,8,R-Respiratory system,"Million US$, purchasing power parity",2052.8 +33864,United Kingdom,2012,8,R-Respiratory system,"/capita, US$ purchasing power parity",32.2 +33865,United Kingdom,2012,8,R-Respiratory system,"/capita, US$ exchange rate",35.7 +33866,United Kingdom,2012,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",29.8 +33867,United Kingdom,2012,8,R-Respiratory system,Million of national currency units,1440.3 +33868,United Kingdom,2012,8,R-Respiratory system,Million US$ at exchange rate,2275.2 +33869,United Kingdom,2012,8,C-Cardiovascular system,"/capita, US$ exchange rate",33.0 +33870,United Kingdom,2012,8,C-Cardiovascular system,% of total sales,9.7 +33871,United Kingdom,2012,8,J-Antiinfectives for systemic use,Million of national currency units,1606.0 +33872,United Kingdom,2012,8,Total pharmaceutical sales,"/capita, US$ exchange rate",341.5 +33873,United Kingdom,2012,8,Total pharmaceutical sales,"Million US$, purchasing power parity",19629.2 +33874,United Kingdom,2012,8,Total pharmaceutical sales,Million US$ at exchange rate,21755.9 +33875,United Kingdom,2012,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",826.6 +33876,United Kingdom,2012,8,B-Blood and blood forming organs,Million US$ at exchange rate,916.2 +33877,United Kingdom,2012,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",308.1 +33878,United Kingdom,2012,8,B-Blood and blood forming organs,Million of national currency units,580.0 +33879,United Kingdom,2012,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1081.0 +33880,United Kingdom,2012,8,G-Genito urinary system and sex hormones,Million of national currency units,684.3 +33881,United Kingdom,2012,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2288.9 +33882,United Kingdom,2012,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,2536.9 +33883,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",975.3 +33884,United Kingdom,2012,8,G-Genito urinary system and sex hormones,% of total sales,5.0 +33885,United Kingdom,2012,8,Total pharmaceutical sales,Million of national currency units,13772.5 +33886,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.3 +33887,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.0 +33888,United Kingdom,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,20802.4 +33889,United Kingdom,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",328.7 +33890,United Kingdom,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",18389.0 +33891,United Kingdom,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",290.6 +33892,United Kingdom,2011,9,Total pharmaceutical sales,Million of national currency units,12983.6 +33893,United Kingdom,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.0 +33894,United Kingdom,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2 +33895,United Kingdom,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3820.8 +33896,United Kingdom,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,634.1 +33897,United Kingdom,2017,7,M-Musculo-skeletal system,Million of national currency units,492.7 +33898,United Kingdom,2017,7,N-Nervous system,"/capita, US$ exchange rate",62.2 +33899,United Kingdom,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",23.1 +33900,United Kingdom,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",70.6 +33901,United Kingdom,2017,7,N-Nervous system,% of total sales,16.3 +33902,United Kingdom,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",57.9 +33903,United Kingdom,2017,7,B-Blood and blood forming organs,% of total sales,6.1 +33904,United Kingdom,2017,7,J-Antiinfectives for systemic use,% of total sales,13.4 +33905,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8 +33906,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +33907,United Kingdom,2017,7,N-Nervous system,Million US$ at exchange rate,4107.6 +33908,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4 +33909,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,685.7 +33910,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",778.3 +33911,United Kingdom,2017,7,N-Nervous system,"Million US$, purchasing power parity",4661.8 +33912,United Kingdom,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.6 +33913,United Kingdom,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",719.7 +33914,United Kingdom,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.9 +33915,United Kingdom,2017,7,N-Nervous system,Million of national currency units,3191.5 +33916,United Kingdom,2017,7,M-Musculo-skeletal system,% of total sales,2.5 +33917,United Kingdom,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",1727.9 +33918,United Kingdom,2017,7,A-Alimentary tract and metabolism,Million of national currency units,1854.8 +33919,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,532.8 +33920,United Kingdom,2017,7,C-Cardiovascular system,Million of national currency units,1301.0 +33921,United Kingdom,2017,7,C-Cardiovascular system,Million US$ at exchange rate,1674.4 +33922,United Kingdom,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.0 +33923,United Kingdom,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",36.1 +33924,United Kingdom,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",1900.4 +33925,United Kingdom,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2709.3 +33926,United Kingdom,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,2387.2 +33927,United Kingdom,2017,7,R-Respiratory system,% of total sales,8.5 +33928,United Kingdom,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",36.9 +33929,United Kingdom,2017,7,R-Respiratory system,"/capita, US$ exchange rate",32.5 +33930,United Kingdom,2017,7,R-Respiratory system,"Million US$, purchasing power parity",2433.7 +33931,United Kingdom,2017,7,R-Respiratory system,Million US$ at exchange rate,2144.3 +33932,United Kingdom,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",25.4 +33933,United Kingdom,2017,7,R-Respiratory system,Million of national currency units,1666.1 +33934,United Kingdom,2017,7,C-Cardiovascular system,% of total sales,6.7 +33935,United Kingdom,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.8 +33936,United Kingdom,2017,7,A-Alimentary tract and metabolism,% of total sales,9.5 +33937,United Kingdom,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",28520.4 +33938,United Kingdom,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,25129.6 +33939,United Kingdom,2017,7,Total pharmaceutical sales,Million of national currency units,19525.1 +33940,United Kingdom,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",380.5 +33941,United Kingdom,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,1522.4 +33942,United Kingdom,2017,7,B-Blood and blood forming organs,Million of national currency units,1182.9 +33943,United Kingdom,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",431.9 +33944,United Kingdom,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,757.8 +33945,United Kingdom,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3366.5 +33946,United Kingdom,2017,7,J-Antiinfectives for systemic use,Million of national currency units,2615.7 +33947,United Kingdom,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,975.3 +33948,United Kingdom,2017,7,G-Genito urinary system and sex hormones,% of total sales,3.9 +33949,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.8 +33950,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.8 +33951,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1106.9 +33952,United Kingdom,2010,10,Total pharmaceutical sales,"/capita, US$ exchange rate",323.9 +33953,United Kingdom,2010,10,Total pharmaceutical sales,"Million US$, purchasing power parity",18733.4 +33954,United Kingdom,2010,10,Total pharmaceutical sales,Million US$ at exchange rate,20328.4 +33955,United Kingdom,2010,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",298.5 +33956,United Kingdom,2010,10,Total pharmaceutical sales,Million of national currency units,13156.1 +33957,United Kingdom,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",47.0 +33958,United Kingdom,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,661.6 +33959,United Kingdom,2014,8,M-Musculo-skeletal system,Million of national currency units,402.1 +33960,United Kingdom,2014,8,N-Nervous system,"/capita, US$ exchange rate",75.3 +33961,United Kingdom,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.4 +33962,United Kingdom,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.9 +33963,United Kingdom,2014,8,N-Nervous system,% of total sales,18.5 +33964,United Kingdom,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",65.5 +33965,United Kingdom,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.9 +33966,United Kingdom,2014,8,B-Blood and blood forming organs,% of total sales,4.8 +33967,United Kingdom,2014,8,J-Antiinfectives for systemic use,% of total sales,11.5 +33968,United Kingdom,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",575.7 +33969,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6 +33970,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0 +33971,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,478.3 +33972,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,787.0 +33973,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",684.8 +33974,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.2 +33975,United Kingdom,2014,8,N-Nervous system,Million US$ at exchange rate,4863.8 +33976,United Kingdom,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9 +33977,United Kingdom,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.2 +33978,United Kingdom,2014,8,N-Nervous system,Million of national currency units,2955.9 +33979,United Kingdom,2014,8,N-Nervous system,"Million US$, purchasing power parity",4232.1 +33980,United Kingdom,2014,8,M-Musculo-skeletal system,% of total sales,2.5 +33981,United Kingdom,2014,8,A-Alimentary tract and metabolism,Million of national currency units,1537.2 +33982,United Kingdom,2014,8,C-Cardiovascular system,Million of national currency units,1186.8 +33983,United Kingdom,2014,8,C-Cardiovascular system,Million US$ at exchange rate,1952.8 +33984,United Kingdom,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",1699.2 +33985,United Kingdom,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2529.4 +33986,United Kingdom,2014,8,A-Alimentary tract and metabolism,% of total sales,9.6 +33987,United Kingdom,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.1 +33988,United Kingdom,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",39.2 +33989,United Kingdom,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2200.9 +33990,United Kingdom,2014,8,R-Respiratory system,% of total sales,9.9 +33991,United Kingdom,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",35.0 +33992,United Kingdom,2014,8,R-Respiratory system,"/capita, US$ exchange rate",40.3 +33993,United Kingdom,2014,8,R-Respiratory system,"Million US$, purchasing power parity",2263.7 +33994,United Kingdom,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",30.2 +33995,United Kingdom,2014,8,R-Respiratory system,Million of national currency units,1581.1 +33996,United Kingdom,2014,8,C-Cardiovascular system,% of total sales,7.4 +33997,United Kingdom,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",26.3 +33998,United Kingdom,2014,8,R-Respiratory system,Million US$ at exchange rate,2601.6 +33999,United Kingdom,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",407.4 +34000,United Kingdom,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",22901.2 +34001,United Kingdom,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,26319.6 +34002,United Kingdom,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1090.1 +34003,United Kingdom,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,1252.9 +34004,United Kingdom,2014,8,Total pharmaceutical sales,Million of national currency units,15995.2 +34005,United Kingdom,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",354.5 +34006,United Kingdom,2014,8,B-Blood and blood forming organs,Million of national currency units,761.4 +34007,United Kingdom,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1120.1 +34008,United Kingdom,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,680.7 +34009,United Kingdom,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,3034.6 +34010,United Kingdom,2014,8,J-Antiinfectives for systemic use,Million of national currency units,1844.2 +34011,United Kingdom,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2640.4 +34012,United Kingdom,2014,8,G-Genito urinary system and sex hormones,% of total sales,4.3 +34013,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1 +34014,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.3 +34015,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",974.6 +34016,United Kingdom,2015,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.8 +34017,United Kingdom,2015,8,M-Musculo-skeletal system,Million US$ at exchange rate,672.8 +34018,United Kingdom,2015,8,M-Musculo-skeletal system,Million of national currency units,440.4 +34019,United Kingdom,2015,8,N-Nervous system,"/capita, US$ exchange rate",75.6 +34020,United Kingdom,2015,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1 +34021,United Kingdom,2015,8,N-Nervous system,"/capita, US$ purchasing power parity",71.5 +34022,United Kingdom,2015,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.0 +34023,United Kingdom,2015,8,N-Nervous system,% of total sales,18.2 +34024,United Kingdom,2015,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",46.1 +34025,United Kingdom,2015,8,J-Antiinfectives for systemic use,% of total sales,11.8 +34026,United Kingdom,2015,8,B-Blood and blood forming organs,% of total sales,5.1 +34027,United Kingdom,2015,8,R-Respiratory system,"Million US$, purchasing power parity",2337.6 +34028,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.1 +34029,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +34030,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,589.6 +34031,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,900.8 +34032,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",851.3 +34033,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.8 +34034,United Kingdom,2015,8,N-Nervous system,Million US$ at exchange rate,4923.1 +34035,United Kingdom,2015,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.8 +34036,United Kingdom,2015,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.3 +34037,United Kingdom,2015,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",635.9 +34038,United Kingdom,2015,8,N-Nervous system,Million of national currency units,3222.4 +34039,United Kingdom,2015,8,N-Nervous system,"Million US$, purchasing power parity",4652.9 +34040,United Kingdom,2015,8,M-Musculo-skeletal system,% of total sales,2.5 +34041,United Kingdom,2015,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1300.7 +34042,United Kingdom,2015,8,A-Alimentary tract and metabolism,Million of national currency units,1710.8 +34043,United Kingdom,2015,8,C-Cardiovascular system,Million of national currency units,1267.8 +34044,United Kingdom,2015,8,C-Cardiovascular system,Million US$ at exchange rate,1936.9 +34045,United Kingdom,2015,8,C-Cardiovascular system,"Million US$, purchasing power parity",1830.6 +34046,United Kingdom,2015,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2613.7 +34047,United Kingdom,2015,8,A-Alimentary tract and metabolism,% of total sales,9.7 +34048,United Kingdom,2015,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.9 +34049,United Kingdom,2015,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2470.3 +34050,United Kingdom,2015,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",40.1 +34051,United Kingdom,2015,8,R-Respiratory system,% of total sales,9.2 +34052,United Kingdom,2015,8,R-Respiratory system,"/capita, US$ purchasing power parity",35.9 +34053,United Kingdom,2015,8,R-Respiratory system,"/capita, US$ exchange rate",38.0 +34054,United Kingdom,2015,8,C-Cardiovascular system,"/capita, US$ exchange rate",29.7 +34055,United Kingdom,2015,8,R-Respiratory system,Million of national currency units,1618.9 +34056,United Kingdom,2015,8,R-Respiratory system,Million US$ at exchange rate,2473.3 +34057,United Kingdom,2015,8,C-Cardiovascular system,% of total sales,7.2 +34058,United Kingdom,2015,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.1 +34059,United Kingdom,2015,8,Total pharmaceutical sales,"Million US$, purchasing power parity",25538.8 +34060,United Kingdom,2015,8,Total pharmaceutical sales,Million US$ at exchange rate,27021.7 +34061,United Kingdom,2015,8,Total pharmaceutical sales,Million of national currency units,17686.9 +34062,United Kingdom,2015,8,Total pharmaceutical sales,"/capita, US$ exchange rate",415.0 +34063,United Kingdom,2015,8,B-Blood and blood forming organs,Million US$ at exchange rate,1376.2 +34064,United Kingdom,2015,8,B-Blood and blood forming organs,Million of national currency units,900.8 +34065,United Kingdom,2015,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",392.2 +34066,United Kingdom,2015,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3002.7 +34067,United Kingdom,2015,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1081.5 +34068,United Kingdom,2015,8,G-Genito urinary system and sex hormones,Million of national currency units,707.9 +34069,United Kingdom,2015,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,3177.0 +34070,United Kingdom,2015,8,J-Antiinfectives for systemic use,Million of national currency units,2079.5 +34071,United Kingdom,2015,8,G-Genito urinary system and sex hormones,% of total sales,4.0 +34072,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.7 +34073,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.6 +34074,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1022.2 +34075,United Kingdom,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.3 +34076,United Kingdom,2016,7,N-Nervous system,"/capita, US$ exchange rate",66.9 +34077,United Kingdom,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,618.1 +34078,United Kingdom,2016,7,M-Musculo-skeletal system,Million of national currency units,457.8 +34079,United Kingdom,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.2 +34080,United Kingdom,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",72.0 +34081,United Kingdom,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.9 +34082,United Kingdom,2016,7,N-Nervous system,% of total sales,17.5 +34083,United Kingdom,2016,7,B-Blood and blood forming organs,% of total sales,5.5 +34084,United Kingdom,2016,7,J-Antiinfectives for systemic use,% of total sales,12.6 +34085,United Kingdom,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.8 +34086,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4 +34087,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3 +34088,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,607.3 +34089,United Kingdom,2016,7,N-Nervous system,Million US$ at exchange rate,4392.2 +34090,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,820.0 +34091,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",881.9 +34092,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.5 +34093,United Kingdom,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.4 +34094,United Kingdom,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",664.8 +34095,United Kingdom,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.1 +34096,United Kingdom,2016,7,N-Nervous system,Million of national currency units,3253.0 +34097,United Kingdom,2016,7,N-Nervous system,"Million US$, purchasing power parity",4724.1 +34098,United Kingdom,2016,7,M-Musculo-skeletal system,% of total sales,2.5 +34099,United Kingdom,2016,7,A-Alimentary tract and metabolism,Million of national currency units,1773.2 +34100,United Kingdom,2016,7,C-Cardiovascular system,Million of national currency units,1280.2 +34101,United Kingdom,2016,7,C-Cardiovascular system,Million US$ at exchange rate,1728.5 +34102,United Kingdom,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",1859.1 +34103,United Kingdom,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.2 +34104,United Kingdom,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",36.5 +34105,United Kingdom,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2575.1 +34106,United Kingdom,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,2394.2 +34107,United Kingdom,2016,7,A-Alimentary tract and metabolism,% of total sales,9.6 +34108,United Kingdom,2016,7,R-Respiratory system,% of total sales,8.9 +34109,United Kingdom,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",36.6 +34110,United Kingdom,2016,7,R-Respiratory system,"/capita, US$ exchange rate",34.0 +34111,United Kingdom,2016,7,R-Respiratory system,Million US$ at exchange rate,2231.9 +34112,United Kingdom,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",26.3 +34113,United Kingdom,2016,7,R-Respiratory system,Million of national currency units,1653.0 +34114,United Kingdom,2016,7,C-Cardiovascular system,% of total sales,6.9 +34115,United Kingdom,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.3 +34116,United Kingdom,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",1495.3 +34117,United Kingdom,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",26944.6 +34118,United Kingdom,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,25051.6 +34119,United Kingdom,2016,7,R-Respiratory system,"Million US$, purchasing power parity",2400.5 +34120,United Kingdom,2016,7,Total pharmaceutical sales,Million of national currency units,18554.1 +34121,United Kingdom,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",381.6 +34122,United Kingdom,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,1390.3 +34123,United Kingdom,2016,7,B-Blood and blood forming organs,Million of national currency units,1029.7 +34124,United Kingdom,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.4 +34125,United Kingdom,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3408.2 +34126,United Kingdom,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,960.1 +34127,United Kingdom,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,711.1 +34128,United Kingdom,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3168.8 +34129,United Kingdom,2016,7,J-Antiinfectives for systemic use,Million of national currency units,2346.9 +34130,United Kingdom,2016,7,G-Genito urinary system and sex hormones,% of total sales,3.8 +34131,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.7 +34132,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.6 +34133,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1032.7 +34134,United Kingdom,2013,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.2 +34135,United Kingdom,2013,8,M-Musculo-skeletal system,Million US$ at exchange rate,585.3 +34136,United Kingdom,2013,8,M-Musculo-skeletal system,Million of national currency units,374.4 +34137,United Kingdom,2013,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.8 +34138,United Kingdom,2013,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.6 +34139,United Kingdom,2013,8,N-Nervous system,% of total sales,18.9 +34140,United Kingdom,2013,8,B-Blood and blood forming organs,% of total sales,4.4 +34141,United Kingdom,2013,8,N-Nervous system,"/capita, US$ purchasing power parity",61.9 +34142,United Kingdom,2013,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.8 +34143,United Kingdom,2013,8,J-Antiinfectives for systemic use,% of total sales,11.8 +34144,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7 +34145,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,391.9 +34146,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.8 +34147,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,612.7 +34148,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",563.7 +34149,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.6 +34150,United Kingdom,2013,8,N-Nervous system,Million US$ at exchange rate,4315.1 +34151,United Kingdom,2013,8,N-Nervous system,"/capita, US$ exchange rate",67.3 +34152,United Kingdom,2013,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.4 +34153,United Kingdom,2013,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.1 +34154,United Kingdom,2013,8,N-Nervous system,Million of national currency units,2760.2 +34155,United Kingdom,2013,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",538.5 +34156,United Kingdom,2013,8,M-Musculo-skeletal system,% of total sales,2.6 +34157,United Kingdom,2013,8,N-Nervous system,"Million US$, purchasing power parity",3970.1 +34158,United Kingdom,2013,8,A-Alimentary tract and metabolism,Million of national currency units,1410.4 +34159,United Kingdom,2013,8,C-Cardiovascular system,Million of national currency units,1156.4 +34160,United Kingdom,2013,8,C-Cardiovascular system,Million US$ at exchange rate,1807.8 +34161,United Kingdom,2013,8,C-Cardiovascular system,"Million US$, purchasing power parity",1663.3 +34162,United Kingdom,2013,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2204.9 +34163,United Kingdom,2013,8,A-Alimentary tract and metabolism,% of total sales,9.7 +34164,United Kingdom,2013,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",31.6 +34165,United Kingdom,2013,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.4 +34166,United Kingdom,2013,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2028.6 +34167,United Kingdom,2013,8,C-Cardiovascular system,"/capita, US$ exchange rate",28.2 +34168,United Kingdom,2013,8,R-Respiratory system,% of total sales,10.5 +34169,United Kingdom,2013,8,R-Respiratory system,"Million US$, purchasing power parity",2195.6 +34170,United Kingdom,2013,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.3 +34171,United Kingdom,2013,8,R-Respiratory system,"/capita, US$ exchange rate",37.2 +34172,United Kingdom,2013,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",25.9 +34173,United Kingdom,2013,8,R-Respiratory system,Million of national currency units,1526.5 +34174,United Kingdom,2013,8,R-Respiratory system,Million US$ at exchange rate,2386.4 +34175,United Kingdom,2013,8,C-Cardiovascular system,% of total sales,7.9 +34176,United Kingdom,2013,8,Total pharmaceutical sales,"/capita, US$ exchange rate",356.1 +34177,United Kingdom,2013,8,Total pharmaceutical sales,"Million US$, purchasing power parity",21002.7 +34178,United Kingdom,2013,8,Total pharmaceutical sales,Million US$ at exchange rate,22827.9 +34179,United Kingdom,2013,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",934.2 +34180,United Kingdom,2013,8,B-Blood and blood forming organs,Million US$ at exchange rate,1015.4 +34181,United Kingdom,2013,8,B-Blood and blood forming organs,Million of national currency units,649.5 +34182,United Kingdom,2013,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",327.6 +34183,United Kingdom,2013,8,Total pharmaceutical sales,Million of national currency units,14602.1 +34184,United Kingdom,2013,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1063.2 +34185,United Kingdom,2013,8,G-Genito urinary system and sex hormones,Million of national currency units,680.1 +34186,United Kingdom,2013,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2487.5 +34187,United Kingdom,2013,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,2703.6 +34188,United Kingdom,2013,8,J-Antiinfectives for systemic use,Million of national currency units,1729.4 +34189,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",978.2 +34190,United Kingdom,2013,8,G-Genito urinary system and sex hormones,% of total sales,4.7 +34191,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.6 +34192,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.3 diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb b/exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb new file mode 100644 index 0000000..4afa1df --- /dev/null +++ b/exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb @@ -0,0 +1,1306 @@ +{ + "cells": [ + { + "cell_type": "markdown", + "metadata": {}, + "source": [ + "# Projeto Semana 11 - Python Reprograma - Cris Pereira\n", + "\n", + "## Introdução\n", + "Nesse notebook realizo edições e faço uma análise inicial de dois bancos de dados, um de morte materna ao redor do mundo e outro relacionado à receita da indústria farmacêutica em diversos países (tema que tem a ver com a minha pesquisa de pós-graduação sobre o Complexo Industrial da Saúde - CEIS). " + ] + }, + { + "cell_type": "markdown", + "metadata": {}, + "source": [ + "## Processamento" + ] + }, + { + "cell_type": "code", + "execution_count": 5, + "metadata": {}, + "outputs": [], + "source": [ + "import pandas as pd" + ] + }, + { + "cell_type": "code", + "execution_count": 6, + "metadata": {}, + "outputs": [], + "source": [ + "df_health = pd.read_csv(\"health_indicators_ocde.csv\")\n", + "df_mortality = pd.read_csv(\"maternal-mortality-who.csv\")" + ] + }, + { + "cell_type": "code", + "execution_count": 7, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
VARVariableUNITMeasureCOUCountryYEAYearValueFlag CodesFlags
0PATCTOTTTotal pharmaceutical salesMLLNCUMTMillion of national currency unitsAUSAustralia201020109795.0DDifference in methodology
1PATCTOTTTotal pharmaceutical salesMLLNCUMTMillion of national currency unitsAUSAustralia2011201110261.0DDifference in methodology
2PATCTOTTTotal pharmaceutical salesMLLNCUMTMillion of national currency unitsAUSAustralia2012201210355.0DDifference in methodology
\n", + "
" + ], + "text/plain": [ + " VAR Variable UNIT \\\n", + "0 PATCTOTT Total pharmaceutical sales MLLNCUMT \n", + "1 PATCTOTT Total pharmaceutical sales MLLNCUMT \n", + "2 PATCTOTT Total pharmaceutical sales MLLNCUMT \n", + "\n", + " Measure COU Country YEA Year Value \\\n", + "0 Million of national currency units AUS Australia 2010 2010 9795.0 \n", + "1 Million of national currency units AUS Australia 2011 2011 10261.0 \n", + "2 Million of national currency units AUS Australia 2012 2012 10355.0 \n", + "\n", + " Flag Codes Flags \n", + "0 D Difference in methodology \n", + "1 D Difference in methodology \n", + "2 D Difference in methodology " + ] + }, + "execution_count": 7, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df_health.head(3)" + ] + }, + { + "cell_type": "code", + "execution_count": 8, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
EntityCodeYearIndicator:Maternal mortality ratio (per 100 000 live births)
0AfghanistanAFG20001450
1AfghanistanAFG20011390
2AfghanistanAFG20021300
\n", + "
" + ], + "text/plain": [ + " Entity Code Year \\\n", + "0 Afghanistan AFG 2000 \n", + "1 Afghanistan AFG 2001 \n", + "2 Afghanistan AFG 2002 \n", + "\n", + " Indicator:Maternal mortality ratio (per 100 000 live births) \n", + "0 1450 \n", + "1 1390 \n", + "2 1300 " + ] + }, + "execution_count": 8, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df_mortality.head(3)" + ] + }, + { + "cell_type": "code", + "execution_count": 9, + "metadata": {}, + "outputs": [], + "source": [ + "# Decidi colocar o dataframe com novas colunas em um novo objeto\n", + "df_newhealth = df_health.drop(columns= ['VAR', 'UNIT','COU','YEA','Flag Codes', 'Flags'])" + ] + }, + { + "cell_type": "code", + "execution_count": 10, + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "Index(['Variable', 'Measure', 'Country', 'Year', 'Value'], dtype='object')" + ] + }, + "execution_count": 10, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Verificando remoção das colunas\n", + "df_newhealth.columns" + ] + }, + { + "cell_type": "code", + "execution_count": 11, + "metadata": {}, + "outputs": [], + "source": [ + "# Decidi colocar o dataframe com novas colunas em um novo objeto\n", + "df_newmortality = df_mortality.drop(columns=[\"Code\"])" + ] + }, + { + "cell_type": "code", + "execution_count": 12, + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "Index(['Entity', 'Year',\n", + " 'Indicator:Maternal mortality ratio (per 100 000 live births)'],\n", + " dtype='object')" + ] + }, + "execution_count": 12, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Verificando remoção das colunas\n", + "df_newmortality.columns" + ] + }, + { + "cell_type": "code", + "execution_count": 13, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
VariableMeasureCountryYearValue
0Total pharmaceutical salesMillion of national currency unitsAustralia20109795.0
37893M-Musculo-skeletal systemMillion of national currency unitsAustralia2013378.0
37892M-Musculo-skeletal systemMillion of national currency unitsAustralia2012312.0
37891M-Musculo-skeletal systemMillion of national currency unitsAustralia2011309.0
37890M-Musculo-skeletal systemMillion of national currency unitsAustralia2010324.0
..................
29781G-Genito urinary system and sex hormonesMillion US$, purchasing power parityUnited Kingdom20161032.7
29780G-Genito urinary system and sex hormonesMillion US$, purchasing power parityUnited Kingdom20151022.2
29779G-Genito urinary system and sex hormonesMillion US$, purchasing power parityUnited Kingdom2014974.6
29792G-Genito urinary system and sex hormones/capita, US$ purchasing power parityUnited Kingdom201315.3
33661H-Systemic hormonal preparations, excluding se...Million of national currency unitsUnited Kingdom2018442.9
\n", + "

62544 rows × 5 columns

\n", + "
" + ], + "text/plain": [ + " Variable \\\n", + "0 Total pharmaceutical sales \n", + "37893 M-Musculo-skeletal system \n", + "37892 M-Musculo-skeletal system \n", + "37891 M-Musculo-skeletal system \n", + "37890 M-Musculo-skeletal system \n", + "... ... \n", + "29781 G-Genito urinary system and sex hormones \n", + "29780 G-Genito urinary system and sex hormones \n", + "29779 G-Genito urinary system and sex hormones \n", + "29792 G-Genito urinary system and sex hormones \n", + "33661 H-Systemic hormonal preparations, excluding se... \n", + "\n", + " Measure Country Year Value \n", + "0 Million of national currency units Australia 2010 9795.0 \n", + "37893 Million of national currency units Australia 2013 378.0 \n", + "37892 Million of national currency units Australia 2012 312.0 \n", + "37891 Million of national currency units Australia 2011 309.0 \n", + "37890 Million of national currency units Australia 2010 324.0 \n", + "... ... ... ... ... \n", + "29781 Million US$, purchasing power parity United Kingdom 2016 1032.7 \n", + "29780 Million US$, purchasing power parity United Kingdom 2015 1022.2 \n", + "29779 Million US$, purchasing power parity United Kingdom 2014 974.6 \n", + "29792 /capita, US$ purchasing power parity United Kingdom 2013 15.3 \n", + "33661 Million of national currency units United Kingdom 2018 442.9 \n", + "\n", + "[62544 rows x 5 columns]" + ] + }, + "execution_count": 13, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Organizando pela coluna \"Country\"\n", + "df_newhealth = df_newhealth.sort_values([\"Country\"])\n", + "df_newhealth" + ] + }, + { + "cell_type": "code", + "execution_count": 14, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
EntityYearIndicator:Maternal mortality ratio (per 100 000 live births)
0Afghanistan20001450
17Afghanistan2017638
16Afghanistan2016673
15Afghanistan2015701
14Afghanistan2014786
............
3403Zimbabwe2001629
3402Zimbabwe2000579
3418Zimbabwe2016468
3409Zimbabwe2007671
3419Zimbabwe2017458
\n", + "

3420 rows × 3 columns

\n", + "
" + ], + "text/plain": [ + " Entity Year \\\n", + "0 Afghanistan 2000 \n", + "17 Afghanistan 2017 \n", + "16 Afghanistan 2016 \n", + "15 Afghanistan 2015 \n", + "14 Afghanistan 2014 \n", + "... ... ... \n", + "3403 Zimbabwe 2001 \n", + "3402 Zimbabwe 2000 \n", + "3418 Zimbabwe 2016 \n", + "3409 Zimbabwe 2007 \n", + "3419 Zimbabwe 2017 \n", + "\n", + " Indicator:Maternal mortality ratio (per 100 000 live births) \n", + "0 1450 \n", + "17 638 \n", + "16 673 \n", + "15 701 \n", + "14 786 \n", + "... ... \n", + "3403 629 \n", + "3402 579 \n", + "3418 468 \n", + "3409 671 \n", + "3419 458 \n", + "\n", + "[3420 rows x 3 columns]" + ] + }, + "execution_count": 14, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Organizando pela coluna \"Entity\" \n", + "df_newmortality.sort_values([\"Entity\"], inplace=True)\n", + "df_newmortality" + ] + }, + { + "cell_type": "code", + "execution_count": 15, + "metadata": {}, + "outputs": [ + { + "name": "stdout", + "output_type": "stream", + "text": [ + "Valores nulos por coluna do dataframe:\n", + "Variable 0\n", + "Measure 0\n", + "Country 0\n", + "Year 0\n", + "Value 0\n", + "dtype: int64\n" + ] + } + ], + "source": [ + "# Não irei realizar a remoção de nulos, porque a pesquisa abaixo indica que não há valores nulos\n", + "print(\"Valores nulos por coluna do dataframe:\")\n", + "print(df_newhealth.isnull().sum())" + ] + }, + { + "cell_type": "code", + "execution_count": 16, + "metadata": {}, + "outputs": [ + { + "name": "stdout", + "output_type": "stream", + "text": [ + "Valores nulos por coluna do dataframe:\n", + "Entity 0\n", + "Year 0\n", + "Indicator:Maternal mortality ratio (per 100 000 live births) 0\n", + "dtype: int64\n" + ] + } + ], + "source": [ + "# Não irei realizar a remoção de nulos, porque a pesquisa abaixo indica que não há valores nulos\n", + "print(\"Valores nulos por coluna do dataframe:\")\n", + "print(df_newmortality.isnull().sum())" + ] + }, + { + "cell_type": "code", + "execution_count": 17, + "metadata": {}, + "outputs": [], + "source": [ + "# Resetando o index de cada banco de dados\n", + "df_newhealth.reset_index(drop=True, inplace=True)" + ] + }, + { + "cell_type": "code", + "execution_count": 18, + "metadata": {}, + "outputs": [], + "source": [ + "# Resetando o index de cada banco de dados\n", + "df_newmortality.reset_index(drop=True, inplace=True)" + ] + }, + { + "cell_type": "markdown", + "metadata": {}, + "source": [ + "# Conclusão\n", + "Irei tentar verificar se há correlação entre vendas farmacêuticas e mortalidade materna." + ] + }, + { + "cell_type": "code", + "execution_count": 19, + "metadata": {}, + "outputs": [], + "source": [ + "import seaborn as sn" + ] + }, + { + "cell_type": "markdown", + "metadata": {}, + "source": [ + "Vou unir os dois dataframes em um só para fazer uma análise de correlação, mas antes vou editar o df de mortalidade mudando o nome da coluna Entity para Country - para ficar igual ao df de saúde. " + ] + }, + { + "cell_type": "code", + "execution_count": 20, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
CountryYearIndicator:Maternal mortality ratio (per 100 000 live births)
0Afghanistan20001450
1Afghanistan2017638
2Afghanistan2016673
3Afghanistan2015701
4Afghanistan2014786
............
3415Zimbabwe2001629
3416Zimbabwe2000579
3417Zimbabwe2016468
3418Zimbabwe2007671
3419Zimbabwe2017458
\n", + "

3420 rows × 3 columns

\n", + "
" + ], + "text/plain": [ + " Country Year \\\n", + "0 Afghanistan 2000 \n", + "1 Afghanistan 2017 \n", + "2 Afghanistan 2016 \n", + "3 Afghanistan 2015 \n", + "4 Afghanistan 2014 \n", + "... ... ... \n", + "3415 Zimbabwe 2001 \n", + "3416 Zimbabwe 2000 \n", + "3417 Zimbabwe 2016 \n", + "3418 Zimbabwe 2007 \n", + "3419 Zimbabwe 2017 \n", + "\n", + " Indicator:Maternal mortality ratio (per 100 000 live births) \n", + "0 1450 \n", + "1 638 \n", + "2 673 \n", + "3 701 \n", + "4 786 \n", + "... ... \n", + "3415 629 \n", + "3416 579 \n", + "3417 468 \n", + "3418 671 \n", + "3419 458 \n", + "\n", + "[3420 rows x 3 columns]" + ] + }, + "execution_count": 20, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Primeiro uma cópia do df de mortalidade materna\n", + "df_mortalitycopy = df_newmortality.copy()\n", + "df_mortalitycopy.rename(columns={'Entity': 'Country'}, inplace = True)\n", + "df_mortalitycopy" + ] + }, + { + "cell_type": "code", + "execution_count": 21, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
CountryYearIndicator:Maternal mortality ratio (per 100 000 live births)VariableMeasureValue
0Australia20166B-Blood and blood forming organsMillion of national currency units667.0
1Australia20166M-Musculo-skeletal systemMillion US$ at exchange rate316.7
2Australia20166M-Musculo-skeletal systemMillion of national currency units426.0
\n", + "
" + ], + "text/plain": [ + " Country Year \\\n", + "0 Australia 2016 \n", + "1 Australia 2016 \n", + "2 Australia 2016 \n", + "\n", + " Indicator:Maternal mortality ratio (per 100 000 live births) \\\n", + "0 6 \n", + "1 6 \n", + "2 6 \n", + "\n", + " Variable Measure Value \n", + "0 B-Blood and blood forming organs Million of national currency units 667.0 \n", + "1 M-Musculo-skeletal system Million US$ at exchange rate 316.7 \n", + "2 M-Musculo-skeletal system Million of national currency units 426.0 " + ] + }, + "execution_count": 21, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Unindos os dataframes em um só\n", + "df_correlation = pd.merge(df_mortalitycopy, df_newhealth, how = 'inner', on = ('Country','Year'))\n", + "df_correlation.head(3)" + ] + }, + { + "cell_type": "code", + "execution_count": 22, + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "Index(['Country', 'Year',\n", + " 'Indicator:Maternal mortality ratio (per 100 000 live births)',\n", + " 'Variable', 'Measure', 'Value'],\n", + " dtype='object')" + ] + }, + "execution_count": 22, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df_correlation.columns" + ] + }, + { + "cell_type": "code", + "execution_count": 23, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
CountryYearIndicator:Maternal mortality ratio (per 100 000 live births)VariableMeasureValue
0Australia20166B-Blood and blood forming organsMillion of national currency units667.0
1Australia20166M-Musculo-skeletal systemMillion US$ at exchange rate316.7
2Australia20166M-Musculo-skeletal systemMillion of national currency units426.0
\n", + "
" + ], + "text/plain": [ + " Country Year \\\n", + "0 Australia 2016 \n", + "1 Australia 2016 \n", + "2 Australia 2016 \n", + "\n", + " Indicator:Maternal mortality ratio (per 100 000 live births) \\\n", + "0 6 \n", + "1 6 \n", + "2 6 \n", + "\n", + " Variable Measure Value \n", + "0 B-Blood and blood forming organs Million of national currency units 667.0 \n", + "1 M-Musculo-skeletal system Million US$ at exchange rate 316.7 \n", + "2 M-Musculo-skeletal system Million of national currency units 426.0 " + ] + }, + "execution_count": 23, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df_correlation.head(3)" + ] + }, + { + "cell_type": "code", + "execution_count": 24, + "metadata": {}, + "outputs": [], + "source": [ + "# Vou mudar o nome das colunas para fazerem mais sentido \n", + "df_correlation.rename(columns={'Variable': 'Type_of_Medicine'}, inplace = True)\n", + "df_correlation.rename(columns={'Value': 'Total_Sales_Value'}, inplace = True)" + ] + }, + { + "cell_type": "code", + "execution_count": 26, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
YearIndicator:Maternal mortality ratio (per 100 000 live births)Total_Sales_Value
count34193.00000034193.0000003.419300e+04
mean2013.5151358.3103854.743234e+03
std2.2663026.5485591.202409e+05
min2010.0000002.0000000.000000e+00
25%2012.0000005.0000004.600000e+00
50%2014.0000006.0000002.050000e+01
75%2015.00000010.0000001.518000e+02
max2017.00000046.0000006.987367e+06
\n", + "
" + ], + "text/plain": [ + " Year \\\n", + "count 34193.000000 \n", + "mean 2013.515135 \n", + "std 2.266302 \n", + "min 2010.000000 \n", + "25% 2012.000000 \n", + "50% 2014.000000 \n", + "75% 2015.000000 \n", + "max 2017.000000 \n", + "\n", + " Indicator:Maternal mortality ratio (per 100 000 live births) \\\n", + "count 34193.000000 \n", + "mean 8.310385 \n", + "std 6.548559 \n", + "min 2.000000 \n", + "25% 5.000000 \n", + "50% 6.000000 \n", + "75% 10.000000 \n", + "max 46.000000 \n", + "\n", + " Total_Sales_Value \n", + "count 3.419300e+04 \n", + "mean 4.743234e+03 \n", + "std 1.202409e+05 \n", + "min 0.000000e+00 \n", + "25% 4.600000e+00 \n", + "50% 2.050000e+01 \n", + "75% 1.518000e+02 \n", + "max 6.987367e+06 " + ] + }, + "execution_count": 26, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "# Dando uma verificada nos dados\n", + "df_correlation.describe()" + ] + }, + { + "cell_type": "code", + "execution_count": 27, + "metadata": {}, + "outputs": [], + "source": [ + "# Vou excluir as colunas com dados string e manter só valores que quero relacionar\n", + "df_correlationvalues = df_correlation.drop(columns= [\"Measure\",\"Country\", \"Year\", \"Type_of_Medicine\"])\n" + ] + }, + { + "cell_type": "code", + "execution_count": 28, + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "Index(['Indicator:Maternal mortality ratio (per 100 000 live births)', 'Total_Sales_Value'], dtype='object')" + ] + }, + "execution_count": 28, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df_correlationvalues.columns" + ] + }, + { + "cell_type": "code", + "execution_count": 29, + "metadata": {}, + "outputs": [], + "source": [ + "# Testando criar a correlação\n", + "correlation = df_correlationvalues.corr()" + ] + }, + { + "cell_type": "code", + "execution_count": 30, + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "" + ] + }, + "execution_count": 30, + "metadata": {}, + "output_type": "execute_result" + }, + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "#Plot da matriz de correlação \n", + "plot = sn.heatmap(correlation, annot = True, fmt=\".1f\", linewidths=.6)\n", + "plot" + ] + }, + { + "cell_type": "markdown", + "metadata": {}, + "source": [ + "O insight por enquanto é que não tem correlação nenhuma, mas preciso limpar mais os dados, pensei em selecionar uma lista de países num ano específico ou um país ao longo do tempo - tentei fazer e não consegui :/" + ] + }, + { + "cell_type": "markdown", + "metadata": {}, + "source": [ + "# Finalizando salvando dataframe de correlação em csv" + ] + }, + { + "cell_type": "code", + "execution_count": 32, + "metadata": {}, + "outputs": [], + "source": [ + "df_correlation.to_csv(\"MaternalMortality_HealthIndicators.csv\")" + ] + } + ], + "metadata": { + "kernelspec": { + "display_name": "Python 3", + "language": "python", + "name": "python3" + }, + "language_info": { + "codemirror_mode": { + "name": "ipython", + "version": 3 + }, + "file_extension": ".py", + "mimetype": "text/x-python", + "name": "python", + "nbconvert_exporter": "python", + "pygments_lexer": "ipython3", + "version": "3.11.4" + } + }, + "nbformat": 4, + "nbformat_minor": 2 +} diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv b/exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv new file mode 100644 index 0000000..aeffb0c --- /dev/null +++ b/exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv @@ -0,0 +1,62545 @@ +"VAR","Variable","UNIT","Measure","COU","Country","YEA","Year","Value","Flag Codes","Flags" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",9795,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",10261,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",10355,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",11820,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",11888,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",12284,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",15305,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",14774,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",14905,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",15559,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",16614,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",17556,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",8984.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",10584.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",10721.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",11411,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",10716.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",9228.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",11377.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",11323.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",11136.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",10816.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",11433.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",13187.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",6514.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",6790.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",6723.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",8167.9,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",8184.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",8335.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",10554,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",9999,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",10136.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",10513.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",11426.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",12127.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",407.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",473.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",471.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",493.4,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",456.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",387.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",470.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",460.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",446,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",426.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",445.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",513.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",295.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",304,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",295.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",353.2,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",348.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",350,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",436.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",406.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",406,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",414.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",445.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",472.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",2493,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",2549.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",2613,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",2635.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",2787.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",2928.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",3006.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",3127.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",3213.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",3312.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",3475.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",3711.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",3305,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",3548.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",3357.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",3499.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",3703.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",3249.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",3327.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",3532.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",3795.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",3708.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",3970.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",4390,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",2959.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",3066.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",3211.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",3306,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",3489.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",3666.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",3869.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",4035.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",4198.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",4421.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",4657.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",4907.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",395.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",422.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",398.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",412.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",433.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",376,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",380.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",401.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",429.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",417.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",445.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",490.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",353.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",365.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",381,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",389.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",408.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",424.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",442.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",458.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",474.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",498,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",522.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",548,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",5881.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",5993.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",5939.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",5947.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",5947.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",6191.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",6242.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",6543.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",6681.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",7355.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",7662,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",8051.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",9006.9,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",7797.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",8342.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",7630.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",7899.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",7901.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",6869.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",6910,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",7391.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",7890,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",8234.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",8751.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",9523,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",9484.8,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",7030.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",7204.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",7224.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",7378,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",7432.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",7739.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",7993,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",8435.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",8717.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",9851.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",10491.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",10929.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",12615.9,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",715.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",755.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",687,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",707.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",704.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",609.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",609.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",649.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",690.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",716.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",758.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",821.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",816.4,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",645.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",652.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",650.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",661.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",663.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",686.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",705.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",741.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",762.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",857.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",909.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",943.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1085.9,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",24297.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",24579.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",25517,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",27126.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",28334.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",29776.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",30603.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",31829.5,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",34260.5,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",36839.6,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",39943.9,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",24313.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",23860.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",23097.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",21212.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",21374.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",22941.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",23617.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",23989.8,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",25545.5,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",29380.5,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",30689.3,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",19522.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",20081,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",20739.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",21735.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",23474.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",24561.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",25365.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",25778.8,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",27830,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",29753.6,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",31857.3,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",700.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",680.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",651.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",594.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",591.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",627.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",637.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",638,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",671.6,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",768.2,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",789.3,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",562.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",572.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",585.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",608.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",650.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",672.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",684.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",685.6,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",731.7,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",778,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",819.3,"E; D","Estimated value; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",81467.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",80927.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",83749.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",79711.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",81080.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",84444.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",87267.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",92013.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",97984.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",103398.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",87781.9,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",93006.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",4265.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",4573.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",4277.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",4073,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",3906.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",3432.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",3570.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",3936.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",4509.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",4508.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",3782,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",4290.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",5958.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",6064.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",6298,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",6234.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",6382.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",6526.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",6939,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",7405.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",7920.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",8423.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",7044.5,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",7298.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",407.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",435.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",407,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",387.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",371.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",325.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",337.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",371.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",424.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",422.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",353.5,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",408.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",568.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",577.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",599.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",593,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",606.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",618.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",656.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",699,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",745.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",789.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",658.5,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",694.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",21171.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",20540.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",20459.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",20422.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",21418.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",21897.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",22110,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",22941.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",23831.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",24553.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",25270.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",25516.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",3764.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",3825.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",3532.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",3636.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",3816.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",3254.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",3284.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",3474.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",3774,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",3681.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",3862.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",4058.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",2788.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",2751,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",2704.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",2776.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",2922.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",2997.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",3122.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",3338.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",3522.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",3701.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",3857.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",3872.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",678.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",686.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",631.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",647.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",676.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",572.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",573.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",602.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",651.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",633.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",662.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",693,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",502.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",493.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",483.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",494.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",517.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",527.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",545.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",579.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",608,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",636.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",661.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",661.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",1880.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",1927.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",1964.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",2012.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",2093.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",2200.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",2288.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",2313.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",2502.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",2658.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",2693.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",2852.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",2492.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",2683.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",2524.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",2673.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",2781.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",2441,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",2533.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",2613.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",2955.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",2976.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",3077,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",3373.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",2087.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",2146.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",2162.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",2223.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",2307.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",2423.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",2598.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",2679,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",2931,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",3171.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",3273.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",3450.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",464.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",498,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",466.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",491.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",509.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",445.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",461,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",474.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",535.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",539,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",556.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",608.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",389.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",398.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",399.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",408.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",422.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",442.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",472.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",486.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",531.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",574.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",591.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",622.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2010","2010",27539,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",27600,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2012","2012",27200,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2013","2013",26800,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2010","2010",36508.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",38418,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2012","2012",34946.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2013","2013",35593.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2010","2010",32221.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",32804,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2012","2012",32216,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2013","2013",33019.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2010","2010",563.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",589.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2012","2012",534,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2013","2013",541.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2010","2010",497.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",503.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2012","2012",492.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2013","2013",502,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",29724.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",29716.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",30442,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",31524.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",33564.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",35349.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",36118.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",37188.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",44230.1,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",46853.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",49155.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",53299.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",39406.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",41363.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",39111.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",41867.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",44590.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",39221,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",39979.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",42011.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",52233.7,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",52451.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",56145.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",63040,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",36921.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",37675.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",38669,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",40687.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",43650.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",45429.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",47991.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",49932.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",60140.3,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",64337.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",67800.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",72391.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",481.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",515.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",486.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",519.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",550.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",480.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",485.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",508.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",630,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",631.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",675.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",757.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",451.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",469.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",480.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",504.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",539,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",556.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",582.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",604.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",725.4,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",774.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",815.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",870.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",498140.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",515299.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",444548.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",430163.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",442945.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",466411.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",498866.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",493022.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",500762.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",527613.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",557449.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",568039.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",597360.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",2395.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",2563,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",1974.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",1923,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",1904.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",1669.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",1772,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",1796.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",1853.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",1815.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",1809.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",1873.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",1603.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",3940.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",4146.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",3538.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",3441.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",3422.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",3518.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",3778.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",3624.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",3600.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",3746.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",3835.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",3670.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",3704.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",239.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",257,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",199.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",194.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",193,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",169.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",180.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",183.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",189.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",185.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",185.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",193,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",165.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",394,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",415.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",356.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",347.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",346.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",357.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",385,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",370.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",368.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",383.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",393.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",378,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",382.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",25011.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",26083.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",24278,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",26023.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",23689.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",24403.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",25384.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",26522.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",30184.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",33635,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",39846.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",45105.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",204.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",224.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",194.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",213,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",202.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",185,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",210.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",248.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",278.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",274.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",294.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",355.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",188.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",193,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",177.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",189.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",171,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",171.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",181.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",191.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",214.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",239.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",271.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",301.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",643.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",705.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",605.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",657.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",619.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",559.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",626.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",722.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",790.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",760.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",802.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",953.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",591.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",605,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",552.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",586.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",522.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",519.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",540.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",558.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",607,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",663,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",741.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",808.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",2050,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",1956.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",2044.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",1959.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",1913.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",1985.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",2076,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",2124.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",2264.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",2406.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",2458.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",2621.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",2717.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",2723.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",2627.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",2602.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",2542.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",2202.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",2298,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",2399.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",2674.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",2693.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",2808.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",3100.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",2413,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",2353.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",2484.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",2415.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",2336.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",2451.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",2613.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",2674.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",2858.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",2986.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",3088.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",3298.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",596,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",594.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",571.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",562.9,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",545.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",468.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",483.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",499.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",549.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",545.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",563.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",616,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",529.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",513.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",540.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",522.4,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",501.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",521.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",549.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",556.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",587.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",605.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",619.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",655.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",19514,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",19077.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",19445,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",19887.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",22615.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",22780.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",22618.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",22361.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",22859.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",23151.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",23842.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",24798.5,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",27162.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",24511,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",25825.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",26420.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",25092,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",25215.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",25552,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",26408,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",25591.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",26444,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",28199.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",26114,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",25720.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",25514.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",26373.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",26888,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",30615.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",32518.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",32785.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",32825.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",34806.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",35744.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",36819.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",40164.8,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",457.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",411.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",428.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",434.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",413.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",415.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",422.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",437.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",428.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",444.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",476.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",442.4,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",433.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",428.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",437.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",442.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",504.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",536.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",541.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",543.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",582.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",601.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",622.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",680.4,"E","Estimated value" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",6779099,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",6987367,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",6976712,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",6894014,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",6589762,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",6748121,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",6623860,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",6721317,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",6907722,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",9489305,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",9264066,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",9180180,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",77228.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",87553.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",87437.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",70638.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",62200,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",55749.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",60885,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",59922.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",62556.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",87050.1,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",86762.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",83643,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",60685,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",65026.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",66907.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",68053.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",63945.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",65218.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",62773.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",63950.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",66319.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",91045.5,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",90444.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",89957.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",603.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",684.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",685.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",554.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",488.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",438.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",479.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",472.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",494.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",690,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",687.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",666.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",473.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",508.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",524.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",534.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",502.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",513.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",494.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",504.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",524.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",721.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",717,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",716.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",20322863,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",22054640,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",21735937.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",22556709.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",23669148,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",24607410,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",25393661.2,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",26957165.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",28893231.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",31031450.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",32522204.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",34704585,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",17573.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",19900.7,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",19289.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",20600.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",22481.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",21758.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",21876.6,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",23834.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",26262.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",26628.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",27555,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",30337.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",24165.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",25807.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",25425.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",25954.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",27147.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",28697.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",29568.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",30892,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",33798.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",36233.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",38824.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",40633.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",354.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",398.5,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",384.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",408.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",443,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",426.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",427.1,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",464.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",509.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",514.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",531.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",586.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",487.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",516.8,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",506.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",514.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",535,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",562.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",577.3,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",601.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",655.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",700,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",749,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",785.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",189.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",190.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",195.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",194.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",191.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",192.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",194.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",194.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",198.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",204.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",209.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",239.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",257.3,"D; P","Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",251.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",265,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",251.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",258.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",254.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",213.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",215.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",219.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",234.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",228.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",238.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",283.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",270.9,"D; P","Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",204.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",210.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",215.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",217.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",216.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",218.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",228.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",228.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",234,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",242.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",244.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",279.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",309.4,"D; P","Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",530.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",549.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",510.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",515.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",497.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",412.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",409.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",409,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",429.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",411.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",421.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",492.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",461.9,"D; P","Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",432.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",436.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",438.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",433.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",423.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",421.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",434.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",426.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",428.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",436.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",430.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",485.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",527.5,"D; P","Difference in methodology; Provisional value" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",141748.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",228114.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",11098.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",11853.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",17978.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",24591,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",93.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",94.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",151.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",196.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",5213.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",5210,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",4608.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",4301.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",4328.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2015","2015",4463.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2016","2016",4532.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2017","2017",4561.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2018","2018",4624,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2019","2019",4846.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2020","2020",4971.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2021","2021",4860.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",6911.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",7252.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",5920.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",5712.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",5750.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2015","2015",4952.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2016","2016",5016.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2017","2017",5152.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2018","2018",5460.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2019","2019",5425.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2020","2020",5678.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2021","2021",5749.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",6103.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",6231.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",5589.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",5388.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",5351.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2015","2015",5510.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2016","2016",5697.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2017","2017",5831.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2018","2018",5953,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2019","2019",6225,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2020","2020",6512.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2021","2021",6313,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",415.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",434.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",353.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",339.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",341,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2015","2015",292.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2016","2016",294.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2017","2017",300.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2018","2018",316.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2019","2019",312.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2020","2020",325.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2021","2021",327.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",367.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",373.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",333.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",320.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",317.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2015","2015",325.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2016","2016",334.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2017","2017",340.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2018","2018",345.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2019","2019",358.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2020","2020",373.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2021","2021",360.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",748.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",817,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",924.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",922.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",959.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",987.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",1072.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",1262.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",1321.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",1492,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",1652,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",1777,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",1903,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",539.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",645.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",748.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",756.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",796,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",688.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",746.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",896.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",914.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",983,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",1071.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",1256.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",1206.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",500.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",549.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",617.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",638.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",666,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",668.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",744,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",882.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",898.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",1053.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",1168.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",1217.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",1319.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",124,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",147.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",169.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",170.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",176.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",149.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",158.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",186.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",186.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",197.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",210.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",245.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",235.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",115,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",125.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",140.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",143.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",147.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",145,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",157.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",183.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",183.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",211.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",229.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",238.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",257.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",17890,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",18200,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",18800,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",19300,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",21077,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",22769,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",24769,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",26650,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",27494,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",28400,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",29708,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",33559,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",36008,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",2959.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",3247.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",3231.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",3285.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",3344.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",2823.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",2948.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",3221.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",3380.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",3227.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",3155.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",3906.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",3745.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",1954.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",2003.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",2080.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",2137.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",2271.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",2292.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",2466.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",2733.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",2868.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",2952.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",3006.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",3528,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",3352.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",605.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",655.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",643.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",646.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",651.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",544.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",563.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",610.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",636.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",603.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",586.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",722.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",690.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",399.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",404.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",414.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",420.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",442.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",441.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",471.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",518,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",540.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",552,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",559,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",652.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",618,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",3237.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",2942.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",2614,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",2409.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",2397.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",2491.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",2530.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",2555.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",2627.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",2789.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",2809.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",2923,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",3187.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",4292.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",4096,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",3358.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",3200.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",3185.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",2764.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",2800.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",2886.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",3103.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",3123.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",3208.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",3457.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",3357,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",5195.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",4722.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",4317.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",4128.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",4141.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",4259,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",4428.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",4438.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",4600.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",4993,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",5042.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",5149.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",5796.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",406,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",388,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",319.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",306,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",306.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",266.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",271.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",280.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",301.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",303.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",311.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",333.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",324.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",491.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",447.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",410.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",394.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",398.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",411.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",428.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",430.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",447.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",485.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",489.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",496.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",559.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",1115.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",1128.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",1104.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",1229.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",1317.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",1384.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",1573.3,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",1563,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",1629.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",1730.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",1661.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",1789.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",1479.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",1570.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",1418.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",1632.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",1749.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",1536.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",1741.5,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",1765.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",1924.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",1936.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",1898,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",2116.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",2222,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",2228.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",2188.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",2502.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",2713.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",2816.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",3126.6,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",3026.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",3097.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",3343.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",3195.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",3354.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",274.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",291,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",262.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",301.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",322.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",283.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",320.7,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",324.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",353.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",355.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",347.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",388.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",412.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",412.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",404.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",462.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",500.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",519.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",575.7,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",556.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",568.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",613,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",585.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",615.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",13238.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",12356.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",11072,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",10669.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",11302.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",11403.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",11833,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",12064.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",18994,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",20007.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",20802.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",22020.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",22932.1,"P","Provisional value" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",17550.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",17199.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",14225.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",14170.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",15015.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",12652.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",13098,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",13629.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",22431.1,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",22397.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",23760.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",26044.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",24148.6,"P","Provisional value" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",18211.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",17302.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",15931.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",15811.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",17064.2,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",17155,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",18412.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",19125.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",30063.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",32640.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",33479.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",35179.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",38462.8,"P","Provisional value" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",376.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",368,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",304.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",304,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",323,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",272.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",281.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",292.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",479.3,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",475.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",501.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",549.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",509.1,"P","Provisional value" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",391,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",370.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",340.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",339.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",367.1,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",369.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",396.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",410.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",642.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",692.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",706.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",741.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",810.9,"P","Provisional value" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",36059.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",36781.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",36116.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",36337.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",37808.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",40557.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",42346.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",43703.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",47840.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",50523.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",52438.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",53870.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",57795.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",5003,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",5664.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",5330.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",5578.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",5510.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",4808.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",4945.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",5112.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",5503.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",5341.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",5693.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",6281.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",5714.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",3995.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",4158.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",4173,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",4226.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",4332.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",4580.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",4799.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",4937,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",5396,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",5800.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",6049.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",6176.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",6669,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",533.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",599.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",560,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",581.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",568.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",490.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",498.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",508.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",540.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",519.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",549.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",603,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",546.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",426,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",440.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",438.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",440.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",446.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",467.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",483.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",490.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",530.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",564.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",584.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",593,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",638,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",5744.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",5776,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",5937,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",5931,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",5931,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",6184,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",6380,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",6520,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",6605,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",6696,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",6836,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",7116,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",7596,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",5507.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",6504.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",6331.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",6398.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",6473.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",6425.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",6474.6,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",6621.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",6754.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",6738.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",7280.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",7786.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",7955.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",3917.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",4133.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",4384.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",4518.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",4627.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",5004.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",5308,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",5489.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",5602.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",5820.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",6019.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",6431.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",7126.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",703.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",822,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",791.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",791,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",790.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",775.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",773.2,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",783.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",793.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",785.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",842.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",894.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",910.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",500.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",522.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",548.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",558.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",565.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",604.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",633.9,"B; D","Break; Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",649.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",658,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",678.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",696.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",738.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",815.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",15588.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",14167,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",13519.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",14335.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",15698.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",18303.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",21893.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",25447.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",32038,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",42070.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",49965.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",64807.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",10372.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",8458.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",7527.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",7530.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",7173.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",6729.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",7249.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",6975.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",6635.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",7414.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",7129.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",7322.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",16937.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",14663,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",13256.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",13394,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",14213.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",15745.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",17641,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",18387.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",19623.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",22569.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",23087.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",23080.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",141.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",114,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",100.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",98.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",92.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",86,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",91.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",86.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",81.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",89.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",85.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",87,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",231.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",197.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",176.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",175.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",184.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",201.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",222.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",228.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",241.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",273.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",276.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",274.3,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2010","2010",13156.1,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2011","2011",12983.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",13772.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",14602.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",15995.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",17686.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",18554.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",19525.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",20446.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2010","2010",20328.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2011","2011",20802.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",21755.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",22827.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",26319.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",27021.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",25051.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",25129.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",27279,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2010","2010",18733.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2011","2011",18389,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",19629.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",21002.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",22901.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",25538.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",26944.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",28520.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",29731.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2010","2010",323.9,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2011","2011",328.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",341.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",356.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",407.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",415,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",381.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",380.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",410.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2010","2010",298.5,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2011","2011",290.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",308.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",327.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",354.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",392.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",410.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",431.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",447.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",826115.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",1179279,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",1248234.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",1446986.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",1546451.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",1823693.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",2023878.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",2067820.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",2296898.5,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",2522481.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",2689451.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",2813418,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",2817224.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",1619,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",2438.2,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",2565.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",2921.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",2711.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",2788,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",2989.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",3187,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",3581.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",3588.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",3392.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",3707,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",3225.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",2295.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",3388.6,"B","Break" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",3594.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",4138,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",4211.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",4662,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",5094.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",5199.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",5796.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",6280.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",6427.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",6465.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",6438.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",94.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",141.3,"B","Break" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",147.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",165.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",152.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",155.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",164.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",173,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",191,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",187.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",174.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",188.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",162.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",134.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",196.4,"B","Break" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",206.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",235,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",236.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",259.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",280.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",282.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",309.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",328.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",330.3,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",328.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",324.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",194.1,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",204.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",221.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",231,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",249.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",265.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",289.9,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",301,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",325.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",344.4,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",358.6,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",408.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",431.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",257.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",284.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",284.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",306.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",331.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",294.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",320.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",340,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",384.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",385.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",409.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",483.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",454.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",379,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",399.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",425.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",442.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",473.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",493.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",549.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",562.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",604,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",641.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",684.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",752.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",757.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",193.2,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",214.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",215.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",232.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",252.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",223.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",243.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",258.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",290.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",290.5,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",308.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",363.3,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",341,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",284.6,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",301,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",321.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",335.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",360.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",375,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",417.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",427.1,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",456.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",483.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",515,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",565.2,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",568.8,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",474.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",470,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",454.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",451.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",432.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",446,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",466.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",484.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",516.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",542.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",568.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",613.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",679.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",628.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",654.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",583.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",599.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",574.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",494.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",516.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",547,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",610.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",606.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",649,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",725.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",715.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",743.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",753.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",748.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",764,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",731.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",749.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",808.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",849.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",910.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",981.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",1038.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",1088.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",1231.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",307,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",318.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",283.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",290.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",278.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",239.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",250.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",264.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",294.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",290.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",308.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",344.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",339.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",363,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",367,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",364,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",370.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",354.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",363.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",391.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",411,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",439,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",470.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",493.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",516.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",584.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",1227,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",1218,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",1214,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",1399,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1351,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",1353,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",1383,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",1424,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1410,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1415,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1493,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1634,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1125.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",1256.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",1257,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1350.6,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",1217.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1016.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",1028.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1091.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1053.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",983.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",1027.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",1227.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",816,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",806.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",788.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",966.7,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",930.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",918.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",953.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",963.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",958.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",956.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",1026.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",1128.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",51.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",56.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",55.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",58.4,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",51.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",42.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",42.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",44.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",42.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",38.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",40,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",47.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",37,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",36.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",34.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",41.8,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",39.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",38.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",39.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",39.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",38.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",37.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",40,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",43.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",12.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",11.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",11.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",11.8,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",11.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",11,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",9.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",9.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",9.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",9.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",274.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",272.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",273,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",275.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",287.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",297.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",296.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",304.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",316.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",343,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",368.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",391.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",363.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",379.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",350.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",365.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",381.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",329.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",328.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",343.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",373.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",384,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",420.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",462.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",325.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",327.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",335.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",345.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",359.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",372,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",382.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",392.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",413.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",457.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",493.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",517.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",43.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",45.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",41.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",43.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",44.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",38.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",37.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",39.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",42.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",43.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",47.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",51.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",39,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",39,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",39.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",40.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",42,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",43,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",43.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",44.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",46.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",51.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",55.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",57.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",11,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",10.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",10.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",10.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",10.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",10.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",9.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",9.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",9.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",10.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",10.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",10.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",627,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",647.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",647.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",649.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",633.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",651.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",677.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",697.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",699.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",750.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",772.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",802.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",876.6,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",831.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",901.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",831.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",862.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",841.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",722.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",750.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",788,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",825.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",840.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",882,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",949,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",923.1,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",749.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",778.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",787.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",805.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",791.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",814.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",867.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",899.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",912.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",1005.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",1057.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",1089.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1227.8,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",76.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",81.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",74.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",77.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",75.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",64.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",66.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",69.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",72.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",73.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",76.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",81.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",79.5,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",68.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",70.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",70.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",72.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",70.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",72.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",76.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",79.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",79.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",87.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",91.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",94,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",105.7,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",10.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",10.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",10.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",10.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",10.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",10.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",10.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",10.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",10.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",10.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",10.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",10,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",9.7,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",3199.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",3245.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",3377.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",3825,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",3822.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",4045.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",4288.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",4648.8,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",5292.6,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",5971.9,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",6932.4,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",3201.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",3150.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",3057.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",2991.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",2883.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",3117.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",3309.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",3503.8,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",3946.3,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",4762.7,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",5326.3,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",2570.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",2651.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",2745.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",3064.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",3166.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",3337.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",3554.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",3765.1,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",4299.2,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",4823.2,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",5529,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",92.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",89.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",86.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",83.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",79.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",85.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",89.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",93.2,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",103.7,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",124.5,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",137,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",74.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",75.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",77.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",85.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",87.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",91.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",95.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",100.1,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",113,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",126.1,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",142.2,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",14.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",13.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",13.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",14,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",14.6,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",15.4,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",16.2,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",17.4,"E; D","Estimated value; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",8968.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",9060.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",9641.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",9350.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",9917.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",10350,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",11002.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",11476.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",12131.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",12817.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",11067.1,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",11646.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",469.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",512,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",492.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",477.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",477.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",420.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",450.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",490.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",558.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",558.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",476.8,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",537.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",656,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",678.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",725.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",731.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",780.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",800,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",874.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",923.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",980.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",1044.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",888.1,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",914,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",44.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",48.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",46.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",45.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",45.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",39.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",42.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",46.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",52.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",52.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",44.6,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",51.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",62.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",64.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",69,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",69.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",74.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",75.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",82.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",87.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",92.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",97.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",83,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",87,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",11,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",11.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",11.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",11.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",12.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",12.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",12.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",12.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",12.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",12.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",12.6,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",12.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1740,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1682.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1777,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1825.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1954.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",2086.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",2214.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",2320.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",2492.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2721,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2800.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",3036,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",309.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",313.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",306.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",325,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",348.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",310.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",328.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",351.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",394.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",408,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",428.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",482.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",229.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",225.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",234.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",248.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",266.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",285.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",312.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",337.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",368.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",410.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",427.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",460.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",55.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",56.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",54.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",57.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",61.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",54.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",57.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",61,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",68.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",70.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",73.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",82.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",41.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",40.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",42,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",44.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",47.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",50.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",54.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",58.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",63.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",70.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",73.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",78.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",8.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",8.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",8.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",8.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",9.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",9.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",10,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",10.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",10.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",11.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",11.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",11.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",227.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",241.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",254.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",265,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",279.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",293,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",302.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",295.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",300.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",309.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",321.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",334.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",301.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",336.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",327.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",352,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",371.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",325.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",334.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",333.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",354.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",346.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",367.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",395.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",252.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",269.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",280.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",292.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",307.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",322.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",343.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",341.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",351.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",369.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",390.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",404.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",56.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",62.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",60.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",64.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",67.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",59.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",60.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",60.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",64.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",62.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",66.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",71.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",47.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",50,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",51.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",53.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",56.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",58.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",62.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",62,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",63.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",66.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",70.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",73,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",12.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",12.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",13,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",13.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",13.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",13.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",13.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",12.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",12,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",11.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",11.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",11.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",2952.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",4109.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",3509,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",63.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",53.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FRA","France","2011","2011",10.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",3714.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",3704,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",3894.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",4031.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",4132.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",4253.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",4404.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",4483.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",4775.5,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",5025.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",5246,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",5597.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",4924.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",5155.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",5003.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",5354.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",5489.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",4719,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",4875.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",5064.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",5639.6,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",5625.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",5992,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",6619.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",4614.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",4696.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",4946.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",5203.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",5374,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",5466,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",5852.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",6019.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",6493.3,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",6900.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",7235.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",7601.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",60.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",64.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",62.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",66.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",67.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",57.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",59.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",61.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",68,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",67.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",72.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",79.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",56.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",58.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",61.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",64.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",66.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",66.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",71.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",72.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",78.3,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",83,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",87,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",91.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",12.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",12.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",12.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",12.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",12.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",12,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",12.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",12.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",10.8,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",10.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",10.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",10.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",856,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",743.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",678.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",630.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",634.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",594.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",749.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",760.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",805,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",833.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",874.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",944.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",813,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1134.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1035.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",871.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",836.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",843.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",659.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",829.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",859.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",950.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",933.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",998.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",1116.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",856.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1185.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1043.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",990.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",998.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1038.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",976.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1272.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1323.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1425.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1519.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1607.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1730.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1538.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",102,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",93.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",78.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",76.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",77.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",61,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",77,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",79.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",88.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",87.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",93.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",105.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",81.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",106.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",93.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",89.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",91,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",95.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",90.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",118.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",123,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",132.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",141.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",150.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",163.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",147.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",64095.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",68963.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",64446.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",60613.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",64320.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",67533,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",73066.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",78667.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",85394.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",94664.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",107184.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",109798.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",117157,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",308.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",343,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",286.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",271,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",276.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",241.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",259.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",286.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",316,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",325.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",348,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",362.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",314.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",507,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",554.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",513,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",485,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",497,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",509.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",553.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",578.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",613.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",672.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",737.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",709.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",726.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",30.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",34.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",28.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",27.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",28,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",24.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",26.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",29.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",32.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",33.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",35.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",37.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",32.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",50.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",55.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",51.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",49,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",50.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",51.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",56.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",59.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",62.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",68.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",75.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",73.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",75,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",12.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",13.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",14.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",14.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",14.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",14.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",14.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",16,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",17.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",17.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",19.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",19.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",19.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",2071.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1894.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1700.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",2134,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1897.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",2003.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",2188.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",2159.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",2463.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",2929.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",3578.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",4281.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",16.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",16.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",13.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",17.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",16.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",15.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",18.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",20.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",22.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",23.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",26.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",33.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",15.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",14,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",12.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",15.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",13.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",14.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",15.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",15.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",17.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",20.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",24.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",28.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",53.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",51.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",42.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",53.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",49.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",45.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",54,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",58.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",64.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",66.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",72.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",90.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",49,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",43.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",38.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",48.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",41.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",42.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",46.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",45.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",49.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",57.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",66.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",76.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",8.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",7.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",8.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",8.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",8.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",8.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",8.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",8.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",9.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",263.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",239,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",248.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",233.4,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",207.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",206,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",210.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",215.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",227,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",242,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",260.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",282,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",349.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",332.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",319.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",310,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",275.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",228.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",232.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",243.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",268,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",270.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",297.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",333.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",310,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",287.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",302.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",287.7,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",253.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",254.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",264.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",271.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",286.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",300.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",327.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",354.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",76.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",72.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",69.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",67,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",59.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",48.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",49,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",50.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",55.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",54.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",59.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",66.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",68,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",62.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",65.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",62.2,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",54.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",54.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",55.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",56.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",58.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",60.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",65.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",70.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",12.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",12.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",12.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",11.9,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",10.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",10.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",10.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",10.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",10,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",10.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",10.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",10.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",2281.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",2363.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",2478.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",2584.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",2654.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",2695.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",2754,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",2837.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",2901.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",2878.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",3064.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",3258.6,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",3176.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",3036.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",3292,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",3433.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",2945.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",2983.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",3111.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3350.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3247.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",3287.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",3624.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",3431.5,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",3007.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",3160.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",3361.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",3494.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",3594,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",3847.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",3992,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4165.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",4417.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",4444.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",4732.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",5277.8,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",53.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",51,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",54.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",56.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",48.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",49.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",51.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",55.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",54.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",55.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",61.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",58.1,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",50.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",53.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",55.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",57.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",59.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",63.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",65.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",68.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",74,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",74.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",80,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",89.4,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",11.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",12.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",12.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",13,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",11.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",11.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",12.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",12.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",12.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",12.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",12.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",13.1,"E","Estimated value" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",581966,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",570135,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",572354,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",532593,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",484331,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",464073,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",400328,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",403493,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",375517,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",561901,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",560631,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",540915,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",6629.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",7143.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",7173.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",5457.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",4571.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",3833.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",3679.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",3597.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",3400.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",5154.6,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",5250.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",4928.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",5209.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",5305.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",5488.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",5257.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",4699.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",4485.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",3793.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",3839.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",3605.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",5391.2,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",5473.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",5300.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",51.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",55.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",56.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",42.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",35.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",30.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",29,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",28.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",26.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",40.9,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",41.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",39.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",40.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",41.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",43,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",41.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",36.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",35.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",29.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",30.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",28.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",42.7,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",43.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",42.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",8.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",8.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",8.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",7.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",7.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",6.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",5.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",5.9,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",6.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",5.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",3258189,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",3370253.9,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",3197570.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",3351225.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",3508305.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",3705647.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",3857818.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",4137071.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",4431342.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",4752462.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",5102463.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",5476282.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",2817.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",3041.1,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",2837.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",3060.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",3332.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",3276.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",3323.5,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",3657.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",4027.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",4078.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",4323.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",4787.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",3874.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",3943.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",3740.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",3856.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",4023.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",4321.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",4492.1,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",4741,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",5183.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",5549.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",6091.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",6411.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",56.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",60.9,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",56.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",60.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",65.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",64.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",64.9,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",71.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",78.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",78.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",83.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",92.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",78.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",79,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",74.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",76.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",79.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",84.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",87.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",92.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",100.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",107.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",117.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",123.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",16,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",15.3,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",14.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",14.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",14.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",15.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",15.2,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",15.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",15.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",15.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",15.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",15.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",28.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",28.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",29.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",31.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",32.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",33.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",34.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",35.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",36.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",38.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",39.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",42.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",42.7,"D; P","Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",37.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",39.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",38.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",42,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",43.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",36.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",38,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",39.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",43.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",42.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",44.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",50,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",45,"D; P","Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",30.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",31.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",33,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",35.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",37.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",37.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",40.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",41.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",43.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",45.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",45.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",49.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",51.3,"D; P","Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",79.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",82,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",78,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",83.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",85.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",71.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",72.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",74.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",79.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",76.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",79,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",87,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",76.6,"D; P","Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",65.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",65.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",66.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",70.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",72.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",76.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",77.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",78.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",81.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",80.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",85.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",87.5,"D; P","Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",15.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",14.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",15.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",16.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",17.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",17.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",17.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",18.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",18.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",18.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",18.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",17.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",16.6,"D; P","Difference in methodology; Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",668,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",684.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",646.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",651.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",651.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",885.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",952.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",830.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",865.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",865.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",782.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",818.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",784.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",816.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",805.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",53.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",57.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",49.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",51.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",51.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",47.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",49,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",46.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",48.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",47.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",12.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",13.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",14,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",15.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",15.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",68.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",71.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",71.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",75.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",79.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",90.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",91.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",88.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",97.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",98.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",116.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",132.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",174,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",49.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",56.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",58.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",61.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",65.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",62.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",63.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",63,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",67.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",64.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",75.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",93.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",110.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",45.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",48.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",48,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",52,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",55,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",61,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",63.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",62,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",66.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",69.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",82.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",90.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",120.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",11.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",12.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",13.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",14.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",13.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",13.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",13.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",13.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",13,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",14.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",18.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",21.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",10.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",11,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",10.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",11.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",13.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",12.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",13.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",13.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",16.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",17.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",23.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",9.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",8.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",7.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",8.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",8.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",9.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",8.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",7.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",6.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",7.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",9.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1829,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1886,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1910,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1915,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",2061,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",2224,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2559,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2775,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2944,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",3134,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",3470,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",4141,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",5090,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",302.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",336.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",328.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",326,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",327.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",275.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",304.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",335.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",362,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",356.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",368.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",482.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",529.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",199.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",207.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",211.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",212.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",222.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",223.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",254.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",284.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",307.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",325.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",351.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",435.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",473.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",61.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",67.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",65.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",64.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",63.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",53.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",58.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",63.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",68.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",66.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",68.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",89.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",97.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",40.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",41.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",42.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",41.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",43.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",43.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",48.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",53.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",57.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",60.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",65.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",80.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",87.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",10.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",10.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",10.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",9.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",9.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",9.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",10.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",10.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",10.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",11,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",11.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",12.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",14.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",511.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",455.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",400.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",396.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",404.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",440,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",460.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",478,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",513,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",561.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",596.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",658.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",747.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",677.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",634.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",515,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",526,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",537.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",488.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",509.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",540,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",605.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",629,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",681,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",779.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",787.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",820.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",731.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",662.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",678.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",699.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",752.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",806,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",830.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",898.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",1005.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",1070.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",1160.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",1359.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",64.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",60.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",49,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",50.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",51.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",47.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",49.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",52.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",58.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",61.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",66.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",75.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",76.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",77.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",69.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",63,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",64.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",67.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",72.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",78.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",80.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",87.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",97.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",103.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",112,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",131.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",15.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",15.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",15.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",16.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",16.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",17.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",18.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",18.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",19.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",20.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",21.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",22.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",23.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",116.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",120.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",112.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",127.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",136.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",152.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",186,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",186.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",196.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",211.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",216,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",238.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",154.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",167.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",144.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",168.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",181.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",169.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",205.8,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",210.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",232.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",236.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",246.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",282.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",231.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",237.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",223.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",258.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",281.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",310.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",369.6,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",361.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",374.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",408.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",415.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",447.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",28.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",31,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",26.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",31.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",33.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",31.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",37.9,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",38.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",42.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",43.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",45.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",51.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",43,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",44,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",41.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",47.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",52,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",57.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",68,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",66.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",68.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",74.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",76.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",82.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",10.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",10.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",10.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",10.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",10.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",11,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",11.8,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",11.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",12.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",12.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",13,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",13.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1778.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1777.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",1678.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",1685.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",1852.4,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1958,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",2104.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",2215.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",2612.3,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",2797,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",2955,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",3246.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",3474.2,"P","Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",2358,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",2474.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",2156.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",2238.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",2460.9,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",2172.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",2329.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",2502.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",3085,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",3131.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",3375.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",3839.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",3658.5,"P","Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",2446.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",2489,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",2415.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",2497.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",2796.7,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",2945.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",3274.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",3512,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",4134.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",4563,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",4755.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",5186,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",5827.1,"P","Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",50.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",52.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",46.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",48,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",52.9,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",46.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",50.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",53.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",65.9,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",66.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",71.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",81,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",77.1,"P","Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",52.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",53.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",51.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",53.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",60.2,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",63.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",70.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",75.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",88.4,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",96.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",100.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",109.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",122.8,"P","Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",13.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",14.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",15.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",15.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",16.4,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",17.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",17.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",18.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",13.8,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",14,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",14.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",14.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",15.2,"P","Provisional value" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3736.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3675.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",3732,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",3749.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3841.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",4115.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",4397.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",4618.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",4954,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",5382.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",5723.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",6118.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",6826,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",518.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",566.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",550.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",575.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",560,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",487.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",513.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",540.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",569.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",569.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",621.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",713.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",674.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",414,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",415.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",431.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",436.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",440.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",464.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",498.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",521.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",558.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",618,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",660.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",701.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",787.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",55.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",59.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",57.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",60,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",57.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",49.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",51.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",53.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",56,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",55.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",60,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",68.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",64.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",44.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",44,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",45.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",45.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",45.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",47.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",50.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",51.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",54.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",60.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",63.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",67.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",75.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",10.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",10,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",10.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",10.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",10.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",10.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",10.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",10.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",10.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",10.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",10.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",11.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",11.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",875.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",847,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",851,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",858,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",863,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",890,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",923,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",934,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",925,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",943,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",987,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",1037,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",1112,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",839.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",953.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",907.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",925.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",942,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",924.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",936.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",948.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",945.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",949,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",1051.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",1134.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",1164.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",597.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",606.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",628.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",653.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",673.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",720.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",767.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",786.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",784.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",819.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",869.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",937.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",1043.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",107.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",120.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",113.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",114.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",115,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",111.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",111.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",112.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",111.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",110.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",121.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",130.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",133.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",76.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",76.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",78.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",80.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",82.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",87,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",91.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",93,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",92.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",95.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",100.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",107.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",119.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",15.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",14.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",14.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",14.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",14.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",14.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",14.5,"B; D","Break; Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",14.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",14,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",14.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",14.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",14.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",14.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",2158.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1965.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1947.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",2115.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",2328.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",2779.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",3349.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",4164.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",5223.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",6893.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",9117.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",12158.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1436.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",1173.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",1084.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",1111.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",1064,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",1021.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",1109.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",1141.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",1081.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",1215,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",1300.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",1373.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2345.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",2034.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1909.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1976.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",2108.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",2390.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",2699.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",3008.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",3199.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",3698.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",4213,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",4330.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",19.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",15.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",14.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",14.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",13.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",13.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",14,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",14.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",13.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",14.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",15.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",16.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",32.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",27.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",25.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",26,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",27.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",30.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",34,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",37.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",39.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",44.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",50.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",51.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",13.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",13.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",14.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",14.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",14.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",15.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",15.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",16.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",16.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",16.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",18.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",18.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1384.3,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1410.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1537.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",1710.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1773.2,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1854.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1981.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2186.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",2204.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",2529.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",2613.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",2394.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",2387.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",2643.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",1973,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",2028.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",2200.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",2470.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",2575.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",2709.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",2880.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",34.3,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",34.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",39.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",40.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",36.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",36.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",39.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",31,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",31.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",34.1,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",37.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",39.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",41,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",43.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",10.1,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",9.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",9.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",9.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",9.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",9.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",9.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",151311.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",184612.6,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",203569.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",220594,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",260015,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",317777.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",361148.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",385291.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",397573.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",479315.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",508617,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",542926.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",498922,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",296.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",381.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",418.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",445.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",455.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",485.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",533.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",593.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",620,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",681.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",641.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",715.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",571.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",420.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",530.5,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",586.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",630.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",708.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",812.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",909.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",968.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",1003.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",1193.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",1215.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1247.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",1140.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",17.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",22.1,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",24,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",25.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",25.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",27,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",29.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",32.2,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",33.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",35.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",33,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",36.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",28.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",24.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",30.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",33.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",35.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",39.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",45.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",50,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",52.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",53.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",62.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",62.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",63.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",57.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",18.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",15.7,"B","Break" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",16.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",15.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",16.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",17.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",17.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",18.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",17.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",19,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",18.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",19.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",17.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",23.5,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",24.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",26.9,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",28.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",30.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",32.7,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",34.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",35.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",38.1,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",39.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",41.3,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",43.4,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",50,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",31.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",33.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",34.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",38.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",40.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",36.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",38,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",40.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",45,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",44.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",47.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",51.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",52.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",46,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",47.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",51.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",54.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",58.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",60.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",65.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",66.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",70.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",73.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",78.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",79.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",87.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",23.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",25.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",26.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",28.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",31.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",27.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",28.9,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",30.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",34.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",33.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",35.5,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",38.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",39.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",34.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",35.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",39,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",41.7,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",44.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",46.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",49.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",50.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",53.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",55.6,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",59.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",60,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",66,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",12.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",11.9,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",12.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",12.4,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",12.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",12.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",11.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",11.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",11.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",11.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",11.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",10.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",11.6,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",55.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",55.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",51.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",49.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",50.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",52.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",56.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",57.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",62.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",67.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",72.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",76.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",87.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",73.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",76.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",66.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",66.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",66.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",58.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",62.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",65.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",73.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",75.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",82.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",90.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",92.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",86.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",88.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",85.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",84.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",84.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",88.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",97.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",101.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",109.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",121.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",132,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",136.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",158.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",35.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",37.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",32.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",32.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",32.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",28.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",30.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",31.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",35.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",36,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",39.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",43.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",43.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",42.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",43.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",41.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",41,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",41.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",43,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",47.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",49,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",52.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",58.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",62.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",64.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",75.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",11.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",11.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",11.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",11.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",11.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",11.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",12,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",11.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",12,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",12.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",12.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",12.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",12.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",2,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",2.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",2.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1.9,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",1.4,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",1.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",1.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",1.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",1.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",1.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",1.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",1.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",1.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",1.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",10.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",11.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",11.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",11.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",10.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",9.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",9.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",9.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",9.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",10.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",9.8,"E","Estimated value" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",14.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",16,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",14.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",14.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",13.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",11.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",10.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",10.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",11.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",11.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",11.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",11.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",10.3,"E","Estimated value" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",12.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",13.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",14.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",13.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",13.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",12.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",12.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",12.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",12.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",13.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",14.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",13.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",13.7,"E","Estimated value" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",1.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",1.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",1.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",1.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",0.9,"E","Estimated value" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",1.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",1.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1.2,"E","Estimated value" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.1,"E","Estimated value" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",103.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",101.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",102.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",110.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",100.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",97.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",101,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",100.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",100.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",98.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",5.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",5.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",5.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",5.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",4.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",4.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",4.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",4.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",4.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",7.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",7.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",7.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",8.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",7.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",7.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",8.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",8.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",2.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",2.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",3.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",3.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",3.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",3.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",3.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",3.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",3.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",3.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",3.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",3.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",3.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",4.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",3.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",3.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",3.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",4.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",4.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",3.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",3.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",3.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",3.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",3.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",3.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",3.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",4.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",4.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",4.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.9,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",14.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",14.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",14.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",15.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",17.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",17.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",19.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",19.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",21,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",23.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",25.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",27.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",19.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",20.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",19.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",20.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",22.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",19.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",21.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",21.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",24.8,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",26.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",28.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",32.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",18,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",18.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",18.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",19.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",22.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",22.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",25.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",25.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",28.6,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",32.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",34.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",37.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",5.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",5.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",5.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",5.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",5.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",4.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",4.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",4.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",5.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",5.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",5.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",5.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",7.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",8.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",6.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",7.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",7.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",5.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",4.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",5.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",5.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",6.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",6.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",5.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",8.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",7.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",8.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",8.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",8.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",7.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",7.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",8.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",9.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",10.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",9.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",10.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",0.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",0.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",53.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",1.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",1.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",21.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",21.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",22.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",24.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",24.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",25.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",25.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",26,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",23.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",24.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",25,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",32.8,"E","Estimated value" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",30.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",27.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",29.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",32.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",27.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",28,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",28.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",30.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",26.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",28.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",29.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",34.6,"E","Estimated value" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",28.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",29.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",30,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",32.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",33.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",36.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",36.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",38.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",36.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",38.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",38.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",53.2,"E","Estimated value" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.6,"E","Estimated value" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.9,"E","Estimated value" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.1,"E","Estimated value" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",107888,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",94392,"B","Break" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",83934.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",79360.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",78601.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",75437.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",68368.6,"B","Break" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",68847,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",70990.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",73827.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",80978.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",79702.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",93.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",85.2,"B","Break" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",74.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",72.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",74.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",66.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",58.9,"B","Break" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",60.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",64.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",63.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",68.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",69.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",128.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",110.5,"B","Break" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",98.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",91.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",90.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",88,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",79.6,"B","Break" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",78.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",83,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",86.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",96.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",93.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",1.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",1.7,"B","Break" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",1.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",1.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",1.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",1.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",1.1,"B","Break" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",1.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",1.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",1.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",2.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",2.2,"B","Break" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",1.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.6,"B","Break" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.8,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.5,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.4,"B","Break" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.4,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.4,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.3,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.3,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.3,"B","Break" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.3,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0.3,"D; P","Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0.3,"D; P","Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",0.6,"D; P","Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",28,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",28,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",28,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",29,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",28,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",28,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",30,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",29,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",28,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",29,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",33,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",36,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",35,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",4.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",4.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",4.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",4.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",3.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",3.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",3.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",3.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",3.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",3.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",4.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",3.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",3.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",3.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",3.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",3.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",2.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",2.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",3.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",3.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",3.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",6.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",6.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",5.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",4.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",5.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",5.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",5.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",5.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",5.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",5.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",8.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",8.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",7.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",6.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",6.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",6.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",5.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",6.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",6.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",6.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",6.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",6.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",5.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",10.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",9.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",10,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",8.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",8.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",9.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",9.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",10.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",10.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",10.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",10.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",9.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",9.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",0.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",0.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",0.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",0.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",0.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",0.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",0.9,"B","Break" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",0,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",0.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",0.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",0.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",0.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",1.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",0.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",0.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",1,"B","Break" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",0,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",0.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",1.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",1.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",1.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",1.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",1.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",1.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",1.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",1.8,"B","Break" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",0,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",1.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",1.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",1.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",1.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",0.2,"B","Break" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",0.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",0.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",0.3,"B","Break" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",0,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",0.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",0.3,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.1,"B","Break" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",19.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",17.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",11.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",25.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",24.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",15,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",26.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",25,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",16.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",62.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",70.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",70.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",75.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",81.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",92.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",95.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",98.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",99,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",104.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",104.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",108,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",107.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",8.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",10.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",10.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",11.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",11.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",11,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",11.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",11.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",11.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",11,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",11.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",12.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",10.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",6.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",8.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",8.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",9.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",10.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",10.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",11.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",11.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",11.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",12,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",12.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",12.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",1.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",94.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",102.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",101.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",93.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",99,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",125.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",161.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",198.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",221.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",265.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",333.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",424,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",62.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",61,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",56.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",49.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",45.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",46.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",53.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",54.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",45.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",46.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",47.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",47.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",102.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",105.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",99.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",87.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",89.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",108,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",130.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",143.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",135.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",142.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",154,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",151,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",1.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",1.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",1.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",1.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",1.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",1.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.8,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.8,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.8,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",8337.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",9337.8,"B","Break" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",9204.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",9763.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",10396.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",11322.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",11264.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",11617,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",12658.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",11513.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",11755.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",9854.6,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",10301.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",16.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",19.3,"B","Break" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",18.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",19.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",18.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",17.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",16.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",17.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",19.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",16.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",14.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",13,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",11.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",23.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",26.8,"B","Break" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",26.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",27.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",28.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",28.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",28.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",29.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",31.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",28.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",28.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",22.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",23.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",1.1,"B","Break" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.6,"B","Break" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",1.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",1.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",1.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.8,"B","Break" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.7,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.6,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.5,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.4,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.4,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",0.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",0.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",0.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",0.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",0.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",0.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",0.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",0.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",0.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",0.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",0.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",0.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",0.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",0.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",0.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",0.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",0.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",0.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",0.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",0.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",0.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",0.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",0.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",0.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",0.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",1.2,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",0.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",0.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.7,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.9,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",1.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",1.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",1.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",1.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",1.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",1.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",628,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",567,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",502,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",589,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",532,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",492,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",486,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",452,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",406,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",378,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",376,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",394,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",576.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",584.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",519.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",568.6,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",479.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",369.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",361.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",346.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",303.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",262.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",258.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",296,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",417.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",375.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",325.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",407,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",366.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",333.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",335.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",305.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",276.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",255.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",258.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",272.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",26.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",26.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",22.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",24.6,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",20.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",15.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",14.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",14.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",12.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",10.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",10.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",11.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",19,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",14.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",17.6,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",15.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",14,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",13.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",12.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",11.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",10.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",10.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",6.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",4.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",3.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",2.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",2.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",2.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",107.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",96.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",88.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",83,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",79.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",76.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",51.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",38.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",35.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",33.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",31,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",30.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",142.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",134,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",113.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",110.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",105.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",84.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",57.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",43.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",41.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",37.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",35.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",35.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",127.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",115.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",108.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",104.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",99.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",95.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",66.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",49.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",45.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",44.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",41.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",40,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",17.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",16,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",13.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",13,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",12.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",9.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",6.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",4.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",4.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",15.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",13.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",12.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",12.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",11.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",11.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",7.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",5.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",4.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",4.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",4.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",3.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",3.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",2.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",177.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",176.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",158.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",142.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",144.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",154.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",163.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",155.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",157.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",166.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",163.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",159.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",155.3,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",235.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",246,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",203.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",189.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",191.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",171.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",180.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",175.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",185.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",186.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",186.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",188.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",163.6,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",212,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",212.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",192.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",177.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",180,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",193.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",209,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",200.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",205.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",222.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",224.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",216,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",217.6,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",21.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",22.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",18.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",17,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",17.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",15.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",15.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",15.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",16.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",16.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",16.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",16.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",14.1,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",19.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",19.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",17.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",15.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",16.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",17.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",18.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",17.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",18,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",19.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",19.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",18.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",18.7,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.7,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1298.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1195.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1134.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1146.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1037.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",994,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",854.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",835.9,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",889.5,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",892.8,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",890.1,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1299,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1160.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1027.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",896.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",782.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",765.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",659.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",630,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",663.2,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",712.1,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",683.9,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1043.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",976.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",922.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",919,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",859.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",819.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",708.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",677,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",722.6,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",721.1,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",709.9,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",37.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",33.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",29,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",25.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",21.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",21,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",17.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",16.8,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",17.4,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",18.6,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",17.6,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",30,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",27.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",26,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",25.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",23.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",22.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",19.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",18,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",19,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",18.9,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",18.3,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",4.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",2.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.6,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.6,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.4,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.2,"E; D","Estimated value; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1324,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1357.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1465.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1250.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1081.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",915.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",955.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",823.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",775.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",808.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",739.4,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",747.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",69.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",76.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",74.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",63.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",52.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",37.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",39.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",35.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",35.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",35.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",31.9,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",34.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",96.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",101.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",110.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",97.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",85.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",70.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",76,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",66.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",62.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",65.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",59.3,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",58.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",6.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",7.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",7.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",6.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",3.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",3.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",3.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",3,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",3.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",9.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",9.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",10.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",9.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",8.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",6.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",7.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",6.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",5.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",6.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",5.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.8,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",33.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",29.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",30.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",32,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",33,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",35.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",35.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",34.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",31.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",29.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",27.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",26.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",44,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",40.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",39.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",42.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",43.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",39.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",39.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",38.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",37.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",32.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",31.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",31.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",36.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",32.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",33.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",35.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",36.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",39,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",40.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",39.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",37.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",34.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",33,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",31.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",8.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",7.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",7.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",7.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",7.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",7.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",6.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",5.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",6.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",6.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",6.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",7.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",7.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",7.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",6.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",6.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",5.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",912,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",796.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",805.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",778.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",795.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",796.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",772.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",695.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",687,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",670.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",620,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",595.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1209.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1109,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1034.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1034.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1056.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",883.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",855,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",785.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",811.3,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",750.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",708.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",704.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1132.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1010.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",1023.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1005.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1034.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1023.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1026.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",934.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",934.1,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",921,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",855.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",809.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",14.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",13.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",12.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",12.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",13.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",10.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",9.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",9.8,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",8.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",8.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",13.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",12.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",11.3,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",10.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",9.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",3.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.6,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",321.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",264.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",222.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",180,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",161.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",155.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",166.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",152.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",150.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",146.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",144.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",154.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",118.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",425.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",368.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",286.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",239,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",214.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",172,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",184.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",172.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",177.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",164.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",164.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",182.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",124.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",444.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",371.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",325.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",285.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",264.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",254.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",283.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",265.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",266.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",267.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",264.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",283.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",223.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",38.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",33.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",25.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",21.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",19.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",15.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",17.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",16,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",16.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",15.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",15.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",17.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",11.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",40,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",33.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",29.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",26,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",24.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",23.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",26.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",24.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",24.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",24.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",24.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",26.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",21.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",18687.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",18507.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",12740.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",9057.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",8814.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",8905.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",8548.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",8825.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",9239.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",11030.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",13882.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",13825.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",14075.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",89.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",92.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",56.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",40.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",37.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",31.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",30.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",32.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",34.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",38,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",45.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",45.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",37.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",147.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",148.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",101.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",72.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",68.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",67.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",64.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",64.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",66.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",78.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",95.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",89.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",87.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",9.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",5.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",3.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",3.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",4.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",4.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",14.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",14.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",10.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",7.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",6.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",6.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",6.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",6.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",6.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",9.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",9.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",3.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",853.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",808.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",581,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",621,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",569.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",561.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",596.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",626.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",666.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",700.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",778.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",838.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",4.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",4.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",5.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",6.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",5.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",5.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",6.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",6.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",4.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",4.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",4.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",4.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",4.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",5.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",22,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",21.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",14.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",15.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",14.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",12.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",14.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",17.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",17.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",15.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",15.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",17.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",20.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",18.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",13.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",14,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",12.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",11.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",12.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",13.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",13.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",13.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",14.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",15,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",135,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",107.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",108.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",95,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",66.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",55.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",52.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",51.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",52,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",53,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",54.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",56.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",178.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",150,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",139.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",126.2,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",88.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",61.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",58,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",58.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",61.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",59.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",61.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",66.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",158.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",129.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",131.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",117.2,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",81,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",68.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",66,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",65.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",65.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",65.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",68.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",70.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",39.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",32.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",30.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",27.3,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",18.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",13.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",12.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",12.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",12.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",12,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",12.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",13.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",34.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",28.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",28.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",25.3,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",13.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",13.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",13.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",13.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",6.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",5.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",5.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.8,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",987.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",979.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",997.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1037,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",981.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",907.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",889.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",843.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",791.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",753.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",753,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",720,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1374.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1259,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1324.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1377.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1089.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1004.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1005.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",995.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",886,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",860.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",890.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",758.2,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1301.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1310.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1352.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1402,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1328.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1294.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1289.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1237.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1205,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1163.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1162.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1166.2,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",23.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",21.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",22,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",22.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",17.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",16.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",16.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",16.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",14.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",14.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",15.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",12.8,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",21.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",23.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",21.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",21.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",21.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",20.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",20.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",19.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",19.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",19.8,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",3.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",3.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",3.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",2.9,"E","Estimated value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",727243,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",785646.1,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",750318.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",779352.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",824285.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",872847.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",900276.8,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",961820.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1039828.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1070467.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1093712,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1225994.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",628.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",708.9,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",665.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",711.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",782.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",771.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",775.6,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",850.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",945.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",918.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",926.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1071.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",864.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",919.3,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",877.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",896.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",945.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1017.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1048.3,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1102.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1216.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1249.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1305.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1435.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",12.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",14.2,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",13.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",14.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",15.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",15.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",15.1,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",16.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",18.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",17.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",17.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",20.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",17.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",18.4,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",17.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",17.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",18.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",20,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",20.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",21.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",23.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",24.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",27.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",3.6,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",3.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",10.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",8.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",8.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",8.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",8.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",7.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",7.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",6.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",6.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",6.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",5.8,"D; P","Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",14,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",12,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",11.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",11.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",11.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",8.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",7.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",8.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",7.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",7.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",7.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",6.1,"D; P","Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",11.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",9.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",10,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",9.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",8.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",8.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",8.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",8.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",8.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",7.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",7.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",6.9,"D; P","Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",29.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",25,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",22.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",23.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",21.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",15.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",15.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",14.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",15,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",13.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",13,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",12.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",10.4,"D; P","Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",19.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",19.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",19.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",18.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",15.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",16.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",15.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",15,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",14.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",13.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",12.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",11.8,"D; P","Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",4.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",4.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",4.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",3.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",3.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",3.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",3.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",2.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",2.2,"D; P","Difference in methodology; Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",202.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",185.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",125.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",118.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",117.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",268,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",257.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",161.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",157.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",155.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",236.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",221.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",152.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",148.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",144.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",16.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",15.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",9.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",9.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",9.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",14.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",13.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",9.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",8.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",8.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",3.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",12.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",11.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",7.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",6.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",6.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",5.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",5.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",4.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",5.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",5.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",9.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",6.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",5.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",5.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",4.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",3.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",2.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",8.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",5.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",4.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",4.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",4.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",3.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",3.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",2.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",1.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",1.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",1.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",1.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",459,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",447,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",414,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",387,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",373,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",320,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",329,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",330,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",329,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",327,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",368,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",383,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",405,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",75.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",79.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",71.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",65.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",59.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",39.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",39.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",39.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",40.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",37.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",39.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",44.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",42.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",50.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",49.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",45.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",42.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",40.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",32.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",32.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",33.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",34.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",34,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",37.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",40.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",37.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",15.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",16.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",14.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",13,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",11.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",7.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",7.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",7.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",7.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",6.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",7.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",8.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",7.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",10.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",8.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",7.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",6.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",6.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",6.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",6.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",6.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",6.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",186.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",124.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",66.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",62.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",62.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",62.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",64.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",61.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",63.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",70,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",70.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",75.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",78.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",247.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",173.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",86,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",83.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",83.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",69.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",71.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",69.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",75,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",78.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",80.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",88.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",82.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",299.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",199.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",110.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",107.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",108.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",107.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",113.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",107,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",111.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",125.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",126.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",132.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",142.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",23.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",16.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",8.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",7.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",6.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",6.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",6.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",7.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",7.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",7.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",8.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",28.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",18.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",10.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",10.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",10.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",11,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",12.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",12.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",12.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",13.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",5.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",9.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",8.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",7.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",8.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",8.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",9.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",10.4,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",10,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",10.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",11.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",11.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",12.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",12.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",12,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",9.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",11.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",11.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",10.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",11.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",11.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",12.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",12.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",13.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",14.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",19.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",17,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",15.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",17.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",18.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",18.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",20.7,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",19.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",20.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",21.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",22.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",22.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",2.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",2.1,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",2.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",2.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",2.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",3.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",3.8,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",4.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.7,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",655.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",562.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",449.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",419.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",420.8,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",414.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",422.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",423.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",449.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",463.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",472,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",505.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",526.7,"P","Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",868.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",783.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",577.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",556.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",559.1,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",459.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",468,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",478.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",530.9,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",518.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",539.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",597.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",554.6,"P","Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",901.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",788.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",646.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",621.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",635.4,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",623.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",657.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",671.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",711.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",755.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",759.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",807,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",883.4,"P","Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",18.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",16.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",12.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",11.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",12,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",9.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",10.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",10.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",11.3,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",11,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",11.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",12.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",11.7,"P","Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",19.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",16.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",13.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",13.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",13.7,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",13.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",14.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",14.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",15.2,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",16,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",16,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",17,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",18.6,"P","Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",3.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",3.7,"B; D","Break; Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",3.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.4,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.3,"P","Provisional value" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",727.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",560.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",536.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",500.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",474.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",493.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",493.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",482.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",492.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",528.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",523.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",500.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",534.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",101,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",86.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",79.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",76.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",69.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",58.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",57.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",56.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",56.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",55.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",56.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",58.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",52.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",80.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",63.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",62,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",58.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",54.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",55.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",56,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",54.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",55.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",60.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",60.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",57.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",61.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",10.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",9.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",8.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",7.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",5.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",5.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",5.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",6.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",6.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",6.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",5.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",5.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",5.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",5.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",5.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",5.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",633.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",429.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",424.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",416,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",423.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",517.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",595.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",671.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",739.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",824.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",854.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1162.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",421.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",256.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",236.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",218.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",193.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",190.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",197.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",184,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",153.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",145.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",121.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",131.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",688.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",444.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",416.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",388.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",383,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",445.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",479.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",485.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",453,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",442.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",394.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",414.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",5.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",2.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",2.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",2.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",9.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",5.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",5.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",5.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",2.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",2.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",2.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",2.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",16183.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",21124.4,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",22320.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",24042.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",26581.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",30504,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",27671.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",31943,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",28521.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",32593.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",31750.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",44395.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",45021.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",31.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",43.7,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",45.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",48.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",46.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",46.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",40.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",49.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",44.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",46.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",40.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",58.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",51.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",45,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",60.7,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",64.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",68.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",72.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",78,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",69.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",80.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",72,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",81.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",75.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",102,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",102.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",2.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",2.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",2.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",2.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",3.5,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",3.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",4.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",3.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",4.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",3.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",4.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",5.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",5.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",1.8,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",1.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",3.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",3.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",4.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",4.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",4.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",4.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",4.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",4.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",4.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",4.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",4.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",5.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",5.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",7.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",6.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",6.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",6.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",6.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",7.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",8.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",8.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",8.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",8.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",3.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",3.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",3.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",3.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",5.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",5.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",5.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",5.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",5.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",6.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",19.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",17.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",13.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",11.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",10.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",10.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",10.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",9.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",9.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",9.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",9.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",9.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",10.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",26.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",24.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",17.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",15.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",14.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",11.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",11.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",10.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",11.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",11.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",10.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",11.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",10.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",31.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",28.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",22.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",19.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",18.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",18,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",18.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",16.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",17.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",18,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",17.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",17.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",18.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",12.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",12.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",8.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",7.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",5.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",5.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",5.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",5.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",5.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",5.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",5.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",15.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",14,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",10.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",9.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",8.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",8.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",8.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",8.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",8.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",8.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",8.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",8.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",8.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",3.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",2.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",424,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",470,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",519,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",594,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",589,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",617,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",648,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",718,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",747,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",784,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",868,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",977,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",388.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",484.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",537.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",573.4,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",530.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",463.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",481.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",550.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",558.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",545,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",597.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",733.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",282,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",311,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",337,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",410.5,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",405.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",418.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",446.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",485.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",508,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",529.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",597,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",674.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",17.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",21.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",23.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",24.8,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",22.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",19.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",19.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",22.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",22.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",21.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",23.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",28.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",12.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",13.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",14.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",17.7,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",17.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",18.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",19.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",20.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",20.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",23.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",26.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",4.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",5.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",5.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",96.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",104.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",110.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",115.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",123.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",134,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",149.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",165.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",179.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",195.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",214.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",228.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",128.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",144.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",142,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",152.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",164.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",148.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",165.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",187.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",211.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",219.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",245.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",270.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",114.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",125.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",135.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",144.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",155,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",167.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",192.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",213.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",234,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",261.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",287.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",302.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",15.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",17.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",16.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",18,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",19.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",17.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",19,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",21.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",23.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",24.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",27.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",30.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",16.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",17,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",18.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",19.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",22.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",24.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",26.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",29.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",32.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",33.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",4.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",4.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",4.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",4.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",4.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",5.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",5.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",5.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",6.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",6.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",139.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",150.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",155.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",163.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",171.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",178.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",191.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",201.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",210.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",237.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",258.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",287.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",330.6,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",184.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",209.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",199.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",216.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",227.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",198.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",212.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",227.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",249.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",266.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",295,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",339.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",348.2,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",166.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",180.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",188.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",202.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",214.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",223.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",245.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",259.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",275.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",318.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",353.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",389.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",463.1,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",17,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",19,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",18,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",19.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",20.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",17.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",18.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",20,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",21.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",23.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",25.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",29.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",30,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",15.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",16.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",17,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",18.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",19.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",19.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",21.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",22.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",24.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",27.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",30.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",33.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",39.9,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",2.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",2.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",3.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",3.7,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1233.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1369,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1514.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1702.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1947.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",2175.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",2402.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",2673.1,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",3086.4,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",3536.2,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",4299.2,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1234.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1328.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1370.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1331,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1468.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1676.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1854.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",2014.7,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",2301.3,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",2820.2,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",3303.1,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",991.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1118.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1230.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1363.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1613.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1794.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1991.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",2164.9,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",2507.1,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",2856,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",3428.9,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",35.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",37.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",38.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",37.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",40.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",45.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",50,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",53.6,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",60.5,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",73.7,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",85,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",28.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",31.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",38.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",44.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",49.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",53.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",57.6,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",65.9,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",74.7,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",88.2,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",5.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",6.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",6.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",7.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",7.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",8.4,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",9.6,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",10.8,"E; D","Estimated value; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",3639.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3775,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",4194.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",4098.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",4614,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",5120.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",5517.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",5999.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",6345,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",6768.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",7133.6,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",7499.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",190.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",213.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",214.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",209.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",222.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",208.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",225.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",256.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",292,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",295.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",307.3,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",346,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",266.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",282.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",315.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",320.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",363.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",395.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",438.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",482.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",512.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",551.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",572.5,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",588.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",18.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",20.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",20.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",19.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",21.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",19.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",21.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",24.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",27.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",27.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",28.7,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",32.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",25.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",26.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",30,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",30.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",34.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",37.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",41.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",45.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",48.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",51.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",53.5,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",56,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",4.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",4.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",5.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",5.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",8.1,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",8.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",104.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",117.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",127.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",131,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",140,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",148.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",153.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",148,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",154.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",161.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",170.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",180.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",138.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",163,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",163.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",174,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",186,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",164.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",169.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",167.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",182.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",180.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",195.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",213.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",116.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",130.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",140,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",144.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",154.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",163.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",174.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",171.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",181.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",192.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",207.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",218.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",25.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",30.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",30.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",32,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",34.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",30,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",30.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",30.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",33.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",32.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",35.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",38.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",21.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",24.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",25.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",26.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",28.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",29.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",31.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",31.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",32.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",34.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",37.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",39.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",6.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",6.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",6.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",6.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",6.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1888.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1947.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",2068.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2203,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2229.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",2303.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",2416.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",2502,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",2635.8,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2791.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2972,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",3234.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2504.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2710.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2658,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2925.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2962,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",2555.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",2675.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",2826.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",3112.8,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",3125.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",3394.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",3825.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2346.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2468.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2627.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2843.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2899.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2960.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",3211.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",3359.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",3583.9,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",3833.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",4099.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",4392.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",30.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",33.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",33,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",36.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",36.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",31.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",32.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",34.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",37.5,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",37.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",40.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",46,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",28.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",30.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",32.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",35.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",35.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",36.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",39,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",40.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",43.2,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",46.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",49.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",52.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",6.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",6.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",6.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",6.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",6.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",6.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",6,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",6.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",303.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",277.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",281.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",286.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",306.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",283.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",398.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",408.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",418,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",442.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",426.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",513.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",472.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",401.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",386.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",361.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",380.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",406.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",314.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",440.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",461.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",493.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",495.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",487.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",607.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",497.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",419.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",388.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",410.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",453.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",500.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",465.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",676.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",710.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",740.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",805.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",784.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",941.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",893.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",36.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",34.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",32.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",34.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",37.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",29.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",40.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",42.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",46,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",46.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",45.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",57.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",47.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",37.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",35,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",37.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",41.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",46,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",43.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",62.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",66.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",69,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",75.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",73.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",89.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",85.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",30573.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",33416.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",34389.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",35559.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",38486.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",40546,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",45267.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",50037.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",55484.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",61900.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",69245.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",71161.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",78318.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",147,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",166.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",152.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",159,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",165.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",145.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",160.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",182.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",205.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",213,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",224.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",234.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",210.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",241.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",268.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",273.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",284.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",297.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",305.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",342.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",367.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",398.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",439.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",476.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",459.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",485.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",14.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",16.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",15.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",16.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",16.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",14.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",16.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",18.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",21,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",21.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",23.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",24.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",21.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",24.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",27,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",27.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",28.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",30.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",31.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",34.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",37.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",40.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",45,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",48.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",47.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",50.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",6.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",7.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",8.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",8.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",8.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",9.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",10.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",11.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",11.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",12.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",12.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",13.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",612.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",645.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",673.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",738,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",726.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",731.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",838.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",845.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1057.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1327.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1834.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",2435.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",5.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",5.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",6.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",7.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",9.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",10.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",13.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",19.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",4.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",4.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",5.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",7.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",9.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",12.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",16.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",15.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",17.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",16.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",18.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",19,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",16.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",20.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",23.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",27.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",30,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",37,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",51.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",14.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",15,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",15.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",16.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",15.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",17.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",17.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",21.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",26.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",34.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",43.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",2.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",3.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",3.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",3.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",3.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",4.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",5.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",68,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",73.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",81.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",82,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",83.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",89.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",94,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",97.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",104.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",114.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",124.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",134.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",90.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",102.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",104.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",108.9,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",111.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",99.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",104,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",110.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",123.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",128.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",142,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",159.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",80,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",88.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",98.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",101,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",102.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",110.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",118.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",123.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",132.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",142,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",156.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",169.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",19.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",22.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",23.5,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",23.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",21.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",21.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",23,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",25.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",26,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",28.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",31.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",19.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",21.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",21.9,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",21.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",23.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",24.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",25.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",27.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",28.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",31.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",33.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",3.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.2,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",4.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",4.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",4.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",4.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",4.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",5.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",5.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",742.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",779.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",812,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",809.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",869.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",898.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",904.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",945.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1010,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1095,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1178.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1346.6,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1033.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1001.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1078.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1075.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",965.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",994.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1021.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1116.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1130.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1250.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1393.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1418,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",978.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1042.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1101.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1094.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1177.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1282.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1310.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1387.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1537.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1690.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1819.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",2180.9,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",17.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",16.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",17.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",17.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",15.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",16.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",16.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",18.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",18.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",21,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",23.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",24,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",16.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",17.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",18.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",18,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",19.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",21.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",21.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",23,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",25.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",28.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",30.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",36.9,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",4.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",4.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",4.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",3.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",4.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",4.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",4.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",5.4,"E","Estimated value" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",554852,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",585107.5,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",573474.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",634317.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",690951.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",772617.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",845488.9,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",954874.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1087093.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1193608.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1310982.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1419692.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",479.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",528,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",508.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",579.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",656.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",683.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",728.4,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",844.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",988.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1024.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1110.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1241,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",659.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",684.7,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",670.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",729.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",792.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",901,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",984.5,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1094.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1271.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1393.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1565,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1662.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",9.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",10.6,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",10.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",11.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",12.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",13.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",14.2,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",16.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",19.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",19.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",21.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",24,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",13.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",13.7,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",13.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",14.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",15.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",17.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",19.2,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",21.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",24.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",26.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",30.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",32.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",2.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.7,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",2.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",2.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",3.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",3.3,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",3.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",4.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",9.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",10.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",11,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",12.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",15.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",15.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",17.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",18.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",19.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",21,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",22.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",22.6,"D; P","Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",12.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",14.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",14.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",16.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",18.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",16.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",17.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",19.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",21.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",21.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",24,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",26.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",23.8,"D; P","Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",9.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",11.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",12.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",13.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",15.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",17.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",18.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",20.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",21.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",23.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",24.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",26,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",27.1,"D; P","Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",25.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",29.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",28.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",32,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",36,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",32.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",33.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",36,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",39.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",39.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",42.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",46,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",40.5,"D; P","Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",20.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",23.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",24.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",26.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",30.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",33.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",35.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",37.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",39,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",41.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",43.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",45.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",46.3,"D; P","Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",4.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",5.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",6.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",7.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",7.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",8.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",8.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",9.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",9.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",10,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",9.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",8.8,"D; P","Difference in methodology; Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",242.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",252,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",260.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",269.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",268.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",321.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",350.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",334.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",358.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",356.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",283.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",301.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",315.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",338,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",331.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",19.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",21,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",19.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",21.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",21.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",17.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",18.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",18.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",20.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",19.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",4.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",4.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",5.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",6.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",6.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",29.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",32.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",35.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",39.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",42.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",46.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",50,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",53.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",57.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",60.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",75.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",86.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",123,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",21.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",25.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",28.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",32.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",35.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",32.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",34.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",37.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",39.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",40,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",48.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",61,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",78,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",19.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",21.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",23.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",27,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",29.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",31.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",34.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",37.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",39.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",42.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",53.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",59.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",85.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",5.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",7.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",7.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",7.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",7.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",8.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",9.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",11.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",15.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",5.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",6.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",6.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",7.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",7.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",8.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",10.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",11.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",16.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",4.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",4.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",4.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",4.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",4.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",4.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",4.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",4.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",517,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",556,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",596,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",601,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",683,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",786,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",913,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1001,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1099,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1218,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1405,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1907,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",2663,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",85.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",99.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",102.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",102.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",108.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",97.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",108.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",121,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",135.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",138.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",149.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",222,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",277,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",56.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",61.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",66,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",66.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",73.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",79.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",90.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",102.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",114.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",126.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",142.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",200.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",248,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",17.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",20,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",20.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",20.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",21.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",18.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",20.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",22.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",25.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",25.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",27.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",41,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",51.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",11.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",12.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",13.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",13.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",14.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",15.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",17.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",19.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",21.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",23.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",26.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",37.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",45.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",3.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",3.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",3.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",3.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",3.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",3.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",4.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",5.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",7.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",208.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",222.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",224.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",228.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",238.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",265,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",279.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",291.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",322,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",359.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",395.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",440.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",515.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",276.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",309.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",288.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",303.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",317.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",294,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",309.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",329.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",380.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",402.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",452.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",521,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",543.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",334.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",356.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",370.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",391.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",412.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",453,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",488.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",506.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",563.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",644,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",710.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",775.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",937.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",26.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",29.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",27.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",29,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",30.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",28.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",29.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",32,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",37,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",39.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",43.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",50.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",52.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",31.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",33.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",35.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",37.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",39.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",43.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",47.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",49.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",54.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",62.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",69,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",74.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",90.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",6.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",7.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",8.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",9.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",10,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",10.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",11,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",11.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",12.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",12.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",14.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",15.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",16.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",39.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",43,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",39.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",45.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",52.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",62.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",67.6,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",67.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",69.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",74.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",80.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",84.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",52.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",59.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",51,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",60.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",69.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",69.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",74.8,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",76,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",82.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",83.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",92.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",99.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",78.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",84.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",78.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",92.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",107.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",127.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",134.4,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",130.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",132.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",144.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",155.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",158.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",9.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",11.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",9.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",11.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",12.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",12.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",13.8,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",14,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",15.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",15.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",16.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",18.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",14.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",15.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",14.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",17.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",19.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",23.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",24.7,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",23.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",24.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",26.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",28.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",29,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",3.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",3.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",3.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",3.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",4.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",4.3,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",4.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",4.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",4.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",4.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",802.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",890.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",941.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",1024.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",1167.2,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1269.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",1383.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",1467.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1594.8,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1711.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1834.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",2012.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",2175.3,"P","Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1063.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1239.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1210.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1361,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1550.7,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",1408.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",1531.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",1657.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1883.4,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1915.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2094.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2380.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",2290.7,"P","Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1103.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1247.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1355.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1518.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1762.2,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1910,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",2153.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",2325.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2524.2,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",2792.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2951.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",3215.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",3648.6,"P","Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",22.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",26.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",25.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",29.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",33.4,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",30.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",33,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",35.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",40.2,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",40.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",44.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",50.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",48.3,"P","Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",23.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",26.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",29,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",32.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",37.9,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",41.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",46.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",49.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",53.9,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",59.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",62.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",67.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",76.9,"P","Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",6.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",7.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",8.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",9.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",10.3,"B; D","Break; Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",11.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",11.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",12.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",8.4,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",8.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",8.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",9.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",9.5,"P","Provisional value" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1293.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1322.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1384,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1366.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1410.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1535.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1687.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1855,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",2100,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",2372.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",2640.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2951.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",3474.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",179.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",203.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",204.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",209.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",205.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",182.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",197.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",217,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",241.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",250.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",286.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",344.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",343.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",143.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",149.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",159.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",159,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",161.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",173.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",191.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",209.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",236.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",272.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",304.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",338.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",400.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",19.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",21.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",21.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",21.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",21.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",18.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",19.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",21.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",23.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",24.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",27.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",33,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",32.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",15.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",15.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",16.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",16.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",16.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",17.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",20.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",23.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",26.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",29.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",32.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",38.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",3.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",3.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",3.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",3.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",4.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",4.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",4.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",5.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",699.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",658,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",658.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",798,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",913.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1051.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1234.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1534.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1933.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",2630.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",3713.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",4640.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",465.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",392.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",366.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",419.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",417.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",386.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",408.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",420.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",400.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",463.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",529.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",524.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",759.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",681,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",645.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",745.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",827.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",904.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",994.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1108.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1184.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1411.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1715.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1652.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",6.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",5.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",5.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",5.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",5.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",6.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",6.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",9.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",8.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",9.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",10.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",11.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",12.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",13.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",14.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",17.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",20.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",19.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",4.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",5.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",5.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",7.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",7.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",21597.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",34618.4,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",41736.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",50330.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",66175.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",87238.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",96716.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",111563.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",105573.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",138703.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",180033.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",219396.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",249712.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",42.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",71.6,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",85.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",101.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",116,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",133.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",142.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",171.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",164.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",197.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",227.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",289.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",285.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",60,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",99.5,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",120.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",143.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",180.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",223,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",243.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",280.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",266.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",345.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",430.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",504.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",570.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",2.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",4.1,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",5.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",7.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",7.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",9.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",8.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",10.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",11.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",14.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",14.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",5.8,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",6.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",8.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",12.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",13.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",15.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",14.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",18.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",22.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",25.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",28.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.9,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",3.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",3.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",4.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",5.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",4.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",5.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",6.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",7.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",8.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",11.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",13.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",14.1,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",15.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",16.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",17.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",18,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",19.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",20.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",22.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",24.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",29.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",15.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",16.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",17.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",18.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",20.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",18.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",19.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",20.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",23.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",23.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",25.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",28.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",30.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",22.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",23.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",25.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",27.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",29.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",30.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",32.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",33.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",36.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",38.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",42.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",44.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",51.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",11.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",12.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",13,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",14.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",15.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",13.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",14.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",15.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",17.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",17.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",19.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",21.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",23.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",16.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",17.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",19.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",20.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",22.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",23.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",24.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",25.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",27.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",29.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",32.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",33.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",38.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",6.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",6.2,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",6.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",5.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",6.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",25.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",26.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",28.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",28,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",28.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",28.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",30.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",31.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",34,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",36.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",39.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",43.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",52.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",34,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",37.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",36.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",37.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",37.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",32,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",33.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",35.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",40.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",41,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",45,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",51.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",55.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",40.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",43.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",46.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",47.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",47.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",48.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",52.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",55.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",59.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",66.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",72,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",77.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",95.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",16.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",18.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",17.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",18,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",18.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",15.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",16.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",17.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",19.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",19.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",21.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",24.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",26.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",19.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",21,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",22.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",23,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",23.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",23.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",25.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",26.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",28.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",31.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",34.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",36.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",45.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",5.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",6.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",6.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",6.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",6.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",6.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",6.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",7.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",7.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",406,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",417,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",405,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",481,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",545,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",617,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",667,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",748,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",816,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",880,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",947,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1022,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",372.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",430.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",419.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",464.4,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",491.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",463.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",495.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",573.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",609.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",611.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",651.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",767.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",270,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",276,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",263,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",332.4,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",375.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",418.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",460,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",506.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",554.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",594.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",651.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",706,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",16.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",19.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",18.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",20.1,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",20.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",19.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",20.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",23.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",24.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",24.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",25.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",29.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",12.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",12.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",11.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",14.4,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",16,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",19,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",20.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",22.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",23.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",25.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",27.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",4.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",3.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",4.1,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",5.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",5.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",5.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",5.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",5.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",151.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",145.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",164.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",191.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",220.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",246.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",280.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",309.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",335,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",355.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",381.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",406.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",200.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",203,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",211.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",254.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",292.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",273.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",310.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",350,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",395.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",398.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",435.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",481.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",179.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",175.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",202.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",240.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",275.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",308.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",360.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",399.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",437.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",475.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",511.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",538,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",24,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",24.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",25.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",30,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",34.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",31.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",35.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",39.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",44.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",44.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",48.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",53.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",21.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",20.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",24,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",28.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",32.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",35.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",41.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",45.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",49.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",53.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",57.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",60.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",6.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",5.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",6.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",7.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",7.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",8.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",9.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",9.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",10.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",10.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",11,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",11,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",448.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",444.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",450.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",491.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",501.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",522.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",559.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",595,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",611.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",683,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",745.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",816.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",891.1,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",595.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",618.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",578.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",652.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",666.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",580,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",619.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",672.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",722.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",764.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",851.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",966,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",938.4,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",536.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",533.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",548,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",609.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",626.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",653.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",716.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",767.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",797.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",914.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",1020.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",1108.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1248.2,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",54.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",56,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",52.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",58.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",59.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",51.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",54.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",59.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",63.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",66.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",73.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",83.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",80.8,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",49.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",48.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",49.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",54.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",55.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",58,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",63.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",67.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",69.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",79.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",88.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",95.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",107.4,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",7.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",7.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",7.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",8.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",8.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",8.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",9.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",9.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",9.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",9.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",10.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",9.9,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",742.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",774.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",870.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",954.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1064.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1161.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1246.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1345.5,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1476.1,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1572.2,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1611.6,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",743.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",751.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",787.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",746.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",802.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",895.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",961.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1014.1,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1100.6,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1253.9,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1238.2,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",596.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",632.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",707.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",765,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",881.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",958.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1032.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1089.7,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1199.1,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1269.8,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1285.4,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",21.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",21.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",22.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",20.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",22.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",24.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",25.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",27,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",28.9,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",32.8,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",31.8,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",17.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",18,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",20,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",21.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",24.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",26.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",27.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",29,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",31.5,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",33.2,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",33.1,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",3.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",3.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",3.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",3.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",4.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",4.2,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",4.3,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",4.3,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",4,"E; D","Estimated value; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",5259.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",5429,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",6184.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",6193.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",6890.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",7422.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",7961.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",8615.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",9450.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",9824.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",9517.8,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",10694.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",275.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",306.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",315.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",316.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",332,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",301.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",325.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",368.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",434.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",428.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",410.1,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",493.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",384.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",406.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",465.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",484.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",542.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",573.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",633.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",693.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",763.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",800.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",763.8,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",839.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",26.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",29.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",30.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",30.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",31.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",28.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",30.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",34.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",40.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",40.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",38.3,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",47,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",36.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",38.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",44.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",46.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",51.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",54.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",59.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",65.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",71.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",75,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",71.4,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",79.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",6.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",6.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",7.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",8.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",8.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",9.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",9.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",9.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",9.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",10.8,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",11.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1243.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1206,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1344.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1405.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1593.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",1721.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",1851.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1993.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",2168.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2239,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2370.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",2521,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",221.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",224.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",232,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",250.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",284,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",255.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",275.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",302,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",343.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",335.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",362.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",401,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",163.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",161.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",177.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",191.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",217.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",235.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",261.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",290.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",320.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",337.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",361.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",382.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",39.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",40.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",41.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",44.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",50.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",45,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",48,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",52.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",59.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",57.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",62.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",68.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",29.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",29,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",31.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",34,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",38.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",41.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",45.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",50.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",55.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",58,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",62,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",65.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",5.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",5.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",6.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",6.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",7.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",7.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",8.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",9.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",9.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",9.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",9.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",131.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",138.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",152.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",156.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",162.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",177.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",195.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",217.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",237.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",268.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",284.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",296.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",174.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",192.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",195.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",207.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",215.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",196.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",216.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",245.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",280.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",300.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",325.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",350.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",145.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",154.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",167.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",172.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",178.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",195.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",222.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",251.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",278.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",320,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",345.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",358.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",32.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",35.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",36.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",38.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",39.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",35.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",39.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",44.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",50.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",54.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",58.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",63.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",27.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",28.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",31,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",31.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",32.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",35.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",40.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",45.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",50.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",58,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",62.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",64.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",7.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",7.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",8.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",8.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",9.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",9.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",10.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",10.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",10.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",2128.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",2963.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",2530.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",45.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",38.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FRA","France","2011","2011",7.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1650.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1592.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1758.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2013.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2317.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",2564.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",2837.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",3168.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",3675,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",4064.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",4566.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",5290.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2188.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2217,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2258.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2674.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",3079.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",2845,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",3140.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",3579.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",4340,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",4550.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",5216,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",6257.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2050.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2019.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2233.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2598.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",3014.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",3295.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",3770,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",4254.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",4997,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",5581.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",6298.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",7185.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",26.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",27.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",28.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",33.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",38,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",34.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",38.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",43.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",52.3,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",54.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",62.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",75.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",25.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",25.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",27.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",32.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",37.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",40.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",45.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",51.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",60.3,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",67.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",75.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",86.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",5.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",5.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",5.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",6.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",6.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",7.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",7.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",8.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",8.3,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",8.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",9.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",9.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",643.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",579.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",509.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",463.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",492,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",449.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",1701.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",1024.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",1090.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",809.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",765,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",819.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",810.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",853.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",806.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",655.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",615.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",653.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",498.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",1883.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",1157.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",1288.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",906.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",873.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",969,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",853.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",891.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",812.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",744.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",734.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",805.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",737.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",2891.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1781.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1931,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1475.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1406.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1501.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1534.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",76.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",72.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",59.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",56.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",60,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",46.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",174.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",107.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",120,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",84.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",81.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",91.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",81.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",80.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",73.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",67.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",67,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",73.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",68.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",268.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",165.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",179.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",137.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",131.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",142.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",146.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",39342.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",40274.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",39070,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",38973.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",43658.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",48375.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",53187.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",50338.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",46539.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",53924.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",61036.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",67066,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",72200.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",189.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",200.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",173.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",174.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",187.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",173.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",188.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",183.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",172.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",185.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",198.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",221.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",193.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",311.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",324.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",311,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",311.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",337.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",364.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",402.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",370,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",334.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",382.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",419.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",433.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",447.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",18.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",20.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",17.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",17.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",19,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",17.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",19.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",18.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",17.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",19,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",20.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",22.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",20,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",31.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",32.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",31.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",31.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",34.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",37.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",41,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",37.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",34.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",39.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",43.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",44.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",46.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",7.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",7.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",8.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",9.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",9.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",10.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",10.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",10.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",9.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",10.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",10.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",11.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",12.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1316,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1283.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1325.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1557,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1526.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1575.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1922.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1768.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1992.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",2454,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",2952.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",3356.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",10.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",11.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",10.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",12.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",13.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",11.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",15.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",16.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",18.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",20,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",21.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",26.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",9.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",9.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",9.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",11.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",11,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",11.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",13.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",12.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",14.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",17.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",20.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",22.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",33.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",34.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",33,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",39.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",39.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",36.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",47.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",48.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",52.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",55.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",59.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",70.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",31.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",29.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",30.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",35.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",33.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",33.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",40.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",37.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",40.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",48.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",54.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",60.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",5.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",4.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",5.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",6.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",6.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",7.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",6.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",6.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",7.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",7.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",7.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",93.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",89.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",91.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",89.7,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",90.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",95.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",104.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",113.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",123.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",132.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",141.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",148.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",124.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",124.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",117.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",119.2,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",120.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",105.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",116.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",127.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",146.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",147.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",161.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",175.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",110.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",107.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",111.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",110.6,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",110.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",117.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",132.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",142.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",156.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",164,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",177.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",186.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",27.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",27.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",25.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",25.8,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",25.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",22.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",24.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",26.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",30,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",30,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",32.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",34.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",24.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",23.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",24.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",23.9,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",23.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",25,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",27.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",29.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",32.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",33.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",35.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",37.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.6,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",4.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",4.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",5.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",5.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",5.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",5.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",5.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",5.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1775.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1764.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1717.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1853.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1981.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",2027,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",2088.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",2082.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",2178.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",2304.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",2349.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",2406.8,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",2471.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",2267.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",2280.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",2462.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",2198.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",2243.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",2359.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",2459.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",2439.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",2632.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",2778.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",2534.4,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",2340.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",2360.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",2329.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",2506.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",2683,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",2893.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",3027,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",3057.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",3317.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",3558.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",3628.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",3898.1,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",41.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",38.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",37.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",40.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",36.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",37,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",39,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",40.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",40.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",44.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",47,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",42.9,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",39.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",39.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",38.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",41.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",44.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",47.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",50,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",50.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",55.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",59.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",61.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",66,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",9.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",9.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",8.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",9.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",8.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",8.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",9.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",9.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",9.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",10,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",9.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",9.7,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",446699,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",463919,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",510891,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",497196,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",448987,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",461825,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",425618,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",420896,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",469262,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",683211,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",641276,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",616820,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",5088.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",5813,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",6402.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",5094.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",4237.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",3815.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",3912.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",3752.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",4249.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",6267.4,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",6005.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",5620,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",3998.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",4317.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",4899.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",4908,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",4356.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",4463.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",4033.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",4004.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",4505.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",6555.1,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",6260.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",6044.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",39.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",45.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",50.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",40,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",33.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",30,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",30.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",29.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",33.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",49.7,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",47.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",44.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",31.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",33.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",38.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",38.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",34.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",35.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",31.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",31.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",35.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",52,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",49.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",48.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",6.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",6.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",7.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",7.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",6.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",6.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",6.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",6.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",6.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",7.2,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",6.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",6.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1647148,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1767579.5,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1782148.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1852464.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1967406.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",2093006.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",2000397.8,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",2107041.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",2300183.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",2470833.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",2608157,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",2786025.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1424.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1595,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1581.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1691.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1868.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1850.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1723.3,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1863,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",2090.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",2120.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",2209.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",2435.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1958.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",2068.3,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",2084.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",2131.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",2256.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",2440.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",2329.3,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",2414.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",2690.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",2885.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",3113.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",3262,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",28.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",31.9,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",31.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",33.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",36.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",36.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",33.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",36.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",40.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",41,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",42.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",47.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",39.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",41.4,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",41.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",42.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",44.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",47.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",45.5,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",47,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",52.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",55.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",60.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",63,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",8.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",8,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",8.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",8.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",8.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",8.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",7.9,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",9.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",9.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",10.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",10.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",11.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",13,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",14.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",15.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",16.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",18.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",19.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",22.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",22.6,"D; P","Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",12.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",12.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",12.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",14.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",15.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",14.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",15.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",17.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",20.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",22.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",26.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",23.8,"D; P","Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",10.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",10.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",11.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",12.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",13.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",14.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",16.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",18.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",21.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",23.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",26.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",27.2,"D; P","Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",26.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",26.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",26.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",28.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",30.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",27.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",30.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",32.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",36.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",37,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",40.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",46.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",40.6,"D; P","Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",21.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",21,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",22.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",24.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",26.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",28.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",32.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",34.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",36.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",39.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",41,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",45.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",46.4,"D; P","Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",4.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",6.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",6.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",7.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",8.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",9.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",9.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",8.8,"D; P","Difference in methodology; Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",3930,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",2231,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",4172,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",2218,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",2176,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",2320,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",1766,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",1640,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",1401,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",1889,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",2109,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",2435.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",2290.7,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",311,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",179.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",316.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",173.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",163.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",146.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",94.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",86.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",72.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",98.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",98.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",120.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",113.8,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",511.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",290.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",530.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",281.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",270.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",278.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",209.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",184,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",151,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",195.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",210.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",234.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",216.6,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",2.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",1.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",2.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",1.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",1.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",1.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",0.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",0.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",0.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",0.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",0.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",0.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",0.9,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",4.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",2.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",4.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",2.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",2.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",2.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",1.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",1.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",1.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",1.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",1.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",1.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",1.7,"E","Estimated value" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",1.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",0.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",245.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",242.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",244.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",258.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",267.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",325.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",337.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",313.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",342.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",355.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",287.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",290.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",296.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",323.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",330.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",19.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",20.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",18.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",20.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",21.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",17.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",17.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",17.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",19.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",19.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",4.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",4.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",5.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",6.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",26.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",26.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",42.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",48.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",87.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",99,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",84.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",68.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",80,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",81,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",99.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",113.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",126,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",18.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",34.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",39.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",72.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",69.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",59,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",48.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",55.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",53.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",64.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",80.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",79.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",17.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",17.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",28.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",33.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",60.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",67,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",58.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",47.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",54.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",57.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",70.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",77.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",87.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",4.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",7.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",8.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",16,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",15,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",12.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",10.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",11.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",10.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",12.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",15.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",15.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",6.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",7.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",13.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",14.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",12.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",9.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",11.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",11.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",13.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",15.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",17,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",5.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",9.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",10,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",7.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",5.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",6.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",5.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",6.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",6.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1188,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1203,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1274,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1498,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1654,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1846,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2127,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2330,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2510,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",2679,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",2762,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",2931,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",3082,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",196.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",214.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",219,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",255,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",262.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",228.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",253.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",281.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",308.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",304.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",293.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",341.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",320.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",129.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",132.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",141,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",165.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",178.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",185.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",211.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",239,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",261.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",278.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",279.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",308.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",287,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",40.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",43.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",43.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",50.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",51.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",44.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",48.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",53.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",58.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",56.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",54.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",63.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",59.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",26.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",26.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",28.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",32.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",34.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",35.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",40.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",45.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",49.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",52.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",52,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",57,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",52.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",6.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",6.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",6.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",8.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",8.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",9.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",9.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",9.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",8.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",120.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",105.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",87.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",91.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",110.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",140.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",175.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",192.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",225.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",258.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",262.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",283.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",303,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",159.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",147.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",112.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",121.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",147.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",155.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",194.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",217,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",266.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",289.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",299.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",335.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",319.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",193.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",169.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",144.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",157.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",191.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",240.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",307.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",333.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",394.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",463.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",470.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",499.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",551,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",15.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",13.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",10.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",11.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",14.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",15.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",18.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",21.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",25.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",28.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",29.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",32.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",30.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",18.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",16.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",13.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",15,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",18.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",23.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",29.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",32.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",38.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",45,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",45.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",48.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",53.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",3.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",3.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",5.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",7.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",8.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",9.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",9.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",9.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",9.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",102.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",97.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",106.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",118.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",134.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",146.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",180.7,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",191.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",213.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",217.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",203.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",176,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",135.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",136,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",137.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",157.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",178.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",162.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",200,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",215.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",252.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",243,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",232.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",208.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",203.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",193,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",211.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",241.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",276.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",298.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",359.1,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",370,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",406.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",419.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",392,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",329.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",25.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",25.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",25.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",29.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",32.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",30,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",36.8,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",39.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",46.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",44.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",42.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",38.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",37.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",35.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",39.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",44.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",51,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",55.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",66.1,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",68,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",74.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",76.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",71.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",60.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",9.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",8.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",9.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",9.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",10.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",10.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",11.5,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",12.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",13.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",12.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",12.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",9.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",612.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",529.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",501.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",526.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",593.7,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",652.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",729,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",806.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1638.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1746.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1847.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",2023.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",2090.9,"P","Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",812.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",737.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",644.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",699.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",788.8,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",724.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",806.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",910.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1935.2,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1954.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2109.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2393,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",2201.8,"P","Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",842.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",741.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",722,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",780.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",896.4,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",982,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1134.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1277.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2593.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",2848.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2973,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",3232.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",3507,"P","Provisional value" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",17.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",15.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",13.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",15,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",17,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",15.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",17.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",19.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",41.4,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",41.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",44.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",50.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",46.4,"P","Provisional value" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",18.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",15.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",15.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",16.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",19.3,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",21.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",24.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",27.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",55.4,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",60.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",62.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",68.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",73.9,"P","Provisional value" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",5.3,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",5.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",6.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",6.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",8.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",8.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",9.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",9.1,"P","Provisional value" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3079.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3169.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",3172.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",3148.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3223,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",3520.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",3887.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",4294.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",4641.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",5018.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",5405,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",5630.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",5980.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",427.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",488.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",468.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",483.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",469.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",417.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",454,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",502.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",534,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",530.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",586.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",656.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",591.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",341.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",358.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",366.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",366.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",369.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",397.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",440.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",485.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",523.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",576.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",623.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",645.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",690.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",45.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",51.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",49.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",50.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",48.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",42.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",45.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",49.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",52.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",51.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",56.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",63,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",56.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",36.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",37.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",38.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",38.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",38.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",40.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",44.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",48.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",51.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",56.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",60.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",62,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",66,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",8.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",8.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",8.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",8.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",9.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",9.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",9.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",9.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",10.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",10.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",10.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",215.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",208,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",222,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",245,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",263,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",285,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",320,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",354,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",387,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",397,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",422,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",453,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",455,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",206.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",234.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",236.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",264.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",287.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",296.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",324.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",359.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",395.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",399.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",449.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",495.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",476.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",147,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",148.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",163.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",186.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",205.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",230.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",266.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",298,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",328.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",345.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",371.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",409.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",426.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",26.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",29.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",29.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",32.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",35.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",35.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",38.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",42.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",46.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",46.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",52,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",56.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",54.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",18.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",18.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",20.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",23.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",25.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",27.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",31.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",35.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",38.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",40.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",43,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",47,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",48.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",3.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",3.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",3.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",4.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",4.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",4.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",5,"B; D","Break; Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",5.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",5.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",5.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",6.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",6.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",716.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",739,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",744.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",824.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",959.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1179,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1410.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1774.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",2309.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",3114.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",3935,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5042,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",476.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",441.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",414.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",433.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",438.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",433.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",467.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",486.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",478.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",549,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",561.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",569.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",778.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",764.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",729.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",770.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",869.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1014.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1136.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1282.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1414.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1671,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1818.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1795.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",6.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",5.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",5.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",5.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",5.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",5.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",6.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",5.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",6.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",6.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",6.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",10.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",9.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",10.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",11.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",13,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",14.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",16,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",17.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",20.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",21.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",21.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",5.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",5.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",5.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",6.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",6.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",6.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",7.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",7.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",7.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",7.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",580,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",649.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",761.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",900.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1029.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1182.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1335,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",916.2,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",1015.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",1252.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",1376.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",1390.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",1522.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",1781.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",826.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",934.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",1090.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",1300.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",1495.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",1727.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",1941.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",14.4,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",15.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",19.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",21.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",21.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",23.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",26.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",13,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",14.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",16.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",20,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",22.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",26.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",29.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",4.2,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",4.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",4.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",5.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",5.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",6.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",6.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",19663.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",55202.5,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",66082.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",75138.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",68583.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",92673.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",99840,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",93218.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",117343.5,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",137320.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",139350.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",199401.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",178790.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",38.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",114.1,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",135.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",151.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",120.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",141.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",147.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",143.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",183,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",195.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",175.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",262.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",204.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",54.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",158.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",190.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",214.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",186.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",236.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",251.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",234.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",296.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",341.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",333,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",458.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",408.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",2.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",6.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",7.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",8.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",6.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",7.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",8.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",7.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",9.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",10.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",13.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",10.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",9.2,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",10.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",12.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",13.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",13.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",12.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",15.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",17.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",17.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",23.3,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",20.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",4.7,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",5.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",5.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",5.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",4.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",5.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",5.4,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",5.2,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",7.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",6.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",10.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",13.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",14.1,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",17.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",21.3,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",25.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",29.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",35.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",37.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",40.4,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",42.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",46,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",13.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",16.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",18.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",23.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",23.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",28.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",33.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",42,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",42.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",46.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",50.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",48.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",20.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",22.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",25.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",27,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",33,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",39.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",48,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",54.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",66,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",70.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",77.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",78.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",80.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",10.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",12.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",14.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",17.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",17.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",21.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",25.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",31.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",31.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",34.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",38,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",36.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",19.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",20.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",25.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",30.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",36.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",41.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",50,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",53.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",58,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",59.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",60.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",6.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",8.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",9.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",10.9,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",11,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",11.3,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",10.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",10.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",25.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",25.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",25.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",28.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",31.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",35,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",40,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",46.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",54.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",60.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",67.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",74.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",79.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",33.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",35,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",32.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",38.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",41.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",38.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",44.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",52.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",64.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",68.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",77.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",88.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",83.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",39.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",40.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",41.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",48.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",52.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",58.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",69.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",81.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",95.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",110.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",123.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",132.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",143.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",16.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",17.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",15.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",18.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",20.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",18.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",21.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",25.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",31,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",32.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",36.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",41.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",39.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",19.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",19.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",20.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",23.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",25.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",28.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",33.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",39.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",46.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",52.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",58.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",62.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",68.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",5.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",6.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",7.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",7.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",8.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",9.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",10.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",11.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",11.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",12.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",11.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",2744,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",2825,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",2538,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",2516,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",2200,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",1992,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",1860,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",1798,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1822,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1862,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1962,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",2061,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",2517.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",2914,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",2627.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",2428.9,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",1983.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1496.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",1382.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1378,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1361.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",1294.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",1350.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",1548.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1824.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1869.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1647.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",1738.6,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",1514.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",1351.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",1282.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",1216.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",1239.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",1258.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",1349.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",1423.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",114.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",130.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",115.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",105,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",84.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",62.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",57.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",56,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",54.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",51.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",52.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",60.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",82.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",83.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",72.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",75.2,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",64.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",56.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",53,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",49.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",49.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",49.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",52.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",55.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",28,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",27.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",24.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",21.3,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",18.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",16.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",12.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",12.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",12.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",12,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",11.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",11.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",498,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",495.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",483.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",437.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",432.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",426.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",427.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",434.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",415.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",394.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",388.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",380.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",660.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",690.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",620.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",581.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",574.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",473.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",473.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",491,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",491.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",441.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",443.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",450.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",591.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",596.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",593.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",549.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",541.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",534.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",550.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",560.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",543.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",526.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",520.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",503.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",78.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",82.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",73.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",68.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",67.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",54.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",54.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",55.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",55.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",49.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",49.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",50.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",70.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",71.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",70.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",64.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",63.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",61.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",63,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",63.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",61.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",59.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",58.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",56.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",20,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",19.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",18.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",16.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",15.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",14.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",14.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",13.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",12.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",11.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",11.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",10.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",893.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",889.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",840.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",782.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",724.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",701.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",686.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",655.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",586.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",596.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",581.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",569.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",595.3,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1184.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",1238.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1079.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1039.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",962.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",778.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",760.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",740.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",692.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",667.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",664,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",674,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",626.9,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1068.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1069.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1021.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",971.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",905,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",877.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",879.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",845.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",765.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",798.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",796.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",773.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",833.9,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",108.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",112.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",97.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",93.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",85.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",69.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",67.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",65.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",60.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",58.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",57.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",58.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",54,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",98.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",96.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",92,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",87,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",80.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",77.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",77.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",74.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",67,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",69.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",69,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",66.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",71.8,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",15.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",14.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",14.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",13.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",12.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",11.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",11,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",10,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",8.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",8.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",7.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",7.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",6.6,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",4627.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",4082.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",3973.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",3888.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",3942.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",3999.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",3386.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",3162.5,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",3318.3,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",3394.2,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",3557.2,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",4630.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",3963.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",3596.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",3040.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",2974,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",3081.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",2613.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",2383.6,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",2474.2,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",2707,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",2733,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",3717.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",3335.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",3229.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",3115.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",3266.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",3298.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",2807,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",2561.3,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",2695.4,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",2741.4,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",2837,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",133.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",113,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",101.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",85.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",82.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",84.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",70.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",63.4,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",65,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",70.8,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",70.3,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",107.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",95.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",91.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",87.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",90.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",90.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",75.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",68.1,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",70.9,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",71.7,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",73,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",19,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",16.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",15.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",14.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",13.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",13.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",11.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",9.9,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",9.7,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",9.2,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",8.9,"E; D","Estimated value; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",12949.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",12647.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",12682.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",11618.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",10632.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",10160.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",10153,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",10372.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",10425.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",10754.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",9837.8,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",9928.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",678.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",714.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",647.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",593.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",512.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",413.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",415.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",443.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",479.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",469,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",423.9,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",458,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",947.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",947.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",953.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",908.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",837,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",785.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",807.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",834.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",842.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",876.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",789.5,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",779.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",64.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",68.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",61.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",56.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",48.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",39.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",39.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",41.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",45.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",43.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",39.6,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",43.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",90.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",90.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",90.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",86.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",79.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",74.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",76.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",78.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",79.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",82.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",73.8,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",74.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",15.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",15.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",15.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",14.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",13.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",12,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",11.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",11.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",10.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",10.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",11.2,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",10.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1722,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1418.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1273.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1128.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1153.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",1152.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",1084.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1079.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",978.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",1192.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",1217.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",1051,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",306.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",264.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",219.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",200.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",205.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",171.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",161.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",163.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",155,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",178.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",186.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",167.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",226.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",190,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",168.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",153.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",157.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",157.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",153.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",157.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",144.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",179.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",185.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",159.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",55.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",47.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",39.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",35.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",36.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",30.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",28.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",28.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",26.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",30.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",31.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",28.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",40.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",34.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",30.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",27.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",27.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",27.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",26.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",27.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",25,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",30.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",31.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",27.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",8.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",6.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",6.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",5.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",5.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",5.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",4.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",4.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",4.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",4.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",4.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",4.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",195,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",178.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",176.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",181.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",190.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",203.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",210.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",197.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",172.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",150.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",138.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",130.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",258.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",248,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",226.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",241.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",253.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",225.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",232.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",223.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",203.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",168.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",158,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",154.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",216.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",198.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",193.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",200.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",210.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",223.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",238.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",228.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",201.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",179.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",168,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",158.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",48.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",46,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",41.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",44.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",46.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",41.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",42.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",40.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",36.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",30.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",28.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",27.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",40.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",36.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",35.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",36.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",38.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",40.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",43.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",41.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",36.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",32.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",30.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",28.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",10.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",9.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",9.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",9.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",9.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",8.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",6.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",5.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",5.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",4.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",3937,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",5480.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",4679.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",84.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",71.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FRA","France","2011","2011",14.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",4869.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",4794.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",4529.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",4455.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",4399.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",4273.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",4366.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",4431.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",4541.9,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",4692.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",4771.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",4907.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",6455.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",6673.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",5819.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",5918,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",5845,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",4741.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",4833.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",5006.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",5363.8,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",5253.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",5449.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",5804.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",6048.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",6078.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",5753.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",5751.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",5721.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",5492.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",5802,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",5949.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",6175.7,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",6443.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",6580.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",6665.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",78.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",83.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",72.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",73.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",72.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",58,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",58.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",60.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",64.7,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",63.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",65.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",69.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",74,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",75.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",71.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",71.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",70.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",67.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",70.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",72,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",74.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",77.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",79.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",80.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",16.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",16.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",14.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",14.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",13.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",12.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",12.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",11.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",10.3,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",10,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",9.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",9.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",1425.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",1314.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",1196.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",1018,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",953.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",885.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",939.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",873.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",853,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",850.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",810.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",829,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",650.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1889.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1829.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",1537.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",1352,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",1267.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",982.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",1039.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",987,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",1007.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",952.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",925.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",980.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",685,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1974.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1843.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",1748.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",1612.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1560.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",1454.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1596.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1519.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1510.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1550.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1489.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1519.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1230.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",169.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",164.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",139.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",123.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",116.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",90.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",96.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",91.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",93.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",88.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",86.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",92.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",65.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",177.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",166,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",158.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",147.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",143.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",134.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",148.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",141.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",140.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",144.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",139.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",143.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",117.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",129978.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",127453,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",105895,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",95396.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",90647.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",90577.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",92167.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",92973.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",93271.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",94477.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",99352.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",96764.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",100396.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",625.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",633.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",470.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",426.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",389.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",324.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",327.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",338.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",345.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",325,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",322.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",319.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",269.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",1028.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",1025.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",843,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",763.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",700.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",683.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",698.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",683.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",670.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",670.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",683.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",625.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",622.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",62.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",63.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",47.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",43.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",39.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",32.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",33.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",34.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",35.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",33.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",33.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",32.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",27.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",102.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",102.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",85,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",77.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",71,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",69.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",71.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",69.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",68.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",68.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",70.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",64.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",64.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",26.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",24.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",23.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",22.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",20.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",19.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",18.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",18.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",18.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",17.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",17.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",17,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",16.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1906.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1946.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1866.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1814,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1783.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1713.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1734.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1827.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1998.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",2169.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",2440.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",2639.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",15.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",16.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",14.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",14.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",15.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",13,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",14.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",17.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",18.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",17.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",18,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",20.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",14.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",14.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",13.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",13.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",12.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",12.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",12.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",13.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",14.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",15.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",16.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",17.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",49,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",52.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",46.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",45.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",46.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",39.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",42.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",49.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",52.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",49.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",49.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",55.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",45.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",45.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",42.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",40.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",39.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",36.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",36.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",38.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",40.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",42.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",45.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",47.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",7.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",7.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",7.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",7.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",6.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",6.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",6.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",6.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",6.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",5.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",398.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",339.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",337.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",288.4,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",233.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",217.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",218.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",211.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",209.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",203.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",207.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",214.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",528.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",473.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",433.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",383,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",310.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",241.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",241.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",238.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",247.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",227.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",237.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",253.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",469,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",408.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",410,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",355.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",285.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",269,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",274.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",266,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",264.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",252.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",260.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",270,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",115.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",103.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",94.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",82.8,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",66.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",51.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",50.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",49.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",50.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",46.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",47.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",50.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",102.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",89.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",89.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",76.9,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",61.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",57.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",57.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",55.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",54.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",51.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",52.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",53.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",19.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",17.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",16.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",14.7,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",12.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",11,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",10.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",9.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",9.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",8.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",8.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",8.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",4542.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",3968.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",3769.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",3624,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",3617.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",3629.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",3549.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",3241.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",3182.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",3276.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",3318.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",3393.8,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",6323.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",5098.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",5006.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",4814.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",4013.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",4017.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",4010,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3827.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3562.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",3742.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",3924.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",3573.9,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",5987.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",5307.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",5112.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",4899.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",4897.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",5181,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",5145.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4758,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",4845.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",5058.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",5124.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",5496.8,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",106.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",85.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",83.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",79.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",66.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",66.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",66.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",63.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",59.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",63,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",66.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",60.5,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",100.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",89.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",84.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",80.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",80.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",85.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",85,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",78.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",81.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",85.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",86.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",93.1,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",23.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",20.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",19.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",18.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",16,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",15.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",15.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",14.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",13.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",14.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",13.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",13.7,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",1401736,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",1347996,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",1297037,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",1255017,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",1157221,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",1088475,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",1007745,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",934437,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",802634,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",996769,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",939361,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",898665,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",15968.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",16890.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",16255.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",12859.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",10922.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",8992.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",9263,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",8330.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",7268.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",9143.9,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",8797.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",8188,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",12548,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",12544.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",12438.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",12388.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",11229.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",10519.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",9550.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",8890.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",7705.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",9563.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",9171,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",8806.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",124.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",132.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",127.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",100.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",85.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",70.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",73,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",65.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",57.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",72.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",69.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",65.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",98,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",98.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",97.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",97.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",88.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",82.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",75.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",70.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",60.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",75.8,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",72.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",70.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",20.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",19.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",18.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",18.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",17.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",16.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",15.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",13.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",11.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",10.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",10.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",9.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",2801238,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",2980199.5,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",2861087.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",2909973.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",2959711.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",3047770.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",3208747.7,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",3475580.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",3753638.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",3981146.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",4466464.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",4922786,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",2422.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",2689.1,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",2539.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",2657.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",2811.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",2694.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",2764.3,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",3073,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",3411.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",3416.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",3784.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",4303.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",3330.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",3487.3,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",3346.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",3348.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",3394.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",3554.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",3736.3,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",3982.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",4390.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",4648.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",5332,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",5763.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",48.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",53.9,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",50.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",52.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",55.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",52.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",54,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",59.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",66.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",66,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",73,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",83.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",67.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",69.8,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",66.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",66.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",66.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",69.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",72.9,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",77.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",85.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",89.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",102.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",111.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",13.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",13.5,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",13.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",12.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",12.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",12.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",12.6,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",12.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",13,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",12.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",13.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",14.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",41.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",42,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",41.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",38.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",34.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",33,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",32.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",30.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",26.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",26.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",26.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",26.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",27.3,"D; P","Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",54.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",58.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",53.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",51.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",45.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",36.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",36,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",34.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",31.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",29.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",30.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",31.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",28.7,"D; P","Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",44.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",46.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",46,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",43.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",38.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",37.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",38.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",35.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",31.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",31.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",30.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",31.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",32.8,"D; P","Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",115.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",121.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",108.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",102.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",88.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",70.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",68.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",63.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",57.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",52.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",53.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",55.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",49,"D; P","Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",93.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",96.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",93.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",86.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",75.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",72.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",66.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",57.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",55.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",54.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",54.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",55.9,"D; P","Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",21.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",22,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",21.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",19.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",17.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",17.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",16.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",15.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",13.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",12.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",12.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",11.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",10.6,"D; P","Difference in methodology; Provisional value" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",10123,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",10277,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",9747,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",9926,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",8388,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",9583,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",11846,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",10490,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",10015,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",9183.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",9090,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",7824.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",7963.2,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",801.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",827.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",740.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",777.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",631,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",604.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",634.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",554.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",520.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",476.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",423.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",386,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",395.6,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",1318.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",1339.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1240.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",1258.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",1042.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",1150.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",1402.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",1176.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",1079.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",950.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",905.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",752.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",752.9,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",7.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",6.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",6.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",5.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",5.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",4.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",4.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",3.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",3.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",3,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",11.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",11.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",10.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",10.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",8.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",9.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",11.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",9.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",8.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",7.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",7.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",5.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",5.8,"E","Estimated value" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",4.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",906.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",896.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",776.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",714.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",682.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",1201.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",1247.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",997.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",948.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",906.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",1061.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",1071.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",942,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",894.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",843.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",72.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",74.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",59.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",56.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",53.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",63.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",64.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",56.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",53.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",50,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",17.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",17.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",16.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",16.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",15.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",122.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",134.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",153.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",86.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",69.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",66.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",51,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",51.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",46.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",45.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",47.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",59.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",71.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",88.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",106.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",124.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",70.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",58,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",46.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",35.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",36.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",32.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",30.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",31.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",41.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",45.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",81.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",90.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",102.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",59.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",48.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",45.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",35.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",36.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",31.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",32.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",33.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",40.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",49.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",20.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",24.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",28.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",16,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",12.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",10.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",7.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",7.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",6.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",6.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",6.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",8.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",8.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",18.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",23.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",13.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",10.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",9.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",7.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",7.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",6.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",6.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",6.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",9.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",16.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",16.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",16.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",9.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",7.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",6.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",4.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",3.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",3.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",2.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",3.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",3.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1869,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1797,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1631,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1481,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1477,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1508,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1632,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1708,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1732,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1793,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1825,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1873,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1974,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",309.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",320.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",280.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",252.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",234.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",187,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",194.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",206.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",213,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",203.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",193.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",218,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",205.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",204.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",197.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",180.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",164,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",159.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",151.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",162.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",175.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",180.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",186.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",184.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",196.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",183.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",63.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",64.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",55.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",49.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",45.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",36,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",37.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",39.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",40.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",38.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",36,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",40.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",37.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",41.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",39.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",36,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",32.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",31,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",29.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",31,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",33.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",34,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",34.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",34.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",36.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",33.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",10.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",9.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",8.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",7.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",6.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",6.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",6.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",6.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",6.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",6.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",5.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",5.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",892.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",781.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",668.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",591.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",568.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",554.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",539.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",519.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",493.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",507.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",532.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",556.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",590.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",1182.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",1088,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",859.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",785.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",755.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",615.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",597.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",587,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",582.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",568.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",608.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",658.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",621.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",1431.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",1254.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",1104.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",1013,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",981.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",947.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",944.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",902.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",863.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",908.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",956.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",980.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",1072.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",111.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",103.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",81.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",75.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",72.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",59.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",57.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",57,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",56.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",55.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",59.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",63.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",60,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",135.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",118.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",105.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",96.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",94.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",91.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",91.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",87.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",84,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",88.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",92.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",94.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",103.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",27.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",26.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",25.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",24.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",23.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",22.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",21.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",20.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",18.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",18.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",19,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",19.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",18.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",183.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",189.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",165,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",159.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",155.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",154.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",194.1,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",188.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",187.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",191.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",199.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",207.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",242.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",263.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",212,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",211.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",207.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",171.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",214.9,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",213.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",221.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",214.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",228,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",245.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",365,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",373.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",327,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",324,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",321.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",314.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",385.8,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",365.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",357,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",369.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",384,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",389.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",45.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",48.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",39.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",39,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",38.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",31.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",39.6,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",39.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",40.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",39.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",41.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",45.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",67.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",69.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",60.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",59.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",59.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",58.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",71,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",67.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",65.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",67.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",70.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",71.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",16.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",16.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",14.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",12.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",11.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",11.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",12.3,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",12.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",11.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",11.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",12,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",11.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",3077.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",2591,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",2209.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",2078.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",2140.8,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",2151.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",2235.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",2202.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",2299.8,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",2363.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",2438.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",2443.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",2540,"P","Provisional value" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",4080.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",3606.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",2838.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",2760.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",2844.1,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",2387.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",2474.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",2488.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",2716,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",2645.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2785.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2890.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",2674.8,"P","Provisional value" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",4233.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",3628.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",3179.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",3080.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",3232.1,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",3237.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",3478.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",3491.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",3640.1,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",3855.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",3924.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",3904.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",4260.3,"P","Provisional value" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",87.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",77.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",60.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",59.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",61.2,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",51.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",53.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",53.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",58,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",56.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",58.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",61,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",56.4,"P","Provisional value" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",90.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",77.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",68,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",66.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",69.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",69.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",74.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",74.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",77.8,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",81.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",82.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",82.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",89.8,"P","Provisional value" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",23.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",21,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",20,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",19.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",18.9,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",18.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",18.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",18.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",12.1,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",11.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",11.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",11.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",11.1,"P","Provisional value" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3118.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3035.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",2543.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",2295.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",2338.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",2404.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",2398.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",2515.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",2545.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",2802.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",3029.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2993.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",3235.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",432.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",467.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",375.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",352.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",340.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",285,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",280.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",294.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",292.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",296.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",328.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",349,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",319.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",345.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",343.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",293.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",267,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",267.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",271.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",271.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",284.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",287.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",321.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",349.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",343.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",373.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",46.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",49.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",39.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",36.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",35.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",29.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",28.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",29.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",28.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",28.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",31.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",33.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",30.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",36.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",36.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",30.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",27.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",27.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",27.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",27.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",28.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",28.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",31.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",33.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",32.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",35.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",8.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",8.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",6.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",6.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",5.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",5.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",5.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",5.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",5.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",5.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",5.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",5.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",946.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",929,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",876,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",791,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",770,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",777,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",799,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",792,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",774,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",797,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",797,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",865,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",900,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",907.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",1046.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",934.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",853.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",840.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",807.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",810.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",804.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",791.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",802,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",848.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",946.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",942.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",645.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",664.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",646.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",602.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",600.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",628.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",664.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",666.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",656.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",692.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",701.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",781.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",844.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",115.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",132.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",116.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",105.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",102.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",97.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",96.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",95.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",93,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",93.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",98.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",108.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",107.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",82.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",84,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",80.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",74.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",73.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",75.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",79.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",78.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",77.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",80.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",81.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",89.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",96.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",16.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",16.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",14.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",13.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",13,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",12.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",12.5,"B; D","Break; Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",12.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",11.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",11.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",11.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",12.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",11.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1834.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1624.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1396.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1389.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1434.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1541.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1743.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",2133.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",2609,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",3441.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",4375.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5358,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1220.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",969.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",777.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",729.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",655.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",566.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",577.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",584.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",540.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",606.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",624.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",605.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1993.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1681.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1369.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1298.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1298.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1326.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1405.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1541.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1598.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1846.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2021.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1908.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",16.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",13.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",10.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",9.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",8.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",7.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",7.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",7.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",6.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",7.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",7.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",7.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",27.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",22.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",18.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",17,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",16.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",17,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",17.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",19.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",19.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",22.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",24.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",22.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",11.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",11.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",10.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",9.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",9.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",8.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",8.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",8.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",8.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",8.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",8.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1332.3,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1156.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1186.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",1267.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1280.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1301,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1287.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2104.6,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",1807.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",1952.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",1936.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",1728.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",1674.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",1717.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",1898.9,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",1663.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",1699.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",1830.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",1859.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",1900.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",1871.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",33,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",28.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",30.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",29.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",26.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",25.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",25.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",29.8,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",25.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",26.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",28.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",28.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",28.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",28.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",9.7,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",7.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",7.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",7.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",6.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",6.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",6.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",74875.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",91532.1,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",100837.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",105559,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",124399.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",138496.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",152031.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",146723.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",154799.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",184317.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",193006.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",179534.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",213450.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",146.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",189.2,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",207.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",213.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",218.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",211.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",224.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",226.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",241.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",262.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",243.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",236.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",244.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",208.1,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",263,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",290.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",301.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",338.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",354,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",382.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",368.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",390.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",458.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",461.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",412.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",487.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",8.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",11,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",11.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",12.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",12.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",11.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",12.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",12.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",12.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",13.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",12.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",12,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",12.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",12.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",15.2,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",16.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",17.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",19,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",19.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",21.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",20,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",20.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",24,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",23.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",21,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",24.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",9.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",7.8,"B","Break" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",8.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",7.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",7.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",7.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",7.1,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",6.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",7.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",7.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",6.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",7.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",35,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",31.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",32.6,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",31.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",32,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",31.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",30.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",29.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",30.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",31.8,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",34.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",34.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",36.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",46.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",43.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",41.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",42.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",42.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",34.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",34.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",33.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",36.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",35.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",39.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",40.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",38.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",68.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",60.9,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",62.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",60.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",60.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",58.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",58.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",56,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",57.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",59.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",65.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",63.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",63.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",34.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",32.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",31.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",31.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",32.4,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",26.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",25.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",25.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",27.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",26.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",29.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",30.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",28.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",51.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",45.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",47.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",46,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",46.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",44.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",44.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",42.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",43.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",44.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",49.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",47.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",47.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",18,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",15.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",14.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",13.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",12.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",11.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",10.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",9.9,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",9.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",9.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",9.6,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",8.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",8.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",122.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",113.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",105.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",100.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",81.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",77,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",75.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",75.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",76,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",78.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",83.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",85.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",90.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",162.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",158.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",135.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",133.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",107.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",85.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",83.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",85.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",89.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",88,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",95.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",100.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",94.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",192,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",182.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",173.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",170.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",137.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",129.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",130.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",133.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",133.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",142.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",152.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",151.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",163.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",79.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",77.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",65.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",64.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",52.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",41.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",40.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",41.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",43.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",42.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",45.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",47.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",45,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",93.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",88.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",84.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",82.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",66.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",62.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",63.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",64.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",64.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",68.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",72.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",71.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",77.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",25.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",24.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",23.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",22.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",18.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",17.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",16.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",15.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",14.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",14.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",14.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",13.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",13.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",4,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",3.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",4.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",4.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",3.9,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",3.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",3.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",3.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",3.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",3.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",3.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",3.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",2.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",2.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",2.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",2.8,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",2.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",3.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.2,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",0.6,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",0.6,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",0.8,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",0.1,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",0.1,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",22.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",21.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",20.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",19,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",17.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",16.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",16.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",16,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",16.8,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",15.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",14.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",22.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",21.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",18.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",14.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",13.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",12.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",12.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",12.1,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",12.5,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",12.2,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",11,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",17.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",17.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",16.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",15.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",14.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",13.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",13.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",13,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",13.6,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",12.4,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",11.4,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",0.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",0.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.1,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0,"E; D","Estimated value; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",22.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",21.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",23.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",22.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",20.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",19,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",18.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",20.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",19.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",21.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",19.5,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",18.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",0.8,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",1.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",1.6,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",39.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",35.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",33.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",30.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",28.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",26.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",23.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",21.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",20.8,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",19.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",18.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",18.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",52.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",49.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",43.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",40.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",38.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",29.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",26.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",24.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",24.6,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",22.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",21.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",21.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",48.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",45.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",42.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",39.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",37.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",33.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",31.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",29.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",28.3,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",27.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",26.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",24.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",279.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",260.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",234.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",219.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",204,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",188.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",174.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",162.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",149.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",134.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",132.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",115.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",101.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",2.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",2.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",1.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",1.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",1.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",9.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",10,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",10.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",11.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",11.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",11.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",11.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",11.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",10.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",10.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",9.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",9.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",1.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",1.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",1.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",1.5,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",2.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",2.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",2,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",1.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",1.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",1.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",1.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",1.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",1.9,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",1.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",1.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",1.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",0.4,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0.4,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",10.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",9.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",8.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",8.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",7.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",6.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",5.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",5.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",4.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",4.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",4.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",3.9,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",14.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",12.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",11.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",10.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",7.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",6.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",6.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",5.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",5.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",4.1,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",14,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",13,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",11.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",10.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",9.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",9.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",8.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",7.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",7.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",6.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",6.3,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.1,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.1,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0,"E","Estimated value" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",781,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",788.4,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",770.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",952.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",883.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",864,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",740.8,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",704.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",667.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",625.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",679.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",620,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",0.7,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",0.6,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",0.9,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",0.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",6.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",6.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",6.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",6.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",8.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",8.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",8.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",7.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",7.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",7.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",7.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",8.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",7.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",0.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",0.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",1.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",1.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",1.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",1.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",1.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",1.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",1.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",1.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",0.3,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",0.4,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",0.6,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",3.7,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",3.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",3.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",3.2,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",2.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",2.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",2.3,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",2.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1.6,"P","Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",5.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",5.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",4.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",4.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",4.2,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",3.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",3.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",2.9,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",2.7,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",2.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1.7,"P","Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",5.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",5.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",4.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",4.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",4.8,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",4.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",4.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",3.6,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",3.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",3.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",2.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2.7,"P","Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",0.1,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",0,"P","Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",0.1,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",0.1,"P","Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0,"B; D","Break; Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0,"P","Provisional value" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",14.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",13.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",13.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",14.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",15.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",13.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",12.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",12.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",12.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",11.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",11.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",10.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",13.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",2.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",2.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",1.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",2.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",4.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",4.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",2.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",49,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",91.5,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",185.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",136,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",247.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",173.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",335.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",198.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",337.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",304.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",361.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",438.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",691.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",0.2,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",0.3,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",0.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",0.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",0.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",0.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",0.6,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",0.5,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",17,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",17,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",17,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",18,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",19,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",19,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",20,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",20,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",21,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",22,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",24,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",26,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",15.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",17.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",17.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",17.4,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",17.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",14.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",14.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",15.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",15.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",15.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",16.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",19.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",11.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",11.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",11,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",12.4,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",13.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",12.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",13.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",13.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",14.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",14.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",16.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",18,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.8,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.5,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.2,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",6.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",7.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",7.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",7.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",7.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",6.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",6.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",6.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",5.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",4.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",4.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",10.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",9.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",9.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",9.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",7.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",7.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",7.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",7.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",6.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",5.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",8.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",9.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",9.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",8.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",8.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",8.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",8.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",7.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",6.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",5.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",16,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",15.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",15.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",15.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",15.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",15.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",14.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",14.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",14.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",14.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",14,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",13.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",13.4,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",21.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",21,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",19.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",20.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",20.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",16.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",16.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",16.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",17.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",16.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",15.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",16.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",14.1,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",19.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",18.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",18.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",19.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",19.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",19.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",19,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",19.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",19.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",20,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",19.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",18.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",18.7,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",1.2,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1.6,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.1,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",30.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",28.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",28.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",28.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",29,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",29.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",25.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",23.7,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",25.2,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",22.8,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",23.4,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",30.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",27.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",26.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",22.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",21.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",22.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",19.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",17.8,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",18.8,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",18.2,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",18,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",24.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",23.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",23.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",22.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",24,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",24.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",21,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",19.2,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",20.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",18.4,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",18.6,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",0.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",0.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.1,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.1,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.1,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.1,"E; D","Estimated value; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",176.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",222.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",233.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",206.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",198.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",195.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",194.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",197.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",200.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",208.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",209.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",212.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",9.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",12.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",11.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",10.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",9.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",7.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",8.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",9.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",9.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",9,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",9.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",12.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",16.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",17.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",16.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",15.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",15.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",15.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",15.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",16.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",17,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",16.8,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",16.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0.8,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",1.6,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",3.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",3.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",3.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",3.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",4.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",3.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",2.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",2.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",5.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",4.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",4.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",4.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",4.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",4.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",4.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",3.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",3.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",4.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",4.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",4.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",4.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",4.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",3.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",76.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",87.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",79.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",79.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",80.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",77.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",75.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",71.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",68.3,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",68.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",61.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",59.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",100.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",122.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",101.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",105.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",106.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",86.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",83.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",80.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",80.7,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",76.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",70.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",70,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",94.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",111.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",100.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",102.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",104.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",100.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",100.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",95.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",92.9,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",93.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",84.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",80.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",1.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",1,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.2,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",5.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",6.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",5.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",6.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",6.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",6.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",7.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",7.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",8.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",8.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",8.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",8.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",6.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",7.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",8.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",7.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",8.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",8.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",7.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",8.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",8.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",9.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",9.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",9.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",10.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",6.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",7.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",8.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",8.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",10.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",10.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",10.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",12.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",13.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",14.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",15.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",15.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",15.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",11.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",1511.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",1522.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",1427.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",1406.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",1405,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",1391.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",1384.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",1380.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",1362.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",1378.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",1571.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",1469.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",1451.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",7.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",7.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",6.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",6.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",4.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",4.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",5.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",4.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",12,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",12.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",11.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",11.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",10.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",10.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",10.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",10.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",9.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",9.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",10.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",9.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",61.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",69.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",77.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",79.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",73,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",69.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",77.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",83.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",92.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",104.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",126.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",121.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",2.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",2.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",2.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",2.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",2.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",2.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",2.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",2.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",2.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",3.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",3,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",2.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",3.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",3.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",4.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",3.9,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",3.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",3.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",3.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",3.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",3.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",3.6,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",2.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",3.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.2,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",75.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",73.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",74.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",75.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",77.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",77.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",79,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",80.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",81.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",83.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",82.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",82,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",104.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",94.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",99.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",100.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",85.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",86,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",89.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",95,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",91.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",95.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",97.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",86.4,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",99.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",98.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",101.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",102.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",104.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",110.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",114.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",118.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",124.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",128.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",127.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",132.9,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",1.5,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",2.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",2.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",2.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",2.3,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.3,"E","Estimated value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",8636,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",11558.9,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",11018.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",11041.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",11754,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",12980.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",14174.3,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",16183.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",18654.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",21623.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",25886.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",28729.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",7.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",10.4,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",9.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",10.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",11.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",11.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",12.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",14.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",17,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",18.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",21.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",25.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",10.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",13.5,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",12.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",12.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",13.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",15.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",16.5,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",18.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",21.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",25.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",30.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",33.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.3,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.3,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0.5,"D; P","Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",1.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",1.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",1.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",1.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",1.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",0.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.8,"D; P","Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.2,"D; P","Difference in methodology; Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",10.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",10.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",9.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",9.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",9.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",14.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",14.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",12.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",12.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",12.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",12.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",12.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",11.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",12.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",11.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",4.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",4.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",5.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",4.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",4.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",4.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",4.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",2.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",1.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",1.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",3.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",3.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",3.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",4.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",4.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",3.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",3.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",2.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",1.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",3.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",3.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",3.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",3.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",3.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",3.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",2.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",1.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",25,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",29,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",29,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",31,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",33,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",36,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",38,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",41,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",44,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",47,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",43,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",36,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",35,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",4.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",5.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",5.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",5.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",4.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",4.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",5.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",5.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",3.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",2.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",3.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",3.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",3.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",3.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",3.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",3.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",4.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",3.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",3.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",4.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",4.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",4.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",3.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",3.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",3.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",3.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",6.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",5.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",5.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",5.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",4.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",4.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",4.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",4.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",4.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",4.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",4.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",7.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",6.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",6.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",6.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",6.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",6.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",6.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",6.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",6.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",6.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",6.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",6.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",6.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",3.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",4.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",5.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",5.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",5.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",6.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",5.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",5.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",5.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",5.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",5.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",6.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",5.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",6.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",6.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",6.7,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",6.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",6.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",6.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",6.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",6.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",6.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",8.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",8.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",10.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",10.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",11.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",12.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",11.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",10.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",11.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",11.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",11,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",2.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",2.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.4,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",22.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",33.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",31.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",31.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",35.5,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",36.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",35.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",29.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",29.6,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",27.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",23,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",22.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",22.6,"P","Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",30.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",46.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",40.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",42.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",47.1,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",40.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",39.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",33.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",35,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",30.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",26.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",26.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",23.8,"P","Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",31.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",47.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",44.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",47,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",53.5,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",55.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",55.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",47,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",46.9,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",44.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",36.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",36.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",37.9,"P","Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",1,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",0.7,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.2,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",0.8,"P","Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.3,"B; D","Break; Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.1,"P","Provisional value" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",36.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",49.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",50.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",54.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",60.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",66.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",74.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",80.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",88.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",97.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",88.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",88.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",55.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",7.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",7.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",8.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",8.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",7.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",8.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",9.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",10.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",10.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",9.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",10.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",5.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",5.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",5.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",6.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",6.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",7.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",8.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",9.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",10,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",11.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",10.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",10.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",6.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",6.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",7.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",9.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",10.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",13.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",17.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",23.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",31.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",37.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",53.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",3.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",4.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",4.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",5.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",5.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",6.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",6.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",7.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",7.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",8.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",8.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",11.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",12.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",14.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",17.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",17.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",19.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",1169.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",1341.3,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",1457.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",1625.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",1688.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",1679.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",2214.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",2149.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",2166.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",3246.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",3705.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",4299.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",4747.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",2.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",2.8,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",3.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",2.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",3.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",3.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",3.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",4.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",5.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",5.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",3.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",3.9,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",4.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",4.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",5.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",5.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",5.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",8.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",8.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",9.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",10.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",1.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",1.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",1.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",1.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",0.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",0.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",1.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",1.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",1.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",1.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",1.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",1.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",1.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",1.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",1.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",1.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",64,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",72,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",78,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",88,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",83,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",91,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",98,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",107,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",116,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",134,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",150,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",169,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",58.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",74.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",80.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",85,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",74.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",68.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",72.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",82,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",86.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",93.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",103.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",127,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",42.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",47.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",50.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",60.8,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",57.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",61.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",67.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",72.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",78.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",90.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",103.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",116.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",3.7,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",4.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",2.6,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.7,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",39.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",39.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",41.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",42.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",42.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",45.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",48.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",49.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",45.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",47.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",49.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",50.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",52.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",55.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",53.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",55.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",56.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",50.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",53.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",56,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",53.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",52.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",56.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",59.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",46.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",47.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",50.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",52.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",53.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",57.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",62.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",64,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",59.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",63,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",66.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",66.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",6.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",6.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",6.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",6.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",5.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",6.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",5.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",5.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",7.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",7.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",6.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",7.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",7.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",7.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",17.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",20.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",19.6,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",19.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",20.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",24.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",25.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",26.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",26.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",30.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",33,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",32.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",36.2,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",23.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",28.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",25.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",25.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",26.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",27,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",28.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",29.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",30.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",33.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",37.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",38.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",38.1,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",21.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",24.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",23.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",24,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",25.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",30.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",33.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",33.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",34.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",40.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",45.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",43.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",50.7,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",2.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",2.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",2.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",2.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",3.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",3.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",3.3,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",2.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",2.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",2.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",2.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",2.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",2.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",3.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",3.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",4.4,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.4,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",73.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",76.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",92,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",104.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",119.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",129.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",107.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",116.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",125.2,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",127.2,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",113.2,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",73.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",74.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",83.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",81.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",89.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",99.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",82.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",87.8,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",93.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",101.4,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",87,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",59,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",62.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",74.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",83.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",98.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",106.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",88.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",94.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",101.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",102.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",90.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",2.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",2.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",2.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",2.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",2.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",2.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",2.2,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",2.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",2.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",2.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",2.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",2.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",2.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.4,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",879.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",800.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",796,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",752.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",734.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",689.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",690.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",725.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",733.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",731.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",682.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",625.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",46.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",45.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",40.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",38.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",35.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",28,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",28.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",31,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",33.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",31.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",29.4,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",28.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",64.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",60,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",59.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",58.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",57.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",53.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",54.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",58.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",59.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",59.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",54.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",49.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",4.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",4.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",3.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",3.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",3.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",2.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",3.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",2.7,"B","Break" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",2.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",6.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",5.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",5.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",5.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",5.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",5.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",5.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",5.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",5.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",5.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",5.1,"B","Break" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",4.7,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.7,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.7,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",4.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",5.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",5.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",5.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",6.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",7.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",7.6,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",6.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",7.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",9.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",9.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",6.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",7.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",6.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",7.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",8.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",7.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",8.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",7.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",8.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",8.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",10.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",10.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",5.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",5.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",5.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",6.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",6.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",7.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",8.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",7.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",8.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",9.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",11.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",11.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",1.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",1.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",1.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",1.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",1.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",1.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",1.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",1.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",1.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",1.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",1.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",306.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",299.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",310.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",326,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",356.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",371.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",390.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",391.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",316,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",323.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",305.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",301.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",406.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",416.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",399.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",433,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",473.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",412.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",431.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",442,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",373.2,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",362.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",348.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",356.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",381,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",379.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",394.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",420.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",463.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",477.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",518.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",525.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",429.7,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",444.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",421.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",409.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",5.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",5.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",5.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",5.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",5.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",4.5,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",4.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",4.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",4.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",4.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",4.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",5.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",5.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",5.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",6.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",6.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",5.2,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",5.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",5.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",4.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.7,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",41.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",39.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",32.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",27,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",25.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",25.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",26,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",24.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",24.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",25.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",33.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",30.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",23,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",55.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",54.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",41.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",35.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",33.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",27.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",28.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",28.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",29.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",28.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",38.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",35.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",24.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",57.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",55.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",47.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",42.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",41.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",41.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",44.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",43.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",44,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",47,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",61.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",55.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",43.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",4.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",3.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",3.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",3.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",3.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",3.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",2.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",5.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",4.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",3.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",3.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",3.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",4.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",4.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",4.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",5.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",5.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",4.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",7338.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",7703.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",7380.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",7583.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",8102.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",8633.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",9311.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",9804.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",9734.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",10135.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",10964.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",10709.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",11191.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",35.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",38.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",32.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",33.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",34.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",30.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",33.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",35.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",36,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",34.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",35.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",35.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",30,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",58,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",62,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",58.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",60.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",62.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",65.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",70.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",72.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",70,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",72,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",75.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",69.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",69.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",3.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",3.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",5.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",6.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",7.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",7.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",7.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",7.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",7.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",7.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",37.6,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",48.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",57.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",50.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",45.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",50.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",49,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",51,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",59.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",76,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",83.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",103.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",0.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",1.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",1.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",1.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",1.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",1.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",1.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",1.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",1.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",1.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",1.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",2.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",0.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",1.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",1.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",1.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",1.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",21.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",21.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",21.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",16.9,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",16.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",17.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",18.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",17.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",17.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",17.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",17.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",17.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",28,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",29.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",27.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",22.4,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",22,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",19.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",20.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",20.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",20.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",19.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",20.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",21.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",24.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",25.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",25.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",20.8,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",20.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",21.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",23.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",22.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",21.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",21.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",22.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",22.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",6.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",5.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",4.8,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",4.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",5.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",5.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",5.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.5,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",4.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.9,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",197.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",194.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",189.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",197.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",224.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",227.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",221.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",177.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",175,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",177.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",165,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",166.7,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",274.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",249.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",251.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",262.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",248.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",251.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",250.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",209.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",195.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",202.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",195.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",175.6,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",260.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",260.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",256.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",267.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",303.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",324.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",321.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",260.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",266.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",273.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",254.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",270.1,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",4.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",4.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",4.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",4.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",4.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",4.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",4.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",3.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",3.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",3.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",3.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",3,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",4.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",4.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",4.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",4.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",5.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",5.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",4.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",4.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",4.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",4.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",4.6,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.7,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.7,"E","Estimated value" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",35631,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",36901.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",33694.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",33695.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",31250.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",29043.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",29877.4,"B","Break" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",32908.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",35023.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",36730,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",39405.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",44689.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",30.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",33.3,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",29.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",30.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",29.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",25.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",25.7,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",29.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",31.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",31.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",33.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",39.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",42.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",43.2,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",39.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",38.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",35.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",33.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",34.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",37.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",41,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",42.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",47,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",52.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.7,"B","Break" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.5,"B","Break" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.7,"B","Break" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.2,"B","Break" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.1,"B","Break" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0.8,"D; P","Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",1.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",1.2,"D; P","Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.3,"D; P","Difference in methodology; Provisional value" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",35.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",34.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",34.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",34.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",35,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",47.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",48.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",44.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",45.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",46.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",41.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",41.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",42.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",42.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",43.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",3.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",2.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",3.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",2.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",2.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",2.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",54,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",56,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",61,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",69,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",74,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",91,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",103,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",110,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",104,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",99,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",106,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",105,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",121,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",8.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",10,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",10.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",11.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",11.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",11.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",12.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",13.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",12.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",11.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",11.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",12.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",12.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",5.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",6.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",6.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",7.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",9.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",10.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",11.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",10.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",10.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",10.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",11,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",11.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",1.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",2.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",2.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",2.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",1.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",1.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",1.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",1.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",1.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",1.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",5.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",4.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",7.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",6.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",6.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",5.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",5.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",5.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",5.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",5.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",4.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",5.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",13.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",14.6,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",15,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",16.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",17.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",17.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",22.9,"B","Break" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",20.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",18.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",18.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",18.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",17.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",17.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",20.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",19.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",22.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",23,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",19.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",25.3,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",22.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",22.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",20.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",20.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",20.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",26.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",28.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",29.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",34.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",35.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",36.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",45.5,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",39.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",35.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",35.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",35.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",32.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",3.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",3.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",3.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",4.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",4.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",4.7,"B","Break" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",4.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",4.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",3.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",3.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",3.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",4.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",5.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",6.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",6.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",6.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",8.4,"B","Break" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",7.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",6.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",6.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",6.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",6,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.5,"B","Break" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",59.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",45,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",40.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",40.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",41.3,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",40.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",41.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",45.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",116.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",128.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",128,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",100.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",103.5,"P","Provisional value" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",78.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",62.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",52.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",53.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",54.9,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",45.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",45.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",51.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",137.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",143.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",146.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",119.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",108.9,"P","Provisional value" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",81.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",63.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",58.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",59.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",62.4,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",61.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",64,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",71.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",184.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",209.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",206,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",161.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",173.5,"P","Provisional value" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",1.2,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",1.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",3.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.3,"P","Provisional value" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.3,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",4.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",4.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.7,"P","Provisional value" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.4,"B; D","Break; Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.6,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.6,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",137.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",145.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",147.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",154.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",181.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",214.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",211.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",226.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",221.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",251.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",307.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",299.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",305.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",19.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",22.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",21.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",23.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",26.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",25.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",24.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",26.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",25.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",26.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",33.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",34.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",30.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",15.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",16.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",17,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",17.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",20.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",24.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",24,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",25.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",25,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",28.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",35.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",34.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",35.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",2.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",2.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",2.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",2.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",3.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",3.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",2.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",1.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",1.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",1.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",1.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",3.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",3.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",3.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.6,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.6,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",26.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",26.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",26.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",27.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",28.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",28.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",27.6,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",45,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",52.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",70.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",88.6,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",117.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",17.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",15.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",14.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",14.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",13,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",10.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",9.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",12.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",10.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",12.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",12.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",13.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",28.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",27.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",26,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",25.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",25.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",24.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",22.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",32.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",31.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",37.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",40.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",41.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",1699.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",2317.9,"B","Break" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",2551.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",2861.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",3129,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",3557.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",4456.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",4932.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",6971.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",8295.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",7817.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",6964.7,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",7014.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",3.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",4.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",5.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",5.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",5.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",5.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",6.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",7.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",10.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",11.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",9.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",9.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",4.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",6.7,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",7.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",8.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",8.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",9.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",11.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",12.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",17.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",20.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",18.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",16,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",16,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.3,"B","Break" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.4,"B","Break" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.9,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.2,"B","Break" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.2,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",0.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",0.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",0.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",1.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",1.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",1.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",1.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",1.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",1.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",1.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",1.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",0.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",0.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",1.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",1.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",1.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",1.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",1.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",1.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",1.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",1.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",1.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",1.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",1.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",1.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",1.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",1.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",2.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",2.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",2.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",0.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.6,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",1.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",1.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",1.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",1.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",1.7,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",1.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",1.7,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.5,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.4,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.3,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",4.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",4.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",3.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",4.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",4.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",4.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",5.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",6.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",5.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",5.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",5.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",3.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",4.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",5.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",5.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",5.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",6.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",7.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",7.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",7.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",6.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",5.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",5.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",5.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",6.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",7.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",8.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",8.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",8.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",3.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",31,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",30,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",30,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",37,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",38,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",43,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",46,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",48,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",49,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",54,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",62,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",65,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",28.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",30.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",31.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",35.7,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",34.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",32.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",34.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",36.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",36.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",37.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",42.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",48.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",20.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",19.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",19.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",25.6,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",26.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",29.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",31.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",32.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",33.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",36.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",42.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",44.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",1.5,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",1.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",1.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.3,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",15.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",15.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",15.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",15.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",16.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",16.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",16.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",18.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",20,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",21.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",24,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",24.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",21,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",21.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",20.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",20.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",21.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",18.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",18.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",20.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",23.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",24.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",27.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",29.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",18.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",18.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",19.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",19.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",20.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",20.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",21.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",23.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",26.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",29,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",32.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",32.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",2.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",2.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",2.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",2.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",2.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",2.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",2.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",38.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",36.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",35.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",35.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",34.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",33.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",33,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",32.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",31.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",29,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",28.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",27.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",28.2,"E","Estimated value" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",50.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",51.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",45.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",46.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",46.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",37.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",36.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",37.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",37.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",32.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",32.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",32.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",29.7,"E","Estimated value" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",45.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",44.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",43.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",43.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",43.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",41.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",42.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",42.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",41.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",38.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",39.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",37.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",39.6,"E","Estimated value" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",4.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",4.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",4.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",4.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",4.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",3.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",3.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",3.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",3.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",2.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",2.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",2.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",2.6,"E","Estimated value" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",4.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",3.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",3.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",3.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",3.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",3.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",3.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",3.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",3.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",3.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",3.4,"E","Estimated value" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.3,"E","Estimated value" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",198.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",200.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",201.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",207,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",214.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",226.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",258.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",265.8,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",298.5,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",342.8,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",365.6,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",198.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",194.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",182.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",161.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",161.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",174.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",199.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",200.3,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",222.6,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",273.4,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",280.9,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",159.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",163.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",164.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",165.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",177.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",187,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",214.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",215.3,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",242.5,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",276.9,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",291.6,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",5.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",5.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",5.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",4.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",4.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",5.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",5.3,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",5.9,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",7.1,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",7.2,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",4.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",4.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",4.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",4.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",4.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",5.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",5.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",5.7,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.4,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",7.2,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",7.5,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.8,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.9,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.9,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.9,"E; D","Estimated value; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",433.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",420.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",476.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",493.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",534.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",524.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",530.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",525.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",535.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",542.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",531.2,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",547.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",22.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",23.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",24.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",25.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",25.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",21.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",21.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",22.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",24.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",23.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",22.9,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",25.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",31.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",31.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",35.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",38.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",42.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",40.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",42.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",42.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",43.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",44.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",42.6,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",43,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",2.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",2.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",2.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",2.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",2.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",2.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",2.1,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",3.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",3.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",3.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",4.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",4.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",4,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",4.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.6,"B","Break" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",8.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",8.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",8.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",8.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",8.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",7.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",8.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",8.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",9.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",9.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",11.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",12.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",10.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",11,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",11.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",9.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",8.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",8.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",9.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",9.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",10.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",10.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",10,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",9.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",9.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",9.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",9.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",9.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",9.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",9.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",10.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",11.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",11.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",2.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",1.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",2.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",1.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",1.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",1.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",1.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",392.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",389.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",401.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",418.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",440.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",443.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",449.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",448.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",490.3,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",531,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",559.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",586.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",520.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",541.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",515.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",556.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",585.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",491.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",498,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",506.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",579,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",594.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",638.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",693.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",487.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",493.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",509.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",540.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",572.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",569.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",597.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",602.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",666.7,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",729.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",771.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",796.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",6.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",6.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",6.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",6.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",7.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",6.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",7,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",7.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",7.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",8.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",6.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",6.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",6.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",7.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",7.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",7.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",8,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",8.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",9.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",9.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",36.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",35.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",36.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",38.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",36.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",30.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",34.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",34.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",33.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",32,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",29.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",30,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",23.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",48.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",49.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",47.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",50.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",48.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",34.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",38.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",39.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",39.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",35.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",34.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",35.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",24.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",50.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",50.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",53.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",60.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",59.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",50.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",58.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",60.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",59.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",58.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",54.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",55.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",43.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",4.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",4.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",4.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",4.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",4.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",3.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",3.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",3.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",3.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",3.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",3.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",3.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",2.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",4.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",4.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",4.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",5.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",5.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",4.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",5.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",5.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",5.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",5.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",5.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",5.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",4.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",4641.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",4864.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",4833,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",4641.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",4504.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",4496.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",4527.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",4545.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",4568.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",4743.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",4975.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",4916.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",5138.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",22.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",24.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",21.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",20.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",19.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",16.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",16.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",16.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",16.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",16.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",16.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",16.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",13.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",36.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",39.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",38.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",37.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",34.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",33.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",34.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",33.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",32.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",33.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",34.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",31.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",31.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",3.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",3.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",204.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",219.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",221.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",225,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",206.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",186.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",205.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",216.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",202.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",212.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",232.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",234.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",1.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",1.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",1.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",1.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",1.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",1.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",1.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",1.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",1.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",1.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",1.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",1.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",1.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",1.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",1.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",1.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",1.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",1.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",1.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",1.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",1.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",1.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",5.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",5.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",5.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",5.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",5.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",4.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",5.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",5.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",5.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",4.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",4.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",4.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",5.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",4.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",4.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",4.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",4.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",4.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",4.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",4.2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",15.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",15.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",16.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",16.4,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",15.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",15.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",14.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",14.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",14,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",13.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",13.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",14,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",20.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",22,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",21.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",21.8,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",21.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",17.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",16.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",16.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",16.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",15.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",15.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",16.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",18.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",19,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",20,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",20.2,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",19.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",19,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",18.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",18,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",17.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",17.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",17.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",17.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",4.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",4.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",4.7,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",4.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",3.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",4.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",4.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.4,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",3.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",108.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",108.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",110.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",115.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",114.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",109.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",113,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",115.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",121.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",122.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",120.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",117,"E","Estimated value" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",151.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",139.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",146.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",153.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",127,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",121.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",127.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",136.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",136.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",140.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",142.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",123.2,"E","Estimated value" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",143.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",145,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",149.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",156.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",155,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",156.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",163.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",169.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",185.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",189.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",186.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",189.5,"E","Estimated value" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",2.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",2.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",2.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",2.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",2.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",2.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",2.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",2.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",2.1,"E","Estimated value" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",2.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",3.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",3.2,"E","Estimated value" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.5,"E","Estimated value" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",25582,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",25540.4,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",22108.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",22273.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",22818.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",22838.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",21289,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",21832.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",22899.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",24483.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",29067.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",32086.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",22.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",23,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",19.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",20.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",21.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",20.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",18.3,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",19.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",20.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",21,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",24.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",28,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",30.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",29.9,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",25.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",25.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",26.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",26.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",24.8,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",25,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",26.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",28.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",34.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",37.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.5,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.4,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.6,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.5,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.1,"B","Break" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.1,"B","Break" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",1.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",1.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",1.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",1.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",1.5,"D; P","Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",4.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",4.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",4.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",4.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",2.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",2.3,"D; P","Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",3.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",2.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",2.6,"D; P","Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.5,"D; P","Difference in methodology; Provisional value" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",74.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",78,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",79,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",81.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",80.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",98.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",108.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",101.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",108.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",106.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",87.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",93.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",95.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",102.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",99.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",5.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",6.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",6.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",6.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",6.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",5.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",5.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",5.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",6.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",5.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",1.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",2.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",2.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",3.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",4.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",1.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",2.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",99,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",102,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",99,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",98,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",105,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",110,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",112,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",122,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",131,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",141,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",148,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",143,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",144,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",16.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",18.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",17,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",16.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",16.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",13.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",13.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",14.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",16.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",16,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",15.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",16.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",15,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",10.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",11.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",11,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",10.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",11.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",11.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",11.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",12.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",13.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",14.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",15,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",15,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",13.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",3.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",3.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",3.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",3.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",3.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",3.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",2.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",2.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",28.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",24.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",23.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",22.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",22.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",22.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",21.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",21.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",21.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",21.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",22.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",21.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",21,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",38.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",34.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",30.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",30,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",29.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",24.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",24.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",24.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",25.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",24.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",25.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",25.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",22.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",46.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",39.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",39.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",38.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",38.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",38,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",38.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",37.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",37.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",39.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",39.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",38.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",2.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",2.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",4.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",3.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",3.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",3.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",5.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",5.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",6.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",6.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",6.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",9,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",8.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",9.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",9.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",9.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",6.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",7.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",7.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",8.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",9.9,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",9.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",10.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",10.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",10.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",10.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",9.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",10.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",11.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",12.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",14,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",12.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",17.8,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",16.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",17.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",17.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",17.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",16.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",1.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.8,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",1.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",2.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",3.3,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",3.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.6,"B","Break" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",124.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",120.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",111.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",101.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",102.8,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",92.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",94.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",96,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",111.6,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",119.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",125.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",126.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",120.3,"P","Provisional value" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",165.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",167.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",143.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",135,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",136.6,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",102.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",104.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",108.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",131.8,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",133.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",143.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",149.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",126.7,"P","Provisional value" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",171.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",168.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",160.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",150.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",155.2,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",139.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",147.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",152.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",176.6,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",194.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",201.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",202.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",201.8,"P","Provisional value" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",2.9,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.8,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",3.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.7,"P","Provisional value" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.3,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.8,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",4.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",4.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",4.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",4.3,"P","Provisional value" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.9,"B; D","Break; Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",269.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",265.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",259,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",257,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",255.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",241.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",223,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",221.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",221,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",218.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",237.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",227.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",248.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",37.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",40.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",38.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",39.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",37.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",28.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",26,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",25.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",25.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",23.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",25.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",26.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",24.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",29.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",30,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",29.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",29.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",29.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",27.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",25.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",25,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",24.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",25,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",27.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",26,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",28.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",4.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",4.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",3.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",2.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",2.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",2.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",3.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",3.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",3.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",2.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",38.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",39.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",37.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",40.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",47.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",53.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",64.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",79.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",97.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",158.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",246.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",339,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",25.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",23.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",21.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",21.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",21.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",19.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",21.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",21.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",20.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",28,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",35.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",38.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",41.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",41.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",37.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",37.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",42.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",45.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",52.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",57.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",59.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",85.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",113.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",120.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",1.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.5,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",1770.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",2756,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",3547.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",3467.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",4497.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",6793.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",6034.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",5534.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",6312.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",7955.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",6086,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",8160.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",9498.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",3.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",5.7,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",7.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",7.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",10.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",8.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",8.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",9.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",11.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",7.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",10.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",10.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",4.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",7.9,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",10.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",9.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",12.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",17.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",15.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",13.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",15.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",19.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",14.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",18.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",21.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.3,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.5,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",1.1,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.2,"B","Break" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",1.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",1.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",1.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",1.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1.8,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",1.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",2.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",2.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",2.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",2.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",2.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",2.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",2.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",2.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",2.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",2.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",2.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",2.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",2.5,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",2.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",2.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",2.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",2.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",3.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",3.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",3.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",3.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",3.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",3.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",3.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",3.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",3.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",3.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",4.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",4.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",1.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",1.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",1.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",2.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",2.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",2.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",2.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2.9,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",3.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",3.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",3,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.6,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",6.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",6.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",6.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",6.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",6.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",6.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",6.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",6.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",6.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",6.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",6.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",8.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",8.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",7.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",8.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",8.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",7.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",7.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",7.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",7.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",6.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",9.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",9.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",10,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",10.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",10.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",10.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",11,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",11,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",10.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",11.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",11.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",11.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",11.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",4.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",4.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",3.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",3.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",3.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",3.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",5.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",5.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",5.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",5.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",5.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",5.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",5.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",142,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",141,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",137,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",151,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",142,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",144,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",153,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",153,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",158,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",163,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",176,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",187,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",130.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",145.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",141.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",145.8,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",128,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",108.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",113.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",117.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",118.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",113.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",121.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",140.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",94.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",93.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",89,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",104.3,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",97.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",97.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",105.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",103.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",107.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",110.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",121,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",129.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",5.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",6.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",6.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",6.3,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",4.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",4.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",4.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",4.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.5,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",4.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",4.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.3,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",63.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",57.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",51.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",46.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",46.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",44.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",43.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",41.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",35.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",34.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",33.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",31.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",84.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",79.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",65.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",61.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",61.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",49.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",48.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",46.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",42.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",38.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",38.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",37.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",75.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",69,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",63,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",58.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",57.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",55.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",56.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",53,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",46.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",46.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",45.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",41.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",10.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",9.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",4.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",4.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",8.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",7.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",5.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",4.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",2.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",2.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",108.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",99.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",97.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",97.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",91.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",87.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",86.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",82.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",78.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",76.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",69.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",62.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",60.4,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",143.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",138.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",125.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",128.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",122.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",96.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",95.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",93.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",92.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",85.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",79.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",73.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",63.6,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",129.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",119.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",119,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",120.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",114.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",109.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",110.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",106.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",102.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",102.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",95.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",84.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",84.6,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",13.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",12.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",11.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",11.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",10.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",8.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",8.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",8.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",8.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",7.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",6.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",6.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",5.5,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",11.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",10.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",10.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",10.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",10.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",9.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",9.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",9.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",8.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",8.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",7.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",7.3,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.7,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",321.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",308.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",311.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",316.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",320.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",326.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",299.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",288.8,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",291.7,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",281.6,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",258.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",321.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",299.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",282.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",247.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",241.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",251.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",231.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",217.7,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",217.5,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",224.6,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",198.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",258.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",252,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",253.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",253.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",265.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",269.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",248.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",233.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",237,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",227.4,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",206.4,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",9.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",8.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",6.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",6.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",6.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",6.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",5.8,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",5.7,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",5.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",5.1,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",6.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",6.2,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.2,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",5.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",5.3,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.9,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.8,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.6,"E; D","Estimated value; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1182.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1140,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1148.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1118.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1122.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1089.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1079.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1125.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1096.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1088.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1085.8,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",1100.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",61.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",64.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",58.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",57.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",54.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",44.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",44.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",48.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",50.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",47.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",46.8,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",50.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",86.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",85.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",86.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",87.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",88.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",84.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",85.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",90.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",88.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",88.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",87.1,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",86.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",5.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",6.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",5.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",5.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",5.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",4.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",4.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",4.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",4.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",4.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",4.4,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",4.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",8.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",8.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",8.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",8.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",8.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",8.1,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",8.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1.2,"B","Break" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",29.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",25,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",26.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",27.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",27.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",27.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",26.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",23.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",21.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",20.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",19.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",18.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",39.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",34.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",33.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",36,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",36.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",30.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",29.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",26.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",25.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",22.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",22,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",21.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",33.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",27.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",28.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",29.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",30.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",30.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",30.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",27.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",25.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",24.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",23.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",22.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",7.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",6.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",6.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",6.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",6.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",5.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",5.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",4.8,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",4.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",4.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",3.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",5.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",5.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",5.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",5.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",5.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",5.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",4.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",4.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",4.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",4.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",666,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",647.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",654.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",661.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",669.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",668.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",659.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",654.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",662.8,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",677.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",681.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",683,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",882.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",900.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",840.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",878.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",889.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",742.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",730.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",739.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",782.7,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",758.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",778.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",807.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",827.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",820.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",831.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",853.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",871.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",859.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",876.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",879.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",901.2,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",930.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",939.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",927.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",10.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",11.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",10.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",10.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",11,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",9.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",8.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",9.4,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",9.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",9.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",10.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",10.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",10.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",10.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",10.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",10.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",10.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",10.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",10.9,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",11.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",11.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.5,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",81.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",81.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",79.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",64.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",58.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",57.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",59.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",57.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",58.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",60.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",67.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",78,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",60.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",107.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",113.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",102.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",85.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",78,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",63.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",66.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",65,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",69,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",68.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",77.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",92.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",63.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",112.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",114.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",116.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",101.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",96,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",94.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",101.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",100.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",103.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",110.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",124.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",143,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",114.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",9.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",10.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",9.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",7.8,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",7.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",5.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",6.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",6.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",6.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",7.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",8.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",6.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",10.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",10.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",9.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",8.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",8.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",9.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",9.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",9.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",10.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",11.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",13.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",10.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",12071.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",12185.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",10376.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",9953.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",9722.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",9746,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",9800,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",9854.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",9925.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",9790.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",10122.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",9312.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",9446.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",58.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",60.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",46.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",44.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",41.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",34.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",34.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",35.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",36.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",33.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",32.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",30.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",25.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",95.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",98.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",82.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",79.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",75.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",73.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",74.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",72.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",71.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",69.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",69.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",60.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",58.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",5.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",6.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",4.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",2.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",9.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",9.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",8.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",8.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",6.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",327.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",346.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",345.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",353.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",342.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",339.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",340.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",349.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",368.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",380.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",441.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",482.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",2.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",2.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",2.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",2.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",2.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",2.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",3.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",3.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",3.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",3.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",3.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",2.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",2.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",2.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",2.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",2.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",2.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",2.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",2.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",2.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",3.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",8.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",9.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",8.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",8.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",8.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",7.8,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",8.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",9.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",9.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",8.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",8.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",10.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",7.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",7.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",7.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",7.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",7.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",7.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",7.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",7.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",8.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",8.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",27.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",23.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",23.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",23.6,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",23.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",22.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",22.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",22.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",21.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",21.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",21.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",21.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",36.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",32.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",30.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",31.3,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",31,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",25.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",25.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",25.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",25.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",24,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",24.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",25.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",32.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",28,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",28.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",29,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",28.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",28,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",28.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",28.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",27.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",26.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",26.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",27.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",6.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",6.8,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",6.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",4.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",5.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",6.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",6.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",6.3,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",6.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",6.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",5.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",5.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.2,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",284.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",289.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",302.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",323.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",333.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",343.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",347.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",352.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",359.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",369.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",373.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",375.1,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",396,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",372.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",402.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",429.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",369.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",379.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",392.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",416,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",402.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",421.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",441.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",395,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",375,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",387.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",410.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",437.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",451.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",489.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",504,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",517,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",547.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",570,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",576.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",607.5,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",6.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",6.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",6.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",7.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",6.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",6.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",6.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",6.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",6.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",7.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",6.7,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",6.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",6.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",6.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",7.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",8.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",9.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",9.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",9.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",10.3,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.5,"E","Estimated value" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",200847,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",194869,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",152919.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",133036.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",127839.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",127385.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",123930.9,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",126933.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",132278.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",134990.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",145065.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",151300.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",173.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",175.8,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",135.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",121.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",121.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",112.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",106.8,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",112.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",120.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",115.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",122.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",132.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",238.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",228,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",178.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",153.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",146.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",148.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",144.3,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",145.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",154.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",157.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",173.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",177.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",3.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",3.5,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",2.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",2.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",2.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",2.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",2.1,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",2.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",2.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",2.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",2.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",2.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",4.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",4.6,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",2.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",2.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",2.8,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",2.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",3.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",3.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.9,"B","Break" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.5,"B","Break" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",3.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",3.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",3.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",3.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",3.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",3,"D; P","Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",4.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",4.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",4.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",3.2,"D; P","Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",3.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",3.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",3.6,"D; P","Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",9.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",9.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",9.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",9.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",9.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",7.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",7.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",5.4,"D; P","Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",7.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",8.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",8.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",7.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",6.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",6.2,"D; P","Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",1.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.2,"D; P","Difference in methodology; Provisional value" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",110.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",96.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",93.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",93.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",93.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",146.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",134.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",120.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",124.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",123.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",129.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",115.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",113.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",117.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",115.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",8.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",8.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",6.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",23.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",18.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",18.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",14.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",14.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",14.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",7.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",12.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",6.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",8.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",16.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",14.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",15,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",11.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",9.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",8.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",4.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",5.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",15.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",12.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",12.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",10,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",10.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",9.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",8.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",5.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",4.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",3.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",2.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",168,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",166,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",165,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",167,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",172,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",174,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",180,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",183,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",186,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",202,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",206,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",208,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",225,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",27.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",29.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",28.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",28.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",27.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",21.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",21.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",22.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",22.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",23,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",21.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",24.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",23.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",18.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",18.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",18.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",18.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",18.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",17.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",17.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",18.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",19.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",21,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",20.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",21.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",21,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",5.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",5.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",5.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",5.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",4.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",4.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",4.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",4.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",4.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",4.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",4.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",4.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",3.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",3.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",3.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",3.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",3.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",3.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",3.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",3.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",3.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",3.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",34.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",31.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",29.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",30.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",30.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",31.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",32.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",32.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",34.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",36,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",37.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",38.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",39,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",45.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",43.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",37.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",40,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",40.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",35,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",36,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",37,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",40.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",40.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",43.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",45.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",41.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",55.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",50.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",48.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",51.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",52.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",53.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",57,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",56.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",59.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",64.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",67.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",67.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",70.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",3.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",3.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",3.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",3.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",4.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",5.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",4.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",4.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",4.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",5.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",5.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",5.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",6.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",6.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",6.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",6.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",15.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",15.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",14,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",15.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",15,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",15,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",21.9,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",22,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",22.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",23,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",24.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",24.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",20.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",21.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",18,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",20.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",19.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",16.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",24.2,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",24.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",26.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",25.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",27.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",28.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",30.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",30.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",27.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",30.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",30.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",30.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",43.5,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",42.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",42.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",44.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",46.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",45.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",3.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",3.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",3.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",3.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",4.5,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",4.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",4.8,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",4.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",5.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",5.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",5.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",5.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",5.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",5.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",5.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",8,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",7.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",7.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",8.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",8.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",8.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.4,"B","Break" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",99,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",84.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",79.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",80.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",84.4,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",82.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",85.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",88.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",92.7,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",96.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",100.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",103.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",104.9,"P","Provisional value" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",131.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",118.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",101.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",107.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",112.1,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",91.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",95.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",100,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",109.4,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",108.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",114.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",122.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",110.5,"P","Provisional value" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",136.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",118.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",113.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",119.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",127.4,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",124.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",133.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",140.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",146.7,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",158.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",161.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",165.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",175.9,"P","Provisional value" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",2.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",2.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",2.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",2.4,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.3,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.3,"P","Provisional value" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",2.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",2.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",2.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",2.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",2.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.1,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.7,"P","Provisional value" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.7,"B; D","Break; Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.5,"B","Break" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",430,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",403,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",393,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",411,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",419.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",429.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",394.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",397.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",419.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",437.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",475.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",443.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",454.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",59.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",62.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",58,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",63.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",61.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",50.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",46,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",46.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",48.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",46.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",51.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",51.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",44.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",47.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",45.6,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",45.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",47.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",48,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",48.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",44.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",44.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",47.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",50.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",54.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",50.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",52.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",6.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",6.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",6.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",6.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",6.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",5.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",4.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",4.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",4.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",4.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",4.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",5.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",4.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",4.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",4.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",4.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",4.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",4.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",4.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",161.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",167.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",176.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",196.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",223.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",246.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",293.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",347,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",409.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",545,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",682.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",827.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",107.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",99.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",98.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",103,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",102.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",90.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",97.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",95.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",84.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",96.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",97.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",93.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",175.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",173.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",172.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",183.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",202.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",212.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",236.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",250.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",250.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",292.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",315.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",294.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",1.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",1.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",2.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",2.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",2.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",2.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",3.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",3.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",3.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",3.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",3.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",8640.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",10586.3,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",11971.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",12752.7,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",15358.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",16311,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",19105.1,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",18779.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",18941.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",21320.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",25554,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",22481.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",25660.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",16.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",21.9,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",24.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",25.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",26.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",24.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",28.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",28.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",29.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",30.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",32.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",29.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",29.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",24,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",30.4,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",34.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",36.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",41.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",41.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",48.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",47.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",47.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",53.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",61.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",51.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",58.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",1.3,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",1.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",1.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",1.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",1.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",1.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",1.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",1.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",1.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",1.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.8,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",2.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",2.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",2.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",2.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",2.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",2.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",3.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",2.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.9,"B","Break" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",5.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",4.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",5.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",5.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",5.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",5.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",5.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",5.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",5.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",5.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",5.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",5.9,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",7.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",6.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",6.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",7.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",7.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",6.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",6.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",6.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",6.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",6.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",6.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",6.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",10.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",9.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",10.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",10.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",10.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",10.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",10.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",10.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",10.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",10.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",11.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",10.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",10.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",5.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",5.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",5.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",5.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",4.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",4.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",4.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",4.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",4.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",5.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",7.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",7.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",7.9,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",7.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",7.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",7.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",7.8,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",8.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",8.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",2.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",2.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",2.3,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.6,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",8.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",7.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",8.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",8.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",9.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",10.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",10.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",10.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",10.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",11.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",11,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",11.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",11.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",10.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",10.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",11.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",11.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",10.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",11.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",11.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",12.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",12.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",13,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",11.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",13.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",12.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",13.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",14.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",15.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",15.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",17.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",17.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",18.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",19.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",20.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",19.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",20.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",5.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",5.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",5.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",5.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",5.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",6.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",6.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",5.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",6.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",6.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",7.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",8.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",8.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",9.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",9.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",9.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",9.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",159,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",142,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",118,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",131,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",119,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",124,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",133,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",130,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",132,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",134,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",142,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",148,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",145.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",146.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",122.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",126.5,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",107.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",93.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",98.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",99.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",98.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",93.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",97.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",111.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",105.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",94,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",76.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",90.5,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",81.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",84.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",91.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",88,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",89.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",90.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",97.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",102.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",6.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",6.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",5.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",5.5,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",3.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",3.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",3.9,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",3.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",3.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",34.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",30.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",29.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",28.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",27.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",20.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",10.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",10.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",9.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",9.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",8.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",8.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",45.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",42.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",37.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",37.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",36.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",22.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",12,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",11.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",11.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",10.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",10.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",10.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",40.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",36.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",36.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",35.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",34.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",25.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",14,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",13,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",12.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",12.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",11.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",11.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",5.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",4.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",4.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",4.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",72.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",67.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",63.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",57.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",57.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",48.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",45.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",43.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",35.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",35.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",33.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",31.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",30.3,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",95.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",94.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",82,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",76.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",75.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",53.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",50.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",48.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",41.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",39.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",38.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",37.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",31.9,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",86.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",81.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",77.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",71.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",71.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",60.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",58.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",55.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",46.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",47.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",46.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",43,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",42.4,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",8.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",8.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",7.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",6.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",6.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",4.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",4.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",4.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",3.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",3.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",3.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",3.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",2.7,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",6.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",6.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",5.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",5.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",4.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",4.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",4.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",3.7,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.3,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",613.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",562.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",547.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",545.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",546.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",531.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",472,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",427.3,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",422.5,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",414.4,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",417.4,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",613.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",545.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",495.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",426.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",412.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",409.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",364.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",322,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",315.1,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",330.5,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",320.7,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",492.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",459.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",445,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",437.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",453.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",438.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",391.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",346.1,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",343.2,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",334.7,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",332.9,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",17.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",15.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",14,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",12,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",11.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",11.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",9.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",8.6,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",8.3,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",8.6,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",8.2,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",14.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",13.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",12.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",12.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",12.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",12,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",10.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",9.2,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",8.8,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",8.6,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.3,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",1.2,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",1.1,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1,"E; D","Estimated value; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1005.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",817.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",765.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",730.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",710,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",590.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",515.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",501.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",445.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",436.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",395,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",373.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",52.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",46.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",39.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",37.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",34.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",24,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",21.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",21.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",20.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",19,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",17,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",17.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",73.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",61.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",57.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",57.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",55.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",45.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",41,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",40.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",36,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",35.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",31.7,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",29.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",4.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",3.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",3.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",3.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",2.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",1.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",1.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",1.6,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",1.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",5.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",5.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",5.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",5.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",4.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",3.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",3.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",3.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",3.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",3,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",2.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.4,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",17,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",15.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",15.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",16.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",18.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",19,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",19.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",18.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",16.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",12.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",11.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",11.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",22.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",21.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",19.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",22.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",24,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",21.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",21.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",20.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",19.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",14.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",13,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",13.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",18.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",16.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",16.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",18.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",20,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",20.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",22,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",21.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",19.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",15.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",13.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",13.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",4.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",3.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",3.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",4.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",4.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",3.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",3.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",3.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",3.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",2.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",2.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",3.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",3.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",3.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",3.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",3.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",3.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",3.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",2.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",308,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",292,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",289.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",283.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",284.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",284.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",285,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",287.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",297.5,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",318.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",330.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",341.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",408.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",406.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",372.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",376.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",378.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",316.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",315.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",324.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",351.3,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",356.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",377.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",404.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",382.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",370.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",367.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",365.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",370.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",366.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",378.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",385.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",404.5,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",436.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",456.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",464.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",5.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",3.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",3.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",4.2,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",4.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",4.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",4.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",4.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",4.9,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",5.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",5.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.7,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",94.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",77.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",68.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",61,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",56,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",50.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",50.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",49.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",45.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",44.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",40.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",39.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",28.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",125,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",108.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",88.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",81,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",74.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",55.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",55.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",55.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",54.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",49.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",46.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",46.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",30.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",130.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",108.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",100.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",96.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",91.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",82.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",85.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",85.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",81.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",81,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",75.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",71.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",54.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",11.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",9.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",7.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",6.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",5.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",5.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",5.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",4.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",4.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",4.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",2.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",11.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",9.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",9.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",8.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",8.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",7.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",7.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",7.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",7.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",7.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",6.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",5.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",6967.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",6798.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",5530.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",3769.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",3109.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",2946.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",2787.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",2649.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",2558.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",2496.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",2522.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",2313.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",2220.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",33.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",33.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",24.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",16.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",13.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",10.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",9.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",9.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",9.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",8.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",8.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",55.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",54.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",44,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",30.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",24,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",21.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",19.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",18.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",17.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",17.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",15,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",13.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",1.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",2.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",1.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",223.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",229.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",211.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",198.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",185.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",156.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",165.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",164.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",180.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",199.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",236.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",289.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",1.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",1.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",1.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",1.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",1.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",1.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",1.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",2.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",1.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",1.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",1.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",1.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",1.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",1.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",1.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",1.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",1.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",1.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",5.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",6.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",5.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",4.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",3.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",4.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",4.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",4.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",4.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",4.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",6.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",5.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",4.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",4.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",4.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",3.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",3.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",3.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",3.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",3.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",4.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",5.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",26.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",24.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",25.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",24,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",22.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",18,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",18.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",17.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",17.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",17.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",18.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",18.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",35.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",34.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",32.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",31.8,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",29.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",20,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",20,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",19.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",20.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",19.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",20.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",22.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",31.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",29.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",30.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",29.6,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",27.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",22.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",22.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",22.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",22.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",21.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",22.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",23.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",7.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",7.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",6.9,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",6.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",6.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",6.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",6.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",6.4,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",5.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.2,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",389,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",332.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",323.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",318.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",301.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",296.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",286.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",281,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",274.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",271.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",264.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",256.5,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",541.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",427.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",429.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",422.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",335,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",328.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",323.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",331.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",307.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",310.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",312.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",270.1,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",512.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",444.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",438.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",430.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",408.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",423.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",415.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",412.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",418.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",419.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",408.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",415.4,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",9.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",7.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",7.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",5.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",5.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",5.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",5.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",5.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",5.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",5.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",4.6,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",8.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",7.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",7.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",6.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",6.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",6.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",7.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",6.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",7,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1,"E","Estimated value" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",514083,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",493836.7,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",439045.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",412627,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",380517.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",364513.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",345301,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",337442.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",334169.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",326138.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",344643.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",345302.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",444.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",445.6,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",389.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",376.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",361.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",322.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",297.5,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",298.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",303.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",279.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",292,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",301.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",611.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",577.9,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",513.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",474.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",436.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",425.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",402.1,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",386.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",390.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",380.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",411.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",404.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",8.9,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",7.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",7.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",7.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",6.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",5.8,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",5.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",5.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",5.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",5.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",12.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",11.6,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",10.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",9.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",8.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",8.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",7.9,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",7.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",7.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",7.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",7.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",2.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.2,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",1.4,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",1.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",1.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",1.1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",1.1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",2.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",1.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",1.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",1,"D; P","Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",3.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",2.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",1.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",1.1,"D; P","Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",2.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",2.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",1.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",1.2,"D; P","Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",7.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",6.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",2.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",1.8,"D; P","Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",6.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",5.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",2.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",2.1,"D; P","Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",62.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",60.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",60.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",64.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",65.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",82.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",84.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",78.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",86.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",87.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",72.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",72.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",73.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",81.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",81.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",5.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",5.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",5.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",13.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",14.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",13.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",9.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",8.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",8.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",5.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",5.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",5.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",5.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",6.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",7.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",9.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",11.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",10.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",7.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",6.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",5.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",3.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",3.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",4.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",8.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",10,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",6.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",5.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",3.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",5.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",159,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",141,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",132,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",128,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",130,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",121,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",126,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",128,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",111,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",108,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",111,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",109,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",114,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",26.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",25.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",22.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",21.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",20.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",15,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",15,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",15.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",13.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",12.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",11.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",12.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",11.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",17.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",15.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",14.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",14.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",14,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",12.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",12.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",13.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",11.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",11.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",11.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",11.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",10.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",5.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",5.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",4.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",4.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",2.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",2.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",2.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",54.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",44.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",35.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",29.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",27,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",26,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",25.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",24.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",23.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",23.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",23.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",23,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",23.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",72.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",61.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",45.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",38.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",35.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",28.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",27.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",27.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",28.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",26.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",26.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",27.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",24.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",87.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",71.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",58,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",50.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",46.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",44.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",43.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",42.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",41.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",42,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",41.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",40.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",42.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",6.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",5.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",3.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",8.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",6.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",4.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",1.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",17.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",16.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",10.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",10,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",8.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",11.3,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",10.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",9.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",9.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",9.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",8.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",22.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",22.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",12.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",13.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",12,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",9.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",12.6,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",11.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",11.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",10.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",10.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",10.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",34.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",31.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",19.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",20.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",18.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",16.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",22.5,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",20.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",18.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",17.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",17.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",15.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",4.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",4.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",2.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",2.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",2.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",2.3,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",2.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",2.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",1.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",6.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",3.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",3.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",3.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",4.1,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.7,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",238.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",187,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",126.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",110.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",112.6,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",108.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",108.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",107.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",109.5,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",110.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",109.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",110,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",109.5,"P","Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",316,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",260.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",162.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",147.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",149.5,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",120.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",120.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",121.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",129.3,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",123.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",125.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",130.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",115.3,"P","Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",327.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",261.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",182.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",164.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",169.9,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",162.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",168.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",170.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",173.3,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",179.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",176.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",175.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",183.7,"P","Provisional value" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",6.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",5.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",3.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",3.2,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.8,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.4,"P","Provisional value" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",5.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.7,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.7,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.9,"P","Provisional value" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",1.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",1,"B; D","Break; Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",206.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",195.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",193,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",198.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",202,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",203.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",200.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",202.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",209.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",239.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",275.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",249.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",254.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",28.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",30.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",28.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",30.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",29.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",24.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",23.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",23.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",24.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",25.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",29.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",29.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",25.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",22.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",22.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",22.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",23.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",23.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",23,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",22.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",22.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",23.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",27.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",31.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",28.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",29.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",3.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",3.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",3.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",2.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",2.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",2.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",3.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",2.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",2.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",131.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",121.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",112.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",126.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",127.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",140.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",158.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",197.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",240.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",286.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",368.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",424.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",87.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",72.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",62.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",66.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",58.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",51.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",52.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",54.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",49.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",50.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",52.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",48,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",143,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",125.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",110.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",118.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",115.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",121,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",128,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",142.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",147,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",153.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",170.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",151.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",1.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",1.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",1.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.6,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",1.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",1.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",4975.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",5881.7,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",5913.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",5672.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",6613,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",6710.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",6996.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",8473.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",6690.4,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",7243.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",8829.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",7415.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",7600.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",9.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",12.2,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",12.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",11.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",11.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",10.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",10.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",13.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",10.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",10.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",11.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",9.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",8.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",13.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",16.9,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",17,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",16.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",18,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",17.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",17.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",21.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",16.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",18,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",21.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",17,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",17.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.7,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.8,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.5,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",4.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",3.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",3.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",2.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",2.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",2.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",2.1,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",1.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",1.8,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",1.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",1.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",6.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",5.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",4.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",3.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",3.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",2.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",2.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",2.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",2.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",1.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",1.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",1.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",1.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",9.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",7.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",6.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",5.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",4.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",4.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",3.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",3.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",3.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",3.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",2.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",2.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",4.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",3.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",3.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",2.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",1.5,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",1.4,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",5.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",3.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",3.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.7,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",2.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2.4,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",2.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.8,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.6,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.5,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",10,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",8.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",6.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",6.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",6.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",6.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",5.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",5.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",5.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",5.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",13.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",11.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",8.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",8.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",8.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",6.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",6.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",6.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",6.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",6.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",6.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",6.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",5.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",15.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",13.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",11,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",11.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",10.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",10.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",10.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",10.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",9.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",10,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",10.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",9.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",9.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",6.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",4.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",3.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",3.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",3.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",5.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",5.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",5.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",4.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",4.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",4.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",592,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",609,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",562,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",740,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",706,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",679,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",636,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",598,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",624,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",654,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",705,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",757,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",543,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",628.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",581.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",714.4,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",636.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",510.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",472.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",458.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",466.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",454.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",485.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",568.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",393.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",403,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",364.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",511.4,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",486.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",460.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",438.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",404.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",424.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",441.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",484.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",522.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",24.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",28.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",25.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",30.9,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",27.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",21.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",19.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",18.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",18.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",17.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",18.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",22.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",17.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",18,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",16.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",22.1,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",20.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",19.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",18.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",16.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",18.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",20.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",6.3,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",4.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",4.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",4.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",195.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",197,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",194.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",167.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",160.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",157.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",159.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",160.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",155.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",142.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",138.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",127.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",259.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",274.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",250,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",221.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",213.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",174.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",176.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",181.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",183.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",159.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",157.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",151,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",232,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",237,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",239.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",209.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",201.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",197.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",204.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",207,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",202.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",189.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",185.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",168.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",31,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",32.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",29.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",26.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",25,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",20.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",20.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",20.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",20.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",17.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",17.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",16.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",27.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",28.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",28.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",24.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",23.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",22.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",23.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",23.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",22.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",21.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",20.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",18.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",7.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",7.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",7.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",6.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",5.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",5.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",5.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",5.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",4.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",4.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",3.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",234.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",233,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",226.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",218.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",199.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",196.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",190.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",175.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",169.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",188.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",189.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",190,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",190.7,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",311.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",324.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",290.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",289.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",264.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",218,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",210.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",198.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",200.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",211.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",216.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",224.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",200.8,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",280.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",280,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",275.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",270.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",249.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",245.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",243.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",226.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",221.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",252.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",259.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",257.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",267.1,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",28.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",29.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",26.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",26,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",23.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",19.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",18.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",17.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",17.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",18.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",18.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",19.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",17.3,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",25.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",25.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",24.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",24.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",22.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",21.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",21.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",19.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",19.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",22,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",22.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",22.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",23,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",3.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",3.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.1,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1362.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1207.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1208.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1229,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1272.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1310,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1051.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",946.4,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",994,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",971.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1013.8,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1363.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1172.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1094.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",961.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",959.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1009.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",811.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",713.3,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",741.2,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",774.8,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",778.9,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1094.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",986.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",982.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",984.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1053.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1080.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",871.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",766.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",807.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",784.6,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",808.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",39.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",33.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",30.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",26.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",26.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",27.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",19,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",19.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",20.3,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",20,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",31.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",28.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",27.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",27.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",29.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",29.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",23.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",20.4,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",21.2,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",20.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",20.8,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",4.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",4.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",4.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",3,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.9,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.6,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.5,"E; D","Estimated value; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",3919.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3853.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",3699.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",3409.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",3058.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2834,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2861.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2895.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2896.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",3060.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",3164.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",3292.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",205.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",217.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",188.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",174.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",147.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",115.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",117.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",123.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",133.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",133.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",136.3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",151.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",286.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",288.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",278.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",266.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",240.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",219,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",227.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",233,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",234.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",249.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",254,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",258.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",19.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",20.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",18,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",16.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",14,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",10.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",11.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",11.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",12.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",12.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",12.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",14.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",27.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",27.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",26.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",25.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",22.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",20.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",21.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",22,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",22,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",23.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",23.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",24.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",4.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",3.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",3.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",3.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",3.6,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",3.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",77.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",71.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",63,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",57.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",54.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",55,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",54.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",50.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",46.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",43.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",38.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",34.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",103.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",99.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",80.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",75.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",72.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",61,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",60,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",57,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",54.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",48.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",44,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",40.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",86.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",79.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",69.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",63.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",60.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",60.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",61.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",58.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",54.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",51.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",46.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",41.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",19.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",18.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",15,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",13.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",11.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",10.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",10.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",10,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",8.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",7.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",16.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",14.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",12.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",11.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",11,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",10.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",8.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",7.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",2144.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",2149.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1919.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1860.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1739.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1590,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1604.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1609.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1680,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1770.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1838,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",1921.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2842.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2992.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2465.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2470.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2311.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1764.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1775.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1818.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",1984,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",1981.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2099.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",2272.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2663.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2725.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2437.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2401.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2262.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2043.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2131.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2161,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",2284.3,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",2430.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",2535.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",2610,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",34.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",37.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",30.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",30.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",28.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",21.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",21.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",22,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",23.9,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",23.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",25.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",27.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",32.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",34,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",30.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",29.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",27.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",25,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",25.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",26.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",27.6,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",29.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",30.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",31.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",7.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",7.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",6.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",5.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",5.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",4.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",4.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",3.8,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",3.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",3.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",3.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",539.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",523.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",473.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",400.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",364.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",331.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",362.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",334.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",304.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",299.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",273.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",258.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",201.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",715.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",728.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",608,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",531.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",484.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",367.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",401.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",377.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",359.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",335.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",312.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",305.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",212,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",747.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",733.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",691.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",633.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",596.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",543.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",616.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",581.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",538.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",545.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",502.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",474,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",380.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",64.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",65.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",55.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",48.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",44.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",34,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",37.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",35.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",33.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",31.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",29.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",28.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",20.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",67.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",66.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",62.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",57.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",54.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",50.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",57.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",54.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",50.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",50.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",47,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",44.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",36.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",48076.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",45712.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",37976.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",35227.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",34341.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",35167.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",36400.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",37305.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",38914.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",40873.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",43416.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",43066.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",44307.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",231.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",227.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",168.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",157.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",147.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",125.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",129.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",135.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",144,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",140.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",141,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",142.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",118.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",380.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",367.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",302.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",281.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",265.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",265.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",275.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",274.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",279.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",290.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",298.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",278.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",274.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",23.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",22.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",17,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",15.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",15,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",12.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",13.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",13.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",14.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",14.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",14.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",14.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",38,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",36.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",30.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",28.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",26.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",27,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",28.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",28,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",28.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",29.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",30.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",28.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",28.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",9.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",8.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",8.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",8.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",7.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",7.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",7.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",7.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",7.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",7.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",7.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",7.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",543.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",520.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",435.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",417.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",439.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",438,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",448,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",454.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",522.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",597.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",663.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",711.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",3.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",3.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",3.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",4.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",5.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",3.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",3.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",3.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",4.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",14,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",14.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",10.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",10.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",11.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",10,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",11.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",12.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",13.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",13.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",13.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",15,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",12.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",12.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",9.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",9.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",9.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",9.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",9.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",10.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",11.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",12.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",12.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",2.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",95.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",85.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",85.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",76.8,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",67.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",59.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",59.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",53.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",54.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",55,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",57.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",60,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",127,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",118.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",110.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",102,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",89.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",66,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",65.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",60,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",64.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",61.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",65.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",70.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",112.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",102.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",104.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",94.7,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",82,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",73.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",74.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",66.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",68.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",68.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",72.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",75.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",27.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",25.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",23.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",22.1,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",19.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",14,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",13.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",12.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",13.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",12.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",13.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",14.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",24.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",22.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",22.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",20.5,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",15.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",15.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",13.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",14.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",15,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",4.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.9,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1932.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1645.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1551.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1398.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1378.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1342.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1212.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1186.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1177.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1198.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1202.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1211.6,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",2689.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",2114.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",2061.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1857.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1529.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1486.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1370,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1400.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1318.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1369.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1421.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1275.8,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",2546.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",2201.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",2104.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1890.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1865.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1916.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1757.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1741.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1793.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1850.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1856.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1962.3,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",45.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",35.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",34.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",30.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",25.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",24.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",22.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",23.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",22.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",23,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",24,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",21.6,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",42.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",37,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",34.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",31.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",30.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",31.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",29,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",28.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",30,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",31.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",31.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",33.2,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",9.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",8.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",6.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",5.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",5.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",5.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",5.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",5.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",4.9,"E","Estimated value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",961836,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1069530.1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1064218.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1080388,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1087636.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1101576.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1155427.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1216111.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1305044.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1358778.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1501478.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1601805.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",831.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",965.1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",944.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",986.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1033.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",974,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",995.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1075.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1186.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1166,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1272.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1400.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1143.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1251.5,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1244.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1243.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1247.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1284.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1345.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1393.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1526.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1586.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1792.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1875.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",16.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",19.3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",18.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",19.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",20.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",19.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",19.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",20.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",23,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",22.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",24.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",27.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",23.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",25.1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",24.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",24.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",24.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",25.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",26.3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",27.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",29.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",30.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",34.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",36.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",4.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",4.8,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",4.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",4.6,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",4.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",4.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",14.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",14.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",14.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",13.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",11.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",11,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",10.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",9.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",10,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",10.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",10,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",10,"D; P","Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",19.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",20.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",18.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",17.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",15.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",12.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",11.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",11,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",11.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",11.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",11.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",10.6,"D; P","Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",16.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",16.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",15.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",14.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",12.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",12.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",12.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",11.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",11.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",12.1,"D; P","Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",41.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",42.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",37.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",35.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",29.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",23.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",22.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",20.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",20,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",20,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",20.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",20.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",18,"D; P","Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",34,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",33.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",32.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",29.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",25.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",24.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",23.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",21.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",21,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",20.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",20.6,"D; P","Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",7.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",7.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",7.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",6.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",5.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",5.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.9,"D; P","Difference in methodology; Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",265.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",256.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",206.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",167.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",141.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",352,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",356.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",265.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",222.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",187.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",310.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",306.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",250.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",210,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",174.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",21.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",21.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",15.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",13.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",11.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",18.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",18.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",15,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",12.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",10.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",5.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",4.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",4.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",3.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",34.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",34.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",31.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",17.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",14.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",13.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",11.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",11.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",15.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",22.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",31.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",24.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",27.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",25.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",14.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",9.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",8.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",8.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",8.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",7.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",10.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",15.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",20.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",23,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",23.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",21.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",10.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",9.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",8.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",8.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",8.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",8.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",11,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",15.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",22,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",5.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",6.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",5.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",3.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",5.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",5.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",4.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",4.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",4.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",808,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",782,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",647,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",471,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",443,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",420,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",440,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",451,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",472,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",520,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",546,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",570,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",566,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",133.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",139.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",111.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",80.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",70.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",52.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",52.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",54.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",58,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",59.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",58,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",66.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",58.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",88.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",86.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",71.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",52.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",47.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",42.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",43.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",46.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",49.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",54.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",55.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",59.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",52.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",27.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",28.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",22.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",15.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",13.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",10,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",10,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",10.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",10.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",11,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",10.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",12.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",10.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",18.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",17.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",14.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",8.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",8.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",8.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",9.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",10.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",10.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",4.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",397.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",374.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",320.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",268.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",250,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",233.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",217,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",202.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",196.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",204.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",214.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",223.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",237.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",527.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",521.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",411.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",356.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",332.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",258.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",240.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",228.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",231.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",228.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",244.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",264.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",250.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",638.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",600.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",529,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",459.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",431.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",398.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",379.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",352,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",343.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",365.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",384.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",394.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",432.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",49.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",49.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",39.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",34.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",31.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",25,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",23.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",22.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",22.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",22.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",23.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",25.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",24.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",60.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",56.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",50.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",44,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",41.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",38.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",36.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",34.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",33.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",35.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",37.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",41.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",12.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",11.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",10.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",9.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",8.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",7.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",7.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",7.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",7.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",7.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",58.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",60.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",54.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",49.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",46.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",43.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",58.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",58.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",60.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",63.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",67.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",68.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",78,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",84.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",69.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",65.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",61.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",48.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",64.6,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",66.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",71.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",71.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",77.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",80.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",117.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",120.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",107.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",100.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",95.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",89.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",116,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",113.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",114.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",123.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",130.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",127.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",14.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",15.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",12.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",12.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",11.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",11.9,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",12.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",13.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",13.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",14.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",14.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",21.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",22.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",19.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",18.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",17.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",16.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",21.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",20.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",21.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",22.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",23.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",23.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",5.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",5.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",4.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",3.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",3.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",3.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",3.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",3.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1246.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1137.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",963,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",923,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",894.6,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",870.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",884,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",837.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",836.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",852.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",878.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",905.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",935.1,"P","Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1652.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1583.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1237.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1225.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1188.4,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",965.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",978.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",946.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",988.1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",954.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1003.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1071.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",984.7,"P","Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1714.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1592.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1385.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1367.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1350.6,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1308.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1375.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1328,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1324.3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1391.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1413.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1447.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1568.4,"P","Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",35.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",33.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",26.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",26.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",25.6,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",20.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",21.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",20.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",21.1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",20.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",21.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",22.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",20.8,"P","Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",36.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",34.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",29.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",29.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",29.1,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",28.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",29.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",28.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",28.3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",29.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",29.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",30.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",33.1,"P","Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",9.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",9.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",8.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",8.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",7.9,"B; D","Break; Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",7.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",7.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",6.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",4.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",4.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",4.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",4.1,"P","Provisional value" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",998.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",885.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",627.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",457.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",413.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",422,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",414,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",440.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",561.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",707.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",756.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",716.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",800.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",138.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",136.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",92.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",70.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",60.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",50,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",48.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",51.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",64.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",74.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",82.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",83.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",79.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",110.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",100.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",72.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",53.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",47.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",47.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",46.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",49.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",63.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",81.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",87.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",82.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",92.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",14.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",14.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",9.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",7.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",6.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",5.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",5.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",6.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",7.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",7.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",11.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",10.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",7.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",4.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",4.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",6.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",7.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",8.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",827.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",707.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",597.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",586.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",564.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",590.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",648.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",760.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",900.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1189.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1480.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1722.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",550.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",422.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",332.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",307.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",258.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",217.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",214.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",208.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",186.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",209.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",211.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",194.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",899,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",732,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",585.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",547.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",511.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",507.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",522.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",549.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",551.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",638.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",684.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",613.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",7.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",3.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",2.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",2.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",2.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",12.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",9.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",7.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",7.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",6.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",6.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",6.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",6.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",7.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",8.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",7.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",5.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",3.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",28108.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",32614.1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",35202.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",36639.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",44854.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",49040.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",54643.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",55530.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",56121.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",64723.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",83853.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",71737.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",90072.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",55.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",67.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",72.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",74,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",78.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",75,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",80.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",85.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",87.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",92.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",105.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",94.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",103.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",78.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",93.7,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",101.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",104.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",122.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",125.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",137.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",139.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",141.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",161.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",200.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",164.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",205.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3.9,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",4.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",4.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",4.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",5.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",4.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",4.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",5.4,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",5.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",5.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",6.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",7.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",8.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",10.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",8.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",10.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.8,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",3.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",11.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",11.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",12.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",12.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",12.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",12.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",11.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",12.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",12.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",13.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",14,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",14.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",15.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",15.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",16.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",17.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",13.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",13.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",13.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",14.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",14.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",15.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",16.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",15.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",22.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",21.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",22.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",23.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",24.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",23,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",23.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",21.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",22.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",23.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",26.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",25.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",25.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",11.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",11.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",12.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",13,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",10.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",10.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",10.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",10.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",10.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",11.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",12.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",11.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",17.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",17.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",18.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",18.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",17.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",17.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",16.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",17.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",18,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",19.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",19.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",19.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",5.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",5.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",4.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",4.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",3.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",3.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",54.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",51.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",47,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",42.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",33.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",30,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",28.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",28.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",28.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",30,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",31.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",32.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",35.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",72.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",71.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",60.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",56.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",44.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",33.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",31.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",32.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",34,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",33.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",35.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",38.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",37.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",86.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",82.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",77.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",72,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",57.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",50.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",48.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",49.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",50.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",54.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",57.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",58.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",64,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",35.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",35,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",29.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",27.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",21.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",16.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",15.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",15.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",16.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",16.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",17.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",18.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",17.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",42,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",40.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",37.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",35,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",27.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",24.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",23.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",24.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",24.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",26,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",27.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",27.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",30.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",11.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",11,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",10.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",9.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",7.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",6.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",5.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",5.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",5.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",5.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",5.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",1680,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",1756,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",1538,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",1288,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1028,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",820,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",709,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",674,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",657,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",639,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",642,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",646,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1541.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",1811.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",1592.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1243.4,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",926.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",616,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",527.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",516.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",490.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",444.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",441.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",485.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1117.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1162.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",998.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",890,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",707.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",556.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",488.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",456.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",446.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",431.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",441.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",446.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",69.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",81.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",70,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",53.8,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",39.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",25.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",21.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",21,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",19.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",17.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",17.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",18.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",50.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",52,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",43.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",38.5,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",30.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",23.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",20.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",18.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",17.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",17.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",17.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",14.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",10.9,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",8.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",6.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",4.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",96.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",102.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",102.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",90,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",91.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",94.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",102.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",110.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",108.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",101.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",97.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",102.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",127.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",142.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",131.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",119.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",122,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",105.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",113.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",125,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",128.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",113.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",111.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",120.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",114.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",123.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",125.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",113,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",115,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",118.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",131.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",142.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",142.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",135,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",130.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",135,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",15.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",17,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",15.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",14.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",14.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",12.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",12.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",14.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",14.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",12.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",12.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",13.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",14.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",13.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",13.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",13.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",15.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",16.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",16.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",15.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",14.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",15.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",3.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",3.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",3.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",3.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",3.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",3.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",3.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",3.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",2.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",2.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",313.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",328,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",295.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",253.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",226.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",219.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",218.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",212.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",167.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",156.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",152.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",154.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",176.6,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",416.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",456.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",379.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",337.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",300.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",243.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",241.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",240.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",197.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",175.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",174.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",183,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",186,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",375.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",394.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",359.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",314.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",282.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",274.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",279.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",274.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",218.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",209.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",209.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",210.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",247.4,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",38.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",41.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",34.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",30.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",26.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",21.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",21.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",21.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",17.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",15.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",15.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",15.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",16,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",34.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",35.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",32.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",25.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",24.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",24.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",24.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",19.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",18.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",18.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",18.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",21.3,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",5.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",5.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1823.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1484.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1370.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1237.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1239.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1229.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",978.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",912.4,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",958.7,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1014.6,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1085.5,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1824.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1441,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1240.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",967.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",934.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",947.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",755.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",687.6,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",714.8,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",809.1,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",834,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1465,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1212.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1113.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",991.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1026.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1014.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",811.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",738.9,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",778.8,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",819.4,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",865.8,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",52.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",41.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",35,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",27.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",25.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",25.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",20.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",18.3,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",18.8,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",21.2,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",21.5,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",42.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",31.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",27.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",28.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",27.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",19.7,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",20.5,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",21.4,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",22.3,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",7.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",4.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",4.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.9,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.8,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.8,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.7,"E; D","Estimated value; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2875.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2950.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",3248.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2840.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2107.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2029.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2070.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2015.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1993.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1986.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1561.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",1516.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",150.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",166.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",165.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",145.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",101.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",82.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",84.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",86.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",91.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",86.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",67.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",69.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",210.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",221.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",244.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",222.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",165.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",156.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",164.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",162.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",161.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",161.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",125.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",119,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",14.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",15.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",15.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",13.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",9.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",7.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",8.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",8.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",6.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",6.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",20.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",21.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",23.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",21.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",15.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",14.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",15.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",15.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",15.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",15.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",11.7,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",11.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1.8,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",34.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",29.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",35.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",41.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",49.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",58.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",66.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",65.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",45.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",31.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",23.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",22.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",46.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",41.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",45.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",55.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",65.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",65.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",73.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",73.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",53.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",35,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",27.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",26.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",38.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",33.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",38.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",46.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",54.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",64.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",75.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",75.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",52.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",37.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",28.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",26.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",8.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",7.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",8.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",10.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",11.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",11.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",13.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",13.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",9.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",6.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",4.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",4.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",7.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",7.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",8.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",9.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",13.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",13.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",6.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",5.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",4.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",708.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",672.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",641.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",594,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",587,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",596.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",665.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",733.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",792.7,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",779.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",775.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",800,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",939.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",936.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",824.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",788.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",779.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",662.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",736.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",828.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",936.1,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",873,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",885.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",946.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",880.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",852.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",815.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",766.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",763.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",767.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",884.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",985,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1077.8,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1070.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1069.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1086.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",11.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",11.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",10.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",9.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",9.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",8.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",8.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",10,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",11.3,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",10.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",10.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",11.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",10.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",10.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",10.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",9.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",9.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",9.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",10.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",13,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",12.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",12.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",13.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.8,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",543.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",480.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",434.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",362,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",348.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",304.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",344.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",311.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",328.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",331.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",306.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",330.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",264.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",720.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",668.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",558.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",480.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",463,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",337.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",381.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",352.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",388.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",371.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",350.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",391,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",278.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",752.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",673.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",635.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",573.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",570.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",499.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",585.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",542.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",582.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",603.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",563.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",605.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",500.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",64.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",60.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",50.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",43.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",42.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",31.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",35.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",32.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",36.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",34.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",32.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",37,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",26.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",67.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",60.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",57.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",52.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",52.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",46.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",54.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",50.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",54.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",56.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",52.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",57.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",47.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",37190,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",37000.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",27959.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",22838.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",19830.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",18929.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",19032,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",19139.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",18500.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",17695.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",18469.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",18235.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",20344.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",178.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",184,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",124.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",102.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",85.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",67.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",67.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",69.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",68.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",60.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",60,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",60.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",54.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",294.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",297.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",222.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",182.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",153.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",142.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",144.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",140.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",133,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",125.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",127.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",117.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",126.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",17.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",18.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",12.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",10.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",8.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",6.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",6.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",7.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",6.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",6.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",6.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",5.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",29.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",29.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",22.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",18.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",15.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",14.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",14.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",14.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",13.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",12.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",13,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",12.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",13,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",7.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",7.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",6.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",5.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",4.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",4.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",3.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",3.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",3.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",3.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",3.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",335.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",366,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",367.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",308.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",333.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",308.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",326.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",344.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",380,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",420.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",473.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",518.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",2.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",3.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",2.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",2.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",2.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",2.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",2.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",3.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",3.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",3.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",3.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",4.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",2.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",2.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",2.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",2.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",2.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",2.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",2.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",2.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",3.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",3.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",8.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",9.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",9.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",7.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",8.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",7.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",8.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",9.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",9.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",9.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",9.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",11,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",7.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",8.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",8.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",7.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",6.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",6.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",7.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",7.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",8.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",8.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",9.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",193.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",150.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",145.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",112.4,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",69.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",65.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",65.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",66.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",64.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",58.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",58.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",61.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",256.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",209.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",187.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",149.2,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",92.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",72.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",72.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",74.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",76,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",65.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",66.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",72.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",227.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",181.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",177.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",138.5,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",84.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",80.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",82.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",83.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",81.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",72.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",73.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",77.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",56.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",45.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",40.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",32.3,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",19.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",15.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",15.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",15.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",15.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",13.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",13.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",14.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",50,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",39.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",38.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",30,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",17.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",17.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",17.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",16.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",14.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",14.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",15.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",9.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",7.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",7.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",5.7,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",3.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",3.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1377.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1145,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1033.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1008.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1012.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1039.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1092.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",875.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",830.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",890.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",955.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1037.3,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1917,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1471.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1372.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1339.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1123.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1150.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1233.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1033.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",929.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1017.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1130.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1092.4,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1815.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1531.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1401.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1363.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1370.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1483.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1583.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1284.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1264.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1375.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1476,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1680.1,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",32.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",24.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",22.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",22,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",18.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",19,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",20.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",17.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",15.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",17.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",19.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",18.5,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",30.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",25.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",23.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",22.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",22.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",24.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",26.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",21.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",21.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",23.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",25,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",28.5,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",7.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",4.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",3.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",3.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",3.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",4.2,"E","Estimated value" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",675149,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",782416.7,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",810160.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",892862.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",970126.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1051102.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1183828.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1343510.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1501571.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1659196.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1932203,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",2227864,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",583.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",706,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",719,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",815.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",921.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",929.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1019.9,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1187.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1364.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1423.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1637.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1947.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",802.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",915.6,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",947.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1027.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1112.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1225.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1378.5,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1539.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1756.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1937.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",2306.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",2608.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",11.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",14.1,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",14.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",16.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",18.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",18.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",19.9,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",23.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",26.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",27.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",31.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",37.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",16.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",18.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",18.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",20.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",21.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",24,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",26.9,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",30,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",34.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",37.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",44.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",50.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",3.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",3.5,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",3.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",4.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",4.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",4.7,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",5.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",5.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",5.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",6.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",15.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",17.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",15.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",13.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",12.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",12.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",11.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",8.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",10,"D; P","Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",21,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",24.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",22.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",20.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",14.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",13.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",13.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",10.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",9.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",10.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",10.5,"D; P","Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",17.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",19.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",19.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",14.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",14.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",14.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",13.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",10.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",9.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",9.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",10.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",12,"D; P","Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",44.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",50.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",45.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",41.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",34.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",27.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",26.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",24.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",19.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",16.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",16.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",18.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",17.9,"D; P","Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",36.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",40,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",39.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",34.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",29.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",27.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",28.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",25.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",19.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",17.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",16.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",18.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",20.5,"D; P","Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",8.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",9.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",8.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",6.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",6.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",6.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",3.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",3.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",3.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.9,"D; P","Difference in methodology; Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",298.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",309.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",242.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",213.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",213.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",396.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",431.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",311.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",283.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",283.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",349.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",370.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",294,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",267.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",264.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",23.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",25.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",18.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",16.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",16.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",21.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",22.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",17.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",15.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",15.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",5.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",5.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",5.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",4.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",37.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",53.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",76.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",30.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",17.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",11.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",9.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",7.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",8.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",8.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",27.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",42.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",62,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",24.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",14.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",12.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",8.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",6.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",5.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",4.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",5.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",5.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",25.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",36,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",51.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",20.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",12.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",11.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",8.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",6.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",5.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",5.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",6.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",6.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",9.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",14.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",5.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",5.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",8.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",11.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",4.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",5.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",6.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",8.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",440,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",405,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",375,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",391,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",377,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",406,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",473,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",504,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",509,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",493,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",473,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",502,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",554,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",72.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",72.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",64.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",66.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",59.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",50.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",56.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",60.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",62.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",56,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",50.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",58.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",57.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",48.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",44.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",41.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",43.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",40.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",40.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",47.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",51.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",53.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",51.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",47.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",52.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",51.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",14.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",12.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",13.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",11.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",9.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",10.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",11.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",11.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",10.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",9.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",10.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",10.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",8.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",8.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",7.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",7.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",9.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",10,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",9.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",8.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",9.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",256.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",202.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",163.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",153.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",157.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",161,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",166.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",160.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",143.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",149.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",160.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",170.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",188.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",340.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",281.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",210.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",203.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",209.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",178.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",184,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",181,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",169.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",167.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",182.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",201.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",198.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",411.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",324.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",270.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",262.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",272.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",275.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",291,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",278.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",251.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",267.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",287.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",300.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",342.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",32.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",26.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",20,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",19.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",20.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",17.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",17.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",17.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",16.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",16.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",17.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",19.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",19.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",38.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",30.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",25.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",25.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",26.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",26.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",28.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",27,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",24.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",26,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",27.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",29,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",33.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",7.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",6.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",6.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",6.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",6.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",6.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",6.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",5.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",5.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",32.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",32.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",26.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",22,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",21.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",23.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",25.8,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",27,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",27.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",27.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",29.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",32.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",43.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",45.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",33.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",29.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",28.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",25.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",28.6,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",30.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",32.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",30.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",34,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",38,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",65.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",64.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",51.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",44.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",44.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",47.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",51.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",52.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",51.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",53,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",57.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",60.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",8.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",8.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",6.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",5.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",5.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",4.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",5.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",5.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",5.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",5.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",6.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",12.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",11.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",9.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",8.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",8.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",8.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",9.5,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",9.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",9.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",9.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",10.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",11.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",2.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",2.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",2.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.6,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1024,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",751.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",662,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",650.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",715.3,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",765.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",827.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",858.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",861,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",886.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",931.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",928.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",999.7,"P","Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1357.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1045.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",850.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",864,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",950.3,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",849.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",915.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",969.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1016.8,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",992.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1064,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1097.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1052.8,"P","Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1408.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1051.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",952.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",964.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1080,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1151.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1287.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1360.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1362.8,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1446.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1499.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1482.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1676.8,"P","Provisional value" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",29.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",22.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",18.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",18.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",20.4,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",18.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",19.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",20.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",21.7,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",21.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",22.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",23.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",22.2,"P","Provisional value" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",30.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",22.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",20.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",20.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",23.2,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",24.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",27.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",29.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",29.1,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",30.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",31.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",31.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",35.4,"P","Provisional value" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",7.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",6.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",6.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",6.3,"B; D","Break; Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",6.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",7.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",4.5,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",4.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",4.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",4.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",4.4,"P","Provisional value" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",722.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",767.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",558.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",440.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",480.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",482.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",522.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",587.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",451.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",468.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",525.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",585.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",730.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",100.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",118.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",82.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",67.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",70.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",57.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",61,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",68.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",51.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",49.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",57,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",68.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",72.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",80.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",86.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",64.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",51.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",55.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",54.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",59.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",66.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",50.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",53.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",60.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",67.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",84.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",10.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",12.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",8.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",7.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",5.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",6.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",6.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",5.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",4.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",5.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",6.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",9.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",6.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",5.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",6.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",5.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",6.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",449.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",329,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",207.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",140,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",138.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",152.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",180.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",235.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",302,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",377.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",527.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",679.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",298.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",196.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",115.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",73.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",63.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",55.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",59.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",64.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",62.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",66.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",75.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",76.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",488.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",340.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",203.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",130.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",125.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",130.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",145.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",170.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",185,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",202.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",243.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",241.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",4.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",6.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",2.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",2.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",2.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",2.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",2.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",2.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",19420.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",25005.3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",27634.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",30013.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",33677,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",39621.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",42911.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",35776.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",41618.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",40294.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",42777.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",41213.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",52646.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",38.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",51.7,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",56.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",60.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",59,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",60.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",63.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",55.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",64.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",57.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",54,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",54.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",60.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",54,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",71.9,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",79.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",85.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",91.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",101.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",108,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",90,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",105,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",100.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",102.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",94.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",120.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",2.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",3.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",3.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",3.4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",3.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",3.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",2.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",2.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.2,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",4.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",5.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",5.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",4.9,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",5.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",5.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",5.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",4.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",6.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.1,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",1.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1.6,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",1.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",5.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",3.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",3.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",3.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",3.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",3.7,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",4.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",4.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",7.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",5.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",5.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",4.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",3.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",3.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",3.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",4.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",4.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",5.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",10.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",7.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",7.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",6.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",6.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",5.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",5.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",6.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",6.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",8.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",8.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",5.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",4.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",3.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",2.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",2.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",3.1,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",3.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",5.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",4.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",4.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",4.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",5.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.7,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.8,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",31,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",27.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",25.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",24.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",14.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",14,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",14.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",14.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",14.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",15.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",18.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",20.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",41.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",38.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",32.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",32.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",19.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",15.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",16.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",17.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",17.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",19.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",21.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",21.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",48.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",44.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",41.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",41.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",24.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",23.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",24.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",25.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",25.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",28.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",31.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",32.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",36.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",20.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",18.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",15.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",15.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",9.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",7.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",7.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",7.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",8.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",8.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",10.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",10.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",23.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",21.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",20.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",20.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",11.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",11.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",11.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",12.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",13.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",15.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",15.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",17.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",6.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",5.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",3.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",3.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",138,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",143,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",155,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",225,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",240,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",298,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",359,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",362,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",367,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",383,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",404,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",438,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",126.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",147.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",160.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",217.2,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",216.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",223.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",266.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",277.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",274.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",266.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",278,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",329,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",91.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",94.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",100.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",155.5,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",165.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",202.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",247.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",245,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",249.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",258.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",277.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",302.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",5.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",6.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",7.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",9.4,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",9.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",9.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",11,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",11,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",10.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",10.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",12.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",8.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",10.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",10,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",10,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",10.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",11.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.9,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",43.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",43.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",45.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",45.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",45.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",45.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",46.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",46.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",43.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",44.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",40.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",40.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",57.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",61.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",58.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",60.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",60.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",50.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",51.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",52.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",50.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",49.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",46.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",47.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",51.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",52.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",55.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",56.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",56.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",57,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",60,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",59.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",56.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",59.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",54.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",53.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",6.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",7.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",6.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",7.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",5.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",5.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",5.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",5.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",6.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",6.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",6.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",6.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",239.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",241.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",236.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",232,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",226.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",224.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",225.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",223.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",217.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",226.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",216,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",219.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",224.2,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",317.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",336.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",303.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",308.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",301.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",249.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",249.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",252.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",257.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",253.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",246.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",259.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",236.1,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",286.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",290.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",287.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",287.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",283.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",280.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",288.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",288.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",284.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",303.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",295.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",298.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",314,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",29.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",30.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",27.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",27.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",26.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",22.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",22,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",22.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",22.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",22.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",21.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",22.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",20.3,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",26.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",26.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",25.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",25.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",25.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",24.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",25.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",25.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",24.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",26.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",25.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",25.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",27,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.5,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1430.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1473.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1512.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1511.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1485,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1517.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1563.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1543,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1532.3,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1550.1,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1566.4,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1431.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1430.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1369.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1181.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1120.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1169.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1206.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1163,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1142.5,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1236.2,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1203.5,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1149.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1204.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1229.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1210.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1230.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1251.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1295.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1249.7,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1244.7,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1251.9,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1249.3,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",41.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",40.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",38.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",33.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",31,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",32,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",32.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",30.9,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",30,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",32.3,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",31,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",33.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",34.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",34.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",35,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",33.2,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",32.7,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",32.7,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",32.1,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",5.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",5.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",5.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",5.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",4.8,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",4.5,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",4.2,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",3.9,"E; D","Estimated value; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",4979.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",4855,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",5036,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",4559.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",4503.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",4399.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",4373.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",4303.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",4442.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",4467.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2158.7,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2049,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",260.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",274.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",257.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",233,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",216.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",178.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",178.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",184.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",204.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",194.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",93,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",94.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",364.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",363.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",378.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",356.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",354.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",340.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",347.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",346.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",359.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",364,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",173.2,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",160.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",24.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",26.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",24.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",22.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",20.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",17,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",16.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",17.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",19.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",18.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8.7,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",34.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",34.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",36,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",33.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",33.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",32.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",32.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",32.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",33.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",34.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",16.2,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",15.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",6.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",5.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",5.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",5.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",4.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",4.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",4.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.5,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1041.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",946.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",978,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",870.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",813.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",834.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",831.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",830.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",798.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",808.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",784.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",790,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",185.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",176.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",168.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",155,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",144.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",124.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",123.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",125.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",126.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",121.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",120,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",125.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",137.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",126.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",129.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",118.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",110.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",114.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",117.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",120.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",118,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",121.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",119.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",119.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",33.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",31.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",30.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",27.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",25.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",21.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",21.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",21.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",21.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",20.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",20.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",21.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",24.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",22.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",23.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",21.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",19.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",20.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",20.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",21,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",20.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",21,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",20.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",20.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",4.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",4.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",3.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",3.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",3.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",3.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",108.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",105,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",105.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",108.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",111.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",112,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",114.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",112.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",110.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",112.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",104.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",92,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",143.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",146.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",135,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",144.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",148,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",124.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",127,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",127.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",130.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",126.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",119.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",108.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",120,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",116.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",115.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",120.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",122.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",123.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",130.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",130.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",129.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",134.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",126.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",111.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",26.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",27.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",24.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",26.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",27.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",22.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",23.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",23.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",23.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",22.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",21.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",19.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",22.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",21.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",21.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",22.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",22.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",22.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",23.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",23.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",23.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",24.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",22.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",20.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",5.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",5.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",5.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",5.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",5.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",5.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",4.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",4.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",4.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",3.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",1033.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",1438.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",1228.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",22.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",18.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FRA","France","2011","2011",3.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",812.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",788.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",779.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",780.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",815.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",829.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",784.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",751,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",781.8,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",815.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",797.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",805.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1076.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1097.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1001.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1036.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1083.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",920.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",868.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",848.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",923.3,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",912.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",911.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",952.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1008.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1000,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",990.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1007.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1060.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1066.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1042.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",1008.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1063,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1119.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1100.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1094.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",13.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",13.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",12.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",12.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",13.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",10.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",11.1,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",11,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",11,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",11.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",12.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",13.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",13.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",12.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",12.8,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",13.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",13.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",13.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.8,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",211.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",191.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",161.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",149,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",152.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",125.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",155.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",166.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",167.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",175.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",159.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",164.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",133.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",280.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",266,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",207.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",197.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",202.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",139.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",172.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",188.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",197.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",196.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",181.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",194.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",140.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",292.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",268,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",235.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",236,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",249.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",206.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",264.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",290,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",296.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",319.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",292.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",302.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",252.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",25.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",24,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",18.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",18,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",18.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",12.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",16,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",17.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",18.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",18.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",17,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",18.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",13.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",26.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",24.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",21.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",21.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",22.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",19.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",24.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",27,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",27.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",29.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",27.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",28.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",24.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",7875,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",8316,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",8098.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",9141.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",9549.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",10463.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",11251.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",11937,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",12197.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",12269,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",12167.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",12856.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",13703.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",37.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",41.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",36,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",40.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",41.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",37.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",40,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",43.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",45.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",42.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",39.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",42.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",36.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",62.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",66.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",64.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",73.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",73.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",78.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",85.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",87.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",87.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",87.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",83.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",83.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",85,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",4.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",4.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",6.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",6.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",7.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",8.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",8.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",8.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",8.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1497.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1436.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1476.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1498.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1343.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1315.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1335,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1308.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1441.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1549.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1691.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1807,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",12.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",12.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",11.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",12.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",11.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",10,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",11.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",12.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",13.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",12.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",12.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",14.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",11.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",10.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",10.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",10.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",9.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",9.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",9.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",9.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",10.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",11,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",11.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",12.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",38.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",38.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",36.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",37.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",35.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",30.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",32.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",35.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",37.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",35.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",34.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",38.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",35.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",33.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",33.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",33.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",29.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",28,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",28.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",27.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",29,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",30.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",31.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",32.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",5.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",6.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",5.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",5.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",5.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",5.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",4.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",4.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",84.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",82.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",85.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",79.7,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",74.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",74.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",76.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",71.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",73.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",77.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",79.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",93.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",111.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",115.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",110.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",105.8,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",98.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",82.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",84.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",80.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",86.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",87.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",90.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",110.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",99.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",99.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",104.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",98.2,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",90.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",91.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",96.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",89.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",92.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",96.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",100,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",117.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",24.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",25.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",24,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",22.9,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",21.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",17.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",17.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",16.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",17.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",17.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",18.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",22,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",21.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",21.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",21.2,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",19.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",19.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",20.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",18.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",19,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",19.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",20.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",23.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.1,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",3.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",3.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",503.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",500.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",516.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",532.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",548,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",560.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",514.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",437.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",441.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",396.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",409.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",405,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",700.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",643.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",686,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",707.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",608.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",620.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",581.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",516.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",494.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",452.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",484.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",426.5,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",663.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",669.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",700.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",720.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",741.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",800.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",746,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",642.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",672.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",611.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",632.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",655.9,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",11.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",10.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",11.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",11.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",10,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",10.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",9.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",8.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",8.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",8.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",7.2,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",11.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",11.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",11.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",11.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",12.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",13.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",12.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",10.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",11.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",10.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",11.1,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",2.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",2.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",2.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",2.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.6,"E","Estimated value" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",158560,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",156118,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",176807,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",168011,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",152239,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",147680,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",134491,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",162419,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",157943,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",167072,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",178904,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",158339,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",1806.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",1956.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",2215.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",1721.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",1437,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",1220.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1236.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1448,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1430.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",1532.6,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",1675.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",1442.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",1419.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",1452.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",1695.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",1658.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",1477.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",1427.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1274.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1545.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1516.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",1603,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",1746.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",1551.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",14.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",15.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",17.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",13.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",9.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",9.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",11.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",12.1,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",13.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",11.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",11.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",11.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",13.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",13,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",11.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",11.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",10,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",12.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",12,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",12.7,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",13.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",12.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",1.8,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",1.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",1.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",540467,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",643575.9,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",636824.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",646627.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",706494.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",742741.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",731218.5,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",789700.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",842916.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",904006.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",976925.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1048571.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",467.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",580.7,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",565.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",590.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",671,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",656.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",629.9,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",698.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",766.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",775.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",827.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",916.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",642.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",753.1,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",744.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",744,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",810.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",866.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",851.4,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",905,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",986,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1055.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1166.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1227.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",9.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",11.6,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",11.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",11.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",13.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",12.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",12.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",13.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",14.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",15,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",16,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",17.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",13,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",15.1,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",14.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",14.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",16,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",17,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",16.6,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",17.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",19.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",20.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",22.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",23.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.9,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",2.9,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",6.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",8.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",8.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",8.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",8.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",8.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",10.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",9.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",10,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",9.4,"D; P","Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",10.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",10.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",10.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",9.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",9.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",10,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",11.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",10.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",11.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",9.9,"D; P","Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",8.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",9.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",9.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",10.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",10.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",11.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",12,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",11.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",11.3,"D; P","Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",19.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",21,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",21.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",21.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",17.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",18.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",18.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",20.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",20.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",19.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",20.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",16.8,"D; P","Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",15.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",18,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",17.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",18.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",18.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",19.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",19.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",20.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",20.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",19.2,"D; P","Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",4.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.6,"D; P","Difference in methodology; Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",206,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",149.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",147.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",136.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",105,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",273.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",208.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",189.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",181.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",139.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",241.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",179.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",179.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",171.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",129.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",16.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",12.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",10.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",8.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",14.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",10.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",10.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",10.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",2.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",18,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",21.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",22.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",21,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",21.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",22.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",21.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",20.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",19.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",17.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",21.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",26.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",27.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",13,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",16.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",18.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",17.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",17.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",15.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",15,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",14.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",13.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",11.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",14,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",18.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",17.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",12,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",14.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",15.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",14.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",14.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",15.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",15,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",14.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",13,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",12.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",15.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",18.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",19,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",3.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",3.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",2.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",3.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",3.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",2.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",2.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",1.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",914,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",925,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",948,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",983,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1015,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1082,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1162,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1228,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1182,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1204,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1301,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1317,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1298,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",151.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",165,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",163,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",167.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",161.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",134.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",138.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",148.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",145.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",136.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",138.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",153.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",135,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",99.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",101.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",104.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",108.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",109.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",108.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",115.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",126,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",123.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",125.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",131.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",138.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",120.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",30.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",33.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",32.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",32.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",31.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",25.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",26.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",28.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",27.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",25.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",25.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",28.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",24.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",20.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",20.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",20.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",21.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",21.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",21,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",22.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",23.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",23.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",23.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",24.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",25.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",22.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",5.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",5.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",5.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",4.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",4.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",180.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",172.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",159.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",149.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",151.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",151.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",157.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",159,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",156.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",163.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",154.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",158.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",164.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",238.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",239.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",204.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",198.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",200.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",168.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",174.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",179.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",185.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",182.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",176.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",187.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",173,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",289.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",276.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",262.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",255.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",261.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",259,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",275.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",276.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",274.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",292.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",277.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",278.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",298.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",22.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",22.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",19.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",19,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",19.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",16.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",16.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",17.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",18,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",17.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",17.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",18.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",16.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",27.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",26.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",25,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",24.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",25.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",25,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",26.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",26.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",26.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",28.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",27,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",26.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",28.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",5.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",6.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",6.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",6.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",6.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",6.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",5.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",44.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",45.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",43.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",48.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",50.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",51.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",51.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",49.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",47.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",46.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",44.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",47.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",59,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",63.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",55.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",64.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",67.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",56.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",56.8,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",55.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",56.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",52.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",50.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",55.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",88.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",90,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",86.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",99.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",104.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",104.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",101.9,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",95.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",90.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",90.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",84.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",88.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",10.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",11.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",10.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",12,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",12.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",10.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",10.5,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",10.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",10.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",9.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",9.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",10.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",16.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",16.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",15.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",18.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",19.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",19.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",18.8,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",17.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",16.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",16.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",15.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",16.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",3.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",3.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",3.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",3.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",3.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",512.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",502.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",478.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",487,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",515.1,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",534.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",571.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",600.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",627.8,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",593.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",555.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",595.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",630,"P","Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",679,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",699.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",614.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",646.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",684.3,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",593.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",632.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",677.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",741.4,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",664.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",634.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",704.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",663.5,"P","Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",704.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",703.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",688,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",721.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",777.6,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",804.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",889.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",951.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",993.7,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",968,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",894.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",951.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1056.7,"P","Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",14.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",15,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",13.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",13.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",14.7,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",12.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",13.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",14.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",15.8,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",14.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",13.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",14.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",14,"P","Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",15.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",15.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",14.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",16.7,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",17.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",19.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",20.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",21.2,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",20.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",18.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",20.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",22.3,"P","Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",3.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",4.6,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",4.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",4.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",3.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.7,"P","Provisional value" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1715.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1722.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1757.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1729,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1684.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1676.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1693.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1719.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1739.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1772.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",1738.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",1761.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1854.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",238,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",265.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",259.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",265.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",245.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",198.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",197.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",201.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",200.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",187.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",188.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",205.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",183.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",190.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",194.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",203,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",201.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",193,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",189.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",192,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",194.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",196.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",203.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",200.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",201.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",214,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",25.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",28.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",27.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",27.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",25.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",20.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",19.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",20,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",19.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",18.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",18.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",19.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",17.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",20.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",20.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",21.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",20.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",19.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",19.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",19.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",19.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",19.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",19.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",19.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",20.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",4.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",4.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",4.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",4.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",3.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",3.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",3.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",3.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",344.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",349,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",353,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",353,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",346,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",348,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",351,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",347,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",341,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",336,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",331,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",331,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",331,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",330,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",393,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",376.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",380.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",377.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",361.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",356.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",352.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",348.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",338.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",352.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",362.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",346.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",234.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",249.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",260.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",269,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",269.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",281.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",292,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",292.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",289.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",292.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",291.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",299.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",310.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",42.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",49.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",47.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",47.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",46.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",43.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",42.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",41.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",41,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",39.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",40.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",41.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",39.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",30,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",31.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",32.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",33.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",33,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",34,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",34.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",34.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",34,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",34.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",33.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",34.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",35.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",5.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",5.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",5.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",5.5,"B; D","Break; Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",5.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",5.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",4.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",4.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",719.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",618.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",645.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",665.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",731.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",840.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",983.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1193.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1485.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1898,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",2006.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",2871.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",478.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",369.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",359.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",349.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",334.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",309.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",325.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",327.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",307.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",334.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",286.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",324.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",781.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",640,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",633.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",621.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",662.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",723.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",792.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",862.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",909.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1018.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",927,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1022.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",6.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",4.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",4.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",4.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",4.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",3.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",8.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",8.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",8.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",8.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",9.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",10,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",10.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",11.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",12.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",11.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",12.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",4.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",4.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",4.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",4.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",4.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",4.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",4.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",684.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",680.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",680.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",707.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",711.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",757.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",724.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",1081,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",1063.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",1120.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",1081.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",960.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",975.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",966.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",975.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",978.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",974.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",1022.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",1032.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",1106.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",1052.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",17,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",16.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",17.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",16.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",14.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",14.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",14.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",15.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",15.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",15.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",15.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",15.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",16.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",15.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",5,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",4.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",4.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",3.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",81496.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",111351.6,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",122348.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",134181.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",145380,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",165236.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",191680.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",178137.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",188269,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",193008.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",208701.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",241722.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",222620.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",159.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",230.2,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",251.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",270.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",254.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",252.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",283.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",274.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",293.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",274.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",263.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",318.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",254.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",226.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",320,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",352.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",383.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",395.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",422.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",482.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",447.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",475.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",480.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",498.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",555.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",508.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",9.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",13.3,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",14.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",15.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",14.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",14.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",15.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",14.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",15.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",14.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",13.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",16.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",12.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",13.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",18.5,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",20.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",21.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",22.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",23.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",26.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",24.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",25.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",25.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",25.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",28.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",25.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",9.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",9.4,"B","Break" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",9.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",9.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",9.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",9.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",9.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",8.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",8.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",7.7,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",7.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",8.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",7.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",10.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",10.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",11.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",11.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",11.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",11.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",11.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",11.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",11.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",12.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",11.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",12.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",12.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",14.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",14.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",15.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",15.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",12.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",12.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",13,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",13.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",13.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",13.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",14.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",13.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",20.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",21.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",21.5,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",21.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",21.8,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",21.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",22,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",21.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",21.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",23,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",22.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",22.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",22.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",10.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",10.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",11.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",11.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",9.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",9.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",9.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",10.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",10.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",10.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",10.7,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",10.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",15.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",16.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",16.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",16.6,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",16.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",16.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",16.4,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",16.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",17.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",17.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",16.7,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",17,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",5,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",4.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",4.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",3.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",3.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",3,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",26.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",26.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",24.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",23.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",23.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",22.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",23.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",23.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",22.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",22.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",21.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",19.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",19.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",34.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",36.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",31.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",31.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",31.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",25.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",26,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",26.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",26.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",25.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",24.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",22.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",20.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",41.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",42.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",40.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",39.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",40.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",38,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",40.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",41.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",39.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",41.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",39.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",34.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",35.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",17,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",17.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",15.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",15.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",15.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",12.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",12.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",13,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",12.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",12.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",11.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",10.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",9.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",20.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",20.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",19.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",19.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",19.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",18.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",19.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",20.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",19.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",19.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",18.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",16.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",16.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",5.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",5.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",5.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",4.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",4.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",2.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",100,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",100,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",103,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",160,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",167,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",220,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",278,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",271,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",272,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",282,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",295,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",321,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",91.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",103.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",106.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",154.5,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",150.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",165.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",206.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",207.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",203.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",196,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",203,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",241.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",66.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",66.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",66.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",110.6,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",115,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",149.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",191.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",183.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",185,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",190.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",202.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",221.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",4.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",4.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",4.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",6.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",6.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",8.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",8.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",7.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",7.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",9.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.8,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",7.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",7.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",7.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",8.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.4,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",14.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",13.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",13.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",14,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",13.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",13,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",13.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",13.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",12.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",12.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",11.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",11.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",19.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",19.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",17.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",18.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",17.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",14.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",14.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",15.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",14.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",13.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",13.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",14.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",17.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",16.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",16.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",17.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",16.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",16.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",17.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",17.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",15.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",16.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",15.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",15.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",2.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",2.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",2.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",135.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",132.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",124.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",118,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",113.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",111,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",109.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",108,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",106.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",109.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",105.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",106.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",108.9,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",179.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",184.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",159.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",156.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",151,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",123.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",121,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",122,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",125.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",122.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",120.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",125.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",114.7,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",162.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",159.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",151,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",146.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",142,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",138.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",140,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",139.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",139,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",147.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",144.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",144.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",152.6,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",16.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",16.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",14.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",14,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",13.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",10.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",10.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",11,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",10.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",9.9,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",14.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",14.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",13.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",13.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",12.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",12.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",12.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",12.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",12.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",12.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",12.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",12.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",13.1,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.2,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",751.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",784.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",798.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",809.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",804.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",813.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",827.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",813.7,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",787,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",767.7,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",761.9,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",751.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",761.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",722.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",632.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",607.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",626.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",638.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",613.3,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",586.8,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",612.3,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",585.4,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",603.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",641.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",648.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",648.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",666.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",671,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",686,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",659.1,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",639.3,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",620,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",607.7,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",21.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",21.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",20.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",17.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",16.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",17.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",17.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",16.3,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",15.4,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",16,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",15.1,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",17.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",18.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",18.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",18.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",18.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",18.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",18.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",17.5,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",16.8,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",16.2,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",15.6,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",3.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",3.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",3.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",2.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",2.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",2.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.6,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.3,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.1,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1.9,"E; D","Estimated value; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2853.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2666.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",2720.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2500.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2387.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2238.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2154.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2125.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2118.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",2124.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",795,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",800.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",149.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",150.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",139,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",127.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",115,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",91,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",88.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",90.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",97.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",92.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",34.3,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",36.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",208.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",199.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",204.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",195.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",187.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",173,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",171.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",171.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",171.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",173.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",63.8,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",62.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",14.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",14.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",13.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",12.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",8.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",8.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",8.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",9.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",3.2,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",3.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",19.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",19,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",19.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",18.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",17.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",16.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",16.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",16.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",16.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",16.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",6,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.9,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",54.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",55.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",55.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",56.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",57.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",58.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",57.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",57.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",57.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",59.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",56.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",50.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",72.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",77.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",71.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",75.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",76.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",64.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",63.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",65.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",68.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",66.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",64.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",59.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",60.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",62,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",61.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",62.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",63.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",64.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",65.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",66.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",67.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",71.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",68.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",60.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",13.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",14.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",13.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",14,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",11.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",11.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",11.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",12.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",12.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",11.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",10.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",11.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",11.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",11.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",11.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",12.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",12.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",12.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",12.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",11,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",2.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",2.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",419.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",395.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",383.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",377.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",395.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",407.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",401.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",388.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",375.5,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",400,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",396.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",399.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",556.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",550.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",492.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",501.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",524.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",452,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",444.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",438.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",443.4,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",447.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",452.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",472.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",521.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",501.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",487.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",487.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",513.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",523.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",533.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",521.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",510.6,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",549.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",546.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",542.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",6.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",6.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",6.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",6.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",5.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",5.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",5.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",5.3,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",5.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",5.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",5.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",6.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",6.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",6.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",6.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",6.2,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.8,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",67.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",65.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",50.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",38.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",40.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",33.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",37.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",38,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",41.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",41.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",42.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",45.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",38,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",89.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",90.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",64.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",51.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",53.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",37.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",41.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",42.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",48.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",46.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",48.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",53.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",40,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",93.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",91.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",73.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",61.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",66.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",55.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",63.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",66.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",73.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",75,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",78.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",83.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",71.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",8.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",5.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",4.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",4.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",3.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",3.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",4.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",4.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",4.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",3.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",8.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",8.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",6.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",5.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",6.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",5.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",6.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",6.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",7.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",7.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",6.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",3352.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",3483,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",3423.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",4108.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",4324.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",4957.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",5426.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",5743.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",5644.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",5361.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",5013.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",6016.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",6388,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",16.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",17.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",15.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",18.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",18.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",17.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",19.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",20.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",20.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",18.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",16.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",19.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",17.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",26.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",28,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",27.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",32.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",33.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",37.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",41.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",42.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",40.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",38.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",34.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",38.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",39.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",2.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",2.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",4.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",846.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",845,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",865.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",853.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",754.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",723.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",729.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",705.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",770.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",832.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",902.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",968.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",6.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",7.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",5.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",6.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",6.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",6.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",7.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",6.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",6.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",5.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",5.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",5.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",6.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",21.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",22.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",21.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",21.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",19.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",16.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",18,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",19.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",20.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",18.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",18.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",20.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",20,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",19.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",19.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",19.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",15.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",15.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",16.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",16.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",17.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",35.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",34.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",34.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",33.9,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",32.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",34.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",35.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",32.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",33.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",36.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",38.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",51,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",46.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",47.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",44.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",45,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",43.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",38.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",39,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",37,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",39.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",40.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",43.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",60.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",41.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",41.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",42.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",41.8,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",40,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",42.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",44.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",41.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",42.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",45.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",48,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",64.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",10.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",10.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",9.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",9.7,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",9.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",8.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",7.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",8.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",8.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",8.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",12,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",9.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",9,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",8.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",9.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",8.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",8.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",9.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",9.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",12.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.7,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",176.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",169.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",163.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",154.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",149.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",136.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",123.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",112.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",113.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",91.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",108,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",105,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",245.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",218,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",217.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",205.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",165.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",150.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",139.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",132.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",126.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",104.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",127.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",110.6,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",232.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",227,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",222.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",209.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",202.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",194.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",179.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",164.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",172.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",141.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",166.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",170.1,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",4.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",3.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",2.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",1.9,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",3.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",3.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",3.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",2.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",2.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",2.9,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.4,"E","Estimated value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",151191,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",152836.8,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",156433.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",176123.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",195737.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",194402,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",189297.4,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",199206.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",213761.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",231920.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",245225.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",272487.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",130.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",137.9,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",138.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",160.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",185.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",171.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",163.1,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",176.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",194.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",199,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",207.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",238.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",179.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",178.8,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",183,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",202.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",224.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",226.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",220.4,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",228.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",250.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",270.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",292.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",319,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",2.8,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",3.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",3.2,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",3.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",3.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",4.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",3.6,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",4.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",4.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4.3,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",4.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",5.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",5.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",2.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",3.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",4.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",3.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",4.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",4.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",4.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",3.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",4.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",4.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",4.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",5.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.3,"D; P","Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",2.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",2.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",3.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",4.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",4.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",5.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",4.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",5.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",5,"D; P","Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",7.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",9.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",8.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",8.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",7.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",7.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",7.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",8.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",8.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",9.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",7.4,"D; P","Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",7.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",7.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",7.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",7.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",8.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",9.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.5,"D; P","Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.6,"D; P","Difference in methodology; Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",122.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",72.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",68.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",59.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",28.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",162.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",100.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",87.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",79.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",37.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",143.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",86.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",82.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",75.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",34.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",9.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",5.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",4.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",2.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",8.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",5.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",4.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",4.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",12.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",13.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",13.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",11.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",11.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",12.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",12.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",11.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",10.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",12.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",12.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",13.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",15.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",8.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",10.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",11,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",9.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",9.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",8.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",9.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",10,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",8.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",9.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",7.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",7.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",8.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",8.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",7.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",7.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",8.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",8.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",9.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",10.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",433,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",436,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",441,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",454,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",471,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",512,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",545,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",562,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",559,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",580,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",596,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",598,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",576,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",71.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",77.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",75.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",77.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",74.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",63.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",64.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",67.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",68.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",65.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",63.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",69.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",59.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",47.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",48,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",48.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",50.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",50.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",51.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",54.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",57.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",58.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",60.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",60.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",62.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",53.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",15.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",15.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",15.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",14.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",12.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",12.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",12.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",12.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",12.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",11.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",12.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",11,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",9.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",9.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",11,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",11.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",11.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",81.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",78.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",74.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",66.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",63.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",60.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",61,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",61.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",60.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",61.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",58.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",61.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",62.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",108,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",108.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",95.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",88.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",84.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",67.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",67.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",69.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",71.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",68.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",66.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",72.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",66,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",130.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",125.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",123.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",114.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",109.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",104.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",106.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",107,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",106.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",109.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",105.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",108,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",114,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",10.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",10.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",9.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",8.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",6.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",6.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",12.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",11.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",11.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",11,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",10.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",10.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",10.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",10.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",10.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",11,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",2.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",2.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",2.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",2.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",21,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",20.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",19.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",19.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",17.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",17.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",19,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",18.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",18.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",17.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",16,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",18.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",27.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",28.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",24.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",26.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",23.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",19.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",21,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",21.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",21.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",19.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",18.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",21.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",41.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",41,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",37.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",40,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",36.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",35.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",37.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",36.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",34.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",34.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",30.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",33.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",5.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",5.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",4.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",4.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",4.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",3.9,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",3.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",3.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",3.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",7.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",7.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",7.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",6.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",6.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",6.9,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",6.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",6.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",5.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.2,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",124.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",114.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",125.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",121.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",103.4,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",96.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",99.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",107.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",105.6,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",108.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",95,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",106.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",113.9,"P","Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",165.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",159.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",160.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",161.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",137.4,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",107.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",110,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",121.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",124.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",121.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",108.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",125.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",120,"P","Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",171.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",160.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",179.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",180.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",156.1,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",145.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",154.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",170.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",167.1,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",177,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",152.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",169.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",191.1,"P","Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",3.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",3,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.5,"P","Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.4,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.6,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",4,"P","Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.9,"B; D","Break; Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",895.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",898.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",922.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",928.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",923.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",925.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",924.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",927,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",920.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",951.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",931,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",958.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1010.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",124.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",138.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",136.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",142.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",134.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",109.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",108,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",108.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",105.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",100.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",101.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",111.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",99.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",99.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",101.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",106.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",108,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",105.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",104.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",104.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",104.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",103.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",109.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",107.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",109.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",116.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",13.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",14.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",14.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",14.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",13.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",11.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",10.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",9.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",9.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",10.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",9.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",10.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",10.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",11.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",11.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",10.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",10.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",10.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",10.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",10.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",11.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",2.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",2.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",2.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",188.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",187,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",197.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",230.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",263.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",305.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",335.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",406.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",494.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",656.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",721.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1104.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",125.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",111.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",110,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",121.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",120.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",112.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",111,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",111.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",102.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",115.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",102.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",124.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",204.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",193.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",193.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",215.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",238.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",262.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",270.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",293.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",302.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",352.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",333.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",393.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",1.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",3.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",3.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",1.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",64724.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",80168.5,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",87798.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",95808.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",102222,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",117332.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",139368.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",124650.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",130609.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",139258.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",154941.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",189704.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",162563.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",126.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",165.8,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",180.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",193.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",179.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",179.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",205.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",192.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",203.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",198.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",195.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",250,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",186.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",179.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",230.4,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",252.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",274,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",278.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",299.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",350.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",313.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",329.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",346.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",370.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",435.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",371.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",7.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",9.6,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",10.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",11,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",10.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",10,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",11.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",10.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",10.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",10,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",12.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",9.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",10.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",13.4,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",14.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",15.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",15.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",16.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",19.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",17,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",17.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",18.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",19,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",22.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",18.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",7.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",6.8,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",6.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",6.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",6.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",5.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",5.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",5.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",6.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",5.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",6.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",6.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",6.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",5.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",5.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",5.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",5.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",5.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",8.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",9.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",8.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",8.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",8.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",6.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",6.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",5.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",6.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",6.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",12.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",12.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",12.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",12.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",11.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",11.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",11,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",10.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",9.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",10.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",9.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",9.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",10.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",6.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",6.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",6.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",6.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",4.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",4.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",4.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",4.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",4.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",9.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",9.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",8.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",8.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",8.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",7.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",7.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",7.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",7.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",7.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",10.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",9.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",9.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",7.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",7.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",7.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",6.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",6.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",5.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",13.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",13.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",11.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",10.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",10.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",8.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",8.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",8.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",8.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",8.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",7.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",7.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",15.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",15.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",14.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",14,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",13.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",12.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",13,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",13.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",12.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",13.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",11.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",10.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",10.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",6.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",5.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",5.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",4.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",4.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",3.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",3.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",7.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",7.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",6.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",6.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",5.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",5.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",5.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",79,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",86,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",98,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",156,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",168,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",191,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",224,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",237,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",246,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",258,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",264,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",272,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",72.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",88.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",101.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",150.6,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",151.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",143.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",166.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",181.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",183.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",179.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",181.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",204.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",52.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",56.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",63.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",107.8,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",115.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",129.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",154.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",160.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",167.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",174.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",181.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",187.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",4.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",6.5,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",6.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",7.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",7.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",7.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",7.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.7,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",5.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",6.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",6.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",6.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",7.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.3,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",1.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",47.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",47.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",48.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",50.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",51.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",52.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",55,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",56.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",58.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",61.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",64.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",60.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",63,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",66.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",61.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",66.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",67.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",58.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",60.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",63.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",69.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",68.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",73.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",72.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",56.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",57.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",59.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",63,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",64,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",65.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",70.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",73,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",76.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",81.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",86.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",80.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",7.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",7.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",7.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",6.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",7.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",7.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",8.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",7.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",7.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",7.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",8.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",8.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",8.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",9.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",9.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",122.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",125.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",124.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",124.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",123.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",126.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",126.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",128.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",125.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",132.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",127.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",127.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",132.8,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",162.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",174.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",159.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",165.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",163.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",140.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",139.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",144.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",148.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",148.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",145.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",151.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",139.9,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",146.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",150.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",151.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",154.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",153.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",158.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",161.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",165.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",164.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",177.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",174.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",173.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",186,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",14.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",15.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",14.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",14.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",14.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",12.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",12.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",12.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",13,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",12.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",12.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",13,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",12,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",13.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",13.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",13.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",13.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",13.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",14.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",14.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",14.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",14.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",15.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",15.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",15,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",16,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.5,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",413.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",435.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",453.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",474,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",498.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",521.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",560.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",598.3,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",625.1,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",652.4,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",680.7,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",414.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",422.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",410.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",370.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",376,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",401.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",432.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",450.9,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",466.1,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",520.3,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",523,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",332.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",355.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",368.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",379.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",412.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",430,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",464.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",484.6,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",507.7,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",526.9,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",542.9,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",12,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",11.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",10.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",10.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",11,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",11.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",12,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",12.3,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",13.6,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",13.5,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",9.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",10.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",10.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",10.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",11.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",11.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",12.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",12.9,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",13.3,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",13.8,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",14,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.9,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",1.8,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",1.8,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1.7,"E; D","Estimated value; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1641.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1575.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1709.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1668.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1742.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1764.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1814.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1969.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2011,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",2032.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1982.8,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2011.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",86,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",89,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",87.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",85.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",83.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",71.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",74.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",84.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",92.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",88.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",85.4,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",92.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",120.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",118.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",128.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",130.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",137.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",136.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",144.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",158.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",162.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",165.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",159.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",157.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",8.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",8.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",8.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",8.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",6.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",8.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",8.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",11.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",11.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",12.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",12.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",13,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",12.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",13.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",15,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",15.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",15.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",14.9,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",15,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.3,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",497.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",497.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",482.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",437,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",465.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",459.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",466.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",477.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",500.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",504.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",485.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",468,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",88.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",92.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",83.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",77.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",83,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",68.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",69.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",72.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",79.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",75.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",74.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",74.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",65.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",66.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",63.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",59.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",63.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",62.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",66,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",69.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",73.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",76.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",74.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",71,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",15.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",16.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",14.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",13.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",14.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",12,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",12.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",12.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",13.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",13,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",12.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",12.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",11.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",12,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",11.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",10.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",11.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",11.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",11.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",12.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",12.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",13.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",12.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",12.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",38.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",41.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",42.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",39.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",41,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",42.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",45.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",44.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",47,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",48.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",49.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",46.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",51.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",57.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",54.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",51.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",54.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",46.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",50.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",49.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",55.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",54.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",56.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",54.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",43,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",46.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",47,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",43.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",45.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",46.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",51.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",51.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",55.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",57.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",60.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",55.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",9.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",10.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",9.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",10,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",8.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",9.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",9.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",10.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",9.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",10.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",9.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",8.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",8.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",7.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",8.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",8.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",9.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",9.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",10,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",10.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",10.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",10.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",502.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",700,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",597.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",9.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FRA","France","2011","2011",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",987.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",994,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1019.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1046.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1085.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1111.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1115.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1132,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1181.9,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1244.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1257.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",1265.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1308.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1383.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1309.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1389.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1442.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1233.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1234.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1278.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",1395.8,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",1393.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",1436.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",1496.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1226.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1260.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",1294.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1350.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1411.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1428.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1481.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",1519.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1607,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1709.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1734.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1718.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",16,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",17.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",16.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",17.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",17.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",15.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",15,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",15.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",16.8,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",16.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",17.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",18,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",15,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",15.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",16.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",16.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",17.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",17.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",18,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",18.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",19.4,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",20.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",20.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",20.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",3.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",2.7,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",2.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",169.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",157.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",136.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",114.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",115.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",99.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",122.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",129.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",132.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",142.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",150.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",159.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",123.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",224.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",218.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",175.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",152.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",153.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",110.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",135.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",146,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",157,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",159.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",171.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",188.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",130.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",234.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",220.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",199.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",181.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",189.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",163.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",208.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",224.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",235.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",259.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",276.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",291.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",233.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",20.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",19.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",15.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",13.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",14.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",10.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",12.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",13.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",14.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",14.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",16,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",17.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",12.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",21.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",19.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",18,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",16.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",17.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",15.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",19.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",20.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",21.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",24.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",25.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",27.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",22.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",6945,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",7875.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",8192.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",8307.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",9057.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",9969.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",10611,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",10907.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",11179.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",11577.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",11553.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",11391.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",11177.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",33.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",39.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",36.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",37.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",38.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",35.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",37.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",39.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",41.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",39.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",37.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",37.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",30,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",54.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",63.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",65.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",66.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",70,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",75.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",80.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",80.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",80.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",82.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",79.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",73.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",69.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",3.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",4.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",6.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",6.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",8.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",8.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",8.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",8.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",585.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",623.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",617.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",665,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",656.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",636,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",670.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",690.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",761.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",864.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",931.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",998.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",5.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",4.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",5.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",5.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",5.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",6.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",6.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",7.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",4.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",4.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",4.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",4.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",5.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",6.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",6.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",15.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",16.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",15.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",16.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",17.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",14.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",16.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",18.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",19.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",19.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",18.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",21.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",13.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",14.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",14.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",15,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",14.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",13.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",14.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",17,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",17.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",17.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",2.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",2.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",44.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",45.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",48.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",50.1,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",51.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",53.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",55.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",55.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",56.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",60,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",60,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",59.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",58.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",63.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",62.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",66.6,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",68.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",59.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",61.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",62.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",67.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",67.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",68.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",70.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",52.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",55.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",59,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",61.8,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",62.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",65.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",70.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",69.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",71.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",74.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",75.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",75,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",12.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",13.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",13.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",14.4,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",14.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",12.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",13,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",13,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",13.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",13.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",13.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",14,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",11.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",12,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",12.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",13.4,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",13.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",14.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",14.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",15.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",15.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",2.6,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",462.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",478.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",484.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",488.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",481.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",489.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",509.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",520.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",534.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",520.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",481.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",490.8,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",644.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",614.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",643.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",649.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",533.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",542.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",575.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",614.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",598.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",594,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",569.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",516.8,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",610.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",639.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",657.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",661,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",651.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",699,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",738,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",763.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",813.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",802.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",743.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",794.9,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",10.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",10.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",8.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",8.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",9.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",10.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",10,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",10,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",9.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",8.8,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",10.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",10.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",10.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",11.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",12.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",12.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",13.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",13.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",12.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",13.5,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",2,"E","Estimated value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",114985,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",139935,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",152914,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",166912,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",158691,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",182902,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",159150,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",175173,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",155562,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",259390,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",253995,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",275742,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",1309.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",1753.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",1916.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",1710.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",1497.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",1511,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1462.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1561.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1408.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",2379.5,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",2378.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",2512.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",1029.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",1302.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",1466.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",1647.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",1539.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",1767.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1508.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1666.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1493.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",2488.7,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",2479.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",2702,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",10.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",13.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",15,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",13.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",11.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",12.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",11.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",18.9,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",18.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",20,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",10.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",12.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",12.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",13.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",13.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",11.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",19.7,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",19.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",21.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",2.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",2.7,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",137957,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",232848.8,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",245185.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",251932.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",254331.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",259131.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",198179,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",196953.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",233107,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",275688.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",278416.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",336313.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",119.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",210.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",217.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",230.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",241.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",229.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",170.7,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",174.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",211.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",236.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",235.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",294,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",164,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",272.5,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",286.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",289.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",291.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",302.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",230.8,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",225.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",272.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",321.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",332.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",393.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",4.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",4.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",3.3,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",3.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",4.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",5.5,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",5.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",5.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",5.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",5.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4.5,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",5.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",6.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",6.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",1.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",1.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.8,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",4.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",4.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",5.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",5.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",5.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",5.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",5.6,"D; P","Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",5.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",6.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",6.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",7.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",5.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",6.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",6.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",6.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",5.8,"D; P","Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",4.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",4.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",6.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",6.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",6.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",6.7,"D; P","Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",12.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",12.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",13.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",11,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",11.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",11.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",11.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",11.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",11.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",10,"D; P","Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",9.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",10.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",11.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",11.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",11.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",11.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",11.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",11.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",11.4,"D; P","Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",2.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",2.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",2.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",2.2,"D; P","Difference in methodology; Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",169.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",174.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",174.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",127.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",129.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",224.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",242.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",223.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",169.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",172.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",197.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",208.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",211.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",160.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",160.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",13.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",14.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",13.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",10.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",10.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",12.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",12.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",9.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",3.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",18.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",18.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",21.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",22.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",24.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",28.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",28.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",25,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",24.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",25.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",26.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",29.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",25.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",13.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",14.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",17.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",18.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",20.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",19.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",19.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",17.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",17,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",16.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",17.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",20.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",16,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",12.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",12.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",14.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",15.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",17,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",19.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",19.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",17.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",16.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",17.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",18.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",20.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",17.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",4.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",4.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",4.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",4.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",3.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",3.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",3.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",4.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",3.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",3.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",3.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",3.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",2.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",440,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",445,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",468,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",485,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",516,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",549,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",570,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",543,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",571,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",624,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",610,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",609,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",582,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",72.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",79.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",80.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",82.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",81.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",68.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",67.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",65.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",70.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",70.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",64.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",70.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",60.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",48.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",49,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",51.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",53.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",55.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",55.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",56.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",55.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",59.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",64.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",61.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",64,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",54.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",16,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",16,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",16.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",15.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",13.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",13,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",12.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",13.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",13.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",12,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",13.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",11.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",10.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",10.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",11.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",12.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",11.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",10,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",24,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",22.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",20.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",20,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",21.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",23.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",24.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",25.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",26.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",27.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",27.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",29.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",31.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",31.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",26.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",26.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",28.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",25.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",27.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",29,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",31.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",30.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",29.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",32.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",31.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",38.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",36.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",34.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",34.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",37.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",39.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",42.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",44.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",47.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",49.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",46.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",48.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",54.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",2.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",3.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",3.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",3.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",4.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",4.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",4.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",4.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",4.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",20.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",17.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",19.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",22.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",25.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",24.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",27.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",26.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",27.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",28.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",26.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",28.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",27.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",24.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",24.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",29.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",33.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",27.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",30.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",30.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",32.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",31.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",30.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",33.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",40.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",35.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",38.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",45.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",52.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",50,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",54,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",52.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",52.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",54.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",51.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",53.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",5.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",6.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",5.5,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",5.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",5.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",5.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",6.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",7.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",6.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",7.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",8.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",9.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",9.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",10,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",9.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",9.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",10.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",9.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",9.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.7,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",256.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",258.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",235.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",206.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",224.5,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",228.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",236.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",247.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",391.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",407.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",386.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",408.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",428.2,"P","Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",340.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",360.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",302.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",273.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",298.2,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",253.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",261.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",279.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",462,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",456.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",441.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",482.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",450.9,"P","Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",353.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",362.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",339.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",305.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",338.9,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",343.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",368.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",392.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",619.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",664.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",621.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",652,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",718.2,"P","Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",7.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",5.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",6.4,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",5.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",5.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",9.9,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",9.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",9.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",10.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",9.5,"P","Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",7.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",7.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",6.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",7.3,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",7.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",7.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",13.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",14.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",13.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",13.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",15.1,"P","Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",1.9,"P","Provisional value" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",919.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",934.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",965.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",973.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",967.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",983.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1026.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1054.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1090.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1116.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",1102.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",1088.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1109.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",127.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",144,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",142.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",149.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",141,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",116.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",119.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",123.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",125.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",118,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",119.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",126.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",109.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",101.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",105.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",111.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",113.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",110.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",111.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",116.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",119.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",123,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",128.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",127.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",124.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",128,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",13.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",15.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",15,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",15.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",14.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",11.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",12.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",12.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",12.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",11.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",11.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",12.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",10.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",10.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",11.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",11.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",11.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",11.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",11.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",11.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",11.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",12.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",12.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",12.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",12,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",12.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",2.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",2.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",71.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",73,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",83,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",84,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",85,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",87,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",91,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",93,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",86,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",86,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",89,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",85,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",89,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",68.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",82.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",88.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",90.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",92.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",90.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",92.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",94.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",87.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",86.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",94.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",93,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",93.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",48.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",52.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",61.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",64,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",66.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",70.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",75.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",78.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",73,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",74.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",78.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",76.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",83.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",8.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",10.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",11.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",11.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",11.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",10.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",11,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",11.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",10.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",10.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",11,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",10.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",10.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",6.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",6.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",7.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",7.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",8.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",8.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",9.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",8.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",8.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",9.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",8.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",9.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",1.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",1.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",1.4,"B; D","Break; Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",1.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",1.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",1.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",1.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",1.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",237.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",246.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",240.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",258,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",297.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",352.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",411.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",476.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",614.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",753.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",861.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1151.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",157.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",147,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",133.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",135.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",135.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",129.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",136.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",130.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",127.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",132.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",122.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",130.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",257.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",254.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",235.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",241.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",269.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",303.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",331.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",344.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",376.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",404.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",397.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",410.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",3.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",3.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",4.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",338.3,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",391.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",478.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",589.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",607.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",532.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",442.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",534.4,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",612.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",787,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",900.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",820,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",685.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",590.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",482.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",563.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",684.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",851.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",881.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",778.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",644,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",8.4,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",9.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",12.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",13.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",12.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",10.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",8.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",7.6,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",8.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",10.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",13.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",13.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",11.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",9.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",2.5,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",12798,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",18495.4,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",27115.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",23741.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",38190.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",43736.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",50996.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",55462.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",62490.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",49123.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",58708.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",74745.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",76368.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",25.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",38.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",55.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",47.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",67,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",66.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",75.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",85.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",97.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",69.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",74.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",98.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",87.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",35.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",53.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",78.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",67.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",104,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",111.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",128.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",139.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",157.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",122.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",140.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",171.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",174.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",2.2,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",3.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",3.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",5.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",3.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",3.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",3.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",3.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",6.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",6.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",7.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",8.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",8.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",1.6,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",2.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",5.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",3.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",3.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",4.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",5.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",5.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",5.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",6.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",4.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",5.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",5.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",6.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",6.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",7.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",8.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",8.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",8.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",9.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",9.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",9.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",2.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",2.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",2.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",3.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",3.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",4.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",3.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",5.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",5.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",6.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",6.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",6.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",7.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",7.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",1.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",9.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",8.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",9.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",9.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",10.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",10.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",11.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",11,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",10.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",12.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",11.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",12.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",11,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",11.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",12.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",13.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",13,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",12.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",12.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",12.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",14.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",14.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",14.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",15,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",15.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",16.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",18.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",19,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",20.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",21,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",20,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",19.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",20.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",6.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",5.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",6.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",6.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",6.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",7.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",7.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",8.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",9.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",9.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",354,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",386,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",446,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",790,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",801,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",822,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",3422,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",2540,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1794,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1378,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1133,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1030,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",324.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",398.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",461.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",762.7,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",722,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",617.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",2543.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1946.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1340.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",957.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",779.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",773.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",235.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",255.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",289.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",545.9,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",551.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",557.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",2359.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",1719.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",1220.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",931.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",779.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",711.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",14.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",17.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",20.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",33,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",30.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",25.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",105.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",79.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",53.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",37.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",30.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",30.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",10.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",11.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",23.6,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",23.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",23.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",97.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",69.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",48.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",36.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",30.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",27.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",3.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",3.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",6.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",6.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",22.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",17.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",12,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",8.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",6.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",5.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",162.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",166.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",177.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",182.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",241.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",294.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",260.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",265.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",247.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",213.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",188,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",182.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",215.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",231.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",228.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",242.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",320.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",326.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",288.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",300.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",292.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",238.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",214.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",215.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",193.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",200.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",218.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",229.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",302.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",368.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",335.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",343.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",323.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",284.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",251.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",240.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",25.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",27.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",27.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",28.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",37.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",37.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",33,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",34.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",33.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",26.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",24.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",24,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",23.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",23.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",25.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",27.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",35.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",42.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",38.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",39,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",36.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",32.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",28.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",26.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",6.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",6.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",6.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",6.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",8.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",10.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",8.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",8.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",7.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",6.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",5.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",4.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",571.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",586.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",583.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",581.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",576.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",680.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",634.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",674.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",638.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",701.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",638.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",632.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",678,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",757.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",815.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",750,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",772,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",765.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",755.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",702.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",761.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",754.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",785,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",729.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",747.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",714,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",683.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",704.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",710,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",721,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",720.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",851,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",812.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",869.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",833.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",939.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",874.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",858,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",949.7,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",69.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",73.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",67.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",69.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",68.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",67,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",62,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",66.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",66,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",68.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",63.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",64.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",61.5,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",62.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",63.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",63.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",64.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",64.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",75.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",71.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",76.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",72.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",81.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",75.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",74.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",81.7,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",9.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",9.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",11,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",10.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",10.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",9.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",9.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",7.5,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1441.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1482.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1678.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",2447.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",2295.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",2328,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",2435.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",2275.2,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1981,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1952.7,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",2066.1,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1442.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1438.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1519,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1913.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1731.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1793.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1879.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1714.8,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1477.1,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1557.3,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1587.4,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1158.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1210.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1363.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1960.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1901.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1920.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",2018.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1842.7,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1609.2,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1577.1,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1647.9,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",41.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",41,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",42.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",53.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",47.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",49.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",50.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",45.6,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",38.8,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",40.7,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",40.8,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",38.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",54.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",52.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",52.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",54.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",49,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",42.3,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",41.2,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",42.4,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",6.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",8.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",7.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",7.1,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",5.8,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",5.3,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",5.2,"E; D","Estimated value; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",7138.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",7669,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",7424.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",6568.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",6451.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",6692.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",7213.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",7622.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",8324.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",9284.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",7833.4,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",8201.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",373.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",433.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",379.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",335.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",310.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",272.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",295.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",326.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",383.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",404.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",337.5,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",378.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",522.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",574.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",558.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",513.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",507.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",517.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",573.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",613.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",672.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",756.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",628.6,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",643.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",35.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",41.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",36.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",31.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",29.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",25.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",27.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",30.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",36,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",37.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",31.5,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",36,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",49.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",54.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",53.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",48.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",48.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",49.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",54.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",57.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",63.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",70.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",58.8,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",61.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",8.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",9.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",8.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",8.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",8.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",8.9,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",8.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",2056.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",2036.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",2015.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",2066.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",2107.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",2220.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",2066,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1983.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",1929.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2032.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2186.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",2006,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",365.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",379.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",348,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",367.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",375.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",330,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",306.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",300.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",305.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",304.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",334.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",319.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",270.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",272.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",266.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",280.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",287.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",303.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",291.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",288.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",285.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",306.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",333.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",304.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",65.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",68.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",62.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",65.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",66.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",58.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",53.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",52.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",52.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",52.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",57.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",54.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",48.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",49,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",47.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",50,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",51,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",53.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",50.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",50.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",49.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",52.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",57.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",52,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",9.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",9.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",9.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",10.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",10.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",9.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",8.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",8.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",8.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",148.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",152.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",140.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",144.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",145.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",182.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",184.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",196.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",246.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",268,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",256.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",245.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",197.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",212.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",180.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",191.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",193.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",202,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",203.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",222.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",291.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",300,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",293.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",290,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",165.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",170.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",155,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",159.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",160.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",200.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",209,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",228,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",289.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",319.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",312,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",296.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",36.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",39.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",33.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",35.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",35.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",36.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",37.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",40.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",52.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",54.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",53,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",52.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",30.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",31.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",28.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",29.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",29.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",36.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",38,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",41.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",52.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",57.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",56.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",53.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",7.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",7.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",8.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",9.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",10.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",9.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",8.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",3056.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",4254.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",3632.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",65.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",55.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FRA","France","2011","2011",11.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",2029,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",2098.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",2411.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2395.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2966.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",3743.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",3238.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",2922.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",2898.8,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2717.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2544.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2623,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2689.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2921.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",3097.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",3181.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",3940.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",4153.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",3584.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",3301.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",3423.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",3042.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2906,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",3102.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2520.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2661.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",3062.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",3091.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",3857.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",4811.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",4302.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",3924.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",3941.5,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",3731.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",3509.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",3562.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",32.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",36.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",38.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",39.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",48.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",50.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",43.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",39.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",41.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",36.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",34.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",37.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",30.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",33.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",38.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",38.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",47.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",58.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",52.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",47.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",47.5,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",44.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",42.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",42.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",6.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",7.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",7.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",7.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",8.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",7.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",6.6,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",5.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",5.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",4.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",748.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",693.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",600.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",518.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",548.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",538.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",633.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",653.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",685.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",700.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",702,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",666.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",735.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",992.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",965.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",771.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",688.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",728.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",597.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",701.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",737.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",809.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",784,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",801.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",788.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",774.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1036.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",972.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",877.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",821.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",897,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",883.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1076.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1135.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1213.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1275.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1290.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1221.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1392.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",89.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",86.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",69.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",62.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",66.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",55.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",65.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",68.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",75.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",73.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",74.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",74.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",74.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",93.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",87.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",79.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",74.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",82.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",81.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",99.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",105.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",113.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",119,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",120.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",115.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",133.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",22127.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",22409.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",21233.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",24081.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",26838.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",31313.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",39211.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",29379.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",22607.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",22177.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",19574.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",20729.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",23726.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",106.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",111.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",94.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",107.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",115.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",112.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",139.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",107.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",83.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",76.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",63.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",68.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",63.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",175,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",180.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",169,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",192.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",207.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",236.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",297,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",216,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",162.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",157.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",134.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",134,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",147.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",11.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",9.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",10.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",11.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",11.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",14.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",10.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",8.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",7.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",6.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",6.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",17.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",18.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",17,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",19.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",21,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",24,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",30.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",22.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",16.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",16.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",13.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",13.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",15.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",4.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",4.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",4.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",6.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",6.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",7.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",4.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",4.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",3.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",2185.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",2615.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",2794.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",2618.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",2663.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",2857.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",3055.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",3067.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",3463.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",4032.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",4515.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",5216.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",17.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",22.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",22.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",21.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",22.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",21.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",25.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",28.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",32,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",32.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",33.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",41.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",16.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",19.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",20.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",19.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",19.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",20.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",21.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",22.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",24.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",28.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",30.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",34.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",56.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",70.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",69.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",66.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",69.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",65.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",75.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",83.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",90.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",91.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",91,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",110.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",51.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",60.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",63.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",59,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",58.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",60.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",65,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",64.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",69.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",79.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",84,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",93.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",8.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",10,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",11.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",10.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",11.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",11.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",12,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",11.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",11.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",12,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",11.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",11.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",66.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",60.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",69.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",64.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",68.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",89.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",102.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",113.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",122.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",102.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",75.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",77.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",87.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",83.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",89.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",85.4,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",91,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",99.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",113.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",128.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",144.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",114.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",86.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",91.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",77.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",72.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",84.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",79.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",83.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",110.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",129.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",143,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",154.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",127.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",94.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",97.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",19.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",18.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",19.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",18.5,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",19.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",21.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",23.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",26.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",29.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",23.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",17.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",18.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",15.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",18.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",17.2,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",23.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",27.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",29.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",31.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",25.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",19,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",19.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",3.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",3.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",5.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",5.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",3.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",2396.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",2356.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",2435.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",2447.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",4373.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",4413.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",3501.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",2918,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",2728.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",2478.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",2504,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",2603.1,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",3335.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",3027.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",3234.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",3251.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",4852.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",4885.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",3955.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3446.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3054.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",2831,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",2961.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",2741.2,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",3158.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",3151.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",3302.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",3309,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",5920.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",6300.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",5075.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4283.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",4154.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",3826.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",3866.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",4216.1,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",56.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",50.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",53.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",53.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",79.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",80.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",65.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",57,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",51.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",47.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",50.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",46.4,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",53.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",52.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",54.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",54.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",97.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",103.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",83.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",70.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",69.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",64.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",65.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",71.4,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",12.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",12.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",12.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",12.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",19.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",19.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",15.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",13,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",11.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",10.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",10.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",10.5,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",240226,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",265932,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",251567,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",234817,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",236305,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",219483,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",209885,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",169135,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",125509,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",155485,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",157486,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",115171,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",2736.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",3332.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",3152.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",2406,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",2230.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",1813.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1929.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1507.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1136.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",1426.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",1474.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",1049.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",2150.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",2474.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",2412.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",2318,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",2293.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",2121.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1989.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1609.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1205,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",1491.8,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",1537.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",1128.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",21.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",26.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",24.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",18.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",17.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",14.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",15.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",11.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",11.3,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",11.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",8.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",16.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",19.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",18.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",18.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",18,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",16.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",15.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",12.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",9.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",11.8,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",12.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",3.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",3.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",3.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",3.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",3.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",3.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",3.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",1.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",1.6,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",1.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",1.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",2549474,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",2880536.3,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",2716710.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",2795930.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",2840189.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",2908070.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",3044109.3,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",3072355.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",3031844.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",3112659.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",3021018.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",2889419.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",2204.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",2599.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",2411,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",2553.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",2697.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",2571.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",2622.5,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",2716.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",2755.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",2671,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",2559.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",2525.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",3031.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",3370.7,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",3177.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",3217.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",3257.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",3391.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",3544.6,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",3520.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",3546.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",3634.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",3606.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",3383,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",44.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",52.1,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",48,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",50.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",53.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",50.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",51.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",52.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",53.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",51.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",49.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",48.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",61.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",67.5,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",63.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",63.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",64.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",66.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",69.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",68.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",68.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",70.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",69.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",65.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",12.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",13.1,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",12.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",12.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",12,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",11.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",12,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",11.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",10.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",10,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",9.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",10.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",11.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",10.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",9.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",9.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",8.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",9.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",9.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",14.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",16.7,"D; P","Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",14.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",14.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",14.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",13.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",12.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",10.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",10,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",10,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",11.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",10.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",10.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",17.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",17.6,"D; P","Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",11.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",11.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",12.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",11.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",10.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",10.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",11.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",17.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",20.1,"D; P","Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",29.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",30.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",28.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",27.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",24.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",20,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",19,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",18.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",21.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",19.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",19.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",30.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",30,"D; P","Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",24.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",24.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",23.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",20.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",20.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",20.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",19.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",21.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",20.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",30,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",34.2,"D; P","Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",4.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",4.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",6.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",6.5,"D; P","Difference in methodology; Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",7478,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",7936,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",12173,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",18213,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",17720,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",19023,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",20942,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",22564,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",23071,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",22621,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",24725.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",22990.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",23059.8,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",591.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",638.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",924.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",1426,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",1333.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",1200.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",1122,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",1192.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",1198.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",1174.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",1150.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",1134.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",1145.7,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",973.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",1034.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1549,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",2310,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",2202.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",2284.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",2479.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",2531.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",2487.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",2340.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",2462.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",2210.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",2180.4,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",5.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",5.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",12,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",11.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",9.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",9.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",9.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",9.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",9.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",8.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",8.8,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",8.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",13.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",19.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",18.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",18.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",20.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",20.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",19.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",18.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",19.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",17.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",16.8,"E","Estimated value" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",12.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",10.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",350.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",358.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",375.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",393.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",387.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",465.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",498.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",482.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",522.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",515,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",410.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",428.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",455.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",493.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",479.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",28,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",29.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",28.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",31.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",30.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",24.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",25.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",27.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",29.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",28.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",6.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",8.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",9.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",43.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",50,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",53.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",98.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",101.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",109.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",114.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",170.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",133.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",173.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",151.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",109.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",91.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",31.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",39.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",43.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",80.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",84.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",76.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",80,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",121,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",92.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",114.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",98.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",77.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",58.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",28.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",33.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",35.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",67.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",70.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",74.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",79.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",119,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",90.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",122.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",107.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",75.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",63.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",7.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",9.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",18.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",18.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",16.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",17,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",25.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",18.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",23,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",19.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",15.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",11.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",6.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",7.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",8.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",15.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",15.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",16.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",16.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",24.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",18.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",24.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",21.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",14.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",12.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",5.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",6.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",5.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",11.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",10.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",13.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",10.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",11.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",9.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",6.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",4.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1256,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1426,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1534,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1514,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1830,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",2214,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2279,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2352,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2198,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",2135,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1710,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",3055,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",3511,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",207.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",254.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",263.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",257.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",290.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",274.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",271.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",284.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",270.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",242.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",181.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",355.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",365.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",137.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",157,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",169.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",167.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",197.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",222.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",226.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",241.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",229.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",221.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",173.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",321.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",326.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",42.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",51.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",52.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",50.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",56.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",52.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",51.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",53.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",50.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",45.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",33.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",65.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",67.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",28.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",31.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",33.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",33,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",38.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",43,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",43.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",45.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",43.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",41.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",32.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",59.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",60.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",7.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",8.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",7.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",8.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",9.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",9.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",8.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",7.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",5.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",9.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",182.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",163.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",130,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",116.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",119,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",133.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",118.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",116.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",121.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",129.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",121.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",103.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",118.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",241.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",227.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",167,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",154.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",158.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",148.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",130.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",131.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",143.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",145.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",138.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",122.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",125.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",292.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",262.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",214.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",198.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",205.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",228.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",206.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",202.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",212.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",232.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",217.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",182.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",215.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",22.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",21.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",15.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",14.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",15.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",14.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",12.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",12.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",13.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",14.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",13.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",11.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",12.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",27.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",24.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",20.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",19,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",19.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",22,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",20,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",19.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",20.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",22.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",21.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",17.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",20.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",5.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",4.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",4.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",4.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",4.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",4.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",3.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",3.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",106.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",115.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",120.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",111.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",122,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",134.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",114.8,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",112.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",116.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",118.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",110.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",135.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",140.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",160.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",155,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",148.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",162.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",148.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",127.1,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",126.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",138.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",133.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",126.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",160.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",211.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",228,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",239.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",227.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",251.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",273,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",228.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",217.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",222.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",229.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",213.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",254.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",26.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",29.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",28.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",27.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",29.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",27.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",23.4,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",23.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",25.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",24.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",23.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",29.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",39.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",42.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",44.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",42.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",46.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",50.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",42,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",40,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",40.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",42.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",39.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",46.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",9.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",10.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",10.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",9.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",9.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",9.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",7.3,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",7.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",7.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",6.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",6.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",7.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",365.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",311.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",274.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",274.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",302.2,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",302.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",297.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",293.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1868.6,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1850.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1794.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1794.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1780.6,"P","Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",485,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",433.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",353.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",364.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",401.5,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",335.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",329.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",331.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",2206.7,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",2072,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2049.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2122.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1875,"P","Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",503.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",436.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",395.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",406.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",456.2,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",455,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",463.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",464.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2957.6,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",3019.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2887.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",2867.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2986.5,"P","Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",10.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",9.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",7.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",7.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",8.6,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",7.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",7.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",7.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",47.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",44,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",43.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",44.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",39.5,"P","Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",10.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",9.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",8.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",8.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",9.8,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",9.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",10,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",10,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",63.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",64.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",61,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",60.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",63,"P","Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",2.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",2.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",2.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",2.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",9.8,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",9.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",8.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",8.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",7.8,"P","Provisional value" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",2649.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",2551,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",2540.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",2367.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3029.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",3983.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",3888.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",3285.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",4538.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",3807.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",3307.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",3341.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",3543.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",367.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",392.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",374.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",363.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",441.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",472.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",454.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",384.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",522.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",402.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",359.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",389.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",350.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",293.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",288.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",293.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",275.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",347.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",449.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",440.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",371.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",511.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",437.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",381.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",383.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",408.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",39.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",41.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",39.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",37.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",45.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",48.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",45.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",38.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",51.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",39.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",34.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",37.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",33.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",31.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",30.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",30.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",28.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",35.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",45.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",44.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",36.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",50.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",42.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",36.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",36.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",39.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",7.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",6.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",6.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",9.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",7.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",9.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",7.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",6.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",6.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",6.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",437.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",445,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",463,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",449,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",459,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",569,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",546,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",554,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",553,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",551,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",490,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",476,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",523,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",419.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",501.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",493.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",484.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",501,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",591.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",554.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",562.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",565.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",554.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",521.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",520.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",547.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",298.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",318.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",341.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",342.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",358.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",460.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",454.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",466.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",469.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",479,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",431.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",430.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",490.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",53.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",63.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",61.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",59.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",61.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",71.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",66.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",66.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",66.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",64.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",60.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",59.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",62.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",38.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",40.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",42.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",42.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",43.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",55.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",54.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",55.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",55.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",55.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",49.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",49.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",56.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",7.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",7.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",7.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",7.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",7.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",9.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",8.6,"B; D","Break; Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",8.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",8.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",8.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",7.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",6.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",6.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",2580.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1976.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1910.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1992.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",2049.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",2341.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",2699.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",3002.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",3895.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",5252,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",5511.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",6853.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1717.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",1180,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",1063.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",1046.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",936.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",860.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",893.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",823,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",806.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",925.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",786.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",774.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2803.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",2045.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1873.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1861.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1855.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",2014.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",2174.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",2169.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",2386.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2817.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2546.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",2440.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",23.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",15.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",14.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",13.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",12.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",11,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",11.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",10.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",9.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",11.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",9.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",9.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",38.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",27.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",24.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",24.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",24,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",25.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",27.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",27,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",29.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",34.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",30.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",29,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",16.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",14,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",14.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",13.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",13.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",12.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",12.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",11.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",12.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",12.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",11,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",10.6,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1606,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1729.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1844.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",2079.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",2346.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",2615.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",2657.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2536.9,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",2703.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",3034.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",3177,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",3168.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",3366.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",3545.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",2288.9,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",2487.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",2640.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",3002.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",3408.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",3820.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",3864.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",39.8,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",42.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",47,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",48.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",48.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",51,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",53.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",35.9,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",38.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",40.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",46.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",51.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",57.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",58.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",11.7,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",11.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",11.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",11.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",12.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",13.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",13,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",58760.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",177900.9,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",132266.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",209955.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",180250.2,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",241797.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",281371,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",255295,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",351495.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",359508.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",433351.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",310910.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",391011.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",115.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",367.8,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",271.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",423.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",316,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",369.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",415.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",393.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",548.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",511.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",546.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",409.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",447.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",163.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",511.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",380.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",600.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",490.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",618.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",708.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",641.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",887.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",895.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",1035.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",714.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",893.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",6.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",21.3,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",15.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",24.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",17.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",20.6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",22.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",21.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",29.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",26.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",28.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",20.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",22.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",9.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",29.6,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",21.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",34.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",27.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",34.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",39,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",34.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",47.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",46.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",53.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",36.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",45.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",7.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",15.1,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",10.6,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",14.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",11.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",13.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",13.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",12.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",15.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",14.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",16.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",11.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",13.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",19.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",22.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",24.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",23.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",28,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",31.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",44.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",43.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",46.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",48.4,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",44,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",75.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",60.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",26.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",31.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",31.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",31.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",37.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",35.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",49.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",49.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",55.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",54.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",50.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",89.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",63.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",38.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",43.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",47.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",45.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",53.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",59.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",84,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",81.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",87.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",90.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",84.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",139.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",106.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",19.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",23.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",23.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",24.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",28.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",26.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",37.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",37.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",41.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",40.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",37.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",67.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",47.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",29.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",32.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",35.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",34.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",40.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",45,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",63.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",62.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",65.9,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",68,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",63.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",104.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",79.7,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",10.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",10.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",11.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",10.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",11.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",12,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",15.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",14.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",14.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",14.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",12.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",18.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",14,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",19,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",19.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",19.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",21.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",19.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",26.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",29.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",27.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",29.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",27.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",22.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",22.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",25.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",25.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",27.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",25.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",28.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",26.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",29.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",32.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",30.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",34.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",31,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",25.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",26.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",27.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",29.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",31.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",32.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",36,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",33.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",44.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",51.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",47.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",51.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",50.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",40.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",39.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",46.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",12.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",13.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",12.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",13.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",12.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",14.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",15.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",14.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",16.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",14.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",12.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",12.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",12.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",14.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",15.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",15.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",17.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",16.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",21.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",24.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",23.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",25,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",24,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",19.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",18.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",22.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",4.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",4.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",4.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",4.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",6.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",5.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",5.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",5.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",194,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",198,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",184,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",320,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",320,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",363,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",392,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",395,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",389,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",400,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",311,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",323,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",178,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",204.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",190.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",308.9,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",288.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",272.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",291.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",302.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",290.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",278.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",214,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",242.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",129,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",131,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",119.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",221.1,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",220.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",246.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",270.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",267.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",264.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",270.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",213.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",223.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",8.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",9.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",8.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",13.4,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",12.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",11.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",12.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",11.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",11,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",8.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",5.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",5.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",5.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",9.6,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",10.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",10.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",10.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",8.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",8.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",2.7,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",74.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",71.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",68.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",69.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",66.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",65.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",62.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",59.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",58.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",54.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",43.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",41.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",98.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",100,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",87.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",92.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",87.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",72.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",69.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",67.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",68.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",60.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",49.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",49.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",88.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",86.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",83.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",87.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",82.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",81.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",80.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",77.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",75.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",72.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",58.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",55.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",11.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",10.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",10.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",8.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",7.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",7.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",7.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",6.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",5.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",5.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",10.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",10.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",9.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",10.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",9.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",8.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",8.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",8.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",6.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",251.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",244.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",225.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",218.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",213.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",215.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",197.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",189.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",186.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",193.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",168.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",177.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",203,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",333.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",340.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",290.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",290.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",283.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",239.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",218.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",214.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",220.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",216.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",192.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",209.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",213.8,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",300.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",294.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",274.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",271.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",266.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",269.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",252.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",244.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",243.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",258.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",231.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",240.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",284.3,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",30.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",30.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",26.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",26.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",25.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",21.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",19.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",18.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",19.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",18.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",16.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",18.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",18.4,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",26.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",24.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",24.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",23.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",23.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",22.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",21.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",21.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",22.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",20,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",20.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",24.5,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",3.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.3,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",694.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",678.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",683.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",678.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",687.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",694.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",646.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",564.5,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",460.8,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",445.2,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",494.8,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",694.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",658.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",618.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",530.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",518.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",535.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",498.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",425.5,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",343.6,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",355.1,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",380.2,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",557.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",554.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",555.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",543.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",569.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",573,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",535.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",457.2,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",374.3,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",359.6,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",394.6,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",20,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",18.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",17.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",14.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",14.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",14.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",13.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",11.3,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",9.3,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",9.8,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",16.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",15.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",15.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",15.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",15.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",15.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",14.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",12.2,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",9.8,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",9.4,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",10.1,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",2.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.8,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",1.3,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",1.2,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1.2,"E; D","Estimated value; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2686.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2528.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",2592,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2544.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2245.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2167.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2101,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2230.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2392.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",2440.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2014.9,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2113.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",140.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",142.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",132.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",130,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",108.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",88.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",86,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",95.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",110.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",106.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",86.8,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",97.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",196.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",189.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",194.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",199.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",176.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",167.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",167.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",179.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",193.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",198.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",161.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",165.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",13.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",13.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",12.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",12.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",10.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",8.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",8.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",10.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",10,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8.1,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",9.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",18.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",18.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",18.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",18.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",16.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",15.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",15.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",16.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",18.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",18.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",15.1,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",15.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.3,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",67.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",65.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",55,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",53.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",50.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",51.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",55.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",52.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",49.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",44.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",41.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",39,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",89,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",91.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",70.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",71.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",66.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",57.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",61.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",59.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",58.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",50,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",47.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",46.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",74.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",73,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",60.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",59.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",55.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",57.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",62.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",60.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",58.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",53.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",50.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",47.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",16.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",16.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",13.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",12.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",10.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",11.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",10.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",10.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",9.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",8.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",8.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",13.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",13.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",10.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",10.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",10.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",11.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",10.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",9.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",8.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",3.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",3.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",740.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",712.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",772.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",828.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",782.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",769.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",754.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",732.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",746,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",713.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",576.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",541,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",981.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",991.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",993,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1099.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1039.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",854,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",835.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",827.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",881,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",798.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",658.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",639.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",919.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",903.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",981.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1068.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1017.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",989.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1002.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",983.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1014.3,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",979.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",795.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",734.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",12.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",12.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",13.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",12.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",10.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",10,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",10.6,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",7.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",7.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",13.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",12.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",12.2,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",9.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",8.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.7,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",366.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",340.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",294.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",227.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",235.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",228.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",231.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",226.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",224.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",227.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",211.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",223.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",209.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",485.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",474.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",377.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",301.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",313.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",253.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",256.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",255.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",265.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",254.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",241.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",264.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",220.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",507.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",477.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",429.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",360.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",385.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",375.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",393.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",393.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",397.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",414,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",388.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",410.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",396,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",43.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",42.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",34.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",27.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",28.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",23.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",23.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",23.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",24.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",23.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",22.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",25.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",21.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",45.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",43,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",38.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",32.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",35.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",34.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",36.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",36.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",37.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",38.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",36.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",38.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",37.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",14338.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",14278.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",12925.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",12938.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",13239.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",13565.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",12865.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",12714.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",12637.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",11775.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",9059.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",9655,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",12042.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",69,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",71,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",57.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",57.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",56.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",48.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",45.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",46.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",46.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",40.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",29.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",31.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",32.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",113.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",114.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",102.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",103.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",102.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",102.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",97.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",93.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",90.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",83.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",62.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",62.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",74.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",6.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",7.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",4.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",4.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",4.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",4.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",11.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",11.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",10.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",9.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",9.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",942.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",966.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1031.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1047.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",997.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1040.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1062.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1066.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1161.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1102.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1063.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1195.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",8.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",8.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",8.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",8.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",7.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",8.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",10,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",10.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",7.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",7.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",7.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",7.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",7.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",7.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",7.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",7.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",8.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",7.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",7.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",24.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",26.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",25.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",26.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",26.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",23.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",26.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",29.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",30.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",24.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",21.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",25.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",22.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",22.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",23.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",23.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",22,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",22.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",22.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",22.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",23.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",21.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",19.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",4.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",4.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",4.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",4.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",3.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",3.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",48.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",44.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",54.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",48.1,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",48,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",47.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",44.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",42.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",41.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",39.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",33.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",38.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",64,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",61.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",69.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",63.8,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",63.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",53,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",49.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",48.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",49,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",44,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",38.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",45.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",56.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",53.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",65.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",59.2,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",58.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",58.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",56.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",54,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",52.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",48.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",42.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",48.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",14,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",13.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",15.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",13.8,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",13.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",11.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",8.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",7.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",9.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",12.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",11.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",14.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",12.8,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",12.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",12.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",10.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",9.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",8.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",9.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",2.5,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",1.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",1.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",1.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1124.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",998.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",979.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",974.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",956.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",884.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",871,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",864.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",839.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",689.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",653.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",740.5,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1565.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1282.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1300.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1294.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1060.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",978.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",983.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1020.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",939.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",787.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",773.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",779.7,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1482.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1334.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1328.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1317.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1294.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1262.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1262.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1268.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1277.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1064.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1009.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1199.3,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",26.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",21.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",21.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",21.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",17.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",16.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",16.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",16.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",15.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",13.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",13.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",13.2,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",25,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",21.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",21.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",20.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",20.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",21,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",21.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",17.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",17.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",20.3,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",4.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",3.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",3.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",3.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",3.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",2.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",3,"E","Estimated value" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1524345,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1553418.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1384956.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1321304.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1328207.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1345422.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1264533.9,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1268716.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1313986.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1306743.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1093254.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1064966.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1318.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1401.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1229.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1206.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1261.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1189.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1089.4,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1121.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1194.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1121.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",926.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",931,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1812.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1817.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1620,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1520.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1523.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1569,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1472.4,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1453.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1537.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1525.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1305.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1246.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",26.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",28.1,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",24.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",23.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",24.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",23.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",21.3,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",21.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",23.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",21.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",17.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",18,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",36.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",36.4,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",32.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",30.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",30,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",30.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",28.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",28.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",29.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",29.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",24.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",7.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",6.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",5.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",5.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",5.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",5,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",4.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",4.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",4.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",7.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",6.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",6.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",5.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",4.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.5,"D; P","Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",8.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",8.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",7.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",6.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.7,"D; P","Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",7.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",6.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",6.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",6.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",4.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",5.4,"D; P","Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",19.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",16.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",16.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",15.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",12.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",12.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",11.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",10.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",8.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",8.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",8.1,"D; P","Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",16.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",14.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",14,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",12.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",9.2,"D; P","Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",3.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.8,"D; P","Difference in methodology; Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",131.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",126.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",120.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",120.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",102.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",174.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",176.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",155,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",159.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",136.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",154.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",151.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",146.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",150.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",127.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",10.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",10.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",9.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",8.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",9.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",9.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",8.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",16.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",18.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",18.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",15.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",15,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",17,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",18.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",15.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",13.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",14.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",15.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",16.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",16.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",14.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",15.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",13,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",12.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",12.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",10.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",9.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",11.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",11.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",12.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",12.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",11,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",10.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",11.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",12.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",10.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",10.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",10.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",454,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",448,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",458,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",423,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",454,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",460,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",469,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",434,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",414,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",409,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",413,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",403,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",495,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",75.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",79.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",78.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",72,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",72,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",57,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",55.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",52.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",50.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",46.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",43.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",46.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",51.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",49.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",49.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",50.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",46.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",48.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",46.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",46.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",44.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",43.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",42.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",41.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",42.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",46.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",15.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",16.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",15.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",14.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",14,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",11,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",10.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",9.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",9.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",8.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",8.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",8.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",9.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",10.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",10,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",10.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",8.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",8.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",8.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",8.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",7.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",8.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",102.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",91.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",75.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",68.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",64.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",66.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",63.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",59.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",61.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",60.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",45.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",45.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",57.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",135.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",127.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",97.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",91.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",86.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",74.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",70.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",67.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",72.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",67.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",52.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",53.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",61,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",164.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",146.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",125.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",117.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",112,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",114.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",110.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",104.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",108,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",108.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",82,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",80,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",105.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",12.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",9.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",8.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",8.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",7.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",6.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",6.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",7.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",6.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",5.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",5.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",5.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",15.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",13.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",11,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",10.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",10.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",10.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",1.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",52.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",64.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",74.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",55.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",60.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",65.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",42.3,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",41,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",41.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",40.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",32.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",38.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",69.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",89.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",95.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",73.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",80.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",72.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",46.8,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",46.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",49.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",45.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",37.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",45.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",104.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",126.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",147.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",113.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",125.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",132.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",84.1,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",79.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",79.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",78.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",62.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",71.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",13,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",16.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",17.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",13.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",14.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",13.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",8.6,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",8.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",9.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",8.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",6.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",8.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",19.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",23.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",27.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",20.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",23.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",24.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",15.5,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",14.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",14.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",14.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",11.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",13.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",4.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",5.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",6.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",4.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",4.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",4.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",2.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",305.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",260.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",227.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",227.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",250.8,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",249.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",243,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",237.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",480,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",488.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",449.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",466.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",486.7,"P","Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",404.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",363.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",292.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",302.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",333.1,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",277.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",268.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",268.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",566.9,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",546.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",513.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",551.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",512.5,"P","Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",419.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",365.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",327.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",337.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",378.6,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",375.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",378.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",376.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",759.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",796.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",723,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",745,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",816.3,"P","Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",8.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",7.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",6.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",7.2,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",5.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",12.1,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",11.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",10.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",11.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",10.8,"P","Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",7.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",7.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",8.1,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",8.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",8.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",16.2,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",16.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",15.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",15.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",17.2,"P","Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2.2,"B; D","Break; Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.5,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.1,"P","Provisional value" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1003,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",934.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",850.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",720.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",710.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",749.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",724.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",694.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",692.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",738.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",713.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",686.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",728.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",139.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",143.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",125.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",110.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",103.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",88.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",84.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",81.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",79.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",78.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",77.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",80.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",72,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",111.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",105.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",98.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",83.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",81.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",84.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",82.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",78.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",78.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",84.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",82.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",78.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",84.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",14.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",15.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",13.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",11.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",10.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",9.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",8.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",8.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",7.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",7.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",11.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",11.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",10.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",8.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",8.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",8.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",7.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",7.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1925.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1340.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1246.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1182.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1141.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1289.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1450.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1448.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1701.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",2350.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1985.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",2387.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1281.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",800.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",694.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",621.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",521.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",474,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",480.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",397.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",352.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",414.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",283.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",269.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2091.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1387.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1222.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1105.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1033.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1109.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1169,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1046.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1042.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1260.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",917.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",850.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",17.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",10.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",8.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",6.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",6.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",6.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",4.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",4.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",3.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",3.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",28.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",18.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",16.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",14.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",13.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",14.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",14.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",13,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",12.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",15.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",11,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",10.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",12.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",9.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",8.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",7.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",6.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",5.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",5.3,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",5.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",3.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",38463.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",60319.9,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",67944,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",70741,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",72295.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",79384.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",83434.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",79791.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",77671.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",79619.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",71250.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",77557.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",100217.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",75.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",124.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",139.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",142.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",126.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",121.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",123.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",123,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",121.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",113.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",89.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",102.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",114.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",106.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",173.3,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",195.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",202.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",196.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",202.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",210,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",200.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",196,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",198.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",170.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",178.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",229,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",4.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",7.2,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",8.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",7.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",6.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",6.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",6.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",6.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",5.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",6.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",10,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",11.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",11.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",11.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",11.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",11.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",10.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",10.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",10.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",8.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",9.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",11.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",4.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",5.1,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",5.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",4.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",4.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",3.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",3.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",3.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",7.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",8.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",7.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",7.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",6.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",6.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",6.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",6.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",6.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",6.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",6.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",7.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",10.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",11.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",10.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",9.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",9.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",7.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",7.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",7.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",7.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",7.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",7.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",7.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",15.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",15.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",15.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",14,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",13.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",12.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",13,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",12.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",12.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",12.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",12.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",11.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",12.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",7.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",8.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",7.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",7.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",5.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",5.8,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",5.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",5.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",5.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",5.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",5.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",11.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",11.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",11.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",10.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",10.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",9.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",9.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",9.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",9.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",8.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",9.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",3.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",2.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",11.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",11.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",11.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",11.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",11.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",9.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",12.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",15.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",16.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",14.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",15.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",14.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",12.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",12.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",12.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",13.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",13.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",10.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",12.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",18.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",18.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",18.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",19.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",18.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",19.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",19.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",19.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",19.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",21.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",17.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",17.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",22.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",7.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",7.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",7.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",7.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",6.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",6.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",6.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",5.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",5.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",6.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",9.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",8.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",8.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",10.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",324,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",309,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",312,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",378,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",383,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",401,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",426,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",429,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",500,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",535,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",570,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",584,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",297.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",318.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",323,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",364.9,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",345.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",301.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",316.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",328.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",373.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",371.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",392.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",438.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",215.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",204.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",202.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",261.2,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",263.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",272.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",293.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",290.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",340,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",361.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",392,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",403.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",13.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",14.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",14.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",15.8,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",14.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",12.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",13.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",13.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",15,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",14.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",15.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",17.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",9.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",9.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",8.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",11.3,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",11.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",11.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",12.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",11.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",13.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",14.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",15.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",3.2,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",109.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",109.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",107.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",101.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",100.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",100.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",102.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",105.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",105.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",107.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",106.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",116.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",145.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",152.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",138.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",134.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",133.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",111.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",113.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",119.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",124.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",120.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",121.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",137.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",130.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",131.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",132.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",127,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",125.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",125.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",132.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",136.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",137.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",143.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",142.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",154.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",17.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",18.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",16.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",15.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",12.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",13,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",13.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",14,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",13.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",13.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",15.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",15,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",14.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",14.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",15.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",15.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",15.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",16.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",16,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",17.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",4.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",4.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",3.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",3.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",250.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",250.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",249.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",251.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",254.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",256.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",254.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",247.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",236.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",253.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",231.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",218.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",242.6,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",331.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",349.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",320.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",334.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",338.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",284.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",281.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",279.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",279.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",283.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",264.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",258.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",255.4,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",299.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",301.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",303.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",312.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",318.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",320.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",325.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",319.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",308.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",339.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",316.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",296.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",339.7,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",30.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",31.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",28.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",30,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",30.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",25.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",24.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",24.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",24.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",24.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",22.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",22.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",22,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",28.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",28.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",28.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",27,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",29.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",27.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",25.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",29.2,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",4.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",4.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",4.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.7,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",980.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",989.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",988,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",907,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",910.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",929.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",978,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1061.5,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1060.8,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1182.8,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1176.3,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",981.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",960.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",894.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",709.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",687.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",716.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",754.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",800,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",791,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",943.3,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",903.8,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",788,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",808.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",803,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",726.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",754.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",766.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",810.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",859.7,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",861.7,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",955.3,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",938.2,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",28.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",27.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",25.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",19.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",19,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",19.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",20.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",21.3,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",20.8,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",24.7,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",23.2,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",22.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",23,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",22.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",20.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",20.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",21,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",22.9,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",22.7,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",25,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",24.1,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",3.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",3.3,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",3.1,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",3.2,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.9,"E; D","Estimated value; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",4066.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3994.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",4113.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",4023.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",4051.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",3999.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",4145.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",4340.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",5176.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",5269.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2204.5,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2384.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",212.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",225.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",210.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",205.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",195.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",162.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",169.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",185.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",238.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",229.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",95,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",110,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",297.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",299.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",309.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",314.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",319,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",309.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",329.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",349.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",418.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",429.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",176.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",187.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",20.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",21.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",20,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",19.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",18.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",15.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",16.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",17.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",22.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",21.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",10.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",28.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",28.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",29.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",29.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",30.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",29.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",31.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",33,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",39.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",40.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",16.5,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",17.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",4.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",4.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",4.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",4.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",4.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",5.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.5,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",618.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",646,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",543.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",551.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",534.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",578.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",593.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",598.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",630.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",713.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",667.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",610,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",109.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",120.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",93.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",98.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",95.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",86,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",88.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",90.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",99.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",107,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",102,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",97,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",81.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",86.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",71.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",75,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",72.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",79.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",83.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",87,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",93.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",107.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",101.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",92.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",19.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",21.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",16.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",17.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",16.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",15.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",15.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",15.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",17.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",18.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",17.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",16.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",14.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",15.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",12.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",13.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",12.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",13.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",14.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",15.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",16.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",18.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",17.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",15.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",2.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",3.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",2.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",2.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",2.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",2.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",2.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",91,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",91,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",96.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",96.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",98.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",98.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",97.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",96.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",101.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",102.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",97.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",99.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",120.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",126.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",123.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",128.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",131.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",109,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",108.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",108.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",120.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",114.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",111.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",117.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",101.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",101.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",105.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",106.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",109,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",108.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",111,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",111.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",119.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",122.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",118.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",120.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",22.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",23.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",22.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",23.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",24.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",19.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",19.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",19.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",21.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",20.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",20.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",21.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",18.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",18.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",19.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",19.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",20,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",19.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",20.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",20.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",21.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",22.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",21.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",21.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",4.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",4.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",4.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",4.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",4.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",4.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",4.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",4.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",4.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",3.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",3.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",934.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",1301.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",1111.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",20,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",17.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FRA","France","2011","2011",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1336.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1285.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1338.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1361.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1386,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1397.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1405.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1390.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1295.1,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1296.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1242.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",1413.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1771.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1788.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1719.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1808.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1841.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1550.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1555.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1570.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",1529.5,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",1451.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",1419.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",1671.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1659.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1629.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",1699.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1757.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1802.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1795.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1867,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",1866.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1761,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1780,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1714.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1919.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",21.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",22.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",21.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",22.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",22.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",19,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",18.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",19,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",18.4,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",17.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",17.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",20.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",20.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",20.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",21.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",21.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",22.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",22,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",22.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",22.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",21.2,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",21.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",20.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",23.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",4.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",4.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",4.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",3.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",3.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",2.9,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",2.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",2.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",2.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",317.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",275.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",245,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",221,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",211.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",187.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",215.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",212.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",236.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",233.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",237.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",243.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",228.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",420.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",383.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",314.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",293.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",280.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",207.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",238.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",239.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",279.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",261.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",271.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",288.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",240.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",439.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",386.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",357.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",350.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",345.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",307.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",366.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",368.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",419.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",426.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",437.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",446.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",432.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",37.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",34.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",28.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",26.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",25.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",19.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",22.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",22.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",26.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",24.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",25.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",27.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",23,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",39.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",34.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",32.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",31.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",31.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",28.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",34,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",34.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",39.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",39.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",40.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",42.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",41.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",22271.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",21144.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",19341.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",18632.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",17751.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",17492.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",17665.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",17723.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",17843.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",18397.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",17674.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",17380.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",18106.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",107.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",105.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",85.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",83.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",76.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",62.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",62.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",64.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",66,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",63.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",57.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",57.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",48.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",176.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",170.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",154,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",149.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",137.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",132,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",133.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",130.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",128.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",130.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",121.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",112.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",112.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",10.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",10.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",8.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",8.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",7.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",6.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",6.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",6.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",6.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",5.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",5.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",17.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",17.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",15.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",15.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",13.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",13.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",13.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",13.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",13.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",13.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",12.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",11.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",11.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",4.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",4.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",4.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",3.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",3.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",3.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1220.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",760.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",765,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",945.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",699.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",645.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",697.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",698.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",761.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",936.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1184.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1260.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",10,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",6.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",7.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",4.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",5.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",6.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",8.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",9.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",5.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",5.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",6.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",4.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",5.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",8.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",31.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",20.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",19.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",23.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",18.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",14.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",17.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",19,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",19.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",21.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",23.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",26.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",28.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",17.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",17.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",21.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",15.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",13.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",14.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",18.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",22,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",22.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",3.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",88.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",74.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",74.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",67.1,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",66,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",66.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",67.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",67.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",68.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",70.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",71.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",75.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",116.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",104.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",96.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",89.1,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",87.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",73.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",74.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",76.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",80.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",79.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",81.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",89.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",103.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",90.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",90.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",82.7,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",80.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",81.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",84.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",85,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",86.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",87.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",89.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",95.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",25.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",22.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",20.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",19.3,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",18.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",15.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",16.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",16,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",16.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",17.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",22.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",19.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",19.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",17.9,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",17.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",17.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",17.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",17.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",17.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",18,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",18.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",3.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.4,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",640.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",589.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",551.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",505.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",485.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",467.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",462,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",534.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",538.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",521.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",533.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",579.1,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",891,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",757.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",732,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",672.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",538.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",517.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",521.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",630.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",603,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",595.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",631.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",609.8,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",843.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",788.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",747.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",683.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",656.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",667.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",669.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",784,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",820.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",804.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",824.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",937.9,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",15,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",12.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",12.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",11.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",8.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",8.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",8.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",10.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",10.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",10,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",10.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",10.3,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",14.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",13.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",12.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",11.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",10.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",11,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",11.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",13,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",13.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",13.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",13.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",15.9,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",3.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",3.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",2.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",2.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",2.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",2.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",2.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",2.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",2.3,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1236172,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1380748.4,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1278113.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1291743.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1352796.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1360086.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1350832.8,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1415318.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1521399.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1642015.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1708187.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1819792.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1068.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1245.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1134.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1179.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1284.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1202.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1163.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1251.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1382.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1409,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1447.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1590.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1469.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1615.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1495.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1486.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1551.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1586.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1572.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1621.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1779.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1917.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",2039.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",2130.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",21.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",24.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",22.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",23.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",25.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",23.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",22.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",24.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",26.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",27.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",27.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",30.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",29.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",32.4,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",29.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",29.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",30.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",31.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",30.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",31.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",34.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",37,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",39.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",41.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",6.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",6.3,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",5.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",5.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",5.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",5.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",5.3,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",5.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",9.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",9.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",9.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",10.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",10.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",10.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",11.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",10.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",10.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",9.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",8.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",9.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",9.1,"D; P","Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",12.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",12.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",12.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",13.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",14.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",11.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",12.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",12.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",12.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",11.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",9.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",10.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",9.6,"D; P","Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",10.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",10.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",10.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",11.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",12.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",12.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",13.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",12.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",12.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",10.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",10.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",11,"D; P","Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",27,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",26.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",25.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",27.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",27.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",23,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",23.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",22.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",22.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",20,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",17.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",18.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",16.4,"D; P","Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",22,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",21.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",21.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",23.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",23.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",23.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",25,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",23.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",22.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",17.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",18.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",18.7,"D; P","Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",4.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",5.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",5.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",5.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",5.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",5.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",3.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.5,"D; P","Difference in methodology; Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",5495,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",4208,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",4445,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",3553,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",3091,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",3283,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",2604,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",2708,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",2023,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",2559.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",2274.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",2395.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",2280.5,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",434.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",338.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",337.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",278.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",232.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",207.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",139.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",143.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",105.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",132.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",105.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",118.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",113.3,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",715.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",548.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",565.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",450.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",384.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",394.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",308.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",303.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",218.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",264.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",226.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",230.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",215.6,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",3.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",2.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",2.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",2.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",1.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",1.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",1.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",1.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",0.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",0.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",0.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",0.9,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",6.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",4.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",4.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",3.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",3.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",3.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",2.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",2.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",1.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",2.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",1.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",1.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",1.7,"E","Estimated value" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",0.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",160.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",148.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",136.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",133.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",121.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",212.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",206.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",175.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",177.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",160.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",187.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",177.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",165.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",167.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",149.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",12.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",12.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",10.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",10.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",9.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",11.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",10.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",9.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",8.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",2.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",25.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",26.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",23.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",24.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",24.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",21.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",21.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",21.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",23.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",24,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",12.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",14.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",18.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",18.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",18.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",19.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",20.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",15.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",15.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",15.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",16.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",15.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",8.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",10.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",12,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",17.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",17.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",16.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",17.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",14.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",15.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",15.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",16,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",16.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",10.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",13.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",4.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",4.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",4.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",4.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",1.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",2.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",3.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",609,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",630,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",661,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",714,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",754,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",833,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",922,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",998,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1137,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1165,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1152,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1336,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1417,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",100.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",112.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",113.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",121.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",119.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",103.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",109.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",120.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",139.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",132.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",122.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",155.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",147.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",66.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",69.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",73.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",79.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",81.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",83.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",91.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",102.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",118.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",121.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",116.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",140.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",131.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",20.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",22.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",22.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",23.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",23.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",19.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",21,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",22.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",26.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",24.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",22.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",28.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",27.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",13.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",14,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",14.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",15.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",15.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",16.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",17.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",19.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",22.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",22.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",21.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",26,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",24.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",3.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",3.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",3.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",3.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",3.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",3.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",252.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",226.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",204.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",184.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",172.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",169.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",167,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",161.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",161,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",165.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",151.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",160.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",176.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",334.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",315.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",262.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",245.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",229.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",187.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",184.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",182,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",190.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",185,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",173.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",190,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",185.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",405.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",363.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",337.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",316.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",298,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",289.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",292.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",279.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",281.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",295.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",272.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",282.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",321.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",31.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",29.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",25,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",23.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",22,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",18.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",17.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",17.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",18.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",18,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",16.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",18.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",18,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",38.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",34.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",32.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",30.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",28.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",27.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",28.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",27.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",27.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",28.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",26.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",27.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",31,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",7.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",7.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",7.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",7.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",7.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",6.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",6.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",6.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",5.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",62.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",63.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",59.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",65.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",69.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",67,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",76.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",79.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",84.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",98.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",94.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",107.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",83.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",87.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",77,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",87.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",91.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",74.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",84.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",90.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",99.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",109.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",108.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",127.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",125.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",124.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",118.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",133.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",142.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",136.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",152.4,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",154.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",160.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",189.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",182,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",201.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",15.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",16.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",14.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",16.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",16.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",13.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",15.6,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",16.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",18.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",20.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",19.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",23.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",23.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",23.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",22,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",24.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",26.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",25.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",28.1,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",28.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",29.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",34.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",33.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",37,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",5.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",5.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",5.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",5.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",5.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",4.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",4.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",5.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",5.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",5.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",5.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",845.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",759.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",635.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",548.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",509.4,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",461.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",465.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",448.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",512.4,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",531.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",511.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",560.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",611,"P","Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1121,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1056.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",816.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",728.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",676.7,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",512.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",515.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",506.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",605.1,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",595.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",584.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",662.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",643.4,"P","Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1163.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1063,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",914.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",812.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",769.1,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",694.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",724.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",710.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",811,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",867.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",823.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",895.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1024.7,"P","Provisional value" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",24.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",22.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",17.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",14.6,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",11,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",11.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",10.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",12.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",12.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",12.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",14,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",13.6,"P","Provisional value" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",25,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",22.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",19.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",17.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",16.5,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",14.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",15.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",17.3,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",18.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",17.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",18.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",21.6,"P","Provisional value" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",6.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",6.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",5.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",5.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",4.5,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",3.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",3.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.7,"P","Provisional value" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1241.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1181.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1188.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1249.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1287.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1375.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1502.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1595.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1751.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1913.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",1861.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",1920.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1984.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",172.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",182,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",175.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",191.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",187.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",163,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",175.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",186.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",201.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",202.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",202.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",224,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",196.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",137.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",133.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",137.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",145.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",147.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",155.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",170.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",180.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",197.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",219.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",214.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",220.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",229,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",18.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",19.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",18.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",20,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",19.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",16.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",17.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",18.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",19.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",19.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",19.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",21.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",18.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",14.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",14.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",14.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",15.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",15.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",15.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",17.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",17.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",19.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",21.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",20.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",21.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",21.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",3.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",3.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",3.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",3.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",3.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",3.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",3.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",3.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",3.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",3.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",3.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",346.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",345,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",356,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",355,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",383,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",398,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",416,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",427,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",418,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",430,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",408,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",421,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",412,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",331.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",388.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",379.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",383,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",418.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",413.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",422.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",433.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",427.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",432.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",434.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",460.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",431.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",236.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",246.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",262.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",270.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",298.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",322.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",346.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",359.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",354.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",373.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",359.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",380.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",386.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",42.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",49.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",47.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",47.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",51.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",49.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",50.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",51.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",50.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",50.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",50.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",52.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",49.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",30.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",31.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",32.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",33.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",36.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",38.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",41.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",42.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",41.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",43.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",41.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",43.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",44.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",6.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",6.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",6.5,"B; D","Break; Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",6.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",6.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",6.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",5.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",5.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1085.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",954.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",911,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",913.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",955.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1082.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1295.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1578.9,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1915.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",2441.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",2509.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",3327.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",722.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",569.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",507.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",479.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",436.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",398.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",428.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",432.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",396.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",430.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",358,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",376,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1179.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",987.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",893.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",853.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",865.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",931.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1043.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1140.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1173,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1309.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1159.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1185.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",9.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",7.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",6.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",6.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",5.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",5.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",5.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",5.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",4.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",5.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",4.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",4.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",16.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",13.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",11.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",11.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",11.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",11.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",13.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",14.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",14.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",15.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",13.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",14.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",6.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",6.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",6.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",6.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",5.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",5.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",6.2,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",5.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",5.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",359.8,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",374.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",402.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",440.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",457.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",492.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",532.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",568.4,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",585.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",661.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",672.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",618.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",634.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",710.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",512.8,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",538.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",575.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",635.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",664.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",719.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",774,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",8.9,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",9.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",10.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",10.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",9.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",9.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",10.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",8,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",8.4,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",8.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",9.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",10.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",10.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",11.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",2.6,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",2.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",2.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",2.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",68438.5,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",61502,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",86133.7,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",87138.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",107902.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",123321.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",120374.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",116144,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",121434.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",98242.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",105910.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",151550.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",129489.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",134.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",127.2,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",177.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",175.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",189.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",188.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",177.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",179,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",189.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",139.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",133.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",199.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",148.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",190.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",176.7,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",248.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",249.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",293.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",315.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",303,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",292,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",306.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",244.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",253.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",348.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",295.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",7.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",7.4,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",10.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",10,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",10.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",10.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",9.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",9.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",10.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",7.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",6.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",10.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",7.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",11.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",10.2,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",14.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",14.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",16.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",17.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",16.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",15.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",16.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",12.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",13,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",17.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",14.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",8.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",5.2,"B","Break" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",6.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",6.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",5.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",5.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",3.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",3.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",5.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",4.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",10.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",12.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",13.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",14.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",15.6,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",16.4,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",16.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",17.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",18.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",18.2,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",19.3,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",24.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",14.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",15.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",17.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",19.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",17.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",18.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",19,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",20.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",20.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",20.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",22.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",26.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",21.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",21.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",23.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",25.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",27.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",29.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",31,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",31.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",31.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",33.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",34.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",35.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",43.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",10.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",11.9,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",13.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",14.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",13.2,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",13.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",14.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",15.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",15.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",15.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",17.1,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",19.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.8,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.3,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",17.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",19.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",20.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",22.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",23.6,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",23.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",24.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",25.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",26.2,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",26.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",32.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5.5,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",5.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",5.8,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",5.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",5.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",5.6,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",5.3,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",5.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",4.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",5.8,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",21,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",19.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",18.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",17.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",16.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",17.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",18.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",19,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",19.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",29.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",27.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",26.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",23.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",23.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",20.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",17.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",17.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",18.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",20.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",21.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",21.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",23.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",30.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",32.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",31,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",30.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",29.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",26.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",26.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",27,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",28.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",31.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",34.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",34.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",35.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",52.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",13.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",13.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",11.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",11.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",10.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",8.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",8.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",10.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",10.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",10.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",11.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",14.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",16.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",15.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",14.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",14.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",12.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",12.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",13.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",13.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",15,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",16.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",16.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",16.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",25.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",4.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",4.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",3.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",3.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",3.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",3.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",3.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",4.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",102,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",93,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",85,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",128,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",122,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",119,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",115,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",104,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",104,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",102,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",103,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",103,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",93.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",95.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",88,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",123.6,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",110,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",89.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",85.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",79.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",77.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",70.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",70.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",77.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",67.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",61.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",55.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",88.5,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",84,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",80.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",79.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",70.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",70.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",68.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",70.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",71.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",4.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",5.3,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",3.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",3.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",3.8,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",3.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",3.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",3.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",2.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",2.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",42.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",42.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",43.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",43.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",42.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",41.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",41.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",40.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",37.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",37.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",35.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",35.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",55.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",59.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",55.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",57.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",56.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",46.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",46,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",45.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",44.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",41.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",40.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",42.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",50,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",51.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",53.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",54.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",53.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",52.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",53.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",52.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",49.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",49.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",47.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",47.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",6.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",7.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",6.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",5.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",5.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",5.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",5.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",112,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",117.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",117.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",114.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",110.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",109.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",109,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",104.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",96,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",96.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",79.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",81.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",94.3,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",148.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",163.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",150.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",151.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",147.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",121.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",120.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",118.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",113.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",107.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",90.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",95.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",99.3,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",133.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",141.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",142.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",141.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",138.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",137.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",139.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",134.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",125.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",128.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",108.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",110.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",132,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",13.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",14.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",13.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",13.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",13.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",10.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",10.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",9.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",7.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",8.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",8.5,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",12.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",12.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",12.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",12.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",12.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",12.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",12.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",11.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",11,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",11.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",9.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",11.4,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",454.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",455.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",450.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",338,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",321.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",308.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",331.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",361.6,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",292.3,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",336.6,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",305.7,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",454.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",441.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",407.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",264.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",242.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",237.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",256,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",272.5,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",217.9,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",268.4,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",234.9,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",364.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",371.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",365.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",270.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",266.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",254.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",275,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",292.8,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",237.4,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",271.8,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",243.8,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",13.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",12.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",11.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",7.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",6.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",6.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",7.2,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",5.7,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",7,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",6,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",10.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",10.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",10.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",7.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",7.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",7.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",7.8,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.2,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",7.1,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",6.3,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.1,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.9,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.9,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.8,"E; D","Estimated value; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1746.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1757.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1849,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1848.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1840.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1783.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1788.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1841.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1941.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1973.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",884.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",898.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",91.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",99.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",94.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",94.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",88.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",72.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",73.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",78.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",89.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",86.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",38.1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",41.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",127.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",131.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",139,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",144.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",144.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",137.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",142.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",148.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",157,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",160.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",71,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",70.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",8.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",6.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",6.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",7.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",3.6,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",3.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",12.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",12.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",13.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",13.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",13.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",13.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",13.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",14,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",14.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",15.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",6.6,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",6.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",51.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",53.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",55.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",53.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",54,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",52.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",52.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",49.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",45.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",45.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",42.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",42.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",68.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",74.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",71.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",71.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",71.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",58.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",57.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",55.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",53.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",51.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",48.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",49.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",57.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",59.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",61.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",59.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",59.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",57.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",59.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",57,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",53.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",54.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",52,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",50.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",12.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",13.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",13.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",13.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",10.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",10.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",10.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",9.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",9.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",8.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",11,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",10.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",10.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",10.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",10.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",9.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",9.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",2.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",2.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",555.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",555,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",591.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",617.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",620.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",606.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",588.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",556.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",531.4,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",517.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",482.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",496.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",735.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",772.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",759.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",820.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",824.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",672.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",651.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",628.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",627.6,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",579.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",550.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",586.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",689.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",703.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",751.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",797.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",806.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",779.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",782.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",747.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",722.6,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",710.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",665,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",673.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",9.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",9.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",10.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",10.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",8.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",7.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",7.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",7.6,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",7.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",8.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",8.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",9.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",9.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",10,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",9.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",9.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",8.7,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",8.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",8.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.2,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",101.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",83.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",74.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",67.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",66,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",62.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",66.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",64.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",65.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",63.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",55.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",57,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",55.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",134.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",115.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",95.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",89.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",87.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",69.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",73.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",72.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",77.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",71.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",63.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",67.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",58.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",140.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",116.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",108.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",107.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",108.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",102.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",112.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",111.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",116,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",116.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",102.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",104.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",104.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",12.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",10.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",8.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",8.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",8.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",6.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",6.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",6.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",7.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",6.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",6.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",5.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",12.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",9.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",9.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",10.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",10.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",10.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",10.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",9.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",10,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",6442.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",5672.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",5181.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",5250,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",5568.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",5542.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",5595.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",5629.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",5578.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",5610.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",5439.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",5220.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",4952.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",31,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",28.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",23,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",23.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",23.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",19.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",19.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",20.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",20.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",19.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",17.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",17.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",13.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",51,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",45.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",41.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",42,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",43,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",41.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",42.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",41.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",40.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",39.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",37.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",33.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",30.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",2.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",4.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",4.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",903.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",485.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",482.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",638.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",446,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",430.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",431.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",431.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",404.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",426.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",504.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",550.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",7.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",4.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",3.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",5.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",3.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",3.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",3.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",3.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",3.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",4.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",6.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",3.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",4.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",3.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",3.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",3.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",3.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",3.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",23.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",13.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",12,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",16.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",11.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",10.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",11.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",9.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",10.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",11.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",21.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",11.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",11,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",14.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",9.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",9.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",9.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",8.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",9.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",34.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",29.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",27.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",21.3,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",19.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",19.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",19.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",17.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",15.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",15,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",14.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",15.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",45.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",41.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",35.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",28.3,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",26.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",21.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",21.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",20.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",18.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",16.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",17,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",18,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",40.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",36,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",33.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",26.3,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",24.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",24.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",24.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",22.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",19.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",18.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",18.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",19.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",10,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",9.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",7.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",6.1,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",5.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",3.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",3.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",3.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",8.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",7.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",7.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",5.7,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",5.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.1,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",250,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",234.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",235.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",232.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",209.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",195.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",174.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",152.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",149.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",139.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",146.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",155.9,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",347.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",301.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",312.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",309,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",232,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",216,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",197.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",180.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",167.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",159.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",173.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",164.1,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",329.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",313.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",319,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",314.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",283.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",278.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",253.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",223.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",228.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",215.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",226.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",252.4,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",5.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",5.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",5.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",5.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",3.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",3.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",3.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",2.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",2.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",2.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",2.8,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",5.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",5.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",5.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",5.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",4.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",4.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",4.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",3.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",3.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",3.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",3.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",4.3,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.6,"E","Estimated value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",621791,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",637074,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",576586.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",574582.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",610839.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",633297.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",598544.4,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",619492.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",668448,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",705416.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",713909.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",747821.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",537.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",574.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",511.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",524.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",580.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",560,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",515.6,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",547.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",607.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",605.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",604.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",653.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",739.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",745.5,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",674.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",661.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",700.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",738.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",696.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",709.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",781.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",823.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",852.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",875.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",10.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",11.5,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",10.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",10.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",11.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",11,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",10.1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",10.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",11.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",11.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",11.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",12.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",14.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",14.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",13.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",13.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",13.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",14.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",13.6,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",13.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",15.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",15.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",16.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",16.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",3.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",2.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",2.4,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",5.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",6.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",7.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",7.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",7.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",8.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",8.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",6.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",5.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",4.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.3,"D; P","Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",6.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",6.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",6.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",5.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",4.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",4.9,"D; P","Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",15.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",15.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",15.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",16.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",15.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",12.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",12.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",11.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",11.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",9.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",8.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",7.3,"D; P","Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",12.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",12.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",13.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",13.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",13.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",12,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",11.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",10.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.4,"D; P","Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",2.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",2.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",3.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.6,"D; P","Difference in methodology; Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",94.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",91.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",83.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",80.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",69,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",125,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",127.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",107.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",107.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",91.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",110.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",109.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",101.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",101.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",85.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",7.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",7.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",6.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",6.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",5.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",5.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",1.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",7.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",7.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",7.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",7.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",7.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",6.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",7.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",6.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",6.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",10.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",5.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",6.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",5.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",4.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",4.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",4.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",6.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",4.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",4.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",4.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",5.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",5.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",4.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",5.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",4.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",4.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",7.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",1.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",425,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",437,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",446,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",464,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",474,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",515,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",537,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",550,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",514,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",528,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",540,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",594,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",620,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",70.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",78,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",76.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",79,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",75.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",63.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",63.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",66.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",63.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",60,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",57.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",69.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",64.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",46.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",48.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",49.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",51.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",51.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",51.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",53.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",56.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",53.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",54.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",54.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",62.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",57.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",15.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",15.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",15.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",14.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",12.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",12.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",12.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",11.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",11.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",10.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",12.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",11.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",10,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",10.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",10.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",10.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",127.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",112.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",105,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",99.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",98.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",97.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",96.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",93,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",92,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",92.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",80.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",81.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",94.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",169.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",156.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",135,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",132.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",130.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",108.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",107.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",105.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",108.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",103.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",92.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",96.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",99.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",205.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",180.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",173.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",171,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",169.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",166.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",169.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",161.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",161.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",164.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",145.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",144.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",171.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",16,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",14.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",12.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",12.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",12.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",10.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",10.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",10.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",10.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",10,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",9.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",9.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",19.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",17.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",16.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",16.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",16.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",16.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",16.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",15.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",15.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",16,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",14.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",13.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",16.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",3.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",3.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",3.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",2.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",2.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",28.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",28.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",25.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",29.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",30.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",28.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",34.1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",28.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",35.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",36.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",36,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",41.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",37.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",39.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",33.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",38.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",40.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",32.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",37.7,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",32.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",41.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",40.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",41.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",49.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",56.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",55.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",51.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",59.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",62.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",58.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",67.7,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",55.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",66.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",70.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",69.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",78,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",7.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",6.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",7.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",7.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",5.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",6.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",5.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",7.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",7.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",7.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",10.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",11,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",11.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",10.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",12.5,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",10.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",12.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",12.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",12.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",14.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",2.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",2.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",2.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",2.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",2.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",2.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",2.2,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",403,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",385,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",352.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",332.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",309.3,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",272.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",269.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",246.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",225.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",222.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",209.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",232.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",257.3,"P","Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",534.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",535.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",452.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",441.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",410.9,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",302,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",298.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",278.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",266.8,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",248.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",239.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",275.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",271,"P","Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",554.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",539,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",507.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",493,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",467,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",409.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",420,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",391.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",357.6,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",362.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",337.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",372,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",431.6,"P","Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",11.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",11.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",9.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",9.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",8.8,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",6.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",5.7,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",5.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",5.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",5.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",5.7,"P","Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",11.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",11.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",10.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",10.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",10,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",8.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",7.6,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",7.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",7.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",7.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",9.1,"P","Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",3.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",3.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",1.2,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",1.1,"P","Provisional value" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",739.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",710,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",722.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",715.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",718.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",752.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",800.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",761.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",746.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",756.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",658.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",639.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",722.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",102.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",109.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",106.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",109.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",104.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",89.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",93.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",89,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",85.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",80,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",71.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",74.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",71.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",82,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",80.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",83.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",83.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",82.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",85,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",90.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",86,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",84.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",86.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",76,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",73.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",83.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",10.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",11.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",11.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",11.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",10.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",9.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",9.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",8.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",6.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",7.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",8.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",8.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",8.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",8.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",9.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",8.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",8.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",7.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",492.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",413.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",403.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",377,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",402.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",458.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",557.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",668.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",766.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1119.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1180.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1320.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",327.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",246.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",224.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",198,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",184.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",168.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",184.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",183.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",158.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",197.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",168.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",149.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",535,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",428,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",395.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",352.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",364.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",394.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",449.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",482.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",469.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",600.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",545.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",470.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",4.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",3.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",7.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",5.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",5.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",4.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",4.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",5.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",7.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",6.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",5.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",3.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",2.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",2.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",35363.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",47430.8,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",50640.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",54075.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",57880.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",65023.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",61219.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",57012.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",56688.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",40188.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",65698.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",88252.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",97525.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",69.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",98.1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",104.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",109.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",101.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",99.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",90.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",87.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",88.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",57.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",82.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",116.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",111.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",98.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",136.3,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",145.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",154.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",157.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",166.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",154.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",143.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",143.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",100.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",157,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",202.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",222.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",4.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",5.7,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",6.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",5.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",5.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",4.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",5.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",7.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",8.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",8.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",9.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",8.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",7.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",5.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",8.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",11.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",4.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",4,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",4.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",3.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",3.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",3.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",3.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",6.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",6.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",7.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",7.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",8.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",9.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",9.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",9.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",9.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",9.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",11.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",8.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",8.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",9.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",10.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",11.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",10.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",10.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",10.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",11.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",10.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",11.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",11.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",11.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",11.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",12.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",13.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",15.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",16.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",17.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",18,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",17.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",17.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",18.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",18.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",18.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",19.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",6.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",6.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",6.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",8.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",7.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",8.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",8.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",8.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",8.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",8.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",8.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",10.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",11.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",12.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",13.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",13.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",13.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",13.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",13.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",14.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",13.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",14.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",3.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",3.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",3.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",2.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",2.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",2.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",9.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",8.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",7.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",8.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",8.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",8.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",8.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",8.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",8.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",7.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",7.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",8.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",12.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",11.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",10.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",10.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",11.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",9.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",9.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",9.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",9.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",9.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",8.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",9.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",9.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",14.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",13.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",12.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",13.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",14.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",15,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",14.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",14.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",14.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",15,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",14.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",14.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",15.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",5.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",4.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",5.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",4.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",4.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",4.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",4.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",4.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",4.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",6.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",6.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",7.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",7.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",7.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",6.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",7.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",6.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",6.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",7.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",1707,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",1790,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",1768,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",1998,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1924,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",1926,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",1899,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",1920,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1944,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1940,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",2007,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",2072,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1565.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",1846.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",1830.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1928.9,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",1734.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1446.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",1411.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1471.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1452.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",1348.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",1381.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",1556.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1135.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1184.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1148,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",1380.7,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",1324.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",1306.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",1309.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",1299.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",1322.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",1310.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",1380.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",1431.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",71.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",82.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",80.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",83.4,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",73.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",60.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",58.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",59.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",58.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",53.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",53.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",60.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",51.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",53,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",50.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",59.7,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",56.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",54.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",54.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",52.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",53,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",51.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",53.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",55.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",17.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",17.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",17.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",16.9,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",16.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",15.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",12.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",13,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",13,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",12.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",12.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",11.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",467.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",490.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",487.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",473.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",477.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",465.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",443.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",439.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",439.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",433.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",456.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",501.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",619.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",682.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",625.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",629.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",634.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",516,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",491.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",496.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",518.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",485.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",521.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",593.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",554.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",589.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",598.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",594.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",597.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",582.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",571.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",567.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",573.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",579.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",611.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",663.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",74.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",81.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",74.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",74.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",74.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",59.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",56.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",56.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",58.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",54.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",58.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",66.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",66.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",70.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",71,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",70.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",70,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",67.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",65.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",64.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",64.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",65.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",68.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",74.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",18.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",19.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",18.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",18,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",17.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",15.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",14.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",14.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",13.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",13.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",13.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",13.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",1019.6,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",1050.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",1005.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",978.6,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",958.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",940.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",910.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",901,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",861.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",865.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",862.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",884.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",999.7,"E","Estimated value" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1351.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",1462.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1291.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1299.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",1273.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",1043.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",1008.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",1017.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",1017.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",969.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",984.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",1046.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",1052.7,"E","Estimated value" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1218.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1263,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1223.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",1213.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",1197.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",1176,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",1166.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",1161.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",1123.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",1159.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",1180.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",1201.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1400.2,"E","Estimated value" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",124.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",132.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",116.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",116.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",113.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",92.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",89,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",89.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",89,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",84.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",85.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",90.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",90.6,"E","Estimated value" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",111.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",114.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",110.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",108.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",106.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",104.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",102.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",102.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",98.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",100.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",102.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",103.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",120.5,"E","Estimated value" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",17.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",17.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",16.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",16.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",16.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",15.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",14.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",13.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",12.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",11.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",11.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",11,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",11.1,"E","Estimated value" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",5200.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",5224.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",5321.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",5435.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",5608.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",5705.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",5547.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",5554.1,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",6017.4,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",6528.7,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",7071.4,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",5203.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",5071.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",4817.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",4250.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",4230.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",4395.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",4280.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",4186.1,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",4486.7,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",5206.8,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",5433,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",4178.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",4268.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",4325.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",4355.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",4646.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",4706.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",4597.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",4498.3,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",4888,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",5272.9,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",5639.8,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",149.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",144.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",135.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",119.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",117.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",120.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",115.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",111.3,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",118,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",136.1,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",139.7,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",120.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",121.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",122.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",122,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",128.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",128.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",124,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",119.6,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",128.5,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",137.9,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",145,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",21.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",21.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",20.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",20,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",19.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",19.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",18.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",17.4,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",17.6,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",17.7,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",17.7,"E; D","Estimated value; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",9951.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",9889.6,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",10162,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",9599,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",9618.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",9677,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",9666,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",10331.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",10668.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",10951.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",8569.9,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",9038.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",521.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",558.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",519.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",490.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",463.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",393.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",395.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",442,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",490.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",477.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",369.2,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",417,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",727.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",741.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",764.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",750.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",757.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",747.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",768.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",831.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",862.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",892.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",687.7,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",709.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",49.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",53.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",49.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",46.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",44,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",37.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",37.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",41.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",46.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",44.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",34.5,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",39.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",69.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",70.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",72.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",71.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",71.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",70.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",72.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",78.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",81.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",83.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",64.3,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",67.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",12.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",12.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",12.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",12,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",11.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",11.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",11.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",11.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",10.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",10.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",9.8,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",9.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",4646,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",4583.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",4090.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",3689.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",3658.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",3596.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",3484.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",3316.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",3354.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",3397.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",3478.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",3456.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",826.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",853.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",706.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",657,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",651.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",534.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",517.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",502.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",531.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",509.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",531.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",549.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",612,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",613.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",540.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",501.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",499.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",492.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",492.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",482.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",495.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",512.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",531,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",524.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",148.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",153.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",126.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",117,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",115.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",94.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",90.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",87.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",91.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",87.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",91.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",93.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",110.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",110.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",96.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",89.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",88.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",86.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",85.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",83.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",85.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",88.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",91.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",89.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",21.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",22.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",20,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",18.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",17.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",16.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",15.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",14.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",14.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",13.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",13.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",13.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",344,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",353.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",350.6,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",341.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",335.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",319.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",307,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",297.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",294.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",306.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",320.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",395.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",456,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",492.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",450.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",453.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",445.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",354.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",339.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",335.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",347.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",343,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",366,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",468.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",382,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",394,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",385.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",376.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",369.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",352.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",348.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",344.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",344.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",365.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",389.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",478.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",85,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",91.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",83.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",83.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",81.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",64.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",61.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",61,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",63,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",62.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",66.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",84.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",71.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",73.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",71.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",69.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",67.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",64.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",63.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",62.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",62.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",66.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",70.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",86.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",18.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",18.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",17.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",17,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",16,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",14.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",13.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",12.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",11.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",11.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",11.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",13.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",3898.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",5427.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",4634,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",83.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",71.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FRA","France","2011","2011",14.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",5688.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",5679.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",5439.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",5380.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",5672.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",5401.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",5260.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",5004.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",5091.8,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",5267.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",5384.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",5731.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",7540.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",7905.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",6989.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",7145.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",7536.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",5993.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",5822.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",5653.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",6013.2,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",5896.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",6150.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",6779.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",7065.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",7200.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",6910,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",6944.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",7377.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",6942.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",6989.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",6719,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",6923.4,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",7232.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",7426.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",7784.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",92.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",98.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",86.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",88.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",93.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",73.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",70.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",68.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",72.5,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",71,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",74,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",81.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",86.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",89.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",85.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",86.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",91.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",85,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",84.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",81.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",83.5,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",87,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",89.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",93.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",19.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",19.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",17.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",17.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",16.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",15.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",14.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",13.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",11.5,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",11.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",11,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",10.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",1043.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",914.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",790,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",706.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",665.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",564.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",680.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",647,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",671.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",692.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",663.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",670.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",546.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1383.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1272.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",1015,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",938.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",883.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",626.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",753,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",730.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",792.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",775,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",758.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",792.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",575.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1445.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1281.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",1153.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",1119.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1088.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",926.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1155.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1125.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1188.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1261.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1219.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1228.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1034.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",124.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",114.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",91.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",85.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",81.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",57.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",69.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",68,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",73.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",72.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",70.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",75,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",55,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",130,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",115.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",104.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",102.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",99.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",85.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",107.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",104.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",110.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",117.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",114,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",116.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",98.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",62105.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",64409,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",58615.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",58867.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",59797.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",60933.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",59756.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",59790.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",60008.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",60953,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",60723.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",59597.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",53713.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",298.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",320.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",260.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",263.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",257.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",218.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",212.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",217.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",222.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",209.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",197.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",196.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",144.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",491.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",518.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",466.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",471,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",462.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",459.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",452.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",439.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",431.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",432.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",417.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",385.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",333.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",29.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",32.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",26.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",26.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",26.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",21.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",22.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",22.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",21.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",20.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",20.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",14.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",49.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",52,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",47,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",47.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",46.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",46.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",46.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",44.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",44.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",44.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",42.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",39.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",34.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",12.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",12.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",13.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",13.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",13.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",13.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",12.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",11.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",10.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",10.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",6783.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",5703.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",5666.6,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",6429.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",5314.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",5341.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",5561.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",5265,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",5364.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",5953.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",7013.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",7969.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",55.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",49.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",45.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",52.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",45.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",40.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",46,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",49.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",49.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",48.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",51.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",62.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",51,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",42.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",41.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",46.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",38.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",37.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",39.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",38.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",38.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",42.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",47.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",53.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",174.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",154.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",141.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",162.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",139,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",122.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",137.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",143.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",140.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",134.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",141.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",168.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",160.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",132.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",129,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",144.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",117.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",113.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",118.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",110.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",107.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",117.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",130.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",142.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",27.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",21.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",23.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",24.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",22.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",21.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",21.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",19.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",17.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",17.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",17.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",17.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",345.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",358.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",387.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",357.7,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",352.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",349.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",338.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",311.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",288.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",280,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",278,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",279.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",457.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",498.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",498.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",475.1,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",468.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",387.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",375,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",351.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",340.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",313.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",317.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",330.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",406.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",430.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",471.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",441,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",430.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",431.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",426.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",391.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",363.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",347.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",349.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",352.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",100.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",108.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",108.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",102.8,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",100.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",82.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",78.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",73.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",69.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",63.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",63.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",65.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",89.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",94.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",102.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",95.4,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",92.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",91.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",89.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",81.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",74.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",70.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",70,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",70,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",16.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",18.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",19,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",18.3,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",18.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",17.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",16.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",14.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",12.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",11.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",11.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",10.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1995.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1936.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1897.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1881.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1902,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1807.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1787.6,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1793.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1852.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1888,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1918.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1990.7,"E","Estimated value" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",2778,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",2488.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",2520.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",2499.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",2110.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",2000.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",2019.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",2118.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",2074.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",2156.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",2269.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",2096.3,"E","Estimated value" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",2630.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",2590.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",2574.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",2544.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",2574.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",2579.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",2591.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",2633.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",2820.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",2914.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",2962.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",3224.2,"E","Estimated value" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",46.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",41.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",41.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",41.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",34.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",33,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",33.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",35.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",34.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",36.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",38.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",35.5,"E","Estimated value" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",44.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",43.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",42.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",41.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",42.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",42.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",42.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",43.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",47.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",49,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",50.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",54.6,"E","Estimated value" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",10.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",10.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",9.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",9.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",8.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",7.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",7.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",8.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",8.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",8,"E","Estimated value" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",812255,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",890011,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",884343,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",830706,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",821393,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",814267,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",830000,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",779318,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",806949,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",1151962,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",1086297,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",971269,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",9253.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",11152,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",11083.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",8511.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",7753,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",6727,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",7629.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",6947.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",7307.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",10567.5,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",10173.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",8849.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",7271.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",8282.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",8481,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",8200.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",7970.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",7869.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",7865.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",7414.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",7747.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",11052.5,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",10605.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",9517.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",72.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",87.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",86.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",66.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",60.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",52.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",60.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",54.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",57.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",83.8,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",80.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",70.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",56.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",64.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",66.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",64.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",62.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",61.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",62,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",58.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",61.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",87.6,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",84.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",75.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",12.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",12.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",12.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",12.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",12.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",11.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",11.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",12.1,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",11.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",10.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1551504,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1818155.8,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1787843.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1891529.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",2006379.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",2123722.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",2089238.2,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",2269880.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",2464267.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",2711705.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",3009813.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",3272920.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1341.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1640.6,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1586.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1727.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1905.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1877.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1799.9,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",2007,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",2239.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",2326.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",2550.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",2861.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1844.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",2127.5,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",2091.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",2176.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",2301.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",2476.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",2432.7,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",2601.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",2882.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",3166.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",3593.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",3832,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",27.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",32.9,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",31.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",34.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",37.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",36.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",35.1,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",39.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",43.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",45,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",49.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",55.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",37.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",42.6,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",41.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",43.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",45.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",48.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",47.5,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",50.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",55.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",61.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",69.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",74.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",7.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",8.2,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",8.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",8.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",8.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",8.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",8.2,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",8.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",8.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",8.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",9.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",9.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",32.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",33.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",32.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",31.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",31.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",33.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",31.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",31.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",31.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",32.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",33.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",35.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",36.1,"D; P","Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",43.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",46.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",42.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",42,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",42.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",36.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",35.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",35.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",37.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",36.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",38.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",42.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",38.1,"D; P","Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",35.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",37,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",36.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",35.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",36,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",37.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",37.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",37.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",37.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",39.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",39.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",41.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",43.5,"D; P","Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",91.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",96.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",85.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",83.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",82.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",71.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",66.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",66.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",69,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",66.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",68.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",73.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",64.9,"D; P","Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",74.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",76.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",73.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",70.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",70.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",70.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",69.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",68.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",70.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",69.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",72.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",74.1,"D; P","Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",17.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",17.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",16.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",16.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",16.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",17.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",16.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",16.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",16,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",16.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",16.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",14.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",14,"D; P","Difference in methodology; Provisional value" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",14077,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",12584,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",12804,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",13836,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",14128,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",14984,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",15668,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",16565,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",15443,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",17275.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",18357.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",18875.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",20539.3,"E","Estimated value" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",1114,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",1012.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",972.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",1083.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",1062.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",945.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",839.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",875.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",802.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",896.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",854.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",931.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",1020.5,"E","Estimated value" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",1833,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",1640,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1629.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",1754.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",1756.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",1799.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",1855.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",1858.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",1664.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",1787.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",1828.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",1814.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",1942,"E","Estimated value" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",9.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",8.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",8.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",9.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",8.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",7.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",6.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",7.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",6.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",7.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",6.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",7.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",7.8,"E","Estimated value" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",16.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",14.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",13.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",14.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",14.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",14.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",15.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",15,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",13.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",14.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",14.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",14.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",14.9,"E","Estimated value" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",9.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",6.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",598.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",630.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",592.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",568.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",571.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",793.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",877.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",761.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",754.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",759.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",700.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",753.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",719.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",711.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",706.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",47.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",52.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",45.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",44.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",45,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",42.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",45.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",42.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",42.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",41.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",11.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",12.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",12.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",13.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",13.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",164.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",182.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",156.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",147.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",136,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",167.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",171.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",167.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",174,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",173.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",169.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",189.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",197.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",118.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",144.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",126.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",120.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",112.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",116.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",119.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",119.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",120.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",114.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",110,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",134,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",125.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",109.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",122.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",104.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",101.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",94.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",113.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",119.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",117.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",118.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",122.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",119.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",129.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",137.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",27.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",32.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",28.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",27.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",25,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",25.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",25.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",24.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",24.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",22.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",21.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",26.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",24.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",25.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",28,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",23.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",22.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",20.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",24.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",25.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",24.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",24.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",24.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",23.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",25.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",26.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",22,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",22.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",17,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",16,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",14.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",17,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",16,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",13.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",13.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",11.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",10.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",10.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",10.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",3463,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",3458,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",3599,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",3570,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",3753,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",3929,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",4133,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",4277,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",4313,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",4521,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",5159,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",5550,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",5871,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",572.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",617,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",618.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",607.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",595.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",487.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",492,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",517.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",530.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",513.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",547.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",646.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",610.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",378.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",380.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",398.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",395.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",404.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",395.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",411.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",438.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",450,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",470,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",522.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",583.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",546.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",117.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",124.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",123.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",119.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",115.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",93.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",94,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",98,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",99.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",96.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",101.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",119.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",112.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",77.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",76.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",79.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",77.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",78.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",76.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",78.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",83.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",84.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",87.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",97.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",107.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",100.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",19.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",19,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",19.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",18.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",17.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",17.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",16.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",16,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",15.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",15.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",17.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",16.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",16.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",700.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",645.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",571.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",512.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",511.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",509.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",506.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",517.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",527.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",552.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",562.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",576.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",601.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",928.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",898.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",734.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",680.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",678.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",565,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",561,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",584.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",622.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",618.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",642.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",681.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",633.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",1124,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",1035.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",944.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",877.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",882.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",870.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",887,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",898.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",922.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",989.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",1010.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",1014.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",1093.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",87.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",85.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",69.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",65.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",65.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",54.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",54.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",56.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",60.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",60.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",62.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",65.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",61.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",106.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",98.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",89.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",83.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",84.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",84,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",85.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",87.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",89.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",96.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",98.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",97.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",105.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",21.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",21.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",21.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",21.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",21.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",20.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",20,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",20.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",20.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",19.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",20,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",19.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",18.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",134.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",135.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",124.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",136.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",139.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",140,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",156.6,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",147.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",145.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",147.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",148.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",157.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",178,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",188,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",160.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",180.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",185.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",155.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",173.4,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",166.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",172.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",164.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",169.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",186.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",267.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",266.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",247.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",277.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",287,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",284.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",311.3,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",285.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",277.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",284.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",285,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",295.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",33,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",34.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",29.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",33.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",34.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",28.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",31.9,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",30.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",31.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",30.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",31,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",34.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",49.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",49.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",45.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",51.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",53,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",52.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",57.3,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",52.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",50.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",52.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",52.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",54.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",11.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",11.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",10.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",10.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",10,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",9.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",8.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",8.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",8.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",3140.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",3080.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",2838.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",2862.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",3043.9,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",2946.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",3022.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",3070.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",3413.3,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",3390,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",3561.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",3674.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",3713.2,"P","Provisional value" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",4163.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",4287.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",3647.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",3802.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",4043.9,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",3268.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",3345.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",3468.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",4031,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",3795.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",4067.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",4345.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",3910.2,"P","Provisional value" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",4320.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",4313.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",4084.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",4242.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",4595.6,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",4432.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",4702.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",4866.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",5402.6,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",5530.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",5731.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",5869.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",6228,"P","Provisional value" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",89.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",91.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",78,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",81.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",87,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",70.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",72,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",74.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",86.1,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",80.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",85.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",91.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",82.4,"P","Provisional value" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",92.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",92.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",87.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",91,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",98.9,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",95.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",101.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",104.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",115.4,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",117.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",121,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",123.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",131.3,"P","Provisional value" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",23.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",24.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",25.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",26.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",26.9,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",25.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",25.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",25.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",18,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",16.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",17.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",16.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",16.2,"P","Provisional value" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",7256.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",7595.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",7234.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",7295,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",7342.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",7485.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",7411.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",7573.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",7843.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",8349.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",8805.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",8532.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",9178.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",1006.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",1169.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",1067.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",1119.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",1070.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",887.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",865.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",885.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",902.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",882.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",956,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",994.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",907.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",804.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",858.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",835.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",848.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",841.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",845.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",840.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",855.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",884.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",958.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",1015.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",978.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",1059.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",107.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",123.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",112.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",116.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",110.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",90.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",87.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",88.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",88.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",85.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",92.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",95.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",86.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",85.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",90.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",87.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",88.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",86.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",86.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",84.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",85.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",86.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",93.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",98.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",93.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",101.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",20.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",20.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",20,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",20.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",19.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",18.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",17.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",17.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",16.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",16.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",16.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",15.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",15.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",1042.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",1063,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",1060,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",1045,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",1028,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",1036,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",1221,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",1214,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",1224,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",1174,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",1194,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",1217,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",1250,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",999.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",1197,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",1130.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",1127.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",1122.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",1076.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",1239.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",1232.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",1251.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",1181.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",1271.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",1331.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",1309.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",710.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",760.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",782.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",796.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",802,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",838.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",1015.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",1022.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",1038.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",1020.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",1051.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",1099.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",1172.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",127.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",151.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",141.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",139.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",137,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",130,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",148,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",145.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",147,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",137.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",147.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",153,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",149.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",90.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",96.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",97.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",98.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",97.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",101.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",121.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",120.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",121.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",119,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",121.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",126.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",134.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",18.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",18.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",17.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",17.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",17.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",16.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",19.1,"B; D","Break; Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",18.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",18.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",17.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",17.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",17.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",16.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1782.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1661.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1498.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1583,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1693.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1972,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",2512.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",3002.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",3607.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",4659.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",5563.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",7050.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1186,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",992,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",834.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",831.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",773.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",725,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",832,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",823,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",747.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",821.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",793.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",796.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1936.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1719.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1469.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1479,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1533.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1696.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",2024.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",2169.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",2209.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2499.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2570.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",2511,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",16.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",13.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",11.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",10.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",10,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",9.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",10.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",10.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",9.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",9.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",9.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",9.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",26.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",23.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",19.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",19.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",19.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",21.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",25.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",27,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",27.1,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",30.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",30.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",29.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",11.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",11.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",11.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",11,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",10.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",10.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",11.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",11.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",11.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",11.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",11.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",10.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",2581.8,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",2760.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",2955.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",3222.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",3253,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",3191.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",3170.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",4078.4,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",4315.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",4863.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",4923.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",4392.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",4107.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",4229.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",3679.7,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",3970.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",4232.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",4652.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",4724.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",4661.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",4609.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",64,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",67.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",75.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",75.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",66.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",62.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",63.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",57.8,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",61.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",65.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",71.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",72,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",70.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",69.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",18.7,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",18.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",18.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",18.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",17.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",16.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",15.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",154950.4,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",187215,"B","Break" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",205981.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",214727.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",249601.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",283661.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",303392,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",310804,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",321757.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",331298.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",380815.7,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",446706.8,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",424777.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",303.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",387.1,"B","Break" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",423.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",433.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",437.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",433.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",448.2,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",479,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",501.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",471.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",480.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",588.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",486.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",430.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",537.9,"B","Break" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",593.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",614.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",679.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",725.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",763.7,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",781.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",812,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",824.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",910.1,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1026.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",970.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",17.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",22.4,"B","Break" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",24.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",24.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",24.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",24.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",24.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",26,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",26.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",24.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",24.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",29.9,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",24.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",25.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",31.2,"B","Break" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",34,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",34.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",38.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",40.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",42,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",42.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",43.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",43.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",46.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",52.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",49,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",18.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",15.9,"B","Break" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",16.5,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",14.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",16.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",15.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",15,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",15,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",14,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",13.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",14.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",15.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",15.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",21.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",22.1,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",22.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",23.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",23.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",25,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",25.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",26.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",28.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",30.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",32.2,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",34.5,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",38.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",28.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",30.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",29.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",30.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",31.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",27.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",28,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",29.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",33.3,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",33.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",36.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",40.8,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",40.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",42,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",43.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",43.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",44.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",45.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",46.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",47.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",49,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",52.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",56.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",61.5,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",63.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",68.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",21.4,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",23.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",22.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",23.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",24.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",21.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",21.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",22.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",25.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",25.5,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",27.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",30.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",30.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",31.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",32.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",33.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",33.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",34.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",35.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",36.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",37.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",39.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",42.5,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",46.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",47.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",51.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",11.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",10.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",10.3,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",10,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",9.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",9.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",8.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",8.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",8.7,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",8.8,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",8.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",80.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",79.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",74.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",71.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",69.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",65.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",65.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",63.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",64.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",65.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",67.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",70.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",75.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",106.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",111.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",95.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",95.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",92.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",73.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",72.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",71.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",76.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",73.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",77.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",83.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",79.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",126,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",128.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",122.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",121.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",117.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",110.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",112.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",110.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",114.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",118.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",123.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",125.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",136.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",52,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",54.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",46.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",46.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",44.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",35.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",34.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",34.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",36.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",35.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",36.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",39.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",37.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",61.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",62.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",59.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",59.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",57.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",53.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",54.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",53.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",55,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",56.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",58.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",59.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",64.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",16.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",17,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",16.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",15.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",16.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",14.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",14,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",13.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",12.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",11.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",11.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",11.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",378,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",408,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",433,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",503,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",516,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",554,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",497,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",512,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",516,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",499,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",498,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",525,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",346.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",420.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",448.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",485.6,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",465.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",416.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",369.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",392.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",385.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",346.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",342.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",394.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",251.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",270,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",281.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",347.6,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",355.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",375.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",342.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",346.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",350.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",337.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",342.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",362.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",15.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",18.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",19.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",21,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",19.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",17.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",15.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",16,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",15.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",13.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",13.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",15.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",11.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",12.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",15,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",15.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",15.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",14.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",14.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",14.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",13.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",13.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",14.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",3.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",4.3,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",4.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",4.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",3.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",3.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",61.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",59.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",60.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",58.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",61.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",63.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",65.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",67.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",66.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",68.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",74.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",81.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",82,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",82.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",77.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",78.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",81.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",70.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",72.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",76.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",79,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",76.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",85,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",96.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",73.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",71.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",74.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",73.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",77.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",79.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",84.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",87.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",87.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",90.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",99.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",108.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",9.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",9.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",9.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",9.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",8.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",8.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",8.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",8.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",8.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",9.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",10.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",8.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",8.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",8.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",8.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",9.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",9.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",10.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",11.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",12.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",2.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",245.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",255.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",250.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",245.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",236.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",239.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",246.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",246.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",240.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",239,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",238.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",253,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",286.3,"E","Estimated value" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",325.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",355.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",321.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",326.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",314,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",266.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",273.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",278.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",284.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",267.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",272.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",299.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",301.5,"E","Estimated value" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",293.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",306.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",304.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",304.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",295.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",299.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",316,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",318,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",314,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",320.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",326.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",343.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",401,"E","Estimated value" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",29.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",32.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",28.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",29.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",28,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",23.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",24.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",24.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",24.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",23.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",23.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",25.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",26,"E","Estimated value" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",26.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",27.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",26.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",26.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",27.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",27.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",27.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",28.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",29.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",34.5,"E","Estimated value" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",3.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",3.2,"E","Estimated value" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1115.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1093.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1107.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1117.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1117.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1077.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",995.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",937.1,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1016,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1048.8,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1069.4,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1116.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1061.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1002.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",873.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",842.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",829.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",768,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",706.3,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",757.6,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",836.4,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",821.6,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",896.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",893.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",900.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",895.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",925.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",888.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",824.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",759,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",825.3,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",847.1,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",852.9,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",32.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",30.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",28.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",24.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",23.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",22.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",20.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",18.8,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",19.9,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",21.9,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",21.1,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",25.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",25.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",25.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",25.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",25.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",24.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",22.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",20.2,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",21.7,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",22.1,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",21.9,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",4.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",4.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.9,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",3,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.8,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.7,"E; D","Estimated value; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2309.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2704.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",2841.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2923.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2967.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",3119.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",3154.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",3451.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",3532.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",3331.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2331,"B","Break" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2423.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",120.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",152.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",145.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",149.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",143,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",126.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",129.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",147.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",162.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",145.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",100.4,"B","Break" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",111.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",168.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",202.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",213.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",228.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",233.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",241.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",250.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",277.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",285.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",271.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",187.1,"B","Break" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",190.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",11.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",14.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",13.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",14.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",13.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",12,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",12.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",13.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",15.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",13.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",9.4,"B","Break" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",10.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",16.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",19.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",20.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",21.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",22.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",22.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",23.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",26.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",26.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",25.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",17.5,"B","Break" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",18.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",3.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",3.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",3.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.7,"B","Break" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",66.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",67.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",70.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",69.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",70.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",71.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",72.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",66.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",63.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",74.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",82.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",81.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",87.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",94.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",91,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",92.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",93.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",79.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",79.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",75.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",75.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",83.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",93.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",96.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",73.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",75.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",77.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",77,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",77.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",79.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",82,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",77.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",74.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",88.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",99.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",98.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",16.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",17.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",16.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",17,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",17.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",14.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",14.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",13.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",13.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",15.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",17,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",17.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",13.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",14,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",14.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",14.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",14.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",14.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",14.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",14,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",13.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",16.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",18.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",17.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",3.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",3.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",3.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",3.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",3.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",3.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",2.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",2.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1561.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1574.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1629.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1654.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1675.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1692,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1735.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1763.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1818.4,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1883.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1873.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2252.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2069.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2192.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2093,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2197.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2226.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1877.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1921.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1992.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",2147.4,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",2108.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2140,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",2663.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1939.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1996.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2069.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2135.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2179.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2174.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2306.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2368.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",2472.5,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",2585.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",2584.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",3059,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",25.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",27.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",26,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",27.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",27.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",23,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",23.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",24.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",25.9,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",25.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",25.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",32,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",23.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",24.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",25.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",26.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",26.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",26.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",28,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",28.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",29.8,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",31.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",31.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",36.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",5.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",5.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",5.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",5.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",4.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",4.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",4.1,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",3.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",76.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",80.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",84.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",82.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",89.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",84.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",143.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",141.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",147.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",169.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",127.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",115.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",115.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",101.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",112.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",108.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",110.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",119.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",93.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",158.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",160.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",174.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",189.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",145.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",136.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",121.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",106,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",113.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",123.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",131.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",146.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",138.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",243.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",246.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",261.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",308.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",234.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",211.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",218.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",9.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",10.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",9.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",10,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",10.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",8.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",14.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",14.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",16.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",17.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",13.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",12.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",11.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",9.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",11.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",12,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",13.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",12.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",22.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",22.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",24.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",28.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",21.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",20,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",20.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",5356.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",5439.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",5276.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",5228.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",5304.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",5270.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",5247.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",5346.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",5501.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",5247.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",5043.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",4857.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",4869.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",25.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",27.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",23.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",23.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",22.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",18.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",18.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",19.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",20.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",18.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",16.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",16,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",13.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",42.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",43.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",42,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",41.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",41,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",39.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",39.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",39.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",39.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",37.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",34.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",31.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",30.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",2.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",4.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1011.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",789.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",787.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",998.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",843.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",841.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",873.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",903,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",899.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",974.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1100.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1218.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",8.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",6.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",8.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",7.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",6.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",7.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",8.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",8.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",8.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",7.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",5.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",5.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",7.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",6.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",6.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",6.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",6.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",7.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",26,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",21.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",19.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",25.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",22.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",19.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",21.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",24.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",23.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",22,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",22.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",25.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",23.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",18.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",17.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",22.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",18.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",17.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",18.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",19,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",18.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",19.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",20.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",3.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",3.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",55.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",57.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",59.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",54.7,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",54.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",57.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",58,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",54.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",54,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",53.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",55.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",56.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",73.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",79.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",76,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",72.7,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",73,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",63.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",64.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",61.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",63.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",59.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",63.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",66.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",64.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",68.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",71.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",67.5,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",67.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",71,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",73,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",69,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",68.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",66.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",69.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",70.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",16,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",17.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",16.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",15.7,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",15.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",13.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",13.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",12.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",13.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",12.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",12.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",13.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",14.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",15,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",15.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",14.6,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",14.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",15.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",15.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",14.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",13.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",2.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",2.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",2.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",2.8,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",2.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",285,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",306.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",326.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",346.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",337.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",358.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",372.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",380.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",386.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",377.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",390.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",369.8,"E","Estimated value" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",396.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",393.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",433.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",460.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",374,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",396.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",421.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",448.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",432.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",431.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",461.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",389.4,"E","Estimated value" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",375.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",409.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",442.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",468.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",456.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",511.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",540.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",557.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",588.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",582.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",602.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",598.9,"E","Estimated value" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",6.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",6.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",7.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",7.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",6.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",6.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",7.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",7.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",7.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",6.6,"E","Estimated value" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",6.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",6.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",7.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",7.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",9.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",9.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",9.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",10.1,"E","Estimated value" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.5,"E","Estimated value" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",313776,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",323074.3,"B","Break" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",323368.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",341579.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",368535.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",373609.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",381135.2,"B","Break" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",395424.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",419795.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",460197.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",487736.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",548535.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",271.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",291.5,"B","Break" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",287,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",311.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",350,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",330.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",328.3,"B","Break" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",349.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",381.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",394.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",413.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",479.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",373.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",378,"B","Break" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",378.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",393,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",422.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",435.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",443.8,"B","Break" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",453.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",491.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",537.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",582.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",642.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",5.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",5.8,"B","Break" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",5.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",6.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",6.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",6.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",6.4,"B","Break" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",6.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",7.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",7.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",9.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",7.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",7.6,"B","Break" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",7.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",7.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",8.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",8.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",8.7,"B","Break" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",8.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",9.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",10.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",11.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",12.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",1.5,"B","Break" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",1.5,"B","Break" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",1.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",7.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",7.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",7.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",7.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",7.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",7.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",7.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",8.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",8.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",9.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",10.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",10.7,"D; P","Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",10.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",9.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",10.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",10.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",8.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",8.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",8.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",9.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",11,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",12.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",11.2,"D; P","Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",8.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",8.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",8.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",8.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",9.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",9.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",9.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",10.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",12.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",12.8,"D; P","Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",21,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",19.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",20.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",19.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",16.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",16.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",16.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",17.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",17.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",19.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",21.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",19.1,"D; P","Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",15.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",16.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",16.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",17,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",16.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",16.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",17.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",17,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",17.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",18.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",21.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",21.9,"D; P","Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",146.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",159.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",162.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",148.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",143.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",194.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",222.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",208.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",197.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",190.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",171.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",191.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",197.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",186.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",177.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",11.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",13.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",12.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",11.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",11.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",10.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",11.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",11.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",11.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",10.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",3.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",3.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",29.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",29.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",28.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",23.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",21.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",20.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",19.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",16.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",18.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",17.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",16.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",25.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",25,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",21.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",23.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",23.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",19.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",17.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",14.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",12,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",12.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",11.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",10.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",18.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",15.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",19.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",20.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",19.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",16.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",14.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",13.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",13.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",11.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",12.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",12.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",11.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",17.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",17.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",5.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",5.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",4.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",3.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",2.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",2.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",2.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",4.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",2.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1194,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1219,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1256,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1255,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1317,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1391,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1465,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1482,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1459,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1520,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1818,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",2006,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",2213,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",197.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",217.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",215.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",213.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",209,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",172.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",174.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",179.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",179.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",172.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",193.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",233.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",230.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",130.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",134.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",139,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",139,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",141.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",140,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",145.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",152,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",152.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",158,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",184,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",210.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",206.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",40.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",43.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",43,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",42.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",40.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",33.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",33.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",34,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",33.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",32.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",35.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",43.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",42.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",26.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",27.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",27.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",27.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",27.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",27,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",27.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",28.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",28.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",29.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",34.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",39,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",38,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",6.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",6.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",6.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",6.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",6.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",6.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",5.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",5.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",5.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",5.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",6.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",6.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",110.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",108.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",111.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",108.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",121.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",122.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",119.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",125,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",128.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",138.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",140.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",144.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",164.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",146.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",150.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",143.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",144.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",161.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",135.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",131.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",141.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",151.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",154.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",160.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",170.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",172.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",176.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",173.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",184.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",186.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",210,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",209.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",208.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",217.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",224.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",247.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",252.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",254,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",298.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",13.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",14.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",13.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",13.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",15.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",13.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",12.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",13.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",14.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",15,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",15.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",16.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",16.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",16.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",16.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",17.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",17.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",20.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",20.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",20.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",21.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",21.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",24.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",24.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",24.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",28.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",4.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",5.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",4.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",28.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",31.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",30.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",33.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",32,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",32.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",40.8,"B","Break" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",40.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",41,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",41.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",42.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",44.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",38.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",43.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",39.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",44.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",42.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",35.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",45.1,"B","Break" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",45.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",48.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",46.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",48.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",53,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",57.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",62.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",60.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",68.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",65.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",65.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",81,"B","Break" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",77.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",77.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",79.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",81.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",84,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",7.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",8.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",7.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",8.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",7.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",6.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",8.3,"B","Break" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",8.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",8.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",8.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",8.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",9.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",10.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",11.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",11.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",12.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",12.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",12.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",14.9,"B","Break" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",14.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",14.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",14.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",14.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",15.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",2.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",2.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",2.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",2.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",2.6,"B","Break" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",485,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",482.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",468.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",489.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",570.2,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",620,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",687.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",718.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",749.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",773.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",796.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",831.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",857,"P","Provisional value" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",643,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",671.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",602.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",649.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",757.6,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",687.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",760.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",811.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",885.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",866,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",909.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",983.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",902.5,"P","Provisional value" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",667.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",675.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",674.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",725,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",860.9,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",932.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1069.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1138.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1186.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1262.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1281.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1328.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1437.4,"P","Provisional value" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",13.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",14.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",12.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",13.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",16.3,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",14.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",16.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",17.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",18.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",18.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",19.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",20.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",19,"P","Provisional value" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",14.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",14.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",14.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",18.5,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",20.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",23,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",24.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",25.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",26.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",27.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",28,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",30.3,"P","Provisional value" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",3.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",3.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",5,"B; D","Break; Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",5.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",5.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",3.9,"B","Break" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",3.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",3.7,"P","Provisional value" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",2021.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",2016.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1936.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1972,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1985.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",2044.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",2020,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1969.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",2291.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",2453.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",2538.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2487,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",2726.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",280.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",310.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",285.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",302.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",289.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",242.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",235.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",230.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",263.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",259.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",275.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",290,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",269.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",223.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",228,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",223.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",229.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",227.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",230.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",229,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",222.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",258.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",281.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",292.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",285.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",314.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",29.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",32.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",30,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",31.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",29.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",24.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",23.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",22.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",25.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",25.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",26.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",27.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",25.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",23.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",24.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",23.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",23.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",23.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",23.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",23.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",22.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",25.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",27.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",28.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",27.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",30.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",5.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",5.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",5.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",5.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",5.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",4.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",4.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",4.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",4.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",4.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",4.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",306.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",291.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",264.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",295.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",320.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",352.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",447.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",582.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",696.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",936.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1051.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1401.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",204.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",174.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",147.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",155.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",146.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",129.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",148.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",159.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",144.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",165,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",150,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",158.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",333.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",302.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",259.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",276.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",290.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",303.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",360.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",420.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",426.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",502.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",485.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",499,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",2.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",4.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",4.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",5.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",6.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",5.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",5.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",2.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",2.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",2.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",2.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",54002.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",58995.7,"B","Break" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",64056.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",63983.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",66475.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",75558.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",85860.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",79662.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",84241.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",73963.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",75501.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",89508.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",84258.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",105.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",122,"B","Break" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",131.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",129.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",116.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",115.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",126.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",122.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",131.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",105.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",95.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",117.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",96.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",150.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",169.5,"B","Break" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",184.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",183,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",181,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",193.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",216.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",200.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",212.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",184.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",180.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",205.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",192.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",6.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",7.1,"B","Break" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",7.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",7.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",6.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",6.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",6.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",5.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",4.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",8.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",9.8,"B","Break" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",10.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",10.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",10.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",11.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",10.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",11.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",9.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",9.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",9.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",6.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",5,"B","Break" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",5.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",4.4,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",4.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",3.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",3.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",3.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",5.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",5.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",5.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",5.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",6.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",6.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",7.5,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",7.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",8.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",9.4,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",10.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",10.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",13.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",6.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",7.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",7.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",7.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",8.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",7.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",8.3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",10.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",10.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",11.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",12.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",14.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",10.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",10.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",10.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",11.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",12,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",12.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",14.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",14.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",16.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",17.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",19.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",19.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",23.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",5.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",5.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",5.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",6.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",5.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",6.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",6.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",7.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",8.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",9.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",10.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",7.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",8.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",9.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",9.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",10.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",11.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",12.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",13.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",14.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",15,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",17.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",2.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.5,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",2.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",2.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",2.9,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",2.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",3.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",17.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",16.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",16,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",17.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",17.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",18.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",18.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",18.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",18.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",18.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",20.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",22.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",24.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",22.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",23.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",20.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",22.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",23.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",20.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",20.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",20.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",21.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",20.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",23.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",26.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",26.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",26.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",26.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",26.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",29.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",30.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",30.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",32.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",32.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",32.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",33.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",37.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",39.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",45.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",11.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",11.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",10,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",11.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",11.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",10,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",10,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",10.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",11.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",12.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",12.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",13.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",13,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",12.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",14.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",14.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",15,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",15.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",15.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",16.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",17.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",18.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",21.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",3.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",3.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",4.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",4.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",3.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",3.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",29,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",28,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",27,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",34,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",33,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",39,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",45,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",48,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",50,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",48,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",48,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",46,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",26.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",28.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",28,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",32.8,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",29.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",29.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",33.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",36.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",37.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",33.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",33,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",34.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",19.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",18.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",17.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",23.5,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",22.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",26.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",31,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",32.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",34,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",32.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",33,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",31.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",1.4,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",1,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.3,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",6.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",6.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",6.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",6.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",7.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",6.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",6.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",6.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",6.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",5.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",5.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",8.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",8.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",9.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",7.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",7.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",7.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",8.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",7.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",6.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",6.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",7.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",7.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",8.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",8.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",8.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",8.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",8.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",9.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",8.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",7.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",7.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",64.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",65,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",63.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",68.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",70.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",69.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",72.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",68.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",66.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",63.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",63.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",63.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",63.4,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",85.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",90.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",82,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",90.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",93.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",77.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",80.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",77.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",78.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",70.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",72.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",75.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",66.7,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",76.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",78.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",77.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",84.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",87.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",87.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",92.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",88.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",87,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",84.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",86.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",86.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",88.8,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",7.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",8.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",7.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",8.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",8.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",6.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",7.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",6.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",6.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",6.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",6.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",6.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",5.7,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",7.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",7.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",7.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",8.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",7.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",7.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",7.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",7.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",7.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",7.6,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.9,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.7,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",164.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",164.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",163.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",163.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",163.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",160.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",155.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",151,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",152.8,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",146.9,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",141.6,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",164.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",159.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",148.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",127.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",123.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",123.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",119.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",113.8,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",113.9,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",117.1,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",108.8,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",132.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",134.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",133.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",130.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",135.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",132.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",128.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",122.3,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",124.1,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",118.6,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",112.9,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",4.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",4.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",4.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",3.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",3.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",3,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",3,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",3.1,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",2.8,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",3.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",3.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",3.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",3.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",3.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",3.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",3.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",3.3,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",3.3,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",3.1,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",2.9,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.4,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.4,"E; D","Estimated value; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",344.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",372.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",421.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",424.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",414.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",397.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",396.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",397,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",381.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",393.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",255.9,"B","Break" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",264.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",18,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",21.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",21.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",21.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",20,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",16.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",16.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",17,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",17.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",17.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",11,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",12.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",25.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",27.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",31.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",33.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",32.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",30.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",31.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",32,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",30.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",32.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",20.5,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",20.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",1.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",2.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",2.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",1.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",1.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",1.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",1.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",1.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",1,"B","Break" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",1.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",2.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",2.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",3.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",3.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",2.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",2.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",1.9,"B","Break" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.3,"B","Break" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",8.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",8.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",8.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",7.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",7.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",7.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",7.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",6.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",6.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",6.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",7.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",11,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",11.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",10.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",10.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",10.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",8.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",7.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",7.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",6.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",7.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",8.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",9.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",9.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",8.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",8.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",8.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",8.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",8.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",7.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",7.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",7.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",8.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",8.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",2.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",2.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",1.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",1.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",1.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",85,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",80.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",78.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",77,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",76.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",73.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",68.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",65.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",65.2,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",63.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",62.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",62.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",112.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",111.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",101.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",102.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",102,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",81.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",76.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",74.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",77,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",71.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",71,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",73.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",105.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",101.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",100.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",99.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",99.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",94.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",91.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",88.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",88.7,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",87.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",85.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",84.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",0.9,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.1,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",22.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",22.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",21.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",21.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",20.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",20.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",21.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",22.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",22.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",21.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",25.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",23.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",15.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",29.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",31.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",27.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",29,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",26.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",23,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",23.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",25.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",26.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",24.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",28.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",27.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",16.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",30.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",31.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",30.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",34.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",33.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",34,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",36.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",38.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",40,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",39.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",46.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",42.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",29.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",2.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",2.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",2.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",2.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",2.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",2.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",2.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",2.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",2.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",2.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",2.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",2.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",1.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",2.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",2.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",2.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",3.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",3.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",3.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",3.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",3.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",3.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",4.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",4.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",2.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",2903.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",3057.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",2947,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",2974.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",2958.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",2888.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",2872.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",2831.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",2756.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",2709.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",2664.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",2500.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",2400.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",14,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",15.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",13.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",13.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",12.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",10.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",10.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",10.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",10.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",9.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",8.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",8.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",6.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",23,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",24.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",23.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",23.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",22.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",21.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",21.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",20.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",19.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",19.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",18.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",16.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",14.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",262.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",214.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",256.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",270.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",263.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",268,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",265.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",276.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",286,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",282.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",316.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",345.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",2.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",1.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",2.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",2.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",2.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",2.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",2.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",2.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",2.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",1.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",1.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",1.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",1.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",2.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",2.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",6.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",5.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",6.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",6.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",6.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",6.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",6.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",7.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",7.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",6.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",6.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",7.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",6.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",5.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",6.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",5.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",5.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",5.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",5.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",5.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",5.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",5.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",6.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.9,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",9.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",9.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",9.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",9.5,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",9.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",9.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",9.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",8.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",8.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",8.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",8.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",12.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",13.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",12.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",12.6,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",12.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",10.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",10.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",10.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",10.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",9.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",9.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",10.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",11.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",11.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",11.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",11.7,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",11.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",11.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",11.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",11.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",11,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",10.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",10.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",10.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",2.7,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",2.5,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.5,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",3.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",3.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",3.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",3.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",3.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",3.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",3.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",4.5,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",5.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",5.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",4.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",3.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",3.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",3.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",4.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",4.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",4.8,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",4.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",5.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",5.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",4.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",4.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",4.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",4.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",5.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",5.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",6.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",7.4,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.1,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.1,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0,"E","Estimated value" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",70183,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",69662.7,"B","Break" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",65916.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",63671.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",63182.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",63755.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",59216.6,"B","Break" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",59332.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",60670.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",61587.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",65347.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",68390.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",60.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",62.9,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",58.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",58.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",60,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",56.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",51,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",52.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",55.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",52.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",55.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",59.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",83.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",81.5,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",77.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",73.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",72.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",74.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",69,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",68,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",71,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",71.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",78,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",80.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",1.3,"B","Break" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",1,"B","Break" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",1.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",1.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",1.6,"B","Break" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.3,"B","Break" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.3,"B","Break" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.2,"B","Break" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",2.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",2.3,"D; P","Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",3.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",3.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",3.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",2.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",2.4,"D; P","Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",2.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",2.8,"D; P","Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",6.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",6.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",6.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",6.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",6.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",5.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",5.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",5.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",5.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",5.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",5.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",5.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",5.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",5.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",5.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",5.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",5.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",4.7,"D; P","Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.9,"D; P","Difference in methodology; Provisional value" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",21.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",20.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",19.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",20.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",20.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",28.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",28.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",25.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",26.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",27.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",25,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",24.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",23.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",25.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",25.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",1.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",1.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",122,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",118,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",116,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",114,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",121,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",115,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",119,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",116,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",113,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",136,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",142,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",151,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",145,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",20.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",21.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",19.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",19.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",19.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",14.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",14.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",14,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",13.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",15.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",15.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",17.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",15.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",13.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",13,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",12.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",12.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",13,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",11.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",11.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",11.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",11.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",14.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",14.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",15.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",13.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",4.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",4.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",3.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",3.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",2.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",2.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",3.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",2.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",2.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",61.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",57.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",56.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",54.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",54.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",54.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",52.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",51.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",50.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",49.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",49.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",49.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",48.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",81.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",80.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",72.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",71.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",72.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",60.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",58.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",58,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",59.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",55.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",56.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",58.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",51.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",98.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",92.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",92.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",92.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",94.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",92.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",92,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",89.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",88.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",88.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",88.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",86.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",88.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",7.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",7.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",6.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",6.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",5.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",5.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",5.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",5.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",5.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",4.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",9.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",8.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",8.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",8.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",9.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",8.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",8.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",8.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",8.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",8.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",8.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",8.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",5.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",4.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",5.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",5.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",6.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",7.4,"B","Break" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",6.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",7.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",8.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",9.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",10.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",6.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",5.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",6.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",7.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",7.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",8.2,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",7.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",8.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",9.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",10.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",12.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",10,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",10,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",9.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",10.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",11.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",13,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",14.7,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",13.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",14.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",16.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",17.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",19.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.5,"B","Break" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",1.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",2.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.7,"B","Break" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",2.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",2.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",3.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.5,"B","Break" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",122,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",113.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",98.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",98.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",103.8,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",100.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",100.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",100.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",101.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",101.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",105.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",109,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",108,"P","Provisional value" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",161.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",157.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",126.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",130.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",137.9,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",111.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",111.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",113.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",119.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",113.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",120.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",128.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",113.8,"P","Provisional value" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",167.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",158.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",141.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",145.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",156.8,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",151.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",157,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",159.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",160.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",165.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",169.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",174.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",181.2,"P","Provisional value" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",3.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",3,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.4,"P","Provisional value" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.4,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.5,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.8,"P","Provisional value" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.9,"B; D","Break; Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.5,"B","Break" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",187.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",190.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",191.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",200.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",201.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",199.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",198.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",197,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",188.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",185.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",176.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",167.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",168,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",26,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",29.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",28.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",30.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",29.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",23.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",23.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",23,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",21.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",19.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",19.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",19.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",16.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",20.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",21.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",22.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",23.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",23.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",22.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",22.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",22.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",21.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",21.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",20.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",19.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",19.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",2.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",3.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",3.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",1.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",1.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",2.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",2.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",2.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",2.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",1.9,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.3,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",14.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",14.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",12.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",13.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",15.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",17.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",14.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",16,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",25.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",34,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",44.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",57.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",9.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",8.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",6.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",6.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",6.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",4.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",4.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",5.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",6.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",6.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",15.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",14.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",12.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",12.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",13.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",15.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",11.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",11.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",15.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",18.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",20.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",20.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",8596,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",9773,"B","Break" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",10633.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",11038.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",11744.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",12721.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",13974.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",15592.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",16516.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",15342.7,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",15030.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",17699.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",17471.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",16.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",20.2,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",21.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",22.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",20.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",19.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",20.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",24,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",25.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",21.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",19,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",23.3,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",20,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",23.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",28.1,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",30.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",31.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",32,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",32.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",35.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",39.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",41.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",38.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",35.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",40.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",39.9,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",1.2,"B","Break" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.6,"B","Break" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",2.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.8,"B","Break" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.9,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",1.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",1.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",1.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",1.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",1.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",1.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",1.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",1.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",1.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",1.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",1.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",1.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",1.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",1.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",1.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",2.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",2.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",2.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",2.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",2.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",2.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",2.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",2.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",2.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",1.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",1.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",1.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.7,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",2.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",2.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",4.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",3.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",3.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",3.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",3.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",3.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",3.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",4.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",4.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",4.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",4.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",4.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",4.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",4.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",4.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",5.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",5.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",1.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",1.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",19,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",18,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",17,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",21,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",21,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",24,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",28,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",28,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",28,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",27,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",26,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",24,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",17.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",18.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",17.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",20.3,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",18.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",18,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",20.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",21.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",20.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",18.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",17.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",18,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",12.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",11.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",11,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",14.5,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",14.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",16.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",19.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",19,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",19,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",18.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",17.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",16.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.9,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.6,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.2,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",2.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",3.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",3.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",3.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",67.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",71.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",70.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",75.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",75.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",78,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",77.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",77.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",74,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",66.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",72.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",74.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",73.6,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",89.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",99.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",90.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",100.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",100,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",86.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",85.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",87.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",87.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",74.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",82.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",88.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",77.5,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",80.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",85.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",85.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",93.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",94,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",97.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",99.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",99.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",96.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",89.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",99.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",101.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",103.1,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",8.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",8.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",8.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",7.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",7.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",6.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",7.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",7.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",6.7,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",8.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",8.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",8.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",8.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",8.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",8.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",7.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",8.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",8.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",8.9,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.8,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",187,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",193.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",199.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",204.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",203.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",202.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",179.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",173.9,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",179.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",190.2,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",202.4,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",187.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",187.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",180.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",159.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",153.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",156.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",138.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",131.1,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",133.8,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",151.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",155.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",150.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",157.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",162.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",163.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",168.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",167.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",148.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",140.9,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",145.8,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",153.6,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",161.4,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",5.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",5.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",5.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",3.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",3.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",3.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",4,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",4.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",4.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",4.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",4.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",3.7,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",3.8,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",4.2,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",454.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",459.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",468.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",455.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",460.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",436.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",430.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",463.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",477.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",497.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",44.2,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",58.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",23.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",26,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",23.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",23.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",22.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",17.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",17.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",19.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",22,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",21.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",1.9,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",2.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",33.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",34.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",35.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",35.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",36.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",33.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",34.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",37.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",38.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",40.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",3.5,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",4.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",2.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",2.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",2.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",2.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0.2,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",3.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",3.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",3.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",0.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.1,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",9.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",10.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",12.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",12.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",12.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",12.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",12.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",12.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",13.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",14,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",14.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",14.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",13,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",14.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",15.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",16.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",17,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",13.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",13.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",14.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",16.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",15.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",16.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",16.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",10.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",11.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",13.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",13.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",14.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",13.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",13.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",14.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",15.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",16.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",17.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",17.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",2.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",2.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",2.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",2.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",2.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",2.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",2.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",2.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",110.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",103.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",99.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",97.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",97.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",94.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",90.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",89.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",81.3,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",84.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",87.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",94.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",146.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",144.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",127.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",129.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",129.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",104.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",100.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",101.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",96,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",95,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",100.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",111.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",137,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",131.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",126.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",125.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",126.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",121.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",120.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",120.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",110.5,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",116.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",121.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",128.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",1.2,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.3,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.2,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",10.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",10.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",8.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",8.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",8.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",7.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",8.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",8.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",8.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",9.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",10,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",14.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",10.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",14.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",14.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",11.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",10.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",11.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",8.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",9.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",9.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",10.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",10.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",11.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",16.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",11.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",14.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",14.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",13,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",13,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",14.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",12.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",13.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",14.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",15.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",16.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",18.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",25.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",19.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",9.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",2.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",461.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",466.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",463.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",449.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",451.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",460.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",471.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",509.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",572.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",623,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",736.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",838.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",3.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",3.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",3.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",3.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",3.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",4.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",5.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",5.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",6.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",3.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",3.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",3.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",3.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",3.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",4.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",4.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",5.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",11.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",12.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",11.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",11.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",11.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",10.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",11.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",13.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",15,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",14.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",14.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",17.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",10.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",10.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",10.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",10.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",10,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",10,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",10.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",11.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",12.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",13.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",15,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",16.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",17,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",17.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",18.2,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",18.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",18.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",18.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",18.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",18,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",17.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",18.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",17.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",22.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",23.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",24.2,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",24.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",20.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",20.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",20.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",21.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",19.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",20.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",20.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",19.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",20.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",21.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",22.5,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",22.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",22.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",23.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",23.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",22.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",22.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",23,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",22.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",4.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",5.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",4.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",5.2,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",5.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",4.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",4.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.9,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.9,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",4.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",7.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",10.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",11.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",12.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",19.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",13.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",8.6,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",4.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",4.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",4.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",3.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",4.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",7.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",11.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",13.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",14.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",22.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",16.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",9,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",4.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",4.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",5.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",10.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",14.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",17.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",19.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",30,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",21.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",13.9,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.2,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.2,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0,"E","Estimated value" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",37011,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",40290.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",36827.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",39454.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",42828.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",47029,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",48946.6,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",50664.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",49591.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",60192.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",68593.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",77611,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",32,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",36.4,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",32.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",36,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",40.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",41.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",42.2,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",44.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",45.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",51.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",58.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",67.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",44,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",47.1,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",43.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",45.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",49.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",54.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",57,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",58.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",58,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",70.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",81.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",90.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.7,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.8,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.1,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.2,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.2,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",3.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",3.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",3,"D; P","Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",4.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",4.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",3.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",3.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",3.1,"D; P","Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",3.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",3.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",3.5,"D; P","Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",8.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",8.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",7.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",8.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",7.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",7.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",7.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",6.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",6.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",6.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",5.3,"D; P","Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",6.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",6.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",6.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",7.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",7.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",6.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",6.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",6.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",6,"D; P","Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.4,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.1,"D; P","Difference in methodology; Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",11.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",12.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",12.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",12.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",13.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",15.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",17.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",16,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",16.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",18.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",13.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",14.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",15.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",16,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",17.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",1.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",1.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",1.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",5.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",6.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",6.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",3.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",3.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",4.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",4.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",172,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",172,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",194,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",191,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",211,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",222,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",254,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",257,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",263,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",275,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",364,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",385,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",375,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",28.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",30.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",33.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",32.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",33.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",27.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",30.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",31.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",32.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",31.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",38.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",44.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",39,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",18.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",18.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",21.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",21.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",22.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",22.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",25.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",26.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",27.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",28.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",36.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",40.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",34.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",5.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",6.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",6.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",6.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",6.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",5.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",5.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",5.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",6.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",5.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",7.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",8.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",7.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",4.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",4.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",4.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",4.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",4.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",5.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",5.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",6.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",6.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",18.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",17.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",18.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",20.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",21.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",20.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",19.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",19,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",18.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",18,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",18,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",18.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",18.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",24.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",24.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",24,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",26.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",28.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",23.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",22,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",21.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",21.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",20.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",20.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",21.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",19.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",29.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",28.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",30.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",34.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",36.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",35.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",34.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",32.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",31.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",32.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",32.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",32.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",34.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",2.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",2.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",2.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",1.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",3.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",3.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",3.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",3.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",4.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",4.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",3.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",4.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",4.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",4.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",6.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",4.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",6.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",6.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",6.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",5.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",4.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",5.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",6.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",5.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",6.9,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",7.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",7.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",7.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",9.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",8.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",8.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",7.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",9.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",9.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",10,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",12.4,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",8.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",12.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",12.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",12.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",14.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",2.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",2.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",2.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.4,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",42.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",41.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",40.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",41.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",44.7,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",45.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",46.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",47.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",54.7,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",58.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",69.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",66.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",59.8,"P","Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",55.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",57.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",51.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",55.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",59.4,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",50.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",51.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",53.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",64.6,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",65.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",79.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",78.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",63,"P","Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",57.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",57.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",57.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",62.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",67.6,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",68.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",73,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",75.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",86.6,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",95.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",112.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",105.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",100.4,"P","Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",1.3,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",1.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",1.4,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",1.3,"P","Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.5,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",1.9,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",2.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",2.1,"P","Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.4,"B; D","Break; Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.3,"P","Provisional value" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",271.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",280.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",298.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",314.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",342.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",364.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",433.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",523.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",607.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",690.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",816.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",604.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",663.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",37.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",43.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",44,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",48.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",49.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",43.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",50.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",61.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",69.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",73,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",88.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",70.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",65.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",30.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",31.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",34.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",36.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",39.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",41.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",49.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",59.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",68.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",79.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",94.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",69.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",76.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",4.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",4.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",4.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",6.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",6.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",8.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",6.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",3.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",5.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",6.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",9.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",6.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",7.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",7.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",8.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",9.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",10.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",11.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",12,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",19.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",21.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",18.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",20.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",29.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",51.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",5.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",5.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",5.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",5.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",4.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",6.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",5.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",3.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",3.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",4.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",5.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",8.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",8.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",9.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",9.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",10.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",10.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",16.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",15.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",11.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",11.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",13.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",18.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",3361.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",5170.6,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",5909.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",7153.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",8655.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",9241.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",10849.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",12193.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",14373.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",20030,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",33988.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",37671.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",29554.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",6.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",10.7,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",12.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",14.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",15.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",14.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",16,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",18.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",22.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",28.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",42.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",49.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",33.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",9.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",14.9,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",17,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",20.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",23.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",23.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",27.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",30.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",36.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",49.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",81.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",86.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",67.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.6,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.9,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",4.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",4.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.4,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",2.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",2.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",2.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",2.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",2.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",2.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",3.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",2.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",2.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",2.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",2.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",3.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",3.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",3.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",4.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",4.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",5.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",4.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",1.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",1.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",2.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",2.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",2.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",2.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",3.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",3.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",3.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",3.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",3.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",2.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",2.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",2.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",4.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",4.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",4.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",4.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",1.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",1.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",1.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",2.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",2.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",468,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",488,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",446,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",524,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",464,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",438,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",441,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",433,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",445,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",464,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",506,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",549,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",429.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",503.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",461.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",505.9,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",418.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",329.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",327.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",331.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",332.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",322.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",348.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",412.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",311.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",323,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",289.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",362.1,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",319.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",297.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",304.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",293.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",302.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",313.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",348,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",379.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",19.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",22.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",20.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",21.9,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",17.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",13.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",13.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",13.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",13.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",12.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",13.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",16.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",14.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",14.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",15.7,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",13.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",12.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",12.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",12.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",12.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",13.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",14.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",4.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",4.4,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",3.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",3.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",94,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",99.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",103.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",107.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",109.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",95.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",85.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",80.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",77.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",77,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",75.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",74.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",124.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",138.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",132.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",142.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",145.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",105.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",94.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",90.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",91.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",86.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",86.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",88.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",111.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",119.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",126.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",134.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",137.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",119.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",110,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",103.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",100.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",102.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",101.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",98.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",14.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",16.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",15.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",16.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",17,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",12.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",10.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",10.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",10.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",9.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",9.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",9.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",15,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",15.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",16,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",13.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",12.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",11.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",11.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",11.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",11,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",3.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",3.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",4.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",3.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",3.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",2.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",2.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",186.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",188.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",185.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",181.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",179.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",155.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",130.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",125.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",119.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",122.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",115.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",113.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",122.1,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",247.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",262.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",238.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",240.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",238,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",172.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",144,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",141.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",141.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",137.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",132.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",134.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",128.5,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",223.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",226.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",225.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",224.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",223.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",194.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",166.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",161.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",156.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",164.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",158.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",154.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",171,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",22.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",23.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",21.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",21.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",21.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",15.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",12.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",12.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",12.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",12,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",11.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",11.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",11.1,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",20.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",20.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",20.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",20.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",20,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",17.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",14.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",14.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",13.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",14.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",13.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",13.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",14.7,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",3.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",3.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",3.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",2.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.4,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1444.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1456.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1496.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1432.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1418,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1391.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1283.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1316.6,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1385.1,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1488.4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1609.1,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1445.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1413.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1354.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1120.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1069.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1072.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",990.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",992.3,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1032.7,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1187,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1236.3,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1160.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1189.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1216.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1148.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1174.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1148,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1063.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1066.3,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1125.1,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1202.1,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1283.4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",41.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",40.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",38.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",31.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",29.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",29.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",26.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",26.4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",27.2,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",31,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",31.8,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",33.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",32.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",32.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",31.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",28.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",28.4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",29.6,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",31.4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",33,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",5.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",4.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",4.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",4.1,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",4,"E; D","Estimated value; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1740.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1649.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1714.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1496.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1423,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1238.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1163.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1307.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1447,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1543.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1536.4,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",1621.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",91.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",93.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",87.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",76.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",68.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",50.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",47.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",55.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",66.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",67.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",66.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",74.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",127.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",123.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",128.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",117.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",112,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",95.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",92.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",105.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",117,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",125.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",123.3,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",127.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",8.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",8.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",8.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",7.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",6.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",4.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",4.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",5.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",6.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",6.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",6.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",7.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",12.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",11.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",12.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",11.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",10.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",9.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",8.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",9.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",11,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",11.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",11.5,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",12.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",1.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1.8,"B","Break" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",31.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",29.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",29.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",30.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",32.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",32.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",30.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",30.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",31.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",33.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",36,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",38.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",42,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",40.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",37.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",40.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",43.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",35.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",34.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",34.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",37.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",37.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",41.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",45.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",35.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",32.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",32.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",34,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",36.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",35.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",35,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",35.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",36.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",40,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",43.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",46.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",7.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",7.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",7.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",6.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",6.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",6.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",6.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",6.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",7.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",8.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",6.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",6.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",6.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",6.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",6.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",6.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",7.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",7.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",8.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",798.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",765.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",746.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",791.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",832.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",805.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",759.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",702.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",716.7,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",737.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",711,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",714,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1058.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1065.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",959.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1051.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1106.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",894,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",840.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",793.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",846.4,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",825.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",812.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",844.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",991.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",970.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",948.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1021.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1082.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1035.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1008.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",943.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",974.5,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1012.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",980.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",969.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",12.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",13.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",13,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",13.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",10.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",9.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",10.2,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",9.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",10.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",12.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",11.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",13.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",11.8,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",12.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",11.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.6,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",186.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",156.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",137,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",134.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",119.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",105.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",107.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",100,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",106.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",110.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",113.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",114,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",93.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",247.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",217.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",176,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",179.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",158.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",116.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",119.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",112.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",125.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",124.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",129.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",134.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",98.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",258.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",218.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",200,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",213.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",195.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",172.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",182.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",173.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",188,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",202.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",208.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",208.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",177.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",22.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",19.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",15.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",16.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",14.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",10.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",11.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",10.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",11.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",11.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",12.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",12.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",9.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",23.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",19.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",18.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",19.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",17.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",16,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",17,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",16.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",17.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",18.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",19.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",19.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",17,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",11947.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",12569.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",11070.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",10723.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",10500.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",9404.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",8047.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",8013.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",8189.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",8103.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",7985.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",7905.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",8264,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",57.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",62.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",49.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",47.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",45.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",33.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",28.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",29.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",30.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",27.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",25.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",26.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",22.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",94.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",101.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",88.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",85.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",81.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",71,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",61,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",58.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",58.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",57.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",54.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",51.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",51.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",5.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",4.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",2.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",2.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",9.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",10.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",8.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",8.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",8.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",6.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",5.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",5.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",5.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1101.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",865.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",842.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",767.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",730.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",759.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",744.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",769.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",854.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",960.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1119.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1217.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",7.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",6.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",5.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",6.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",7.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",8.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",8.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",6.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",6.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",5.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",5.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",6.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",7.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",28.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",23.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",21,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",19.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",19.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",17.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",18.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",21,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",22.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",21.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",22.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",25.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",26.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",20.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",19.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",17.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",16.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",15.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",16.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",17.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",18.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",20.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",67.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",67.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",72.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",72.7,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",70.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",56.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",49.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",44.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",44.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",45.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",47.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",49.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",89.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",93.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",93.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",96.6,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",93.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",62.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",55,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",50.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",52.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",50.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",54.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",59.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",79.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",80.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",88.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",89.7,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",85.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",69.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",62.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",55.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",56.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",56.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",59.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",62.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",19.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",20.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",20.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",20.9,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",20,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",13.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",11.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",10.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",10.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",10.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",10.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",17.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",19.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",19.4,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",13.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",11.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",11.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",11.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",12.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",3.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",3.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.7,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",1.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",1.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",1.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",497.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",493,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",493.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",464.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",406.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",359.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",369,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",382.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",391.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",399.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",406.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",413.3,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",692.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",633.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",655,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",617.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",450.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",397.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",416.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",451.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",438.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",456.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",481.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",435.2,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",655.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",659.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",668.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",628,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",550,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",512.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",534.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",560.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",596.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",616.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",628.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",669.4,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",11.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",10.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",10.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",10.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",7.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",6.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",6.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",7.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",7.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",8.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",7.4,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",11,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",11.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",11.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",10.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",9.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",9.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",10,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",10.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",11.3,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",2.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.7,"E","Estimated value" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",151818,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",175161.8,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",165576.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",175592.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",188434.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",205375.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",177097.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",194400.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",214513.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",240231.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",272925.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",315802.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",131.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",158.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",146.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",160.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",179,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",181.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",152.6,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",171.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",195,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",206.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",231.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",276.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",180.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",205,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",193.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",202,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",216.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",239.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",206.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",222.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",250.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",280.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",325.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",369.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",2.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",3.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",2.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",3.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",3.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",3.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",3,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",3.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",3.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",4.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",4.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",4.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",4.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",4.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",5.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",6.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.8,"B","Break" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.7,"B","Break" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",7.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",6.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",6.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",6.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",5.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.3,"D; P","Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",8.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",8.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",8.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",5.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",5.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",5.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",5.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.6,"D; P","Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",7.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",7.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",7.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",6.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",6.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",5.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",5.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",5.2,"D; P","Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",19.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",17.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",17.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",16.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",12.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",11.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",10.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",10.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",10.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",9.7,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",7.8,"D; P","Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",16.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",15.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",14.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",11.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",10.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",10.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",9.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.9,"D; P","Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",3.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.7,"D; P","Difference in methodology; Provisional value" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",91.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",95.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",94.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",98.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",99.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",121.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",133.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",121.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",130.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",132.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",107.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",114.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",115.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",123.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",123.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",7.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",7.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",7.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",7.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",6.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",7.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",29.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",32.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",32.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",29.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",17.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",15.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",13.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",8.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",9.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",9.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",10.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",11.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",21.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",25.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",26.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",24,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",14.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",10.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",9.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",9.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",6.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",7.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",7.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",19.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",21.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",22,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",20.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",12.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",10.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",9.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",9.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",5.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",6.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",6.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",7.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",7.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",5.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",5.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",1.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",4.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",324,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",266,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",266,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",261,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",263,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",264,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",267,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",277,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",280,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",291,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",311,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",307,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",316,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",53.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",47.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",45.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",44.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",41.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",32.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",31.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",33.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",34.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",33.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",33,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",35.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",32.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",35.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",29.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",29.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",28.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",28.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",26.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",26.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",28.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",29.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",30.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",31.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",32.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",29.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",11,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",9.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",9.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",8.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",8.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",6.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",6.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",6.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",6.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",6.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",6.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",6.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",6.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",7.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",5.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",5.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",5.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",5.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",5.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",5.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",5.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",5.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",5.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",5.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",5.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",158.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",140.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",116.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",97.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",95.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",92.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",93.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",96,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",99.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",107.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",111.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",119.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",128.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",209.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",195.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",149.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",129.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",126.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",103.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",103.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",108.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",117.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",119.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",127.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",141,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",135.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",254.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",225.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",192.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",167.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",164.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",158.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",163.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",166.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",174.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",191.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",200.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",210,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",233.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",19.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",18.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",14.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",12.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",12.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",10,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",10,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",10.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",11.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",12.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",13.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",13.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",24,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",21.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",18.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",16,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",15.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",15.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",15.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",16.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",17,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",18.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",19.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",20.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",22.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",4.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",4.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",4.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",3.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",3.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",3.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",4.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",16.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",15.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",12.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",12.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",14,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",14.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",16.7,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",15.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",16.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",16.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",16.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",17.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",21.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",20.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",16.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",16.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",18.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",16.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",18.5,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",17.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",19.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",18.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",19.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",20.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",32.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",29.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",25.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",25.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",28.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",30.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",33.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",30.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",31,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",32.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",32.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",32.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",3.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",3.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",3.4,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",3.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",3.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",3.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",3.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",3.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",4.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",4.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",5.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",5.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",6.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",5.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",5.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",5.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",5.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",5.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",687.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",590.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",488.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",500.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",535.3,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",484.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",483.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",500.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",526.6,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",538.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",568.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",610.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",655.9,"P","Provisional value" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",911,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",821.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",627.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",664.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",711.2,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",537.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",535.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",565.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",621.9,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",602.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",649,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",721.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",690.7,"P","Provisional value" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",945.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",826.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",703.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",741.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",808.2,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",729,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",753,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",793.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",833.5,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",877.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",914.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",975.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1100.1,"P","Provisional value" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",19.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",17.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",13.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",14.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",15.3,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",11.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",11.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",12.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",13.3,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",12.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",13.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",15.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",14.6,"P","Provisional value" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",20.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",17.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",15,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",17.4,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",15.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",16.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",17,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",17.8,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",18.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",19.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",20.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",23.2,"P","Provisional value" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",5.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",4.7,"B; D","Break; Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",4.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",4.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",4.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.8,"B","Break" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.9,"P","Provisional value" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",625.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",660.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",678.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",744.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",721.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",668.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",590.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",618.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",724.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",788.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",842.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",754.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",753.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",86.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",101.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",100.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",114.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",105.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",79.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",68.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",72.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",83.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",83.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",91.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",88,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",74.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",69.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",74.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",78.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",86.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",82.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",75.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",66.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",69.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",81.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",90.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",97.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",86.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",86.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",9.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",10.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",10.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",11.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",10.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",8.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",6.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",7.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",8.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",8.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",8.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",8.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",7.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",7.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",7.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",8.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",7.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",6.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",9.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",8.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",372.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",338.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",269.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",263,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",278.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",317.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",367.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",446.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",527.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",664.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",974.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1043.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",248.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",202.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",150.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",138.2,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",127.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",116.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",121.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",122.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",109.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",117.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",139.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",117.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",405.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",350.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",264.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",245.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",252.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",273.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",296.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",322.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",323.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",356.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",450.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",371.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",3.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",5.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",5.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",2.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",31955.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",25714.6,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",28119.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",30007.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",48805.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",56272,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",60183.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",62830.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",64587.1,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",67892.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",79843.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",92278.8,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",104325.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",62.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",53.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",57.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",60.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",85.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",86,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",88.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",96.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",100.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",96.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",100.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",121.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",119.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",88.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",73.9,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",81,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",85.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",132.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",143.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",151.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",158,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",163,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",169,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",190.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",212.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",238.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",3.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",3.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",4.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",4.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",5.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",5.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",5.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",5.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",6.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",5.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.3,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",4.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",7.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",8.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",8.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",8.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",9.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",12,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",3.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",3.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",3.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",3.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",2.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",2.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",2.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",3.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",3.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",3.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",4.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",4.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",4.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",3.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",3.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",3.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",3.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",4.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",4.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",4.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",5.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",5.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",5.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",5.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",5.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",5.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",6.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",6.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",7.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",8.5,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",3.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",2.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",2.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",2.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",2.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",3.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",3.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",3.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",4.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",4.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",4.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",4.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",5.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",5.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",15.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",15.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",14.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",14.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",13.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",11.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",10.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",11.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",11.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",11.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",12.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",20.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",22.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",18.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",19.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",17.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",13,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",12.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",13.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",13.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",13.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",14,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",12.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",24.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",25.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",24.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",24.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",22.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",19.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",19.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",18.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",19.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",21.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",21.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",21,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",21.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",10.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",10.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",9.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",9.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",8.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",6.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",6.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",12.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",11.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",11.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",11.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",9.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",10.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",10,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",10.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",3.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",3.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",3.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",551,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",572,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",598,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",638,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",659,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",697,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",710,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",729,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",728,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",908,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1067,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1088,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",505.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",590,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",619.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",615.9,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",594,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",523.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",527.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",558.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",543.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",631.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",734.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",817.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",366.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",378.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",388.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",440.9,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",453.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",473,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",489.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",493.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",495.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",613.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",733.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",751.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",22.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",26.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",27.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",26.6,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",25.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",22,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",21.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",22.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",21.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",24.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",28.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",31.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",16.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",17.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",19.1,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",19.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",19.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",20.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",20.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",19.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",24.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",28.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",29.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",5.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5.4,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",6.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",154.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",159.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",161.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",164.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",163.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",168.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",172.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",177.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",186.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",202.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",219.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",251.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",205.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",222.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",207.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",218.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",217.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",186.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",190.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",200.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",220.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",226.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",251,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",296.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",183.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",192,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",198.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",206.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",205,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",210.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",221.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",228.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",244,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",270.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",294.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",331.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",24.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",26.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",24.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",25.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",25.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",21.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",21.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",22.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",24.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",25.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",28.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",33.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",22,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",22.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",23.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",24.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",24,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",24.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",25.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",26,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",27.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",30.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",33,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",37.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",6.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",5.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",5.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",5.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",6.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",6.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",6.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",512.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",522.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",517.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",530.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",505.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",525.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",510.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",509.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",520,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",539,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",497,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",511.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",716.2,"E","Estimated value" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",679.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",726.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",664.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",705.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",671.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",583.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",565.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",575.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",614,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",603.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",567.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",604.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",754.2,"E","Estimated value" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",612.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",627.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",629,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",658.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",631.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",657.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",653.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",657.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",678.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",721.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",680.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",693.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1003.2,"E","Estimated value" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",62.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",65.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",59.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",63.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",59.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",51.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",49.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",50.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",53.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",52.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",49.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",52.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",64.9,"E","Estimated value" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",56.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",56.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",56.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",59,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",56.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",58.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",57.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",57.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",59.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",62.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",59,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",59.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",86.4,"E","Estimated value" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",8.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",8.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",8.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",8.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",8.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",8.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",8.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",7.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",7.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",7.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",6.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",6.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",8,"E","Estimated value" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1676.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1729.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1794.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1874.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1936,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1991.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",2127.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",2246.9,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",2423.6,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",2380.1,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",2624.3,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1677.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1678.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1624.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1465.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1460.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1534.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1642.1,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1693.5,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1807.1,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1898.2,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",2016.3,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1346.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1412.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1458.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1502,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1603.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1642.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1763.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1819.7,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1968.7,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1922.3,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",2093,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",48.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",47.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",45.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",41.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",40.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",42,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",44.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",45,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",47.5,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",49.6,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",51.9,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",38.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",40.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",41.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",42.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",44.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",44.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",47.6,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",48.4,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",51.8,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",50.3,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",53.8,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",6.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",6.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",7.1,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",7.1,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",6.5,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",6.6,"E; D","Estimated value; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",6506.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",6696.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",6786.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",6744.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",6900.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",7138.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",6983.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",7450.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",7632.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",7854.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",5139.3,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",5237.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",340.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",378.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",346.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",344.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",332.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",290.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",285.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",318.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",351.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",342.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",221.4,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",241.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",475.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",501.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",510.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",527.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",543.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",551.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",555.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",599.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",616.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",639.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",412.4,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",411,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",32.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",36.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",33,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",32.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",31.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",27.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",27,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",30.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",33,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",32.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",20.7,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",23,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",45.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",47.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",48.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",50.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",51.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",52.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",52.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",56.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",58,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",60,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",38.6,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",39.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",8.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",8.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",8.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",8.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",8.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",8.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",7.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",7.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",5.9,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",5.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1917.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1913.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1977.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1909.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1944.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",1968.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",1954.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1925.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",1989.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2074.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2121.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",2168.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",341,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",356.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",341.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",340,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",346.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",292.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",290.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",291.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",315.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",311,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",324.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",344.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",252.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",256.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",261.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",259.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",265.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",269.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",276.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",280.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",294.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",312.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",323.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",329.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",61.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",64,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",61.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",60.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",61.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",51.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",50.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",50.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",54.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",53.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",55.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",58.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",45.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",46,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",46.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",46.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",47,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",47.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",48.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",48.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",50.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",53.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",55.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",56.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",9.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",9.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",9.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",9.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",9.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",8.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",8.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",8.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",8.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",8.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",8.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",147.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",148.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",154.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",146.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",148.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",144.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",150.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",150.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",154.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",152.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",148.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",151,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",195.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",207,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",198.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",194.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",197.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",160.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",166.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",169.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",182.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",171.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",169.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",178.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",163.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",165.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",170,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",161.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",164,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",159.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",170.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",173.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",180.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",182.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",180.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",182.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",36.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",38.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",36.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",35.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",36.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",29.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",30.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",30.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",33,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",31,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",30.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",32.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",30.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",30.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",31.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",29.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",30,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",29,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",31,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",31.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",32.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",33,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",32.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",33,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",7.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",7.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",7.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",7.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",7.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",6.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",6.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",6.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",6.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",5.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",5.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",5.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",2016,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",2806.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",2396.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",43.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",36.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FRA","France","2011","2011",7.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",2051.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1987.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1927.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2036.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2047.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",2054.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",2134.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",2146.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",2313,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2508,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2620.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2931.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2719.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2766.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2476.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2704.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2720.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",2279.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",2362.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",2424.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",2731.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",2807.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2992.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",3467.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2548.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2519.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2448.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2628.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2662.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2640.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2835.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2881.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",3145,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",3443.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",3614.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",3982.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",33.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",34.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",30.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",33.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",33.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",27.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",28.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",29.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",32.9,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",33.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",36,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",41.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",31.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",31.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",30.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",32.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",32.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",32.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",34.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",34.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",37.9,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",41.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",43.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",47.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",6.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",6.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",6.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",6.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",5.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",5.2,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",5.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",5.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",5.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",459.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",451.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",398.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",359.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",365.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",331.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",405.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",410.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",419.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",430.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",418,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",405.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",471.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",609.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",628.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",511.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",477,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",485.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",367.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",448.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",463.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",495.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",481.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",477.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",479.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",496.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",636.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",633.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",581.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",568.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",597.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",544.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",688.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",713.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",742.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",784.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",768.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",742.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",892.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",54.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",56.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",46.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",43.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",44.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",34,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",41.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",43.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",46.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",44.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",44.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",45.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",47.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",57.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",57,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",52.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",51.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",54.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",50.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",63.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",66.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",69.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",73.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",71.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",70.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",85.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",34020,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",35728.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",33762.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",34278.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",34198.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",33515.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",34173.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",34496.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",35063.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",35957,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",37471.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",35884.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",36809.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",163.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",177.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",150,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",153.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",147,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",120,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",121.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",125.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",129.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",123.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",121.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",118.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",98.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",269.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",287.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",268.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",274.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",264.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",252.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",258.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",253.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",252.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",255.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",257.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",231.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",228.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",16.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",17.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",15.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",15.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",14.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",12.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",12.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",12.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",13.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",12.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",12.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",12.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",10.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",26.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",28.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",27.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",26.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",25.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",26.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",25.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",25.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",26.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",26.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",23.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",23.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",6.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",7.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",7.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",6.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",6.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",6.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1762.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1558.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1582.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1836.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1516.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1444.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1508.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1532.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1706.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1899.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",2155,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",2301.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",14.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",13.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",12.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",15,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",13,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",11,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",12.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",14.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",15.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",15.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",15.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",18.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",13.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",11.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",11.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",13.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",10.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",10.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",10.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",11.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",12.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",13.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",14.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",15.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",45.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",42.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",39.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",46.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",39.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",33.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",37.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",41.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",44.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",43,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",43.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",48.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",41.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",36.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",36,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",41.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",33.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",30.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",32.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",32.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",34.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",37.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",40.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",41.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",6.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",7.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",6.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",5.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",5.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",5.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",5.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",5.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",5.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",5.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",158.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",151,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",156,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",163.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",165,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",169.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",167.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",181.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",225.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",243.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",216.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",213,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",210.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",210.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",200.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",217.1,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",219.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",188.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",185.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",205.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",266.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",272.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",247.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",251.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",186.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",181.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",189.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",201.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",201.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",209.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",211.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",228.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",284.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",302.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",272.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",268,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",46.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",45.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",43.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",47,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",47.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",40,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",39.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",42.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",54.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",55.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",49.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",50.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",40.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",39.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",41.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",43.6,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",43.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",44.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",44.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",47.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",58.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",61.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",54.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",53.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",7.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",8.3,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",8.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",8.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",8.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",8.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",9.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",10.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",8.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",8.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1136.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1109.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1076.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1103.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1125.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1107.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1119.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1166.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1242.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1308.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1294.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1426.1,"E","Estimated value" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1582.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1425.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1429.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1465.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1248.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1225.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1265,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1377.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1391,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1494.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1530.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1501.7,"E","Estimated value" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1498.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1484.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1459.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1491.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1523.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1580.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1623.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1712.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1891.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",2019.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1998.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",2309.8,"E","Estimated value" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",26.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",23.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",23.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",24.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",20.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",20.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",20.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",22.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",23.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",25.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",25.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",25.4,"E","Estimated value" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",25.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",24.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",24.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",24.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",25.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",26.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",26.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",28.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",31.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",34,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",33.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",39.1,"E","Estimated value" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",5.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",5.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",5.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",5.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",5.8,"E","Estimated value" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",123160,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",123835,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",127386,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",118406,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",98066,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",119017,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",119619,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",135053,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",112068,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",138720,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",124575,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",97931,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",1403.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",1551.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",1596.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",1213.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",925.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",983.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1099.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1204,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1014.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",1272.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",1166.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",892.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",1102.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",1152.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",1221.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",1168.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",951.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",1150.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1133.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1285,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1075.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",1331,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",1216.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",959.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",11,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",12.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",12.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",9.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",7.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",8.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",9.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",10.1,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",9.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",7.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",8.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",9.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",9.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",7.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",9.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",8.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",10.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",8.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",10.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",9.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",7.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",1.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",1.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",1.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",1.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",1.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",1.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",1.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",1.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",1.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",1.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",1.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1005103,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",989661.7,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",955295.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",951300.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1026144.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1048376.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1097011.9,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1125767.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1217876.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1244223.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1098631,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1036337.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",869.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",893,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",847.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",868.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",974.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",927,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",945.1,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",995.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1107,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1067.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",930.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",905.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1195.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1158.1,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1117.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1094.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1176.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1222.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1277.4,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1290.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1424.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1452.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1311.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1213.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",17.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",17.9,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",16.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",17.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",19.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",18.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",18.5,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",19.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",21.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",20.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",18,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",17.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",24.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",23.2,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",22.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",21.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",23.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",24,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",24.9,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",25.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",27.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",28.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",23.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",4.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",4.5,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",4.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",4.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",4.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",4.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",4.3,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",4.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",4.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",15.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",15,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",15.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",15.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",14.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",14.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",14.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",13.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",13.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",13.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",13.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",17.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",19.3,"D; P","Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",20.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",20.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",19.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",20.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",19.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",16.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",15.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",14.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",16.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",15.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",15.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",20.8,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",20.3,"D; P","Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",16.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",16.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",16.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",17.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",16.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",16.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",16.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",15.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",16.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",16.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",16.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",20.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",23.2,"D; P","Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",42.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",43.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",39.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",41.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",38.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",31.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",29.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",29.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",27.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",36.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",34.6,"D; P","Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",34.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",34.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",33.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",34.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",32.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",31.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",31.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",28.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",29.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",29.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",28.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",35.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",39.5,"D; P","Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",8.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",7.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",7.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",6.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",6.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",6.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",7.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",7.5,"D; P","Difference in methodology; Provisional value" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",8936,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",7354,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",7999,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",7254,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",6950,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",5656,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",6149,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",5570,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",5722,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",5741.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",5030.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",3975.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",5965,"E","Estimated value" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",707.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",592,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",607.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",568,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",522.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",356.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",329.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",294.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",297.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",298,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",234.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",196.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",296.4,"E","Estimated value" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",1163.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",958.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1017.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",920,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",863.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",679.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",728,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",624.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",616.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",594.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",501.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",382.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",564,"E","Estimated value" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",6.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",5.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",5.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",4.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",4.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",2.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",2.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",2.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",2.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",2.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",1.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",1.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",2.3,"E","Estimated value" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",10.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",8.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",8.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",7.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",7.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",5.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",5.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",4.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",4.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",3.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",4.3,"E","Estimated value" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",5.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",2.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",566.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",586.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",559.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",540.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",516.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",751,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",816.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",719,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",718,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",686.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",663.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",701.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",678.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",677.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",638.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",45.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",48.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",42.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",42.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",40.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",39.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",42,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",40.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",40.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",37.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",10.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",11.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",12.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",12.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",11.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",75.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",83.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",88.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",90,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",92.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",100.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",103.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",97.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",107.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",111.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",122.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",133.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",157.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",54.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",65.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",71.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",73.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",76.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",70.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",71.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",69.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",74.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",73.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",79.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",94.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",100.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",50.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",56,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",59.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",62.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",63.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",68.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",71.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",68.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",73.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",78.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",86.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",91.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",109.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",12.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",15,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",16.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",16.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",16.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",15.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",15.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",14.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",15.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",14.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",15.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",18.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",19.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",11.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",12.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",13.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",14,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",14.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",14.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",15.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",14.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",14.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",15.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",17,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",17.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",21.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",10.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",10.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",9.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",9.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",9.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",10.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",9.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",8.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",7.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",7.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",7.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",8.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1917,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1902,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1928,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1859,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",2001,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",2093,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2273,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2421,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2484,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",2653,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",2716,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",2924,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",3355,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",317.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",339.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",331.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",316.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",317.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",259.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",270.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",292.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",305.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",301.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",288.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",340.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",349,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",209.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",209.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",213.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",205.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",215.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",210.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",226.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",248.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",259.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",275.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",274.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",307.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",312.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",64.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",68.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",66,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",62.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",61.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",50,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",51.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",55.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",57.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",56.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",53.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",62.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",64.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",42.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",42.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",42.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",40.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",42,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",40.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",43.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",47.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",48.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",51.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",51.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",56.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",57.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",10.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",10.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",10.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",9.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",9.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",9.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",9.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",9.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",9.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",9.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",8.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",9.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",214.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",213.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",214.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",201.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",192.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",214.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",222.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",222.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",232.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",244.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",232.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",223.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",272.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",284.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",297,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",275.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",268.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",255.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",237.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",246.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",251.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",274.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",274.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",265.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",264.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",286.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",344.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",342.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",354.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",346,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",332.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",366.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",389.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",386.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",406.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",438.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",417.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",394,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",495.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",26.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",28.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",26.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",25.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",24.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",23,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",23.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",24.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",26.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",26.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",25.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",32.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",32.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",33.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",33.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",31.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",35.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",37.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",37.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",39.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",42.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",40.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",47.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",6.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",7.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",8.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",8.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",8.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",8.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",8.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",8.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",8.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",8.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",8.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",83.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",86.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",76.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",87.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",91.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",97.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",119.3,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",120.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",118.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",122.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",112.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",133.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",110.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",120.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",97.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",116.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",121.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",108.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",132,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",135.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",140.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",136.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",128.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",158.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",166,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",171.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",151,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",178.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",188.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",198.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",237,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",232.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",225.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",236.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",216.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",250.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",20.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",22.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",18.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",21.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",22.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",20,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",24.3,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",25,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",25.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",25.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",23.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",29.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",30.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",31.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",27.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",32.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",34.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",36.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",43.6,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",42.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",41.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",43.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",39.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",46.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",7.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",7.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",7.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",6.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",7.6,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",7.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",7.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",7.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",6.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",7.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1304.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1311.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",1201.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",1092.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",1150.2,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1182.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",1161.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",1134.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1340.1,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1384.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1454.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1470.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1655.1,"P","Provisional value" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1729.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1825.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1543.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1451.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1528,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",1312.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",1285.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",1281.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1582.6,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1550.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1661.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1738.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1742.9,"P","Provisional value" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1794.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1836.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1729,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1619.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1736.5,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1779.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1807.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1798.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2121,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",2259.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2340.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",2348.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2776,"P","Provisional value" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",37.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",39.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",33,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",31.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",32.9,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",28.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",27.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",33.8,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",32.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",35.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",36.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",36.7,"P","Provisional value" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",38.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",39.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",37,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",34.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",37.4,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",38.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",38.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",38.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",45.3,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",47.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",49.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",49.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",58.5,"P","Provisional value" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",9.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",10.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",10.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",10.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",10.2,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",10.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",9.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",9.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",7.1,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",6.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",6.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",7.2,"P","Provisional value" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3323.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3447.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",3572.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",3551.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3534.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",3332.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",3456.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",3523.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",3803.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",4222.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",4310.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",4261,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",4814.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",461.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",530.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",527.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",545.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",515.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",395.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",403.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",412.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",437.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",446.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",468,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",496.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",476,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",368.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",389.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",412.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",413,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",405,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",376.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",391.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",398.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",429,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",484.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",497.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",488.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",555.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",49.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",56.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",55.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",56.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",53.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",40.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",40.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",41,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",43,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",43.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",45.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",47.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",45.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",39.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",41.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",43.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",43,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",41.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",38.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",39.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",39.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",42.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",47.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",48,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",46.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",53.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",9.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",9.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",9.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",9.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",9.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",8.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",8.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",8.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",8.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",8.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",7.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",8.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",484.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",487,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",494,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",513,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",476,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",503,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",497,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",507,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",521,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",527,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",486,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",457,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",593,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",464.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",548.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",526.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",553.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",519.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",522.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",504.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",514.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",532.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",530.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",517.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",500.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",621.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",330.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",348.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",364.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",390.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",371.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",407,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",413.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",426.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",442,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",458.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",427.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",413,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",556.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",59.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",69.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",65.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",68.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",63.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",63.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",60.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",60.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",62.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",61.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",59.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",57.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",71.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",42.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",44,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",45.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",48.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",45.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",49.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",49.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",50.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",51.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",53.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",49.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",47.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",63.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",8.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",8.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",8.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",8.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",8.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",7.8,"B; D","Break; Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",7.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",7.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",7.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",7.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",6.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",7.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1716.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1627.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1382.8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1432,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1549.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1685.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",2002.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",2431.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",3020,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",3906.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",4172,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5267.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1142.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",971.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",769.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",752.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",708,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",619.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",663,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",666.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",625.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",688.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",595.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",595.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1865,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1684.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1355.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1337.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1403,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1450.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1613.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1756.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1849.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2095.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1927.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1876.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",15.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",13.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",10.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",9.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",9.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",7.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",8.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",8.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",7.7,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",8.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",7.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",7.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",25.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",22.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",18,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",17.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",18.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",18.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",20.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",21.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",22.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",25.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",23.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",22.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",11,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",11.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",10.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",10,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",9.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",9.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",9.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",9.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",9.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",9.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",8.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",8.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1440.3,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1526.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1581.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",1618.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1653,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1666.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1630.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2275.2,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",2386.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",2601.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",2473.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",2231.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",2144.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",2174.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",2052.8,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",2195.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",2263.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",2337.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",2400.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",2433.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",2370.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",35.7,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",37.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",40.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",38,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",34,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",32.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",32.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",32.2,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",34.3,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",35,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",35.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",36.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",36.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",35.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",10.5,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",10.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",9.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",9.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",8.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",8.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",8,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",108206.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",124669.7,"B","Break" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",133945.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",140586,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",153706.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",175733,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",190353.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",200656.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",207557.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",206047.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",163545.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",181298.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",237300,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",212.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",257.8,"B","Break" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",275.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",283.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",269.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",268.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",281.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",309.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",323.7,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",293.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",206.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",238.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",271.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",300.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",358.2,"B","Break" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",385.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",402,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",418.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",449.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",479.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",504.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",523.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",513,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",390.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",416.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",542.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",12.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",14.9,"B","Break" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",15.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",16.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",15.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",14.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",15.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",16.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",17.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",15.3,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",10.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",12.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",13.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",17.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",20.8,"B","Break" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",22.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",22.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",23.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",25,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",26.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",27.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",27.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",26.9,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",20.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",21.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",27.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",13.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",10.6,"B","Break" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",10.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",9.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",9.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",9.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",9.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",9.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",8.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",6.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",6.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",8.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",14.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",15.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",16.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",18.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",19.7,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",20.4,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",21.3,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",22.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",24.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",24.6,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",24.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",26.1,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",32.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",19.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",21,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",21.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",24.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",26.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",22.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",23.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",25,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",28.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",27.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",27.6,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",30.9,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",34.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",28.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",29.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",32,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",35.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",37.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",37.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",40.4,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",41.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",44.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",45.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",46.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",48,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",57,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",14.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",15.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",16.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",18.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",20,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",17.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",17.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",18.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",21.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",20.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",20.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",23.2,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",25.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",21.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",22.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",24.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",27.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",28.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",28.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",30.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",31.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",33.8,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",34.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",34.7,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",36.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",42.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",7.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",7.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",7.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",8.1,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",7.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",7.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",7.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",7.3,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",7.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",7.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",6.7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",6.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",7.5,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",29.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",29.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",28.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",27.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",26.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",26.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",27.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",25.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",24.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",25.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",36.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",40.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",38.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",40.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",36.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",36.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",35.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",29.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",30.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",28.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",28.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",28.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",31.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",42.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",42.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",45.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",46.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",46.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",46.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",45.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",44.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",47.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",44.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",42.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",46.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",50.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",64.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",73.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",18.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",19.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",17.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",17.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",17.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",14.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",14.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",14,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",13.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",13.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",15,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",20.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",20.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",22.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",22.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",22.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",22.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",21.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",21.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",22.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",21.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",20.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",22.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",24.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",30.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",34.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",5.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",5.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",5.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",4.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",4.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",4.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",5.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",542,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",562,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",586,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",617,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",634,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",618,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",629,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",650,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",633,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",668,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",743,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",746,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",497.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",579.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",606.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",595.7,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",571.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",464.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",467.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",498.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",472.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",464.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",511.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",560.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",360.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",371.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",380.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",426.4,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",436.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",419.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",433.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",439.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",430.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",451.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",511,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",515.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",22.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",25.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",26.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",25.8,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",24.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",19.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",19.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",20.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",18.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",18.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",19.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",21.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",16.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",16.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",18.4,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",18.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",17.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",17.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",19.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",20.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",5.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5.2,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",4.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",4.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",4.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",132.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",136.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",139.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",143.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",141.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",146.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",146.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",148.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",155.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",164.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",173.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",179,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",175.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",190.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",179.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",190.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",188.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",162.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",162.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",167.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",183.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",183.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",198,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",211.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",157.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",164.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",171.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",180.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",177.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",183.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",188.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",191.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",202.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",219.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",232.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",236.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",21,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",22.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",21.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",22.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",22.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",18.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",18.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",19,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",20.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",20.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",22.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",23.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",18.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",19.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",20.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",21.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",20.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",21.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",21.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",21.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",22.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",24.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",26,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",26.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",5.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",5.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",4.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",250.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",255.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",253.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",256.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",250.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",247.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",243.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",251.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",261.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",279.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",275.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",286.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",309.3,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",332.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",355.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",326,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",340.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",333.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",274.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",269.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",283.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",309.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",312.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",314.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",338.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",325.7,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",299.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",306.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",308.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",318,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",313.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",309.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",311.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",324,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",341.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",374.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",376.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",388.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",433.2,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",30.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",32.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",29.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",30.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",29.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",24.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",23.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",25,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",27.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",27.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",27.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",29.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",28,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",28,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",27.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",27.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",29.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",32.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",32.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",33.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",37.3,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",4.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",3.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",3.4,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1350.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1399.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1464,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1498.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1540,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1593.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1695,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1784.2,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1926.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1866.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",2060.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1351.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1358.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1325.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1171.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1161.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1227.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1308,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1344.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1436.7,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1488.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1583.4,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1085,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1143.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1189.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1200.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1275.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1314.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1404.8,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1445.1,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1565.1,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1507.7,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1643.6,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",38.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",38.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",37.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",32.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",32.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",33.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",35.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",35.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",37.8,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",38.9,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",40.7,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",31.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",32.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",33.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",33.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",35.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",36,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",37.9,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",38.4,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",41.1,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",39.4,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",42.3,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",5.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",5.5,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",5.6,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",5.6,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",5.1,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",5.2,"E; D","Estimated value; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",3200.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3155.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",3344.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",3073.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",3286.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",3432,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",3470.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",3722.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",3754.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",3906.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",3877.4,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",3971.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",167.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",178.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",170.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",157.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",158.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",139.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",142,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",159.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",172.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",170.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",167.1,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",183.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",234.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",236.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",251.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",240.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",258.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",265.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",275.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",299.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",303.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",318.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",311.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",311.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",16,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",17,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",16.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",14.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",15,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",13.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",13.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",15,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",16.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",16,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",15.6,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",17.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",22.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",22.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",23.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",22.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",24.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",25.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",26.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",28.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",28.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",29.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",29.1,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",29.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",4.4,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",95.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",93.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",95.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",92.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",90.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",87.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",90.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",92.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",93.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",91,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",93.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",90.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",126.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",130.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",123.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",122.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",120.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",97.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",100.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",104.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",110.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",101.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",107.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",106.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",106,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",104.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",105.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",102.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",100.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",96.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",102.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",107,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",109.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",108.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",114,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",109.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",23.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",24.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",22.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",22.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",22.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",17.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",18.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",19,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",20,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",18.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",19.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",19.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",19.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",19.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",19.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",18.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",18.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",17.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",18.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",19.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",19.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",19.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",20.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",19.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",5.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",4.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",3.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",3.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",3.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1723,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1670.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1625.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1687.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1708.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1697.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1743.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1776.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1903.7,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2018.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2103.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2181.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2284.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2325.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2088.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2241.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2270.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1883.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1929.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",2006.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",2248.2,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",2259.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2402.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",2579.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2140.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2117.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2065,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2178.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2222.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2181.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2316.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2385,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",2588.5,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",2772,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",2901.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",2962.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",27.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",29,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",26,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",27.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",28,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",23.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",23.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",24.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",27.1,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",27.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",28.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",31,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",26.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",26.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",25.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",27,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",27.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",26.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",28.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",28.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",31.2,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",33.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",34.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",35.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",5.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",5.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",5.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",5.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",4.3,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",4.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",4.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",4.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",322.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",315,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",277.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",247.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",247.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",211.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",260.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",267.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",279.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",284.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",295.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",298.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",282.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",427.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",438.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",356.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",328.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",328.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",234.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",288.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",301.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",330.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",318.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",337.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",353.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",297.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",446.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",441.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",405.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",391.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",404.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",347.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",442.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",464.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",495,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",519,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",542.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",547.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",534,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",38.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",39.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",32.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",29.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",30.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",21.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",26.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",28.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",30.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",29.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",31.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",33.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",28.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",40.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",39.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",36.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",35.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",37.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",32.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",41,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",43.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",46.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",48.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",50.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",51.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",51.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",27620.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",29340.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",28440.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",29536.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",29679.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",28986.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",29620.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",29875.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",30450.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",31314.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",33090.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",31572.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",32216.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",132.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",145.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",126.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",132,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",127.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",103.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",105.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",108.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",112.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",107.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",107.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",104.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",86.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",218.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",236.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",226.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",236.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",229.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",218.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",224.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",219.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",218.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",222.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",227.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",204,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",199.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",13.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",14.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",12.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",13.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",12.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",10.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",10.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",11.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",11.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",11,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",11,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",10.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",8.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",21.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",23.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",22.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",23.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",23.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",22.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",22.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",22.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",22.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",23.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",21,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",20.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",6.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",6.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",6.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",6.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",5.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",6.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",6.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",5.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",5.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",5.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1114.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1180.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1196.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1215.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1164.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1085.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1141.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1136.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1285.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1458.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1710.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1809.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",9.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",10.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",9.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",9.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",10,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",8.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",9.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",10.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",11.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",11.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",12.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",14.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",8.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",8.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",8.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",8.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",8.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",7.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",8.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",8.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",9.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",10.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",11.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",12.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",28.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",31.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",29.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",30.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",30.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",24.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",28.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",31,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",33.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",33,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",34.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",38.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",26.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",27.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",27.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",27.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",25.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",23.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",24.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",23.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",25.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",28.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",31.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",32.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",4.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",134.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",129.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",132.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",119,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",113.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",115.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",111.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",102.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",101.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",102.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",108.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",106.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",178.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",179.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",170.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",158.1,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",150.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",128,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",123.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",116.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",120.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",114.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",123.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",125.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",158.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",155.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",161,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",146.7,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",138.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",142.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",140.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",129.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",128.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",127.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",135.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",133.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",39.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",39.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",37,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",34.2,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",32.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",27.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",25.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",24.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",24.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",23.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",24.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",25,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",34.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",33.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",35,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",31.7,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",29.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",30.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",29.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",26.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",26.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",25.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",27.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",26.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",6.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",6.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",6.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",6.1,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",5.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",5.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",4.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",4.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",4.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1030.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1008.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",986.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1009.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1020.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",991.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",988.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1001.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1055.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1084.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1029.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1020.3,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1434.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1295.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1309.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1340.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1131.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1097.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1116.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1182.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1181.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1238.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1217.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1074.5,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1358.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1348.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1337.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1364.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1380.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1415.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1432.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1470,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1607.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1674,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1590,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1652.6,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",24.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",21.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",21.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",22.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",18.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",18.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",18.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",19.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",19.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",20.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",20.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",18.2,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",22.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",22.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",22.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",23.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",23.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",24.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",26.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",28.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",26.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",28,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",4.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",4.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",4.1,"E","Estimated value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",273823,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",307833.9,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",293533.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",287375.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",305537.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",314131.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",311925.5,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",311635,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",349710.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",368692.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",346455.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",346440.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",236.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",277.8,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",260.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",262.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",290.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",277.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",268.7,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",275.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",317.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",316.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",293.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",302.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",325.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",360.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",343.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",330.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",350.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",366.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",363.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",357.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",409.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",430.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",413.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",405.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",4.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",5.6,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",5.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",5.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",6.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",6.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",5.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",6.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",7.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",6.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",6.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",6.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",7.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",7.1,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",7.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",8.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",1.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",1.4,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",1.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",1.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",1.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",1.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",1.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",1.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",10.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",11,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",11.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",11.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",10.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",10.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",10,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",9.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",9.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",10.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",11.1,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",11.4,"D; P","Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",14.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",15.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",14.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",15.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",14.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",11.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",11,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",10.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",11.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",10.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",11.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",13.2,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",12,"D; P","Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",11.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",12.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",12.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",12.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",12,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",11.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",11.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",11.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",11.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",13,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",13.6,"D; P","Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",29.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",31.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",29.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",30.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",27.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",22.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",20.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",19.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",20.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",19.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",20.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",22.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",20.4,"D; P","Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",25.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",25,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",25.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",23.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",22.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",22.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",20.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",20.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",20.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",20.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",22.5,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",23.3,"D; P","Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",5.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",5.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",5.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",5.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.6,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",4.4,"D; P","Difference in methodology; Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",436,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",457.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",445.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",430.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",414.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",578,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",636.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",572.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",571.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",550.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",510.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",546.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",540.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",538.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",512,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",34.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",38.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",34.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",34,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",32.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",30.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",32.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",32.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",32.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",30.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",8.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",8.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",9.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",10,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",9.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",68.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",73.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",77.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",79.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",84.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",90.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",92.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",89.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",100.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",102,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",112.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",116.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",135.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",49.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",57.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",62.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",65.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",70.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",63.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",64.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",63.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",69.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",67.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",72.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",82.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",85.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",45.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",49.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",51.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",55,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",58.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",61.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",64.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",62.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",68.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",72,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",79.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",79.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",93.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",11.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",13.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",14.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",14.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",15.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",13.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",13.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",14.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",13.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",14.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",16.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",16.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",10.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",11.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",11.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",12.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",13,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",13.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",12.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",14,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",14.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",15.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",15.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",18.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",9.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",8.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",8.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",8.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",9.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",8.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",7.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",7.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",6.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",6.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",6.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",7.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1156,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1136,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1119,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1045,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1098,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1108,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1186,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1214,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1212,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1257,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1347,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1427,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1490,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",191.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",202.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",192.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",177.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",174.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",137.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",141.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",146.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",149,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",142.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",143.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",166.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",155,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",126.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",125.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",123.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",115.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",118.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",111.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",118.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",124.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",126.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",130.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",136.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",150,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",138.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",39.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",40.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",38.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",35,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",33.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",26.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",27,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",27.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",28.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",26.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",26.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",30.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",28.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",25.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",25.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",24.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",22.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",23,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",21.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",22.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",23.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",23.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",24.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",25.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",27.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",25.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",6.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",6.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",4.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",4.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",131.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",132.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",130.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",124.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",117.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",124.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",130.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",131.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",135.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",143.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",147.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",141.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",152.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",174.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",183.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",167.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",165.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",155.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",138,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",144.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",148.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",159.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",160.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",168.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",167.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",160.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",211,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",212,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",215.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",212.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",202.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",212.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",228.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",228.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",236.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",256.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",265.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",249.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",277.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",16.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",17.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",16,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",15.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",15,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",13.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",14,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",14.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",15.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",15.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",16.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",16.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",15.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",20,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",20.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",20.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",20.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",19.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",20.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",22.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",22.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",23,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",24.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",24.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",26.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",4.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",4.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",5.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",5.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",5.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",5.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",34.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",36.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",34,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",38.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",41.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",42.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",49.8,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",48.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",43.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",44.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",42.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",41.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",45.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",51.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",43.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",51.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",55.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",47.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",55.1,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",54.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",51.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",49.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",48.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",48.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",68.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",72.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",67.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",78.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",85.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",87.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",99,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",93.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",82.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",85.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",81.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",77.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",8.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",9.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",8.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",9.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",10.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",8.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",10.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",10,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",9.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",9.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",8.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",12.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",13.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",12.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",14.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",15.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",16.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",18.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",17.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",15.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",15.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",15,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",14.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",3.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",3.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",3.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",3.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",3.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",3.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",3.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",3.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1043.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1063,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",1009,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",945,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",985.8,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1007.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",981.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",961.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1143.7,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1176.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1191.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1189.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1243.9,"P","Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1383.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1479.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1296.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1255.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1309.6,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",1117.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",1086.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",1085.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1350.7,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1317.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1361,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1406.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1309.9,"P","Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1435.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1488.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1451.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1400.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1488.3,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1515.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1527.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1523.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1810.3,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1919.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1917.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1899.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2086.3,"P","Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",29.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",31.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",27.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",26.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",28.2,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",24.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",23.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",23.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",28.9,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",28,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",28.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",29.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",27.6,"P","Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",30.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",31.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",31,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",30,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",32,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",32.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",32.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",32.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",38.7,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",40.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",40.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",40.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",44,"P","Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",7.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",8.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",9.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",8.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",8.7,"B; D","Break; Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",8.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",8.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",6,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",5.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",5.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",5.4,"P","Provisional value" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1932.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1999.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",2058.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",2029.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1982.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1702.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1741.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1731.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1807.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1920.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",2097.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2019.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",2124.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",268.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",308,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",303.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",311.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",289,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",201.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",203.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",202.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",208,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",203.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",227.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",235.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",210,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",214.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",226.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",237.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",236,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",227.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",192.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",197.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",195.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",203.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",220.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",242,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",231.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",245.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",28.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",32.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",31.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",32.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",29.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",20.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",20.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",20.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",20.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",19.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",22,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",22.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",20.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",22.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",23.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",25,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",24.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",23.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",19.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",19.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",20,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",21.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",23.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",22.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",23.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",5.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",5.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",4.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",3.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",3.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",899,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",860,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",707.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",727.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",777,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",857.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",973.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1171.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1451.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1853,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",2231.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",2679.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",598.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",513.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",393.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",382,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",355,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",315.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",322.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",321,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",300.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",326.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",318.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",302.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",976.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",890.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",693.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",679.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",703.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",737.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",784.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",846.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",888.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",994.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1031.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",954.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",8.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",6.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",4.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",3.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",3.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",13.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",12,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",9.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",8.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",9.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",9.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",9.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",10.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",10.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",12,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",12.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",11.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",5.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",6.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",5.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",4.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",4.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",4.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",4.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",15206.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",26263.5,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",29207.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",30901.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",37615.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",46814.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",52879.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",56041,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",59206.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",57730.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",63661.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",80618.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",88464,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",29.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",54.3,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",60,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",62.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",66,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",71.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",78.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",86.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",92.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",82.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",80.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",106.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",101.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",42.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",75.5,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",84.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",88.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",102.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",119.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",133.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",140.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",149.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",143.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",152.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",185.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",202.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3.1,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",3.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",3.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",4.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",4.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.4,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",6.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",7.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",7.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",9.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",10.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.2,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",6.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",6.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",7.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",8.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",8.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",8.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",8.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",9.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",10.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",10.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",11.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",11.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",11.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",8.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",9.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",9.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",11.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",11.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",9.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",9.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",10.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",12,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",11.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",12.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",13.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",12.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",12.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",13.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",14.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",16,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",16.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",16,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",16.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",17.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",18.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",19.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",21.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",20.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",20.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",6.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",7.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",8.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",8.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",7.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",7.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",7.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",9.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",8.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",9.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",10.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",9.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",10.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",12.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",12.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",12.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",12.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",13.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",14.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",14.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",15.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",15.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",15.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",3.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",3.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",3.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",3.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",3.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",3.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",3.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",2.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",2.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",23,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",23,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",22.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",22.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",21.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",21.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",22.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",20.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",18.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",20.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",21.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",23,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",24.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",30.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",32,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",29.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",29.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",28.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",23.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",24.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",23.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",22.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",22.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",24.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",27.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",25.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",36,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",36.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",37.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",37.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",36.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",35.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",38.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",36.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",33.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",36.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",39.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",40.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",43.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",14.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",15.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",14.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",14.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",13.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",11.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",11.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",11.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",10.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",10.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",11.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",12.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",12.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",17.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",18,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",18.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",18.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",17.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",17.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",18.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",17.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",16,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",17.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",18.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",19.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",20.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",4.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",4.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",4.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",3.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",3.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",2266,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",2515,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",2822,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",3239,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",3616,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",3987,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",4356,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",4587,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",5280,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",5999,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",6768,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",7354,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",2078.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",2594.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",2921.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",3126.9,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",3259.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",2995.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",3238.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",3515.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",3945,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",4170.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",4657.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",5524.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1507,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1664.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1832.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",2238.2,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",2489.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",2705.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",3003.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",3104.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",3590.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",4053.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",4654.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",5080.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",94.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",116.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",128.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",135.2,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",138.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",125.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",133.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",142.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",158,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",164.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",181.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",215.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",68.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",74.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",80.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",96.8,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",106,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",113.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",124.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",126.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",143.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",160,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",181.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",197.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",23.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",24.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",27.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",27.4,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",30.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",32.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",28.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",31,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",35.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",38.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",40.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",41.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",583.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",617.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",664.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",712.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",767.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",832.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",920.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",987.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",1066,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",1155.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",1262,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",1380.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",773.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",859.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",853.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",946.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",1020,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",923.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",1018.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",1115.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",1258.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",1294,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",1441.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",1632.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",693,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",743.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",816.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",893.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",961.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",1041.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",1184.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",1274.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",1392.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",1543,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",1691,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",1824.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",92.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",102.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",101.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",111.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",119.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",106.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",116.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",126.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",142.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",145.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",161.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",182.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",82.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",88.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",96.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",105.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",112.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",120.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",135.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",144.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",157.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",173.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",189.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",203.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",23.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",24.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",25.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",27,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",27.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",28.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",30.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",31.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",33.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",34.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",36.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",37.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",1195.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",1234.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",1284.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",1324.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",1443.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",1560.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",1656.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",1910.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",2183.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",2606.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",2990.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",3268.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",3650.4,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1584.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",1719,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1650.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1759.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",1917.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",1731.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",1833.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",2158.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",2578.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",2918.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",3415.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",3865.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",3844.1,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1428.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1484.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1562.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",1643.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",1803.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",1950.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",2120.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",2463.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",2848.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",3491.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",4095.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",4436.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",5113.1,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",145.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",155.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",148.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",157.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",171.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",153.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",161.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",189.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",225.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",254,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",296,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",333.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",330.9,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",131.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",134.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",140.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",147.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",160.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",173,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",187.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",216.6,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",249.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",303.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",354.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",382.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",440.1,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",20.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",20.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",21.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",22.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",24.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",25.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",26.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",29.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",32.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",35.4,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",39,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",40.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",40.5,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",4584,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",5143,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",5547,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",6123.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",6771.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",7576.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",8470,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",9393.8,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",10533.4,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",11654.6,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",12657.3,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",4586.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",4992.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",5021.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",4788.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",5108,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",5837.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",6536.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",7080.1,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",7854,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",9294.8,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",9724.8,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",3683.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",4201.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",4508.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",4906.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",5609.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",6249.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",7020.2,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",7608.1,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",8556.3,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",9412.8,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",10094.9,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",132.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",142.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",141.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",134.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",141.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",159.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",176.3,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",188.3,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",206.5,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",243,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",250.1,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",106.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",119.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",127.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",137.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",155.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",171,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",189.4,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",202.3,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",224.9,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",246.1,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",259.6,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",18.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",20.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",21.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",22.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",23.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",25.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",27.7,"E; B; D","Estimated value; Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",29.5,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",30.7,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",31.6,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",31.7,"E; D","Estimated value; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",20004.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",19111.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",20008.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",19385.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",20371.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",22839.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",23953.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",25531,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",27722.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",30142.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",29470.5,"B","Break" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",31813.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",1047.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",1080,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",1022,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",990.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",981.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",928.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",980.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",1092.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",1275.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",1314.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",1269.7,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",1467.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",1463.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",1432,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",1504.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",1516.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",1603.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",1765.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",1904.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",2054.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",2240.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",2455.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",2365,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",2496.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",100,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",102.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",97.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",94.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",93.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",88,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",92.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",103.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",120,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",123.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",118.7,"B","Break" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",139.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",139.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",136.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",143.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",144.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",152.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",167.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",180.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",194,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",210.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",230.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",221.1,"B","Break" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",237.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",24.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",23.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",23.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",24.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",25.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",27,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",27.4,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",27.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",28.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",29.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",33.6,"B","Break" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",34.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",5687.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",5610,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",5976.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",6538.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",7193,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",7278.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",7562.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",8416.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",8988.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",8869.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",9157.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",9298,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",1011.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",1044.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",1031.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",1164.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",1281.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",1081.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",1123.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",1274.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",1423.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",1329.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",1399.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",1478.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",749.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",751.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",790.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",889,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",981.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",996.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",1068.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",1224.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",1328.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",1337,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",1397.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",1411,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",182.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",187.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",184.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",207.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",227.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",190.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",196.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",221.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",245.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",228.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",240.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",252.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",135,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",134.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",141.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",158.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",173.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",175.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",186.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",212.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",229.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",229.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",239.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",240.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",26.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",27.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",29.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",32,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",33.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",33.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",34.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",36.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",37.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",36.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",36.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",36.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",6585.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",6791.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",7344.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",8022.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",8741.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",9719.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",10572.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",11759.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",17675.4,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",19221.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",20725.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",22734.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",8730.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",9453.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",9435.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",10655.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",11612.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",10784,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",11702.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",13284.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",20873.8,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",21518.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",23672.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",26888.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",8179.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",8610.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",9328.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",10354.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",11368,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",12491.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",14047.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",15788.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",24033.5,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",26394.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",28586.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",30877.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",106.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",117.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",117.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",132.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",143.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",132,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",142.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",160.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",251.8,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",259,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",284.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",323.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",100,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",107.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",116,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",128.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",140.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",152.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",170.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",191,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",289.9,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",317.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",343.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",371.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",22.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",22.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",24.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",25.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",26,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",27.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",29.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",31.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",40,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",41,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",42.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",42.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",5683.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",8260.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",6983.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",6524.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",6288.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",6869.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",7341.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",8027.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",10229.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",10845.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",13383.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",15274.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",46.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",71.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",55.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",53.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",53.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",52.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",60.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",75.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",94.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",88.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",98.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",120.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",42.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",61.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",51,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",47.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",45.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",48.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",52.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",58.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",72.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",77.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",91.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",102,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",146.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",223.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",174.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",164.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",164.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",157.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",181.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",218.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",267.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",245.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",269.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",322.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",134.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",191.6,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",159,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",147.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",138.6,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",146.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",156.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",169.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",205.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",213.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",249,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",273.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",22.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",31.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",28.8,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",25.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",26.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",28.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",28.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",30.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",33.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",32.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",33.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",33.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",507.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",514.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",544.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",565.6,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",604.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",663.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",733.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",783.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",870.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",1040.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",1067.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",1177.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",673.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",716.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",699.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",751.2,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",803.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",736.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",811.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",885.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",1028,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",1165.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",1219.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",1392.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",597.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",619.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",661.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",697.2,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",738.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",819.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",923.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",986.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",1098.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",1291.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",1341.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",1481.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",147.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",156.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",152,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",162.5,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",172.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",156.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",170.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",184.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",211.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",236.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",244.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",276.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",131.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",135.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",143.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",150.8,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",158.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",174.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",194.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",205.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",225.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",261.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",269,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",294.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",24.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",26.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",26.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",28.9,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",31.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",33.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",35.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",36.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",38.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",43.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",43.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",44.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",2899512,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",3029486,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",3003413,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",3090356,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",3032529,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",3250399,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",3337024,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",3541392,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",3902278,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",5374795,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",5321541,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",5505328,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",33031.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",37960.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",37641.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",31664.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",28623.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",26853,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",30673.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",31572.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",35339.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",49305.7,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",49839,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",50160.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",25955.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",28193.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",28803.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",30506.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",29427.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",31414.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",31624.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",33694.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",37464.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",51568.7,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",51954.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",53947.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",257.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",296.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",295,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",248.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",225,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",211.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",241.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",249.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",279.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",390.8,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",395.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",399.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",202.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",220.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",225.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",239.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",231.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",247.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",249.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",265.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",296.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",408.7,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",411.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",429.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",42.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",43.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",43,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",44.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",46,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",48.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",50.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",52.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",56.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",56.6,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",57.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",60,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",5595610,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",5991080.2,"B","Break" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",6275160,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",6613982.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",7047389.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",7318854.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",7816107.1,"B","Break" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",8367494.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",9096656.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",9936708.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",10252126.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",11116136.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",4838.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",5406,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",5569,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",6040.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",6693.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",6471.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",6733.6,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",7398.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",8268.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",8526.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",8686.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",9717.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",6653.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",7010.5,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",7340.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",7610.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",8083,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",8535.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",9101.1,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",9588.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",10641,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",11602.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",12238.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",13015.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",97.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",108.3,"B","Break" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",110.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",119.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",131.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",126.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",131.5,"B","Break" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",144,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",160.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",164.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",167.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",187.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",134.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",140.4,"B","Break" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",146.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",150.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",159.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",167.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",177.7,"B","Break" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",186.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",206.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",224.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",236.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",251.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",27.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",27.2,"B","Break" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",28.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",29.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",29.8,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",29.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",30.8,"B","Break" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",31,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",31.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",32,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",31.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",32,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",40,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",42.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",55,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",68.6,"D; P","Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",44.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",49,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",65,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",72.2,"D; P","Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",47.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",50.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",64,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",82.5,"D; P","Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",80.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",86.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",113,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",123.1,"D; P","Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",85.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",88.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",111.3,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",140.6,"D; P","Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",19.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",20.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",22.9,"B; D; P","Break; Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",26.7,"D; P","Difference in methodology; Provisional value" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",17216,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",17014,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",15972,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",17807.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",17108.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",17559.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",19174.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",19800.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",19951.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",20779.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",20184.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",21170.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",24535.8,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",1362.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",1369.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",1212.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",1394.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",1287.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",1108,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",1027.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",1046.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",1036.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",1078.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",939.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",1044.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",1219,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",2241.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",2217.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",2032.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",2258.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",2126.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",2108.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",2270.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",2221.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",2150.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",2150.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",2010.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",2035.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",2319.9,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",12,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",11.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",10.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",11.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",10.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",9.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",8.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",8.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",8.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",8.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",7.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",8.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",9.4,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",19.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",19.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",17.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",19.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",17.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",17.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",18.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",17.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",17.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",17,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",15.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",15.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",17.8,"E","Estimated value" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",12.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",8.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",186.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",202.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",290,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",311.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",323.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",343.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",383.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",653.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",614.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",758.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",904.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",968.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",1012.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",134.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",160,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",234.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",255.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",268,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",239.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",267,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",464.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",425,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",499.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",586.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",685.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",641.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",124.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",136.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",193.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",215.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",224.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",232.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",266.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",456.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",417.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",535.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",640.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",664,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",701.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",30.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",36.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",53.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",57.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",59.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",51.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",56.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",96.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",86.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",100.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",115.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",134.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",125.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",28.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",31.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",44,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",48.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",49.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",50.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",56.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",94.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",85.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",107.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",125.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",129.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",137,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",24.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",24.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",31.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",33.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",33.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",34.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",35.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",51.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",46.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",50.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",54.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",54.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",53.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",4403,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",4498,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",4842,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",5243,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",6014,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",6491,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",7112,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",8018,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",8422,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",8490,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",9002,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",9822,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",9826,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",728.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",802.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",832.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",892.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",954.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",804.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",846.7,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",969.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",1035.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",964.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",956,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",1143.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",1022,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",481.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",495.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",535.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",580.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",648.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",653.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",708.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",822.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",878.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",882.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",911.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",1032.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",914.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",149,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",162,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",165.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",175.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",185.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",155.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",161.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",183.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",195,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",180.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",177.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",211.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",188.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",98.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",100,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",106.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",114.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",126.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",126,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",135.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",155.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",165.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",165,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",169.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",190.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",168.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",24.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",24.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",25.8,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",27.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",28.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",28.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",28.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",30.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",30.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",29.9,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",30.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",29.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",27.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",262.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",257.4,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",275.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",352,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",390,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",415.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",466.6,"B","Break" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",460.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",489.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",548.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",505.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",556.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",348.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",358.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",353.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",467.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",518.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",461.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",516.4,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",520.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",578.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",614.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",576.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",658.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",523,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",508.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",545.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",716.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",803.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",845.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",927.2,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",892,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",930.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",1060.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",971.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",1043.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",64.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",66.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",65.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",86.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",95.6,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",85.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",95.1,"B","Break" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",95.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",106.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",112.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",105.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",120.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",97,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",94.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",100.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",132.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",148.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",156,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",170.7,"B","Break" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",164,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",170.9,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",194.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",178,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",191.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",23.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",22.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",24.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",28.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",29.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",30,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",29.7,"B","Break" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",29.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",30,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",31.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",30.4,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",31.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",980.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",1030,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",1180,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",1238,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",1258,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",1291,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",1218,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",1298,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",1377,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",1454,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",1631,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",1772,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",1931,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",940.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",1159.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",1258.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",1335.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",1373.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",1341.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",1236.1,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",1318.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",1408.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",1463.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",1737,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",1939.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",2022.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",668.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",737,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",871.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",943.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",981.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",1044.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",1013.3,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",1092.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",1168.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",1263.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",1436.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",1601.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",1811.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",120.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",146.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",157.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",165.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",167.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",162,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",147.6,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",156,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",165.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",170.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",201.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",222.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",231.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",85.5,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",93.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",109,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",116.6,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",119.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",126.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",121,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",129.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",137.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",147.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",166.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",184,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",207.3,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",17.1,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",17.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",19.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",20.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",21.2,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",20.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",19.1,"B; D","Break; Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",19.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",20.8,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",21.7,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",23.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",24.9,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",25.4,"D","Difference in methodology" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",2757.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",2753.9,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",2842.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",3163,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",3698.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",4528.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",5484.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",5689.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",7358.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",9709.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",11913.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",15726.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1835.1,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",1644.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",1582.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",1661.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",1689.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",1664.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",1815.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",1559.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",1524,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",1711.3,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",1699.9,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",1776.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2996.6,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",2850.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",2787.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",2955.2,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",3348.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",3895.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",4419,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",4111.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",4507.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",5209.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",5504.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",5600.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",25.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",22.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",21.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",21.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",21.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",21.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",22.9,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",19.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",18.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",20.7,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",20.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",21.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",41,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",38.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",37.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",38.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",43.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",49.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",55.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",51.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",55.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",63.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",66,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",66.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",17.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",19.4,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",21,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",22.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",23.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",24.7,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",25,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",22.4,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",23,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",23.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",23.8,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",24.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",95614.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",166797.1,"B","Break" +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",169953.3,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",235364.6,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",218422.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",241259,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",272690.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",326087.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",374177.7,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",484298.5,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",497444.1,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",484621.8,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",444493.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",187.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",344.9,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",349.4,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",475.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",383,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",368.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",402.8,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",502.6,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",583.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",689,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",627.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",638.5,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",509,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",265.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",479.3,"B","Break" +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",489.5,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",673.1,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",594.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",616.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",686.4,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",820,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",944.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",1205.9,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",1188.8,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1113.7,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",1015.8,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",11,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",20,"B","Break" +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",20,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",27,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",21.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",20.5,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",22.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",27.3,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",31.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",36.1,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",32.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",32.4,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",25.7,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",15.6,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",27.8,"B","Break" +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",28.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",38.2,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",33.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",34.3,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",37.8,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",44.5,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",50.4,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",63.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",61.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",56.6,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",51.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",11.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",14.1,"B","Break" +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",13.6,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",16.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",14.1,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",13.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",13.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",15.8,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",16.3,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",19.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",18.5,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",17.2,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",15.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",3.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",3.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",3.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",3.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",3.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",2.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",2.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",6.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",6.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",6.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",6.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",6.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",7.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",7.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",8.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",9.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",8.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",3.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",3.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",3.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",2.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",2.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",12,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",11.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",11.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",10.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",10.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",10.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",9.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",9.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",9.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",9.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",9.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",10,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",10.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",2.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",2.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",2.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",2.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",6.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",6.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",6.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",6.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",6.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",6.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",6.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",6.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",18.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",18.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",18.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",18,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",17.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",16.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",14.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",13.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",13.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",12.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",12.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",11.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",1.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",4.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",4.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",4.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",4.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",4.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",3.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",3.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",9.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",9.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",9.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",10.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",9.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",10.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",15,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",15.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",15.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",13,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",13.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",11.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",10.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",5.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",5.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",5.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",5.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",5.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",5.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",5.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",6.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",7.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",7.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",7.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",7.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",7.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",7.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",6.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",6.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",8.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",3.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",4.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",4.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",3.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",3.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",3.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",13,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",13.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",13.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",13.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",13.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",13.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",12.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",12.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",13.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",13.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",14.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",14.4,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",6.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",6.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",6.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",6.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",6.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",5.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",5.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",4.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",4.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",4.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",4.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",276.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",289.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",295.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",307.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",315.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",331.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",369.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",392.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",411.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",426.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",447.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",458.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",521.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",35.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",38.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",38.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",40.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",42.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",45.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",49.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",50.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",52,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",56,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",60.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",65.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",75.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",4.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",4.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",4.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",4.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",5.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",5.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",5.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",6.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",7.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",15.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",16.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",16.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",17.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",18.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",19.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",21.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",22.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",22.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",24.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",27,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",29.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",34,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",18.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",18.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",19.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",20.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",22.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",23.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",24.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",28.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",31.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",38.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",40,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",43.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",45.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",52.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",53.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",55.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",55.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",54.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",53.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",54.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",56.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",56.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",59.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",57.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",58,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",60.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",3.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",6.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",6.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",7.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",7.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",7.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",7.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",6.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",3.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",3.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",1.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",1.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",1.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",18,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",18.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",19,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",19.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",19.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",18.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",18.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",19.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",20.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",20.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",19.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",18.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",18.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",7.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",7.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",7.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",6.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",5.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",5.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",5.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",6.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",6.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",7.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",8.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",9.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",10.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",12.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",13,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",13.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",13.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",14.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",14.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",14.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",14.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",14.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",15.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",14.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",14.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",16.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",5.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",5.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",5.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",6.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",6.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",6.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",7.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",8.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",4.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",5.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",5.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",6.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",6.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",6.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",25.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",26.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",29.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",32,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",31.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",35.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",55.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",60.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",65.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",55.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",62.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",51.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",57.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",9.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",9.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",9.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",9.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",10.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",10.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",10.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",9.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",9.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",10.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",18.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",19.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",19.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",20.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",20.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",21.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",22.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",24.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",25.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",28.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",29.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",31.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",35.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",10.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",11.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",11.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",13,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",13.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",15.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",15.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",16.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",16.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",19.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",33.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",33.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",33.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",33.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",33.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",34.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",35.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",37.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",39,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",41.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",43.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",46,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",52.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",7.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",7.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",7.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",7.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",7.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",7.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",7.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",8.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",8.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",9.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",10.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",12.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",16.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",2.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",3.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",4.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",4.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",3.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",4.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",20.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",21.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",22.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",23.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",24,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",24.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",25.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",27.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",28.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",29.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",27.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",28.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",43.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",8.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",8.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",9.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",9.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",9.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",9.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",9.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",9.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",9.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",9.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",9.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",10.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",365.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",406.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",379.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",408.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",419.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",367.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",408.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",443.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",485.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",477.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",511.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",542.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",549.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",47.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",53.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",49.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",53.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",56.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",50.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",54.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",57,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",61.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",62.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",68.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",77.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",79.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",5.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",6.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",5.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",6.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",6.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",5.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",5.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",5.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",6.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",6.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",7.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",20.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",23.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",21.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",22.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",24,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",22,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",23.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",25.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",26.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",27.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",30.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",34.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",35.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",24.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",26.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",25.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",27.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",29.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",25.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",27.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",32,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",37.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",42.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",45.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",51.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",48.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",69.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",75.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",70.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",73.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",72,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",59.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",60.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",64.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",67.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",66.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",65.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",68.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",63.3,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",3.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",3.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",3.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",4.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",4.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",2.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",2.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",2.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",3.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",3.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",3.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",3.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",8.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",9.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",9.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",10,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",8.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",8.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",8.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",8.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",7.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",5.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",5.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",4.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",4.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",23.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",25.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",24.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",25.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",25.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",20.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",20.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",22.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",23.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",23,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",22.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",22.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",19.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",9.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",10.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",9.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",9.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",7.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",5.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",6.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",7.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",8.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",9.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",11.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",16.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",18.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",16.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",18.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",19,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",15.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",15.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",16.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",17.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",17,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",16.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",17.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",17.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",7.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",8.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",7.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",8.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",6.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",6.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",7.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",7.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",8.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",8.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",8.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",6.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",6.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",7.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",7.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",7.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",6.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",33.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",37.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",37.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",42.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",41.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",39.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",61.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",68.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",77,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",62.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",71.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",60.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",60.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",12.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",13.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",12.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",12.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",13,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",11,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",11.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",12,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",12.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",11.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",11.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",11.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",24.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",26.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",24.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",26.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",27.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",24.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",25.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",27.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",30.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",32.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",33.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",36.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",37.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",13.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",15.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",14.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",16.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",17.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",15.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",16.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",17.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",18.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",18.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",18.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",19.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",20.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",43.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",47,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",43,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",44.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",44.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",38.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",39.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",42.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",46.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",46.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",50.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",54.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",55.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",9.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",10.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",9.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",9.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",9.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",8.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",8.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",9.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",10.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",10.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",11.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",15.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",17.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",3.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",3.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",3.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",3.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",3.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",3.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",4.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",5.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",5.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",3.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",4.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",27.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",30,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",28.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",30.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",31.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",26.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",28.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",31.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",34.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",33.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",31.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",33.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",46,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",11.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",12.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",11.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",12.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",12.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",10.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",10.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",11,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",11.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",10.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",11,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",11.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",567.2,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",581.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",583.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",616,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",634.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",666.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",762,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",810.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",839.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",876.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",926.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",901.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",1024.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",73.5,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",76.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",76.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",81.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",85.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",91.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",101.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",104,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",106.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",114.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",124.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",128.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",147.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",0.9,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",1.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",1.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",8.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",8.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",9.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",9.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",9.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",10.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",10.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",10.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",12.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",13.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",14.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",31.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",33.7,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",33,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",34.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",36.3,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",39.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",43.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",46.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",46.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",49.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",56,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",57.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",66.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",38.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",38,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",38.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",41.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",44.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",46.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",50.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",58.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",64.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",78.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",82.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",85.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",90.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",107.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",108.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",108.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",110.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",108.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",107.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",113.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",117.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",116.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",121.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",119.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",113.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",118.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",0.2,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",0.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",1.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",1.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",1.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",1.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",2.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",2.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",5.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",5.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",5.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",6.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",6.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",7.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",7.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",7.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",7.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",7.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",6.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",5.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",4.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",4.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",4.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",4.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",4.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",4.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",5.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",5.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",5.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",6.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",6.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",13.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",13.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",13.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",14.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",15.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",15.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",16.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",16.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",14.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",14.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",12.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",12.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",8.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",7.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",7.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",6.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",6.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",5.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",4.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",4.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",3.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",36.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",36.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",37.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",39,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",38.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",37.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",38.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",40.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",40.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",42.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",40.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",36.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",36,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",14.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",15.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",15,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",13.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",11.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",10.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",11.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",12.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",13.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",17.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",18.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",20.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",25.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",26.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",25.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",27.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",28.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",28.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",29.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",30.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",30.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",31.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",29.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",28.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",32,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",11.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",11.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",11.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",12.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",12.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",12.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",12.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",13.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",13.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",14.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",13.4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",15.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",9.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",10,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",10.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",11.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",11.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",12.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",12.6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",13,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",13.2,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",12.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",12.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",52.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",53.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",57.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",64,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",62.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",70.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",114.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",124.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",133,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",113.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",129,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",100.6,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",112.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",19.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",19.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",18.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",19.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",19.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",19.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",20.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",21.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",21.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",21.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",20.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",19,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",21,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",37.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",38.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",38.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",40.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",41.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",43.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",47.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",50.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",52.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",59.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",60.4,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",61.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",70.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",21.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",22.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",22.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",24.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",26.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",28,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",30.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",31.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",32.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",33.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",33.6,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",33,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",38.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",67.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",67.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",66.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",66.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",67.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",69.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",72.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",77.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",79.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",85.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",90.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",90.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",103.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",14.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",14.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",14.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",14.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",14.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",15.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",16.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",17.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",18,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",19.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",21.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",25.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",32,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",4.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",4.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",4.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",5.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",5.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",5.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",6.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",6.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",5.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",5.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",5.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",6.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",6.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",6.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",7.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",8.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",9.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",9.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",4.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",4.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",4.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",4.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",5.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",5.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",5.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",6.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",6.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",6.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",42.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",43,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",44.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",46.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",48.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",48.8,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",53,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",57.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",58.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",61.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",56.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",55.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",85.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",17.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",17.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",18,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",18.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",19.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",18.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",19.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",20.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",19.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",19.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",19.9,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",18.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",21,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",174.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",197.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",186.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",202.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",210.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",186,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",208.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",228.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",252.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",249.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",268.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",288,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",293,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",22.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",25.9,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",24.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",26.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",28.4,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",25.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",27.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",29.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",31.8,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",32.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",36.2,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",41.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",42.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",0.2,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",0.3,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",2.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",3.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",3.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",3.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",4.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",4.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",9.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",11.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",10.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",11.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",12,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",11.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",11.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",13,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",13.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",14.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",16.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",18.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",19.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",11.8,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",12.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",12.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",13.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",14.7,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",13,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",13.9,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",16.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",19.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",22.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",24,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",27.2,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",25.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",33,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",36.7,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",34.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",36.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",36.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",30.1,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",31,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",33,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",34.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",34.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",34.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",36.4,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",33.8,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",0.3,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.6,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",2.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",2.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",2.4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.5,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",1.8,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1.9,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",1.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",4.1,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",4.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",4.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",4.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",4.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",4.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",4.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",4.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",3.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",3.9,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",3.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",2.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",2.3,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",11.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",12.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",12,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",12.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",12.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",10.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",10.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",11.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",12.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",12,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",11.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",11.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",10.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",4.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",5.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",4.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",3.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",3.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",4.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",5.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",5.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",7.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",8.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",8.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",9.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",9.5,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",7.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",8.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",8.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",8.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",9.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",9.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",3.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",3.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",4.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",3.5,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3.8,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",4.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",4,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",4.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",4.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",2.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",3.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",3.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",3.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",3.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",4.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",3.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",16.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",18.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",18.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",21.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",20.7,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",19.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",31.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",35.2,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",39.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",32.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",37.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",32.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",32.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",5.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",6.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",6.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",5.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",5.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",6.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",6.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",6.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",5.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",6.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",11.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",13,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",12.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",13.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",13.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",12.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",12.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",14.3,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",15.7,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",16.9,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",17.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",19.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",20,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",6.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",7.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",7.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",8.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",8.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",7.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",8.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",9.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",9.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",9.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",10.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",11,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",20.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",22.8,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",21.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",22,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",22.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",19.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",19.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",21.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",23.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",24.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",26.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",28.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",29.7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",4.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",4.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",4.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",4.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",5.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",5.6,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",6.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",8.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",9.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.5,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.5,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.7,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",2.1,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.4,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.8,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",1.9,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",2.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",2.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",13,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",14.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",14.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",15.3,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",16,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",13.6,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",14.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",16.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",17.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",17.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",16.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",17.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",24.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",5.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",6.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",6.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",6.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",5.1,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",5.2,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",5.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",5.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",5.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",5.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",270.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",282.3,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",286.8,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",306.1,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",318.5,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",337,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",388.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",417.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",435.6,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",457.9,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",487.7,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",478.4,"D","Difference in methodology" +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",546.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",35,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",37.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",37.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",40.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",43,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",46.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",51.7,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",53.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",55,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",60.1,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",65.6,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",68.3,"D","Difference in methodology" +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",78.8,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",4.3,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",4.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",4.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",5.4,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",5.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",5.6,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",6.5,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7.2,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",7.1,"D","Difference in methodology" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",7.6,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",14.9,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",16.4,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",16.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",17.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",18.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",20.1,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",22.2,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",23.8,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",24,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",26,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",29.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",30.5,"D","Difference in methodology" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",35.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",18.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",18.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",19,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",20.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",22.3,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",23.5,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",26,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",30.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",33.4,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",41.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",43.6,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",45.1,"D","Difference in methodology" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",48,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",51.2,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",52.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",53.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",55,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",54.6,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",54.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",57.9,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",60.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",60.3,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",63.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",62.8,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",60.5,"D","Difference in methodology" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",63,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.6,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",1.2,"D","Difference in methodology" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.5,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.8,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",3.7,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",4.1,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",4,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.4,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",2.6,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",2.7,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.1,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.3,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",3.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",6.4,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",6.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",6.8,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",7.2,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",7.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",8.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",8.3,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7.7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",7.6,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",6.5,"D","Difference in methodology" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",3.8,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",3.6,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",3.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",2.4,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",2.1,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",1.7,"D","Difference in methodology" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",17.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",17.9,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",18.5,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",19.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",19.3,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",19,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",19.8,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",21.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",21.2,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",22.1,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",21.4,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",19.6,"D","Difference in methodology" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",19.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",7.1,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",7.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",7.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",5.4,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",5.9,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.6,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",8.5,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",9.3,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",9.8,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",12.2,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",12.7,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",12.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",13.8,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",14.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",14.4,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",15.9,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",15.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",15.6,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",15.1,"D","Difference in methodology" +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",17.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",5.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",5.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",6.3,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",6.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.9,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",7.6,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7.2,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",7.1,"D","Difference in methodology" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",8.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",4.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",5.3,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",5.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",6,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",6.4,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.5,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",6.7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",6.9,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",25,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",26.1,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",28.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",31.8,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",31.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",35.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",58.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",64.3,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",69,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",59.5,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",67.9,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",53.4,"D","Difference in methodology" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",59.8,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",9.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",9.2,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",9.5,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",9.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",10.6,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",11.3,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",10.9,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",11.4,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",10.7,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",10.1,"D","Difference in methodology" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",17.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",18.6,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",18.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",20,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",21,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",22.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",24,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",26.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",27.1,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",31,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",31.8,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",32.5,"D","Difference in methodology" +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",37.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",10.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",10.9,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",11.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",13.1,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",14.2,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",15.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",16.4,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",16.8,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",17.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",17.7,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",17.5,"D","Difference in methodology" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",20.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",32.4,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",32.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",32.5,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",33.1,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",34,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",35.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",37.2,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",39.7,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",41.3,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",44.6,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",47.9,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",48,"D","Difference in methodology" +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",55.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",7,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",7.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",7.1,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",7.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",7.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",7.8,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",8.4,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",8.9,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",9.3,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",10.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",11.2,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",13.5,"D","Difference in methodology" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",17,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3.1,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.4,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",2.6,"D","Difference in methodology" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.6,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",3.2,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",4.3,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",4.9,"D","Difference in methodology" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",5.1,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.2,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.5,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.6,"D","Difference in methodology" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",4.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",20.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",20.9,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",21.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",23.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",24.2,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",24.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",27,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",29.4,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",30.5,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",32.1,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",29.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",29.7,"D","Difference in methodology" +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",45.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",8.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",8.7,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",8.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",9.6,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",9.3,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",9.8,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",10.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",10,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",10.4,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",10.5,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",10,"D","Difference in methodology" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",3.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",4.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",5.5,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",4.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",4.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",4.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",3.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",4.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",5.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",5.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",6.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",7.2,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",6.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",5.5,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",6.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",6.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",5.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",6.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",5.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.3,"B","Break" +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",314.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",501.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",591.5,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",622.3,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",656.4,"B","Break" +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",830.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",868.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",941,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",809.4,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",624.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",555.8,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",827.2,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",786.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",14.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",14.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",14.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",15.4,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",19.2,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",16.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",16,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",19,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",21.8,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",28.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",26.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",29.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",24.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.6,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",3.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break" +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",2.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",2.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",2.5,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.3,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",2.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",2.7,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",3.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",3.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",3.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",3.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1900.8,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1973.1,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",2104.9,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1969.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",2949.9,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1710.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1683.6,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1908.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2382.3,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",2725.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",2369.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",2916.5,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",2082.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",2333.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",2218.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",2194.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",2416.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",2700.8,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",2298.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",2333.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",2446.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2655.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",2947,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",2647.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",5575.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",5031.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",3.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",4.6,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",4.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",12.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",11.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",10.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",9.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",4.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",4.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",5,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",4.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",4.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",7.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",1.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",1.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",1.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",1.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.7,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",5.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",6.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",7.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",7.9,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",7.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",7.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",8.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",8.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",9.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",9.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",10.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",8.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.1,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",18.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",16.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",14.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",14.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",16.3,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",13.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",14.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",12.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",11.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",12.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",10.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",8.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",4.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",4.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",5,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",5.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",9.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",8.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",9.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",272.4,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",277.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",282.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",314,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",351.2,"B","Break" +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",348.3,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",355.5,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",399.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",477.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",602.8,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",557.9,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",418.6,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",394.8,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",2715.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",2834,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",3318.6,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",3557.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",4269.6,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",4018,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",4281.7,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",4591,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",4795,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",5364.2,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",5744.4,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",6260.3,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",5540.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",2.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",2.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",2.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",4.9,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",4.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",4.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",3.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",3.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",4.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",2.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",3.2,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",3.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",4.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",4.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",4.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",4.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",3.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.7,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.4,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.4,"B","Break" +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",7.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",6.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",6,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",6.6,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",6.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",7.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",7.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",7.5,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",7.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",6.8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.4,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",2.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",2.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",2.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",2.2,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.3,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",649.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",749.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",765.2,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",975.1,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",864,"B","Break" +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",882.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",927.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1006.5,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1082.3,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1422.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1514.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1764.4,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1483.9,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",11435.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",11848,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",12208.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",14811.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",18566,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",16694.8,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",15990.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",15352.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",17700.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",20126.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",16108.2,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",20289.6,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",19316.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",1.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",1.2,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",1.2,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",1.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",1.6,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",1.7,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",1.4,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",1.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",1.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",1.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",1.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",1.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",1.6,"B","Break" +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",1.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",1.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",1.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",1.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.6,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.8,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",2.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",21.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",23.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",24.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",29.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",34.5,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",31.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",29.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",27.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",30.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",34.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",27.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",32.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",29.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.6,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",55.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",73.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",74.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",114,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",71.7,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",64.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",75.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",76.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",91,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",131,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",136.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",154.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",121.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",3327.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",3103.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",3202.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",3657.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",4275.6,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",3675.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",3104.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",3015.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2987.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",3517.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",4240,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",5193.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",4805.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",1.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",1.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",1.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1.2,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",1.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",1.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",1.5,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.6,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",0.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",0.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",0.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",11.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",9.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",8.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",8.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",10,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",10.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",11.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",11.6,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",12.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",13.4,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",13.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",14.3,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",12.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",8.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",8.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",9.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",10.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",12.1,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",11.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",12.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",13.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",14.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",16.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",17.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",18.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",16,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.5,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3.1,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",2.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.2,"B","Break" +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",2.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",2.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",2.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",2.6,"B","Break" +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",2.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",2.1,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",2.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",2.6,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",3.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",2.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",3.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",2.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",17239.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",14773.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",13948.3,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",14080.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",16847.2,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",17281.8,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",19042.5,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",19558.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",20937.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",22322,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",22117.7,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",25408.9,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",22871,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1530.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1662.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1763.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1915.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1674.9,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1858.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1877.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1901.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1715.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1506.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1339.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1681,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1475.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",32.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",29.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",27.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",28.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",31.3,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",32.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",35,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",34.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",36.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",38,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",37.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",40.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",35.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",4.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",4.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",5.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",8,"B","Break" +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",7.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",7.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",8.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",9.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",14.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",14.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",14.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",15,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",2.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",2.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",2.5,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.4,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.5,"B","Break" +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",5.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",5.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",6.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",5.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",8.4,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",4.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",8.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",7.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",8.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",7.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",7.7,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",7.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",11,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",9.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",9.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",9.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",10.5,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",12.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",9.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",11.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",10.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",7.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",6.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",6.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",6.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",7.6,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",6.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",6.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",7.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",8.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",16.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",14.5,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.1,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.7,"B","Break" +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.7,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",1.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",1.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1.4,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",1.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",2.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",2.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",2.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",2.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",2.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.9,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",1.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",1.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",1.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.1,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.7,"B","Break" +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.8,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.1,"B","Break" +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.6,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.9,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",3.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",2.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",1.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2.1,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",2.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",2.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",2.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",2.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",2.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.4,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.3,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3.2,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",2.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",1.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1450,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1540.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1696.3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1924,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",2811.6,"B","Break" +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",2634.7,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",2631.2,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",2796.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",3307.8,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",4698.6,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",4616,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",5044.9,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",5191.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.3,"B","Break" +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.2,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1617.5,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1440.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",933.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1043,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1118.1,"B","Break" +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1278.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1494.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1423.3,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1429.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1564.6,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1400.7,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1403.9,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1269.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",3.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",5.2,"B","Break" +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",4.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",4.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",4.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",5.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",7.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",8.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.5,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",0.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",0.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",10.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",9.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",9.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",10.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",12.1,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",10.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",9.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",8.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",8.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",10.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",12.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",15.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",13.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.9,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",2.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",2.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",2.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",2.4,"B","Break" +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",2.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",2.7,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",3.2,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",4.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",5.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",4.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.4,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.3,"B","Break" +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.3,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",157,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",132.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",126.1,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",137.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",227.2,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",200.6,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",201.9,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",185.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",131.8,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",110.4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",96.3,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",114.7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",90.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",3.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3.3,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",5.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",4.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",5.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",4.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",488,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",671.9,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",364.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",406.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",427.6,"B","Break" +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",413.6,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",427.5,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",405,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",426.4,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",470.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",474.1,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",516.7,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",461.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",2.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",2.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",6.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",5.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.1,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1443.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",996.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1212.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1436,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1623.3,"B","Break" +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1579.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1357.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1954.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2352.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",4129.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",3669.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",3703.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",3442.2,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.8,"B","Break" +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1471.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1661.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1597.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1682.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1766.7,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1760.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1812.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",2033.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2534.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",3072.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",2721.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",3171,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",2788.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",6059.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",5512.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",4854,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",5081.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",5751.6,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",4904.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",5106.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",4383.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",3832.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",3984.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",3027.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",3675.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",3049.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",52.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",44.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",40.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",40.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",47.7,"B","Break" +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",48.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",55.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",57.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",62,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",67.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",67.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",73.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",66,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.3,"B","Break" +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",166.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",129.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",141.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",138.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",176.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",195.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",213,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",212,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",190.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",187,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",133.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",298,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",134.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",3.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",3.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",3.2,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",3.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",4,"B","Break" +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",3.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",3.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",3.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",4.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",5.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",5.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",5.7,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",4.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",6.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",6.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",6.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",7.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",7.9,"B","Break" +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",6.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",5.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",5.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",5.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",7.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",8.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",7.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.3,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.9,"B","Break" +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",1.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",1.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",1.3,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",1.4,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",1.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",1.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",9.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",9.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",10.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",10.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",12.6,"B","Break" +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",10.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",10.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",11.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",12.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",16,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",14.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",16.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",13.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.1,"B","Break" +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",4821.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",4872.5,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",5057.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",5356.4,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",6768.8,"B","Break" +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",5719.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",5484.2,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",6494.7,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",7363.9,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",9396,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",8609,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",10195,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",8505.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",924.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",886.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1000.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1381.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1732.8,"B","Break" +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1648.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1689.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1838.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1590.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1394.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1250.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1377.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1170.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",5.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",5.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",4.7,"B","Break" +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",5.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",5.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",5.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",4.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",4.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",4.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break" +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",1.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.8,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",1.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",1.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break" +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",286.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",347.1,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",379.8,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",394,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",481.8,"B","Break" +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",519.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",539.3,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",625.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",703.5,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",755,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",837.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",968.4,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",833.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",35,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",35.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",35.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",42.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",52.6,"B","Break" +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",47.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",46.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",45,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",52.4,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",61.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",49.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",59,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",55.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",175.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",177.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",204,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",276.6,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",319.1,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",362.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",298.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",364,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",425,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",424.5,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",459.7,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",513.3,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",444.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break" +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",0.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",4.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",3.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",3.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",3.4,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",2.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.8,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.6,"B","Break" +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.6,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.7,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.4,"B","Break" +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.5,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.1,"B","Break" +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1.1,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.2,"B","Break" +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.2,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",1.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",1.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",1.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",1.5,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.7,"B","Break" +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1.6,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",11.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",10.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",9.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",10.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",10.7,"B","Break" +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",9.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",9.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",7.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",6.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",6.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",5.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",5.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",4.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",1.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",1.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",1.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1.9,"B","Break" +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",2.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",2.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",2.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",2.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",2.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",2.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.1,"B","Break" +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3.4,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",3.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",3.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",3.2,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",2.9,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",2.8,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.6,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2.3,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",2.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",2.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",2.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",2.3,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.4,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.9,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.7,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.6,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.7,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.8,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.9,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",13.2,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",13.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",14,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",13.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",13.8,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",13.7,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",13.3,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",13,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",12.5,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",11.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",10.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",9.3,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",9.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",9.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",8.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",8.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",8.2,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",7.8,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",8.4,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",9.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",9.1,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",9.3,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",8.5,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",14,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",2.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",2.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",2.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",2.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",4.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4.9,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",4.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",2.5,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",2.4,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",2.3,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.1,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.2,, +"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",4.4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",4.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",3.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",4.9,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",4.7,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",4,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",3.1,, +"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.8,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.7,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.6,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.5,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.4,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.3,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.2,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.9,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",3.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",3.7,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.6,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3.2,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",3,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2.8,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",2.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",20.2,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",19.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",19.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",18.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",15.5,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",14.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",13.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",12.8,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",12,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",10.7,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",10.3,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",8.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",4.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",3.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",2.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",2.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",16.2,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",16,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",16.1,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",15.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",15.9,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",15.4,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",14.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",13.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",13,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",11.6,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",11,, +"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",9.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.4,, +"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.4,, +"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5.9,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",5.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",5.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",5.7,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",5.8,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",5.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",5.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",5.1,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",4.5,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",3.6,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",3.2,, +"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",3.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.2,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.1,, +"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.1,, +"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.9,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.8,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.7,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.5,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.4,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.2,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.1,, +"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1,, +"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",4.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",4.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",3.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",3.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",2.2,, +"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",5.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",5.6,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",5.5,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",7.7,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",8.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",7.8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",8.1,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",8,, +"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",7.9,, +"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",7,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",6.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",6.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",6.4,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6.6,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",6.2,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",5.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",5.8,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",5.5,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",4.9,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",4.2,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.9,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.8,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.7,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.6,, +"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.2,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.1,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.8,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.7,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.6,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.5,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.4,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.2,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.1,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.9,, +"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",5.1,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",5.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",5.8,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6.5,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",6.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",6.7,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",6.3,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",5.6,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",5.4,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",4.9,, +"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",6.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",7.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",6.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",5.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",5.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",4.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",3.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",3.4,, +"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",3.2,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1338515.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",83.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",91.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",96.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",101.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",105.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",110.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",116.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",120.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",122.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",128.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",133,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",130,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",32.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",13.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",204.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",227.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",213.6,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",221.3,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",214.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",188,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",205.4,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",220.1,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",242,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",248.7,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",250.8,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",275,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",6.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",5.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",6.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",5.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",6.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",5.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",5.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",5.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",5.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",4.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",3.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",609.1,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",126.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",151.8,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",152.4,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",129.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",133.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",126.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",107.3,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",129.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",167.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",177.2,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",199.7,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",201,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",414.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",467.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",494.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",462.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",430.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",423.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",349.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",362,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",358.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",369.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",348.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",369.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",401.6,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",120.9,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",121.4,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",135.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",142.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",152.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",181,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",238.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",272.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",287,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",356.2,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",396.1,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",456,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",11.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",55.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",470.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",501.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",507.9,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",472.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",314.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",356.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",327.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",337.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",352.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",370.3,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",395.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",400.2,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",76.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",85.3,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",83.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",93.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",98.1,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",89.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",102.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",112.4,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",121.7,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",120.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",128.9,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",144.9,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",53.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",57.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",55.4,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",58.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",59,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",52.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",57.6,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",60.3,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",66,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",63.7,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",71.8,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",75.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",4.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",4.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",3.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",4.5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",5,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",5.1,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",5.3,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",4.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",5.6,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",5.8,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",5.9,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",4.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",116.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",140.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",154.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",187.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",191.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",208.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",233.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",258.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",268.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",269.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",273.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",279.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",2.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",35.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",63.1,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",378.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",35.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",36.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",34.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",36.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",39,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",33.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",35,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",38.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",44.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",45.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",47,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",39.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",8.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",8.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",8.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",8.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",8.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",8.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",8.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",8.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",8.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",7.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",7.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",163,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",166,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",163,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",161,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",160,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",165,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",172,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",179,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",186,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",196,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",197,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",199.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",10.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",11.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",12.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",14.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",15.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",15.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",17.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",19.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",20.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",20.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",18.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",24,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",175.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",165.1,, +"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",143.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",1583.2,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",27.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",28.6,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",26.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",27.3,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",27.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",23.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",24.4,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",24.8,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",26.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",26,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",26.5,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",27.9,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",146,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",145,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",137,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",123,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",114,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",102,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",98,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",83,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",79,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",68,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",63,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",57,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",1.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",27,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",97.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",12.4,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",13.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",13,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",13.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",13.9,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",12.5,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",13.8,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",14.6,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",16.1,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",15.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",17.7,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",19.2,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",361.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",389.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",392.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",398.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",393.4,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",401.1,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",409.9,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",414.7,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",452.8,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",506.3,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",564.5,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",548.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",2.2,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",261.9,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",296,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",1896.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",1975.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",2066.6,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",1993.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",1654.3,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",1677.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1731,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1779,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1802.2,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1915,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",2055.5,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",2035.7,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",389.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",407.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",377.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",389.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",377.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",326.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",333.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",354.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",358.8,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",310.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",304.2,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",361.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",41.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",44.5,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",46.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",46.6,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",45.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",45.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",47.7,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",50.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",52.4,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",55.3,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",55.1,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",86,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",87,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",89,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",88,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",90,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",91,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",92,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",90,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",91,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",93,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",94,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",93,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",153.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",383.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",401.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",413.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",343.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",267.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",244.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",249.5,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",262.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",277.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",300,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",285.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",300.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",22.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",27.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",32.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",36.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",44.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",49.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",56.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",62.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",65.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",66.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",67.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",70.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",2.7,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",32,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",109.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",117.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",119,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",111,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",74.3,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",84.6,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",78.5,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",81.8,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",86.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",91.1,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",97.7,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",101.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",111,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",110,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",113,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",118,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",126,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",129,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",132,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",139,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",152,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",163,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",167,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",133,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",6.9,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",241,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",259,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",278,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",302,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",317,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",344,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",386,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",408,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",415,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",432,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",458,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",483,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",410.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",417.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",421.5,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",438.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",423.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",437.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",483.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",516.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",735,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",846.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",807.4,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",718.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",285490.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",1151.1,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",476,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",463,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",428,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",429,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",408,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",411,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",487,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",609,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",604,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",714,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",714,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",1382,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",640,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",690,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",708,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",713,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",692,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",720,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",774,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",799,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",825,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",889,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",891,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",916.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",9408.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",10175.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",10435.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",10923.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",10644.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",11298.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",12928,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",13896.6,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",15077.8,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",17931.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",20028.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",22848.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",85,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",84.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",81.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",81.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",80,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",69.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",67.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",70.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",76.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",74,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",68.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",74.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",37.4,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",1.6,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",1.2,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",1.3,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",1.5,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",1.4,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",1.1,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",0.9,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",171.2,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",174.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",176.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",177,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",174.4,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",173.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",182.7,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",181.3,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",179.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",178.1,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",185.8,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",185.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",107.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",109.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",97.4,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",103.1,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",99.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",90.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",95.5,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",98.6,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",112.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",118,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",114.8,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",124.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",2.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",80.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",73.2,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",337,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",333,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",323,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",332,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",323,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",348,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",360,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",358,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",385,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",422,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",408,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",414.3,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",39,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",41,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",43,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",44,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",45,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",48,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",52,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",53,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",55,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",56,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",63,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",64,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",154.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",164.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",172.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",161.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",162.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",162.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",174.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",172.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",171.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",176.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",190.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",198.6,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",1525,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",1628.3,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",1677.9,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",1709.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",1690.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",1741.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1891.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1890,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1957,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",2074.4,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",2200.8,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",2150.6,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",300.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",652.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",652.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",551.2,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",566.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",534.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",451.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",539.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",692.7,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",724.8,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",812.3,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",813.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1637.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",19.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",17.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",19.2,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",20.7,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",21.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",22.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",24.5,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",27.8,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",29.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",30.6,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",32.3,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",37.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",37.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",83.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",235.2,, +"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",47.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",60.5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",5,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",4,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",552.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",580.3,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",602.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",621.7,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",612.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",637.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",670.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",707.1,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",680.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",639.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",635.9,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",705.6,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",17.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",18.1,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",16.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",19,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",21.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",21.5,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",22.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",20.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",22.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",23.4,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",23.8,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",16.2,, +"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",1018.5,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",10.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",200.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",204.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",176.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",162.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",149.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",112.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",108.5,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",94.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",94.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",77.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",71.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",67.5,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",62.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",65.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",60.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",50.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",39,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",29.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",29.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",31.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",35.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",35.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",33.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",39,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",4.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",15.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",311,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",323.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",303.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",293.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",240.7,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",204.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",206.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",216.2,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",232.3,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",228.5,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",242.9,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",264,, +"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1066.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",59.3,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",63.9,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",57.6,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",58.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",57.2,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",48.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",48.8,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",50.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",58.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",60.4,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",66.7,, +"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",71.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",4.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",14992.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",28.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",28.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",25.9,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",26.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",25.4,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",21.1,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",21.8,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",22,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",23.2,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",21.3,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",22,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",24,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",223.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",234,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",209.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",212.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",209.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",181.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",190.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",203.6,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",223.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",223,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",224.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",236.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",13.7,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",15.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",15.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",16.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",16.1,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",12.8,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",11.4,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",12.9,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",15.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",16.5,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",20.3,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",21.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",330.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",365.2,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",358,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",398.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",415.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",377.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",427.3,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",464.1,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",498,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",491.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",521.7,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",572.2,, +"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",53.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",152.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",155.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",145.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",155.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",165.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",141.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",146.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",158.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",182.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",185.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",190.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",157.6,, +"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.2,, +"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",4775,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",44.7,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",48.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",53.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",61.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",63.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",66.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",73.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",79.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",84.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",82,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",76.2,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",94.8,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",46.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",47.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",41.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",38.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",35.3,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",26.6,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",26,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",22.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",23.2,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",19,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",17.7,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",17.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",35,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",38.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",35,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",37.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",34,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",36.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",35.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",36.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",34.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",32.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",31,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",30.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.2,, +"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",28.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",28.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",30.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",30.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",30.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",32.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",32.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",34,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",35.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",37.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",35.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",36.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",117.9,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",122.7,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",114.6,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",116.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",118,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",100,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",101.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",102.4,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",109.2,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",105.8,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",107.1,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",110.2,, +"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",699.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",52,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",54.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",49.2,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",50,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",49.5,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",43.1,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",45.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",49.3,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",54.6,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",54.8,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",55.4,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",60,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",104.9,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",89.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",519.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",520,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",579.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",604.8,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",644.3,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",761.5,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",993.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1124.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1174.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1448.6,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",1602.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",1800.8,, +"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",15.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",8.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",15.6,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",284,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",289,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",293,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",295,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",288,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",297,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",301,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",312,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",299,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",273,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",267,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",305,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",270,, +"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",574.1,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1408.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",461.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",469.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",416,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",438.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",423.4,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",382.3,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",398.5,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",407.2,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",462,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",480.1,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",464.8,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",490.9,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",128.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",135.5,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",141.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",146.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",144.6,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",151.4,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",160.7,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",171.2,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",166.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",157.3,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",157.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",178.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",62,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",60,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",63,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",62,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",61,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",63,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",61,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",62,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",64,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",65,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",60,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",63,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",179,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",190.7,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",199.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",198.1,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",193.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",190.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",189.4,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",197.2,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",204.8,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",213.3,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",223.9,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",217.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",227.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",877.1,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",972.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",911.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",941.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",907,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",791,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",856.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",908.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",990,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",1011.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",1015,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1086.1,, +"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5.1,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",341,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",351,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",359,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",326,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",323,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",318,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",327,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",315,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",308,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",306,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",324,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",339,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",359.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",393.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",413.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",432,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",448.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",465.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",487.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",498.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",502.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",522.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",538.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",513.6,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",354.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",380.2,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",393,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",401.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",399,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",413.9,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",453.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",457.7,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",478.4,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",510,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",543.8,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",544.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",12.3,, +"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",0.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",289.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",293.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",264,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",274.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",260.8,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",224.1,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",240.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",259.3,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",387.6,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",410.7,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",386.2,, +"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",367.9,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",9.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",8,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",10.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",8.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",10.6,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",10.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",11.1,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",11.3,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",11.4,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",11.7,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",9.5,, +"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",6.9,, +"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.5,, +"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",87.9,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",29.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",31.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",29.3,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",29.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",28.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",23.2,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",22.6,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",24,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",26.4,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",25.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",26.5,, +"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",28.2,, +"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",411.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",163,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",23,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",24,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",26,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",29,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",30,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",31,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",33,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",35,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",37,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",35,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",32,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",41,, +"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",2.6,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",167.3,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",174.7,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",183,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",185.5,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",191.4,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",195.2,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",205,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",204,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",207.1,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",218,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",223.9,, +"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",215.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",270,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",282,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",258.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",215.3,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",165.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",125.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",124,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",131.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",146.4,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",145.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",136.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",154,, +"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",110.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",77.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",82.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",74.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",69.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",45.8,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",43.3,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",39,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",41,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",45.5,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",44.2,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",46.7,, +"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",51.9,, +"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",518.1,, +"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",14.2,, +"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",170.9,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",784,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",811,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",816,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",811,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",795,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",812,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",849,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",834,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",860,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",885,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",924,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",929.7,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",267,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",259,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",282,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",287,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",303,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",355,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",446,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",496,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",516,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",618,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",673,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",778.5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",73.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",77.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",78.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",79.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",80.3,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",84.1,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",91.8,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",98.2,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",103.5,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",113,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",115.9,, +"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",117.1,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",254.9,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",273.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",246,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",249.6,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",242.5,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",205.4,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",203.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",208.2,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",238.8,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",245.7,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",270,, +"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",280.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",468.8,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",520,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",571.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",636.5,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",674,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",737.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",859.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",924.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",944.4,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1012.6,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",1090.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",1117.3,, +"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",36.7,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",9,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",10,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",7,, +"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",4.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",215.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",217.1,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",206.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",212.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",204.8,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",209.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",260,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",334.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",336,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",411.5,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",420.2,, +"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",809.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",591.1,, +"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",11.9,, +"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",429.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",655.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",668.6,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",664.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",699.7,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",686.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",746.5,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",802,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",811.3,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",876.1,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",989.2,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",971.8,, +"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",958.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",6628.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",7145.5,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",6536,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",6845.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",6561.7,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",5786.3,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",6424.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",6975.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",7950.9,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",8703.4,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",9579.2,, +"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",11700.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",59,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",64.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",60.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",63.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",65.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",56.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",58.1,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",60.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",64.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",62.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",63.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",66.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",82.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",98.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",96.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",117.5,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",118,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",106.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",116.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",129.7,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",141.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",130.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",131,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",143,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",5.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",6.3,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",5.1,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",5.6,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",5,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",4.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",4.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",3.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",3.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",3.9,, +"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",23.6,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",92,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",95,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",97,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",94,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",91,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",89,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",85,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",87,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",90,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",91,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",94,, +"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",94,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",18,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",19,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",17,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",18,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",16,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",17,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",16,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",16,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",15,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",14,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",13,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",13,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",152.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",156.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",155.6,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",164.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",162.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",177.4,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",192.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",196.5,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",214.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",243.2,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",240.1,, +"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",242.7,, +"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.1,, +"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",36.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",58.9,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",67.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",65.7,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",70,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",68.2,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",53.8,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",47.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",53.5,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",63.6,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",67.1,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",82,, +"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",85.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",289.8,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",323.5,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",341,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",353.2,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",347.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",367,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",413.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",438.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",458.9,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",512.3,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",524.4,, +"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",537,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",1542.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",1668.4,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",1531,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",1609,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",1549,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",1375.1,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",1539.7,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",1688.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",1943.6,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",2139.9,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",2366.8,, +"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",2962.7,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",1336.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",1387.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",1294.3,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",1249.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",1019.8,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",859.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",860.2,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",892.9,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",950.4,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",929.5,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",983.1,, +"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1042.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",87.8,, +"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",30.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",19.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",23,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",22.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",27.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",27.8,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",25.3,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",27.9,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",31.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",34.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",32.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",32.4,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",36.2,, +"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",12.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.2,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",109.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",121.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",133.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",149.6,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",159.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",175.4,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",206.1,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",223.9,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",230.8,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",249,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",269.5,, +"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",282.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",50.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",51.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",54.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",58.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",63.2,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",65.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",70.5,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",76.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",84.6,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",93.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",98.3,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",77.9,, +"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",216.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",110.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",120.6,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",122.7,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",110.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",110.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",107.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",89,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",90.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",91,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",94.8,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",86.5,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",88.9,, +"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",94.8,, +"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",22.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",67.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",68.5,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",61.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",64.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",61.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",53.3,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",57.6,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",62.8,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",94.7,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",101,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",95.4,, +"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",93.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",120.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",120.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",129.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",130.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",129.7,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",135.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",135.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",140.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",145.6,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",152.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",142.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",145.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",149.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",38.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",40.8,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",42.9,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",43.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.2,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",46.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",49.1,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",49.4,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",50.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",53.6,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",55.3,, +"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",54.5,, +"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",2015.1,, +"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",4.6,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",75.9,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",82.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",88.4,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",92.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",95.7,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",103,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",115.8,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",120.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",125.2,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",131.3,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",150.1,, +"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",148.1,, +"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",764629.4,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",242,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",250,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",247,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",224,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",148,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",166,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",147,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",149,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",155,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",158,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",166,, +"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",173,, +"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",31,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",663.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",704.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",738.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",687,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",686.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",682.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",728.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",713.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",700.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",717.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",771.7,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",784.2,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",94.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",8.6,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",2.3,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",1.9,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",2.4,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",2,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",2.5,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",2.5,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",2.7,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",2.7,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",2.8,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",2.9,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",2.4,, +"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",1.8,, +"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",2771.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",185,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",196,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",201,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",205,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",211,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",217,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",219,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",220,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",221,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",223,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",226,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",222,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",4.6,, +"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",59.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",261.2,, +"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",7.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",365.9,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",365.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",363.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",379,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",397.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",390,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",493.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",564.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",619.2,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",703.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",766.7,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",922.2,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",83.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",96.4,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",104.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",111.7,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",110.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",105.1,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",95.8,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",106.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",120.6,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",138.3,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",171.5,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",166.6,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",12.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",12.7,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",10.3,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",11.9,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",13.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",11,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",11.1,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",10.2,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",12,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",11.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",11.4,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",8.3,, +"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.9,, +"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",5.8,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",285.4,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",108.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",115.5,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",108.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",101.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",99.9,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",83,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",86.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",86.8,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",90.3,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",85.6,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",91.2,, +"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",101.7,, +"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",804.4,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",24.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",26.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",21.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",23.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",21,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",18.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",17.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",18.2,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",18,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",15.9,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",14.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",15.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",2189.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",2375.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",2444.5,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",2567.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",2512.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",2685,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",3098.4,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",3364.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",3685.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",4408.8,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",4948.7,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",5785.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",31.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",33.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",33.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",38.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",39.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",34.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",36.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",39.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",44.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",39.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",36.5,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",48.6,, +"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",72.4,, +"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",1074.4,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",1143.5,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",1050.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",1071.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",1042.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",892.1,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",939.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",948.7,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",1032,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",1006.9,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",1052.6,, +"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1101.3,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",19.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",19.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",19,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",19.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",18.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",16.4,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",16.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",17.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",18.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",18.2,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",16.9,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",18.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",14.8,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",14,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",211,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",208,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",205,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",208,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",199,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",204,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",217,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",228,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",323,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",361,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",339,, +"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",310.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",95.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",97.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",98.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",103,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",99.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",104,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",115.9,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",125.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",179.7,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",208,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",199.5,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",181.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",100.3,, +"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1224.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",253.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",276.3,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",258.9,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",270.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",276.6,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",238.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",242.4,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",250.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",265.2,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",253.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",257.5,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",263,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",90.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",95.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",88.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",91.6,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",89.1,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",77.5,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",79.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",85.9,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",87.7,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",76.4,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",75.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",91.5,, +"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",0.1,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",60,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",70,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",75,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",89,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",90,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",97,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",105,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",114,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",118,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",115,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",115,, +"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",120.7,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",4837,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",5068,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",5075,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",5183,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",5006,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",5267,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",5803,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",6132,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",6626,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",7650,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",8409,, +"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",9877,, +"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1005,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",89.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",93.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",96.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",80.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",63.2,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",58.1,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",59.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",63.7,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",67.9,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",73.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",70.6,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",76.1,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",1.5,, +"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",100.8,, +"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",0.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",84.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",90.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",92,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",93.6,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",92.9,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",95.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",98.2,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",100.4,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",110.7,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",124.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",139.5,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",138.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",284,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",291.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",281.7,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",259.2,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",242.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",218.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",218.3,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",188.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",179.8,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",159.4,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",150.1,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",131.9,, +"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",40153.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",66.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",68,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",66,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",60.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",57.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",52,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",52.3,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",45.5,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",43.9,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",39.2,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",37.1,, +"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",33.4,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",88,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",87,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",86,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",84,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",82,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",81,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",82,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",80,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",79,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",76,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",78,, +"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",80,, +"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",3.2,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",43,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",48,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",51,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",53,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",52,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",49,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",43,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",47,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",53,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",59,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",72,, +"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",72,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",39.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",40.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",41.4,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",41.6,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",41.2,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",41.3,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",43.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",43.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",43.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",43.8,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",45.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",46.9,, +"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",27.3,, +"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",2727.7,, +"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",3,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",186,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",194,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",191,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",189,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",185,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",187,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",184,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",183,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",199,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",216,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",237,, +"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",237,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5.3,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",975,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",984,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",1005,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",946,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",778,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",782,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",777,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",785,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",792,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",817,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",863,, +"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",880,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",925.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",929.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",880.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",904.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",867.5,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",881.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1084.9,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1380.1,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1374.4,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1673.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",1700.6,, +"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",3197,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",215.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",220.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",232.4,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",248.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",267.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",276.7,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",294.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",315,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",345.9,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",382.1,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",397.8,, +"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",307.7,, +"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",60.9,, +"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",51.1,, +"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",11.3,, +"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.8,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",197,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",200,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",201,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",163,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",126,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",114,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",112,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",116,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",122,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",128,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",120,, +"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",130,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",2.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",3,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",2.4,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",2.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",3.1,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",2.6,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",2.7,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",2.5,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",2.9,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",2.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",2.8,, +"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",2.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",317.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",333.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",335.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",339.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",340.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",353.9,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",383.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",405.7,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",423.3,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",459.4,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",469.2,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",462.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",42.2,, +"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",5.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",1244.9,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",1385.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",1455.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",1502.6,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",1471.4,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",1544.5,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1724.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1810.7,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1877.3,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",2083.8,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",2122.2,, +"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",2120.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",85.2,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",85.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",85.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",89.1,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",93.8,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",92.7,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",118.3,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",136.6,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",151.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",172.9,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",189.4,, +"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",233.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",126.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",133.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",124.9,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",124.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",119.3,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",97.8,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",94.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",99,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",108,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",103.5,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",107.1,, +"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",111.4,, +"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",472.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",250.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",267,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",246.2,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",251.8,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",246,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",212,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",225.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",229.7,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",252.3,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",247.6,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",260.1,, +"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",278.9,, +"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.1,, +"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",41.8,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",19.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",22.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",24.6,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",26.3,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",26.1,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",25,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",23,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",25.8,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",29.5,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",34,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",42.4,, +"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",42.2,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",331.6,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",352.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",318.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",295.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",194,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",182.4,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",162.7,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",169.5,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",186,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",179.8,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",189.1,, +"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",204.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",441.4,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",461.3,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",484.1,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",468.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",390.5,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",398.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",414.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",430.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",440.6,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",470.8,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",507.9,, +"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",515.5,, +"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",7.1,, +"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",214.4,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",7.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",7.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",7.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",9.3,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",8.1,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",8.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",9.6,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",10.9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",9.8,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",9,, +"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",12.3,, diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv b/exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv new file mode 100644 index 0000000..e7333d4 --- /dev/null +++ b/exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv @@ -0,0 +1,3421 @@ +Entity,Code,Year,Indicator:Maternal mortality ratio (per 100 000 live births) +Afghanistan,AFG,2000,1450 +Afghanistan,AFG,2001,1390 +Afghanistan,AFG,2002,1300 +Afghanistan,AFG,2003,1240 +Afghanistan,AFG,2004,1180 +Afghanistan,AFG,2005,1140 +Afghanistan,AFG,2006,1120 +Afghanistan,AFG,2007,1090 +Afghanistan,AFG,2008,1030 +Afghanistan,AFG,2009,993 +Afghanistan,AFG,2010,954 +Afghanistan,AFG,2011,905 +Afghanistan,AFG,2012,858 +Afghanistan,AFG,2013,810 +Afghanistan,AFG,2014,786 +Afghanistan,AFG,2015,701 +Afghanistan,AFG,2016,673 +Afghanistan,AFG,2017,638 +Africa,,2000,857 +Africa,,2001,837 +Africa,,2002,822 +Africa,,2003,801 +Africa,,2004,771 +Africa,,2005,735 +Africa,,2006,701 +Africa,,2007,673 +Africa,,2008,653 +Africa,,2009,634 +Africa,,2010,615 +Africa,,2011,599 +Africa,,2012,585 +Africa,,2013,572 +Africa,,2014,562 +Africa,,2015,548 +Africa,,2016,536 +Africa,,2017,525 +Albania,ALB,2000,23 +Albania,ALB,2001,23 +Albania,ALB,2002,21 +Albania,ALB,2003,21 +Albania,ALB,2004,18 +Albania,ALB,2005,22 +Albania,ALB,2006,18 +Albania,ALB,2007,19 +Albania,ALB,2008,20 +Albania,ALB,2009,20 +Albania,ALB,2010,21 +Albania,ALB,2011,22 +Albania,ALB,2012,17 +Albania,ALB,2013,16 +Albania,ALB,2014,16 +Albania,ALB,2015,15 +Albania,ALB,2016,16 +Albania,ALB,2017,15 +Algeria,DZA,2000,161 +Algeria,DZA,2001,155 +Algeria,DZA,2002,148 +Algeria,DZA,2003,145 +Algeria,DZA,2004,134 +Algeria,DZA,2005,127 +Algeria,DZA,2006,122 +Algeria,DZA,2007,119 +Algeria,DZA,2008,117 +Algeria,DZA,2009,117 +Algeria,DZA,2010,115 +Algeria,DZA,2011,116 +Algeria,DZA,2012,116 +Algeria,DZA,2013,115 +Algeria,DZA,2014,114 +Algeria,DZA,2015,114 +Algeria,DZA,2016,113 +Algeria,DZA,2017,112 +Americas,,2000,73 +Americas,,2001,72 +Americas,,2002,71 +Americas,,2003,70 +Americas,,2004,70 +Americas,,2005,68 +Americas,,2006,67 +Americas,,2007,66 +Americas,,2008,65 +Americas,,2009,66 +Americas,,2010,64 +Americas,,2011,62 +Americas,,2012,61 +Americas,,2013,60 +Americas,,2014,60 +Americas,,2015,59 +Americas,,2016,59 +Americas,,2017,57 +Angola,AGO,2000,827 +Angola,AGO,2001,766 +Angola,AGO,2002,690 +Angola,AGO,2003,628 +Angola,AGO,2004,574 +Angola,AGO,2005,519 +Angola,AGO,2006,473 +Angola,AGO,2007,431 +Angola,AGO,2008,395 +Angola,AGO,2009,359 +Angola,AGO,2010,326 +Angola,AGO,2011,300 +Angola,AGO,2012,281 +Angola,AGO,2013,269 +Angola,AGO,2014,258 +Angola,AGO,2015,251 +Angola,AGO,2016,246 +Angola,AGO,2017,241 +Antigua and Barbuda,ATG,2000,44 +Antigua and Barbuda,ATG,2001,44 +Antigua and Barbuda,ATG,2002,43 +Antigua and Barbuda,ATG,2003,44 +Antigua and Barbuda,ATG,2004,41 +Antigua and Barbuda,ATG,2005,40 +Antigua and Barbuda,ATG,2006,46 +Antigua and Barbuda,ATG,2007,48 +Antigua and Barbuda,ATG,2008,50 +Antigua and Barbuda,ATG,2009,45 +Antigua and Barbuda,ATG,2010,44 +Antigua and Barbuda,ATG,2011,43 +Antigua and Barbuda,ATG,2012,44 +Antigua and Barbuda,ATG,2013,43 +Antigua and Barbuda,ATG,2014,42 +Antigua and Barbuda,ATG,2015,43 +Antigua and Barbuda,ATG,2016,43 +Antigua and Barbuda,ATG,2017,42 +Argentina,ARG,2000,66 +Argentina,ARG,2001,67 +Argentina,ARG,2002,65 +Argentina,ARG,2003,65 +Argentina,ARG,2004,61 +Argentina,ARG,2005,59 +Argentina,ARG,2006,57 +Argentina,ARG,2007,56 +Argentina,ARG,2008,53 +Argentina,ARG,2009,56 +Argentina,ARG,2010,51 +Argentina,ARG,2011,48 +Argentina,ARG,2012,47 +Argentina,ARG,2013,44 +Argentina,ARG,2014,42 +Argentina,ARG,2015,41 +Argentina,ARG,2016,40 +Argentina,ARG,2017,39 +Armenia,ARM,2000,43 +Armenia,ARM,2001,42 +Armenia,ARM,2002,39 +Armenia,ARM,2003,38 +Armenia,ARM,2004,36 +Armenia,ARM,2005,35 +Armenia,ARM,2006,36 +Armenia,ARM,2007,32 +Armenia,ARM,2008,36 +Armenia,ARM,2009,32 +Armenia,ARM,2010,32 +Armenia,ARM,2011,30 +Armenia,ARM,2012,30 +Armenia,ARM,2013,26 +Armenia,ARM,2014,27 +Armenia,ARM,2015,28 +Armenia,ARM,2016,26 +Armenia,ARM,2017,26 +Australia,AUS,2000,7 +Australia,AUS,2001,6 +Australia,AUS,2002,6 +Australia,AUS,2003,6 +Australia,AUS,2004,5 +Australia,AUS,2005,5 +Australia,AUS,2006,5 +Australia,AUS,2007,5 +Australia,AUS,2008,5 +Australia,AUS,2009,5 +Australia,AUS,2010,5 +Australia,AUS,2011,6 +Australia,AUS,2012,6 +Australia,AUS,2013,6 +Australia,AUS,2014,6 +Australia,AUS,2015,6 +Australia,AUS,2016,6 +Australia,AUS,2017,6 +Austria,AUT,2000,6 +Austria,AUT,2001,6 +Austria,AUT,2002,6 +Austria,AUT,2003,6 +Austria,AUT,2004,5 +Austria,AUT,2005,6 +Austria,AUT,2006,5 +Austria,AUT,2007,5 +Austria,AUT,2008,5 +Austria,AUT,2009,5 +Austria,AUT,2010,5 +Austria,AUT,2011,5 +Austria,AUT,2012,5 +Austria,AUT,2013,5 +Austria,AUT,2014,5 +Austria,AUT,2015,5 +Austria,AUT,2016,5 +Austria,AUT,2017,5 +Azerbaijan,AZE,2000,47 +Azerbaijan,AZE,2001,44 +Azerbaijan,AZE,2002,43 +Azerbaijan,AZE,2003,44 +Azerbaijan,AZE,2004,39 +Azerbaijan,AZE,2005,42 +Azerbaijan,AZE,2006,35 +Azerbaijan,AZE,2007,34 +Azerbaijan,AZE,2008,32 +Azerbaijan,AZE,2009,32 +Azerbaijan,AZE,2010,31 +Azerbaijan,AZE,2011,30 +Azerbaijan,AZE,2012,29 +Azerbaijan,AZE,2013,28 +Azerbaijan,AZE,2014,28 +Azerbaijan,AZE,2015,27 +Azerbaijan,AZE,2016,26 +Azerbaijan,AZE,2017,26 +Bahamas,BHS,2000,75 +Bahamas,BHS,2001,76 +Bahamas,BHS,2002,78 +Bahamas,BHS,2003,79 +Bahamas,BHS,2004,78 +Bahamas,BHS,2005,77 +Bahamas,BHS,2006,78 +Bahamas,BHS,2007,77 +Bahamas,BHS,2008,77 +Bahamas,BHS,2009,78 +Bahamas,BHS,2010,78 +Bahamas,BHS,2011,78 +Bahamas,BHS,2012,78 +Bahamas,BHS,2013,78 +Bahamas,BHS,2014,77 +Bahamas,BHS,2015,74 +Bahamas,BHS,2016,72 +Bahamas,BHS,2017,70 +Bahrain,BHR,2000,27 +Bahrain,BHR,2001,19 +Bahrain,BHR,2002,25 +Bahrain,BHR,2003,21 +Bahrain,BHR,2004,21 +Bahrain,BHR,2005,19 +Bahrain,BHR,2006,24 +Bahrain,BHR,2007,16 +Bahrain,BHR,2008,18 +Bahrain,BHR,2009,19 +Bahrain,BHR,2010,18 +Bahrain,BHR,2011,15 +Bahrain,BHR,2012,18 +Bahrain,BHR,2013,17 +Bahrain,BHR,2014,15 +Bahrain,BHR,2015,15 +Bahrain,BHR,2016,15 +Bahrain,BHR,2017,14 +Bangladesh,BGD,2000,434 +Bangladesh,BGD,2001,423 +Bangladesh,BGD,2002,410 +Bangladesh,BGD,2003,395 +Bangladesh,BGD,2004,372 +Bangladesh,BGD,2005,343 +Bangladesh,BGD,2006,315 +Bangladesh,BGD,2007,297 +Bangladesh,BGD,2008,280 +Bangladesh,BGD,2009,269 +Bangladesh,BGD,2010,258 +Bangladesh,BGD,2011,248 +Bangladesh,BGD,2012,238 +Bangladesh,BGD,2013,227 +Bangladesh,BGD,2014,214 +Bangladesh,BGD,2015,200 +Bangladesh,BGD,2016,186 +Bangladesh,BGD,2017,173 +Barbados,BRB,2000,50 +Barbados,BRB,2001,48 +Barbados,BRB,2002,47 +Barbados,BRB,2003,45 +Barbados,BRB,2004,43 +Barbados,BRB,2005,42 +Barbados,BRB,2006,41 +Barbados,BRB,2007,40 +Barbados,BRB,2008,39 +Barbados,BRB,2009,38 +Barbados,BRB,2010,36 +Barbados,BRB,2011,35 +Barbados,BRB,2012,34 +Barbados,BRB,2013,32 +Barbados,BRB,2014,31 +Barbados,BRB,2015,31 +Barbados,BRB,2016,30 +Barbados,BRB,2017,27 +Belarus,BLR,2000,22 +Belarus,BLR,2001,19 +Belarus,BLR,2002,18 +Belarus,BLR,2003,15 +Belarus,BLR,2004,13 +Belarus,BLR,2005,11 +Belarus,BLR,2006,9 +Belarus,BLR,2007,7 +Belarus,BLR,2008,6 +Belarus,BLR,2009,6 +Belarus,BLR,2010,5 +Belarus,BLR,2011,5 +Belarus,BLR,2012,4 +Belarus,BLR,2013,3 +Belarus,BLR,2014,3 +Belarus,BLR,2015,3 +Belarus,BLR,2016,3 +Belarus,BLR,2017,2 +Belgium,BEL,2000,8 +Belgium,BEL,2001,8 +Belgium,BEL,2002,7 +Belgium,BEL,2003,7 +Belgium,BEL,2004,7 +Belgium,BEL,2005,7 +Belgium,BEL,2006,7 +Belgium,BEL,2007,7 +Belgium,BEL,2008,7 +Belgium,BEL,2009,6 +Belgium,BEL,2010,6 +Belgium,BEL,2011,6 +Belgium,BEL,2012,6 +Belgium,BEL,2013,6 +Belgium,BEL,2014,6 +Belgium,BEL,2015,5 +Belgium,BEL,2016,5 +Belgium,BEL,2017,5 +Belize,BLZ,2000,89 +Belize,BLZ,2001,88 +Belize,BLZ,2002,82 +Belize,BLZ,2003,80 +Belize,BLZ,2004,75 +Belize,BLZ,2005,70 +Belize,BLZ,2006,65 +Belize,BLZ,2007,61 +Belize,BLZ,2008,59 +Belize,BLZ,2009,57 +Belize,BLZ,2010,54 +Belize,BLZ,2011,52 +Belize,BLZ,2012,50 +Belize,BLZ,2013,48 +Belize,BLZ,2014,46 +Belize,BLZ,2015,43 +Belize,BLZ,2016,39 +Belize,BLZ,2017,36 +Benin,BEN,2000,520 +Benin,BEN,2001,516 +Benin,BEN,2002,511 +Benin,BEN,2003,510 +Benin,BEN,2004,505 +Benin,BEN,2005,500 +Benin,BEN,2006,493 +Benin,BEN,2007,486 +Benin,BEN,2008,480 +Benin,BEN,2009,471 +Benin,BEN,2010,464 +Benin,BEN,2011,458 +Benin,BEN,2012,450 +Benin,BEN,2013,441 +Benin,BEN,2014,432 +Benin,BEN,2015,421 +Benin,BEN,2016,408 +Benin,BEN,2017,397 +Bhutan,BTN,2000,423 +Bhutan,BTN,2001,384 +Bhutan,BTN,2002,365 +Bhutan,BTN,2003,348 +Bhutan,BTN,2004,332 +Bhutan,BTN,2005,310 +Bhutan,BTN,2006,291 +Bhutan,BTN,2007,275 +Bhutan,BTN,2008,264 +Bhutan,BTN,2009,255 +Bhutan,BTN,2010,247 +Bhutan,BTN,2011,239 +Bhutan,BTN,2012,231 +Bhutan,BTN,2013,223 +Bhutan,BTN,2014,214 +Bhutan,BTN,2015,203 +Bhutan,BTN,2016,193 +Bhutan,BTN,2017,183 +Bolivia,BOL,2000,331 +Bolivia,BOL,2001,320 +Bolivia,BOL,2002,309 +Bolivia,BOL,2003,297 +Bolivia,BOL,2004,283 +Bolivia,BOL,2005,271 +Bolivia,BOL,2006,258 +Bolivia,BOL,2007,246 +Bolivia,BOL,2008,234 +Bolivia,BOL,2009,222 +Bolivia,BOL,2010,212 +Bolivia,BOL,2011,202 +Bolivia,BOL,2012,192 +Bolivia,BOL,2013,184 +Bolivia,BOL,2014,175 +Bolivia,BOL,2015,168 +Bolivia,BOL,2016,161 +Bolivia,BOL,2017,155 +Bosnia and Herzegovina,BIH,2000,17 +Bosnia and Herzegovina,BIH,2001,16 +Bosnia and Herzegovina,BIH,2002,14 +Bosnia and Herzegovina,BIH,2003,14 +Bosnia and Herzegovina,BIH,2004,14 +Bosnia and Herzegovina,BIH,2005,13 +Bosnia and Herzegovina,BIH,2006,13 +Bosnia and Herzegovina,BIH,2007,13 +Bosnia and Herzegovina,BIH,2008,11 +Bosnia and Herzegovina,BIH,2009,11 +Bosnia and Herzegovina,BIH,2010,11 +Bosnia and Herzegovina,BIH,2011,10 +Bosnia and Herzegovina,BIH,2012,10 +Bosnia and Herzegovina,BIH,2013,10 +Bosnia and Herzegovina,BIH,2014,10 +Bosnia and Herzegovina,BIH,2015,10 +Bosnia and Herzegovina,BIH,2016,10 +Bosnia and Herzegovina,BIH,2017,10 +Botswana,BWA,2000,262 +Botswana,BWA,2001,271 +Botswana,BWA,2002,278 +Botswana,BWA,2003,278 +Botswana,BWA,2004,264 +Botswana,BWA,2005,239 +Botswana,BWA,2006,221 +Botswana,BWA,2007,209 +Botswana,BWA,2008,203 +Botswana,BWA,2009,189 +Botswana,BWA,2010,179 +Botswana,BWA,2011,176 +Botswana,BWA,2012,170 +Botswana,BWA,2013,164 +Botswana,BWA,2014,160 +Botswana,BWA,2015,156 +Botswana,BWA,2016,151 +Botswana,BWA,2017,144 +Brazil,BRA,2000,69 +Brazil,BRA,2001,68 +Brazil,BRA,2002,69 +Brazil,BRA,2003,70 +Brazil,BRA,2004,71 +Brazil,BRA,2005,71 +Brazil,BRA,2006,72 +Brazil,BRA,2007,71 +Brazil,BRA,2008,70 +Brazil,BRA,2009,69 +Brazil,BRA,2010,65 +Brazil,BRA,2011,61 +Brazil,BRA,2012,60 +Brazil,BRA,2013,61 +Brazil,BRA,2014,62 +Brazil,BRA,2015,63 +Brazil,BRA,2016,62 +Brazil,BRA,2017,60 +Brunei,BRN,2000,28 +Brunei,BRN,2001,28 +Brunei,BRN,2002,29 +Brunei,BRN,2003,30 +Brunei,BRN,2004,30 +Brunei,BRN,2005,29 +Brunei,BRN,2006,28 +Brunei,BRN,2007,27 +Brunei,BRN,2008,27 +Brunei,BRN,2009,27 +Brunei,BRN,2010,28 +Brunei,BRN,2011,28 +Brunei,BRN,2012,29 +Brunei,BRN,2013,28 +Brunei,BRN,2014,29 +Brunei,BRN,2015,30 +Brunei,BRN,2016,31 +Brunei,BRN,2017,31 +Bulgaria,BGR,2000,19 +Bulgaria,BGR,2001,18 +Bulgaria,BGR,2002,17 +Bulgaria,BGR,2003,16 +Bulgaria,BGR,2004,16 +Bulgaria,BGR,2005,15 +Bulgaria,BGR,2006,14 +Bulgaria,BGR,2007,13 +Bulgaria,BGR,2008,13 +Bulgaria,BGR,2009,12 +Bulgaria,BGR,2010,12 +Bulgaria,BGR,2011,12 +Bulgaria,BGR,2012,11 +Bulgaria,BGR,2013,10 +Bulgaria,BGR,2014,11 +Bulgaria,BGR,2015,10 +Bulgaria,BGR,2016,10 +Bulgaria,BGR,2017,10 +Burkina Faso,BFA,2000,516 +Burkina Faso,BFA,2001,501 +Burkina Faso,BFA,2002,486 +Burkina Faso,BFA,2003,471 +Burkina Faso,BFA,2004,454 +Burkina Faso,BFA,2005,437 +Burkina Faso,BFA,2006,422 +Burkina Faso,BFA,2007,410 +Burkina Faso,BFA,2008,401 +Burkina Faso,BFA,2009,393 +Burkina Faso,BFA,2010,385 +Burkina Faso,BFA,2011,377 +Burkina Faso,BFA,2012,369 +Burkina Faso,BFA,2013,362 +Burkina Faso,BFA,2014,353 +Burkina Faso,BFA,2015,343 +Burkina Faso,BFA,2016,331 +Burkina Faso,BFA,2017,320 +Burundi,BDI,2000,1010 +Burundi,BDI,2001,956 +Burundi,BDI,2002,925 +Burundi,BDI,2003,890 +Burundi,BDI,2004,844 +Burundi,BDI,2005,814 +Burundi,BDI,2006,785 +Burundi,BDI,2007,756 +Burundi,BDI,2008,733 +Burundi,BDI,2009,698 +Burundi,BDI,2010,665 +Burundi,BDI,2011,635 +Burundi,BDI,2012,608 +Burundi,BDI,2013,591 +Burundi,BDI,2014,576 +Burundi,BDI,2015,568 +Burundi,BDI,2016,558 +Burundi,BDI,2017,548 +Cambodia,KHM,2000,488 +Cambodia,KHM,2001,456 +Cambodia,KHM,2002,430 +Cambodia,KHM,2003,404 +Cambodia,KHM,2004,378 +Cambodia,KHM,2005,351 +Cambodia,KHM,2006,326 +Cambodia,KHM,2007,303 +Cambodia,KHM,2008,284 +Cambodia,KHM,2009,265 +Cambodia,KHM,2010,248 +Cambodia,KHM,2011,232 +Cambodia,KHM,2012,215 +Cambodia,KHM,2013,202 +Cambodia,KHM,2014,189 +Cambodia,KHM,2015,178 +Cambodia,KHM,2016,168 +Cambodia,KHM,2017,160 +Cameroon,CMR,2000,886 +Cameroon,CMR,2001,844 +Cameroon,CMR,2002,803 +Cameroon,CMR,2003,771 +Cameroon,CMR,2004,732 +Cameroon,CMR,2005,692 +Cameroon,CMR,2006,658 +Cameroon,CMR,2007,635 +Cameroon,CMR,2008,618 +Cameroon,CMR,2009,606 +Cameroon,CMR,2010,597 +Cameroon,CMR,2011,589 +Cameroon,CMR,2012,580 +Cameroon,CMR,2013,567 +Cameroon,CMR,2014,564 +Cameroon,CMR,2015,554 +Cameroon,CMR,2016,538 +Cameroon,CMR,2017,529 +Canada,CAN,2000,9 +Canada,CAN,2001,10 +Canada,CAN,2002,10 +Canada,CAN,2003,10 +Canada,CAN,2004,10 +Canada,CAN,2005,11 +Canada,CAN,2006,11 +Canada,CAN,2007,11 +Canada,CAN,2008,12 +Canada,CAN,2009,12 +Canada,CAN,2010,11 +Canada,CAN,2011,11 +Canada,CAN,2012,11 +Canada,CAN,2013,11 +Canada,CAN,2014,11 +Canada,CAN,2015,11 +Canada,CAN,2016,10 +Canada,CAN,2017,10 +Cape Verde,CPV,2000,118 +Cape Verde,CPV,2001,109 +Cape Verde,CPV,2002,101 +Cape Verde,CPV,2003,96 +Cape Verde,CPV,2004,91 +Cape Verde,CPV,2005,86 +Cape Verde,CPV,2006,82 +Cape Verde,CPV,2007,78 +Cape Verde,CPV,2008,75 +Cape Verde,CPV,2009,72 +Cape Verde,CPV,2010,70 +Cape Verde,CPV,2011,67 +Cape Verde,CPV,2012,65 +Cape Verde,CPV,2013,63 +Cape Verde,CPV,2014,62 +Cape Verde,CPV,2015,61 +Cape Verde,CPV,2016,59 +Cape Verde,CPV,2017,58 +Central African Republic,CAF,2000,1280 +Central African Republic,CAF,2001,1290 +Central African Republic,CAF,2002,1280 +Central African Republic,CAF,2003,1250 +Central African Republic,CAF,2004,1230 +Central African Republic,CAF,2005,1200 +Central African Republic,CAF,2006,1170 +Central African Republic,CAF,2007,1130 +Central African Republic,CAF,2008,1090 +Central African Republic,CAF,2009,1050 +Central African Republic,CAF,2010,1000 +Central African Republic,CAF,2011,981 +Central African Republic,CAF,2012,963 +Central African Republic,CAF,2013,1030 +Central African Republic,CAF,2014,961 +Central African Republic,CAF,2015,912 +Central African Republic,CAF,2016,890 +Central African Republic,CAF,2017,829 +Chad,TCD,2000,1420 +Chad,TCD,2001,1410 +Chad,TCD,2002,1400 +Chad,TCD,2003,1370 +Chad,TCD,2004,1350 +Chad,TCD,2005,1330 +Chad,TCD,2006,1340 +Chad,TCD,2007,1300 +Chad,TCD,2008,1310 +Chad,TCD,2009,1270 +Chad,TCD,2010,1240 +Chad,TCD,2011,1210 +Chad,TCD,2012,1190 +Chad,TCD,2013,1170 +Chad,TCD,2014,1170 +Chad,TCD,2015,1160 +Chad,TCD,2016,1140 +Chad,TCD,2017,1140 +Chile,CHL,2000,31 +Chile,CHL,2001,32 +Chile,CHL,2002,28 +Chile,CHL,2003,27 +Chile,CHL,2004,27 +Chile,CHL,2005,25 +Chile,CHL,2006,25 +Chile,CHL,2007,23 +Chile,CHL,2008,21 +Chile,CHL,2009,21 +Chile,CHL,2010,20 +Chile,CHL,2011,18 +Chile,CHL,2012,17 +Chile,CHL,2013,16 +Chile,CHL,2014,15 +Chile,CHL,2015,14 +Chile,CHL,2016,13 +Chile,CHL,2017,13 +China,CHN,2000,59 +China,CHN,2001,55 +China,CHN,2002,51 +China,CHN,2003,48 +China,CHN,2004,46 +China,CHN,2005,44 +China,CHN,2006,42 +China,CHN,2007,40 +China,CHN,2008,40 +China,CHN,2009,37 +China,CHN,2010,36 +China,CHN,2011,34 +China,CHN,2012,33 +China,CHN,2013,32 +China,CHN,2014,31 +China,CHN,2015,30 +China,CHN,2016,29 +China,CHN,2017,29 +Colombia,COL,2000,94 +Colombia,COL,2001,93 +Colombia,COL,2002,92 +Colombia,COL,2003,88 +Colombia,COL,2004,85 +Colombia,COL,2005,83 +Colombia,COL,2006,82 +Colombia,COL,2007,83 +Colombia,COL,2008,84 +Colombia,COL,2009,87 +Colombia,COL,2010,85 +Colombia,COL,2011,84 +Colombia,COL,2012,85 +Colombia,COL,2013,85 +Colombia,COL,2014,85 +Colombia,COL,2015,85 +Colombia,COL,2016,84 +Colombia,COL,2017,83 +Comoros,COM,2000,444 +Comoros,COM,2001,437 +Comoros,COM,2002,429 +Comoros,COM,2003,423 +Comoros,COM,2004,414 +Comoros,COM,2005,404 +Comoros,COM,2006,393 +Comoros,COM,2007,382 +Comoros,COM,2008,370 +Comoros,COM,2009,356 +Comoros,COM,2010,341 +Comoros,COM,2011,326 +Comoros,COM,2012,313 +Comoros,COM,2013,302 +Comoros,COM,2014,293 +Comoros,COM,2015,285 +Comoros,COM,2016,279 +Comoros,COM,2017,273 +Congo,COG,2000,739 +Congo,COG,2001,752 +Congo,COG,2002,769 +Congo,COG,2003,757 +Congo,COG,2004,724 +Congo,COG,2005,677 +Congo,COG,2006,623 +Congo,COG,2007,580 +Congo,COG,2008,552 +Congo,COG,2009,526 +Congo,COG,2010,506 +Congo,COG,2011,488 +Congo,COG,2012,468 +Congo,COG,2013,449 +Congo,COG,2014,433 +Congo,COG,2015,416 +Congo,COG,2016,397 +Congo,COG,2017,378 +Costa Rica,CRI,2000,40 +Costa Rica,CRI,2001,37 +Costa Rica,CRI,2002,38 +Costa Rica,CRI,2003,37 +Costa Rica,CRI,2004,36 +Costa Rica,CRI,2005,33 +Costa Rica,CRI,2006,35 +Costa Rica,CRI,2007,29 +Costa Rica,CRI,2008,29 +Costa Rica,CRI,2009,29 +Costa Rica,CRI,2010,32 +Costa Rica,CRI,2011,30 +Costa Rica,CRI,2012,29 +Costa Rica,CRI,2013,29 +Costa Rica,CRI,2014,29 +Costa Rica,CRI,2015,28 +Costa Rica,CRI,2016,28 +Costa Rica,CRI,2017,27 +Cote d'Ivoire,CIV,2000,704 +Cote d'Ivoire,CIV,2001,706 +Cote d'Ivoire,CIV,2002,713 +Cote d'Ivoire,CIV,2003,711 +Cote d'Ivoire,CIV,2004,709 +Cote d'Ivoire,CIV,2005,704 +Cote d'Ivoire,CIV,2006,699 +Cote d'Ivoire,CIV,2007,698 +Cote d'Ivoire,CIV,2008,694 +Cote d'Ivoire,CIV,2009,700 +Cote d'Ivoire,CIV,2010,701 +Cote d'Ivoire,CIV,2011,703 +Cote d'Ivoire,CIV,2012,702 +Cote d'Ivoire,CIV,2013,691 +Cote d'Ivoire,CIV,2014,676 +Cote d'Ivoire,CIV,2015,658 +Cote d'Ivoire,CIV,2016,636 +Cote d'Ivoire,CIV,2017,617 +Croatia,HRV,2000,11 +Croatia,HRV,2001,10 +Croatia,HRV,2002,10 +Croatia,HRV,2003,10 +Croatia,HRV,2004,10 +Croatia,HRV,2005,10 +Croatia,HRV,2006,9 +Croatia,HRV,2007,9 +Croatia,HRV,2008,9 +Croatia,HRV,2009,9 +Croatia,HRV,2010,9 +Croatia,HRV,2011,9 +Croatia,HRV,2012,8 +Croatia,HRV,2013,9 +Croatia,HRV,2014,8 +Croatia,HRV,2015,8 +Croatia,HRV,2016,7 +Croatia,HRV,2017,8 +Cuba,CUB,2000,46 +Cuba,CUB,2001,44 +Cuba,CUB,2002,41 +Cuba,CUB,2003,41 +Cuba,CUB,2004,40 +Cuba,CUB,2005,41 +Cuba,CUB,2006,38 +Cuba,CUB,2007,38 +Cuba,CUB,2008,40 +Cuba,CUB,2009,40 +Cuba,CUB,2010,41 +Cuba,CUB,2011,38 +Cuba,CUB,2012,39 +Cuba,CUB,2013,40 +Cuba,CUB,2014,39 +Cuba,CUB,2015,38 +Cuba,CUB,2016,37 +Cuba,CUB,2017,36 +Cyprus,CYP,2000,14 +Cyprus,CYP,2001,9 +Cyprus,CYP,2002,10 +Cyprus,CYP,2003,9 +Cyprus,CYP,2004,9 +Cyprus,CYP,2005,12 +Cyprus,CYP,2006,9 +Cyprus,CYP,2007,8 +Cyprus,CYP,2008,9 +Cyprus,CYP,2009,8 +Cyprus,CYP,2010,8 +Cyprus,CYP,2011,8 +Cyprus,CYP,2012,7 +Cyprus,CYP,2013,6 +Cyprus,CYP,2014,8 +Cyprus,CYP,2015,7 +Cyprus,CYP,2016,6 +Cyprus,CYP,2017,6 +Czechia,CZE,2000,7 +Czechia,CZE,2001,7 +Czechia,CZE,2002,6 +Czechia,CZE,2003,6 +Czechia,CZE,2004,5 +Czechia,CZE,2005,5 +Czechia,CZE,2006,5 +Czechia,CZE,2007,5 +Czechia,CZE,2008,5 +Czechia,CZE,2009,4 +Czechia,CZE,2010,4 +Czechia,CZE,2011,4 +Czechia,CZE,2012,4 +Czechia,CZE,2013,4 +Czechia,CZE,2014,4 +Czechia,CZE,2015,4 +Czechia,CZE,2016,4 +Czechia,CZE,2017,3 +Democratic Republic of Congo,COD,2000,760 +Democratic Republic of Congo,COD,2001,740 +Democratic Republic of Congo,COD,2002,734 +Democratic Republic of Congo,COD,2003,699 +Democratic Republic of Congo,COD,2004,661 +Democratic Republic of Congo,COD,2005,627 +Democratic Republic of Congo,COD,2006,598 +Democratic Republic of Congo,COD,2007,578 +Democratic Republic of Congo,COD,2008,565 +Democratic Republic of Congo,COD,2009,555 +Democratic Republic of Congo,COD,2010,542 +Democratic Republic of Congo,COD,2011,532 +Democratic Republic of Congo,COD,2012,524 +Democratic Republic of Congo,COD,2013,514 +Democratic Republic of Congo,COD,2014,500 +Democratic Republic of Congo,COD,2015,490 +Democratic Republic of Congo,COD,2016,481 +Democratic Republic of Congo,COD,2017,473 +Denmark,DNK,2000,8 +Denmark,DNK,2001,8 +Denmark,DNK,2002,8 +Denmark,DNK,2003,7 +Denmark,DNK,2004,7 +Denmark,DNK,2005,6 +Denmark,DNK,2006,6 +Denmark,DNK,2007,6 +Denmark,DNK,2008,6 +Denmark,DNK,2009,6 +Denmark,DNK,2010,5 +Denmark,DNK,2011,5 +Denmark,DNK,2012,5 +Denmark,DNK,2013,4 +Denmark,DNK,2014,4 +Denmark,DNK,2015,4 +Denmark,DNK,2016,4 +Denmark,DNK,2017,4 +Djibouti,DJI,2000,507 +Djibouti,DJI,2001,490 +Djibouti,DJI,2002,470 +Djibouti,DJI,2003,449 +Djibouti,DJI,2004,426 +Djibouti,DJI,2005,393 +Djibouti,DJI,2006,361 +Djibouti,DJI,2007,335 +Djibouti,DJI,2008,320 +Djibouti,DJI,2009,299 +Djibouti,DJI,2010,283 +Djibouti,DJI,2011,272 +Djibouti,DJI,2012,262 +Djibouti,DJI,2013,256 +Djibouti,DJI,2014,256 +Djibouti,DJI,2015,247 +Djibouti,DJI,2016,246 +Djibouti,DJI,2017,248 +Dominican Republic,DOM,2000,80 +Dominican Republic,DOM,2001,75 +Dominican Republic,DOM,2002,75 +Dominican Republic,DOM,2003,76 +Dominican Republic,DOM,2004,81 +Dominican Republic,DOM,2005,83 +Dominican Republic,DOM,2006,86 +Dominican Republic,DOM,2007,90 +Dominican Republic,DOM,2008,92 +Dominican Republic,DOM,2009,95 +Dominican Republic,DOM,2010,96 +Dominican Republic,DOM,2011,95 +Dominican Republic,DOM,2012,94 +Dominican Republic,DOM,2013,94 +Dominican Republic,DOM,2014,94 +Dominican Republic,DOM,2015,94 +Dominican Republic,DOM,2016,94 +Dominican Republic,DOM,2017,95 +East Timor,TLS,2000,745 +East Timor,TLS,2001,720 +East Timor,TLS,2002,668 +East Timor,TLS,2003,603 +East Timor,TLS,2004,507 +East Timor,TLS,2005,415 +East Timor,TLS,2006,348 +East Timor,TLS,2007,300 +East Timor,TLS,2008,269 +East Timor,TLS,2009,242 +East Timor,TLS,2010,219 +East Timor,TLS,2011,198 +East Timor,TLS,2012,185 +East Timor,TLS,2013,176 +East Timor,TLS,2014,168 +East Timor,TLS,2015,160 +East Timor,TLS,2016,152 +East Timor,TLS,2017,142 +Eastern Mediterranean,,2000,330 +Eastern Mediterranean,,2001,319 +Eastern Mediterranean,,2002,306 +Eastern Mediterranean,,2003,298 +Eastern Mediterranean,,2004,286 +Eastern Mediterranean,,2005,275 +Eastern Mediterranean,,2006,267 +Eastern Mediterranean,,2007,255 +Eastern Mediterranean,,2008,241 +Eastern Mediterranean,,2009,230 +Eastern Mediterranean,,2010,220 +Eastern Mediterranean,,2011,208 +Eastern Mediterranean,,2012,199 +Eastern Mediterranean,,2013,190 +Eastern Mediterranean,,2014,186 +Eastern Mediterranean,,2015,175 +Eastern Mediterranean,,2016,169 +Eastern Mediterranean,,2017,164 +Ecuador,ECU,2000,122 +Ecuador,ECU,2001,117 +Ecuador,ECU,2002,110 +Ecuador,ECU,2003,100 +Ecuador,ECU,2004,94 +Ecuador,ECU,2005,94 +Ecuador,ECU,2006,90 +Ecuador,ECU,2007,85 +Ecuador,ECU,2008,82 +Ecuador,ECU,2009,80 +Ecuador,ECU,2010,78 +Ecuador,ECU,2011,76 +Ecuador,ECU,2012,71 +Ecuador,ECU,2013,67 +Ecuador,ECU,2014,65 +Ecuador,ECU,2015,63 +Ecuador,ECU,2016,61 +Ecuador,ECU,2017,59 +Egypt,EGY,2000,64 +Egypt,EGY,2001,63 +Egypt,EGY,2002,60 +Egypt,EGY,2003,57 +Egypt,EGY,2004,54 +Egypt,EGY,2005,52 +Egypt,EGY,2006,50 +Egypt,EGY,2007,47 +Egypt,EGY,2008,45 +Egypt,EGY,2009,45 +Egypt,EGY,2010,45 +Egypt,EGY,2011,42 +Egypt,EGY,2012,42 +Egypt,EGY,2013,40 +Egypt,EGY,2014,39 +Egypt,EGY,2015,39 +Egypt,EGY,2016,38 +Egypt,EGY,2017,37 +El Salvador,SLV,2000,73 +El Salvador,SLV,2001,75 +El Salvador,SLV,2002,68 +El Salvador,SLV,2003,66 +El Salvador,SLV,2004,64 +El Salvador,SLV,2005,62 +El Salvador,SLV,2006,60 +El Salvador,SLV,2007,58 +El Salvador,SLV,2008,57 +El Salvador,SLV,2009,57 +El Salvador,SLV,2010,54 +El Salvador,SLV,2011,53 +El Salvador,SLV,2012,52 +El Salvador,SLV,2013,50 +El Salvador,SLV,2014,49 +El Salvador,SLV,2015,48 +El Salvador,SLV,2016,47 +El Salvador,SLV,2017,46 +Equatorial Guinea,GNQ,2000,454 +Equatorial Guinea,GNQ,2001,421 +Equatorial Guinea,GNQ,2002,392 +Equatorial Guinea,GNQ,2003,370 +Equatorial Guinea,GNQ,2004,357 +Equatorial Guinea,GNQ,2005,344 +Equatorial Guinea,GNQ,2006,331 +Equatorial Guinea,GNQ,2007,322 +Equatorial Guinea,GNQ,2008,314 +Equatorial Guinea,GNQ,2009,310 +Equatorial Guinea,GNQ,2010,308 +Equatorial Guinea,GNQ,2011,308 +Equatorial Guinea,GNQ,2012,305 +Equatorial Guinea,GNQ,2013,300 +Equatorial Guinea,GNQ,2014,295 +Equatorial Guinea,GNQ,2015,296 +Equatorial Guinea,GNQ,2016,301 +Equatorial Guinea,GNQ,2017,301 +Eritrea,ERI,2000,1280 +Eritrea,ERI,2001,1180 +Eritrea,ERI,2002,1130 +Eritrea,ERI,2003,1060 +Eritrea,ERI,2004,938 +Eritrea,ERI,2005,804 +Eritrea,ERI,2006,705 +Eritrea,ERI,2007,635 +Eritrea,ERI,2008,605 +Eritrea,ERI,2009,583 +Eritrea,ERI,2010,567 +Eritrea,ERI,2011,558 +Eritrea,ERI,2012,549 +Eritrea,ERI,2013,540 +Eritrea,ERI,2014,530 +Eritrea,ERI,2015,518 +Eritrea,ERI,2016,498 +Eritrea,ERI,2017,480 +Estonia,EST,2000,29 +Estonia,EST,2001,27 +Estonia,EST,2002,25 +Estonia,EST,2003,20 +Estonia,EST,2004,18 +Estonia,EST,2005,18 +Estonia,EST,2006,16 +Estonia,EST,2007,17 +Estonia,EST,2008,14 +Estonia,EST,2009,14 +Estonia,EST,2010,11 +Estonia,EST,2011,13 +Estonia,EST,2012,12 +Estonia,EST,2013,10 +Estonia,EST,2014,11 +Estonia,EST,2015,10 +Estonia,EST,2016,11 +Estonia,EST,2017,9 +Eswatini,SWZ,2000,521 +Eswatini,SWZ,2001,528 +Eswatini,SWZ,2002,534 +Eswatini,SWZ,2003,538 +Eswatini,SWZ,2004,539 +Eswatini,SWZ,2005,532 +Eswatini,SWZ,2006,518 +Eswatini,SWZ,2007,496 +Eswatini,SWZ,2008,474 +Eswatini,SWZ,2009,460 +Eswatini,SWZ,2010,450 +Eswatini,SWZ,2011,441 +Eswatini,SWZ,2012,435 +Eswatini,SWZ,2013,432 +Eswatini,SWZ,2014,434 +Eswatini,SWZ,2015,435 +Eswatini,SWZ,2016,436 +Eswatini,SWZ,2017,437 +Ethiopia,ETH,2000,1030 +Ethiopia,ETH,2001,988 +Ethiopia,ETH,2002,985 +Ethiopia,ETH,2003,972 +Ethiopia,ETH,2004,929 +Ethiopia,ETH,2005,865 +Ethiopia,ETH,2006,795 +Ethiopia,ETH,2007,731 +Ethiopia,ETH,2008,681 +Ethiopia,ETH,2009,638 +Ethiopia,ETH,2010,597 +Ethiopia,ETH,2011,558 +Ethiopia,ETH,2012,527 +Ethiopia,ETH,2013,498 +Ethiopia,ETH,2014,472 +Ethiopia,ETH,2015,446 +Ethiopia,ETH,2016,422 +Ethiopia,ETH,2017,401 +Europe,,2000,27 +Europe,,2001,26 +Europe,,2002,25 +Europe,,2003,24 +Europe,,2004,23 +Europe,,2005,22 +Europe,,2006,20 +Europe,,2007,19 +Europe,,2008,18 +Europe,,2009,17 +Europe,,2010,17 +Europe,,2011,16 +Europe,,2012,15 +Europe,,2013,15 +Europe,,2014,14 +Europe,,2015,14 +Europe,,2016,13 +Europe,,2017,13 +Fiji,FJI,2000,51 +Fiji,FJI,2001,49 +Fiji,FJI,2002,48 +Fiji,FJI,2003,48 +Fiji,FJI,2004,47 +Fiji,FJI,2005,46 +Fiji,FJI,2006,44 +Fiji,FJI,2007,43 +Fiji,FJI,2008,42 +Fiji,FJI,2009,40 +Fiji,FJI,2010,39 +Fiji,FJI,2011,38 +Fiji,FJI,2012,38 +Fiji,FJI,2013,37 +Fiji,FJI,2014,36 +Fiji,FJI,2015,35 +Fiji,FJI,2016,34 +Fiji,FJI,2017,34 +Finland,FIN,2000,6 +Finland,FIN,2001,5 +Finland,FIN,2002,5 +Finland,FIN,2003,5 +Finland,FIN,2004,5 +Finland,FIN,2005,5 +Finland,FIN,2006,4 +Finland,FIN,2007,4 +Finland,FIN,2008,4 +Finland,FIN,2009,4 +Finland,FIN,2010,4 +Finland,FIN,2011,4 +Finland,FIN,2012,4 +Finland,FIN,2013,4 +Finland,FIN,2014,3 +Finland,FIN,2015,3 +Finland,FIN,2016,3 +Finland,FIN,2017,3 +France,FRA,2000,10 +France,FRA,2001,10 +France,FRA,2002,10 +France,FRA,2003,9 +France,FRA,2004,9 +France,FRA,2005,9 +France,FRA,2006,9 +France,FRA,2007,9 +France,FRA,2008,9 +France,FRA,2009,9 +France,FRA,2010,9 +France,FRA,2011,9 +France,FRA,2012,9 +France,FRA,2013,9 +France,FRA,2014,8 +France,FRA,2015,8 +France,FRA,2016,8 +France,FRA,2017,8 +Gabon,GAB,2000,380 +Gabon,GAB,2001,370 +Gabon,GAB,2002,361 +Gabon,GAB,2003,356 +Gabon,GAB,2004,354 +Gabon,GAB,2005,348 +Gabon,GAB,2006,340 +Gabon,GAB,2007,336 +Gabon,GAB,2008,332 +Gabon,GAB,2009,324 +Gabon,GAB,2010,314 +Gabon,GAB,2011,304 +Gabon,GAB,2012,292 +Gabon,GAB,2013,277 +Gabon,GAB,2014,267 +Gabon,GAB,2015,261 +Gabon,GAB,2016,256 +Gabon,GAB,2017,252 +Gambia,GMB,2000,932 +Gambia,GMB,2001,905 +Gambia,GMB,2002,876 +Gambia,GMB,2003,843 +Gambia,GMB,2004,802 +Gambia,GMB,2005,756 +Gambia,GMB,2006,716 +Gambia,GMB,2007,690 +Gambia,GMB,2008,675 +Gambia,GMB,2009,668 +Gambia,GMB,2010,661 +Gambia,GMB,2011,656 +Gambia,GMB,2012,650 +Gambia,GMB,2013,644 +Gambia,GMB,2014,637 +Gambia,GMB,2015,625 +Gambia,GMB,2016,611 +Gambia,GMB,2017,597 +Georgia,GEO,2000,31 +Georgia,GEO,2001,33 +Georgia,GEO,2002,42 +Georgia,GEO,2003,37 +Georgia,GEO,2004,38 +Georgia,GEO,2005,39 +Georgia,GEO,2006,33 +Georgia,GEO,2007,36 +Georgia,GEO,2008,39 +Georgia,GEO,2009,43 +Georgia,GEO,2010,32 +Georgia,GEO,2011,32 +Georgia,GEO,2012,30 +Georgia,GEO,2013,30 +Georgia,GEO,2014,29 +Georgia,GEO,2015,27 +Georgia,GEO,2016,26 +Georgia,GEO,2017,25 +Germany,DEU,2000,7 +Germany,DEU,2001,7 +Germany,DEU,2002,7 +Germany,DEU,2003,6 +Germany,DEU,2004,6 +Germany,DEU,2005,6 +Germany,DEU,2006,6 +Germany,DEU,2007,6 +Germany,DEU,2008,6 +Germany,DEU,2009,6 +Germany,DEU,2010,6 +Germany,DEU,2011,6 +Germany,DEU,2012,5 +Germany,DEU,2013,5 +Germany,DEU,2014,5 +Germany,DEU,2015,5 +Germany,DEU,2016,5 +Germany,DEU,2017,7 +Ghana,GHA,2000,484 +Ghana,GHA,2001,445 +Ghana,GHA,2002,415 +Ghana,GHA,2003,398 +Ghana,GHA,2004,384 +Ghana,GHA,2005,371 +Ghana,GHA,2006,359 +Ghana,GHA,2007,349 +Ghana,GHA,2008,342 +Ghana,GHA,2009,339 +Ghana,GHA,2010,339 +Ghana,GHA,2011,339 +Ghana,GHA,2012,336 +Ghana,GHA,2013,331 +Ghana,GHA,2014,325 +Ghana,GHA,2015,320 +Ghana,GHA,2016,314 +Ghana,GHA,2017,308 +Greece,GRC,2000,3 +Greece,GRC,2001,3 +Greece,GRC,2002,3 +Greece,GRC,2003,3 +Greece,GRC,2004,3 +Greece,GRC,2005,3 +Greece,GRC,2006,3 +Greece,GRC,2007,3 +Greece,GRC,2008,3 +Greece,GRC,2009,3 +Greece,GRC,2010,3 +Greece,GRC,2011,3 +Greece,GRC,2012,3 +Greece,GRC,2013,3 +Greece,GRC,2014,3 +Greece,GRC,2015,3 +Greece,GRC,2016,3 +Greece,GRC,2017,3 +Grenada,GRD,2000,38 +Grenada,GRD,2001,36 +Grenada,GRD,2002,34 +Grenada,GRD,2003,34 +Grenada,GRD,2004,38 +Grenada,GRD,2005,33 +Grenada,GRD,2006,31 +Grenada,GRD,2007,31 +Grenada,GRD,2008,30 +Grenada,GRD,2009,30 +Grenada,GRD,2010,29 +Grenada,GRD,2011,28 +Grenada,GRD,2012,28 +Grenada,GRD,2013,27 +Grenada,GRD,2014,26 +Grenada,GRD,2015,25 +Grenada,GRD,2016,25 +Grenada,GRD,2017,25 +Guatemala,GTM,2000,161 +Guatemala,GTM,2001,147 +Guatemala,GTM,2002,145 +Guatemala,GTM,2003,137 +Guatemala,GTM,2004,137 +Guatemala,GTM,2005,142 +Guatemala,GTM,2006,137 +Guatemala,GTM,2007,132 +Guatemala,GTM,2008,125 +Guatemala,GTM,2009,131 +Guatemala,GTM,2010,129 +Guatemala,GTM,2011,122 +Guatemala,GTM,2012,118 +Guatemala,GTM,2013,113 +Guatemala,GTM,2014,107 +Guatemala,GTM,2015,103 +Guatemala,GTM,2016,98 +Guatemala,GTM,2017,95 +Guinea,GIN,2000,1020 +Guinea,GIN,2001,1070 +Guinea,GIN,2002,1090 +Guinea,GIN,2003,1080 +Guinea,GIN,2004,1020 +Guinea,GIN,2005,920 +Guinea,GIN,2006,831 +Guinea,GIN,2007,772 +Guinea,GIN,2008,754 +Guinea,GIN,2009,750 +Guinea,GIN,2010,747 +Guinea,GIN,2011,748 +Guinea,GIN,2012,744 +Guinea,GIN,2013,731 +Guinea,GIN,2014,767 +Guinea,GIN,2015,699 +Guinea,GIN,2016,621 +Guinea,GIN,2017,576 +Guinea-Bissau,GNB,2000,1210 +Guinea-Bissau,GNB,2001,1180 +Guinea-Bissau,GNB,2002,1150 +Guinea-Bissau,GNB,2003,1110 +Guinea-Bissau,GNB,2004,1050 +Guinea-Bissau,GNB,2005,979 +Guinea-Bissau,GNB,2006,912 +Guinea-Bissau,GNB,2007,860 +Guinea-Bissau,GNB,2008,827 +Guinea-Bissau,GNB,2009,800 +Guinea-Bissau,GNB,2010,779 +Guinea-Bissau,GNB,2011,762 +Guinea-Bissau,GNB,2012,744 +Guinea-Bissau,GNB,2013,726 +Guinea-Bissau,GNB,2014,711 +Guinea-Bissau,GNB,2015,694 +Guinea-Bissau,GNB,2016,679 +Guinea-Bissau,GNB,2017,667 +Guyana,GUY,2000,231 +Guyana,GUY,2001,216 +Guyana,GUY,2002,227 +Guyana,GUY,2003,226 +Guyana,GUY,2004,220 +Guyana,GUY,2005,223 +Guyana,GUY,2006,221 +Guyana,GUY,2007,208 +Guyana,GUY,2008,192 +Guyana,GUY,2009,185 +Guyana,GUY,2010,179 +Guyana,GUY,2011,180 +Guyana,GUY,2012,185 +Guyana,GUY,2013,175 +Guyana,GUY,2014,174 +Guyana,GUY,2015,172 +Guyana,GUY,2016,170 +Guyana,GUY,2017,169 +Haiti,HTI,2000,437 +Haiti,HTI,2001,437 +Haiti,HTI,2002,441 +Haiti,HTI,2003,446 +Haiti,HTI,2004,513 +Haiti,HTI,2005,459 +Haiti,HTI,2006,467 +Haiti,HTI,2007,473 +Haiti,HTI,2008,484 +Haiti,HTI,2009,484 +Haiti,HTI,2010,506 +Haiti,HTI,2011,496 +Haiti,HTI,2012,500 +Haiti,HTI,2013,496 +Haiti,HTI,2014,492 +Haiti,HTI,2015,488 +Haiti,HTI,2016,489 +Haiti,HTI,2017,480 +Honduras,HND,2000,85 +Honduras,HND,2001,83 +Honduras,HND,2002,80 +Honduras,HND,2003,78 +Honduras,HND,2004,77 +Honduras,HND,2005,77 +Honduras,HND,2006,77 +Honduras,HND,2007,77 +Honduras,HND,2008,76 +Honduras,HND,2009,75 +Honduras,HND,2010,74 +Honduras,HND,2011,72 +Honduras,HND,2012,70 +Honduras,HND,2013,69 +Honduras,HND,2014,68 +Honduras,HND,2015,67 +Honduras,HND,2016,65 +Honduras,HND,2017,65 +Hungary,HUN,2000,16 +Hungary,HUN,2001,15 +Hungary,HUN,2002,16 +Hungary,HUN,2003,15 +Hungary,HUN,2004,15 +Hungary,HUN,2005,15 +Hungary,HUN,2006,14 +Hungary,HUN,2007,15 +Hungary,HUN,2008,14 +Hungary,HUN,2009,13 +Hungary,HUN,2010,13 +Hungary,HUN,2011,13 +Hungary,HUN,2012,12 +Hungary,HUN,2013,12 +Hungary,HUN,2014,12 +Hungary,HUN,2015,12 +Hungary,HUN,2016,12 +Hungary,HUN,2017,12 +Iceland,ISL,2000,6 +Iceland,ISL,2001,6 +Iceland,ISL,2002,6 +Iceland,ISL,2003,6 +Iceland,ISL,2004,6 +Iceland,ISL,2005,5 +Iceland,ISL,2006,5 +Iceland,ISL,2007,5 +Iceland,ISL,2008,5 +Iceland,ISL,2009,5 +Iceland,ISL,2010,5 +Iceland,ISL,2011,5 +Iceland,ISL,2012,4 +Iceland,ISL,2013,4 +Iceland,ISL,2014,5 +Iceland,ISL,2015,4 +Iceland,ISL,2016,4 +Iceland,ISL,2017,4 +India,IND,2000,370 +India,IND,2001,354 +India,IND,2002,336 +India,IND,2003,319 +India,IND,2004,303 +India,IND,2005,286 +India,IND,2006,270 +India,IND,2007,255 +India,IND,2008,240 +India,IND,2009,225 +India,IND,2010,210 +India,IND,2011,197 +India,IND,2012,185 +India,IND,2013,175 +India,IND,2014,166 +India,IND,2015,158 +India,IND,2016,150 +India,IND,2017,145 +Indonesia,IDN,2000,272 +Indonesia,IDN,2001,269 +Indonesia,IDN,2002,265 +Indonesia,IDN,2003,261 +Indonesia,IDN,2004,264 +Indonesia,IDN,2005,252 +Indonesia,IDN,2006,249 +Indonesia,IDN,2007,243 +Indonesia,IDN,2008,239 +Indonesia,IDN,2009,234 +Indonesia,IDN,2010,228 +Indonesia,IDN,2011,221 +Indonesia,IDN,2012,214 +Indonesia,IDN,2013,207 +Indonesia,IDN,2014,199 +Indonesia,IDN,2015,192 +Indonesia,IDN,2016,184 +Indonesia,IDN,2017,177 +Iran,IRN,2000,48 +Iran,IRN,2001,44 +Iran,IRN,2002,41 +Iran,IRN,2003,39 +Iran,IRN,2004,36 +Iran,IRN,2005,34 +Iran,IRN,2006,32 +Iran,IRN,2007,30 +Iran,IRN,2008,28 +Iran,IRN,2009,25 +Iran,IRN,2010,22 +Iran,IRN,2011,19 +Iran,IRN,2012,18 +Iran,IRN,2013,17 +Iran,IRN,2014,17 +Iran,IRN,2015,17 +Iran,IRN,2016,16 +Iran,IRN,2017,16 +Iraq,IRQ,2000,79 +Iraq,IRQ,2001,76 +Iraq,IRQ,2002,74 +Iraq,IRQ,2003,136 +Iraq,IRQ,2004,122 +Iraq,IRQ,2005,127 +Iraq,IRQ,2006,158 +Iraq,IRQ,2007,138 +Iraq,IRQ,2008,90 +Iraq,IRQ,2009,75 +Iraq,IRQ,2010,70 +Iraq,IRQ,2011,67 +Iraq,IRQ,2012,66 +Iraq,IRQ,2013,75 +Iraq,IRQ,2014,92 +Iraq,IRQ,2015,83 +Iraq,IRQ,2016,78 +Iraq,IRQ,2017,79 +Ireland,IRL,2000,7 +Ireland,IRL,2001,7 +Ireland,IRL,2002,6 +Ireland,IRL,2003,6 +Ireland,IRL,2004,6 +Ireland,IRL,2005,7 +Ireland,IRL,2006,6 +Ireland,IRL,2007,6 +Ireland,IRL,2008,7 +Ireland,IRL,2009,7 +Ireland,IRL,2010,6 +Ireland,IRL,2011,7 +Ireland,IRL,2012,6 +Ireland,IRL,2013,6 +Ireland,IRL,2014,6 +Ireland,IRL,2015,6 +Ireland,IRL,2016,6 +Ireland,IRL,2017,5 +Israel,ISR,2000,7 +Israel,ISR,2001,7 +Israel,ISR,2002,7 +Israel,ISR,2003,6 +Israel,ISR,2004,6 +Israel,ISR,2005,5 +Israel,ISR,2006,5 +Israel,ISR,2007,5 +Israel,ISR,2008,4 +Israel,ISR,2009,4 +Israel,ISR,2010,4 +Israel,ISR,2011,4 +Israel,ISR,2012,4 +Israel,ISR,2013,4 +Israel,ISR,2014,4 +Israel,ISR,2015,3 +Israel,ISR,2016,3 +Israel,ISR,2017,3 +Italy,ITA,2000,4 +Italy,ITA,2001,3 +Italy,ITA,2002,3 +Italy,ITA,2003,3 +Italy,ITA,2004,3 +Italy,ITA,2005,3 +Italy,ITA,2006,2 +Italy,ITA,2007,2 +Italy,ITA,2008,2 +Italy,ITA,2009,2 +Italy,ITA,2010,2 +Italy,ITA,2011,2 +Italy,ITA,2012,2 +Italy,ITA,2013,2 +Italy,ITA,2014,2 +Italy,ITA,2015,2 +Italy,ITA,2016,2 +Italy,ITA,2017,2 +Jamaica,JAM,2000,77 +Jamaica,JAM,2001,79 +Jamaica,JAM,2002,78 +Jamaica,JAM,2003,79 +Jamaica,JAM,2004,80 +Jamaica,JAM,2005,80 +Jamaica,JAM,2006,79 +Jamaica,JAM,2007,79 +Jamaica,JAM,2008,79 +Jamaica,JAM,2009,79 +Jamaica,JAM,2010,79 +Jamaica,JAM,2011,79 +Jamaica,JAM,2012,79 +Jamaica,JAM,2013,79 +Jamaica,JAM,2014,78 +Jamaica,JAM,2015,78 +Jamaica,JAM,2016,80 +Jamaica,JAM,2017,80 +Japan,JPN,2000,9 +Japan,JPN,2001,8 +Japan,JPN,2002,8 +Japan,JPN,2003,7 +Japan,JPN,2004,7 +Japan,JPN,2005,7 +Japan,JPN,2006,7 +Japan,JPN,2007,6 +Japan,JPN,2008,6 +Japan,JPN,2009,6 +Japan,JPN,2010,6 +Japan,JPN,2011,6 +Japan,JPN,2012,5 +Japan,JPN,2013,5 +Japan,JPN,2014,5 +Japan,JPN,2015,5 +Japan,JPN,2016,5 +Japan,JPN,2017,5 +Jordan,JOR,2000,70 +Jordan,JOR,2001,68 +Jordan,JOR,2002,65 +Jordan,JOR,2003,63 +Jordan,JOR,2004,62 +Jordan,JOR,2005,62 +Jordan,JOR,2006,58 +Jordan,JOR,2007,56 +Jordan,JOR,2008,55 +Jordan,JOR,2009,54 +Jordan,JOR,2010,53 +Jordan,JOR,2011,52 +Jordan,JOR,2012,52 +Jordan,JOR,2013,51 +Jordan,JOR,2014,49 +Jordan,JOR,2015,48 +Jordan,JOR,2016,47 +Jordan,JOR,2017,46 +Kazakhstan,KAZ,2000,61 +Kazakhstan,KAZ,2001,57 +Kazakhstan,KAZ,2002,52 +Kazakhstan,KAZ,2003,49 +Kazakhstan,KAZ,2004,46 +Kazakhstan,KAZ,2005,43 +Kazakhstan,KAZ,2006,40 +Kazakhstan,KAZ,2007,36 +Kazakhstan,KAZ,2008,30 +Kazakhstan,KAZ,2009,24 +Kazakhstan,KAZ,2010,22 +Kazakhstan,KAZ,2011,19 +Kazakhstan,KAZ,2012,17 +Kazakhstan,KAZ,2013,14 +Kazakhstan,KAZ,2014,13 +Kazakhstan,KAZ,2015,12 +Kazakhstan,KAZ,2016,10 +Kazakhstan,KAZ,2017,10 +Kenya,KEN,2000,708 +Kenya,KEN,2001,702 +Kenya,KEN,2002,692 +Kenya,KEN,2003,678 +Kenya,KEN,2004,653 +Kenya,KEN,2005,618 +Kenya,KEN,2006,583 +Kenya,KEN,2007,545 +Kenya,KEN,2008,513 +Kenya,KEN,2009,472 +Kenya,KEN,2010,432 +Kenya,KEN,2011,398 +Kenya,KEN,2012,373 +Kenya,KEN,2013,364 +Kenya,KEN,2014,358 +Kenya,KEN,2015,353 +Kenya,KEN,2016,346 +Kenya,KEN,2017,342 +Kiribati,KIR,2000,136 +Kiribati,KIR,2001,131 +Kiribati,KIR,2002,127 +Kiribati,KIR,2003,124 +Kiribati,KIR,2004,121 +Kiribati,KIR,2005,119 +Kiribati,KIR,2006,117 +Kiribati,KIR,2007,115 +Kiribati,KIR,2008,115 +Kiribati,KIR,2009,113 +Kiribati,KIR,2010,112 +Kiribati,KIR,2011,110 +Kiribati,KIR,2012,107 +Kiribati,KIR,2013,104 +Kiribati,KIR,2014,100 +Kiribati,KIR,2015,97 +Kiribati,KIR,2016,94 +Kiribati,KIR,2017,92 +Kuwait,KWT,2000,10 +Kuwait,KWT,2001,10 +Kuwait,KWT,2002,10 +Kuwait,KWT,2003,10 +Kuwait,KWT,2004,10 +Kuwait,KWT,2005,10 +Kuwait,KWT,2006,10 +Kuwait,KWT,2007,10 +Kuwait,KWT,2008,10 +Kuwait,KWT,2009,10 +Kuwait,KWT,2010,10 +Kuwait,KWT,2011,10 +Kuwait,KWT,2012,11 +Kuwait,KWT,2013,11 +Kuwait,KWT,2014,11 +Kuwait,KWT,2015,11 +Kuwait,KWT,2016,12 +Kuwait,KWT,2017,12 +Kyrgyzstan,KGZ,2000,79 +Kyrgyzstan,KGZ,2001,76 +Kyrgyzstan,KGZ,2002,83 +Kyrgyzstan,KGZ,2003,82 +Kyrgyzstan,KGZ,2004,79 +Kyrgyzstan,KGZ,2005,82 +Kyrgyzstan,KGZ,2006,85 +Kyrgyzstan,KGZ,2007,84 +Kyrgyzstan,KGZ,2008,81 +Kyrgyzstan,KGZ,2009,80 +Kyrgyzstan,KGZ,2010,79 +Kyrgyzstan,KGZ,2011,79 +Kyrgyzstan,KGZ,2012,74 +Kyrgyzstan,KGZ,2013,70 +Kyrgyzstan,KGZ,2014,69 +Kyrgyzstan,KGZ,2015,66 +Kyrgyzstan,KGZ,2016,63 +Kyrgyzstan,KGZ,2017,60 +Laos,LAO,2000,544 +Laos,LAO,2001,517 +Laos,LAO,2002,491 +Laos,LAO,2003,465 +Laos,LAO,2004,437 +Laos,LAO,2005,410 +Laos,LAO,2006,385 +Laos,LAO,2007,360 +Laos,LAO,2008,336 +Laos,LAO,2009,314 +Laos,LAO,2010,292 +Laos,LAO,2011,272 +Laos,LAO,2012,254 +Laos,LAO,2013,238 +Laos,LAO,2014,223 +Laos,LAO,2015,209 +Laos,LAO,2016,196 +Laos,LAO,2017,185 +Latvia,LVA,2000,34 +Latvia,LVA,2001,35 +Latvia,LVA,2002,33 +Latvia,LVA,2003,34 +Latvia,LVA,2004,32 +Latvia,LVA,2005,30 +Latvia,LVA,2006,32 +Latvia,LVA,2007,32 +Latvia,LVA,2008,29 +Latvia,LVA,2009,28 +Latvia,LVA,2010,26 +Latvia,LVA,2011,26 +Latvia,LVA,2012,23 +Latvia,LVA,2013,27 +Latvia,LVA,2014,24 +Latvia,LVA,2015,23 +Latvia,LVA,2016,26 +Latvia,LVA,2017,19 +Lebanon,LBN,2000,28 +Lebanon,LBN,2001,27 +Lebanon,LBN,2002,26 +Lebanon,LBN,2003,25 +Lebanon,LBN,2004,24 +Lebanon,LBN,2005,24 +Lebanon,LBN,2006,24 +Lebanon,LBN,2007,23 +Lebanon,LBN,2008,23 +Lebanon,LBN,2009,23 +Lebanon,LBN,2010,23 +Lebanon,LBN,2011,25 +Lebanon,LBN,2012,25 +Lebanon,LBN,2013,27 +Lebanon,LBN,2014,28 +Lebanon,LBN,2015,29 +Lebanon,LBN,2016,29 +Lebanon,LBN,2017,29 +Lesotho,LSO,2000,614 +Lesotho,LSO,2001,633 +Lesotho,LSO,2002,653 +Lesotho,LSO,2003,671 +Lesotho,LSO,2004,680 +Lesotho,LSO,2005,679 +Lesotho,LSO,2006,668 +Lesotho,LSO,2007,652 +Lesotho,LSO,2008,623 +Lesotho,LSO,2009,607 +Lesotho,LSO,2010,594 +Lesotho,LSO,2011,585 +Lesotho,LSO,2012,586 +Lesotho,LSO,2013,583 +Lesotho,LSO,2014,579 +Lesotho,LSO,2015,574 +Lesotho,LSO,2016,559 +Lesotho,LSO,2017,544 +Liberia,LBR,2000,894 +Liberia,LBR,2001,913 +Liberia,LBR,2002,1010 +Liberia,LBR,2003,878 +Liberia,LBR,2004,837 +Liberia,LBR,2005,816 +Liberia,LBR,2006,782 +Liberia,LBR,2007,754 +Liberia,LBR,2008,738 +Liberia,LBR,2009,724 +Liberia,LBR,2010,708 +Liberia,LBR,2011,694 +Liberia,LBR,2012,683 +Liberia,LBR,2013,674 +Liberia,LBR,2014,688 +Liberia,LBR,2015,691 +Liberia,LBR,2016,661 +Liberia,LBR,2017,661 +Libya,LBY,2000,70 +Libya,LBY,2001,68 +Libya,LBY,2002,66 +Libya,LBY,2003,64 +Libya,LBY,2004,61 +Libya,LBY,2005,57 +Libya,LBY,2006,55 +Libya,LBY,2007,53 +Libya,LBY,2008,52 +Libya,LBY,2009,53 +Libya,LBY,2010,53 +Libya,LBY,2011,56 +Libya,LBY,2012,55 +Libya,LBY,2013,58 +Libya,LBY,2014,63 +Libya,LBY,2015,70 +Libya,LBY,2016,73 +Libya,LBY,2017,72 +Lithuania,LTU,2000,17 +Lithuania,LTU,2001,16 +Lithuania,LTU,2002,14 +Lithuania,LTU,2003,14 +Lithuania,LTU,2004,13 +Lithuania,LTU,2005,14 +Lithuania,LTU,2006,14 +Lithuania,LTU,2007,14 +Lithuania,LTU,2008,13 +Lithuania,LTU,2009,11 +Lithuania,LTU,2010,10 +Lithuania,LTU,2011,10 +Lithuania,LTU,2012,10 +Lithuania,LTU,2013,10 +Lithuania,LTU,2014,9 +Lithuania,LTU,2015,9 +Lithuania,LTU,2016,8 +Lithuania,LTU,2017,8 +Luxembourg,LUX,2000,10 +Luxembourg,LUX,2001,10 +Luxembourg,LUX,2002,9 +Luxembourg,LUX,2003,8 +Luxembourg,LUX,2004,8 +Luxembourg,LUX,2005,9 +Luxembourg,LUX,2006,9 +Luxembourg,LUX,2007,8 +Luxembourg,LUX,2008,6 +Luxembourg,LUX,2009,7 +Luxembourg,LUX,2010,8 +Luxembourg,LUX,2011,8 +Luxembourg,LUX,2012,7 +Luxembourg,LUX,2013,6 +Luxembourg,LUX,2014,6 +Luxembourg,LUX,2015,5 +Luxembourg,LUX,2016,5 +Luxembourg,LUX,2017,5 +Madagascar,MDG,2000,559 +Madagascar,MDG,2001,552 +Madagascar,MDG,2002,547 +Madagascar,MDG,2003,543 +Madagascar,MDG,2004,539 +Madagascar,MDG,2005,526 +Madagascar,MDG,2006,513 +Madagascar,MDG,2007,503 +Madagascar,MDG,2008,491 +Madagascar,MDG,2009,474 +Madagascar,MDG,2010,453 +Madagascar,MDG,2011,432 +Madagascar,MDG,2012,413 +Madagascar,MDG,2013,394 +Madagascar,MDG,2014,378 +Madagascar,MDG,2015,363 +Madagascar,MDG,2016,348 +Madagascar,MDG,2017,335 +Malawi,MWI,2000,749 +Malawi,MWI,2001,735 +Malawi,MWI,2002,714 +Malawi,MWI,2003,687 +Malawi,MWI,2004,654 +Malawi,MWI,2005,610 +Malawi,MWI,2006,566 +Malawi,MWI,2007,526 +Malawi,MWI,2008,493 +Malawi,MWI,2009,466 +Malawi,MWI,2010,444 +Malawi,MWI,2011,428 +Malawi,MWI,2012,413 +Malawi,MWI,2013,396 +Malawi,MWI,2014,381 +Malawi,MWI,2015,370 +Malawi,MWI,2016,358 +Malawi,MWI,2017,349 +Malaysia,MYS,2000,38 +Malaysia,MYS,2001,36 +Malaysia,MYS,2002,34 +Malaysia,MYS,2003,33 +Malaysia,MYS,2004,32 +Malaysia,MYS,2005,31 +Malaysia,MYS,2006,30 +Malaysia,MYS,2007,30 +Malaysia,MYS,2008,29 +Malaysia,MYS,2009,29 +Malaysia,MYS,2010,30 +Malaysia,MYS,2011,30 +Malaysia,MYS,2012,30 +Malaysia,MYS,2013,30 +Malaysia,MYS,2014,30 +Malaysia,MYS,2015,30 +Malaysia,MYS,2016,29 +Malaysia,MYS,2017,29 +Maldives,MDV,2000,125 +Maldives,MDV,2001,111 +Maldives,MDV,2002,105 +Maldives,MDV,2003,97 +Maldives,MDV,2004,89 +Maldives,MDV,2005,75 +Maldives,MDV,2006,71 +Maldives,MDV,2007,71 +Maldives,MDV,2008,72 +Maldives,MDV,2009,71 +Maldives,MDV,2010,67 +Maldives,MDV,2011,62 +Maldives,MDV,2012,60 +Maldives,MDV,2013,58 +Maldives,MDV,2014,56 +Maldives,MDV,2015,54 +Maldives,MDV,2016,54 +Maldives,MDV,2017,53 +Mali,MLI,2000,836 +Mali,MLI,2001,797 +Mali,MLI,2002,764 +Mali,MLI,2003,739 +Mali,MLI,2004,715 +Mali,MLI,2005,691 +Mali,MLI,2006,675 +Mali,MLI,2007,663 +Mali,MLI,2008,661 +Mali,MLI,2009,661 +Mali,MLI,2010,660 +Mali,MLI,2011,663 +Mali,MLI,2012,663 +Mali,MLI,2013,663 +Mali,MLI,2014,642 +Mali,MLI,2015,620 +Mali,MLI,2016,590 +Mali,MLI,2017,562 +Malta,MLT,2000,9 +Malta,MLT,2001,10 +Malta,MLT,2002,9 +Malta,MLT,2003,10 +Malta,MLT,2004,9 +Malta,MLT,2005,8 +Malta,MLT,2006,8 +Malta,MLT,2007,8 +Malta,MLT,2008,8 +Malta,MLT,2009,7 +Malta,MLT,2010,8 +Malta,MLT,2011,7 +Malta,MLT,2012,7 +Malta,MLT,2013,7 +Malta,MLT,2014,6 +Malta,MLT,2015,7 +Malta,MLT,2016,6 +Malta,MLT,2017,6 +Mauritania,MRT,2000,834 +Mauritania,MRT,2001,835 +Mauritania,MRT,2002,836 +Mauritania,MRT,2003,836 +Mauritania,MRT,2004,830 +Mauritania,MRT,2005,826 +Mauritania,MRT,2006,821 +Mauritania,MRT,2007,820 +Mauritania,MRT,2008,819 +Mauritania,MRT,2009,822 +Mauritania,MRT,2010,824 +Mauritania,MRT,2011,822 +Mauritania,MRT,2012,812 +Mauritania,MRT,2013,805 +Mauritania,MRT,2014,796 +Mauritania,MRT,2015,785 +Mauritania,MRT,2016,777 +Mauritania,MRT,2017,766 +Mauritius,MUS,2000,59 +Mauritius,MUS,2001,54 +Mauritius,MUS,2002,54 +Mauritius,MUS,2003,57 +Mauritius,MUS,2004,54 +Mauritius,MUS,2005,53 +Mauritius,MUS,2006,55 +Mauritius,MUS,2007,56 +Mauritius,MUS,2008,53 +Mauritius,MUS,2009,59 +Mauritius,MUS,2010,66 +Mauritius,MUS,2011,54 +Mauritius,MUS,2012,63 +Mauritius,MUS,2013,60 +Mauritius,MUS,2014,70 +Mauritius,MUS,2015,73 +Mauritius,MUS,2016,67 +Mauritius,MUS,2017,61 +Mexico,MEX,2000,55 +Mexico,MEX,2001,55 +Mexico,MEX,2002,56 +Mexico,MEX,2003,55 +Mexico,MEX,2004,54 +Mexico,MEX,2005,54 +Mexico,MEX,2006,51 +Mexico,MEX,2007,49 +Mexico,MEX,2008,49 +Mexico,MEX,2009,51 +Mexico,MEX,2010,46 +Mexico,MEX,2011,43 +Mexico,MEX,2012,41 +Mexico,MEX,2013,39 +Mexico,MEX,2014,38 +Mexico,MEX,2015,36 +Mexico,MEX,2016,34 +Mexico,MEX,2017,33 +Micronesia (country),FSM,2000,154 +Micronesia (country),FSM,2001,150 +Micronesia (country),FSM,2002,163 +Micronesia (country),FSM,2003,141 +Micronesia (country),FSM,2004,137 +Micronesia (country),FSM,2005,133 +Micronesia (country),FSM,2006,128 +Micronesia (country),FSM,2007,123 +Micronesia (country),FSM,2008,118 +Micronesia (country),FSM,2009,114 +Micronesia (country),FSM,2010,110 +Micronesia (country),FSM,2011,106 +Micronesia (country),FSM,2012,103 +Micronesia (country),FSM,2013,99 +Micronesia (country),FSM,2014,96 +Micronesia (country),FSM,2015,95 +Micronesia (country),FSM,2016,90 +Micronesia (country),FSM,2017,88 +Moldova,MDA,2000,44 +Moldova,MDA,2001,39 +Moldova,MDA,2002,38 +Moldova,MDA,2003,36 +Moldova,MDA,2004,32 +Moldova,MDA,2005,34 +Moldova,MDA,2006,31 +Moldova,MDA,2007,31 +Moldova,MDA,2008,29 +Moldova,MDA,2009,28 +Moldova,MDA,2010,29 +Moldova,MDA,2011,21 +Moldova,MDA,2012,22 +Moldova,MDA,2013,21 +Moldova,MDA,2014,23 +Moldova,MDA,2015,22 +Moldova,MDA,2016,20 +Moldova,MDA,2017,19 +Mongolia,MNG,2000,155 +Mongolia,MNG,2001,138 +Mongolia,MNG,2002,124 +Mongolia,MNG,2003,114 +Mongolia,MNG,2004,106 +Mongolia,MNG,2005,98 +Mongolia,MNG,2006,91 +Mongolia,MNG,2007,85 +Mongolia,MNG,2008,80 +Mongolia,MNG,2009,73 +Mongolia,MNG,2010,66 +Mongolia,MNG,2011,59 +Mongolia,MNG,2012,54 +Mongolia,MNG,2013,51 +Mongolia,MNG,2014,49 +Mongolia,MNG,2015,47 +Mongolia,MNG,2016,46 +Mongolia,MNG,2017,45 +Montenegro,MNE,2000,12 +Montenegro,MNE,2001,12 +Montenegro,MNE,2002,11 +Montenegro,MNE,2003,11 +Montenegro,MNE,2004,10 +Montenegro,MNE,2005,9 +Montenegro,MNE,2006,9 +Montenegro,MNE,2007,8 +Montenegro,MNE,2008,8 +Montenegro,MNE,2009,8 +Montenegro,MNE,2010,7 +Montenegro,MNE,2011,7 +Montenegro,MNE,2012,7 +Montenegro,MNE,2013,6 +Montenegro,MNE,2014,6 +Montenegro,MNE,2015,6 +Montenegro,MNE,2016,6 +Montenegro,MNE,2017,6 +Morocco,MAR,2000,188 +Morocco,MAR,2001,174 +Morocco,MAR,2002,162 +Morocco,MAR,2003,152 +Morocco,MAR,2004,142 +Morocco,MAR,2005,131 +Morocco,MAR,2006,121 +Morocco,MAR,2007,113 +Morocco,MAR,2008,106 +Morocco,MAR,2009,99 +Morocco,MAR,2010,92 +Morocco,MAR,2011,86 +Morocco,MAR,2012,81 +Morocco,MAR,2013,78 +Morocco,MAR,2014,76 +Morocco,MAR,2015,74 +Morocco,MAR,2016,72 +Morocco,MAR,2017,70 +Mozambique,MOZ,2000,798 +Mozambique,MOZ,2001,745 +Mozambique,MOZ,2002,700 +Mozambique,MOZ,2003,657 +Mozambique,MOZ,2004,615 +Mozambique,MOZ,2005,577 +Mozambique,MOZ,2006,539 +Mozambique,MOZ,2007,505 +Mozambique,MOZ,2008,471 +Mozambique,MOZ,2009,439 +Mozambique,MOZ,2010,412 +Mozambique,MOZ,2011,389 +Mozambique,MOZ,2012,371 +Mozambique,MOZ,2013,356 +Mozambique,MOZ,2014,339 +Mozambique,MOZ,2015,318 +Mozambique,MOZ,2016,301 +Mozambique,MOZ,2017,289 +Myanmar,MMR,2000,340 +Myanmar,MMR,2001,331 +Myanmar,MMR,2002,323 +Myanmar,MMR,2003,314 +Myanmar,MMR,2004,307 +Myanmar,MMR,2005,299 +Myanmar,MMR,2006,293 +Myanmar,MMR,2007,287 +Myanmar,MMR,2008,289 +Myanmar,MMR,2009,274 +Myanmar,MMR,2010,265 +Myanmar,MMR,2011,259 +Myanmar,MMR,2012,254 +Myanmar,MMR,2013,251 +Myanmar,MMR,2014,247 +Myanmar,MMR,2015,246 +Myanmar,MMR,2016,245 +Myanmar,MMR,2017,250 +Namibia,NAM,2000,348 +Namibia,NAM,2001,352 +Namibia,NAM,2002,356 +Namibia,NAM,2003,359 +Namibia,NAM,2004,358 +Namibia,NAM,2005,346 +Namibia,NAM,2006,328 +Namibia,NAM,2007,306 +Namibia,NAM,2008,284 +Namibia,NAM,2009,276 +Namibia,NAM,2010,266 +Namibia,NAM,2011,256 +Namibia,NAM,2012,240 +Namibia,NAM,2013,231 +Namibia,NAM,2014,223 +Namibia,NAM,2015,217 +Namibia,NAM,2016,207 +Namibia,NAM,2017,195 +Nepal,NPL,2000,553 +Nepal,NPL,2001,521 +Nepal,NPL,2002,520 +Nepal,NPL,2003,470 +Nepal,NPL,2004,447 +Nepal,NPL,2005,415 +Nepal,NPL,2006,386 +Nepal,NPL,2007,361 +Nepal,NPL,2008,342 +Nepal,NPL,2009,323 +Nepal,NPL,2010,305 +Nepal,NPL,2011,285 +Nepal,NPL,2012,266 +Nepal,NPL,2013,248 +Nepal,NPL,2014,231 +Nepal,NPL,2015,236 +Nepal,NPL,2016,200 +Nepal,NPL,2017,186 +Netherlands,NLD,2000,13 +Netherlands,NLD,2001,13 +Netherlands,NLD,2002,13 +Netherlands,NLD,2003,12 +Netherlands,NLD,2004,11 +Netherlands,NLD,2005,11 +Netherlands,NLD,2006,9 +Netherlands,NLD,2007,9 +Netherlands,NLD,2008,8 +Netherlands,NLD,2009,8 +Netherlands,NLD,2010,7 +Netherlands,NLD,2011,7 +Netherlands,NLD,2012,7 +Netherlands,NLD,2013,6 +Netherlands,NLD,2014,6 +Netherlands,NLD,2015,6 +Netherlands,NLD,2016,6 +Netherlands,NLD,2017,5 +New Zealand,NZL,2000,12 +New Zealand,NZL,2001,11 +New Zealand,NZL,2002,12 +New Zealand,NZL,2003,12 +New Zealand,NZL,2004,11 +New Zealand,NZL,2005,11 +New Zealand,NZL,2006,11 +New Zealand,NZL,2007,11 +New Zealand,NZL,2008,10 +New Zealand,NZL,2009,11 +New Zealand,NZL,2010,11 +New Zealand,NZL,2011,10 +New Zealand,NZL,2012,10 +New Zealand,NZL,2013,9 +New Zealand,NZL,2014,10 +New Zealand,NZL,2015,10 +New Zealand,NZL,2016,10 +New Zealand,NZL,2017,9 +Nicaragua,NIC,2000,162 +Nicaragua,NIC,2001,157 +Nicaragua,NIC,2002,151 +Nicaragua,NIC,2003,145 +Nicaragua,NIC,2004,138 +Nicaragua,NIC,2005,131 +Nicaragua,NIC,2006,124 +Nicaragua,NIC,2007,121 +Nicaragua,NIC,2008,116 +Nicaragua,NIC,2009,113 +Nicaragua,NIC,2010,112 +Nicaragua,NIC,2011,110 +Nicaragua,NIC,2012,108 +Nicaragua,NIC,2013,105 +Nicaragua,NIC,2014,103 +Nicaragua,NIC,2015,101 +Nicaragua,NIC,2016,100 +Nicaragua,NIC,2017,98 +Niger,NER,2000,813 +Niger,NER,2001,803 +Niger,NER,2002,795 +Niger,NER,2003,782 +Niger,NER,2004,770 +Niger,NER,2005,755 +Niger,NER,2006,739 +Niger,NER,2007,725 +Niger,NER,2008,709 +Niger,NER,2009,688 +Niger,NER,2010,663 +Niger,NER,2011,639 +Niger,NER,2012,616 +Niger,NER,2013,594 +Niger,NER,2014,573 +Niger,NER,2015,555 +Niger,NER,2016,530 +Niger,NER,2017,509 +Nigeria,NGA,2000,1200 +Nigeria,NGA,2001,1200 +Nigeria,NGA,2002,1180 +Nigeria,NGA,2003,1170 +Nigeria,NGA,2004,1130 +Nigeria,NGA,2005,1080 +Nigeria,NGA,2006,1040 +Nigeria,NGA,2007,1010 +Nigeria,NGA,2008,996 +Nigeria,NGA,2009,987 +Nigeria,NGA,2010,978 +Nigeria,NGA,2011,972 +Nigeria,NGA,2012,963 +Nigeria,NGA,2013,951 +Nigeria,NGA,2014,943 +Nigeria,NGA,2015,931 +Nigeria,NGA,2016,925 +Nigeria,NGA,2017,917 +North Korea,PRK,2000,139 +North Korea,PRK,2001,128 +North Korea,PRK,2002,122 +North Korea,PRK,2003,121 +North Korea,PRK,2004,120 +North Korea,PRK,2005,120 +North Korea,PRK,2006,120 +North Korea,PRK,2007,119 +North Korea,PRK,2008,118 +North Korea,PRK,2009,113 +North Korea,PRK,2010,106 +North Korea,PRK,2011,100 +North Korea,PRK,2012,96 +North Korea,PRK,2013,94 +North Korea,PRK,2014,93 +North Korea,PRK,2015,91 +North Korea,PRK,2016,90 +North Korea,PRK,2017,89 +North Macedonia,MKD,2000,13 +North Macedonia,MKD,2001,12 +North Macedonia,MKD,2002,12 +North Macedonia,MKD,2003,10 +North Macedonia,MKD,2004,11 +North Macedonia,MKD,2005,10 +North Macedonia,MKD,2006,10 +North Macedonia,MKD,2007,10 +North Macedonia,MKD,2008,8 +North Macedonia,MKD,2009,8 +North Macedonia,MKD,2010,8 +North Macedonia,MKD,2011,8 +North Macedonia,MKD,2012,8 +North Macedonia,MKD,2013,8 +North Macedonia,MKD,2014,8 +North Macedonia,MKD,2015,8 +North Macedonia,MKD,2016,8 +North Macedonia,MKD,2017,7 +Norway,NOR,2000,6 +Norway,NOR,2001,5 +Norway,NOR,2002,5 +Norway,NOR,2003,5 +Norway,NOR,2004,5 +Norway,NOR,2005,5 +Norway,NOR,2006,4 +Norway,NOR,2007,4 +Norway,NOR,2008,4 +Norway,NOR,2009,4 +Norway,NOR,2010,4 +Norway,NOR,2011,4 +Norway,NOR,2012,3 +Norway,NOR,2013,3 +Norway,NOR,2014,3 +Norway,NOR,2015,3 +Norway,NOR,2016,3 +Norway,NOR,2017,2 +Oman,OMN,2000,20 +Oman,OMN,2001,20 +Oman,OMN,2002,20 +Oman,OMN,2003,20 +Oman,OMN,2004,19 +Oman,OMN,2005,19 +Oman,OMN,2006,18 +Oman,OMN,2007,18 +Oman,OMN,2008,18 +Oman,OMN,2009,18 +Oman,OMN,2010,18 +Oman,OMN,2011,18 +Oman,OMN,2012,18 +Oman,OMN,2013,18 +Oman,OMN,2014,18 +Oman,OMN,2015,19 +Oman,OMN,2016,19 +Oman,OMN,2017,19 +Pakistan,PAK,2000,286 +Pakistan,PAK,2001,275 +Pakistan,PAK,2002,264 +Pakistan,PAK,2003,254 +Pakistan,PAK,2004,243 +Pakistan,PAK,2005,237 +Pakistan,PAK,2006,222 +Pakistan,PAK,2007,214 +Pakistan,PAK,2008,205 +Pakistan,PAK,2009,199 +Pakistan,PAK,2010,191 +Pakistan,PAK,2011,180 +Pakistan,PAK,2012,173 +Pakistan,PAK,2013,166 +Pakistan,PAK,2014,161 +Pakistan,PAK,2015,154 +Pakistan,PAK,2016,143 +Pakistan,PAK,2017,140 +Panama,PAN,2000,91 +Panama,PAN,2001,86 +Panama,PAN,2002,91 +Panama,PAN,2003,93 +Panama,PAN,2004,88 +Panama,PAN,2005,88 +Panama,PAN,2006,88 +Panama,PAN,2007,86 +Panama,PAN,2008,84 +Panama,PAN,2009,82 +Panama,PAN,2010,79 +Panama,PAN,2011,76 +Panama,PAN,2012,74 +Panama,PAN,2013,66 +Panama,PAN,2014,60 +Panama,PAN,2015,58 +Panama,PAN,2016,55 +Panama,PAN,2017,52 +Papua New Guinea,PNG,2000,249 +Papua New Guinea,PNG,2001,242 +Papua New Guinea,PNG,2002,234 +Papua New Guinea,PNG,2003,225 +Papua New Guinea,PNG,2004,213 +Papua New Guinea,PNG,2005,200 +Papua New Guinea,PNG,2006,187 +Papua New Guinea,PNG,2007,179 +Papua New Guinea,PNG,2008,173 +Papua New Guinea,PNG,2009,170 +Papua New Guinea,PNG,2010,168 +Papua New Guinea,PNG,2011,166 +Papua New Guinea,PNG,2012,164 +Papua New Guinea,PNG,2013,160 +Papua New Guinea,PNG,2014,155 +Papua New Guinea,PNG,2015,151 +Papua New Guinea,PNG,2016,148 +Papua New Guinea,PNG,2017,145 +Paraguay,PRY,2000,165 +Paraguay,PRY,2001,160 +Paraguay,PRY,2002,155 +Paraguay,PRY,2003,150 +Paraguay,PRY,2004,144 +Paraguay,PRY,2005,137 +Paraguay,PRY,2006,130 +Paraguay,PRY,2007,124 +Paraguay,PRY,2008,118 +Paraguay,PRY,2009,113 +Paraguay,PRY,2010,108 +Paraguay,PRY,2011,103 +Paraguay,PRY,2012,98 +Paraguay,PRY,2013,94 +Paraguay,PRY,2014,91 +Paraguay,PRY,2015,88 +Paraguay,PRY,2016,86 +Paraguay,PRY,2017,84 +Peru,PER,2000,144 +Peru,PER,2001,138 +Peru,PER,2002,132 +Peru,PER,2003,127 +Peru,PER,2004,122 +Peru,PER,2005,118 +Peru,PER,2006,114 +Peru,PER,2007,112 +Peru,PER,2008,108 +Peru,PER,2009,106 +Peru,PER,2010,104 +Peru,PER,2011,102 +Peru,PER,2012,100 +Peru,PER,2013,98 +Peru,PER,2014,96 +Peru,PER,2015,94 +Peru,PER,2016,91 +Peru,PER,2017,88 +Philippines,PHL,2000,160 +Philippines,PHL,2001,163 +Philippines,PHL,2002,160 +Philippines,PHL,2003,156 +Philippines,PHL,2004,156 +Philippines,PHL,2005,156 +Philippines,PHL,2006,156 +Philippines,PHL,2007,149 +Philippines,PHL,2008,148 +Philippines,PHL,2009,149 +Philippines,PHL,2010,144 +Philippines,PHL,2011,141 +Philippines,PHL,2012,139 +Philippines,PHL,2013,136 +Philippines,PHL,2014,131 +Philippines,PHL,2015,127 +Philippines,PHL,2016,124 +Philippines,PHL,2017,121 +Poland,POL,2000,7 +Poland,POL,2001,6 +Poland,POL,2002,5 +Poland,POL,2003,5 +Poland,POL,2004,5 +Poland,POL,2005,4 +Poland,POL,2006,4 +Poland,POL,2007,4 +Poland,POL,2008,4 +Poland,POL,2009,3 +Poland,POL,2010,3 +Poland,POL,2011,3 +Poland,POL,2012,3 +Poland,POL,2013,3 +Poland,POL,2014,2 +Poland,POL,2015,2 +Poland,POL,2016,2 +Poland,POL,2017,2 +Portugal,PRT,2000,10 +Portugal,PRT,2001,10 +Portugal,PRT,2002,10 +Portugal,PRT,2003,10 +Portugal,PRT,2004,10 +Portugal,PRT,2005,9 +Portugal,PRT,2006,9 +Portugal,PRT,2007,9 +Portugal,PRT,2008,9 +Portugal,PRT,2009,9 +Portugal,PRT,2010,9 +Portugal,PRT,2011,9 +Portugal,PRT,2012,9 +Portugal,PRT,2013,8 +Portugal,PRT,2014,8 +Portugal,PRT,2015,9 +Portugal,PRT,2016,9 +Portugal,PRT,2017,8 +Qatar,QAT,2000,14 +Qatar,QAT,2001,14 +Qatar,QAT,2002,13 +Qatar,QAT,2003,13 +Qatar,QAT,2004,13 +Qatar,QAT,2005,12 +Qatar,QAT,2006,11 +Qatar,QAT,2007,11 +Qatar,QAT,2008,11 +Qatar,QAT,2009,10 +Qatar,QAT,2010,10 +Qatar,QAT,2011,10 +Qatar,QAT,2012,10 +Qatar,QAT,2013,10 +Qatar,QAT,2014,10 +Qatar,QAT,2015,9 +Qatar,QAT,2016,9 +Qatar,QAT,2017,9 +Romania,ROU,2000,54 +Romania,ROU,2001,49 +Romania,ROU,2002,47 +Romania,ROU,2003,43 +Romania,ROU,2004,39 +Romania,ROU,2005,35 +Romania,ROU,2006,32 +Romania,ROU,2007,30 +Romania,ROU,2008,28 +Romania,ROU,2009,28 +Romania,ROU,2010,27 +Romania,ROU,2011,24 +Romania,ROU,2012,23 +Romania,ROU,2013,21 +Romania,ROU,2014,21 +Romania,ROU,2015,21 +Romania,ROU,2016,21 +Romania,ROU,2017,19 +Russia,RUS,2000,56 +Russia,RUS,2001,53 +Russia,RUS,2002,51 +Russia,RUS,2003,49 +Russia,RUS,2004,45 +Russia,RUS,2005,42 +Russia,RUS,2006,36 +Russia,RUS,2007,32 +Russia,RUS,2008,30 +Russia,RUS,2009,27 +Russia,RUS,2010,25 +Russia,RUS,2011,23 +Russia,RUS,2012,22 +Russia,RUS,2013,20 +Russia,RUS,2014,19 +Russia,RUS,2015,18 +Russia,RUS,2016,18 +Russia,RUS,2017,17 +Rwanda,RWA,2000,1160 +Rwanda,RWA,2001,1100 +Rwanda,RWA,2002,961 +Rwanda,RWA,2003,870 +Rwanda,RWA,2004,758 +Rwanda,RWA,2005,643 +Rwanda,RWA,2006,541 +Rwanda,RWA,2007,469 +Rwanda,RWA,2008,427 +Rwanda,RWA,2009,424 +Rwanda,RWA,2010,373 +Rwanda,RWA,2011,349 +Rwanda,RWA,2012,329 +Rwanda,RWA,2013,308 +Rwanda,RWA,2014,291 +Rwanda,RWA,2015,275 +Rwanda,RWA,2016,260 +Rwanda,RWA,2017,248 +Saint Lucia,LCA,2000,86 +Saint Lucia,LCA,2001,86 +Saint Lucia,LCA,2002,90 +Saint Lucia,LCA,2003,92 +Saint Lucia,LCA,2004,89 +Saint Lucia,LCA,2005,83 +Saint Lucia,LCA,2006,82 +Saint Lucia,LCA,2007,87 +Saint Lucia,LCA,2008,93 +Saint Lucia,LCA,2009,100 +Saint Lucia,LCA,2010,109 +Saint Lucia,LCA,2011,116 +Saint Lucia,LCA,2012,116 +Saint Lucia,LCA,2013,108 +Saint Lucia,LCA,2014,104 +Saint Lucia,LCA,2015,115 +Saint Lucia,LCA,2016,117 +Saint Lucia,LCA,2017,117 +Saint Vincent and the Grenadines,VCT,2000,80 +Saint Vincent and the Grenadines,VCT,2001,75 +Saint Vincent and the Grenadines,VCT,2002,72 +Saint Vincent and the Grenadines,VCT,2003,69 +Saint Vincent and the Grenadines,VCT,2004,64 +Saint Vincent and the Grenadines,VCT,2005,59 +Saint Vincent and the Grenadines,VCT,2006,62 +Saint Vincent and the Grenadines,VCT,2007,67 +Saint Vincent and the Grenadines,VCT,2008,70 +Saint Vincent and the Grenadines,VCT,2009,67 +Saint Vincent and the Grenadines,VCT,2010,63 +Saint Vincent and the Grenadines,VCT,2011,64 +Saint Vincent and the Grenadines,VCT,2012,71 +Saint Vincent and the Grenadines,VCT,2013,73 +Saint Vincent and the Grenadines,VCT,2014,69 +Saint Vincent and the Grenadines,VCT,2015,64 +Saint Vincent and the Grenadines,VCT,2016,67 +Saint Vincent and the Grenadines,VCT,2017,68 +Samoa,WSM,2000,88 +Samoa,WSM,2001,85 +Samoa,WSM,2002,84 +Samoa,WSM,2003,80 +Samoa,WSM,2004,74 +Samoa,WSM,2005,72 +Samoa,WSM,2006,66 +Samoa,WSM,2007,62 +Samoa,WSM,2008,60 +Samoa,WSM,2009,58 +Samoa,WSM,2010,58 +Samoa,WSM,2011,54 +Samoa,WSM,2012,52 +Samoa,WSM,2013,48 +Samoa,WSM,2014,47 +Samoa,WSM,2015,45 +Samoa,WSM,2016,44 +Samoa,WSM,2017,43 +Sao Tome and Principe,STP,2000,179 +Sao Tome and Principe,STP,2001,173 +Sao Tome and Principe,STP,2002,169 +Sao Tome and Principe,STP,2003,167 +Sao Tome and Principe,STP,2004,166 +Sao Tome and Principe,STP,2005,163 +Sao Tome and Principe,STP,2006,158 +Sao Tome and Principe,STP,2007,154 +Sao Tome and Principe,STP,2008,150 +Sao Tome and Principe,STP,2009,145 +Sao Tome and Principe,STP,2010,140 +Sao Tome and Principe,STP,2011,137 +Sao Tome and Principe,STP,2012,134 +Sao Tome and Principe,STP,2013,132 +Sao Tome and Principe,STP,2014,131 +Sao Tome and Principe,STP,2015,130 +Sao Tome and Principe,STP,2016,130 +Sao Tome and Principe,STP,2017,130 +Saudi Arabia,SAU,2000,24 +Saudi Arabia,SAU,2001,24 +Saudi Arabia,SAU,2002,23 +Saudi Arabia,SAU,2003,23 +Saudi Arabia,SAU,2004,22 +Saudi Arabia,SAU,2005,22 +Saudi Arabia,SAU,2006,21 +Saudi Arabia,SAU,2007,21 +Saudi Arabia,SAU,2008,20 +Saudi Arabia,SAU,2009,20 +Saudi Arabia,SAU,2010,19 +Saudi Arabia,SAU,2011,18 +Saudi Arabia,SAU,2012,18 +Saudi Arabia,SAU,2013,17 +Saudi Arabia,SAU,2014,17 +Saudi Arabia,SAU,2015,17 +Saudi Arabia,SAU,2016,17 +Saudi Arabia,SAU,2017,17 +Senegal,SEN,2000,553 +Senegal,SEN,2001,545 +Senegal,SEN,2002,537 +Senegal,SEN,2003,532 +Senegal,SEN,2004,526 +Senegal,SEN,2005,519 +Senegal,SEN,2006,514 +Senegal,SEN,2007,504 +Senegal,SEN,2008,492 +Senegal,SEN,2009,472 +Senegal,SEN,2010,447 +Senegal,SEN,2011,423 +Senegal,SEN,2012,400 +Senegal,SEN,2013,381 +Senegal,SEN,2014,364 +Senegal,SEN,2015,346 +Senegal,SEN,2016,330 +Senegal,SEN,2017,315 +Serbia,SRB,2000,13 +Serbia,SRB,2001,13 +Serbia,SRB,2002,13 +Serbia,SRB,2003,13 +Serbia,SRB,2004,13 +Serbia,SRB,2005,12 +Serbia,SRB,2006,12 +Serbia,SRB,2007,12 +Serbia,SRB,2008,12 +Serbia,SRB,2009,12 +Serbia,SRB,2010,12 +Serbia,SRB,2011,12 +Serbia,SRB,2012,12 +Serbia,SRB,2013,12 +Serbia,SRB,2014,12 +Serbia,SRB,2015,13 +Serbia,SRB,2016,12 +Serbia,SRB,2017,12 +Seychelles,SYC,2000,53 +Seychelles,SYC,2001,54 +Seychelles,SYC,2002,54 +Seychelles,SYC,2003,54 +Seychelles,SYC,2004,55 +Seychelles,SYC,2005,55 +Seychelles,SYC,2006,55 +Seychelles,SYC,2007,55 +Seychelles,SYC,2008,55 +Seychelles,SYC,2009,55 +Seychelles,SYC,2010,55 +Seychelles,SYC,2011,55 +Seychelles,SYC,2012,55 +Seychelles,SYC,2013,55 +Seychelles,SYC,2014,55 +Seychelles,SYC,2015,54 +Seychelles,SYC,2016,54 +Seychelles,SYC,2017,53 +Sierra Leone,SLE,2000,2480 +Sierra Leone,SLE,2001,2250 +Sierra Leone,SLE,2002,2080 +Sierra Leone,SLE,2003,1960 +Sierra Leone,SLE,2004,1850 +Sierra Leone,SLE,2005,1760 +Sierra Leone,SLE,2006,1680 +Sierra Leone,SLE,2007,1610 +Sierra Leone,SLE,2008,1530 +Sierra Leone,SLE,2009,1450 +Sierra Leone,SLE,2010,1360 +Sierra Leone,SLE,2011,1270 +Sierra Leone,SLE,2012,1210 +Sierra Leone,SLE,2013,1180 +Sierra Leone,SLE,2014,1190 +Sierra Leone,SLE,2015,1180 +Sierra Leone,SLE,2016,1120 +Sierra Leone,SLE,2017,1120 +Singapore,SGP,2000,13 +Singapore,SGP,2001,13 +Singapore,SGP,2002,14 +Singapore,SGP,2003,13 +Singapore,SGP,2004,14 +Singapore,SGP,2005,13 +Singapore,SGP,2006,13 +Singapore,SGP,2007,12 +Singapore,SGP,2008,11 +Singapore,SGP,2009,10 +Singapore,SGP,2010,10 +Singapore,SGP,2011,10 +Singapore,SGP,2012,10 +Singapore,SGP,2013,9 +Singapore,SGP,2014,8 +Singapore,SGP,2015,9 +Singapore,SGP,2016,8 +Singapore,SGP,2017,8 +Slovakia,SVK,2000,8 +Slovakia,SVK,2001,8 +Slovakia,SVK,2002,7 +Slovakia,SVK,2003,7 +Slovakia,SVK,2004,7 +Slovakia,SVK,2005,7 +Slovakia,SVK,2006,6 +Slovakia,SVK,2007,7 +Slovakia,SVK,2008,6 +Slovakia,SVK,2009,6 +Slovakia,SVK,2010,6 +Slovakia,SVK,2011,6 +Slovakia,SVK,2012,6 +Slovakia,SVK,2013,6 +Slovakia,SVK,2014,5 +Slovakia,SVK,2015,6 +Slovakia,SVK,2016,6 +Slovakia,SVK,2017,5 +Slovenia,SVN,2000,12 +Slovenia,SVN,2001,10 +Slovenia,SVN,2002,11 +Slovenia,SVN,2003,10 +Slovenia,SVN,2004,11 +Slovenia,SVN,2005,10 +Slovenia,SVN,2006,8 +Slovenia,SVN,2007,8 +Slovenia,SVN,2008,8 +Slovenia,SVN,2009,8 +Slovenia,SVN,2010,8 +Slovenia,SVN,2011,8 +Slovenia,SVN,2012,7 +Slovenia,SVN,2013,7 +Slovenia,SVN,2014,7 +Slovenia,SVN,2015,7 +Slovenia,SVN,2016,7 +Slovenia,SVN,2017,7 +Solomon Islands,SLB,2000,245 +Solomon Islands,SLB,2001,233 +Solomon Islands,SLB,2002,222 +Solomon Islands,SLB,2003,210 +Solomon Islands,SLB,2004,199 +Solomon Islands,SLB,2005,188 +Solomon Islands,SLB,2006,177 +Solomon Islands,SLB,2007,172 +Solomon Islands,SLB,2008,159 +Solomon Islands,SLB,2009,152 +Solomon Islands,SLB,2010,141 +Solomon Islands,SLB,2011,134 +Solomon Islands,SLB,2012,127 +Solomon Islands,SLB,2013,122 +Solomon Islands,SLB,2014,120 +Solomon Islands,SLB,2015,112 +Solomon Islands,SLB,2016,108 +Solomon Islands,SLB,2017,104 +Somalia,SOM,2000,1210 +Somalia,SOM,2001,1170 +Somalia,SOM,2002,1140 +Somalia,SOM,2003,1100 +Somalia,SOM,2004,1080 +Somalia,SOM,2005,1040 +Somalia,SOM,2006,1040 +Somalia,SOM,2007,1030 +Somalia,SOM,2008,1010 +Somalia,SOM,2009,994 +Somalia,SOM,2010,985 +Somalia,SOM,2011,955 +Somalia,SOM,2012,943 +Somalia,SOM,2013,893 +Somalia,SOM,2014,878 +Somalia,SOM,2015,855 +Somalia,SOM,2016,865 +Somalia,SOM,2017,829 +South Africa,ZAF,2000,160 +South Africa,ZAF,2001,168 +South Africa,ZAF,2002,177 +South Africa,ZAF,2003,186 +South Africa,ZAF,2004,195 +South Africa,ZAF,2005,201 +South Africa,ZAF,2006,201 +South Africa,ZAF,2007,199 +South Africa,ZAF,2008,191 +South Africa,ZAF,2009,179 +South Africa,ZAF,2010,171 +South Africa,ZAF,2011,161 +South Africa,ZAF,2012,143 +South Africa,ZAF,2013,133 +South Africa,ZAF,2014,128 +South Africa,ZAF,2015,125 +South Africa,ZAF,2016,122 +South Africa,ZAF,2017,119 +South Korea,KOR,2000,17 +South Korea,KOR,2001,15 +South Korea,KOR,2002,15 +South Korea,KOR,2003,16 +South Korea,KOR,2004,15 +South Korea,KOR,2005,15 +South Korea,KOR,2006,14 +South Korea,KOR,2007,15 +South Korea,KOR,2008,15 +South Korea,KOR,2009,16 +South Korea,KOR,2010,15 +South Korea,KOR,2011,14 +South Korea,KOR,2012,13 +South Korea,KOR,2013,13 +South Korea,KOR,2014,12 +South Korea,KOR,2015,12 +South Korea,KOR,2016,11 +South Korea,KOR,2017,11 +South Sudan,SSD,2000,1730 +South Sudan,SSD,2001,1690 +South Sudan,SSD,2002,1660 +South Sudan,SSD,2003,1610 +South Sudan,SSD,2004,1550 +South Sudan,SSD,2005,1480 +South Sudan,SSD,2006,1410 +South Sudan,SSD,2007,1330 +South Sudan,SSD,2008,1250 +South Sudan,SSD,2009,1170 +South Sudan,SSD,2010,1100 +South Sudan,SSD,2011,1070 +South Sudan,SSD,2012,1050 +South Sudan,SSD,2013,1090 +South Sudan,SSD,2014,1140 +South Sudan,SSD,2015,1110 +South Sudan,SSD,2016,1130 +South Sudan,SSD,2017,1150 +South-east Asia,,2000,355 +South-east Asia,,2001,341 +South-east Asia,,2002,326 +South-east Asia,,2003,311 +South-east Asia,,2004,297 +South-east Asia,,2005,280 +South-east Asia,,2006,266 +South-east Asia,,2007,252 +South-east Asia,,2008,239 +South-east Asia,,2009,226 +South-east Asia,,2010,214 +South-east Asia,,2011,202 +South-east Asia,,2012,191 +South-east Asia,,2013,182 +South-east Asia,,2014,173 +South-east Asia,,2015,165 +South-east Asia,,2016,157 +South-east Asia,,2017,152 +Spain,ESP,2000,5 +Spain,ESP,2001,5 +Spain,ESP,2002,5 +Spain,ESP,2003,5 +Spain,ESP,2004,5 +Spain,ESP,2005,5 +Spain,ESP,2006,4 +Spain,ESP,2007,4 +Spain,ESP,2008,4 +Spain,ESP,2009,4 +Spain,ESP,2010,4 +Spain,ESP,2011,4 +Spain,ESP,2012,4 +Spain,ESP,2013,4 +Spain,ESP,2014,4 +Spain,ESP,2015,4 +Spain,ESP,2016,4 +Spain,ESP,2017,4 +Sri Lanka,LKA,2000,56 +Sri Lanka,LKA,2001,53 +Sri Lanka,LKA,2002,50 +Sri Lanka,LKA,2003,50 +Sri Lanka,LKA,2004,48 +Sri Lanka,LKA,2005,45 +Sri Lanka,LKA,2006,47 +Sri Lanka,LKA,2007,43 +Sri Lanka,LKA,2008,42 +Sri Lanka,LKA,2009,41 +Sri Lanka,LKA,2010,38 +Sri Lanka,LKA,2011,38 +Sri Lanka,LKA,2012,37 +Sri Lanka,LKA,2013,37 +Sri Lanka,LKA,2014,36 +Sri Lanka,LKA,2015,36 +Sri Lanka,LKA,2016,36 +Sri Lanka,LKA,2017,36 +Sudan,SDN,2000,667 +Sudan,SDN,2001,645 +Sudan,SDN,2002,614 +Sudan,SDN,2003,598 +Sudan,SDN,2004,580 +Sudan,SDN,2005,529 +Sudan,SDN,2006,508 +Sudan,SDN,2007,479 +Sudan,SDN,2008,454 +Sudan,SDN,2009,433 +Sudan,SDN,2010,408 +Sudan,SDN,2011,390 +Sudan,SDN,2012,368 +Sudan,SDN,2013,349 +Sudan,SDN,2014,333 +Sudan,SDN,2015,320 +Sudan,SDN,2016,308 +Sudan,SDN,2017,295 +Suriname,SUR,2000,221 +Suriname,SUR,2001,218 +Suriname,SUR,2002,207 +Suriname,SUR,2003,189 +Suriname,SUR,2004,176 +Suriname,SUR,2005,164 +Suriname,SUR,2006,165 +Suriname,SUR,2007,167 +Suriname,SUR,2008,169 +Suriname,SUR,2009,159 +Suriname,SUR,2010,148 +Suriname,SUR,2011,139 +Suriname,SUR,2012,134 +Suriname,SUR,2013,129 +Suriname,SUR,2014,124 +Suriname,SUR,2015,122 +Suriname,SUR,2016,121 +Suriname,SUR,2017,120 +Sweden,SWE,2000,5 +Sweden,SWE,2001,5 +Sweden,SWE,2002,5 +Sweden,SWE,2003,5 +Sweden,SWE,2004,5 +Sweden,SWE,2005,5 +Sweden,SWE,2006,5 +Sweden,SWE,2007,5 +Sweden,SWE,2008,5 +Sweden,SWE,2009,5 +Sweden,SWE,2010,4 +Sweden,SWE,2011,5 +Sweden,SWE,2012,5 +Sweden,SWE,2013,5 +Sweden,SWE,2014,5 +Sweden,SWE,2015,4 +Sweden,SWE,2016,4 +Sweden,SWE,2017,4 +Switzerland,CHE,2000,7 +Switzerland,CHE,2001,7 +Switzerland,CHE,2002,7 +Switzerland,CHE,2003,7 +Switzerland,CHE,2004,7 +Switzerland,CHE,2005,7 +Switzerland,CHE,2006,7 +Switzerland,CHE,2007,6 +Switzerland,CHE,2008,6 +Switzerland,CHE,2009,6 +Switzerland,CHE,2010,6 +Switzerland,CHE,2011,6 +Switzerland,CHE,2012,6 +Switzerland,CHE,2013,6 +Switzerland,CHE,2014,5 +Switzerland,CHE,2015,5 +Switzerland,CHE,2016,5 +Switzerland,CHE,2017,5 +Syria,SYR,2000,26 +Syria,SYR,2001,26 +Syria,SYR,2002,26 +Syria,SYR,2003,25 +Syria,SYR,2004,26 +Syria,SYR,2005,25 +Syria,SYR,2006,26 +Syria,SYR,2007,26 +Syria,SYR,2008,26 +Syria,SYR,2009,26 +Syria,SYR,2010,27 +Syria,SYR,2011,28 +Syria,SYR,2012,28 +Syria,SYR,2013,29 +Syria,SYR,2014,30 +Syria,SYR,2015,30 +Syria,SYR,2016,30 +Syria,SYR,2017,31 +Tajikistan,TJK,2000,53 +Tajikistan,TJK,2001,52 +Tajikistan,TJK,2002,43 +Tajikistan,TJK,2003,35 +Tajikistan,TJK,2004,33 +Tajikistan,TJK,2005,32 +Tajikistan,TJK,2006,29 +Tajikistan,TJK,2007,27 +Tajikistan,TJK,2008,26 +Tajikistan,TJK,2009,26 +Tajikistan,TJK,2010,23 +Tajikistan,TJK,2011,22 +Tajikistan,TJK,2012,21 +Tajikistan,TJK,2013,20 +Tajikistan,TJK,2014,19 +Tajikistan,TJK,2015,18 +Tajikistan,TJK,2016,17 +Tajikistan,TJK,2017,17 +Tanzania,TZA,2000,854 +Tanzania,TZA,2001,819 +Tanzania,TZA,2002,788 +Tanzania,TZA,2003,763 +Tanzania,TZA,2004,741 +Tanzania,TZA,2005,721 +Tanzania,TZA,2006,703 +Tanzania,TZA,2007,685 +Tanzania,TZA,2008,666 +Tanzania,TZA,2009,656 +Tanzania,TZA,2010,644 +Tanzania,TZA,2011,628 +Tanzania,TZA,2012,615 +Tanzania,TZA,2013,593 +Tanzania,TZA,2014,574 +Tanzania,TZA,2015,556 +Tanzania,TZA,2016,539 +Tanzania,TZA,2017,524 +Thailand,THA,2000,43 +Thailand,THA,2001,43 +Thailand,THA,2002,44 +Thailand,THA,2003,44 +Thailand,THA,2004,46 +Thailand,THA,2005,43 +Thailand,THA,2006,42 +Thailand,THA,2007,42 +Thailand,THA,2008,43 +Thailand,THA,2009,43 +Thailand,THA,2010,42 +Thailand,THA,2011,41 +Thailand,THA,2012,39 +Thailand,THA,2013,39 +Thailand,THA,2014,38 +Thailand,THA,2015,38 +Thailand,THA,2016,37 +Thailand,THA,2017,37 +Togo,TGO,2000,489 +Togo,TGO,2001,489 +Togo,TGO,2002,489 +Togo,TGO,2003,489 +Togo,TGO,2004,488 +Togo,TGO,2005,492 +Togo,TGO,2006,482 +Togo,TGO,2007,480 +Togo,TGO,2008,473 +Togo,TGO,2009,458 +Togo,TGO,2010,440 +Togo,TGO,2011,422 +Togo,TGO,2012,410 +Togo,TGO,2013,404 +Togo,TGO,2014,401 +Togo,TGO,2015,398 +Togo,TGO,2016,395 +Togo,TGO,2017,396 +Tonga,TON,2000,77 +Tonga,TON,2001,73 +Tonga,TON,2002,71 +Tonga,TON,2003,69 +Tonga,TON,2004,67 +Tonga,TON,2005,66 +Tonga,TON,2006,64 +Tonga,TON,2007,62 +Tonga,TON,2008,60 +Tonga,TON,2009,61 +Tonga,TON,2010,57 +Tonga,TON,2011,56 +Tonga,TON,2012,56 +Tonga,TON,2013,56 +Tonga,TON,2014,55 +Tonga,TON,2015,54 +Tonga,TON,2016,53 +Tonga,TON,2017,52 +Trinidad and Tobago,TTO,2000,81 +Trinidad and Tobago,TTO,2001,78 +Trinidad and Tobago,TTO,2002,74 +Trinidad and Tobago,TTO,2003,75 +Trinidad and Tobago,TTO,2004,76 +Trinidad and Tobago,TTO,2005,76 +Trinidad and Tobago,TTO,2006,73 +Trinidad and Tobago,TTO,2007,65 +Trinidad and Tobago,TTO,2008,72 +Trinidad and Tobago,TTO,2009,74 +Trinidad and Tobago,TTO,2010,71 +Trinidad and Tobago,TTO,2011,72 +Trinidad and Tobago,TTO,2012,71 +Trinidad and Tobago,TTO,2013,70 +Trinidad and Tobago,TTO,2014,69 +Trinidad and Tobago,TTO,2015,68 +Trinidad and Tobago,TTO,2016,68 +Trinidad and Tobago,TTO,2017,67 +Tunisia,TUN,2000,66 +Tunisia,TUN,2001,63 +Tunisia,TUN,2002,60 +Tunisia,TUN,2003,57 +Tunisia,TUN,2004,54 +Tunisia,TUN,2005,51 +Tunisia,TUN,2006,49 +Tunisia,TUN,2007,47 +Tunisia,TUN,2008,47 +Tunisia,TUN,2009,46 +Tunisia,TUN,2010,46 +Tunisia,TUN,2011,46 +Tunisia,TUN,2012,46 +Tunisia,TUN,2013,46 +Tunisia,TUN,2014,46 +Tunisia,TUN,2015,46 +Tunisia,TUN,2016,45 +Tunisia,TUN,2017,43 +Turkey,TUR,2000,42 +Turkey,TUR,2001,41 +Turkey,TUR,2002,39 +Turkey,TUR,2003,38 +Turkey,TUR,2004,35 +Turkey,TUR,2005,33 +Turkey,TUR,2006,30 +Turkey,TUR,2007,28 +Turkey,TUR,2008,27 +Turkey,TUR,2009,25 +Turkey,TUR,2010,24 +Turkey,TUR,2011,23 +Turkey,TUR,2012,22 +Turkey,TUR,2013,20 +Turkey,TUR,2014,19 +Turkey,TUR,2015,19 +Turkey,TUR,2016,18 +Turkey,TUR,2017,17 +Turkmenistan,TKM,2000,29 +Turkmenistan,TKM,2001,27 +Turkmenistan,TKM,2002,25 +Turkmenistan,TKM,2003,21 +Turkmenistan,TKM,2004,20 +Turkmenistan,TKM,2005,18 +Turkmenistan,TKM,2006,18 +Turkmenistan,TKM,2007,15 +Turkmenistan,TKM,2008,13 +Turkmenistan,TKM,2009,12 +Turkmenistan,TKM,2010,10 +Turkmenistan,TKM,2011,10 +Turkmenistan,TKM,2012,9 +Turkmenistan,TKM,2013,9 +Turkmenistan,TKM,2014,8 +Turkmenistan,TKM,2015,8 +Turkmenistan,TKM,2016,8 +Turkmenistan,TKM,2017,7 +Uganda,UGA,2000,578 +Uganda,UGA,2001,550 +Uganda,UGA,2002,537 +Uganda,UGA,2003,520 +Uganda,UGA,2004,512 +Uganda,UGA,2005,491 +Uganda,UGA,2006,473 +Uganda,UGA,2007,465 +Uganda,UGA,2008,455 +Uganda,UGA,2009,442 +Uganda,UGA,2010,430 +Uganda,UGA,2011,419 +Uganda,UGA,2012,412 +Uganda,UGA,2013,401 +Uganda,UGA,2014,394 +Uganda,UGA,2015,387 +Uganda,UGA,2016,381 +Uganda,UGA,2017,375 +Ukraine,UKR,2000,35 +Ukraine,UKR,2001,33 +Ukraine,UKR,2002,33 +Ukraine,UKR,2003,32 +Ukraine,UKR,2004,33 +Ukraine,UKR,2005,33 +Ukraine,UKR,2006,31 +Ukraine,UKR,2007,33 +Ukraine,UKR,2008,33 +Ukraine,UKR,2009,27 +Ukraine,UKR,2010,25 +Ukraine,UKR,2011,23 +Ukraine,UKR,2012,24 +Ukraine,UKR,2013,23 +Ukraine,UKR,2014,24 +Ukraine,UKR,2015,21 +Ukraine,UKR,2016,20 +Ukraine,UKR,2017,19 +United Arab Emirates,ARE,2000,6 +United Arab Emirates,ARE,2001,6 +United Arab Emirates,ARE,2002,5 +United Arab Emirates,ARE,2003,5 +United Arab Emirates,ARE,2004,5 +United Arab Emirates,ARE,2005,5 +United Arab Emirates,ARE,2006,4 +United Arab Emirates,ARE,2007,4 +United Arab Emirates,ARE,2008,4 +United Arab Emirates,ARE,2009,4 +United Arab Emirates,ARE,2010,4 +United Arab Emirates,ARE,2011,4 +United Arab Emirates,ARE,2012,4 +United Arab Emirates,ARE,2013,3 +United Arab Emirates,ARE,2014,3 +United Arab Emirates,ARE,2015,3 +United Arab Emirates,ARE,2016,3 +United Arab Emirates,ARE,2017,3 +United Kingdom,GBR,2000,10 +United Kingdom,GBR,2001,11 +United Kingdom,GBR,2002,11 +United Kingdom,GBR,2003,11 +United Kingdom,GBR,2004,11 +United Kingdom,GBR,2005,11 +United Kingdom,GBR,2006,11 +United Kingdom,GBR,2007,11 +United Kingdom,GBR,2008,11 +United Kingdom,GBR,2009,10 +United Kingdom,GBR,2010,10 +United Kingdom,GBR,2011,9 +United Kingdom,GBR,2012,8 +United Kingdom,GBR,2013,8 +United Kingdom,GBR,2014,8 +United Kingdom,GBR,2015,8 +United Kingdom,GBR,2016,7 +United Kingdom,GBR,2017,7 +United States,USA,2000,12 +United States,USA,2001,13 +United States,USA,2002,13 +United States,USA,2003,13 +United States,USA,2004,13 +United States,USA,2005,13 +United States,USA,2006,14 +United States,USA,2007,14 +United States,USA,2008,14 +United States,USA,2009,15 +United States,USA,2010,15 +United States,USA,2011,15 +United States,USA,2012,16 +United States,USA,2013,16 +United States,USA,2014,16 +United States,USA,2015,18 +United States,USA,2016,19 +United States,USA,2017,19 +Uruguay,URY,2000,26 +Uruguay,URY,2001,25 +Uruguay,URY,2002,25 +Uruguay,URY,2003,23 +Uruguay,URY,2004,23 +Uruguay,URY,2005,22 +Uruguay,URY,2006,20 +Uruguay,URY,2007,20 +Uruguay,URY,2008,19 +Uruguay,URY,2009,19 +Uruguay,URY,2010,17 +Uruguay,URY,2011,17 +Uruguay,URY,2012,17 +Uruguay,URY,2013,18 +Uruguay,URY,2014,17 +Uruguay,URY,2015,18 +Uruguay,URY,2016,18 +Uruguay,URY,2017,17 +Uzbekistan,UZB,2000,41 +Uzbekistan,UZB,2001,41 +Uzbekistan,UZB,2002,41 +Uzbekistan,UZB,2003,39 +Uzbekistan,UZB,2004,37 +Uzbekistan,UZB,2005,38 +Uzbekistan,UZB,2006,37 +Uzbekistan,UZB,2007,35 +Uzbekistan,UZB,2008,34 +Uzbekistan,UZB,2009,32 +Uzbekistan,UZB,2010,31 +Uzbekistan,UZB,2011,32 +Uzbekistan,UZB,2012,32 +Uzbekistan,UZB,2013,31 +Uzbekistan,UZB,2014,30 +Uzbekistan,UZB,2015,30 +Uzbekistan,UZB,2016,29 +Uzbekistan,UZB,2017,29 +Vanuatu,VUT,2000,140 +Vanuatu,VUT,2001,135 +Vanuatu,VUT,2002,128 +Vanuatu,VUT,2003,123 +Vanuatu,VUT,2004,119 +Vanuatu,VUT,2005,113 +Vanuatu,VUT,2006,108 +Vanuatu,VUT,2007,103 +Vanuatu,VUT,2008,99 +Vanuatu,VUT,2009,96 +Vanuatu,VUT,2010,92 +Vanuatu,VUT,2011,88 +Vanuatu,VUT,2012,85 +Vanuatu,VUT,2013,82 +Vanuatu,VUT,2014,80 +Vanuatu,VUT,2015,76 +Vanuatu,VUT,2016,74 +Vanuatu,VUT,2017,72 +Venezuela,VEN,2000,119 +Venezuela,VEN,2001,123 +Venezuela,VEN,2002,135 +Venezuela,VEN,2003,127 +Venezuela,VEN,2004,119 +Venezuela,VEN,2005,113 +Venezuela,VEN,2006,114 +Venezuela,VEN,2007,114 +Venezuela,VEN,2008,116 +Venezuela,VEN,2009,119 +Venezuela,VEN,2010,117 +Venezuela,VEN,2011,116 +Venezuela,VEN,2012,116 +Venezuela,VEN,2013,115 +Venezuela,VEN,2014,113 +Venezuela,VEN,2015,115 +Venezuela,VEN,2016,121 +Venezuela,VEN,2017,125 +Vietnam,VNM,2000,68 +Vietnam,VNM,2001,65 +Vietnam,VNM,2002,62 +Vietnam,VNM,2003,59 +Vietnam,VNM,2004,57 +Vietnam,VNM,2005,54 +Vietnam,VNM,2006,51 +Vietnam,VNM,2007,49 +Vietnam,VNM,2008,49 +Vietnam,VNM,2009,48 +Vietnam,VNM,2010,47 +Vietnam,VNM,2011,47 +Vietnam,VNM,2012,46 +Vietnam,VNM,2013,46 +Vietnam,VNM,2014,45 +Vietnam,VNM,2015,45 +Vietnam,VNM,2016,44 +Vietnam,VNM,2017,43 +Western Pacific,,2000,75 +Western Pacific,,2001,72 +Western Pacific,,2002,69 +Western Pacific,,2003,66 +Western Pacific,,2004,63 +Western Pacific,,2005,61 +Western Pacific,,2006,59 +Western Pacific,,2007,56 +Western Pacific,,2008,55 +Western Pacific,,2009,53 +Western Pacific,,2010,51 +Western Pacific,,2011,49 +Western Pacific,,2012,47 +Western Pacific,,2013,46 +Western Pacific,,2014,44 +Western Pacific,,2015,43 +Western Pacific,,2016,42 +Western Pacific,,2017,41 +World,OWID_WRL,2000,342 +World,OWID_WRL,2001,335 +World,OWID_WRL,2002,328 +World,OWID_WRL,2003,319 +World,OWID_WRL,2004,309 +World,OWID_WRL,2005,296 +World,OWID_WRL,2006,284 +World,OWID_WRL,2007,274 +World,OWID_WRL,2008,265 +World,OWID_WRL,2009,257 +World,OWID_WRL,2010,248 +World,OWID_WRL,2011,241 +World,OWID_WRL,2012,234 +World,OWID_WRL,2013,229 +World,OWID_WRL,2014,224 +World,OWID_WRL,2015,219 +World,OWID_WRL,2016,214 +World,OWID_WRL,2017,211 +Yemen,YEM,2000,301 +Yemen,YEM,2001,290 +Yemen,YEM,2002,278 +Yemen,YEM,2003,266 +Yemen,YEM,2004,254 +Yemen,YEM,2005,242 +Yemen,YEM,2006,230 +Yemen,YEM,2007,219 +Yemen,YEM,2008,208 +Yemen,YEM,2009,200 +Yemen,YEM,2010,192 +Yemen,YEM,2011,187 +Yemen,YEM,2012,184 +Yemen,YEM,2013,175 +Yemen,YEM,2014,174 +Yemen,YEM,2015,169 +Yemen,YEM,2016,165 +Yemen,YEM,2017,164 +Zambia,ZMB,2000,528 +Zambia,ZMB,2001,491 +Zambia,ZMB,2002,465 +Zambia,ZMB,2003,453 +Zambia,ZMB,2004,437 +Zambia,ZMB,2005,421 +Zambia,ZMB,2006,406 +Zambia,ZMB,2007,387 +Zambia,ZMB,2008,356 +Zambia,ZMB,2009,329 +Zambia,ZMB,2010,305 +Zambia,ZMB,2011,283 +Zambia,ZMB,2012,267 +Zambia,ZMB,2013,254 +Zambia,ZMB,2014,242 +Zambia,ZMB,2015,232 +Zambia,ZMB,2016,222 +Zambia,ZMB,2017,213 +Zimbabwe,ZWE,2000,579 +Zimbabwe,ZWE,2001,629 +Zimbabwe,ZWE,2002,666 +Zimbabwe,ZWE,2003,680 +Zimbabwe,ZWE,2004,686 +Zimbabwe,ZWE,2005,685 +Zimbabwe,ZWE,2006,680 +Zimbabwe,ZWE,2007,671 +Zimbabwe,ZWE,2008,657 +Zimbabwe,ZWE,2009,632 +Zimbabwe,ZWE,2010,598 +Zimbabwe,ZWE,2011,557 +Zimbabwe,ZWE,2012,528 +Zimbabwe,ZWE,2013,509 +Zimbabwe,ZWE,2014,494 +Zimbabwe,ZWE,2015,480 +Zimbabwe,ZWE,2016,468 +Zimbabwe,ZWE,2017,458 \ No newline at end of file